<SEC-DOCUMENT>0001193125-14-367938.txt : 20141015
<SEC-HEADER>0001193125-14-367938.hdr.sgml : 20141009
<ACCEPTANCE-DATETIME>20141009171733
ACCESSION NUMBER:		0001193125-14-367938
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		32
FILED AS OF DATE:		20141009
DATE AS OF CHANGE:		20141009

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN DIAGNOSTICS INC
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-198850
		FILM NUMBER:		141150706

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d693329ds1a.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM S-1
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 1 to Form S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on October 9, 2014 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-198850</B></P>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Amendment
No. 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>FORM S-1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION
STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN
DIAGNOSTICS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>8071</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>20-0434866</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1261 Liberty Way, Suite C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vista, California 92081 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(760) 560-1501 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address,
including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fortunato Ron
Rocca </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1261 Liberty Way, Suite C </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vista, California 92081 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(760) 560-1501 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name,
address, including zip code, and telephone number, including area code, of agent for service) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to:
</I></B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cheston J. Larson, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Steven T. Chinowsky, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Matthew T. Bush, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Latham &amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>12670 High Bluff Drive</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San
Diego, California 92130</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858) 523-5400</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jason L. Kent, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Charles S. Kim, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jonathan R. Russo, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>4401 Eastgate
Mall</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92121</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858) 550-6000</B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after this Registration Statement is declared
effective. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If this form is
filed to register additional securities for an offering pursuant to Rule 462(b)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the
same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities To Be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed Maximum<BR>Aggregate Offering<BR>Price(1)</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount&nbsp;of<BR>Registration<BR>Fee(2)(3)</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, $0.001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$69,000,000</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$8,887.20</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of calculating the registration fee pursuant to Rule&nbsp;457(o)&nbsp;under the Securities Act of 1933, as amended. Includes the offering price of shares that the underwriters have the
option to purchase to cover over-allotments, if any. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Previously paid. </TD></TR></TABLE>  <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman"><B>The Registrant
hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become
effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#de1a1e"><B>The information in this preliminary prospectus is not complete and may be changed. We may
not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities
in any state or other jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#de1a1e"><B>Subject to completion, dated October 9, 2014 </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g693329g39n30.jpg" ALT="LOGO">
 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SHARES OF COMMON STOCK </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exagen
Diagnostics, Inc. is offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of its common stock. This is our initial public offering, and no public market currently exists for our
shares. We anticipate that the initial public offering price will be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. We have applied to list our common stock on The NASDAQ Global
Market under the symbol &#147;EXDX.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012, and, as such, have elected to comply with certain reduced public company reporting requirements. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. Before buying any shares, you should carefully read the discussion of
material risks of investing in our common stock in &#147;<A HREF="#toc693329_2">Risk Factors</A>&#148; beginning on page&nbsp;13 of this prospectus. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:13%;border-bottom:1px solid #000000; width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We have agreed to reimburse the underwriters for certain expenses in connection with this offering. See &#147;Underwriting.&#148; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option for a period of 30 days to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to cover any over-allotments. The underwriters can exercise this right at any time within 30 days after the date of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon
the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters expect to
deliver the shares of common stock to investors on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>Leerink Partners</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Baird</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>William Blair </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g693329g57y14.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_4">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_5">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_6">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_7">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_8">Selected Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_12">Executive and Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_13">Certain Relationships and Related Person Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_14">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_15">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_16">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_17">Material United States Federal Income Tax Consequences to Non-U.S. Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_18">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_20">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_24">Change in Independent Accountant </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_22">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc693329_23">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this prospectus or in any free writing prospectus we may authorize to be delivered or
made available to you. We have not authorized anyone to provide you with different information. We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The
information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of shares of our common stock. Our business, financial condition, results of operations and
prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside the United States: We have not and the underwriters have not done
anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of
this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including
our general expectations and market position, market opportunity and market share, is based on information from our own management estimates and research, as well as from industry and general publications and research, surveys and studies conducted
by third parties. Management estimates are derived from publicly available information, our knowledge of our industry and assumptions based on such information and knowledge, which we believe to be reasonable. Our management estimates have not been
verified by any independent source, and we have not independently verified any third-party information. In addition, assumptions and estimates of our and our industry&#146;s future performance are necessarily subject to a high degree of uncertainty
and risk due to a variety of factors, including those described in &#147;Risk Factors.&#148; These </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and other factors could cause our future performance to differ materially from our assumptions and estimates. See &#147;Special Note Regarding Forward-Looking Statements.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our registered trademarks, including Avise, Avise PG, Avise MCV and Avise SLE, in this prospectus. This prospectus also includes
trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this prospectus appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and
&#153; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and
tradenames. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our common stock. You should read this entire prospectus carefully, especially the section in this prospectus entitled &#147;Risk Factors&#148; beginning on page&nbsp;13 and our consolidated financial statements and the
related notes thereto included at the end of this prospectus, before making an investment decision. As used in this prospectus, unless the context otherwise requires, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;our
company&#148; and &#147;Exagen&#148; refer to Exagen Diagnostics, Inc. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a commercial-stage diagnostics company committed to addressing the significant unmet need for the accurate diagnosis and monitoring of
patients affected by autoimmune rheumatic diseases. These chronic diseases can cause lifelong inflammation in the joints, tissues and internal organs, resulting in serious complications, such as irreversible organ damage. The accurate, timely and
differential diagnosis for patients suffering from the approximately 30 autoimmune rheumatic diseases, or ARDs, is critical as treatment for each disease can vary, and inappropriate or delayed therapy may expose patients to unnecessary risks or the
hazards of uncontrolled disease activity. Physicians face significant difficulties in making a definitive diagnosis of a specific ARD because patients with different diseases often present with a common set of symptoms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently market four products under our Avise brand to provide an accurate, timely and differential diagnosis and to optimize the
treatment of ARDs. We processed approximately 9,300 patient specimens for our lead diagnostic product line, Avise SLE, in 2013 and approximately 11,100 in the first six months of 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagnosis and treatment of ARDs is generally provided by the community rheumatologist, a sub-specialty of internal medicine which includes
approximately 3,500 physicians in the United States. Patients often present to a rheumatologist after a lengthy referral process because of the similarity and overlap of symptoms among ARDs, the waxing and waning of these symptoms and the
shortcomings of current diagnostic tests. Establishing a definitive diagnosis is often difficult and can take years. Throughout this time, patients may continue to suffer from the debilitating effects of their disease, receive inappropriate
treatments and may face a significant financial burden. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product, Avise SLE+CT, is a proprietary diagnostic test that provides an
enhanced solution for patients presenting with symptoms indicative of a wide variety of ARDs such as Systemic Lupus Erythematosus, or SLE, Rheumatoid Arthritis, or RA, Sj&ouml;gren&#146;s syndrome, scleroderma and other disorders that mimic ARDs
such as fibromyalgia. Avise SLE+CT allows physicians to more accurately rule-in or rule-out SLE, and inform decisions about the presence of other ARDs, all with the convenience of one blood draw. Differential diagnosis of these diseases is
critically important because earlier diagnosis has been shown to improve patient outcomes. Once diagnosed, physicians can tailor therapy to a patient&#146;s specific disease and avoid the &#147;trial and error&#148; approach that often takes place
when a definitive diagnosis cannot be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have validated the clinical utility of Avise SLE 2.0, the proprietary component of our
Avise SLE+CT solution, in a multi-center study in an aggregate of 794 subjects. The results of this study, which were presented at the American College of Rheumatology, or ACR, annual conference in 2013, showed that Avise SLE 2.0 demonstrated
superior ability to distinguish SLE from other ARDs. Avise SLE 2.0 is powered by our proprietary CB-CAPs technology, which we exclusively license from the University of Pittsburgh. This technology is the result of over a decade of extensive research
and development conducted at the Lupus Center of Excellence at the University of Pittsburgh Medical Center. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to develop
additional innovative, high value diagnostic solutions for the rheumatologist while continuing to improve the performance characteristics of our currently marketed products. In particular, we are </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;1&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
developing and validating testing solutions that are designed to assist rheumatologists with the monitoring of disease activity in patients with SLE and monitoring the active drug levels of some
of the more commonly prescribed pharmaceuticals for the treatment of ARDs. We are conducting validation studies for these products in collaboration with academic centers of excellence and intend to publish the results of these studies in
peer-reviewed medical journals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Autoimmune Rheumatic Diseases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ARDs are a
group of approximately 30 chronic disorders which create a significant burden on the healthcare system. These chronic diseases can cause lifelong inflammation in the joints, tissues and internal organs, resulting in serious complications, such as
irreversible organ damage. Untreated chronic inflammation can also lead to premature hardening of the arteries, heart attacks and strokes. It is estimated that 11&nbsp;million patients in the United States suffer from ARDs, and patients afflicted
with fibromyalgia and autoimmune thyroid disease have many of the same clinical symptoms as patients with ARDs. Examples of these disorders include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Systemic Lupus Erythematosus (SLE). </I>A chronic autoimmune disease involving inflammation and destruction of organs such as the brain, kidneys and lungs resulting in irreversible damage and in severe cases death.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Rheumatoid Arthritis (RA).</I> A chronic autoimmune disease involving inflammation and destruction of joints, bone and in some cases organs, including eyes and lungs. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Sj&ouml;gren&#146;s Syndrome. </I>A chronic autoimmune disease involving inflammation and destruction of secretory glands such as salivary glands and tear ducts. This disease can occur with RA and SLE.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Fibromyalgia.</I> A chronic condition characterized by widespread pain and tenderness to touch. Although not an autoimmune disease, this syndrome has been reported to occur in 25% of RA patients, 30% of SLE patients
and 50% of Sj&ouml;gren&#146;s patients. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Autoimmune Thyroid Disease</I>. A chronic autoimmune disease that results in antibodies causing decreased thyroid hormone production, or hypothyroidism, or increased thyroid hormone production, or hyperthyroidism.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with these disorders often present with a common set of symptoms, which can include joint pain, fatigue,
inflammation, stiffness and muscle aches, among others. Additionally, these patients may experience unpredictable periods of disease flares and disease inactivity, which can meaningfully change the patients&#146; symptoms and how they present to the
physician. The combination of overlapping symptoms and disease biology can lead these patients to cycle from physician to physician for months or even years before receiving a definitive diagnosis. Due to this, we believe physicians are in critical
need of objective tests capable of differentially diagnosing these disorders, especially for potentially life threatening ARDs such as SLE. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Systemic
Lupus Erythematosus </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SLE is the most common and one of the most serious forms of lupus. It is estimated that over one million people in
the United States suffer from some form of lupus. SLE is characterized by unpredictable, intermittent increases and decreases of disease activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diagnosing SLE is difficult due to overlapping symptoms with other ARDs, fibromyalgia and autoimmune thyroid disease. A Lupus Foundation of
America survey suggests that more than half of those afflicted with lupus waited at least four years, and saw three or more doctors, before obtaining a correct diagnosis. Earlier diagnosis of SLE allows physicians to initiate therapies sooner in
order to help protect the patient from organ damage. An independent study funded by GlaxoSmithKline plc and published in a peer-reviewed medical journal concluded </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;2&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that early diagnosis of SLE is associated with better clinical outcomes, including lower flare rates, as well as reduced resource utilization and healthcare costs. Once diagnosed, treatment of
SLE generally involves the use of antimalarials, corticosteroids, immunosuppressants and newer biologic agents to prevent or suppress active disease or flares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a significant need for frequent monitoring of disease activity to guide therapeutic choices and optimize drug effectiveness.
Physicians and patients are in need of improved, objective testing solutions to help with the diagnosis, prognosis and monitoring of patients with SLE and other ARDs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is estimated that over 14&nbsp;million people in the United States have been diagnosed with ARDs, fibromyalgia and autoimmune thyroid
disease, with approximately 470,000 people diagnosed annually. Additionally, in the United States, over one million patients annually are prescribed methotrexate, or MTX, therapy, and over 700,000 patients annually are prescribed hydroxychloroquine,
or HCQ, therapy. We estimate the market potential of our existing products to be as much as $870&nbsp;million annually, based on our internal research and analysis utilizing these incidence and prevalence rates, the prescription information of
pharmaceuticals for our drug monitoring products and the Medicare allowable reimbursement rate for our products. We estimate our pipeline products will create an additional $350 million annually in market potential based on these same factors, as
well as estimates that over 250,000 patients annually in the United States are prescribed anti-TNF therapy and approximately 220,000 people in the United States have been diagnosed with SLE. Because these calculations are based on internal estimates
and assume rates of reimbursement that may change, there is no guarantee that these assumptions will prove to be accurate and consequently, our actual market potential may not be as large as we expect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to
providing physicians with products that address the significant unmet need for accurate and timely diagnosis, prognosis and monitoring of ARDs. We market four products under our Avise brand, which facilitate the accurate and timely differential
diagnosis and prognosis of certain ARDs and drug-level monitoring of one of the most widely prescribed pharmaceuticals in rheumatology. These tests are designed to seamlessly integrate with a rheumatologist&#146;s daily workflow and each of our
tests are processed in our laboratory in California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our differentiated product offering includes: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Diagnosis</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prognosis</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Monitoring</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center">


<IMG SRC="g693329g07q40.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329g79b67.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329g72g81.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329g31f69.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Diagnostic test incorporating our proprietary CB-CAPs technology to rule-in or rule-out SLE from other ARDs</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">Comprehensive SLE prognostic panel to assist in determining risk for kidney damage or neurologic or cardiovascular complications associated with SLE</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">Test to monitor levels of active MTX, a first-line therapy for&nbsp;RA</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">Blood test to monitor levels of HCQ, a commonly prescribed treatment for patients with SLE and other ARDs</TD></TR>
</TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;3&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise SLE+CT </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise SLE+CT is a proprietary diagnostic test that provides an enhanced solution for patients presenting with symptoms indicative of a wide
variety of ARDs such as SLE, RA, Sj&ouml;gren&#146;s, scleroderma and other disorders that mimic ARDs such as fibromyalgia and autoimmune thyroid disease. Avise SLE+CT is comprised of two distinct components: our proprietary Avise SLE 2.0 solution
and other established biomarkers to diagnose ARDs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise SLE is a ten-marker panel test that includes two biomarkers based on our Cell
Bound Complement Activation Products, or CB-CAPs, technology, which we exclusively license from the University of Pittsburgh, and a proprietary algorithm to optimize its performance. CB-CAPs are relatively stable biomarkers found in the blood that
are associated with the presence and activity of SLE. CB-CAPs, measured by flow cytometry, drives the superior performance of our solution versus the existing standards of diagnosis. We added additional established autoantibodies for assisting in
the diagnosis of a broader set of ARDs to our proprietary Avise SLE solution. We developed this offering to enhance the clinical utility of our test and respond to our customer&#146;s need for a more comprehensive solution to assist in
differentially diagnosing ARDs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have demonstrated significant growth in demand for our Avise SLE diagnostic products. For example, in
the quarter ended June&nbsp;30, 2014, our quarterly orders for our Avise SLE diagnostic products increased 46% over the prior quarter and increased 209% over the quarter ended June&nbsp;30, 2013. We believe this strong demand is a reflection of the
value proposition we are providing to our physician customers and represents the market need for an enhanced solution to differentially diagnose ARDs. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g693329g07c28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We validated Avise SLE 2.0 in a multi-center clinical study involving 794 subjects comprised of 304 SLE
patients, 285 patients with other ARDs and fibromyalgia, and 205 normal healthy subjects from two cohorts. The study was conducted in collaboration with leading academic centers with expertise in SLE and other ARDs including Albert Einstein College
of Medicine, Northwestern University, North Shore-LIJ Health System and NYU College of Medicine, among others, and the preliminary results were presented at the ACR annual conference in 2013. The primary endpoint of the study was the performance
characteristics, specifically sensitivity and specificity, of Avise SLE 2.0 compared to common autoantibodies used to diagnose SLE and other ARDs, such as antinuclear antibodies, or ANA, and anti-double stranded DNA, or anti-dsDNA. Sensitivity
measures the proportion of patients who are correctly identified as having a particular condition, while specificity </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;4&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
measures the proportion of patients who are correctly identified as not having a particular condition. The final results of this study showed that Avise SLE 2.0: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstrated balanced performance consisting of 86% specificity and 80% sensitivity in distinguishing SLE from other ARDs and fibromyalgia; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">was 33% more specific than ANA (53% specificity/89% sensitivity); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">was 48% more sensitive than anti-dsDNA (32% sensitivity/97% specificity). </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thus, this data suggests that Avise
SLE 2.0 has improved accuracy as compared to ANA and anti-dsDNA in distinguishing SLE patients from patients with other ARDs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise SLE Prognostic
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise SLE Prognostic, which we launched in June 2014, is a blood test that complements Avise SLE+CT by providing results that
inform the prognosis of SLE patients and provide physicians with more information to tailor treatment for their patients. This test is a ten-marker panel of autoantibodies that have established predictive value for assessing the potential for
complications affecting the brain, cardiovascular system and kidneys. When physicians are ordering Avise SLE+CT, they can also request that we perform our Avise SLE Prognostic test if the initial Avise SLE+CT result suggests that the patient has
SLE. This provides additional convenience for ordering physicians and their patient. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise MTX </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise MTX is the first therapeutic drug monitoring test to precisely measure levels of methotrexate polyglutamates, or MTXPG, the active form
of MTX in the patient&#146;s blood. MTX is a first-line therapy for RA, and Avise MTX can allow physicians to personalize therapy by targeting the appropriate dose to individual patients. There is large variability in the way patients absorb and
metabolize MTX, and several studies have shown that low levels of MTXPG in the blood correlate with a lack of response to MTX therapy. Avise MTX provides crucial information as to whether a patient has achieved MTXPG blood levels consistent with an
appropriate response to MTX or if the MTXPG levels are too low to produce adequate effects. The physician can then adjust MTX dosing as necessary to maximize the benefit of MTX therapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise HCQ </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise HCQ, which we
launched in September 2014, is a blood test to help physicians objectively monitor blood levels of HCQ as they treat patients with SLE and other ARDs, including RA. HCQ is typically prescribed daily to patients to control ARD activity and prevent
flares. However, there is a large variability in the response to HCQ therapy, and patients can be poorly compliant. In order to optimize HCQ therapy, it is crucial to determine if the patient is taking the drug as prescribed, and also to determine
whether the blood levels are adequate and consistent with clinical efficacy. By measuring HCQ concentration in the blood, we believe that Avise HCQ will help physicians optimize HCQ therapy, identify noncompliant patients and identify patients that
are not absorbing the drug adequately. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;5&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on delivering meaningful solutions to aid rheumatologists and other physicians in the diagnosis of patients with ARDs and
providing physicians with additional tools to determine the most appropriate therapy over time to improve patient care. Our near-term pipeline is highlighted below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Test</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Description</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Category</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Status</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>Launch</B></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em" ALIGN="center">


<IMG SRC="g693329g37c05.jpg" ALT="LOGO">
</P> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Measures anti-TNF</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">active drug level and&nbsp;drug</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">neutralizing antibody</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">activity&nbsp;levels</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Drug</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Monitoring</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Validation in process</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">1H 2015</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em" ALIGN="center">


<IMG SRC="g693329g92b06.jpg" ALT="LOGO">
</P> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Measures SLE</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">disease&nbsp;activity</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Disease</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Monitoring</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Validation in process</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">1H 2016</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center">


<IMG SRC="g693329g17c99.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Determines potential risk</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">for bone damage or joint</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">erosion/diagnosis of RA</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Prognostic/</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Diagnostic</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center">Validation complete; evaluation ongoing</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center">2016</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to establish ourselves as the preeminent provider of testing solutions to rheumatologists by offering a comprehensive set of tools
to effectively diagnose and optimize the treatment of patients with ARDs. To achieve this objective, we intend to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Accelerate the adoption of our existing products</I>. We plan to expand the use of our Avise product suite by adding new physicians to our customer base as well as increasing utilization among our existing customers.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Further demonstrate the clinical utility of our products to drive adoption and support reimbursement</I>. We are conducting additional clinical studies to drive the adoption and reimbursement of our Avise product
suite and plan to continue to publish results in peer-reviewed medical journals. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expand our portfolio of high value testing solutions.</I> We are continuing to develop additional products to address the significant challenges in the diagnosis, prognosis and monitoring of patients with ARDs, and
we plan to launch three new products by the end of 2016. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Establish ourselves as the trusted partner to the rheumatologist</I>. Our reputation with our physician customers is built on their confidence in the quality of our testing solutions, the timely delivery of our test
reports and the value of our consultative support. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Engage in partnerships to access additional market opportunities</I>. We believe there is meaningful potential for our current and future products beyond the rheumatology specialty, particularly for those
physician groups that see patients earlier in the diagnostic process, and we intend to selectively seek complementary partnerships to address these broader markets. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;6&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to execute our business strategy is subject to numerous risks, as more fully described in the section entitled &#147;Risk
Factors&#148; immediately following this prospectus summary. These risks include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are at an early stage of commercialization with a history of losses, including an accumulated deficit of $81.8 million as of June 30, 2014, and we expect to incur net losses in the future and may never achieve or
sustain profitability. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our financial results depend solely on sales of our Avise products, and we will need to generate sufficient revenue from these products and other diagnostic, prognostic and monitoring solutions to grow our business.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our commercial success depends upon attaining significant market acceptance of our products among physicians, patients, and third-party payers. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We rely on sole suppliers for some of the reagents, equipment and other materials used in our Avise products, and we may not be able to find replacements or transition to alternative suppliers. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we are unable to support demand for our Avise products or any of our future products or solutions, our business could suffer. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If third-party payers do not provide coverage and adequate reimbursement, breach, rescind or modify their contracts or reimbursement policies or delay payments for our tests, or if we are unable to successfully
negotiate payer contracts, our commercial success could be compromised. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We conduct business in a heavily regulated industry, and any changes in regulations or the U.S. Food and Drug Administration&#146;s enforcement discretion with respect to laboratory developed tests, or any other
healthcare policy changes, or violations of healthcare laws and regulations by us that could result in substantial penalties, could adversely affect our business, prospects, results of operations or financial condition. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Developing new products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other products we are developing. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we are unable to maintain intellectual property protection, our competitive position could be harmed. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>We were
incorporated under the laws of the state of New Mexico in 2002, under the name Exagen Corporation. In 2003, we changed our state of incorporation from New Mexico to Delaware by merging with and<I> </I>into Exagen Diagnostics, Inc., pursuant to which
we changed our name to Exagen Diagnostics, Inc. Our principal executive offices are located at 1261 Liberty Way, Suite C, Vista, California 92081, and we also maintain offices in New Mexico, at 800 Bradbury Drive South East, Suite 108, Albuquerque,
New Mexico 87106. Our telephone number is&nbsp;(760)&nbsp;560-1501 for our Vista facility and (505) 272-7966 for our Albuquerque facility. Our website address is www.exagen.com<I>.</I> The information contained in, or accessible through, our website
does not constitute part of this prospectus. <I> </I></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;7&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.0 billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as
defined in the Jumpstart Our Business Startups Act, or JOBS Act, enacted in April 2012. An emerging growth company may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but
are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being permitted to present only two years of audited financial statements and only two years of related Management&#146;s Discussion&nbsp;&amp; Analysis of Financial Condition and Results of Operations in this
prospectus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the date of the first sale
of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended, or the Securities Act, which such fifth anniversary will occur in 2019. However, if certain events occur prior to the end
of such five-year period, including if we become a &#147;large accelerated filer,&#148; our annual gross revenues exceed $1.0 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an
emerging growth company prior to the end of such five-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure
obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different
than you might receive from other public reporting companies in which you hold equity interests. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;8&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Over-allotment option </P></TD>
<TD>The underwriters have an option for a period of 30 days to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock to cover over-allotments. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their over-allotment option to
purchase additional shares from us in full, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of
this prospectus. We intend to use the net proceeds from this offering as follows: (1)&nbsp;to fund selling and marketing activities, including expansion of our sales force to support the ongoing commercialization of our current products and future
products; (2)&nbsp;to fund research and development activities, including continued expansion of our Avise product portfolio, as well as clinical studies to demonstrate the utility of our Avise products and support reimbursement efforts; (3)&nbsp;to
fund capital expenditures, including lab infrastructure and information systems; and (4)&nbsp;for working capital and other general corporate purposes. See &#147;Use of Proceeds&#148; for a more complete description of the intended use of proceeds
from this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus and the other information in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed NASDAQ Global Market Symbol </P></TD>
<TD>EXDX </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering set forth above includes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">102,307,211 shares of common stock outstanding as of June 30, 2014, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock as of June 30, 2014 into
92,330,247 shares of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock in connection with the completion of this offering as a result of the automatic conversion of the $4.0
million in aggregate principal amount of convertible promissory notes we issued in July 2014, or the 2014 Notes (including accrued interest thereon), assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 (the
expected closing date of this offering); and </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;9&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock as a result of the expected net exercise of outstanding warrants, or the 2013 Warrants, in connection with
the completion of this offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, which 2013 Warrants
will terminate if not exercised prior to the completion of this offering. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be
outstanding after this offering set forth above excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">8,671,470 shares of common stock issuable upon exercise of stock options outstanding as of June 30, 2014, at a weighted average exercise price of $0.16 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon the exercise of outstanding warrants as of June 30, 2014, at a weighted average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which warrants will terminate upon the completion of this offering if not previously exercised; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock reserved for future issuance under our 2014 incentive award plan, or the 2014 plan, which will become effective on the
business day prior to the public trading date of our common stock (including 8,646,496 shares of common stock reserved for future grant or issuance under our 2013 stock option plan as of June 30, 2014, which shares will be added to the shares
reserved under the 2014 plan upon its effectiveness); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for future issuance under our 2014 employee stock purchase plan, or ESPP, which will become effective on the
business day prior to the public trading date of our common stock. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, this prospectus reflects and
assumes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the filing of our amended and restated certificate of incorporation and the adoption of our amended and restated bylaws, which will occur immediately prior to the completion of this offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the automatic conversion of all outstanding shares of our redeemable convertible preferred stock as of June 30, 2014 into 92,330,247 shares of our common stock immediately prior to the completion of this offering and
the resultant reclassification of our redeemable convertible preferred stock warrant liability to stockholders&#146; deficit in connection with such conversion; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a one-for- &nbsp;&nbsp;&nbsp;&nbsp;reverse stock split of our common stock to be effected prior to the effectiveness of the registration statement of which this prospectus is a part; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of the outstanding options and warrants described above, other than the 2013 Warrants; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise by the underwriters of their option to purchase additional shares of our common stock to cover over-allotments. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;10&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth a summary of our consolidated historical financial data as of, and for the periods ended on, the dates
indicated. We have derived the consolidated statements of operations data for the years ended December&nbsp;31, 2012 and 2013 from our audited consolidated financial statements included elsewhere in this prospectus. The consolidated statements of
operations data for the six months ended June 30, 2013 and 2014 and the consolidated balance sheet data as of June 30, 2014 have been derived from our unaudited consolidated financial statements included elsewhere in this prospectus and have been
prepared on the same basis as the audited consolidated financial statements. In the opinion of our management, the unaudited data reflects all adjustments, consisting of normal and recurring adjustments, necessary for the fair statement of results
as of and for these periods. You should read this data together with our audited consolidated financial statements and related notes included elsewhere in this prospectus and the sections in this prospectus entitled &#147;Selected Consolidated
Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results for any prior period are not indicative of our future results. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cost of revenue (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Change in fair value of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,393</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Loss on extinguishment of 2013 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,789</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net income (loss) per share attributable to common stockholders&#151;basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Weighted average shares used to compute net income (loss) per share attributable to common stockholders&#151;basic and
diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,501,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,856,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,786,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,949,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted (unaudited)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Weighted average shares used to compute pro forma net loss per share attributable to common stockholders&#151;basic and diluted
(unaudited)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note&nbsp;4 to our consolidated financial statements included elsewhere in this prospectus for an explanation of the method used to calculate the historical net income (loss) and the historical and pro forma net
income (loss) per share attributable to common stockholders, basic and diluted, and the number of shares used in the computation of these per share amounts. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;11&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30, 2014</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>As&nbsp;Adjusted</B><br><B>(1)(2)</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center"><B>(in thousands)</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="7" VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Working capital (deficit)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Capital lease obligations, long term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Gives effect to: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the automatic conversion of all of our outstanding shares of redeemable convertible preferred stock as of June 30, 2014 into an aggregate of 92,330,247 shares of common stock and the resultant reclassification of our
redeemable convertible preferred stock warrant liability to stockholders&#146; equity in connection with such conversion; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of $4.0 million in aggregate principal amount of 2014 Notes in July 2014 and the automatic conversion of the 2014 Notes (including accrued interest thereon) into
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 (the
expected closing date of this offering); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock as a result of the expected net exercise of the 2013 Warrants in connection with the completion of this
offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, which 2013 Warrants will terminate if not
exercised prior to the completion of this offering. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Gives further effect to the issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase (decrease) the pro forma as adjusted amount of each of cash
and cash equivalents, working capital (deficit), total assets and total stockholders&#146; deficit by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set
forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the
number of shares offered by us at the assumed initial public offering price would increase (decrease) each of cash and cash equivalents, working capital (deficit), total assets and total stockholders&#146; deficit by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The pro forma information discussed above is illustrative only and will be adjusted based on the actual initial public offering price and other terms of our initial public
offering determined at pricing. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Working capital (deficit) represents the difference between current assets and current liabilities as follows: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>As&nbsp;Adjusted</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center"><B>(in thousands)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Working capital (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;12&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below,
together with all of the other information in this prospectus, including our consolidated financial statements and related notes included elsewhere in this prospectus, before making an investment decision. If any of the following risks is realized,
our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline and you could lose part or all of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are at an early
stage of commercialization with a history of losses, and we expect to incur net losses in the future and may never achieve or sustain profitability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net losses since our inception. For the years ended December&nbsp;31, 2012 and 2013, we had a net loss of $7.3&nbsp;million
and $13.5&nbsp;million, respectively, and we expect to incur additional losses this year and in future years. As of December&nbsp;31, 2013 and June 30, 2014, we had an accumulated deficit of $74.3&nbsp;million and $81.8 million, respectively. Over
the next several years, we expect to continue to devote substantially all of our resources to increase adoption of, and reimbursement for, our Avise products and to develop future diagnostic, prognostic and monitoring solutions. To date, we have
generated only limited revenue, and we may never achieve or sustain profitability. Our failure to achieve and sustain profitability in the future could cause the market price of our common stock to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our financial results depend solely on sales of our Avise products, and we will need to generate sufficient revenue from these products and other
diagnostic, prognostic and monitoring solutions to grow our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of our historical revenue has been derived from
the sale of our Avise SLE products, the first of which we commercially launched in January 2012. For the foreseeable future, we expect to derive a majority of our revenue from sales of our existing Avise SLE products. We are in various stages of
research and development for other diagnostic, prognostic and monitoring solutions that we may offer, but there can be no assurance that we will be able to commercialize these solutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The demand for our Avise products may decrease or may not continue to increase at historical rates for a number of reasons. In addition, at
any point in time we may decide to no longer commercialize any of our Avise products for any number of reasons. While we have experienced early revenue growth from the sale of our Avise products, we may not be able to continue revenue growth or
maintain existing revenue levels. Further, we cannot ensure the continued availability of our Avise products in commercial quantities at acceptable costs. If we are unable to increase sales of our Avise products, expand reimbursement for our Avise
products, or successfully develop and commercialize other solutions, our revenue and our ability to achieve and sustain profitability would be impaired, and the market price of our common stock could decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may experience limits on our revenue if physicians decide not to order our Avise products or if we are otherwise unable to create or maintain demand
for our Avise products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to create or maintain demand for our Avise products in sufficient volume, we may not
generate sufficient revenue to become profitable. To generate increased demand, we will need to continue to educate physicians about the benefits of our Avise products through publications in peer-reviewed medical journals, presentations at medical
conferences and one-on-one education by our sales force. We also plan to focus on educating patients about the benefits of our Avise products, which we believe will generate further demand. In addition, our inability to obtain and maintain coverage
and adequate reimbursement from third-party payers may limit physician adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Physicians may rely on guidelines issued by industry
groups regarding the diagnosis, treatment and monitoring of autoimmune rheumatic diseases, or ARDs, and the monitoring of the effectiveness of therapeutic drugs used to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;13&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treat such diseases before utilizing any diagnostic test or monitoring solution. Although we have a number of company-sponsored clinical trials and clinical trials sponsored by individual
physicians underway to demonstrate the clinical utility of our Avise products, our products are not yet, and may never be, listed in any such guidelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its
report on our audited financial statements included in this prospectus. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our report from our independent registered public
accounting firm for the year ended December&nbsp;31, 2013 includes an explanatory paragraph stating that our recurring losses from operations since inception and negative cash flows from operating activities raise substantial doubt about our ability
to continue as a going concern. If we are unable to obtain sufficient funding, our business, prospects, financial condition and results of operations will be materially and adversely affected and we may be unable to continue as a going concern. If
we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited consolidated financial statements, and it is likely that investors will lose all
or a part of their investment. After this offering, future reports from our independent registered public accounting firm may also contain statements expressing substantial doubt about our ability to continue as a going concern. If we seek
additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding on
commercially reasonable terms or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to manage our future growth effectively, which could make it difficult to execute our
business strategy. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the need to scale our testing capacity, future growth will impose significant added
responsibilities on management, including the need to identify, recruit, train and integrate additional employees. In addition, rapid and significant growth may strain our administrative and operational infrastructure. Our ability to manage our
business and growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. The time and resources required to optimize these systems is uncertain, and failure to complete
optimization in a timely and efficient manner could adversely affect our operations. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our commercial success depends upon attaining significant market acceptance of our products among physicians, patients, and third-party payers.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product that we offer may not gain market acceptance among physicians, third-party payers, patients and the medical community.
Market acceptance of our products depends on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the perceived accuracy of our test results by physicians and patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages of our products over alternative products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the demonstration in clinical studies of the performance and clinical validity of our products, the results of which studies may not replicate the positive results from earlier studies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of our products in relation to alternative products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of coverage and adequate reimbursement and pricing by third parties and government authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our sales and marketing efforts. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we had to withdraw a product from
the market, it could harm our business and could impact market acceptance of our other products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;14&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on sole suppliers for some of the reagents, equipment and other materials used in our Avise
products, and we may not be able to find replacements or transition to alternative suppliers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on sole suppliers for
critical supply of reagents, equipment and other materials that we use to perform the tests that comprise our Avise products. We also purchase components used in our Avise product transportation kits from sole-source suppliers. Some of these items
are unique to these suppliers and vendors. While we have developed alternate sourcing strategies for many of these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available
when we need them. We are not a major customer of some of our suppliers, and these suppliers may therefore give other customers&#146; needs higher priority than ours. One of our products in development, Avise Anti-TNF, incorporates iLite technology,
the only commercially available cell-based assay that measures anti-TNF levels and drug neutralizing antibodies. Biomonitor A/S is the sole source capable of providing TNF sensitive cells used in such technology. If Biomonitor is unable to meet any
of our requirements for such cells, or otherwise completely ceases producing such cells, we would be unable to develop and potentially commercialize our Avise Anti-TNF product. If our suppliers can no longer provide us with the materials we need to
perform the tests that comprise our Avise products, if the materials do not meet our quality specifications, or if we cannot obtain acceptable substitute materials, an interruption in test processing could occur. In addition, if we should encounter
delays or difficulties in securing the quality and quantity of equipment we require for our tests, we may need to reconfigure our test processes, which could result in an interruption in sales. Any such interruption may significantly affect our
future revenue and harm our customer relations and reputation. In addition, in order to mitigate these risks, we may need to maintain inventories of these supplies at higher levels than would be the case if multiple sources of supply were available.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to support demand for our Avise products or any of our future products or solutions, our business could suffer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As demand for our Avise products or any of our future products or solutions grows, we will need to continue to scale our testing capacity and
processing technology, expand customer service, billing and systems processes and enhance our internal quality assurance program. We will also need additional certified laboratory scientists and other scientific and technical personnel to process
higher volumes of our tests. We cannot assure you that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available. We will also need to purchase additional
equipment, some of which can take several months or more to procure, setup and validate, and increase our software and computing capacity to meet increased demand. Failure to implement necessary procedures, transition to new processes, hire the
necessary personnel, obtain any necessary additional equipment and increase software and computing capacity could result in higher costs of processing tests or inability to meet demand. There can be no assurance that we will be able to perform our
testing on a timely basis at a level consistent with demand, or that our efforts to scale our operations, expand our personnel, equipment, software and computing capacities, or implement process enhancements will be successfully implemented and will
not negatively affect the quality of test results. In addition, there can be no assurance that we will have adequate space in our laboratory facility to accommodate such required expansion. If we encounter difficulty meeting market demand or quality
standards, our reputation could be harmed and our future prospects and our business could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If third-party payers do not provide coverage and
adequate reimbursement, breach, rescind or modify their contracts or reimbursement policies or delay payments for our tests, or if we are unable to successfully negotiate payer contracts, our commercial success could be compromised. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reimbursement by third-party payers, including governmental payers such as Medicare and Medicaid, may depend on a number of factors, including
the payer&#146;s determination that tests using our technologies are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not experimental or investigational; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">medically necessary; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appropriate for the specific patient; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;15&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effective; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">supported by peer-reviewed medical journals; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">included in clinical practice guidelines. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is uncertainty concerning third-party payer
coverage and reimbursement of any new products that we may launch. Several entities conduct technology assessments of new medical tests and devices and provide the results of their assessments for informational purposes to other parties. These
assessments may be used by third-party payers and health care providers as grounds to deny coverage for a test or procedure. In addition, insurers, including managed care organizations as well as government payers such as Medicare and Medicaid, have
increased their efforts to control the cost, utilization and delivery of healthcare services. These measures have resulted in reduced payment rates and decreased utilization for the diagnostics industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective April&nbsp;25, 2012, the then-Medicare contractor for California, Palmetto GBA, LLC, assigned the Avise MTX assay a unique
identifier and determined that our product met the applicable Medicare coverage criteria. Other payers make their own decisions as to whether to establish a policy to reimburse our tests, however, and because approvals must be sought on a payer by
payer basis, establishing broad coverage is a time-consuming and costly process. There are many payers who have not yet established a coverage policy applicable to our tests. Even if we are being reimbursed for our tests, Medicare, Medicaid and
private and other payers may withdraw coverage at any time, review and adjust the rate of reimbursement, require co-payments from patients or stop paying for our tests altogether, any of which would reduce our revenues. Further, from time to time
payers change processes that may affect timely payment. These changes may result in uneven cash flow or impact the timing of revenue recognized with these payers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our tests are reimbursed by a number of governmental and private payers, we do not have contracts with any significant large private
payers. If we are unable to obtain or maintain coverage and reimbursement from third-party payers for our existing tests or new tests or test enhancements we may develop in the future, our ability to generate revenues could be limited. We have in
the past, and will likely in the future, experience delays and temporary interruptions in the receipt of payments from third-party payers due to changes in their internal processes, documentation requirements and other issues, which could cause our
revenues to fluctuate from period to period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Billing for our products is complex, and we must dedicate substantial time and resources to the
billing process to be paid for our tests. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Billing for our products is complex, time consuming and expensive. Depending on the
billing arrangement and applicable law, we bill various payers, including Medicare, insurance companies and patients, all of which have different billing requirements. We generally bill third-party and government payers for our products and pursue
reimbursement on a case-by-case basis where pricing contracts are not in place. We may also face increased risk in our collection efforts, including long collection cycles, which could adversely affect our business, results of operations and
financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Several factors make the billing process complex, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differences between the list price for our products and the reimbursement rates of payers;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with complex federal and state regulations related to billing Medicare;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes among payers as to which party is responsible for payment;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differences in coverage among payers and the effect of patient co-payments or co-insurance;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differences in information and billing requirements among payers;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incorrect or missing billing information; and</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the resources required to manage the billing and claims appeals process. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;16&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, the list price for our primary product, Avise SLE+CT, is $1,475 while our
reimbursement rates received from third-party payers for this test range from $0 to $1,475 per test. These billing complexities, and the related uncertainty in obtaining payment for our products could negatively affect our revenue and cash flow, our
ability to achieve profitability, and the consistency and comparability of our results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on a third party for substantially
all of our billing and collection processing, and any delay in transmitting and collecting claims could have an adverse effect on our revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on a third-party provider to process and collect our claims. We have previously experienced delays in claims processing when our
third-party provider made changes to its invoicing system, and again when it did not submit claims to payers within the timeframe we require. If claims for our products are not submitted to payers on a timely basis, or if we are required to switch
to a different provider to handle claim processing it could have an adverse effect on our revenue and our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We conduct business in a
heavily regulated industry, and any changes in regulations or the U.S. Food and Drug Administration&#146;s, or FDA&#146;s, enforcement discretion, or violations of regulations by us, could adversely affect our business, prospects, results of
operations or financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagnostics industry is highly regulated, and we cannot assure you that the regulatory
environment in which we operate will not change significantly and adversely in the future. In particular, the laws and regulations governing the marketing of diagnostic products are extremely complex and in many instances there are no significant
regulatory or judicial interpretations of these laws and regulations. The Federal Food, Drug and Cosmetic Act, or FDCA, defines a medical device to include any instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or
other similar or related article, including a component, part, or accessory, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals. Our in vitro
diagnostic products are considered by the FDA to be subject to regulation as medical devices. Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling,
storage, recordkeeping, premarket clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended
uses. In addition, the FDA regulates the import and export of medical devices manufactured between the United States and international markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the FDA has statutory authority to assure that medical devices are safe and effective for their intended uses, the FDA has generally
exercised its enforcement discretion and not enforced applicable regulations with respect to in vitro diagnostics that are developed, validated, and offered within a single laboratory for use only in that laboratory. These tests are referred to as
laboratory developed tests, or LDTs. We currently market our diagnostic products as LDTs, although one of the products we market under a license from Orgentec Diagnostika GmbH, or Orgentec, is subject to a 510(k) clearance held by Orgentec and is
subject to the FDA&#146;s regulations applicable to 510(k)-cleared devices. While we believe that we are currently in material compliance with applicable laws and regulations as historically enforced by the FDA, we cannot assure you that the FDA
will agree with our determination, and a determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of
operations or financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Food and Drug Administration Safety and Innovation Act of 2012, the FDA is prohibited from
issuing guidance on the regulation of LDTs unless it provides Congress with details of the proposed action at least 60 days in advance. The FDA provided such notification to Congress on July 31, 2014, and proposed to modify its enforcement
discretion on LDTs in a risk-based manner, to start with the publication of a draft Framework Guidance, that when finalized, may subject us to medical device regulations of registration and listing, premarket clearance or approval, and adverse event
reporting. Any new FDA enforcement policies affecting LDTs may result in increased regulatory burdens on our ability to continue marketing our products and to develop and introduce new products in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;17&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA begins to actively regulate our diagnostic tests, we may be required to obtain
premarket clearance under Section&nbsp;510(k) of the FDCA or a premarket approval, or PMA. The process for submitting a 510(k) premarket notification and receiving FDA clearance usually takes from three to twelve months, but it can take
significantly longer and clearance is never guaranteed. The process for submitting and obtaining FDA approval of a PMA is much more costly, lengthy and uncertain. It generally takes from one to three years or even longer, and approval is not
guaranteed. PMA approval typically requires extensive clinical data and can be significantly longer, more expensive and more uncertain than the 510(k) clearance process. Despite the time, effort and expense expended, there can be no assurance that a
particular device ultimately will be cleared or approved by the FDA through either the 510(k) clearance process or the PMA process on a timely basis, or at all. Moreover, there can be no assurance that any cleared or approved labeling claims will be
consistent with our current claims or adequate to support continued adoption of and reimbursement for our products. If premarket review is required for some or all of our products, the FDA may require that we stop selling our products pending
clearance or approval, which would negatively impact our business. Even if our products are allowed to remain on the market prior to clearance or approval, demand or reimbursement for our products may decline if there is uncertainty about our
products, if we are required to label our products as investigational by the FDA, or if the FDA limits the labeling claims we are permitted to make for our products. As a result, we could experience significantly increased development costs and a
delay in generating additional revenue from our Avise products, or from other products now in development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA imposes significant
changes to the regulation of LDTs it could reduce our revenues or increase our costs and adversely affect our business, prospects, results of operations or financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our experience in marketing and selling our products is in the early stages, and if we are unable to expand our direct sales and marketing force to
adequately address our customers&#146; needs, our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We sell our Avise products through our own
sales force. However, we have limited experience in marketing and selling our Avise products, the first of which was commercially launched in January 2012 with a nine-person sales force. Starting in the fourth quarter of 2013, we expanded our sales
team to approximately 30 sales professionals. We may not be able to market and sell our Avise products or other products or solutions we may develop effectively enough to support our planned growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future sales will depend in large part on our ability to maintain and substantially expand our sales force and to increase the scope of
our marketing efforts. We expect to expand our sales force to approximately 40 sales representatives by mid-2015, which sales force we believe can cover approximately 80% of community rheumatologists in the United States. Rheumatology is a
concentrated specialty, and as such, we believe it is necessary to maintain a sales force that includes sales representatives with specific technical backgrounds. We will also need to attract and develop marketing personnel with industry expertise.
Competition for such employees is intense. We may not be able to attract and retain personnel or be able to maintain an efficient and effective sales and marketing force, which could negatively impact sales and marketing acceptance of our products
and limit our revenue growth and potential profitability. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to compete successfully, we may be unable to increase or sustain
our revenue or achieve profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal competition for our Avise products comes from traditional methods used by
physicians to test patients with rheumatic disease-like symptoms. Such traditional methods include testing for a broad range of diagnostic, immunology and chemistry markers, such as anti-nuclear antibodies, or ANA and anti-double-stranded DNA, or
anti-dsDNA, and serum complement, such as C3 and C4. We also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, ARUP Laboratories, Inc. and Mayo Clinic, all of which
have strong infrastructures to support the commercialization of diagnostic services. Large, multispecialty group medical clinics, health systems and academic medical university-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;18&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
based clinics may provide in-house clinical laboratories offering autoimmune rheumatic testing services. Additionally, we compete against regional clinical laboratories providing testing in the
autoimmune rheumatic field, such as Rheumatology Diagnostics Laboratories, Inc. Other potential competitors include companies that might develop diagnostic or disease or drug monitoring products, such as Myriad Genetics, Inc. In the future, we may
also face competition from companies developing new products or technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To compete successfully we must be able to demonstrate,
among other things, that our diagnostic, prognostic and monitoring test results are accurate and cost effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our potential
competitors have widespread brand recognition and substantially greater financial, technical and research and development resources and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could
be viewed by physicians and payers as functionally equivalent to our solution, or offer solutions at prices designed to promote market penetration, which could force us to lower the list price of our products and affect our ability to achieve
profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from
increasing our revenue or achieving profitability and could cause the market price of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Developing new products involves
a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other products we are developing. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are devoting considerable resources to the research and development of our planned future Avise products and enhancements to our current
Avise products. We may not be able to develop products with the diagnostic or monitoring performance or accuracy necessary to be clinically useful and commercially successful. We are in the process of developing three additional disease and
therapeutic drug monitoring products for rheumatic diseases, which we plan to launch by the end of 2016. These products may not be fully developed and introduced on our expected time line, if at all. Also, there are certain products for which a
commercial launch would trigger additional payment obligations to licensors of the technology. In these cases, if the economic projections of the product do not outweigh the additional obligations, we may not launch these products. In order to
develop and commercialize diagnostic, prognostic and monitoring products, we need to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expend significant funds to conduct substantial research and development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct successful validation studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop and scale our laboratory processes to accommodate different tests; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achieve and maintain required regulatory certifications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop and scale our infrastructure to be able to analyze increasingly large amounts of data; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">build the commercial infrastructure to market and sell new products. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development
process involves a high degree of risk and may take several years. Our product development efforts may fail for many reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to identify additional biomarkers to incorporate into our diagnostic products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure or sub-optimal performance of the product at the research or development stage; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in accessing archival patient blood specimens, especially specimens with known clinical results; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of clinical validation studies to support the effectiveness of the test. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Typically,
few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a product candidate or we may be required to expend
considerable resources repeating clinical studies, which would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;19&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adversely affect the timing for generating potential revenue from a new product and our ability to invest in other products in our pipeline. In addition, as we develop products, we will have to
make significant investments in product development, marketing and selling resources. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study, we might choose to abandon the development of the product or
product feature that was the subject of the clinical study, which could harm our business. Additionally, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may acquire businesses or assets, form joint ventures or make investments in other companies or technologies that could harm our operating results,
dilute our stockholders&#146; ownership, increase our debt or cause us to incur significant expense. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our business
strategy, we may pursue acquisitions of complementary businesses or assets, as well as technology licensing arrangements. We also may pursue strategic alliances that leverage our core technology and industry experience to expand our offerings or
distribution, or make investments in other companies. To date, other than our acquisition of the medical diagnostics division of Cypress Bioscience, Inc., we have not acquired other companies and have limited experience with respect to the formation
of strategic alliances and joint ventures. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any future acquisitions by us
also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. Integration of an acquired company or business also may require management resources that otherwise
would be available for ongoing development of our existing business. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition,
technology license, strategic alliance, joint venture or investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To finance any acquisitions or investments, we may choose to issue
shares of our stock as consideration, which would dilute the ownership of our stockholders. Once we become a public company, if the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. Alternatively,
it may be necessary for us to raise additional funds for these activities through public or private financings or through the issuance of debt. Additional funds may not be available on terms that are favorable to us, or at all, and any debt
financing may involve covenants limiting or restricting our ability to take certain actions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The diagnostics industry is subject to rapidly
changing technology, which could make our Avise products, and other products we develop, obsolete. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry is characterized
by rapid technological changes, frequent new product introductions and enhancements and evolving industry standards. These advances require us to continuously develop our technology and work to develop new solutions to keep pace with evolving
standards of care. Our products could become obsolete unless we continually innovate and expand our product offerings to include new clinical applications. If we are unable to develop new products or to demonstrate the applicability of our products
for other diseases, our sales could decline and our competitive position could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to maintain relationships or build new
relationships with key opinion leaders could materially adversely impact our business and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Key opinion leaders are able
to influence clinical practice by publishing research and determining whether new tests should be integrated into practice guidelines. We have collaborated with key opinion leaders in the field of rheumatology to further expand the clinical utility
of our tests, including through their participation in validation studies for Avise SLE and supporting the publication of results from such studies in peer-reviewed medical journals. Our failure to maintain or build new relationships with such key
opinion leaders could affect physician and patient perception of our tests and result in a loss of existing and future physician customers and therefore materially adversely impact our business and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;20&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are sued for errors and omissions or professional liability, we could face substantial liabilities
that exceed our resources. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The marketing, sale and use of our Avise products could lead to liability claims if someone were to
allege that any such product failed to perform as it was designed. We may also be subject to liability for errors in the results we provide to physicians or for a misunderstanding of, or inappropriate reliance upon, the information we provide. We
may also be subject to similar types of claims related to products we may develop in the future. An errors and omissions or professional liability claim could result in substantial damages and be costly and time consuming for us to defend. Although
we maintain professional liability insurance, we cannot assure you that our insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of any such
claims. Any errors or omissions or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit
could cause injury to our reputation or cause us to suspend sales of our products and solutions. The occurrence of any of these events could have an adverse effect on our business and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The loss of members of our senior management team or our inability to attract and retain highly skilled scientists, technicians and salespeople could
adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends largely on the skills, experience and performance of key members of our
executive management team, including Fortunato Ron Rocca, our President and Chief Executive Officer, and others in key management positions. The efforts of each of these persons will be critical to us as we continue to develop our technologies and
test processes and focus on our growth. If we were to lose one or more of these key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our research and development programs and commercial laboratory operations depend on our ability to attract and retain highly
skilled scientists, including licensed clinical laboratory scientists and biostatisticians. We may not be able to attract or retain qualified scientists and technicians in the future due to the intense competition for qualified personnel among life
science businesses, particularly in Southern California. Because it is expected that there will be a shortage of clinical laboratory scientists in coming years, it may become more difficult to hire sufficient numbers of qualified personnel. We also
face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. Additionally, our success depends on our ability to attract and retain qualified salespeople. We may
have difficulties locating, recruiting or retaining qualified salespeople, which could cause a delay or decline in the rate of adoption of our products. If we are not able to attract and retain the necessary personnel to accomplish our business
objectives, we may experience constraints that could adversely affect our ability to support our research and development, clinical laboratory and sales efforts. All of our employees are at-will, which means that either we or the employee may
terminate their employment at any time. We do not carry key man insurance for any of our employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our sole laboratory facility becomes damaged
or inoperable, we are required to vacate our existing facility or we are unable to expand our existing facility as needed, we will be unable to perform our testing services and our business will be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently derive all of our revenue from tests conducted at a single laboratory facility located in Vista, California. Vista is situated on
or near earthquake fault lines. Our facility and equipment could be harmed or rendered inoperable by natural or man-made disasters, including earthquake, fire, flood, power loss, communications failure or terrorism. In particular, we store all of
our flow cytometers, the instrument we use to detect CB-CAPs on cells, at our Vista facility. If all of our flow cytometers were rendered inoperable simultaneously pursuant to a natural or man-made disaster, we would be unable to perform these key
tests as we do in the ordinary course of our business. The inability to perform our tests or to reduce the backlog of analyses that could develop if our facility is inoperable, for even a short period of time, may result in the loss of customers
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;21&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or harm to our reputation, and we may be unable to regain those customers or repair our reputation in the future. Additionally, we store our bio-repository of specimens, which were collected in
collaboration with leading academic institutions and help us to further validate our Avise products, at our Vista facility. If these specimens were destroyed pursuant to a natural or man-made disaster or otherwise become unavailable, our ability to
develop new products may be delayed. Furthermore, our facility and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and
expensive to rebuild our facility or license or transfer our proprietary technology to a third-party, particularly in light of the licensure and accreditation requirements for a commercial laboratory like ours. Even in the unlikely event we are able
to find a third party with such qualifications to enable us to conduct our tests, we may be unable to negotiate commercially reasonable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to rely on a third party to perform our tests, we would need to engage another facility with established state licensure and Clinical
Laboratory Improvement Amendments of 1988, or CLIA, accreditation under the scope of which tests could be performed following validation and other required procedures. We cannot assure you that we would be able to find another CLIA-certified
facility willing to comply with the required procedures, that any such facility would be willing to perform our tests for us on commercially reasonable terms, or that it would be able to meet our quality standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to establish an additional clinical reference laboratory facility, we would have to spend considerable time and money securing
adequate space, constructing the facility, recruiting and training employees, and establishing the additional operational and administrative infrastructure necessary to support a second facility. We may not be able, or it may take considerable time,
to replicate our testing processes or results in a new facility. Additionally, any new clinical reference laboratory facility opened by us would be subject to certification under CLIA and licensing by several states, including California and New
York, which could take a significant amount of time and result in delays in our ability to begin operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expanded our laboratory
into available space immediately next to our existing laboratory in July 2014, and we have entered into a lease to further expand our space beginning in February 2015. With this expansion and our planned further expansion, we believe we have the
capacity to meet our projected needs for at least the next 12 months, although we may grow at a rate that is faster than we expect. Beyond this time frame, we may need to further expand our laboratory space. Any future expansion, including our
planned expansion in February 2015, could disrupt laboratory operations, resulting in an inability to meet customer turnaround time expectations, and could be delayed, resulting in slower realization of laboratory efficiencies anticipated from the
use of the expanded facilities. Adverse consequences resulting from a delay in the laboratory expansion could harm our relationships with our customers and our reputation, and could affect our ability to generate revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated
with damage or disruption to our business, provide coverage in amounts sufficient to cover our potential losses or continue to be available to us on acceptable terms, if at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our testing process involves the use of sophisticated state-of-the-art equipment that requires precise calibration, and issues affecting such equipment
may delay delivery of the test results to physicians or otherwise adversely affect our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our process of
determining CB-CAPs, which is part of our Avise SLE products, we utilize a number of flow cytometers that require calibration and performance validation according to the requirements of the College of American Pathologists, or CAP, at specified time
intervals. While we believe we have implemented appropriate controls and metrics in our laboratory to meet such requirements, we cannot provide any assurance that our instruments will not fall out of specification, in which case we would be required
to re-calibrate them. Patient specimens degrade and become unusable generally within 48 hours of collection. Therefore, if we do not have other sufficient properly functioning flow cytometers due to failure to meet specifications or they otherwise
become inoperable, our ability to process patient specimens in the required timeframe would be compromised and our business could be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;22&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we cannot enter into new clinical study collaborations, our product development and subsequent
commercialization could be delayed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, we have entered into clinical study collaborations, and our success in the future
depends in part on our ability to enter into additional collaborations with highly regarded institutions. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may limit the number of
collaborations they have with any one company so as to not be perceived as biased or conflicted. Organizations may also have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can
extend the time it takes to develop, negotiate and implement a collaboration. Additionally, organizations often insist on retaining the rights to publish the clinical data resulting from the collaboration. The publication of clinical data in
peer-reviewed medical journals is a crucial step in commercializing and obtaining reimbursement for diagnostic products such as our Avise products, and our inability to control when and if results are published may delay or limit our ability to
derive sufficient revenue from any solution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we use hazardous materials in a manner that causes contamination or injury, we could be liable for
resulting damages. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to federal, state and local laws, rules and regulations governing the use, discharge, storage,
handling and disposal of biological material, chemicals and waste. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of
contamination or injury, we could be held liable for any resulting damages, remediation costs and any related penalties or fines, and any liability could exceed our resources or any applicable insurance coverage we may have. The cost of compliance
with these laws and regulations may become significant, and our failure to comply may result in substantial fines or other consequences, either of which could negatively affect our operating results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure in our information technology, telephone or other systems could significantly disrupt our operations and adversely affect our business and
financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information technology and telephone systems are used extensively in virtually all aspects of our business,
including laboratory testing, sales, billing, customer service, logistics and management of medical data. The success of our business depends on the ability to obtain, process, analyze, maintain and manage this data. Our management relies on our
information systems because: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient specimens must be received, tracked and processed on a timely basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">test results must be reported on a timely basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">billings and collections for all customers must be managed efficiently and accurately; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third party ancillary billing services require proper tracking and reporting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pricing and other information related to our services is needed by our sales force and other personnel in a timely manner to conduct business; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient-identifiable health information must be securely held and kept confidential; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory compliance requires proper tracking and reporting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">proper recordkeeping is required for operating our business, managing employee compensation and other personnel matters. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business, results of operations and financial condition may be adversely affected if, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our information technology, telephone or other systems fail or are interrupted for any extended length of time; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;23&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">services relating to our information technology, telephone or other systems are not kept current; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our information technology, telephone or other systems do not have the capacity to support expanded operations and increased levels of business; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">data is lost or unable to be restored or processed; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">data is corrupted due to a breach of security. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the precautionary measures we have
taken to prevent breakdowns in our information technology, telephone and other systems, sustained or repeated system failures that interrupt our ability to process test orders, deliver test results or perform testing in a timely manner or that cause
us to inadvertently disclose or lose patient information could adversely affect our business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Security breaches, loss of data and other disruptions to us or our third-party service providers could compromise sensitive information related to our
business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we and our third-party service providers collect and store sensitive data, including legally protected
health information, personally identifiable information about our patients, credit card information, intellectual property, and our proprietary business and financial information. We manage and maintain our applications and data utilizing a
combination of on-site and vendor-owned systems. We face a number of risks related to our protection of, and our service providers&#146; protection of, this critical information, including loss of access, unauthorized disclosure and unauthorized
access, as well as risks associated with our ability to identify and audit such events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The secure processing, storage, maintenance and
transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or
disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or otherwise breached due to employee error, malfeasance or other activities. While we have not experienced any such attack or breach, if
such an event were to occur, our networks would be compromised and the information we store on those networks could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information
could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology
for Economic and Clinical Health Act, or the HITECH Act, and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process tests, provide test results, bill payers or patients,
process claims and appeals, provide customer assistance services, conduct research and development activities, collect, process and prepare company financial information, provide information about our products and other patient and physician
education and outreach efforts through our website and manage the administrative aspects of our business and could damage our reputation, any of which could adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the interpretation and application of federal and state consumer, health-related and data protection laws in the United States
are often uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we
change our practices, which could adversely affect our business. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our
business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;24&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance issues, service interruptions or price increases by our shipping carrier could adversely affect
our business, results of operations and financial condition, and harm our reputation and ability to provide our specialized diagnostic services on a timely basis. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expedited, reliable shipping is essential to our operations. We rely almost exclusively on a single carrier, Federal Express Corporation, for
reliable and secure point-to-point transport of patient specimens to our laboratory and enhanced tracking of these patient specimens. Should Federal Express, or any other carrier we may use in the future, encounter delivery performance issues such
as loss, damage or destruction of a specimen, it may be difficult to replace our patient specimens in a timely manner and such occurrences may damage our reputation and lead to decreased utilization from physicians for our specialized diagnostic
services and increased cost and expense to our business. In addition, any significant increase in shipping time could adversely affect our ability to receive and process patient specimens on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or Federal Express were to terminate our relationship, we would be required to find another party to provide expedited, reliable
point-to-point transport of our patient specimens. There are only a few other providers of such nationwide transport services, and there can be no assurance that we will be able to enter into arrangements with such other providers on acceptable
terms, if at all. Finding a new provider of transport services would be time-consuming and costly and result in delays in our ability to provide our specialized diagnostic services. Even if we were to enter into an arrangement with any such
provider, there can be no assurance that they will provide the same level of quality in transport services currently provided to us by Federal Express. If any new provider does not provide, or if Federal Express does not continue to provide, the
required quality and reliability of transport services at the same or similar costs, it could adversely affect our business, reputation, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be further limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#147;ownership change&#148; (generally
defined as a greater than 50% change (by value) in its equity ownership over a three year period), the corporation&#146;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change
income may be limited. Our ability to use a portion of our net operating loss carryforwards is subject to limitation under Section&nbsp;382 as a result of a prior ownership change. If we undergo an ownership change in connection with this offering,
or as a result of subsequent shifts in our stock ownership, our ability to utilize our net operating loss carryforwards and other pre-change tax attributes could be further limited by Section&nbsp;382 and as a result, if we earn net taxable income,
our ability to use such pre-change net operating loss carryforwards and other pre-change tax attributes to offset U.S. federal taxable income may be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our term loan contains restrictions that limit our flexibility in operating our business, and if we fail to comply with the covenants and other
obligations under our loan agreement, the lenders may be able to accelerate amounts owed under the facility and may foreclose upon the assets securing our obligations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, we entered into a term loan agreement, or the loan agreement, with Capital Royalty Partners II L.P., Capital Royalty Partners
II&#151;Parallel Fund &#147;A&#148; L.P. and Parallel Investment Opportunities Partners II L.P., which we refer to collectively as Capital Royalty. The loan agreement is collateralized by substantially all of our personal property, including our
intellectual property. The loan agreement also subjects us to certain affirmative and negative covenants, including limitations on our ability to transfer or dispose of assets, merge with or acquire other companies, make investments, pay dividends,
incur additional indebtedness and liens and conduct transactions with affiliates. We are also subject to certain covenants that require us to maintain a minimum liquidity of at least $2.0 million and achieve certain minimum amounts of annual
revenue, and are required under certain conditions to make mandatory prepayments of outstanding principal. As a result of these covenants, we have certain limitations on the manner in which we can conduct our business, and we may be restricted from
engaging in favorable business activities or financing future operations or capital needs until our current debt obligations are paid in full or we obtain the consent of Capital Royalty, which we may not be able to obtain. As of June 30, 2014, there
was $15.0 million in principal outstanding under the term loan and an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;25&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional $0.3&nbsp;million outstanding representing interest at 4% per annum paid in-kind in the form of additional term loans. We are required to repay any outstanding principal and
capitalized interest in quarterly installments over a two-year period, commencing on December&nbsp;31, 2016. We cannot be certain that we will be able to generate sufficient cash flow or revenue to meet the financial covenants or pay the principal
and accrued interest on our debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, upon the occurrence of an event of default, Capital Royalty, among other things, can
declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes. An event of
default includes, but is not limited to, our failure to pay any amount due and payable under the loan agreement, the occurrence of a material adverse change in our business as defined in the loan agreement, our breach of any representation or
warranty in the loan agreement, our breach of any covenant in the loan agreement (subject to a cure period in some cases), a change in control as defined in the loan agreement, our default on any debt payments to a third party in an amount exceeding
$300,000 or any voluntary or involuntary insolvency proceeding. If an event of default occurs and we are unable to repay amounts due under the loan agreement, Capital Royalty could foreclose on substantially all of our personal property, including
our intellectual property. We cannot be certain that future working capital, borrowings or equity financings will be available to repay or refinance our debt to Capital Royalty or any other debt we may incur in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our inability to raise additional capital on acceptable terms in the future may limit our ability to develop and commercialize new solutions and
technologies and expand our operations. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect capital expenditures and operating expenses to increase over the next
several years as we expand our infrastructure, commercial operations and research and development activities. We believe, based on our current plan, that the net proceeds from this offering, together with our current cash and cash equivalents and
anticipated future product revenue, will be sufficient to meet our anticipated cash requirements over at least the next 18 months, including funding the completion of our ongoing validation studies for the products in our pipeline, and, if
successful, the potential launch of Avise Anti-TNF. However, if our available cash balances, net proceeds from this offering and anticipated future product revenue are insufficient to satisfy our liquidity requirements, including because of lower
demand for our products as a result of lower-than-expected rates of reimbursement from commercial third-party payers and government payers or if our ongoing validation studies for the products in our pipeline or our ongoing clinical studies of our
existing products take longer to complete than we currently expect or are unsuccessful, or other risks described in this &#147;Risk Factors&#148; section, we may seek to raise additional capital through equity offerings, debt financings,
collaborations or licensing arrangements. We may also consider raising additional capital in the future to expand our business, pursue strategic investments, take advantage of financing opportunities, or for other reasons. The timing and amounts of
our future capital requirements are difficult to forecast and will depend on numerous factors, including our ability to maintain and grow sales of our Avise products, as well as the costs associated with conducting clinical studies to demonstrate
the utility of our products and support reimbursement efforts; fluctuations in working capital; the costs to expand our sales and marketing capabilities; the costs of developing our product pipeline, including the costs associated with conducting
our ongoing and future validation studies; the additional costs we may incur as a result of operating as a public company and the extent to which we in-license, acquire or invest in complementary businesses or products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional funding may not be available to us on acceptable terms, or at all. In addition, our loan agreement restricts our ability to raise
funds through additional debt financings. If we raise funds by issuing equity securities, dilution to our stockholders could result, and the market price of our common stock could decline. Any equity securities issued also may provide for rights,
preferences or privileges senior to those of holders of our common stock. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive
covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our
ability to conduct our business. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;26&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required to accept unfavorable terms. These agreements may require that we relinquish or license to a third party on unfavorable terms our rights to technologies or product candidates that we
otherwise would seek to develop or commercialize ourselves, or reserve certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. If we are not able to secure additional funding when needed, we may
have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives. In addition, we may have to work with a partner on one or more of our products or market development programs, which
could lower the economic value of those programs to our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA has stated its intention to modify its enforcement discretion policy with
respect to LDTs in a risk-based manner, and we may become subject to extensive regulatory requirements and may be required to conduct additional clinical trials prior to continuing to sell our existing tests or launching any other tests we may
develop, which may increase the cost of conducting, or otherwise harm, our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July 31, 2014, the FDA notified Congress
of its intent to modify, in a risk-based manner, its policy of enforcement discretion with respect to LDTs. Our diagnostic products may become subject to FDA regulation, and we may be required to cease commercial sales of our products and conduct
additional clinical testing prior to making submissions to the FDA to obtain premarket clearance or approval. If we are required to conduct such clinical trials, delays in the commencement or completion of clinical testing could significantly
increase our test development costs and delay commercialization of any currently-marketed tests that we may be required to cease selling or the commercialization of any future tests that we may develop. Many of the factors that may cause or lead to
a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a
function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical
trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions and contract research organizations to perform the trials, and would control only certain aspects of their
activities. Nevertheless, we would be responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties would not relieve us
of our regulatory responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our third party contractors are required to comply with good clinical practices, or GCPs,
which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities for products in clinical development. Regulatory
authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any third party contractor fails to comply with applicable GCPs, the clinical data generated in clinical trials may be
deemed unreliable and the FDA, Competent Authorities of the Member States of the EEA or comparable foreign regulatory authorities may require us to perform additional clinical trials before clearing or approving our marketing applications. A failure
to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory clearance or approval process. In addition, if these parties do not successfully carry out their contractual duties or obligations or meet
expected deadlines, or if the quality, completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or
terminated. Many of these factors would be beyond our control. We may not be able to enter into replacement arrangements without undue delays or considerable expenditures. If there are delays in testing or clearances or approvals as a result of the
failure to perform by third parties, our research and development costs would increase, and we may not be able to obtain regulatory clearance or approval for our tests. In addition, we may not be able to establish or maintain relationships with
these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market our tests, or to achieve sustained profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA requires medical device manufacturers to comply with, among other things, current good manufacturing practices for medical devices,
known as the Quality System Regulation, which requires </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;27&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures during the manufacturing process; the medical device reporting regulation, which
requires that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; labeling
regulations, including the FDA&#146;s general prohibition against promoting products for unapproved or &#147;off-label&#148; uses; and the reports of corrections and removals regulation, which requires manufacturers to report to the FDA if a device
correction or removal was initiated to reduce a risk to health posed by the device or to remedy a violation of the FDCA caused by the device which may present a risk to health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we were able to obtain FDA clearance or approval for one or more of our products, if required, a product may be subject to limitations
on the indications for which it may be marketed or to other regulatory conditions. In addition, such clearance or approval may contain requirements for costly post-market testing and surveillance to monitor the safety or efficacy of the product. The
FDA has broad post-market enforcement powers, and if unanticipated problems with our products arise, or if we or our suppliers fail to comply with regulatory requirements following FDA clearance or approval, we may become subject to enforcement
actions such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on manufacturing processes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on product marketing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal or recall of products from the market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to approve pending PMAs, 510(k)s or supplements to approved PMAs or cleared 510(k)s that we submit; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, restitution or disgorgement of profits or revenue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or withdrawal of regulatory clearances or approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitation on, or refusal to permit, import or export of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory and Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare system, may have a material adverse effect on our
financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reimbursement to healthcare providers, such as specialized diagnostic service
providers like us, is subject to continuing change in policies by governmental payers, such as Medicare and Medicaid, private insurers, including managed care organizations, and other private payers, such as hospitals and private medical groups.
Statutory and regulatory changes, retroactive rate adjustments and administrative rulings, and other policy changes may be implemented with little or no prior notice, all of which could materially decrease the range of services for which we are
reimbursed or the reimbursement rates paid for our Avise products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, on April&nbsp;1, 2014, the Protecting Access to Medicare
Act of 2014, or PAMA, was signed into law, which, among other things, significantly alters the current payment methodology under the Medicare Clinical Laboratory Fee Schedule, or CLFS. Under the new law, starting January&nbsp;1, 2016 and every three
years thereafter (or annually in the case of advanced diagnostic lab tests), clinical laboratories must report laboratory test payment data for each Medicare-covered clinical diagnostic lab test that it furnishes during a time period to be defined
by future regulations. The reported data must include the payment rate (reflecting all discounts, rebates, coupons and other price concessions) and the volume of each test that was paid by each private payer
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;28&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(including health insurance issuers, group health plans, Medicare Advantage plans and Medicaid managed care organizations). Beginning in 2017, the Medicare payment rate for each clinical
diagnostic lab test will be equal to the weighted median amount for the test from the most recent data collection period. The payment rate will apply to laboratory tests furnished by a hospital laboratory if the test is separately paid under the
hospital outpatient prospective payment system. It is too early to predict the impact on reimbursement for our Avise products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also under
PAMA, the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, is required to adopt temporary billing codes to identify new tests and new advanced diagnostic laboratory tests that have been cleared or approved by the FDA. For an existing test
that is cleared or approved by the FDA and for which Medicare payment is made as of April&nbsp;1, 2014, CMS is required to assign a unique billing code if one has not already been assigned by the agency. In addition to assigning the code, CMS must
publicly report payment for the tests no later than January&nbsp;1, 2016. We cannot determine at this time the full impact of the new law on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other recent laws make changes impacting clinical laboratories, many of which have already gone into effect. The Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the ACA, enacted in March 2010, includes a reduction in the annual update factor used to adjust payments under the CLFS for inflation. This update
factor reflects the consumer price index for all urban consumers, or CPI-U, and the ACA reduces the CPI-U by 1.75% for the years 2011 through 2015. The ACA also imposes a multifactor productivity adjustment in addition to the CPI-U, which may
further reduce payment rates. In addition, each medical device manufacturer is required to pay an excise tax in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices that are listed with the FDA. Although the FDA
has contended that LDTs, such as our tests, are medical devices, none of our products are currently listed with the FDA. We cannot assure you that the tax will not be extended to services such as ours in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other significant measures contained in the ACA include, for example, coordination and promotion of research on comparative clinical
effectiveness of different technologies and procedures, initiatives to revise Medicare payment methodologies, such as bundling of payments across the continuum of care by providers and physicians, and initiatives to promote quality indicators in
payment methodologies. The ACA also includes significant new fraud and abuse measures, including required disclosures of financial arrangements with physician customers, lower thresholds for violations and increasing potential penalties for such
violations. We are monitoring the impact of the ACA in order to enable us to determine the trends and changes that may be necessitated by the legislation and that, in turn, may potentially impact our business over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select
Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction (known
as sequestration) to several government programs. This includes aggregate reductions to Medicare payments to providers of 2%&nbsp;per fiscal year, beginning April&nbsp;1, 2013, which will remain in effect through 2024 unless additional congressional
action is taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2012, the Middle Class Tax Relief and Job Creation Act of 2012 was passed, which, among other things,
reduced by 2% the 2013 Medicare CLFS, and rebased payments at the reduced rate for subsequent years. Overall, when adding this 2% reduction to the ACA&#146;s 1.75% reduction to the update factor and the productivity adjustment, the payment rates
under the CLFS declined by 2.95% and 0.75% for 2013 and 2014, respectively. This reduction does not include the additional sequestration adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, increased the statute of
limitations period for the government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative freezes and updates
affect some of our flow cytometry tests, which are reimbursed by the Medicare program under the Medicare Physician Fee Schedule, or MPFS. The schedule, which is updated on an annual basis </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;29&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
using a prescribed statutory formula, requires Congressional intervention to avoid significant reductions in reimbursement. In the past, when the application of the statutory formula resulted in
lower payments, Congress has passed interim legislation to prevent the reductions. The most recent legislative intervention was passed with PAMA, which provided for a 0.5% update from 2013 MPFS payment rates through 2014 and a 0% update from
January&nbsp;1 until April&nbsp;1, 2015. If Congress fails to intervene to prevent the negative update factor in future years, the resulting decrease in payment may adversely affect our revenue and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further with respect to the MPFS, CMS also reviews from time to time the relative value units, or RVUs, which are translated to payments rates
under the schedule for established billing codes, including flow cytometry codes that describe some of our tests. In developing the RVUs, CMS in 2013 proposed to cap RVUs at rates paid to hospitals under the Medicare hospital outpatient rule, which
would have resulted in decreases in payments to independent laboratories. CMS did not adopt the proposal for 2014 and its RVU proposals for 2015 would result in an increase in RVUs for our flow cytometry tests. CMS continues to evaluate its
proposals, however, and identified in its proposed 2015 rule at least one flow cytometry billing code as potentially incorrectly valued. We cannot predict how CMS will value RVUs in the future or whether downward changes to the MPFS RVUs, if any,
will impact our business. Any change in reimbursement that materially lowers reimbursement for our Avise products could materially affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medicare payments are significant to our business, not only because approximately 25% of the total payments we received from payers in 2013
were derived from the Medicare program, but also because other payers often use the MPFS and CLFS amounts as a benchmark to develop their payment rates. We cannot predict whether Medicare and other third-party payer reimbursement rates that mirror
Medicare&#146;s will be sufficient to make our tests commercially attractive. Moreover, some states have passed or proposed legislation that would revise reimbursement methodology for clinical laboratory payment rates under their respective Medicaid
programs. For example, in October 2011, CMS approved California&#146;s plan to reduce certain Medi-Cal payments by 10% retroactive to June&nbsp;1, 2011. In February 2012, Medi-Cal began the recoupment process, adjusting payments on new claims.
According to the California Department of Health Care Services, the cut would apply to various healthcare providers and outpatient services, including laboratory services, with exceptions for certain acute illness and physician specialties. There is
currently pending legislation in California to reverse the 10% cut in Medi-Cal provider rates. In addition, the California legislature introduced an amendment to the state Medicaid plan, which if approved by CMS could potentially apply an additional
10% reduction to laboratory payments retroactive to July&nbsp;1, 2012. CMS has requested additional information from the Medi-Cal program and has not yet issued a response to Medi-Cal&#146;s reimbursement reduction recommendation. Although recent
changes to reimbursement for laboratory tests in states outside of California have not changed the payment rate for our tests to date, we cannot be certain that state payment rates for our tests will not be affected in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also cannot predict whether future healthcare initiatives will be implemented at the federal or state level or in countries outside of the
United States in which we may do business in the future, or the effect any future legislation or regulation will have on us. Although we cannot predict the full effect of the recent legislative changes discussed above, including taxes imposed by the
ACA, cost reduction measures, the expansion in government&#146;s role in the U.S. healthcare industry and PAMA&#146;s changes to the reimbursement methodology under the CLFS, such changes individually or in the aggregate may result in decreased
profits to us and/or lower reimbursement by payers for tests, which may adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in
substantial penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on
specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations mandate specific standards in the areas of personnel qualifications, administration, and participation in
proficiency testing, patient test management, quality control, quality assurance and inspections. We have a current certificate of accreditation under CLIA to perform testing through our accreditation by CAP.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;30&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
To renew this certificate, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our clinical reference laboratory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we are required to hold a certificate of accreditation or compliance under CLIA that allows us to perform high complexity testing, we
are not required to hold a certificate of accreditation through CAP. We could alternatively maintain a certificate of accreditation from another accrediting organization or a certificate of compliance through inspection by surveyors acting on behalf
of the CLIA program. If our accreditation under CAP were to terminate, either voluntarily or involuntarily, we would need to convert our certification under CLIA to a certificate of compliance (or to a certificate of accreditation with another
accreditation organization) in order to maintain our ability to perform clinical testing and to continue commercial operations. Whether we would be able to successfully maintain operations through either of these alternatives would depend upon the
facts and circumstances surrounding termination of our CAP accreditation, such as whether any deficiencies were identified by CAP as the basis for termination and, if so, whether these were addressed to the satisfaction of the surveyors for the CLIA
program (or another accrediting organization). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with CLIA requirements can result in enforcement actions, including
the revocation, suspension, or limitation of our CLIA certificate of accreditation, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit and/or criminal penalties. We must maintain CLIA
compliance and certification to be eligible to bill for tests provided to Medicare beneficiaries. If we were to be found out of compliance with CLIA program requirements and subjected to sanctions, our business and reputation could be harmed. Even
if it were possible for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also required to maintain a license to conduct testing in California. California laws establish standards for day-to-day operation of
our clinical reference laboratory, including the training and skills required of personnel and quality control. In addition, our clinical reference laboratory is required to be licensed on a product-specific basis by New York as an out of state
laboratory and our products, as LDTs, must be approved by the New York State Department of Health, or NYDOH, on a product-by-product basis before they are offered in New&nbsp;York. Once approved, we would also be subject to periodic inspection by
the NYDOH and required to demonstrate ongoing compliance with NYDOH regulations and standards. To the extent NYDOH identified any non-compliance and we are unable to implement satisfactory corrective actions to remedy such non-compliance, the State
of New York could withdraw approval for our tests. New York law also mandates proficiency testing for laboratories licensed under New York state law, regardless of whether or not such laboratories are located in New York. Moreover, several other
states require that we hold licenses to test specimens from patients in those states. Other states may have similar requirements or may adopt similar requirements in the future. Although we have obtained licenses from states where we believe we are
required to be licensed, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have
such requirements in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we were to lose our CLIA accreditation or California license, whether as a result of a revocation,
suspension or limitation, we would no longer be able to sell our tests, which would limit our revenues and harm our business. If we were to lose our license or fail to obtain or maintain NYDOH approval for our laboratory developed tests in New York
or if we were to lose our license in other states where we are required to hold licenses, we would not be able to test specimens from those states which would limit our revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with healthcare laws and regulations, we could face substantial penalties and our business, operations and financial condition
could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our partners, including those with whom we may enter into co-promotion or co-marketing
arrangements, are also subject to healthcare fraud and abuse regulation by both the federal government and the states in which we or our partners conduct our business. These laws include, without limitation, state and federal anti-kickback,
self-referral, fraud and abuse, false claims, and physician sunshine laws and regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;31&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-kickback Statute prohibits, among other things, knowingly and willfully
offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the
purchase, lease or order of any good, facility, item or service, including laboratory services, reimbursable, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. The term &#147;remuneration&#148; has been
broadly interpreted to include anything of value. The Anti-kickback Statute has been interpreted to apply to arrangements between manufacturers on one hand and prescribers, purchasers and formulary mangers on the other. Although there are a number
of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Our practices may not in all cases meet all of the criteria for safe harbor protection
from anti-kickback liability. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor, however, does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality
of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute&#146;s intent requirement to mean that if any one purpose of an arrangement
involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated. Further, the ACA amends the intent requirement of the Federal Anti-kickback Statute and certain criminal health care
fraud statutes. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal
Anti-kickback Statute constitutes a false or fraudulent claim for purposes of the false claims laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;25, 2014, the Office of
Inspector General of the Department of Health and Human Services, or the OIG, released a Special Fraud Alert, expressing concern regarding laboratory payments made to referring physicians and physician group practices for blood specimen collection,
processing, and packaging. Specifically, the OIG expressed concern that such arrangements may implicate the Federal Anti-Kickback Statute when laboratories make payments to physicians for services that are already covered and reimbursed by Medicare,
or are not commercially reasonable or exceed fair market value, all in order to induce physicians to order tests from such laboratory. Because the choice of laboratory and the decision to order laboratory tests is made or strongly influenced by the
physician, with little or no input from patients, such payment may induce physicians to order more laboratory tests than are medically necessary, particularly when the payments are tied to, or take into account, the volume or value of business
generated by the physician. We have entered into certain arrangements with physicians for services related to specimen collection, transporting and handling. To the extent our arrangements are found to be inconsistent with applicable laws, we may be
required to restructure or discontinue such arrangements, or be subject to other significant penalties, including criminal penalties and exclusion from participation in U.S. federal or state health care programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Federal civil False Claims Act prohibits, among other things, any person from knowingly presenting or causing to be presented a false
claim for payment to the federal government, or knowingly making or causing to be made a false statement to get a false or fraudulent claim paid by the federal government. A claim includes &#147;any request or demand&#148; for money or property
presented to the U.S. government. Penalties for a Federal civil False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties of between $5,500 and $11,000 for each separate false
claim, the potential for exclusion from participation in federal healthcare programs and criminal liability. If the government were to allege that we were, or convict us of, violating these false claims laws, we could be subject to a substantial
fine and adversely affect our operations. In addition, private individuals have the ability to bring actions under these false claims laws in the name of the government alleging false and fraudulent claims presented to or paid by the government (or
other violations of the statutes) and to share in any amounts paid by the entity to the government in fines or settlement. Such suits, known as qui tam actions, have increased significantly in the healthcare industry in recent years. In addition,
the federal civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know
is for an item or service that was not provided as claimed or is false or fraudulent. The majority of states also have statutes or regulations similar to the federal anti-kickback and false </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;32&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, which prohibits, among other things,
physicians who have a financial relationship, including an investment, ownership or compensation relationship with an entity, from referring Medicare patients for designated health services, which include clinical laboratory services, unless an
exception applies. Similarly, entities may not bill Medicare or any other party for services furnished pursuant to a prohibited referral. Many states have their own self-referral laws as well, which in some cases apply to all third-party payers, not
just Medicare and Medicaid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration,
including waivers of co-payments and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#146;s selection of a particular provider, practitioner or supplier of Medicare or Medicaid
payable items or services may be liable for civil monetary penalties of up to $10,000 for each wrongful act. Moreover, in certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be
held liable under the Anti-kickback Statute and civil False Claims Act, which can impose additional penalties associated with the wrongful act. One of the statutory exceptions to the prohibition is non-routine, unadvertised waivers of copayments or
deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts. The Office of Inspector General of the Department of Health and Human Services emphasizes, however, that this exception
should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to federal healthcare program beneficiaries, the routine waivers of copayments and deductibles offered to patients
covered by commercial payers may implicate applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud. To the extent
our programs are found to be inconsistent with applicable laws, we may be required to restructure or discontinue such programs, or be subject to other significant penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA, among other things, also imposed new reporting requirements on manufacturers of certain devices, drugs and biologics for certain
payments and transfers of value by them and in some cases their distributors to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required
information timely, completely and accurately for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties of up to an aggregate of $150,000 per year (or up to an aggregate of $1.0 million per
year for &#147;knowing failures&#148;). The period between August&nbsp;1, 2013 and December&nbsp;31, 2013 was the first reporting period, and manufacturers were required to report aggregate payment data by March&nbsp;31, 2014, and to report detailed
payment data and submit legal attestation to the completeness and accuracy of such data by June&nbsp;30, 2014. Thereafter, manufacturers must submit reports by the 90th day of each subsequent calendar year. CMS will release the data on a public
website by September&nbsp;30, 2014. Any failure to comply with these reporting requirements could result in significant fines and penalties. Because we manufacture our own LDTs solely for use by or within our own laboratory, we believe that we are
exempt from these reporting requirements. We cannot assure you, however, that the government will agree with our determination, and a determination that we have violated these laws and regulations, or a public announcement that we are being
investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is
possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge, regardless of the outcome, could have a material adverse effect on our business, business relationships, reputation,
financial condition and results of operations. Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation
of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. Moreover, achieving and sustaining compliance with these laws
may prove costly. If we or our operations, or any of the healthcare providers or entities with whom we do business are found to be in violation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;33&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including administrative, civil and/or criminal penalties, damages,
fines, disgorgement, individual imprisonment, exclusion from participation in U.S. federal or state health care programs, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate
our business and our financial results. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements,
including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to comply with HIPAA, the Health Information Technology for Economic and Clinical Health Act, the HITECH Act, their implementing regulations,
and similar comparable state laws and regulations affecting the transmission, security and privacy of health information could result in significant penalties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous federal and state laws and regulations, including HIPAA and the HITECH Act, govern the collection, dissemination, security, use and
confidentiality of patient-identifiable health information. HIPAA and the HITECH Act require us to comply with standards for the use and disclosure of health information within our company and with third parties. The Standards for Privacy of
Individually Identifiable Health Information, or Privacy Standards, and the Security Standards for the Protection of Electronic Protected Health Information, or Security Standards, under HIPAA establish a set of basic national privacy and security
standards for the protection of individually identifiable health information by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities
contract for services. Notably, whereas HIPAA previously directly regulated only these covered entities, the HITECH Act, which was signed into law as part of the stimulus package in February 2009, made certain of the Security Standards directly
applicable to business associates. Further, the HITECH Act and the Final HIPAA Omnibus Rule that was promulgated in 2013, made additional parts of HIPAA directly applicable to business associates. As a result, both covered entities and business
associates are now subject to significant civil and criminal penalties for failure to comply with the Privacy Standards and/or the Security Standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA and the HITECH Act also include standards for common healthcare electronic transactions and code sets, such as claims information, plan
eligibility, payment information and the use of electronic signatures, and privacy and electronic security of individually identifiable health information. Covered entities, such as health care providers, are required to conform to such transaction
set standards, known as the Standards for Electronic Transactions, pursuant to HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA requires covered entities to develop and
maintain policies and procedures with respect to protected health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information. The HITECH Act expands the notification
requirement for breaches of patient-identifiable health information, restricts certain disclosures and sales of patient-identifiable health information and provides a tiered system for civil monetary penalties for HIPAA violations. The Final HIPAA
Omnibus Rule modifies the breach reporting standard in a manner that will likely make more data security incidents qualify as reportable breaches. The HITECH Act also increased the civil and criminal penalties that may be imposed against covered
entities, business associates and possibly other persons and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney fees and costs associated
with pursuing federal civil actions. Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not comply with the requirements of HIPAA, the HITECH Act or applicable state privacy and security laws, we could be subject to
criminal or civil sanctions that could adversely affect our financial condition. The costs of complying with privacy and security related legal and regulatory requirements are burdensome and could have a material adverse effect on our business.
These laws are subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us, as well as our physician clients. In addition, we are unable to predict what changes to the
HIPAA Privacy Standards </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;34&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Security Standards might be made in the future or how those changes could affect our business. Any new legislation or regulation in the area of privacy and security of personal information,
including personal health information, could also adversely affect our business operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to maintain intellectual property protection, our competitive position could be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to protect our technologies such as CB-CAPs, red blood cell methotrexate polyglutamates, or MTXPG, exposure assessments and
anti-MCV antibodies, affects our ability to compete and to achieve sustained profitability. We rely on a combination of U.S. and foreign patents and patent applications, copyrights, trademarks and trademark applications, and contractual restrictions
to protect our intellectual property rights. We cannot be certain that the claims in our granted patents and pending patent applications covering our Avise products will be considered patentable or enforceable by the United States Patent and
Trademark Office, or the USPTO, courts in the United States, or by patent offices and courts in foreign countries. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur
substantial litigation costs in our attempts to recover or restrict use of our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We apply for patents covering our
products and technologies and uses thereof, as we deem appropriate, however we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant
jurisdictions, or we may cease our prosecution and maintenance of patents in potentially relevant jurisdictions. Currently, we have an exclusive license to 10 issued U.S. patents, three pending U.S. patent applications, and certain corresponding
foreign counterpart patents and patent applications, relevant to our Avise products. We also own three pending U.S. patent applications, two corresponding foreign counterpart applications, and one pending international Patent Cooperation Treaty, or
PCT, application relevant to our Avise products. While we intend to pursue additional patent applications, it is possible that our pending patent applications and any future applications may not result in issued patents. Even if such patents do
successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to our patents could deprive us of exclusive
rights necessary for the further development of our Avise products. Furthermore, even if they are unchallenged, our patents may not adequately protect our intellectual property, provide exclusivity for our Avise products or prevent others from
designing around our claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We might not have been the first to make the inventions covered by each of our pending patent applications
and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings
declared by the USPTO that could result in substantial cost to us. No assurance can be given that our patent applications will have priority over other patent applications. In addition, recent changes to the patent laws of the United States allow
for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and
management distraction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality
agreements to protect proprietary know-how that is not patentable, or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our Avise products and development processes that involve proprietary
know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. While we use commercially reasonable efforts to protect our trade secrets, our licensors, employees, consultants, contractors and
other advisors may unintentionally or willfully disclose such trade secret information to third parties and competitors. We attempt to protect our proprietary technology in large part by entering into confidentiality and non-disclosure agreements
with our employees, consultants and other contractors. We cannot assure you, however, that these agreements will not be breached, that we will have adequate remedies for any breach or that competitors will not know of, or independently discover, our
trade secrets. We cannot assure you that others will not independently develop substantially equivalent proprietary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;35&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information or be issued patents that may prevent the sale of our products, technologies, services or know-how or require licensing and the payment of significant fees or royalties by us in order
to produce our products, technologies or services. Further, we cannot be certain that the steps we have taken will prevent the misappropriation of our trade secrets and other confidential information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will
be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States
may be less willing to protect trade secrets. If we are unable to prevent unauthorized material disclosure of our trade secrets and other confidential information to third parties, and in particular in jurisdictions where we have not filed for
patent protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our products utilize unpatented technology that is publicly available and can be used by our competitors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our Avise products, such as Avise SLE+CT, utilize both patented technology and publicly available technology that is not protected
by patents or other intellectual property rights. We believe that using certain publicly available technology allows us to offer a better and more comprehensive product. However, the publicly available technology which we rely upon is also used in,
and may continue to be used in, products which are competitive with our Avise products. Our competitors may independently develop competing diagnostic products and services that do not infringe our intellectual property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our Avise products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other diagnostics companies, our success is heavily dependent on intellectual property, particularly on obtaining and
enforcing patents. Obtaining and enforcing patents in the diagnostics industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. From time-to-time the U.S. Supreme Court, other
federal courts, the U.S. Congress or the USPTO, may change the standards of patentability and any such changes could have a negative impact on our business. For instance, on October&nbsp;30, 2008, the Court of Appeals for the Federal Circuit issued
a decision that methods or processes cannot be patented unless they are tied to a machine or involve a physical transformation. The U.S. Supreme Court later reversed that decision in&nbsp;<I>Bilski v. Kappos</I>, finding that the
&#147;machine-or-transformation&#148; test is not the only test for determining patent eligibility. The Court, however, declined to specify how and when processes are patentable. On March&nbsp;30, 2012, in the case&nbsp;<I>Mayo&nbsp;Collaborative
Services v.&nbsp;Prometheus&nbsp;Laboratories, Inc.</I>, the U.S. Supreme Court reversed the Federal Circuit&#146;s application of&nbsp;<I>Bilski</I>&nbsp;and invalidated a patent focused on a diagnostic process because the patent claim embodied a
law of nature. On July&nbsp;30, 2012, the USPTO released a memorandum entitled &#147;2012 Interim Procedure for Subject Matter Eligibility Analysis of Process Claims Involving Laws of Nature,&#148; with guidelines for determining patentability of
diagnostic or other processes in line with the <I>Mayo</I> decision. On June&nbsp;13, 2013, in <I>Association for Molecular Pathology v. Myriad Genetics</I>, the Supreme Court held that a naturally occurring DNA segment is a product of nature and
not patent eligible merely because it has been isolated. The Supreme Court did not address the patentability of any innovative method claims involving the manipulation of isolated genes. On March&nbsp;4, 2014, the USPTO released a memorandum
entitled &#147;2014 Procedure For Subject Matter Eligibility Analysis Of Claims Reciting Or Involving Laws Of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products.&#148; This memorandum provides guidelines for the USPTO&#146;s new
examination procedure for subject matter eligibility under 35 U.S.C. &#167;101 for claims embracing natural products or natural principles. Although the guidelines do not have the force of law, patent examiners have been instructed to follow them.
Some aspects of our technology involve processes that may be subject to this evolving standard and we cannot guarantee that any of our pending process claims will be patentable as a result of such evolving standards. In addition, patents we own or
license that issued before these recent cases may be subject to challenge in court or before the USPTO in view of these current legal standards. Changes in either the patent laws or in interpretations of patent laws in the United States or other
countries could weaken our ability to obtain new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;36&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party
patents. We may not develop additional proprietary products, methods and technologies that are patentable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our
intellectual property rights throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on our Avise products in all
countries throughout the world would be prohibitively expensive. Moreover, we believe that obtaining foreign patents may be more difficult than obtaining domestic patents because of differences in patent laws and, accordingly, our patent position
may be stronger in the United States than abroad. In addition, the laws of some foreign countries do not protect intellectual property rights in the same manner and to the same extent as laws in the United States. Various countries limit the subject
matter that can be patented and limit the ability of a patent owner to enforce patents in the medical and other related fields. This may limit our ability to obtain or utilize those patents internationally. In order to manage our foreign patent
costs and focus on the U.S. market, we made the decision to cease the prosecution and maintenance of certain of our foreign patents and patent applications related to our CB-CAPs technology, which is used in our Avise products. Consequently, we may
not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and
further, may export otherwise infringing products to territories where we have patent protection but enforcement of such patent protection is not as strong as that in the United States. These products may compete with our Avise products and our
patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have
encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade
secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our
proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being
invalidated or interpreted narrowly, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly,
our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise
experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to a number of license agreements under which we are granted intellectual property rights that are important to our business.
For example, certain patent rights related to Avise SLE are licensed from the University of Pittsburgh, certain patent rights related to Avise MCV are licensed from Orgentec, and certain patent rights related to Avise MTX are licensed from
Prometheus Laboratories Inc., or Prometheus. Our existing license agreements as related to our Avise products impose various regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail
to comply with our obligations under a license agreement, the license agreement may be terminated, in which event we would not be able to further develop or market certain Avise products. Additionally, we may not always have the first right to
maintain, enforce or defend our licensed intellectual property rights and, although we would likely have the right to assume the maintenance, enforcement and defense of such intellectual property rights if our licensors do not, our ability to do so
may be compromised by our licensors&#146; acts or omissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property rights is of critical importance to our
business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;37&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights subject to a license agreement, including the scope of rights granted under the license agreement and other interpretation-related issues, and whether and the extent to which our
technology and processes infringe on intellectual property rights of the licensor that are not subject to the licensing agreement. If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our
current licensing arrangements on acceptable terms, our business, results of operations, financial condition and prospects may be adversely affected. We may enter into additional licenses in the future and if we fail to comply with obligations under
those agreements, we could suffer adverse consequences. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various
procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
similar provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patents and/or applications are due to be paid to the USPTO and foreign patent agencies in several
stages over the lifetime of the patents and/or applications. Our outside counsel has systems in place to monitor deadlines to pay these fees and to remind us of these fees, and our outside counsel employs an outside firm to pay these fees due to the
USPTO and to foreign patent agencies based on our instructions. In the aggregate, these fees can be cost prohibitive for an early-stage company. Accordingly, we made a financially-driven decision to prioritize our payment of these fees and to allow
certain of our applications to lapse, particularly with respect to our ex-U.S. rights licensed from the University of Pittsburgh related to our CB-CAPs technology. The permanent lapse of certain of these ex-U.S. rights may result in our patent
position being stronger in the United States than abroad, such as in countries that are part of the European Patent Convention, and third parties may be able to compete more effectively against us in countries outside the United States, including in
those countries that belong to the European Patent Convention. Additionally, while an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which
noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market earlier
than should otherwise have been the case, which would have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or
maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Presently we have intellectual property rights, through licenses from third parties and under patents that we own, related to our Avise
products. Because our programs may involve additional products that require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary
rights. We may be unable to acquire or in-license proprietary rights that we identify as being necessary for our Avise products. Even if we are able to obtain a license to such proprietary rights, it may be non-exclusive, thereby giving our
competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have
greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to further develop our Avise products. More established companies may have a
competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that
would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to further develop our Avise
products, and our business, financial condition and prospects for growth could suffer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;38&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims alleging intellectual property infringement may prevent or delay our development
efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third
parties. There is a substantial amount of litigation, both within and outside the United States, involving patents and other intellectual property rights in the diagnostics industry, as well as administrative proceedings for challenging patents,
including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. The Leahy-Smith America Invents Act introduced new procedures including inter partes review and post
grant review. The implementation of these procedures bring the possibility of third party challenges to our patents and the outcome of such challenges could result in a loss or narrowing of our patent rights. In such an event, our competitors might
be able to enter the market earlier than should otherwise have been the case, which would have a material adverse effect on our business. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties,
exist in the fields in which we are developing our Avise products. As the diagnostics industry expands and more patents are issued, the risk increases that our activities related to our Avise products may give rise to claims of infringement of the
patent rights of others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that any of our current or future Avise products will not infringe existing or future
patents. Although we are not aware of any issued patents that will prevent us from marketing our Avise products, there may be patents that have already issued that a third party might assert are infringed by one of our current or future Avise
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party
patents of which we are currently unaware with claims to materials or methods of manufacture related to the use or manufacture of our Avise products. Because patent applications can take many years to issue and may be confidential for 18&nbsp;months
or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that our Avise products or our technologies may infringe, or which such third parties claim are infringed by the use of our
technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and
obtain injunctive or other equitable relief, which could effectively block our ability to further develop one or more of our Avise products. Defense of these claims, regardless of their merit, would involve substantial expenses and would be a
substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees if we are found to be willfully
infringing a third party&#146;s patents, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any
such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or development of our
Avise products. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop our Avise products, which could harm our business significantly. Even if we were
able to obtain a license, the rights may be nonexclusive, which may give our competitors access to the same intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to infringement claims against us, if third parties have prepared and filed patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO to
determine the priority of invention. Third parties may also attempt to initiate reexamination, post grant review or inter partes review of our patents in the USPTO. We may also become involved in similar proceedings in the patent offices in other
jurisdictions regarding our intellectual property rights with respect to our Avise products and technology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in proceedings to
protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third
parties may infringe, misappropriate or otherwise violate our existing patents, patents that may issue to us in the future, or the patents of our licensors that are licensed to us. To counter infringement or unauthorized
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;39&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual
property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if
we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering one of our Avise products, the defendant could counterclaim that the patent covering such Avise product is invalid and/or unenforceable. In
patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Such
proceedings could result in an invalidation of our patents. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no
invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent
protection on our Avise products. Such a loss of patent protection could have a material adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation
proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation,
there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or
developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our patents or
other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In addition, there can be no assurance that our licensors
will be willing to bring and enforce claims to prevent third parties from infringing intellectual property that is licensed to us, particularly if the affected intellectual property is less important to the licensor&#146;s business than to ours. In
such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of
third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have received confidential and proprietary information from third parties. In addition, we employ individuals
who were previously employed at other companies in our industry. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of
these third parties or our employees&#146; former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our Avise
products. We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims
challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a material adverse effect on
our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;40&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Being a Public Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs and demands on management as a result of compliance with laws and regulations applicable to public companies, which could
harm our operating results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will incur significant legal, accounting and other expenses that we did not
incur as a private company, including costs associated with public company reporting requirements. In addition, the Sarbanes-Oxley Act of 2002 and the Dodd-Frank Wall Street Reform and Protection Act, as well as rules implemented by the Securities
and Exchange Commission and The NASDAQ Stock Market, impose a number of requirements on public companies, including with respect to corporate governance practices. Our management and other personnel will need to devote a substantial amount of time
to these compliance and disclosure obligations. Moreover, these rules and regulations will increase our legal, accounting and financial compliance costs and will make some activities more time-consuming and costly. We also expect that it will be
more expensive for us to obtain director and officer liability insurance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to implement and maintain effective internal control
over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will be required to maintain internal control over financial reporting and to report any material weaknesses in such
internal control. Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 requires that we evaluate and determine the effectiveness of our internal control over financial reporting and, beginning with our second annual report following this offering,
which will be for our year ending December&nbsp;31, 2015, provide a management report on the internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we have a material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our
consolidated financial statements may be materially misstated. We are in the process of compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section&nbsp;404 of the Sarbanes-Oxley Act. We may
not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, our
management will be unable to conclude that our internal control over financial reporting is effective. Moreover, when we are no longer an emerging growth company, our independent registered public accounting firm will be required to issue an
attestation report on the effectiveness of our internal control over financial reporting. Even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm may
conclude that there are material weaknesses with respect to our internal controls or the level at which our internal controls are documented, designed, implemented or reviewed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to assert that our internal control over financial reporting is effective, or when we are no longer an emerging growth
company, if our independent registered public accounting firm were to express an adverse opinion on the effectiveness of our internal control over financial reporting because we had one or more material weaknesses, investors could lose confidence in
the accuracy and completeness of our financial disclosures, which could cause the price of our common stock to decline. Internal control deficiencies could also result in a restatement of our financial results in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future
that may cause us to fail to meet our reporting obligations or result in material misstatements of our consolidated financial statements. If we fail to remediate one or more of our material weaknesses or if we fail to establish and maintain
effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is a process designed to provide reasonable assurance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;41&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. generally accepted accounting principles. A material weakness is a deficiency,
or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the completion of this offering, we have been a private company with limited accounting personnel and other resources to address
our internal control over financial reporting. During the course of preparing for this offering, we determined that material adjustments to various accounts were necessary, which required us to restate the financial statements as of and for the
years ended December&nbsp;31, 2012, which had been previously audited by another independent audit firm, and December 31, 2013. The adjustments leading to the restatements of those financial statements led us to conclude that we had a material
weakness in internal control over financial reporting as of December&nbsp;31, 2012 and 2013 as follows: We did not maintain a sufficient complement of resources with an appropriate level of accounting knowledge, experience and training commensurate
with our structure and financial reporting requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of our remediation plan and the actions that we have executed
during 2014, see &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Controls and Procedures.&#148; The actions we have taken are subject to continued review, supported by confirmation and testing by
management as well as audit committee oversight. While we have implemented a plan to remediate this weakness we cannot assure you that we will be able to remediate this weakness, which could impair our ability to accurately and timely report our
financial position, results of operations or cash flows. If we are unable to successfully remediate this material weakness, and if we are unable to produce accurate and timely financial statements, our stock price may be adversely affected and we
may be unable to maintain compliance with applicable stock exchange listing requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our failure to remediate the material weakness
identified above, or the identification of additional material weaknesses in the future, could adversely affect our ability to report financial information, including our filing of quarterly or annual reports with the Securities and Exchange
Commission on a timely and accurate basis. Moreover, our failure to remediate the material weakness identified above or the identification of additional material weaknesses, could prohibit us from producing timely and accurate consolidated financial
statements, which may adversely affect our stock price and we may be unable to maintain compliance with exchange listing requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an
emerging growth company and may elect to comply with reduced public company reporting requirements applicable to emerging growth companies, which could make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act, or the JOBS Act, enacted in April 2012, and, for as
long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies, including, but not limited to, reduced disclosure obligations regarding
executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously
approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended
transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an &#147;emerging growth company&#148; can delay the
adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we are choosing to opt out of such extended transition period, and as a result, we will comply with new or revised accounting
standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section&nbsp;107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or
revised accounting standards is irrevocable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;42&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could remain an emerging growth company for up to five years, or until the earliest of
(i)&nbsp;the last day of the first fiscal year in which our annual gross revenues exceed $1.0 billion, (ii)&nbsp;the date that we become a &#147;large accelerated filer&#148; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as
amended, or the Exchange Act, which would occur if, among other things, the market value of common equity securities held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or
(iii)&nbsp;the date on which we have issued more than $1.0 billion in nonconvertible debt during the preceding three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
cannot predict whether investors will find our common stock less attractive if we choose to rely on one or more of these exemptions. If some investors find our common stock less attractive as a result of any decisions to reduce future disclosure,
there may be a less active trading market for our common stock and our stock price may be more volatile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering and Our Common
Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price may be volatile, and you may not be able to sell shares of our common stock at or above the price you paid. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock, and an active public market for our stock may not develop or be
sustained after this offering. We and the representatives of the underwriters will determine the initial public offering price of our common stock through negotiation. This price will not necessarily reflect the price at which investors in the
market will be willing to buy and sell our stock following this offering. In addition, the trading price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in response to various
factors, some of which are beyond our control. These factors include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated variations in our and our competitors&#146; financial condition and results of operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or our competitors of new products, strategic partnerships or capital commitments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in reimbursement by current or potential payers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issuance of new securities analysts&#146; reports or changed recommendations for our stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated changes in regulatory oversight of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning our intellectual property or other proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">commencement of, or our involvement in, litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announced or completed acquisitions of businesses or technologies by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any major change in our management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcement or expectation of additional financing efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">future sales of our common stock by our executive officers, directors and other stockholders; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic conditions and slow or negative growth of our markets. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the
stock market in general, and the market for stock of life sciences companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies.
Broad market and industry factors, as well as general economic, political and market conditions such as recessions or interest rate changes, may seriously affect the market price of our common stock, regardless of our actual operating performance.
These fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. If the market price of our common stock after this offering does not exceed the initial public offering price, you may not realize
any return on your investment in us and may lose some or all of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;43&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the past, following periods of volatility in the overall market and the market
price of a particular company&#146;s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our
management&#146;s attention and resources. Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts issue an adverse opinion regarding our stock or do not publish research or reports about our company, our stock price
and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will depend in part on the research and reports that
equity research analysts publish about us and our business. Currently, we do not have any analyst coverage and we may not obtain analyst coverage in the future. In the event we obtain analyst coverage, we would not have any control over such
analysts or the content and opinions included in their reports. Securities analysts may elect not to provide research coverage of our company after the completion of this offering, and such lack of research coverage may adversely affect the market
price of our common stock. The price of our common stock could also decline if one or more equity research analysts downgrade our common stock or if those analysts issue other unfavorable commentary or cease publishing reports about us or our
business. If one or more equity research analysts cease coverage of our company, we could lose visibility in the market, which in turn could cause our stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of shares by existing stockholders could cause our stock price to decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the
lock-up and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline. Based on the number of shares of common stock outstanding as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014, upon the completion of this offering, we will have outstanding a total of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, assuming the net exercise of all outstanding warrants we issued in 2013, or the 2013 Warrants, no exercise of the underwriters&#146; over-allotment
option and no exercise of outstanding options or warrants (other than the 2013 Warrants). Of these shares, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will be freely tradable, without restriction, in the public market
immediately after the offering. Each of our directors and officers and substantially all of our other stockholders has entered into a lock-up agreement with the underwriters described in &#147;Underwriting&#148; elsewhere in this prospectus, which
restricts their ability to sell or transfer their shares. The lock-up agreements pertaining to this offering will expire 180&nbsp;days from the date of this prospectus. The underwriters, however, may, in their sole discretion, waive the contractual
lock-up prior to the expiration of the lock-up agreements. After the lock-up agreements expire, based on shares outstanding as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014, up to an
additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock will be eligible for sale in the public market, of which &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares are
held by directors, executive officers and other affiliates and will be subject to volume limitations under Rule&nbsp;144 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that are subject to outstanding
options as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 will become eligible for sale in the public market to the extent permitted by the provisions of various option agreements, the
lock-up agreements and Rules&nbsp;144 and 701 under the Securities Act. We intend to file&nbsp;a registration statement on Form&nbsp;S-8 under the Securities Act covering all of the shares of common stock subject to options outstanding and reserved
for issuance under our employee benefit plans. This registration statement will become effective immediately upon filing, and shares covered by this registration statement will be eligible for sale in the public markets, subject to Rule&nbsp;144
limitations applicable to affiliates, the terms of the applicable plan and the option agreements entered into with option holders, and any lock-up agreements described above. In addition, our directors and executive officers may establish programmed
selling plans under Rule 10b5-1 of the Exchange Act for the purpose of effecting sales of our common stock. Any sales of securities by these stockholders, or the perception that those sales may occur, including the entry into such programmed selling
plans, could have a material adverse effect on the trading price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the holders of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock and holders of warrants to purchase an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock will be
entitled to rights with respect to registration of such shares under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;44&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Securities Act pursuant to an investors&#146; rights agreement between such holders and us. See &#147;Certain Relationships and Related Person Transactions&#151;Investors&#146; Rights
Agreement&#148; below. If such holders, by exercising their registration rights, sell a large number of shares, they could adversely affect the market price for our common stock. If we file a registration statement for the purpose of selling
additional shares to raise capital and are required to include shares held by these holders pursuant to the exercise of their registration rights, our ability to raise capital may be impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Insiders have substantial control over us and will be able to influence corporate matters. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, our existing stockholders, directors, executive officers and their affiliates will beneficially own, in the
aggregate, approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding shares of common stock, and if the underwriters&#146; option to purchase additional shares is exercised in full, such persons and their affiliates will
beneficially own, in the aggregate, approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding shares of common stock. As a result, these stockholders will be able to exercise significant influence over all matters requiring
stockholder approval, including the election of directors and approval of significant corporate transactions, such as a merger or other sale of our company or its assets. This concentration of ownership could limit stockholders&#146; ability to
influence corporate matters and may have the effect of delaying or preventing a third party from acquiring control over us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover
provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management and
limit the market price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our amended and restated certificate of incorporation and amended and
restated bylaws, which will become effective upon the completion of this offering, may have the effect of delaying or preventing a change of control or changes in our management. Some of these provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize our board of directors to issue, without further action by the stockholders, up to 10,000,000 shares of undesignated preferred stock and up to approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of authorized but unissued shares of common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">specify that special meetings of our stockholders can be called only by our board of directors, the Chairman, the Chief Executive Officer or the President; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish that our board of directors is divided into three classes, Class&nbsp;I, Class&nbsp;II and Class&nbsp;III, with each class serving staggered terms; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that our directors may be removed only for cause; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that vacancies on our board of directors may, except as otherwise required by law, be filled only by a majority of directors then in office, even if less than a quorum. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which limits the ability of
stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make
it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest
involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or
prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;45&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management will have discretion in the use of the net proceeds from this offering and may not use them
in a way which increases the value of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering as follows:
(1)&nbsp;to fund selling and marketing activities, including expansion of our sales force to support the ongoing commercialization of our current products and future products; (2)&nbsp;to fund research and development activities, including continued
expansion of our Avise product portfolio, as well as clinical studies to demonstrate the utility of our Avise products and support reimbursement efforts; (3)&nbsp;to fund capital expenditures, including lab infrastructure and information systems;
and (4)&nbsp;for working capital and other general corporate purposes, as outlined in &#147;Use of Proceeds&#148; elsewhere in this prospectus. The amounts and timing of our actual expenditures will depend on numerous factors, including the timing
and amount of our cash receipts from the sale of our products, the development efforts for our products and diagnostic solutions and other factors described in this &#147;Risk Factors&#148; section, as well as the amount of cash used in our
operations. We therefore cannot predict with certainty the amount of net proceeds to be used for the purposes described above. The costs and timing of the expansion of our sales and marketing capabilities and the conduct of our research and
development activities are highly uncertain, subject to substantial risks and can often change. Depending on the outcome of these activities, our plans and priorities may change, and we may apply the net proceeds from this offering differently than
we currently anticipate. For example, if our research and development of new testing solutions require more time or resources than we currently anticipate or if we encounter unforeseen difficulties in securing reimbursement for our Avise products,
we may allocate additional proceeds of this offering to our research and development efforts. If our research and development efforts progress faster than we currently expect, or if our sales and marketing needs expand faster than we currently
expect, we may elect to reallocate a portion of the proceeds of this offering from research and development to sales and marketing activities to support the launch and commercialization of our new and existing products. In addition, in the event we
identify other opportunities that we believe are in the best interests of our stockholders, we may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products, although we have no current
commitments or obligations to do so. As a result, our management will have considerable discretion in the application of the net proceeds from this offering and investors will be relying on the judgment of our management regarding the application of
those proceeds. Our management may spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock, and you will not have the opportunity to influence management&#146;s decisions on how to use the
proceeds from this offering. Our failure to apply these funds effectively could have a material adverse effect on our business, delay the development of new tests and cause the price of our common stock to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purchasers in this offering will experience immediate and substantial dilution in the book value of their investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price of our common stock is substantially higher than the net tangible book value per share of our common stock
immediately after this offering. Therefore, if you purchase our common stock in this offering, you will incur an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in net tangible book value per share from the price you paid,
based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus. In addition, new investors who purchase shares in this
offering will contribute approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the total amount of equity capital raised by us through the date of this offering, but will only own approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding equity capital. The
exercise of outstanding options and warrants will result in further dilution. In addition, if we raise additional funds by issuing equity securities, our stockholders may experience further dilution. For a detailed description of the dilution that
you will experience immediately after this offering, see &#147;Dilution.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never paid dividends on our capital stock, and we do not
anticipate paying dividends in the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our common stock and
do not intend to pay any cash dividends in the foreseeable future. We currently intend to retain any future earnings to fund the growth of our business. In addition, our loan agreement restricts our ability to pay cash dividends on our common stock
and we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;46&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any determination to pay
dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem
relevant. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If an active,
liquid trading market for our common stock does not develop, you may not be able to sell your shares quickly or at or above the initial offering price. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has not been a public market for our common stock. An active and liquid trading market for our common stock may not develop or be
sustained following this offering. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market
value of your shares. An inactive market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration. You
may not be able to sell your shares quickly or at or above the initial offering price. The initial public offering price will be determined by negotiations with the representatives of the underwriters. This price may not be indicative of the price
at which our common stock will trade after this offering, and our common stock could trade below the initial public offering price.<I> </I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;47&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus,
including statements regarding our future results of operations and financial position, business strategy, current and future product offerings, reimbursement and coverage, research and development costs, timing and likelihood of success and plans
and objectives of management for future operations are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be
materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some
cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148;
&#147;project,&#148; &#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. The forward-looking
statements in this prospectus are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial
condition and results of operations. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described under the sections in this prospectus entitled
&#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our
forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge
from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a
result of any new information, future events, changed circumstances or otherwise. The forward-looking statements contained in this prospectus are excluded from the safe harbor protection provided by the Private Securities Litigation Reform Act of
1995 and Section&nbsp;27A of the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus also contains estimates and other statistical data
made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition,
projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;48&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>We estimate that the net proceeds to us from the sale of the common stock that we are offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million (or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their over-allotment option to purchase additional shares in full), assuming an initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range listed on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase (decrease) the net proceeds to us from this offering by
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase (decrease) of 1.0&nbsp;million in the number of shares we are offering would increase (decrease) the net
proceeds to us from this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the assumed
initial public offering price stays the same. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal purposes of this offering are to obtain additional capital to support
our operations, to create a public market for our common stock and to facilitate our future access to the public equity markets. Our estimated use of the net proceeds from this offering are as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million for selling and marketing activities, including expansion of our sales force to support the ongoing commercialization of our current products and
future products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million for research and development activities, including continued expansion of our Avise product portfolio, as well as clinical studies to demonstrate
the utility of our Avise products and support reimbursement efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million for capital expenditures, including lab infrastructure and information systems; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the remaining proceeds for working capital and other general corporate purposes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe,
based on our current operating plan, that the net proceeds from this offering and our existing cash and cash equivalents and anticipated future product revenue, will be sufficient to fund our operations for at least the next 18 months, including
funding the completion of our ongoing validation studies for the products in our pipeline, and, if successful, the potential launch of Avise Anti-TNF. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts and timing of our actual expenditures will depend on numerous factors, including the timing and amount of our cash receipts from
the sale of our products, the development efforts for our products and diagnostic solutions and other factors described under &#147;Risk Factors&#148; in this prospectus, as well as the amount of cash used in our operations. We therefore cannot
predict with certainty the amount of net proceeds to be used for the purposes described above. The costs and timing of the expansion of our sales and marketing capabilities and the conduct of our research and development activities are highly
uncertain, subject to substantial risks and can often change. Depending on the outcome of these activities, our plans and priorities may change, and we may apply the net proceeds from this offering differently than we currently anticipate. For
example, if our research and development of new testing solutions require more time or resources than we currently anticipate or if we encounter unforeseen difficulties in securing reimbursement for our Avise products, we may allocate additional
proceeds of this offering to our research and development efforts. If our research and development efforts progress faster than we currently expect, or if our sales and marketing needs expand faster than we currently expect, we may elect to
reallocate a portion of the proceeds of this offering from research and development to sales and marketing activities to support the launch and commercialization of our new and existing products. In addition, in the event we identify other
opportunities that we believe are in the best interests of our stockholders, we may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products, although we have no current commitments or
obligations to do so. As a result, we will have broad discretion in the application of the net proceeds. Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing
obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;49&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation
of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition,
results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. In addition, our ability to pay cash dividends is
currently prohibited by the terms of our term loan agreement with Capital Royalty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;50&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents, and our capitalization as of June&nbsp;30, 2014 as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an actual basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma basis to reflect (1)&nbsp;the issuance of $4.0 million in aggregate principal amount of 2014 Notes in July 2014 and the automatic conversion of the 2014 Notes (including accrued interest thereon) into
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 (the expected closing date of this offering), (2)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock as of June 30,
2014 into 92,330,247 shares of common stock immediately prior to the completion of this offering and the resultant reclassification of our redeemable convertible preferred stock warrant liability to stockholders&#146; deficit in connection with such
conversion, (3)&nbsp;the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock as a result of the expected net exercise of the 2013 Warrants in connection with the
completion of this offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, which 2013 Warrants
will terminate if not exercised prior to the completion of this offering, and (4)&nbsp;the filing of our amended and restated certificate of incorporation immediately prior to the completion of this offering; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma as adjusted basis to give further effect to our issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this
offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma and pro forma as adjusted
information below is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this
information in conjunction with our consolidated financial statements and the related notes included in this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section and other
financial information contained in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Actual&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Pro&nbsp;Forma&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B><br><B>&nbsp;&nbsp;&nbsp;&nbsp;As&nbsp;Adjusted(1)&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Borrowings and capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.001 par value per share; 145,000,000 shares authorized; 92,330,247 shares issued and
outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Preferred stock, $0.001 par value per share;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized; no shares outstanding, actual, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Common stock, $0.001 par value per share; 163,000,000 shares authorized, 9,976,964 shares issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized; pro forma and pro forma as adjusted;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81,847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;51&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus,
would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, total stockholders&#146; deficit and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number
of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of
1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price per share would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, total stockholders&#146; deficit
and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares in the
table above excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">8,671,470 shares of common stock issuable upon exercise of stock options outstanding as of June 30, 2014, at a weighted average exercise price of $0.16 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon the exercise of outstanding warrants as of June 30, 2014, at
a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which warrants will terminate upon the completion of this offering if not previously exercised; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock reserved for future issuance under our 2014 incentive award plan, or the 2014 plan, which will
become effective on the business day prior to the public trading date of our common stock (including 8,646,496 shares of common stock reserved for future grant or issuance under our 2013 stock option plan as of June 30, 2014, which shares will be
added to the shares reserved under the 2014 plan upon its effectiveness); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for future issuance under our 2014 employee stock purchase plan, which will become
effective on the business day prior to the public trading date of our common stock. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;52&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference
between the initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2014, we had a historical net tangible book value (deficit) of $(37.2) million, or $(3.73) per share of common stock. Our
historical net tangible book value (deficit) per share represents total tangible assets less total liabilities, divided by the number of shares of common stock outstanding at June 30, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On a pro forma basis, after giving effect to (1)&nbsp;the issuance of $4.0 million in aggregate principal amount of 2014 Notes in July 2014
and the automatic conversion of the 2014 Notes (including accrued interest thereon) into shares of our common stock in connection with the completion of this offering, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 (the expected closing date of this offering), (2)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock as of
June&nbsp;30, 2014 into 92,330,247 shares of our common stock immediately prior to the completion of this offering and the resultant reclassification of our redeemable convertible preferred stock warrant liability to stockholders&#146; equity in
connection with such conversion, and (3)&nbsp;the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock as a result of the expected net exercise of the 2013 Warrants in
connection with the completion of this offering, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, which
2013 Warrants will terminate if not exercised prior to the completion of this offering, our pro forma net tangible book value (deficit) as of June 30, 2014 would have been approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving further effect to the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock that we are offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, and after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June 30, 2014 would have been approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This amount represents an immediate increase in pro forma net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to our existing stockholders and an immediate dilution in pro forma net tangible book value of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to new
investors purchasing shares of common stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors is determined by subtracting pro forma
as adjusted net tangible book value per share after this offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution (without giving effect to any exercise by the underwriters of
their option to purchase additional shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of June 30, 2014</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in historical net tangible book value per share attributable to the pro forma transactions described in the
preceding paragraphs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of June 30, 2014</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;53&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjusted net tangible book value per share after this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and dilution in pro forma net tangible book value per share to
new investors by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting
discounts and commissions and the estimated offering expenses payable by us. Each increase (decrease) of 1.0 million shares in the number of shares offered by us would increase (decrease) our pro forma as adjusted net tangible book value per share
after this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and decrease (increase) the dilution to investors participating in this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share, assuming that the assumed initial public offering price remains the same, and after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their over-allotment option to purchase additional shares of our common stock in full in this offering, the pro
forma as adjusted net tangible book value after the offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the increase in pro forma net tangible book value per share to existing stockholders would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and the dilution per share to new investors would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, in each case assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes on the pro forma as adjusted basis described above, as of June 30, 2014, the differences between the number of
shares purchased from us, the total consideration paid to us in cash and the average price per share paid by existing stockholders for shares issued prior to this offering and the price to be paid by new investors in this offering. The calculation
below is based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of the prospectus, before deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Price</B><br><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing tables and calculations exclude: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">8,671,470 shares of common stock issuable upon exercise of stock options outstanding as of June 30, 2014, at a weighted average exercise price of $0.16 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon the exercise of outstanding warrants as of June 30, 2014, at
a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which warrants will terminate upon the completion of this offering if not previously exercised; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock reserved for future issuance under our 2014 incentive award plan, or the 2014 plan, which will
become effective on the business day prior to the public trading date of our common stock (including 8,646,496 shares of common stock reserved for future grant or issuance under our 2013 stock option plan as of June 30, 2014, which shares will be
added to the shares reserved under the 2014 plan upon its effectiveness); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for future issuance under our 2014 employee stock purchase plan, which will become
effective on the business day prior to the public trading date of our common stock . </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent any outstanding options
or warrants are exercised, there will be further dilution to new investors. If all of such outstanding options and warrants had been exercised as of June 30, 2014, the pro forma as adjusted net tangible book value per share after this offering would
be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and total dilution per share to new investors would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;54&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their over-allotment option to purchase additional shares of our
common stock in full: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the percentage of shares of common stock held by existing stockholders will decrease to approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares held by new investors will increase to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the total
number of shares of our common stock outstanding after this offering. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;55&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_8"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth selected consolidated historical financial data as of, and for the periods ended on, the dates indicated. We
have derived the consolidated statements of operations data for the years ended December&nbsp;31, 2012 and 2013 and the consolidated balance sheet data as of December&nbsp;31, 2012 and 2013 from our audited consolidated financial statements included
elsewhere in this prospectus. The consolidated statements of operations data for the six months ended June 30, 2013 and 2014 and the consolidated balance sheet data as of June&nbsp;30, 2014 have been derived from our unaudited consolidated financial
statements included elsewhere in this prospectus and have been prepared on the same basis as the audited consolidated financial statements. In the opinion of our management, the unaudited data reflects all adjustments, consisting of normal and
recurring adjustments, necessary for the fair statement of results as of and for these periods. You should read this data together with our audited consolidated financial statements and related notes included elsewhere in this prospectus and the
section in this prospectus entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results for any prior period are not indicative of our future results. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7.5pt">
<TD ROWSPAN="2" VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended</B><br><B>June 30,</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and&nbsp;per share data) </B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">3,055</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cost of revenue (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">1,974</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">2,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">5,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">6,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">1,055</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">214</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">214</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Change in fair value of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">1,265</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">7,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">12,199</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(6,826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(9,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,393</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(463</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Loss on extinguishment of 2013 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(3,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(7,282</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(13,454</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(7,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(13,496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(18,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,789</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net income (loss) per share attributable to common stockholders&#151;basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt"> 0.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(1.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (0.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Weighted average shares used to compute net income (loss) per share attributable to common stockholders&#151;basic and
diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">6,501,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">9,856,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,786,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,949,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders&#151;basic and diluted (unaudited)(1)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Weighted average shares used to compute pro forma net loss per share attributable to common stockholders&#151;basic and diluted
(unaudited)(1)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>See Note 4 to our consolidated financial statements included elsewhere in this prospectus for an explanation of the method used to calculate the historical net income
(loss) and the historical and pro forma net income (loss) per share attributable to common stockholders, basic and diluted, and the number of shares used in the computation of these per share amounts. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;56&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>June&nbsp;30,</B><br><B>2014</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD COLSPAN="9" VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital (deficit)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital lease obligations, long term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Working capital (deficit) represents the difference between current assets and current liabilities as follows for the periods included: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>June&nbsp;30,</B><br><B>2014</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Working capital (deficit)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;57&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations
together with our consolidated financial statements and the related notes and other financial information included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this
prospectus, including information with respect to our plans and strategy for our business and future financial performance, includes forward-looking statements that are based on current beliefs, plans and expectations and involve risks,
uncertainties and assumptions. You should review the &#147;Risk Factors&#148; section of this prospectus for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the
forward-looking statements contained in the following discussion and analysis. Please also see the section of this prospectus entitled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a commercial-stage
diagnostics company committed to addressing the significant unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. These chronic diseases can cause lifelong inflammation in the joints, tissues and
internal organs, resulting in serious complications, such as irreversible organ damage. Untreated chronic inflammation can also lead to premature hardening of the arteries, heart attacks and strokes. The accurate, timely and differential diagnosis
for patients suffering from the approximately 30&nbsp;autoimmune rheumatic diseases, or ARDs, is critical as treatment for each disease can vary, and inappropriate or delayed therapy may expose patients to unnecessary risks or the hazards of
uncontrolled disease activity. Physicians face significant difficulties in making a definitive diagnosis of a specific ARD because patients with different diseases often present with a common set of symptoms. We currently market four products under
our Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. We processed approximately 9,300 patient specimens for our lead diagnostic product line, Avise SLE, in 2013 and approximately 11,100 in
the first six months of 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is estimated that 11&nbsp;million adults in the United States suffer from ARDs, including Rheumatoid
Arthritis, or RA, Systemic Lupus Erythematosus, or SLE, Sj&ouml;gren&#146;s syndrome, scleroderma, and Mixed Connective Tissue Disease, or MCTD. In addition, patients afflicted with fibromyalgia, a chronic neurologic disorder, or autoimmune thyroid
disease have many of the same clinical symptoms as patients with ARDs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagnosis and treatment of ARDs is generally provided by the
community rheumatologist, a sub-specialty of internal medicine which includes approximately 3,500 physicians in the United States. Patients often present to a rheumatologist after a lengthy referral process because of the similarity and overlap of
symptoms among ARDs, the waxing and waning of these symptoms and the shortcomings of current diagnostic tests. Establishing a definitive diagnosis is often difficult and can take years. Throughout this time, patients may continue to suffer from the
debilitating effects of their disease, receive inappropriate treatments and may face a significant financial burden. As a result, physicians strive to make an accurate diagnosis in a timely manner, especially for more serious ARDs, such as SLE,
which can be life threatening. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We market and sell our solutions to community rheumatologists with our approximately 30 person sales
force. Reimbursement for our testing services comes from several sources, including commercial third-party payers, such as insurance companies and health maintenance organizations, government payers, such as Medicare, and patients. Reimbursement
rates vary by product and payer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception we have devoted substantially all our efforts developing and marketing products for the
diagnosis, prognosis and monitoring of ARDs. Our revenues increased from $0.9 million in 2012 to $3.1 million in 2013, or 230%. We have never been profitable and, as of June 30, 2014, had an accumulated deficit of $81.8&nbsp;million. We incurred net
losses of $7.3 million, $13.5&nbsp;million and $7.6&nbsp;million in the years ended </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;58&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&nbsp;31, 2012 and 2013 and for the six months ended June 30, 2014, respectively. As of June 30, 2014, we had cash and cash equivalents of $6.1 million. In its report on our consolidated
financial statements for the year ended December 31, 2013, our independent registered public accounting firm included an explanatory paragraph expressing substantial doubt regarding our ability to continue as a going concern. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We derive our revenue from the sale of our Avise products, most of which is attributable to our Avise SLE+CT test. We primarily market our
products to rheumatologists and their physician assistants. The healthcare professionals who order our tests and to whom results are reported are generally not responsible for payment for these services. The parties that pay for these services, or
payers, consist of commercial third-party payers, government payers, and patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2014, substantially all of our revenue
is recognized upon the earlier of payment notification, if applicable, or cash receipt. In those instances where payment notification is received in advance of the cash receipt, the notification received from third-party payers is generally received
no more than one business day in advance of the cash receipt. Our service is completed upon the delivery of test results to the prescribing physician, which triggers billing for the service. Because the timing and amount of cash payments received is
difficult to predict, we expect that our revenue could fluctuate significantly in any given quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to increase our revenue
will depend on our ability to further penetrate the market for our current and any future products, and increase our reimbursement and collection rates for tests performed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue
represents the expenses associated with obtaining and testing patient specimens. The components of our cost of revenue include materials costs, direct labor, equipment and infrastructure expenses associated with testing specimens, shipping charges
to transport specimens, blood specimen collections fees, royalties, depreciation and allocated overhead, including rent and utilities. Costs associated with performing tests are recorded as the test is processed regardless of whether and when
revenue is recognized with respect to that test. Because we currently recognize substantially all of our revenue upon cash receipt, the costs of our tests are often recognized in advance of any associated revenues. As a result, our cost of revenue
as a percentage of revenue may vary significantly from period to period because we generally do not recognize the corresponding revenue in the period in which the associated costs are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect cost of revenue in absolute dollars to increase as the number of tests we perform increases. However, we expect that the cost per
test will decrease over time due to volume discounts on materials and shipping costs and other volume efficiencies we may gain as the number of tests we perform increases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses consist of personnel costs, including stock-based compensation expense, direct marketing expenses,
accounting and legal expenses, consulting costs, and allocated overhead including rent, information technology, depreciation and utilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our selling, general and administrative expenses will increase in absolute dollars in future periods as we expand our sales
and sales support functions. We also expect our selling, general and administrative expenses will increase as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the Securities and
Exchange Commission, additional insurance expenses, investor relations activities and other administrative and professional services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;59&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses include costs incurred to develop our technology, products and product candidates, collect clinical specimens
and conduct clinical studies to develop and support our products and product candidates. These costs consist of personnel costs, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with
setting up and conducting clinical studies and allocated overhead including rent and utilities. We expense all research and development costs in the periods in which they are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses will increase in absolute dollars, potentially significantly, in future periods as we continue
to invest in research and development activities related to our existing products and product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amortization of Intangible Assets
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets represents the total amortization expense for our purchased technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our amortization of intangible assets in absolute dollars to remain relatively constant over the next several years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value of Acquisition-Related Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc., or Cypress, in 2010, we are required to pay
an additional amount not to exceed $9.2&nbsp;million in the event specified revenue, contractual and product launch milestones are achieved. The fair value of this contingent consideration is determined at the end of each reporting period based on
probabilities assigned to the milestones being achieved, and interest rates. Changes in fair value are recorded in the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense
consists of cash and non-cash interest expense associated with our financing arrangements, including the borrowings under our term loan agreement with Capital Royalty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense will likely increase in absolute dollars over current levels for the next several years due to the draws we made under our
term loan agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Loss on Extinguishment of 2013 Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2013, we converted previously outstanding convertible promissory notes into shares of our Series D redeemable convertible preferred stock.
Loss on extinguishment of 2013 Notes represents the difference in the carrying amount of the convertible promissory notes and the fair value of the shares of Series D redeemable convertible preferred stock issued upon conversion of the notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense), Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other
income (expense), net consists primarily of changes in the measurement of the value of the liability associated with outstanding warrants exercisable for shares of our Series&nbsp;D redeemable convertible preferred stock, and in 2013, changes in the
value of an embedded derivative recorded in connection with then-outstanding convertible promissory notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding warrants to
purchase shares of our Series D redeemable convertible preferred stock are expected to be exercised in connection with this offering, or they will terminate, and will no longer be subject to measurement once exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;60&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income taxes include federal and state income taxes in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Management Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are
based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily
apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our
historical and future performance, as these policies relate to the more significant areas involving management&#146;s judgments and estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenues
are derived from sales of our diagnostic, prognostic and monitoring products. We primarily market our testing services to rheumatologists and their physician assistants. The healthcare professionals who order our products and to whom test results
are reported are generally not responsible for payment for these products. The parties that pay for these services consist of commercial third-party payers, Medicare and other government payers, and patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue when the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or
services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our service is completed
upon the delivery of test results to the prescribing physician which triggers billing for the service. We recognize revenue related to billings to third-party payers on an accrual basis, net of contractual adjustments, only when we have established
pricing with our third-party payers as indicated by contractual pricing arrangements or predictable patterns of payments for our services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of a predictable pattern of reimbursement or a contract with a third-party payers, revenue is recognized upon the earlier of
payment notification, if applicable, or cash receipt. In those instances where payment notification is received in advance of the cash receipt, the notification received from third-party payers is generally received no more than one business day in
advance of the cash receipt. We currently recognize revenue on a cash basis from sales of our products. The assessment of the fixed or determinable nature of the fees charged and the collectability of those fees requires significant judgment by
management. Accordingly, we expect to recognize revenue on a cash basis until we have sufficient history to reliably estimate payment patterns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2012 and 2013 and June 30, 2013 and 2014, substantially all of our revenue is recognized upon the earlier of payment
notification, if applicable, or cash receipt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill and Intangible Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We apply Financial Accounting Standards Codification, or FASB, Accounting Standards Codification, or ASC, Topic 805, &#147;<I>Business
Combinations</I>&#148; and FASB ASC Topic 350<I>, </I>&#147;<I>Intangibles&#151;Goodwill and Other</I>&#148; to account for goodwill and intangible assets. In accordance with these standards, we amortize all finite lived
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;61&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intangible assets over their respective estimated useful lives, while goodwill has an indefinite life and is not amortized. We review finite lived intangible assets subject to amortization for
impairment whenever events or circumstances indicate that the associated carrying amount may not be recoverable. Goodwill is not amortized but is tested for impairment at least annually or more frequently whenever a triggering event or change in
circumstances occurs, at the reporting unit level. We are required to recognize an impairment charge if the carrying amount of the reporting unit exceeds its fair value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management uses all available information to make this fair value determination, including the present values of expected future cash flows
using discount rates commensurate with the risks involved in the assets and observed market multiples of operating cash flows. In addition, if the estimated fair value of the reporting unit is less than the book value (including the goodwill),
further management judgment must be applied in determining the fair values of individual assets and liabilities for purposes of the hypothetical purchase price allocation. No provision for goodwill or other intangible asset impairments was recorded
during the six months ended June 30, 2014, or the years ended December&nbsp;31, 2012 and 2013. However, a lower fair value estimate in the future could result in impairment. Following the completion of this offering, our stock price and associated
market capitalization will also be considered in the determination of reporting unit fair value. A prolonged or significant decline in our share price could provide evidence of a need to record a material impairment of goodwill. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
recognize compensation costs related to stock options granted to employees based on the estimated fair value of the awards on the date of grant, net of estimated forfeitures. We estimate the grant date fair value, and the resulting stock-based
compensation expense, using the Black-Scholes option-pricing model. The grant date fair value of stock-based awards is expensed on a straight-line basis over the vesting period of the respective award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for stock-based compensation arrangements with non-employees using a fair value approach. The fair value of these options is
measured using the Black-Scholes option-pricing model reflecting the same assumptions as applied to employee options in each of the reported periods, other than the expected life, which is assumed to be the remaining contractual life of the option.
The compensation costs of these arrangements are subject to remeasurement over the vesting terms as earned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded stock-based
compensation expense of approximately $116,000, $152,000 and $52,000 for the years ended December&nbsp;31, 2012 and 2013, and the six months ended June 30, 2014, respectively. We expect to continue to grant stock options and other equity-based
awards in the future, and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option-pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of
stock-based awards. If we had made different assumptions, our stock-based compensation expense, net loss and net income (loss) per share of common stock could have been significantly different. Our assumptions are as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Fair value of our common stock.</I> Because our stock was not publicly traded prior to this offering, we estimate the fair value of our common stock. See &#147;&#151;Significant Factors, Assumptions and Methodologies
Used in Determining Fair Value of Our Common Stock&#148; below. Upon the completion of this offering, our common stock will be valued by reference to the publicly-traded price of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected term.</I> The expected term represents the period that the stock-based awards are expected to be outstanding. Our historical share option exercise experience does not provide a reasonable basis upon which to
estimate an expected term because of a lack of sufficient data. Therefore we estimate the expected term by using the simplified method, which calculates the expected term as the average of the time-to-vesting and the contractual life of the options.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><I>Expected volatility.</I> As our common stock has never been publicly traded, the expected volatility is derived from the average historical
volatilities of publicly traded companies within our industry that we </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;62&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
consider to be comparable to our business over a period approximately equal to the expected term. We intend to continue to consistently apply this process using the same or similar public
companies until a sufficient amount of historical information regarding the volatility of our own common stock price becomes available, or unless circumstances change such that the identified companies are no longer similar to us, in which case,
more suitable companies whose share prices are publicly available would be utilized in the calculation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Risk-free interest rate.</I> The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected
term. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected dividend.</I> The expected dividend is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected forfeiture.</I> We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures
differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Significant Factors, Assumptions and Methodologies Used in Determining Fair Value of Our Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also required to estimate the fair value of the common stock underlying our stock-based awards when performing the fair value
calculations using the Black-Scholes option-pricing model. Our board of directors, with the assistance of management, determined the fair value of our common stock on each grant date. All options to purchase shares of our common stock are intended
to be granted with an exercise price per share no less than the fair value per share of our common stock underlying those options on the date of grant, based on the information known to us on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because there has been no public market for our common stock, the fair value of the common stock that underlies our stock options has
historically been determined by our board of directors based upon information available to it at the time of grant, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">contemporaneous valuations performed by independent third-party firms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our current and projected operating and financial performance, including our levels of available capital resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trends and developments in our industry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the valuation of publicly traded companies in our sector, as well as recently completed initial public offerings and mergers and acquisitions of comparable companies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">rights, preferences and privileges of our common stock compared to the rights, preferences and privileges of our other outstanding equity securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">U.S. and global economic and capital market conditions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of achieving a liquidity event for the shares of common stock, such as an initial public offering or an acquisition of our company given prevailing market and sector conditions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the illiquidity of our securities by virtue of being a private company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business risks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">management and board experience. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The valuations of our common stock performed by independent
third-party firms were performed in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. Historically, we
utilized an option </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;63&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pricing method to allocate our business enterprise value to our common stock and common stock equivalents. Beginning in March 2014, we began utilizing a probability-weighted expected returns
method, or PWERM, valuation approach. Under this approach, the valuation of our common stock was based upon the probability-weighted present value of expected future returns, considering each of the possible future scenarios available to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business enterprise value was estimated using a combination of two generally accepted approaches: the income approach and the market-based
approach. The income approach estimates enterprise value based on the estimated present value of future net cash flows the business is expected to generate over its remaining life. The estimated present value is calculated using a discount rate
reflective of the cost of capital associated with an investment in a similar company and risks associated with our cash flow projections. Our discounted cash flow projections are sensitive to highly subjective assumptions that we were required to
make each valuation date. The market-based approach measures the value of a business through an analysis of recent sales or offerings of comparable investments or assets, and in our case, focuses on comparing us to the group of peer companies. In
applying this method, valuation multiples are derived from historical operating data of the peer company group. We then apply multiples to our operating data to arrive at a range of indicated values of the company. For each valuation, we prepared a
financial forecast to be used in the computation of the value of invested capital for both the market approach and income approach. The financial forecasts took into account our past results and expected future financial performance. There is
inherent uncertainty in these estimates as the assumptions used are highly subjective and subject to changes as a result of new operating data and economic and other conditions that impact our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we had made different assumptions than those used, the amount of our stock-based compensation expense, net loss and net income (loss) per
share amounts could have been significantly different. Following the completion of this offering, the fair value per share of our common stock for purposes of determining stock-based compensation expense will be the closing price of our common stock
as reported on the applicable grant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation cost that has been included in the consolidated statement of operations and
comprehensive loss for all stock-based compensation arrangements is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended<BR>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, the intrinsic value of stock options outstanding as of June 30, 2014 would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, of which $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and
$&nbsp;&nbsp;&nbsp;&nbsp; million would have been related to stock options that were vested and unvested, respectively, at that date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Estimated
Fair Value of Redeemable Convertible Preferred Stock Warrants, Embedded Derivative Liabilities and Acquisition-Related Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for our redeemable convertible preferred stock warrant liabilities as freestanding instruments for shares that are puttable or
redeemable. These warrants are classified as liabilities on our consolidated balance sheets and are recorded at their estimated fair values. At the end of each reporting period, changes in estimated fair value during the period are recorded as a
component of other income (expense), net in the accompanying statement of operations and comprehensive loss. We will continue to re-measure the fair value of the warrant liabilities until: (i)&nbsp;exercise, (ii)&nbsp;expiration of the related
warrant, or (iii)&nbsp;conversion of the preferred stock underlying the security into common stock, which will occur in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;64&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the fair values of our warrant liabilities using an option pricing model based on
inputs as of the valuation measurement dates, including the fair value of our redeemable convertible preferred stock, the estimated volatility of the price of our redeemable convertible preferred stock, the expected term of the warrants and the
risk-free interest rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2013, we converted previously outstanding convertible promissory notes into shares of our Series D
redeemable convertible preferred stock at a 20% discount to the issuance price of such shares. We determined this discount to be an embedded put feature derivative requiring bifurcation and separate accounting. Accordingly, we recorded a derivative
liability which was remeasured to fair value through the conversion of the convertible notes. The related remeasurement adjustments were recognized as a change in fair value of derivative liabilities associated with the convertible promissory notes
in the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The inputs used to determine the estimated fair value of these
derivative instruments included the probability of potential settlement scenarios for the convertible promissory notes, an estimate of the expected timing of settlement, expected volatility and risk-free interest rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the acquisition of the medical diagnostics division of Cypress in 2010, we are required to pay an additional amount not to
exceed $9.2&nbsp;million in the event specified revenue, contractual and product launch milestones are achieved. This contingent liability requires the use of inputs which are not observable in the market to assess its fair value at the end of each
reporting period. For this liability, fair value is determined based on probabilities assigned to the milestones being achieved, revenue projections, and interest rates. Changes in fair value are recorded in the consolidated statements of operations
and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file&nbsp;U.S. federal income tax returns and tax returns in California and New Mexico. To date, we have not been audited by the Internal
Revenue Service or any state income tax authority, however all tax years remain open for examination by federal tax authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2013, our gross deferred tax assets were $13.9&nbsp;million. The deferred tax assets were primarily comprised of federal and state tax net operating loss and tax credit carryfowards. We have performed an analysis to determine
whether an &#147;ownership change&#148; occurred from inception to December&nbsp;31, 2013. Based on this analysis, we determined that we did experience a historical ownership change of greater than 50% in 2008. Therefore, our ability to utilize our
net operating losses incurred prior to this date is limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to reduce our deferred tax assets by a valuation allowance
if it is more likely than not that some or all of our deferred tax assets will not be realized. We must use judgment in assessing the potential need for a valuation allowance, which requires an evaluation of both negative and positive evidence. The
weight given to the potential effect of negative and positive evidence should be commensurate with the extent to which it can be objectively verified. In determining the need for and amount of our valuation allowance, if any, we assess the
likelihood that we will be able to recover our deferred tax assets using historical levels of income, estimates of future income and tax planning strategies. As a result of historical cumulative losses and uncertainties surrounding our ability to
generate future taxable income and, based on all available evidence, we believe it is more likely than not that our recorded net deferred tax assets will not be realized. Accordingly, we recorded a valuation allowance against all of our net deferred
tax assets at December&nbsp;31, 2013. We will continue to maintain a full valuation allowance on our deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of this allowance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above listing is not intended to be a comprehensive list of all of our accounting policies. In many cases, the accounting treatment of a
particular transaction is specifically dictated by GAAP. There are also areas in which our management&#146;s judgment in selecting any available alternative would not produce a materially different result. Please see our audited consolidated
financial statements and notes thereto included elsewhere in this prospectus, which contain accounting policies and other disclosures required by GAAP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;65&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Six Months Ended June 30, 2013 and 2014 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months Ended </B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar<BR>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,393</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(918</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,951</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue increased $2.7&nbsp;million, or 265%, in the six months ended June 30, 2014 compared to the six months ended June 30, 2013, primarily
due to an increase in the number of Avise SLE diagnostic products for which we collected revenue and an increase in average reimbursement per test. We increased the number of Avise SLE diagnostic products for which we collected revenue by 209% to
7,611 for the six months ended June&nbsp;30, 2014 compared to 2,460 for the six months ended June 30, 2013 due to the continued acceptance of our products by rheumatologists and improved billing and collection efforts. Of tests for which we received
at least one payment, our average reimbursement per test for our Avise SLE diagnostic products increased by 48% for the six months ended June 30, 2014 compared to the six months ended June 30, 2013 primarily as a result of an increase in the
procedures included in our primary product, Avise SLE+CT, starting in the first quarter of 2014 and improved billing and collection efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue
increased $1.5 million, or 126%, in the six months ended June 30, 2014 compared to the six months ended June 30, 2013. This increase is primarily due to a 137% increase in variable costs associated with processing more Avise&nbsp;SLE diagnostic
patient specimens, offset by efficiencies gained in the laboratory due to larger testing volumes. Avise&nbsp;SLE diagnostic patient specimens tested increased 229% from 3,364 to 11,073 for the six months ended June&nbsp;30, 2013 and June&nbsp;30,
2014, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses increased $3.7 million, or 122%, in the six months ended June&nbsp;30, 2014 compared to the six
months ended June 30, 2013. This increase was primarily due to increases in headcount, including expansion of the sales force to 29 representatives at June&nbsp;30, 2014 from nine at June&nbsp;30, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;66&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs that tend to vary based on revenue, which include commissions and performance-based
compensation and other sales and marketing employee related expenses, increased $2.0 million in the six months ended June&nbsp;30, 2014 compared to the six months ended June 30, 2013, resulting from continuing expansion of our dedicated sales force.
In addition, third party billing fees increased $0.2 million due to increases in the number of tests performed and billed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation
and other employee related expenses for our general and administrative support functions increased $0.4 million in the six months ended June&nbsp;30, 2014 compared to the six months ended June&nbsp;30, 2013, resulting primarily from additions to our
headcount. In addition, expenses incurred for accounting and legal services increased $0.5 million in the six months ended June&nbsp;30, 2014 compared to the six months ended June&nbsp;30, 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased $0.2 million, or 33%, in the six months ended June&nbsp;30, 2014 compared to the six months ended
June&nbsp;30, 2013 primarily from increased clinical trial expenses of $0.1&nbsp;million incurred in the six months ended June&nbsp;30, 2014 in connection with additional studies to further document the performance of our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amortization of Intangible Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets remained consistent for the six months ended June 30, 2014 compared to the six months ended June 30, 2013.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value of Acquisition-Related Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Change in fair value of acquisition-related liabilities decreased $0.6 million, or 97%, in the six months ended June 30, 2014 compared to the
six months ended June 30, 2013. These amounts result from changes in our estimates of the probabilities and timing associated with achieving certain revenue, contractual and product launch milestones in connection with our acquisition of the medical
diagnostics division of Cypress Bioscience in 2010. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense increased $0.9 million, or 446%, in the six months ended June 30, 2014 compared to the six months ended June 30, 2013
primarily as result of increased interest expense related to the $15.0&nbsp;million outstanding under our term loan agreement, $10.0&nbsp;million of which we drew down in October 2013 and the remaining $5.0&nbsp;million of which we drew down in
March 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense), Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income (expense), net remained relatively consistent for the six months ended June 30, 2014 compared to the six months ended June 30,
2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;67&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2012 and 2013 </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar<BR>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of 2013 Notes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue increased $2.1&nbsp;million, or 230%, in 2013 compared to 2012. This increase was primarily due to an increase in the number of Avise
SLE diagnostic products for which we collected revenue following the launch of our Avise SLE diagnostic test in January 2012 and our Avise SLE+CT diagnostic test in August 2012. We increased the number of Avise SLE diagnostic products for which we
collected revenue by 354% to 6,909 in 2013 compared to 1,520 in 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue increased $0.9&nbsp;million, or 43%, in 2013 compared to 2012. This increase is primarily due to a 55% increase in variable
costs associated with processing more Avise&nbsp;SLE diagnostic patient specimens, offset by efficiencies gained in the lab due to larger testing volumes. Avise&nbsp;SLE diagnostic patient specimens tested increased 378% from 1,940 to 9,266 in 2012
and 2013, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses increased $1.8&nbsp;million, or 36%, in 2013 compared to 2012. This increase was primarily due to
increases in headcount, including higher commissions, bonus and stock-based compensation expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs that tend to vary based on
revenue, which include commissions and performance-based compensation and other sales and marketing employee related expenses, increased $1.0 million in 2013 compared to 2012, resulting from continuing expansion of our dedicated sales force. In
addition, third party billing fees increased $0.2 million due to increases in the number of tests performed and billed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation and
other employee related expenses for our general and administrative support functions increased $0.5 million in 2013 as compared to 2012, resulting from additions to our headcount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;68&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses decreased $0.2 million, or 15%, in 2013 compared to 2012 primarily due to the completion of clinical trials
in 2012 related to the Avise SLE product launch. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amortization of Intangible Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets remained consistent in 2013 compared to 2012. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value of Acquisition-Related Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Change in fair value of acquisition-related liabilities increased $1.9 million, or 298%, in 2013 compared to 2012 due to changes in our
estimates of the probabilities and timing associated with achieving certain revenue, contractual and product launch milestones in connection with our acquisition of the medical diagnostics division of Cypress in 2010. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense
increased $0.5 million, or 103%, in 2013 compared to 2012 primarily as result of increased interest expense related to the $10.0 million outstanding under our term loan agreement, which we drew down in October&nbsp;2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Loss on Extinguishment of 2013 Notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2013, we converted previously outstanding convertible promissory notes into shares of our Series&nbsp;D redeemable convertible preferred
stock. Loss on extinguishment of 2013 Notes of $3.3 million represents the difference in the carrying amount of the convertible promissory notes and the fair value of the shares of Series&nbsp;D redeemable convertible preferred stock issued upon
conversion of the notes. No comparable transaction occurred in 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense), Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income (expense), net decreased $0.1 million in 2013 compared to 2012 primarily as result of changes in the fair value of the redeemable
convertible preferred stock warrant liabilities and other embedded derivatives that existed in 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net losses since our inception. For the years ended December&nbsp;31, 2012 and 2013 and for the six months ended June 30,
2014, we had a net loss of $7.3 million, $13.5 million and $7.6&nbsp;million, respectively, and we expect to incur additional losses this year and in future years. As of June 30, 2014, we had an accumulated deficit of $81.8&nbsp;million. To date, we
have generated only limited revenue, and we may never achieve revenue sufficient to offset our expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, our operations
have been financed primarily by net proceeds of approximately $82.0&nbsp;million from sales of our common and redeemable convertible preferred stock and borrowings under various debt financings. As of December&nbsp;31, 2013 and June 30, 2014, we had
$7.7&nbsp;million and $6.1 million of cash and cash equivalents, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, we entered into a term loan agreement,
under which we drew down an initial $10.0&nbsp;million in October 2013 and another $5.0 million on March&nbsp;31, 2014. Loans drawn under the term loan agreement are being used for working capital and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loan accrues interest at an annual rate equal of 14%, 10% of which is payable in cash on a quarterly basis and 4% of which we have elected
to capitalize as part of the outstanding loan obligation. We are required to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;69&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
repay any outstanding principal and capitalized interest in quarterly installments over a two-year period, commencing on December&nbsp;31, 2016. We may, at our option, prepay the term loan
borrowings by paying the lender a prepayment premium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations under the term loan agreement are secured by a security interest in
substantially all of our personal property, including our intellectual property. The loan and security agreement contains customary conditions to borrowing, events of default, and covenants, including covenants requiring us to maintain a minimum
liquidity of at least $2.0 million and achieve certain minimum amounts of revenue, and limiting our ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other
distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with the execution of the term loan agreement, we issued the lenders a ten-year warrant to purchase 3,186,430 shares of our Series&nbsp;D redeemable convertible preferred stock at an exercise price of $0.25&nbsp;per share, and a ten-year
warrant to purchase 3,186,430 shares of our common stock at an exercise price of $0.01 per share. In November 2013, we also issued a warrant to purchase 988,000 shares of our Series D redeemable convertible preferred stock at an exercise price of
$0.25 per share to an investment advisor involved in the consummation of the term loan agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary uses of cash are to fund
our operations as we continue to grow our business. We expect to continue to incur operating losses in the near term as our operating expenses will be increased to support the growth of our business. We expect that our cost of revenue, selling,
general and administrative, research and development expenses will continue to increase as we increase our test volume, expand our marketing efforts and increase our internal sales force to drive increased adoption of and reimbursement for our Avise
products, prepare to commercialize new products, continue our research and development efforts and further develop our product pipeline. We expect that we will use a substantial portion of the net proceeds of this offering, in combination with our
existing cash and cash equivalents, for these purposes and for the increased expenses associated with being a public company. We recently completed the build-out of our laboratory in Vista, California, and we have entered into a lease to further
expand our space beginning in February 2015. We believe we have sufficient laboratory capacity to support increased test volume. Other than the addition of laboratory equipment, we expect that we will not need to make material capital expenditures
in the near term related to our laboratory facilities. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our near- and longer-term liquidity requirements will continue to consist of working capital and general corporate expenses
associated with the growth of our business. The report of our independent registered public accounting firm on our audited consolidated financial statements for the year ended December&nbsp;31, 2013 includes an explanatory paragraph stating that our
recurring losses from operations and negative cash flows from operating activities raise substantial doubt about our ability to continue as a going concern.&nbsp;Based on our current business plan, we believe that the estimated net proceeds from
this offering, together with our existing cash and cash equivalents as of June 30, 2014 and our anticipated future product revenue, will be sufficient to meet our anticipated cash requirements for at least the next 18&nbsp;months, including funding
the completion of our ongoing validation studies for the products in our pipeline, and, if successful, the potential launch of Avise Anti-TNF. In addition, if these validation studies are successful, we believe that only minimal additional capital
investment will be required in order to launch our other two pipeline products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our estimate of the period of time through which our
financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain and grow sales of our Avise products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our products and support reimbursement efforts;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fluctuations in working capital; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;70&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs to expand our sales and marketing capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation studies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the additional costs we may incur as a result of operating as a public company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we in-license, acquire or invest in complementary businesses or products. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have based
this estimate on assumptions that may prove to be wrong, and we may utilize our available capital resources sooner than we currently expect. For example, if our ongoing validation studies for the products in our pipeline or our ongoing clinical
studies of our existing products take longer to complete than we currently expect or are unsuccessful, we may require additional funding on a faster timeline than we currently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate more substantial revenue, we may be required, or we may elect, to finance operations by utilizing
additional debt or selling equity securities. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or
declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be diluted, and the terms of these securities may include liquidation or
other preferences that adversely affect the rights of our common stockholders. If additional funding is required or desired, there can be no assurance that additional funds will be available to us on acceptable terms on a timely basis, if at all, or
that we will generate sufficient cash from operations to adequately fund our operating needs or achieve or sustain profitability. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our
operations, we will need to curtail planned activities to reduce costs. Doing so will likely have an unfavorable effect on our ability to execute on our business plan. If we cannot expand our operations or otherwise capitalize on our business
opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the six months ended June 30, 2013 and 2014 and the years ended December&nbsp;31, 2012 and
2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar<BR>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months Ended</B><br><B>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar<BR>Change </B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,477</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,865</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,133</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Decrease) Increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,358</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Operating Activities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities was $5.9&nbsp;million for the six months ended June 30, 2014 compared to $3.2&nbsp;million for the six months
ended June 30, 2013. The $2.7&nbsp;million increase in cash used in operating activities was primarily due to increases in changes in accounts payable and accrued expenses of approximately $0.6&nbsp;million due to growth in our operations and the
timing of payments offset by a $3.2&nbsp;million increase in net cash used by losses, as adjusted for change in fair value of acquisition-related liabilities, amortization of debt discount and other non-cash interest expense, depreciation and
amortization expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities was $6.9&nbsp;million in 2013 compared to $7.5 million in 2012. The
$0.6&nbsp;million decrease in cash used in operating activities was primarily due to increases in changes in accounts </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;71&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payable and accrued liabilities of approximately $1.3&nbsp;million due to the growth in our operations and the timing of payments offset by a $0.6 million increase in net cash used by losses, as
adjusted for change in fair value of acquisition-related liabilities, amortization of debt discount and other non-cash interest expense, loss on extinguishment of 2013 Notes, depreciation and amortization expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Investing Activities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in investing activities was $0.4&nbsp;million for the six months ended June 30, 2014 compared to cash provided by investing
activities of $0.7 million for the six months ended June 30, 2013. The $1.1 million decrease in cash provided by investing activities is primarily attributable to the return of approximately $0.7 million of restricted cash related to the
subsequently retired borrowing facility with a bank received in the six months ended June 30, 2013 and increased purchases of property and equipment of $0.4 million in the six months ended June 30, 2014 compared to the six months ended June 30,
2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by investing activities was $0.5&nbsp;million in 2013 compared to cash used in investing activities of $1.1 million
in 2012. The $1.7 million decrease in cash used in investing activities is primarily attributable to the $1.4 million change in the activity in restricted cash related to a borrowing facility with a bank that was retired in 2013, offset by a
decrease of approximately $0.3 million in purchases of intangible assets, property and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Financing Activities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities was $4.7&nbsp;million for the six months ended June 30, 2014 compared to $0.4 million for the six months
ended June 30, 2013. The $4.3&nbsp;million increase in cash provided by financing activities is primarily due to a $5.0 million draw made under our term loan agreement in March 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities was $11.3&nbsp;million in 2013 compared to $7.3 million in 2012. The $4.1&nbsp;million increase in cash
provided from financing activities is due to a $10.0 million draw made under our term loan agreement in October 2013, offset by increases in payments on long term debt of $2.6 million and a decrease of $2.9 million in the net proceeds received from
the sale of our redeemable convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations as of December&nbsp;31, 2013: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1 to 3<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3 to 5<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating leases(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Firm purchase commitments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2013 term loan agreement(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We currently lease 14,000 square feet of office and laboratory space in Vista, California, under a lease that expires in 2017, with options to extend the lease for two additional 36-month periods. We also lease
approximately 3,200 square feet of office space in Albuquerque, New Mexico, under a lease that expires in November 2014. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In
September 2014, we entered into a lease agreement for additional office space in Vista, California. The lease, which commences in February 2015 and expires in January 2018, requires initial monthly rental payments of approximately $16,000 which are
subject to escalation, as described in the lease agreement. We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;72&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
have a one-time option to terminate the lease agreement on or before November&nbsp;1, 2014 and an option to extend the lease for an additional 24&nbsp;month term. These rental payments are not
included in the table above. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">In October 2013, we entered into our term loan agreement and made an initial draw of $10.0&nbsp;million. In March 2014, we drew an additional $5.0 million under the term loan agreement that is not included in the table
above. Payments above include principal and interest consisting of 10% per annum in cash and 4% per annum paid in-kind in the form of additional term loans, or PIK Loans. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The contractual obligations table does not include any potential contingent payments upon the achievement by us of specified sales-based and
other milestones, or royalty payments we may be required to make under license agreements we have entered into pursuant to which we have in-licensed certain intellectual property, including our license agreements with the University of Pittsburgh,
Prometheus, Orgentec and Dr.&nbsp;Dervieux. See &#147;Business&#151;Intellectual Property Overview&#151;License Agreements&#148; for additional information. The timing of when these payments will actually be made is uncertain and the payments are
contingent upon the completion of future activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not entered into any off-balance sheet arrangements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Controls and Procedures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A company&#146;s
internal control over financial reporting is a process designed by, or under the supervision of, a company&#146;s principal executive and principal financial officers, or persons performing similar functions, and effected by a company&#146;s board
of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. Because of its
inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of
changes in conditions, or that the degree of compliance with policies or procedures may deteriorate. In connection with our preparation for this offering, we concluded that there was a material weakness in our internal control over financial
reporting that caused the restatements of our previously issued financial statements as of and for the years ended December&nbsp;31, 2012 and 2013. A material weakness is a deficiency, or a combination of deficiencies, in internal control over
financial reporting such that there is a reasonable possibility that a material misstatement of a company&#146;s annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness that we identified was
that we did not maintain a sufficient complement of resources with an appropriate level of accounting knowledge, experience and training commensurate with our company&#146;s structure and financial reporting requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fourth quarter of 2013 and in preparation for this offering, we initiated various remediation efforts, including hiring additional
resources with the appropriate public company and technical accounting expertise and have taken other actions that are more fully described below. As such remediation efforts are still ongoing, we have concluded that the material weakness has not
been remediated. Our remediation efforts to date have included the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Addition of employee resources.</I> We continue to add appropriate resources to our finance team and are leveraging external consultants to facilitate accurate and timely accounting closes and to accurately prepare
and review financial statements and related footnote disclosure. Our finance team has been expanded to include a Corporate Controller, Director of Financial Planning and Analysis, both with significant public company and life science industry
experience, a Director of Revenue Assurance, and external consultants with significant financial and accounting technical experience. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Other actions to strengthen the internal control environment.</I> As a result of the additional resources added to the finance function, we are allowing for separate preparation and review of the reconciliations and
other account analyses. In addition, we are implementing a new accounting software system which will allow us to strengthen certain control procedures. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;73&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a 2013 restatement was identified in September 2014, we acknowledge that additional planned
remediation efforts are necessary. We plan to provide ongoing technical accounting training to our accounting team to ensure that their knowledge of recent accounting pronouncements is current, and to supplement their existing knowledge of
accounting for complex transactions, including complex debt and equity transactions. We will continue to evaluate the competency and technical acumen of our accounting team and assess the need to hire additional or more specialized employees.
Finally, we will continue to supplement our employee resources by leveraging external consultants who have specialized experience in the life sciences industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The actions that have been taken are subject to continued review, supported by confirmation and testing by management as well as audit
committee oversight. While we have implemented a plan to remediate this weakness, we cannot assure you that we will be able to remediate this weakness, which could impair our ability to accurately and timely report our financial position, results of
operations or cash flows. For additional information about this material weakness, see &#147;Risk Factors&#151;Risks Related to this Offering and the Ownership of Our Common Stock&#151;We have identified a material weakness in our internal control
over financial reporting and may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If we fail to remediate one or more
material weaknesses or if we fail to establish and maintain effective control over financial reporting, our ability to accurately report our financial results could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rates. We had cash and cash
equivalents of $7.7&nbsp;million and $6.1 million as of December&nbsp;31, 2013 and June 30, 2014, respectively, which consist of bank deposits. Such interest-bearing instruments carry a degree of risk; however, we have not been exposed to, nor do we
anticipate being exposed to, material risks due to changes in interest rates. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Accounting Election </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April
2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an &#147;emerging growth company.&#148; As an emerging
growth company, we are electing not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards, and as a result, we will comply with new or revised accounting standards
on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section 107 of the JOBS Act provides that our decision not to take advantage of the extended transition period is irrevocable. In addition, we
are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if as an emerging growth company we choose to rely
on such exemptions, we may not be required to, among other things, (1)&nbsp;provide an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (2)&nbsp;provide all of the compensation
disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (3) comply with any requirement that may be adopted by the Public Company Accounting Oversight Board
regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements (auditor discussion and analysis), and (4) disclose certain executive
compensation-related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive Officer&#146;s compensation to median employee compensation. These exemptions will apply for a period of five
years following the completion of our initial public offering or until we no longer meet the requirements of being an emerging growth company, whichever is earlier. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;74&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued Accounting Standards Update, or ASU, 2014-09, <I>Revenue from Contracts with Customers</I>, which provides a
five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the
consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December&nbsp;15, 2016 (fiscal 2018) and shall be applied retrospectively to each period
presented or as a cumulative-effect adjustment as of the date of adoption. We are currently in the process of evaluating the impact of adoption of this ASU on our consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2013, the FASB issued ASU 2013-11, which provides for changes to the presentation of an unrecognized tax benefit when a net operating
loss carryforward, a similar tax loss, or a tax credit carryforward exists. These changes require an entity to present an unrecognized tax benefit as a liability in the financial statements if (i)&nbsp;a net operating loss carryforward, a similar
tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position, or (ii)&nbsp;the tax law
of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset to settle any additional income taxes that would result from the disallowance of a tax position. Otherwise, an
unrecognized tax benefit is required to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. These changes became effective for us on
January&nbsp;1, 2014. There was no material impact to our consolidated financial statements upon adoption of this ASU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2014,
the FASB issued ASU 2014-15, <I>Presentation of Financial Statements&#151;Going Concern</I>, which defines management&#146;s responsibility to evaluate whether there is substantial doubt about an organization&#146;s ability to continue as a going
concern and to provide related footnote disclosures. The new standard provides management with principles to evaluate whether substantial doubt exists by (i) providing a definition of substantial doubt, (ii) requiring an evaluation every annual and
interim reporting period, and (iii) providing principles for considering the mitigating effects of management&#146;s plans. If substantial doubt is identified, the ASU requires that an organization provide enhanced disclosures about (i) principal
conditions or events that raise substantial doubt, (ii) management&#146;s evaluation of the significance of these events in relation to its ability to meet obligations, and (iii) management&#146;s plans that are either intended to mitigate the
conditions that raise substantial doubt, or alleviate substantial doubt. The ASU is effective for annual periods ending after December 15, 2016. We are currently in the process of evaluating the impact of the adoption of this ASU on our consolidated
financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;75&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a commercial-stage
diagnostics company committed to addressing the significant unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. These chronic diseases can cause lifelong inflammation in the joints, tissues and
internal organs, resulting in serious complications, such as irreversible organ damage. Untreated chronic inflammation can also lead to premature hardening of the arteries, heart attacks and strokes. The accurate, timely and differential diagnosis
for patients suffering from the approximately 30 autoimmune rheumatic diseases, or ARDs, is critical as treatment for each disease can vary, and inappropriate or delayed therapy may expose patients to unnecessary risks or the hazards of uncontrolled
disease activity. Physicians face significant difficulties in making a definitive diagnosis of a specific ARD because patients with different diseases often present with a common set of symptoms. We currently market four products under our Avise
brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. We processed approximately 9,300 patient specimens for our lead diagnostic product line, Avise SLE, in 2013 and approximately 11,100 in the first
six months of 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is estimated that 11&nbsp;million adults in the United States suffer from ARDs, including Rheumatoid Arthritis, or
RA, Systemic Lupus Erythematosus, or SLE, Sj&ouml;gren&#146;s syndrome, scleroderma, and Mixed Connective Tissue Disease, or MCTD. In addition, patients afflicted with fibromyalgia, a chronic neurologic disorder, and autoimmune thyroid disease have
many of the same clinical symptoms as patients with ARDs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagnosis and treatment of ARDs is generally provided by the community
rheumatologist, a sub-specialty of internal medicine which includes approximately 3,500 physicians in the United States. Patients often present to a rheumatologist after a lengthy referral process because of the similarity and overlap of symptoms
among ARDs, the waxing and waning of these symptoms and the shortcomings of current diagnostic tests. Establishing a definitive diagnosis is often difficult and can take years. Throughout this time, patients may continue to suffer from the
debilitating effects of their disease, receive inappropriate treatments and may face a significant financial burden. As a result, physicians strive to make an accurate diagnosis in a timely manner, especially for more serious ARDs, such as SLE,
which can be life threatening. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product, Avise SLE+CT, is a proprietary diagnostic test that provides an enhanced solution for
patients presenting with symptoms indicative of a wide variety of ARDs, such as SLE, RA, Sj&ouml;gren&#146;s, scleroderma and other disorders that mimic ARDs such as fibromyalgia and autoimmune thyroid disease. Avise SLE+CT allows physicians to more
accurately rule-in or rule-out SLE and inform decisions about the presence of other ARDs, all with the convenience of one blood draw. Differential diagnosis of these diseases is critically important because earlier diagnosis has been shown to
improve patient outcomes. Once diagnosed, physicians can tailor therapy to a patient&#146;s specific disease and avoid the &#147;trial and error&#148; approach that often takes place when a definitive diagnosis cannot be made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have validated the clinical utility of Avise SLE 2.0, the proprietary component of our Avise SLE+CT solution, in a multi-center study in an
aggregate of 794 subjects, preliminary results of which were presented at the American College of Rheumatology, or ACR, annual conference in 2013. The primary endpoint of the study was the performance characteristics, specifically sensitivity and
specificity, of Avise SLE 2.0 compared to common autoantibodies used to diagnose SLE and other ARDs, such as antinuclear antibodies, or ANA, and anti-double stranded DNA, or anti-dsDNA. The final results of this study showed that Avise SLE 2.0
demonstrated 86% specificity and 80% sensitivity in distinguishing SLE from other ARDs, was 33% more specific than ANA (53% specificity/89% sensitivity) and was 48% more sensitive than anti-dsDNA (32% sensitivity/97% specificity). Avise SLE 2.0
includes Cell Bound Complement Activation Products, or CB-CAPs, technology, which we exclusively license from the University of Pittsburgh. This technology is the result of over a decade of extensive research and development conducted at the Lupus
Center of Excellence at the University of Pittsburgh Medical Center. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;76&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to Avise SLE+CT, we also offer Avise SLE Prognostic, a test that provides additional
information to better manage patients diagnosed with SLE. Specifically, our Avise SLE Prognostic report includes information regarding an SLE patient&#146;s risk of developing kidney damage, or neurologic or cardiovascular complications. We offer
the Avise SLE Prognostic test, which we launched in June 2014, to physicians as a complement to Avise SLE+CT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also market Avise MTX, a
drug monitoring solution that provides physicians with information to support the optimization of methotrexate, or MTX, a front-line treatment prescribed in over 70% of patients with RA. This solution has been validated prospectively in a number of
studies published in peer-reviewed medical journals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also offer Avise&nbsp;HCQ, a blood test we launched in September 2014 to help
physicians objectively monitor blood levels of hydroxychloroquine, or HCQ, which is typically prescribed daily to patients to control ARD activity and prevent flares. By measuring HCQ concentration in the blood, we believe that Avise&nbsp;HCQ will
help physicians optimize HCQ therapy, identify noncompliant patients and identify patients that are not absorbing the drug adequately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
intend to develop additional innovative, high value diagnostic solutions for the rheumatologist while continuing to improve the performance characteristics of our currently marketed products. In particular, we are developing and validating testing
solutions that are designed to assist rheumatologists with the monitoring of disease activity in patients with SLE and monitoring the active drug levels of some of the more commonly prescribed pharmaceuticals for the treatment of ARDs. We are
conducting validation studies for these products in collaboration with academic centers of excellence and intend to publish the results of these studies in peer-reviewed medical journals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is estimated that over 14&nbsp;million people in the United States have been diagnosed with ARDs, fibromyalgia and autoimmune thyroid
disease, with approximately 470,000 diagnosed annually. Additionally, in the United States, over one million patients annually are prescribed MTX therapy, and over 700,000 patients annually are prescribed HCQ therapy. We estimate the market
potential of our existing products to be as much as $870&nbsp;million annually, based on our internal research and analysis utilizing these incidence and prevalence rates, the prescription information of pharmaceuticals for our drug monitoring
products and the Medicare allowable reimbursement rate for our products. We estimate our pipeline products will create an additional $350&nbsp;million annually in market potential based on these same factors, as well as estimates that over 250,000
patients annually in the United States are prescribed anti-TNF therapy and approximately 220,000 people in the United States have been diagnosed with SLE. Because these calculations are based on internal estimates and assume rates of reimbursement
that may change, there is no guarantee that these assumptions will prove to be accurate and consequently, our actual market potential may not be as large as we expect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to establish
ourselves as the preeminent provider of testing solutions to rheumatologists by offering a comprehensive set of tools to effectively diagnose and optimize the treatment of patients with ARDs. To achieve this objective, we intend to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Accelerate the adoption of our existing products.</I> We plan to expand the use of our Avise product suite by adding new physicians to our customer base as well as increasing utilization among our existing customers.
We have recently increased our specialty sales force and expect to selectively add more sales representatives to extend our reach and frequency of engagement with community rheumatologists. In addition, we are conducting medical education seminars
for physicians through our community speaker programs, where national and regional thought leaders present information regarding the clinical utility of our products. We will continue to heighten awareness by seeking exhibit and speaker sponsorship
opportunities at leading rheumatology medical conferences. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;77&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Further demonstrate the clinical utility of our products to drive adoption and support reimbursement.</I> We are conducting additional clinical studies to facilitate the adoption of our testing solutions. We plan to
continue to present the results of our studies at national scientific meetings and publish results in peer-reviewed medical journals. We plan to use data from our ongoing trials combined with existing data and our core expertise in managed care,
claims adjudication and billing to drive broader access and support reimbursement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expand our portfolio of high value testing solutions.</I> We are continuing to develop additional products to address the significant challenges in the diagnosis, prognosis and monitoring of patients with ARDs, and
plan to launch three new products by the end of 2016. We believe that by providing a broader set of innovative solutions, we can enhance our value proposition to rheumatologists. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Establish ourselves as the trusted partner to the rheumatologist.</I> We intend to continue to build upon our relationship with the rheumatology community. Our reputation with our physician customers is built on
their confidence in the quality of our testing solutions, the timely delivery of our test reports and the value of our consultative support. Our laboratory reports deliver critical information in a form that is optimized for the physician&#146;s
ease of use. We will also explore opportunities for physicians to access our extensive database of test results. We believe that these measures will position us as a trusted partner to our physician customers and allow us to leverage the resources
and infrastructure that we have dedicated to these customers. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Engage in partnerships to access additional market opportunities.</I> We believe there is meaningful potential for our current and future products beyond the rheumatology specialty, particularly for those physician
groups that see patients earlier in the diagnostic process. For example, because ARDs are most common in women, obstetrics and gynecology, or OB/GYN, specialists are often the first physicians to see a patient presenting with ARDs. We intend to
selectively seek complementary partnerships to address these broader markets. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Autoimmune Rheumatic Diseases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ARDs are a group of serious, chronic and debilitating autoimmune diseases involving inflammation of the joints, tissues and internal organs.
There are approximately 30 ARDs, many of which have overlapping symptoms. Additionally, other rheumatic disorders that are not autoimmune in nature, such as fibromyalgia, can present similar symptoms. It is estimated that 11 million patients in the
United States suffer from ARDs, including RA, SLE, Sj&ouml;gren&#146;s syndrome, scleroderma and MCTD, and patients afflicted with fibromyalgia or autoimmune thyroid disease have many of the same clinical symptoms as patients with ARDs. These
diseases create a significant burden on the healthcare system, due in part to the difficulty in obtaining a differential diagnosis. These chronic diseases can cause lifelong inflammation in the joints, tissues and internal organs, resulting in
serious complications, such as irreversible organ damage. Untreated chronic inflammation can also lead to premature hardening of the arteries, heart attacks and strokes. Due to the overlapping symptoms, unpredictable periods of disease flares and
disease inactivity, patients may cycle from physician to physician for months or even years before receiving a definitive diagnosis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
ARDs and other rheumatic conditions that may be confused in diagnosis include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Systemic Lupus Erythematosus (SLE).</I> A chronic autoimmune disease involving inflammation and destruction of organs such as the brain, kidneys and lungs resulting in irreversible damage and in severe cases death.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Rheumatoid Arthritis (RA).</I> A chronic autoimmune disease involving inflammation and destruction of joints, bone and in some cases organs, including eyes and lungs. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Sj&ouml;gren&#146;s Syndrome.</I> A chronic autoimmune disease involving inflammation and destruction of secretory glands such as salivary glands and tear ducts. This disease can occur with RA and SLE.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Scleroderma.</I> A chronic autoimmune disease involving scar tissue build-up in tissues, such as the skin or, in more serious cases, muscles, blood vessels and internal organs. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;78&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Mixed Connective Tissue Disease (MCTD). </I>A chronic autoimmune disease having features of other ARDs, most commonly RA, SLE, Sj&ouml;gren&#146;s and scleroderma. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Fibromyalgia.</I> A chronic condition characterized by wide-spread pain and tenderness to touch. Although not an autoimmune disease, this disease has been reported to occur in 25% of RA patients, 30% of SLE patients
and 50% of Sj&ouml;gren&#146;s patients. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Autoimmune Thyroid Disease</I>. A chronic autoimmune disease that results in antibodies causing decreased thyroid hormone production, or hypothyroidism, or increased thyroid hormone production, or hyperthyroidism.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with these disorders often present with a common set of symptoms, which can include joint pain, fatigue,
inflammation, stiffness and muscle aches, among others. Additionally, these patients may experience unpredictable periods of disease flares and disease inactivity, which can meaningfully change the patients&#146; symptoms and how they present to the
physician. The combination of overlapping symptoms and disease biology can lead these patients to cycle from physician to physician for months or even years before receiving a definitive diagnosis. Due to this, we believe physicians are in critical
need of objective tests capable of differentially diagnosing these disorders, especially for more potentially life threatening ARDs, such as SLE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary goal in the treatment of ARDs is suppressing disease activity in order to prevent tissue or bone destruction and/or organ damage.
Powerful drugs that suppress the immune system are utilized to minimize the inflammatory process caused by autoantibodies. In RA, these drugs are referred to as Disease-Modifying Anti-Rheumatic Drugs, or DMARDs, because in clinical studies they have
demonstrated the ability to change the natural course of ARDs if utilized effectively. Optimization of DMARDs requires physicians to closely monitor disease activity on an ongoing basis and adjust exposure to active drug to achieve and maintain
disease control. We believe drug monitoring tools allow for the personalization and optimization of biological DMARD therapy which will improve clinical and economic outcomes. DMARDs commonly used by rheumatologists to treat ARDs are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Methotrexate (MTX)</I>&#151;MTX is one of the most widely used drugs to treat RA. It is estimated that over one&nbsp;million patients annually are prescribed MTX in the United States and over 70% of RA patients
receive this drug. Physicians typically start patients on MTX, but because approximately 40% of patients do not respond adequately, other DMARDs are often added. This variability in effectiveness of MTX can be caused by variable absorption,
metabolism and excretion of the drug. Patient compliance may also be an issue with MTX. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Hydroxychloroquine (HCQ)</I>&#151;HCQ is one of the most widely used drugs in SLE and RA. It is estimated that over 700,000 patients annually are prescribed HCQ therapy in the United States. HCQ is used in SLE to
control disease activity or flares. HCQ is also regarded as a DMARD and is commonly used in combination with MTX to treat RA. Patient compliance issues with HCQ can lead to loss of disease control in both RA and SLE. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-Tumor Necrosis Factor Alpha (Anti-TNF)</I>&#151;Anti-TNF drugs are biological DMARDs and are regarded as one of the most effective classes of agents for the treatment of RA. In RA alone, it is estimated that
over 250,000 patients in the United States are prescribed anti-TNF therapy annually. In most cases, anti-TNF drugs are used in combination with MTX. The most widely prescribed anti-TNF drugs are etanercept (marketed as Enbrel), adalimumab (marketed
as Humira) and infliximab (marketed as Remicade). These treatments cost approximately $20,000 per patient per year. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Systemic Lupus
Erythematosus </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is
estimated that over one million people in the United States suffer from some form of lupus. SLE, the most common and serious form of lupus, is a chronic, inflammatory disorder that can damage any part of the body, including the skin, joints and
internal organs. SLE varies in severity, from mild cases to those in which significant and potentially fatal damage occurs to vital organs such as the brain, heart, kidneys and lungs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;79&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SLE is characterized by unpredictable, intermittent increases and decreases of disease
activity, or flares, with a rise in symptoms and/or abnormal laboratory test values. The blood of a person afflicted with SLE contains autoantibodies, which are the cause of the inflammation and organ damage, and are one indicator of immune system
abnormalities. Earlier diagnosis of SLE allows physicians to initiate the most appropriate therapy sooner in order to minimize organ damage. An independent study funded by GlaxoSmithKline plc and published in a peer-reviewed medical journal
concluded that early diagnosis of SLE is associated with better clinical outcomes, including lower flare rates, as well as reduced resource utilization and healthcare costs. However, more than half of those afflicted with lupus waited at least four
years, and saw three or more doctors, before obtaining a correct diagnosis, according to a Lupus Foundation of America survey. Patients with delayed or undiagnosed SLE will often continue to experience disease activity, potentially leading to
irreversible tissue or organ damage. Conversely, patients incorrectly diagnosed with SLE may be unnecessarily prescribed potentially toxic and harmful medications, such as high dose corticosteroids, and often undergo unnecessary referrals and
laboratory tests. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SLE is most common in women and usually develops during childbearing years, but men and children can also develop
the disease. The cause of SLE is unknown and, while it is more common in people who have a first-degree relative with SLE, most cases of SLE occur episodically, indicating that both genetic and environmental factors may play a role in disease
development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Diagnosis </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diagnosing
SLE is difficult due to the fluctuating nature of the disease and overlapping symptoms with other ARDs, fibromyalgia and autoimmune thyroid disease. Compounding this issue, the current immunological tests used to diagnose SLE lack combined
sensitivity and specificity. The ACR and the Systemic Lupus International Collaborating Clinics, or SLICC, have developed patient classification criteria for clinical trials that are used to support an SLE diagnosis. These criteria, which were
created as a classification tool for clinical studies rather than a diagnostic tool, are difficult to apply in practice due to SLE symptoms that evolve, change, disappear and reappear over time. Many SLE patients do not meet the ACR criteria
necessary for SLE classification at initial disease presentation and may not meet the criteria for months or even years. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Standard
laboratory tests for diagnosing SLE include measuring immunological biomarkers, such as ANA or anti-dsDNA, and other autoantibody tests. ANA is a useful screening tool for ARDs in general, including SLE, and the vast majority of SLE patients test
positive for ANA. However, the good sensitivity of ANA for SLE is counterbalanced by somewhat poor specificity. For instance, an analysis of serum samples from 4,754 people aged 12 or older in the National Health and Nutrition Examination Survey
taken from 1999-2004 found that 13.8% of these patients tested positive for ANA. If this rate was applied generally to the U.S. population over the age of 12, an estimated 32&nbsp;million Americans would test positive for ANA, but the vast majority
of these individuals would not have SLE, as only approximately 11-13% of individuals with a positive ANA test have SLE. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients who
test positive for anti-dsDNA are likely to have SLE, as anti-dsDNA is relatively specific for that disease. However, most patients with SLE do not have a positive anti-dsDNA test result. Thus, the diagnosis of SLE can be missed if the physician is
relying on the presence of a positive anti-dsDNA test. For instance, in our validation study for Avise SLE 2.0, the second generation of our integrated algorithmic test, 68% of patients with SLE tested negative for anti-dsDNA and would have not been
diagnosed with SLE based on the anti-dsDNA test. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a published study involving 476 patients, there was less than 50% agreement between
the diagnosis of the referring physician and the final diagnosis by an autoimmune sub-specialist. In the study, 27% of patients referred by a rheumatologist with an initial diagnosis of SLE were found to be misdiagnosed. Moreover, 29% of the
patients in the study with presumptive SLE diagnoses tested positive for ANA, but did not have an ARD. In addition, 39 patients who were positive for ANA but had no ARD were inappropriately treated with corticosteroids at doses as high as 60 mg per
day. We believe the drawbacks with ANA and anti-dsDNA testing contribute to the diagnostic challenges faced by physicians in definitively diagnosing SLE. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;80&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Physicians also measure components of the complement system, including serum levels of C3 and C4,
to help diagnose SLE and monitor SLE disease activity. In active SLE, C3 and C4 complement proteins are activated and broken down to fragments, known as complement activation products. Therefore, low levels of C3 and C4 suggest diagnosis of SLE and
that the disease is active. However, variability in the levels of C3 and C4 can occur due to factors unrelated to SLE disease presence or disease activity, making them less reliable as biomarkers for SLE. For example, deficiencies of C4 may occur in
SLE patients due to lower natural production of the C4 protein on a genetic basis, obscuring the impact of the disease on C4 levels. Furthermore, as with anti-dsDNA antibodies, many SLE patients have normal complement levels even when the disease is
active. Although relatively specific for SLE, low complement levels can also be seen in certain chronic infections, including non-lupus related kidney inflammation, severe liver disease and other ARDs. Despite these shortcomings, in 2012 the SLICC
added low C3 and low C4 as immunologic criteria for classifying SLE. The limitations of these tests for SLE diagnosis and the need for additional and better SLE biomarkers are generally recognized by the rheumatology community. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Treatment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once diagnosed, treatment of
SLE generally involves the use of antimalarials, corticosteroids, immunosuppressants, and newer biologic agents to prevent or suppress active disease or flares. During acute periods of more severe disease flares, physicians use corticosteroids at
high doses to control the autoimmune response and inflammation. While often effective at controlling disease, long-term use of these powerful agents can have serious, wide-ranging and long-term adverse effects, such as diabetes, osteoporosis and
high blood pressure. Due to the unpredictability of disease flares, there is a significant need for frequent monitoring of disease activity to guide therapeutic choices and optimize drug effectiveness. Even in patients who are appropriately
diagnosed, monitoring disease activity is imperfect because of the lack of accurate biomarkers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Large biopharmaceutical companies are
seeking to develop and commercialize new biologic therapies for SLE. In March 2011, the first new biologic drug targeting treatment of SLE in over 50&nbsp;years, Benlysta, was approved by the U.S. Food and Drug Administration, or FDA. Additionally,
five biologic therapies are currently in phase&nbsp;III clinical trials for SLE or Lupus Nephritis, a serious and common complication of SLE. We believe the significant investment made by the companies seeking to develop and commercialize these
therapies will result in a dramatic increase in the awareness and understanding of SLE, and that our products and our strategy of focusing on the rheumatologist and ARDs will benefit from this increased awareness and understanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due in part to the over and under diagnosis of SLE and the lack of tools to effectively monitor disease flares, treatment and management of
SLE remains suboptimal. Patients misdiagnosed with SLE may be unnecessarily prescribed potentially toxic and harmful medications and often undergo unnecessary referrals and laboratory tests. In addition, patients with a delayed or missed diagnosis
of SLE may continue to experience disease progression potentially leading to serious tissue or irreversible organ damage, such as renal failure or pulmonary fibrosis that could otherwise have been prevented with a prompt and correct initial
diagnosis and treatment. Physicians and patients are in need of improved, objective testing solutions to help with the diagnosis, prognosis and monitoring of patients with SLE. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to
providing physicians with products that address the significant unmet need for accurate and timely diagnosis, prognosis and monitoring of ARDs. We market four products under our Avise brand, which facilitate the accurate, timely and differential
diagnosis and prognosis of certain ARDs and drug-level monitoring of one of the most widely prescribed pharmaceuticals in rheumatology. These tests are designed to seamlessly integrate with a rheumatologist&#146;s daily workflow and each of our
tests are processed in our laboratory in California, which is certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA and accredited by the College of American Pathologists, or CAP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;81&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our differentiated product offering includes: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Diagnosis</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prognosis</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Monitoring</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center">


<IMG SRC="g693329g07q40.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329g79b67.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329g72g81.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g693329g31f69.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Diagnostic test incorporating our proprietary CB-CAPs technology to rule-in or rule-out SLE from other
ARDs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">Comprehensive SLE prognostic panel to assist in determining risk for kidney damage or neurologic or cardiovascular complications associated with SLE</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">Test to monitor levels of active methotrexate, a first-line therapy for&nbsp;RA</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">Blood test to monitor levels of HCQ, a commonly prescribed treatment for patients with SLE and other ARDs</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise SLE+CT </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product, which we
market under our Avise SLE+CT brand, is a proprietary diagnostic test that provides an enhanced solution for patients presenting with symptoms indicative of a wide variety of ARDs such as SLE, RA, Sj&ouml;gren&#146;s, scleroderma and other disorders
with similar symptoms, such as fibromyalgia and autoimmune thyroid disease. Avise SLE+CT allows physicians to more accurately rule-in or rule-out SLE, and inform decisions about the presence of other ARDs. Differential diagnosis of these diseases is
critically important because earlier diagnosis has been shown to improve patient outcomes. Once diagnosed, physicians can tailor therapy to a patient&#146;s specific disease and avoid the &#147;trial and error&#148; approach that often takes place
when a definitive diagnosis cannot be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise SLE+CT is comprised of our proprietary Avise SLE solution and other established
biomarkers to diagnose ARDs. Avise SLE is a ten-marker panel test that includes two biomarkers based on our CB-CAPs technology, which we exclusively license from the University of Pittsburgh, and a proprietary algorithm to optimize its performance.
CB-CAPs are relatively stable biomarkers found in the blood that are associated with the presence and activity of SLE. CB-CAPs, measured by flow cytometry, drive superior performance of our solution versus existing standards of diagnosis, including
ANA and anti-dsDNA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched Avise SLE in January 2012, following the completion of our CAPITAL study, which was published in
<I>Arthritis and Rheumatism</I> in 2012. Avise SLE incorporated our CB-CAPs technology with three existing autoantibodies, ANA, anti-dsDNA and anti-mutated citrullinated vimentin, or anti-MCV, to produce a proprietary five-marker SLE diagnostic with
an enhanced ability to distinguish SLE from selected ARDs, such as RA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2012 we launched Avise SLE+CT, which added additional
established autoantibodies for assisting in the diagnosis of a broader set of ARDs to our proprietary Avise SLE solution. We developed this offering to enhance the clinical utility of our test and respond to our customer&#146;s need for a more
comprehensive solution to assist in differentially diagnosing ARDs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched the second generation of our integrated algorithmic test,
Avise SLE 2.0, in February 2014, by integrating five additional autoantibodies into the algorithm of Avise SLE, resulting in a ten-marker proprietary test. This test further improves the ability to distinguish SLE from other ARDs, including RA,
scleroderma, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;82&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sj&ouml;gren&#146;s and polymyositis/dermatomyositis. Similar to our previous version, we added a panel of autoantibodies to Avise SLE 2.0, including extractable nuclear antigens,
anti-phospholipid syndrome, RA and thyroid autoantibodies for the detection of autoimmune thyroid disease. We market this improved second generation test as Avise SLE+CT 2.0. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Physicians are able to order our Avise SLE or our Avise SLE+CT solution. We believe physicians prefer our comprehensive panel to help diagnose
a broader set of ARDs, as well as the associated convenience for patients of a single blood draw. This is evidenced by Avise SLE+CT representing over 90% of our currently-marketed Avise SLE diagnostic products ordered during the six months ended
June&nbsp;30, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Test Report </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
provide the results of our Avise SLE diagnostic products to physicians typically within five business days following receipt from the physician of the blood draw from a patient. Our test&#146;s ability to provide accurate and timely information on a
broad range of ARDs is convenient for both physicians and their patients. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results are provided to physicians in an intuitive, easy to understand
report. A sample of an Avise SLE+CT report is shown below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;
</P><DIV STYLE="position:relative;float:left; margin-right:1%; width:48%;padding-right:9pt;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g693329g12o97.jpg" ALT="LOGO">
 </P></DIV><DIV STYLE="position:relative;float:right; width:48%;padding-right:9pt;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P>&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g693329g21a42.jpg" ALT="LOGO">
 </P></DIV><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;83&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Commercial Performance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have demonstrated significant growth in demand for our Avise SLE diagnostic products. For example, in the quarter ended June 30, 2014, our
quarterly orders for our Avise SLE diagnostic products increased 46% over the prior quarter and 209% over the quarter ended June&nbsp;30, 2013. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g693329g07c28.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have experienced growth in both the number of physicians utilizing our tests and the number of tests
ordered per physician. As of June&nbsp;30, 2014, the number of physicians utilizing our test had grown to more than 475, from 180 at June&nbsp;30, 2013. Each physician ordered an average of nearly 14 tests per quarter in the quarter ended June 30,
2014, as compared to an average of nearly 12 tests per quarter in the quarter ended June 30, 2013. Additionally, the number of physicians who order more than 10 tests from us per quarter has increased in every quarter since 2012, including from 49
at June&nbsp;30, 2013, to 149 at June&nbsp;30, 2014, and the number of physicians who re-order our tests has remained relatively stable at more than 70%. We believe this strong demand is a reflection of the value proposition we are providing to our
physician customers and represents the market need for an enhanced solution to differentially diagnose ARDs. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Validation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We validated Avise SLE 2.0 in a multi-center clinical study involving 794 subjects comprised of 304 SLE patients, 285 patients with other ARDs
and fibromyalgia, and 205 normal healthy subjects from two cohorts. The study was conducted in collaboration with leading academic centers with expertise in SLE and other ARDs, including Albert Einstein College of Medicine, Northwestern University,
North Shore-LIJ Health System and NYU College of Medicine, and the preliminary results were presented at the ACR annual conference in 2013. The primary endpoint of the study was the performance characteristics, specifically sensitivity and
specificity, of Avise SLE&nbsp;2.0 compared to common autoantibodies used to diagnose SLE and other ARDs, such as ANA and anti-dsDNA. Sensitivity measures the proportion of patients who are correctly identified as having a particular condition,
while specificity measures the proportion of patients who are correctly identified as not having a particular condition. The final results of this study showed that Avise SLE&nbsp;2.0: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstrated 86% specificity and 80% sensitivity in distinguishing SLE from other ARDs and fibromyalgia; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">was 33% more specific than ANA (53% specificity/89% sensitivity); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">was 48% more sensitive than anti-dsDNA (32% sensitivity/97% specificity). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;84&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This data suggests that Avise SLE&nbsp;2.0 ruled-in SLE effectively, allowing for greater
confidence in diagnosing the disease. The superior performance of Avise SLE&nbsp;2.0 over ANA and anti-dsDNA in this study is further demonstrated on the Receiver Operating Characteristic, or ROC, curve below. Each point on the ROC curve illustrates
a possible combined sensitivity and specificity. On a ROC curve, an ideal test (100% specific and 100% sensitive) would begin in the lower left corner, go straight to the upper left corner, then to the upper right corner, and the area under the
curve, or AUC, would be 1.0. On the other hand, a test without predictive value would be a straight diagonal line from the lower left corner to the upper right corner, with an AUC of 0.5. The superior performance of Avise SLE&nbsp;2.0 compared to
ANA and anti-dsDNA alone is highlighted in the diagram below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g693329g67l84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ROC curve also indicates the superior performance of Avise SLE 2.0 compared to Anti-Smith&#146;s
antibody, or Anti-Sm, another common biomarker for SLE due to its high specificity (greater than 99%). However, like anti-dsDNA, <FONT STYLE="white-space:nowrap">Anti-Sm</FONT> has low sensitivity and is found in only approximately 20% of patients
with SLE. In our validation studies for Avise SLE 2.0, Anti-Sm was 14% sensitive and 100% specific for SLE. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ongoing Clinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our ongoing efforts to further validate and establish Avise SLE 2.0 as the leading diagnostic solution for ARDs, we have initiated
additional studies that will expand the clinical utility of our solution. For example, we are collaborating with Columbia University on a study to further support the clinical utility of <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> for the
diagnosis of SLE. We are also conducting a study with a leading fibromyalgia expert to further establish the clinical utility of Avise SLE&nbsp;2.0 in distinguishing SLE from fibromyalgia, a common affliction with overlapping symptoms to ARDs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise SLE Prognostic </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise SLE
Prognostic, which was launched in June 2014, is a blood test that complements Avise SLE+CT by providing results which inform the prognosis of SLE patients and provide physicians with more information
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;85&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to tailor treatment for their patients. This test is a ten-marker panel of autoantibodies that have established predictive value for assessing the potential for complications affecting the
kidney, brain and cardiovascular system, including lupus nephritis, lupus psychosis, and thrombosis or blood clots. When physicians are ordering Avise SLE+CT, they can also request that we perform our Avise SLE Prognostic test if the initial Avise
SLE+CT result suggests that the patient has SLE. This provides additional convenience for ordering physicians and their patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise MTX
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise MTX is the first therapeutic drug monitoring test to precisely measure levels of methotrexate polyglutamates, or MTXPG, the
active form of MTX in the patient&#146;s blood. MTX is a first-line therapy for RA, and Avise MTX can allow physicians to personalize therapy by targeting the appropriate dose to individual patients. There is large variability in the way patients
absorb and metabolize MTX, and several studies have shown that low levels of MTXPG in the blood correlate with a lower response to MTX therapy. Avise MTX provides crucial information as to whether a patient has achieved MTXPG blood levels consistent
with an appropriate response to MTX, also known as the therapeutic level, or if the MTXPG levels are too low to produce adequate effects, which is known as the sub therapeutic level. The physician can then adjust MTX dosing as necessary to maximize
the benefit of MTX therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical validity and utility of Avise MTX has been established in numerous independent studies. In a
pivotal study published in peer-reviewed medical journals and sponsored by Prometheus Laboratories, our licensor and the original developer of the MTXPG technology, 258 patients with RA were treated with MTX. The study demonstrated that patients who
achieved MTXPG levels above 60 nanomoles per liter of red blood cells were five times more likely to respond adequately to MTX than patients who presented with MTXPG levels below 60 nanomoles per liter. Two other independent studies enrolling 500
patients in the aggregate also demonstrated the validity of MTXPG measurement as a drug monitoring solution in RA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise HCQ </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise HCQ is a blood test to help physicians objectively monitor blood levels of HCQ as they treat patients with SLE and other ARDs, including
RA. HCQ is typically prescribed daily to patients to control ARD activity and prevent flares. However, there is a large variability in the response to HCQ therapy, and patients can be poorly compliant. In order to optimize HCQ therapy, it is crucial
to determine if the patient is taking the drug as prescribed, and also to determine whether the blood levels are adequate and consistent with clinical efficacy. By measuring HCQ concentration in the blood, we believe that Avise HCQ will help
physicians optimize HCQ therapy, identify noncompliant patients and identify patients that are not absorbing the drug adequately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
launched our Avise HCQ drug monitoring solution in September 2014. By offering Avise HCQ along with our currently marketed Avise MTX test, we now address two drugs commonly prescribed by rheumatologists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are collaborating with leading academic centers, including Johns Hopkins University, to conduct a clinical study to generate support for
the utility of our test. This study, which is expected to enroll 50 subjects, is designed to evaluate the value of monitoring MTXPG and HCQ in the treatment of patients with SLE. The HCQ assay performance characteristics are supported by multiple
peer-reviewed medical journals, which established that HCQ levels in the blood correlate with disease control in SLE and RA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on delivering meaningful solutions to aid rheumatologists and other physicians in the diagnosis of patients with ARDs and
providing physicians with additional tools to determine the most appropriate therapy over time to improve patient care. Our pipeline includes solutions that differentially diagnose ARDs, provide prognosis of ARDs and monitor disease activity and
active drug levels. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;86&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our near-term pipeline is highlighted below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="10%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Test</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Description</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Category</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Status</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Estimated<BR>Launch</B></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em" ALIGN="center">


<IMG SRC="g693329g37c05.jpg" ALT="LOGO">
</P> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Measures anti-TNF active&nbsp;drug&nbsp;level&nbsp;and&nbsp;drug neutralizing
antibody</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">activity levels</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Drug<BR>Monitoring</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Validation in process</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1H</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2015</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em" ALIGN="center">


<IMG SRC="g693329g92b06.jpg" ALT="LOGO">
</P> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Measures SLE<BR>disease activity</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Disease<BR>Monitoring</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Validation in process</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1H</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2016</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center">


<IMG SRC="g693329g17c99.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="middle"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Determines&nbsp;potential&nbsp;risk
for&nbsp;bone&nbsp;damage&nbsp;or&nbsp;joint erosion/diagnosis&nbsp;of&nbsp;RA</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center">Prognostic/<BR>Diagnostic</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center">Validation complete; evaluation ongoing</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="middle" ALIGN="center">2016</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise Anti-TNF </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>Avise Anti-TNF is a blood test to help physicians monitor the levels of anti-TNF bioactivity in patients with RA. Many patients with RA
are treated with monoclonal antibodies that selectively inhibit the proinflammatory cytokine tumor necrosis factor <B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><B></B><B></B>, or
TNF<B>-</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><B></B><B></B>. Anti-TNF biologics are estimated to generate more than $5 billion in annual sales in the United States for RA and are used in an estimated 250,000 RA patients. However,
approximately 30% of patients either do not respond at all or have insufficient responses to these therapies. The<B> </B>lack of response is due to refractoriness to the mechanism of action of the drug itself, referred to as TNF blockade, or the
development of drug neutralizing antibodies. Due to this, rheumatologists are in need of a solution to precisely identify the cause of non-response to anti-TNF therapy. We believe Avise Anti-TNF can provide crucial information to help physicians
determine when to adjust the anti-TNF dose or switch to a different drug. <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently conducting analytical validation of
Avise Anti-TNF in the United States. If such analytical validation is successful, we anticipate launching this product in the first half of 2015 to monitor infliximab, etanercept and adalimumab, the three most utilized anti-TNF drugs. We intend to
expand the application of Avise Anti-TNF to include the other two currently commercialized anti-TNFs, certolizumab and golimumab. We believe that we will provide additional value to the rheumatologist by offering our Avise Anti-TNF along with our
currently marketed Avise MTX test because MTX, which is commonly prescribed with anti-TNF, is effective at improving anti-TNF efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise Anti-TNF incorporates iLite technology, the only commercially available cell-based assay that measures anti-TNF levels and drug
neutralizing antibodies. Avise Anti-TNF uses TNF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-sensitive cells in a bioassay that measures TNF<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> activity. The key advantage of the iLite technology
compared to other currently available anti-TNF monitoring tests is that it measures functional levels of anti-TNF. In addition, the iLite technology determines the presence of antidrug antibodies. The FDA has released guidance indicating that
cell-based assays are the preferred technology platform for determining immunogenicity for therapeutic proteins. The iLite technology is currently available in certain European countries through Biomonitor A/S, and has received a CE mark. We have a
distribution agreement with Biomonitor that allows us to sell and market the iLite technology in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;87&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise SLE Monitoring </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise SLE Monitoring is a multi-analyte panel blood test to help physicians track the disease status of their SLE patients. SLE is
characterized by the emergence of disease flares that may result in serious and irreversible damage to organs, including kidneys, lungs and brain. As such, rheumatologists and their patients are in need of methods that can help monitor disease
activity. We believe rheumatologists are in need of better monitoring solutions for their SLE patients and that the lack of validated disease activity biomarkers in SLE is a major hurdle to improving long term outcomes. We believe that our test will
facilitate the monitoring of SLE disease activity and provide the rheumatologists with actionable tools to improve therapy and patient outcomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are conducting two clinical validation studies to evaluate our proprietary CB-CAPs technology to monitor SLE disease activity.
Participating institutions include Albert Einstein College of Medicine, Northwestern University, North Shore-LIJ Health System, NYU College of Medicine and Oklahoma Medical Research Foundation. If these studies are successful, we anticipate
launching this product in the first half of 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Avise RA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise RA is a blood test to determine if a patient is at risk of bone damage or joint erosion. We expect that this test will also be helpful in
diagnosing RA, which impacts over one million adults in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the major complications of RA is the development of
bone damage or joint erosion that leads to severe disability and poor quality of life for the patient. The ACR guidelines have established disease remission and/or minimal disease activity as the clinical goals of therapy. Achieving these goals
requires early diagnosis and effective therapy. We believe that rheumatologists are in need of solutions to better diagnose and identify the patients having a high likelihood of rapid disease progression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Avise RA is a combination of our proprietary anti-mutated citrullinated vimentin, or anti-MCV, technology, which is licensed to us for the
United States and Mexico, and other well-established autoantibodies having prognostic and diagnostic value in RA, including anti-cyclic citrullinated peptide, or CCP, and rheumatoid factors, or RF. Several peer-reviewed medical journals have
published studies supporting the strong predictive value of anti-MCV for the development of bone damage and joint erosion in patients with RA. For example, in a study of 238 patients followed longitudinally for 10 years, a patient with a positive
anti-MCV test was 7.3&nbsp;times more likely to present with progressive bone damage than a patient with a negative anti-MCV test. In contrast, a patient with a positive anti-CCP antibody test, the standard of care test, was 5.7 times more likely to
present with progressive bone damage than a patient with a negative anti-CCP antibody test. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, not all RA patients test
positive for autoantibodies commonly ordered to assist in diagnosing RA, such as RF and CCP. RF may be found in as few as 30% of patients with early RA, while 30-40% of RA patients have no detectable anti-CCP. Such patients are referred to as
sero-negative patients and represent a group of patients that can be missed for RA diagnosis. We believe that our solution containing anti-MCV will assist the physician in the diagnosis of these sero-negative patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently evaluating the addition of a novel RA biomarker to Avise&nbsp;RA, which, if added, may require an additional validation
study. We currently anticipate launching this product in 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and Marketing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We target the approximately 3,500 community rheumatologists in the United States. We launched Avise SLE in January 2012 with a nine-person
sales force. In the fourth quarter of 2013, we began the expansion of our sales team to approximately 30 sales professionals. This expansion was mostly completed by the end of the first quarter of 2014. These sales professionals generally have
experience in healthcare sales with backgrounds in rheumatology, therapeutics, and/or laboratory services. Our sales professionals are divided into three regions of the United States, East, Southeast and West, which are each led by a dedicated
regional director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;88&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our sales force has a focused approach that emphasizes execution in three core areas: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Targeting</I>.<I></I> We utilize market analytics, demographic data and pharmaceutical and historical diagnostic test usage to create the most effective territories for us to target community rheumatologists.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Messaging.</I> We emphasize increased accuracy over current standard of care methodologies, which is achieved through the proprietary components of our Avise products. In addition, we offer timely results along with
the convenience of one blood draw and a transportation kit that we provide to customers. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Frequency.</I> We execute a high-frequency calling strategy for key physician targets and their office personnel. We believe that repetition builds knowledge, understanding and retention of the benefits of our Avise
product suite. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to expand our sales force to approximately 40 sales representatives by mid-2015, which sales
force we believe can cover approximately 80% of community rheumatologists in the United States. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ multi-faceted marketing
programs to educate and inform physicians, patients and other key stakeholders of the value of our solutions in order to facilitate adoption. We primarily achieve this through advertising, promotion, social media, working with key opinion leaders at
national and regional clinical conventions focused on ARDs and continuing medical education programs. In these settings, academic and community physicians can educate their peers on the benefits of Avise products and provide personal testimony of
the value they have received from using our Avise products. We participate with patient advocacy organizations, such as the Lupus Foundation of America, and medical societies, such as the ACR, directly through support of their meetings, medical
conferences, and direct educational efforts. Finally, our website provides educational material for healthcare professionals, payers and patients. We intend to expand the scale and scope of our marketing programs to target internet marketing,
patient awareness and educational programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have a centralized, dedicated client services department that augments our
sales force and marketing activity by providing personalized customer support. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our sales strategy is focused on achieving sustainable
long-term growth of our market share for products addressing ARDs. Specifically, we intend to grow our market share by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the number of physicians that order our tests; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the number of tests ordered by each physician; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the number of products offered to each physician. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reimbursement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reimbursement for our testing services comes from several sources, including commercial third-party payers, government payers and patients. We
bill for testing procedures using common Current Procedural Terminology, or CPT, codes that describe the procedures performed in the lab for our Avise SLE diagnostic products, Avise SLE Prognostic, Avise MTX and Avise HCQ. We have received a
positive Local Coverage Determination for Avise MTX from Palmetto GBA, the then-Medicare contractor for California, which became effective in April 2012. In 2014, we have received payments from major payer organizations such as Aetna, Anthem Blue
Cross/Blue Shield, Blue Shield, Cigna, Managed Medicaid, Medicare, Medicare Advantage and United Healthcare, along with additional commercial carriers and patients; however, we do not have contracts with any significant large private payers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even though we are currently being reimbursed for our tests, continued reimbursement depends on a number of factors, including payer
determination that our tests are medically necessary, appropriate for the patient, cost effective and clinically valid. In addition, our commercial success depends on payers agreeing to pay for new tests we launch. If we are unable to obtain or
maintain coverage and adequate reimbursement from third-party payers for our existing tests or new tests, our ability to generate revenue may be limited. In addition, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;89&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have in the past and will likely in the future experience delays and temporary interruptions in the receipt of payments from government and other third-party payers due to changes in their
internal processes, which could cause our revenues to fluctuate from period to period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Protecting Access to Medicare Act of 2014, or
PAMA, which was signed into law on April 1, 2014, significantly alters the current payment methodology under the Medicare Clinical Laboratory Fee Schedule, or CLFS. Under PAMA, beginning January&nbsp;1, 2016, clinical laboratories must report
laboratory test payment data for each Medicare-covered clinical diagnostic lab test that it furnishes during a time period to be defined by future regulations. The reported data must include the payment rate (reflecting all discounts, rebates,
coupons and other price concessions) and the volume of each test that was paid by each private payer (including health insurance issuers, group health plans, Medicare Advantage plans and Medicaid managed care organizations). Beginning in 2017, the
Medicare payment rate for each clinical diagnostic lab test will be equal to the weighted median amount for the test from the most recent data collection period. Although it is too early to predict the impact on reimbursement for our Avise products,
we expect reimbursement rates to be relatively stable through January&nbsp;1, 2017 when implementation of the market-based payment system and separate recognition of advanced diagnostic tests goes into effect. We anticipate that the implementation
of the advanced diagnostic laboratory test category under PAMA may allow for our primary product, Avise SLE, to realize additional reimbursement based on the proprietary nature of the test&#146;s unique CB-CAPs markers and testing algorithm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ a multi-pronged strategy designed to achieve broad coverage and reimbursement for our Avise brands. The key elements of our strategy
for Avise SLE, which we also intend to pursue for our other products, include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Demonstrated Product Demand.</I> We intend to facilitate interactions between the expanding base of providers using the test and the payer community to raise payer awareness of the clinical benefits of Avise SLE.
Orders of Avise SLE increased by 378% from 2012 to 2013. In addition, the number of new ordering providers increased by 244% from 2012 to 2013. These trends, along with the high retention rate of frequent users, demonstrate substantial momentum in
the growing demand for this test. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Demonstrated Product Performance.</I> We have conducted clinical studies to help demonstrate the ability of Avise SLE to meet or exceed performance of established testing in the area of ARD diagnosis, which we
believe is important to establishing positive coverage decisions. For example, we conducted a multi-center study which enrolled 794 subjects with a primary endpoint that consisted of performance characteristics, specifically sensitivity and
specificity, of Avise SLE compared to common autoantibodies used to diagnose SLE and other ARDs, such as ANA and anti-dsDNA. The results of this study showed that Avise SLE demonstrated 86% specificity and 80% sensitivity in distinguishing SLE from
other ARDs, was 33% more specific than ANA (53% specificity/89% sensitivity) and was 48% more sensitive than anti-dsDNA (32% sensitivity/97% specificity). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expanding our Clinical Data Package</I>. Clinical validation of Avise SLE was demonstrated through a collaborative effort with multiple centers of excellence specializing in ARDs. We believe that our continued
collaborative efforts with key opinion leaders and ARD centers of excellence to further expand our clinical utility data which we intend to publish in peer-reviewed medical journals to support potential inclusion in clinical guidelines and help
drive payer coverage and reimbursement. We believe that inclusion of Avise SLE into clinical guidelines will help to establish us as a standard of care for the diagnosis of patients with ARDs. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Execution of an Internal Managed Care Policy and Claims Adjudication Function.</I> We believe that obtaining adequate and widespread coverage and reimbursement is a critical factor to our success. We employ a team of
revenue assurance professionals that collaborate with our contracted billing provider to work with payers to maximize reimbursement. In parallel, a managed care director collaborates with our reimbursement specialists to ensure our payer outreach
strategy reacts to and anticipates the changing needs of our customer base. Our customer service team is an integral part of our reimbursement strategy, working with patients and physician practices to effectively navigate the claims process.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;90&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Technology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary technology platform determines the blood levels of complement pathway components stably deposited on cells known as Cell Bound
Complement Activation Products, or CB-CAPs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The complement pathway is an important part of the immune system and refers to a complex
network of over 30 soluble and membrane bound proteins that interact in a highly regulated manner to provide many of the effector functions of immunity and inflammation. The integrity of the complement system is critically important for preventing
infections and the development of autoimmune diseases, including SLE. Once activated, the proteins within the complement system perform various functions, including the eradication of pathogens, such as bacteria and fungi, and also the effective
removal of cellular debris and immune complexes from the blood. Additionally, the activation of the complement system releases proteins that mediate inflammation, which is observed in a variety of diseases beyond ARDs, including Alzheimer&#146;s
disease, asthma, Crohn&#146;s disease and macular degeneration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The determination of complement proteins in a patient&#146;s blood is a
mainstay in clinical laboratory science, and state-of-the-art methods traditionally rely on measurement of serum or plasma levels of soluble complements. C3 and C4 are the most commonly determined complement proteins in the blood and the precursors
to activation of complement proteins into biologically active breakdown products. However, there are limitations with measuring C3 and/or C4 blood levels as indicators of complement activation. For example, increased synthesis of C3 and C4 by the
liver can offset increased C3 and C4 breakdown during activation of the complement cascade, resulting in no change in serum levels. Conversely, genetic alteration in C4 genes can result in abnormally low serum/plasma levels of C4 due to lack of
synthetic capacity that can be misinterpreted as being due to increased C4 consumption during complement activation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitations and
drawbacks of measuring standard components of the complement system, such as C3&nbsp;and C4, are well recognized by the medical community. We believe the availability of novel complement biomarkers supporting or replacing standard C3 and C4 measures
will be of great value for the clinicians and ultimately their patients. Our CB-CAPs technology, which we exclusively license from the University of Pittsburgh, is the result of a decade of extensive research and development conducted in academia
and has the potential to fulfill the unmet need for better biomarkers assessing complement system&#146;s function and role in health and disease. The technology directly measures protein products of complement activation, such as C3d, the product of
C3&nbsp;activation, and C4d, the product of C4 activation. These complement activation products become stably attached to surfaces of circulating blood cells to become CB-CAPs. For example, the deposition of the C4d&nbsp;fragment to erythrocytes
forms erythrocyte C4d, or EC4d. Similarly, the deposition of C4d fragment on B&nbsp;lymphocytes forms BC4d. As such, the determination of CB-CAPs in the blood provides the following benefits when compared to the traditional complement measurement:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">accurate and unequivocal information of complement activation that has occurred in a given patient; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">stable biomarkers of complement activation enabling accurate and consistent measurement after collection and transportation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">better ability to assess and monitor changes in biological activity related to activation of the complement system. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CB-CAPs are determined using blood collected from the patient by standard venipuncture in collection tubes and shipped overnight to our
central laboratory for processing. Because of their stability, we were able to demonstrate that this transportation process does not impair our ability to accurately measure CB-CAPs levels. The process in our clinical laboratory consists of the
isolation of the cells (e.g. erythrocytes and B-lymphocytes) using techniques such as centrifugation or lysis, followed by their incubation and processing with a combination of antibodies that specifically label the CB-CAPs with a light emitting
compound detectable by fluorescence assisted cell sorting, or FACS. The instrument used to detect these labeled CB-CAPs is a flow cytometer, which readily measures the fluorescence signal (expressed as mean fluorescence intensity, or MFI) and thus,
the level of CB-CAPs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;91&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our differentiated CB-CAPs technology can be used to more effectively diagnose,
prognose and monitor patients with certain inflammatory diseases, including autoimmune, hematologic, vascular, or infectious diseases. For example, CB-CAPs such as EC4d and BC4d are significantly higher in patients with SLE compared to patients with
other ARDs and, as such, forms the basis of the diagnostic value of our Avise SLE diagnostic products. The table below highlights several published clinical studies demonstrating the higher CB-CAPs level in patients with SLE compared to other ARDs.
For example, in the Kalunian study, BC4d levels were 3.1 times higher (110.4 versus 34.9 units) in SLE than in patients with other ARDs and 4.7 fold higher than normal subjects (110.4 vs 23.5 units). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:66.15pt; font-size:8pt; font-family:Times New Roman"><B>Author/Publication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">CB-CAP</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Patients</B><br><B>(SLE/non<BR>SLE)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SLE*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other</B><br><B>ARDs*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Normals*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manzi et al. Arthritis Rheum 2004</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">EC4d</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">100/217</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liu et al., Clin Trans Sci 2009</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">BC4d</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">224/293</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liu et al, Arthritis Rheum 2005</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">EC4d</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">156/299</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yang et al. Rheumatology 2009</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">EC4d</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">63/69</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kao et al. Arthritis Rheum 2010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">EC4d</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">157/546</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kalunian et al. Arthritis Rheum 2012</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kalunian et al. Arthritis Rheum 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ALIGN="right">EC4d<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">BC4d</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">210/383<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210/383</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ALIGN="right">17.6<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">110.4</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ALIGN="right">6.3<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">34.9</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom" ALIGN="right">5.3<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">23.5</P></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Results are expressed as average or median MFI for each group </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we are currently focusing
our CB-CAPs technology on differentially diagnosing SLE (as part of our Avise SLE diagnostic products), this technology has potential applications in many of the disease states in which the complement system plays a role. In addition to expanding
application in ARDs, such as monitoring for disease activity in SLE, we believe that CB-CAPs has the potential to be relevant in broader indications, such as monitoring complications in organ transplantation, pregnancy and vascular disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research
and development efforts are focused on developing novel solutions for rheumatologists and enhancing our current product offering. Additionally, we believe there is significant potential to capitalize on our CB-CAPs and iLite technology platforms and
integrate them with commercially available markers to create high-value tests with superior clinical utility. We intend to continue to establish the value of our Avise products, as well as introduce new and improved versions of these tests. For
example, in February 2014 we added extractable nuclear antigens to our Avise SLE test to improve the ability of the test to distinguish SLE from other ARDs, such as Sj&ouml;gren&#146;s, scleroderma and polymyositis/dermatomyositis. Furthermore, we
believe our bio-repository of well-characterized specimens, collected in collaboration with leading academic institutions, will help us to further validate our Avise products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have an extensive track record of accomplishments in all phases of research and development, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expertise in Assay Development, Validation, and Technology Transfer</I>.<I></I> Our team of scientists has extensive experience and demonstrated ability with the development of analytical techniques in the areas of
drug monitoring, cellular immunology, immunoassays and molecular diagnostics. We also have expertise with the validation of analytical assays and the establishment of performance characteristics satisfying the standard requirement from regulatory
bodies including CAP. Our analytical techniques have been subjected to rigorous review from the New York State Department of Health, or NYDOH, and are marketed as laboratory developed tests, or LDTs. We are also continuously improving the
performance characteristics of our assays, enhancing throughput and robustness. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><I>Expertise with the Clinical Development and Validation of Multivariate Index Assays/Algorithms.</I> Our clinical development and validation team
has extensive knowledge and a track record in the clinical </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;92&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
development of a wide range of complex tests, including large, well-designed clinical trial in collaboration with leading academic institutions. We have also been successful in publishing the
results of our clinical validation studies in peer-reviewed medical journals. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Laboratory Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We perform all of our Avise tests in our 8,500 square foot CLIA-certified, CAP accredited laboratory located in Vista, California. Our
laboratory is certified for performance of high-complexity testing by the Centers for Medicare and Medicaid Services, or CMS, in accordance with CLIA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a physician orders an Avise test, the physician or physician&#146;s staff completes a test requisition. A&nbsp;blood draw is performed on
the patient, and the specimen is placed in a temperature-controlled transportation kit provided by us. The specimen is sent to our laboratory via commercial overnight shipment. Upon receipt, we examine each specimen for integrity. We label each
specimen with a unique identifier and pertinent information is entered into our laboratory information system, or LIS. The labeled specimen is then delivered to the flow cytometry and special chemistry laboratory for processing. The results are
entered into the LIS and reviewed by a technical supervisor who ensures they conform to specifications. Following this, the LIS generates a test report, which is reviewed and approved by the laboratory director and is then delivered to the
physician. Reports for our Avise tests are typically delivered to the physician in less than five business days following the receipt of the sample. Despite significant increases in the volume of tests we have performed in recent quarters, we have
maintained our ability to provide timely results to our physician customers. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to continue to increase automation, enhance
our information systems and optimize our workflows to enhance and improve the efficiency of our processes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quality Assurance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our quality assurance function oversees the quality of our laboratory as well as research and development, client services, billing, sales and
marketing operations. We have established oversight for systems implementation and maintenance procedures, document control processes, supplier qualification, preventive or corrective actions, and employee training processes that we believe achieves
excellence in operations. We continuously monitor and improve our processes and procedures and believe this high quality service leads to customer satisfaction and retention. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the principal
competitive factors in our target market include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">quality and strength of clinical and analytical validation data; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">confidence in diagnostic results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales and marketing capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent of reimbursement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inclusion in practice guidelines; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effectiveness; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ease of use. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we compete favorably on the factors described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal competition for our Avise products comes from traditional methods used by physicians to test patients with rheumatic
disease-like symptoms. Such traditional methods include testing for a broad range of diagnostic, immunology and chemistry markers, such as ANA and anti-dsDNA, and serum complement, such as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;93&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
C3 and C4. We also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, ARUP Laboratories, Inc. and Mayo Clinic, all
of which have strong infrastructures to support the commercialization of diagnostic services. Large, multispecialty group medical clinics, health systems and academic medical university-based clinics may provide in-house clinical laboratories
offering autoimmune rheumatic testing services. Additionally, we compete against regional clinical laboratories providing testing in the autoimmune rheumatic field, including Rheumatology Diagnostics Laboratories, Inc.&nbsp;Other potential
competitors include companies that might develop diagnostic or disease or drug monitoring products, such as Myriad Genetics, Inc. In the future, we may also face competition from companies developing new products or technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and
development resources and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could be viewed by physicians and payers as functionally equivalent to our solution, or offer solutions at prices
designed to promote market penetration, which could force us to lower the list price of our products and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against
current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause the market price of our common stock to decline.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
strive to protect and enhance the proprietary technologies that we believe are important to our business and seek to obtain and maintain patents for any patentable aspects of our diagnostic products and services and any other inventions that are
important to the development of our business. Our success will depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, to defend and
enforce our patents, to maintain our licenses to use intellectual property owned by third parties, to preserve the confidentiality of our trade secrets and to operate without infringing the valid and enforceable patents and other proprietary rights
of third parties. We also rely on continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the fields targeted by our diagnostic products and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are the owner or licensee of a portfolio of patents and patent applications and possess substantial know-how and trade secrets which
protect various aspects of our business. The patent families comprising our patent portfolio are primarily focused on our Avise products for the diagnosis and use in treatment of ARDs, and are generally directed to CB-CAPs, red blood cell MTXPG
exposure assessments, and anti-MCV antibodies. We intend to leverage the intellectual property surrounding our Avise products as an important component of our business strategy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of
individual patents and patent applications listed below will depend upon the legal term of the patents in the countries in which they are obtained. In most countries, the patent term is 20 years from the date of filing of the patent application (or
parent application, if applicable). For example, if an international Patent Cooperation Treaty, or PCT, application is filed, any patent issuing from the PCT application in a specific country will expire 20 years from the filing date of the PCT
application. In the United States, however, if a patent was in force on June&nbsp;8, 1995, or issued on an application that was filed before June&nbsp;8, 1995, that patent will have a term that is the greater of 20 years from the filing date, or 17
years from the date of issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;94&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Protection for our Avise Products </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our portfolio of patents and patent applications related to our Avise products generally relates to three aspects: CB-CAPs, red blood cell
MTXPG exposure assessments, and anti-MCV antibodies. The patent families which we believe are important for the protection of Avise are summarized below in the section entitled &#147;&#151;License Agreements.&#148; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Cell Bound Complement Activation Products and Services (CB-CAPs)</I>. We are the exclusive licensee of five patent families related to CB-CAPs technology from the University of Pittsburgh. We expect that these patent
families (U.S. Patent Nos. 7,361,517; 7,390,631; 7,585,640; 7,588,905; 8,080,382; and 8,126,654) will expire in 2024 or 2025. A foreign patent corresponding to U.S. Patent No.&nbsp;7,361,517 has issued in Europe (EP 1,756,571). Foreign patents
corresponding to U.S. Patent No.&nbsp;7,390,631 have issued in Japan (JP 4570872 and JP 4906898). Foreign patents corresponding to U.S. Patent No.&nbsp;7,585,640 have issued in Australia (AU&nbsp;2005242719) and Canada (CA 2,564,492). A foreign
patent corresponding to U.S. Patent Nos. 7,588,905 and 8,126,654 has issued in Japan (JP 45500051). We also own two pending patent application families that relate to our Avise SLE diagnostic products. In order to manage our foreign filing costs and
focus on the U.S. market, we made the decision to cease the prosecution and maintenance of several of our foreign patents and patent applications related to our CB-CAPs technology, including EP 1,432,731; EP 1,618,379; EP 1,635,692; EP 1,745,287; EP
2,214,014; EP 2,216,650, and certain of their corresponding family members<B><I>.</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Methotrexate (MTX) Exposure Assessment Products and Services</I>. We are the exclusive licensee of four patents and one pending patent application that relate to our Avise MTX product line and methods for monitoring
MTX therapy using red blood cell MTXPG exposure assessments. These patents and patent application are owned by Prometheus Laboratories and are exclusively licensed to us for all uses except for use in gastrointestinal diseases. These patents include
U.S. Patent Nos. 6,921,667; 7,563,590; 7,582,282 and 7,695,908, which are expected to expire between 2023 and 2027. We also own two pending U.S. patent applications and are the exclusive licensee of two pending patent applications that relate to our
Avise MTX product. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-mutated Citrullinated Vimentin (anti-MCV) Antibodies and Related Services. </I>We are the exclusive licensee of a patent family related to anti-MCV, an autoantibody having diagnostic and prognostic value in RA.
This family, owned by Orgentec Diagnostika, includes a pending U.S. patent application. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proprietary Rights and Processes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may rely, in some circumstances, on proprietary technology and processes (including trade secrets) to protect our technology. However, these
can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, consultants,
scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information
technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any such breach. In addition, our proprietary technology and
processes may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants, scientific advisors, contractors, or any future collaborators use intellectual property owned by others in their work
for us, disputes may arise as to the rights in related or resulting know-how and inventions. For this and more comprehensive risks related to our proprietary technology and processes, please see &#147;Risk Factors&#151;Risks Related to our
Intellectual Property.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own the registered trademarks &#147;Avise,&#148; &#147;Avise PG,&#148; &#147;Avise MCV&#148; and &#147;Avise SLE,&#148; in the United States
for use in connection with our diagnostic products, namely, our Avise SLE diagnostic products, Avise SLE </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;95&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prognostic, and Avise MTX. We intend to pursue additional registrations in markets outside the United States where we plan to sell our Avise products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amended and Restated
Exclusive License Agreement with the University of Pittsburgh </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2011, we entered into an amended and restated exclusive
license agreement with the University of Pittsburgh, or UPitt, to amend and restate the exclusive license agreement we obtained by our purchase of the medical diagnostics division of Cypress Bioscience, Inc., or Cypress, in 2010, or the Cypress
Purchase, and to obtain an exclusive license to UPitt&#146;s patent rights in certain inventions, or the UPitt Patent Rights, related to the use of <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology in the diagnosis, prognosis and monitoring
of diseases, including certain patents related to our Avise SLE diagnostic products. The agreement was amended twice, once in May 2012 to, among other things, limit the territory of the license to the United States and exclude certain foreign
patents and applications from the agreement, and once in September 2013 to add (1)&nbsp;an additional U.S. patent to the UPitt Patent Rights licensed under the agreement and (2)&nbsp;the field of monitoring of organ transplantation and organ
rejection to the scope of the license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we are permitted to make, use and sell products and services utilizing the
UPitt Patent Rights in the field of SLE and the field of monitoring of organ transplantation and organ rejection, and to sublicense such rights. UPitt retained the right to practice under the UPitt Patent Rights and to use such rights for
non-commercial education and research purposes. In addition, this agreement is subject to the rights of the United States government, if any, as set forth in 35 U.S.C. &#167;200, et seq. Pursuant to this law, the U.S. government may have acquired a
nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the U.S. government the inventions described in the UPitt Patent Rights throughout the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for the rights granted to us under the agreement, we made certain upfront payments to UPitt on the first and second
anniversaries of the agreement, which payments increased and will continue on the third and subsequent anniversaries of the agreement until the first sale of products or services utilizing the UPitt Patent Rights. We are required to pay UPitt a low
single-digit royalty on net sales of products or services utilizing the UPitt Patent Rights sold by us or our affiliates, subject to minimum annual royalty payments and other adjustment in certain circumstances. We are also required to make a
$0.2&nbsp;million milestone payment to UPitt if we achieve certain levels of net sales. Our royalty obligations continue for each licensed product or service on a country-by-country basis until the expiration of the last licensed patent covering the
applicable licensed product or service in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we sublicense any of the UPitt Patent Rights, we are obligated to
pay UPitt a low single-digit percentage sublicense royalty on net sales of products or services sold by our sublicensees that utilize the sublicensed UPitt Patent Rights and a low double-digit percentage of all non-royalty sublicensing income
received by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement requires that we diligently develop and commercialize products that are covered by the UPitt Patent Rights,
and we have agreed to meet certain development and commercial milestones. UPitt may terminate the agreement if we fail to meet such milestones. In addition, if we fail to meet a milestone relating to development of the UPitt Patent Rights in the
monitoring of organ transplantation and organ rejection field, UPitt may remove that field from our licensed rights. We are currently in compliance with these milestone requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate the agreement upon six months&#146; written notice to UPitt. UPitt may terminate the agreement in the event of our
nonperformance of any of our obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of our insolvency. Absent early
termination, the agreement will continue until the expiration date of the longest-lived patent right included in the UPitt Patent Rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;96&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusive License Agreement with the University of Pittsburgh </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We made an economic decision to cease the maintenance and licensing of UPitt Patent Rights outside the United States, which led to such rights
returning to UPitt. We subsequently made the determination to re-license these foreign patent rights from UPitt, but at the time of re-licensing these patent rights, a number of the foreign patent rights had permanently lapsed. Accordingly, in
September 2013, we entered into an exclusive license agreement with UPitt to obtain an exclusive license to UPitt&#146;s remaining ex-U.S. patent rights in certain inventions, or the ex-U.S. UPitt Patent Rights, related to the use of CB-CAPs
technology in the diagnosis, prognosis and monitoring of diseases, including certain patents related to our Avise SLE diagnostic products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we are permitted to make, use and sell products and services utilizing the ex-U.S. UPitt Patent Rights in the field of
SLE and the field of monitoring of organ transplantation and organ rejection outside of the United States, and to sublicense such rights. UPitt retained the right to practice under the ex-U.S. UPitt Patent Rights and to use such rights for
non-commercial education and research purposes. In addition, this agreement is subject to the rights of the U.S. government, if any, as set forth in 35 U.S.C. &#167;200, et seq. Pursuant to this law, the U.S. government may have acquired a
nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the U.S. government the inventions described in the ex-U.S. UPitt Patent Rights throughout the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for the rights granted to us under the agreement, we paid an initial license fee to UPitt. We are also required to pay UPitt
a low single-digit royalty on net sales of products or services utilizing the ex-U.S. UPitt Patent Rights sold by us or our affiliates, subject to adjustment in certain circumstances. Our royalty obligations continue for each licensed product or
service on a country-by-country basis until the expiration of the last licensed patent covering the applicable licensed product or service in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we sublicense any of the ex-U.S. UPitt Patent Rights, we are obligated to pay UPitt a low single-digit percentage sublicense
royalty on net sales of products or services sold by our sublicensees that utilize the sublicensed ex-U.S. UPitt Patent Rights and a low double-digit percentage of all non-royalty sublicensing income received by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement requires that we diligently develop and commercialize products that are covered by the ex-U.S. UPitt Patent Rights, and we have
agreed to meet certain commercial milestones. UPitt may terminate the agreement if we fail to meet such milestones. We are currently in compliance with these milestone requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate the agreement upon six months&#146; written notice to UPitt. UPitt may terminate the agreement in the event of our
nonperformance of any of our obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of our insolvency. Absent early
termination, the agreement will continue until the expiration date of the longest-lived patent right included in the UPitt Patent Rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License
Agreement with Prometheus Laboratories, Inc. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Cypress Purchase, we acquired a license agreement, dated September
2007, between Prometheus Laboratories, Inc., or Prometheus, and Proprius Pharmaceuticals, Inc., or Proprius, a company which had been previously acquired by Cypress. Pursuant to this agreement, we obtained an exclusive, worldwide license to
Prometheus&#146;s patent rights in certain inventions, or the Prometheus Patent Rights, related to the diagnosis, prognosis and monitoring of diseases, including certain patents related to our Avise products and services. This agreement was
subsequently amended in October 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we are permitted to research, develop, manufacture and commercialize products
utilizing the Prometheus Patent Rights and to sublicense such rights; provided, however, that any such sublicenses may only be granted with Prometheus&#146;s consent. We are not permitted to develop or commercialize products utilizing the Prometheus
Patent Rights for use in diagnosing or treating any gastrointestinal diseases or to promote any such products to gastroenterologists. Pursuant to the agreement, we are obligated to use </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;97&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonable commercial efforts to undertake certain development activities with respect to products utilizing the Prometheus Patent Rights, including the completion of certain clinical studies. In
addition, in the event that we do not timely complete these studies or approved substitute studies, we will become obligated to pay to Prometheus a one-time payment of $50,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to make a milestone payment of $2.0 million upon the achievement of certain net sales. In addition, we are required to pay
Prometheus tiered royalties in the mid-single-digit range on sales of any products utilizing the Prometheus Patent Rights by us, our affiliates or our sublicensees. Our royalty obligations continue on a licensed product-by-licensed product and
country-by-country basis until the expiration, lapse or invalidation of the last valid claim in a licensed patent covering the applicable licensed product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we sublicense any of the Prometheus Patent Rights, we are obligated to pay to Prometheus a fee based on a percentage of
sublicense fees received by us, which percentage is in the mid-twenties. In addition, we are also required to pay to Prometheus a percentage of the royalty payments we receive from our sublicensees, which may not be less than a certain low
single-digit percentage of net sales of products or services sold by our sublicensees that utilize the sublicensed Prometheus Patent Rights, nor more than a certain mid-single digit percentage of such net sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may unilaterally terminate the agreement for any reason upon 60 days&#146; written notice to Prometheus. Either party may terminate this
agreement in the event of the other party&#146;s material breach of the agreement if such breach remains uncured for a certain period of time following receipt of written notice of such breach or in the event of the other party&#146;s insolvency.
Absent early termination, the agreement will continue until the expiration date of the longest-lived patent right included in the Prometheus Patent Rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License Agreement with Orgentec Diagnostika GmbH </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Cypress Purchase, we acquired a license agreement, dated February 2008, between Proprius and Orgentec Diagnostika GmbH,
or Orgentec. Pursuant to this agreement, we obtained an exclusive license to Orgentec&#146;s patent rights and know-how in certain inventions, or the Orgentec Patent Rights, related to anti-MCV, an autoantibody, including certain patent applications
related to our Avise products and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we are permitted to research, develop, manufacture and commercialize
products utilizing the Orgentec Patent Rights for diagnosis, prognosis and monitoring applications, including diagnosis, prognosis and monitoring of RA, in the United States and Mexico, and to sublicense such rights. We are not permitted to use the
Orgentec Patent Rights for therapeutic applications. We have a right of first negotiation to license additional products from Orgentec for use in the diagnostic, prognostic and monitoring field in the United States or Mexico. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to pay Orgentec a low single-digit royalty on any products utilizing the Orgentec Patent Rights, subject to adjustment in
certain circumstances. We are also obligated to pay Orgentec a percentage in the mid-twenties of sublicense revenues received by us for products or services sold by our sublicensees that utilize the sublicensed Orgentec Patent Rights. Our royalty
obligations continue on a licensed product-by-licensed product and country-by-country basis until the expiration of the last licensed patent covering the applicable licensed product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may unilaterally terminate the agreement for any reason upon 90 days&#146; written notice to Orgentec. Either party may terminate this
agreement in the event of the other party&#146;s material breach of the agreement if such breach remains uncured for a certain period of time following receipt of written notice of such breach. Absent early termination, the agreement will continue
until the expiration date of the longest-lived patent right included in the Orgentec Patent Rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;98&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Asset Purchase Agreement with Cypress and Proprius </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2010, we completed the Cypress Purchase pursuant to an asset purchase agreement with Cypress and its wholly-owned subsidiary,
Proprius, under which we obtained certain assets related to our Avise products and services. The agreement was amended three times, once in March 2011 to change certain obligations relating to certain accounts receivable we acquired from Cypress,
once in August 2012 to convert a one-time payment obligation to a payment plan over four years with interest, and once in February 2013 to convert a one-time contingent milestone payment obligation concerning a CB-CAPs monitoring assay to a payment
plan over two years with interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for the acquisition, we made certain initial cash payments to Cypress and to Proprius
and we are currently making payments to Cypress pursuant to the August 2012 amendment, which payments are subject to acceleration in certain circumstances. In addition, we are required to make certain one-time contingent milestone payments for two
third-party commercial programs, for the launch of a CB-CAPs monitoring assay, and for the achievement of an annual, worldwide net sales level for CB-CAPs products, which milestone payments are estimated at an aggregate of between $3.0 and $4.0
million. The agreement requires that we use commercially reasonable efforts to cause each of the milestones to be achieved. We are required to pay Cypress a low double-digit royalty on the world wide net sales of CB-CAPs products for a period of
several years, and we are required to pay Proprius a low double-digit royalty on the net sales of certain new products for a period of several years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Asset Purchase Agreement With Cellatope </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Cypress Purchase, we acquired an asset purchase agreement, dated February 2009 and amended December 2012, between
Cypress and Cellatope Corporation, or Cellatope. Pursuant to this agreement, we obtained assets related to our Avise products. In the event we or a licensee sells an SLE monitoring product, we are required to issue Cellatope a promissory note for
$3.0&nbsp;million, bearing interest at a rate of 5% per annum. On the first anniversary of such note, accrued interest for the previous 12 months shall be added to the principal amount, and following such first anniversary, the adjusted amount shall
accrue interest at the same rate, and we must pay off the note plus accrued interest in 48 equal monthly payments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Thierry Dervieux and De
Novo Diagnostics, Inc. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2011, we entered into a license agreement with Dr.&nbsp;Thierry Dervieux, our Chief Scientific
Officer, and his company De Novo Diagnostics, Inc., under which we obtained an exclusive, worldwide (except for Australia and New Zealand) license to Dr.&nbsp;Dervieux&#146;s patent rights and know-how in certain inventions, or the Dervieux Patent
Rights, related to the diagnosis, prognosis and monitoring of diseases, including certain patents related to our Avise products and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement, we are permitted to develop, manufacture and commercialize products utilizing the Dervieux Patent Rights in the human
healthcare market, and to sublicense such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considerations for the rights granted to us under the agreement, we are required to
make milestone payments, up to an aggregate of $600,000, upon achievement of certain sales milestones. In addition, we are required to pay Dr.&nbsp;Dervieux a mid-single-digit royalty on net sales by us or our affiliates of any products utilizing
the Dervieux Patent Rights, subject to adjustment in certain circumstances. We are also obligated to pay Dr.&nbsp;Dervieux a percentage in the mid-twenties of sublicense fees and royalties received by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement requires that we diligently develop and commercialize products that are covered by the Dervieux Patent Rights, and we have
agreed to use commercially reasonable efforts to bring technology covered by the Dervieux Patent Rights to market as soon as practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may unilaterally terminate the agreement upon 12 months&#146; written notice to Dr.&nbsp;Dervieux. Either party may terminate this
agreement in the event of the other party&#146;s nonperformance of any of its obligations under the agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;99&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
if such nonperformance remains uncured for a specified period of time following receipt of written notice of such nonperformance or in the event of the other party&#146;s insolvency. Absent early
termination, the agreement will continue until the expiration date of the longest-lived patent right included in the Dervieux Patent Rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Laboratory Improvement
Amendments of 1988 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a clinical reference laboratory, we are required to hold certain federal, state and local licenses,
certifications and permits to conduct our business. Under CLIA, we are required to hold a certificate applicable to the type of laboratory tests we perform and to comply with standards applicable to our operations, including test processes,
personnel, facilities administration, equipment maintenance, recordkeeping, quality systems and proficiency testing. We must maintain CLIA compliance and certification to be eligible to bill for diagnostic services provided to Medicare
beneficiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have current certification under CLIA to perform testing at our Vista facility. To renew our CLIA certificate, we are
subject to survey and inspection every two years to assess compliance with program standards. The regulatory and compliance standards applicable to the testing we perform may change over time, and any such changes could have a material effect on our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our clinical laboratory were to be found to be out of compliance with CLIA requirements, we may be subject to sanctions,
such as suspension, limitation or revocation of our CLIA certificate, as well as directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit or criminal penalties, any of which could adversely affect our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>California Laboratory Licensing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to federal certification requirements of laboratories under CLIA, licensure is required and maintained for our Vista clinical
reference laboratory under California law. Such laws establish standards for the day-to-day operation of a clinical reference laboratory, including the training and skills required of personnel and quality control. In addition, California laws
mandate proficiency testing, which involves testing of specimens that have been specifically prepared for the laboratory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our clinical
reference laboratory were to be found out of compliance with California standards, the California Department of Health Services, or DHS, may suspend, restrict or revoke our license to operate our clinical reference laboratory, assess substantial
civil money penalties, or impose specific corrective action plans, any of which could materially affect our business. We maintain a current license in good standing with DHS. However, we cannot provide assurance that DHS will at all times in the
future find us to be in compliance with all such laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>New York Laboratory Licensing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we receive specimens from New York, our clinical reference laboratory is required to be licensed by New York, under New York laws and
regulations, which establish standards for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">day-to-day operation of a clinical laboratory, including training and skill levels required of laboratory personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">physical requirements of a facility; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">equipment; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">validation and quality control. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York law also mandates proficiency testing for
laboratories licensed under New York state law, regardless of whether such laboratories are located in New York. If a laboratory is out of compliance with New&nbsp;York statutory or regulatory standards, the NYDOH may suspend, limit, revoke or annul
the laboratory&#146;s New York license, censure the holder of the license or assess civil money penalties. Statutory or regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;100&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
noncompliance may result in a laboratory&#146;s operator being found guilty of a misdemeanor under New York law. NYDOH also must approve the LDT before the test is offered in New York. We have
received written approval from NYDOH to offer our products in New York. If we were to be found out of compliance with New York laboratory requirements, we could be subject to such sanctions, which could harm our business. We maintain a current
license in good standing with NYDOH for our laboratory. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other States&#146; Laboratory Licensing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to New York and California, other states, including Florida, Maryland, Pennsylvania and Rhode Island, require licensing of
out-of-state laboratories under certain circumstances. We have obtained licenses from states where we believe we are required to be licensed, and believe we are in compliance with applicable licensing laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens
from the state, and it is possible that other states currently have such requirements or will have such requirements in the future. If we identify any other state with such requirements or if we are contacted by any other state advising us of such
requirements, we intend to comply with such requirements. Collecting specimens from a state that requires us to obtain and maintain an out-of-state laboratory license, without receiving such license, may result in sanctions, any of which could harm
our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Federal Oversight of Laboratory Developed Tests </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws and regulations governing the marketing of diagnostic products are evolving, extremely complex, and in many instances there are no
significant regulatory or judicial interpretations of these laws and regulations. Clinical laboratory tests like Avise SLE+CT, Avise SLE Prognostic and Avise MTX are regulated under CLIA, as administered by CMS, as well as by applicable state laws.
In addition, the Federal Food, Drug and Cosmetic Act, or FDCA, defines a medical device to include any instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component
part, or accessory, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals. Our in vitro diagnostic products are considered by the FDA to be subject
to regulation as medical devices. Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, pre-market clearance or approval,
marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. In addition, the FDA regulates the export of medical
devices manufactured in the United States to international markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the FDA has statutory authority to assure that medical
devices are safe and effective for their intended uses, the FDA has generally exercised its enforcement discretion and not enforced applicable regulations with respect to in vitro diagnostics that are developed, validated, and offered within a
single laboratory for use only in that laboratory. We believe that the Avise SLE+CT and Avise MTX are LDTs, as are our near term pipeline candidate tests. As a result, we believe our diagnostic services should not be subject to regulation under
established FDA policies. However, one of the devices we market under license is subject to a 510(k) clearance held by Orgentec Diagnostika GmbH and is subject to the FDA&#146;s regulations applicable to 510(k)-cleared devices. In addition,
reagents, instruments, software or components provided by third parties and used to perform LDTs may be subject to regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant
to the Food and Drug Administration Safety and Innovation Act, the FDA notified Congress on July&nbsp;31, 2014 that FDA intends to issue, on or after September&nbsp;30, 2014, a draft guidance entitled &#147;Framework for Regulatory Oversight of
Laboratory Developed Tests (LDTs),&#148; or the Framework Guidance. The anticipated details of the Framework Guidance state that FDA intends to modify its policy of enforcement discretion with respect to LDTs in a risk-based manner consistent with
the classification of medical devices generally in Classes I through III. The FDA states its intention in the Framework Guidance to publish general LDT classification guidance within 18 months of date on which the Framework Guidance is finalized.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;101&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA begins to actively regulate LDTs, we may be required to obtain premarket clearance
under Section&nbsp;510(k) of the FDCA or a premarket approval, or PMA. The process for submitting a 510(k) premarket notification and receiving FDA clearance usually takes from three to twelve months, but it can take significantly longer and
clearance is never guaranteed. The process for submitting and obtaining FDA approval of a PMA is much more costly, lengthy and uncertain. It generally takes from one to three years or even longer and approval is not guaranteed. PMA approval
typically requires extensive clinical data and can be significantly longer, more expensive and more uncertain than the 510(k) clearance process. If premarket review is required for some or all of our products, the FDA could require that we stop
selling our products pending clearance or approval and conduct clinical testing prior to making submissions to FDA to obtain premarket clearance or approval. If our diagnostic services are allowed to remain on the market but there is uncertainty
about the legal status of our services, if we are required by the FDA to label them as investigational, or if labeling claims the FDA allows us to make are limited, order levels may decline and reimbursement may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the FDA&#146;s notification to Congress on July&nbsp;31, 2014 of its intent to publish the draft Framework Guidance in 60 days or
more, we cannot predict the ultimate form of any LDT guidance or other agency action with respect to LDTs and the potential effect on our solutions or materials used to perform our diagnostic services. While we qualify all materials used in our
diagnostic services according to CLIA regulations, we cannot be certain that the FDA might not ultimately promulgate rules or issue guidance documents that could affect our ability to purchase materials necessary for the performance of our
diagnostic services. Should any of the reagents obtained by us from vendors and used in conducting our diagnostic services be affected by future regulatory actions, our business could be adversely affected by those actions, including increasing the
cost of service or delaying, limiting or prohibiting the purchase of reagents necessary to perform the service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative proposals
addressing oversight of LDTs have been introduced in recent years and we expect that new legislative proposals will be introduced in the future. It is possible that legislation could be enacted into law or regulations or guidance could be issued by
the FDA which may result in new or increased regulatory requirements for us to continue to offer our diagnostic services or to develop and introduce new services. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Health Insurance Portability and Accountability Act </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, and the Health Information Technology for Economic and
Clinical Health Act, or HITECH Act, the U.S. Department of Health and Human Services, or HHS, has issued regulations to protect the privacy and security of protected health information used or disclosed by certain entities including health care
providers, such as us. HIPAA also regulates standardization of data content, codes and formats used in certain health care transactions and standardization of identifiers for health plans and providers. Penalties for violations of HIPAA and HITECH
laws and regulations include civil and criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Three standards have been promulgated under HIPAA&#146;s and HITECH&#146;s
regulations: the Standards for Privacy of Individually Identifiable Health Information, which restrict the use and disclosure of certain individually identifiable health information, the Standards for Electronic Transactions, which establish
standards for common healthcare transactions, such as claims information, plan eligibility, payment information and the use of electronic signatures, and the Security Standards for the Protection of Electronic Protected Health Information, which
require covered entities and business associates to implement and maintain certain security measures to safeguard certain electronic health information, including the adoption of administrative, physical and technical safeguards to protect such
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2009, Congress passed the American Recovery and Reinvestment Act of 2009, or ARRA, which included sweeping changes to
HIPAA, including an expansion of HIPAA&#146;s privacy and security standards. ARRA includes the HITECH Act, which, among other things, made HIPAA&#146;s security standards directly applicable to business associates of covered entities effective
February&nbsp;17, 2010. A business associate is a person or entity that performs certain functions or activities on behalf of a covered entity that involve the use or disclosure of protected health information for or on behalf of the covered entity.
As a result, business associates are now </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;102&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to significant civil and criminal penalties for failure to comply with applicable standards. Moreover, HITECH creates a new requirement to report certain breaches of unsecured,
individually identifiable health information and imposes penalties on entities that fail to do so. This requirement was modified and expanded by the final HIPAA Omnibus Rule of 2013. HITECH also increased the civil and criminal penalties that may be
imposed against covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney fees and costs associated
with pursuing federal civil actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA also governs patient access to laboratory test reports. Effective October&nbsp;6, 2014,
individuals (or their personal representatives, as applicable) have the right to access test reports directly from laboratories and to direct that copies of those reports be transmitted to persons or entities designated by the individual. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed and implemented policies and procedures designed to comply with these regulations. The requirements under these regulations
may change periodically and could have an effect on our business operations if compliance becomes substantially more costly than under current requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to federal privacy regulations, there are a number of state laws governing confidentiality of health information that are
applicable to our business, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New laws governing privacy and security may be adopted in the future as well. We have taken steps to comply with federal and state health
information privacy and security requirements to which we are aware that we are subject. However, we can provide no assurance that we are or will remain in compliance with diverse privacy and security requirements in all of the jurisdictions in
which we do business. Failure to comply with privacy and security requirements could result in civil or criminal penalties, which could have a materially adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Federal and State Physician Self-Referral Prohibitions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, and to similar state law restrictions,
such as California&#146;s Physician Ownership and Referral Act, or PORA, and other comparable state laws. Together these restrictions generally prohibit us from billing a patient or any governmental or private payer for certain designated health
services, including clinical laboratory services, when the physician ordering the service, or any member of such physician&#146;s immediate family, has a financial interest, such as an ownership or investment interest in or compensation arrangement
with us, unless the arrangement meets an exception to the prohibition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both the Stark Law and PORA, as well as many other state law
equivalents, contain an exception for compensation paid to a physician for personal services rendered by the physician provided that the arrangement meets certain regulatory requirements. We have compensation arrangements with a number of physicians
for personal services, such as speaking engagements and consulting activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, we cannot be certain that regulators would find
these arrangements to be in compliance with Stark, PORA or similar state laws. We would be required to refund any payments we receive pursuant to a referral prohibited by these laws to the patient, the payer or the Medicare program, as applicable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sanctions for a Stark Law violation include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">denial of payment for the services provided in violation of the prohibition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refunds of amounts collected by an entity in violation of the Stark Law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a civil penalty of up to $15,000 for each bill or claim for a service arising out of the prohibited referral; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the imposition of up to three times the amounts for each item or service wrongfully claimed; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;103&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">possible exclusion from federal healthcare programs, including Medicare and Medicaid; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a civil penalty of up to $100,000 for each arrangement or scheme that the parties know (or should know) has the principal purpose of circumventing the Stark Law&#146;s prohibition. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These prohibitions apply regardless of any intent by the parties to induce or reward referrals or the reasons for the financial relationship
and the referral. In addition, knowing violations of the Stark Law may also serve as the basis for liability under the Federal False Claims Act, which can result in additional civil and criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a violation of PORA is a misdemeanor and could result in civil penalties and criminal fines. Other states also have self-referral
restrictions with which we have to comply, some of which differ from those imposed by the Stark Law or California law. It is possible that some of our financial arrangements with physicians could be subject to regulatory scrutiny at some point in
the future, and we cannot provide assurance that we will be found to be in compliance with these laws following any such regulatory review. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Federal
and State Fraud and Abuse Laws </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Federal Anti-kickback Statute makes it a felony for a person or entity, including a clinical
laboratory, to knowingly and willfully offer, pay, solicit or receive any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in order to induce business that is reimbursable under any federal health care program. A
violation of the Anti-kickback Statute may result in imprisonment for up to five years and fines of up to $25,000 for each violation and administrative civil money penalties of $50,000 plus up to three times the amount of the remuneration paid.
Convictions under the Anti-kickback Statute result in mandatory exclusion from federal health care programs for a minimum of five years. In addition, The U.S. Department of Health and Human Services, or HHS, has the authority to impose civil
assessments and fines and to exclude health care providers and others engaged in prohibited activities from Medicare, Medicaid and other federal health care programs. In addition, the government may now assert that a claim that includes items or
services resulting from a violation of the Anti-kickback Statute constitutes a false or fraudulent claim under the Federal False Claims Act, which is discussed in greater detail below. Additionally, the intent standard under the Anti-Kickback
Statute was amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the ACA, to a stricter standard such that a person or entity no longer needs to have
actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Anti-kickback
Statute applies only to items and services reimbursable under any federal health care program, a number of states, including California, have passed statutes substantially similar to the Anti-kickback Statute that apply to all third-party payers,
including commercial insurers. The California Attorney General and courts have interpreted the California anti-kickback and fee-splitting laws in substantially the same way as HHS and the courts have interpreted the Anti-kickback Statute. Penalties
of such state laws include imprisonment and significant monetary fines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal and state law enforcement authorities scrutinize
arrangements between health care providers and potential referral sources to ensure that the arrangements are not designed as a mechanism to induce patient care referrals or induce the purchase or prescribing of particular products or services. The
law enforcement authorities, the courts and Congress have also demonstrated a willingness to look behind the formalities of a transaction to determine the underlying purpose of payments between health care providers and actual or potential referral
sources. Generally, courts have taken a broad interpretation of the scope of the Anti-kickback Statute, holding that the statute may be violated if merely one purpose of a payment arrangement is to induce referrals or purchases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to statutory exceptions to the Anti-kickback Statute, regulations provide for a number of safe harbors. If an arrangement meets
the provisions of a safe harbor, it is deemed not to violate the Anti-kickback Statute. An arrangement must fully comply with each element of an applicable safe harbor in order to qualify for protection. There are no regulatory safe harbors under
California laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;104&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the safe harbors that may be relevant to us is the discount safe harbor. The discount safe
harbor potentially protects certain discounts provided by providers and suppliers, including laboratories, to physicians or institutions. If the terms of the discount safe harbor are met, the discounts will not be considered prohibited remuneration
under the Anti-kickback Statute. Although California does not have a discount safe harbor, the California statute has generally been interpreted consistent with the Anti-kickback Statute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The personal services safe harbor to the Anti-kickback Statute protects certain remuneration paid to a referral source for personal services,
provided all of the elements of that safe harbor are met. One element is that if the agreement is intended to provide for the services of the physician on a periodic, sporadic or part-time basis, rather than on a full-time basis for the term of the
agreement, the agreement specifies exactly the schedule of such intervals, their precise length, and the exact charge for such intervals. Our personal services arrangements with some physicians may not meet the specific requirement of this safe
harbor that the agreement specify exactly the schedule of the intervals of time to be spent on the services because the nature of the services, such as speaking engagements and blood-draw fee agreements, does not lend itself to exact scheduling.
Failure to meet the requirements of the safe harbor, however, does not render an arrangement illegal. Rather, the government may evaluate such arrangements on a case-by-case basis, taking into account all facts and circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that our relationships with physicians, academic institutions and other customers will not be subject to
investigation or challenge under such laws. If imposed for any reason, sanctions under these laws could have a negative effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other
Federal and State Health Care Laws </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the requirements discussed above, several other health care fraud and abuse laws
could have an effect on our business. For example, provisions of the Social Security Act permit Medicare and Medicaid to exclude an entity that charges the federal health care programs substantially in excess of its usual charges for its services.
The terms &#147;usual charge&#148; and &#147;substantially in excess&#148; are subject to varying interpretations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the Federal
civil False Claims Act prohibits, among other things, a person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval and from, making, using, or causing to be made or used, a false record or
statement material to a false or fraudulent claim in order to secure payment or retaining an overpayment by the federal government. In addition to actions initiated by the government itself, the statute authorizes actions to be brought on behalf of
the federal government by a private party having knowledge of the alleged fraud. Because the complaint is initially filed under seal, the action may be pending for some time before the defendant is even aware of the action. If the government
intervenes and is ultimately successful in obtaining redress in the matter or if the plaintiff succeeds in obtaining redress without the government&#146;s involvement, then the plaintiff will receive a percentage of the recovery. Finally, the Social
Security Act includes its own provisions that prohibit the filing of false claims or submitting false statements in order to obtain payment. Violation of these provisions may result in fines, imprisonment or both, and possible exclusion from
Medicare or Medicaid programs. Several states, including California, have enacted comparable false claims laws that apply to all payers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to
have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. A person who offers or provides to a Medicare or
Medicaid beneficiary any remuneration, including waivers of co-payments and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#146;s selection of a particular provider, practitioner
or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary penalties of up to $10,000 for each wrongful act and up to three times the amount improperly claimed. Moreover, in certain cases, providers who routinely
waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Anti-Kickback Statute and False Claims Act. One of the statutory exceptions to the prohibition is non-routine,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;105&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts. The Office of Inspector General
of the Department of Health and Human Services, or OIG, emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this prohibition applies only to federal
healthcare program beneficiaries, applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud, may also be implicated
for similar practices offered to patients covered by commercial payers. It is possible that some of our business practices, including the waiver and/or reduction of co-payments and deductible amounts, could be subject to regulatory scrutiny at some
point in the future, and we cannot provide assurance that we will be found to be in compliance with these laws following any such regulatory review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, HIPAA created new federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting
to execute, a scheme to defraud any healthcare benefit program, including private third-party payers, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent
statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Federal Anti-kickback Statute, the ACA amended the intent standard for certain healthcare fraud under HIPAA such that a person or entity no
longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, many
states have similar fraud and abuse laws that may be broader in scope and may apply regardless of payer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to
be in violation of any of the fraud and abuse laws described above or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal and civil and/or administrative penalties, damages, fines,
disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our
operations, any of which could adversely affect our ability to operate our business and our results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA, among other
things, also imposed new reporting requirements on manufacturers of certain devices, drugs and biologics for certain payments and transfers of value by them and in some cases their distributors to physicians and teaching hospitals, as well as
ownership and investment interests held by physicians and their immediate family members. Any failure to comply with these reporting requirements could result in significant fines and penalties. Because we manufacture our own LDTs solely for use by
or within our own laboratory, we believe that we are exempt from these reporting requirements. We cannot assure you, however, that the government will agree with our determination, and a determination that we have violated these laws and
regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2014, we had 71
employees, all but one of whom are full-time, 12 of whom work in laboratory operations, six in research and development, 42 in sales and marketing and 11 in general and administrative. None of our employees is represented by a labor union or covered
by a collective bargaining agreement. We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Suppliers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on sole suppliers for critical supply of reagents, equipment and other materials that we use to perform the tests that comprise our
Avise products. We also purchase components used in our Avise product transportation kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;106&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lease approximately 14,000 square feet of office and laboratory space in Vista, California, under a lease that expires in 2017, with options
to extend the lease for two additional 36-month periods. We have also entered into a lease for an additional approximately 19,500 square feet of office space in Vista, California, which commences on February 1, 2015 and expires in 2018, with an
option to extend for an additional 24 months. We also lease approximately 3,200 square feet of office space in Albuquerque, New Mexico, under a lease that expires in November 2014. We believe that our existing facilities and arrangements are
adequate to meet our business needs for at least the next 12 months and that additional space will be available on commercially reasonable terms, if required. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Environmental Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations
require the use of hazardous materials (including biological and chemical materials) which subject us to a variety of federal, state and local environmental and safety laws and regulations. We could be held liable for damages and fines as a result
of our business operations. We cannot predict how changes in laws or regulations will affect our business, operations or the cost of compliance. We mitigate this risk by being in compliance with these laws and the CAP checklists. We have established
Universal Precautions, as mandated by the Occupational Safety &amp; Health Administration, to be practiced to prevent employee exposure to blood and other potentially infectious materials. Engineering and work practice controls are used to eliminate
or minimize employee exposure. Personal protective equipment is used when occupational exposure may occur even though the engineering and work practice controls are in place. This Injury and Illness Prevention Program, or IIPP, is designed to
furnish employees with a safe and healthy place of employment. This IIPP describes specific requirements for program responsibility, compliance, communication, hazard assessment, accident/exposure investigations, hazard correction, training and
recordkeeping. In addition, appropriate biohazardous, chemical and sharps waste disposal are in place. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us
that we believe are likely to have a material adverse effect on our business, operating results or financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;107&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the name, age and position of each of our executive officers, key employees and directors as of September&nbsp;19, 2014. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:27.50pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wendy Swedick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thierry Dervieux, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Key Employees</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Claudia Ibarra</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Laboratory Operations</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Wegener</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Sales and Managed Markets</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dennis Takasugi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Business Development and Marketing</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Littlefield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Information Services</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Non-Employee Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Curt LaBelle, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board of Directors</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ebetuel Pallares, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Birk<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John M. Radak<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arthur Weinstein, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frank Witney, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Member of the compensation committee </I></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(2)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Member of the audit committee </I></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(3)</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Member of the nominating and corporate governance committee </I></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Fortunato Ron Rocca</I> has served as our President and Chief Executive Officer and as a member of our board of directors since December
2011. From 2005 to October 2011, Mr.&nbsp;Rocca served as Vice President, Sales and Marketing, and as General Manager, at Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company which was acquired by Nestl&eacute; SA in 2011,
where he was responsible for leading the commercial organization, strategic planning and implementing projects designed to maximize brand sales. Prior to Prometheus, Mr.&nbsp;Rocca was the General Manager of Alpharma Inc., a specialty pharmaceutical
company. Earlier in his career, Mr. Rocca served in senior sales and marketing management positions for Elan Pharmaceuticals, Inc., a neuroscience-focused biotechnology company and Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson
&amp; Johnson. Mr.&nbsp;Rocca received a B.A. in Marketing and Personnel Management from Towson State University. Mr.&nbsp;Rocca&#146;s extensive knowledge of our business, as well as his over 25 years of experience in the diagnostic and
pharmaceutical industries, contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Wendy Swedick </I>has served as our Chief Financial Officer since June 2010. Prior to joining Exagen, Ms.&nbsp;Swedick founded Vector B
Consulting, a business consulting practice, in 2003 and she served as its President until August 2010. Ms.&nbsp;Swedick previously served as the Director of Product Development for Qynergy Corporation, a company which designs and develops energy and
power solutions, and Chief Financial Officer of Zia Laser, Inc., a semiconductor laser manufacturing company. Prior to that, Ms.&nbsp;Swedick served as Vice President and Controller at the cable division of Media One Group, Inc., a
telecommunications company which was acquired by AT&amp;T Corp. in 2000, and as a senior accountant at KPMG LLP. Ms.&nbsp;Swedick is currently a senior mentor for the New Directions Institute and graduated with honors with a B.A. in Business
Administration&nbsp;&amp; Accounting from the University of New Mexico. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;108&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><I>Thierry Dervieux, Ph.D. </I><B><I></I></B>has served as our Chief Scientific
Officer and Medical Laboratory Director since October 2010. Dr.&nbsp;Dervieux has nearly 20 years of experience with the development of drug monitoring and molecular diagnostic assays in partnership with academia and diagnostic industry. Prior to
joining Exagen, Dr.&nbsp;Dervieux was Vice President of Research and Development with Cypress Bioscience, Inc., a pharmaceutical company with a focus on drugs to treat central nervous system disorders, where he developed our current portfolio in the
rheumatology space from 2008 to October 2010. He previously served as Senior Director Research&nbsp;and Development with Proprius Pharmaceuticals, Inc., a specialty pharmaceutical and personalized medicine company focused in rheumatology and pain
management, until its acquisition by Cypress Bioscience. Prior to that, he served as Principal Scientist and Director of Research&nbsp;and Development at Prometheus Laboratories. Dr.&nbsp;Dervieux is board certified by the American Board of Clinical
Chemistry and holds certificates of qualification as medical laboratory director in the categories of cellular immunology, clinical chemistry, drug monitoring, genetic testing and diagnostic immunology. Dr.&nbsp;Dervieux holds Pharm.D. and Ph.D.
degrees from Claude Bernard University in Lyon, France, an inter-university diploma in biostatistics from the University of Pierre et Marie Curie in Paris, France, and trained at St. Jude Children&#146;s Research Hospital in Memphis, Tennessee.
<B><I> </I></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Claudia Ibarra </I>has served as our Vice President, Laboratory Operations since January 2014, after joining Exagen in February 2012 as our
Senior Director, Laboratory Operations. Ms.&nbsp;Ibarra previously served in numerous positions at Genoptix, Inc., a diagnostic services company focused on the needs of community hematologists and oncologists, from 2006 to January 2012, including as
the Director, Molecular Laboratory and as the Molecular Genetic Training Program Coordinator. Prior to Genoptix, Ms.&nbsp;Ibarra worked in a variety of clinical laboratories in the fields of clinical chemistry, endocrinology and immunology.
Ms.&nbsp;Ibarra holds a degree in Biochemistry with specialization in clinical laboratory science from the University of Buenos Aires, Argentina.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>John Wegener </I>has served as our Vice President, Sales and Managed Markets since November 2013. Prior to joining Exagen, Mr.&nbsp;Wegener
served in various capacities with Prometheus Laboratories from 1999 to October 2013, including as the National Director, Managed Care and a Regional Sales Director. During his time at Prometheus, Mr.&nbsp;Wegener launched five new diagnostic tests
and managed diagnostic channels with national general reference laboratories. Prior to Prometheus, Mr.&nbsp;Wegener worked in sales for Novartis. Mr.&nbsp;Wegener holds a B.S. in Business from the University of Arizona.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dennis Takasugi </I>has served as our Vice President, Business Development and Marketing since April 2011. Prior to joining Exagen, from
2005 to April 2011, Mr.&nbsp;Takasugi served as the Head of Strategic Business Development, Gastroenterology, at Prometheus Laboratories. Prior to Prometheus, Mr.&nbsp;Takasugi served as the Senior Director of Marketing for Santarus, Inc., a
gastroenterology-focused specialty pharmaceutical company, from 2002 to 2005. Prior to that, Mr.&nbsp;Takasugi worked in business development and marketing for Maxim Pharmaceuticals, Inc., a biopharmaceutical company developing cancer therapeutics,
from 2000 to 2002, and for Ligand Pharmaceuticals, Inc., a pharmaceutical company, from 1998 to 2000. Mr.&nbsp;Takasugi began his career by spending 15 years at Eli Lilly and Company. Mr.&nbsp;Takasugi holds a B.S. in Pharmacy from Idaho State
University, where he graduated with honors.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Brian Littlefield </I>has served as our Vice President, Information Services since
April 2014. Prior to joining Exagen, Mr.&nbsp;Littlefield served as the Senior Director, Information Services at Prometheus Laboratories from 1998 to March 2014. At Prometheus, Mr.&nbsp;Littlefield led the establishment of the IT function and was
highly involved with the creation and execution of controls necessary for regulatory compliance. Prior to Prometheus, Mr.&nbsp;Littlefield worked as a consultant with Deloitte and as the Director of Support Services at Quidel Corporation, a
diagnostics company. Mr.&nbsp;Littlefield holds a B.S. in Biochemistry from Purdue University and an M.B.A. from Pepperdine University.<I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;109&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-Employee Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Curt LaBelle, M.D.</I> has served as a member of our board of directors since April 2011 and as chairman of the board since December 2011.
Dr.&nbsp;LaBelle has served as the Managing Director of Tullis Health Investors, a venture capital firm, since 2008. Since October 2011, Dr.&nbsp;LaBelle has served as chairman of the board of SafeOp Surgical, Inc., a medical device and technology
company. He previously served on the board of Impulse Monitoring, Inc., a neuromonitoring company, from June 2008 until the company was sold to NuVasive, Inc. in October 2011. Dr.&nbsp;LaBelle has also previously served as a member of the board of
directors of Sirion Therapeutics, Inc., a company specializing in ophthalmology drugs which was sold to Bausch&nbsp;&amp; Lomb, Inc. and Alcon, Inc. in a two-part transaction in 2010, KAI Pharmaceuticals, a pharmaceutical company developing drugs
for patients with chronic kidney disease which was sold to Amgen Inc. in 2012, and TransMolecular, Inc., a neuroscience biotechnology company developing products to treat central nervous system disorders which was sold to Morphotek, Inc. in 2011. He
has also served in other advisory capacities with Coherex Medical, Inc. and Endoscopic Technologies, Inc. d/b/a Estech. Dr.&nbsp;LaBelle holds an M.D. and M.B.A. from Columbia University and a B.S. from Brigham Young University.
Dr.&nbsp;LaBelle&#146;s extensive experience serving as a venture capitalist and board member to numerous companies in the healthcare industry contributed to our board of directors&#146; conclusion that Dr.&nbsp;LaBelle should serve as a director of
our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Ebetuel Pallares, Ph.D.</I> has served as a member of our board of directors since October 2012. Dr.&nbsp;Pallares
founded Joseph Advisory Services, LLC, a strategic consulting firm, in 2006, and has served as its manager since that time. In June 2009, he co-founded Cottonwood Capital Partners, the general partner of Cottonwood Technology Fund, a seed and
early-stage venture fund with headquarters in El Paso, Texas, and he has served as its managing partner since that time. Dr.&nbsp;Pallares also serves on several corporate and non-profit boards, as an advisor to the UT Horizon Fund, the venture
capital investment fund of the University of Texas system, as an Investor in Residence for New Mexico State University&#146;s Arrowhead Center and on the limited partnership advisory committee for several venture funds. He received a B.A. in
economics from Brandeis University, an M.B.A. from The University of Texas at El Paso, or UTEP, and a Ph.D. in International Business from UTEP. Dr.&nbsp;Pallares&#146;s extensive venture capital experience and his service as a director for numerous
companies contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Brian Birk</I> has
served as a member of our board of directors since June 2008. In 2006, Mr.&nbsp;Birk co-founded Sun Mountain Capital, a boutique private equity firm focused on the Southwest and Rocky Mountain regions which currently manages direct investment funds
and funds of funds vehicles. Prior to forming Sun Mountain Capital, Mr.&nbsp;Birk was a Vice President and Director of Private Equity at Fort Washington Capital Partners, a professional investment management services company. Mr.&nbsp;Birk was also
a senior executive at MetaWeb Technologies, Inc., a technology and web development company acquired by Google Inc. in 2010, the vice president of technology commercialization at Applied Minds, LLC, a technology consulting company, and the president
of a division at BiosGroup Inc., a company which commercialized complex science software<I>.</I> In addition, Mr.&nbsp;Birk held a senior manager position at the Boston Consulting Group, Inc., a global management consulting firm, and finance manager
positions at General Electric Company and GE Capital Corporation. Mr.&nbsp;Birk is a currently a member of the board of directors of several private companies, including Aspen Avionics, Inc., an aircraft avionics manufacturer, and American Clay
Enterprises, LLC, a plaster manufacturing and sales company. Mr.&nbsp;Birk received a B.S. in Economics from Carleton College and an M.B.A. from Northwestern University&#146;s Kellogg School of Management. Mr.&nbsp;Birk&#146;s experience as a
venture capitalist and prior executive experience contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>John M. Radak</I> has served as a member of our board of directors since September 2014. Since August 2014, Mr.&nbsp;Radak has served as
chief financial officer of ArborGen Inc., a developer of biotechnology tree seedling products. From March 2012 to September 2013, he served as chief financial officer of SkinIt Inc., a company specializing in the personalization of consumer
electronic devices. From February 2007 to October 2011, Mr.&nbsp;Radak served as the chief financial officer of Quidel Corporation, a medical diagnostics company, after which he continued to serve as special advisor to the chief executive officer of
Quidel from November 2011 to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;110&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
</I>July 2012. Before his time with Quidel, Mr.&nbsp;Radak served as chief accounting officer and vice president of finance at Life Technologies Corporation, a life science tools manufacturing
company, from 2003 to 2007, as vice president of finance and corporate controller of Sunrise Medical Inc., a durable home medical device company, from 1994 to 2001, and as vice president of finance for Bird Products Corporation, a medical device
manufacturer, from 1992 to 1994. Mr.&nbsp;Radak also served as an independent consultant for various companies from 2001 to 2003. Mr.&nbsp;Radak has served on several non-profit boards, including Project Concern International, an organization
promoting disease prevention and the improvement of community health worldwide, where he has served from 2002 to 2008. Mr.&nbsp;Radak received a B.A. in Business Administration, Accounting and Finance from California State University, Fullerton and
an M.B.A. from the University of Southern California. Mr.&nbsp;Radak&#146;s significant financial experience with other companies in the healthcare, life sciences and emerging technologies industries contributed to our board of directors&#146;
conclusion that he should serve as a director of our company.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Arthur Weinstein, M.D.</I> has served as a member of our board of
directors since December 2013. Dr.&nbsp;Weinstein has served as a Professor of Medicine at Georgetown University since 2002, and as the Chief of Rheumatology and Associate Chair of Medicine at the Washington Hospital Center since 2001. He has served
as the co-chair of the board of directors for the Lupus Foundation of America&#146;s regional chapter for Washington, D.C., Maryland and Virginia since September 2013, and prior to that, served as its vice chair from September 2012 to September
2013, and has served as a member of the board since 2002. He also served as the chair of that board&#146;s medical scientific advisory committee from 2005 to September 2012. Dr.&nbsp;Weinstein was a Fellow at the Royal College of Physicians (UK) in
2011 and was recognized as a Master by the American College of Rheumatology in 2009. Dr.&nbsp;Weinstein received an M.D. from the University of Toronto, and completed his residency and fellowship training in Internal Medicine and Rheumatology at the
University of Toronto and University of London (UK). Dr.&nbsp;Weinstein&#146;s academic and professional work, specifically in the areas of rheumatology and lupus, contributed to our board of directors&#146; conclusion that he should serve as a
director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Frank Witney, Ph.D.</I> has served as a member of our board of directors since September 2014. Since July
2011, Dr.&nbsp;Witney has served as president, chief executive officer and a director of Affymetrix, Inc, a company focused on genomics analysis, and previously served as Affymetrix&#146;s executive vice president and chief commercial officer from
December 2008 to April 2009. Dr.&nbsp;Witney served as president and chief executive officer of Dionex Corporation, a manufacturer of chromatography systems, from April 2009 to May 2011. Previously, Dr.&nbsp;Witney served as president and chief
executive officer of Panomics, Inc., a provider of life sciences research reagents, from 2002 to 2008. Since March 2014, Dr.&nbsp;Witney has served as a member of the board of directors of Cerus Corporation, a biomedical products company focused in
the field of blood safety. Dr.&nbsp;Witney was a post-doctoral fellow at the National Institutes of Health and holds a Ph.D. in Molecular and Cellular Biology and an M.S. in Microbiology from Indiana University, and a B.S. in Microbiology from the
University of Illinois. Dr.&nbsp;Witney&#146;s industry experience serving in various management roles of other biotechnology companies contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and Election of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director
Independence </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors currently consists of seven members. Our board of directors has determined that all of our
directors, other than Mr.&nbsp;Rocca, are independent directors in accordance with the listing requirements of The NASDAQ Global Market. The NASDAQ independence definition includes a series of objective tests, including that the director is not, and
has not been for at least three years, one of our employees and that neither the director nor any of his family members has engaged in various types of business dealings with us. In addition, as required by NASDAQ rules, our board of directors has
made a subjective determination as to each independent director that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a
director. In making these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;111&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director&#146;s business and personal activities and relationships
as they may relate to us and our management. There are no family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Classified Board of
Directors </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of our amended and restated certificate of incorporation that will go into effect immediately
prior to the completion of this offering, our board of directors will be divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to
serve from the time of election and qualification until the third annual meeting following election. Effective upon the completion of this offering, our directors will be divided among the three classes as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class I directors will be Brian Birk and Ebetuel Pallares, Ph.D., and their terms will expire at our first annual meeting of stockholders following this offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class II directors will be John M. Radak and Arthur Weinstein, M.D., and their terms will expire at our second annual meeting of stockholders following this offering; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class III directors will be Curt LaBelle, M.D., Fortunato Ron Rocca and Frank Witney, Ph.D., and their terms will expire at our third annual meeting of stockholders following this offering. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation that will go into effect immediately prior to the completion of this offering will
provide that the authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as
nearly as possible, each class will consist of one-third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our
company. Our directors may be removed only for cause by the affirmative vote of the holders of at least two thirds of our outstanding voting stock then entitled to vote in the election of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of
directors is currently led by its chairman, Curt LaBelle, M.D. Our board of directors recognizes that it is important to determine an optimal board leadership structure to ensure the independent oversight of management as the company continues to
grow. We separate the roles of chief executive officer and chairman of the board in recognition of the differences between the two roles. The chief executive officer is responsible for setting the strategic direction for the company and the
day-to-day leadership and performance of the company, while the chairman of the board of directors provides guidance to the chief executive officer and presides over meetings of the full board of directors. We believe that this separation of
responsibilities provides a balanced approach to managing the board of directors and overseeing the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has
concluded that our current leadership structure is appropriate at this time. However, our board of directors will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of Board in Risk Oversight Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has responsibility for the oversight of the company&#146;s risk management processes and, either as a whole or through
its committees, regularly discusses with management our major risk exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from board committees and
members of senior management to enable our board to understand the company&#146;s risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory,
strategic and reputational risk. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;112&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee reviews information regarding liquidity and operations, and oversees our
management of financial risks. Periodically, the audit committee reviews our policies with respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct communication with
our external auditors, and discussions with management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing whether any of our
compensation policies or programs has the potential to encourage excessive risk-taking. The nominating/corporate governance committee manages risks associated with the independence of the board, corporate disclosure practices, and potential
conflicts of interest. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire board is regularly informed through committee reports about such risks. Matters of significant strategic
risk are considered by our board as a whole. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees and Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board has established three standing committees&#151;audit, compensation and nominating and corporate governance&#151;each of which
operates under a charter that has been approved by our board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board has determined that all of the members of each of the
board&#146;s three standing committees are independent as defined under the rules of The NASDAQ Global Market. In addition, all members of the audit committee meet the independence requirements contemplated by Rule 10A-3 under the Exchange Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit
committee&#146;s main function is to oversee our accounting and financial reporting processes and the audits of our financial statements. This committee&#146;s responsibilities include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appointing our independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evaluating the qualifications, independence and performance of our independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approving the audit and non-audit services to be performed by our independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls and our critical accounting policies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discussing with management and the independent registered public accounting firm the results of our annual audit and the review of our quarterly unaudited financial statements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing, overseeing and monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to financial statements or accounting matters; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing on a periodic basis, or as appropriate, any investment policy and recommending to our board any changes to such investment policy; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing with management and our auditors any earnings announcements and other public announcements regarding our results of operations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparing the report that the SEC requires in our annual proxy statement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving any related party transactions and reviewing and monitoring compliance with our code of conduct and ethics; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and evaluating, at least annually, the performance of the audit committee and its members including compliance of the audit committee with its charter. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our audit committee are John M. Radak, Brian Birk and Ebetuel Pallares, Ph.D. Mr.&nbsp;Radak serves as the chairperson of the
committee. All members of our audit committee meet the requirements for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;113&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial literacy under the applicable rules and regulations of the SEC and The NASDAQ Global Market. Our board of directors has determined that Mr.&nbsp;Radak is an &#147;audit committee
financial expert&#148; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable NASDAQ rules and regulations. Our board of directors has determined each of Mr.&nbsp;Radak and Dr.&nbsp;Pallares
is independent under the applicable rules of the SEC and The NASDAQ Global Market. Under the applicable NASDAQ Global Market rules, we are permitted to phase in our compliance with the independent audit committee requirements of The NASDAQ Global
Market on the same schedule as we are permitted to phase in our compliance with the independent audit committee requirements pursuant to Rule 10A-3 under the Exchange Act, which require: (1)&nbsp;one independent member at the time of listing, (2) a
majority of independent members within 90 days of listing and (3) all independent members within one year of listing. We will comply with the phase-in requirements of the NASDAQ Global Market rules, and within one year of our listing on the NASDAQ
Global Market, all members of our audit committee will be independent under NASDAQ rules and Rule 10A-3. Upon the listing of our common stock on The NASDAQ Global Market, the audit committee will operate under a written charter that satisfies the
applicable standards of the SEC and The NASDAQ Global Market. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee approves policies relating to compensation and benefits of our officers and employees. The compensation committee
approves corporate goals and objectives relevant to the compensation of our chief executive officer and other executive officers, evaluates the performance of these officers in light of those goals and objectives and approves the compensation of
these officers based on such evaluations. The compensation committee also approves the issuance of stock options and other awards under our equity plan. The compensation committee will review and evaluate, at least annually, the performance of the
compensation committee and its members, including compliance by the compensation committee with its charter. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our
compensation committee are Frank Witney, Ph.D., Curt LaBelle, M.D. and John&nbsp;M. Radak. Dr.&nbsp;Witney serves as the chairperson of the committee. Our Board has determined that each of Dr.&nbsp;Witney, Dr.&nbsp;LaBelle and Mr.&nbsp;Radak is
independent under the applicable rules and regulations of The NASDAQ Global Market, is a &#147;non-employee director&#148; as defined in Rule 16b-3 promulgated under the Exchange Act and is an &#147;outside director&#148; as that term is defined in
Section&nbsp;162(m) of the U.S. Internal Revenue Code of 1986, as amended, or Section&nbsp;162(m). Upon the listing of our common stock on The NASDAQ Global Market, the compensation committee will operate under a written charter, which the
compensation committee will review and evaluate at least annually. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee is responsible for assisting our board of directors in discharging the board&#146;s
responsibilities regarding the identification of qualified candidates to become board members, the selection of nominees for election as directors at our annual meetings of stockholders (or special meetings of stockholders at which directors are to
be elected), and the selection of candidates to fill any vacancies on our board of directors and any committees thereof. In addition, the nominating and corporate governance committee is responsible for overseeing our corporate governance policies,
reporting and making recommendations to our board of directors concerning governance matters and oversight of the evaluation of our board of directors. The members of our nominating and corporate governance committee are Frank Witney, Ph.D., Curt
LaBelle, M.D. and Arthur Weinstein, M.D. Dr. Witney serves as the chairman of the committee. Our board has determined that each of Dr.&nbsp;Witney, Dr.&nbsp;LaBelle and Dr. Weinstein is independent under the applicable rules and regulations of The
NASDAQ Global Market relating to nominating and corporate governance committee independence. Upon the listing of our common stock on The NASDAQ Global Market, the nominating and corporate governance committee will operate under a written charter,
which the nominating and corporate governance committee will review and evaluate at least annually. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;114&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2013, the members of our compensation committee were Dr.&nbsp;LaBelle and Mr.&nbsp;Birk, each of whom is affiliated with certain of our
principal stockholders, and Michael&nbsp;Walsh, a former director. See &#147;Certain Relationships and Related Person Transactions&#148; for additional information on the securities acquired by such principal stockholders and related agreements such
stockholders are party to with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee has ever been one of our officers or employees. None
of our executive officers currently serves, or has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Diversity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion
of this offering, our nominating and corporate governance committee will be responsible for reviewing with the board of directors, on an annual basis, the appropriate characteristics, skills and experience required for the board of directors as a
whole and its individual members. In evaluating the suitability of individual candidates (both new candidates and current members), the nominating and corporate governance committee, in recommending candidates for election, and the board of
directors, in approving (and, in the case of vacancies, appointing) such candidates, will take into account many factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">personal and professional integrity, ethics and values; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience in corporate management, such as serving as an officer or former officer of a publicly-held company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience as a board member or executive officer of another publicly-held company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">strong finance experience; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diversity of expertise and experience in substantive matters pertaining to our business relative to other board members; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience relevant to our business industry and with relevant social policy concerns; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relevant academic expertise or other proficiency in an area of our business operations. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, our board of directors evaluates, and following the completion of this offering will evaluate, each individual in the context of
the board of directors as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these
various areas. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Upon the completion of this offering, our code of business conduct and ethics will be available under the Corporate
Governance section of our website at www.exagen.com. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of The NASDAQ Global Market concerning any amendments to, or waivers from, any
provision of the code. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;115&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_12"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section discusses the material components of the executive compensation program for our executive officers who are named in the
&#147;2013 Summary Compensation Table&#148; below. In 2013, our chief executive officer and our two other highest-paid executive officers, or our named executive officers, were as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fortunato Ron Rocca, President and Chief Executive Officer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Wendy Swedick, Chief Financial Officer; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Thierry Dervieux, Ph.D., Chief Scientific Officer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion may contain
forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt following the completion of this offering may differ
materially from the currently planned programs summarized in this discussion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2013 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning the compensation of our named executive officers during the fiscal year ended
December&nbsp;31, 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:97.90pt; font-size:8pt; font-family:Times New Roman"><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-Equity<BR>Incentive Plan<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other</B><br><B>Compensation<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wendy Swedick</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thierry Dervieux, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Represents employer contributions under our 401(k) plan on behalf of each executive. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure
to Compensation Tables </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Offer Letter with Thierry Dervieux. Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2010, we entered into an offer letter with Dr.&nbsp;Dervieux, which was amended in September 2011. The offer letter with
Dr.&nbsp;Dervieux will be terminated effective upon consummation of this offering and will be superseded by Dr.&nbsp;Dervieux&#146;s new employment agreement, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the offer letter, Dr.&nbsp;Dervieux receives an annual base salary of $240,000. Dr.&nbsp;Dervieux is eligible to participate in
our management bonus plan, with the goals and payments under the management bonus plan to be defined and approved by our board of directors. Pursuant to the offer letter, Dr.&nbsp;Dervieux received options to purchase 100,000 shares of our common
stock in connection with the commencement of his employment. Such options vest as to 25% of the total number of option shares on the first anniversary of the date of grant and in equal monthly installments over the ensuing 36 months, and will become
fully vested (1)&nbsp;upon the acquisition of our company and (2)&nbsp;the termination of Dr.&nbsp;Dervieux&#146;s employment by us without cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Dr.&nbsp;Dervieux&#146;s offer letter, if we terminate Dr.&nbsp;Dervieux&#146;s employment without cause or Dr.&nbsp;Dervieux
resigns for good reason (as defined below), Dr.&nbsp;Dervieux will be entitled to the following payments and benefits: (1)&nbsp;his fully earned but unpaid base salary through the date of termination at the rate then in effect, plus all other
amounts under any compensation plan or practice to which he is entitled, and (2)&nbsp;a lump sum cash </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;116&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment in an amount equal to his monthly base salary as in effect immediately prior to the date of termination for the 12-month period following the date of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Dr.&nbsp;Dervieux&#146;s offer letter, &#147;good reason&#148; generally means: (1)&nbsp;a material reduction in
Dr.&nbsp;Dervieux&#146;s duties or responsibilities; (2)&nbsp;the relocation of our company&#146;s principal business location to a point more than 250 miles east of its previous Albuquerque location or more than 1,000 miles from
Dr.&nbsp;Dervieux&#146;s principal residence; or (3)&nbsp;a material reduction by us of Dr.&nbsp;Dervieux&#146;s base salary as the result of a company-wide compensation reduction or in connection with similar decreases for the management team of
our company. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Employment Agreements with Fortunato Ron Rocca, Wendy Swedick and Thierry Dervieux, Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with each of Mr. Rocca, Ms. Swedick and Dr.&nbsp;Dervieux, to be effective as of the date prior to
the date on which our common stock commences trading pursuant to this offering. The following is a summary of the material terms of the employment agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the employment agreements, Mr.&nbsp;Rocca, Ms.&nbsp;Swedick and Dr.&nbsp;Dervieux will have initial annual base
salaries of $440,000, $295,000 and $295,000, respectively, which amounts will be subject to review annually by and at the sole discretion of the compensation committee of our board of directors or its designee. In addition, each of Mr.&nbsp;Rocca,
Ms.&nbsp;Swedick and Dr.&nbsp;Dervieux shall participate in any bonus plan our board of directors or its designee may approve for our senior executives. Mr.&nbsp;Rocca, Ms.&nbsp;Swedick and Dr.&nbsp;Dervieux&#146;s target bonus under any such bonus
plan shall be 55%, 35% and 30%, respectively, of each such executive&#146;s then-applicable base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the
employment agreements, if the company terminates any of Mr.&nbsp;Rocca, Ms.&nbsp;Swedick or Dr.&nbsp;Dervieux without &#147;cause&#148; or if any such executive resigns for &#147;good reason&#148; (each as defined in the applicable employment
agreement), such executive will be entitled to the following payments and benefits: (1) his or her fully earned but unpaid base salary through the date of termination at the rate then in effect, accrued and unused paid time off, plus all other
benefits, if any, under any group retirement plan, nonqualified deferred compensation plan, equity award plan or agreement, health benefits plan or other group benefit plan to which such executive may be entitled to under the terms of such plans or
agreements; (2) a lump sum cash payment in an amount equal to 12 months of his or her base salary as in effect immediately prior to the date of termination; (3) continuation of health benefits for a period of 12 months following the date of
termination; and (4) the automatic acceleration of the vesting and exercisability of any outstanding unvested stock awards as to the number of stock awards that would have vested over the 12-month period following termination had the executive
remained continuously employed by the company during such period. In addition, in the event the company terminates any of Mr.&nbsp;Rocca, Ms.&nbsp;Swedick or Dr.&nbsp;Dervieux without cause or if any such executive resigns for good reason within 12
months following a &#147;change in control&#148; (as defined in the applicable employment agreement), such executive will be entitled to receive, in addition to the severance benefits described in clauses (1), (2) and (3) above, a lump sum cash
payment in an amount equal to such executive&#146;s target bonus for the year in which the date of termination occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
terms of the employment agreements, in the event of any of Mr. Rocca, Ms.&nbsp;Swedick or Dr.&nbsp;Dervieux&#146;s separation from service by reason of such executive&#146;s death or discharge following such executive&#146;s permanent disability,
such executive will be entitled to the automatic acceleration of the vesting and exercisability of any outstanding unvested stock awards as to the number of stock awards that would have vested over the 12-month period following termination had the
executive remained continuously employed by the company during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the event the company terminates any of
Mr.&nbsp;Rocca, Ms.&nbsp;Swedick or Dr.&nbsp;Dervieux without cause or if any such executive resigns for good reason within three months prior to or 12 months following a change in control, the vesting and/or exercisability of any outstanding
unvested portion of the executive&#146;s stock awards will be automatically accelerated on the later of the date of such executive&#146;s separation from service and the date of the change in control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;117&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employment agreements also contain standard confidentiality, non-competition and
non-solicitation covenants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Executive Relocation Agreement with Wendy Swedick </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, we entered into an executive relocation agreement with Wendy Swedick. Pursuant to the terms of the relocation agreement, Ms.
Swedick is entitled to certain benefits in connection with her relocation to the San Diego, California area. Specifically, Ms.&nbsp;Swedick is entitled to reimbursement of home selling expenses up to a maximum of $30,000 and household and vehicle
moving expenses up to a maximum of $20,000, as well as a make-whole payment for any discount below fair market value necessary to sell her home in an expedited manner. The company will reimburse Ms.&nbsp;Swedick for income taxes payable in
connection with any moving expenses or make-whole payments that are deemed taxable to Ms.&nbsp;Swedick as well as income taxes payable on the reimbursed amount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Base Salaries </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, base
salaries for our named executive officers are initially established through arm&#146;s length negotiation at the time the executive officer is hired, taking into account such executive officer&#146;s qualifications, experience and prior salary. Base
salaries of our named executive officers are generally reviewed annually and are based on the scope of an executive officer&#146;s responsibilities, individual contribution, prior experience and sustained performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2013 base salaries for our named executive officers is set forth above under &#147;2013 Summary Compensation Table.&#148; In 2014, the
base salaries of our named executive officers were increased to $312,000, $235,000 and $244,800, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2013 Exagen Management Bonus Program
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers were eligible to participate in the 2013 Exagen Management Bonus Program, or the Bonus Program. The
Bonus Program was administered by our board of directors, and our board of directors was responsible for the approval of participation, award targets, performance measures and earned awards under the Bonus Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Bonus Program, our board of directors made awards based on annual corporate objectives determined for the performance
measurement period. The relative weight between the corporate performance factors for 2013 was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Corporate Performance Factors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Revenue Objective</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Material Transaction Objective</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bonus Program allowed for annual cash incentive awards, which are determined by (1)&nbsp;applying a
target bonus multiplier, as set forth below, to each covered employee&#146;s base salary; (2)&nbsp;allocating such amount between the corporate performance factors, as set forth above; and (3)&nbsp;with respect to the portion of the bonus tied to
the Net Revenue Objective, multiplying each such allocated amount by an award multiplier ranging from 0% to 150% (with 0% credit awarded for performance below 85% of the targeted level and 150% credit awarded for performance at or above 150% of the
targeted level), as determined by our board of directors based on corporate achievement for the applicable year. Our board of directors, however, retained the discretion to increase or reduce the final bonus payments, regardless of actual company
performance. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The target bonuses for our named executive officers for 2013 were as follows (and remain unchanged for 2014): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="24%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target&nbsp;Bonus&nbsp;as&nbsp;a<BR>Percentage of<BR>Base Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wendy Swedick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thierry Dervieux, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;118&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Corporate objectives for the Bonus Program for 2013 were established in February 2013. The
Net Revenue Objective for the year ending December&nbsp;31, 2013 was $3.4 million. The Material Transaction Objective generally related to our company&#146;s successful completion of significant, material strategic transactions that either realize
or have the potential to realize more than $2.0 million of value to our company (i.e., co-promotion agreements, corporate financing transactions, successful negotiation of licensing or royalty arrangements). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net revenues for 2013 were 90% of our goal, and thus our board of directors awarded an achievement level of 90% relative to the Net
Revenue Objective for 2013 bonus purposes. Based on our strategic transactions during 2013, including the closing of our term loan agreement and obtaining NYDOH approval for the new release of our Avise SLE+CT test, our board of directors awarded
100% relative to the Material Transaction Objective for 2013 bonus purposes. With the specified weighting of each of these components, our board of directors awarded an overall achievement level of 90% for the 2013 bonus program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the bonuses paid to our named executive officers under the Bonus Program for 2013 were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013&nbsp;Bonus&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wendy Swedick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thierry Dervieux, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We offer stock options to our employees, including our named executive officers, as the long-term incentive component of our compensation
program. We typically grant equity awards to new hires upon their commencing employment with us. Our stock options allow employees to purchase shares of our common stock at a price per share equal to the fair market value of our common stock on the
date of grant and may or may not be intended to qualify as &#147;incentive stock options&#148; for U.S. federal income tax purposes. In the past, our board of directors has determined the fair market value of our common stock based upon inputs
including valuation reports prepared by third-party valuation firms from time to time. Generally, the stock options we grant vest as to 25% of the total number of option shares on the first anniversary of the date of grant and in equal monthly
installments over the ensuing 36 months, subject to the employee&#146;s continued employment with us on the vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options
granted to our named executive officers may be subject to accelerated vesting in certain circumstances. For additional discussion, please see &#147;&#151;Employment Agreements&#148; above and &#147;&#151;Other Elements of Compensation&#151;Change in
Control Benefits&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2014, each of Mr. Rocca, Ms. Swedick and Mr. Dervieux was granted an option to purchase 3,015,000,
600,000 and 475,000 shares of our common stock, respectively, with an exercise price of $0.18 per share. The stock options vest as to 25% of the total number of option shares on the first anniversary of the date of grant and in equal monthly
installments over the ensuing 36 months, subject to the employee&#146;s continued employment with us on the vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the
effectiveness of this offering, we intend to adopt a 2014 Incentive Award Plan, referred to below as the 2014 Plan, in order to facilitate the grant of cash and equity incentives to directors, employees (including our named executive officers) and
consultants of our company and certain of our affiliates and to enable our company and certain of our affiliates to obtain and retain services of these individuals, which is essential to our long-term success. For additional information about the
2014 Plan, please see the section titled &#147;Equity Incentive Award Plans&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Elements of Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Retirement Plans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
currently maintain a 401(k) retirement savings plan that allows eligible employees to defer a portion of their compensation, within limits prescribed by the Internal Revenue Code, on a pre-tax basis through
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;119&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contributions to the plan. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees generally. Currently, we make employer
contributions under the 401(k) plan up to a specified percentage, and these employer contributions are fully vested as of the date on which the contribution is made. We believe that providing a vehicle for tax-deferred retirement savings though our
401(k) plan, and making employer contributions, adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Employee Benefits and Perquisites </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers are eligible to participate in our health and welfare plans to the same extent as all full-time employees
generally. We do not provide our named executive officers with any other perquisites or other personal benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>No Tax Gross-Ups
</I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not made gross-up payments to cover our named executive officers&#146; personal income taxes that may pertain to
any of the compensation paid or provided by our company. However, we have agreed to provide Ms. Swedick with a gross-up for certain relocation expenses in connection with her move to the San Diego, California area. For additional discussion, please
see &#147;&#151;Employment Agreements&#151;Executive Relocation Agreement with Wendy Swedick.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Control Benefits
</I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers may become entitled to certain benefits or enhanced benefits in connection with a change in control
of our company under their employment arrangements. In addition, stock options granted to our employees, including our named executive officers, may be subject to acceleration in connection with a change in control under our equity plans. For
additional discussion, please see &#147;&#151;Employment Agreements&#148; above and &#147;&#151;Equity Incentive Award Plans&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2013 Fiscal Year-End </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the outstanding equity incentive plan awards held by each named executive officer as of December&nbsp;31, 2013.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/9/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,541,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,822,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/9/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thierry Dervieux, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/9/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">356,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/9/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wendy Swedick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/18/2010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/18/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/9/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">356,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/9/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The options vest at the rate of 25% of the total number of shares subject to the option on the first anniversary of the grant date, and 1/48th of the total number of shares subject to the option monthly thereafter.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;120&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2013 Director Compensation Table </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information for the year ended December&nbsp;31, 2013 regarding the compensation awarded to, earned by or paid
to our non-employee directors who served on our board of directors during 2013. Employees of our company who also serve as directors do not receive additional compensation for their performance of services as directors. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-Equity<BR>Incentive Plan<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Curt LaBelle, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ebetuel Pallares, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Birk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samuel D. Riccitelli(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael J. Walsh(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arthur Weinstein, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Effective September 2014, Mr. Riccitelli and Mr. Walsh no longer serve as directors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
table below shows the aggregate numbers of option awards held as of December&nbsp;31, 2013 by each non-employee director who was serving as of December&nbsp;31, 2013. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options<BR>Outstanding<BR>at Fiscal<BR>Year End</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Curt LaBelle, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ebetuel Pallares, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Birk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samuel D. Riccitelli(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">605,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael J. Walsh(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">672,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arthur Weinstein, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Effective September 2014, Mr. Riccitelli and Mr. Walsh no longer serve as directors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
November 2013, we entered into a director and consulting services agreement with Dr.&nbsp;Weinstein, pursuant to which he receives $18,000 per year, payable monthly, for his service as a member of our board of directors. In addition,
Dr.&nbsp;Weinstein has provided and may continue to provide consulting services to us from time to time, for which he is compensated at the rate of $300 per hour or $2,400 per full day worked. In 2013 and the first quarter of 2014,
Dr.&nbsp;Weinstein was paid de minimis amounts for his consulting services to us. The director and consulting services agreement with Dr.&nbsp;Weinstein will be terminated effective upon consummation of this offering and will be superseded by our
new non-employee director compensation program, as described below. </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the effective date of this offering, each non-employee director
shall automatically be granted an option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, other than Dr.&nbsp;Weinstein, who shall automatically be granted an option to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock due to his existing holdings, or the IPO Awards. Each IPO Award shall vest on the first to occur of (1)&nbsp;the first anniversary of the date of
grant, subject to the non-employee director continuing in service on our board of directors through such vesting date, or (2)&nbsp;in the event a non-employee director does not stand for re-election or fails to be re-elected at the first annual
meeting of our stockholders, the date of such annual meeting, subject to the non-employee director continuing in service on our board of directors through such vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has approved a compensation program for our non-employee directors, to be effective on the date prior to the date on
which our common stock commences trading pursuant to this offering, that will consist of annual retainer fees, meeting fees and long-term equity awards. Pursuant to the terms of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;121&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
non-employee director compensation program, each non-employee director will receive an annual cash retainer for his or her services in an amount equal to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. In addition, the chair of our board of directors will receive an additional annual cash retainer of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
the chair of our audit committee will receive an additional annual cash retainer of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, the chair of our compensation committee will receive an additional annual cash retainer of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the chair of our nominating and corporate governance committee will receive an additional annual cash retainer of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Audit committee members will receive an additional annual cash retainer of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, compensation committee
members will receive an additional annual cash retainer of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and nominating and corporate governance committee members will receive an additional annual cash retainer of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Each non-employee director shall be eligible to receive $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for each board meeting attended in person.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, non-employee directors initially elected or appointed to our board of directors shall automatically be granted an option to
purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock on the date of such initial election or appointment, or the Initial Awards. Each Initial Award shall vest in substantially equal
installments on each of the first three anniversaries of the date of grant, subject to the non-employee director continuing in service on our board of directors through each such vesting date. A non-employee director who (1)&nbsp;is serving on our
board of directors as of the date of any annual meeting of our stockholders after the effective date and (2)&nbsp;will continue to serve as a non-employee director immediately following such annual meeting, shall automatically be granted an option
to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock on the date of such annual meeting, or the Subsequent Awards. Each Subsequent Award shall vest as to one-third of the total number
of shares subject to such Subsequent Award on the first anniversary of the date of grant, and one thirty-sixth of the total number of shares subject to such Subsequent Award following each one-month period of the non-employee director&#146;s service
on our board of directors thereafter, so that all of the shares subject to each Subsequent Award shall be fully vested and exercisable on the third anniversary of the date of grant, subject to the non-employee director continuing in service on our
board of directors through each such vesting date. The per share exercise price of each option shall equal the fair market value of a share of our common stock on the date the option is granted; provided, however, that the per share exercise price
of each IPO Award shall equal the initial public offering price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of a non-employee director&#146;s IPO Awards,
Initial Awards and Subsequent Awards shall vest in full upon the occurrence of a Change in Control of our company (as defined in the 2014 Plan). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Award Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2014
Incentive Award Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with this offering, we intend to establish the Exagen Diagnostics, Inc. 2014 Incentive Award
Plan, or the 2014 Plan. We expect our board of directors to adopt, and our stockholders to approve, the 2014 Plan prior to the completion of this offering. The 2014 Plan will become effective on the day prior to the public trading date of our common
stock. The material terms of the 2014 Plan, as it is currently contemplated, are summarized below. Our board of directors is still in the process of developing, approving and implementing the 2014 Plan and, accordingly, this summary is subject to
change. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. A total of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will initially be reserved for issuance under the 2014 Plan. In addition, the number of shares initially reserved under the
2014 Plan will be increased by (1)&nbsp;the number of shares that, as of the effective date of the 2014 Plan, have been reserved but not issued pursuant to any awards granted under our 2013 Plan (as defined below) and are not subject to any awards
granted thereunder, and (2)&nbsp;the number of shares subject to stock options or similar awards granted under our 2013 Plan or our 2002 Plan (as defined below) that expire or otherwise terminate without having been exercised in full and unvested
shares issued pursuant to awards granted under the 2013 Plan or 2002 Plan that are forfeited to or repurchased by us, with the maximum number of shares to be added to the 2014 Plan pursuant to clauses (1)&nbsp;and (2)&nbsp;above equal to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. In addition, the number of shares available for issuance under the 2014 Plan will be annually increased on the first day of each calendar year
during the term of the 2014 Plan, beginning with January 1, 2015, by an amount equal to the lesser of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4% of the outstanding shares of our common stock as of the last day of the preceding calendar year; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;122&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such lesser amount as our board of directors may determine. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock may be issued upon the exercise of incentive stock options under the 2014 Plan. The 2014 Plan will also provide for an aggregate limit of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that may be issued under the 2014 Plan over the course of its ten-year term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares issued pursuant to awards under the 2014 Plan that we repurchase or that are forfeited, as well as shares used to pay the exercise
price of an award or to satisfy the tax withholding obligations related to an award and any shares subject to a stock appreciation right that are not issued in connection with the stock settlement of the stock appreciation right on exercise thereof,
will become available for future grant under the 2014 Plan. In addition, to the extent that an award is paid out in cash rather than shares, such cash payment will not reduce the number of shares available for issuance under the 2014 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. The compensation committee of our board of directors will administer the 2014 Plan (except with respect to any
award granted to &#147;independent directors&#148; (as defined in the 2014 Plan), which must be administered by our full board of directors). Following the completion of this offering, to administer the 2014 Plan, our compensation committee must
consist solely of at least two members of our board of directors, each of whom is a &#147;non-employee director&#148; for purposes of Rule 16b-3 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, an &#147;outside
director&#148; for purposes of Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended, or the Code and an &#147;independent director&#148; under the rules of any securities exchange or automated quotations system on which the shares
are listed, quoted or traded. Subject to the terms and conditions of the 2014 Plan, our compensation committee has the authority to select the persons to whom awards are to be made, to determine the type or types of awards to be granted to each
person, the number of awards to grant, the number of shares to be subject to such awards, and the terms and conditions of such awards, and to make all other determinations and decisions and to take all other actions necessary or advisable for the
administration of the 2014 Plan. Our compensation committee is also authorized to establish, adopt, amend or revise rules relating to administration of the 2014 Plan. Our board of directors may at any time revest in itself the authority to
administer the 2014 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. Options, stock appreciation rights, or SARs, restricted stock and other awards under the
2014 Plan may be granted to individuals who are then our officers or employees or are the officers or employees of any of our subsidiaries. Such awards may also be granted to our non-employee directors and consultants but only employees may be
granted incentive stock options, or ISOs. As of December&nbsp;31, 2013, there were six non-employee directors and 53 employees who would have been eligible for awards under the 2014 Plan had it been in effect on such date. At such time after the
completion of this offering when we are subject to the requirements of Section&nbsp;162(m) of the Code, the maximum number of shares that may be subject to awards granted under the 2014 Plan to any individual other than a non-employee director in
any calendar year cannot exceed &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and the maximum amount that may be paid to a participant in cash during any calendar year with respect to one or more
cash based awards under the 2014 Plan is $20,000,000. In addition, the maximum number of shares of our common stock that may be subject to one or more awards granted to any non-employee director pursuant to the 2014 Plan during any calendar year
cannot exceed &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Awards</I>.
The 2014 Plan provides that our compensation committee (or the board of directors, in the case of awards to non-employee directors) may grant or issue stock options, SARs, restricted stock, restricted stock units, dividend equivalents, stock
payments and performance awards, or any combination thereof. Our compensation committee (or the board of directors, in the case of awards to non-employee directors) will consider each award grant subjectively, considering factors such as the
individual performance of the recipient and the anticipated contribution of the recipient to the attainment of our long-term goals. Each award will be set forth in a separate agreement with the person receiving the award and will indicate the type,
terms and conditions of the award. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Nonqualified stock options, or NQSOs, will provide for the right to purchase shares of our common stock at a specified price which may not be less
than the fair market value of a share of common stock on the date of grant, and usually will become exercisable (at the discretion of our compensation committee or our board of directors, in the case of awards to non-employee directors) in one or
more </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;123&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
installments after the grant date, subject to the participant&#146;s continued employment or service with us and/or subject to the satisfaction of performance targets established by our
compensation committee (or our board of directors, in the case of awards to non-employee directors). NQSOs may be granted for any term specified by our compensation committee (or our board of directors, in the case of awards to non-employee
directors). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ISOs will be designed to comply with the provisions of the Code and will be subject to specified restrictions contained in the Code. Among such restrictions, ISOs must have an exercise price of not less than the fair
market value of a share of common stock on the date of grant, may only be granted to employees, must expire within a specified period of time following the optionee&#146;s termination of employment, and must be exercised within ten years after the
date of grant. In the case of an ISO granted to an individual who owns (or is deemed to own) more than 10% of the total combined voting power of all classes of our capital stock, the 2014 Plan provides that the exercise price must be at least 110%
of the fair market value of a share of common stock on the date of grant and the ISO must expire upon the fifth anniversary of the date of grant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Restricted stock may be granted to participants and made subject to such restrictions as may be determined by our compensation committee (or our board of directors, in the case of awards to non-employee directors).
Typically, restricted stock may be forfeited for no consideration or repurchased for consideration if the conditions or restrictions are not met, and it may not be sold or otherwise transferred to third parties until the restrictions are removed or
expire. Recipients of restricted stock, unlike recipients of options, may have voting rights and may receive dividends, if any, prior to the time when the restrictions lapse. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Restricted stock units may be awarded to participants, typically without payment of consideration or for a nominal purchase price, but subject to vesting conditions including continued employment or performance criteria
established by our compensation committee (or our board of directors, in the case of awards to non-employee directors). Like restricted stock, restricted stock units may not be sold or otherwise transferred or hypothecated until vesting conditions
are removed or expire. Unlike restricted stock, stock underlying restricted stock units will not be issued until the restricted stock units have vested, and recipients of restricted stock units generally will have no voting or dividend rights prior
to the time when vesting conditions are satisfied. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">SARs granted under the 2014 Plan typically will provide for payments to the holder based upon increases in the price of our common stock over the exercise price of the SAR. Except as required by Section&nbsp;162(m) of
the Code with respect to SARs intended to qualify as performance-based compensation as described in Section&nbsp;162(m) of the Code, there are no restrictions specified in the 2014 Plan on the exercise of SARs or the amount of gain realizable
therefrom. Our compensation committee (or the board of directors, in the case of awards to non-employee directors) may elect to pay SARs in cash or in common stock or in a combination of both. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dividend equivalents represent the value of the dividends, if any, per share paid by us, calculated with reference to the number of shares covered by the stock options, SARs or other awards held by the participant.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Performance awards may be granted by our compensation committee on an individual or group basis. Generally, these awards will be based upon the attainment of specific performance goals that are established by our
compensation committee and relate to one or more performance criteria on a specified date or dates determined by our compensation committee. Any such cash bonus paid to a &#147;covered employee&#148; within the meaning of Section&nbsp;162(m) of the
Code may be, but need not be, qualified performance-based compensation as described below and will be paid in cash. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stock payments may be authorized by our compensation committee (or our board of directors, in the case of awards to non-employee directors) in the form of common stock or an option or other right to purchase common
stock as part of a deferred compensation arrangement, made in lieu of all or any part of compensation, including bonuses, that would otherwise be payable to employees, consultants or members of our board of directors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;124&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability of Awards</I>. Unless the administrator provides otherwise, our 2014 Plan
generally does not allow for the transfer of awards and only the recipient of an option or SAR may exercise such an award during his or her lifetime. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Qualified Performance-Based Compensation</I>. The compensation committee may designate employees as &#147;covered employees&#148; whose
compensation for a given fiscal year may be subject to the limit on deductible compensation imposed by Section&nbsp;162(m) of the Code. The compensation committee may grant to such covered employees restricted stock, dividend equivalents, stock
payments, restricted stock units, cash bonuses and other stock-based awards that are paid, vest or become exercisable upon the attainment of company performance criteria which are related to one or more of the following performance criteria as
applicable to our performance or the performance of a division, business unit or an individual: operating or other costs and expenses, improvements in expense levels, cash flow (including, but not limited to, operating cash flow and free cash flow),
return on assets, return on capital, stockholders&#146; equity, return on stockholders&#146; equity, total stockholder return, return on sales, gross or net profit or operating margin, working capital, net earnings (either before or after interest,
taxes, depreciation and amortization), gross or net sales or revenue, net income (either before or after taxes), adjusted net income, operating earnings or profits, earnings per share, adjusted earnings per share, price per share of common stock,
regulatory body approval for commercialization of a product, capital raised in financing transactions or other financing milestones, market recognition (including but not limited to awards and analyst ratings), financial ratios, implementation or
completion of critical projects, market share, economic value, comparisons with various stock market indices, and implementation, completion or attainment of objectively determinable objectives relating to research, development, regulatory,
commercial, or strategic milestones or development. These performance criteria may be measured in absolute terms or as compared to any incremental increase or decrease or as compared to results of a peer group or to market performance indicators or
indices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee may provide that one or more objectively determinable adjustments will be made to one or more of the
performance goals established for any performance period. Such adjustments may include one or more of the following: items related to a change in accounting principle, items relating to financing activities, expenses for restructuring or
productivity initiatives, other non-operating items, items related to acquisitions, items attributable to the business operations of any entity acquired by us during the performance period, items related to the disposal of a business or segment of a
business, items related to discontinued operations that do not qualify as a segment of a business under applicable accounting standards, items attributable to any stock dividend, stock split, combination or exchange of stock occurring during the
performance period, any other items of significant income or expense that are determined to be appropriate adjustments, items relating to unusual or extraordinary corporate transactions, events or developments, items related to amortization of
acquired intangible assets, items that are outside the scope of our core, on-going business activities, items related to acquired in-process research and development, items relating to changes in tax laws, items relating to major licensing or
partnership arrangements, items relating to asset impairment charges, items relating to gains and losses for litigation, arbitration or contractual settlements, or items relating to any other unusual or nonrecurring events or changes in applicable
laws, accounting principles or business conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Forfeiture, Recoupment and Clawback Provisions</I>. Pursuant to its general
authority to determine the terms and conditions applicable to awards under the 2014 Plan, the compensation committee has the right to provide, in an award agreement or otherwise, that an award shall be subject to the provisions of any recoupment or
clawback policies implemented by us, including, without limitation, any recoupment or clawback policies adopted to comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated
thereunder, to the extent set forth in such recoupment or clawback policy and/or in the applicable award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Adjustments</I>. If there is any stock dividend, stock split, combination or exchange of shares, merger, consolidation or other
distribution (other than normal cash dividends) of our assets to stockholders, or any other change affecting the shares of our common stock or the share price of our common stock other than an equity restructuring (as defined in the 2014 Plan), the
plan administrator may make such equitable adjustments, if any, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;125&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as the plan administrator in its discretion may deem appropriate to reflect such change with respect to (1)&nbsp;the aggregate number and type of shares that may be issued under the 2014 Plan
(including, but not limited to, adjustments of the number of shares available under the 2014 Plan and the maximum number of shares which may be subject to one or more awards to a participant pursuant to the 2014 Plan during any calendar year),
(2)&nbsp;the number and kind of shares, or other securities or property, subject to outstanding awards, (3)&nbsp;the number and kind of shares, or other securities or property, for which automatic grants are to be subsequently made to new and
continuing non-employee directors, (4)&nbsp;the terms and conditions of any outstanding awards (including, without limitation, any applicable performance targets or criteria with respect thereto), and (5)&nbsp;the grant or exercise price per share
for any outstanding awards under the 2014 Plan. If there is any equity restructuring, (1)&nbsp;the number and type of securities subject to each outstanding award and/or the grant or exercise price per share for each outstanding award, if
applicable, the grant of new awards, and/or the making of a cash payment to holders of awards, will be proportionately adjusted, and (2)&nbsp;the plan administrator will make proportionate adjustments to reflect such equity restructuring with
respect to the aggregate number and type of shares that may be issued under the 2014 Plan (including, but not limited to, adjustments of the number of shares available under the 2014 Plan and the maximum number of shares which may be subject to one
or more awards to a participant pursuant to the 2014 Plan during any calendar year). Adjustments in the event of an equity restructuring will not be discretionary. Any adjustment affecting an award intended as &#147;qualified performance-based
compensation&#148; will be made consistent with the requirements of Section&nbsp;162(m) of the Code. The plan administrator also has the authority under the 2014 Plan to take certain other actions with respect to outstanding awards in the event of a
corporate transaction, including provision for the cash-out, termination, assumption or substitution of such awards. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate
Transactions</I>. In the event of a change in control where the acquirer does not assume awards granted under the 2014 Plan, awards issued under the 2014 Plan will be subject to accelerated vesting such that 100% of the awards will become vested and
exercisable or payable, as applicable. Under the 2014 Plan, a change in control is generally defined as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction or series of related transactions (other than an offering of our stock to the general public through a registration statement filed with the Securities and Exchange Commission, or SEC) whereby any person
or entity or related group of persons or entities (other than us, our subsidiaries, an employee benefit plan maintained by us or any of our subsidiaries or a person or entity that, prior to such transaction, directly or indirectly controls, is
controlled by, or is under common control with, us) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of more than 50% of the total combined voting power of our securities outstanding
immediately after such acquisition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">during any two-year period, individuals who, at the beginning of such period, constitute our board of directors together with any new director(s) whose election by our board of directors or nomination for election by
our stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for
any reason to constitute a majority of our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our consummation (whether we are directly or indirectly involved through one or more intermediaries) of (x)&nbsp;a merger, consolidation, reorganization, or business combination or (y)&nbsp;the sale or other disposition
of all or substantially all of our assets in any single transaction or series of transactions or (z)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">which results in our voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into our voting securities or the voting securities of
the person that, as a result of the transaction, controls us, directly or indirectly, or owns, directly or indirectly, all or substantially all of our assets or otherwise succeeds to our business (we or such person being referred to as a successor
entity)) directly or indirectly, at least a majority of the combined voting power of the successor entity&#146;s outstanding voting securities immediately after the transaction; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;126&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the successor entity; provided, however, that no person or group is treated as beneficially
owning 50% or more of combined voting power of the successor entity solely as a result of the voting power held in us prior to the consummation of the transaction. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment, Termination</I>. Our board of directors has the authority to amend, suspend or terminate the 2014 Plan at any time. However,
stockholder approval of any amendment to the 2014 Plan will be obtained to the extent necessary to comply with any applicable law, regulation or stock exchange rule. Additionally, stockholder approval is required within 12 months of an increase in
the maximum number of shares issuable under the 2014 Plan or that may be issued to an individual in any calendar year. Except as necessary to comply with Section&nbsp;409A of the Code, no amendment, suspension or termination of the 2014 Plan will
impair the rights or obligations of a holder under an award theretofore granted, unless such award expressly so provides or such holder consents. If not terminated earlier by our board of directors, the 2014 Plan will terminate on the tenth
anniversary of the date it becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Repricing Permitted</I>. Our compensation committee (or the board of directors, in the
case of awards to non-employee directors) shall have the authority, without the approval of our stockholders, to authorize the amendment of any outstanding award to reduce its price per share and to provide that an award will be canceled and
replaced with the grant of an award having a lesser price per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Securities Laws and Federal Income Taxes</I>. The 2014 Plan is
designed to comply with various securities and federal tax laws as follows: </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Securities Laws</I>. The 2014 Plan is intended to
conform to all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the SEC thereunder, including, without limitation, Rule 16b-3 of the Exchange Act. The 2014 Plan will be administered, and
awards will be granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Federal
Income Tax Consequences</I>. The material federal income tax consequences of the 2014 Plan under current federal income tax law are summarized in the following discussion, which deals with the general tax principles applicable to the 2014 Plan. The
following discussion is based upon laws, regulations, rulings and decisions now in effect, all of which are subject to change. Foreign, state and local tax laws, and employment, estate and gift tax considerations are not discussed due to the fact
that they may vary depending on individual circumstances and from locality to locality. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Stock Options and Stock Appreciation Rights.</I> A 2014 Plan participant generally will not recognize taxable income and we generally will not be entitled to a tax deduction upon the grant of a stock option or stock
appreciation right. The tax consequences of exercising a stock option and the subsequent disposition of the shares received upon exercise will depend upon whether the option qualifies as an ISO as defined in Section&nbsp;422 of the Code. The 2014
Plan permits the grant of options that are intended to qualify as ISOs as well as options that are not intended to so qualify; however, ISOs generally may be granted only to our employees and employees of our parent or subsidiary corporations, if
any. Upon exercising an option that does not qualify as an ISO when the fair market value of our stock is higher than the exercise price of the option, a 2014 Plan participant generally will recognize taxable income at ordinary income tax rates
equal to the excess of the fair market value of the stock on the date of exercise over the purchase price, and we (or our subsidiaries, if any) generally will be entitled to a corresponding tax deduction for compensation expense, in the amount equal
to the amount by which the fair market value of the shares purchased exceeds the purchase price for the shares. Upon a subsequent sale or other disposition of the option shares, the participant will recognize a short-term or long-term capital gain
or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;127&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Upon exercising an ISO, a 2014 Plan participant generally will not recognize taxable income, and
we will not be entitled to a tax deduction for compensation expense. However, upon exercise, the amount by which the fair market value of the shares purchased exceeds the purchase price will be an item of adjustment for alternative minimum tax
purposes. The participant will recognize taxable income upon a sale or other taxable disposition of the option shares. For federal income tax purposes, dispositions are divided into two categories: qualifying and disqualifying. A qualifying
disposition generally occurs if the sale or other disposition is made more than two years after the date the option was granted and more than one year after the date the shares are transferred upon exercise. If the sale or disposition occurs before
these two periods are satisfied, then a disqualifying disposition generally will result. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Upon a qualifying disposition of ISO shares, the
participant will recognize long-term capital gain in an amount equal to the excess of the amount realized upon the sale or other disposition of the shares over their purchase price. If there is a disqualifying disposition of the shares, then the
excess of the fair market value of the shares on the exercise date (or, if less, the price at which the shares are sold) over their purchase price will be taxable as ordinary income to the participant. If there is a disqualifying disposition in the
same year of exercise, it eliminates the item of adjustment for alternative minimum tax purposes. Any additional gain or loss recognized upon the disposition will be recognized as a capital gain or loss by the participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">We will not be entitled to any tax deduction if the participant makes a qualifying disposition of ISO shares. If the participant makes a
disqualifying disposition of the shares, we should be entitled to a tax deduction for compensation expense in the amount of the ordinary income recognized by the participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Upon exercising or settling an SAR, a 2014 Plan participant will recognize taxable income at ordinary income tax rates, and we should be
entitled to a corresponding tax deduction for compensation expense, in the amount paid or value of the shares issued upon exercise or settlement. Payments in shares will be valued at the fair market value of the shares at the time of the payment,
and upon the subsequent disposition of the shares the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares.
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Restricted Stock and Restricted Stock Units</I>. A 2014 Plan participant generally will not recognize taxable income at ordinary income tax rates and we generally will not be entitled to a tax deduction upon the
grant of restricted stock or restricted stock units. Upon the termination of restrictions on restricted stock or the payment of restricted stock units, the participant will recognize taxable income at ordinary income tax rates, and we should be
entitled to a corresponding tax deduction for compensation expense, in the amount paid to the participant or the amount by which the then fair market value of the shares received by the participant exceeds the amount, if any, paid for them. Upon the
subsequent disposition of any shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares. However, a
2014 Plan participant granted restricted stock that is subject to forfeiture or repurchase through a vesting schedule such that it is subject to a &#147;risk of forfeiture&#148; (as defined in Section&nbsp;83 of the Code) may make an election under
Section&nbsp;83(b) of the Code to recognize taxable income at ordinary income tax rates, at the time of the grant, in an amount equal to the fair market value of the shares of common stock on the date of grant, less the amount paid, if any, for such
shares. We will be entitled to a corresponding tax deduction for compensation, in the amount recognized as taxable income by the participant. If a timely Section&nbsp;83(b) election is made, the participant will not recognize any additional ordinary
income on the termination of restrictions on restricted stock, and we will not be entitled to any additional tax deduction. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><I>Dividend Equivalents, Stock Payment Awards and Cash-Based Awards</I>. A 2014 Plan participant will not recognize taxable income and we will not be
entitled to a tax deduction upon the grant of dividend equivalents, stock payment awards or cash-based awards until cash or shares are paid or distributed to the participant. At that time, any cash payments or the fair market value of shares that
the participant receives will be taxable to the participant at ordinary income tax rates and we should be entitled to a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;128&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
corresponding tax deduction for compensation expense. Payments in shares will be valued at the fair market value of the shares at the time of the payment, and upon the subsequent disposition of
the shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Section&nbsp;409A of the Code.</I> Certain types of awards under the 2014 Plan may constitute, or provide for, a deferral of compensation under Section&nbsp;409A. Unless certain requirements set forth in
Section&nbsp;409A are complied with, holders of such awards may be taxed earlier than would otherwise be the case (e.g., at the time of vesting instead of the time of payment) and may be subject to an additional 20% federal income tax (and,
potentially, certain interest penalties). To the extent applicable, the 2014 Plan and awards granted under the 2014 Plan will be structured and interpreted to comply with Section&nbsp;409A and the Department of Treasury regulations and other
interpretive guidance that may be issued pursuant to Section&nbsp;409A. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Section&nbsp;162(m) Limitation</I>. In general, under Section&nbsp;162(m) of the Code, income tax deductions of publicly held corporations may be limited to the extent total compensation (including base salary,
annual bonus, stock option exercises and non-qualified benefits paid) for certain executive officers exceeds $1.0 million (less the amount of any &#147;excess parachute payments&#148; as defined in Section&nbsp;280G of the Code) in any one year.
However, under Section&nbsp;162(m), the deduction limit does not apply to certain &#147;performance-based compensation&#148; if an independent compensation committee determines performance goals and if the material terms of the performance-based
compensation are disclosed to and approved by our stockholders. In particular, stock options and SARs will satisfy the &#147;performance-based compensation&#148; exception if the awards are made by a qualifying compensation committee, the plan sets
the maximum number of shares that can be granted to any person within a specified period and the compensation is based solely on an increase in the stock price after the grant date. Specifically, the option exercise price must be equal to or greater
than the fair market value of the stock subject to the award on the grant date. Under a Section&nbsp;162(m) transition rule for compensation plans of corporations which are privately held and which become publicly held in an initial public offering,
certain awards under the 2014 Plan will not be subject to Section&nbsp;162(m) until a specified transition date, which is the earlier of (1)&nbsp;the material modification of the 2014 Plan, (2)&nbsp;the issuance of all employer stock and other
compensation that has been allocated under the 2014 Plan, or (3)&nbsp;the first annual meeting of stockholders at which directors are to be elected that occurs after the close of the third calendar year following the calendar year in which the
initial public offering occurs. After the transition date, rights or awards granted under the 2014 Plan, other than options and SARs, will not qualify as &#147;performance-based compensation&#148; for purposes of Section&nbsp;162(m) unless such
rights or awards are granted or vest upon pre-established objective performance goals, the material terms of which are disclosed to and approved by our stockholders. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">We have attempted to structure the 2014 Plan in such a manner that, after the transition date, the compensation attributable to stock options
and SARs which meet the other requirements of Section&nbsp;162(m) will not be subject to the $1.0 million limitation. We have not, however, requested a ruling from the Internal Revenue Service or an opinion of counsel regarding this issue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2013 Stock Option Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors and certain of our stockholders approved the Exagen Diagnostics, Inc. 2013 Stock Option Plan, or the 2013 Plan, which
became effective in December 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2014, a total of 8,893,246 shares of our common stock were reserved for issuance under
the 2013 Plan. As of June 30, 2014, 213,000 shares of our common stock were subject to outstanding option awards and 8,646,496 shares of our common stock remained available for future issuance. The 2013 Plan will expire in December 2022 unless
earlier terminated by our board of directors. Following the effectiveness of the 2014 Plan, no additional awards will be granted under the 2013 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;129&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. The board of directors administers the 2013 Plan. Subject to the terms and
conditions of the 2013 Plan, the administrator has the authority to select the persons to whom awards are to be made, to determine the type or types of awards to be granted to each person, determine the number of awards to grant, determine the
number of shares to be subject to such awards, and the terms and conditions of such awards, and make all other determinations and decisions and to take all other actions necessary or advisable for the administration of the 2013 Plan. The plan
administrator is also authorized to establish, adopt, amend or revise rules relating to administration of the 2013 Plan, subject to certain restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. Options may be granted to individuals who are then our employees, consultants and members of our board of directors. Only
employees may be granted ISOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Awards</I>. The 2013 Plan permits the award of stock options. Only stock options have been granted
under the 2013 Plan to date. Each award is set forth in a separate agreement with the person receiving the award and indicates the type, terms and conditions of the award. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">NQSOs provide for the right to purchase shares of our common stock at a specified price which may not be less than the fair market value of a share of stock on the date of grant, and usually will become exercisable (at
the discretion of our board of directors) in one or more installments after the grant date, subject to the participant&#146;s continued employment or service with us and/or subject to the satisfaction of performance targets established by our
compensation committee (or the board of directors, in the case of awards to non-employee directors). NQSOs may be granted for any term specified by our compensation committee (or the board of directors, in the case of awards to non-employee
directors), but the term may not exceed ten years. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ISOs are designed to comply with the provisions of the Internal Revenue Code and are subject to specified restrictions contained in the Internal Revenue Code applicable to ISOs. Among such restrictions, ISOs must have
an exercise price of not less than the fair market value of a share of common stock on the date of grant, may only be granted to employees, must expire within a specified period of time following the optionee&#146;s termination of employment, and
must be exercised within the ten years after the date of grant. In the case of an ISO granted to an individual who owns (or is deemed to own) more than 10% of the total combined voting power of all classes of our capital stock on the date of grant,
the 2013 Plan provides that the exercise price must be at least 110% of the fair market value of a share of common stock on the date of grant and the ISO must expire on the fifth anniversary of the date of its grant. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. In the event of a corporate transaction, all outstanding stock options will become fully vested and exercisable
for the 30-day period immediately preceding the closing of such transaction (provided that the exercise of any stock option that would have been unvested but for the consummation of the change in control will be subject to the closing of the
transaction). In addition, in the event of a corporate transaction, the board of directors may provide for the cash-out of outstanding stock options for an amount equal to the fair market value of the shares of our common stock subject to the stock
option immediately prior to the consummation of such transaction less the exercise price of such option. Any options that are outstanding as of the consummation of a corporate transaction will terminate unless the acquirer assumes such awards or are
otherwise continued in effect pursuant to the terms of the transaction. Under the 2013 Plan, a corporate transaction is generally defined as: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a merger or consolidation in which securities possessing more than 50% of the total combined voting power of our outstanding securities are transferred to a person or persons different from the persons holding those
securities immediately prior to such transaction; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sale, transfer or other disposition of all or substantially all of our assets in complete liquidation or dissolution of our company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment or Termination of the 2013 Plan</I>. Our board of directors may terminate, amend or modify the 2013 Plan, provided that any
termination of the plan must be upon 30 days&#146; written notice to participants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;130&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
However, stockholder approval of any amendment to the 2013 Plan must be obtained to reduce the option price per share after the option has been granted or the extent necessary and desirable to
comply with any applicable law, regulation or stock exchange rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Securities Laws and Federal Income Taxes</I>. The 2013 Plan is
designed to comply with applicable securities laws in the same manner as described above in the description of the 2014 Plan under the heading &#147;&#151;2014 Incentive Award Plan&#151;Securities Laws and Federal Income Taxes&#151;Securities
Laws.&#148; The general federal tax consequences of awards under the 2013 Plan are the same as those described above in the description of the 2014 Plan under the heading &#147;&#151;2014 Incentive Award Plan&#151;Securities Laws and Federal Income
Taxes&#151;Federal Income Taxes.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2002 Stock Option Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;29, 2002, our board of directors and our stockholders approved the Exagen Corporation Stock Option Plan, as amended, or the
2002 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2014, 8,458,470 shares of our common stock were subject to outstanding option awards under the 2002 Plan. The
2002 Plan expired in accordance with its terms in December 2012 and no additional awards will be granted under the 2002 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. The board of directors administers the 2002 Plan. Subject to the terms and conditions of the 2002 Plan, the
administrator has the authority to select the persons to whom awards are to be made, to determine the type or types of awards to be granted to each person, determine the number of awards to grant, determine the number of shares to be subject to such
awards, and the terms and conditions of such awards, and make all other determinations and decisions and to take all other actions necessary or advisable for the administration of the 2002 Plan. The plan administrator is also authorized to
establish, adopt, amend or revise rules relating to administration of the 2002 Plan, subject to certain restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>.
Options were able to be granted to individuals who are then our employees, consultants and members of our board of directors. Only employees may be granted ISOs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Awards</I>. The 2002 Plan permitted the award of stock options. Only stock options were granted under the 2002 Plan. Each award is set
forth in a separate agreement with the person receiving the award and indicates the type, terms and conditions of the award. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">NQSOs provide for the right to purchase shares of our common stock at a specified price which may not be less than the fair market value of a share of stock on the date of grant, and usually will become exercisable (at
the discretion of our board of directors) in one or more installments after the grant date, subject to the participant&#146;s continued employment or service with us and/or subject to the satisfaction of performance targets established by our
compensation committee (or the board of directors, in the case of awards to non-employee directors). NQSOs may be granted for any term specified by our compensation committee (or the board of directors, in the case of awards to non-employee
directors), but the term may not exceed ten years. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ISOs are designed to comply with the provisions of the Internal Revenue Code and are subject to specified restrictions contained in the Internal Revenue Code applicable to ISOs. Among such restrictions, ISOs must have
an exercise price of not less than the fair market value of a share of common stock on the date of grant, may only be granted to employees, must expire within a specified period of time following the optionee&#146;s termination of employment, and
must be exercised within the ten years after the date of grant. In the case of an ISO granted to an individual who owns (or is deemed to own) more than 10% of the total combined voting power of all classes of our capital stock on the date of grant,
the 2002 Plan provides that the exercise price must be at least 110% of the fair market value of a share of common stock on the date of grant and the ISO must expire on the fifth anniversary of the date of its grant. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;131&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. In the event of a corporate transaction where the acquirer
does not assume awards granted under the 2002 Plan, awards issued under the 2002 Plan will terminate as of a date to be fixed by our board of directors. Under the 2002 Plan, a corporate transaction is generally defined as a merger or consolidation
in which securities possessing more than 50% of the total combined voting power of our company&#146;s outstanding securities are transferred to a person or persons different from the persons holding those securities immediately prior to such
transaction, or the sale, transfer or other disposition of all or substantially all of our assets in a complete liquidation or dissolution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment of the 2002 Plan</I>. Our board of directors may amend or modify the 2002 Plan. However, stockholder approval of any amendment to
the 2002 Plan must be obtained to reduce the option price per share after the option has been granted or the extent necessary and desirable to comply with any applicable law, regulation or stock exchange rule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Securities Laws and Federal Income Taxes</I>. The 2002 Plan is designed to comply with applicable securities laws in the same manner as
described above in the description of the 2014 Plan under the heading &#147;&#151;2014 Incentive Award Plan&#151;Securities Laws and Federal Income Taxes&#151;Securities Laws.&#148; The general federal tax consequences of awards under the 2002 Plan
are the same as those described above in the description of the 201 Plan under the heading &#147;&#151;2014 Incentive Award Plan&#151;Securities Laws and Federal Income Taxes&#151;Federal Income Taxes.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2014 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with this offering, we intend to establish the Exagen Diagnostics, Inc. 2014 Employee Stock Purchase Plan, or the ESPP. We expect
our board of directors to adopt, and our stockholders to approve, the ESPP prior to the completion of this offering. The ESPP will become effective on the business day prior to the public trading date of our common stock. Our executive officers and
all of our other employees will be allowed to participate in our ESPP, subject to the eligibility requirements described below. The material terms of the ESPP, as it is currently contemplated, are summarized below. Our board of directors is still in
the process of developing, approving and implementing the ESPP and, accordingly, this summary is subject to change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will initially be reserved for issuance under our ESPP. In addition, the number of shares available for issuance under the
ESPP will be annually increased on the first day of each calendar year during the term of the ESPP, beginning with January 1, 2015, by an amount equal to the least of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the outstanding shares of our common stock as of the last day of our immediately preceding calendar year; or </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such other amount as may be determined by our board of directors. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP will also
provide for an aggregate limit of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that may be issued under the ESPP during the term of the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors or its committee has full and exclusive authority to interpret the terms of the ESPP and determine eligibility. We
expect that our compensation committee will be the initial administrator of the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our employees are eligible to participate in the
ESPP if they are customarily employed by us or any participating subsidiary for at least 20 hours per week and more than five months in any calendar year. However, an employee may not be granted rights to purchase stock under our ESPP if such
employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of our common or other class of stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;132&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ESPP is intended to qualify under Code Section&nbsp;423 and stock will be offered under the
ESPP during offering periods. The length of the offering periods under the ESPP will be determined by our compensation committee and may be up to 27 months long. Employee payroll deductions will be used to purchase shares on each purchase date
during an offering period. The purchase dates will be determined by the compensation committee for each offering period, but will generally be the last day in each offering period. Offering periods under the ESPP will commence when determined by our
compensation committee. The compensation committee may, in its discretion, modify the terms of future offering periods. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ESPP
permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation, which includes a participant&#146;s gross base compensation for services to the company, excluding overtime payments, sales
commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. A participant may purchase a maximum of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock
during each offering period. In addition, no employee will be permitted to accrue the right to purchase stock under the ESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding
(based on the fair market value per share of our common stock as of the first day of the offering period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the first trading day of
each offering period, each participant automatically is granted an option to purchase shares of our common stock. The option expires at the end of the offering period or upon termination of employment, whichever is earlier, but is exercised at the
end of each purchase period to the extent of the payroll deductions accumulated during such purchase period. The purchase price of the shares will be 85% of the lower of the fair market value of our common stock on the first trading day of the
offering period or on the applicable purchase date, unless designated otherwise by the administrator. Participants may end their participation at any time during an offering period, and will be paid their accrued payroll deductions that have not yet
been used to purchase shares of common stock. Participation ends automatically upon termination of employment with us. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant
may not transfer rights granted under the ESPP other than by will, the laws of descent and distribution or as otherwise provided under the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of certain significant transactions or a change in control (as defined in the ESPP), the compensation committee may provide for:
(1)&nbsp;either the termination of outstanding rights in exchange for cash or replacement of outstanding rights in exchange for other rights or property selected by the administrator; (2)&nbsp;the assumption or substitution of outstanding rights by
the successor or survivor corporation or parent or subsidiary thereof, if any; (3)&nbsp;the adjustment in the number and type of shares of stock subject to outstanding rights and/or in the terms and conditions of outstanding rights and rights that
may be granted in the future; (4)&nbsp;the use of participants&#146; accumulated payroll deductions to purchase stock on a new purchase date prior to the next purchase date and termination of any rights under ongoing offering periods; or
(5)&nbsp;the termination of all outstanding rights without being exercised. Under the ESPP, a change in control has the same definition as given to such term in the 2014 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee may amend, suspend or terminate the ESPP. However, stockholder approval of any amendment to the ESPP will be
obtained for any amendment which changes the aggregate number or type of shares that may be sold pursuant to rights under the ESPP, changes the corporations or classes of corporations whose employees are eligible to participate in the ESPP or
changes the ESPP in any manner that would cause the ESPP to no longer be an employee stock purchase plan within the meaning of Section&nbsp;423(b) of the Code. The ESPP will terminate no later than the tenth anniversary of the ESPP&#146;s initial
adoption by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Securities Laws</I>. The ESPP has been designed to comply with various securities laws in the same
manner as described above in the description of the 2014 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Federal Income Taxes</I>. The material federal income tax consequences
of the ESPP under current federal income tax law are summarized in the following discussion, which deals with the general tax principles applicable to the ESPP. The following discussion is based upon laws, regulations, rulings and decisions now in
effect, all of which are subject to change. Foreign, state and local tax laws, and employment, estate and gift tax </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;133&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
considerations are not discussed due to the fact that they may vary depending on individual circumstances and from locality to locality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP, and the right of participants to make purchases thereunder, is intended to qualify under the provisions of Section&nbsp;423 of the
Code. Under the applicable Code provisions, no income will be taxable to a participant until the sale or other disposition of the shares purchased under the ESPP. This means that an eligible employee will not recognize taxable income on the date the
employee is granted an option under the ESPP (i.e., the first day of the offering period). In addition, the employee will not recognize taxable income upon the purchase of shares. Upon such sale or disposition, the participant will generally be
subject to tax in an amount that depends upon the length of time such shares are held by the participant prior to disposing of them. If the shares are sold or disposed of more than two years from the first day of the offering period during which the
shares were purchased and more than one year from the date of purchase, or if the participant dies while holding the shares, the participant (or his or her estate) will recognize ordinary income measured as the lesser of: (1)&nbsp;the excess of the
fair market value of the shares at the time of such sale or disposition over the purchase price; or (2)&nbsp;an amount equal to 15% of the fair market value of the shares as of the first day of the offering period. Any additional gain will be
treated as long-term capital gain. If the shares are held for the holding periods described above but are sold for a price that is less than the purchase price, there is no ordinary income and the participating employee has a long-term capital loss
for the difference between the sale price and the purchase price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the shares are sold or otherwise disposed of before the expiration
of the holding periods described above, the participant will recognize ordinary income generally measured as the excess of the fair market value of the shares on the date the shares are purchased over the purchase price and we will be entitled to a
tax deduction for compensation expense in the amount of ordinary income recognized by the employee. Any additional gain or loss on such sale or disposition will be long-term or short-term capital gain or loss, depending on how long the shares were
held following the date they were purchased by the participant prior to disposing of them. If the shares are sold or otherwise disposed of before the expiration of the holding periods described above but are sold for a price that is less than the
purchase price, the participant will recognize ordinary income equal to the excess of the fair market value of the shares on the date of purchase over the purchase price (and we will be entitled to a corresponding deduction), but the participant
generally will be able to report a capital loss equal to the difference between the sales price of the shares and the fair market value of the shares on the date of purchase. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify our directors and
officers to the fullest extent permitted by the Delaware General Corporation Law, which prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the&nbsp;following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any breach of the director&#146;s duty of loyalty to us or our stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unlawful payment of dividends or unlawful stock repurchases or redemptions; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction from which the director derived an improper personal benefit. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and
restated certificate of incorporation and our amended and restated bylaws also provide that if Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of our
directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. This limitation of liability does not apply to liabilities arising under the federal securities laws and does not affect the availability of
equitable remedies such as injunctive relief or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and
restated bylaws also provide that we shall have the power to indemnify our employees and agents to the fullest extent permitted by law. Our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;134&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amended and restated bylaws also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in this capacity,
regardless of whether our amended and restated bylaws would permit indemnification. We have obtained directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into separate indemnification agreements with our directors and executive officers, in addition to indemnification provided
for in our amended and restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, provide for indemnification of our directors and executive officers for expenses, judgments, fines and settlement
amounts incurred by this person in any action or proceeding arising out of this person&#146;s services as a director or executive officer or at our request. We believe that these provisions in our amended and restated certificate of incorporation
and amended and restated bylaws and indemnification agreements are necessary to attract and retain qualified persons as directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of our amended and restated certificate of incorporation, our amended and restated
bylaws and our indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated
bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful,
might benefit us and our stockholders. A stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as
indemnification for liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against
public policy as expressed in the Securities Act and is therefore unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or
threatened litigation that may result in claims for indemnification by any director or&nbsp;officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;135&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_13"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following includes a summary of transactions since January&nbsp;1, 2011 to which we have been a party in which the amount involved
exceeded or will exceed $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will
have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#147;Executive and Director Compensation.&#148; We also describe below certain
other transactions with our directors, executive officers and stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock Financings and Convertible Notes and Warrant Financing
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series A-1, A-2 and A-3 Redeemable Convertible Preferred Stock Financings</I>. In December 2011, in connection with our Series A-2
and Series B-2 redeemable convertible preferred stock financing, all 3,896,531 of our outstanding shares of Series A-1 redeemable convertible preferred stock and 273,182 outstanding warrants to purchase shares of Series A-1 redeemable convertible
preferred stock were converted into 3,896,531 shares of our common stock and warrants to purchase an aggregate of 273,182 shares of our common stock, and we converted 1,598,226 shares of common stock into 1,598,226 shares of our Series A-2
redeemable convertible preferred stock. In February and April 2012, we converted an additional 45,710 shares of common stock into Series A-2 redeemable convertible preferred stock. In September 2012, in connection with our Series C redeemable
convertible preferred stock financing described below, all 1,643,396 of our Series A-2 redeemable convertible preferred stock were converted into 1,643,396 shares of common stock. In September 2012, in connection with our Series C redeemable
convertible preferred stock financing described below, we converted 1,474,795 shares of common stock into 1,474,795 shares of Series A-3 redeemable convertible preferred stock.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series B-1, B-2 and B-3 Redeemable Convertible Preferred Stock, Note and Warrant Financings</I>. Between January 2011 and October 2011, we
issued and sold 1,896,367 shares of our Series B-1 redeemable convertible preferred stock and 1,090,514 warrants to purchase shares of our Series B-1 redeemable convertible preferred stock. In December 2011, in connection with our Series A-2 and
Series B-2 redeemable convertible preferred stock financing, all 1,896,367 shares of our Series B-1 redeemable convertible preferred stock were converted into 1,896,367 shares of common stock, and all of our outstanding Series B-1 warrants to
purchase up to an aggregate of 1,812,288 shares of Series B-1 redeemable convertible preferred stock were converted into warrants to purchase an aggregate of up to 1,812,288 shares of our common stock. In December 2011, we issued 24,283,557 shares
our Series B-2 redeemable convertible preferred stock at a purchase price of $0.25 per share, for aggregate consideration of approximately $6.0 million, and we also converted an aggregate principal amount of $5,810,422 of promissory notes plus
interest of $105,418 into 23,663,361 shares of Series B-2 redeemable convertible preferred stock. In February 2012 and April 2012, we also issued 1,651,134 shares of our Series B-2 redeemable convertible preferred stock at a purchase price of $0.25
per share, for aggregate consideration of approximately $0.4 million. In September 2012, in connection with the sales of Series C redeemable convertible preferred stock, all 49,598,052 outstanding shares of our Series B-2 redeemable convertible
preferred stock were converted into 49,598,052 shares of common stock. In September 2012, we converted 44,539,977 shares of common stock into 44,539,977 shares of our Series B-3 redeemable convertible preferred stock.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series C Redeemable Convertible Preferred Stock Financing</I>. From September 2012 to December 2012, we issued and sold to investors in
private placements an aggregate of 23,750,389 shares of our Series C redeemable convertible preferred stock at a purchase price of $0.25 per share, for aggregate consideration of approximately $5.9 million. In connection with this financing, in
September 2012 all 1,643,396 outstanding shares of our Series&nbsp;A-2 redeemable convertible preferred stock and 49,598,052 shares of our Series B-2 redeemable convertible preferred stock were converted into 1,643,396 and 49,598,052 shares of
common stock, respectively. <I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Series D Redeemable Convertible Preferred Stock, Note and Warrant Financings</I>. In May
2013,&nbsp;June 2013 and August 2013, we issued a total of $2,430,531 in unsecured convertible promissory notes, or the 2013 Notes, which accrued interest at 10%. In October 2013, the 2013 Notes and $66,653 in accrued interest were converted into
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;136&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
12,485,914&nbsp;shares of Series D redeemable convertible preferred stock, at a 20% discount to the offering price of $0.25 per share. In October 2013, we also issued and sold to investors in
private placements an aggregate of 10,079,172 shares of our Series D redeemable convertible preferred stock at a purchase price of $0.25 per share, for aggregate consideration of approximately $2.5 million. From October 2013 to November 2013, we
also issued warrants to purchase up to an aggregate of 4,174,430 shares of our Series D redeemable convertible preferred stock at an exercise price of $0.25 per share and warrants to purchase up to 3,186,430 shares of our common stock at an exercise
price of $0.01 per share. We expect the 2013 Warrants to be net exercised in connection with the completion of this offering, resulting in the issuance of an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
of common stock, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus. If these 2013 Warrants are not
exercised prior to the completion of this offering, they will terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>2014 Convertible Note Financing</I>. In July 2014, we sold an
aggregate of $4.0 million of convertible promissory notes to certain existing investors in a private placement with certain existing investors, or the 2014 Notes. The 2014 Notes accrue interest at a rate of 12%&nbsp;per annum and become due and
payable nine months from the date of issuance. The principal amount of the 2014 Notes and accrued interest thereon will automatically convert into shares of our common stock upon completion of this offering at a conversion price equal to 80% of our
initial public offering price. If a liquidation (as defined in our current amended and restated certificate of incorporation) occurs prior to the completion of this offering, the holders of the 2014 Notes may elect to (1)&nbsp;receive the repayment
of the notes or (2)&nbsp;convert the notes into shares of Series D redeemable convertible preferred stock at a conversion price of $0.25 per share, subject to adjustment pursuant to the terms thereof. In connection with the completion of this
offering, the 2014 Notes (including accrued interest thereon) will automatically convert into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 (the expected closing date of this offering). <I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the aggregate number of these securities acquired by the listed directors, executive officers or holders of more than 5% of our capital stock, or their affiliates. Each share of, or warrants exercisable for shares of,
redeemable convertible preferred stock identified in the following table will convert into one share of, or warrants exercisable for, one share of common stock, upon completion of this offering. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:41.70pt; font-size:8pt; font-family:Times New Roman"><B>Participants</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A-3</B><br><B>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B-3<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount of<BR>2014 Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>5% or Greater Stockholders(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Entities affiliated with NMSIC Co-Investment Fund, L.P.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">607,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,215,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,081,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,916,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,217,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Tullis-Dickerson Capital Focus III, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,049,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,382,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Hunt Holdings, L.P.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,586,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,922,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,969,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Entities affiliated with Capital Royalty Partners(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,186,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,186,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Entities affiliated with vSpring Partners(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,953,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Ebetuel Pallares, Ph.D.(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">768,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">542,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Samuel Riccitelli(6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;137&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Additional details regarding these stockholders and their equity holdings are provided herein under &#147;Principal Stockholders.&#148; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Represents securities held by NMSIC Co-Investment Fund, L.P. and NMSIC Focused LLC. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Represents securities held by Capital Royalty Partners II L.P., Capital Royalty Partners II Parallel Fund &#147;A&#148; L.P. and Parallel Investment Opportunities Partners II L.P. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Represents securities held by vSpring SBIC, L.P., vSpring L.P. and vSpring Partners, L.P. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Represents securities held by CCP/Exagen, L.P. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Effective September 2014, Mr. Riccitelli no longer serves as a director. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our
directors are associated with our principal stockholders as indicated in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:28.85pt; font-size:8pt; font-family:Times New Roman"><B>Director</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal Stockholder</B></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Birk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">NMSIC&nbsp;Co-Investment&nbsp;Fund,&nbsp;L.P.</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Curt LaBelle, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Tullis-Dickerson&nbsp;Capital&nbsp;Focus&nbsp;III,&nbsp;L.P.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a fourth amended and restated investors&#146; rights agreement in October 2013 with the holders of our redeemable convertible
preferred stock, including entities with which certain of our directors are affiliated. This agreement provides for certain rights relating to the registration of their shares of common stock issuable upon conversion of their redeemable convertible
preferred stock and certain additional covenants made by us. Except for the registration rights (including the related provisions pursuant to which we have agreed to indemnify the parties to the investors&#146; rights agreement), all rights under
this agreement will terminate upon completion of this offering. The registration rights will continue following this offering and will terminate three years following the completion of this offering, or for any particular holder with registration
rights, at such time following this offering when such holder holds less than one percent of our outstanding common stock and may immediately sell all of such shares pursuant to Rule 144 under the Securities Act in a 90-day period. See
&#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a fourth amended stockholders&#146; agreement in October 2013 by and among us and certain of our stockholders, pursuant to
which the following directors were each elected to serve as members on our board of directors and, as of the date of this prospectus, continue to so serve: Brian Birk, Curt LaBelle, M.D., Ebetuel Pallares, Ph.D., Fortunato Ron Rocca, Frank Witney,
Ph.D. and John M. Radak. Pursuant to the stockholders&#146; agreement, Mr.&nbsp;Rocca, as our Chief Executive Officer, was initially selected to serve on our board of directors as a representative of holders of our common stock, as designated by a
majority of our common stockholders. Mr.&nbsp;Birk, Dr.&nbsp;LaBelle and Dr.&nbsp;Pallares were initially selected to serve on our board of directors as representatives of holders of our redeemable convertible preferred stock, as designated by NMSIC
Co-Investment Fund, L.P., Tullis-Dickerson Capital Focus III, L.P. and CCP/Exagen, L.P. and Hunt Holdings, L.P., respectively. Dr.&nbsp;Witney and Mr.&nbsp;Radak were selected to serve on our board of directors as designated by a majority of our
common and redeemable convertible preferred stockholders, voting together as a single class. The stockholders&#146; agreement also provides for certain other rights, including among others, a right of first refusal to purchase future securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stockholders&#146; agreement, and all the rights granted pursuant to it, will terminate upon the completion of this offering, and
members previously elected to our board of directors pursuant to this agreement will continue to serve as directors until they resign, are removed or their successors are duly elected by holders of our common stock. The composition of our board of
directors after this offering is described in more detail under &#147;Management&#151;Board Composition and Election of Directors.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;138&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an offer letter with Dr.&nbsp;Dervieux. For more information regarding this agreements, see the section in this prospectus
entitled &#147;Executive and Director Compensation&#151;Narrative Disclosure to Compensation Tables&#151;Employment Agreements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
September 2011, we entered into a license agreement with Dr.&nbsp;Dervieux, the Company&#146;s Chief Scientific Officer, and his company, DeNovo. The license agreement, covering novel methods for monitoring low-dose methotrexate therapy, relates to
technology developed by Dr.&nbsp;Dervieux prior to joining the Company. The technology has yet to be used by us. Under the agreement, Dr.&nbsp;Dervieux would be eligible to receive up to $600,000 when and if we achieve certain sales milestones and a
single-digit percentage royalty on sales on an ongoing basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Loan Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2010, we entered into a subordinated secured promissory note agreement with existing equity holders and a mezzanine lender, and $750,000 of
the loan proceeds committed under such agreement were provided by NMSIC Co-Investment Fund L.P., or the NMSIC Note. The NMSIC Note was secured by substantially all of our assets, bore interest at 6.0% and matured in October 2012, at which time, it
was repaid in full. In conjunction with the NMSIC Note, NMSIC received warrants to purchase up to 131,250 shares of our common stock at a price of $3.75 per share. These warrants contained the right to require us to purchase the warrants for a total
of $150,000, which right NMSIC exercised in October 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers prior to the completion of this offering.
These agreements, among other things, require us or will require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including
indemnification of expenses such as attorneys&#146; fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the
person&#146;s services as a director or executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and
restated bylaws provide that we will indemnify each of our directors and officers to the fullest extent permitted by the Delaware General Corporation Law. Further, we have entered into indemnification agreements with each of our directors and
officers, and we have purchased a policy of directors&#146; and officers&#146; liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment under certain circumstances. For further
information, see &#147;Executive and Director Compensation&#151;Limitations of Liability and Indemnification Matters.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Option Grants to
Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted stock options to our executive officers and certain of our directors as more fully
described in the section entitled &#147;Executive and Director Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors will adopt written related person transaction policy, to be effective upon the completion of this offering, setting
forth the policies and procedures for the review and approval or ratification of related-person transactions. This policy will cover, with certain exceptions set forth in Item&nbsp;404 of Regulation S-K under the Securities Act, any transaction,
arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000 and a related person had or will have a direct or indirect
material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;139&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all
relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction and the extent of the related person&#146;s interest in the
transaction. All of the transactions described in this section occurred prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;140&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_14"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our common stock as of August&nbsp;31, 2014, and as
adjusted to reflect the sale of shares of common stock in this offering, by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our named executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our then-current directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our executive officers and directors as a group; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person or group of affiliated persons known by us to beneficially own more than 5% of our common stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, beneficial
ownership includes any shares as to which a person has sole or shared voting power or investment power. Applicable percentage ownership is based on 102,307,211 shares of common stock outstanding on August&nbsp;31, 2014, which gives effect to the
automatic conversion of all outstanding shares of redeemable convertible preferred stock into shares of common stock. Our calculation of beneficial ownership after the offering gives additional effect to the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in connection with the completion of this offering as a result of the automatic conversion of the $4.0 million in aggregate principal amount of
convertible promissory notes we issued in July 2014, or the 2014 Notes (including accrued interest thereon), assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price
range listed on the cover page of this prospectus and assuming the conversion occurs on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 (the expected closing date of this offering). In computing the number of shares
beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options, warrants or other rights held by such person that are currently exercisable or will become exercisable within 60 days of
August&nbsp;31, 2014 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address of each beneficial owner listed below is c/o Exagen Diagnostics, Inc., 1261 Liberty Way, Suite C,
Vista, California 92081. We believe, based on information provided to us, that each of the stockholders listed below has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise,
subject to community property laws where applicable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Beneficially</B><br><B>Owned Prior to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially&nbsp;Owned</B><br><B>After Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:89.90pt; font-size:8pt; font-family:Times New Roman"><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% or Greater Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with NMSIC Co-Investment Fund, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,463,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">301 Griffin Street</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Santa Fe, NM 87501</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tullis-Dickerson Capital Focus III, L.P.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,168,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One Stamford Plaza</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">263 Tresser Boulevard</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stamford, CT 06901</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hunt Holdings, L.P.(3).</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,092,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o Joseph Advisory Services, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3800 N. Mesa St., Suite A-2, #371</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">El Paso, TX 79902</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;141&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Beneficially</B><br><B>Owned Prior to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially&nbsp;Owned</B><br><B>After Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:89.90pt; font-size:8pt; font-family:Times New Roman"><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with vSpring Partners(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,112,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o Signal Peak Ventures</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2795 E. Cottonwood Parkway, Suite #360</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salt Lake City, UT 84121</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Capital Royalty Partners(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,372,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1000 Main Street, Suite 2500</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Houston TX, 77002</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Named Executive Officers and Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca(6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,242,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wendy Swedick(7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thierry Dervieux, Ph.D.(8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">579,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Curt LaBelle, M.D.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,168,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Birk(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,463,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ebetuel Pallares, Ph.D.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,785,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samuel Riccitelli(10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">491,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael J. Walsh(11)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">614,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arthur Weinstein, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (9&nbsp;persons) (12)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,930,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Less than 1%. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;37,203,826 shares of common stock and 426,525 shares of common stock issuable upon the exercise of warrants to purchase common stock, which warrants will terminate if not exercised upon completion
of this offering, held by NMSIC Co-Investment Fund, L.P., or NMSIC, and (b)&nbsp;833,180 shares of common stock held by NMSIC Focused, LLC, or NMSIC Focused. In addition, beneficial ownership after the offering gives additional effect to the
issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the conversion of 2014 Notes held by NMSIC Focused, LLC, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range listed on the cover page of this prospectus, and assuming the conversion occurs
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2014 (the expected closing date of this offering). The general partner of NMSIC is Sun Mountain Capital Partners LLC, or Sun Mountain. NMSIC is the
sole member of NMSIC Focused. The members of Sun Mountain are Brian Birk, one of our directors, Sally Corning, Lee Rand and Leslie Shaw. As a result, each of Sun Mountain, Mr.&nbsp;Birk, Ms.&nbsp;Corning, Mr.&nbsp;Rand and Ms.&nbsp;Shaw may be
deemed to possess voting and investment control over, and may be deemed to have indirect beneficial ownership with respect to, all shares held by NMSIC or NMSIC Focused. Neither Sun Mountain, Mr.&nbsp;Birk, Ms.&nbsp;Corning, Mr.&nbsp;Rand nor
Ms.&nbsp;Shaw owns directly any of the shares. Each of Sun Mountain, Mr.&nbsp;Birk, Ms.&nbsp;Corning, Mr.&nbsp;Rand and Ms.&nbsp;Shaw disclaims beneficial ownership of the shares held by NMSIC or NMSIC Focused, except to the extent of their
pecuniary interest therein. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 29,918,318 shares of common stock and 250,000 shares of common stock issuable upon the exercise of warrants to purchase common stock, which warrants will terminate if not exercised upon completion of this
offering. In addition, beneficial ownership after the offering gives additional effect to the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the
conversion of 2014 Notes held by Tullis-Dickerson Capital Focus III, L.P., or Tullis, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range listed on the
cover page of this prospectus, and assuming the conversion occurs on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 (the expected closing date of this offering). Tullis-Dickerson
Partners&nbsp;III, LLC is the sole general partner of Tullis. Curt LaBelle, M.D., one of our directors, is a Principal of Tullis-Dickerson Partners III, LLC. As a result, each of Tullis-Dickerson Partners III, LLC and Dr.&nbsp;LaBelle may be deemed
to possess voting and investment control over, and may be deemed to have an indirect beneficial ownership with respect to, all shares held by Tullis. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;142&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 15,828,725 shares of common stock and 263,347 shares of common stock issuable upon the exercise of warrants to purchase common stock, which warrants will terminate if not exercised upon completion of this
offering, held by Hunt Holdings, L.P., or Hunt. In addition, beneficial ownership after the offering gives additional effect to the issuance of shares of common stock issuable upon the conversion of 2014 Notes held by Hunt, assuming an initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range listed on the cover page of this prospectus, and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 (the expected closing date of this offering). </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;5,079,948 shares of common stock and 139,727 shares of common stock issuable upon the exercise of warrants to purchase common stock, which warrants will terminate if not exercised upon completion of
this offering, held by vSpring SBIC, L.P., or vSpring SBIC, (b)&nbsp;773,714&nbsp;shares of common stock and 17,515 shares of common stock issuable upon the exercise of warrants to purchase common stock, which warrants will terminate if not
exercised upon completion of this offering, held by vSpring L.P., or vSpring, and (c)&nbsp;99,450 shares of common stock and 2,251&nbsp;shares of common stock issuable upon the exercise of warrants to purchase common stock, which warrants will
terminate if not exercised upon completion of this offering, held by vSpring Partners, L.P., or vSpring Partners. The general partner of vSpring SBIC, L.P. is vSpring SBIC Management LLC. The general partner of vSpring and vSpring Partners is
vSpring Management, LLC. The managing members of vSpring SBIC Management LLC and vSpring Management, LLC are Scott Petty and Dinesh Patel. As a result, each of vSpring SBIC Management LLC, vSpring Management, LLC, Mr. Petty and Mr. Patel may be
deemed to possess voting and investment control over, and may be deemed to have indirect beneficial ownership with respect to, all shares held by vSpring, vSpring SBIC and vSpring Partners. Neither vSpring SBIC Management LLC, vSpring Management,
LLC, Mr. Petty nor Mr. Patel owns directly any of the shares. Each of vSpring SBIC Management LLC, vSpring Management, LLC, Mr.&nbsp;Petty and Mr. Patel disclaims beneficial ownership of the shares held by vSpring, vSpring SBIC and vSpring Partners,
except to the extent of their pecuniary interest therein. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Includes (a)&nbsp;1,614,300 shares of common stock issuable upon the exercise of the 2013 Warrants held by Capital Royalty Partners II L.P., which warrants will terminate if not exercised upon completion of this
offering, (b)&nbsp;2,702,302 shares of common stock issuable upon the exercise of the 2013 Warrants held by Capital Royalty Partners II Parallel Fund &#147;A&#148; L.P., which warrants will terminate if not exercised upon completion of this
offering, and (c)&nbsp;2,056,258 shares of common stock issuable upon the exercise of the 2013 Warrants to purchase common stock held by Parallel Investment Opportunities Partners II L.P., which warrants will terminate if not exercised upon
completion of this offering. In addition, beneficial ownership after the offering gives additional effect to the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to Capital Royalty Partners II
L.P., Capital Royalty Partners II Parallel Fund &#147;A&#148; L.P. and Parallel Investment Opportunities Partners II L.P., respectively, as a result of the expected net exercise of the 2013 Warrants in connection with the completion of this
offering. Capital Royalty Partners II L.P.&#146;s general partner is Capital Royalty Partners II GP L.P., whose general partner is Capital Royalty Partners II GP LLC. Capital Royalty Partners II&#151;Parallel Fund &#147;A&#148; L.P.&#146;s general
partner is Capital Royalty Partners II&#151;Parallel Fund &#147;A&#148; GP L.P., whose general partner is Capital Royalty Partners II&#151;Parallel Fund &#147;A&#148; GP LLC. Parallel Investment Opportunities Partners II L.P.&#146;s general partner
is Parallel Investment Opportunities Partners II GP L.P., whose general partner is Parallel Investment Opportunities Partners II LLC. Capital Royalty Partners II GP LLC, Capital Royalty Partners II&#151;Parallel Fund &#147;A&#148; GP LLC and
Parallel Investment Opportunities Partners II LLC are controlled by Charles Tate, as is Capital Royalty LP, the investment manager for all of the foregoing. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,242,908 shares which Mr.&nbsp;Rocca has the right to acquire pursuant to outstanding options which are or will be immediately exercisable within 60 days of August&nbsp;31, 2014. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 584,131 shares which Ms.&nbsp;Swedick has the right to acquire pursuant to outstanding options which are or will be immediately exercisable within 60 days of August&nbsp;31, 2014. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 579,964 shares which Dr.&nbsp;Dervieux has the right to acquire pursuant to outstanding options which are or will be immediately exercisable within 60 days of August 31, 2014. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Consists of 1,749,018 shares of common stock and 36,654&nbsp;shares of common stock issuable upon the exercise of warrants to purchase common stock,
which warrants will terminate if not exercised upon completion of this offering, held by CCP/Exagen, L.P., or CCP. In addition, beneficial ownership after the offering gives </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;143&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
additional effect to the issuance of shares of common stock issuable upon the conversion of 2014 Notes held CCP, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range listed on the cover page of this prospectus, and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 (the expected closing date of this offering). Dr.&nbsp;Pallares, one of our directors, is a co-manager of CCP. As a result, each of CCP and Dr.&nbsp;Pallares may be
deemed to possess voting and investment control over, and may be deemed to have an indirect beneficial ownership with respect to, all shares held by CCP. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 87,953 shares of common stock and 403,723 shares which Mr.&nbsp;Riccitelli has the right to acquire pursuant to outstanding options which are or will be immediately exercisable within 60 days of
August&nbsp;31, 2014. In addition, beneficial ownership after the offering gives additional effect to the issuance of shares of common stock issuable upon the conversion of 2014 Notes held by Mr.&nbsp;Riccitelli, assuming an initial public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range listed on the cover page of this prospectus, and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 (the expected closing date of this offering). Effective September 2014, Mr.&nbsp;Riccitelli no longer serves as a director. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 614,775 shares which Mr.&nbsp;Walsh has the right to acquire pursuant to outstanding options which are or will be immediately exercisable within 60 days of August&nbsp;31, 2014. Effective September 2014,
Mr.&nbsp;Walsh no longer serves as a director. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Includes shares of common stock issuable upon the exercise of outstanding options, which are or will be immediately exercisable within 60 days of August&nbsp;31, 2014, as set forth in the previous footnotes. In
addition, beneficial ownership after this offering includes shares of common stock issuable upon the conversion of the 2014 Notes, as set forth in the previous footnotes. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;144&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_15"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of this
offering, our authorized capital stock will consist of 200,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share. The following description summarizes some of the terms of
our fifteenth amended and restated certificate of incorporation and amended and restated bylaws, our outstanding warrants, the investors&#146; rights agreement and of the Delaware General Corporation Law. Because it is only a summary, it does not
contain all the information that may be important to you. For a complete description you should refer to our amended and restated certificate of incorporation, amended and restated bylaws, warrants and investors&#146; rights agreement, copies of
which have been filed or incorporated by reference as exhibits to the registration statement of which the prospectus is a part, as well as the relevant provisions of the Delaware General Corporation Law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2014, there
were &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock outstanding and held of record by 48&nbsp;stockholders, assuming (1) the automatic conversion of all outstanding shares
of our redeemable convertible preferred stock into shares of common stock, which will automatically occur immediately prior to the completion of this offering and (2) the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock as a result of the expected net exercise of outstanding warrants, or the 2013 Warrants, in connection with the completion of this offering, assuming an
initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range on the cover page of this prospectus, which 2013 Warrants will terminate if not exercised prior to the completion
of this offering. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of
a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may
be entitled to elect. Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally
available funds. In the event of our liquidation, dissolution or winding up, the holders of common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of
our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds
provisions applicable to the common stock. All outstanding shares of common stock are, and the common stock to be outstanding upon the completion of this offering will be, duly authorized, validly issued, fully paid and nonassessable. The rights,
preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this
offering, all of our previously outstanding shares of redeemable convertible preferred stock will have been converted into common stock, there will be no authorized shares of our previously redeemable convertible preferred stock and we will have no
shares of preferred stock outstanding. Under the terms of our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, our board of directors has the authority, without
further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the dividend, voting and other rights,
preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such
series then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could
adversely affect the voting power or other rights of the holders of the common stock. The issuance of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;145&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing
a change in our control and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2014, options to
purchase 8,671,470 shares of our common stock were outstanding under our 2002 and 2013 stock option plans, of which 5,670,308 were vested and exercisable as of that date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2014, 4,881,900
shares of our common stock were issuable upon exercise of outstanding warrants to purchase common stock with a weighted average exercise price of $1.31 per share. Of these warrants, we expect warrants to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be net exercised in connection with the completion of this offering, resulting in the issuance of an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share, which is the midpoint of the price range set forth on the cover page of this prospectus. If the remaining warrants are not exercised prior to the completion of this offering, they will terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2014, 4,174,430 shares of our Series D redeemable convertible preferred stock were issuable upon exercise of outstanding
warrants with a weighted average exercise price of $0.25 per share. We expect these warrants to be net exercised in connection with the completion of this offering, resulting in the issuance of an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the
midpoint of the price range set forth on the cover page of this prospectus. If these warrants are not exercised prior to the completion of this offering, they will terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the above warrants has a net exercise provision under which the holder may, in lieu of payment of the exercise price in cash,
surrender the warrant and receive a net amount of shares of our common stock based on the fair market value of our common stock at the time of the net exercise of the warrant after deduction of the aggregate exercise price. These warrants also
contain provisions for the adjustment of the exercise price and the aggregate number of shares issuable upon the exercise of the warrants in the event of stock dividends, stock splits, reorganizations and reclassifications and consolidations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Convertible Promissory Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July
2014, we sold an aggregate of $4.0 million of convertible promissory notes to certain existing investors in a private placement with certain existing investors. We refer to these notes as the 2014 Notes. The 2014 Notes accrue interest at a rate of
12%&nbsp;per annum and become due and payable nine months from the date of issuance. The principal amount of the 2014 Notes and accrued interest thereon will automatically convert into shares of our common stock upon completion of this offering at a
conversion price equal to 80% of our initial public offering price. If a liquidation (as defined in our current amended and restated certificate of incorporation) occurs prior to the completion of this offering, the holders of the 2014 Notes may
elect to (1)&nbsp;receive the repayment of the notes or (2)&nbsp;convert the notes into shares of Series D redeemable convertible preferred stock at a conversion price of $0.25 per share, subject to adjustment pursuant to the terms thereof. In
connection with the completion of this offering, the 2014 Notes (including accrued interest thereon) will automatically convert into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of
common stock, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share , which is the midpoint of the price range set forth on the cover page of this prospectus and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 (the expected closing date of this offering). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2014, holders of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, which includes all of the shares of common stock issuable upon the automatic conversion of our redeemable convertible
preferred stock immediately </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;146&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior to the completion of this offering and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable in connection
with the completion of this offering as a result of the automatic conversion of the $4.0 million in aggregate principal amount of 2014 Notes (including accrued interest thereon), assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range listed on the cover page of this prospectus and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 (the expected closing date of this offering), will be entitled to the
following rights with respect to the registration of such shares for public resale under the Securities Act, pursuant to an investor rights agreement by and among us and certain of our stockholders. The registration of shares of common stock as a
result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Form S-1.
</I>If at any time for a period of three years following the completion of this offering, the holders of at least 50% of the registrable securities request in writing that we effect a registration with respect to their shares in an offering, we may
be required to register their shares. We are obligated to effect at most two registrations for the holders of registrable securities in response to these demand registration rights, subject to certain exceptions. <I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Form S-</I>3. If at any time beginning 180 days following the completion of this offering and we become entitled under the Securities Act
to register our shares on Form S-3, a holder of registrable securities requests in writing that we register their shares for public resale on Form S-3 and the price to the public of the offering is $1.0 million or more, we will be required to
provide notice to all holders of registrable securities and to use our best efforts to effect such registration; provided, however, that we will not be required to effect such a registration if, within the preceding 12 months, we have already
effected two registrations on Form S-3 for the holders of registrable securities. <I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In each of the above registrations, if the
holders requesting registration intend to distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of
the shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any time for a period of three years following the completion of this offering we propose to register any shares of our common stock
under the Securities Act, subject to certain exceptions, the holders of registrable securities will be entitled to notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration
involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ordinarily, other than
underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees,
printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling securityholders, blue sky fees and expenses and the expenses of any special audits incident to the registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
registration rights terminate upon the earlier of three years after the completion of this offering, or for any particular holder with registration rights, at such time following this offering when such holder holds less than one percent of our
outstanding common stock and may immediately sell all of such shares pursuant to Rule 144 under the Securities Act in a 90-day period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;147&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions
that could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that
these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium
over the market price for our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are intended to discourage coercive takeover practices and
inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to
negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Undesignated Preferred Stock </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability
of our board of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any
attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder Meetings </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and
restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president, or by a resolution adopted by a majority of our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Requirements for Advance Notification of Stockholder Nominations and Proposals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder
meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Elimination of Stockholder Action by Written Consent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws eliminate the right of stockholders to act by written
consent without a meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Staggered Board </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected
each year by our stockholders. For more information on the classified board, see &#147;Management&#151;Board Composition and Election of Directors.&#148; This system of electing and removing directors may tend to discourage a third-party from making
a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Removal of Directors </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and
restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds
of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;148&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholders Not Entitled to Cumulative Voting </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors.
Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our
preferred stock may be entitled to elect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware Anti-Takeover Statute </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed to be &#147;interested
stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction
in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or
within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction
resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Choice of Forum </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate
of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1)&nbsp;any derivative action or proceeding brought on
our behalf; (2)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&nbsp;any action asserting a claim against us arising pursuant
to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or
(5)&nbsp;any action asserting a claim governed by the internal affairs doctrine. Our restated certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be
deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our restated certificate of incorporation is inapplicable or
unenforceable if it is challenged in a proceeding or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment of Charter Provisions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock,
would require approval by holders of at least two thirds of the total voting power of all of our outstanding voting stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions
of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary
fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible
that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NASDAQ Global
Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to have our common stock listed on The NASDAQ Global Market under the symbol &#147;EXDX.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;149&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_16"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to this offering, there was no public market for our common stock. Future sales of substantial amounts of common stock in
the public market, or the perception that such sales may occur, could adversely affect the market price of our common stock. Although we have applied to have our common stock listed on The NASDAQ Global Market, we cannot assure you that there will
be an active public market for our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the number of shares of our common stock outstanding as of June 30, 2014 and
assuming (1)&nbsp;the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares in this offering, (2)&nbsp;the conversion of all outstanding shares of our redeemable convertible
preferred stock into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, which will occur automatically occur immediately prior to the completion of the offering,
(3)&nbsp;no exercise of the underwriters&#146; over-allotment option to purchase additional shares of common stock, (4) the net exercise of the 2013 Warrants, and (5)&nbsp;no exercise of outstanding options or warrants (other than the 2013
Warrants), we will have outstanding an aggregate of approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of these shares, all shares sold in this offering will be freely tradable without restriction or further registration under the Securities
Act, except for any shares purchased by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. Shares purchased by our affiliates would be subject to the Rule 144 resale restrictions described below, other than the
holding period requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock will be &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act. These restricted
securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule 144 or 701 under the Securities Act, each of which is summarized below. We expect that
substantially all of these shares will be subject to the 180-day lock-up period under the lock-up agreements described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, of the 8,671,470 shares of our common stock that were subject to stock options outstanding as of June 30, 2014, options to purchase 5,670,308 of such shares of common stock were vested as of such date and, upon exercise, these shares will
be eligible for sale subject to the lock&#150;up agreements described below and Rules 144 and 701 under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lock-Up Agreements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, along with our directors, executive officers and substantially all of our other stockholders, optionholders and warrantholders,
have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, subject to specified exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant to sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand
that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Upon
expiration of the lock-up period, certain of our stockholders and warrantholders will have the right to require us to register their shares under the Securities Act. See &#147;&#151;Registration Rights&#148; below and &#147;Description of Capital
Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC and Robert W. Baird&nbsp;&amp; Co. Incorporated may, in their sole discretion
and at any time or from time to time before the termination of the lock-up period, without public notice, release all or any portion of the securities subject to lock-up agreements. There are no existing agreements between the underwriters and any
of our stockholders who will execute a lock-up agreement providing consent to the sale of shares prior to the expiration of the lock-up period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the expiration of the lock-up period, substantially all of the shares subject to such lock-up restrictions will become eligible for sale,
subject to the limitations discussed above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;150&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Affiliate Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an
affiliate of ours, or who was an affiliate at any time during the 90 days before a sale, who has beneficially owned shares of our common stock for at least six months would be entitled to sell in &#147;broker&#146;s transactions&#148; or certain
&#147;riskless principal transactions&#148; or to market makers, a number of shares within any three-month period that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of shares of our common stock then outstanding, which will equal approximately shares immediately after this offering; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume in our common stock on The NASDAQ Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Affiliate resales under Rule 144 are also subject to the availability of current public information about us. In addition, if the number of
shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000, the seller must file a notice on Form 144 with the Securities and Exchange Commission and The
NASDAQ Global Market concurrently with either the placing of a sale order with the broker or the execution of a sale directly with a market maker. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Non-Affiliate Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not an
affiliate of ours at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell
such shares subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell under Rule&nbsp;144(b)(1) without regard to any Rule 144 restrictions, including
the 90-day public company requirement and the current public information requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-affiliate resales are not subject to the manner
of sale, volume limitation or notice filing provisions of Rule 144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 701, any of an issuer&#146;s employees, directors, officers, consultants or advisors who purchases shares from the
issuer in connection with a compensatory stock or option plan or other written agreement before the effective date of a registration statement under the Securities Act is entitled to sell such shares 90 days after such effective date in reliance on
Rule 144. An affiliate of the issuer can resell shares in reliance on Rule 144 without having to comply with the holding period requirement, and non-affiliates of the issuer can resell shares in reliance on Rule 144 without having to comply with the
current public information and holding period requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration statements on Form S-8 under the Securities Act to register all shares of common stock subject to
outstanding stock options and common stock issued or issuable under the 2014 plan, 2013 plan, 2002 plan and ESPP. We expect to file the registration statement covering shares offered pursuant to these stock plans shortly after the date of this
prospectus, permitting the resale of such shares by non-affiliates in the public market without restriction under the Securities Act and the sale by affiliates in the public market subject to compliance with the resale provisions of Rule 144. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;151&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2014, holders of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of
our common stock, which includes all of the shares of common stock issuable upon the automatic conversion of our redeemable convertible preferred stock immediately prior to the completion of this offering, or their transferees will be entitled to
various rights with respect to the registration of these shares under the Securities Act upon the completion of this offering. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without
restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. Shares covered
by a registration statement will be eligible for sale in the public market upon the expiration or release from the terms of the lock-up agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;152&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_17"></A>MATERIAL UNITED STATES FEDERAL INCOME TAX </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSEQUENCES TO NON-U.S. HOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of the material U.S. federal income tax consequences to Non-U.S. Holders (as defined below) of the
purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and
any applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, Treasury regulations promulgated thereunder, judicial decisions, and published rulings
and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation
may be applied retroactively in a manner that could adversely affect a Non-U.S. Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a
court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is limited to Non-U.S. Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of
Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a Non-U.S. Holder&#146;s particular circumstances, including the impact of the Medicare
contribution tax on net investment income. In addition, it does not address consequences relevant to Non-U.S. Holders subject to special rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">U.S. expatriates and former citizens or long-term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons subject to the alternative minimum tax; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">banks, insurance companies, and other financial institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">brokers, dealers or traders in securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that accumulate earnings to avoid U.S. federal income tax; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax-exempt organizations or governmental organizations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our common stock under the constructive sale provisions of the Code; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax-qualified retirement plans. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity treated as a partnership for U.S. federal income
tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships
holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE
APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;153&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX
TREATY. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of a Non-U.S. Holder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#147;Non-U.S. Holder&#148; is any beneficial owner of our common stock that is neither a &#147;U.S.
person&#148; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more &#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has
a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in the section entitled &#147;Dividend Policy,&#148; we do not anticipate declaring or paying dividends to holders of our common
stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated
earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce a Non-U.S. Holder&#146;s
tax basis in its common stock, but not below zero. Any excess will be treated as capital gain from a sale or other taxable disposition and will be treated as described below under &#147;&#151;Sale or Other Taxable Disposition.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below on effectively connected income, dividends paid to a Non-U.S. Holder of our common stock will be subject to
U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the Non-U.S. Holder furnishes a valid IRS Form W-8BEN or W-8BEN-E (or other applicable
documentation) certifying qualification for the lower treaty rate). If a Non-U.S. Holder holds the stock through a financial institution or other agent acting on the Non-U.S. Holder&#146;s behalf, the Non-U.S. Holder will be required to provide
appropriate documentation to the agent, who then will be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. A Non-U.S. Holder that does not timely furnish the required
documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. Holders should consult their tax advisors regarding their
entitlement to benefits under any applicable income tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If dividends paid to a Non-U.S. Holder are effectively connected with the
Non-U.S. Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment in the United States maintained by the Non-U.S. Holder), the Non-U.S.
Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the Non-U.S. Holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI, certifying that the dividends are effectively
connected with the Non-U.S. Holder&#146;s conduct of a trade or business within the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such effectively connected
dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A Non-U.S. Holder that is a corporation may also be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an
applicable income tax treaty) on such effectively connected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;154&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividends, as adjusted for certain items. Non-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Taxable Disposition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the gain is effectively connected with the Non-U.S. Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, is attributable to a permanent
establishment in the United States maintained by the Non-U.S. Holder); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Non-U.S. Holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S.&nbsp;real property holding corporation, or USRPHC, for U.S. federal income tax purposes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular
graduated rates. A Non-U.S. Holder that is a corporation may also be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain
items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate
specified by an applicable income tax treaty), which may be offset by U.S. source capital losses of the Non-U.S. Holder (even though the Non-U.S. Holder is not considered a resident of the United&nbsp;States), provided the Non-U.S. Holder has timely
filed U.S. federal income tax returns with respect to such losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the third bullet point above, we believe we currently
are not, and do not anticipate becoming, a USRPHC. However, because the determination of whether we are a USRPHC depends on the fair market value of our USRPIs relative to the fair market value of our non-U.S. real property interests and our other
business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury regulations, on an established
securities market, and such Non-U.S. Holder owned, actually or constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the Non-U.S. Holder&#146;s
holding period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-U.S. Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide
for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have
actual knowledge or reason to know the holder is a United States person and the holder either certifies its non-U.S. status, such as by furnishing a valid IRS Form W-8BEN, <FONT STYLE="white-space:nowrap">W-8BEN-E</FONT> or W-8ECI, or otherwise
establishes an exemption. However, information returns are required to be filed with the IRS in connection with any dividends on our common stock paid to the Non-U.S. Holder, regardless of whether any tax was actually withheld. In addition, proceeds
of the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting, if the applicable withholding agent
receives the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;155&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certification described above and does not have actual knowledge or reason to know that such holder is a United&nbsp;States person, or the holder otherwise establishes an exemption. Proceeds of a
disposition of our common stock conducted through a non-U.S. office of a non-U.S. broker generally will not be subject to backup withholding or information reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement
to the tax authorities of the country in which the Non-U.S. Holder resides or is established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional
tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a Non-U.S. Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax
Compliance Act, or FATCA) on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on dividends on, or gross proceeds from the sale or other
disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a &#147;non-financial foreign entity&#148; (each as defined in the Code), unless (1)&nbsp;the foreign financial institution undertakes certain diligence and
reporting obligations, (2)&nbsp;the non-financial foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United
States owner, or (3)&nbsp;the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting
requirements in (1)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United States persons&#148; or
&#147;United States-owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to non-compliant foreign financial institutions and certain other account
holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury regulations and IRS guidance, withholding under FATCA generally applies to payments of dividends on our common
stock made on or after July&nbsp;1, 2014 and will apply to payments of gross proceeds from the sale or other disposition of our common stock on or after January&nbsp;1, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in
our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;156&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_18"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC and Robert W. Baird&nbsp;&amp; Co. Incorporated are acting as representatives of each of the underwriters named below.
Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the number
of shares of common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:43.10pt; font-size:8pt; font-family:Times New Roman"><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert W. Baird&nbsp;&amp; Co. Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Blair&nbsp;&amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed,
severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the non-defaulting
underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against
certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officers&#146; certificates and legal opinions. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set
forth on the cover of this prospectus and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. After the initial offering, the public offering price, concession or any other term of
the offering may be changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, underwriting discount and proceeds before expenses to
us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares of our common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and
commissions referred to above, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . We also have agreed to reimburse the underwriters for up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for their FINRA counsel fee. In
accordance with FINRA Rule 5110, this reimbursed fee is deemed underwriting compensation for this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;157&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions contained
in the underwriting agreement, to purchase a number of additional shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our
executive officers and directors and all of our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this
prospectus without first obtaining the written consent of Leerink Partners LLC and Robert W. Baird&nbsp;&amp; Co. Incorporated. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">offer, pledge, sell or contract to sell any common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell any option or contract to purchase any common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchase any option or contract to sell any common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">grant any option, right or warrant for the sale of any common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise dispose of or transfer any common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">request or demand that we file a registration statement related to the common stock; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into any swap or other agreement or any transaction that transfers, in whole or in part, the economic consequence of ownership of any common stock, whether any such swap, agreement or transaction is to be settled
by delivery of shares or other securities, in cash or otherwise. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This lock-up provision applies to common stock and to
securities convertible into or exchangeable or exercisable for common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power
of disposition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NASDAQ Global Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our common stock on the NASDAQ Global Market, subject to notice of issuance, under the symbol &#147;EXDX.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before this offering, there has been no public market for our common stock. The initial public offering price will be determined through
negotiations between us and the representatives. In addition to prevailing market conditions, the factors to be considered in determining the initial public offering price are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial information; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the history of, and the prospects for, our company and the industry in which we compete; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an assessment of our management, its past and present operations, and the prospects for, and timing of, our future revenues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the present state of our development; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;158&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An active trading market for the shares may not develop. It is also possible that after the
offering the shares will not trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters do not expect to
sell more than 5% of the shares in the aggregate to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions
and Penalty Bids </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from
bidding for and purchasing our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option described above. The underwriters may close out any covered short position by either exercising their option or purchasing shares in the open
market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may
purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more
likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions
consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the
underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriters may conduct these transactions on the NASDAQ Global Market, in the over-the-counter market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any
of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any
representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection
with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as e-mail. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other
Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the underwriters and their affiliates may in the future engage in investment banking and other commercial
dealings in the ordinary course of business with us or our affiliates. They may in the future receive customary fees and commissions for these transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;159&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their
affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and
their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short
positions in such securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc693329_19"></A>Notice to Prospective Investors in the European Economic Area </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each, a &#147;Relevant Member State&#148;), no offer of shares may be made to
the public in that Relevant Member State other than: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">A. to any legal entity which is a qualified investor as defined in the Prospectus
Directive; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">B. to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive,
150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">C. in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of shares shall require the
Company or the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant Member State who initially acquires any shares or to whom any offer is made will be deemed to have represented,
acknowledged and agreed that it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive. In the case of any shares being offered to a financial
intermediary as that term is used in Article 3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a
non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant Member
State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The company, the representatives and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements
and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has been prepared on the basis that any offer of shares in any Relevant Member State will be made
pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an offer in that Relevant Member State of shares which are the subject of
the offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for the company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such
offer. Neither the company nor the underwriters have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the company or the underwriters to publish a prospectus for such offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purpose of the above provisions, the expression &#147;an offer to the public&#148; in relation to any shares in any Relevant Member
State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied in the
Relevant Member State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (including the 2010 PD Amending Directive, to the extent
implemented in the Relevant Member&nbsp;States) and includes any relevant implementing measure in the Relevant Member State and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;160&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered hereby will be passed upon for us by Latham&nbsp;&amp; Watkins LLP, San Diego, California.
The underwriters are being represented by Cooley LLP, San Diego, California. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements as of December&nbsp;31, 2012 and 2013 and for each of the two years in the period ended
December&nbsp;31, 2013 included in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company&#146;s ability to continue as a going concern as described in Note&nbsp;2 and the
restatement of its consolidated financial statements as described in Note&nbsp;3 to the consolidated financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as
experts in auditing and accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_24"></A>CHANGE IN INDEPENDENT ACCOUNTANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;25, 2013, the Audit Committee of the board of directors determined to dismiss McGladrey LLP and retain PricewaterhouseCoopers
LLP, or PwC, as our independent registered public accounting firm. Effective February&nbsp;13, 2014, we retained PwC as our independent registered public accounting firm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reports of McGladrey LLP on our consolidated financial statements for each of the two fiscal years prior to its dismissal did not contain
any adverse opinion or disclaimer of opinion, nor were such reports qualified or modified as to uncertainty, audit scope or accounting principles. However, the reports of McGladrey LLP included an emphasis of matter regarding the Company&#146;s
ability to continue as a going concern. We had no disagreements with McGladrey LLP on any matter of accounting principles or practices, consolidated financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved
to its satisfaction, would have caused McGladrey LLP to make reference in connection with its opinion to the subject matter of the disagreement during its audits for each of the two fiscal years prior to its dismissal or the subsequent interim
period through November&nbsp;25, 2013. During the two most recent fiscal years preceding McGladrey LLP&#146;s dismissal, and the subsequent interim period through November&nbsp;25, 2013, there were no &#145;&#145;reportable events&#146;&#146; as
such term is defined in Item&nbsp;304(a)(1)(v) of Regulation&nbsp;S-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the two years ended December&nbsp;31, 2012 and the
subsequent interim period through February&nbsp;13, 2014, neither we, nor anyone acting on our behalf, consulted with PwC on matters that involved the application of accounting principles to a specified transaction, either completed or proposed, the
type of audit opinion that might be rendered on our consolidated financial statements, and neither a written report nor oral advice was provided to us by PwC that PwC concluded was an important factor considered by us in reaching a decision as to
the accounting, auditing or financial reporting issue or any other matter that was the subject of a disagreement as that term is used in Item&nbsp;304 (a)(1)(iv) of Regulation&nbsp;S-K and the related instructions to Item&nbsp;304 of
Regulation&nbsp;S-K or a reportable event as that term is used in Item&nbsp;304(a)(1)(v) and the related instructions to Item 304 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have provided McGladrey LLP with a copy of the foregoing disclosure and have requested that McGladrey LLP furnish us with a letter
addressed to the SEC stating whether or not McGladrey LLP agrees with the above statements and, if not, stating the respects in which it does not agree. A copy of the letter from McGladrey LLP is filed as an exhibit to the registration statement of
which this prospectus is a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;161&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>We have filed with the Securities and Exchange Commission a registration statement on Form S-1 under the Securities Act with respect to
the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For
further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus regarding the contents of any contract or any other
document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the
registration statement. Upon the completion of this offering, we will be required to file periodic reports, proxy statements and other information with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934. You may
read and copy this information at the Public Reference Room of the Securities and Exchange Commission, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may obtain information on the operation of the public reference rooms by calling the
Securities and Exchange Commission at 1-800-SEC-0330. The Securities and Exchange Commission also maintains an Internet website that contains reports, proxy statements and other information about registrants, like us, that file electronically with
the Securities and Exchange Commission. The address of that website is <I>www.sec.gov</I>. <I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;162&nbsp;- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc693329_23"></A>Index to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin693329_1">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin693329_2">Consolidated Balance Sheets (Restated)</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin693329_3">Consolidated Statements of Operations and Comprehensive Loss (Restated)</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin693329_4">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit
(Restated)</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin693329_5">Consolidated Statements of Cash Flows (Restated)</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin693329_6">Notes to Consolidated Financial Statements (Restated)</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin693329_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exagen
Diagnostics, Inc.: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations and comprehensive
loss, consolidated statements of redeemable convertible preferred stock and stockholders&#146; deficit, and consolidated statements of cash flow, present fairly, in all material respects, the financial position of Exagen Diagnostics, Inc. and its
subsidiary at December&nbsp;31, 2012 and 2013, and the results of their operations and their cash flows for each of the two years in the period ended December&nbsp;31, 2013 in conformity with accounting principles generally accepted in the United
States of America. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in
accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the
overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial
statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations since inception and has negative
cash flows from operating activities that raise substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 3 to the consolidated financial statements, the Company has
restated its 2013 financial statements to correct an error. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>/s/ PricewaterhouseCoopers LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Denver, Colorado </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>August 4, 2014, except for the
effects of the restatement discussed in Note 3 to the consolidated financial statements, as to which the date is September 19, 2014 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin693329_2"></A>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June 30,</B><br><B>2014</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June 30,</B><br><B>2014</B><br><B>Pro&nbsp;Forma</B><br><B>Balance&nbsp;Sheet</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="2" ALIGN="center"><B>(Restated)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Unaudited)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" COLSPAN="12"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued payroll and related expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Capital lease obligations, current portion</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Borrowings, current portion</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Borrowings, non current portion</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Acquisition-related liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other non current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Commitments and Contingencies (Note 9)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.001 par value &#151; 94,000,000, 145,000,000 and 145,000,000 shares authorized at
December&nbsp;31, 2012 and 2013 and June 30, 2014 (unaudited), respectively; 69,765,161, 92,330,247 and 92,330,247 shares issued and outstanding at December&nbsp;31, 2012 and 2013 and June 30, 2014 (unaudited), respectively; (Liquidation value of
$34,704, $42,533 and $42,533 at December&nbsp;31, 2012 and 2013 and June 30, 2014 (unaudited), respectively); &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma
(unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Common stock, $0.001 par value&nbsp;&#151;&nbsp;112,000,000, 163,000,000 and 163,000,000 shares authorized at December&nbsp;31, 2012 and
2013 and June 30, 2014 (unaudited), respectively; 9,775,058, 9,943,214 and 9,976,964 shares issued and outstanding at December 31, 2012 and 2013 and June 30, 2014 (unaudited), respectively;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding , pro forma (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81,847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin693329_3"></A>Consolidated Statement of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended </B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Restated)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue (excluding amortization of purchased technology)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,826</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,393</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,433</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of 2013 Notes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders &#151; basic and diluted (Note&nbsp;4)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,789</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share attributable to common stockholders &#151; basic and diluted (Note&nbsp;4)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares used to compute net income (loss) per share attributable to common stockholders &#151; basic and
diluted (Note&nbsp;4)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,501,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,856,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,786,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,949,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders &#151; basic and diluted (unaudited) (Note&nbsp;4)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average number of shares used to compute net loss per share attributable to common stockholders &#151; basic and
diluted (unaudited) (Note&nbsp;4)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin693329_4"></A>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-In</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balances at December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of Series A-2 redeemable convertible preferred stock at a fair value of $3.23 per share and issuance of Series B-2 redeemable
convertible preferred stock at $0.25 per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Gain on recapitalization upon conversion of common stock into Series A-2 redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Conversion of Series A-2 and B-2 redeemable convertible preferred stock into common stock as part of recapitalization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Conversion of common stock into Series A-3 redeemable convertible preferred stock as part of recapitalization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,344</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Gain on recapitalization upon conversion of common stock into Series A-3 and B-3 redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of Series C redeemable convertible preferred stock at $0.25 per share, less issuance costs of $51</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Repurchase of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(109</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balances at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of Series&nbsp;D redeemable convertible preferred stock at $0.25 per share for cash, net of issuance costs of $8</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deemed dividend on issuance of Series D redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Conversion of 2013 Notes into Series D redeemable convertible preferred stock at a fair value of $0.49 per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock warrants in connection with 2013 Loan at relative fair value, net of issuance costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock to consultants in exchange for services</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balances at December&nbsp;31, 2013 (Restated)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balances at June 30, 2014 (Unaudited) (Restated)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(81,847</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin693329_5"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash flows from operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Amortization of debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Amortization of deferred financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Noncash interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of embedded derivatives and warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Loss on extinguishment of 2013 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Loss on disposal of assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock in exchange for services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Changes in assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,477</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash flows from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(425</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash flows from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from borrowings of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payments on borrowings of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payments for deferred financing costs and costs paid to lender</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from issuance of redeemable convertible preferred stock for cash, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from issuance of convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payments on promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(511</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payments on warrant obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payments on line of credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from issuance of common stock, net of repurchases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payments on capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Costs paid in connection with initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">(Decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Supplemental disclosure of cash flow information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Supplemental disclosure of noncash items (Restated)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion of notes payable and accrued interest into redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accretion to redemption value of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series A-2, B-2 and B-3 redeemable convertible preferred stock at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deemed dividend on issuance of Series D redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Equipment purchased under capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of warrants to purchase redeemable convertible preferred stock and common stock in 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cost incurred, but not paid, in connection with initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin693329_6"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Organization and Business </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Exagen Diagnostics, Inc. (the Company) was incorporated under
the laws of the state of New Mexico in 2002, under the name Exagen Corporation. In 2003, Exagen Corporation changed its state of incorporation from New Mexico to Delaware by merging with and into Exagen Diagnostics, Inc., pursuant to which the
Company changed its name to Exagen Diagnostics, Inc. The Company is a commercial-stage diagnostics company committed to addressing the significant unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic
diseases (ARDs). These chronic diseases can cause lifelong inflammation in the joints, tissues and internal organs, resulting in serious complications, such as irreversible organ damage. The accurate, timely and differential diagnosis for patients
suffering from the approximately 30 ARDs is critical as treatment for each disease varies, and inappropriate or delayed therapy may expose patients to unnecessary risks or the hazards of uncontrolled disease activity. Physicians face significant
difficulties in making a definitive diagnosis of a specific ARD because patients with different diseases often present with a common set of symptoms. The Company currently markets four products under its Avise brand to provide an accurate, timely
and differential diagnosis and to optimize the treatment of ARDs. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Summary of Significant Accounting Policies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation and Use of
Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States (U.S. GAAP). The preparation of the accompanying consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities, the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those
estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared on a going concern basis that contemplates the
realization of assets and discharge of liabilities in their normal course of business. The Company has suffered recurring losses from operations since inception and negative cash flows from operating activities during each of 2012, 2013 and the six
months ended June 30, 2014. As of December&nbsp;31, 2013 and June 30, 2014 (unaudited), the Company had working capital deficits of $(2.6)&nbsp;million and $(10.6)&nbsp;million, respectively, and an accumulated deficit of $74.3 million and
$81.8&nbsp;million, respectively. The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i)&nbsp;expands sales and marketing efforts to promote its Avise product line (ii)&nbsp;develops additional
products and prepares to commercialize any new products, and (iii)&nbsp;expands its corporate infrastructure, including the costs associated with becoming a public company. These factors raise substantial doubt about the Company&#146;s ability to
continue as a going concern. The Company needs to raise additional funds through equity or debt financing and, when and if necessary, to reduce discretionary spending. Although management has been successful in raising capital in the past, most
recently in July 2014 (Note 17), there can be no assurance that they will be successful or that any needed financing will be available in the future at terms acceptable to the Company. Failure to achieve these plans may result in the Company not
being able to achieve its business objectives. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company plans to fund its losses from operations and capital funding needs through current cash on hand and future debt and equity
financings. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs.
Any of these actions could materially harm the Company&#146;s business, results of operations, and future prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The accompanying interim consolidated balance sheet as of June 30, 2014, consolidated statements of operations and comprehensive loss and cash
flows for the six months ended June 30, 2013 and 2014 and the consolidated statements of redeemable convertible preferred stock and stockholders&#146; deficit for the six months ended June 30, 2014 are unaudited. The unaudited interim consolidated
financial statements have been prepared on a basis consistent with the audited financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) considered necessary to fairly present the
Company&#146;s financial position as of June 30, 2014 and the Company&#146;s results of operations and cash flows for the six months ended June 30, 2013 and 2014. The results for the six months ended June 30, 2014 are not necessarily indicative of
the results to be expected for the year ended December&nbsp;31, 2014 or for any other period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Unaudited Pro Forma Balance Sheet
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma balance sheet information as of June 30, 2014 in the accompanying consolidated balance sheet gives effect to:
(i)&nbsp;the automatic conversion of all outstanding shares of convertible preferred stock into shares of common stock and (ii)&nbsp;the net exercise of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;warrants to
purchase shares of our common stock and Series&nbsp;D redeemable convertible preferred stock, and (iii)&nbsp;the resultant reclassification of the redeemable convertible preferred stock warrant liability to additional paid-in-capital, a component of
stockholders&#146; deficit, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus and assuming the conversion occurs on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2014 (the expected closing date of this offering). The unaudited pro forma balance sheet information excludes any shares of
common stock issued in the proposed initial public offering (&#147;IPO&#148;) and related proceeds therefrom. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Unaudited Pro Forma Net
Loss per Share of Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma basic and diluted net loss per share reflects the automatic conversion of all
outstanding shares of redeemable convertible preferred stock, net exercise of warrants and the reclassification of certain redeemable convertible preferred stock warrants to common stock warrants in additional paid-in capital, as if the conversions
had occurred at the beginning of the period presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma basic and diluted net loss per share amounts do not give
effect to the issuance of shares from the planned initial public offering nor do they give effect to potential dilutive securities where the impact would be anti-dilutive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Consolidation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements include the accounts of the Company and its 60% owned subsidiary, Computational Engines Inc. Computational Engines, Inc. has been an inactive subsidiary since inception and was dissolved in May 2014 (Note 17).
Intercompany balances and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Segments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal
reporting. All long-lived assets are maintained in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Cash and Cash Equivalents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Restricted Cash </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At
December&nbsp;31, 2012, a deposit of $707,425 was restricted from withdrawal and held by a bank as collateral in accordance with the terms of a line of credit agreement. In 2013, the restriction was released upon repayment of the line of credit.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company derives its revenue from sales of its diagnostic, prognostic and monitoring products. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company primarily markets its testing services to rheumatologists and their physician assistants. The </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">healthcare professionals who order the Company&#146;s products and to whom test results are reported are generally not responsible for payment
for these products. The parties that pay for these services (the Payers) consist of commercial third-party companies, Medicare and other government payers, and patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue when the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has
occurred or services have been rendered; (3) the fee is fixed or </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">determinable; and (4) collectability is reasonably assured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s service is completed upon the delivery of test results to the prescribing physician which triggers billing for the service.
The Company recognizes revenue related to billings to Payers on an accrual basis, net of contractual adjustments, only when the Company has established pricing with its Payers as indicated by contractual pricing arrangements or predictable patterns
of payments for its services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the absence of a predictable pattern of reimbursement or a contract with a Payer, revenue is recognized
upon the earlier of payment notification, if applicable, or cash receipt. In those instances where payment notification is received in advance of the cash receipt, the notification received from third-party payers is generally received no more than
one business day in advance of the cash receipt. The Company currently recognizes revenue on a cash basis from sales of its products. The assessment of the fixed or determinable nature of the fees charged and the collectability of those fees
requires significant judgment by management. Accordingly, the Company expects to recognize revenue on a cash basis until it has sufficient history to reliably estimate payment patterns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2012 and 2013 and June 30, 2013 (unaudited) and 2014 (unaudited), substantially all of the Company&#146;s revenue is
recognized upon the earlier of payment notification, if applicable, or cash receipt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Concentration of Credit Risk and Other Risk and
Uncertainties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents,
and accounts receivable. Substantially all the Company&#146;s cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Approximately 9%, 25%, 32% and 31% of the Company&#146;s revenue is derived from sales billed to Medicare for the years ended
December&nbsp;31, 2012 and 2013 and the six months ended June 30, 2013 (unaudited) and 2014 (unaudited), respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company is dependent on key suppliers for certain laboratory materials. An interruption
in the supply of these materials would temporarily impact the Company&#146;s ability to perform testing services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Property and
Equipment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are recorded at cost. Depreciation is computed using the
<FONT STYLE="white-space:nowrap">straight-line</FONT> method over the estimated useful lives of the assets, generally between three and ten years, or the lease term of the respective assets. Leasehold improvements are amortized on a <FONT
STYLE="white-space:nowrap">straight-line</FONT> basis over the lesser of their useful life or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are
retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in operations in the period realized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Goodwill and Intangible Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has recorded goodwill and intangible assets on the consolidated balance sheets. The Company classifies intangible assets into two
categories: (1)&nbsp;goodwill; and (2)&nbsp;intangible assets with definite lives subject to amortization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Goodwill is not amortized. The
Company assesses goodwill for impairment on an annual basis in the fourth quarter of each year or more frequently if indicators of impairment exist. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The goodwill impairment assessment involves a two-step process. The Company first assesses the book value and market value of the Company to
determine if an impairment of goodwill exists by reporting unit. A potential impairment exists if the fair value of the reporting unit is lower than its net book value. The second step of the process is only performed if a potential impairment
exists, and it involves comparing the aggregate fair value of the reporting unit&#146;s net assets, other than goodwill, to the fair value of the reporting unit as a whole. Goodwill is considered impaired, and an impairment charge is recorded, if
the excess of the fair value of the reporting unit over the fair value of the net assets is less than the carrying value of goodwill. This evaluation requires use of internal business plans that are based on the Company&#146;s judgments regarding
future economic conditions, product demand and pricing, costs, inflation rates and discount rates, among other factors. These judgments and estimates involve inherent uncertainties, and the measurement of the fair value is dependent on the accuracy
of the assumptions used in making the estimates and how those estimates compare to the Company&#146;s future operating performance. There was no impairment of goodwill identified through December&nbsp;31, 2013 or June 30, 2014 (unaudited). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Impairment of <FONT STYLE="white-space:nowrap">Long-Lived</FONT> Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Purchased intangible assets with finite lives are amortized using the straight-line method over the estimated economic lives of the assets. The
Company analyzed and determined that the use of straight-line amortization method was appropriate to reflect the pattern over which the economic benefits of the assets are realized. Long-lived assets, including intangible assets, with definite lives
and property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Such conditions may include an economic downturn or a change in the
assessment of future operations. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset (or asset group) and its eventual disposition. Measurement of an impairment loss for
long-lived assets that management expects to hold and use is based on the amount that the carrying value of the asset (or asset group) exceeds its fair value. If such assets are considered to be impaired, the impairment to be recognized is measured
as the amount by which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported as a separate caption at the lower of the carrying amount or fair value less costs to
sell. There were no impairment charges, or changes in estimated useful lives, recorded through December&nbsp;31, 2013 or June&nbsp;30, 2014 (unaudited).<B> </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Deferred Offering Costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Deferred offering costs, which primarily consist of direct incremental legal and accounting fees relating to the IPO, are capitalized. The
deferred offering costs will be offset against IPO proceeds upon the consummation of the offering. In the event the offering is terminated, deferred offering costs will be expensed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has multiple classes of redeemable convertible preferred stock, all of which are classified as temporary equity in the consolidated
balance sheets. Shares of Series B-3, Series C and Series D redeemable convertible preferred stock are redeemable at any time after October&nbsp;4, 2018 upon the written request of the holders of 60% of the outstanding shares of these issuances,
voting together as a single class. Holders of the Series A-3 redeemable convertible preferred stock can cause redemption of the Series A-3 redeemable convertible preferred shares due to certain change in control events that are outside the
Company&#146;s control, including liquidation, sale or transfer of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock which is
redeemable on or after a certain date upon the option of the holder is accreted to its redemption value from the date of issuance to the earliest redemption date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Redeemable Convertible Preferred Stock Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for its redeemable convertible preferred stock warrants as liabilities based upon the characteristics and provisions of
each instrument. The redeemable convertible preferred stock warrants classified as liabilities are recorded on the Company&#146;s consolidated balance sheet at their fair value on the date of issuance and are revalued on each subsequent balance
sheet, with fair value changes recognized as increases or reductions in the consolidated statements of operations and comprehensive loss. The Company adjusts the liability for changes in fair value of these redeemable convertible preferred stock
warrants until the earlier of: (i)&nbsp;exercise of warrants; (ii)&nbsp;expiration of redeemable convertible preferred stock warrants; (iii)&nbsp;a change of control of the Company; or (iv)&nbsp;the consummation of the Company&#146;s initial public
offering. At that time, the redeemable convertible preferred stock warrant liability will be adjusted to fair value in the consolidated statements of operations and comprehensive loss with the final fair value reclassified to additional paid-in
capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses are expensed as incurred and include, but are not limited to, payroll and personnel-related expenses,
stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Advertising and Marketing Costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Costs incurred for advertising and marketing are expensed as incurred. Total advertising and marketing costs were approximately $294,000,
$429,000, $122,000 and $416,000 for the years ended December&nbsp;31, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
2012 and 2013 and the six months ended June 30, 2013 (unaudited) and 2014 (unaudited), respectively, and are included in selling, general and administrative expenses in the accompanying
consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Shipping and Handling Costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Costs incurred for shipping and handling are included in cost of revenues in the accompanying consolidated statements of operations and
comprehensive loss and totaled approximately $199,000, $272,000, $121,000 and $236,000 for the years ended December&nbsp;31, 2012 and 2013 and the six months ended June 30, 2013 (unaudited) and 2014 (unaudited), respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Fair Value of Financial Instruments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The carrying value of the Company&#146;s cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, other
assets, accounts payable, accrued liabilities, and convertible notes payable approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and
consideration of default and credit risk, the carrying value of the term loan approximates their fair value and is classified as Level II liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of
unobservable inputs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level&nbsp;I</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Unadjusted quoted prices in active markets for identical assets or liabilities;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level&nbsp;II</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for
substantially the full term of the related assets or liabilities; and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level&nbsp;III</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of
input that is significant to the fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s redeemable convertible preferred stock warrant liabilities
and acquisition-related liabilities are classified as Level III liabilities. The liabilities that are measured at fair value on a recurring basis consist of redeemable convertible preferred stock warrant liability, derivative liabilities and
acquisition-related obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based
on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years
that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#146;s sustainability and is measured at the largest amount of benefit that
is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i)&nbsp;the factors underlying the
sustainability assertion have changed and (ii)&nbsp;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of
a tax benefit might change as new information becomes available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Stock-Based</FONT> Compensation
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date
estimated fair values. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period. The fair value of stock options is determined using the
Black-Scholes option pricing model. The determination of fair value for stock-based awards on the date of grant using an option-pricing model requires management to make certain assumptions regarding a number of complex and subjective variables.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense related to stock options granted to nonemployees is recognized based on the fair value of the stock
options, determined using the Black-Scholes option pricing model, as they are earned. The awards generally vest over the time period the Company expects to receive services from the nonemployee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Comprehensive Loss </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner
sources. There have been no items qualifying as other comprehensive income (loss) and, therefore, for all periods presented, the Company&#146;s comprehensive loss was the same as its reported net loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Net Income (Loss) Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company follows the two-class method when computing net income (loss) per share, as the Company has issued shares that meet the definition
of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The
two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been
distributed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss)
attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) attributable to common stockholders is computed by adjusting income (loss) attributable to common
stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities, including outstanding stock options, and warrants for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
purchase of redeemable convertible preferred stock. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to
common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of outstanding stock options and warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s redeemable convertible preferred stock contractually entitles the holders of such shares to participate in dividends but
does not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common
stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common
stockholders for the year ended December&nbsp;31, 2013 and for the six months ended June 30, 2013 and 2014 (unaudited). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Recent
Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board
(FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the
Company&#146;s consolidated financial position or results of operations upon adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued Accounting Standards
Update (ASU) 2014-09, Revenue from Contracts with Customers, which provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of
promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December&nbsp;15, 2016
and shall be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently in the process of evaluating the impact of adoption of this ASU on the consolidated financial
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In July 2013, the FASB issued ASU 2013-11, which provides for changes to the presentation of an unrecognized tax benefit when
a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. These changes require an entity to present an unrecognized tax benefit as a liability in the financial statements if (i)&nbsp;a net operating loss
carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position,
or (ii)&nbsp;the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset to settle any additional income taxes that would result from the disallowance of a tax
position. Otherwise, an unrecognized tax benefit is required to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. These changes
became effective for the Company on January&nbsp;1, 2014. There was no material impact to the consolidated financial statements upon adoption of this ASU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU 2014-15, <I>Presentation of Financial Statements&#151;Going Concern</I>, which defines management&#146;s
responsibility to evaluate whether there is substantial doubt about an organization&#146;s ability to continue as a going concern and to provide related footnote disclosures. The new standard provides management with principles to evaluate whether
substantial doubt exists by (i) providing a definition of substantial doubt, (ii) requiring an evaluation every annual and interim reporting period, and (iii) providing principles for considering the mitigating effects of management&#146;s plans. If
substantial doubt </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
is identified, the ASU requires that an organization provide enhanced disclosures about (i) principal conditions or events that raise substantial doubt, (ii) management&#146;s evaluation of the
significance of these events in relation to its ability to meet obligations, and (iii) management&#146;s plans that are either intended to mitigate the conditions that raise substantial doubt, or alleviate substantial doubt. The ASU is effective for
annual periods ending after December 15, 2016. The Company is currently in the process of evaluating the impact of the adoption of this ASU on its consolidated financial statements. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Restatement </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In October 2013, the Company sold 10,079,168 shares of Series&nbsp;D
redeemable convertible preferred stock to existing preferred stock investors at $0.25 per share, resulting in net proceeds of approximately $2.5&nbsp;million. The Series&nbsp;D redeemable convertible preferred stock was sold at a price per share
below the estimated fair value of $0.49 per share. The Company previously recorded the issuance of Series D redeemable convertible preferred stock at its issuance price of $0.25. The Company should have recorded the issuance at its estimated fair
value of $0.49. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In accordance with authoritative guidance, the Company should have recorded a deemed dividend on the issuance of the
Series&nbsp;D redeemable convertible preferred stock of $2.4&nbsp;million, which is equal to the number of shares of Series&nbsp;D redeemable convertible preferred stock sold multiplied by the difference between the estimated fair value of the
preferred stock and the cash issuance price. The deemed dividend increases the net loss applicable to common stockholders in the calculation of basic and diluted net loss per common share for the year ended December&nbsp;31, 2013 and is reported as
a charge to additional paid-in capital. Due to the material nature of this adjustment, the Company has determined that a restatement is required to previously issued financial statements for the year ended December&nbsp;31, 2013 to correct for this
error. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A summary of the impact of the correction of the errors on the financial statements is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="12" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Consolidated Balance Sheet and Consolidated Statements of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;previously<BR>reported</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:64.65pt; font-size:8pt; font-family:Times New Roman"><B>December&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="13"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="12" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Earnings per Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;previously<BR>reported</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:106.00pt; font-size:8pt; font-family:Times New Roman"><B>Year ended December&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders&nbsp;&#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,807</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&nbsp;&#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Net Income (Loss) Per Share and Unaudited Pro Forma Net Loss Per Share </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A reconciliation
of the numerator and denominator used in the calculation of the basic and diluted net income (loss) per share is as follows (in thousands, except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Restated)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on recapitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend on issuance of Series&nbsp;D redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncumulative dividend on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Undistributed earnings allocated to preferred stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to common stockholders &#151; basic and diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,789</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,501,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,856,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,786,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,949,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per share attributable to common stockholders:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following outstanding shares of potentially dilutive securities were excluded from the computation of
diluted net income (loss) per share of common stock for the periods presented, because including them would have been anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,765,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,765,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,670,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,810,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,968,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,671,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,174,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,174,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,091,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,085,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,526,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,196,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,819,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,058,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Unaudited pro forma basic and diluted net loss per share attributable to common stockholders
is computed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B><br><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months<BR>Ended&nbsp;June&nbsp;30,</B><br><B>2014</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncumulative dividends on redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of redeemable convertible preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss attributable to common stockholders &#151; basic and diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustments to assume conversion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average number of shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share attributable to common stockholders &#151; basic and diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Property and Equipment </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following as of
December&nbsp;31, 2012 and 2013 and June 30, 2014 (unaudited) (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2014</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense for the years ended December&nbsp;31, 2012 and 2013 and the six months ended
June&nbsp;30, 2013 (unaudited) and 2014 (unaudited) was approximately $183,000, $241,000 and $112,000 and $151,000, respectively. At December&nbsp;31, 2012 and 2013, the net book value of assets recorded under capital leases, all of which are
included in laboratory equipment, was approximately $168,000 and $559,000, respectively, reflecting accumulated amortization of approximately $28,000 and $95,000, respectively. Amortization of assets under capital leases is included in depreciation
expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Goodwill and Intangible Assets </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table provides information about goodwill
and intangible asset balances as of December&nbsp;31, 2012 and 2013 and June 30, 2014 (unaudited) (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Amortization<BR>Period</B><br><B>(In years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net<BR>Book<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible Assets Subject to Amortization:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade name and trademarks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(476</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible Assets Not Subject to Amortization:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="12"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-Average<BR>Amortization<BR>Period</B><br><B>(In years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net<BR>Book<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible Assets Subject to Amortization:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased technologies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade name and trademarks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible Assets Not Subject to Amortization:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="12"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June 30, 2014 (Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-Average<BR>Amortization<BR>Period</B><br><B>(In years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net<BR>Book<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible Assets Subject to Amortization:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased technologies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade name and trademarks</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(797</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible Assets Not Subject to Amortization:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total expense related to the amortization of intangible assets was approximately $214,000, $214,000, $107,000
and $107,000 for the years ended December&nbsp;31, 2012 and 2013 and the six months ended June 30, 2013 (unaudited) and 2014 (unaudited), respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total future amortization expense related to intangible assets subject to amortization at
December&nbsp;31, 2013 and June 30, 2014 (unaudited) is set forth in the table below (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:95.55pt; font-size:8pt; font-family:Times New Roman"><B>Years Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future amortization expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Borrowings </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Line of Credit Arrangement (Line) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2010, the Company entered into a secured Line with a financial institution to borrow up to $750,000. The Line accrued interest at 6.0% and
matured in June 2012. The Company amended the Line in 2012 to extend the maturity to June 2013. In accordance with the terms of the amendment, the amount available for borrowing was decreased to $707,725 and required the Company to maintain a
restricted cash balance of $707,725 to secure the Line. The amendment in 2012 was accounted for as a modification. The Line was fully repaid in June 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Subordinated Secured Promissory Notes (2010 SSPNs) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2010, the Company entered into SSPNs with existing equity holders and a mezzanine lender to borrow up to $2 million. The 2010 SSPNs bore
interest at 18.0%&nbsp;per annum and were secured by substantially all of the assets of the Company. The 2010 SSPNs matured in October 2012 at which time, they were repaid in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Royalty Pharma Collection Trust Secured Promissory Note (RP Note) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with a historical acquisition, the Company was required to pay $2.0 million to Royalty Pharma Collection Trust, in October 2012.
This additional consideration was recorded at its initial present value amount of $1.7 million on the date of acquisition using a discount rate of 9.5% and accreted to $2.0&nbsp;million. In October 2012, the obligation to pay $2.0 million was
converted to a secured promissory note, accruing interest at 10%&nbsp;per year, payable over four years and was collateralized by the intellectual property purchased by the Company in the acquisition. The Company accounted for this amendment as a
modification. The principal outstanding as of December&nbsp;31, 2012 was $1.9 million and the outstanding RP Note was fully repaid in October 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Convertible Notes with Related Parties (2013 Notes) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In May, June and August 2013, the Company entered into unsecured convertible promissory notes with existing equity holders to borrow $2.4
million. The 2013 Notes accrued interest at 10.0%&nbsp;per annum and were convertible into shares of either an anticipated new series of preferred stock sold in a qualified financing (defined as a financing of $10.0 million or greater), at a 20%
discount to the issuance price or, if no additional qualified financing occurred, into shares of Series C redeemable convertible preferred stock at a price of $0.25 per share. The conversion into shares at a 20% discount was determined to be an
embedded put feature which required bifurcation and separate accounting as the discount was substantial. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
embedded derivative was recorded as a liability at a fair value of approximately $668,000 upon issuance and debt discount to the 2013 Notes. The Company valued the embedded derivative using a
probability weighted scenario based option pricing model using the following inputs &#150; expected life of approximately 0.5 years, estimated volatility of approximately 40%, expected risk-free rate of 0.1% and a probability of 99% for a qualified
financing to occur. The embedded derivative was remeasured just prior to extinguishment of the 2013 Notes and the change in fair value was recorded in other income (expense), net in the accompanying consolidated statements of operations and
comprehensive loss. In October 2013, the Company amended the 2013 Notes to modify the definition of a qualified financing to reduce the amount of required financing from $10.0 million to $4.0 million and contemporaneously converted the 2013 Notes
into Series D redeemable convertible preferred stock. The Company recorded this amendment as an extinguishment and recorded a loss of $3.3 million as the difference between the reacquisition price and the net carrying amount of the 2013 Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Term Loan (2013 Loan) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In
October&nbsp;2013, the Company executed a Term Loan Agreement with Capital Royalty Partners II L.P. and its affiliates Parallel Fund &#147;a&#148; L.P. and Parallel Investment Opportunities Partners II L.P. (collectively Capital Royalty). The 2013
Loan may be drawn in two tranches. The first tranche in the amount of $10.0 million or $ 15.0&nbsp;million was required to be drawn prior to March&nbsp;31, 2014, and the Company drew $10&nbsp;million in October 2013 and another $5&nbsp;million in
March 2014. The availability of the second tranche in the amount of $5.0 million or $10.0 million was subject to achieving $3.3 million or $3.8 million in revenue measured on a consecutive three month period prior to June&nbsp;30, 2014. The Company
did not achieve the specified revenue milestones prior to June&nbsp;30, 2014, therefore the second tranche is no longer available to the Company for future borrowings. The 2013 Loan bears interest at 14.0%&nbsp;per annum. Interest-only payments are
due on a quarterly basis with payment dates fixed at the end of each calendar quarter (&#147;Payment Dates&#148;) through September&nbsp;30, 2016. Prior to December&nbsp;31, 2016, the Company may at its election pay the interest as follows:
10.0%&nbsp;per annum in cash and 4.0%&nbsp;per annum paid in-kind in the form of additional term loans, or PIK Loans. In connection with the 2013 Loan, the Company paid a financing fee of $200,000 (recorded as debt discount) and issued warrants to
purchase 3,186,430 shares of each of common stock and Series D redeemable convertible preferred stock. Since the Company has issued multiple instruments (2013 Loan, Series D redeemable convertible preferred stock warrants and common stock warrants)
in a bundled transaction, the Company recorded the Series D redeemable convertible preferred stock warrants at full fair value, while the common stock warrants and 2013 Loan have been recorded at relative fair value. Likewise, the debt issuance
costs have been allocated to all instruments based on their relative fair value (Note 8). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The 2013 Loan has a prepayment premium of 3% of
the aggregate outstanding principal, including PIK Loans, if the loan is prepaid prior to September&nbsp;30, 2014. The amount of the Prepayment Premium decreases by 1% during each subsequent 12-month period thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The first Payment Date for the $10 million drawn in October 2013 was December&nbsp;31, 2013, and the Company elected the paid in-kind interest
option paying 10% per annum in cash and issuing PIK Loans for the remaining 4% per annum totaling $71,000 and $254,000 in 2013 and 2014 (unaudited), respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The 2013 Loan is collateralized by a first priority security interest on substantially all of the Company&#146;s personal property, including
intellectual property. The Company must maintain a minimum liquidity of $2.0&nbsp;million and achieve certain minimum amounts of annual revenue under the terms of the 2013 Loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The 2013 Loan contains customary representations and warranties, covenants, events of defaults and termination provisions. The affirmative
covenants include, among other things, that the Company timely file </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
taxes, maintain good standing and government compliance, maintain liability and other insurance, furnish audited financial statements within 120 days of fiscal year end without qualification as
to the scope of the audit or as to going concern and without any other similar qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The negative covenants provide, among other
things, that without the prior consent of Capital Royalty (subject to certain exceptions), the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the
Company&#146;s property, pay dividends on the Company&#146;s capital stock or make prohibited investments. The 2013 Loan agreement provides that an event of default will occur if, among other triggers, (1)&nbsp;the Company defaults in the payment of
any amount payable under the agreement when due, (2)&nbsp;there occurs any circumstance or circumstances that could reasonably be expected to result in a material adverse effect on the Company&#146;s business, operations or condition, or on the
Company&#146;s ability to perform its obligations under the agreement, (3)&nbsp;the Company becomes insolvent, (4)&nbsp;the Company undergoes a change in control or (5)&nbsp;the Company breaches any negative covenants or certain affirmative
covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement. The repayment of the term loan may be accelerated, at the option of Capital Royalty, following the occurrence of an
event of default, which would require the Company to pay to Capital Royalty an amount equal to the sum of: (i)&nbsp;all outstanding principal plus accrued interest, (ii)&nbsp;the final payment, plus (iii)&nbsp;all other sums, that shall have become
due and payable but have not been paid, including interest at the default rate with respect to any past due amounts plus the Prepayment Premium. The Company has obtained an extension to submit the audited consolidated financial statements by
July&nbsp;31, 2014 and a waiver to relinquish the going concern qualification requirement for the year ended December&nbsp;31, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Though the Company&#146;s borrowings have stated maturities in excess of one year, the outstanding balance has been classified as a current
liability as of December&nbsp;31, 2013 and June 30, 2014 primarily due to the subjective nature of the material adverse clause included in the term loan agreement. This clause permits the lender to accelerate the maturity of the debt upon factors
that are subjective in nature, such as material changes in the business, operations, performance or prospects of the Company, other than those resulting from changes in interest rates or economic and political conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The future minimum aggregate payments as of December&nbsp;31, 2013 and June 30, 2014 (unaudited) under the above borrowings are as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:95.55pt; font-size:8pt; font-family:Times New Roman"><B>Years Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018 and after</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt discount</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total borrowings, current portion</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Warrants to Purchase Common or Preferred Stock </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common stock warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2010 SSPN common stock warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the 2010 SSPNs (Note 7), the Company issued warrants to purchase 390,000 shares of common stock at a price of $3.75 per
share. The warrants expired three years from the date of issuance (October 2013) and contained an automatic exercise or put feature which was to be effected immediately prior to the expiration of the warrants, based on the highest value to the
holders if no earlier exercise or put has been affected by the holders. The put feature allowed the holders, upon the earlier of the occurrence of a change in control or the expiration date, to require the Company to repurchase the warrants for an
aggregate purchase price of $400,000. The value of this put feature was recorded as a warrant liability on the consolidated balance sheet at the higher of the fair value or $400,000 and as a discount against the 2010 SSPNs, with such discount being
amortized to interest expense over the initial term of the 2010 SSPNs. The put feature was exercised in October 2013 and the Company repurchased these warrants for $400,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2013 Loan common stock warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the 2013 Loan issued in October 2013, the Company issued warrants to purchase 3,186,430 shares of common stock at $0.01 per
share. The relative fair value of approximately $319,000, net of issuance costs, was recorded in additional paid-in capital and was determined using the option pricing model with the following assumptions: risk-free interest rate of 2.51%, expected
life of 10 years, dividend yield of 0% and expected volatility of 57% and as a discount against 2013 Loan, with such discount being amortized to interest expense over the term of the 2013 Loan. The Company amortized approximately $13,000 and $33,000
as interest expense for the year ended December&nbsp;31, 2013 and the six months ended June 30, 2014 (unaudited), respectively. The warrants expire in October 2023 and remain outstanding as of December&nbsp;31, 2013 and June 30, 2014 (unaudited).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition to the above, the Company has 1,695,470 common stock warrants outstanding as of December&nbsp;31, 2013 at an exercise price
of $3.75 per share. These common stock warrants expire between June 2018 and October 2021. No amounts have been recorded for these common stock warrants as their fair value was determined to be immaterial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable convertible preferred stock warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>2013 Loan redeemable convertible preferred stock warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the 2013 Loan issued in October 2013, the Company issued warrants to purchase 3,186,430 shares of Series D redeemable
convertible preferred stock at $0.25 per share. The fair value (determined using residual approach) of approximately $0.8 million was recorded as a liability and was determined using the option pricing model with the following assumptions: risk-free
interest rate of 0.4%, expected life of 2 years, dividend yield of 0% and expected volatility of 61% and as a discount against 2013 Loan, with such discount being amortized to interest expense over the term of the 2013 Loan. The Company has
amortized $30,000 and $77,000 as interest expense for the year ended December&nbsp;31, 2013 and the six months ended June 30, 2014 (unaudited), respectively. The fair value of these redeemable convertible preferred stock warrants were remeasured at
December&nbsp;31, 2013 and June 30, 2014 (unaudited) using updated assumptions for the fair value of the underlying securities, the risk-free interest rate, expected life, dividend yield and expected volatility. The warrants expire in October 2023
and remain outstanding as of December&nbsp;31, 2013 and June&nbsp;30, 2014 (unaudited). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2013, the Company engaged an investment
advisor to provide financial advisory services in connection with raising capital. In November 2013 in connection with the consummation of the 2013 Loan, the Company paid </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
$500,000 to the investment advisor and also issued warrants to purchase 988,000 shares of Series D redeemable convertible preferred stock at an exercise price of $0.25. The fair value of
approximately $240,000 was recorded as a liability and was determined using the option pricing model with the following assumptions: risk-free interest rate of 0.4%, expected life of 2 years, dividend yield of 0% and expected volatility of 61%. The
total debt issuance cost of approximately $740,000 (fair value of the Series D redeemable convertible preferred stock warrant plus cash payment of $500,000) was allocated to the 2013 Loan, 2013 Loan common stock warrants and 2013 Loan redeemable
convertible preferred stock warrants based on relative fair value allocation. The amount allocated to the 2013 Loan was recorded as debt issuance cost, the amount allocated to 2013 Loan common stock warrants was offset against the amount recorded in
additional paid-in capital, and the amount allocated to 2013 Loan redeemable convertible preferred stock warrants was recorded as an expense. The fair value of the preferred stock warrants was remeasured at December&nbsp;31, 2013 and June 30, 2014
(unaudited) using updated assumptions for the fair value of the underlying securities, the risk-free interest rate, expected life, dividend yield and expected volatility. The warrants expire in November 2023 and remain outstanding as of
December&nbsp;31, 2013 and June 30, 2014 (unaudited). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2013 and the six months ended June 30, 2014
(unaudited), the Company recognized changes in fair value of $83,000 and $21,000, respectively, for all liability classified warrants (redeemable convertible preferred stock warrants and 2010 SSPN common stock warrants), which was recorded in other
income (expense), net in the accompanying consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All outstanding warrants to
purchase shares of common stock and Series D redeemable convertible preferred stock terminate if not exercised prior to the completion of an initial public offering. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Commitments and Contingencies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating and Capital Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company leases office and lab facilities under non-cancelable operating leases in Albuquerque, New Mexico and Vista, California. Rent under
the Vista, California lease is subject to escalation, as defined in the lease agreement. The Company has the option to extend the lease in Vista, California for two 36 month terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2012 and 2013, the Company leased certain lab equipment under capital leases. The equipment and related liability have been recorded at the
present value of the future payments under the leases with an interest rate of 8.2% and 16.0%, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Minimum annual lease payments under noncancelable lease arrangements at December&nbsp;31,
2013 are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Capital<BR>Leases</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating<BR>Leases</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Years Ending December&nbsp;31:</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum lease payments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less amount representing interest</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of future minimum lease payments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less current portion</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term capital lease obligations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Rent expense for the years ended December&nbsp;31, 2012 and 2013 and the six months ended June 30, 2013
(unaudited) and 2014 (unaudited) was approximately $145,000, $141,000, $68,000 and $109,000, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition-related liabilities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010 (the Cypress acquisition), the
Company is required to pay an amount not to exceed $9.2 million in the event that certain revenue milestones are achieved and upon the first commercial sale of a product associated with this historical acquisition. This $9.2 million includes amounts
that may be due under several licensing agreements acquired in the acquisition and is summarized as follows: <B></B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:68.45pt; font-size:8pt; font-family:Times New Roman"><B>Amount Payable To</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B><br><B>Additional</B><br><B>Payment</B><br><B>Amount</B><br><B>(in&nbsp;millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Probability&nbsp;of<BR>Achievement</B><br><B>as of<BR>December&nbsp;31,<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Probability&nbsp;of<BR>Achievement<BR>as of</B><br><B>June 30,</B><br><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value</B><br><B>as&nbsp;of</B><br><B>December&nbsp;31,</B><br><B>2013</B><br><B>(in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value</B><br><B>as of</B><br><B>June&nbsp;30,</B><br><B>2014</B><br><B>(in millions)</B><br><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cellatope Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">&nbsp;&nbsp;3.0</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Launch a monitoring product using <FONT STYLE="white-space:nowrap">CB-CAPs&nbsp;technology</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">&nbsp;&nbsp;1.3</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">&nbsp;&nbsp;1.4</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Royalty Pharma</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman">Achieve&nbsp;certain&nbsp;annual worldwide net sales levels for <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> products, the launch of a <FONT
STYLE="white-space:nowrap">CB-CAPs</FONT> monitoring assay and launch of two-third party commercial programs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR></TD>
<TD VALIGN="top" ALIGN="right">87<BR></TD>
<TD NOWRAP VALIGN="top">%&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prometheus&nbsp;Laboratories</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Achieve&nbsp;certain&nbsp;revenue levels from Avise PG</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">University of Pittsburgh</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Achieve certain revenue levels from products utilizing <FONT STYLE="white-space:nowrap">CB-CAPs</FONT> technology in a calendar year</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="top">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of the acquisition-related liability is determined using widely accepted valuation techniques,
which include the income approach for estimating future consideration to be paid based on projected earnings. The income approach involves the use of a probability-weighted discounted revenue model based on significant inputs not observable in the
market such as revenue projections, the interest rate and the probabilities assigned to the milestones being achieved. The significant inputs include discount rates of 2.60% to 15.18%. A significant change in such projected earnings may result in a
material change to the fair value of such acquisition-related liability with a corresponding adjustment to net loss and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Licensing Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company is a party to various licensing agreements, the most significant of which were acquired in connection with the Cypress acquisition.
In accordance with the terms of these agreements, rights to the ownership and use of specified technology are defined. In addition to the milestone payments required by these agreements as described above, the agreements generally provide for
ongoing royalty payments on net sales of products, as defined, ranging from 3% to 10%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Contingencies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and
provide for general indemnifications. The Company&#146;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such
matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Litigation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company is not a party to any litigation and does not have contingent reserves established for any litigation liabilities.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Fair Value Measurements </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the Company&#146;s financial
instruments that were measured at fair value on a recurring basis at December&nbsp;31, 2012 and 2013 and June 30, 2014 (unaudited) by level within the fair value hierarchy (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June 30,&nbsp;2014&nbsp;(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Level&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The inputs and assumptions used to estimate the fair value of embedded derivatives and warrant liabilities are
discussed in Note 7 and Note 8, respectively. The inputs and assumptions used to estimate the fair value of acquisition-related liabilities are discussed in Note 9. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table includes a roll forward of the financial instruments classified within
Level&nbsp;3 of the fair value hierarchy (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Amounts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Acquisition<BR>Related<BR>Liabilities </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liability<BR>Classified<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Embedded<BR>Derivative</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December 31, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>$</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>3,432</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December 31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,792<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,392<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400 <B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of 2013 Notes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of put feature</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(400</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series D redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of financial instruments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Extinguishment and conversion of 2013 Notes into Series D redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at December 31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,742<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,657<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of financial instruments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances at June 30, 2014 (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$<B></B></TD>
<TD VALIGN="bottom" ALIGN="right">1,064<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Redeemable Convertible Preferred Stock </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The authorized, issued and outstanding shares of
redeemable convertible preferred stock by series are as follows as of December&nbsp;31, 2012: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Redemption</B><br><B>Price</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:22.40pt; font-size:8pt; font-family:Times New Roman"><B>Series </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,474,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,539,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,750,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,765,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2013, the redeemable convertible preferred stock consists of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Redemption</B><br><B>Price</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.40pt; font-size:8pt; font-family:Times New Roman"><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,474,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,539,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,750,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,565,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At June 30, 2014 (unaudited), the redeemable convertible preferred stock consists of the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share<BR>Redemption</B><br><B>Price</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying</B><br><B>Value</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.40pt; font-size:8pt; font-family:Times New Roman"><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,474,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,539,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,750,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,565,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The significant rights and preferences of redeemable convertible preferred stock are as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With the
exception of Series A-3 redeemable convertible preferred stock, each holder of preferred stock is entitled to non-cumulative dividends at an annual rate of 8.0% of the original issue price when and if declared by the Board of Directors. Dividends
are paid in the following order of preference: (i)&nbsp;Series D, (ii)&nbsp;Series C, (iii)&nbsp;Series&nbsp;B-3, (iv)&nbsp;Series A-3 and (v)&nbsp;common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">No dividend shall be declared or be payable on the outstanding shares of the Series B-3 redeemable convertible preferred stock without the
consent of the holders of at least two-thirds of the outstanding shares of the Series C and Series D redeemable convertible preferred stock, voting together as a single class, and no dividend shall be declared or be payable on the outstanding shares
of the Series A-3 redeemable convertible preferred stock or the common stock (other than a dividend on shares of common stock payable entirely in shares of common stock) without the consent of the holders of at least 60% of the outstanding shares of
the Series B-3, Series C and Series D redeemable convertible preferred stock. As of December&nbsp;31, 2013 and June 30, 2014 (unaudited), the Board of Directors has not declared any dividends. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Liquidation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Series
A-3, B-3, C and D redeemable convertible preferred shares have liquidation preferences of $7.50, $0.25, $0.50 and $0.38 per share, respectively. In the event of a liquidation, the Series D liquidation preference is paid prior to any other
preferences, the Series C liquidation preference is paid prior to the preferences for Series B-3 and A-3, the Series B-3 liquidation preference is paid prior to the preference for Series A-3, then the Series A-3 preference is paid. Following the
satisfaction of the liquidation preferences, all shares participate in any remaining distribution based on the number of common shares into which their shares are convertible. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Conversion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All shares of
the Company&#146;s Series A-3, B-3, C and D redeemable convertible preferred stock are convertible at the option of the holder, into shares of common stock by dividing the initial conversion prices by the conversion price in effect at the time of
conversion. The initial conversion price is $7.50 for Series <FONT STYLE="white-space:nowrap">A-3</FONT> redeemable convertible preferred stock and $0.25 for Series B-3, C and D redeemable convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Automatic Conversion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each share of redeemable convertible preferred stock is automatically convertible into common stock at its then effective conversion price,
(i)&nbsp;upon the election of the holders of at least 60% of the outstanding of Series B-3, C, and D redeemable convertible preferred stock, voting together as a single class, or (ii)&nbsp;upon the completion of a firm underwritten public offering
of the Company&#146;s common stock with aggregate proceeds of at least $30.0 million and an initial public offering price of at least $0.75 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Voting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With the
exception of the Series A-3 redeemable convertible preferred stock, the holder of each share of preferred stock is entitled to one vote for each share of common stock into which it would convert. The holders of Series A-3 redeemable convertible
preferred stock have no voting rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Upon the request in writing of the holders of 60% of the outstanding shares of Series B-3, C and D redeemable convertible preferred stock,
voting together as a single class, at any time after October&nbsp;4, 2018, the holders may redeem the outstanding Series B-3, C and D redeemable convertible preferred stock at the stated redemption price as noted in the table above (plus any
declared but unpaid dividends). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, upon the request in writing of the holders of 60% of the outstanding shares of Series B-3, C
and D redeemable convertible preferred shares, voting together as a single class, on or after a Redemption Event, as defined in the certificate of incorporation, the Company may be required to purchase the outstanding Series B-3, C and D redeemable
convertible preferred shares at the stated redemption price as noted in the table above (plus any declared but unpaid dividends). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
Company is accreting the carrying amounts of the preferred stock up to the redemption amount at October&nbsp;4, 2018, the earliest possible date using the effective interest method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Shares of Series A-3 redeemable convertible preferred stock have been included as temporary equity in the consolidated balance sheets as
holders of these shares can cause redemption of the Series A-3 redeemable convertible preferred shares due to certain change in control events that are outside the Company&#146;s control, including liquidation, sale or transfer of the Company. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Recapitalization </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In September 2012, the Company recapitalized its outstanding shares of
Series A-2 and B-2 redeemable convertible preferred stock (Old Preferred) in connection with the Series C preferred stock financing. Pursuant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to the recapitalization agreement, the Company raised approximately $5.9 million in gross proceeds by issuing 23,750,389 shares of Series C redeemable convertible preferred stock at $0.25 per
share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As part of recapitalization, Series A-2 and Series B-2 redeemable convertible preferred stock converted into common stock,
Reclassified Series A-2 and Series B-2 common stock, respectively. If an investor participated pro rata in at least 70% of the Series C preferred stock financing, the Company converted their shares of Series A-2 and B-2 Reclassified common stock
into shares of Series A-3 and B-3 redeemable convertible preferred stock, respectively, on a one-for-one basis. The Company issued 1,474,795 shares of Series A-3 redeemable convertible preferred stock and 44,539,977 shares of Series B-3 redeemable
convertible preferred stock for no consideration to the investors who purchased at least 70% of their pro-rata share of the $5.9 million of Series C redeemable convertible preferred stock. Substantially all (approximately 90%) of the existing Series
A-2 and B-2 redeemable convertible preferred stockholders participated in Series C financing and converted their holdings of Series A-2 and B-2 redeemable convertible preferred stock into shares of Series A-3 and B-3 redeemable convertible preferred
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recorded the issuance of Series A-3 and Series B-3 redeemable convertible preferred stock at their fair values of
$0.55 and $0.05 per share, respectively. The difference between the carrying value of the Reclassified Series A-2 and B-2 common stock and the fair value of Series A-3 and B-3 redeemable convertible preferred stock of approximately $12.3 million was
recorded as a capital contribution (gain on extinguishment of Old Preferred) in additional paid-in capital as the transaction was among existing equity holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In June 2011, the Company had recapitalized its then outstanding preferred stock, i.e. Series A-1 and B-1 redeemable convertible preferred
stock, in connection with the Series B-2 preferred stock financing. As part of the recapitalization, outstanding redeemable convertible preferred stock was first converted into common stock (reclassified common stock) and, investors who participated
in Series B-2 preferred stock financing were issued shares of Series A-2 redeemable convertible preferred stock (amount invested in B-2 divided by $7.50) for no consideration. All existing investors participated in this transaction and there was no <FONT
STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> and B-1 redeemable convertible preferred stock outstanding after this transaction. In February and April 2012, the Company issued a total of 1,651,134 shares of Series B-2 redeemable convertible
preferred stock for $398,556 at an issuance price of $0.25 per share as part of the above recapitalization. Accordingly, a portion of the reclassified common stock converted into Series A-2 redeemable convertible preferred shares and 45,170 shares
of Series A-2 redeemable convertible preferred stock was recorded at a fair value of $3.23&nbsp;per share. The difference between the carrying value of reclassified common stock and the fair value of Series A-2 redeemable convertible preferred stock
of approximately $23,450 was recorded as a capital contribution in additional paid-in capital as the transaction was among existing equity holders. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Stockholders&#146; Deficit </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Common stockholders are entitled to dividends as and when declared by the Board of Directors, subject to the rights of holders of all classes
of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During 2013, the Company increased the number of authorized shares of common stock from 112,000,000 shares to 163,000,000 shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company had common shares reserved for future issuance upon the exercise or conversion of
the following as of December&nbsp;31, 2012 and 2013 and June 30, 2014 (unaudited): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June 30,</B><br><B>2014</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,765,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,330,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,174,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,174,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,091,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock option grants issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,670,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,810,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,671,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares available for grant under the stock option plan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,708,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,646,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total common shares reserved for future issuance</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,234,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,556,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,704,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Stock Option Plan </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s 2002 Stock Option Plan expired on
December&nbsp;31, 2012 and was replaced by the 2013 Stock Option Plan, which was adopted in December 2012 (collectively, the &#147;Plans&#148;). Pursuant to the Plans, employees, consultants, and directors may be granted either incentive stock
options or nonqualified stock options to purchase shares of the Company&#146;s common stock. As of December&nbsp;31, 2012 and 2013, 1,708,000 and 1,360,000&nbsp;shares, respectively, remained available for future awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The exercise price of each stock option is established by the board of directors and is based on the estimated fair value of the
Company&#146;s common stock on the grant date. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the board of directors and is generally no longer than four years from
the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Activity under the Company&#146;s stock option plans is set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances, December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,621,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,807,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(757,986</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances, December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,670,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options cancelled/expired</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(131,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances, December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,810,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">439,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options cancelled/expired</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balances, June 30, 2014 (Unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,671,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">580,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable, December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,669,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">206,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable, June 30, 2014 (Unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,670,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">359,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value at December&nbsp;31, 2013 represents the difference between the
fair value of common stock and the exercise price of outstanding and in-the-money options. The estimated weighted average grant date fair value of each share of common stock was $0.06 and $0.01 at December&nbsp;31, 2012 and 2013, respectively.
During the year ended December&nbsp;31, 2013, the Company received $20,638 from the exercise of options which had no intrinsic value. No options were exercised in 2012. The total fair value of options that vested during the year ended
December&nbsp;31, 2012 and 2013 was $115,000 and $152,000, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Stock-Based</FONT>
Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation recognized was $116,000, $152,000, $76,000 and $52,000 for the years ending December&nbsp;31,
2012 and 2013 and the six months ended June 30, 2013 (unaudited) and 2014 (unaudited), respectively. As of December&nbsp;31, 2013, there was total unrecognized compensation cost of $189,000. This cost is expected to be recognized over a period of a
weighted average term of 1.6 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For purposes of calculating stock-based compensation, the Company estimates the fair value of stock
options using the Black-Scholes option-pricing model on the date of grant and recognizes expense on straight line basis over the requisite service period of the award. The Black-Scholes option-pricing model incorporates various highly sensitive
assumptions, including the fair value of our common stock, expected volatility, expected term and risk-free interest rates. The weighted average expected life of options was calculated using the simplified method as prescribed by the Securities and
Exchange Commission (SEC) Staff Accounting Bulletin&nbsp;No.&nbsp;107 (SAB&nbsp;No.&nbsp;107). This decision was based on the lack of relevant historical data due to the Company&#146;s limited historical experience. In addition, due to the
Company&#146;s limited historical data, the estimated volatility also reflects the application of SAB&nbsp;No.&nbsp;107, incorporating the historical volatility of comparable companies whose share prices are publicly available. The risk-free
interest rate for periods within the contractual life of the option is based on the U.S.&nbsp;Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so
in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of employee stock options was estimated using the following assumptions for the periods
presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">No stock options were granted in the six months ended June&nbsp;30, 2014 (unaudited). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Nonemployee <FONT STYLE="white-space:nowrap">Stock-Based</FONT> Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2012 and 2013, the Company has issued 865,588 and zero options to purchase common stock, respectively, to
non-employees. The stock based compensation expense for non-employees for 2012 and 2013 is not material. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">Stock-Based</FONT> Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense recorded related to options granted to employee and non-employees is as below (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Related Party Transactions </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into various agreements under which
directors of the Company are paid for consulting services and for serving on the board of directors. Total compensation expense related to these agreements for the years ending December&nbsp;31, 2012 and 2013 and the six months ended June&nbsp;30,
2013 (unaudited) and 2014 (unaudited) was $54,000, $49,500, $24,000 and $27,500, respectively, which has been recorded in sales, general and administrative expense in the accompanying consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A total of $750,000 of the loan commitment under the 2010 SSPNs was provided by NMSIC Co-Investment Fund L.P. (NMSIC), an organization that is
a significant stockholder in the Company and maintains a seat on the board of directors of the Company. In addition, 131,250 of the 390,000 warrants with the put feature (Note 8) were held by NMSIC. When NMSIC exercised the put feature in October
2013, the Company made a payment of $150,000 to NMSIC to repurchase these warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In September, 2011, the Company entered into a
license agreement with the Company&#146;s Chief Scientific Officer, and a related company, DeNovo. The license agreement, covering novel methods for monitoring low-dose methotrexate therapy, relates to technology developed by the Company&#146;s
Chief Scientific Officer, prior to joining the Company. The technology has yet to be used by the Company. Under the agreement, the Company&#146;s Chief Scientific Officer will be eligible to receive up to $600,000 upon the achievement of certain
sales milestones and an ongoing royalty of 5% on sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2012, the Company entered into a recapitalization transaction with existing
equity holders as discussed in Note 12. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2013, the Company issued 2013 Notes to existing equity holders and converted the outstanding
principal and unpaid accrued interest into Series D redeemable convertible preferred stock at a discount of 20% to the issue price of $0.25 per share, as described in Note 7. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income Taxes </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The provision for taxes consists of the following at December&nbsp;31,
2012 and 2013 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income tax</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The effective tax rate of our provision for incomes taxes differs from the federal statutory rate as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal statutory tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes, net of federal tax benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7.7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on recapitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of 2013 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23.9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Significant components of the Company&#146;s deferred tax assets at December&nbsp;31, 2012 and 2013 are shown
below (in thousands). A valuation allowance has been established as realization of such deferred tax assets </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">has not met the more
likely-than-not threshold requirement. If the Company&#146;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred
tax assets will be accounted for as a reduction to income tax expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Valuation allowance</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition-related liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(581</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred financing costs</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indefinite lived assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred income tax liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Changes in the valuation allowance for deferred tax assets during the years ended December&nbsp;31, 2012 and
2013, which related primarily to increases in net operating loss carryforwards, accrued revenue and accruals and reserves, were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decreases recorded as benefits to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases recorded to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance at the end of the year</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2012 and 2013, the Company had federal net operating loss carryforwards of approximately
$25.0 million and $31.4 million, respectively. At December&nbsp;31, 2012 and 2013, the Company had state net operating loss carryforwards of $24.2 million and $29.6 million, respectively. The federal and state tax loss carryforwards will begin to
expire in 2014 and 2022, respectively, unless previously utilized. Included in the net operating loss deferred tax asset above is approximately $10,000 of deferred tax assets attributable to excess stock compensation deductions. Excess tax benefits
are not recorded in additional paid in capital until the deduction reduces income taxes payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Internal Revenue Code (IRC),
Section&nbsp;382 and 383, use of the Company&#146;s U.S. federal and state net operating loss and research and development income tax credit carryforwards may be limited in the event of a cumulative change in ownership of more than 50.0% within a
three-year period. The Company had an ownership change in 2008 and, as a result, certain carryfowards are subject to an annual limitation, reducing the amount available to offset income tax liabilities absent the limitation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Uncertain Tax Positions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions based on prior period tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reductions based on prior period tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions based on current period tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at the end of the year</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company believes it is reasonably possible that the total amount of unrecognized tax benefits will
decrease within the next 12&nbsp;months due to the Company requesting permission to change its tax accounting methods and the scheduled reversal of timing differences. The amount of unrecognized tax benefit that, if recognized, would favorably
impact the effective income tax rate is $44,000. During the years ended December&nbsp;31, 2012 and 2013, the Company recognized no amounts related to interest or penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in the United States and various state jurisdictions. The Company currently has no years under examination
by any jurisdiction. The Company&#146;s tax years for 2002 and forward are subject to examination by the federal tax authorities and tax years for 2009 and forward are subject to examination by the state tax authorities due to the carryforward of
unutilized net operating losses and research and development credits. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Subsequent Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company did not achieve the specified revenue milestones set
forth in the 2013 Term Loan agreement, therefore, no amounts remain available to the Company for future borrowings under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In May 2014, Computational Engines was dissolved and is no longer a subsidiary of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the Company effected an increase in the number of shares of common stock reserved for issuance under the 2013 Plan to 8.9
million&nbsp;shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In July 2014, the Company granted 7.2&nbsp;million options to purchase common stock to employees at an exercise
price of $0.18 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In July 2014, the Company entered into unsecured convertible promissory notes (2014 Notes) with existing equity
holders to borrow approximately $4.0 million. The 2014 Notes accrue interest at 12.0%&nbsp;per annum and are convertible into shares of either common stock in the event of an initial public offering, at a 20% discount to the issuance price or, if an
initial public offering does not occur prior to the maturity date (April&nbsp;10, 2015), into shares of Series D redeemable convertible preferred stock at $0.25 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events through August&nbsp;4, 2014, the date the consolidated financial statements were available for
issuance. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Subsequent Events (Unaudited) </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In September 2014, the Company entered into a lease
agreement for additional office space in Vista, California. The lease, which commences in February 2015 and expires in January 2018, requires initial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Diagnostics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
monthly rental payments of approximately $16,000 which are subject to escalation, as described in the lease agreement. The Company has a one-time option to terminate the lease agreement on or
before November&nbsp;1, 2014 and an option to extend the lease for an additional 24&nbsp;month term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent
events through September 19, 2014, the date the unaudited interim consolidated financial statements were available for issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g693329g39n30.jpg" ALT="LOGO">
 </P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SHARES OF COMMON
STOCK </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>Leerink Partners</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><B>Baird</B></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>William Blair </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:24pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 (25 days after the commencement of this offering), all dealers that buy, sell or trade shares of our common stock, whether or not participating in this offering, may be
required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Part II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than
underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and The NASDAQ
Global Market listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NASDAQ Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue Sky fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be provided by amendment. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of directors
of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or
knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation provides that no director of the
Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the General Corporation Law
of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director,
officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#146;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or
completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding,
had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall
have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such
person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation, which will become effective immediately
prior to the completion of this offering, provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right
of us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity
with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against all
expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a
manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated
certificate of incorporation provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to
become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other
enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in
connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be
made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to
indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#146; fees) actually
and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered
into indemnification agreements with each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#146; fees, judgments, fines
and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides
services at our request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of
our corporation arising out of claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any underwriting
agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the
Securities Act of 1933, as amended, or Securities Act, against certain liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding shares of capital stock issued by us since January 2011. Also included is the consideration received
by us for such shares and information relating to the section of the Securities Act, or rule of the Securities and Exchange Commission, under which exemption from registration was claimed. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Issuances of Capital Stock and Warrants to Purchase Capital Stock </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">In December 2011, in connection with our Series A-2 and Series B-2 redeemable convertible preferred stock financing, all 3,896,531 of our outstanding
shares of Series A-1 redeemable convertible preferred stock and 273,182 outstanding warrants to purchase shares of Series A-1 redeemable convertible </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
preferred stock were converted into 3,896,531 shares of our common stock and warrants to purchase an aggregate of 273,182 shares of our common stock, and we converted 1,598,226 shares of common
stock into 1,598,226 of shares of our Series A-2 redeemable convertible preferred stock. In February and April 2012, we converted an additional 45,710 shares of common stock into Series A-2 redeemable convertible preferred stock. In September 2012,
in connection with our Series C redeemable convertible preferred stock financing described below, all 1,598,226 of our Series A-2 redeemable convertible preferred stock were converted into 1,598,226 shares of common stock. In September 2012, in
connection with our Series C redeemable convertible preferred stock financing described below, we converted 1,474,795 shares of common stock into 1,474,795 shares of Series A-3 redeemable convertible preferred stock. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Between January 2011 and October 2011, we issued and sold 1,896,367 shares of our Series B-1 redeemable convertible preferred stock and 1,090,514 warrants to purchase shares of our Series B-1 redeemable convertible
preferred stock. In December 2011, in connection with our Series A-2 and Series B-2 redeemable convertible preferred stock financing, all 1,896,367 shares of our Series B-1 redeemable convertible preferred stock were converted into 1,896,367 shares
of common stock, and all of our outstanding Series B-1 warrants to purchase up to an aggregate of 1,812,288 shares of Series B-1 redeemable convertible preferred stock were converted into warrants to purchase an aggregate of up to 1,812,288 shares
of our common stock. In December 2011, we issued 24,283,557 shares our Series B-2 redeemable convertible preferred stock at a purchase price of $0.25 per share, for aggregate consideration of approximately $6.0 million, and we also converted an
aggregate principal amount of $5,810,422 of promissory notes plus interest of $105,418 into 23,663,361 shares of Series B-2 redeemable convertible preferred stock. In February 2012 and April 2012, we also issued 1,651,134 shares of our Series B-2
redeemable convertible preferred stock at a purchase price of $0.25 per share, for aggregate consideration of approximately $0.4 million. In September 2012, in connection with the sales of Series C redeemable convertible preferred stock, all
49,598,052 outstanding shares of our Series B-2 redeemable convertible preferred stock were converted into 49,598,052 shares of common stock. In September 2012, we converted 44,539,977 shares of common stock into 44,539,977 shares of our Series B-3
redeemable convertible preferred stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">From September 2012 to December 2012, we issued and sold to investors in private placements an aggregate of 23,750,389 shares of our Series C redeemable convertible preferred stock at a purchase price of $0.25 per
share, for aggregate consideration of approximately $5.9 million. In connection with this financing, in September 2012 all 1,598,226 outstanding shares of our Series A-2 redeemable convertible preferred stock and 49,598,052 shares of our Series B-2
redeemable convertible preferred stock were converted into 1,598,226 and 49,598,052 shares of common stock, respectively. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">In May 2013,&nbsp;June 2013 and August 2013, we issued a total of $2,430,531 in unsecured convertible promissory notes, or the 2013 Notes, which accrued interest at 10%. In October 2013, the 2013 Notes and $66,653 in
accrued interest were converted into 12,485,914 shares of Series D redeemable convertible preferred stock, at a 20% discount to the offering price of $0.25 per share. In October 2013, we also issued and sold to investors in private placements an
aggregate of 10,079,172 shares of our Series D redeemable convertible preferred stock at a purchase price of $0.25 per share, for aggregate consideration of approximately $2.5 million. From October 2013 to November 2013, we also issued warrants to
purchase up to an aggregate of 4,174,430 shares of our Series D redeemable convertible preferred stock at an exercise price of $0.25 per share. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No underwriters were involved in the foregoing sales of securities. The securities described in this section (a)&nbsp;of Item&nbsp;15 were
issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(2) under the Securities Act and Regulation D promulgated thereunder relative to transactions by an issuer not
involving any public offering, to the extent an exemption from such registration was required. All purchasers of shares of redeemable convertible preferred stock described above represented to us in connection with their purchase that they were
accredited investors and were acquiring the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and
could hold the securities for an indefinite period of time. The purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration statement or an
available exemption from such registration. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Grants and Exercise of Stock Options </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">From January&nbsp;1, 2011 through September 30, 2014, we granted stock options to purchase an aggregate of 16,251,182&nbsp;shares of our common stock at a weighted average exercise price of $0.15 per share, to certain
of our employees, consultants and directors in connection with services provided to us by such persons. Of these, options to purchase 899,338 shares have been exercised through September 30, 2014. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stock options and the common stock issuable upon the exercise of such options as described in this section (b)&nbsp;of Item&nbsp;15 were
issued pursuant to written compensatory plans or arrangements with our employees and directors, in reliance on the exemption from the registration requirements of the Securities Act provided by Rule 701 promulgated under the Securities Act or the
exemption set forth in Section&nbsp;4(2) under the Securities Act and Regulation D promulgated thereunder relative to transactions by an issuer not involving any public offering. All recipients either received adequate information about us or had
access, through employment or other relationships, to such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the foregoing securities are deemed restricted securities
for purposes of the Securities Act. All certificates representing the issued shares of capital stock described in this Item&nbsp;15 included appropriate legends setting forth that the securities had not been registered and the applicable
restrictions on transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(a) Exhibits.</B> The list of exhibits is set forth under &#147;Exhibit Index&#148; at the end of this registration statement and is incorporated by
reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) Financial Statement Schedules.</B> Schedules not listed above have been omitted because the information required to be set forth
therein is not applicable or is shown in the financial statements or notes thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriter, at the closing specified in the underwriting agreement,
certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby undertakes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this
registration statement in reliance upon Rule 430A and contained in a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it
was declared effective. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">That, for the purpose of determining liability under the Securities Act to any purchaser: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than
prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or
prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time
of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first
use. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering
of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the
following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of Vista, State of California, on this 9<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of October, 2014. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EXAGEN DIAGNOSTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Fortunato Ron Rocca</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Fortunato Ron Rocca</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed
by the following persons in the capacities held on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Fortunato Ron Rocca</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fortunato Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>(Principal Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;9, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Wendy Swedick</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Wendy Swedick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>(Principal Financial
and Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;9, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Curt LaBelle, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;9, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ebetuel Pallares, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;9, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Brian Birk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;9, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Frank Witney, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;9, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">John M. Radak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;9, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Arthur Weinstein, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October&nbsp;9, 2014</TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Fortunato Ron Rocca</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Fortunato Ron Rocca</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><I>Attorney-in-Fact</I></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fifteenth Amended and Restated Certificate of Incorporation (currently in effect).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Bylaws (currently in effect).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation (to be effective immediately prior to the completion of this offering).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws (to be effective immediately prior to the completion of this offering).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Specimen stock certificate evidencing the shares of common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fourth Amended and Restated Investors&#146; Rights Agreement, dated October 4, 2013, by and among the Registrant and certain of its stockholders.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fourth Amended and Restated Stockholders&#146; Agreement, dated October 4, 2013, by and among the Registrant and certain of its stockholders.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Warrant to purchase common stock issued to investors in connection with private placement financings.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.5<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Warrant issued to lenders and related advisors in connection with the Registrant&#146;s term loan agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of Latham &amp; Watkins LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exagen Corporation Stock Option Plan, as amended, and form of option agreement thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exagen Diagnostics, Inc. 2013 Stock Option Plan, as amended, and form of option agreement thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exagen Diagnostics, Inc. 2014 Incentive Award Plan and form of option agreement thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exagen Diagnostics, Inc. 2014 Employee Stock Purchase Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5&#134;<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">License Agreement, dated September 13, 2007, by and between Prometheus Laboratories Inc. and the Registrant (as successor in interest to Proprius, Inc.).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6&#134;<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">First Amendment to License Agreement, dated October 23, 2013, by and between Prometheus Laboratories Inc. and the Registrant (as successor in interest to Cypress Bioscience, Inc.).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7&#134;<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">License Agreement, dated February 19, 2008, by and between Orgentec Diagnostika GmbH and the Registrant (as successor in interest to Proprius, Inc.).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Asset Purchase Agreement, dated February 9, 2009, by and between the Registrant (as successor in interest to Cypress Bioscience, Inc.) and Cellatope Corporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment No. One to Asset Purchase Agreement, dated December 14, 2012, by and between the Registrant and Cellatope Corporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10&#134;<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Asset Purchase Agreement, dated October 8, 2010, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11&#134;<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment No. One to Asset Purchase Agreement, dated March 10, 2011, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment No. Two to Asset Purchase Agreement, dated August 21, 2012, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant.</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13&#134;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amendment No. Three to Asset Purchase Agreement, dated February 6, 2013, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14#<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Offer Letter, dated October 12, 2010, by and between Thierry Dervieux, Ph.D. and the Registrant, as amended on September 9, 2011.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15&#134;<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Exclusive License Agreement, dated August 2, 2011, by and between the University of Pittsburgh &#150; Of the Commonwealth System of Higher Education and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16&#134;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">First Amendment to Amended and Restated Exclusive License Agreement, dated May&nbsp;17, 2012, by and between the University of Pittsburgh &#150; Of the Commonwealth System of Higher Education and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17&#134;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Second Amendment to Amended and Restated Exclusive License Agreement, dated September&nbsp;30, 2013, by and between the Registrant and the University of Pittsburgh &#150; Of the Commonwealth System of Higher Education.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18&#134;<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exclusive License Agreement, dated September 30, 2013, by and between the Registrant and the University of Pittsburgh&#151;Of the Commonwealth System of Higher Education.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19&#134;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Exclusive License Agreement, dated September 5, 2011, by and between Thierry Dervieux, Ph.D. and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Standard Industrial/Commercial Multi-Tenant Lease, dated January 13, 2012, by and between RGS Properties and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">First Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated December 1, 2013, by and between RGS Properties and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lease of Real Property, dated May 7, 2013, by and between The Regents of the University of New Mexico and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.23<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">First Amendment to Lease of Real Property, dated May&nbsp;7, 2013, by and between The Regents of the University of New Mexico and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.24<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Standard Industrial/Commercial Single-Tenant Lease, dated September 4, 2014, by and between Geiger Court, LLC and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.25<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Term Loan Agreement, dated October 10, 2013, by and between Capital Royalty Partners II L.P., Capital Royalty Partners II&#151;Parallel Fund &#147;A&#148; L.P., Parallel Investment Opportunities Partners II L.P. and the
Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.26<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Security Agreement, dated October 10, 2013, by and between Capital Royalty Partners II L.P., Capital Royalty Partners II&#151;Parallel Fund &#147;A&#148; L.P., Parallel Investment Opportunities Partners&nbsp;II L.P. and the
Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Indemnity Agreement for Directors and Officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.28#*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Non-Employee Director Compensation Program.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.29#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employment Agreement by and between Fortunato Ron Rocca and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.30#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employment Agreement by and between Wendy Swedick and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.31#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Employment Agreement by and between Thierry Dervieux and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.32#</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Relocation Agreement, dated April 1, 2014, by and between Wendy Swedick and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>16.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Letter from McGladrey LLP addressed to the SEC provided in connection with the change in independent accountant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of Latham &amp; Watkins LLP (included in Exhibit 5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page).</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Filed with the Registrant&#146;s Registration Statement on Form S-1 on September 19, 2014. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment pursuant to Rule 406 under the Securities Act of 1933. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>2
<FILENAME>d693329dex33.htm
<DESCRIPTION>EX-3.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXAGEN DIAGNOSTICS, INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(originally incorporated on November&nbsp;17, 2003) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FIRST:&nbsp;The name of the Corporation is Exagen Diagnostics, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECOND:&nbsp;The address of the Corporation&#146;s registered office in the State of Delaware is 1209 Orange Street in the City of Wilmington,
County of New Castle, Zip Code 19801.&nbsp;The name of its registered agent at that address is The Corporation Trust Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIRD:&nbsp;The nature of the business or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity
for which corporations may be organized under the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOURTH:&nbsp;The total number of
shares of all classes of stock which the Corporation shall have authority to issue is 210,000,000 shares, consisting of (a)&nbsp;200,000,000 shares of Common Stock, $0.001 par value per share (&#147;Common Stock&#148;), and (b)&nbsp;10,000,000
shares of Preferred Stock, $0.001 par value per share (&#147;Preferred Stock&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and
the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. <U>COMMON STOCK</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;<U>General</U>.&nbsp;The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by
the rights of the holders of the Preferred Stock of any series as may be designated by the Board of Directors upon any issuance of the Preferred Stock of any series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;<U>Voting</U>.&nbsp;The holders of the Common Stock shall have voting rights at all meetings of stockholders, each such holder being
entitled to one vote for each share thereof held by such holder; <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation
(which, as used herein, shall mean the certificate of incorporation of the Corporation, as amended from time to time, including the terms of any certificate of designations of any series of Preferred Stock) that relates solely to the terms of one or
more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to this Certificate of Incorporation
or the General Corporation Law of the State of Delaware.&nbsp;There shall be no cumulative voting. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of authorized shares of Common Stock may be increased or decreased (but not below the
number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law of the State of
Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;<U>Dividends</U>.&nbsp;Dividends may be declared and paid on the Common Stock as and when determined by the Board of
Directors subject to any preferential dividend or other rights of any then outstanding Preferred Stock and to the requirements of applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;<U>Liquidation</U>.&nbsp;Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of Common
Stock will be entitled to receive all assets of the Corporation available for distribution to its stockholders, subject to any preferential or other rights of any then outstanding Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. <U>PREFERRED STOCK</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preferred Stock may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed herein
and in the resolution or resolutions providing for the issue of such series adopted by the Board of Directors of the Corporation as hereinafter provided. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Authority is hereby expressly granted to the Board of Directors from time to time to issue the Preferred Stock in one or more series, and in
connection with the creation of any such series, by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designations relating thereto in accordance with the General Corporation Law of
the State of Delaware, to determine and fix the number of shares of such series and such voting powers, full or limited, or no voting powers, and such designations, preferences and relative participating, optional or other special rights, and
qualifications, limitations or restrictions thereof, including without limitation thereof, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be stated and expressed in such resolutions, all to the
fullest extent now or hereafter permitted by the General Corporation Law of the State of Delaware. Without limiting the generality of the foregoing, the resolution or resolutions providing for the issuance of any series of Preferred Stock may
provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding)
by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law of the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FIFTH:&nbsp;Except as otherwise provided herein, the Corporation reserves the right to amend,
alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute and this Certificate of Incorporation, and all rights conferred upon stockholders herein are granted subject
to this reservation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SIXTH:&nbsp;In furtherance and not in limitation of the powers conferred upon it by the General Corporation Law of
the State of Delaware, and subject to the terms of any series of Preferred Stock, the Board of Directors shall have the power to adopt, amend, alter or repeal the Bylaws of the Corporation.&nbsp;The stockholders may not adopt, amend, alter or repeal
the Bylaws of the Corporation, or adopt any provision inconsistent therewith, unless such action is approved, in addition to any other vote required by this Certificate of Incorporation, by the affirmative vote of the holders of at least two-thirds
in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon.&nbsp;Notwithstanding any other provisions of law, this Certificate of Incorporation or the Bylaws of the Corporation, and notwithstanding the
fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon shall be required to amend or
repeal, or to adopt any provision inconsistent with, this Article SIXTH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEVENTH:&nbsp;Except to the extent that the General Corporation
Law of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty, no director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for
any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability.&nbsp;No amendment to or repeal of this provision shall apply to or have any effect on the liability or alleged liability of any director of the
Corporation for or with respect to any acts or omissions of such director occurring prior to such amendment or repeal.&nbsp;If the General Corporation Law of the State of Delaware is amended to permit further elimination or limitation of the
personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of the State of Delaware as so amended.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EIGHTH:&nbsp;This Article EIGHTH is inserted for the management of the business and for the conduct of the affairs of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;<U>General Powers</U>.&nbsp;The business and affairs of the Corporation shall be managed by or under the direction of the Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;<U>Number of Directors; Election of Directors</U>.&nbsp;Subject to the rights of holders of any series of Preferred
Stock to elect directors, the number of directors of the Corporation shall be established from time to time by the Board of Directors.&nbsp;Election of directors need not be by written ballot, except as and to the extent provided in the Bylaws of
the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Classes of Directors</U>.&nbsp;Subject to the rights of holders of any series of Preferred
Stock to elect directors, the Board of Directors shall be and is divided into three classes, designated as Class I, Class II and Class III.&nbsp;Each class shall consist, as nearly as may be possible, of one-third of the total number of directors
constituting the entire Board of Directors.&nbsp;The Board of Directors is authorized to assign members of the Board of Directors to Class I, Class II or Class III. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;<U>Terms of Office</U>.&nbsp;Subject to the rights of holders of any series of Preferred Stock to elect directors, each director shall
serve for a term ending on the date of the third annual meeting of stockholders following the annual meeting of stockholders at which such director was elected; <U>provided</U> that each director initially assigned to Class I shall serve for a term
expiring at the Corporation&#146;s first annual meeting of stockholders held after the effectiveness of this Amended and Restated Certificate of Incorporation; each director initially assigned to Class II shall serve for a term expiring at the
Corporation&#146;s second annual meeting of stockholders held after the effectiveness of this Amended and Restated Certificate of Incorporation; and each director initially assigned to Class III shall serve for a term expiring at the
Corporation&#146;s third annual meeting of stockholders held after the effectiveness of this Amended and Restated Certificate of Incorporation; <U>provided</U> <U>further</U>, that the term of each director shall continue until the election and
qualification of his or her successor and be subject to his or her earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Quorum</U>.&nbsp;The
greater of (a)&nbsp;a majority of the directors at any time in office and (b)&nbsp;one-third of the number of directors fixed pursuant to Section&nbsp;2 of this Article EIGHTH shall constitute a quorum of the Board of Directors.&nbsp;If at any
meeting of the Board of Directors there shall be less than such a quorum, a majority of the directors present may adjourn the meeting from time to time without further notice other than announcement at the meeting, until a quorum shall be present.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Action at Meeting</U>.&nbsp;Every act or decision done or made by a majority of the directors present at a meeting duly held at
which a quorum is present shall be regarded as the act of the Board of Directors unless a greater number is required by law or by this Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Removal</U>.&nbsp;Subject to the rights of holders of any series of Preferred Stock, directors of the Corporation may be removed only
for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Vacancies</U>.&nbsp;Subject to the rights of holders of any series of Preferred Stock, any vacancy or newly created directorship in the
Board of Directors, however occurring, shall be filled only by vote of a majority of the directors then in office, although less than a quorum, or by a sole remaining director and shall not be filled by the stockholders, unless the Board of
Directors determines by resolution that any such vacancy or newly created directorship shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
filled by the stockholders.&nbsp;A director elected to fill a vacancy shall hold office until the next election of the class for which such director shall have been chosen, subject to the
election and qualification of a successor and to such director&#146;s earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;<U>Stockholder
Nominations and Introduction of Business, Etc</U>.&nbsp;Advance notice of stockholder nominations for election of directors and other business to be brought by stockholders before a meeting of stockholders shall be given in the manner provided by
the Bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;<U>Amendments to Article</U>.&nbsp;Notwithstanding any other provisions of law, this Certificate
of Incorporation or the Bylaws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock
of the Corporation entitled to vote thereon shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article EIGHTH. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NINTH:&nbsp;Stockholders of the Corporation may not take any action by written consent in lieu of a meeting.&nbsp;Notwithstanding any other
provisions of law, this Certificate of Incorporation or the Bylaws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least two-thirds in voting power of the
outstanding shares of capital stock of the Corporation entitled to vote thereon shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article NINTH. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TENTH:&nbsp;Special meetings of stockholders for any purpose or purposes may be called at any time only by the Board of Directors, the
chairperson of the Board of Directors, the chief executive officer or the president (in the absence of a chief executive officer), and may not be called by any other person or persons.&nbsp;Business transacted at any special meeting of stockholders
shall be limited to the purpose or purposes stated in the notice of meeting.&nbsp;Notwithstanding any other provisions of law, this Certificate of Incorporation or the Bylaws of the Corporation, and notwithstanding the fact that a lesser percentage
may be specified by law, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon shall be required to amend or repeal, or to adopt any
provision inconsistent with, this Article TENTH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ELEVENTH: Unless the Corporation consents in writing to the selection of an alternative
forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (a)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (b)&nbsp;any action asserting
a claim of breach of fiduciary duty owed by, or other wrongdoing by, any director, officer, employee or agent of the Corporation to the Corporation or the Corporation&#146;s stockholders, creditors or other constituents, (c)&nbsp;any action
asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware or this Certificate of Incorporation or the Bylaws of the Corporation, (d)&nbsp;any action to interpret, apply, enforce or determine the
validity of this Certificate of Incorporation or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Bylaws of the Corporation or (e)&nbsp;any action asserting a claim governed by the internal affairs doctrine, in each case subject to said Court of Chancery having personal jurisdiction over the
indispensable parties named as defendants therein; provided that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal
court sitting in the State of Delaware. To the fullest extent permitted by applicable law, any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and
consented to the provisions of this Article ELEVENTH. Notwithstanding any other provisions of law, this Certificate of Incorporation or the Bylaws of the Corporation, and notwithstanding the fact that a lesser percentage may be specified by law, the
affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon shall be required to amend or repeal, or to adopt any provision inconsistent with, this
Article ELEVENTH. If any provision or provisions of this Article ELEVENTH shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by
law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article ELEVENTH (including, without limitation, each portion of any sentence of this Article ELEVENTH containing any
such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or
impaired thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, this Certificate of Incorporation, which restates, integrates and amends the certificate of
incorporation of the Corporation, and which has been duly adopted in accordance with Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware, has been executed by its duly authorized officer this
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">EXAGEN DIAGNOSTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Fortunato Ron Rocca</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>3
<FILENAME>d693329dex34.htm
<DESCRIPTION>EX-3.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.4 </B></P>
<P STYLE="margin-top:280pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN DIAGNOSTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(a Delaware corporation) </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE I - CORPORATE OFFICES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">REGISTERED OFFICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">OTHER OFFICES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE II - MEETINGS OF STOCKHOLDERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">PLACE OF MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ANNUAL MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">SPECIAL MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ADVANCE NOTICE PROCEDURES FOR NOMINATIONS OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NOTICE OF STOCKHOLDERS&#146; MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">MANNER OF GIVING NOTICE; AFFIDAVIT OF NOTICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">QUORUM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ADJOURNED MEETING; NOTICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">CONDUCT OF BUSINESS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">VOTING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">RECORD DATE FOR STOCKHOLDER NOTICE; VOTING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">PROXIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">LIST OF STOCKHOLDERS ENTITLED TO VOTE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">POSTPONEMENT AND CANCELLATION OF MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">INSPECTORS OF ELECTION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE III - DIRECTORS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">POWERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NUMBER OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">RESIGNATION AND VACANCIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">PLACE OF MEETINGS; MEETINGS BY TELEPHONE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">REGULAR MEETINGS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">SPECIAL MEETINGS; NOTICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">QUORUM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">BOARD ACTION BY CONSENT WITHOUT A MEETING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">FEES AND COMPENSATION OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">REMOVAL OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IV - COMMITTEES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">COMMITTEES OF DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">COMMITTEE MINUTES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">MEETINGS AND ACTION OF COMMITTEES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE V - OFFICERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">APPOINTMENT OF OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">SUBORDINATE OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">REMOVAL AND RESIGNATION OF OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">VACANCIES IN OFFICES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">REPRESENTATION OF SHARES OF OTHER CORPORATIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">AUTHORITY AND DUTIES OF OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VI - RECORDS AND REPORTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">MAINTENANCE OF RECORDS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VII - GENERAL MATTERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">STOCK CERTIFICATES; PARTLY PAID SHARES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">SPECIAL DESIGNATION ON CERTIFICATES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">LOST CERTIFICATES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">CONSTRUCTION; DEFINITIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">DIVIDENDS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">FISCAL YEAR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">SEAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">TRANSFER OF STOCK</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">STOCK TRANSFER AGREEMENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">REGISTERED STOCKHOLDERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">WAIVER OF NOTICE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VIII - NOTICE BY ELECTRONIC TRANSMISSION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NOTICE BY ELECTRONIC TRANSMISSION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">DEFINITION OF ELECTRONIC TRANSMISSION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IX - INDEMNIFICATION AND ADVANCEMENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ACTIONS, SUITS AND PROCEEDINGS OTHER THAN BY OR IN THE RIGHT OF THE CORPORATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ACTIONS OR SUITS BY OR IN THE RIGHT OF THE CORPORATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">INDEMNIFICATION FOR EXPENSES OF SUCCESSFUL PARTY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">NOTIFICATION AND DEFENSE OF CLAIM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ADVANCE OF EXPENSES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">PROCEDURE FOR INDEMNIFICATION AND ADVANCEMENT OF EXPENSES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">REMEDIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">LIMITATIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">SUBSEQUENT AMENDMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">OTHER RIGHTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">PARTIAL INDEMNIFICATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">INSURANCE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">SAVINGS CLAUSE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">DEFINITIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE X - AMENDMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iii- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED BYLAWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN DIAGNOSTICS,
INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I - CORPORATE OFFICES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 REGISTERED OFFICE.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
registered office of Exagen Diagnostics, Inc. (the &#147;<U>Corporation</U>&#148;) shall be fixed in the Corporation&#146;s certificate of incorporation, as the same may be amended from time to time (the &#147;<U>certificate of
incorporation</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 OTHER OFFICES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation&#146;s board of directors (the &#147;<U>Board</U>&#148;) may at any time establish other offices at any place or places where
the Corporation is qualified to do business. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II - MEETINGS OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 PLACE OF MEETINGS.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Meetings
of stockholders shall be held at any place, within or outside the State of Delaware, designated by the Board. The Board may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held
solely by means of remote communication as authorized by Section&nbsp;211(a)(2) of the General Corporation Law of the State of Delaware (the &#147;<U>DGCL</U>&#148;). In the absence of any such designation or determination, stockholders&#146;
meetings shall be held at the Corporation&#146;s principal executive office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 ANNUAL MEETING.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board shall designate the date and time of the annual meeting. At the annual meeting, directors shall be elected and other proper business
properly brought before the meeting in accordance with Section&nbsp;2.4 of these bylaws may be transacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 SPECIAL MEETING.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A special meeting of the stockholders may be called at any time by the Board, chairperson of the Board, chief executive officer or president
(in the absence of a chief executive officer), but such special meetings may not be called by any other person or persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No business
may be transacted at such special meeting other than the business specified in such notice to stockholders. Nothing contained in this paragraph of this Section&nbsp;2.3 shall be construed as limiting, fixing, or affecting the time when a meeting of
stockholders called by action of the Board may be held. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) At an annual meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting. To
be properly brought before an annual meeting, business must be (i)&nbsp;brought before the meeting by the Corporation and specified in the notice of meeting given by or at the direction of the Board, (ii)&nbsp;brought before the meeting by or at the
direction of the Board or (iii)&nbsp;otherwise properly brought before the meeting by a stockholder who (A)&nbsp;was a stockholder of record of the Corporation (and, with respect to any beneficial owner, if different, on whose behalf such business
is proposed, only if such beneficial owner was the beneficial owner of shares of the Corporation) both at the time of giving the notice provided for in this Section&nbsp;2.4 and at the time of the meeting, (B)&nbsp;is entitled to vote at the meeting
and (C)&nbsp;has complied with this Section&nbsp;2.4 as to such business. Except for proposals properly made in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder
(as so amended and inclusive of such rules and regulations, the &#147;<U>Exchange Act</U>&#148;), and included in the notice of meeting given by or at the direction of the Board, the foregoing clause&nbsp;(iii) shall be the exclusive means for a
stockholder to propose business to be brought before an annual meeting of the stockholders. Stockholders shall not be permitted to propose business to be brought before a special meeting of the stockholders, and the only matters that may be brought
before a special meeting are the matters specified in the notice of meeting given by or at the direction of the person calling the meeting pursuant to Section&nbsp;2.3 of these bylaws. Stockholders seeking to nominate persons for election to the
Board must comply with Section&nbsp;2.5 of these bylaws, and this Section&nbsp;2.4 shall not be applicable to nominations except as expressly provided in Section&nbsp;2.5 of these bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Without qualification, for business to be properly brought before an annual meeting by a stockholder, the stockholder must
(i)&nbsp;provide Timely Notice (as defined below) thereof in writing and in proper form to the secretary of the Corporation and (ii)&nbsp;provide any updates or supplements to such notice at the times and in the forms required by this
Section&nbsp;2.4. To be timely, a stockholder&#146;s notice must be delivered to, or mailed and received at, the principal executive offices of the Corporation not less than ninety (90)&nbsp;days nor more than one hundred twenty (120)&nbsp;days
prior to the first anniversary of the preceding year&#146;s annual meeting; <I>provided, however</I>, that (x)&nbsp;if the date of the annual meeting is more than thirty (30)&nbsp;days before or more than sixty (60)&nbsp;days after such anniversary
date or (y)&nbsp;with respect to the first annual meeting held after February&nbsp;1, 2014, notice by the stockholder to be timely must be so delivered, or mailed and received, not earlier than the one hundred twentieth (120<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;day prior to such annual meeting and not later than the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;day prior to such annual meeting or, if later, the tenth (10<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;day following the day on which public disclosure of the date of such annual meeting was first made (such notice within such time periods, &#147;<U>Timely Notice</U>&#148;). In no event shall
any adjournment or postponement of an annual meeting or the announcement thereof commence a new time period for the giving of Timely Notice as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) To be in proper form for purposes of this Section&nbsp;2.4, a stockholder&#146;s notice to the secretary of the Corporation shall set
forth: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) As to each Proposing Person (as defined below), (A)&nbsp;the name and address of such Proposing Person
(including, without limitation, if applicable, the name and address that appear on the Corporation&#146;s books and records) and (B)&nbsp;the class or series and number of shares of the Corporation that are, directly or indirectly, owned of record
or beneficially owned (within the meaning of Rule 13d-3 under the Exchange Act) by such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
Proposing Person, except that such Proposing Person shall in all events be deemed to beneficially own any shares of any class or series of the Corporation as to which such Proposing Person has a
right to acquire beneficial ownership at any time in the future (the disclosures to be made pursuant to the foregoing clauses (A)&nbsp;and (B)&nbsp;are referred to as &#147;<U>Stockholder Information</U>&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) As to each Proposing Person, (A)&nbsp;any derivative, swap or other transaction or series of transactions engaged in,
directly or indirectly, by such Proposing Person, the purpose or effect of which is to give such Proposing Person economic risk similar to ownership of shares of any class or series of the Corporation, including, without limitation, due to the fact
that the value of such derivative, swap or other transactions are determined by reference to the price, value or volatility of any shares of any class or series of the Corporation, or which derivative, swap or other transactions provide, directly or
indirectly, the opportunity to profit from any increase in the price or value of shares of any class or series of the Corporation (&#147;<U>Synthetic Equity Interests</U>&#148;), which Synthetic Equity Interests shall be disclosed without regard to
whether (x)&nbsp;the derivative, swap or other transactions convey any voting rights in such shares to such Proposing Person, (y)&nbsp;the derivative, swap or other transactions are required to be, or are capable of being, settled through delivery
of such shares or (z)&nbsp;such Proposing Person may have entered into other transactions that hedge or mitigate the economic effect of such derivative, swap or other transactions, (B)&nbsp;any proxy (other than a revocable proxy or consent given in
response to a solicitation made pursuant to, and in accordance with, Section&nbsp;14(a) of the Exchange Act by way of a solicitation statement filed on Schedule 14A), agreement, arrangement, understanding or relationship pursuant to which such
Proposing Person has or shares a right to vote any shares of any class or series of the Corporation, (C)&nbsp;any agreement, arrangement, understanding or relationship, including, without limitation, any repurchase or similar so-called &#147;stock
borrowing&#148; agreement or arrangement, engaged in, directly or indirectly, by such Proposing Person, the purpose or effect of which is to mitigate loss to, reduce the economic risk (of ownership or otherwise) of shares of any class or series of
the Corporation by, manage the risk of share price changes for, or increase or decrease the voting power of, such Proposing Person with respect to the shares of any class or series of the Corporation, or which provides, directly or indirectly, the
opportunity to profit from any decrease in the price or value of the shares of any class or series of the Corporation (&#147;<U>Short Interests</U>&#148;), (D)&nbsp;any rights to dividends on the shares of any class or series of the Corporation
owned beneficially by such Proposing Person that are separated or separable from the underlying shares of the Corporation, (E)&nbsp;any performance related fees (other than an asset based fee) that such Proposing Person is entitled to based on any
increase or decrease in the price or value of shares of any class or series of the Corporation, or any Synthetic Equity Interests or Short Interests, if any, (F)(x) if such Proposing Person is not a natural person, the identity of the natural person
or persons associated with such Proposing Person responsible for the formulation of and decision to propose the business to be brought before the meeting (such person or persons, the &#147;<U>Responsible Person</U>&#148;), the manner in which such
Responsible Person was selected, any fiduciary duties owed by such Responsible Person to the equity holders or other beneficiaries of such Proposing Person, the qualifications and background of such Responsible Person and any material interests or
relationships of such Responsible Person that are not shared generally by any other record or beneficial holder of the shares of any class or series of the Corporation and that reasonably could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
have influenced the decision of such Proposing Person to propose such business to be brought before the meeting, and (y)&nbsp;if such Proposing Person is a natural person, the qualifications and
background of such natural person and any material interests or relationships of such natural person that are not shared generally by any other record or beneficial holder of the shares of any class or series of the Corporation and that reasonably
could have influenced the decision of such Proposing Person to propose such business to be brought before the meeting, (G)&nbsp;any significant equity interests or any Synthetic Equity Interests or Short Interests in any principal competitor of the
Corporation held by such Proposing Persons, (H)&nbsp;any direct or indirect interest of such Proposing Person in any contract with the Corporation, any affiliate of the Corporation or any principal competitor of the Corporation (including, without
limitation, in any such case, any employment agreement, collective bargaining agreement or consulting agreement), (I)&nbsp;any pending or threatened litigation in which such Proposing Person is a party or material participant involving the
Corporation or any of its officers or directors, or any affiliate of the Corporation, (J)&nbsp;any material transaction occurring during the prior twelve months between such Proposing Person, on the one hand, and the Corporation, any affiliate of
the Corporation or any principal competitor of the Corporation, on the other hand, (K)&nbsp;a summary of any material discussions regarding the business proposed to be brought before the meeting (x)&nbsp;between or among any of the Proposing Persons
or (y)&nbsp;between or among any Proposing Person and any other record or beneficial holder of the shares of any class or series of the Corporation (including, without limitation, their names) and (L)&nbsp;any other information relating to such
Proposing Person that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought
before the meeting pursuant to Section&nbsp;14(a) of the Exchange Act (the disclosures to be made pursuant to the foregoing clauses (A)&nbsp;through (L)&nbsp;are referred to as &#147;<U>Disclosable Interests</U>&#148;); <I>provided, however</I>,
that Disclosable Interests shall not include any such disclosures with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being
the stockholder directed to prepare and submit the notice required by these bylaws on behalf of a beneficial owner; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) As to each item of business that the stockholder proposes to bring before the annual meeting, (A)&nbsp;a reasonably brief
description of the business desired to be brought before the annual meeting, the reasons for conducting such business at the annual meeting and any material interest in such business of each Proposing Person, (B)&nbsp;the text of the proposal or
business (including, without limitation, the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend the bylaws of the Corporation, the language of the proposed amendment), (C)&nbsp;a
reasonably detailed description of all agreements, arrangements and understandings between or among any of the Proposing Persons or between or among any Proposing Person and any other person or entity (including, without limitation, their names) in
connection with the proposal of such business by such stockholder, (D)&nbsp;a representation that the stockholder is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the
meeting to propose such business, (E)&nbsp;a representation whether the Proposing Person intends or is part of a group which intends (1)&nbsp;to deliver a proxy statement and/or form of proxy to holders of at least
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
the percentage of the Corporation&#146;s outstanding capital stock required to approve or adopt the proposal and/or (2)&nbsp;otherwise to solicit proxies or votes from stockholders in support of
such proposal and (F)&nbsp;any other information relating to such item of business that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies in support of the business
proposed to be brought before the meeting pursuant to Section&nbsp;14(a) of the Exchange Act; <I>provided, however</I>, that the disclosures required by this paragraph&nbsp;(c) shall not include any disclosures with respect to any broker, dealer,
commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to prepare and submit the notice required by these bylaws on behalf of a beneficial owner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) For purposes of this Section&nbsp;2.4, the term &#147;<U>Proposing Person</U>&#148; shall mean (i)&nbsp;the stockholder providing the
notice of business proposed to be brought before an annual meeting, (ii)&nbsp;the beneficial owner or beneficial owners, if different, on whose behalf the notice of the business proposed to be brought before the annual meeting is made,
(iii)&nbsp;any affiliate or associate (each within the meaning of Rule 12b-2 under the Exchange Act for the purposes of these bylaws) of such stockholder or beneficial owner and (iv)&nbsp;any other person with whom such stockholder or beneficial
owner (or any of their respective affiliates or associates) is Acting in Concert (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) A person shall be deemed to be
&#147;<U>Acting in Concert</U>&#148; with another person for purposes of these bylaws if such person knowingly acts (whether or not pursuant to an express agreement, arrangement or understanding) in concert with, or towards a common goal relating to
the management, governance or control of the Corporation in parallel with, such other person where (i)&nbsp;each person is conscious of the other person&#146;s conduct or intent and this awareness is an element in their decision-making processes and
(ii)&nbsp;at least one additional factor suggests that such persons intend to act in concert or in parallel, which such additional factors may include, without limitation, exchanging information (whether publicly or privately), attending meetings,
conducting discussions, or making or soliciting invitations to act in concert or in parallel; <I>provided</I>, that a person shall not be deemed to be Acting in Concert with any other person solely as a result of the solicitation or receipt of
revocable proxies or consents from such other person in response to a solicitation made pursuant to, and in accordance with, the Section&nbsp;14(a) of the Exchange Act by way of a proxy or consent solicitation statement filed on Schedule 14A. A
person Acting in Concert with another person shall be deemed to be Acting in Concert with any third party who is also Acting in Concert with such other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) A stockholder providing notice of business proposed to be brought before an annual meeting shall further update and supplement such
notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section&nbsp;2.4 shall be true and correct as of the record date for determining stockholders entitled to notice of the annual meeting
and as of the date that is ten (10)&nbsp;business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the secretary of the Corporation at the
principal executive offices of the Corporation not later than five (5)&nbsp;business days after the record date for determining stockholders entitled to notice of the annual meeting (in the case of the update and supplement required to be made as of
the record date), and not later than eight (8)&nbsp;business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the
meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of ten (10)&nbsp;business days prior to the meeting or any adjournment or postponement thereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) Notwithstanding anything in these bylaws to the contrary, no business shall be conducted at
an annual meeting except in accordance with this Section&nbsp;2.4. The presiding officer of an annual meeting shall, if the facts warrant, determine that the business was not properly brought before the meeting in accordance with this
Section&nbsp;2.4, and if he or she should so determine, he or she shall so declare to the meeting and any such business not properly brought before the meeting shall not be transacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) The foregoing notice requirements of this Section&nbsp;2.4 shall be deemed satisfied by a stockholder with respect to business other than
a nomination if the stockholder has notified the Corporation of his, her or its intention to present a proposal at an annual meeting in compliance with applicable rules and regulations promulgated under the Exchange Act and such stockholder&#146;s
proposal has been included in a proxy statement that has been prepared by the Corporation to solicit proxies for such annual meeting. Nothing in this Section&nbsp;2.4 shall be deemed to affect the rights of stockholders to request inclusion of
proposals in the Corporation&#146;s proxy statement pursuant to Rule 14a-8 under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) For purposes of these bylaws,
&#147;public disclosure&#148; shall mean disclosure in a press release reported by a national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d) of the
Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) Notwithstanding the foregoing provisions of this Section&nbsp;2.4, unless otherwise required by law, if the stockholder
(or a qualified representative of the stockholder) does not appear at the annual meeting to present proposed business, such proposed business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the
Corporation. For purposes of this Section&nbsp;2.4, to be considered a qualified representative of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by
such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the annual meeting and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing
or electronic transmission, at the annual meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 ADVANCE NOTICE PROCEDURES FOR NOMINATIONS OF DIRECTORS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Nominations of any person for election to the Board at an annual meeting or at a special meeting (but only if the election of directors is
a matter specified in the notice of meeting given by or at the direction of the person calling such special meeting) may be made at such meeting only (i)&nbsp;by or at the direction of the Board, including, without limitation, by any committee or
persons appointed by the Board, or (ii)&nbsp;by a stockholder who (A)&nbsp;was a stockholder of record of the Corporation (and, with respect to any beneficial owner, if different, on whose behalf such nomination is proposed to be made, only if such
beneficial owner was the beneficial owner of shares of the Corporation) both at the time of giving the notice provided for in this Section&nbsp;2.5 and at the time of the meeting, (B)&nbsp;is entitled to vote at the meeting and (C)&nbsp;has complied
with this Section&nbsp;2.5 as to such nomination. The foregoing clause (ii)&nbsp;shall be the exclusive means for a stockholder to make any nomination of a person or persons for election to the Board to be considered by the stockholders at an annual
meeting or special meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Without qualification, for a stockholder to make any nomination of a person or persons for election to
the Board at an annual meeting, the stockholder must (i)&nbsp;provide Timely Notice (as defined in Section&nbsp;2.4(b) of these bylaws) thereof in writing and in proper form to the secretary of the Corporation and (ii)&nbsp;provide any updates or
supplements to such notice at the times and in the forms </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required by this Section&nbsp;2.5. Without qualification, if the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling such
special meeting, then for a stockholder to make any nomination of a person or persons for election to the Board at a special meeting, the stockholder must (i)&nbsp;provide timely notice thereof in writing and in proper form to the secretary of the
Corporation at the principal executive offices of the Corporation and (ii)&nbsp;provide any updates or supplements to such notice at the times and in the forms required by this Section&nbsp;2.5. To be timely, a stockholder&#146;s notice for
nominations to be made at a special meeting must be delivered to, or mailed and received at, the principal executive offices of the Corporation not earlier than the one hundred twentieth
(120<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;day prior to such special meeting and not later than the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;day prior to such special meeting or, if later, the
tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;day following the day on which public disclosure (as defined in Section&nbsp;2.4(i) of these bylaws) of the date of such special meeting was first made. In no event shall any
adjournment or postponement of an annual meeting or special meeting or the announcement thereof commence a new time period for the giving of a stockholder&#146;s notice as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) To be in proper form for purposes of this Section&nbsp;2.5, a stockholder&#146;s notice to the secretary of the Corporation shall set
forth: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) As to each Nominating Person (as defined below), the Stockholder Information (as defined in
Section&nbsp;2.4(c)(i) of these bylaws) except that for purposes of this Section&nbsp;2.5, the term &#147;Nominating Person&#148; shall be substituted for the term &#147;Proposing Person&#148; in all places it appears in Section&nbsp;2.4(c)(i); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) As to each Nominating Person, any Disclosable Interests (as defined in Section&nbsp;2.4(c)(ii), except that for purposes
of this Section&nbsp;2.5 the term &#147;Nominating Person&#148; shall be substituted for the term &#147;Proposing Person&#148; in all places it appears in Section&nbsp;2.4(c)(ii) and the disclosure in clause (L)&nbsp;of Section&nbsp;2.4(c)(ii) shall
be made with respect to the election of directors at the meeting); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) As to each person whom a Nominating Person
proposes to nominate for election as a director, (A)&nbsp;all information with respect to such proposed nominee that would be required to be set forth in a stockholder&#146;s notice pursuant to this Section&nbsp;2.5 if such proposed nominee were a
Nominating Person, (B)&nbsp;all information relating to such proposed nominee that is required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors in a
contested election pursuant to Section&nbsp;14(a) under the Exchange Act (including, without limitation, such proposed nominee&#146;s written consent to being named in the proxy statement as a nominee and to serving as a director if elected),
(C)&nbsp;a description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings during the past three (3)&nbsp;years, and any other material relationships, between or among any Nominating
Person, on the one hand, and each proposed nominee, his or her respective affiliates and associates and any other persons with whom such proposed nominee (or any of his or her respective affiliates and associates) is Acting in Concert (as defined in
Section&nbsp;2.4(e) of these bylaws), on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Item&nbsp;404 under Regulation S-K if such Nominating Person were the &#147;registrant&#148;
for purposes of such rule and the proposed nominee were a director or executive officer of such registrant (the disclosures to be made pursuant to the foregoing clauses (A)&nbsp;through (C)&nbsp;are referred to as &#147;<U>Nominee
Information</U>&#148;), (D)&nbsp;a representation that the Nominating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
Person is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to propose such nomination, (E)&nbsp;a
representation whether the Nominating Person intends or is part of a group which intends (1)&nbsp;to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation&#146;s outstanding capital stock required to
elect the nominee and/or (2)&nbsp;otherwise to solicit proxies or votes from stockholders in support of such nomination and (F)&nbsp;a completed and signed questionnaire, representation and agreement as provided in Section&nbsp;2.5(g); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The Corporation may require any proposed nominee to furnish such other information (A)&nbsp;as may reasonably be required
by the Corporation to determine the eligibility of such proposed nominee to serve as an independent director of the Corporation in accordance with the Corporation&#146;s Corporate Governance Guidelines or (B)&nbsp;that could be material to a
reasonable stockholder&#146;s understanding of the independence or lack of independence of such proposed nominee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) For purposes of
this Section&nbsp;2.5, the term &#147;<U>Nominating Person</U>&#148; shall mean (i)&nbsp;the stockholder providing the notice of the nomination proposed to be made at the meeting, (ii)&nbsp;the beneficial owner or beneficial owners, if different, on
whose behalf the notice of the nomination proposed to be made at the meeting is made, (iii)&nbsp;any affiliate or associate of such stockholder or beneficial owner and (iv)&nbsp;any other person with whom such stockholder or such beneficial owner
(or any of their respective affiliates or associates) is Acting in Concert. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) A stockholder providing notice of any nomination proposed
to be made at a meeting shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section&nbsp;2.5 shall be true and correct as of the record date for
determining stockholders entitled to notice of the meeting and as of the date that is ten (10)&nbsp;business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and
received by, the secretary of the Corporation at the principal executive offices of the Corporation not later than five (5)&nbsp;business days after the record date for determining stockholders entitled to notice of the meeting (in the case of the
update and supplement required to be made as of the record date), and not later than eight (8)&nbsp;business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first
practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of ten (10)&nbsp;business days prior to the meeting or any adjournment or postponement
thereof). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding anything in these bylaws to the contrary, no person shall be eligible for election as a director of the
Corporation unless nominated in accordance with this Section&nbsp;2.5. The presiding officer at the meeting shall, if the facts warrant, determine that a nomination was not properly made in accordance with this Section&nbsp;2.5, and if he or she
should so determine, he or she shall so declare such determination to the meeting and the defective nomination shall be disregarded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g)
To be eligible to be a nominee for election as a director of the Corporation, the proposed nominee must deliver (in accordance with the time periods prescribed for delivery of notice under this Section&nbsp;2.5) to the secretary of the Corporation
at the principal executive offices of the Corporation a written questionnaire with respect to the background and qualification of such proposed nominee (which questionnaire shall be provided by the secretary upon written request) and a written
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representation and agreement (in form provided by the secretary upon written request) that such proposed nominee (i)&nbsp;is not and will not become a party to (A)&nbsp;any agreement, arrangement
or understanding with, and has not given any commitment or assurance to, any person or entity as to how such proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a &#147;<U>Voting
Commitment</U>&#148;) that has not been disclosed to the Corporation or (B)&nbsp;any Voting Commitment that could limit or interfere with such proposed nominee&#146;s ability to comply, if elected as a director of the Corporation, with such proposed
nominee&#146;s fiduciary duties under applicable law, (ii)&nbsp;is not, and will not become a party to, any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect
compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed to the Corporation and (iii)&nbsp;in such proposed nominee&#146;s individual capacity and on behalf of the stockholder (or
the beneficial owner, if different) on whose behalf the nomination is made, would be in compliance, if elected as a director of the Corporation, and will comply with applicable publicly disclosed corporate governance, conflict of interest,
confidentiality and stock ownership and trading policies and guidelines of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) In addition to the requirements of this
Section&nbsp;2.5 with respect to any nomination proposed to be made at a meeting, each Nominating Person shall comply with all applicable requirements of the Exchange Act with respect to any such nominations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Notwithstanding the foregoing provisions of this Section&nbsp;2.5, unless otherwise required by law, if the stockholder (or a qualified
representative of the stockholder) does not appear at the meeting to present the proposed nomination, such proposed nomination shall not be considered, notwithstanding that proxies in respect of such vote may have been received by the
Corporation.&nbsp;For purposes of this Section&nbsp;2.5, to be considered a qualified representative of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or must be authorized by a writing executed
by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of
the writing or electronic transmission, at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 NOTICE OF STOCKHOLDERS&#146; MEETINGS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided by law, the certificate of incorporation or these bylaws, the notice of any meeting of stockholders shall be sent or
otherwise given in accordance with either Section&nbsp;2.7 or Section&nbsp;8.1 of these bylaws not less than ten (10)&nbsp;nor more than sixty (60)&nbsp;days before the date of the meeting to each stockholder entitled to vote at such meeting as of
the record date for determining the stockholders entitled to notice of the meeting. The notice shall specify the place, if any, date and hour of the meeting, the record date for determining the stockholders entitled to vote at the meeting (if such
date is different from the record date for stockholders entitled to notice of the meeting), the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in
the case of a special meeting, the purpose or purposes for which the meeting is called. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 MANNER OF GIVING NOTICE; AFFIDAVIT OF
NOTICE.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of any meeting of stockholders shall be deemed given: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) if mailed, when deposited in the United States mail, postage prepaid, directed to the
stockholder at such stockholder&#146;s address as it appears on the Corporation&#146;s records; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) if electronically transmitted as
provided in Section&nbsp;8.1 of these bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An affidavit of the secretary or an assistant secretary of the Corporation or of the
transfer agent or any other agent of the Corporation that the notice has been given by mail or by a form of electronic transmission, as applicable, shall, in the absence of fraud, be prima facie evidence of the facts stated therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8 QUORUM.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise
provided by law, the certificate of incorporation or these bylaws, the holders of a majority in voting power of the capital stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or
represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. If, however, a quorum is not present or represented at any meeting of the stockholders, then either (a)&nbsp;the chairperson of the
meeting or (b)&nbsp;a majority in voting power of the stockholders entitled to vote thereon, present in person, or by remote communication, if applicable, or represented by proxy, shall have power to adjourn the meeting from time to time in the
manner provided in Section&nbsp;2.9 of these bylaws until a quorum is present or represented. At such adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the meeting as
originally noticed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9 ADJOURNED MEETING; NOTICE.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a meeting is adjourned to another time or place, unless these bylaws otherwise require, notice need not be given of the adjourned meeting
if the time, place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the
adjournment is taken. At the adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30)&nbsp;days, or if after the adjournment a new record
date for determining the stockholders entitled to vote is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the adjourned meeting as of the record date for determining
the stockholders entitled to notice of the adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10 CONDUCT OF BUSINESS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be
announced at the meeting by the person presiding over the meeting. The Board may adopt by resolution such rules and regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such
rules and regulations as adopted by the Board, the person presiding over any meeting of stockholders shall have the right and authority to convene and (for any or no reason) to recess and/or adjourn the meeting, to prescribe such rules, regulations
and procedures (which need not be in writing) and to do all such acts as, in the judgment of such presiding person, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board or
prescribed by the presiding person of the meeting, may include, without limitation, the following: (a)&nbsp;the establishment of an agenda or order of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business for the meeting; (b)&nbsp;rules and procedures for maintaining order at the meeting and the safety of those present (including, without limitation, rules and procedures for removal of
disruptive persons from the meeting); (c)&nbsp;limitations on attendance at or participation in the meeting to stockholders entitled to vote at the meeting, their duly authorized and constituted proxies or such other persons as the presiding person
of the meeting shall determine; (d)&nbsp;restrictions on entry to the meeting after the time fixed for the commencement thereof; and (e)&nbsp;limitations on the time allotted to questions or comments by participants. The presiding person at any
meeting of stockholders, in addition to making any other determinations that may be appropriate to the conduct of the meeting (including, without limitation, determinations with respect to the administration and/or interpretation of any of the
rules, regulations or procedures of the meeting, whether adopted by the Board or prescribed by the person presiding over the meeting), shall, if the facts warrant, determine and declare to the meeting that a matter or business was not properly
brought before the meeting and if such presiding person should so determine, such presiding person shall so declare to the meeting and any such matter or business not properly brought before the meeting shall not be transacted or considered. Unless
and to the extent determined by the Board or the person presiding over the meeting, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11 VOTING.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stockholders
entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of Section&nbsp;2.13 of these bylaws, subject to Section&nbsp;217 (relating to voting rights of fiduciaries, pledgors and joint owners of stock)
and Section&nbsp;218 (relating to voting trusts and other voting agreements) of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as may be otherwise provided in the
certificate of incorporation or these bylaws, each stockholder shall be entitled to one (1)&nbsp;vote for each share of capital stock held by such stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At all duly called or convened meetings of stockholders, at which a quorum is present, for the election of directors, a plurality of the votes
cast shall be sufficient to elect a director. Except as otherwise provided by the certificate of incorporation, these bylaws, the rules or regulations of any stock exchange applicable to the Corporation, or applicable law or pursuant to any
regulation applicable to the Corporation or its securities, all other elections and questions presented to the stockholders at a duly called or convened meeting, at which a quorum is present, shall be decided by the affirmative vote of the holders
of a majority in voting power of the votes cast affirmatively or negatively (excluding abstentions) at the meeting by the holders entitled to vote thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12 STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special
meeting of stockholders of the Corporation and may not be effected by any consent in writing by such stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.13 RECORD DATE FOR
STOCKHOLDER NOTICE; VOTING. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order that the Corporation may determine the stockholders entitled to notice of any meeting of
stockholders or any adjournment thereof, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board, and which record date shall, unless otherwise required
by law, not be more than sixty (60)&nbsp;nor less than ten (10)&nbsp;days </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
before the date of such meeting. If the Board so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board
determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board, the record date for determining stockholders entitled
to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the
meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <I>provided, however</I>, that the Board may fix a new record date for
determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of
stockholders entitled to vote in accordance herewith at the adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order that the Corporation may determine the
stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action,
the Board may fix a record date, which shall not be more than sixty (60)&nbsp;days prior to such other action. If no such record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on
the day on which the Board adopts the resolution relating thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.14 PROXIES.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy
authorized by an instrument in writing or by a transmission permitted by law filed in accordance with the procedure established for the meeting, but no such proxy shall be voted or acted upon after three (3)&nbsp;years from its date, unless the
proxy provides for a longer period. The revocability of a proxy that states on its face that it is irrevocable shall be governed by the provisions of Section&nbsp;212 of the DGCL. A proxy may be in the form of a telegram, cablegram or other means of
electronic transmission which sets forth or is submitted with information from which it can be determined that the telegram, cablegram or other means of electronic transmission was authorized by the stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.15 LIST OF STOCKHOLDERS ENTITLED TO VOTE.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officer who has charge of the stock ledger of the Corporation shall prepare and make, at least ten (10)&nbsp;days before every meeting of
stockholders, a complete list of the stockholders entitled to vote at the meeting (provided, however, if the record date for determining the stockholders entitled to vote is less than ten (10)&nbsp;days before the date of the meeting, the list shall
reflect the stockholders entitled to vote as of the tenth day before the date of the meeting), arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. The
Corporation shall not be required to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of at
least ten (10)&nbsp;days prior to the meeting: (a)&nbsp;on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (b)&nbsp;during ordinary
business hours, at the Corporation&#146;s principal executive office. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is
available only to stockholders of the Corporation. If the meeting is to be held at a place, then the list shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting is to be held solely by means of
remote communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with
the notice of the meeting. Except as otherwise provided by law, the stock ledger shall be the only evidence as to the identity of the stockholders entitled to vote in person or by proxy and the number of shares held by each of them, and as to the
stockholders entitled to examine the list of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.16 POSTPONEMENT AND CANCELLATION OF MEETING. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any previously scheduled annual or special meeting of the stockholders may be postponed, and any previously scheduled annual or special
meeting of the stockholders may be canceled, by resolution of the Board upon public notice given prior to the time previously scheduled for such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.17 INSPECTORS OF ELECTION. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before any meeting of stockholders, the Board shall appoint an inspector or inspectors of election to act at the meeting or its adjournment or
postponement and make a written report thereof. The number of inspectors shall be either one (1)&nbsp;or three (3). If any person appointed as inspector fails to appear or fails or refuses to act, then the chairperson of the meeting may, and upon
the request of any stockholder or a stockholder&#146;s proxy shall, appoint a person to fill that vacancy. Unless otherwise required by law, inspectors may be officers, employees or agents of the Corporation. Such inspectors shall have the duties
prescribed by law and shall take charge of the polls and, when the vote is completed, shall make a certificate of the result of the vote taken and of such other facts as may be required by law. The inspectors of election shall perform their duties
impartially, in good faith, to the best of their ability and as expeditiously as is practical. If there are three (3)&nbsp;inspectors of election, the decision, act or certificate of a majority is effective in all respects as the decision, act or
certificate of all. Any report or certificate made by the inspectors of election is prima facie evidence of the facts stated therein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III - DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 POWERS.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the
provisions of the DGCL and any limitations in the certificate of incorporation relating to action required to be approved by the stockholders or by the outstanding shares, the business and affairs of the Corporation shall be managed and all
corporate powers shall be exercised by or under the direction of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 NUMBER OF DIRECTORS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The authorized number of directors shall be determined from time to time by resolution of the Board, provided the Board shall consist of at
least one&nbsp;(1) member. No reduction of the authorized number of directors shall have the effect of removing any director before that director&#146;s term of office expires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in Section&nbsp;3.4 of these bylaws, each director, including, without limitation, a director elected to fill a vacancy,
shall hold office until the expiration of the term for which elected and until such director&#146;s successor is elected and qualified or until such director&#146;s earlier death, resignation or removal. Directors need not be stockholders unless so
required by the certificate of incorporation or these bylaws. The certificate of incorporation or these bylaws may prescribe other qualifications for directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so provided in the certificate of incorporation, the directors of the Corporation shall be divided into three (3)&nbsp;classes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 RESIGNATION AND VACANCIES.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any director may resign at any time upon notice given in writing or by electronic transmission to the Corporation. When one or more directors
so resigns and the resignation is effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation
or resignations shall become effective, and each director so chosen shall hold office as provided in this section in the filling of other vacancies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the certificate of incorporation or these bylaws, vacancies and newly created directorships resulting from any
increase in the authorized number of directors shall, unless the Board determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled only by a majority of the directors then in office,
although less than a quorum, or by a sole remaining director. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until
such director&#146;s successor shall have been elected and qualified. A vacancy in the Board shall be deemed to exist under these bylaws in the case of the death, removal or resignation of any director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5 PLACE OF MEETINGS; MEETINGS BY TELEPHONE.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may hold meetings, both regular and special, either within or outside the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of incorporation or these bylaws, members of the Board, or any committee designated by the
Board, may participate in a meeting of the Board, or any committee, by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a
meeting pursuant to this bylaw shall constitute presence in person at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6 REGULAR MEETINGS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regular meetings of the Board may be held without notice at such time and at such place as shall from time to time be determined by the Board.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7 SPECIAL MEETINGS; NOTICE.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special meetings of the Board for any purpose or purposes may be called at any time by the chairperson of the Board, the chief executive
officer, the president, the secretary or a majority of the authorized number of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of the time and place of special
meetings shall be: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">delivered personally by hand, by courier or by telephone; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">sent by United States first-class mail, postage prepaid; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">sent by facsimile; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">sent by electronic mail, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">directed to each director at that director&#146;s address, telephone number,
facsimile number or electronic mail address, as the case may be, as shown on the Corporation&#146;s records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the notice is
(a)&nbsp;delivered personally by hand, by courier or by telephone, (b)&nbsp;sent by facsimile or (c)&nbsp;sent by electronic mail, it shall be delivered or sent at least twenty-four (24)&nbsp;hours before the time of the holding of the meeting. If
the notice is sent by United States mail, it shall be deposited in the United States mail at least four (4)&nbsp;days before the time of the holding of the meeting. Any oral notice may be communicated to the director. The notice need not specify the
place of the meeting (if the meeting is to be held at the Corporation&#146;s principal executive office) nor the purpose of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.8 QUORUM.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The greater of
(a)&nbsp;a majority of the directors at any time in office and (b)&nbsp;one-third of the number of directors established by the Board pursuant to Section&nbsp;3.2 of these bylaws shall constitute a quorum of the Board for the transaction of
business. The vote of a majority of the directors present at any meeting at which a quorum is present shall be the act of the Board, except as may be otherwise specifically provided by statute, the certificate of incorporation or these bylaws. If a
quorum is not present at any meeting of the Board, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.9 BOARD ACTION BY CONSENT WITHOUT A MEETING.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of incorporation or these bylaws, any action required or permitted to be taken at any meeting
of the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing or by electronic transmission and the writing or writings or electronic transmission
or transmissions are filed with the minutes of proceedings of the Board or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.10 FEES AND COMPENSATION OF DIRECTORS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise restricted by the certificate of incorporation or these bylaws, the Board shall have the authority to fix the compensation of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.11 REMOVAL OF DIRECTORS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the rights of the holders of the shares of any series of Preferred Stock, the Board or any individual director may be removed from
office only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV - COMMITTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 COMMITTEES OF DIRECTORS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may designate one (1)&nbsp;or more committees, each committee to consist of one (1)&nbsp;or more of the directors of the
Corporation. The Board may designate one (1)&nbsp;or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a
committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of
any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board or in these bylaws, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs
of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority to (a)&nbsp;approve or adopt, or recommend to the stockholders, any action or
matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (b)&nbsp;adopt, amend or repeal any bylaw of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 COMMITTEE MINUTES.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each
committee shall keep regular minutes of its meetings and report the same to the Board when required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 MEETINGS AND ACTION OF
COMMITTEES.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Meetings and actions of committees shall be governed by, and held and taken in accordance with, the provisions of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Section&nbsp;3.5 of these bylaws (place of meetings and meetings by telephone); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Section&nbsp;3.6 of these bylaws (regular meetings); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Section&nbsp;3.7 of these bylaws (special meetings and notice); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Section&nbsp;3.8 of these bylaws (quorum); </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">Section&nbsp;7.12 of these bylaws (waiver of notice); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">Section&nbsp;3.9 of these bylaws (action without a meeting), </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with such changes in the context of those bylaws
as are necessary to substitute the committee and its members for the Board and its members. <I>However</I>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the time
of regular meetings of committees may be determined either by resolution of the Board or by resolution of the committee; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) special meetings of committees may also be called by resolution of the Board; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) notice of special meetings of committees shall also be given to all alternate members, who shall have the right to attend
all meetings of the committee. The Board may adopt rules for the government of any committee not inconsistent with the provisions of these bylaws. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V - OFFICERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1
OFFICERS.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The officers of the Corporation shall be a president and a secretary. The Corporation may also have, at the discretion of the
Board, a chairperson of the Board, a vice chairperson of the Board, a chief executive officer, a chief financial officer or treasurer, one (1)&nbsp;or more vice presidents, one (1)&nbsp;or more assistant vice presidents, one (1)&nbsp;or more
assistant treasurers, one (1)&nbsp;or more assistant secretaries, and any such other officers as may be appointed in accordance with the provisions of these bylaws. Any number of offices may be held by the same person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 APPOINTMENT OF OFFICERS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board shall appoint the officers of the Corporation, except such officers as may be appointed in accordance with the provisions of
Section&nbsp;5.3 of these bylaws, subject to the rights, if any, of an officer under any contract of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 SUBORDINATE
OFFICERS.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may appoint, or empower the chief executive officer or, in the absence of a chief executive officer, the president, to
appoint, such other officers and agents as the business of the Corporation may require. Each of such officers and agents shall hold office for such period, have such authority, and perform such duties as are provided in these bylaws or as the Board
may from time to time determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 REMOVAL AND RESIGNATION OF OFFICERS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the rights, if any, of an officer under any contract of employment, any officer may be removed, either with or without cause, by
the Board at any regular or special meeting of the Board or, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
except in the case of an officer chosen by the Board, by any officer upon whom such power of removal may be conferred by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any officer may resign at any time by giving written notice to the Corporation. Any resignation shall take effect at the date of the receipt
of that notice or at any later time specified in that notice. Unless otherwise specified in the notice of resignation, the acceptance of the resignation shall not be necessary to make it effective. Any resignation is without prejudice to the rights,
if any, of the Corporation under any contract to which the officer is a party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 VACANCIES IN OFFICES.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any vacancy occurring in any office of the Corporation shall be filled by the Board or as provided in Section&nbsp;5.2 of these bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 REPRESENTATION OF SHARES OF OTHER CORPORATIONS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chairperson of the Board, the president, any vice president, the treasurer, the secretary or assistant secretary of this Corporation, or
any other person authorized by the Board or the president or a vice president, is authorized to vote, represent and exercise on behalf of this Corporation all rights incident to any and all securities of any other entity or entities standing in the
name of this Corporation. The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 AUTHORITY AND DUTIES OF OFFICERS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All officers of the Corporation shall respectively have such authority and perform such duties in the management of the business of the
Corporation as may be designated from time to time by the Board and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI - RECORDS AND REPORTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 MAINTENANCE OF RECORDS.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Corporation shall, either at its principal executive office or at such place or places as designated by the Board, keep a record of its stockholders listing their names and addresses and the number and class of shares held by each stockholder, a
copy of these bylaws as amended to date, accounting books and other records. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII - GENERAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board, except as otherwise provided in these bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract
or execute any instrument in the name of and on behalf of the Corporation; such authority may be general or confined to specific instances. Unless so authorized or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ratified by the Board or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the Corporation by any contract or engagement or to pledge
its credit or to render it liable for any purpose or for any amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 STOCK CERTIFICATES; PARTLY PAID SHARES.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of the Corporation shall be represented by certificates or shall be uncertificated. Certificates for the shares of stock, if any,
shall be in such form as is consistent with the certificate of incorporation and applicable law. Every holder of stock represented by a certificate shall be entitled to have a certificate signed by, or in the name of the Corporation by the
chairperson or vice chairperson of the Board, or the president or vice president, and by the treasurer or an assistant treasurer, or the secretary or an assistant secretary of the Corporation representing the number of shares registered in
certificate form. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer,
transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer, transfer agent or registrar at the date of issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation may issue the whole or any part of its shares as partly paid and subject to call for the remainder of the consideration to be
paid therefor. Upon the face or back of each stock certificate issued to represent any such partly paid shares, or upon the books and records of the Corporation in the case of uncertificated partly paid shares, the total amount of the consideration
to be paid therefor and the amount paid thereon shall be stated. Upon the declaration of any dividend on fully paid shares, the Corporation shall declare a dividend upon partly paid shares of the same class, but only upon the basis of the percentage
of the consideration actually paid thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 SPECIAL DESIGNATION ON CERTIFICATES.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Corporation is authorized to issue more than one class of stock or more than one series of any class, then the powers, the
designations, the preferences and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full
or summarized on the face or back of the certificate that the Corporation shall issue to represent such class or series of stock; <I>provided, however</I>, that, except as otherwise provided in Section&nbsp;202 of the DGCL, in lieu of the foregoing
requirements, there may be set forth on the face or back of the certificate that the Corporation shall issue to represent such class or series of stock a statement that the Corporation will furnish without charge to each stockholder who so requests
the powers, the designations, the preferences and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4 LOST CERTIFICATES.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except
as provided in this Section&nbsp;7.4, no new certificates for shares shall be issued to replace a previously issued certificate unless the latter is surrendered to the Corporation and cancelled at the same time. The Corporation may issue a new
certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such
owner&#146;s legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5 CONSTRUCTION; DEFINITIONS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, the general provisions, rules of construction and definitions in the DGCL shall govern the construction
of these bylaws. Without limiting the generality of this provision, the singular number includes the plural, the plural number includes the singular, and the term &#147;person&#148; includes both a corporation and a natural person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.6 DIVIDENDS.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board,
subject to any restrictions contained in either (a)&nbsp;the DGCL or (b)&nbsp;the certificate of incorporation, may declare and pay dividends upon the shares of its capital stock. Dividends may be paid in cash, in property or in shares of the
Corporation&#146;s capital stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board may set apart out of any of the funds of the Corporation available for dividends a reserve or
reserves for any proper purpose and may abolish any such reserve. Such purposes shall include but not be limited to equalizing dividends, repairing or maintaining any property of the Corporation, and meeting contingencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.7 FISCAL YEAR.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fiscal
year of the Corporation shall be fixed by resolution of the Board and may be changed by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.8 SEAL.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation may adopt a corporate seal, which shall be adopted and which may be altered by the Board. The Corporation may use the
corporate seal by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.9 TRANSFER OF
STOCK.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of the Corporation shall be transferable in the manner prescribed by law and in these bylaws. Shares of stock of the
Corporation shall be transferred on the books of the Corporation only by the holder of record thereof or by such holder&#146;s attorney duly authorized in writing, upon surrender to the Corporation of the certificate or certificates representing
such shares endorsed by the appropriate person or persons (or by delivery of duly executed instructions with respect to uncertificated shares), with such evidence of the authenticity of such endorsement or execution, transfer, authorization and
other matters as the Corporation may reasonably require, and accompanied by all necessary stock transfer stamps. No transfer of stock shall be valid as against the Corporation for any purpose until it shall have been entered in the stock records of
the Corporation by an entry showing the names of the persons from and to whom it was transferred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.10 STOCK TRANSFER AGREEMENTS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock
of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.11 REGISTERED STOCKHOLDERS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) shall be
entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) shall be entitled to hold liable for calls and assessments the person registered on its books as the owner of shares; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of another person, whether
or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.12 WAIVER OF NOTICE.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever notice is required to be given under any provision of the DGCL, the certificate of incorporation or these bylaws, a written waiver,
signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to notice. Attendance of a
person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not
lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified in any written waiver of notice or any waiver by electronic transmission unless so
required by the certificate of incorporation or these bylaws. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII - NOTICE BY ELECTRONIC TRANSMISSION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 NOTICE BY ELECTRONIC TRANSMISSION.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without limiting the manner by which notice otherwise may be given effectively to stockholders pursuant to the DGCL, the certificate of
incorporation or these bylaws, any notice to stockholders given by the Corporation under any provision of the DGCL, the certificate of incorporation or these bylaws shall be effective if given by a form of electronic transmission consented to by the
stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written notice to the Corporation. Any such consent shall be deemed revoked if: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) the Corporation is unable to deliver by electronic transmission two (2)&nbsp;consecutive notices given by the Corporation in accordance
with such consent; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) such inability becomes known to the secretary or an assistant secretary of the Corporation or
to the transfer agent, or other person responsible for the giving of notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the inadvertent failure to treat such inability as a revocation
shall not invalidate any meeting or other action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any notice given pursuant to the preceding paragraph shall be deemed given: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of (i)&nbsp;such posting and (ii)&nbsp;the giving of such separate notice; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">if by any other form of electronic transmission, when directed to the stockholder. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An
affidavit of the secretary or an assistant secretary of the Corporation or of the transfer agent or other agent of the Corporation that the notice has been given by a form of electronic transmission shall, in the absence of fraud, be prima facie
evidence of the facts stated therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 DEFINITION OF ELECTRONIC TRANSMISSION.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of these bylaws, an &#147;electronic transmission&#148; means any form of communication, not directly involving the physical
transmission of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX - INDEMNIFICATION AND ADVANCEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1 ACTIONS, SUITS AND PROCEEDINGS OTHER THAN BY OR IN THE RIGHT OF THE CORPORATION. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation shall indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that he or she is or was, or has agreed to become, a director or officer of the
Corporation, or, while a director or officer of the Corporation, is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another
corporation, partnership, joint venture, trust or other enterprise (including, without limitation, any employee benefit plan) (all such persons being referred to hereafter as an &#147;<U>Indemnitee</U>&#148;), or by reason of any action alleged to
have been taken or omitted in such capacity, against all expenses (including, without limitation, attorneys&#146; fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee
Retirement Income Security Act of 1974), and amounts paid in settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and
in a manner which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.&nbsp;The
termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of <U>nolo contendere</U> or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith and in a manner
which Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his or her conduct was unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2 ACTIONS OR SUITS BY OR IN THE RIGHT OF THE CORPORATION.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation shall indemnify any Indemnitee who was or is a party to or threatened to be made a party to any threatened, pending or
completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that Indemnitee is or was, or has agreed to become, a director or officer of the Corporation, or, while a director or officer of
the Corporation, is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other
enterprise (including, without limitation, any employee benefit plan), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including, without limitation, attorneys&#146; fees) actually and
reasonably incurred by or on behalf of Indemnitee in connection with such action, suit or proceeding and any appeal therefrom, if Indemnitee acted in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, the
best interests of the Corporation, except that no indemnification shall be made under this Section&nbsp;9.2 in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged to be liable to the Corporation, unless, and only to
the extent, that the Court of Chancery of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of such liability but in view of all the circumstances of the case, Indemnitee
is fairly and reasonably entitled to indemnity for such expenses (including, without limitation, attorneys&#146; fees) which the Court of Chancery of Delaware or such other court shall deem proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3 INDEMNIFICATION FOR EXPENSES OF SUCCESSFUL PARTY.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provisions of this Article IX, to the extent that an Indemnitee has been successful, on the merits or otherwise, in
defense of any action, suit or proceeding referred to in Sections 9.1 and 9.2 of these bylaws, or in defense of any claim, issue or matter therein, or on appeal from any such action, suit or proceeding, Indemnitee shall be indemnified against all
expenses (including, without limitation, attorneys&#146; fees) actually and reasonably incurred by or on behalf of Indemnitee in connection therewith.&nbsp;Without limiting the foregoing, if any action, suit or proceeding is disposed of, on the
merits or otherwise (including, without limitation, a disposition without prejudice), without (a)&nbsp;the disposition being adverse to Indemnitee, (b)&nbsp;an adjudication that Indemnitee was liable to the Corporation, (c)&nbsp;a plea of guilty or
<U>nolo contendere</U> by Indemnitee, (d)&nbsp;an adjudication that Indemnitee did not act in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Corporation and (e)&nbsp;with respect to any
criminal proceeding, an adjudication that Indemnitee had reasonable cause to believe his or her conduct was unlawful, Indemnitee shall be considered for the purposes hereof to have been wholly successful with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4 NOTIFICATION AND DEFENSE OF CLAIM.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a condition precedent to an Indemnitee&#146;s right to be indemnified, such Indemnitee must notify the Corporation in writing as soon as
practicable of any action, suit, proceeding or investigation involving such Indemnitee for which indemnity will or could be sought.&nbsp;With respect to any action, suit, proceeding or investigation of which the Corporation is so notified, the
Corporation will be entitled to participate therein at its own expense and/or to assume the defense thereof at its own expense, with legal counsel reasonably acceptable to Indemnitee.&nbsp;After notice from the Corporation to Indemnitee of its
election so to assume such defense, the Corporation shall not be liable to Indemnitee for any legal or other expenses subsequently incurred by Indemnitee in connection with such action, suit, proceeding or investigation, other than as provided below
in this Section&nbsp;9.4.&nbsp;Indemnitee shall have the right to employ his or her own counsel in connection with such action, suit, proceeding or investigation, but the fees and expenses of such counsel incurred after notice from the Corporation
of its assumption of the defense thereof shall be at the expense of Indemnitee unless (a)&nbsp;the employment of counsel by Indemnitee has been authorized by the Corporation, (b)&nbsp;counsel to Indemnitee shall have reasonably concluded that there
may be a conflict of interest or position on any significant issue between the Corporation and Indemnitee in the conduct of the defense of such action, suit, proceeding or investigation or (c)&nbsp;the Corporation shall not in fact have employed
counsel to assume the defense of such action, suit, proceeding or investigation, in each of which cases the fees and expenses of counsel for Indemnitee shall be at the expense of the Corporation, except as otherwise expressly provided by this
Article IX.&nbsp;The Corporation shall not be entitled, without the consent of Indemnitee, to assume the defense of any claim brought by or in the right of the Corporation or as to which counsel for Indemnitee shall have reasonably made the
conclusion provided for in clause (b)&nbsp;above.&nbsp;The Corporation shall not be required to indemnify Indemnitee under this Article IX for any amounts paid in settlement of any action, suit, proceeding or investigation effected without its
written consent.&nbsp;The Corporation shall not settle any action, suit, proceeding or investigation in any manner which would impose any penalty or limitation on Indemnitee without Indemnitee&#146;s written consent.&nbsp;Neither the Corporation nor
Indemnitee will unreasonably withhold or delay its consent to any proposed settlement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5 ADVANCE OF EXPENSES.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of Sections 9.4 and 9.6 of these bylaws, in the event of any threatened or pending action, suit, proceeding or
investigation of which the Corporation receives notice under this Article IX, any expenses (including, without limitation, attorneys&#146; fees) incurred by or on behalf of Indemnitee in defending an action, suit, proceeding or investigation or any
appeal therefrom shall be paid by the Corporation in advance of the final disposition of such matter; <I>provided</I>, <I>however</I>, that the payment of such expenses incurred by or on behalf of Indemnitee in advance of the final disposition of
such matter shall be made only upon receipt of an undertaking by or on behalf of Indemnitee to repay all amounts so advanced in the event that it shall ultimately be determined by final judicial decision from which there is no further right to
appeal that Indemnitee is not entitled to be indemnified by the Corporation as authorized in this Article IX; and <I>provided further</I> that no such advancement of expenses shall be made under this Article IX if it is determined (in the manner
described in Section&nbsp;9.6 of these bylaws) that (a)&nbsp;Indemnitee did not act in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the Corporation, or (b)&nbsp;with respect to any
criminal action or proceeding, Indemnitee had reasonable cause to believe his or her conduct was unlawful.&nbsp;Such undertaking shall be accepted without reference to the financial ability of Indemnitee to make such repayment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6 PROCEDURE FOR INDEMNIFICATION AND ADVANCEMENT OF EXPENSES.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to obtain indemnification or advancement of expenses pursuant to Section&nbsp;9.1, 9.2, 9.3 or 9.5 of these bylaws, an Indemnitee
shall submit to the Corporation a written request.&nbsp;Any such advancement of expenses shall be made promptly, and in any event within 60 days after receipt by the Corporation of the written request of Indemnitee, unless (a)&nbsp;the Corporation
has assumed the defense pursuant to Section&nbsp;9.4 of these bylaws (and none of the circumstances described in Section&nbsp;9.4 of these bylaws that would nonetheless entitle the Indemnitee to indemnification for the fees and expenses of separate
counsel have occurred) or (b)&nbsp;the Corporation determines within such 60-day period that Indemnitee did not meet the applicable standard of conduct set forth in Section&nbsp;9.1, 9.2 or 9.5 of these bylaws, as the case may be.&nbsp;Any such
indemnification, unless ordered by a court, shall be made with respect to requests under Section&nbsp;9.1 or 9.2 of these bylaws only as authorized in the specific case upon a determination by the Corporation that the indemnification of Indemnitee
is proper because Indemnitee has met the applicable standard of conduct set forth in Section&nbsp;9.1 or 9.2 of these bylaws, as the case may be.&nbsp;Such determination shall be made in each instance (a)&nbsp;by a majority vote of the directors of
the Corporation consisting of persons who are not at that time parties to the action, suit or proceeding in question (&#147;<U>disinterested directors</U>&#148;), whether or not a quorum, (b)&nbsp;by a committee of disinterested directors designated
by majority vote of disinterested directors, whether or not a quorum, (c)&nbsp;if there are no disinterested directors, or if the disinterested directors so direct, by independent legal counsel (who may, to the extent permitted by law, be regular
legal counsel to the Corporation) in a written opinion or (d)&nbsp;by the stockholders of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.7 REMEDIES.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The right to indemnification or advancement of expenses as granted by this Article IX shall be enforceable by Indemnitee in any court of
competent jurisdiction.&nbsp;Neither the failure of the Corporation to have made a determination prior to the commencement of such action that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of
conduct, nor an actual determination by the Corporation pursuant to Section&nbsp;9.6 of these bylaws that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Indemnitee has not met the applicable standard of conduct.&nbsp;In any suit brought by Indemnitee to enforce a right to indemnification or advancement, or brought by the Corporation to recover an
advancement of expenses pursuant to the terms of an undertaking, the Corporation shall have the burden of proving that Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Article IX.&nbsp;Indemnitee&#146;s
expenses (including, without limitation, attorneys&#146; fees) reasonably incurred in connection with successfully establishing Indemnitee&#146;s right to indemnification or advancement, in whole or in part, in any such proceeding shall also be
indemnified by the Corporation to the fullest extent permitted by law.&nbsp;Notwithstanding the foregoing, in any suit brought by Indemnitee to enforce a right to indemnification hereunder it shall be a defense that the Indemnitee has not met any
applicable standard for indemnification set forth in the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.8 LIMITATIONS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Article IX, except as set forth in Section&nbsp;9.7 of these bylaws, the Corporation shall
not indemnify an Indemnitee pursuant to this Article IX in connection with a proceeding (or part thereof) initiated by such Indemnitee unless the initiation thereof was approved by the Board.&nbsp;Notwithstanding anything to the contrary in this
Article IX, the Corporation shall not indemnify (or advance expenses to) an Indemnitee to the extent such Indemnitee is reimbursed (or advanced expenses) from the proceeds of insurance, and in the event the Corporation makes any indemnification (or
advancement) payments to an Indemnitee and such Indemnitee is subsequently reimbursed from the proceeds of insurance, such Indemnitee shall promptly refund indemnification (or advancement) payments to the Corporation to the extent of such insurance
reimbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.9 SUBSEQUENT AMENDMENT.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No amendment, termination or repeal of this Article IX or of the relevant provisions of the DGCL or any other applicable laws shall adversely
affect or diminish in any way the rights of any Indemnitee to indemnification or advancement of expenses under the provisions hereof with respect to any action, suit, proceeding or investigation arising out of or relating to any actions,
transactions or facts occurring prior to the final adoption of such amendment, termination or repeal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.10 OTHER RIGHTS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indemnification and advancement of expenses provided by this Article IX shall not be deemed exclusive of any other rights to which an
Indemnitee seeking indemnification or advancement of expenses may be entitled under any law (common or statutory), agreement or vote of stockholders or disinterested directors or otherwise, both as to action in Indemnitee&#146;s official capacity
and as to action in any other capacity while holding office for the Corporation, and shall continue as to an Indemnitee who has ceased to be a director or officer, and shall inure to the benefit of the estate, heirs, executors and administrators of
Indemnitee.&nbsp;Nothing contained in this Article IX shall be deemed to prohibit, and the Corporation is specifically authorized to enter into, agreements with officers and directors providing indemnification and advancement rights and procedures
different from those set forth in this Article IX.&nbsp;In addition, the Corporation may, to the extent authorized from time to time by the Board, grant indemnification and advancement rights to other employees or agents of the Corporation or other
persons serving the Corporation and such rights may be equivalent to, or greater or less than, those set forth in this Article IX. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.11 PARTIAL INDEMNIFICATION.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an Indemnitee is entitled under any provision of this Article IX to indemnification by the Corporation for some or a portion of the
expenses (including, without limitation, attorneys&#146; fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974) or amounts paid in
settlement actually and reasonably incurred by or on behalf of Indemnitee in connection with any action, suit, proceeding or investigation and any appeal therefrom but not, however, for the total amount thereof, the Corporation shall nevertheless
indemnify Indemnitee for the portion of such expenses (including, without limitation, attorneys&#146; fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee Retirement
Income Security Act of 1974) or amounts paid in settlement to which Indemnitee is entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.12 INSURANCE.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation may purchase and maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the
Corporation or another corporation, partnership, joint venture, trust or other enterprise (including, without limitation, any employee benefit plan) against any expense, liability or loss incurred by him or her in any such capacity, or arising out
of his or her status as such, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.13 SAVINGS CLAUSE.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this
Article IX or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each Indemnitee as to any expenses (including, without limitation, attorneys&#146; fees),
liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974) and amounts paid in settlement in connection with any action, suit, proceeding or
investigation, whether civil, criminal or administrative, including, without limitation, an action by or in the right of the Corporation, to the fullest extent permitted by any applicable portion of this Article IX that shall not have been
invalidated and to the fullest extent permitted by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.14 DEFINITIONS.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Terms used in this Article IX and defined in Section&nbsp;145(h) and Section&nbsp;145(i) of the DGCL shall have the respective meanings
assigned to such terms in such Section&nbsp;145(h) and Section&nbsp;145(i). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X - AMENDMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the limitations set forth in Section&nbsp;9.9 of these bylaws or the provisions of the certificate of incorporation, the Board is
expressly empowered to adopt, amend or repeal the bylaws of the Corporation. The stockholders also shall have power to adopt, amend or repeal the bylaws of the Corporation; <I>provided, however</I>, that, in addition to any vote of the holders of
any class or series of stock of the Corporation required by law or by the certificate of incorporation, such action by stockholders shall require the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of
capital stock of the Corporation entitled to vote thereon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN DIAGNOSTICS, INC.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT AND RESTATEMENT OF BYLAWS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
hereby certifies that he or she is the duly elected, qualified, and acting Secretary of Exagen Diagnostics, Inc., a Delaware corporation, and that the foregoing bylaws were amended and restated effective as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 by the Corporation&#146;s board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned has hereunto set his or her hand this &nbsp;&nbsp;&nbsp;&nbsp; day of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2">Wendy Swedick, Chief Financial Officer and Secretary</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt"></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>d693329dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXAGEN CORPORATION </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>STOCK OPTION PLAN </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(as
amended) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Purposes of the Plan</U>. The purpose of this Stock Option Plan (as more fully defined as &#147;Plan&#148; below) is to
provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Corporation (as defined below). The Plan provides for options, which qualify as incentive stock options
pursuant to section&nbsp;422 of the Internal Revenue Code of 1986, as amended, as well as options, which do not so qualify. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.
<U>Effective Date and Duration of Plan</U>. The Plan will become effective immediately upon its adoption by the Board of Directors of the Corporation. The Plan is subject to approval by the shareholders of the Corporation within 12&nbsp;months
before or after the date the Board of Directors adopts the Plan. The Plan will terminate on December&nbsp;31, 2012, or at an earlier time as the Board of Directors may fix, and no Option will be granted under the Plan after that date. An Option
outstanding at the date of termination will remain in effect until it is exercised, expires, or is otherwise canceled, settled or terminated as provided herein or in a Stock Option Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Definitions</U>. The following terms are used throughout the Plan, and whenever used in the capitalized form, except as otherwise
expressly provided, the term will be deemed to have the following meaning: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. &#147;<U>Affiliate</U>&#148; means any individual,
corporation, partnership, association, joint-stock company, trust, unincorporated association or other entity (other than the Corporation) that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under
common control with the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. &#147;<U>Board of Directors</U>&#148; means the Board of Directors of the Corporation, or any
committee of the Board of Directors established and authorized by the Board of Directors to carry out the obligations of the Board of Directors under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. &#147;<U>Common Stock</U>&#148; means the shares of the common stock of the Corporation that is the subject of this Plan, whether now
issued or to be issued in the future, and any other stock or security resulting from adjustments made in Paragraph&nbsp;17. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">d.
&#147;<U>Corporation</U>&#148; means Exagen Corporation, and includes any successor or assignee corporation(s) into which the Corporation may be merged, changed or consolidated, any corporation for whose securities the securities of the Corporation
will be exchanged, and any assignee of or successor to substantially all of the assets of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">e. &#147;<U>Fair Market
Value</U>&#148; means the most recent value for this purpose based upon the good faith determination of the Board of Directors, or at the discretion of that board by an independent appraiser or appraisers selected by the board. If the stock is
publicly traded, the closing price of stock of that class as of the day in question (or, if such day is not a trading day in the principal securities market or markets for such stock, on the nearest preceding trading day),
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as reported with respect to the market (or the composite of markets, if more than one) in which shares of such stock are then traded. If no such closing prices are reported, then the Fair Market
Value will be determined on the basis of the mean between the high bid and low asking prices that day on the principal market or quotation system on which shares of such stock are then quoted, or, if not so quoted, as furnished by a professional
securities dealer making a market in such stock selected by or under authority of the Board of Directors of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">f.
&#147;<U>Greater Than 10% Shareholder</U>&#148; means a Participant who at the time of the grant of the Option owns more than ten percent of the total combined voting power of all classes of stock of the Corporation or its Affiliates. For purposes
of this definition, a Participant is considered to own the stock owned by the Participant&#146;s spouse, lineal descendants, parents, siblings, and grandparents, as well as a proportional interest of stock owned by a corporation, partnership, trust,
or estate of which the Participant is a shareholder, partner, or beneficiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">g. &#147;<U>Incentive Stock Option</U>&#148; means an
Option that is intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Code or any successor provision thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">h. &#147;<U>Management Objectives</U>&#148; means the achievement of performance objectives established pursuant to this Plan, which may be
described in terms of Corporation-wide objectives or objectives that are related to the performance of the individual Participant, or the division, department or function within the Corporation in which the Participant is employed or with respect to
which the Participant provides consulting services. The Board of Directors may adjust Management Objectives and the related minimum acceptable level of achievement if, in the sole judgment of the Board of Directors, events or transactions have
occurred after the Option Grant Date that are unrelated to the performance of the Participant and result in distortion of the Management Objectives or the related minimum acceptable level of achievement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">i. &#147;<U>Nonqualified Option</U>&#148; means an Option that is not intended to qualify as an Incentive Stock Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">j. &#147;<U>Option</U>&#148; means an Incentive Stock Option or Nonqualified Option to purchase Common Stock in the Corporation granted under
the Plan. To the extent that the aggregate Fair Market Value of stock to which Incentive Stock Options are exercisable for the first time by any Participant during any calendar year (under all plans of the Corporation and its Affiliates) exceeds
$100,000, such options will be treated as Nonqualified Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">k. &#147;<U>Option Grant Date</U>&#148; means the date on which the Board
of Directors authorizes the grant to a Participant of an Option to purchase shares of the Common Stock of the Corporation under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">l. &#147;<U>Option Price</U>&#148; means the price at which the Corporation&#146;s Common Stock may be purchased under an Option as provided
in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">m. &#147;<U>Participant</U>&#148; means a person who is selected by the Corporation to receive benefits under this Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">n. &#147;<U>Plan</U>&#148; means the Exagen Corporation Stock Option Plan, as set forth in this document and as amended from time to
time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">o. &#147;<U>Representative</U>&#148; means, if the Participant is living, but incapacitated, the
person or entity acting as the conservator, guardian or temporary guardian of the Participant or as his attorney-in-fact or agent under a valid durable power of attorney. If the Participant has died, then &#147;Representative&#148; means:
(a)&nbsp;the person or entity acting as the personal representative of a Participant&#146;s estate pursuant to the last will and testament of a Participant or appointed by a judge in an intestate probate action, or, if applicable, (b)&nbsp;the
person or entity which is the beneficiary of the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">p. &#147;<U>Stock Option Agreement</U>&#148; means an agreement entered
into between a Participant and the Corporation as described in paragraphs&nbsp;8 and 9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">q. &#147;<U>Stock Restriction Agreement</U>&#148;
means an agreement in the form prescribed by the Corporation whereby Stock is subject to certain restrictions and the Corporation is given certain rights to require the sale of stock upon the occurrence of certain events or, if a restriction is
violated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">r. &#147;<U>Termination</U>&#148; means, for purposes of this Plan with respect to a Participant, that the Participant no
longer is providing services as any of an employee, officer, Director or consultant to the Corporation. For determining whether and when a Participant has incurred a Termination of Employment for cause, &#147;cause&#148; will mean any act or
omission defined in any employment agreement or arrangement in existence on the date of Termination of Employment between the Participant and the Corporation or Affiliate which permits the Corporation or Affiliate to terminate the employment
agreement or arrangement between the Participant and the Corporation or Affiliate, for cause. In the event there is no employment agreement or arrangement in existence between the Participant and the Corporation or Affiliate at Termination of
Employment, or if the term &#147;cause&#148; is not defined in the employment agreement or arrangement, then &#147;cause&#148; will mean (a)&nbsp;any act or omission of a criminal nature, or any act of malfeasance or wrongdoing affecting the
Corporation or an Affiliate the result of which is detrimental to the interests of the Corporation or an Affiliate; (b)&nbsp;the material breach of a fiduciary duty owing to the Corporation or Affiliate, including without limitation, fraud and
embezzlement; (c)&nbsp;conduct or the omission of conduct on the part of the Participant which constitutes a material breach of any statutory or common-law duty of loyalty to the Corporation or its Affiliate; (d)&nbsp;the breach of any covenant not
to compete with the Corporation or its Affiliate; or (e)&nbsp;engaging in any act of disloyalty or any conduct clearly tending to bring discredit upon the Corporation or its Affiliate, or any conduct which causes or reasonably could cause
substantial harm to the Corporation or its Affiliate, as determined by the Board of Directors in their sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">s.
&#147;<U>Transfer</U>&#148; means any sale, gift, assignment, distribution, conveyance, pledge, hypothecation, encumbrance, or other transfer of title, whether by operation of law or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Stock Subject to the Plan</U>. Subject to adjustment as provided in paragraph&nbsp;17, an aggregate of 10,867,150&nbsp;shares of the
Corporation&#146;s common stock will be available for issuance pursuant to Options which may be granted under the Plan. The shares may be either authorized and unissued shares of Common Stock or issued shares of Common Stock that have been
reacquired by the Corporation and held as treasury shares. Options which remain unissued at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
termination of this Plan will cease to be reserved for the purpose of the Plan, but until termination of the Plan, the Corporation will at all times reserve a sufficient number of shares of Stock
to meet the requirements of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Terms of Options</U>. Options will be granted on such terms as the Board of Directors will
determine, but no Incentive Stock Option will be exercisable after ten years from the Option Grant Date. Notwithstanding the above, if an Incentive Stock Option is granted to a Participant who is a Greater Than 10% Shareholder at the time the
Incentive Stock Option is granted, the term with respect to such Incentive Stock Option will not be in excess of five years from the Option Grant Date. The term of any Incentive Stock Option may be subject to termination prior to the expiration of
the ten-year period as provided in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Release of Shares</U>. If any Option granted is subsequently cancelled, forfeited,
expires or is terminated for any reason without having been exercised, any shares of Common Stock subject to such Option will again be available and may thereafter be granted or otherwise applied under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Eligible Employees; Successive Grants</U>. Incentive Stock Options may be granted only to employees (including officers and directors
who are also employees) of the Corporation. Non Qualified Stock Options may be granted to employees, officers, directors and consultants of the Company, provided such consultants render bona fide services not in connection with the offer and sale of
securities in a capital-raising transaction. The Corporation, by action of the Board of Directors and subject to the provisions of the Plan, may grant Options to individuals selected by the Board of Directors of such number of shares as may be
determined by the Board of Directors. In making this selection the Board of Directors may give consideration to the functions and responsibilities of the respective individual, the present and potential contributions of such individual to the
Corporation, the value of the individual&#146;s service to the Corporation and such other factors deemed relevant by the Board of Directors. Successive grants may be made to the same Participant regardless of whether any Options previously granted
to the Participant remain unexercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Granting of Option</U>. The Corporation in its discretion may require as a condition of the
granting of an Option that a Participant make any representation or warranty to the Corporation as the Board of Directors may deem necessary to be required under any applicable law or regulation. This may include, but not be limited to a
representation or warranty that the shares are being acquired only for investment and without any present intention to sell or distribute such shares. An Option will be deemed to have been granted only when (i)&nbsp;the Board of Directors has
designated the Participant to receive an Option and determined the number of shares to be granted and the exercise price of the Option, and (ii)&nbsp;a Stock Option Agreement has been executed by the Corporation and delivered or mailed to the
selected individual. Nothing contained in the Plan or any resolution adopted or to be adopted by the Board of Directors, and no action taken by the Board of Directors will constitute the granting of any Option without the execution by the
Corporation of a Stock Option Agreement. In addition, any grants of Options will be subject to the following conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. Each grant
shall specify the conditions, if any, including as and to the extent determined by the Board of Directors, the period or periods of continuous employment, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continuous engagement of the consulting services, of the optionee by the Corporation, or the achievement of Management Objectives, that are necessary before the Option Rights or installments
thereof shall become exercisable, and any grant may provide for the acceleration of the exercise dates of an Option, including, without limitation, in the event of a change in control of the Corporation or other similar transaction or event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. Option Rights granted may be Nonqualified Options or Incentive Stock Options or combinations thereof, as set forth in the Stock Option
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. The aggregate Fair Market Value per share, determined as of the Option Grant Date, of the Common Stock for which any
Participant may be awarded Incentive Stock Options which are first exercisable by the Participant during any calendar year under this Plan (or any other stock option plan required to be taken into account under Section&nbsp;422(d) of the Code) shall
not exceed $100,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Acceptance of Option by Participant</U>. Any person selected to receive an Option must elect to accept the
Option under this Plan within ten business days after the date on which the Stock Option Agreement executed by the Corporation has been delivered or mailed to them. The person selected may elect to accept such Option by executing and delivering a
copy of the Stock Option Agreement to the Corporation, and will at that time become a &#147;Participant.&#148; No Option granted may be exercised prior to such acceptance. If the Option is not accepted, it will expire automatically at the end of the
ten-day period, unless extended in writing by the President of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Option Price</U>. The price per share of Common
Stock purchasable under Options granted pursuant to the Plan may be less than, equal to or greater than the Fair Market Value on the Option Grant Date, provided, however, that the Option Price with respect to each Incentive Stock Option shall not be
less than 100% (or 110%, in the case of an individual described in Section&nbsp;422(b)(6) of the Code (relating to certain 10% owners)) of the Fair Market Value on the Option Grant Date. The full Option Price for the shares purchased will be paid
when the Option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Exercise of Option in Installments</U>. The Board of Directors may provide that an Option will vest
over time and become exercisable in one or more installments. If the grant provides for the vesting of an Option on an installment basis, a Participant will have the right, after an Option has been granted and accepted by the Participant as provided
in the Plan, to purchase from the Corporation only those number of shares of Common Stock in which the Participant has vested in accordance with the dates and times provided for by the Board of Directors in the installment schedule included in the
Stock Option Agreement. A Participant has no right whatsoever to exercise any Option granted until such installment accrues as provided in the Stock Option Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Method of Exercising Option</U>. Subject to the terms and conditions of the Plan, the Participant or Representative may exercise the
Option by delivery of written notice of intent to exercise to the Corporation, at the corporate offices at 2704&nbsp;Yale Blvd. SE, Albuquerque, NM, 87106. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. Each notice must state the election to exercise the Option and the number of shares which are
being purchased, indicate in what name the certificate will be issued (including joint tenancy with right of survivorship between the Participant and another person, if so opted and if permitted under the Stock Option Agreement and Stock Restriction
Agreement), and will be signed by the Participant or Representative exercising the Option and, if Participant is married, by his or her spouse. If a Representative is exercising the Option, the Representative will attach proof, satisfactory to the
Corporation, of such person&#146;s right to exercise the Option as a Representative of the Participant. Each notice will be accompanied by a check payable to the order of the Corporation for the full purchase price for the shares being purchased. If
the Corporation is required to withhold on account of any present or future tax imposed as a result of such exercise, the notice of exercise will be accompanied by a check payable to the order of the Corporation for payment of the amount of any
withholding tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. If the Board of Directors requires the execution of a Stock Restriction Agreement, or other agreement, as a condition
of exercise of an Option, the Stock Restriction Agreement, or other agreement, will be executed by the Participant or Representative and, if Participant is married, by his or her spouse before any certificate for Common Stock is issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. The Corporation will deliver the certificate representing the shares of Common Stock purchased as soon as practicable after receipt of the
notice, the payment and the signed Stock Restriction Agreement (if applicable). The certificate evidencing the ownership of the Common Stock of the Corporation will be registered in the name of the person indicated in the notice, or if none, then in
the name of the Participant or Representative. The certificate will be delivered to the Participant or Representative as provided in the notice, or to others, if so provided in the notice. All shares of Common Stock that will be purchased upon the
exercise of the Option as provided in the Plan will be fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Nontransferability of Options</U>. Except as
provided in the Plan or the Stock Option Agreement, no Participant, Representative, or any other person or entity may Transfer an Option in any way (whether by operation of law or otherwise), other than by will or the laws of descent and
distribution. The Option is exercisable during a Participant&#146;s lifetime only by the Participant or his Representative. The Option will not be subject to execution, attachment, or similar process. Any attempted Transfer contrary to the
provisions of the Plan or the Stock Option Agreement, and the levy, attachment, or any similar process upon the Option will be null and void and without effect. The Corporation will have the right to terminate the Option in the event of any Transfer
of the Option, or levy, attachment or similar process, by notice to that effect to the person entitled to exercise the Option under the Plan, provided that termination of the Option will not prejudice any rights or remedies which the Corporation may
have under the Plan, the Stock Option Agreement, or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Termination</U>. In the event that the Participant is terminated,
any unexercised Incentive Stock Options held by the Participant must be exercised as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. Within twelve (12)&nbsp;months after
Termination of Employment if such termination is the result of the Participant&#146;s disability as defined in Internal Revenue Code Section&nbsp;22(e)(3), or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. Within three (3)&nbsp;months after Termination of Employment, if such termination is for any
other reason, except the death or disability of the Participant or as provided in paragraph&nbsp;14.c. below. Any unexercised Option at the end of the three-month period will expire automatically. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. The Corporation may cancel and rescind grants of Options if the Termination of Employment is for cause, or if during the three-month period
after Termination of Employment, the former employee engages in conduct, which would have constituted cause for Termination of Employment. This is at the sole discretion of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Death of a Participant</U>. If a Participant is terminated because of Participant&#146;s death (or the Participant dies within three
months after a Termination other than for Cause), then Participant&#146;s Option may be exercised, to the extent that the Participant will have been entitled to do so at the date of his death, by his Representative within twelve months of the date
of the Participant&#146;s death, unless the Option expires earlier by its own terms or by the terms of the Plan. Any portion of the Option, which is not exercised at the end of the twelve-month period, will expire automatically. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Administration of the Plan</U>. The Board of Directors of the Corporation will administer the Plan. Subject to the provisions of the
Plan, the Board of Directors may adopt such rules and regulations for interpreting and carrying out this Plan, as it may deem necessary, desirable or convenient. All questions of interpretation and application of the Plan and any Options issued
under it will be determined solely by the Board of Directors. The determination of the Board of Directors will be final and binding upon all parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. <U>Powers of the Board of Directors</U>. In particular, the Board of Directors will have the authority to determine the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) The Participants who will be granted Options; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) The number of Options to be made available; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) The number of shares of Common Stock to be covered by each Option; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(4) The Option Price, subject to the limits established in the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(5) The times at which such Options will be granted; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(6) The conditions on exercise of any Options; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(7) Additional terms, conditions and restrictions in the Stock Option Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(8) When or whether a Participant is disabled (based upon written opinions from two medical doctors); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(9) Whether and for what reason an employee of Corporation has incurred a Termination of
Employment; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(10) Appointment and compensation of agents, counsel, auditors or other specialists to aid it in the discharge of its
duties; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(11) Construction and interpretation of this Plan and any Stock Option Agreement and all other actions and determinations
deemed necessary or advisable for the administration of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. <U>Authority to Require Conditions Precedent</U>. The Board of
Directors may impose upon any and all Participants any conditions precedent to the receipt of Options under this Plan which it may deem appropriate to assure that the Corporation will secure the expected benefits from granting such Options,
including, without limitation a requirement that a Participant agree to remain in the employ of the Corporation for a specified period or that a Participant agree in writing that, in the event the Participant ceases to be an employee, director,
officer, advisor or consultant of the Corporation for any reason, he will not, for a specified period from the date of such cessation, engage in any activity or business which would be competitive with the business of the Corporation, or that the
Participant will not disclose any trade secrets of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. <U>Modifications to the Plan</U>: The Corporation&#146;s Board of
Directors may at any time and from time to time modify and amend the Plan in such manner as the Board of Directors deems advisable, but may not, without the approval of the Corporation&#146;s shareholders, make any alteration in the Plan (except as
provided in Paragraph&nbsp;17) which operates (i)&nbsp;to increase the total number of shares which may be issued under the Plan, (ii)&nbsp;to extend the term during which Options may be granted under the Plan, (iii)&nbsp;to permit the exercise of
an Option after the date on which the Option would otherwise expire pursuant to its terms or (iv)&nbsp;to reduce the Option price per share after the Option is granted. No notice to eligible employees, Participants, or Representatives need be given
by the Board of Directors upon a modification. The Board may not amend the Plan in any manner which would have the effect of preventing Incentive Stock Options issued under the Plan from being incentive stock options as defined in Section&nbsp;422
of the Internal Revenue Code of 1986, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">d. <U>Termination of the Plan</U>. The Board of Directors may terminate the Plan at any
time upon 30&nbsp;days written notice to the Participants or Representatives of the date fixed for termination, provided however that no such action shall deprive a Participant, without his or her consent, of any Option granted pursuant to the Plan
unless the termination of the Plan is a result of the occurrence of an event specified in Paragraph&nbsp;17. Upon the occurrence of an event specified in Paragraph&nbsp;17 and a decision by the Board of Directors to terminate the plan, the
Participant or Representative may exercise Options at any time during the <FONT STYLE="white-space:nowrap">30-day</FONT> period, unless the Option expired earlier. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Adjustments</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a.
<U>Changes in Capital Structure</U>: In the event that the outstanding shares of the Corporation&#146;s Common Stock is changed by a stock dividend, recapitalization, stock split, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reverse stock split, subdivision, combination, reclassification or similar change in the capital structure of the Corporation without consideration, then (a)&nbsp;the number of shares reserved
for issuance under this Plan, and (b)&nbsp;the Exercise Prices of and number of shares subject to outstanding Options will be proportionately adjusted, subject to any required action by the Board or the shareholders of the Company and compliance
with applicable securities laws; provided, however, that fractions of a share will not be issued but will either be paid in cash at Fair Market Value of such fraction of a share or will be rounded down to the nearest whole share, as determined by
the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. <U>Dissolution or Liquidation</U>: In the event of the dissolution or liquidation of the Corporation, any
Option granted under the Plan will expire as of the date to be fixed by the Board of Directors pursuant to Paragraph&nbsp;16.d. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c.
<U>Corporate Transaction</U>: The term &#147;Corporate Transaction&#148; will mean (i)&nbsp;a merger or consolidation in which securities possessing more than 50% of the total combined voting power of the Corporation&#146;s outstanding securities
are transferred to a person or persons different from the persons holding those securities immediately prior to such transaction or (ii)&nbsp;the sale, transfer or other disposition of all or substantially all of the Corporation&#146;s assets in
complete liquidation or dissolution of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of any Corporate Transaction, each outstanding option shall
accelerate so that each such option shall, immediately prior to the effective date of the Corporate Transaction, become fully exercisable for all of the shares of Common Stock at the time subject to such option and may be exercised for any or all of
those shares as fully vested shares of Common Stock. However, an outstanding option under the Plan shall not so accelerate if and to the extent the acceleration of such option is subject to other limitations imposed by the Board of Directors at the
time of the option grant and recorded in the agreements evidencing such option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Immediately following the consummation of the Corporate
Transaction, all outstanding options shall terminate and cease to be outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Participant&#146;s Employment</U>. Nothing in
this Plan or related documents will be construed to create or imply any contract of employment between a Participant and the Corporation or confer upon the Participant any right to continue in the employ of the Corporation, nor will it affect or
restrict the right of the Corporation to terminate such employment at any time. Unless otherwise expressly set forth in a separate employment agreement between the Participant and the Corporation or its subsidiaries, the employment of a Participant
is at-will, and the Participant or Corporation may terminate employment at any time for any reason, with or without cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>No
Rights of Shareholder</U>. No Participant or Representative will have rights as a shareholder with respect to any shares covered by an Option until the date of issuance of a stock certificate for shares of Common Stock, following the exercise of an
Option. No Participant or Representative will have rights with respect to dividends or other distributions for which a record date is established prior to the date the stock certificate is issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>No Obligation to Disclose</U>. The Corporation will have no duty or obligation to
affirmatively disclose to an employee, Participant or Representative any material information regarding the Corporation at any time prior to or in connection with the grant or exercise of an Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Restriction on Issuance of Shares</U>. Each Option granted under the Plan will be subject to the requirement that if the Board of
Directors determines in its sole discretion that the listing, registration or qualification on any securities exchange or pursuant to any state or federal law, or the consent or approval of any governmental regulatory body is necessary or desirable
in connection with the granting of the shares covered by the Option or the purchase of such shares, then no Option may be exercised in whole or in part unless such listing, registration, qualification, consent or approval has been effected or
obtained free of any conditions not acceptable to the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Registration Under Securities Laws</U>. The Common
Stock, which is the subject of these Options, has not been registered under the Securities Act of 1933. Therefore, all shares of stock issued upon exercise of an Option must be held for investment purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>Legend</U>. All shares of stock issued pursuant to the Plan and the Stock Option Agreement will bear a legend stating the following
restriction or an abbreviation thereof: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;The shares of stock represented by this certificate (1)&nbsp;have not been registered under
the Securities Act of 1933 or under the securities laws of any state and may not be sold or transferred except upon such registration or upon receipt by the Corporation of an opinion of counsel satisfactory to the Corporation, that registration is
not required for such sale or transfer; and (2)&nbsp;are subject to certain restrictions upon the transfer thereof, and to certain rights and obligations, all as more specifically set forth in the Exagen Corporation Stock Option Plan and the Exagen
Corporation Stock Option Agreement. Copies of the Plan and the Stock Option Agreement are available for inspection at the registered office of the Corporation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. <U>Consultation With Advisors</U>. Each Participant or Representative is expected to consult his own advisors with respect to the tax and
securities consequences of holding an Option or exercising an Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25. <U>Indemnification</U>. In addition to any other rights of
indemnification granted by a third party or by law, the Corporation will indemnify, defend and hold harmless the Board of Directors (collectively), and the individual members of the Board of Directors, against the reasonable expenses, (including
attorneys&#146; fees), actually and necessarily incurred in connection with the defense of any action, suit or proceeding, or any threat thereof, or in connection with any appeal, to which they or any of them may be a party by reason of any act or
omission in connection with the Plan or any Option granted by them, and against all amounts paid by them in settlement thereof (provided such settlement is approved by legal counsel selected by the Corporation) or paid by them in satisfaction of a
judgment in any action, suit or proceeding, unless it is adjudged in such action, suit or proceeding that such indemnified party is liable for gross negligence or gross misconduct in the performance of his duties; provided that within
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
60&nbsp;days after institution of any such action, suit or proceeding the indemnified party may in writing elect to defend the same at its sole expense, and if such election is made, the
Corporation will have no further liability or obligations to the indemnified party under this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. <U>Governing Law</U>. The Plan
will be governed by the law of the State of New Mexico (other than its law respecting choice of law), and will be interpreted under, construed under and enforced pursuant to the internal laws of the state of New Mexico applicable to agreements made
and to be performed wholly within the State of New Mexico. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27. <U>Severability</U>. If any provision of this Plan is for any reason held
to be invalid or unenforceable, such invalidity or unenforceability will not affect any other provision thereof, and this Plan will be construed as if such invalid or unenforceable provision were omitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28. <U>Binding Effect</U>. Any actions taken under the provisions of this Plan and any rules adopted by the Board of Directors will bind the
Corporation and all recipients of Options pursuant to this Plan. This Plan will inure to the benefit of and be binding upon the Corporation, its employees, and their respective successors, heirs and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29. <U>Withholding Taxes</U>. To the extent that the Corporation is required to withhold federal, state, local or foreign taxes in connection
with any payment made or benefit realized by a Participant or other person under this Plan, and the amounts available to the Corporation for the withholding are insufficient, it shall be a condition to the receipt of any such payment or the
realization of any such benefit that the Participant or such other person make arrangements satisfactory to the Corporation for payment of the balance of any taxes required to be withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30. <U>Certain Terminations of Employment or Consulting Services, Hardships and Approved Leaves of Absence</U>. Notwithstanding any other
provision of this Plan to the contrary, in the event of termination of employment or consulting services by reason of death, disability, normal retirement, early retirement, with the consent of the Corporation, termination of employment or
consulting services to enter public service with the consent of the Corporation or leave of absence approved by the Corporation, or in the event of hardship or other special circumstances, of a Participant who holds an Option that is not immediately
and fully exercisable, the Board of Directors may take any action that it deems to be equitable under the circumstances or in the best interests of the Corporation, including without limitation, waiving or modifying any limitation or requirement
with respect to any award under this Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN DIAGNOSTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STOCK OPTION AGREEMENT&nbsp;&nbsp; # [&nbsp;&nbsp;&nbsp;&nbsp;] </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This Stock Option Agreement (&#147;<U>Agreemen</U>t&#148;) is made and entered into effective as of the Date of Grant set forth below (the
&#147;<U>Date&nbsp;of&nbsp;Grant</U>&#148;) by and between Exagen Diagnostics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and the participant named below (&#147;<U>Participant</U>&#148;) pursuant to the Company&#146;s Stock
Option Plan (the &#147;<U>Plan</U>&#148;). Capitalized terms not defined herein will have the meaning ascribed to such terms in the Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Participant:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Social&nbsp;Security&nbsp;Number:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Address:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Total Option Shares:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise&nbsp;Price&nbsp;Per&nbsp;Share:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date of Grant:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Dates:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Expiration Date:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Type of Stock Option</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><I></I></B><B>(</B><B><I>Check one</I></B><B>):</B><B><I></I></B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>[&nbsp;&nbsp;&nbsp;&nbsp;] Incentive Stock Option</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>[&nbsp;&nbsp;&nbsp;&nbsp;] Nonqualified Stock Option</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Grant&nbsp;of&nbsp;Option</U>. The Company hereby grants to Participant an option (the
&#147;<U>Option</U>&#148;) to purchase the total number of shares of Common Stock ($.001 par value per share) of the Company set forth above (the &#147;<U>Shares</U>&#148;) at the Exercise Price Per Share set forth above (the &#147;<U>Exercise
Price</U>&#148;), subject to all of the terms and conditions of this Agreement and the Plan. In consideration of and as a precondition to the grant of the Option, Participant, on behalf of Participant and all persons or parties claiming through the
Participant, including any successor or assign, as of the date hereof forever waives, releases, discharges and covenants not to sue the Company or its successors, assigns, shareholders, affiliates, partners, officers, directors, employees, agents,
attorneys, accountants, and representatives from or on any and all past, present, or future claims, demands, causes of action, suits, damages, costs, expenses, losses, liabilities or obligations, whatsoever, whether at law or equity, know or
unknown, arising directly or indirectly from or in connection with any stock option previously granted to Participant by the Company. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Exercise&nbsp;Period</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.1 <U>Exercise Period of Option</U>. As stated pursuant to the vesting dates above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.2 <U>Vesting of Options</U>. Shares that are vested pursuant to the schedule set forth in Section&nbsp;2.1 hereof are &#147;<U>Vested
Shares</U>&#148;. Shares that are not vested pursuant to the schedule set forth in Section&nbsp;2.1 hereof are &#147;<U>Unvested Shares</U>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.3 <U>Expiration</U>. These Options will expire on the Expiration Date set forth above and must be exercised, if at all, on or before the
Expiration Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination</U>. If Participant is terminated for Cause, then this Option will expire on Participant&#146;s
Termination Date, or at such later time and on such conditions as determined by the Board of Directors. In the event of termination for any other reason, this Option will be exercisable, as to Vested Shares, in accordance with the terms of the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Non-transferability&nbsp;of&nbsp;Option</U>. This Option may not be transferred in any manner other than by will or the laws of
descent and distribution and, during the Participant&#146;s lifetime, may be exercised only by Participant. The terms of this Option will be binding upon the successors and assigns of Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Tax&nbsp;Consequences</U>. Set forth below is a brief summary as of the Effective Date of the Plan of some of the tax consequences of
exercise of this Option and disposition of the Shares. THIS SUMMARY IS NECESSARILY INCOMPLETE, AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE. PARTICIPANT SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THE OPTION OR DISPOSING OF THE SHARES.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.1 <U>Exercise&nbsp;of&nbsp;ISO</U>. If this Option qualifies as an ISO, there will be no regular federal or state income tax liability
upon the exercise of this Option, although the excess, if any, of the Fair Market Value of the Shares on the date of exercise over the Exercise Price will be treated as a tax preference item for federal income tax purposes and may subject the
Participant to the alternative minimum tax in the year of exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.2 <U>Exercise&nbsp;of&nbsp;Nonqualified&nbsp;Stock&nbsp;Option</U>.
If this Option does not qualify as an ISO, there may be a regular federal and state income tax liability upon the exercise of this Option. Participant will be treated as having received compensation income (taxable at ordinary income tax rates)
equal to the excess, if any, of the Fair Market Value of the Shares on the date of exercise over the Exercise Price. If Participant is or was an employee of the Company, the Company will be required to withhold from Participant&#146;s compensation
or collect from Participant and pay to the applicable taxing authorities an amount equal to a percentage of this compensation income at the time of exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Governing Plan Document</U>. The Option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of
the Option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of the Option and those of
the Plan, the provisions of the Plan shall control. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Entire&nbsp;Agreement</U>. The Plan is incorporated herein by reference. A copy of the Plan
may be obtained from the Corporation. This Agreement and the Plan constitute the entire agreement of the parties and supersede all prior undertakings and agreements with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Acceptance</U>. Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. Participant has read and understands
the terms and provisions thereof, and accepts this Option subject to all the terms and conditions of the Plan and this Agreement. Participant acknowledges that there may be adverse tax consequences upon exercise of this Option or disposition of the
Shares and that Participant should consult a tax adviser prior to such exercise or disposition. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXAGEN DIAGNOSTICS, INC:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><B>PARTICIPANT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Name</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>d693329dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXAGEN DIAGNOSTICS, INC. </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>2013 STOCK OPTION PLAN </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Purposes of the Plan</U>. This purpose of this Stock Option Plan (as more fully defined as &#147;Plan&#148; below) is to provide
incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Corporation (as defined below). The Plan provides for options, which qualify as incentive stock options
pursuant to Section&nbsp;422 of the Code as well as options which do not so qualify. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Effective Date and Duration of Plan</U>. The
Plan will become effective immediately upon its adoption by the Board of Directors of the Corporation. The Plan is subject to approval by the shareholders of the Corporation within 12 months before or after the date the Board of Directors adopts the
Plan. The Plan will terminate on December&nbsp;31, 2022, or at an earlier time as the Board of Directors may fix, and no Option will be granted under the Plan after that date. An Option outstanding at the date of termination will remain in effect
until it is exercised, expires, or is otherwise canceled, settled or terminated as provided herein or in the applicable Stock Option Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Definitions</U>. The following terms are used throughout the Plan, and whenever used in the capitalized form, except as otherwise
expressly provided, the term will be deemed to have the following meaning: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. &#147;<U>Affiliate</U>&#148; means any individual,
corporation, partnership, association, joint-stock company, trust, unincorporated association or other entity (other than the Corporation) that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under
common control with the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. &#147;<U>Board of Directors</U>&#148; means the Board of Directors of the Corporation, or any
committee of the Board of Directors established and authorized by the Board of Directors to carry out the obligations of the Board of Directors under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. &#147;<U>Cause</U>&#148; means: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) any act or omission defined in any employment agreement or arrangement in existence on the date of Termination between the Participant
and the Corporation or Affiliate which permits the Corporation or Affiliate to terminate the employment agreement or arrangement between the Participant and the Corporation or Affiliate, for cause, or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) in the event there is no employment agreement or arrangement in existence between the Participant and the Corporation or Affiliate at
Termination, or if the term &#147;cause&#148; is not defined in the employment agreement or arrangement, &#147;Cause&#148; means (a)&nbsp;any act or omission of a criminal nature, or any act of malfeasance or wrongdoing affecting the Corporation or
an Affiliate the result of which is detrimental to the interests of the Corporation or an Affiliate; (b)&nbsp;the material breach of a fiduciary duty owing to the Corporation or Affiliate, including without limitation, fraud and embezzlement;
(c)&nbsp;conduct or the omission of conduct on the part of the Participant which constitutes a material breach of any statutory or common-law duty of loyalty to the Corporation or its Affiliate; (d)&nbsp;the breach of any covenant not to compete
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the Corporation or its Affiliate; or (e)&nbsp;engaging in any act of disloyalty or any conduct clearly tending to bring discredit upon the Corporation or its Affiliate, or any conduct which
causes or reasonably could cause substantial harm to the Corporation or its Affiliate, as determined by the Board of Directors in their sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">d. &#147;<U>Common Stock</U>&#148; means the shares of the common stock of the Corporation that are the subject of this Plan under Paragraph
4, whether now issued or to be issued in the future, and any other stock or security resulting from adjustments made in Paragraph 16. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">e.
&#147;<U>Code</U>&#148; means the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">f.
&#147;<U>Corporation</U>&#148; means Exagen Diagnostics, Inc., and includes any successor or assignee corporation(s) into which the Corporation may be merged, changed or consolidated, any corporation for whose securities the securities of the
Corporation will be exchanged, and any assignee of or successor to substantially all of the assets of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">g.
&#147;<U>Disability</U>&#148; means &#147;disability&#148; as defined in Section&nbsp;22(e)(3) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">h. &#147;<U>Fair Market
Value</U>&#148; means the price per share of Common Stock on any relevant date as determined in accordance with the following provisions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) If the Common Stock is at the time listed on any stock exchange, then the Fair Market Value shall be the closing selling price per share
of Common Stock on the date in question on the stock exchange determined by the Board of Directors to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange and published
in The Wall Street Journal. If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) If the Common Stock is at the time not listed on any stock exchange, then the Fair Market Value shall be determined by the Board of
Directors in accordance with Section&nbsp;409A of the Code after taking into account such factors as the Board of Directors shall deem appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">i. &#147;<U>Greater Than 10% Shareholder</U>&#148; means a Participant who at the time of the grant of the Option owns more than ten percent
of the total combined voting power of all classes of stock of the Corporation or its Affiliates after taking into account the constructive ownership rules of Section&nbsp;424(d) of the Code. For purposes of this definition, a Participant is
considered to own the stock owned, directly or indirectly, by or for the Participant&#146;s, spouse, ancestors (such as parents and grandparents), lineal descendants, and siblings (whether by whole or half blood), as well as a proportional interest
of stock owned, directly or indirectly, by or for a corporation, partnership, trust, or estate of which the Participant is a shareholder, partner, or beneficiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">j. &#147;<U>Incentive Stock Option</U>&#148; means an Option that is intended to qualify as an &#147;incentive stock option&#148; under
Section&nbsp;422 of the Code or any successor provision thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">k. <U>&#147;Management Objectives&#148;</U> means the performance objectives established pursuant
to this Plan, which may include, but not be limited to, (1)&nbsp;objectives relating to Corporation-wide performance or (2)&nbsp;objectives relating to the performance of a Participant, the division, department or function within the Corporation or
an Affiliate by which a Participant is employed or with respect to which the Participant provides consulting services. The Board of Directors may adjust Management Objectives and the related minimum acceptable level of achievement if, in the sole
judgment of the Board of Directors, events or transactions have occurred after the Option Grant Date that are unrelated to the performance of the Participant and result in distortion of the Management Objectives or the related minimum acceptable
level of achievement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">l. &#147;<U>Nonqualified Option</U>&#148; means an Option that is not intended to qualify as an Incentive Stock
Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">m. &#147;<U>Option</U>&#148; means an Incentive Stock Option or Nonqualified Option to purchase Common Stock in the Corporation
granted under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">n. &#147;<U>Option Grant Date</U>&#148; means the date on which the Board of Directors authorizes the grant to a
Participant of an Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">o. &#147;<U>Option Price</U>&#148; means the price at which the Corporation&#146;s Common Stock may be
purchased under an Option as provided in the applicable Stock Option Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">p. &#147;<U>Participant</U>&#148; means a person who is
selected by the Corporation to receive an Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">q. &#147;<U>Plan</U>&#148; means the Exagen Diagnostics, Inc. 2013 Stock Option Plan,
as set forth in this document and as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">r. &#147;<U>Representative</U>&#148; means, if the Participant is living,
but incapacitated, the person or entity acting as the conservator, guardian or temporary guardian of the Participant or as his attorney-in-fact or agent under a valid durable power of attorney. If the Participant has died, then
&#147;Representative&#148; means: (a)&nbsp;the person or entity acting as the personal representative of a Participant&#146;s estate pursuant to the last will and testament of a Participant or appointed by a judge in an in testate probate action,
or, if applicable, (b)&nbsp;the person or entity which is the beneficiary of the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">s. &#147;<U>Stock Option
Agreement</U>&#148; means an agreement entered into between a Participant and the Corporation as described in Paragraphs 7 and 8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">t.
&#147;<U>Stock Restriction Agreement</U>&#148; means an agreement in the form prescribed by the Corporation whereby stock of the Corporation is subject to certain restrictions and the Corporation is given certain rights to require the sale of stock
upon the occurrence of certain events or, if a restriction is violated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">u. &#147;<U>Termination</U>&#148; means, for purposes of this
Plan with respect to a Participant, that the Participant no longer is providing services to the Corporation as an employee, officer, director or consultant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">v. &#147;<U>Transfer</U>&#148; means any sale, gift, assignment, distribution, conveyance,
pledge, hypothecation, encumbrance, or other transfer of title, whether by operation of law or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Stock Subject to the
Plan</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. Subject to adjustment as provided in Paragraph 16, an aggregate of 1,708,080 shares of the Corporation&#146;s common stock
will be available for issuance pursuant to the grant of Options. The shares will be authorized and either unissued or issued shares of common stock of the Corporation that have been reacquired by the Corporation and held as treasury shares. Options
which remain unissued at the termination of this Plan will cease to be reserved for the purpose of the Plan, but until termination of the Plan, the Corporation will at all times reserve a sufficient number of shares of common stock of the
Corporation to meet the requirements of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. If any Option granted is subsequently cancelled, forfeited, expires or is terminated
for any reason without having been exercised, any shares of Common Stock subject to such Option will again be available and may thereafter be granted or otherwise applied under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Term of Options</U>. Options will be granted for such terms as the Board of Directors will determine, but no Incentive Stock Option will
be exercisable after ten years from the Option Grant Date. Notwithstanding the above, if an Incentive Stock Option is granted to a Participant who is a Greater Than 10% Shareholder at the time the Incentive Stock Option is granted, the term with
respect to such Incentive Stock Option will not be in excess of five years from the Option Grant Date. The term of any Incentive Stock Option may be subject to termination prior to the expiration of the ten-year period (or five-year period in the
case of a Greater Than 10% Shareholder) as provided in the Plan or applicable Stock Option Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Eligible Employees;
Successive Grants</U>. Incentive Stock Options may be granted only to employees (including officers and directors who are also employees) of the Corporation. Nonqualified Options may be granted to employees, officers, directors and consultants of
the Company, provided that such consultants render bona fide services not in connection with the offer and sale of securities in a capital-raising transaction. The Corporation, by action of the Board of Directors and subject to the provisions of the
Plan, may grant Options to individuals selected by the Board of Directors of such number of shares as may be determined by the Board of Directors. In making this selection the Board of Directors may give consideration to the functions and
responsibilities of the respective individual, the present and potential contributions of such individual to the Corporation, the value of the individual&#146;s service to the Corporation and such other factors deemed relevant by the Board of
Directors in its sole discretion. Successive grants may be made to the same Participant regardless of whether any Options previously granted to the Participant remain unexercised and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Granting of Option</U>. The Corporation in its discretion may require as a condition of the granting of an Option that a Participant
make any representation or warranty to the Corporation as the Board of Directors may deem appropriate, necessary, or required by any applicable law or regulation. This may include, but not be limited to, a representation or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
warranty that the shares are being acquired only for investment and without any present intention to sell or distribute such shares. An Option will be deemed to have been granted only when
(i)&nbsp;the Board of Directors has designated the Participant to receive an Option and determined the number of shares to be granted and the exercise price of the Option and (ii)&nbsp;a Stock Option Agreement has been executed by the Corporation
and delivered or mailed to the selected individual. Nothing contained in the Plan or any resolution adopted or to be adopted by the Board of Directors, and no action taken by the Board of Directors will constitute the granting of any Option without
the execution by the Corporation of a Stock Option Agreement. In addition, any grants of Options will be subject to the following conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. Each grant shall specify the conditions, if any, under which the Option shall become exercisable including, but not limited to, the period
or periods of continuous employment, or continuous engagement of the consulting services, of the Participant by the Corporation or an Affiliate, or the achievement of Management Objectives, that are necessary before the Option, or installments
thereof, shall become exercisable, and any grant may provide for the acceleration of the exercisability of an Option, including, without limitation, in the event of a change in control of the Corporation or other similar transaction or event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. Options granted may be Nonqualified Options, Incentive Stock Options, or combinations thereof, and the type of Option granted shall be set
forth in the applicable Stock Option Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. The aggregate Fair Market Value of the Common Stock subject to Incentive Stock
Options, determined as of the Option Grant Date, which are first exercisable by a Participant during any calendar year under this Plan (or any other stock option plan required to be taken into account under Section&nbsp;422(d) of the Code) shall not
exceed $100,000. To the extent that the aggregate Fair Market Value of the Common Stock to which Incentive Stock Options are exercisable for the first time by any Participant during any calendar year (under all plans of the Corporation and its
Affiliates) exceeds $100,000, such Incentive Stock Options will be treated as Nonqualified Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Acceptance of Option by
Participant</U>. Any person selected to receive an Option must elect to accept the Option under this Plan within ten business days after the date on which the Stock Option Agreement executed by the Corporation has been delivered or mailed to them.
The person selected may elect to accept such Option by executing and delivering a copy of the Stock Option Agreement to the Corporation, and will at that time become a &#147;Participant.&#148; No Option granted may be exercised prior to such
acceptance. If an Option is not accepted with the applicable ten-business day period, the Option will expire automatically at the end of the ten-day period, unless extended in writing by the President of the Corporation, and the person selected to
receive such Option shall have no further rights with respect to that Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Option Price</U>. The price per share of Common Stock
purchasable under Options granted pursuant to the Plan may be equal to or greater than the Fair Market Value on the Option Grant Date, provided, however, that the Option Price with respect to each Incentive Stock Option shall not be less than 100%
(or 110% in the case of a Greater Than 10% Shareholder) of the Fair Market Value on the Option Grant Date. The full Option Price for the shares purchased must be paid when the Option is exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Exercise of Option in Installments</U>. The Board of Directors may provide that an Option
will vest over time and become exercisable in one or more installments. If an Option grant provides for the vesting of the Option in installments, a Participant will have the right, after the Option has been granted and accepted by the Participant
as provided in the Plan, to exercise the Option and purchase from the Corporation the related number of shares of Common Stock only to the extent that the Option has vested in accordance with the dates and times provided for by the Board of
Directors in the installment schedule included in the Stock Option Agreement. A Participant has no right whatsoever to exercise an Option, or any installment thereof, until the Option, or the installment thereof, has vested as provided in the Stock
Option Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Method of Exercising Option</U>. Subject to the terms and conditions of the Plan, the Participant or
Representative may exercise an Option by delivery of written notice of intent to exercise the Option to the Corporation, at the corporate offices at 851 University Blvd SE, Suite 200, Albuquerque, NM, 87106. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. Each notice must state the election to exercise the Option and the number of shares which are being purchased, indicate in what name the
certificate will be issued (including joint tenancy with right of survivorship between the Participant and another person, if so opted and if permitted under the Stock Option Agreement and Stock Restriction Agreement), and will be signed by the
Participant or Representative exercising the Option and, if the Participant is married, by his or her spouse. If a Representative is exercising the Option, the Representative will attach proof, satisfactory to the Corporation, of such person&#146;s
right to exercise the Option as the Representative of the Participant. Each notice will be accompanied by a check payable to the order of the Corporation for the total Option Price for the shares being purchased. If the Corporation is required to
withhold on account of any present or future tax imposed as a result of such exercise, the notice of exercise will be accompanied by a check payable to the order of the Corporation in the amount specified by the Corporation that is sufficient to
cover any taxes required to be withheld by the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. If the Board of Directors requires the execution of a Stock Restriction
Agreement, or other agreement, as a condition of exercise of an Option, the Stock Restriction Agreement, or other agreement, will be executed by the Participant or Representative and, if Participant is married, by his or her spouse before any
certificate for Common Stock is issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. The Corporation will deliver the certificate representing the shares of Common Stock purchased
as soon as practicable after receipt of (i)&nbsp;the notice, (ii)&nbsp;the payment for the total Option Price and any applicable tax withholding, and (iii)&nbsp;the signed Stock Restriction Agreement or other agreement (if applicable). The
certificate evidencing the ownership of the Common Stock of the Corporation will be registered in the name of the person indicated in the notice, or if none, then in the name of the Participant or Representative. The certificate will be delivered to
the Participant or Representative as provided in the notice, or to others, if so provided in the notice. All shares of Common Stock that will be purchased upon the exercise of the Option as provided in the Plan will be fully paid and nonassessable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Nontransferabilitv of Options</U>. Except as provided in the Plan or the Stock Option Agreement, no Participant, Representative,
or any other person or entity may Transfer an Option in any way (whether by operation of law or otherwise), other than by will or the laws of descent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and distribution. The Option is exercisable during a Participant&#146;s lifetime only by the Participant or his Representative. The Option will not be subject to execution, attachment, or similar
process. Any attempted Transfer of an Option contrary to the provisions of the Plan or the Stock Option Agreement, and the levy, attachment, or any similar process upon the Option will be null and void and without effect. In the event of any
Transfer of the Option, or levy, attachment or similar process, the Corporation will have the right to terminate the Option by notice to that effect to the person entitled to exercise the Option under the Plan, provided that the termination of the
Option will not prejudice any rights or remedies which the Corporation may have under the Plan, the Stock Option Agreement, or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Termination</U>. Unless otherwise specified in a Stock Option Agreement, in the event that a Participant is terminated: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. Any unexercised Incentive Stock Options held by the Participant must be exercised as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) Within twelve (12)&nbsp;months after Termination of Employment if such termination is the result of the Participant&#146;s disability as
defined in Section&nbsp;22(e)(3) of the Code and any such Option that is unexercised at the end of the twelve-month period will expire automatically, or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) Within three (3)&nbsp;month after Termination, if such termination is for any reason other than the death or disability of the
Participant or as provided in Paragraph 13.b. below, and any such Option that is unexercised at the end of the three-month period will expire automatically. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. Notwithstanding any other provision of the Plan, unless otherwise provided in the applicable Stock Option Agreement, an Option (whether
vested or unvested) will terminate automatically if (i)&nbsp;the Participant&#146;s Termination is for Cause or (ii)&nbsp;during any post-Termination period in which the Option may be exercised, the Participant engages in conduct that would have
constituted Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Death of a Participant</U>. If a Participant&#146;s Termination is on account of the Participant&#146;s death
(or the Participant dies within three months after a Termination other than for Cause), any Option held by the Participant may be exercised, to the extent that the Participant will have been entitled to do so on the date of the Participant&#146;s
death, by the Participant&#146;s Representative within twelve months of the date of the Participant&#146;s death, unless such an Option expires earlier under the terms of the applicable Stock Option Agreement or the Plan. Any Option or portion
thereof which is not exercised at the end of the twelve-month period will expire automatically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Administration of the Plan</U>.
The Board of Directors of the Corporation will administer the Plan. Subject to the provisions of the Plan, the Board of Directors shall have full power, authority, and discretion to make such interpretations and determinations and to adopt, amend,
and rescind such rules and regulations for the administration of the Plan and Options, as it may deem necessary, desirable or convenient, in its sole discretion. Any interpretation or determination of the Board of Directors will be final and binding
upon all parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. <U>Powers of the Board of Directors</U>. In particular, the Board of Directors will have the
authority to determine the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) The persons who will be granted Options; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) The number of Options to be made available; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) The number of shares of Common Stock to be covered by each Option; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(4) The Option Price, subject to the limits established in the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(5) The times at which Options will be granted </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(6) The conditions on exercise of any Options; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(7) Additional terms, conditions and restrictions to be included in Stock Option Agreements; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(8) When or whether a Participant is disabled (based upon written opinions from two medical doctors); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(9) Whether and for what reason an employee of the Corporation or an Affiliate has incurred a Termination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(10) Appointment and compensation of agents, counsel, auditors or other specialists to aid it in the discharge of its duties with respect to
the Plan; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(11) Construction and interpretation of this Plan and any Stock Option Agreement and all other actions and determinations
deemed necessary or advisable for the administration of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. <U>Authority to Require Conditions Precedent</U>. The Board of
Directors may impose upon any and all Participants any conditions precedent to the receipt of Options under this Plan which it may deem appropriate to assure that the Corporation will secure the expected benefits from granting Options, including,
without limitation a requirement that a Participant agree to remain in the employ of the Corporation for a specified period or that a Participant agree in writing that, in the event the Participant ceases to be an employee, director, officer,
advisor or consultant of the Corporation for any reason, the Participant will not, for a specified period from the date of such cessation, engage in any activity or business which would be competitive with the business of the Corporation, or that
the Participant will not disclose any trade secrets of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. <U>Modifications to the Plan</U>: The Corporation&#146;s Board
of Directors may at any time and from time to time modify and amend the Plan in such manner as the Board of Directors deems advisable, but may not, without the approval of the Corporation&#146;s shareholders, make any alteration in the Plan (except
as provided in Paragraph 16) which operates (i)&nbsp;to increase the total number of shares which may be issued under the Plan, (ii)&nbsp;to extend the term </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
during which Options may be granted under the Plan, or (iii)&nbsp;to reduce the Option price per share after the Option is granted. No notice to eligible employees, Participants, or
Representatives need be given by the Board of Directors upon a modification. The Board may not amend the Plan in any manner which would have the effect of preventing Incentive Stock Options issued under the Plan from being incentive stock options as
defined in Section&nbsp;422 of the Code. Without any obligations to do so, the Board of Directors may amend any Option, without the consent of the Participant, as necessary to comply with applicable laws or to have such Option comply with the
requirements of Section&nbsp;409A of the Code or an applicable exception thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">d. <U>Termination of the Plan</U>. The Board of
Directors may terminate the Plan at any time upon 30 days written notice to the Participants or Representatives of the date fixed for termination; provided, however. no such action shall deprive a Participant, without his or her consent, of any
Option granted pursuant to the Plan unless the termination of the Plan is a result of the occurrence of an event specified in Paragraph 16. Upon the occurrence of an event specified in Paragraph 16 and a decision by the Board of Directors to
terminate the Plan, the Participant or Representative may exercise Options at any time during the 30-day period specified in the preceding sentence or, if earlier, until the date on which the Option otherwise would expire by its terms, and all
Options (whether vested or unvested) shall expire automatically on the date that the Plan terminates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Adjustments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">a. <U>Changes in Capital Structure</U>: In the event that the outstanding shares of the Corporation&#146;s Common Stock is changed by a stock
dividend, recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in the capital structure of the Corporation without consideration, then (a)&nbsp;the number of shares reserved for issuance
under this Plan, and (b)&nbsp;the Exercise Prices of and number of shares subject to outstanding Options will be proportionately adjusted, as determined by the Board of Directors in its sole discretion, subject to any required action by the Board of
Directors or the shareholders of the Corporation and compliance with applicable securities laws; provided, however, fractional shares will be rounded down to the nearest number of whole shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">b. <U>Dissolution or Liquidation</U>: In the event of the dissolution or liquidation of the Corporation, any Option granted under the Plan
will expire as of the date to be fixed by the Board of Directors pursuant to Paragraph 15.d. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">c. <U>Corporate Transaction</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) The term &#147;Corporate Transaction&#148; will mean (i)&nbsp;a merger or consolidation in which securities possessing more than 50% of
the total combined voting power of the Corporation&#146;s outstanding securities are transferred to a person or persons different from the persons holding those securities immediately prior to such transaction or (ii)&nbsp;the sale, transfer or
other disposition of all or substantially all of the Corporation&#146;s assets in complete liquidation or dissolution of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) Except as otherwise set forth in a Stock Option Agreement, in the event of any Corporate Transaction, each outstanding Option shall
become fully vested and shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be exercisable for the 30-day period immediately preceding the consummation of the Corporate Transaction; provided, however, that the exercise of any portion of an Option during such 30-day
period that would not have been vested but for this provision is contingent upon and subject to the consummation of the Corporate Transaction and such exercise and accelerated vesting pursuant to this paragraph will be rescinded if such Corporate
Transaction is not consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) The Board of Directors shall have complete discretion to provide, on such terms and conditions as it
deems appropriate and without the consent of the Participant, to terminate an outstanding Option pursuant to a Corporate Transaction in exchange for a cash payment, to be made to the Participant, equivalent to the difference between (i)&nbsp;the
aggregate Fair Market Value of the shares of Common Stock subject to the Option immediately prior to the consummation of the Corporate Transaction and (ii)&nbsp;the aggregate Option Price for such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(4) Any Options that are outstanding as of the consummation of the Corporate Transaction shall expire automatically, except to the extent
Options are assumed by a successor to the Corporation or otherwise continued in effect pursuant to the terms of the Corporate Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Participant&#146;s Employment</U>. Nothing in this Plan or related documents will be construed to create or imply any contract of
employment between a Participant and the Corporation, confer upon the Participant any right to continue in the employ of the Corporation, or right to continue to provide services to the Corporation, nor will it affect or restrict the right of the
Corporation to terminate such employment or services at any time. Unless otherwise expressly set forth in a separate employment agreement or other agreement between the Participant and the Corporation or an Affiliate, the employment of or engagement
to render services by a Participant is at-will, and the Participant or Corporation may terminate such employment or engagement at any time for any reason, with or without Cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>No Rights of Shareholder</U>. No Participant or Representative will have rights as a shareholder with respect to any shares covered by
an Option until the date of issuance of a stock certificate for shares of Common Stock, following the proper exercise of an Option. No Participant or Representative will have rights with respect to dividends or other distributions for which a record
date is established prior to the date the stock certificate is issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>No Obligation to Disclose</U>. The Corporation will have no
duty or obligation to affirmatively disclose to an employee, Participant or Representative any material information regarding the Corporation at any time prior to or in connection with the grant or exercise of an Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Restriction on Issuance of Shares</U>. Each Option granted under the Plan will be subject to the requirement that if the Board of
Directors determines, in its sole discretion, that the listing, registration or qualification on any securities exchange or pursuant to any state or federal law, or the consent or approval of any governmental regulatory body is necessary or
desirable in connection with the granting of the shares covered by the Option or the purchase of such shares, then no Option may be exercised in whole or in part unless such listing, registration, qualification, consent or approval has been effected
or obtained free of any conditions not acceptable to the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Registration Under Securities Laws</U>. The Common Stock, which is the subject of these
Options, has not been registered under the Securities Act of 1933. Therefore, all shares of stock issued upon exercise of an Option must be held for investment purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Legend</U>. All shares of Common Stock issued pursuant to the Plan and the Stock Option Agreement will bear a legend stating the
following restriction or an abbreviation thereof: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;The shares of stock represented by this certificate (1)&nbsp;have not been
registered under the Securities Act of 1933 or under the securities laws of any state and may not be sold or transferred except upon such registration or upon receipt by the Corporation of an opinion of counsel satisfactory to the Corporation, that
registration is not required for such sale or transfer; and (2)&nbsp;are subject to certain restrictions upon the transfer thereof, and to certain rights and obligations, all as more specifically set forth in the Exagen Diagnostics, Inc. Stock
Option Plan and the Exagen Diagnostics, Inc. Stock Option Agreement. Copies of the Plan and the Stock Option Agreement are available for inspection at the registered office of the Corporation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of Common Stock issued under the Plan may bear such other legends or restrictions as the Board of Directors determines is necessary or advisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>Consultation With Advisors</U>. Each Participant or Representative is expected to consult his own advisors with respect to the tax and
securities consequences of holding an Option and exercising an Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. <U>Indemnification</U>. In addition to any other rights of
indemnification granted by a third party or by law, the Corporation will indemnify, defend and hold harmless the Board of Directors (collectively), and the individual members of the Board of Directors, against the reasonable expenses, (including
attorneys&#146; fees), actually and necessarily incurred in connection with the defense of any action, suit or proceeding, or any threat thereof, or in connection with any appeal, to which they or any of them may be a party by reason of any act or
omission in connection with the Plan or any Option granted by them, and against all amounts paid by them in settlement thereof (provided such settlement is approved by legal counsel selected by the Corporation) or paid by them in satisfaction of a
judgment in any action, suit or proceeding, unless it is adjudged in such action, suit or proceeding that such indemnified party is liable for gross negligence or gross misconduct in the performance of his duties; provided, however, that within 60
days after institution of any such action, suit or proceeding the indemnified party may in writing elect to defend the same at its sole expense, and if such election is made, the Corporation will have no further liability or obligations to the
indemnified party under this paragraph. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25. <U>Governing Law</U>. The Plan will be governed by the law of the State of New Mexico (other
than its law respecting choice of law), and will be interpreted under, construed under and enforced pursuant to the internal laws of the state of New Mexico applicable to agreements made and to be performed wholly within the State of New Mexico.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. <U>Severability</U>. If any term, provision, covenant, paragraph, or condition of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Plan, Stock Option Agreement or any other documents or materials relating to the Plan is held to be invalid, illegal, or unenforceable by any court or arbitrator of competent jurisdiction, as to
such jurisdiction, that provision shall be limited (&#147;blue-penciled&#148;) to the minimum extent necessary so that the Plan, Stock Option Agreement, document, or material, as applicable, shall otherwise remain enforceable in full force and
effect. To the extent such provision cannot be so modified, the offending provision shall, as to such jurisdiction, be deemed severable from the remainder of the Plan, Stock Option Agreement, document, or material, as applicable, and the remaining
provisions thereof shall be construed to preserve, to the maximum permissible extent, the intent and purposes thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27. <U>Binding
Effect</U>. Any actions taken under the provisions of this Plan and any rules adopted by the Board of Directors will bind the Corporation and all recipients of Options pursuant to this Plan. This Plan will inure to the benefit of and be binding upon
the Corporation, its employees, and their respective successors, heirs and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28. <U>Withholding and Taxes</U>. To the extent that
the Corporation is required to withhold federal, state, local or foreign taxes in connection with any payment made or benefit realized by a Participant or other person under this Plan, and the amounts available to the Corporation for the withholding
are insufficient, it shall be a condition to the receipt of any such payment or the realization of any such benefit that the Participant or such other person make arrangements satisfactory to the Corporation for payment of the balance of any taxes
required to be withheld. The Corporation shall not be responsible for payment by any Participant of the proper amount of taxes relating to the grant or exercise of Options. The Corporation intends, but is not required to ensure, that Options issued
under the Plan are exempt from or in compliance in all respects with Section&nbsp;409A of the Code and shall interpret and administer the Options in accordance with such intention. Notwithstanding any provision to the contrary, all liability
associated with participation in the Plan, including, without limitation, any liabilities imposed under Section&nbsp;409A of the Code, shall be borne by the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29. <U>Certain Terminations of Employment or Consulting Services, Hardships and Approved Leaves of Absence</U>. Notwithstanding any other
provision of this Plan to the contrary, in the event of a Termination by reason of death, disability, normal retirement, early retirement, with the consent of the Corporation, termination of employment or consulting services, as applicable, to enter
public service with the consent of the Corporation or leave of absence approved by the Corporation, or in the event of hardship or other special circumstances, of a Participant who holds an Option that is not immediately and fully exercisable, the
Board of Directors may take any action that it deems to be equitable under the circumstances or in the best interests of the Corporation, including without limitation, waiving or modifying any limitation or requirement with respect to any Option
under this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30. <U>Use of Proceeds</U>. Any cash proceeds received by the Corporation from the sale of Common Stock under the Plan
shall be used for any corporate purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exagen Corporation </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2013 Stock Option Plan </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regarding Plan
Amendments </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date of Board<BR>Approval</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date of</B><br><B>Shareholder</B><br><B>Approval</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial adoption of plan (1,708,080 shares)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,&nbsp;2012</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">December&nbsp;13,&nbsp;2012</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase of share reserve (17,835,798 shares)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;27, 2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;27, 2014</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clarification of share reserve (8,893,246 shares)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">May&nbsp;29, 2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXAGEN DIAGNOSTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>STOCK OPTION AGREEMENT&nbsp;&nbsp;&nbsp;&nbsp;# [&nbsp;&nbsp;&nbsp;&nbsp;] </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This Stock Option Agreement (&#147;<U>Agreemen</U>t&#148;) is made and entered into effective as of the Date of Grant set forth below (the
&#147;<U>Date&nbsp;of&nbsp;Grant</U>&#148;) by and between Exagen Diagnostics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and the participant named below (&#147;<U>Participant</U>&#148;) pursuant to the Company&#146;s Stock
Option Plan (the &#147;<U>Plan</U>&#148;). Capitalized terms not defined herein will have the meaning ascribed to such terms in the Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Participant:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Social Security Number:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Address:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Total Option Shares:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Price Per Share:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date of Grant:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Dates:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Expiration Date:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Type of Stock Option</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><I></I></B><B>(</B><B><I>Check one</I></B><B>):</B><B><I></I></B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>[&nbsp;&nbsp;&nbsp;&nbsp;] Incentive Stock Option</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>[&nbsp;&nbsp;&nbsp;&nbsp;] Nonqualified Stock Option</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Grant&nbsp;of&nbsp;Option</U>. The Company hereby grants to Participant an option (the
&#147;<U>Option</U>&#148;) to purchase the total number of shares of Common Stock ($.001 par value per share) of the Company set forth above (the &#147;<U>Shares</U>&#148;) at the Exercise Price Per Share set forth above (the &#147;<U>Exercise
Price</U>&#148;), subject to all of the terms and conditions of this Agreement and the Plan. In consideration of and as a precondition to the grant of the Option, Participant, on behalf of Participant and all persons or parties claiming through the
Participant, including any successor or assign, as of the date hereof forever waives, releases, discharges and covenants not to sue the Company or its successors, assigns, shareholders, affiliates, partners, officers, directors, employees, agents,
attorneys, accountants, and representatives from or on any and all past, present, or future claims, demands, causes of action, suits, damages, costs, expenses, losses, liabilities or obligations, whatsoever, whether at law or equity, know or
unknown, arising directly or indirectly from or in connection with any stock option previously granted to Participant by the Company. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Exercise&nbsp;Period</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.1 <U>Exercise Period of Option</U>. As stated pursuant to the vesting dates above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.2 <U>Vesting of Options</U>. Shares that are vested pursuant to the schedule set forth in Section&nbsp;2.1 hereof are &#147;<U>Vested
Shares</U>&#148;. Shares that are not vested pursuant to the schedule set forth in Section&nbsp;2.1 hereof are &#147;<U>Unvested Shares</U>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.3 <U>Expiration</U>. These Options will expire on the Expiration Date set forth above and must be exercised, if at all, on or before the
Expiration Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Termination</U>. If Participant is terminated for Cause, then this Option will expire on Participant&#146;s
Termination Date, or at such later time and on such conditions as determined by the Board of Directors. In the event of termination for any other reason, this Option will be exercisable, as to Vested Shares, in accordance with the terms of the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Non-transferability&nbsp;of&nbsp;Option</U>. This Option may not be transferred in any manner other than by will or the laws of
descent and distribution and, during the Participant&#146;s lifetime, may be exercised only by Participant. The terms of this Option will be binding upon the successors and assigns of Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Tax&nbsp;Consequences</U>. Set forth below is a brief summary as of the Effective Date of the Plan of some of the tax consequences of
exercise of this Option and disposition of the Shares. THIS SUMMARY IS NECESSARILY INCOMPLETE, AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE. PARTICIPANT SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THE OPTION OR DISPOSING OF THE SHARES.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.1 <U>Exercise&nbsp;of&nbsp;ISO</U>. If this Option qualifies as an ISO, there will be no regular federal or state income tax liability
upon the exercise of this Option, although the excess, if any, of the Fair Market Value of the Shares on the date of exercise over the Exercise Price will be treated as a tax preference item for federal income tax purposes and may subject the
Participant to the alternative minimum tax in the year of exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.2 <U>Exercise&nbsp;of&nbsp;Nonqualified&nbsp;Stock&nbsp;Option</U>.
If this Option does not qualify as an ISO, there may be a regular federal and state income tax liability upon the exercise of this Option. Participant will be treated as having received compensation income (taxable at ordinary income tax rates)
equal to the excess, if any, of the Fair Market Value of the Shares on the date of exercise over the Exercise Price. If Participant is or was an employee of the Company, the Company will be required to withhold from Participant&#146;s compensation
or collect from Participant and pay to the applicable taxing authorities an amount equal to a percentage of this compensation income at the time of exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Governing Plan Document</U>. The Option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of
the Option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of the Option and those of
the Plan, the provisions of the Plan shall control. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Entire&nbsp;Agreement</U>. The Plan is incorporated herein by reference. A copy of the Plan
may be obtained from the Corporation. This Agreement and the Plan constitute the entire agreement of the parties and supersede all prior undertakings and agreements with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Acceptance</U>. Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. Participant has read and understands
the terms and provisions thereof, and accepts this Option subject to all the terms and conditions of the Plan and this Agreement. Participant acknowledges that there may be adverse tax consequences upon exercise of this Option or disposition of the
Shares and that Participant should consult a tax adviser prior to such exercise or disposition. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXAGEN DIAGNOSTICS, INC:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><B>PARTICIPANT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Name</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>d693329dex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">LICENSE AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS LICENSE AGREEMENT the &#147;<I><U>Agreement</U></I>&#148;<I>)</I> is entered into as of September&nbsp;13, 2007
<I>(</I>&#147;<I><U>Effective Date</U></I>&#148;<I>)</I> by and between Prometheus Laboratories Inc., a California corporation, having a principal place of business at 9410 Carroll Park Drive, San Diego, California 92121, and its Affiliates
<I>(</I>&#147;<I><U>Prometheus</U></I>&#148;<I>),</I> and Proprius, Inc., a Delaware corporation, having a principal place of business at 12264 El Camino Real, Suite 350, San Diego, California 92130, and its Affiliates
<I>(</I>&#147;<I><U>Proprius</U></I>&#148;<I>).</I> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BACKGROUND </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Prometheus has developed Patent Rights and Prometheus Know-how (each as defined below) relating to methotrexate metabolites and
pharmacogenetics; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Proprius has expertise regarding research and development, clinical development, marketing and sale of
therapeutics and diagnostics in rheumatologic and autoimmune diseases; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Prometheus desires to grant Proprius a license on the
terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the recitals and the mutual covenants and obligations
contained herein, Prometheus and Proprius agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">DEFINITIONS </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.1 &#147;Affiliate&#148; of an entity shall mean any entity that controls, is
controlled by, or is under common control with such entity. An entity shall be deemed to be in control of another entity if it owns or controls, directly or indirectly, more than fifty percent (50%)&nbsp;of the outstanding voting equity of the other
entity (or other equity or ownership voting interest in the event that such entity is other than a corporation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.2 &#147;Confidential
Information&#148; shall mean all written information and data provided by one Party to the other hereunder and marked &#147;Confidential&#148; or a reasonable equivalent thereof or, if disclosed orally, visually or in some other form, is summarized
in a writing identified as &#147;Confidential&#148; or a reasonable equivalent thereof and provided to the other Party within thirty (30)&nbsp;days of such disclosure; <I>provided, however, </I>that during the term of this Agreement, the Prometheus
Know-how shall be deemed the Confidential Information of both Parties. Notwithstanding the foregoing, Confidential Information of a Party shall not include information that the other Party (the &#147;recipient&#148;) can demonstrate: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) is known to the recipient and not subject to prior confidentiality obligations to Prometheus (i.e., knowledge of former Prometheus
employees), as evidenced by its written records, before receipt thereof under this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) is disclosed to the recipient without
restriction after acceptance of this Agreement by a Third Party who has the right to make such disclosure; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) is or becomes part of the
public domain through no breach of this Agreement; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) is independently developed, as evidenced by its written records, by or for the
recipient by individuals or entities who have not had access to the information disclosed hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.3 &#147;Contract Quarter&#148; shall mean a period of three (3)&nbsp;consecutive months ending
on March&nbsp;31,&nbsp;June&nbsp;30,&nbsp;September&nbsp;30 or December&nbsp;31; provided, however, that each of the first and last Contract Quarters during the term of this Agreement may be less than three (3)&nbsp;full consecutive months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.4 &#147;Contract Year&#148; shall mean a period of four (4)&nbsp;consecutive Contract Quarters ending on December&nbsp;31 of any calendar
year; provided, however, that the first and last Contract Years during the term of this Agreement may be less than four (4)&nbsp;consecutive Contract Quarters in that the first Contract Year shall begin on the Effective Date, and the last Contract
Year shall end upon termination or expiration of this Agreement in accordance with Article 10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.5 &#147;FDA&#148; shall mean the United
States Food and Drug Administration or its successor entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.6 &#147;Inventors&#148; shall mean the inventors named in the patents and
patent applications listed in <U>Exhibit 1.9</U> hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.7 &#147;Licensed Product&#148; shall mean any product, product part or service
which is made, used, distributed or sold and which, but for the licenses granted in Article 2 of this Agreement, would infringe a Valid Claim in the Patent Rights, in a country in which it is made, used, distributed, sold or imported. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.8 &#147;Net Sales&#148; shall mean the gross invoiced price of Licensed Products sold to a Third Party (other than a Sublicensee, unless
such Sublicensee is the end user of such Licensed Products), less the following: (a)&nbsp;credits, allowances, discounts, rebates and chargebacks provided to a Third Party; (b)&nbsp;freight, postage, transportation and insurance costs incurred in
delivering Licensed Products (only to the extent such costs are included in such gross invoiced price); (c)&nbsp;cash, quantity and trade discounts actually given to Third Parties; (d)&nbsp;rebates and administrative fees actually paid to group
purchasing organizations; (e)&nbsp;sales, use, value-added, excise and other similar taxes to the extent included in such gross invoiced price; and (f)&nbsp;custom duties, surcharges and other governmental charges incurred in connection with the
exportation or importation of Licensed Products to the extent such amounts are included in such gross invoiced price. All such amounts set forth above shall be determined in accordance with generally accepted accounting principles
(&#147;GAAP&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if a Licensed Product is sold or provided as part of a system, package, or combination product or
service that contains one or more components that could be sold separately (a &#147;Combination Product&#148;), Net Sales of a Combination Product will be calculated by multiplying the Net Sales from the sale of such Combination Product (determined
in accordance with the preceding paragraph) by the fraction <I>A/B</I> where &#147;A&#148; is the fair market value of the Licensed Product when supplied or priced separately from the other components of the Combination Product, and &#147;B&#148; is
the fair market value of the Combination Product. In the event that no market price is available for the Licensed Product when supplied or priced separately from the other components, fair market value shall be determined in good faith by Proprius
and Prometheus taking into account, among other factors as the parties may deem relevant, the number of components in such Combination Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
purposes of this Section&nbsp;1.8, fair market value shall mean the gross sales price to a Third Party in an arm&#146;s-length sale or exchange of consideration for an identical item or service sold or provided in the same quantity and at the same
time and place as the sale or exchange for which such gross sales price or value is to be determined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.9 &#147;Patent Rights&#148; shall
mean the patents and the patent applications listed in <U>Exhibit 1.9</U>, and all provisionals, substitutions, extensions, re-examinations, reissues, renewals, divisions, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continuations, improvements or continuations-in-part therefor or thereof, and all patents claiming priority to any such patents or patent applications to the extent owned or controlled by
Prometheus and all foreign counterparts of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.10 &#147;Party&#148; shall mean either Prometheus or Proprius and
&#147;Parties&#148; shall mean both Prometheus and Proprius. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.11 &#147;Prometheus Know-how&#148; shall mean all non-patented and
unpublished documentation, information and data relating solely to the development of products based solely on the Patent Rights owned or controlled by Prometheus, as of the Effective Date. Prometheus Know-how shall only include research, clinical
and manufacturing data and documentation, sample report forms from the clinical studies, case report forms, clinical databases, protocols and completed patient informed consent forms, copies of research notebooks standard operating procedures and
laboratory procedures, New York State validation reports, raw clinical data files, marketing materials, clinical experience program data, and animation files, draft sales aids or other promotional material, and market research; all to be provided
&#147;as is&#148; without any representation or warranty regarding accuracy or completeness or compliance with laws, regulations or guidance documents and the extent available and transferable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.12 &#147;Reasonable Commercial Efforts&#148; shall mean a level of effort by a Party [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.13 &#147;Regulatory Authority&#148; or &#147;Regulatory Authorities&#148; shall mean any federal, state, local or international regulatory
agency, department, bureau or other governmental entity, including, but not limited to, the FDA, which is responsible for issuing approvals, licenses, registrations or authorizations necessary for the manufacture, use, storage, import, transport or
sale of Licensed Products in a regulatory jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.14 &#147;Samples&#148; shall mean, to the extent in the possession and control
of Prometheus as of the Effective Date, all serum specimens, plasma specimens, blood specimens, red blood cells, leukocytes, DNA or RNA material and lymphoblastoid cells generated from patients and/or healthy human subjects, used by the Inventors in
their discovery of, and other research on, the development of products based solely on the Patent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.15 &#147;Sublicensee&#148;
shall mean a Third Party to which Proprius, its Affiliate or Sublicensee grants a sublicense of its rights under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.16
&#147;Sublicensee Royalties&#148; shall mean [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.17 &#147;Sublicense Fees&#148; shall mean [***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.18 &#147;Territory&#148; shall mean the entire world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.19 &#147;Third Party&#148; shall mean a natural person, corporation, partnership, joint venture, trust, any governmental authority or other
business entity or organization, and any other recognized organization other than the Parties and/or their Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.20
&#147;Trademarks&#148; shall mean &#147;Trexscore&#148; and &#147;Veritrex&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.21 &#147;Valid Claim&#148; shall mean a claim of
(a)&nbsp;an issued or granted and unexpired patent included in Patent Rights, which claim has not been held invalid or unenforceable by a court or agency of competent jurisdiction from which no further appeal can be taken, or which has not been
admitted by the patentee to be invalid or unenforceable; or (b)&nbsp;a pending patent application included in the Patent Rights, so long as such application is being prosecuted and the claim in question has not been abandoned by the owner of the
application and provided that such patent application has not been pending for more than [***] from the earliest filing date from which such claim takes priority in the country in question. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">RIGHTS GRANTED/MATERIAL TRANSFER </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.1 <U>License to Patent Rights and Prometheus Know-how</U>.
Subject to the terms and conditions of this Agreement, Prometheus hereby grants to Proprius an exclusive (even as to Prometheus) royalty-bearing right and license under the Patent Rights and Prometheus Know-how, with the right to further sublicense
in accordance with this Agreement, to commercialize, develop, research, use, make, have made, sell, offer for sale, have sold and import Licensed Products in the Territory. Provided, however that such right and license shall not include the right to
promote any Licensed Products to gastroenterologists or to directly or indirectly, participate in the development or commercialization of any Licensed Product for use in diagnosing or treating any gastrointestinal diseases. Proprius shall have the
exclusive right (even as to Prometheus) to publicly disclose or use Prometheus Know-how in support of Proprius&#146; and its Sublicensees&#146; development and commercialization efforts related to Licensed Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.2 <U>Sublicensing</U>. [***] agrees that any agreement for the sublicense of any rights granted to it under this Article 2 [***] shall
promptly provide [***] with a copy of each sublicense granted hereunder. In any event, [***] shall remain responsible for all obligations under this Agreement following any sublicense of the rights granted under this Article 2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.3 <U>Material Transfer by Prometheus</U>. Within ninety (90)&nbsp;days of the Effective Date and subject to receipt of any necessary Third
Party approvals or consents (which Prometheus does not guaranty or warrant will be obtainable), Prometheus shall provide to Proprius the Samples for use by Proprius solely for technology validation and development purposes with respect to Licensed
Products in the Territory. Except as otherwise provided under this Agreement, all Samples will remain the sole </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property of Prometheus, will be used only by Proprius and its Sublicensees in furtherance of the development and commercialization of Licensed Products, and only in a manner consistent with the
protocol originally submitted to, and approved by, the respective IRBs of the institutions through which the Samples were collected. Prometheus shall provide to Proprius true and complete copies of each such protocol and a description of the Samples
to which such protocol applies. The Samples supplied under this Section&nbsp;2.3 must be used with prudence and appropriate caution in any experimental work, because not all of their characteristics may be known. THE SAMPLES ARE PROVIDED &#147;AS
IS&#148; AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE SAMPLES WILL NOT INFRINGE OR
VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, PROMETHEUS SHALL HAVE NO LIABILITY (INCLUDING BUT NOT LIMITED TO DIRECT, INDIRECT, CONSEQUENTIAL OR EXEMPLARY) TO PROPRIUS RELATING
TO THE SAMPLES REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH LIABILITY OR DAMAGES. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.4 <U>No Implied Rights</U>. Proprius shall
have no licenses or other rights other than those expressly granted in this Agreement, and, in particular and without limiting the foregoing, nothing in this Agreement shall be construed to grant Proprius any licenses or other rights in any
intellectual property rights, information or data owned or controlled by Prometheus or any of its Affiliates, except as expressly set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.5 <U>Restrictions on Development and Commercialization of Licensed Products</U>. Notwithstanding any other provision of this Agreement,
during the term of this Agreement, Proprius (and its Affiliates and Sublicensees) agrees that it will not, directly or indirectly, market or promote the Licensed Products to gastroenterologists nor will it (or any of its Affiliates or Sublicensees),
directly or indirectly, participate in the development or commercialization of any Licensed Product for use in diagnosing or treating any gastrointestinal diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.6 <U>Right of First Negotiation</U>. If, during the two (2)&nbsp;year period beginning on the First Commercial Sale of a Licensed Product by
Proprius, (i)&nbsp;Proprius desires to divest or sublicense all or substantially all of its business relating to the Licensed Products (whether by sale, license or otherwise) to a Third Party, or (ii)&nbsp;a Third Party initiates such discussions
with Proprius and Proprius is interested in entertaining such discussions (both (1)&nbsp;and (ii)&nbsp;are collectively referred to as a &#147;<I><U>Business Opportunity</U></I>&#148;<I>), </I>then Proprius will promptly notify Prometheus in writing
thereof, with such notice containing a reasonably complete summary of reasonably available information necessary to evaluate the Business Opportunity; provided, however, that Proprius shall not be obligated to disclose to Prometheus the identity of
any such Third Party, the terms proposed by such Third Party (if confidential) or any other confidential or proprietary information of such Third Party. If Prometheus indicates interest in pursuing the Business Opportunity within [***] business days
of Prometheus&#146; receipt of Proprius&#146; written notice, the Parties will negotiate in good faith to enter into a definitive agreement. If the Parties are unable to enter into a definitive agreement within [***] days after Proprius&#146;
receipt of Prometheus&#146; indication of interest, or if Prometheus does not so indicate an interest in pursuing the Business Opportunity within the [***] business day period, Proprius will be free to execute such Business Opportunity with a Third
Party provided that Proprius shall not offer the Business Opportunity to a Third Party on terms more favorable then those offered to Prometheus or on terms worth less to Proprius then those offered by Prometheus for the Business Opportunity. In no
event shall Proprius be obligated to enter into any such transaction with Prometheus. Notwithstanding anything in this Agreement to the contrary, any Business Opportunity entered into by Proprius with a Third Party will be subject to
Prometheus&#146; rights under this Agreement, including, without limitation, Prometheus&#146; right to receive the payments set forth in Article 5. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">LICENSED PRODUCT DEVELOPMENT AND COMMERCIALIZATION </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.1 <U>Development and Clinical Testing
Activities</U>. Proprius shall use Reasonable Commercial Efforts to undertake development activities for the Licensed Product, including, but not limited to, conducting or having conducted, and completing or having completed, all clinical studies
and other activities required for approvals from the applicable Regulatory Authorities. Proprius shall bear the costs and expenses related to the development of the Licensed Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.2 <U>Regulatory Approvals</U>. Proprius shall use Reasonable Commercial Efforts to submit to and obtain acceptance from the applicable
Regulatory Authorities of the appropriate regulatory filing for one or more Licensed Products in the Territory. In addition, and without limiting the generality of the foregoing, Proprius by either Proprius, an Affiliate or a Sublicensee shall use
its Reasonable Commercial Efforts to achieve the first commercial sale of a Licensed Product in the Territory <I>(</I>&#147;<I>First <U>Commercial Sale</U></I>&#148;) on or before December&nbsp;31, 2008. Proprius shall bear the costs and expenses
related to the obtaining of the appropriate regulatory approvals for the Licensed Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.3 <U>Remedies for Failure to use Reasonable
Commercial Efforts to Achieve First Commercial Sale</U>. In the event Proprius does not achieve the First Commercial Sale on or before December&nbsp;31, 2008, the Parties shall discuss in good faith whether a modification of such obligation,
including the date, is appropriate. Except as otherwise agreed to by the Parties pursuant to this Section&nbsp;3.3, if Proprius&#146; failure to achieve the First Commercial Sale continues through March, 31, 2009, then Prometheus shall have the
right to terminate this Agreement by written notice thereof to Proprius, as further set forth in Section&nbsp;10.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.4 <U>Licensed
Product Development and Marketing</U>. Proprius shall use Reasonable Commercial Efforts, by itself, an Affiliate or through a Sublicensee, to develop Licensed Products in the United States and in such other regions in the Territory as Proprius deems
commercially reasonable, and to market and sell Licensed Products in all regions in the Territory where appropriate regulatory and marketing approvals have been obtained from the applicable Regulatory Authorities. Proprius, at Proprius&#146; own
expense, or as applicable, a Sublicensee, at its own expense, shall be responsible for all development and commercial activities related to undertaking the obligations pursuant to this Section&nbsp;3.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.5 <U>Trademark License: Labeling</U>. All packaging for Licensed Products shall display Proprius&#146; trade dress and a trademark suitable
to Proprius which may, but need not, be a Trademark, at Proprius&#146; sole discretion. Prometheus hereby grants to Proprius a royalty-free license to use the Trademarks in connection with the commercialization of Licensed Products in the Territory.
All packaging and labeling for Licensed Products shall include all appropriate trademark and patent markings in order to reasonably protect such Trademarks and Patent Rights. Proprius acknowledges Prometheus&#146; exclusive right, title and interest
in and to the Trademarks and acknowledges that nothing herein will be construed to grant to Proprius any rights in such Trademarks except as expressly provided herein. Proprius further acknowledges that its use of the Trademarks will not create in
Proprius any right, title or interest in the Trademarks, and that all use of the Trademarks and the goodwill generated thereby will inure solely to the benefit of Prometheus. Proprius shall make only claims, representations or warranties directly or
indirectly to any Third Party about the Licensed Product that are consistent with the Licensed Product&#146;s approval from applicable Regulatory Authorities and other scientific literature. During the Term of this Agreement, Proprius shall be
solely responsible for maintaining the Trademarks, including all costs and expenses relating thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.6 <U>Customer Service and
Technical Support</U>. Proprius, at Proprius&#146; own expense, or as applicable, a Sublicensee, at its own expense, shall be responsible for and use Reasonable Commercial Efforts in providing training, customer service and technical support for
Licensed Products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.7 <U>Export Control Laws</U>. Proprius shall comply with all applicable export laws,
restrictions and regulations of the Department of Commerce or other United States or foreign agency or authority, and shall not export, or allow any export or re-export of any Confidential Information or Licensed Products in violation of any such
restrictions, laws or regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.8 <U>Progress Reports</U>. Once every six (6)&nbsp;months prior to the date of the First Commercial
Sale and once every Calendar Year, thereafter, Proprius will submit to Prometheus a progress report covering in reasonable detail (i)&nbsp;activities by Proprius related to the development and testing of Licensed Product (or the commercialization of
Licensed Products after development), and (ii)&nbsp;the obtaining of regulatory approvals necessary for marketing Licensed Product. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">REGULATORY COMPLIANCE MATTERS AND COMPLAINTS </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.1 <U>Regulatory Matters</U>. In addition to the
obligations set forth in Article 3 of this Agreement, Proprius, at Proprius&#146; own expense, or as applicable, a Sublicensee, at its own expense, shall be responsible for and take all appropriate corrective or other actions regarding all
regulatory matters related to the Licensed Products and the Trademarks in the Territory, including responses to inquiries from Regulatory Authorities in accordance with all applicable laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.2 Complaints and Recalls. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Licensed Product Complaints</U>. Proprius, at Proprius&#146; own expense, or as applicable, a Sublicensee at its own expense, shall
investigate, respond to and take all appropriate corrective or other actions regarding all complaints associated with the manufacture and/or distribution of Licensed Products which are made, used, distributed or sold by or on behalf of Proprius or
any of its Sublicensees in accordance with all applicable laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Licensed Product Recalls</U>. Proprius, at Proprius&#146; own
expense, or as applicable, a Sublicensee at its own expense, and, subject to an order or directive from a Regulatory Authority, shall be responsible to conduct and to pay for the costs of any recall or withdrawal of Licensed Products made, used,
distributed or sold by or on behalf of Proprius or any of its Sublicensees in accordance with all applicable laws. Promptly, in accordance with all applicable laws and if possible, prior to making such recall, Proprius shall advise Prometheus of the
situation and any facts relating to the advisability of the recall, destruction or withholding from the market of the Licensed Product in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.3 <U>Record keeping</U>. Proprius (and its Affiliates and Sublicensees) shall keep records of its sales and customers and other records
sufficient to adequately administer a recall of each such Licensed Product and reasonably cooperate in any decision to recall, retrieve and/or replace any Licensed Product, in accordance with all applicable laws and regulatory requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.4 <U>Fines and Penalties</U>. Any fines and/or penalties for failure by Proprius to comply with any requirement or regulation shall be the
sole responsibility of Proprius. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">PAYMENTS </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.1 <U>Up Front Fee</U>. Within sixty (60)&nbsp;days after the Effective Date,
Proprius shall make a nonrefundable up front payment to Prometheus of [***] U.S. Dollars (U.S.$[***] ) (the &#147;<I><U>Up Front Fee</U></I>&#148;<I>).</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.2 <U>Preferred Stock</U>. Within 30 days after the Effective Date, Proprius shall deliver to
Prometheus a certificate for 200,000 shares of Proprius Series A Preferred Stock, $0.0001 par value per share <I>(</I>&#147;<I>Series A Preferred Stock</I>&#148;<I>), </I>registered in the name of Prometheus. In regard to the Preferred Stock,
Proprius hereby represents and warrants as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Proprius has duly authorized the issuance of 38,000,000 shares of its Preferred
Stock, having the rights, restrictions, privileges and preferences set forth in the Certificate of Amendment attached hereto as <U>Exhibit 5.2</U> (the &#147;<I>Certificate of Amendment</I>&#148;<I>)</I> and Proprius has adopted and filed the
Certificate of Amendment with the Secretary of State of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The authorized capital stock of Proprius (immediately
prior to the issuance of the Preferred Stock to Prometheus) consists of 32,000,000 shares of common stock, $0.0001 par value per share (the &#147;<I>Common Stock</I>&#148;<I>),</I> of which 3,004,166 shares are issued and outstanding and 1,170,834
shares have been reserved for issuance pursuant to subscription, warrant, option, convertible security or other right (contingent or otherwise), and 38,000,000 shares of preferred stock <I>(</I>&#147;<I>Preferred Stock</I>&#148;<I>),</I> of which
21,000,000 shares have been designated as Series A Preferred Stock of which 6,105,406 are issued and outstanding. No other shares or series of capital has been designated or is issued or outstanding. All of the issued and outstanding shares of
Common Stock and Preferred Stock have been duly authorized and validly issued and are fully paid and nonassessable. Except for the Preferred Stock and as provided in this Agreement, (i)&nbsp;no subscription, warrant, option, convertible security or
other right (contingent or otherwise) to purchase or acquire any shares of capital stock of the Company is authorized or outstanding, (ii)&nbsp;Proprius has no obligation (contingent or otherwise) to issue any subscription, warrant, option,
convertible security or other such right or to issue or distribute to holders of any shares of its capital stock any evidences of indebtedness or assets of the Company, (iii)&nbsp;Proprius has no obligation (contingent or otherwise) to purchase,
redeem or otherwise acquire any shares of its capital stock or any interest therein or to pay any dividend or make any other distribution in respect thereof, and (iv)&nbsp;there are no outstanding or authorized stock appreciation, phantom stock or
similar rights with respect to Proprius. All of the issued and outstanding shares of capital stock of Proprius have been offered, issued and sold by Proprius in compliance with applicable federal and state securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The issuance and delivery of the shares of Series A Preferred Stock in accordance with this Agreement, and the issuance and delivery of
the shares of Common Stock issuable upon conversion of the Preferred Stock, have been duly authorized by all necessary corporate action on the part of Proprius, and all such shares have been duly reserved for issuance. The shares of Series A
Preferred Stock when so issued and delivered pursuant to this Agreement, and the shares of Common Stock issuable upon conversion of the Preferred Stock, when issued upon such conversion, will be duly and validly issued, fully paid and
non-assessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In regard to the issuance of the shares of the Series A Preferred Stock to Prometheus, Prometheus hereby represents and warrants that
Prometheus is acquiring the Series A Preferred Stock, and the shares of Common Stock into which the Series A Preferred Stock may be converted, for its own account for investment and not with any present intention of distributing or selling the same,
and Prometheus has no present or contemplated agreement, undertaking, arrangement, obligation, indebtedness or commitment providing for the disposition thereof. Prometheus is an &#147;accredited investor&#148; as defined in Rule 501(a) under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.3 <U>Milestone Payments</U>. In addition to the payments described in Sections 5.1 and 5.4 of this Agreement, Proprius
shall make the following one-time cash milestone payments to Prometheus within ninety (90)&nbsp;days of the occurrence of the applicable event: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:73.70pt; font-size:8pt; font-family:Times New Roman">MILESTONE EVENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">PAYMENT</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Commercial Sale by Proprius, its Affiliates or Sublicensees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">U.S.$</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Achievement of greater than or equal to U.S.$[***] in cumulative Net Sales of all Licensed Products (determined in the aggregate for
sales by Proprius, its Affiliates and Sublicensees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">U.S.$</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Achievement of greater than or equal to U.S.$[***] in cumulative Net Sales of all Licensed Products (determined in the aggregate for
sales by Proprius, its Affiliates and Sublicensees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">U.S.$</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Achievement of greater than or equal to U.S.$[***] in cumulative Net Sales of all Licensed Products (determined in the aggregate for
sales by Proprius, its Affiliates and Sublicensees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">U.S.$</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Achievement of greater than or equal to U.S.$[***] in cumulative Net Sales of all Licensed Products (determined in the aggregate for
sales by Proprius, its Affiliates and Sublicensees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">U.S.$</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Proprius shall not be obligated to make payments under this Section&nbsp;5.3 which total more
than [***] U.S. Dollars (U.S.$[***]) in any calendar year (the &#147;<U><I>Milestone Payment Cap</I></U>&#148;). Any amounts in excess of the Milestone Payment Cap for any calendar year shall be carried forward and paid on March&nbsp;31 of the next
calendar year (subject again, in such calendar year, to the Milestone Payment Cap). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4 <U>Royalty Payments to Prometheus</U>. In partial
consideration of the license rights granted to Proprius hereunder, Proprius shall pay to Prometheus royalties based on Net Sales of Licensed Products by Proprius and its Affiliates (but not Sublicensees provided that Sublicensees shall be included
if Proprius has sublicensed its rights hereunder without having devoted material efforts to the development of Licensed Products and without retaining material development and/or commercialization rights related to the Licensed Products), in
countries where a Valid Claim of the Patent Rights covering such Licensed Products exists at the rate of [***] percent ([***]%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the
termination provisions of Article 10 of this Agreement, Proprius&#146; obligation to pay royalties to Prometheus on Licensed Products covered by a Valid Claim of the Patent Rights in each country shall expire on the date when the last patent
containing a Valid Claim in such country expires, lapses or is invalidated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.5 <U>Sublicense Fees and Sublicensee Royalties</U>. In
addition to the royalties and milestones payable pursuant to Sections 5.3 and 5.4 of this Agreement, Proprius shall pay to Prometheus the following amounts: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If the Sublicensee is [***] or any successor organization to [***] (hereinafter &#147;[***]&#148; shall include such successor
organizations), then Proprius shall pay to Prometheus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">[***] percent ([***]%) of any Sublicensee Royalties received by Proprius from [***] or any of its Affiliates or Sublicensees, provided however, that under no circumstances shall such payment to Prometheus by Proprius
under this Section&nbsp;5.5(a)(i) be less then [***] percent ([***]%) of the Net Sales of [***] and its Affiliates or Sublicensees nor shall it be more then [***] percent ([***]%) of the Net Sales of [***] and its Affiliates or Sublicensees; plus
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">[***] percent ([***]%) of Sublicense Fees received by Proprius from [***] or any of its Affiliates or Sublicensees. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) In the case of any other Sublicensee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">[***] percent ([***]%) of any Sublicensee Royalties received by Proprius from such Sublicensee or any of its Affiliates or Sublicensees, provided however, that under no circumstances shall such payment to Prometheus by
Proprius under this Section&nbsp;5.5(b)(i) be less then [***] percent ([***]%) of the Net Sales of such Sublicensee and its Affiliates or Sublicensees nor shall it be more then [***] percent ([***]%) of the Net Sales of such Sublicensee and its
Affiliates or Sublicensees; plus </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">[***] percent ([***]%) of Sublicense Fees received by Proprius from such Sublicensee or any of its Affiliates or Sublicensees. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, except as specifically set forth above relating to [***] under Section&nbsp;5.5 (a), in the event that Proprius sublicenses any or
all of its rights to any other third party without having devoted material efforts to the development of Licensed Products and without retaining material development and/or commercialization rights related to the Licensed Products, Proprius shall
pay to Prometheus a royalty pursuant to Section&nbsp;5.4 (and not Section&nbsp;5.5(b)) based upon the Net Sales of any Sublicensee&#146;s (or its Affiliates). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.6 <U>Royalty Reduction</U>. Any royalty payable to Prometheus under Section&nbsp;5.4 of this Agreement may be reduced up to a maximum of
[***] percent ([***]%) of the royalty otherwise due on a Calendar Quarter basis for any and all royalties to the extent, and only to the extent, it is reasonable and necessary for Proprius to pay such royalties to a Third Party in order to
manufacture, use or sell a Licensed Product (up to the actual extent of the royalties paid to such Third Party) under a license of intellectual property rights entered into by Proprius with respect to the Licensed Product, provided that under no
circumstances shall the royalty rate payable to Prometheus hereunder be reduced below two and one-half percent (2<SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">2</SUB>%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.7 <U>Terms of Payment</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Within [***] days following the end of each Contract Quarter during the Term, Proprius shall make the payments to Prometheus set forth in
Sections 5.4 of this Agreement based on Net Sales during the previous Contract Quarter. Royalty payments due to Prometheus under Section&nbsp;5.5 shall be due within [***] days following the end of each Contract Quarter during the Term as well. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) With each quarterly payment made under this Section&nbsp;5.7, Proprius shall deliver to Prometheus a full and accurate accounting of all
Net Sales by Proprius, and its Affiliates and Sublicensees as well as all Sublicense Fees and Sublicensee Royalties received from Sublicensees and their Affiliates, if any, for the relevant Contract Quarter. Each such report shall include at least
the following information: (i)&nbsp;quantity of each Licensed Product sold by Proprius, and its Affiliates and Sublicensees on a country-by-country basis; (ii)&nbsp;gross sales of Licensed Products by Proprius, and its Affiliates and Sublicensees on
country-by-country basis; (iii)&nbsp;any deductions from gross sales used to arrive at Net Sales; (iv)&nbsp;the quantity and type of Sublicense Fees and Sublicensee Royalties received from Sublicensees and their Affiliates; and
(v)&nbsp;Proprius&#146; computation of the aggregate earned royalties payable to Prometheus under Sections 5.4 and 5.5, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Within [***] calendar days of the end of each Calendar Quarter, Proprius shall provide Prometheus with its best estimate of all the
payments due to Prometheus hereunder for such prior Calendar Quarter from Proprius, its affiliates and its Sublicensees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) All royalty and milestone and Sublicense Royalties and Sublicense Fee payments due
Prometheus shall be made in United States dollars by wire transfer to a bank and account specified by Prometheus in writing. For sales made or Sublicense Fees or Sublicensee Royalties received in currency other than United States dollars, amounts
payable under this Agreement shall be converted to United States dollars as would be required for reporting under GAAP. In no event shall the applicable royalties exceed the maximum amount payable under the applicable laws, regulations or
administrative rulings of the territory or country which restricts the royalty rate or amount payable on Net Sales in such territory or country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.8 <U>Taxation of Royalties</U>. Where any sum due to be paid to Prometheus hereunder is subject to any withholding or similar tax, the
Parties shall use reasonable efforts to do all such acts and things and to sign all such documents as will enable them to take advantage of any applicable double taxation agreement or treaty or appeal procedure. In the event there is no applicable
double taxation agreement or treaty, or appeal procedure, or if any appeal procedure has been exhausted or if an applicable double taxation agreement or treaty or appeal procedure reduces but does not eliminate such withholding or similar tax,
notwithstanding any pending appeal, Proprius shall pay such withholding or similar tax to the appropriate government authority as may be required, deduct the amount paid from the amount due Prometheus and secure and send to Prometheus reasonable
evidence of such payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.9 <U>Restrictions on Remittance</U>. If, at any time, legal restrictions prevent the prompt remittance of
part or all royalties with respect to any country where Licensed Products are sold, Proprius shall have the right to make such payments by depositing the amount thereof in local currency to Prometheus&#146; account in a bank or other depository
institution in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.10 <U>Late Payments</U>. Any payment, including without limitation, royalty, Sublicense Fees, Sublicensee
Royalties, and milestone payments, made by Proprius under this Agreement after the date such payment is due shall bear interest at the lesser of 1&nbsp;1/2%&nbsp;per month and the maximum rate permitted by applicable law. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">BOOKS AND RECORDS </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.1 <U>Procedures</U>. Proprius shall keep full and accurate accounting
records of Net Sales, Sublicense Fees and Sublicensee Royalties in sufficient detail to determine the amounts payable to Prometheus under Sections 5.3, 5.4 and 5.5. Such records, together with all necessary supporting data, shall be kept at
Proprius&#146; offices at the address set forth above or such other address as Proprius may indicate in writing to Prometheus. Upon reasonable notice to Proprius, Prometheus shall have the right during normal business hours to have an independent
certified public accounting firm to audit on a confidential basis Proprius&#146; financial records pertaining to Net Sales, Sublicense Fees and Sublicensee Royalties to verify the amounts payable pursuant to this Agreement; provided, however, that
such audit shall neither (a)&nbsp;take place more frequently than once in a Contract Year, nor (b)&nbsp;cover records for more than the preceding three (3)&nbsp;Contract Years, nor (c)&nbsp;cover any Contract Year that was previously audited
pursuant to this Section&nbsp;6.1. The accounting firm will disclose to Prometheus only whether the amounts reported by Proprius are correct or incorrect and the specific details concerning any discrepancies. An adjustment in payment shall be made
within five (5)&nbsp;business days of demonstration of any underpayment or overpayment. Any underpayment shall include interest as specified in Section&nbsp;5.10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2 <U>Cost of Audits</U>. The fees and expenses of an audit requested by Prometheus pursuant to Section&nbsp;6.1 of this Agreement shall be
borne by Prometheus; provided, however, that if any audit reveals that Proprius underpaid the royalties, milestone payments, Sublicense Fees or Sublicensee Royalties due under this Agreement as to the period being audited by more than ten percent
(10%)&nbsp;of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount that was payable for such period, then Proprius shall, in addition to paying any such deficiency, reimburse Prometheus for the cost of such audit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.3 <U>Period to be Kept</U>. Proprius shall retain all books and records it is required to maintain under Section&nbsp;6.1 for [***] from the
end of the Contract Year of the Net Sales (or Sublicense Fees or Sublicensee Royalties) to which the books and records pertain. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">REPRESENTATIONS AND WARRANTIES </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.1 <U>Mutual Warranties</U>. Each of the Parties represents
and warrants to the other Party as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) It is duly organized and validly existing under the laws of its state of incorporation,
and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) It is duly
authorized to execute and deliver this Agreement and to perform its obligations hereunder, and any person executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) This Agreement is legally binding upon such Party and enforceable in accordance with its terms, subject to the effects of bankruptcy,
insolvency or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity whether enforceability is considered a
proceeding at law or equity. The execution, delivery and performance of this Agreement by it does not conflict with any material agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate
any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) To the
best of its knowledge, it has sufficient legal and/or beneficial title and ownership under its intellectual property rights necessary for it to fulfill its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.2 <U>Intellectual Property Warranties</U>. As of the effective date, Prometheus represents and warrants to Proprius as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Prometheus is the sole and exclusive owner, with the right to license or sublicense, of all its right, title and interest in and to the
Patent Rights with the right to license to Proprius; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) To the best of Prometheus&#146; knowledge and belief without independent
inquiry, the Patent Rights have not been obtained through any fraudulent activity or misrepresentation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) There are no suits, claims
or proceedings pending or, expressly threatened in writing, against Prometheus in any court or by or before any governmental body or agency with respect to the Patent Rights or the Prometheus Know-how or the making, having made, using, selling,
offering for sale or importing Licensed Products; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) To the best of Prometheus&#146; knowledge without independent inquiry, there are
no suits pending or threatened that challenge the validity of any of the patents within Patent Rights, and Prometheus has no actual knowledge of any information or action that may jeopardize the validity, enforcement or ownership of the Patent
Rights; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Prometheus does not own, control or have rights to any patents or patent applications other
than those licensed or sublicensed to Proprius according to the terms of this Agreement, having claims that would restrict Proprius&#146; making, having made, using, selling, offering for sale or importing Licensed Products as such Licensed Products
exist on the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.3 <U>Disclaimer</U>. Except as expressly set forth in this Agreement, NEITHER PARTY MAKES ANY
REPRESENTATIONS OR WARRANTIES, EXPRESSED OR IMPLIED. ALL OTHER REPRESENTATIONS OR WARRANTIES, EXPRESSED AND IMPLIED, INCLUDING, WITHOUT LIMITATION, NONINFRINGEMENT, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE
HEREBY DISCLAIMED. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Without limiting the generality of the foregoing, and except as expressly set forth in this Agreement, Prometheus makes no
(a)&nbsp;representation or warranty as to the validity of any patent or other intellectual property rights which are the subject of this Agreement, (b)&nbsp;representation or warranty that anything made, used, imported, offered for sale, sold or
otherwise disposed of under any of the Patent Rights or the Prometheus Know-how is or will be free from infringement of patents or other intellectual property rights of Third Parties, or (c)&nbsp;grant, by implication, estoppel, or otherwise, of any
license, option, covenant or right other than those which are expressly stated in this Agreement, including without limitation any license under any patent or patent application (or claim thereof) not within the Patent Rights. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">PATENTS. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.1 <U>Prosecution of Patent Rights</U>. Proprius, at Proprius&#146; own expense,
shall file, prosecute, issue and maintain all the Patent Rights. Proprius shaft provide Prometheus the right to review and comment on draft submissions to any patent office with respect to the Patent Rights reasonably in advance of any applicable
due dates. Proprius shall consider in good faith the requests and suggestions of Prometheus with respect to strategies for filing and prosecuting the Patent Rights. In connection with Proprius&#146; performance of its obligations under this
Section&nbsp;8.1, Proprius shall provide written notification to Prometheus of significant activities resulting from Proprius&#146; actions under this Section&nbsp;8.1 and shall provide Prometheus with reasonable access to and copies of the records
related to such activities. Accordingly, Proprius shall provide Prometheus with copies of (a)&nbsp;all actions, notices and other correspondence received from the U.S. Patent and Trademark Office or any foreign equivalent, (b)&nbsp;responses and
correspondence to the U.S. Patent and Trademark Office or any foreign equivalent, and (c)&nbsp;the original issued patent documents, certificates or equivalents thereof. In the event Proprius elects or has elected not to pursue patent protection or
to continue to prosecute or maintain any patent or patent application of the Patent Rights, Proprius shall so advise Prometheus in writing not less than [***] days prior to any potential loss of rights; then, Prometheus shall have the right, but not
the obligation, to assume prosecution or maintenance of such patent or patent application of the Patent Rights. If Prometheus elects to assume maintenance of such patent or if Prometheus elects to assume prosecution of such patent application, then
thereafter, the license to such patent-n the region in question shall either revert to a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license or be removed from the Patent Rights, in the sole discretion, and upon the written election, of
Prometheus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2 <U>Third Party Infringement of Patent Rights</U>. Each Party agrees to bring to the attention of the other Party any
Third Party product it discovers or has discovered which relates to any of the Patent Rights, and to cooperate with each other so that each Party can determine whether a Third Party product may infringe a Valid Claim of a Patent Right. To the extent
a Party believes a Third Party may infringe the Patent Rights, the Parties shall reasonably cooperate to address such concerns. Notwithstanding such cooperation, in the event of alleged Third Party infringement, Proprius, at its sole discretion, may
pursue enforcement within [***] days of obtaining knowledge of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such alleged infringement. Prior to taking any formal action to enforce the Patent Rights or prior to communicating to the alleged infringing Third Party regarding such alleged infringement,
Proprius shall notify Prometheus in writing of Proprius&#146; intentions to so act. [***] In the event Proprius does not pursue enforcement within the [***] day period, Prometheus, at Prometheus&#146; sole cost, upon prior written notice to
Proprius, may (but shall be under no obligation to act) pursue such enforcement action, and if Prometheus obtains any awards or settlement, then Prometheus shall retain exclusively all settlements or awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.3 <U>Infringement involving Third Party Patents</U>. If a Third Party commences suit, or threatens to do so, on the basis of a claim that a
Licensed Product manufactured, used or sold by or on behalf of Proprius infringes a patent of such Third Party, Proprius shall be responsible for defending such claim at its sole expense, except as expressly provided in Section&nbsp;11.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.4 <U>Patent Marking</U>. Proprius shall use reasonable efforts to place all appropriate patent and other intellectual property notices,
markings and indicia on Licensed Product and marketing literature for Licensed Products as needed to protect the Patent Rights and the rights for damages for infringement thereof. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top">CONFIDENTIALITY AND PUBLIC ANNOUNCEMENTS </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.1 <U>Confidentiality</U>. It is contemplated that
in the course of the performance of this Agreement each Party may disclose from time to time Confidential Information to the other Party. Each Party agrees (a)&nbsp;not to use Confidential Information received from the other for any purpose other
than the performance of its rights and obligations hereunder, and (b)&nbsp;not to disclose Confidential Information so received to any Third Party, except as is necessary for such performance (provided such disclosure is subject to similar or more
restrictive confidentiality obligations as set forth herein) or as is required by a court or governmental authority or with the written consent of the disclosing Party. In the event that such disclosure to a Third Party is required as set forth
above, the disclosing Party shall give to the Party from whom the Confidential Information was received the greatest practical prior written notice so as to permit the latter to take all possible action to perfect and/or safeguard its rights in the
Confidential Information. The obligations of the Parties relating to Confidential Information shall expire five (5)&nbsp;years after the later of the termination of this Agreement or the expiration of any Patent Rights; provided, however, each of
Proprius&#146; and Prometheus&#146; obligations to keep Prometheus Know-how confidential shall not expire so long as such know-how is within the definition of Confidential Information provided in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.2 <U>Public Announcements</U>. Within a reasonable time following the Effective Date of this Agreement, the Parties will issue a joint press
release announcing the existence of this Agreement in the form and substance mutually agreed upon by the Parties. Except as set forth in the preceding sentence, neither Party shall make any public announcement concerning the transactions
contemplated herein, or make any public statement which includes the name of the other Party or any of its Affiliates or otherwise use the name of the other Party or any of its Affiliates in any public statement or document, without the written
consent of the other Party, which consent shall not be unreasonably withheld; provided, however, that either Party may make such public announcements or disclosures as may be required by regulation, law or judicial order. Except for any regulatory,
legal or judicial disclosure obligation, any such public announcement proposed by a Party that names the other Party shall first be provided in draft to the other Party which shall have fifteen (15)&nbsp;business days to review such draft prior to
the issue or publication of the disclosure. Except as expressly permitted by this Section&nbsp;9.2, neither Party shall publish or otherwise disclose the existence of this Agreement, or its terms, without the other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Party&#146;s prior written consent; provided, however, that a Party may disclose the existence and/or terms of this Agreement to such Party&#146;s professional advisors and, on a confidential
basis and subject to a written confidentiality agreement not less stringent then the confidentiality terms contained herein and of which the other Party is a third party beneficiary, to potential Third Party investors or acquirors or, in the case of
Proprius, to potential Sublicensees, in each case in connection with due diligence or similar investigations by such Third Parties. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top">TERM AND TERMINATION </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.1 <U>Term</U>. This Agreement shall commence on the Effective Date and
shall remain in effect for the term of any royalty obligations under Sections 5.4 and 5.5 of this Agreement, unless otherwise terminated earlier pursuant to this Article 10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.2 <U>Termination by Either Party</U>. Either Party may terminate this Agreement upon written notice to the other Party in the event the
other Party (a)&nbsp;materially breaches this Agreement and fails to cure such breach within [***] days after receipt of written notice of breach from the non-breaching Party, or (b)&nbsp;makes a general assignment for the benefit of creditors, has
a receiver appointed on its behalf, or files or otherwise becomes subject to bankruptcy or insolvency proceedings which continues unstayed and in effect for a period of [***] days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.3 <U>Termination by Prometheus</U>. In addition to the rights set forth under Section&nbsp;10.2 related to material breach of this
Agreement by Proprius, Prometheus may immediately terminate this Agreement as set forth in Section&nbsp;3.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.4 <U>Termination by
Proprius</U>. In addition to the rights set forth under Section&nbsp;10.2 related to material breach of this Agreement by Prometheus, Proprius may terminate this Agreement with sixty (60)&nbsp;days written notice, without cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.5 <U>Rights Upon Termination</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Upon termination of this Agreement pursuant to Section&nbsp;10.2 or 10.3 or 10.4: (i)&nbsp;all rights under the licenses granted
hereunder shall automatically terminate, and (ii)&nbsp;any sublicenses (but not any liabilities accrued to date) granted hereunder by Proprius to Third Parties shall remain in effect, but shall be assigned to Prometheus provided that: (A)&nbsp;such
sublicense was properly granted hereunder, (B)&nbsp;Prometheus shall have no obligation thereunder other than the obligation to grant the license or sublicense to the applicable Third Party(ies) as set forth in such sublicenses, (C)&nbsp;all
restrictions and limitations of this Agreement shall apply to the sublicense as though this Agreement continued in effect, (D)&nbsp;Prometheus shall receive all consideration due in connection with the sublicense and, in any event, the payments to
Prometheus based upon the sublicense and activity thereunder shall be at least as great as they would have been to Prometheus had the Agreement remained in effect and such actions had been taken by Proprius, and (E)&nbsp;in addition to any
termination rights under the sublicense agreement, Prometheus shall be entitled to terminate such sublicense on the same basis as is provided herein for termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or
termination. Except as set forth below or elsewhere in this Agreement, any accrued rights to payment and the obligations and rights of the Parties under Sections 1, 4, 6, 7, 9, 10, 11, and 12 shall survive expiration or termination of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Within thirty (30)&nbsp;days following the termination of this Agreement, except to the extent and for so long as a Party
is entitled to retain license rights under this Agreement, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each Party shall, upon written request, deliver to the other Party any and all Confidential Information, and any copies thereof, of the other Party in its possession, except that the Party will
be entitled to retain one (1)&nbsp;copy of all documents in its legal archives. [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Upon termination (but not expiration) of this
Agreement, Proprius agrees to immediately discontinue the manufacture and sale of the Licensed Products and the use of the Patent Rights and Prometheus Know-how; <I>provided, however, </I>unless this Agreement is terminated pursuant to
Section&nbsp;10.2 for a breach by Proprius, that for up to [***] months after such termination, Proprius shall have the right to sell any existing merchantable inventory of Licensed Products as of the date of termination at its normal prices, unless
discounted prices were previously allowed or authorized by Proprius. The sale of all such inventory, however, shall be subject to all of the terms and conditions of this Agreement, including the royalty provisions of Article 5. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top">INDEMNIFICATION; INSURANCE AND LIMITATION OF LIABILITY </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.1 <U>Indemnification by
Prometheus</U>. Prometheus shall indemnify, defend and hold harmless Proprius and its officers, directors, employees, agents and representatives (&#147;<I><U>Proprius Indemnitees</U></I>&#148;) from and against any and all liabilities, claims,
demands, actions, suits, losses, damages, costs and expenses (including reasonable attorneys&#146; fees) based upon or arising out of Third Party claims resulting from Prometheus&#146; negligence, willful or deliberate misconduct, recklessness or
breach of any covenant, agreement, representation or warranty made by Prometheus in this Agreement; provided that Prometheus shall not be required to indemnify Proprius or any Proprius Indemnitee to the extent such liabilities, claims, demands,
actions, suits, losses, damages, costs and expenses arise from the negligence, willful or deliberate misconduct, or recklessness of a Proprius Indemnitee, Proprius&#146; breach of this Agreement or any other matter for which Proprius is responsible
to indemnify Prometheus pursuant to Section&nbsp;11.2 of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.2 <U>Indemnification by Proprius</U>. Proprius shall
indemnify, defend and hold harmless Prometheus and its officers, directors, employees, agents and representatives (&#147;<I><U>Prometheus Indemnitees</U></I>&#148;) from and against any and all liabilities, claims, demands, actions, suits, losses,
damages, costs and expenses (including reasonable attorneys&#146; fees) based upon or arising out of Third Party claims resulting from Proprius&#146; (or its Affiliates&#146; or Sublicensees&#146;) negligence, willful or deliberate misconduct,
recklessness, or relating to the development or commercialization of Licensed Products or Patent Rights hereunder by Proprius (or its Affiliates or Sublicensees) or breach of any covenant, agreement, representation or warranty made by Proprius (or
its Affiliates or Sublicensees) in this Agreement; provided that Proprius shall not be required to indemnify Prometheus or any Prometheus Indemnitee to the extent such liabilities, claims, demands, actions, suits, losses, damages, costs and expenses
arise from the negligence, willful or deliberate misconduct, or recklessness of a Prometheus Indemnitee, Prometheus&#146; breach of this Agreement or any other matter for which Prometheus is responsible to indemnify Proprius pursuant to
Section&nbsp;11.1 of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.3 <U>Conditions of Indemnification</U>. If either Party proposes to seek indemnification from the
other under the provisions of this Article 11, it shall notify the other Party within fifteen (15)&nbsp;days of receipt of notice of any such claim or suit and shall cooperate fully with the other Party in the defense of such claims or suits. No
settlement or compromise shall be binding on a Party hereto without </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its prior written consent which shall not be unreasonably withheld. Failure to provide such notice will not relieve indemnity obligation except to the extent adversely effected by failure to
receive notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.4 <U>Insurance</U>. During the Term, Proprius shall carry occurrence-based liability insurance with policy limits of
at least two million dollars ($2,000,000) per occurrence and five million dollars ($5,000,000) annual aggregate. Upon request, Proprius shall provide Prometheus with evidence of such insurance. Proprius shall have Prometheus and its respective
Affiliates, directors, officers, employees, scientists and agents named as additional insured parties on any product liability insurance (or professional liability insurance covering services) policies maintained by Proprius, its Affiliates and
Sublicensees applicable to the Licensed Products, and shall ensure that such insurance may not be amended, terminated or allowed to expire without thirty (30)&nbsp;days&#146; prior notice to such additional insureds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.5 <U>Limitation of Liability</U>. NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INDIRECT, INCIDENTAL,
CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION, LOST PROFITS, IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. FOR THE PURPOSE OF CLARITY, NOTHING IN
THIS SECTION IS INTENDED TO LIMIT THE INDEMNIFICATION OBLIGATIONS OF ANY PARTY WITH RESPECT TO THE CHARACTERIZATION OF ANY CLAIM BY A THIRD PARTY AS SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top">MISCELLANEOUS </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.1 <U>Entire Agreement</U>. This Agreement, together with the exhibits,
constitutes the entire agreement between the Parties concerning the subject matter hereof and supersedes all written or oral prior agreements or understandings with respect thereto. Notwithstanding anything in this Section&nbsp;12.1 to the contrary,
the Confidentiality Agreement between the Parties effective November&nbsp;4, 2005, shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.2
<U>Amendment or Modification</U>. No amendment, modification or release from any provision of this Agreement shall be binding, unless in writing signed by an authorized representative of each Party, and no purchase order or acknowledgment form of a
Party shall be binding on the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.3 <U>Severability</U>. If any term or provision of this Agreement shall for any reason be
held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof, and this Agreement shall be interpreted and construed as if such term or provision, to the
extent the same shall have been held to be invalid, illegal or unenforceable, had never been contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.4 <U>Assignment</U>.
Neither Party shall assign this Agreement in whole or in part without the prior written consent of the other Party; provided, however, that subject to Section&nbsp;2.6 herein, either Party may assign this Agreement without such consent to an
Affiliate, in connection with the transfer or sale of substantially its entire business to which this Agreement pertains, or in the event of its merger or consolidation with another company; provided, that, for purposes of clarity, intellectual
property rights of a party to such transaction other than one of the initial Parties to this Agreement shall not be included in the technology licensed hereunder. The rights and obligations of the Parties under this Agreement shall be binding upon
and inure to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this Agreement shall be void. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.5 <U>Independent Contractor</U>. It is expressly agreed that Prometheus and Proprius shall be
independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency of any kind. Neither Party shall have the authority to make any statement, representations or commitments of any
kind on behalf of the other, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.6 <U>Notices</U>. All notice hereunder shall be in writing and shall be delivered (a)&nbsp;personally, (b)&nbsp;by overnight delivery,
delivery prepaid, (c)&nbsp;mailed by express mail service, or (d)&nbsp;given by facsimile, to the following addresses of the respective Parties: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to Prometheus: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Prometheus
Laboratories Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">9410 Carroll Park Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">San Diego, California 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attn: Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile Number: (858)&nbsp;410-1945 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Legal Department
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Prometheus Laboratories Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">9410 Carroll Park Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">San
Diego, California 92121 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile Number (858)&nbsp;410-1945 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to Proprius: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">12264 El Camino
Real, Suite 350 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">San Diego, California 92130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attn: Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile Number: (858)&nbsp;225-3553 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notices shall be effective upon receipt if personally delivered, on the next business day following deposit with an overnight delivery
service, on the second business day following the date of delivery to the express mail service if sent by express mail, or the date of transmission (or next business day if transmitted on a non-business day) if sent by facsimile and the sending
machine prints a verification of receipt by the receiving machine. A Party may change its address listed above by notice to the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.7 <U>Force Majeure</U>. Any delay in the performance of any of the duties or obligations of either Party under this Agreement caused by an
event outside the affected Party&#146;s reasonable control shall not be considered a breach of this Agreement, and the time required for performance shall be extended for a period equal to the period of such delay. Such events shall include, without
limitation: acts of God; riots; embargoes; labor disputes, including strikes, lockouts, job actions, or boycotts; fires; explosions; earthquakes; floods; shortages of material or energy; or other unforeseeable causes beyond the reasonable control
and without the fault or negligence of the Party so affected. The Party so affected shall give prompt notice to the other Party of such cause and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as
possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.8 <U>Governing Law</U>. This Agreement shall be construed, interpreted and governed by the laws of the State of California,
without regard to conflicts of law principles and without regard to the United Nations Convention on Contracts for the International Sale of Goods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.9 <U>Dispute Resolution</U>. The parties hereto expressly agree that in the event of any
dispute, controversy or claim by any party against the other party regarding this Agreement, the prevailing party shall be entitled to reimbursement by the other party to the proceeding of reasonable attorney&#146;s fees and costs incurred by the
prevailing party. Any dispute, controversy or claim arising hereunder or in any way related to this Agreement shall be resolved by arbitration in the County of San Diego, State of California by JAMS-Endispute. The arbitration shall be conducted by a
sole arbitrator appointed by JAMS-Endispute (the &#147;Arbitrator&#148;). The Arbitrator&#146;s decision shall be final and binding on all parties. The Arbitrator shall have no authority to award damages for emotional distress, punitive damages or
equitable relief. The parties intend that this arbitration provision be irrevocable and be construed as broadly as possible. The arbitration shall be governed by the provisions of California&#146;s Arbitration Act, and judgment upon the award
rendered by the Arbitrator may be entered by any court having jurisdiction thereof. Notwithstanding the above, to the full extent allowed by law, either Party may bring an action in any court of competent jurisdiction for injunctive relief (or any
other provisional remedy) to protect the Parties&#146; rights or enforce the Parties&#146; obligations under this Agreement pending final resolution of any claims related thereto in an arbitration proceeding as provided above. In addition, either
Party may bring an action in any court of competent jurisdiction to resolve disputes pertaining to the validity, construction, scope, enforceability, infringement or other violations of patents or other proprietary or intellectual property rights.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.10 <U>Binding Effect</U>. This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and its respective
assigns and successors in interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.11 <U>Waiver</U>. No waiver or modification of any of the terms of this Agreement shall be valid
unless in writing and signed by an authorized representative of the Parties. Failure by either Party to enforce any rights under this Agreement shall not be construed as a waiver of such rights, nor shall a waiver by either Party in one or more
instances be construed as constituting a continuing waiver or as a waiver in other instances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.12 <U>Exhibits</U>. All exhibits that
are attached to this Agreement are incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.13 <U>Headings</U>. The headings used in this Agreement are for
convenience and reference purposes only and shall not affect the meaning or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">12.14 <U>Counterparts</U>.
This Agreement may be executed in two (2)&nbsp;or more original counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each Party has caused this Agreement to be executed on its behalf by its duly
authorized officer as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PROMETHEUS LABORATORIES INC.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">PROPRIUS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joseph M. Limber</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael J. Walsh</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed&nbsp;Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Joseph M. Limber</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Printed&nbsp;Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Michael J. Walsh</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President, CEO</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President &amp; CEO</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">September 19, 2007</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">September 13, 2007</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit 1.9 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PATENT RIGHTS </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MTX PORTFOLIO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PATENT PROPERTY
STATUS REPORT </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>TTC Ref</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Country</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:64.65pt; font-size:8pt; font-family:Times New Roman"><B>ATTY(s)&nbsp;Handling</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Client&#146;s&nbsp;Ref</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Inventor</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Application</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>No.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Filing Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Patent No.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Issue&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Status Remarks</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>d693329dex106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FIRST AMENDMENT </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TO LICENSE AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS FIRST AMENDMENT, </B>effective as of October 23, 2013 (the &#147;Effective Date&#148;), is to that certain License Agreement dated
September&nbsp;13, 2007, (the &#147;License Agreement&#148;) by and between Prometheus Laboratories Inc. (&#147;<I><U>Prometheus</U></I>&#148;) and Cypress Bioscience, Inc. as successor in interest to Proprius, Inc., which was subsequently assigned
to Exagen Diagnostics, Inc. (&#147;<I><U>Exagen</U></I>&#148;). Prometheus and Exagen are each sometimes referred to individually as a &#147;<I><U>Party</U></I>&#148; and together as the &#147;<I><U>Parties</U></I>.&#148; All capitalized terms not
defined herein shall have the meaning ascribed to them in the License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL>,</B> Prometheus and Exagen
wish to amend the License Agreement with regard to development and clinical testing activities, marketing, milestones and royalties as described below and otherwise amend the License Agreement on the terms set forth herein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>, T<SMALL>HEREFORE</SMALL>,</B> the Parties hereby agree to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">All references to Proprius in the Agreement shall be understood to reference Exagen. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Section&nbsp;3.1 (<U>Development and Clinical Testing Activities</U>) shall be deleted in its entirety and replaced with the following: </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.1 <U>Development and Clinical Testing Activities</U>. Exagen shall use Reasonable Commercial Efforts to undertake development activities for
the Licensed Product, including, but not limited to, conducting or having conducted, and completing or having completed: (a)&nbsp;those three (3)&nbsp;clinical studies described on <U>Exhibit 3.1</U> hereto; and (b)&nbsp;a dossier to be used for
communications with managed care entities that explains the advantageous pharmacoeconomics associated with use of the Licensed Product no later than March&nbsp;30, 2014. Exagen shall bear the costs and expenses related to all development activities
set forth above of the Licensed Products. Exagen acknowledges and agrees that these development activities are critical to the commercial success of the Licensed Product and agrees that should Exagen fail to timely complete the dossier described in
section (b)&nbsp;of this section or to timely accomplish those three (3)&nbsp;clinical studies described on <U>Exhibit 3.1</U>, Exagen will pay Prometheus a one-time payment of Fifty Thousand Dollars ($50,000). In addition, if applicable, Exagen
shall use Reasonable Commercial Efforts to undertake any other development activities for the Licensed Product, required for approvals from the applicable Regulatory Authorities. Exagen shall bear all costs and expenses related to the development of
the Licensed Products. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Section&nbsp;3.4 (<U>Licensed Product Development and Marketing</U>) shall be deleted in its entirety and replaced with the following: </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.4 <U>Licensed Product Development and Marketing</U>. Exagen shall use Reasonable Commercial Efforts, by itself, an Affiliate or through a
Sublicensee, to develop, market and sell Licensed Products in the United States, Exagen shall also use Reasonable Commercial Efforts to develop Licensed Products in such other regions in the Territory as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Exagen deems commercially reasonable, and to market and sell Licensed Products in all regions in the Territory where appropriate regulatory and marketing approvals have been obtained from the
applicable Regulatory Authorities. Exagen, at Exagen&#146;s own expense, or as applicable, a Sublicensee, at its own expense, shall be responsible for all development and commercial activities and expenses related to undertaking the obligations
pursuant to this Section&nbsp;3.4. For the avoidance of doubt, Reasonable Commercial Efforts to commercialize the Licensed Products shall include a compensation structure for the applicable members of Exagen&#146;s Sales Force that are responsible
for detailing the Licensed Products (each a &#147;<I><U>Sales Representative</U></I>&#148;) with a variable incentive compensation component based on the Promotion of the Licensed Products, as described below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) At least [***] of the annual targeted incentive compensation percentage for each Sales Representative for the first (1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP>)&nbsp;year beginning January&nbsp;01, 2014 shall be based on his/her performance related to minimum Details and minimum Sales Achievement of the Licensed Product, where a
&#147;<U><I>Detail</I></U>&#148; is defined as &#147;an interactive face-to-face visit in the Territory by a Sales Representative with a physician or his or her legally empowered designee, during which the indicated uses and other relevant
characteristics of the Licensed Products may be described by such Sales Representative in a fair and balanced manner consistent with Applicable Law; however, incidental contacts between such sales representatives and a physician will not constitute
a Detail;&#148; and &#147;<U><I>Sales Achievement</I></U>&#148; is defined as actual sales of Licensed Products compared to commercially reasonable sales goals prescribed for each individual geographic territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) At least [***] of the incentive compensation percentage for each Sales Representative for the second (2<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP>)&nbsp;year (January 01, 2015) following the Effective Date and for all years thereafter in which there exists a Valid Claim on a Licensed Product shall be based on his/her performance related to the
Detailing of the Product. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">Section&nbsp;5.3 <U>Milestone Payments</U> shall be deleted in its entirety and replaced with the following: </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.3 <U>Milestone Payments</U>. In addition to the payments described in Sections 5.1 and 5.4 of this Agreement, Exagen shall make the
following one-time cash milestone payment to Prometheus within ninety (90)&nbsp;days of the occurrence of the event: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:73.70pt; font-size:8pt; font-family:Times New Roman">MILESTONE EVENT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">PAYMENT</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Achievement of greater than or equal to U.S[***] in cumulative Net Sales of all Licensed Products (determined in the aggregate for
sales by Exagen, its Affiliates and Sublicensees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">U.S$2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the License Agreement is amended to remove the concept of a Milestone Payment Cap, and any
reference to that term or concept is hereby deleted, including, but not limited to the reference in Section&nbsp;5.3. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">Section&nbsp;5.4 <U>Royalty Payments to Prometheus</U> shall be deleted in its entirety and replaced with the following: </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4 <U>Royalty Payments to Prometheus</U>. In partial consideration of the license rights granted
to Exagen hereunder, Exagen shall pay to Prometheus royalties based on Net Sales of Licensed Products by Exagen and its Affiliates and its sublicenses in countries where a Valid Claim of the Patent Rights covering such Licensed Products exists at
the royalty rates set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:30.40pt; font-size:8pt; font-family:Times New Roman">Net Sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Royalty&nbsp;Rate</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On Annual Net Sales in a calendar year less than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On Annual Net Sales in a calendar year equal to or greater than [***] and less than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On Annual Net Sales in an calendar year equal to or greater than [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[***</TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the termination provisions of Article 10 of this Agreement, Exagen&#146;s obligation to pay royalties to Prometheus
on Licensed Products covered by a Valid Claim of the Patent Rights in each country shall expire on the date when the last patent containing a Valid Claim in such country expires, lapses or is invalidated. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">Except as expressly amended in this First Amendment, all terms and provisions of the License Agreement shall remain in full force and effect. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>In witness whereof</B>, the parties have executed this First Amendment as of the date first set forth above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXAGEN DIAGNOSTICS, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PROMETHEUS LABORATORIES INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ron Rocca</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lisa A. Miller</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ron Rocca</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lisa A. Miller</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Approved by the Legal Dept. of Prometheus Laboratories&nbsp;Inc.:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Approved by the Finance Dept. of Prometheus Laboratories&nbsp;Inc.:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit 3.1 </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Clinical Studies </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Avise PG
participating Clinical Trials </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:28.00pt; font-size:8pt; font-family:Times New Roman"><B>Sponsor</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:28.00pt; font-size:8pt; font-family:Times New Roman"><B>Purpose</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Subjects/</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:31.05pt; font-size:8pt; font-family:Times New Roman"><B>Timeline</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:42.90pt; font-size:8pt; font-family:Times New Roman"><B>Exagen Role</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:36.85pt; font-size:8pt; font-family:Times New Roman"><B>Comments</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>University of Alabama at Birmingham</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">To stimulate collaborative efforts of federal funding agencies, voluntary health agencies, professional organizations and industry partners to enable creation of a large, sustainable <B>database and repository</B> to better
understand the molecular basis of <B>treatment</B> and rapidly accelerate translational research in RA.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">N=200</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">February 2010 to August 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Provide methotrexate polyglutamate concentration testing.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exagen performed MTXPG testing from February to June 2013</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Pfizer Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A Randomized, Double-blind, Placebo-controlled Study of the Safety and</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The first 12 weeks of this study will compare the efficacy of etanercept 50 mg once-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">N=168</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">August 2013 to May 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Provide methotrexage polyglutamate concentration testing.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Efficacy of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">weekly to placebo in subjects with rheumatoid arthritis who have not responded well to infliximab or adalimumab plus methotrexate. This comparison will be performed for all subjects and separately for subjects who are anti-drug
antibody positive for one of these medications. From week 12 to week 24, all subjects will receive etanercept 50 mg once-weekly. The effect of anti-drug antibody status on the efficacy of etanercept as well as the safety profile of etanercept in
these subjects will also be evaluated</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">throughout the study.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Keio University</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>MAGIK</U></B> Study:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><U>M</U></B>ethotrexate as an <B><U>A</U></B>nchor drug <B><U>I</U></B>n Japanese Rheumatoid arthritis monitored by erythrocyte polyglutamate concentration
in <B><U>K</U></B>eio Rheumatology Expert Meeting.</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">A proportion of Japanese patients with rheumatoid arthritis can be treated quite will with rather low dose methotrexate (sometimes 6-8mg/week). We suppose that the MTXPG concentration can reach the point at which rheumatoid
arthritis should be controlled (say at 60 as you have reported) with lower MTX dose in Japanese than in Caucasians. We&#146;d like to prove this and establish the optimal usage in Japanese patients.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">N=100</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">September 2012- end of 2014.</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Provide methotrexage polyglutamate concentration testing.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">50 subjects have been enrolled.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>8
<FILENAME>d693329dex107.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORGENTEC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
License Agreement (the &#147;<B><I>Agreement</I></B>&#148;) is entered Into as of February&nbsp;19, 2008 (the &#147;<B><I>Effective Date</I></B>&#148;) by and between <B>ORGENTEC D<SMALL>IAGNOSTIKA</SMALL> G<SMALL>M</SMALL>BH</B>, having an address
of Carl-Zeiss-Strasse 49, 55129 Mainz, Germany (&#147;<B><I>ORGENTEC</I></B>&#148;), and <B>P<SMALL>ROPRIUS</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation, having an address of 12264 El Camino Real, Suite 350, San Diego, California 92130,
USA (&#147;<B><I>Proprius</I></B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, ORGENTEC owns certain patent rights and know-how relating to rheumatology diagnostics and
rheumatology treatment; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Proprius is engaged in the research and development of personalized
medicine solutions in rheumatology and autoimmune diseases; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Proprius wishes to obtain,
and ORGENTEC is willing to grant to Proprius, a license to develop and commercialize Initial Products (as defined below), subject to the terms and conditions set forth herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>, T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the foregoing premises and the mutual covenants
contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>D<SMALL>EFINITIONS</SMALL> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1 </B>&#147;<B>Additional Product</B>&#148; shall mean
any Licensed Product other than an Initial Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2 </B>&#147;<B>Affiliate</B>&#148; shall mean any company or entity controlled
by, controlling, or under common control with a party hereto and shall include any company more than 50% of whose voting stock or participating profit interest is owned or controlled, directly or indirectly, by a party, and any company which owns or
controls, directly or indirectly, more than 50% of the voting stock of a party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3 </B>&#147;<B>Combination Product</B>&#148; shall
mean an Initial Product that includes at least one additional marker that is not covered by the Patent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4
</B>&#147;<B>Confidential Information</B>&#148; shall have the meaning provided in Section&nbsp;7.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5
</B>&#147;<B>Control</B>&#148; shall mean, with respect to any Information, patent right or other intellectual property right, possession by a party of the ability (whether by ownership, license or otherwise) to grant access, a license or a
sublicense to such Information, patent right or intellectual property right without violating the terms of any agreement or other arrangement with any Third Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6 </B>&#147;<B>Field</B>&#148; shall mean any and all diagnostic and prognostic
applications, including, without limitation, diagnosis, prognosis and monitoring of rheumatoid arthritis. For the avoidance of doubt, the Field excludes all therapeutic applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7 </B>&#147;<B>Information</B>&#148; shall mean all kind of information of whatever form, including without limitation, all tangible and
intangible (a)&nbsp;techniques, technology, practices, trade secrets, inventions (whether patentable or not), methods, knowledge, know-how, skill, experience, test data and results (including pharmacological, toxicological and clinical test data and
results), analytical and quality control data, results or descriptions, software and algorithms and (b)&nbsp;compositions of matter, cells, cell lines, assays, animal models and physical, biological or chemical material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8 </B>&#147;<B>Initial Product</B>&#148; shall mean a Licensed Product that includes ORGENTEC&#146;s Anti-MCV (autoantibodies against
mutated citrullinated Vimentin) ELISA technology in 96-well titer plate format, including all improvements to such technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9
</B>&#147;<B>Invention</B>&#148; shall have the meaning provided in Section&nbsp;5.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10 </B>&#147;<B>Inventor(s)</B>&#148; shall
mean the inventor(s) named in the Patent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11 </B>&#147;<B>Joint Invention</B>&#148; shall have the meaning provided in
Section&nbsp;5.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12 </B>&#147;<B>Know-How</B>&#148; shall mean all non-patented and unpublished Information (including
documentation thereof) relating to Licensed Products and Controlled by ORGENTEC as of the Effective Date, including, but not limited to, research, clinical and manufacturing data and documentation, sample report forms from the clinical studies, case
report forms, clinical databases, protocols, completed patient informed consent forms, copies of laboratory notebooks, standard operating procedures and laboratory procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13 </B>&#147;<B>Licensed Product</B>&#148; shall mean any product, product part or service, the making, using, importing or selling of
which would, but for this license, infringe a Valid Claim in the Patent Rights in a country in which it is made, used, imported, or sold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14 </B>&#147;<B>Licensed Technology</B>&#148; shall mean the Patent Rights and Know-How. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15 </B>&#147;<B>Net Sales</B>&#148; shall mean the gross amounts invoiced by Proprius and its Affiliates (but not their respective
Sublicenses) for sales of Initial Products to Third Parties that are not Affiliates or Sublicenses of the selling party (unless such Affiliate or Sublicense is the end user of such Initial Product, in which case the amount billed therefor shall be
deemed to be the amount that would be billed to a Third Party end user in an arm&#146;s-length transaction), less the following items, as allocable to such initial Products: (i)&nbsp;discounts (including cash and quantity discounts), chargeback
payments and rebates granted to managed healthcare organizations or to federal, state or local governments (or their respective agencies, purchasers and reimbursers) or to trade customers, in each case, as determined in accordance with
Proprius&#146; or its Affiliate&#146;s normal accounting procedures, consistently applied; (ii)&nbsp;credits or allowances additionally granted upon returns, rejections or recalls; (iii)&nbsp;freight, shipping and Insurance charges actually allowed
or paid for by Proprius or Its Affiliates for delivery of Initial Products; and (iv)&nbsp;taxes, duties or other governmental tariffs (other than income taxes) levied on, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
absorbed or otherwise imposed on sales of Initial Products at the cost of Proprius or its Affiliates, Proprius and its Affiliates shall be solely responsible for the risk associated with
collection of accounts receivable for Initial Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any Combination Product, Net Sales for such Combination Product
for the purpose of determining royalties shall be calculated by multiplying actual Net Sales of such Combination Product by the fraction A/(A+B) where A is the cost of goods of the Initial Product portion of the Combination Product without any other
component(s) of the Combination Product, and B is the cost of goods of the other component(s) in the Combination Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16
</B>&#147;<B>New MCV IP</B>&#148; shall have the meaning provided in Section&nbsp;5.1(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17 </B>&#147;<B>Patent Rights</B>&#148;
shalt mean: (a)&nbsp;the patent(s) and patent application(s) listed in <B><I>Exhibit A</I></B> attached hereto, together with any and all applications, provisionals, continuations, continuations-in-part, divisionals, re-issues, additions, renewals
or extensions thereof and any patents issuing therefrom, or claiming priority to said applications, together with all embodiments and applications of the patents including, but not limited to its use in, and on all testing platforms and systems; and
(b)&nbsp;all improvements made by ORGENTEC to the inventions claimed in the patent(s) and patent application(s) listed in <B><I>Exhibit A</I></B> attached hereto during the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18 </B>&#147;<B>Kits</B>&#148; shall have the meaning provided in Section&nbsp;2.7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19 </B>&#147;<B>Proprius Invention</B>&#148; shall have the meaning provided in Section&nbsp;5.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20 </B>&#147;<B>Samples</B>&#148; shall mean, to the extent Controlled by ORGENTEC as of the Effective Date, and related to the subject
matter of this Agreement, all serum specimens, blood specimens, DNA material and lymphoblastoid cells generated from patients and/or healthy subjects, which specimens, material or cells were used by the Inventor(s) in the discovery of, or other
research and development with respect to, the Initial Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21 </B>&#147;<B>Sublicenses</B>&#148; shall mean any Third Party to
which Proprius or its Affiliate grants a sublicense of its license under the Licensed Technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22 </B>&#147;<B>Sublicense
Revenue</B>&#148; shall mean: [***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23 </B>&#147;<B>Term</B>&#148; shall have the meaning provided in Section&nbsp;8.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24 </B><I>&#147;</I><B>Territory</B>&#148; shall mean Mexico and the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25 </B><I>&#147;</I><B>Third Party</B>&#148; shall mean any entity other than ORGENTEC or Proprius or any of their respective Affiliates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26 </B>&#147;<B>Valid Claim</B>&#148; shall mean a claim of an issued and unexpired patent, which claim has not been held invalid or
unenforceable, or a claim of a pending patent application. Notwithstanding the foregoing, if a claim of a pending patent application shall not have issued within [***] after the earliest filing date from which such claim takes priority, such claim
shall not constitute a Valid Claim unless and until a patent issues with such claim. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>L<SMALL>ICENSE</SMALL>; R<SMALL>IGHT</SMALL> <SMALL>OF</SMALL> F<SMALL>IRST</SMALL> N<SMALL>EGOTIATION</SMALL> </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1 License Grant</B>. Subject to the terms and conditions of this Agreement, ORGENTEC hereby grants to Proprius an exclusive,
royalty-bearing license, including the right to sublicense through multiple tiers of sublicense, under the Licensed Technology solely to commercialize, develop, research, use, make, have made, sell, offer for sale, have sold and import Initial
Products in the Field in the Territory. Notwithstanding the exclusivity of the foregoing license, ORGENTEC reserves the right to practice the Licensed Technology in the Field in the Territory to the extent necessary to perform its obligations under
Section&nbsp;2.7 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2 Right of First Negotiation</B>. Subject to the terms and conditions of this Agreement, ORGENTEC hereby grants to
Proprius the right of first negotiation to obtain a license with respect to one or more Additional Products in the Field in the Territory in accordance with this Section&nbsp;2.2. If, during the Term, ORGENTEC proposes to introduce (either directly
or through an Affiliate or Third Party licensee or distributor) in the Territory any Additional Product, then ORGENTEC shall promptly notify Proprius thereof in writing of such intent and shall provide to Proprius any and all available scientific
data, patent filings and other relevant information regarding such Additional Product (&#147;<B><I>Diligence Information</I></B>&#148;). At any time during the 30-day period commencing on the date of such notice, provided that all available
Diligence Information regarding an Additional Product has been provided within [***] days following such notice (the &#147;<B><I>Review Period</I></B>&#148;), Proprius, at its sole discretion, may exercise its right of first negotiation with respect
to such Additional Product by delivering written notice of exercise to ORGENTEC. If Proprius exercises such right of first negotiation prior to expiration of the Review Period, the parties shall negotiate in good faith for up to an additional [***]
days (the &#147;<B><I>Negotiation Period</I></B>&#148;) regarding the terms upon which ORGENTEC would exclusively license such Additional Product to Proprius in the Field in the Territory. Until the expiration of the Negotiation Period with respect
to an Additional Product, ORGENTEC shall negotiate exclusively with Proprius regarding the grant of a license with respect to such Additional Product. If Proprius does not exercise its right of first negotiation with respect to an Additional Product
prior to expiration of the Review Period, or if Proprius exercises such right of first negotiation with respect to an Additional Product but the Negotiation Period expires without the parties having entered into a definitive written license
agreement with respect to such Additional Product, then ORGENTEC shall be free to offer such Additional Product to, and to negotiate and enter into a license with, any Third Party with respect to such Additional Product in the Field in the
Territory, except that ORGENTEC shall not license such Additional Product to any Third </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Party on terms more favorable to such Third Party than those offered to Proprius without first offering such license to Proprius on such more favorable terms for a period of at least 30 days.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3 Transfer of Samples</B>. Within 90 days after the Effective Date, ORGENTEC shall, if available and to the extent permitted by
applicable laws and commercially reasonable, the protocols approved by the respective IRBs/ Ethic Committees of the institutions through which the Samples were collected, and any informed consents obtained by ORGENTEC from Sample donors, transfer
(or cause to be transferred) the Samples to Proprius. ORGENTEC hereby grants to Proprius, to the extent permitted by applicable laws an exclusive license, including the right to grant sublicenses, to use the transferred Samples for technology
validation purposes with respect to initial Products in the Field in the Territory. As between the parties, Proprius shall be solely responsible for the costs of any such technology validation activities including the transfer of the samples.
Concurrently with the transfer of any such Samples, ORGENTEC shall provide Proprius with copies of the protocols approved by the respective IRBs/ Ethic Committees of the Institutions through which the Samples were collected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4 Technology Transfer; Consultation with Inventor(s)</B>. Promptly following the Effective Date and from time to time as necessary
thereafter, ORGENTEC shall provide to Proprius true and complete copies of all written materials in ORGENTEC&#146;s possession and Control relating to processes and methods for employing and practicing the Licensed Technology in the Field. In
addition, at Proprius&#146; request from time to time, ORGENTEC shall allow Proprius reasonable access to the Inventor(s) for consultation regarding the practice of the Licensed Technology. The contact to the Inventor(s) shall be coordinated through
a designated officer of Orgentec or Dr.&nbsp;Becker or Dr.&nbsp;Berg, who will act as intermediates between Proprius and Inventor(s) to answer any questions or help in Technology Transfer or relating to questions on processes and methods for
employing and practicing the Licensed Technology in the Field. Should the communication through a designated office of Orgentec or Dr.&nbsp;Becker or Dr.&nbsp;Berg be deemed insufficient or inefficient by both parties, a reasonable, supervised,
direct contact with the Inventor(s) would be made available to Proprius. For the avoidance of doubt, to the extent that the Inventors are not employees of ORGENTEC, it shall be subject to the Inventors&#146; free discretion to accept such request
for consultation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5 Diligence Obligations</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Subject to Section&nbsp;2.5(b) below, Proprius agrees to use commercially reasonable efforts (directly and/or through one or more
Affiliates and Sublicenses) to bring one or more initial Products to market in the Field in the Territory and, following first commercial sale, to promote such Initial Product(s) in the Field in the Territory during the Term. Without limiting the
generality of the foregoing (but subject to Section&nbsp;2.5(b)), Proprius shall achieve first commercial sale of an Initial Product by December&nbsp;31, 2008. If, despite its commercially reasonable efforts, Proprius fails to achieve first
commercial sale of an Initial Product by December&nbsp;31, 2008, the parties shall discuss in good faith an appropriate extension of such deadline and/or other modification of such diligence milestone. If the parties are unable to reach mutual
agreement on such extension or modification, ORGENTEC shall have the right to convert Proprius&#146; license under Section&nbsp;2.1 to a co-exclusive license upon written notice to Proprius. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Proprius&#146; diligence obligations under Section&nbsp;2.5(a) are subject to ORGENTEC using
commercially reasonable efforts to obtain U.S. Food and Drug Administration clearance or approval of its Anti-MCV (autoantibodies against mutated citrullinated vimentin) E LISA technology by December&nbsp;31, 2009. Proprius shall, if available and
to the extent permitted by applicable laws and commercially reasonable, the protocols approved by the respective IRBs/ Ethic Committees of the institutions through which samples were collected, and any informed consents obtained by Proprius from
sample donors, transfer (or cause to be transferred) available patient samples to ORGENTEC to support the FDA approval process. Proprius hereby grants to ORGENTEC, to the extent permitted by applicable laws a non-exclusive license, to use the
transferred samples for FDA approval purposes for Initial Products or Additional Products In the Field in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should ORGENTEC not act
diligently to achieve the FDA approval before or no later then December&nbsp;31, 2009, Proprius has the right, at its own discretion, to solely oversee and manage the FDA approval. In such case ORGENTEC would continue to carry the costs for the FDA
approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6 Disclosure Regarding Proprius Efforts</B>. At ORGENTEC&#146;s written request, Proprius shall provide ORGENTEC
with an bi-annual written progress report summarizing in reasonable detail Proprius&#146; and its Affiliates&#146; and Sublicenses&#146; activities related to the development and Commercialization of Initial Products in the Field in the Territory.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.7 Supply</B>. ORGENTEC shall supply Proprius with ORG 548 Anti-MCV 96-well titer plates and associated reagents
(&#147;<B><I>Plates</I></B>&#148;). During the Term, ORGENTEC agrees to sell and supply to Proprius such quantities of <B>Kits</B> as may be set forth on purchase orders placed by Proprius in accordance with this Section&nbsp;2.7. Proprius shall
order <B>Kits</B> by submitting written purchase orders to ORGENTEC specifying the quantity of <B>Kits</B> ordered, the desired shipment date for such Plates and any relevant shipping instructions. Proprius shall submit each purchase order to
ORGENTEC at least 30 days in advance of the desired shipment date specified in such purchase order. ORGENTEC shall make each shipment of <B>Kits</B> in the quantity and on the shipment date specified for it on Proprius&#146; purchase order, via the
mode(s) of transportation and to the destination specified on such purchase order. Any shipment shall be delivered [EXW ](Incoterms 2000). Any purchase orders for <B>Kits</B> submitted by Proprius to ORGENTEC shall reference this Agreement and shall
be governed exclusively by the terms contained herein. The parties hereby agree that the terms and conditions of this Agreement shall supersede any term or condition in any order, confirmation or other document furnished by Proprius or ORGENTEC that
is in any way inconsistent with these terms and conditions, ORGENTEC agrees to use its commercially reasonable efforts to ensure that <B>Kits</B> ordered by Proprius hereunder shall be delivered on the scheduled delivery dates set forth in the
relevant purchase orders. Promptly upon receipt of a shipment, Proprius shall inspect such shipment. Proprius shall notify ORGENTEC in writing and may reject any portion of any shipment of Plates if such portion of any shipment does not conform to
the applicable specifications established by ORGENTEC for the Plates, as in effect from time to time. If Proprius does not notify ORGENTEC of any such deficiency of the shipment within 7 days upon receipt, the shipment shall be deemed approved,
except for such deficiencies that were not apparent at the time of the inspection. The initial approval is however based on a visual inspection of the plates/kits and a standard QC check to assure performance specifications of a limited sample of
the purchased goods are met. Any change in or loss of performance compared to the product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specifications over time on the rest of the purchased plates/kits would fall under ORGENTEC&#146;S product warranty. In case of a presumed lack of performance, Proprius would, if available and to
the extent permitted by applicable laws and commercially reasonable provide ORGENTEC with patient samples, which seem to have resulted in questionable or wrong results, so that ORGENTEC can use them for their internal QC of the product which did not
fulfill the Proprius QC or performance specifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the total available supply of <B>Kits</B> is insufficient to meet the requirements of Proprius
and ORGENTEC&#146;s other customers, ORGENTEC shall be under no obligation to meet the order by Proprius but agrees that, in allocating the available supply of <B>Kits</B> while such shortage is in effect, ORGENTEC will give Proprius the same
&#147;high&#148; priority that ORGENTEC extends to any of its other comparable customers for <B>Kits</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.8 Territory</B>. ORGENTEC
shall not, directly or indirectly, and shall not cause, authorize or permit any of its Third Party licensees and distributors to: (a)&nbsp;engage in any advertising, promotion or marketing activities with respect to Initial Products in the
Territory; (b)&nbsp;actively solicit orders for Initial Products from any prospective purchaser with its principal place of business located in the Territory; or (c)&nbsp;deliver or tender any Initial Products in the Territory. ORGENTEC shall not
sell or deliver Initial Products to any Third Party licensee or distributor if ORGENTEC knows or has actual reason to believe that such Third Party licensee or distributor intends to resell or distribute such Initial Products in the Territory. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>F<SMALL>EES</SMALL> <SMALL>AND</SMALL> P<SMALL>AYMENTS</SMALL> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1 Upfront Fees</B>.
Proprius shall pay the following upfront fees to ORGENTEC: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Fifty thousand U.S. dollars (US$50,000) within 45 days after the Effective
Date; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Fifty thousand U.S. dollars (US$50,000) within 45 days after ORGENTEC notifies Proprius in writing of the issuance of the
first U.S. patent within the Patent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The upfront fees paid by Proprius pursuant to this Section&nbsp;3.1 shall be fully creditable toward amounts
payable under Section&nbsp;3.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2 Supply; Transfer Price</B>. The transfer price for <B>Kits</B> supplied pursuant to
Section&nbsp;2.7 shall be [***] U.S. dollars (US$[***]) per Plate. ORGENTEC shall invoice Proprius for the transfer price of Plates ordered by Proprius no earlier than the date of shipment to Proprius, and each such invoice shall be due and payable
within 30 days of receipt. Any increases in transfer price commencing after January&nbsp;1, 2009 should be given with a 3 month notice before a given calendar year and shall not be higher than the average German inflation rate of the ending calendar
year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3 Royalties</B>. Proprius shall pay to ORGENTEC a royalty of [***] percent ([***]%) of Net Sales of initial Products by
Proprius and its Affiliates. Royalties under this Section&nbsp;3.3 shall be payable on an Initial Product-by-Initial Product and country-by-country basis </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
until the expiration of the last to expire of the Patent Rights containing a Valid Claim claiming the manufacture, use or sale of such Initial Product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4 Payments on Sublicense Revenue</B>. Proprius shall pay to ORGENTEC [***] percent ([***]%) of Sublicense Revenue received by Proprius
from Sublicenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5 Third Party Royalties</B>. If Proprius is obligated or, following a claim or request by such Third Party, deems
it reasonably necessary to pay royalties or other compensation to any Third Party that holds a patent(s) or patent application(s) that is (or are) in the reasonable judgment of Proprius, infringed by the manufacture, use or sale of an Initial
Product in the Field In the Territory, Proprius may deduct [***] percent ([***]%) of such compensation actually paid to such Third Party(ies) from the royalties payable to ORGENTEC under Section&nbsp;3.3; <I>provided, however</I>, that in no event
shall the royalty payable to ORGENTEC under Section&nbsp;3.3 be reduced to less than [***] percent ([***]%) of Net Sales of Initial Products in any calendar quarter. Within 7 days after Proprius has gained actual knowledge of such claim or request
by a Third Party, Proprius shall notify ORGENTEC in writing of any such claim or request. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>P<SMALL>AYMENT</SMALL>; R<SMALL>ECORDS</SMALL>; A<SMALL>UDITS</SMALL> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1 Payment;
Reports</B>. Royalties and Sublicense Revenues shall be calculated and reported for each calendar quarter. All payments due to ORGENTEC under Sections 3.3 and 3.4 shall be paid within [***] days after the end of each calendar quarter. Each payment
shall be accompanied by a report of Net Sales of Initial Products by Proprius and its Affiliates and Sublicense Revenue received from Sublicenses in sufficient detail to permit confirmation of the accuracy of the payment made, including, without
limitation and on a country-by-country basis, the number and type of Initial Products sold, the gross sales and Net Sales of such Initial Products, consideration paid to Third Parties as described in Section&nbsp;3.5, the amount and type of
Sublicense Revenue received, the amounts payable to ORGENTEC hereunder, the method used to calculate such payments, and the exchange rates used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2 Exchange Rate; Manner and Place of Payment</B>. All payments hereunder shall be payable in U.S. dollars. With respect to Net Sales
Invoiced in a currency other than dollars, the Net Sales shall be calculated using the average of the exchange rate (local currency per US$1) published in <I>The Wall Street Journal</I>, Western Edition, on the last business day of each month during
the applicable calendar quarter. All payments owed under this Agreement shall be made by wire transfer free of any costs and charges and in immediately available funds to a bank and account designated in writing by ORGENTEC, unless otherwise
specified in writing by ORGENTEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3 Income Tax Withholding</B>. ORGENTEC will pay any and all taxes levied on account of any
payments made to it under this Agreement. If any taxes are required to be withheld by Proprius, Proprius shall (a)&nbsp;promptly provide ORGENTEC with the respective tax order (b)&nbsp;deduct such taxes from the payment to ORGENTEC, (c)&nbsp;timely
pay the taxes to the proper taxing authority, and (d)&nbsp;send proof of payment to ORGENTEC and certify its receipt by the taxing authority within 30 days following such payment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4 Audits</B>. During the Term and for a period of three (3)&nbsp;years thereafter, Proprius
shall keep, and shall require its Affiliates and Sublicenses to keep, complete and accurate records pertaining to the sale or other disposition of Initial Products and the receipt of Sublicense Revenue in sufficient detail to permit ORGENTEC to
confirm the accuracy of all payments due hereunder. ORGENTEC shall have the right, no more than <B>twice</B> per calendar year, to cause an independent, certified public accountant reasonably acceptable to Proprius to audit such records to confirm
Net Sales, royalties, Sublicense Revenue and related payments due hereunder for a period covering not more than the preceding three (3)&nbsp;years. Such audits may be exercised during normal business hours upon reasonable prior written notice to
Proprius. In no event shall any given year be subject to audit more than one time. Prompt adjustments shall be made by the parties to reflect the results of such audit. ORGENTEC shall bear the full cost of such audit unless such audit discloses an
underpayment by Proprius of more than [***]% of the amount of royalties or other payments due under this Agreement, in which case, Proprius shall bear the full cost of such audit and shall promptly remit to ORGENTEC the amount of any underpayment.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>I<SMALL>NTELLECTUAL</SMALL> P<SMALL>ROPERTY</SMALL> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1 Inventions</B>. Inventorship
of inventions (whether or not patentable) made in whole or in part by Proprius personnel in practicing the license granted hereunder (&#147;<B><I>Inventions</I></B>&#148;) shall be determined In accordance with the rules of inventorship under U.S.
patent laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Proprius shall solely own all Inventions made solely by Proprius personnel, including all patent and other intellectual
property rights therein (collectively, &#147;<B><I>Proprius Inventions</I></B>&#148;), and ORGENTEC shall have no right or license with respect to Proprius Inventions; <I>provided, however</I>, that if Proprius generates or reduces to practice any
Invention based solely on the inventions claimed in the Patent Rights (&#147;<B><I>New MCV IP</I></B>&#148;), Proprius shall promptly disclose such New MCV IP to ORGENTEC in writing and, at ORGENTEC&#146;s written request made within 30 days after
such disclosure, shall discuss in good faith the grant to ORGENTEC of a non-exclusive, royalty-free license to use such New MCV IP for specified applications outside the Field in Europe (such applications to be mutually agreed in writing by the
parties). In any event Proprius herewith grants ORGENTEC a non-exclusive, royalty-free license, without the right to sublicense, to use such New MCV IP for research purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) The parties shall jointly own all Inventions jointly made by Proprius personnel and ORGENTEC personnel, including all patent and other
intellectual property rights therein (collectively, &#147;<B><I>Joint inventions</I></B>&#148;). Each party shall be entitled to practice, and to grant licenses under its interest in, Joint Inventions throughout the world, without the consent of and
without accounting to the other party; <I>provided, however</I>, that ORGENTEC hereby grants to Proprius, during the Term, an exclusive, royalty-bearing license, including the right to sublicense through multiple tiers of sublicense, under
ORGENTEC&#146;s interest in Joint Inventions solely to commercialize, develop, research, use, make, have made, sell, offer for sale, have sold and import Initial Products in the Field in the Territory and Proprius hereby grants to ORGENTEC such
license with respect to Initial Products in the Field outside the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2 Patent Prosecution and Maintenance</B>. ORGENTEC
shall be solely responsible for prosecution and maintenance of the Patent Rights at its sole expense. With respect to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent rights in Joint Inventions, ORGENTEC shall be solely responsible for prosecution and maintenance, provided that ORGENTEC shall Inform Proprius about any actions it may take in this respect
and that any commercially reasonable costs incurred in connection with such patent rights shall be shared by the parties at the ratio of their respective interest therein. ORGENTEC shall keep Proprius regularly and fully informed of progress with
regard to the preparation, filing, prosecution and maintenance of Patent Rights in the Territory and shall consider in good faith the requests and suggestions of Proprius with respect to strategies for filing and prosecuting Patent Rights in the
Territory. In the event that ORGENTEC desires to abandon any Patent Right in the Territory, ORGENTEC shall provide reasonable prior written notice to Proprius of such intention to abandon, which notice shall, in any event, be given no later than 60
days prior to the next deadline for any action that may be taken with respect to such Patent Right with the U.S. Patent&nbsp;&amp; Trademark Office or any foreign patent office, and Proprius shall have the right, at its expense, to prepare, file,
prosecute, and maintain such Patent Right in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3 Disclosure of ORGENTEC Improvements</B>. if ORGENTEC generates or
reduces to practice any new invention or know-how constituting an improvement to any invention claimed in the patent(s) and patent application(s) listed in <B><I>Exhibit A</I></B> attached hereto, ORGENTEC shall promptly disclose such improvement to
Proprius in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4 Infringement by Third Parties</B>. Proprius and ORGENTEC shall promptly notify the other in writing of any
alleged or threatened infringement of any Patent Right in the Field in the Territory of which they become aware. Proprius shall have the first right, but not the obligation, to bring and control any action or proceeding with respect to infringement
of any Patent Right in the Field in the Territory at its own expense and by counsel of its own choice, and ORGENTEC shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. If Proprius fails to
bring an action or proceeding within (a)&nbsp;90 days following the notice of alleged infringement or (b)&nbsp;10 business days before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions,
whichever comes first, ORGENTEC shall have the right to bring and control any such action at its own expense and by counsel of its own choice, and Proprius shall have the right, at its own expense, to be represented in any such action by counsel of
its own choice. In the event a party brings an infringement action in the Field in the Territory in accordance with this Section&nbsp;5.4, the other party shall cooperate fully, including, if required to bring such action, the furnishing of a power
of attorney or being named as a party. Neither party shall have the right to settle any patent infringement litigation under this Section&nbsp;5.4 relating to any Patent Right in the Field in the Territory without the prior written consent of such
other party, which shall not be unreasonably withheld, conditioned or delayed. Except as otherwise agreed to by the parties as part of a cost-sharing arrangement, any recovery realized as a result of such litigation, after reimbursement of any
litigation expenses of Proprius and ORGENTEC, shall be retained by [***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1
Mutual Representations and Warranties</B>. Each party represents and warrants to the other that: (a)&nbsp;it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other
power and authority to enter into this Agreement and to carry out the provisions hereof; (b)&nbsp;it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this
Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action; and (c)&nbsp;this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2 ORGENTEC Representations and Warranties</B>. ORGENTEC hereby represents and warrants to Proprius as of the Effective Date that:
(a)&nbsp;ORGENTEC has sufficient rights in the patents and patent applications listed on <B><I>Exhibit A</I></B> hereto to grant the license and other rights it purports to grant to Proprius hereunder; (b)&nbsp;other than the patents and patent
applications listed on <B><I>Exhibit A</I></B> hereto, ORGENTEC does not Control any other patent rights that would be infringed by the practice of the Licensed Technology in the Field in the Territory; (c)&nbsp;ORGENTEC is not aware of any action,
suit or inquiry or investigation instituted by or before any court or governmental agency that questions or threatens the validity or enforceability of any of the Patent Rights; (d)&nbsp;ORGENTEC has not received any notice from any Third Party
alleging that the practice of the Licensed Technology in the Field in the Territory infringes the intellectual property rights of such Third Party; and (e)&nbsp;ORGENTEC has not licensed, assigned or otherwise transferred any of its interest in the
patents and patent applications listed on <B><I>Exhibit&nbsp;A</I></B> hereto in the Territory to any Third Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3 Disclaimer</B>.
Except as expressly set forth herein, THE TECHNOLOGY AND INTELLECTUAL PROPERTY RIGHTS PROVIDED BY EACH PARTY HEREUNDER ARE PROVIDED &#147;AS IS,&#148; AND EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED,
INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4 Limitation of Liability</B>. EXCEPT FOR PAYMENTS UNDER ARTICLE 3 OR LIABILITY FOR BREACH OF ARTICLE 7, NEITHER PARTY SHALL BE ENTITLED
TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER; <I>provided, however</I>, that this Section&nbsp;6.4 shall not be construed to limit
either party&#146;s indemnification obligations under Article 9. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>C<SMALL>ONFIDENTIALITY</SMALL> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1 Confidential Information</B>. Except to the
extent expressly authorized by this Agreement or otherwise agreed in writing by the parties, the parties agree that, during the Term and for five (6)&nbsp;years thereafter, the receiving party shall keep confidential and shall not publish or
otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement any Information furnished to it by the other party pursuant to this Agreement (collectively, &#147;<B><I>Confidential
Information</I></B>&#148;). Each party may use such Confidential Information only to the extent required to accomplish the purposes of this Agreement. Each party will use at least the same standard of care as it uses to protect proprietary or
confidential information of its own to ensure that its employees, agents, consultants and other representatives do not disclose or make any unauthorized use of the Confidential Information. Each party will promptly notify the other upon discovery of
any unauthorized use or disclosure of the Confidential Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2 Exceptions</B>. Confidential Information shall not include any
information which the receiving party can prove by competent written evidence: (a)&nbsp;is now, or hereafter becomes, through no act or failure to act on the part of the receiving party, generally known or available; (b)&nbsp;is known by the
receiving party at the time of receiving such information, as evidenced by its records; (c)&nbsp;is hereafter furnished to the receiving party by a Third Party, as a matter of right and without restriction on disclosure; or (d)&nbsp;is independently
discovered or developed by the receiving party without the use of Confidential Information belonging to the disclosing party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3
Authorized Disclosure</B>. Each party may disclose Confidential Information belonging to the other party to the extent such disclosure is reasonably necessary in the following instances: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) filing, prosecuting, maintaining, enforcing or defending Patent Rights as permitted by this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) prosecuting or defending litigation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) complying with applicable court orders or governmental regulations; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) conducting development and/or commercialization of initial Products in accordance with the license granted under Section&nbsp;2.1 and
making regulatory filings with respect thereto; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) disclosure to Affiliates, Sublicenses, employees, consultants, agents or other
Third Parties in connection With due diligence or similar investigations by such Third Parties, and disclosure to potential Third Party investors in confidential financing documents, provided, in each case, that any such Affiliate, Sublicenses,
employee, consultant, agent or Third Party agrees to be bound by reasonable obligations of confidentiality and non-use with respect to the disclosed Confidential Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the event a party is required to make a disclosure of the other party&#146;s Confidential information pursuant to
Section&nbsp;7.3(b) or (c), it will, except where impracticable, give reasonable advance notice to the other party of such disclosure and use efforts to secure confidential treatment of such information at least as diligent as such party
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would use to protect its own confidential information, but in no event less than reasonable efforts. In any event, the parties agree to take all reasonable action to avoid disclosure of
Confidential Information hereunder. The parties will consult with each other on the provisions of this Agreement to be redacted in any filings made by Proprius with the Securities and Exchange Commission or as otherwise required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4 Publications</B>. Proprius shall have the right to initiate, control and publish studies in the Territory. ORGENTEC shall have the
right to initiate, control and publish studies in the outside the Territory. If an ORGENTEC study is to be published in the Territory or if a Proprius study is to be published outside the Territory or if both parties initiate a joint study, both
parties shall have the right to review and comment on any material proposed for disclosure or publication by the other party, such as by oral presentation, manuscript or abstract, which utilizes Licensed Technology and/or includes Confidential
Information of the other party. Before any such material is submitted for publication, the party proposing publication shall deliver a complete copy to the other party for review at least [***] days prior to submitting the material to a publisher or
initiating any other disclosure. The reviewing party shall review any such materiel and give its comments to the publishing party within [***] days of the delivery of such material to the reviewing party. With respect to oral presentation materials
and abstracts, the reviewing party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing party with appropriate comments, if any, but in no event later
than [***] days from the date of delivery to the reviewing party. The publishing party shall comply with the reviewing party&#146;s requests to delete references to the reviewing party&#146;s Confidential Information in any such material and agrees
to delay any submission for publication or other public disclosure for a period of up to an additional [***] days for the purpose of allowing the preparation and filing of appropriate patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5 Publicity</B>. It is understood that each party may desire or be required to issue press releases relating to this Agreement or
activities thereunder. The parties agree to consult with each other reasonably and in good faith with respect to the text and timing of such press releases prior to the issuance thereof, provided that a party may not unreasonably withhold consent to
such releases, and that either party may issue such press releases as it determines, based on advice of counsel, are required to comply with laws or regulations or for appropriate market disclosure. In addition, each party shall be free to disclose,
without the other party&#146;s prior written consent, the existence of this Agreement, the identity of the other party and those terms of this Agreement which have already been publicly disclosed in accordance herewith. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>T<SMALL>ERM</SMALL> <SMALL>AND</SMALL> T<SMALL>ERMINATION</SMALL> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1 Term</B>. The
term of this Agreement (the &#147;<B><I>Term</I></B>&#148;) shall commence on the Effective Date and, unless this Agreement is earlier terminated pursuant to Section&nbsp;8.2 or 8.3, shall continue until the expiration of the last to expire of the
Patent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2 Termination for Cause</B>. Each party shall have the right to terminate this Agreement upon [***] prior written
notice to the other upon or after the material breach of any provision of this Agreement by the other party if the breaching party has not cured such breach within the [***] period following written notice of termination by the non-breaching party.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3 Termination Without Cause</B>. Proprius shall have the right to terminate this Agreement
for any reason or for no reason upon 90 days&#146; prior written notice to ORGENTEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4 Effect of Termination; Surviving
Obligations</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Upon termination of this Agreement by either party pursuant to Section&nbsp;8.2 or 8.3: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the license granted to Proprius under Section&nbsp;2.1 and Section&nbsp;5.1(b) shall automatically terminate and revert to ORGENTEC; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any sublicenses granted under Section&nbsp;2.1 and Section&nbsp;5.1. (b)&nbsp;by Proprius shall remain in effect but shall be
offered by Proprius to ORGENTEC, who shall have the unilateral right &#151; subject to any potentially necessary consent of the sublicense &#151; to request the assignment of such sublicenses from Proprius. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Upon the expiration (but not termination) of the Term of this Agreement, the license granted by ORGENTEC to Proprius under
Section&nbsp;2.1 shall remain in effect in accordance with its terms but shall become non-exclusive, fully-paid, royalty-free, irrevocable and perpetual. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such expiration or
termination. Except as set forth below or elsewhere in this Agreement, the obligations and rights of the parties under Sections 6.3, 6.4, 8.4, 8.5 and 8.6 and Articles 4, 7, 9 and 10 of this Agreement shall survive expiration or termination of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Within 30 days following the expiration or termination of this Agreement, each party shall deliver to the other party any
and all Confidential Information of the other party in its possession, except that each party may retain one archival copy of the other party&#146;s Confidential Information solely for purposes of monitoring compliance with its obligations
hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.5 Exercise of Right to Terminate</B>. The use by either party hereto of a termination right provided for under this
Agreement shall not give rise to the payment of damages or any other form of compensation or relief to the other party with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.6 Damages; Relief</B>. Subject to Section&nbsp;8.5 above, termination of this Agreement shall not preclude either party from claiming any
other damages, compensation or relief that it may be entitled to upon such termination. For the avoidance of doubt, the parties agree that any compensation claims pursuant to Section&nbsp;89b of the German Commercial Code (<I>HGB</I>) shall be
excluded. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>I<SMALL>NDEMNIFICATION</SMALL> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1 Indemnification by Proprius</B>. Proprius hereby
agrees to save, defend and hold Orgentec and its Affiliates and their respective directors, officers, employees and agents (each, an &#147;<B><I>Orgentec Indemnitee</I></B>&#148;) harmless from and against any and all claims, suits, actions,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
demands, liabilities, expenses and/or loss, including reasonable legal expense and attorneys&#146; fees (collectively, &#147;<B><I>Losses</I></B>&#148;), to which any Orgentec Indemnitee may
become subject as a result of any claim, demand, action or other proceeding by any Third Party to the extent such Losses arise directly or indirectly out of: (i)&nbsp;the development, manufacture, labeling, packaging, use, handling, shipment,
storage, distribution, sale or other disposition of any Initial Product by Proprius, its Affiliates or any of their respective Sublicenses; (ii)&nbsp;the gross negligence or willful misconduct of any Proprius Indemnitee (defined below); or
(iii)&nbsp;the breach by Proprius of any warranty, representation, covenant or agreement made by Proprius in this Agreement; except, in each case, to the extent such Losses result from the gross negligence or willful misconduct of any Orgentec
Indemnitee or the breach by Orgentec of any warranty, representation, covenant or agreement made by Orgentec in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2
Indemnification by Orgentec</B>. Orgentec hereby agrees to save, defend and hold Proprius and its Affiliates and their respective directors, officers, employees and agents (each, a &#147;<B><I>Proprius Indemnitee</I></B>&#148;) harmless from and
against any and all Losses to which any Proprius Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party to the extent such Losses arise directly or indirectly out of: (I)&nbsp;the gross
negligence or willful misconduct of any Orgentec Indemnitee; or (ii)&nbsp;the breach by Orgentec of any warranty, representation, covenant or agreement made by Orgentec in this Agreement; except, in each case, to the extent such Losses result from
the gross negligence or willful misconduct of any Proprius Indemnitee or the breach by Proprius of any warranty, representation, covenant or agreement made by Proprius in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3 Control of Defense</B>. Any entity entitled to indemnification under this Article 9 shall give notice to the indemnifying party of any
Losses that may be subject to indemnification, promptly after learning of such Losses, and the indemnifying party shall assume the defense of such Losses with counsel reasonably satisfactory to the indemnified party. If such defense is assumed by
the indemnifying party with counsel so selected, the indemnifying party will not be subject to any liability for any settlement of such Losses made by the indemnified party without its consent (but such consent will not be unreasonably withheld or
delayed), and will not be obligated to pay the fees and expenses of any separate counsel retained by the indemnified party with respect to such Losses. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>G<SMALL>ENERAL</SMALL> P<SMALL>ROVISIONS</SMALL> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1 Governing Law</B>. This
Agreement shall be governed by, and construed and enforced in accordance with, the laws of Germany, excluding its conflicts of laws principles. The parties expressly consent to the exclusive personal jurisdiction and venue of the competent courts of
Mainz, Germany, for any lawsuit filed by either party against the other arising from or related to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2 Entire
Agreement; Modification</B>. This Agreement (including the Exhibit hereto) is both a final expression of the parties&#146; agreement and a complete and exclusive statement with respect to all of its terms. This Agreement supersedes all prior and
contemporaneous agreements and communications, whether oral, written or otherwise, concerning any and all matters contained herein. This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the
parties to this Agreement. Waiver of such written form requirement may only be in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3 Relationship Between the Parties</B>. The parties&#146; relationship, as established by
this Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture, agency or similar business relationship between the parties. Neither party is a legal representative of the other party, and
neither party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other party for any purpose whatsoever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.4 Non-Waiver</B>. The failure of a party to insist upon strict performance of any provision of this Agreement or to exercise any right
arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a party of a particular provision or right
shalt be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.5 Assignment</B>. This Agreement may not be assigned or otherwise transferred by a party without the written consent of the other party;
<I>provided, however</I>, that, either party may, without such consent, assign this Agreement in connection with the transfer or sale of all or substantially all of its business related to this Agreement, including, without any limitation, through
any merger, consolidation, sale of stock, sale of assets or similar transaction. Any purported assignment in violation of the preceding sentence shall be void. Any permitted assignee shall assume all obligations of its assignor under this Agreement,
provided that no assignment shall relieve the assigning party of responsibility for the performance of any accrued obligation that such party then has hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.6 No Third Party Beneficiaries</B>. This Agreement is neither expressly nor impliedly made for the benefit of any party other than those
executing it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.7 Severability</B>. If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or illegal
by a court of competent jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability or legality of any remaining portions of this Agreement. All remaining portions shall remain in full force and
effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.8 Notices</B>. Any
notice to be given under this Agreement must be in writing and delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any of the foregoing, to the
party to be notified at its address(es) given below, or at any address such party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a)&nbsp;the date of
actual receipt; (b)&nbsp;if mailed, seven days after the date of postmark; or (c)&nbsp;if delivered by ovnight courier, the second business day the overnight courier regularly makes deliveries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to Proprius, notices must be addressed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proprius, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">12264 El Camino Real, Suite 350 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">USA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Facsimile: +1 (858)&nbsp;225-3553 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to ORGENTEC, notices must be addressed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ORGENTEC Diagnostika GmbH </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Carl-Zeiss-Strasse 49 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">55129 Mainz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Germany </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Facsimile: <U>+49-6131-925858</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.9 Force Majeure</B>. Each party shall be excused from liability for the failure or delay in performance of any obligation under this
Agreement except for any payment obligations hereunder by reason of any event beyond such party&#146;s reasonable control including but not limited to Acts of God, fire, flood, explosion, earthquake, or other natural forces, war, civil unrest,
accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, any strike or labor disturbance, or any other event similar to those enumerated above. Such excuse from
liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the party has not caused such event(s) to occur. Notice of a party&#146;s failure or delay in performance due
to force majeure must be given to the other party within 10 days after its occurrence. All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such force majeure. In no event shall any
party be required to prevent or settle any labor disturbance or dispute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.10 Interpretation</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Headings</B>. The headings of clauses contained in this Agreement preceding the text of the articles, sections, subsections and
paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Singular&nbsp;&amp; Plural</B>. All references in this Agreement to the singular shall include the plural where applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Articles, Sections&nbsp;&amp; Subsections</B>. Unless otherwise specified, references in this Agreement to any article shall include
all sections, subsections, and paragraphs in such article; references in this Agreement to any section shall include all subsections and paragraphs in such sections; and references in this Agreement to any subsection shall include all paragraphs in
such subsection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Ambiguities</B>. Ambiguities and uncertainties in this Agreement, if any, shall not be
interpreted against either party, irrespective of which party may be deemed to have caused the ambiguity or uncertainty to exist. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e)
<B>English Language</B>. This Agreement has been prepared in the English language and the English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral or
other communications between the parties regarding this Agreement shall be in the English language. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.11 Counterparts</B>. This
Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Remainder of this page intentionally left blank.] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have duly executed this <B>L<SMALL>ICENSE</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ORGENTEC D<SMALL>IAGNOSTIKA</SMALL> G<SMALL>M</SMALL>BH</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>ROPRIUS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Wigbert Berg</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael J. Walsh</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Wigbert Berg</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Michael J. Walsh</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President &amp; CEO</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PATENT RIGHTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>9
<FILENAME>d693329dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDMENT NO. ONE TO ASSET PURCHASE AGREEMENT </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BETWEEN CYPRESS BIOSCIENCE, INC. AND CELLATOPE CORPORATION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No. One is made as of this 14th day of December by and between Exagen Diagnostics, Inc. (&#147;Exagen&#148;), a Delaware
corporation and successor-in-interest to Cypress Bioscience, Inc. (&#147;Cypress&#148;), and Cellatope Corporation Liquidating Trust (the &#147;Trust&#148;), a trust formed pursuant to a certain Agreement and Declaration of Trust dated
February&nbsp;27, 2009 between Cellatope Corporation (&#147;Cellatope&#148;) and the Trustee and successor-in-interest to Cellatope, which, with Cypress, was party to that certain Asset Purchase Agreement, dated as of February&nbsp;9, 2009 (the
&#147;Agreement&#148;). Each of Exagen and the Trust is sometimes referred to herein as a &#147;party,&#148; and together Exagen and the Trust are sometimes referred to herein as &#147;parties.&#148; Capitalized terms used but not defined herein
shall have the respective meanings given to such terms in the Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RECITALS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Agreement, Cypress purchased from Cellatope the Acquired Assets, which included certain assets and rights with
respect to, or necessary for the manufacture, use or sale of, any Lupus Monitoring Product; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Agreement, Exagen,
as the successor in interest to Cypress, is obligated, under certain circumstances, to make payments to the Trust, including the Annual Payments, as the successor-in-interest to Cellatope; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in consideration of the Trust&#146;s willingness to forgo receipt of any Annual Payments under the Agreement in connection with this
Amendment No. One, the parties wish to amend certain provisions of the Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and
for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Amendment and Restatement of Section&nbsp;2.2(a)</U>. Section&nbsp;2.2(a) of the Agreement is amended and restated to read as follows:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.2 Milestone Consideration.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Within 10 business days after the First Commercial Sale by Cypress, any of its Affiliates or any Licensee of a Product for
monitoring of Systemic Lupus Erythematosus (a &#147;<B><I>Lupus Monitoring Product</I></B>&#148;) (the &#147;<B><I>Milestone</I></B>&#148;), Cypress shall notify Cellatope in writing (the &#147;<B><I>Milestone Notice</I></B>&#148;) that the
Milestone has been achieved and the date on which it was achieved. Within 20 business days of achievement of the Milestone, Cypress shall issue to Cellatope a promissory note (the &#147;<B><I>Note</I></B>&#148;) in the principal amount of $3,000,000
(subject to any reduction in such amount pursuant to Section&nbsp;10.6), the form of which is attached </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hereto as Exhibit A-1. The Note shall be unsecured and shall bear interest at the rate of 5% per annum. Interest shall accrue for the twelve-month period following issuance of the Note. On the
first anniversary of the date of issuance of the Note, accrued interest for the previous 12 months shall be added to the principal amount of the Note, which adjusted amount shall thereafter bear interest at 5% per annum. Thereafter, Cypress shall
make equal monthly payments representing principal and accrued interest, each month continuing for <B>48</B> months after such first anniversary, at which point any unpaid balance of the Note will be due and payable in full. Notwithstanding anything
herein to the contrary, the parties acknowledge and agree that in the event the Milestone is not achieved or if Cypress terminates development pursuant to Section&nbsp;2.2(c) below, no payments shall be due under this Agreement and Cypress shall not
be required to issue the Note. Amounts payable pursuant to the Note are referred to herein as the &#147;<B><I>Milestone Consideration</I></B>.&#148; For avoidance of doubt, only a Product for monitoring of Systemic Lupus Erythematosus, and not any
Product designed for diagnosis of Systemic Lupus Erythematosus without a monitoring function, shall constitute a Lupus Monitoring Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Amendment of Section&nbsp;2.2(b) and Related Provisions</U>. The first paragraph of Section&nbsp;2.2(b) of the Agreement is amended to
read as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Cypress shall act in good faith and use commercially reasonable efforts to cause the Milestone to be achieved;
<I>provided</I>, <I>however</I>, that the obligation of Cypress to use commercially reasonable efforts to achieve the Milestone shall not require that the Milestone ever be achieved if doing so, in any case, would require Cypress to use more than
commercially reasonable efforts and, <I>provided</I>, <I>further</I>, that a termination of development by Cypress of all Lupus Monitoring Products pursuant to Section&nbsp;2.2(c) below shall not be deemed a failure by Cypress to use, or otherwise
violate Cypress&#146; obligations to use, commercially reasonable efforts to develop a Lupus Monitoring Product. The parties acknowledge and agree that Cypress may terminate development of all Lupus Monitoring Products at any time if achieving the
Milestone would require Cypress to use more than commercially reasonable efforts to do so, and that any such termination may occur without requiring that Cypress also terminate the Amended Pittsburgh License in accordance with Section&nbsp;2.2(c)
below. Cypress shall provide notice to Cellatope of its determination to terminate development of all Lupus Monitoring Products because achieving the Milestone would require Cypress to use more than commercially reasonable efforts to do so within 15
days of making such determination, including reasonable details supporting such determination and, in such case, Cypress shall comply with the provisions of Section&nbsp;2.2(c)(ii) below. The parties further acknowledge and agree that nothing in
this Agreement shall prohibit Cypress from engaging in a change of control-type transaction or a sale or license of all or any of the Acquired Assets, <I>provided</I> that in the event that Cypress desires to consummate a Change of Control after the
Closing Date while the Milestone has not been attained but remains eligible to be attained, or the Note has been issued but not yet been paid in full, Cypress shall cause the Entity acquiring Cypress (or acquiring substantially all of its assets)
with respect to a Change of Control (the &#147;<B><I>Acquirer</I></B>&#148;) to assume Cypress&#146; obligations under Section&nbsp;2.2 of this Agreement, subject to all of the limitations and qualifications contained in Section&nbsp;2.2 of this
Agreement (including that such Acquirer use commercially reasonable efforts and the right of such Acquirer to terminate development of all Lupus Monitoring Products). With respect to any Change of Control, Cypress shall not consummate such Change of
Control unless (i)&nbsp;Cypress remains liable for Cypress&#146; payment obligations with respect to the </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Milestone Consideration and the Acquirer otherwise assumes Cypress&#146; obligations in Section&nbsp;2.2 in a form and substance reasonably acceptable to Cellatope (<I>provided</I>, that
Cellatope&#146;s prior acceptance or approval shall not be required if such assumption is unqualified), in which case the parties acknowledge and agree that, following any such assumption (unless Cypress is merged with the Acquirer and remains the
surviving Entity or becomes a subsidiary of the Acquirer), Cypress shall have no further liability or obligation, whether primarily or secondarily, with respect to the obligations in Section&nbsp;2.2 hereunder, except for the payment obligations
with respect to the Milestone Consideration or (ii)&nbsp;the Acquirer is an Applicable Public Company and assumes Cypress&#146; obligations under Section&nbsp;2.2 of this Agreement in a form and substance reasonably acceptable to Cellatope
(<I>provided</I>, that Cellatope&#146;s prior acceptance or approval shall not be required if such assumption is unqualified), in which case the parties acknowledge and agree that, following any such assumption (unless Cypress is merged with the
Acquirer and remains the surviving Entity or becomes a subsidiary of the Acquirer), Cypress shall have no further liability or obligation, whether primarily or secondarily, with respect to the obligations in Section&nbsp;2.2 hereunder, including the
payment obligations with respect to the Milestone Consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Amendment of Section&nbsp;2.2(b)(ii)</U>. Section&nbsp;2.2(b)(ii)
is amended to read as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) Cellatope may allege that Cypress is not using commercially reasonable efforts to achieve the
Milestone at any time by providing written notice to Cypress to such effect, including reasonable details supporting such allegation, and setting forth specific reasonable actions that Cellatope requests that Cypress take with respect to its efforts
to achieve the Milestone. If Cellatope provides any such notice, each party shall appoint an executive officer or other authorized person to discuss, and attempt to resolve, the alleged failure to perform to both parties&#146; satisfaction. These
Persons shall, by phone or in person, discuss the alleged failure to perform in good faith within 15 days after Cellatope provides the applicable notice. If, within 30 days after Cellatope provides the applicable notice, the two executive officers
have not reached a mutually acceptable resolution to the alleged failure to perform, Cellatope may submit the matter to arbitration conducted by one arbitrator mutually agreeable to Cypress and Cellatope. In the event that, within 30 days after
submission of any dispute to arbitration, Cypress and Cellatope cannot mutually agree on one arbitrator, then the parties shall arrange for the American Arbitration Association to designate a single arbitrator in accordance with the rules of the
American Arbitration Association. Any such arbitration shall be held in San Diego County, California, under the rules and procedures then in effect of the American Arbitration Association. The arbitrator shall determine how all expenses relating to
the arbitration shall be paid, including the respective expenses of each party, the fees of the arbitrator and the administrative fee to the American Arbitration Association. The arbitrator shall set a limited time period and establish procedures
designed to reduce the cost and time for discovery while allowing Cypress and Cellatope an opportunity, adequate in the sole judgment of the arbitrator, to discover relevant information from the opposing party about the alleged failure to perform.
The arbitrator shall rule upon motions to compel or limit discovery and shall have the authority to impose sanctions, including attorneys&#146; fees and costs, to the same extent as a competent court of law or equity, should the arbitrator determine
that discovery was sought without substantial justification or that discovery was refused or objected to without substantial justification. The </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arbitrator&#146;s decision shall be limited to the precise question of whether Cypress has used commercially reasonable efforts to achieve the Milestone and the specific actions, if any, to be
taken by Cypress that are necessary for Cypress to meet its obligation to use such commercially reasonable efforts, and shall be subject to the limitations set forth in this Agreement and be final, binding and conclusive upon the parties. The
parties acknowledge and agree that Cypress may, in lieu of taking the actions, if any, specified by the arbitrator as being necessary for Cypress to meet its obligation to use commercially reasonable efforts, pay to Cellatope the Milestone
Consideration in accordance with this Section&nbsp;2. The arbitrator&#146;s decision shall be written and shall be supported by written findings of fact and conclusions. The parties acknowledge and agree that the dispute resolution mechanism and
remedy set forth in this Section&nbsp;2.2(b )(ii) shall be the sole and exclusive method of dispute resolution and remedy available to the parties with respect to disputes arising under Section&nbsp;2.2(b), and that the provisions of Section&nbsp;10
shall be inapplicable to any dispute arising under Section&nbsp;2.2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Amendment of Sections 2.2(c)</U>. The first paragraph of
Section&nbsp;2.2(c) of the Agreement is amended to read as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) The parties also acknowledge and agree that, subject to
Section&nbsp;2.2(c)(i) and (ii)&nbsp;below, Cypress may terminate development of all Lupus Monitoring Products at any time prior to achievement of the Milestone by terminating the Amended Pittsburgh License in accordance with its terms and
conditions, and, upon such termination, Cypress&#146; obligations to use commercially reasonable efforts to cause the Milestone to be achieved under Section&nbsp;2.2(b) shall terminate. In the event that Cypress terminates development of all Lupus
Monitoring Products, Cypress shall: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Amendment of Section&nbsp;2.2(d)</U>. Section&nbsp;2.2(d) of the Agreement is amended to read
as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) During the time that Cypress is actively developing any Lupus Monitoring Product, (i)&nbsp;annually, on or before
January&nbsp;30 of each calendar year occurring after 2012, and (ii)&nbsp;semi-annually, upon request of Cellatope, Cypress shall provide Cellatope with a written summary describing in reasonable detail the status of achieving the Milestone. Any
summaries or other information provided by Cypress to Cellatope pursuant to this Section&nbsp;2.2(d) shall be governed by the Mutual Non-Disclosure Agreement dated April&nbsp;21, 2008 by and between Cypress and Cellatope or (y)&nbsp;such other
agreement as shall have identical terms and conditions, to the extent Cypress shall require the execution thereof by Cellatope as a condition precedent to providing such report(s) (the &#147;<B><I>Confidentiality Agreement</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Amendment of Section&nbsp;2.2(e)</U>. Section&nbsp;2.2(e) of the Agreement is deleted, and any and all references to such deleted
provisions of former Section&nbsp;2.2(e) of the Agreement shall be of no further force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Relabeling of
Section&nbsp;2.2(f)</U>. Section&nbsp;2.2(f) of the Agreement is relabeled as Section&nbsp;2.2(e). </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Amendment and Restatement of Section&nbsp;2.2(g)</U>. Section&nbsp;2.2(g) of the Agreement
is relabeled as Section&nbsp;2.2(f) and is amended and restated to read as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>During the period beginning on the
Closing Date and ending on the earlier of the date of payment in full of the Milestone Consideration or the termination of development of all Lupus Monitoring Products (the &#147;<B><I>Payment Period</I></B>&#148;), Cypress shall keep (and shall
cause its Affiliates and Licensees to keep) records pertaining to the development of Lupus Monitoring Products in sufficient detail to permit Cellatope to confirm whether the Milestone has been achieved and the accuracy and completeness of any
summaries provided pursuant to Section&nbsp;2.2(d). Such records shall be maintained for a period of at least one year after the Payment Period (and for the duration of any period in which the process contemplated by Section&nbsp;2.2(b )(ii) shall
be pending). During the Payment Period and for one year thereafter, Cellatope shall have the right to inspect such records, which inspection rights may be exercised during normal business hours upon reasonable prior written notice to Cypress and, in
each case, no more than once a calendar year. Cellatope shall bear the full cost of any such inspection, unless such inspection discloses a payment failure by Cypress of the Milestone Consideration payable under Section&nbsp;2.2(a), in which case,
Cypress shall bear the reasonable cost of the inspection. Information disclosed pursuant to this Section&nbsp;2.2(f) shall be governed by the Confidentiality Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Section References</U>. All references in the Agreement to sections that have been relabeled by this Amendment No. One shall be deemed
to refer to such sections, as relabeled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Capacity of Parties</U>. The parties acknowledge that they are the successors-in-interest
of the original parties to the Agreement that they are bound by the provisions of the Agreement, as amended by this Amendment No. One and that, references in the Agreement, as amended by this Amendment No. One, to Cypress shall be deemed to include
Exagen for all purposes, and references to Cellatope shall be deemed to include the Trust for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Dissolution of
Trust</U>. The parties acknowledge that the Trust may be dissolved prior to the end of the Payment Period and that its assets, including its rights and obligations under the Agreement, may be distributed to the beneficiaries of the Trust. At or
before the time of such dissolution, each beneficiary of the Trust for itself and its successors, shall appoint an individual as such beneficiary&#146;s agent and attorney-in-fact (the &#147;<B><I>Beneficiaries&#146; Representative</I></B>&#148;),
with full power and authority in the name of and for and on behalf of such beneficiary to act on behalf of such beneficiary for purposes of the Agreement. The Beneficiaries&#146; Representative shall exercise all power and authority granted to or
required by Cellatope under the Agreement. The Beneficiaries&#146; Representative will have full power and authority to act on the beneficiaries&#146; behalf in any dispute, litigation, arbitration or other matter involving the Agreement. A
decision, act, consent or instruction of the Beneficiaries&#146; Representative shall constitute a decision of all of the Beneficiaries and shall be binding and conclusive on each Beneficiary and their successors. Exagen agrees that following
receipt of appropriate documentation and instructions from the trustee of the Trust prior to dissolution of the Trust or, following such dissolution; from the Beneficiaries&#146; Representative, it will make payments of the Milestone Consideration
to the persons and in the respective amounts as instructed by the trustee or the Beneficiaries&#146; Representative. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Notice</U>. For purposes of Section&nbsp;11.4 of the Agreement (Notice), each of
Cellatope&#146;s and Cypress&#146; addresses and facsimile numbers (and those of any party required to be provided copies of notices under such section) are set forth on the signature pages hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Miscellaneous</U>. Except as expressly amended hereby, the Agreement remains in full force and effect in accordance with the terms
thereof. This Amendment No. One will be construed in accordance with and governed in all respects by, the internal laws of the State of California (without giving effect to principals of conflicts of laws) and may be executed in multiple
counterparts, each of which will constitute an original and all of which, when taken together, will constitute one agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder
of this page intentionally left blank] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amendment No. One as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EXAGEN DIAGNOSTICS, INC.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">CELLATOPE CORPORATION LIQUIDATING TRUST</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ron Rocca</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard Labuda</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Ron Rocca, CEO</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Richard Labuda, Trustee</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exagen Diagnostics, Inc.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Cellatope Corporation Liquidating Trust</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">801 University Blvd. SE, Suite 103</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">320 Osprey Court</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Albuquerque, NM 87106</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Wexford, PA 15090</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: CEO</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fax: 505.272.7965</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Attention: Trustee</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>with copy to (which copy shall not constitute notice):</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>with a copy to (which copy shall not constitute
notice):</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Brownstein Hyatt Farber Schreck, LLP</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Buchanan Ingersoll &amp; Rooney PC</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">201 Third Street NW</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">301 Grant Street, 20th Floor</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Albuquerque, NM 87102</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">One Oxford Centre</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn: Bonnie J. Paisley</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Pittsburg, PA 15219</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fax: 505-244-9266</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Attn: Perry S. Patterson</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Fax: 412.562.1041</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A-1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROMISSORY NOTE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>$3,000,000</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><B>[Date]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of this Note, for value received, Exagen Diagnostics, Inc., a Delaware
corporation (the &#147;<U>Borrower</U>&#148;), hereby promises to pay to Cellatope Corporation Liquidating Trust, a liquidating trust formed under the laws of the State of Delaware, or its assigns (the &#147;<U>Lender</U>&#148;), the principal sum
of Three Million Dollars and Zero Cents ($3,000,000) (the &#147;<U>Principal Amount</U>&#148;), together with interest thereon accruing on and from the date hereof until the entire balance is paid, at an annual rate equal to 5% (the
&#147;<U>Interest Rate</U>&#148;). Interest shall be calculated based on a 365-day year, compounded annually, but in no event shall the rate of interest exceed the maximum rate, if any, allowable under applicable law. Payments of principal and
interest shall be due within ten days after the end of each month beginning with the month in which the first anniversary of the date of issuance of this Note occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Terms of Note</U>. This Note is issued pursuant to, and is subject to the terms, and entitled to the benefits of, the Asset Purchase
Agreement, dated as of February&nbsp;9, 2009, as amended, modified or supplemented from time to time, including, without limitation, by Amendment No. One dated December&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2012 (the &#147;<U>Asset Purchase
Agreement</U>&#148;), between the Borrower as successor-in-interest to Cypress Bioscience, Inc. and, the Lender (as successor-in-interest of Cellatope Corporation). Capitalized terms used herein and not otherwise defined shall have the meanings set
forth in the Asset Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Interest; Adjustment to Principal</U>. This Note was issued within 20 days after the First
Commercial Sale. The initial principal amount of this Note is $3,000,000, and that amount will accrue interest for 12 months from the date of issuance at the Interest Rate. On the first anniversary of the date of issuance of this Note, the accrued
interest for such 12-month period, in the amount of $150,000, will be added to the principal amount of the Note. Such adjusted principal amount will thereafter bear interest at the applicable Interest Rate until the Note is paid in full. Such
payments will be due within ten days after the end of each month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Payments; Maturity</U>. Equal monthly payments representing
principal and interest on this Note, will be payable beginning within ten days after the last day of the month that is 12 months after the date of issuance of the Note and continuing for 48 months, at which point all accrued interest and any unpaid
principal balance shall be due and payable in full. All payments made under this Note will be applied first, to the most recent amount of accrued interest and principal required to be paid, second, against any overdue amounts, and lastly, pursuant
to Section&nbsp;4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Prepayment</U>. This Note may be prepaid at any time, without premium or penalty, in whole or in part. Any
prepayment of this Note shall be applied to installments of the principal </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount in the inverse order of maturity. Following any prepayment of this Note, the interest amounts payable on this Note shall be adjusted accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Remedy</U>. Upon any default in payment of any amount due hereunder, and if such default continues for thirty (30)&nbsp;days after the
Lender notifies Borrower of the same, a penalty in the amount of five percent (5%)&nbsp;of such overdue payment shall be added to the overdue payment and shall be immediately due and payable. Additionally, if Borrower (a)&nbsp;defaults with respect
to any six or more payments due under this Note (and if each such default continues for thirty (30)&nbsp;days after the Lender notifies Borrower of the same) in any one calendar year or (b)&nbsp;defaults in payment of any amount due under this Note
and such default continues for a period of six (6)&nbsp;months after the original due date for such amount, then upon notice to Borrower, (x)&nbsp;all principal and accrued but unpaid interest shall become immediately due and payable and
(y)&nbsp;such aggregate amount shall thereafter be assessed the penalty amount set forth in the first sentence of this Section&nbsp;5, after which such amount shall accrue interest in accordance with Section&nbsp;1 hereof. This Note is unsecured.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Amendments</U>. This Note may not be amended except by a written instrument duly executed and delivered by Borrower and Lender.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Assignment</U>. This Note may be assigned in accordance with the terms of the Asset Purchase Agreement and Amendment No. One
thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Replacement of Note</U>. Upon receipt by the Borrower of evidence reasonably satisfactory to it of ownership of and the
loss, theft, destruction or mutilation of this Note, and (a)&nbsp;in the case of loss, theft or destruction of indemnity reasonably satisfactory to it, or (b)&nbsp;in the case of mutilation, upon surrender and cancellation of this Note, the
Borrower, at its own expense, shall execute and deliver a new Note, dated and bearing interest from the date to which interest shall have been paid on this lost, stolen, destroyed or mutilated Note or dated the date of this lost, stolen, destroyed
or mutilated Note if no interest shall have been paid hereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Collection Expenses</U>. The Borrower further agrees, subject only to
any limitation imposed by applicable law, to pay all expenses, including reasonable attorneys&#146; fees, incurred by the holder of this Note in endeavoring to collect any amounts payable hereunder which are not paid when due. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Payments in U.S. Dollars</U>. All payments of principal and interest with respect to this Note are to be made in lawful money of the
United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Governing Law</U>. This Note shall be deemed to be a contract made under the laws of the State of
California, and for all purposes shall be governed by and construed in accordance with the laws of the State of California without regard to principles of conflicts of law hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Notices</U>. All notices and demands for payment shall be given in the manner specified in the Asset Purchase Agreement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Borrower has caused this Note to be duly executed and delivered as a
sealed instrument on the date set forth above by the duly authorized representative of the Borrower. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EXAGEN DIAGNOSTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>10
<FILENAME>d693329dex1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSET PURCHASE AGREEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">between: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>YPRESS</SMALL> B<SMALL>IOSCIENCE</SMALL>, I<SMALL>NC</SMALL>.</B>,<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ROPRIUS</SMALL>, I<SMALL>NC</SMALL>.</B>,<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>XAGEN</SMALL> D<SMALL>IAGNOSTICS</SMALL>, I<SMALL>NC</SMALL>.</B>,<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">a Delaware corporation </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of
October&nbsp;8, 2010 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ABLE</SMALL> <SMALL>OF</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>P<SMALL>AGE</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">S<SMALL>ALE</SMALL> <SMALL>AND</SMALL> P<SMALL>URCHASE</SMALL> <SMALL>OF</SMALL> A<SMALL>SSETS</SMALL>; R<SMALL>ELATED</SMALL> T<SMALL>RANSACTIONS</SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sale and Purchase of Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Excluded Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Purchase Price</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Tax Matters; Allocation of Purchase Price</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Security and Subordination Agreements; Ancillary Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Diligence Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Records; Audits; Reports</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Acceleration of Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Assumption of Obligations in Change of Control</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1.11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Late Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> <SMALL>OF</SMALL> S<SMALL>ELLER</SMALL> <SMALL>AND</SMALL> S<SMALL>UBSIDIARY</SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title to Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Patents and Know-How</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Contracts; Real Property Leases; Equipment; Certain Materials</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Compliance with Legal Requirements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Regulatory Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Employee Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Certain Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Legal Proceedings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authority; Binding Nature of Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Non-Contravention; Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Financial Statements for the Diagnostic Business</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Absence of Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.13</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sufficiency of Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASER</SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Due Organization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Absence of Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ABLE</SMALL> <SMALL>OF</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(C<SMALL>ONTINUED</SMALL>) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>P<SMALL>AGE</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authority; Binding Nature of Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Non-Contravention; Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Availability of Funds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">P<SMALL>RE</SMALL>-C<SMALL>LOSING</SMALL> C<SMALL>OVENANTS</SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Access</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Conduct of Diagnostic Business</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Conditions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">O<SMALL>THER</SMALL> C<SMALL>OVENANTS</SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Consents; Releases</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Employment Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Use of Names and Trademarks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Promotion at ACR Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Receipt of Monies or Other Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Payment of Rents, Utilities, Vendor Accounts and Other Operating Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Federal Express Account</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Procedures Relating to Accounts Receivable; Payment of Royalties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Security Interest in Intellectual Property Collateral</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Negative Covenants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Intellectual Property Assignments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">C<SMALL>ONDITIONS</SMALL> P<SMALL>RECEDENT</SMALL> <SMALL>TO</SMALL> P<SMALL>URCHASER</SMALL>&#146;<SMALL>S</SMALL> O<SMALL>BLIGATION</SMALL> <SMALL>TO</SMALL> C<SMALL>LOSE</SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Accuracy of Representations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Performance of Covenants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Additional Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">No Restraints</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">C<SMALL>ONDITIONS</SMALL> P<SMALL>RECEDENT</SMALL> <SMALL>TO</SMALL> S<SMALL>ELLER</SMALL>&#146;<SMALL>S</SMALL> <SMALL>AND</SMALL> S<SMALL>UBSIDIARY</SMALL>&#146;<SMALL>S</SMALL> O<SMALL>BLIGATION</SMALL>
<SMALL>TO</SMALL> C<SMALL>LOSE</SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Accuracy of Representations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Performance of Covenants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ABLE</SMALL> <SMALL>OF</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(C<SMALL>ONTINUED</SMALL>) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>



<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>P<SMALL>AGE</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Delivery of Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Additional Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">No Restraints</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Lienholder</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">T<SMALL>ERMINATION</SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Right to Terminate Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Termination Procedures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Effect of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">I<SMALL>NDEMNIFICATION</SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Survival of Seller and Subsidiary Representations; Indemnification by Seller</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Survival of Purchaser Representations; Indemnification by Purchaser</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Indemnification Procedure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">M<SMALL>ISCELLANEOUS</SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Time of Essence</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">No Other Representations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Knowledge; Materiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Access of Seller to Books and Records Related to the Diagnostic Business or Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Venue and Jurisdiction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Announcements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Assignment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Parties in Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Entire Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.13</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Amendments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.15</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ABLE</SMALL> <SMALL>OF</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(C<SMALL>ONTINUED</SMALL>) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>P<SMALL>AGE</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.16</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Interpretation of Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.17</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">No Setoff</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.18</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Further Assurances</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSET PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Asset Purchase Agreement is being entered into as of October&nbsp;8, 2010, by and between: <B>C<SMALL>YPRESS</SMALL>
B<SMALL>IOSCIENCE</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation (&#147;<B><I>Seller</I></B>&#148;); <B>P<SMALL>ROPRIUS</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation and wholly-owned subsidiary of Seller
(&#147;<B><I>Subsidiary</I></B>&#148;); and <B>E<SMALL>XAGEN</SMALL> D<SMALL>IAGNOSTICS</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation (&#147;<B><I>Purchaser</I></B>&#148;). Seller and Subsidiary, on the one hand, and Purchaser, on the
other hand, are referred to collectively in this Agreement as the &#147;<B><I>Parties.</I></B>&#148; Certain other capitalized terms used in this Agreement are defined in <B>Exhibit A</B>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITAL</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seller and Subsidiary are in the business (among other businesses) of developing and marketing diagnostic and drug products. Seller and
Subsidiary wish to sell and the Purchaser wishes to purchase the Diagnostic Business, and the Parties wish to provide for such purchase and certain related transactions, on the terms and subject to the conditions and other provisions set forth in
this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties, intending to be legally bound, agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. S<SMALL>ALE</SMALL> <SMALL>AND</SMALL> P<SMALL>URCHASE</SMALL> <SMALL>OF</SMALL> A<SMALL>SSETS</SMALL>; R<SMALL>ELATED</SMALL>
T<SMALL>RANSACTIONS</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1 Sale and Purchase of Assets</B>. On the terms and subject to the conditions and other provisions
set forth in this Agreement, at the Closing, Seller and Subsidiary hereby sell, assign and transfer to Purchaser, and Purchaser hereby purchases from Seller and Subsidiary, all of the following (which, subject to Section&nbsp;1.2, are referred to in
this Agreement as the &#147;<B><I>Assets</I></B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>all of Seller&#146;s and Subsidiary&#146;s rights and interests as of
the Closing Date in and to the Patents; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>all of Seller&#146;s and Subsidiary&#146;s rights and interests as of the Closing Date
in and to the Trademarks; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>all of Seller&#146;s and Subsidiary&#146;s rights and interests as of the Closing Date in and to the
Know-How; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>all of Seller&#146;s and Subsidiary&#146;s rights as of the Closing Date under the Contracts, including the right to
the security deposit held by the landlord pursuant to the lease for the Facility; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>all of Seller&#146;s and Subsidiary&#146;s rights and interests as of the Closing Date
in and to the Equipment; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>all of the fixtures and furnishings owned by Seller or Subsidiary as of the Closing Date that are
located and used primarily at the Facility; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g) </B>all sales, marketing and promotional materials owned by Seller or Subsidiary as of
the Closing Date that are located at the Facility; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h) </B>all inventories, work-in-process inventories, product-in-transit
inventories and other inventories of the Existing Products, and all inventories designated exclusively for use in the manufacture of the Existing Products, that are located at the Facility and owned by Seller or Subsidiary as of the Closing Date;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>all Acquired Xifin Accounts Receivable and Post-10/5 Accounts Receivable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(j) </B>all laboratory supplies, reagents and related laboratory materials owned by Seller or Subsidiary as of the Closing Date that are
located at the Facility and all antibodies owned by Seller or Subsidiary and used in the Diagnostic Business that are stored offsite, to the extent freely transferable (subject to applicable contractual use restrictions); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(k) </B>all of Seller&#146;s and Subsidiary&#146;s rights and interests as of the Closing Date in and to the Web Site IP; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(l) </B>those records of Seller and Subsidiary, as they exist on the Closing Date, that only relate to the Existing Products or the
Diagnostic Business (and do not relate to Seller&#146;s or Subsidiary&#146;s other businesses or assets) (it being understood that such records will not be subject to any restrictions on their use by Purchaser and that Seller and Subsidiary may,
subject to the provisions regarding confidentiality, retain copies of such records). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2 Excluded Assets</B>. Notwithstanding anything
to the contrary contained in Section&nbsp;1.1 or elsewhere in this Agreement, neither Seller nor Subsidiary will be required to sell or transfer to Purchaser, and the Assets will not be deemed to include, any of the following or any right or
interest in or to any of the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>any accounts receivable that are not either Acquired Xifin Accounts Receivable or
Post-10/5 Accounts Receivable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>any cash or cash equivalents; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>the telephone server, telephone system and copier/printer located at the Facility; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>any other assets, rights or interests that are not included as Assets pursuant to Section&nbsp;1.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3 Purchase Price</B>. As consideration for the sale of the Assets to Purchaser: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>at the Closing, Purchaser will pay (without deduction or setoff of any nature) by wire transfer of immediately available funds:
(i)&nbsp;to Seller, $[***] and (ii)&nbsp;to Subsidiary $[***] (the aggregate amount paid to Seller and Subsidiary pursuant to clauses (i)&nbsp;and (ii), the &#147;<B><I>Initial Cash Payment</I></B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>at the Closing, subject to the terms and conditions of this Agreement, Purchaser hereby assumes the Assumed Liabilities, each of
Seller and Subsidiary hereby transfers, assigns and delegates to Purchaser the Assumed Liabilities, and Purchaser hereby absolutely and unconditionally accepts such transfer, assignment and delegation and assumes and agrees to pay, honor, perform,
discharge and become liable for all Assumed Liabilities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>on the earlier of (i)&nbsp;the second anniversary of the date hereof
(the &#147;<B><I>Second Cash Payment Date</I></B>&#148;) or (ii)&nbsp;the first date on which a Trigger Event occurs requiring payment pursuant to Section&nbsp;1.9, Purchaser will, subject to Section&nbsp;10.17, pay to Seller, by wire transfer of
immediately available funds, the sum of $[***] (the &#147;<B><I>Second Cash Payment</I></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>for each of the following
contingent milestones (each, a &#147;<B><I>Milestone</I></B>&#148;), subject to Section&nbsp;10.17, Purchaser will pay by wire transfer of immediately available funds the following payments, each of which shall be payable only once, and only for the
first achievement of such Milestone: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>within five (5)&nbsp;business days after the achievement of the [***]
Milestone, Purchaser will pay to Subsidiary the [***] Milestone Amount; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>within five (5)&nbsp;business days
after the achievement of the [***] Milestone, Purchaser will pay to Subsidiary the [***] Milestone Amount; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)
</B>within five (5)&nbsp;business days after the achievement of the CB- CAPS Monitoring Assay [***] Milestone, Purchaser will pay to Seller the sum of $[***]; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>within thirty (30)&nbsp;days after the end of the month in which the CB- CAPS Annual Sales Milestone is first
achieved, Purchaser will pay to Seller the sum of $[***]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>Beginning on the date of the First Commercial Sale of the first
CB-CAPS Product in any country and ending on the [***] anniversary of such date, Purchaser shall, subject to Section&nbsp;10.17, pay to Seller royalties of [***]% of the Net Sales of each CB- CAPS Product anywhere in the world occurring during such
period; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>Beginning on the Closing Date and ending on the [***] anniversary of such date, Purchaser shall, subject to
Section&nbsp;10.17, pay to Subsidiary royalties of [***]% of the Net Sales of any Avise MCV Product and any Avise PG Product, occurring during such period anywhere in the United States of America and Mexico; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g) </B>Purchaser shall, subject to Section&nbsp;10.17, pay to Subsidiary royalties of [***]%
of the Net Sales of any New Product, for sales occurring during the period beginning on the date of the First Commercial Sale of each such New Product and ending on [***] (for purposes of clarity, the Parties acknowledge and agree that, until the
end of the applicable Royalty Term set forth in Section&nbsp;1.3(e) or (f), as applicable, any New Product that may also be deemed an Existing Product shall be paid the royalties set forth in Section&nbsp;1.3(e) or (f), as applicable, without
duplication of royalties set forth in this Section&nbsp;1.3(g) and, following the end of such applicable royalty term, the royalties set forth in this Section&nbsp;1.3(g) shall apply); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h) </B>Within 14 days after the delivery of each monthly reconciliation contemplated by Section&nbsp;1.8(f) of this Agreement, Seller or
Subsidiary, as applicable, shall, subject to Section&nbsp;10.17, pay to Purchaser an amount equal to (i)&nbsp;[***]% multiplied by all amounts received pursuant to Acquired Xifin Accounts Receivable during such month plus (ii)&nbsp;[***]% multiplied
by the amount of license royalties paid by Purchaser under any Contracts which are attributable to such accounts receivable during such month plus (iii)&nbsp;[***]% multiplied by the amount of the collection fee (which amount shall not exceed [***]%
of the amount collected) paid by Purchaser to Xifin with respect to such accounts receivable during such month. For accounts receivable for testing services performed by Purchaser with a date of service of October&nbsp;6, 2010 or later (as defined
by the blood sample draw date) (the &#147;<B><I>Post-10/5 Accounts Receivable</I></B>&#148;), the Parties shall, subject to Section&nbsp;10.17, follow the procedures set forth under &#147;<B><I>Post-10/5 Accounts Receivable</I></B>&#148; in
<B>Schedule&nbsp;5.8</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchaser shall pay all royalty amounts payable pursuant to Sections 1.3(e), (f)&nbsp;and (g)&nbsp;above within [***] days
after the end of each fiscal quarter during the applicable term of each such royalty in U.S. Dollars calculated using the conversion rates published in the Wall Street Journal on the day nearest the last business day of the calendar quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4 Tax Matters; Allocation of Purchase Price</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The Parties will use commercially reasonable efforts to agree upon an allocation of the consideration referred to in
Section&nbsp;1.3, plus the amount of the Assumed Liabilities included in the amount realized on the sale of the Assets for federal income Tax purposes, among the Assets (the &#147;<B><I>Allocation</I></B>&#148;) as soon as possible after the Closing
Date (but at least within 45 days following the Closing Date). The Allocation will be determined in a manner consistent with this Section&nbsp;1.4 and Section&nbsp;1060 of the Internal Revenue Code of 1986 (the &#147;<B><I>Code</I></B>&#148;) and
the Treasury Regulations thereunder. The Allocation will be conclusive and binding upon the Parties for Tax purposes, each Party will file all returns and reports relating to Taxes, including without limitation Form 8594, consistent with the
Allocation, and neither Party will take or permit any of its Affiliates or representatives to take any position on any Tax return, with any taxing authority or in any judicial Tax proceeding that is inconsistent with the Allocation except as
required by a final determination within the meaning of Section&nbsp;1313(a) of the Code or any corresponding provision of any applicable state or local law. Each Party will promptly provide the other Party with any additional information required
to complete Form 8594. Each Party will timely notify the other Party, and will timely provide the other Party with reasonable assistance, in the event of an examination, audit or other proceeding regarding the Allocation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Purchaser shall reimburse each of Seller and Subsidiary for 50% of the amount of any
sales taxes, use taxes, transfer taxes, documentary charges, recording fees, filing fees or similar taxes, charges, fees or expenses (collectively, &#147;<B><I>Transfer Taxes</I></B>&#148;) that may become payable in connection with the sale of the
Assets to Purchaser, the assumption by Purchaser of the Assumed Liabilities or any of the other transactions contemplated by this Agreement. The Parties will cooperate to the extent commercially reasonable to minimize the Transfer Taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>All real property taxes, personal property taxes, ad valorem obligations, similar recurring taxes and fees, general assessments and
special assessments imposed on or with respect to the Assets (&#147;<B><I>Property Taxes</I></B>&#148;) for any Straddle Period shall be prorated between Seller and Subsidiary, on one hand, and Purchaser, on the other hand, as of the close of
business on the Closing Date on a daily basis. Seller and Subsidiary shall be responsible for all such Property Taxes accruing under such daily proration methodology for the portion of the Straddle Period up to and including the Closing Date.
Purchaser shall be responsible for all such Property Taxes accruing under such daily proration methodology for the portion of the Straddle Period beginning on the day after the Closing Date. The Party responsible for filing returns relating to
Property Taxes for a Straddle Period shall file such returns but shall be entitled to reimbursement for any Property Taxes that are allocable to the other Party under this Section&nbsp;1.4(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5 Security and Subordination Agreements; Ancillary Agreements</B>. At the Closing, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Purchaser will execute and deliver to Seller an Intellectual Property Security Agreement in substantially the form of <B>Exhibit
B</B> (the &#147;<B><I>Intellectual Property Security Agreement</I></B>&#148;) and will deliver to Seller a Subordination Agreement in substantially the form of <B>Exhibit C</B> (the &#147;<B><I>Subordination Agreement</I></B>&#148;) validly
executed by Los Alamos National Bank; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>the Parties will enter into the following additional agreements (together with the
agreements contemplated in Section&nbsp;1.5(a) above, the &#147;<B><I>Ancillary Agreements</I></B>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>the
Consent to Assignment in substantially the form of <B>Exhibit D</B> (the &#147;<B><I>Consent to Assignment</I></B>&#148;), which document shall be validly executed by Seller, Purchaser and Landlord; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>the Assignment and Assumption of Lease Agreements in substantially the form of <B>Exhibit E</B> (the
&#147;<B><I>Lease Assumption</I></B>&#148;), which document shall be validly executed by Seller and Purchaser; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>the Assignment and Assumption Agreement in substantially the form of <B>Exhibit F</B>, which document shall be
validly executed by Seller, Purchaser and [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6 Closing</B>. The closing of the purchase of the Assets by Purchaser (the
&#147;<B><I>Closing</I></B>&#148;) will take place at the offices of Cooley LLP, 4401 Eastgate Mall, San Diego, California 92121, at a time and on a date to be designated by the Parties, which will be as promptly as practicable following the
satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in Sections 6 and 7 (other than those conditions that by their nature are to be satisfied at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Closing). For purposes of this Agreement, &#147;<B><I>Closing Date</I></B>&#148; means the date as of which the Closing actually takes place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7 Diligence Obligations</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Purchaser shall act in good faith and shall use commercially reasonable efforts, and shall cause its Affiliates and Licensees to
act in good faith and use commercially reasonable efforts, to (i)&nbsp;cause each of the Milestones to be achieved, including, as applicable, [***] with [***] and [***] discussions and negotiations to attempt to agree upon mutually satisfactory
agreements relating to the [***] Commercial Program and the [***] Commercial Program, timely preparing and filing all documents necessary and diligently pursuing all filings necessary to achieve each Milestone, and developing, commercializing and
selling CB-CAPS Products, (ii)&nbsp;develop, commercialize and sell Products subject to the Royalty Transactions, and (iii)&nbsp;collect, or cause to be collected, the Acquired Xifin Accounts Receivable. In addition, Purchaser [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8 Records; Audits; Reports</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>During the Royalty Term for a Product and for a period of one year thereafter, Purchaser shall keep, and shall cause its
Affiliates, Licensees and Distributors to keep, complete and accurate records pertaining to the Royalty Transactions for such Product or other disposition of such Product in sufficient detail to permit Seller to confirm the accuracy of the payments
for such Royalty Transactions. For a period ending one year after payment of a Milestone, Purchaser shall keep, and shall cause its Affiliates, Licensees and Distributors, if applicable, to keep, complete and accurate records pertaining to the
progress toward achievement of such Milestone in sufficient detail to permit Seller to confirm the diligence of Purchaser&#146;s efforts and progress towards achieving such Milestone. During the Acquired Xifin Accounts Term and for a period of one
year thereafter, Purchaser shall keep, and shall cause its Affiliates and Licensees to keep, complete and accurate records pertaining to the collection of Acquired Xifin Accounts Receivable (including those contemplated by <B>Schedule 5.8</B>) in
sufficient detail to permit Seller to confirm the accuracy of Purchaser&#146;s payments to Seller of the amount set forth in Section&nbsp;1.3(h) and Purchaser&#146;s allocation of such amounts to the specific tests performed, and, in addition,
Purchaser shall permit Seller to have access, during normal business hours, to all documentation (including without limitation test reports and patient- and physician-related information) that is in the possession of Purchaser, its Affiliates and
its and their agents and service providers and that is reasonably useful to Seller to respond to any insurance-related inquiry with respect to any accounts receivable arising prior to January&nbsp;12, 2010. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Until the end of the Royalty Term for a Product and for a period of one year thereafter, until payment of a particular Milestone
and for a period of one year thereafter, and until the end the Acquired Xifin Accounts Term and for a period of one year thereafter, Seller shall have the right to cause an independent, certified public accountant, reasonably acceptable to
Purchaser, to audit such records to confirm the amounts payable to Seller pursuant to Section&nbsp;1.3 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(for periods covering not more than the preceding three years); <I>provided, however</I>, Seller may not exercise the foregoing right more than once every calendar year. Such audits may be
conducted during normal business hours upon reasonable prior written notice to Purchaser and its Affiliates, Licensees, or Distributors, as applicable. If the audit reveals that Purchaser has failed to accurately calculate any payment to Seller due
under this Agreement, then Purchaser shall promptly pay to Seller any resulting amounts due hereunder, or Seller shall promptly refund overpayments made by Purchaser, each together with interest calculated in the manner provided in
Section&nbsp;1.11. Seller shall bear the full cost of each such audit unless such audit discloses an underpayment by Purchaser of at least $[***] and which is [***]% or more of the amount of payments due under this Agreement for any two quarter
period covered by such audit, in which case Purchaser shall bear the full cost of such audit and shall reimburse Seller within five (5)&nbsp;business days of receiving a notice from Seller setting forth the fees and expenses for the applicable
audit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>During the Royalty Term, Purchaser shall furnish to Seller a written report within [***] days after the end of each
fiscal quarter (each such period, a &#147;<B><I>Reporting Period</I></B>&#148;) showing, in reasonably-specific detail: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>the Net Sales (including reasonably specific detail as to the amounts of any deductions or credits applied to
calculate Net Sales and the basis therefor) on a Product-by-Product and country-by-country basis of all Products sold by Purchaser, its Affiliates, Licensees and Distributors during the Reporting Period; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>the royalties payable in U.S. Dollars, if any, which shall have accrued pursuant to Royalty Transactions, on a
per-Royalty Transaction basis, during the Reporting Period; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>the exchange rates used in determining the
amount of U.S. Dollars due to Seller on Net Sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>Until such time as a Milestone is achieved or such time as the Parties
agree in writing that such Milestone will not be achieved, by no later than the [***] day following [***] during such period (beginning with [***]), Purchaser shall provide to Seller a summary report setting out (i)&nbsp;[***] in such [***] (or
shorter, with respect to the period from the Closing Date to December&nbsp;31, 2010) period [***], (ii)&nbsp;the extent to which such Milestone has been accomplished, and (iii)&nbsp;[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>Purchaser shall provide Seller with copies of any agreement that Purchaser or its Affiliates enter into with [***] or [***]
relating to the [***] Commercial Program or the [***] Commercial Program, respectively. Any such agreement with [***] or [***] shall include a covenant by [***] or [***], as applicable, that Purchaser or its Affiliate shall receive, and shall be
entitled to deliver to Seller, the information necessary to determine if the [***] Milestone or the [***] Milestone, as applicable, has been achieved (including, without limitation, client reports from [***] that show enrollment in the [***]
Commercial Program </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the historical weekly average of clients enrolled in such program). Purchaser or its Affiliate shall promptly deliver such information to Seller upon receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>During the Acquired Xifin Accounts Term, Purchaser shall furnish Seller a reconciliation report within [***] days after the end of
each month (each such month, an &#147;<B><I>Accounts Reporting Period</I></B>&#148;) showing, in reasonably-specific detail: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>the amounts collected with respect to all Acquired Xifin Accounts Receivable by Seller, Subsidiary and their agents
and service providers during the Accounts Reporting Period, broken out by specific test performed (which tests shall include, without limitation, the Avise PG Product and the Avise MCV Product); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>the amount of royalties paid with respect to collections of Acquired Xifin Accounts Receivable by Purchaser, its
Affiliates and its and their agents and service providers during the Accounts Reporting Period broken out by payee, including without limitation Orgentec Diagnostika GmbH and Prometheus Laboratories Inc.; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>the amount of the Xifin collection fees associated with Xifin&#146;s collection of such Acquired Xifin Accounts
Receivable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9 Acceleration of Payment</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>If any Trigger Event occurs prior to the date on which Purchaser pays the Second Cash Payment to Seller, the Second Cash Payment
shall become immediately due and payable on the date of such Trigger Event. If any Trigger Event described in clauses (ii)&nbsp;through (vi)&nbsp;of Section&nbsp;1.9(b) below occurs prior to Purchaser&#146;s payment of a Milestone to Seller, any
such unpaid Milestone shall become immediately due and payable on the date of such Trigger Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>A &#147;<B><I>Trigger
Event</I></B>&#148; shall mean the occurrence of any of the following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>The consummation of any Change of
Control; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>Purchaser dissolves, liquidates or terminates its existence as a going business concern; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>Purchaser files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium
law or any other law for the relief of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit of creditors or takes any corporate action in furtherance of any of the foregoing; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>an involuntary petition is filed against Purchaser (unless such petition is dismissed or discharged within 60 days
under any bankruptcy statute now or hereafter in effect), or a custodian, receiver, trustee, assignee for the benefit of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
creditors (or other similar official) is appointed to take possession, custody or control of any property of Purchaser; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) </B>a breach of any of the negative covenants set forth in Section&nbsp;5.10; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vi) </B>Purchaser is in default of its obligations under any of the Junior Lienholder Loan Documents and the Junior
Lienholder elects to demand payment thereunder as a result of such default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10 Assumption of Obligations in Change of Control</B>.
In the event Purchaser experiences a Change of Control, Purchaser shall cause the Person acquiring Purchaser (or acquiring or exclusively licensing substantially all of its assets) with respect to a Change of Control to assume Purchaser&#146;s
obligations under this Agreement, including, without limitation, those obligations with respect to the Second Cash Payment, the Milestones, the Assumed Liabilities, the royalties paid for Royalty Transactions, and the Acquired Xifin Accounts
Receivable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11 Late Payments</B>. In the event that any payment due hereunder is not made when due, the payment shall accrue
interest from the date due at the rate of [***]% per month; <I>provided, however</I>, that in no event shall such rate exceed the maximum legal annual interest rate; and provided, further, that no interest shall be due pending resolution of a good
faith dispute with respect to such underpayment in accordance with Section&nbsp;9.3(c) or Section&nbsp;9.3(d) hereof (it being understood and agreed among the Parties that, in the event it is determined in connection with the resolution of any such
dispute that one Party owed payment to the other under this Agreement and failed to pay when due, interest shall accrue on these overdue payments under this Section&nbsp;1.11 from the date when such payments should have been made under this
Agreement). The payment of such interest shall not limit a Party from exercising any other rights it may have as a consequence of the lateness of any payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> <SMALL>OF</SMALL> S<SMALL>ELLER</SMALL> <SMALL>AND</SMALL>
S<SMALL>UBSIDIARY</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Seller and Subsidiary represents and warrants to Purchaser that, except as set forth in the Seller
Disclosure Schedule: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1 Title to Assets</B>. As of the Closing Date, Seller and Subsidiary, together, will have good and valid title
to the Assets, free and clear of any liens or encumbrances, except for (i)&nbsp;any lien for current taxes not yet due and payable, (ii)&nbsp;liens and encumbrances referred to in the Contracts and (iii)&nbsp;minor liens and encumbrances that have
arisen in the ordinary course of business and that do not materially detract from the value of the Assets subject thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2 Patents
and Know-How</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Each of the Patents is owned solely by Seller or Subsidiary. Seller has made available to Purchaser copies
of the Patents, and has supplied to Purchaser copies of the patent applications included in the Patents that are not publicly available as of the date of this Agreement. To Seller&#146;s knowledge, there are no intellectual property rights owned or
controlled by any third party necessary to make, use, sell, offer for sale and import the Existing Products, as they currently exist, other than those intellectual property rights to be transferred, licensed or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sublicensed to Purchaser pursuant to this Agreement. Neither Seller nor Subsidiary has received any written claim of infringement of any intellectual property rights of any Person arising out of
the development, manufacture, use, sale, offer for sale or import of the Existing Products by Seller or Subsidiary. To Seller&#146;s knowledge, each of Seller and Subsidiary has complied with its obligation under 37 CFR &#167;1.56(a) to disclose to
the United States Patent and Trademark Office, during the pendency of any United States patent application included in the Patents, information known to Seller to be material to the patentability of the pending claims in such application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Neither Seller nor Subsidiary has granted any Person a license that is currently in effect under any of the Patents for any
purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>None of the Patents is involved in any interference or opposition proceeding, and, to Seller&#146;s knowledge, no
such proceeding is being threatened with respect to any of the Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>Seller has disclosed trade secrets of Seller included
in the Know-How only to Persons that have executed written confidentiality agreements governing the use or disclosure of such trade secrets, except to the extent Seller disclosed such information in connection with making filings related to any
Assets or Products with governmental or regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>Seller has required all professional and technical employees
who provided services to Seller or Subsidiary in connection with the Diagnostic Business or the Patents or Know-How to execute agreements under which such employees were required to convey to Seller or Subsidiary ownership of all inventions and
developments conceived or created by them in the course of their employment with Seller. To Seller&#146;s knowledge, none of the activities of Seller&#146;s professional and technical employees who are providing services to Seller in connection with
the Diagnostic Business and the Patents and Know-How is violating any agreement between any such employees and their former employers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3 Contracts; Real Property Leases; Equipment; Certain Materials</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Seller has made available to Purchaser true and correct copies of each of the contracts identified on <B>Schedule 1</B>. Each
contract identified on <B>Schedule 1</B> is valid and in full force and effect. Neither Seller nor Subsidiary is in material breach of any contract identified on <B>Schedule 1</B>, and, to Seller&#146;s knowledge, no other party to any such contract
is in material breach of such contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>The contracts identified on <B>Schedule 1</B> include the real property leases
pursuant to which Seller has the right to occupy the Facility. All security deposits required to be made by Seller under such real property leases have been made by Seller, and no portion of such security deposits has been applied to any default by
Seller under any of such real property leases. Seller has the right to occupy the Facility in accordance with the terms of such real property leases. Seller is not in material breach of any such real property lease identified on <B>Schedule 1</B>,
and, to Seller&#146;s knowledge, no other party to any such real property lease is in material breach of such contract. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> There are no laboratory supplies, reagents or related laboratory materials owned by
Seller or Subsidiary at a location other than the Facility that relate exclusively to the Diagnostic Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4 Compliance with
Legal Requirements</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Each of Seller and Subsidiary is in compliance with all Legal Requirements relating to the Diagnostic
Business. Since January&nbsp;1, 2009, neither Seller nor Subsidiary has received any written notice from any governmental body alleging any failure to comply with any Legal Requirement relating to the Diagnostic Business and the employment of the
Specified Employees, except for any such notice relating to a failure to comply that has since been cured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>To Seller&#146;s
knowledge, at all times prior to January&nbsp;1, 2009, each of Seller and Subsidiary was in compliance with all Environmental Laws applicable to the Diagnostic Business, the Facility and Seller&#146;s operations at the Facility. Each of Seller and
Subsidiary is, and has been at all times since January&nbsp;1, 2009, in compliance with all Environmental Laws applicable to the Diagnostic Business, the Facility and Seller&#146;s operations at the Facility. To Seller&#146;s knowledge, no event has
occurred or condition exists or has existed which would reasonably be expected to give rise to any material liability on the part of Purchaser pursuant to, or to materially impair Purchaser&#146;s compliance with, any Environmental Law applicable to
the Assets and the Facility. The Facility has not been listed or, to Seller&#146;s knowledge, proposed for listing on the National Priorities List established by the United States Environmental Protection Agency, or any similar federal or state
list. To Seller&#146;s knowledge, no material lien has attached to any of Seller&#146;s or Subsidiary&#146;s property at the Facility pursuant to any Environmental Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>There has not been any action taken by Seller or Subsidiary, operating practice by Seller or Subsidiary or failure by Seller or
Subsidiary to act that would reasonably be expected to give rise to a material liability on the part of Purchaser as a result of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>the handling, storage, use, presence, transportation or disposal or arranging for transportation or disposal of any
Hazardous Substance by Seller or Subsidiary in, on, under, near or from the Facility; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>any emission, discharge
or release of any Hazardous Substance by Seller or Subsidiary on or from the Facility into or upon the air, surface water, ground water or land; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>any disposal, handling, manufacturing, processing, distribution, use, treatment or transport of any Hazardous
Substances by Seller or Subsidiary on or from the Facility; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>the presence of any Hazardous Substances
(including asbestos, urea formaldehyde foam installation or similar substances contained in building materials) in or on the Facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>Seller and Subsidiary, together, hold all registrations, permits, licenses and approvals issued by or on behalf of any federal,
state or local government body that are required pursuant to any Environmental Laws for the occupancy of and the conduct of business at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Facility and the ownership of the Assets (&#147;<B><I>Environmental Permits</I></B>&#148;). Any such Environmental Permits held by Seller or Subsidiary are currently in full force and effect.
Each of Seller and Subsidiary is in compliance with all terms and conditions of such Environmental Permits, and with all other applicable limitations, restrictions, conditions, standards, prohibitions, requirements, obligations, schedules and
timetables contained in Environmental Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>To Seller&#146;s knowledge, no underground storage tanks or surface impoundments
exist at the Facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g) </B>Neither Seller nor Subsidiary has, either expressly or by operation of law, assumed or undertaken any
liability or corrective, investigatory or remedial obligation of any other Person relating to any Environmental Laws that would reasonably be expected to result in a material liability to Purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h) </B>Seller has made available to Purchaser copies of any environmental reports, audits, permits, licenses, registrations and other
environmental, health or safety documents relating to the Assets and the Facility that are in Seller&#146;s or Subsidiary&#146;s possession or control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5 Regulatory Matters</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The licensure, certifications and/or accreditations of the laboratory at the Facility under the Clinical Laboratory Improvement
Amendments of 1988, as amended, the 48 contiguous states of the United States and the College of American Pathologists are in full force and effect. Seller has made available to Purchaser copies of all governmental correspondence (including copies
of official notices, citations or decisions) in Seller&#146;s or Subsidiary&#146;s files relating to the Existing Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)
</B>Each of Seller and Subsidiary is in compliance with the laws applicable to the development, manufacture, labeling, testing and distribution of the Existing Products (at the Facility and otherwise) and the operation of manufacturing facilities
used to manufacture the Existing Products, and with all applicable regulations, policies and procedures promulgated by the FDA with respect thereto. Neither Seller nor Subsidiary has received any written notice that any recalls, field notifications
or seizures have been ordered or, to Seller&#146;s knowledge, threatened by any governmental body with respect to any of the Existing Products. Neither Seller nor Subsidiary has received a warning letter or other similar written notice from the FDA
regarding the Existing Products or the manufacturing facilities used to manufacture the Existing Products, except for written notices regarding matters that have since been cured, corrected or resolved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6 Employee Matters</B>. Seller has made available to Purchaser (except to the extent prohibited under applicable Legal Requirements)
accurate information with respect to the employment of, the job responsibilities of, the compensation payable by Seller to and the employee benefits being provided to each of the Specified Employees. As of the date of this Agreement, there are
approximately 4 employees of Seller based at the Facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.7 Certain Liabilities</B>. As of the date of this Agreement, neither
Seller nor Subsidiary has any material liabilities relating to the Assets, the Existing Products or the Specified Employees other than (i)&nbsp;liabilities under or relating to the contracts and other instruments identified on <B>Schedule 1</B>,
(ii)&nbsp;liabilities incurred in the ordinary course of business or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consistent with past practices, (iii)&nbsp;liabilities referred to in, or relating to matters referred to in, the Seller Disclosure Schedule, (iv)&nbsp;liabilities under applicable Legal
Requirements, and (v)&nbsp;liabilities disclosed in any of Seller&#146;s publicly filed materials. Purchaser is not assuming any liabilities other than the Assumed Liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.8 Legal Proceedings</B>. There is no lawsuit or other legal proceeding pending or, to Seller&#146;s knowledge, being threatened against
Seller or Subsidiary as of the date of this Agreement that involve the Diagnostic Business or would reasonably be expected to result in a judgment having a material adverse effect on the value of the Diagnostic Business taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.9 Authority; Binding Nature of Agreement</B>. Each of Seller and Subsidiary has all necessary corporate power and authority to execute
and deliver this Agreement and the Ancillary Agreements to which it is a party and to perform its obligations under this Agreement and the Ancillary Agreements to which it is a party; and the execution, delivery and performance by Seller and
Subsidiary of this Agreement and the Ancillary Agreements to which it is a party have been duly authorized by all necessary action on the part of Seller, Subsidiary and their respective boards of directors. No vote of the holders of Seller&#146;s
common stock is required to authorize the transactions contemplated by this Agreement. This Agreement constitutes the valid and binding obligation of each of Seller and Subsidiary, enforceable against each of Seller and Subsidiary in accordance with
its terms, subject to (i)&nbsp;laws of general application relating to bankruptcy, insolvency and the relief of debtors and (ii)&nbsp;rules of law governing specific performance, injunctive relief and other equitable remedies. Upon execution
thereof, the Ancillary Agreements to which it is a party will constitute the valid and binding obligation of Seller, enforceable against Seller in accordance with its terms, subject to (i)&nbsp;laws of general application relating to bankruptcy,
insolvency and the relief of debtors and (ii)&nbsp;rules of law governing specific performance, injunctive relief and other equitable remedies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.10 Non-Contravention; Consents</B>. Assuming the Consents referred to in Part 2.10 of the Seller Disclosure Schedule are obtained,
neither the execution, delivery or performance by Seller or Subsidiary of this Agreement or the Ancillary Agreements to which it is a party, nor the consummation of any of the transactions contemplated hereby will: (a)&nbsp;conflict with or result
in any violation of any provision of the certificate of incorporation, bylaws or other charter or organizational documents of Seller or Subsidiary, (b)&nbsp;result in a breach or default by Seller or Subsidiary under any Contract, (c)&nbsp;result in
a violation of any Legal Requirement or order to which Seller or Subsidiary is subject, or (d)&nbsp;result in the imposition of any lien or encumbrance upon any of the Assets (other than to the extent provided for in the Intellectual Property
Security Agreement). Except as set forth in Part 2.10 of the Seller Disclosure Schedule, neither Seller nor Subsidiary is required to obtain any Consent from any Person, under any Contract, at or prior to the Closing in connection with the execution
and delivery of this Agreement or any of the Ancillary Agreements to which it is a party or the sale of the Assets to Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.11
Financial Statements for the Diagnostic Business</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Seller has delivered to Purchaser the schedule of the unaudited actual
costs and cash collections of the Diagnostic Business at December&nbsp;31, 2009 (the &#147;<B><I>December</I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B><I>Financial Information</I></B>&#148;). The December Financial Information is true and correct in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Seller has delivered to Purchaser a schedule of the unaudited actual costs, cash collections and a schedule of fixed assets of the
Diagnostic Business as at August&nbsp;31, 2010 (the &#147;<B><I>August Financial Information</I></B>&#148;). The August Financial Information is true and correct in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.12 Absence of Changes</B>. Since August&nbsp;31, 2010, there has not been any material adverse change in the Assets or Diagnostic
Business (including the liabilities, operations, financial performance or prospects thereof). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.13 Sufficiency of Assets</B>. The
Assets constitute all of the material assets necessary to operate the Diagnostic Business in the manner presently operated by Seller. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.
R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASER</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchaser
represents and warrants to Seller as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1 Due Organization</B>. Purchaser is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2 Financial Statements</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The Purchaser has delivered to the Seller the following financial statements and notes (collectively, the &#147;<B><I>Purchaser
Financial Statements</I></B>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>Purchaser&#146;s unaudited balance sheet at December&nbsp;31, 2009 and
audited statements of income and cash flow for the twelve months ending December&nbsp;31, 2009; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)
</B>Purchaser&#146;s unaudited balance sheet as at August&nbsp;31, 2010 (the &#147;<B><I>Statement Date</I></B>&#148;) and unaudited consolidated statements of income and cash flow for the eight month period ending on the Statement Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>The Purchaser Financial Statements have been prepared in accordance with generally accepted accounting principles applied on a
consistent basis throughout the periods indicated, except as disclosed therein, and present fairly the financial condition and position and operating results and cash flows of the Purchaser as of December&nbsp;31, 2009 and the Statement Date;
<I>provided, however</I>, that the unaudited financial statements are subject to normal recurring year-end audit adjustments (which are not expected to be material either individually or in the aggregate), and do not contain all footnotes required
under generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3 Absence of Changes</B>. Since August&nbsp;31, 2010, there has not been any
material adverse change in the business, condition, capitalization, assets (tangible or intangible), liabilities, operations, financial performance or prospects of Purchaser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4 Authority; Binding Nature of Agreement</B>. Purchaser has all necessary power and
authority to execute and deliver this Agreement and the Ancillary Agreements to which it is party, and to perform its obligations hereunder and thereunder; and the execution, delivery and performance by Purchaser of this Agreement and the Ancillary
Agreements to which it is a party have been duly authorized by all necessary action on the part of Purchaser and its board of directors. Purchaser has provided to Seller a copy of the resolutions of the board of directors of Purchaser authorizing
the execution, delivery and performance by Purchaser of this Agreement and the Intellectual Property Security Agreement. No vote of the holders of Purchaser&#146;s capital stock (or any class or series thereof) is required to authorize the purchase
by Purchaser of the Assets or any of the other transactions contemplated by this Agreement or the Ancillary Agreements to which it is a party. This Agreement constitutes, and, upon execution thereof, the Ancillary Agreements to which it is a party
will constitute, the valid and binding obligation of Purchaser, enforceable against Purchaser in accordance with its terms, subject to (i)&nbsp;laws of general application relating to bankruptcy, insolvency and the relief of debtors, and
(ii)&nbsp;rules of law governing specific performance, injunctive relief and other equitable remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5 Non-Contravention;
Consents</B>. Neither the execution, delivery or performance by Purchaser of this Agreement or the Ancillary Agreements to which it is a party, nor the consummation of any of the transactions contemplated by this Agreement or the Ancillary
Agreements to which it is a party, will (a)&nbsp;conflict with or result in any violation of any provision of the certificate of incorporation, bylaws or other charter or organizational documents of Purchaser, (b)&nbsp;result in a breach or default
by Purchaser under any material contract to which Purchaser is a party, (c)&nbsp;result in a violation of any Legal Requirement or order to which Purchaser is subject or (d)&nbsp;except as contemplated by the Intellectual Property Security Agreement
and the lien of the Junior Lienholder, result in the creation of a lien or encumbrance on any material asset of Purchaser, including the Assets. Purchaser is not and will not be required to obtain any Consent from any Person in connection with the
execution, delivery or performance of this Agreement or the Ancillary Agreements to which it is a party or the consummation of any of the transactions contemplated hereby or thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6 Availability of Funds</B>. Purchaser has, and on the Closing Date will have, sufficient funds available to finance and consummate the
transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. P<SMALL>RE</SMALL>-C<SMALL>LOSING</SMALL> C<SMALL>OVENANTS</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1 Access</B>. Subject to the provisions of the Confidentiality Agreement and to applicable Legal Requirements, during the period from the
date of this Agreement through the Closing Date (the &#147;<B><I>Pre-Closing Period</I></B>&#148;), Seller will, after receiving reasonable advance notice from Purchaser, give Purchaser reasonable access (during normal business hours) to the
Facility and to Seller&#146;s and Subsidiary&#146;s books and records relating only to the Diagnostic Business, and will provide Purchaser with such information regarding the Diagnostic Business and any other appropriate matters germane to the
subject matter of this Agreement as Purchaser may reasonably request, for the sole purposes of enabling Purchaser (i)&nbsp;to further investigate, at Purchaser&#146;s sole expense, the Diagnostic Business and any other appropriate matters germane to
the subject matter of this Agreement and (ii)&nbsp;to verify the accuracy of the representations and warranties set forth in Section&nbsp;2; <I>provided, however</I>, that except as provided in Section&nbsp;5.2, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Purchaser will not (without Seller&#146;s approval, which will not be unreasonably withheld) contact or otherwise communicate with any of the Seller&#146;s employees. To the extent requested by
Purchaser, Seller will arrange to permit Purchaser to conduct interviews of any of the Specified Employees during the Pre-Closing Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2 Conduct of Diagnostic Business</B>. Until the earlier of the Closing Date and the close of business on October&nbsp;15, 2010, except
(i)&nbsp;as contemplated or permitted by this Agreement or the Seller Disclosure Schedule, (ii)&nbsp;as may be necessary to carry out any of the transactions contemplated by this Agreement, (iii)&nbsp;as may be necessary to facilitate compliance
with any Legal Requirement or the requirements of any Contract, or (iv)&nbsp;as approved by Purchaser, during the Pre-Closing Period: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Seller will conduct its operations at the Facility in the ordinary course and consistent with its past practices, to the extent
such operations relate to the Diagnostic Business and Assets; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>neither Seller nor Subsidiary will (i)&nbsp;license or
dispose of any material Assets, (ii)&nbsp;prematurely terminate or amend, grant a sublicense under or assign any of the Contracts, or (iii)&nbsp;commit a breach of any Contract entered into after the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Seller requests Purchaser&#146;s approval of a proposed action that would result in a breach by Seller or Subsidiary of this Section&nbsp;4.2, Purchaser
will respond promptly to Seller&#146;s request and will not unreasonably withhold or delay its approval of the proposed action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3
Consents</B>. Each of Seller and Subsidiary will use commercially reasonable efforts during the Pre-Closing Period to obtain the Consents identified in Part 2.10 of the Seller Disclosure Schedule (including the Consents identified on <B>Schedule
5</B>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4 Conditions</B>. Each of Seller and Subsidiary will use commercially reasonable efforts (i)&nbsp;to cause the conditions
set forth in Section&nbsp;6 to be satisfied on a timely basis and (ii)&nbsp;otherwise to cause the Closing to take place as soon as reasonably practicable. Purchaser will use commercially reasonable efforts (a)&nbsp;to cause the conditions set forth
in Section&nbsp;7 to be satisfied on a timely basis and (b)&nbsp;otherwise to cause the Closing to take place as soon as reasonably practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.
O<SMALL>THER</SMALL> C<SMALL>OVENANTS</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1 Consents; Releases</B>. Purchaser will cooperate with Seller and Subsidiary, and
will provide Seller and Subsidiary with such assistance as Seller or Subsidiary may reasonably request, for the purpose of (i)&nbsp;attempting to obtain the Consents identified in Part 2.10 of the Seller Disclosure Schedule and (ii)&nbsp;arranging
for Seller and/or Subsidiary to be released and discharged from its obligations and other liabilities under the Contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2
Employment Matters</B>. Prior to the Closing, on a date mutually agreed by the Parties, Purchaser will extend to each Specified Employee an individualized written offer of employment that, if accepted, would contemplate that such Specified Employee
would commence his or her employment with Purchaser on the day after the Closing Date and would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide such Specified Employee with compensation, benefits and terms of employment (including terms relating to job responsibilities) that in the aggregate are the same or similar to such
Specified Employee as the compensation, benefits and terms of employment provided by Seller to such Specified Employee immediately prior to the Closing. The individualized written offers of employment shall include provisions that provide that, from
and after the time when the applicable Specified Employee begins his or her employment with Purchaser, Seller shall no longer be liable for any compensation or benefits to such Specified Employee (other than compensation and benefits (including
severance payments, if applicable) that have accrued and vested prior to such time). On the day after the Closing Date, Purchaser will hire each Specified Employee who accepts the written offer of employment extended to such Specified Employee by
Purchaser (it being understood that, except as otherwise provided in any individual employment agreement or other agreement between Purchaser and a Specified Employee, Purchaser will not be obligated to maintain the employment of or the compensation
or employee benefits provided to such Specified Employee for any specified period thereafter). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3 Use of Names and Trademarks</B>.
Following the Closing Date, all Purchaser advertising and promotional materials for the Products shall identify Purchaser as the marketer of the Products and all Product labeling and packaging shall reflect Purchaser as the marketer of the Product;
<I>provided, however</I>, with respect to the finished product inventories purchased by Purchaser hereunder, Purchaser shall, for a period of three (3)&nbsp;months following the Closing, be permitted to sell Product from such inventory as labeled
and packaged prior to the Closing Date, without regard to whether such Product references Seller or Subsidiary. Upon the expiration of such transitional period, all Product sold by Purchaser, including such inventory, shall, at Purchaser&#146;s sole
cost, be required to have labeling and packaging which properly identifies Purchaser as the marketer of the Product and shall not contain any references to Seller or Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4 Promotion at ACR Meeting</B>. Purchaser will use commercially reasonable efforts to present and promote the CB-CAPS Diagnostic Assay at
the American College of Rheumatology Scientific Meeting in November 2010. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5 Receipt of Monies or Other Assets</B>. If any monies or
other assets are received by Seller or Subsidiary, on one hand, or Purchaser, on the other hand, after Closing to which the other Party is entitled in accordance with the terms of this Agreement, such Party shall promptly forward such monies or
other assets to the other Party within fifteen (15)&nbsp;days of receipt, along with reasonable details regarding such monies or assets to permit their identification as monies or assets to which one or the other Party is entitled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6 Payment of Rents, Utilities, Vendor Accounts and Other Operating Expenses</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Subject to potential reimbursement to the extent provided in Section&nbsp;5.6(b) below with respect to Transition Operating Costs,
Seller will be responsible for and pay when due all rents and utility and other Vendor Accounts and costs associated with the Facility and the Diagnostic Business through the Closing Date. Subject to potential reimbursement to the extent provided in
Section&nbsp;5.6(b) with respect to Transition Operating Costs, utility or other Vendor Account bills and rent prepaid by Seller prior to the Closing which cover services to be provided </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to Purchaser after the Closing will be proportionately allocated (except that any security deposit that is required to be maintained for the duration of the lease for the Facility shall be
allocated solely to Purchaser) between Seller and Purchaser for the period covered, and Purchaser will reimburse Seller at Closing for any such amount paid by Seller that is allocated to Purchaser (the &#147;<B><I>Prorated Amount</I></B>&#148;).
Utility and other Vendor Account bills and rent paid by Purchaser after the Closing which cover services provided to Seller prior to the Closing Date (other than Transition Operating Costs) shall also be proportionately allocated between Seller and
the Purchaser for the period covered, and, upon Purchaser&#146;s request, Seller will promptly reimburse Purchaser for any such amount paid by Purchaser that is allocated to Seller. Purchaser shall arrange with each vendor of any Vendor Account to
open a new account in its name promptly following the Closing or will replace or discontinue such service but Seller shall not remain a party to any Vendor Account following the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>In addition to, and without duplication of, the Prorated Amount above, at the Closing Purchaser will reimburse Seller for
(i)&nbsp;the costs and expenses of certain products and services relating to the Diagnostic Business which Purchaser has approved in writing, including, without limitation, those costs and expenses set forth in <B>Schedule&nbsp;5.6(b)</B> (which
shall be modified by the Parties prior to the Closing to the extent necessary to reflect any such costs and expenses so approved between the date of this Agreement and Closing), which have already received Purchaser&#146;s written approval and any
others that receive Purchaser&#146;s written approval between the date of this Agreement and Closing, and (ii)&nbsp;the costs of operating the Diagnostic Business in the ordinary course following October&nbsp;5, 2010 which costs shall include,
without limitation, overhead, regular compensation and benefits of the employees of Seller based at the Facility, laboratory supplies, outside laboratory costs, and shipping and distribution costs and be identified, if applicable, by Seller to
Purchaser by written notice provided by Seller to Purchaser prior to the Closing (such costs in clauses (i)&nbsp;and (ii), the &#147;<B><I>Transition Operating Costs</I></B>&#148;). To the extent the amount of any Prorated Amount or Transition
Operating Costs are not identifiable at Closing, Purchaser shall, promptly following the identification of such costs in a written notice from Seller to Purchaser (but in no event later than five (5)&nbsp;business days following delivery of such
notice), reimburse Seller for such costs. The Parties recognize and agree that a portion of the Prorated Amount and Transition Operating Costs identifiable at Closing may be based upon estimates and further agree that, to the extent such amounts are
based upon estimates, promptly following the determination of the final amounts, Seller shall notify Purchaser of the differences in such amounts and the Parties shall reconcile the amounts paid or to be paid with respect thereto, with Seller
reimbursing Purchaser for any previous overpayment and Purchaser reimbursing Seller for any previous underpayment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7 Federal Express
Account</B>. On or within one business day following the Closing Date, Seller and Purchaser shall ensure that the Federal Express account associated with the Diagnostic Business is transferred to Purchaser, and Purchaser shall cooperate with Seller
on a timely basis to the extent necessary to enable such transfer. All charges to such account occurring after October&nbsp;5, 2010 shall be Purchaser&#146;s liability and Purchaser shall, within five (5)&nbsp;business days of notification by
Seller, reimburse Seller for such charges to the extent they are invoiced to Seller. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8 Procedures Relating to Accounts Receivable;
Payment of Royalties</B>. In addition to the other provisions of this Agreement, the Parties shall abide by the procedures set </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
forth in <B>Schedule 5.8</B> relating to the collection, reconciliation and payment of accounts receivable relating to the Diagnostic Business. Purchaser shall timely pay, when due, all royalties
associated with the Acquired Xifin Accounts Receivable and Post-10/5 Accounts Receivable. Seller shall timely pay, when due, all royalties associated with the accounts receivable of the Diagnostic Business with a date of service prior to
January&nbsp;12, 2010 (as defined by the blood sample draw date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.9 Security Interest in Intellectual Property Collateral</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Effective as of the Closing Date, Purchaser does hereby grant to Seller a continuing security interest of first priority in, all of
Purchaser&#146;s right, title and interest in, to and under the Intellectual Property Collateral, whether now or hereafter existing, as security for the prompt and complete payment and performance of Purchaser&#146;s obligation under Sections 1.3(c)
(including to the extent such payment obligation is accelerated pursuant to Section&nbsp;1.9(a)) of this Agreement, and, to the extent payment of such obligation is not made when due, interest payable on such payment owed pursuant to
Section&nbsp;1.11 of this Agreement. In furtherance of the foregoing: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>On a continuing basis, Purchaser will,
upon request by Seller, make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and collateral
agreements and filings with the United States Patent and Trademark Office, and take all such action as may reasonably be deemed necessary or advisable, or as requested by Seller, to perfect Seller&#146;s security interest in the Intellectual
Property Collateral, and otherwise to carry out the intent and purposes of the Intellectual Property Security Agreement, or for assuring and confirming to Seller the grant and perfection of a security interest in all Intellectual Property
Collateral; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>Purchaser hereby irrevocably appoints Seller as Purchaser&#146;s attorney-in- fact, with full
authority in the place and stead of Purchaser and in the name of Purchaser, Seller or otherwise, from time to time in Seller&#146;s discretion, upon Purchaser&#146;s failure or inability to do so, to take any action and to execute any instrument
which Seller may deem necessary or advisable to file, in its sole discretion, one or more financing or continuation statements and amendments thereto, or other notice filings or notations in appropriate filing offices, relative to any of the
Intellectual Property Collateral, with prior notice to Purchaser, with all appropriate jurisdictions, as Seller deems appropriate, in order to further perfect or protect Seller&#146;s interest in the Intellectual Property Collateral. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>This Agreement shall constitute a security agreement for purposes of the UCC in all relevant jurisdictions. In furtherance of the
foregoing, Purchaser hereby authorizes Seller to file one or more financing statements (or similar documents) in all relevant jurisdictions with respect to the Intellectual Property Collateral to evidence the granting of the security interest
described in this Section&nbsp;5.9. For greater certainty, Seller shall not file this Agreement in connection with the filing of any such financing statements (or similar documents). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>The security interests granted pursuant to this Section&nbsp;5.9 shall remain in full force and effect and continue to be effective
should any petition be filed by or against Purchaser </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for liquidation or reorganization, should Purchaser become insolvent or make an assignment for the benefit of creditors or should a receiver or trustee be appointed for all or any significant
part of Purchaser&#146;s property and assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the obligations secured thereby, or any part thereof, are, pursuant to applicable law,
rescinded or reduced in amount, or must otherwise be restored or returned by Seller, whether as a &#147;<B><I>voidable preference,</I></B>&#148; &#147;<B><I>fraudulent conveyance,</I></B>&#148; or otherwise, all as though such payment or performance
had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, such obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.10 Negative Covenants</B>. Until the termination of the security interest in favor of Seller in the Intellectual Property Collateral
under the Intellectual Property Security Agreement (a)&nbsp;Purchaser shall not sell, lease, license, transfer or otherwise dispose of any of the Intellectual Property Collateral, or attempt or contract to do so, other than the granting of
non-exclusive licenses; and (b)&nbsp;Purchaser shall not, directly or indirectly, create, permit or suffer to exist, and shall defend the Intellectual Property Collateral against and take such other action as is necessary to remove, any lien on the
Intellectual Property Collateral, except the lien granted to Seller under the Intellectual Property Security Agreement, the lien of the Junior Lienholder and any other liens granted by Purchaser after the Closing Date and approved in writing prior
to such grant by, and pursuant to documentation satisfactory to, Seller. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.11 Intellectual Property Assignments</B>. Following the
Closing Date, Seller shall execute such intellectual property assignments on terms mutually satisfactory to the Parties and consistent with this Agreement as may be reasonably requested by Purchaser for the purpose of enabling Purchaser to make the
necessary filings with the United States Patent and Trademark Office to transfer the Patents and Trademarks to Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. C<SMALL>ONDITIONS</SMALL>
P<SMALL>RECEDENT</SMALL> <SMALL>TO</SMALL> P<SMALL>URCHASER</SMALL>&#146;<SMALL>S</SMALL> O<SMALL>BLIGATION</SMALL> <SMALL>TO</SMALL> C<SMALL>LOSE</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchaser&#146;s obligation to purchase the Assets and to take the other actions required to be taken by Purchaser at the Closing is subject
to the satisfaction, at or prior to the Closing, of each of the following conditions (any of which may be waived by Purchaser, in whole or in part, in writing): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1 Accuracy of Representations</B>. All representations and warranties of Seller and Subsidiary set forth in Section&nbsp;2 shall be true
and correct at and as of the date of this Agreement and at and as of the Closing Date; <I>provided, however</I>, that, for purposes of this Section&nbsp;6.1, any inaccuracies in the representations and warranties of Seller and Subsidiary will be
disregarded unless all such inaccuracies, considered collectively, have a material adverse effect on the value of the Diagnostic Business and Assets taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2 Performance of Covenants</B>. Each of Seller and Subsidiary shall have performed, in all material respects, all covenants required by
this Agreement to be performed by Seller or Subsidiary on or before the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3 Additional Documents</B>. Each of the following additional documents shall have been
delivered to Purchaser: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>a certificate, executed by an executive officer of Seller, confirming that, to the actual knowledge of
such executive officer, the conditions set forth in Sections 6.1 and 6.2 have been satisfied; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>such bills of sale, assignments
and other instruments including, but not limited to, the Ancillary Agreements to which it is a party, as Seller or Subsidiary may be required to execute in order to evidence and effectuate the transfer of the Assets, including the Contracts, to
Purchaser; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>such good standing certificates and other similar documents as Purchaser may reasonably request to ensure that
the actions required to be taken by Seller and Subsidiary at the Closing have been properly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4 No Restraints</B>. No
injunction or other order preventing the consummation of the transactions contemplated by this Agreement shall have been issued since the date of this Agreement by any United States federal or state court of competent jurisdiction and shall remain
in effect; and no United States federal or state Legal Requirement that makes consummation of the transactions contemplated by this Agreement illegal shall have been enacted or adopted since the date of this Agreement and shall remain in effect.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5 Consents</B>. The Consents identified on <B>Schedule 5</B> shall have been obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. C<SMALL>ONDITIONS</SMALL> P<SMALL>RECEDENT</SMALL> <SMALL>TO</SMALL> S<SMALL>ELLER</SMALL>&#146;<SMALL>S</SMALL> <SMALL>AND</SMALL>
S<SMALL>UBSIDIARY</SMALL>&#146;<SMALL>S</SMALL> O<SMALL>BLIGATION</SMALL> <SMALL>TO</SMALL> C<SMALL>LOSE</SMALL></B><SMALL><B></B></SMALL><B>.</B> Seller&#146;s and Subsidiary&#146;s obligation to sell and transfer the Assets to Purchaser and to
take the other actions required to be taken by Seller or Subsidiary at the Closing is subject to the satisfaction, at or prior to the Closing, of each of the following conditions (any of which may be waived by Seller or Subsidiary, in whole or in
part, in writing): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1 Accuracy of Representations</B>. All representations and warranties of Purchaser set forth in Section&nbsp;3
shall be true and correct at and as of the date of this Agreement and at and as of the Closing Date; <I>provided, however</I>, that, for purposes of this Section&nbsp;7.1, any inaccuracies in the representations and warranties of Purchaser will be
disregarded unless all such inaccuracies, considered collectively, have a material adverse effect on the business, assets (tangible or intangible), liabilities or operations of Purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2 Performance of Covenants</B>. Purchaser shall have performed, in all material respects, all covenants required by this Agreement to be
performed by Purchaser on or before the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3 Delivery of Consideration</B>. At the Closing, Seller and Subsidiary shall
have received the Initial Cash Payment, and Seller shall have received the Prorated Amount and the Transition Operating Costs that are known as of the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4 Additional Documents</B>. The Intellectual Property Security Agreement shall have been executed on behalf of Purchaser, the
Subordination Agreement shall have been executed on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
behalf of Los Alamos National Bank and the Ancillary Agreements shall have been executed by each party thereto and each shall have been delivered to Seller. Purchaser shall have delivered to
Landlord Purchaser&#146;s fully executed counterparts to the Lease Assumption and the Consent to Assignment and an insurance certificate in the form required by the Lease (as defined in the Consent to Assignment). In addition, each of the following
additional documents shall have been delivered to Seller: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>a certificate, executed by an executive officer of Purchaser,
confirming that, to the actual knowledge of such executive officer, the conditions set forth in Sections 7.1 and 7.2 have been satisfied; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>such good standing certificates and other similar documents as Seller may reasonably request to ensure that the actions required to
be taken by Purchaser at the Closing have been properly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5 No Restraints</B>. No injunction or other order preventing the
consummation of the transactions contemplated by this Agreement shall have been issued since the date of this Agreement by any United States federal or state court of competent jurisdiction and shall remain in effect; and no United States federal or
state Legal Requirement that makes consummation of the transactions contemplated by this Agreement illegal shall have been enacted or adopted since the date of this Agreement and shall remain in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6 Consents</B>. The Consents identified on <B>Schedule 5</B> shall have been obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.7 Senior Lienholder</B>. Purchaser shall have obtained all necessary consents or taken such other steps as are necessary or advisable to
ensure that Seller&#146;s lien on the Intellectual Property Collateral and established pursuant to the Intellectual Property Security Agreement will be the senior lien or encumbrance on the Intellectual Property Collateral. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. T<SMALL>ERMINATION</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1
Right to Terminate Agreement</B>. This Agreement may be terminated prior to the Closing: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>by the mutual written consent of the
Parties; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>by any Party (by delivery of a written termination notification in accordance with Section&nbsp;8.2) at any time
after October&nbsp;31, 2010, if the Closing has not taken place on or before October&nbsp;31, 2010, unless the failure of the Closing to take place on or before such date is attributable to a breach by such Party of any of its obligations set forth
in this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>by Seller (by delivery of a written termination notification in accordance with Section&nbsp;8.2) if
(i)&nbsp;there shall have been a breach on the part of Purchaser of any of its representations, warranties or covenants such that the condition set forth in Section&nbsp;7.1 or Section&nbsp;7.2, as the case may be, would not be satisfied as of the
time of such breach, (ii)&nbsp;Seller shall have given written notice of such breach to Purchaser, (iii)&nbsp;at least twenty days shall have elapsed since the delivery of such written notice to Purchaser, (iv)&nbsp;such breach shall not have
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been cured and (v)&nbsp;Purchaser shall not be using its commercially reasonable efforts to attempt to cure such breach; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>by Purchaser (by delivery of a written termination notification in accordance with Section&nbsp;8.2) if (i)&nbsp;there shall have
been a breach on the part of Seller or Subsidiary of any of its representations, warranties or covenants such that the condition set forth in Section&nbsp;6.1 or Section&nbsp;6.2, as the case may be, would not be satisfied as of the time of such
breach, (ii)&nbsp;Purchaser shall have given written notice of such breach to Seller, (iii)&nbsp;at least twenty days shall have elapsed since the delivery of such written notice to Seller, (iv)&nbsp;such breach shall not have been cured and
(v)&nbsp;Seller shall not be using its commercially reasonable efforts to attempt to cure such breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2 Termination Procedures</B>.
If any Party wishes to terminate this Agreement pursuant to Section&nbsp;8.1, such Party will deliver to the other Parties a written termination notification stating that such Party is terminating this Agreement and setting forth a brief statement
of the basis on which such Party is terminating this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3 Effect of Termination</B>. Upon the termination of this Agreement
pursuant to Section&nbsp;8.1, no Party will have any obligation or other liability to any other Party, except that (i)&nbsp;the Parties will remain bound by the provisions of Section&nbsp;10 and by the provisions of the Confidentiality Agreement,
and (ii)&nbsp;no Party will be relieved of any liability for any breach of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. I<SMALL>NDEMNIFICATION</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1 Survival of Seller and Subsidiary Representations; Indemnification by Seller</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>All of the representations and warranties of Seller and Subsidiary set forth in this Agreement and in any certificate delivered
pursuant to this Agreement, and all covenants of Seller and Subsidiary set forth in Section&nbsp;4, will survive the Closing but will terminate and expire, and will cease to be of any force or effect, at 10:00 a.m. (California time) on the twelve
month anniversary of the Closing Date (the &#147;<B><I>Expiration Date</I></B>&#148;), and all liability of Seller and Subsidiary with respect to such representations, warranties and covenants (and any liability with respect to the certificate
delivered to Purchaser pursuant to Section&nbsp;6.3(a)) will thereupon be extinguished; <I>provided, however</I>, that if, prior to the Expiration Date, Purchaser shall have duly delivered to Seller, in conformity with all of the applicable
procedures set forth in Section&nbsp;9.1(d), an Indemnification Demand, then the specific claim set forth in such Indemnification Demand will survive (and will not be extinguished upon) the Expiration Date and will continue to survive until such
claim is resolved in accordance with Section&nbsp;9.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Subject to the limitations set forth in this Section&nbsp;9.1 and
elsewhere in this Agreement, from and after the Closing Date, Seller will indemnify Purchaser against any Damages that Purchaser incurs as a result of (i)&nbsp;any breach by Seller or Subsidiary of any of Seller&#146;s or Subsidiary&#146;s
representations, warranties or covenants hereunder or in any certificate delivered by Seller or Subsidiary pursuant to this Agreement or (ii)&nbsp;any and all liabilities attributable to Seller&#146;s or Subsidiary&#146;s ownership of the Assets or
operation of the Diagnostic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Business before the Closing Date (except for any Assumed Liabilities). Seller&#146;s obligation to indemnify Purchaser pursuant to this Section&nbsp;9.1(b) will not relieve Seller or Subsidiary
of, or alter in any way, Seller&#146;s or Subsidiary&#146;s obligation to fully satisfy all of Seller&#146;s and Subsidiary&#146;s liabilities other than the Assumed Liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>Except in the case of fraud or intentional misrepresentation, the total amount of the payments that Seller can be required to make
under or in connection with Section&nbsp;9.1(b)(i) of this Agreement will be limited in the aggregate to $[***], and Seller&#146;s cumulative liability will in no event exceed such amount. Notwithstanding anything else in this Agreement, except in
the case of fraud or intentional misrepresentation, the indemnification remedies provided in this Section&nbsp;9.1 shall be deemed to be the sole and exclusive remedy of Purchaser with respect to any and all claims (under any theory of liability,
including but not limited to contract claims and tort claims) relating to the subject matter of this Agreement. Furthermore, notwithstanding anything to the contrary herein, the limitations set forth in this Section&nbsp;9.1(c) shall not apply to
the obligations set forth in Sections 1.4, 1.11, 5.5, 5.6 or 5.8 of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>If Purchaser wishes to assert an
indemnification claim against Seller, Purchaser will deliver to Seller, as soon as reasonably practicable, an Indemnification Demand pursuant to Section&nbsp;9.3. Notwithstanding anything to the contrary contained in this Agreement, Purchaser will
not be permitted to deliver any Indemnification Demand to Seller (and will not be entitled to assert any claim set forth in any Indemnification Demand) unless Purchaser has reasonably determined that the breach alleged in such Indemnification Demand
has actually occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>If Purchaser receives notice or otherwise obtains knowledge of any Matter or any threatened Matter that
may reasonably be expected to give rise to an indemnification claim against Seller, then Purchaser will deliver to Seller a written notice describing such Matter in reasonable detail as soon as reasonably practicable. Seller will have the right, at
its election and at its sole expense, to assume the defense of any such Matter with its own counsel. If Seller elects to assume the defense of any such Matter, then: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>notwithstanding anything to the contrary contained in this Agreement, Seller will not be required to pay or
otherwise indemnify Purchaser against any attorneys&#146; fees or other expenses incurred on behalf of Purchaser in connection with such Matter following Seller&#146;s election to assume the defense of such Matter; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>Purchaser will make available to Seller all books, records and other documents and materials that are under the
control of Purchaser or any of Purchaser&#146;s Affiliates, advisors or representatives and that Seller reasonably considers necessary or desirable for the defense of such Matter; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>Purchaser will execute such documents and take such other actions as Seller may reasonably request for the purpose
of facilitating the defense of, or any settlement, compromise or adjustment relating to, such Matter; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>Purchaser will otherwise fully cooperate as reasonably requested by
Seller in the defense of such Matter; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) </B>Purchaser will not admit any liability with respect to such Matter;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vi) </B>Seller will not settle, adjust or compromise such Matter without the consent of Purchaser unless
(A)&nbsp;there is no finding or admission of any violation of any Legal Requirement by Purchaser, and (B)&nbsp;the sole relief provided is monetary damages that are paid in full by Seller. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Seller elects not to assume the defense of such Matter, then Purchaser will proceed diligently to defend such Matter with the assistance of counsel
reasonably satisfactory to Seller; <I>provided, however</I>, that Purchaser will not settle, adjust or compromise such Matter without the consent of Seller unless (A)&nbsp;there is no finding or admission of any violation of any Legal Requirement by
Seller, and (B)&nbsp;the sole relief provided is monetary damages that are paid in full by Purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>To the extent Seller
makes or is required to make any indemnification payment to Purchaser, Seller will be entitled to exercise, and will be subrogated to, any rights and remedies (including rights of indemnity, rights of contribution and other rights of recovery) that
Purchaser or any of Purchaser&#146;s Affiliates may have against any other Person with respect to any Damages, circumstances or Matter to which such indemnification payment is directly or indirectly related. Purchaser will take such actions as
Seller may reasonably request for the purpose of enabling Seller to perfect or exercise Seller&#146;s right of subrogation hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2 Survival of Purchaser Representations; Indemnification by Purchaser</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>All of the representations and warranties of Purchaser set forth in this Agreement and in any certificate delivered pursuant to
this Agreement will survive the Closing but will terminate and expire, and will cease to be of any force or effect, on the Expiration Date, and all liability of Purchaser with respect to such representations and warranties (and any liability with
respect to the certificate delivered to Seller pursuant to Section&nbsp;7.4(a)) will thereupon be extinguished; <I>provided, however</I>, that if, prior to the Expiration Date, Seller shall have delivered to Purchaser, in conformity with all of the
applicable procedures set forth in Section&nbsp;9.2(d), an Indemnification Demand, then the specific claim set forth in such Indemnification Demand will survive (and will not be extinguished upon) the Expiration Date and will continue to survive
until such claim is resolved in accordance with Section&nbsp;9.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Subject to the limitations set forth in this
Section&nbsp;9.2 and elsewhere in this Agreement, from and after the Closing Date, Purchaser will indemnify Seller and Subsidiary against any Damages that Seller or Subsidiary incurs as a result of (i)&nbsp;any breach by Purchaser of any of
Purchaser&#146;s representations, warranties or covenants hereunder or in any certificate delivered by Purchaser pursuant to this Agreement or (ii)&nbsp;any and all Assumed Liabilities and any and all liabilities attributable to Purchaser&#146;s
ownership of the Assets and operation of the Diagnostic Business on or after the Closing Date. The Purchaser&#146;s obligation to indemnify Seller and Subsidiary pursuant to this Section&nbsp;9.2 will not relieve Purchaser of, or alter in any way,
Purchaser&#146;s obligation to fully satisfy all of the Assumed Liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>Except in the case of fraud or intentional misrepresentation, the total amount of the
payments that Purchaser can be required to make under or in connection with Section&nbsp;9.2(b)(i) of this Agreement will be limited in the aggregate to $[***], and Purchaser&#146;s cumulative liability will in no event exceed such amount.
Notwithstanding anything else in this agreement, except in the case of fraud or intentional misrepresentation, the indemnification remedies provided in this Section&nbsp;9.2 shall be deemed to be the sole and exclusive remedy of Seller and
Subsidiary with respect to any and all claims (under any theory of liability, including but not limited to contract claims and tort claims) relating to the subject matter of this Agreement. Furthermore, notwithstanding anything to the contrary
herein, the limitations set forth in this Section&nbsp;9.2(c) shall not apply to the obligations set forth in Sections 1.3, 1.4, 1.7, 1.11, 5.5, 5.6, 5.7, 5.8, or 5.9 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>If Seller wishes to assert an indemnification claim against Purchaser, Seller will deliver to Purchaser, as soon as reasonably
practicable, an Indemnification Demand pursuant to Section&nbsp;9.3. Notwithstanding anything to the contrary contained in this Agreement, Seller will not be permitted to deliver any Indemnification Demand to Purchaser (and will not be entitled to
assert any claim set forth in any Indemnification Demand) unless Seller has reasonably determined that the breach alleged in such Indemnification Demand has actually occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3 Indemnification Procedure</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>In order for any Indemnified Person to seek indemnification under Section&nbsp;9.1 or Section&nbsp;9.2, as applicable, such
Indemnified Person shall deliver, in good faith, a written demand (an &#147;<B><I>Indemnification Demand</I></B>&#148;) to the Indemnifying Person which: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>states that the Indemnified Person has incurred or reasonably anticipates that it will have to incur Damages that
are subject to indemnification under this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>a reasonably detailed description of the facts and
circumstances giving rise to the indemnification claim, copies of any applicable complaints or demands, and the nature of the breach of representation, warranty, contractual provision or covenant to which such item is related; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>a reasonably detailed description of, and a good faith estimate of the total amount of, the Damages actually
incurred or expected to be incurred by the Indemnified Person and subject to indemnification hereunder (the &#147;<B><I>Asserted Damages Amount</I></B>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>a demand for payment in the amount of such Damages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Within 20 days after delivery of an Indemnification Demand, the Indemnifying Person shall deliver to the Indemnified Person a
written response (the &#147;<B><I>Response</I></B>&#148;) in which the Indemnifying Person shall: (i)&nbsp;agree that the Indemnified Person is entitled to receive all of the Asserted Damages Amount (the &#147;<B><I>Agreed Portion</I></B>&#148;);
(ii)&nbsp;agree that the Indemnified Person is entitled to receive part, but not all, of the Asserted Damages Amount (such portion, also the &#147;<B><I>Agreed Portion</I></B>&#148;); or (iii)&nbsp;dispute that the Indemnified Person is entitled to
receive any of the Asserted Damages Amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>In the event that the Indemnifying Person shall (i)&nbsp;dispute that the Indemnified
Person is entitled to receive any of the Asserted Damages Amount, or (ii)&nbsp;agrees that the Indemnified Person is entitled to only the Agreed Portion of the Asserted Damages Amount, the Indemnified Person and the Indemnifying Person shall attempt
in good faith to agree upon the rights of the respective parties with respect to each of the indemnification claims that comprise the Asserted Damages Amount (or the portion of the Asserted Damages Amount not comprising the Agreed Portion). If the
Indemnified Person and the Indemnifying Person should so agree, a memorandum setting forth such agreement shall be prepared and signed by both such parties. If no such agreement can be reached after good faith negotiation within 60 days after
delivery of a Response, either the Indemnified Person or the Indemnifying Person may demand arbitration of any matter set forth in the applicable Indemnification Demand. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>If no agreement is reached, the matter shall be settled by arbitration conducted by one arbitrator mutually agreeable to the
Indemnified Person and the Indemnifying Person. In the event that, within thirty days after submission of any dispute to arbitration, the Indemnified Person and the Indemnifying Person cannot mutually agree on one arbitrator, then the parties shall
arrange for the American Arbitration Association to designate a single arbitrator in accordance with the rules of the American Arbitration Association. Any such arbitration shall be held in San Diego County, California, under the rules and
procedures then in effect of the American Arbitration Association. The arbitrator shall determine how all expenses relating to the arbitration shall be paid, including the respective expenses of each party, the fees of the arbitrator and the
administrative fee of the American Arbitration Association. The arbitrator shall set a limited time period and establish procedures designed to reduce the cost and time for discovery while allowing the Indemnified Person and the Indemnifying Person
an opportunity, adequate in the sole judgment of the arbitrator to discover relevant information from the opposing parties about the subject matter of the dispute. The arbitrator shall rule upon motions to compel or limit discovery and shall have
the authority to impose sanctions, including attorneys&#146; fees and costs, to the same extent as a competent court of law or equity, should the arbitrator determine that discovery was sought without substantial justification or that discovery was
refused or objected to without substantial justification. The decision of the arbitrator as to the validity and amount of any indemnification claim in such Indemnification Demand shall be subject to the limitations set forth in this Agreement and
final, binding and conclusive upon the parties. Such decision shall be written and shall be supported by written findings of fact and conclusions which shall set forth the award, judgment, decree or order awarded by the arbitrator. All payments
required by the arbitrator shall be made within thirty days after the decision of the arbitrator is rendered. Judgment upon any award rendered by the arbitrator may be entered in any court having jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. M<SMALL>ISCELLANEOUS</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1 Time of Essence</B>. Time is of the essence with respect to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2 No Other Representations</B>. The Parties acknowledge that, except as expressly set forth in this Agreement, neither Party has made or
is making any representations or warranties whatsoever to the other, implied or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3 Knowledge; Materiality</B>. Neither Party will be deemed to have breached any
representation or warranty that is made to such Party&#146;s &#147;knowledge&#148; unless an officer of such Party with the rank of Vice President or above has actual knowledge or, solely with respect to Sections 2.4 and 2.5 of this Agreement,
Mariko Matsutani or Curtis McGuire has actual knowledge, as of the date of this Agreement, that such representation or warranty is materially inaccurate. Furthermore, for purposes of the representations and warranties set forth in Sections 2.4 and
2.5, unless a breach of the representation or warranty results in a material adverse effect on the Diagnostic Business, Seller shall not be required to indemnify Purchaser for such breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.4 Access of Seller to Books and Records Related to the Diagnostic Business or Assets</B>. At all times after the Closing Date, Purchaser
will give Seller and Seller&#146;s advisors and representatives reasonable access, during normal business hours and with prior written notice, to all books and records of Seller that are reasonably requested and included in the Assets or relate to
the Diagnostic Business (but only to the extent such books and records relate to any period prior to the Closing Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.5 Governing
Law</B>. This Agreement will be construed in accordance with, and governed in all respects by, the laws of the State of California (without giving effect to principles of conflicts of law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.6 Venue and Jurisdiction</B>. If any legal proceeding or other legal action relating to this Agreement is brought or otherwise
initiated, the venue therefor will be in the County of San Diego in the State of California, which will be deemed to be a convenient forum. The Parties hereby expressly and irrevocably consent and submit to the jurisdiction of the state and federal
courts in the County of San Diego in the State of California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.7 Notices</B>. Any notice or other communication required or
permitted to be delivered to either Party under this Agreement must be in writing and will be deemed properly delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery service or by facsimile) to the
address or facsimile telephone number set forth beneath the name of such Party below (or to such other address or facsimile telephone number as such Party shall have specified in a written notice given to the other Party): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">if to Purchaser: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Exagen
Diagnostics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Science&nbsp;&amp; Technology Park </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">801 University Blvd. SE, Suite 103 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Albuquerque, NM 87106 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention:
President </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile: (505)&nbsp;727-7965 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">if to Seller or Subsidiary: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Cypress Bioscience, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">4350
Executive Drive, Suite 325 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Ciara Kennedy, VP Operations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile: (858)&nbsp;452-1222 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">with a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">4401 Eastgate Mall </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">San Diego, CA
92121-1909 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Matthew T. Browne </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Facsimile: (858)&nbsp;550-6045 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.8 Public Announcements</B>. Except for the press release attached hereto as <B>Exhibit&nbsp;G</B> and Seller&#146;s Form 8-K (the
&#147;<B><I>Form <FONT STYLE="white-space:nowrap">8-K</FONT></I></B>&#148;) disclosing this Agreement and the transactions contemplated hereby, each of which shall be released promptly following the execution of this Agreement, and any subsequent
filings by Seller with the Securities and Exchange Commission (the &#147;<B><I>Subsequent Filings</I></B>&#148;) that disclose this Agreement (including by filing this Agreement) and the transactions contemplated hereby, or as may be required by any
Legal Requirement, neither Party will (and neither Party will permit any of its advisors or representatives to) issue any press release or make any public statement regarding this Agreement or any of the transactions contemplated by this Agreement,
without the other Party&#146;s prior written consent (which will not be unreasonably withheld), except that Seller and Purchaser may make public statements regarding this Agreement or any of the transactions contemplated by this Agreement that are
consistent with the press release attached hereto as <B>Exhibit G</B>, the 8-K or any Subsequent Filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.9 Assignment</B>. Neither
Party may assign any of its rights or delegate any of its obligations under this Agreement to any other Person without the prior written consent of the other Party (which consent shall not be unreasonably withheld or delayed); <I>provided,
however</I>, that Seller and Subsidiary, without Purchaser&#146;s prior consent, may assign to any Person its right to receive all or any portion of any of the cash payments to be made by Purchaser pursuant to Section&nbsp;1.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.10 Parties in Interest</B>. Nothing in this Agreement is intended to provide any rights or remedies to any employee of Seller or to any
other Person other than the Parties or any Indemnified Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.11 Severability</B>. In the event that any provision of this
Agreement, or the application of such provision to any Person or set of circumstances, shall be determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to
Persons or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, will not be affected and will continue to be valid and enforceable to the fullest extent permitted by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.12 Entire Agreement</B>. This Agreement, the Intellectual Property Security Agreement and
the Confidentiality Agreement (which remains in full force and effect) set forth the entire understanding of the Parties and supersede all other agreements and understandings between the Parties relating to the subject matter hereof and thereof.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.13 Waiver</B>. No failure on the part of either Party to exercise any power, right, privilege or remedy under this Agreement, and
no delay on the part of either Party in exercising any power, right, privilege or remedy under this Agreement, will operate as a waiver thereof; and no single or partial exercise of any such power, right, privilege or remedy will preclude any other
or further exercise thereof or of any other power, right, privilege or remedy. Any waiver of any power, right, privilege or remedy under this Agreement must be by means of a written instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.14 Amendments</B>. This Agreement may not be amended, modified, altered or supplemented except by means of a written instrument executed
on behalf of both Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.15 Counterparts</B>. This Agreement may be executed in several counterparts, each of which will
constitute an original and all of which, when taken together, will constitute one agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.16 Interpretation of Agreement</B>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Each Party acknowledges that it has participated in the drafting of this Agreement, and any applicable rule of construction to
the effect that ambiguities are to be resolved against the drafting party will not be applied in connection with the construction or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Whenever required by the context hereof, the singular number will include the plural, and vice versa; the masculine gender will
include the feminine and neuter genders; and the neuter gender will include the masculine and feminine genders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>As used in
this Agreement, the words &#147;include&#148; and &#147;including,&#148; and variations thereof, will not be deemed to be terms of limitation, and will be deemed to be followed by the words &#147;without limitation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>Unless the context otherwise requires, references in this Agreement to &#147;Sections,&#148; &#147;Schedules&#148; and
&#147;Exhibits&#148; are intended to refer to Sections of and Schedules and Exhibits to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>The table of contents
of this Agreement and the bold-faced headings contained in this Agreement are for convenience of reference only, will not be deemed to be a part of this Agreement and will not be referred to in connection with the construction or interpretation of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.17 No Setoff</B>. The Parties agree that any payments required to be made by any Party pursuant to this Agreement
shall be made without any withholding, deduction or set-off, and each Party hereto agrees not to assert a right of set-off with respect to any such payments at common law or otherwise; <I>provided, however</I>, a Party may set-off (a)&nbsp;any
Agreed Portion, (b)</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any amount that is subject to a memorandum setting forth an agreement under Section&nbsp;9.3(c) or (c)&nbsp;any amount that is subject to a final judgment, decree or order awarded by an
arbitrator in connection with the resolution of an Indemnification Demand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.18 Further Assurances</B>. Each of the Parties hereto
shall execute and deliver such additional documents, certificates and instruments, and perform such additional acts, as may be reasonably requested and necessary or appropriate to carry out the purposes and intent and all of the provisions of this
Agreement and the Ancillary Agreements and to consummate all of the transactions contemplated by this Agreement and the Ancillary Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties have caused this Asset Purchase Agreement to be executed as of the date first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>C<SMALL>YPRESS</SMALL> B<SMALL>IOSCIENCE</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jay D. Kranzler</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Jay D. Kranzler</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chairman and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>ROPRIUS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sabrina Martucci Johnson</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Sabrina Martucci Johnson</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>E<SMALL>XAGEN</SMALL> D<SMALL>IAGNOSTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott L. Glenn</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Scott L. Glenn</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chairman and Chief Executive Officer</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>XHIBIT</SMALL> A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ERTAIN</SMALL> D<SMALL>EFINITIONS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Accounts Reporting Period</B>&#148; has the meaning set forth in Section&nbsp;1.8(e) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Acquired Xifin Accounts Receivable</B>&#148; means all Xifin accounts receivable outstanding at the close of business on
October&nbsp;5, 2010 for testing services performed by Seller or Subsidiary, as applicable, with a date of service of January&nbsp;12, 2010 or later (as defined by the blood sample draw date). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Acquired Xifin Accounts Term</B>&#148; means the period of time beginning on the Closing Date and continuing so long as any Acquired
Xifin Account Receivable remains outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person directly
or indirectly controlling, controlled by or under common control with such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreed Portion</B>&#148; has the meaning set
forth in Section&nbsp;9.3(b) of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148; means the Asset Purchase Agreement to which this Exhibit A is
attached, and its attachments and schedules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Allocation</B>&#148; has the meaning set forth in Section&nbsp;1.4(a) of the
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Ancillary Agreements</B>&#148; has the meaning set forth in Section&nbsp;1.5(b) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Asserted Damages Amount</B>&#148; has the meaning set forth in Section&nbsp;9.3(a) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Assets</B>&#148; has the meaning set forth in Section&nbsp;1.1 of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Assumed Liabilities</B>&#148; means (i)&nbsp;all obligations, controversies, claims, demands, debts and other liabilities under or
relating to the Contracts and incurred after the Closing or arising from Purchaser&#146;s performance under the Contracts after the Closing, (ii)&nbsp;all obligations to make payments of license royalties due on the collection of the Acquired Xifin
Accounts Receivable and the Post-10/5 Accounts Receivable, (iii)&nbsp;all Transition Operating Costs and any Prorated Amount, and (iv)&nbsp;the Federal Express charges described in Section&nbsp;5.7 of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>August Financial Information</B>&#148; has the meaning set forth in Section&nbsp;2.11(b) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Avise MCV Product</B>&#148; means a specialized lab test based, in whole or in part, on any Orgentec Technology that measures
antibodies to mutated citrullinated vimentin. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Avise PG Product</B>&#148; means a specialized test based, in whole or in party, on any
intellectual property included in the Assets that measures methotrexate polyglutamate (MTXPG), an indicator of how well the body metabolizes methotrexate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CB-CAPS Annual Sales Milestone</B>&#148; means [***] measured over a calendar year is in excess of [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CB-CAPS Diagnostic Assay</B>&#148; means a product that uses any CB-CAPS Technology and has the claims to diagnose lupus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CB-CAPS Monitoring Assay</B>&#148; means a product that uses any CB-CAPS Technology and has the claims to monitor lupus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CB-CAPS Monitoring Assay [***] Milestone</B>&#148; means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CB-CAPS Product</B>&#148; means a product that uses any CB-CAPS Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CB-CAPS Technology</B>&#148; means any technology based, in whole or in part, on any intellectual property licensed pursuant to that
certain Exclusive License Agreement by and between the University of Pittsburgh &#150; of the Commonwealth System of Higher Education and Stagemark, Inc. (and its successors and assigns) dated as of October&nbsp;11, 2005, and as subsequently
amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cellatope Agreement</B>&#148; means that certain Asset Purchase Agreement by and between Seller and Cellatope
Corporation, dated February&nbsp;9, 2009. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Control</B>&#148; means (a)&nbsp;in the case of Purchaser, more than 50% of
the Assets are exclusively licensed, sold, transferred or otherwise disposed of (including by way of merger, consolidation or reorganization) to any Person which is not a direct or indirect wholly-owned subsidiary of Purchaser, (b)&nbsp;a sale,
exclusive license or other disposition of all or substantially all of the assets of Purchaser on a consolidated basis (other than to any wholly-owned subsidiary (direct or indirect) of Purchaser, (c)&nbsp;a merger or consolidation in which Purchaser
is not the surviving entity and in which the stockholders of Purchaser immediately prior to such consolidation or merger own less than 50% of the surviving entity&#146;s (or its parent&#146;s) voting power immediately after the transaction, and
(d)&nbsp;a reverse merger in which Purchaser is the surviving entity but the shares of Purchaser&#146;s capital stock outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the form of
securities, cash or otherwise, and in which the stockholders of Purchaser immediately prior to such reverse merger own less than 50% of Purchaser&#146;s (or its parent&#146;s) voting power immediately after the transaction; provided that a Change of
Control shall not include any transaction or transactions, whether or not related, that do not involve any merger, reverse merger or consolidation involving Purchaser and that are consummated for bona fide financing purposes where the consideration
received by Purchaser for issuance of its securities is cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing</B>&#148; has the meaning set forth in Section&nbsp;1.6 of
the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing Date</B>&#148; has the meaning set forth in Section&nbsp;1.6 of the Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; has the meaning set forth in Section&nbsp;1.4(a) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Combination Product</B>&#148; means a system, package, or combination product or service that contains one or more other parts that
could be sold separately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Confidentiality Agreement</B>&#148; means the Confidentiality Agreement between the Parties dated as
of December&nbsp;10, 2009. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Consent</B>&#148; means any consent, approval or waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Consent to Assignment</B>&#148; has the meaning set forth in Section&nbsp;1.5(b) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Contracts</B>&#148; means (i)&nbsp;the contracts, purchase orders, sales orders, and other instruments identified on <B>Schedule
1</B> and (ii)&nbsp;each other contract, purchase order, sales order or other instrument relating exclusively to any one or more of the Existing Products that is executed, entered into or accepted on behalf of Seller or Subsidiary on or after the
date of this Agreement and prior to the Closing in the ordinary course of business or with the approval of Purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Damages</B>&#148; means out-of-pocket losses and damages, excluding indirect, consequential, incidental, special and punitive
damages; <I>provided, however</I>, that for purposes of computing the amount of Damages incurred by any Person, there will be deducted an amount equal to the amount of any insurance proceeds, indemnification payments, contribution payments or
reimbursements actually received by such Person or any of such Person&#146;s Affiliates in connection with such Damages or the circumstances giving rise thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>December Financial Information</B>&#148; has the meaning set forth in Section&nbsp;2.11(a) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Diagnostic Business</B>&#148; means Seller&#146;s and Subsidiary&#146;s personalized medicine services business which helps
physicians manage and optimize the care of their patients through Seller&#146;s testing services that provide physicians with actionable information about their patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Distributor</B>&#148; means an independent contractor which has accepted an appointment to sell or otherwise market Products or the
CB-CAPS Monitoring Assay for Purchaser or its Affiliates or Licensees within one or more markets within one or more territories under an arrangement in which neither Distributor nor Purchaser has the authority to control the day-to-day activities of
the other. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Environmental Laws</B>&#148; means all federal, state or local laws (including any statute, rule, regulation,
ordinance, code or rule of common law), and all judicial or administrative interpretations thereof, and all decrees, judgments, policies, written guidance or judicial or administrative orders relating to the environment, health, safety or Hazardous
Substances, including the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. &#167; 9901 et seq., the Resource Conservation and Recovery Act of 1976, 42 U.S.C. &#167; 6901 et seq., the Emergency Planning and Community
Right-to-Know Act, 42 U.S.C. &#167; 11001 et seq., the Clean Air Act, 42 U.S.C. &#167; 7401 et seq., the Federal Water Pollution Control Act, 33 U.S.C. &#167; 1251 et seq., the Toxic Substance Control Act, 15 U.S.C. &#167; 2601 et seq., the Safe
Drinking Water Act, U.S.C. &#167; 300f et seq., the Occupational Safety and Health Act, 42 U.S.C. &#167; 1801 et </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
seq., the Federal Insecticide, Fungicide and Rodenticide Act, 7 U.S.C. &#167; 136 et seq., the Hazardous Materials Transportation Act, 49 U.S.C. &#167; 1801 et seq., and their state counterparts
or equivalents, all as amended, and any regulations or rules adopted or promulgated pursuant thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Environmental
Permits</B>&#148; has the meaning set forth in 2.4(d) of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Equipment</B>&#148; means the equipment identified on
<B>Schedule 3</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Existing Products</B>&#148; means any Avise PG Product, Avise MCV Product or CB-CAPS Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Expiration Date</B>&#148; has the meaning set forth in Section&nbsp;9.1(a) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Facility</B>&#148; means the premises located at 9393 Towne Centre Drive, Suite 140, San Diego, California 92121, that are being
leased to Seller. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>FDA</B>&#148; means the United States Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>First Commercial Sale</B>&#148; means, with respect to any CB-CAPS Monitoring Assay or any Product, the first sale for end use or
consumption of such product in a country. Sales to an Affiliate or Licensee shall not constitute a First Commercial Sale unless the Affiliate or Licensee is the end user of such product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Form 8-K</B>&#148; has the meaning set forth in Section&nbsp;10.8 of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Hazardous Substance</B>&#148; means any: contaminant or pollutant; toxic, radioactive or hazardous waste, chemical, substance,
material or constituent; asbestos; polychlorinated byphenyls (PCBs); paint containing lead or mercury; fixtures containing mercury or urea formaldehyde; natural or liquefied gas; flammable, explosive, corrosive, radioactive, medical and infectious
waste; and oil or other petroleum product, all as defined in Environmental Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnification Demand</B>&#148; has the
meaning set forth in Section&nbsp;9.3(a) of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnified Person</B>&#148; means the Person seeking indemnification
pursuant to Section&nbsp;9.1 or Section&nbsp;9.2 of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnifying Person</B>&#148; means the Party obliged to
provide indemnification pursuant to Section&nbsp;9.1 or Section&nbsp;9.2 of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Initial Cash Payment</B>&#148; has
the meaning set forth in Section&nbsp;1.3(a) of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Intellectual Property Collateral</B>&#148; has the meaning
ascribed to such term in the Intellectual Property Security Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Intellectual Property Security Agreement</B>&#148; has
the meaning set forth in Section&nbsp;1.5(a) of this Agreement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Junior Lienholder</B>&#148; has the meaning ascribed to such term in the Subordination
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Junior Lienholder Loan Documents</B>&#148; has the meaning ascribed to such term in the Subordination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Know-How</B>&#148; means all proprietary inventions, technology, trade secrets, know-how, data, procedures and other information, in
each case that (a)&nbsp;have been reduced to writing or stored electronically or are in another tangible form and (b)&nbsp;relate exclusively to the Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Landlord</B>&#148; means ARE-SD Region No.&nbsp;20, LLC, a Delaware limited liability company. &#147;<B>Lease Assumption</B>&#148;
has the meaning set forth in Section&nbsp;1.5(b) of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Legal Requirement</B>&#148; means any law, rule or regulation
of any governmental body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Licensed IP</B>&#148; means the intellectual property licensed pursuant to the Pittsburgh License, the
LUMC License, the Orgentec License, and the Prometheus Licenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Licensee</B>&#148; means any Person (other than any of the
Parties or an Affiliate of any of the Parties) to which Purchaser or any of its Affiliates grants a license under any of the Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>LUMC License</B>&#148; means that certain Exclusive License Agreement by and between Leiden University Medical Center and Subsidiary
(and its successors and assigns) dated as of September&nbsp;1, 2006 and as subsequently amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Matter</B>&#148; means any
claim, demand, dispute, action, suit, proceeding, investigation or other similar matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>[***]</B>&#148; means [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>[***] Commercial Program</B>&#148; means a commercial program wherein [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>[***] Milestone</B>&#148; means [***] have [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>[***] Milestone Amount</B>&#148; means: (i)&nbsp;[***]; (ii)&nbsp;[***]; or (iii)&nbsp;[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Milestone</B>&#148; has the meaning set forth in Section&nbsp;1.3(d) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Milestone Ratio</B>&#148; means a fraction, (i)&nbsp;the numerator of which is (a)&nbsp;the percentage of the list price of the Avise
PG Product that, in connection with the [***] Commercial Program or the [***] Commercial Program, as applicable, [***] or [***], as applicable, and/or its Affiliates agree to pay or otherwise reimburse, or, if no agreement, providing for such
payment or reimbursement is executed, pay or otherwise reimburse minus (b)&nbsp;[***]% and (ii)&nbsp;the denominator of which is [***]%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>MTX Technology</B>&#148; means any technology incorporating methotextrate, including monitoring, genetics of response, and prediction
of toxicity, based, in whole or in part, on any intellectual property rights included in the Assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Net Sales</B>&#148; means,
with respect to a particular time period, (i)&nbsp;the total amounts collected during such time period by or on behalf of Purchaser, its Affiliates, or their respective Licensees or Distributors (other than from Licensees who are not end users or
from Distributors, in which case the subsequent sale or disposition of such Product by such Licensee or Distributor shall be included in Net Sales) for sales of the Products to independent purchasers in arm&#146;s length transactions less
(ii)&nbsp;the total royalty amount paid by Purchaser to any third party under any Contract with respect to such Net Sales plus (iii)&nbsp;[***]. If any Product is sold or provided as part of a Combination Product, Net Sales shall be calculated by
multiplying the Net Sales from the sale of such Combination Product by the fraction A/B, where &#147;A&#148; is the fair market value of the Product when supplied or priced separately and &#147;B&#148; is the fair market value of the Combination
Product. In the event that no market price is available for the Product when supplied or priced separately, fair market value shall be determined in good faith by Seller and Purchaser. If Purchaser, its Affiliates, or their respective Licensees or
Distributors receive non-cash consideration (a)&nbsp;for the Products sold or otherwise transferred to an independent third party, Net Sales for such sale or transfer will be determined based on the average of the gross invoice prices charged to
other independent third parties in respect of cash sales for such Product during the applicable reporting period or (b)&nbsp;for Products leased or licensed, the Parties shall agree in good faith on the value of such consideration. Where the Product
is sold otherwise than on an arms length basis, the price that would have been charged in an arms length sale shall be the invoice price for such Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Products</B>&#148; mean any products (other than the Existing Products) in any form or formulation that are developed using or
are covered by any of the Patents or Licensed IP, including without limitation any tests based, in whole or in part, on any MTX Technology for toxicity or predicting efficacy. Notwithstanding the foregoing, for purposes of the royalty in
Section&nbsp;1.3(g), after the expiration of the Royalty Term in Section&nbsp;1.3(e) and (f), New Products </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall include any products that combine or integrate, in whole or in part, any Existing Product into such products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Orgentec License</B>&#148; means that certain License Agreement by and between Orgentec Diagnostika GmbH and Subsidiary (and its
successors and assigns) dated as of February&nbsp;19, 2008 and as subsequently amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Orgentec Technology</B>&#148; means any
technology based, in whole or in part, on the intellectual property licensed pursuant to the Orgentec License. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parties</B>&#148;
has the meaning set forth in the introductory paragraph of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Patents</B>&#148; means the patents and patent
applications identified on <B>Schedule 2</B> and all divisions, continuations, continuations-in-part, reissues, extensions, reexaminations and renewals of such patents in the United States and all foreign countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means any individual, corporation, general partnership, limited partnership, limited liability company, trust,
association, firm, organization, company, business, entity, union, society or governmental body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>[***]</B>&#148; means [***]
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>[***] Commercial Program</B>&#148; means a commercial program wherein [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>[***] Milestone</B>&#148; means the [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>[***] Milestone Amount</B>&#148; means: (i)&nbsp;[***]; (ii)&nbsp;[***]; or (iii)&nbsp;[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Pittsburgh License</B>&#148; means that certain Exclusive License Agreement by and between the University of Pittsburgh &#150; of the
Commonwealth System of Higher Education and Stagemark, Inc. (and its successors and assigns) dated as of October&nbsp;11, 2005 and as subsequently amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Post-10/5 Accounts Receivable</B>&#148; has the meaning set forth in Section&nbsp;1.3(h)
of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Pre-Closing Period</B>&#148; has the meaning set forth in Section&nbsp;4.1 of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Product</B>&#148; means the Existing Products and the New Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Prometheus Licenses</B>&#148; mean that certain License Agreement by and between Prometheus Laboratories Inc. and Subsidiary (and its
successors and assigns) dated as of September&nbsp;13, 2007 and as subsequently amended and that certain Sublicense Agreement by and between Prometheus Laboratories Inc. and Subsidiary (and its successors and assigns) dated as of September&nbsp;13,
2007 and as subsequently amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Property Taxes</B>&#148; has the meaning set forth in Section&nbsp;1.4(c) of the Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Prorated Amount</B>&#148; has the meaning in Section&nbsp;5.6(a) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Purchaser</B>&#148; has the meaning set forth in the introductory paragraph of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Purchaser Financial Statements</B>&#148; has the meaning set forth in Section&nbsp;3.2(a) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Reporting Period</B>&#148; has the meaning set forth in Section&nbsp;1.8(c) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Response</B>&#148; has the meaning set forth in Section&nbsp;9.3(b) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Royalty Term</B>&#148; means a period of time beginning on the Closing Date and ending on the last payment of a royalty pursuant to
any Royalty Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Royalty Transactions</B>&#148; mean the transactions set forth in Sections 1.3(e), (f)&nbsp;and
(g)&nbsp;of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Second Cash Payment</B>&#148; has the meaning set forth in Section&nbsp;1.3(c) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Second Cash Payment Date</B>&#148; has the meaning set forth in Section&nbsp;1.3(c) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Seller</B>&#148; has the meaning set forth in the introductory paragraph of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Seller Disclosure Schedule</B>&#148; means the disclosure schedule delivered by Seller to Purchaser contemporaneously with the
execution and delivery of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Specified Employees</B>&#148; means the employees identified on <B>Schedule 6</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Statement Date</B>&#148; has the meaning set forth in Section&nbsp;3.2 of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Straddle Period</B>&#148; means a period commencing before and ending after the Closing Date. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subordination Agreement</B>&#148; has the meaning set forth in Section&nbsp;1.5(a) of
the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subsequent Filings</B>&#148; has the meaning set forth in Section&nbsp;10.8 of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subsidiary</B>&#148; has the meaning set forth in the introductory paragraph of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Taxes</B>&#148; means all sales and use taxes, Property Taxes, gross receipts taxes, documentary transfer taxes, employment taxes,
withholding taxes, unemployment insurance contributions and other taxes or governmental charges of any kind, however denominated, including any interest, penalties and additions to tax in respect thereto, imposed under any federal, state, local,
foreign or other applicable tax law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trademarks</B>&#148; mean the trademark registrations identified on <B>Schedule 4</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer Taxes</B>&#148; has the meaning set forth in Section&nbsp;1.4(b) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transition Operating Costs</B>&#148; has the meaning set forth in Section&nbsp;5.6(b) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trigger Event</B>&#148; has the meaning set forth in Section&nbsp;1.9(b) of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>UCC</B>&#148; means the New York Uniform Commercial Code, as in effect from time to time; <I>provided, however</I>, that in the event
that, by reason of mandatory provisions of law, any or all of the attachment, perfection, priority, or remedies with respect to Seller&#146;s security interest in any Intellectual Property Collateral is governed by the Uniform Commercial Code as
enacted and in effect in a jurisdiction other than the State of New York, the term &#147;UCC&#148; shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to
such attachment, perfection, priority, or remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>U.S. Dollars</B>&#148; means United States dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Vendor Accounts</B>&#148; mean contracts or accounts with utility or third party service providers to the Facility that are provided
on a purchase order or open account basis, including, without limitation, those accounts set forth on <B>Schedule 5.6(a)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Web Site IP</B>&#148; means the &#147;avisetest.com&#148; domain name and the contents of the &#147;www.avisetest.com&#148; web site.
</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>11
<FILENAME>d693329dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDMENT NO. ONE TO </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSET PURCHASE AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">between: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CYPRESS BIOSCIENCE,
INC., </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PROPRIUS, INC., </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXAGEN DIAGNOSTICS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as
of March&nbsp;10, 2011 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDMENT NO. ONE TO ASSET PURCHASE AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No. One is made as of this 10th day of March, 2011 by and among Cypress Bioscience, Inc., a Delaware corporation
(&#147;Seller&#148;), Proprius, Inc., a Delaware corporation (&#147;Subsidiary&#148;), and Exagen Diagnostics, Inc., a Delaware corporation (&#147;Purchaser&#148; and, collectively with Seller and Subsidiary, the &#147;Parties&#148;) to that certain
Asset Purchase Agreement, dated as of October&nbsp;8, 2010, by and among the Parties (the &#147;Agreement&#148;). Capitalized terms used but not defined herein shall have the respective meanings given to such terms in the Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RECITAL </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties wish to set
forth herein amendments to certain provisions of the Agreement pertaining to the Acquired Xifin Accounts Receivable to, among other things, (a)&nbsp;change the amount Seller or Subsidiary is required to pay to Purchaser for the Acquired Xifin
Accounts Receivable, including for royalties and collection fees paid by Purchaser, and (b)&nbsp;provide that Purchaser need not collect receivables from patients except to the extent such patients have received reimbursement from insurance
companies. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDMENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Parties, intending to be legally bound, agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Amendment and Restatement of Section&nbsp;1.3(h)</U>. Section&nbsp;1.3(h) of the
Agreement is amended and restated to read as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;(h) Within [***] days after the delivery of each monthly
reconciliation contemplated by Section&nbsp;1.8(f) of this Agreement, Seller or Subsidiary, as applicable, shall, subject to Section&nbsp;10.17, pay to Purchaser: (i)&nbsp;for monthly reports within the period of time beginning on the Closing Date
and ending on January&nbsp;31, 2011, an amount equal to (x)&nbsp;[***]% multiplied by all amounts received pursuant to Acquired Xifin Accounts Receivable during such month <I>plus</I> (y)&nbsp;[***]% multiplied by the amount of license royalties
paid by Purchaser under any Contracts which are attributable to such accounts receivable during such month <I>plus</I> (z)&nbsp;[***]% multiplied by the amount of the collection fee (which amount shall not exceed [***]% of the amount collected) paid
by Purchaser to Xifin with respect to such accounts receivable during such month, and (ii)&nbsp;for monthly reports within the period of time beginning on February&nbsp;1, 2011 and continuing until the end of the Acquired Xifin Accounts Term, an
amount equal to (x)&nbsp;[***]% multiplied by all amounts received pursuant to Acquired Xifin Accounts Receivable during such month <I>plus</I> (y)&nbsp;[***]% multiplied by the amount of license royalties paid by Purchaser under any Contracts which
are attributable to such accounts receivable during such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
month<I> plus</I> (z)&nbsp;[***]% multiplied by the amount of the collection fee (which amount shall not exceed [***]% of the amount collected) paid by Purchaser to Xifin with respect to such
accounts receivable during such month. For accounts receivable for testing services performed by Purchaser with a date of service of October&nbsp;6, 2010 or later (as defined by the blood sample draw date) (the &#147;<B><I>Post-10/5 Accounts
Receivable</I></B>&#148;), the Parties shall, subject to Section&nbsp;10.17, follow the procedures set forth under &#147;Post-10/5 Accounts Receivable&#148; in <B>Schedule 5.8.</B>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Amendment to Section&nbsp;1.7</U>. Section&nbsp;1.7 of the Agreement is amended by appending subsection (b)&nbsp;thereto, to read as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;(b) Notwithstanding anything to the contrary in Section 1.7(a)(iii), Purchaser shall have no obligation to make any efforts to collect
any patient receivables that are (i) [***] or (ii) [***]. For all collection efforts, Purchaser will have the right to use its patient financial assistance program and its reasonable billing and collection policies.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Treatment of Non-Xifin AR</U>. The portion of Schedule 5.8 of the Agreement under the heading &#147;Non-Xifin Accounts Receivable&#148; is amended and
restated to read as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>&#147;Non-Xifin Accounts Receivable (&#147;<B><I>Non-Xifin AR</I></B>&#148;)</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Claims or Payments for testing Services performed by Seller or Subsidiary, as applicable, with a date of service, as defined by blood sample
draw date, prior to January&nbsp;12, 2010. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Seller will retain all rights to pursue payment for Non-Xifin AR claims. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Seller will not pursue payment for Non-Xifin AR resulting from amounts billed to patients if Seller or its agents have not received such Claims or Payments on or before March&nbsp;10, 2011; provided, however, the
foregoing restriction shall not apply to any Reimbursement Receivables. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Purchaser will make available any information and data required to pursue Non-Xifin AR.&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Treatment
of Xifin AR</U>. The portion of Schedule 5.8 of the Agreement under the heading &#147;Xifin Accounts Receivable&#148; is amended and restated to read as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><U>&#147;Xifin Accounts Receivable (&#147;<B><I>Xifin AR</I></B>&#148;)</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Claims and Payments for testing services performed by Seller with a date of service, as defined by the blood sample draw date, of
January&nbsp;12, 2010 through the close of business on October&nbsp;5, 2010: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All Xifin AR will be submitted for payment using Seller provider identification numbers. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Purchaser will work with Xifin to provide all required information for efficient processing of Xifin AR. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Seller will provide purchaser with electronic copies of all deposits made to Seller for Xifin AR. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On a monthly basis Purchaser will provide Seller with a reconciliation statement detailing the total collections by test for that month, the royalties owed on said payments, the collection fee owed to Xifin on said
payments (per the surviving contract between Purchaser and Xifin, never to exceed [***]%), the [***]% to [***]% or [***]% to [***]% split, as applicable to such month, between Seller and Purchaser of said payments and other payments owed between
Seller and Purchaser relating to the royalties and payments to Xifin. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Seller and Purchaser will settle the monies due within 14 days after the delivery of each monthly reconciliation statement contemplated in the previous bullet point.&#148; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Miscellaneous</U>. Except as expressly amended hereby, the Agreement shall remain in full force and effect in accordance with the terms thereof. This
Amendment No. One will be construed in accordance with, and governed in all respects by, the laws of the State of California (without giving effect to principles of conflicts of law) and may be executed in several counterparts, each of which will
constitute an original and all of which, when taken together, will constitute one agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signatures Follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties have caused this Amendment No. One to be executed as of the date first written above.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CYPRESS BIOSCIENCE, INC.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">PROPRIUS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey A. Meckler</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sabrina Martucci Johnson</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Jeffrey A. Meckler</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Sabrina Martucci Johnson</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Interim Chief Executive Officer</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EXAGEN DIAGNOSTICS, INC.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott L. Glenn</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Scott L. Glenn</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Chairman and Chief Executive Officer</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page to
Amendment No. One] </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>12
<FILENAME>d693329dex1015.htm
<DESCRIPTION>EX-10.15
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.15 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement is made and entered into as of the <U>2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP></U> day of
<U>August</U>, 2011 (&#147;EFFECTIVE DATE&#148;), by and between the UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with
an office at 200 Gardner Steel Conference Center, Thackeray and O&#146;Hara Streets, Pittsburgh, Pennsylvania 15260 (&#147;UNIVERSITY&#148;), and EXAGEN DIAGNOSTICS, INC., a corporation organized and existing under the laws of Delaware, having an
office at 801 University Blvd. SE Suite 103 Albuquerque, NM 87106 (&#147;LICENSEE&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, UNIVERSITY is the owner by assignment
from the inventors of certain PATENT RIGHTS, entitled &#147;Diagnosis and Monitoring of Systemic Lupus Erythematosus,&#148; developed by Drs. Susan Manzi and Joseph Ahearn of the UNIVERSITY faculty, consisting of certain patents and patent
applications, and the UNIVERSITY has the right to grant licenses under such PATENT RIGHTS; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, UNIVERSITY desires to have the PATENT
RIGHTS utilized in the public interest; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, LICENSEE has represented to UNIVERSITY, to induce UNIVERSITY to enter into this
Agreement, that LICENSEE is experienced in the development, production, manufacture, marketing and sale of products and/or the use of similar products to the LICENSED TECHNOLOGY and that LICENSEE shall commit itself to a thorough, vigorous and
diligent program of exploiting the PATENT RIGHTS so that public utilization results therefrom; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, UNIVERSITY and CYPRESS
BIOSCIENCE, INC., as successor in interest to CELLATOPE CORPORATION (formerly STAGEMARK, INC.), entered into an Exclusive License Agreement dated as of October&nbsp;11, 2005, as amended by a First Amendment to Exclusive License Agreement dated
May&nbsp;25, 2006, a Second Amendment to Exclusive License Agreement on February&nbsp;21, 2007, a Third Amendment to Exclusive License Agreement on February&nbsp;23, 2009, and a Fourth Amendment to Exclusive License Agreement on September&nbsp;21,
2010; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, CYPRESS BIOSCIENCE, INC. assigned the Exclusive License Agreement, as amended, to EXAGEN
DIAGNOSTICS, INC., by an Assignment and Assumption Agreement dated October&nbsp;16, 2010; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, LICENSEE desires to amend and
restate in its entirety the Exclusive License Agreement, as amended, and to obtain a license under the PATENT RIGHTS upon the terms and conditions hereinafter set forth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties hereto, intending to be legally bound,
agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I - DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, the following words and phrases shall have the following meanings: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top">&#147;AFFILIATE&#148; shall mean, with respect to the UNIVERSITY, any clinical or research entity that is operated or managed as a facility under the UPMC Health System, whether or not owned by UNIVERSITY.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top">&#147;COMMERCIALLY REASONABLE BEST EFFORTS&#148; shall mean, with respect to the research, development and commercialization of any product, compound or process, the level of efforts and resources used by [***]
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top">&#147;LICENSEE&#148; shall mean Exagen Diagnostics, Inc. and all entities at least fifty percent (50%)&nbsp;owned or controlled by Exagen Diagnostics, Inc. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top">&#147;LICENSED TECHNOLOGY&#148; shall mean any product or part thereof or service which is: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Covered in whole or in part by an issued, unexpired or pending claim contained in the PATENT RIGHTS in the country in which any such product or part thereof is made, used or sold or in which any such service is used or
sold; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Manufactured by using a process or is employed to practice a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the PATENT RIGHTS in the country in which any such
process in the SLE FIELD is used or in which such product or part thereof or service is used or sold. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top">&#147;NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES&#148; shall mean use of PATENT RIGHTS (including distribution of biological materials covered by the PATENT RIGHTS) for academic research or other not-for-profit
scholarly purposes which are undertaken at a nonprofit or governmental institution that does not use the PATENT RIGHTS in the production or manufacture of products for sale or the performance of services for a fee. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top">&#147;NON-ROYALTY SUBLICENSE INCOME&#148; shall mean [***] pursuant to any sublicense granted pursuant to Section 2.3 hereunder, provided however, that NON ROYALTY SUBLICENSE INCOME does not include any [***].
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top">&#147;PATENT RIGHTS&#148; shall mean UNIVERSITY intellectual property described below and assigned to the UNIVERSITY: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">The United States and foreign patents and/or patent applications listed in Exhibit A; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">United States and foreign patents issued from the applications listed in Exhibit A and from divisionals and continuations and continuations in part of these applications; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Claims of U.S. and foreign continuation in part and divisional applications, and of the resulting patents, which are directed to subject matter specifically described in the U.S. and foreign applications listed in
Exhibit A. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, PATENT RIGHTS specifically excludes the patents and/or patent applications listed in
Exhibit&nbsp;B and any U.S. and foreign patents issued therefrom and any divisionals, continuations, and continuations in part of these applications. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top">&#147;NET SALES&#148; shall mean gross invoice price actually charged by LICENSEE or its Sublicensee to third parties for LICENSED TECHNOLOGY and services or testing using the LICENSED TECHNOLOGY and services, less the
following deductions where they are factually applicable and are not already reflected in the gross invoice price: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Actual cost of freight, shipping and insurance charges or freight absorption, separately stated in such invoice; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Actual trade, quantity or cash discounts actually allowed, to include discounts to managed care organizations, so long as such discounts: (i)&nbsp;are in amounts customary in the trade, and (ii)&nbsp;do not violate
federal state laws or regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Actual credits and allowances granted for product returns, rejection for damages and recalls; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Rebates paid or credited to managed care organizations and governmental agencies with respect to Medicaid, Medicare or similar state and federal government programs; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">Sales taxes, tariff duties and/or use taxes actually paid and separately stated on each invoice. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top">&#147;SLE FIELD&#148; shall mean any and all applications of the Patent Rights in Systemic Lupus Erythematosus. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top">&#147;TERRITORY&#148; shall mean worldwide. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 &#150; GRANT </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top">Subject to the terms and conditions of this Agreement, UNIVERSITY hereby grants to LICENSEE, to the extent it may lawfully do so, the right and exclusive license in the TERRITORY to make, have made, use, offer for sale,
import and sell the LICENSED TECHNOLOGY in the SLE FIELD and to practice under the PATENT RIGHTS in the SLE FIELD to the end of the term for which the PATENT RIGHTS are granted, unless this Agreement is terminated as provided herein. UNIVERSITY
reserves the royalty-free, nonexclusive right to practice under the PATENT RIGHTS for NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES and to use the LICENSED TECHNOLOGY for NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top">The license granted hereby is subject to the rights of the United States government, if any, as set forth in 35 U.S.C. &#167;200, et seq. Pursuant to this law, the United States government may have acquired a
nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the United States the inventions described in the PATENT RIGHTS throughout the world. Pursuant to 35 U.S.C. &#167;200, el seq. LICENSED TECHNOLOGY
produced for sale in the United States shall be substantially manufactured in the United States (unless a waiver under 35 U.S.C. &#167;204 is granted by the appropriate United States government agencies). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall have the right to enter into sublicensing arrangements (without the right for further sublicense) for the rights, privileges and licenses granted hereunder. Prior written approval of each sublicensee by
UNIVERSITY which approval shall not be unreasonable withheld or delayed, will be required for all sublicensees, except in such cases where the sublicense: (1)&nbsp;has at least one FDA approved medical diagnostic test currently on the market: and
(2)&nbsp;has yearly revenues from the commercial sale of diagnostic products in excess of [***] dollars ($[***]). Upon termination of this Agreement, rights of any sublicensee granted by Licensee pursuant to this Section&nbsp;2.3 shall survive such
termination at the written request of such sublicensees provided to UNIVERSITY, provided that the action or inaction of such sublicense was not the cause of such termination. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE agrees that any sublicense granted by it shall provide that the obligations to UNIVERSITY of Articles 2, 7, 8, 9, 10, and 13 of this Agreement shall be binding upon the sublicensee as if it were party to this
Agreement. Each sublicense granted by LICENSEE pursuant to this Agreement shall include an audit right by UNIVERSITY of sublicensee of the same scope as provided in Section&nbsp;5.2 with respect to LICENSEE. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE agrees to forward to UNIVERSITY a copy of any and all sublicense agreements promptly upon execution thereof, but in no event later than thirty (30)&nbsp;days after each such sublicense agreement has been
executed by both parties thereto. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.6</TD>
<TD ALIGN="left" VALIGN="top">The license granted hereunder shall not be construed to confer any rights upon LICENSEE by implication, estoppel or otherwise as to any technology other than PATENT RIGHTS. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 - DUE DILIGENCE </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall use its [***] to bring the LICENSED TECHNOLOGY to market as soon as practicable, consistent with sound and reasonable business practice and judgment, and to continue active, diligent marketing efforts for
the LICENSED TECHNOLOGY throughout the term of this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top">In addition, LICENSEE shall adhere to each of the following milestones in the SLE FIELD: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(a)
Within twelve (12)&nbsp;months from the Effective Date of this Agreement, the sale or offer for sale of at least one (1)&nbsp;test system with clinical utility, diagnosis or monitoring, in Systemic Lupus Erythematosus; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(b) Within twenty four months (24)&nbsp;from the Effective Date of this Agreement, begin clinical trials for monitoring claims; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(c) Within twenty four months (24)&nbsp;from the Effective Date of this Agreement, seek expansion of use of the Licensed Technology outside the
United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE&#146;s failure to perform in accordance with Section&nbsp;3.1 or to fulfill on a timely basis anyone of the milestones set forth in Section&nbsp;3.2 hereof shall be grounds for UNIVERSITY to terminate this
Agreement pursuant to Section&nbsp;10.2(a); except that for a single time, if a milestone in Section&nbsp;3.2 has not been completed within the time frame allotted through no fault of LICENSEE and following the best efforts of LICENSEE to meet such
milestone, LICENSEE may, on a one-time basis, notify the UNIVERSITY in writing that it desires a single six (6)&nbsp;month extension to meet such milestone and LICENSEE shall be deemed to have fulfilled the milestone requirement if LICENSEE makes a
penalty payment of [***] dollars ($[***]) with both notice and penalty payment to be received by the UNIVERSITY within ten days of the applicable milestone achievement date. In such case the LICENSEE and UNIVERSITY shall negotiate a new time for
attainment of such missed milestone (not to exceed six months) and subsequent timeframes relying upon the meeting of previous milestones may also be adjusted. If LICENSEE fails to meet any revised milestone including first missed milestone,
UNIVERSITY may terminate the License and upon termination all rights and interest to the PATENT RIGHTS and any other rights granted by UNIVERSITY shall revert to UNIVERSITY. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 - LICENSE CONSIDERATION </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top">In consideration of the rights, privileges and license granted by UNIVERSITY hereunder, LICENSEE shall pay royalties and other monetary consideration as follows:; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Annual maintenance fees, non-refundable and non-creditable against royalties, until the first NET SALES occur as follows: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">[***] Dollars ($[***]) on the first and second anniversary of the EFFECTIVE DATE of this Agreement; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">[***] Dollars ($[***]) on the third anniversary of the EFFECTIVE DATE of this Agreement and annually thereafter until the first NET SALES. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Upon the first NET SALES, no further maintenance fees shall be due hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Royalties in an amount equal to [***] Percent ([***]%) of NET SALES of the LICENSED TECHNOLOGY per calendar quarter and royalties in an amount equal to [***] Percent ([***]%) of sublicensee NET SALES per calendar
quarter; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Beginning with the first NET SALES, a minimum royalty in the following amounts, if such minimum royalty is greater than the aggregate annual royalty computed in accordance with Section&nbsp;4.1(b) above:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">[***] Dollars ($[***]) per calendar year for the first calendar year of the first NET SALES; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">[***] Dollars ($[***]) per calendar year for the second calendar year of the first NET SALES; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">[***] Dollars ($[***]) in each subsequent calendar year during the term of this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Milestone payments shall be paid by LICENSEE to UNIVERSITY as follows: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">Two Hundred Thousand Dollars ($200,000) payable within [***] days following [***] NET SALES in a calendar year. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">A share of NON-ROYALTY SUBLICENSE INCOME of [***] Percent ([***]%). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top">In the event that it should prove necessary for LICENSEE to license intellectual property rights owned by a third party in order to practice the LICENSED TECHNOLOGY in the SLE FIELD in order to avoid infringing the
patent or other intellectual property rights of such third party, then LICENSEE shall be entitled to a credit of such third party royalties against royalties due to UNIVERSITY under Section&nbsp;4.1(b), and Section&nbsp;4.1(c), provided that
(i)&nbsp;in no event shall the royalty rate applicable to NET SALES in the SLE FIELD be less than [***] percent ([***]%) and (ii)&nbsp;in no event shall the royalty rate applicable to NET SALES in the SLE FIELD from a sub-Licensee be less than [***]
percent ([***]%). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">All payments pursuant to this Agreement may be made by check or by wire transfer (along with applicable wire transfer fees) in United States dollars
without deduction or exchange, collection or other charges and directed to the address or , in the case of wire </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
transfer, to the bank, set forth in Article II. Annual maintenance payments pursuant to Section&nbsp;4.1(a) hereof shall be paid on the anniversary of the EFFECTIVE DATE of the calendar year in
which they are due. Royalty payments pursuant to Section&nbsp;4.1 (b)&nbsp;hereof shall be due within thirty (30)&nbsp;days after each March&nbsp;31,&nbsp;June&nbsp;30,&nbsp;September&nbsp;30 and December&nbsp;31. The minimum annual royalty for any
calendar year pursuant to Section&nbsp;4.1(c) shall be paid by January&nbsp;30 of the subsequent calendar year. NONROYALTYSUBLICENSE INCOME payments pursuant to Section&nbsp;4.1(e) hereof shall be paid within thirty (30)&nbsp;days after receipt of
payment by LICENSEE from sublicense. Payments under Section&nbsp;4.1(b) are payable on a country by country basis only in those countries in which there are PATENT RIGHTS with respect to the applicable LICENSED TECHNOLOGY. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top">Taxes imposed by any foreign or United States governmental agency on any payments to be made to the UNIVERSITY by LICENSEE hereunder shall be paid by LICENSEE without deduction from any payment due to the UNIVERSITY
hereunder. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top">Payments pursuant to this Agreement, including those specified in Section&nbsp;6.2, which are overdue shall bear interest calculated from the due date until payment is received at the rate of five percent (5%)&nbsp;per
annum, or the prime rate (as quoted by The Wall Street Journal) plus two percent (2%), whichever is higher. Payment of such interest by LICENSEE shall not negate or waive the right of UNIVERSITY to seek any other remedy, legal or equitable, to which
it may be entitled because of the delinquency of any payment, including, but not limited to, termination of this Agreement as set forth in Article 10. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall sell products and/or processes resulting from LICENSED TECHNOLOGY to UNIVERSITY and its AFFILIATES upon request at such price(s) and on such terms and conditions as such products and/or processes are made
available to LICENSEE&#146;S most favored customer. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 - REPORTS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Within sixty (60)&nbsp;days after each March&nbsp;31,&nbsp;June&nbsp;30,&nbsp;September&nbsp;30 and December&nbsp;31 of each year during the term of
this Agreement beginning in the year of the first commercial </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
sale of LICENSED TECHNOLOGY, LICENSEE shall deliver to UNIVERSITY true, accurate and detailed reports of : </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Number of product and service NET SALES, each stated separately, for LICENSEE and all sublicensees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Total billings and receivables for all such products and services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Deductions set forth in Section&nbsp;1.8, each stated separately; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Total royalties due; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">Name and addresses of sublicensees; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">Total NON-ROYALTY SUBLICENSE INCOME received during such calendar quarter and total amount of payment due pursuant to Section&nbsp;4.1(e). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall keep full, true and accurate books of account, in accordance with generally accepted accounting principles, containing all information that may be necessary for the purpose of showing the amounts payable
to UNIVERSITY hereunder. Such books of account shall be kept at LICENSEE&#146;s principal place of business. Such books and the supporting data related thereto shall be made available at reasonable times for no more than once a calendar year for
[***] years following the end of the calendar year to which they pertain to the inspection of UNIVERSITY or its agents for the purpose of verifying LICENSEE&#146;S royalty statement or compliance in other respects with this Agreement. The fees and
expenses of UNIVERSITY&#146;S representatives shall be borne by UNIVERSITY; however, if an error of more than the greater of [***] percent ([***]%) of the total payments or the cost of such an audit due or owing for any year is discovered, then
LICENSEE shall bear the fees and expenses of UNIVERSITY&#146;S representatives. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">No later than ninety (90)&nbsp;days after December&nbsp;31 of each calendar year during the term of this Agreement, LICENSEE shall provide to
UNIVERSITY a written annual progress report, describing LICENSEE&#146;S progress on market introduction and milestones relating </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
to the LICENSED TECHNOLOGY during the preceding twelve month period ending December&nbsp;31. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 -PATENT PROSECUTION </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top">UNIVERSITY has or shall apply for and seek prompt issuance of and maintain during the term of this Agreement the PATENT RIGHTS in the United States and in such foreign countries as may be designated by LICENSEE in a
written notice to UNIVERSITY within a reasonable time in advance of the required foreign filing dates. LICENSEE shall have the opportunity to advise and cooperate with UNIVERSITY in the prosecution, filing and maintenance of such patents. If
UNIVERSITY decides to abandon the preparation, filing, prosecution or maintenance of any patent or patent application covered by the PATENT RIGHTS, then UNIVERSITY shall provide written notice to LICENSEE, and LICENSEE shall have the right at its
sole expense to assume control of the preparation, filing, prosecution and maintenance of such patent application or patent. If LICENSEE no longer wishes to support the prosecution or maintenance of any patent or patent application covered by the
PATENT RIGHTS, then LICENSEE shall provide written notice to UNIVERSITY, and LICENSEE shall not be responsible for such corresponding patent expenses that are incurred subsequent to the date of receipt by UNIVERSITY of such written notice by
LICENSEE; such returned patent or patent application shall be excluded from the PATENT RIGHTS. LICENSEE shall notify UNIVERSITY immediately if, at any time during the term of this Agreement, LICENSEE or any of its sublicensees does not qualify as a
&#147;Small Entity&#148; as provided by the United States Patent and Trademark Office. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top">All fees and costs including attorneys&#146; fees relating to the filing, prosecution and maintenance of the PATENT RIGHTS whether incurred prior to or after the EFFECTIVE DATE of this Agreement shall be the
responsibility of LICENSEE. LICENSEE shall not be required to reimburse the UNIVERSITY for any fees under this section that have been paid to the UNIVERSITY by prior licensees or any other third party. Fees and costs shall be paid by LICENSEE within
thirty (30)&nbsp;days after receipt of UNIVERSITY&#146;S invoice therefore. Payments pursuant to this Section&nbsp;6.2 are not creditable against royalties. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall own any new patent application, and any patent that issues therefrom, or new technology in the SLE FIELD developed independently of the UNIVERSITY and UNIVERSITY employees and shall not owe the UNIVERSITY
any fee or royalty under section 4 relating to such a new patent application, and any patent that issues therefrom, or new technology. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 -INFRINGEMENT ACTIONS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall inform UNIVERSITY promptly in writing of any alleged infringement of the PATENT RIGHTS by a third party and of any available evidence thereof. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top">During the term of this Agreement, LICENSEE shall have the right, but shall not be obligated, to prosecute at its own expense all infringements of the PATENT RIGHTS in the Field if LICENSEE has notified UNIVERSITY in
writing of its intent to prosecute. In furtherance of such right, UNIVERSITY hereby agrees that LICENSEE may include UNIVERSITY as a party plaintiff in any such suit, without expense to UNIVERSITY. [***] </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top">If within six (6)&nbsp;months after having been notified of any alleged infringement, LICENSEE shall have been unsuccessful in persuading the alleged infringer to desist and shall not have brought and shall not be
diligently prosecuting an infringement action, or if LICENSEE shall notify UNIVERSITY at any time prior thereto of its intention not to bring suit against any alleged infringer, then, and in those events only, UNIVERSITY shall have the right, but
shall not be obligated, to prosecute at its own expense any infringement of the PATENT RIGHTS, and UNIVERSITY may, for such purposes, use the name of LICENSEE as party plaintiff. [***] </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top">In the event that a declaratory judgment action alleging invalidity or infringement of any of the PATENT RIGHTS shall be brought against UNIVERSITY, LICENSEE, at its option, shall have the right, within thirty
(30)&nbsp;days after commencement of such action, to intervene and take over the sole defense of the action at its own expense. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top">In any infringement suit either party may institute to enforce the PATENT RIGHTS pursuant to this Agreement, the other party shall, at the request and expense of the party initiating such suit, cooperate in all respects
and, to the extent possible, have its employees testify when requested and make available relevant records, papers, information, samples, specimens, and the like. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 -INDEMNIFICATION/INSURANCE/LIMITATION OF LIABILITY </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall at all times during the term of this Agreement and thereafter indemnify, defend and hold UNIVERSITY, its trustees, officers, faculty member, employees and Affiliates (&#147;INDEMNIFIED PARTIES&#148;)
harmless against all claims and expenses, including legal expenses and reasonable attorneys&#146; fees, arising out of the death of or injury to any person or persons or out of any damage to property or the environment, and against any other claim,
proceeding, demand, expense and liability of any kind whatsoever resulting from: (i)&nbsp;the production, manufacture, sale, use, lease, consumption or advertisement of the LICENSED TECHNOLOGY by Licensee to its sublicensees, (ii)&nbsp;the practice
by LICENSEE or any Affiliate or sublicensee of the PATENT RIGHTS; or (iii)&nbsp;arising from or relating to this License Agreement. LICENSEE shall provide this defense and indemnity whether or not any INDEMNIFIED PARTIES, either jointly or
severally, is named as a party defendant and whether or not any INDEMNIFIED PARTIES is alleged to be negligent or otherwise responsible for any injuries to person or property. The obligation of LICENSEE to defend and indemnify as set forth herein
shall survive termination of this Agreement and shall not be limited by any other limitation of liability elsewhere in this Agreement. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall obtain and carry in full force and effect liability insurance which shall protect LICENSEE and UNIVERSITY in regard to events covered by Section&nbsp;8.1 above, as provided below: </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:43.70pt; font-size:8pt; font-family:Times New Roman">COVERAGE</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:26.65pt; font-size:8pt; font-family:Times New Roman">LIMITS</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(a)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Commercial General Liability, including, but not limited to, Products, Contractual, Fire, Legal and Personal Injury</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$1,000,000 Combined Single Limits for Bodily Injury and Property Damage</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(b)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Products Liability</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$5,000,000</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The UNIVERSITY of Pittsburgh is to be named as an additional insured with respect to insurance policies
identified in Sections 8.2(a) and 8.2Cb) above. Certificates of insurance evidencing the coverage required above shall be filed with the UNIVERSITY&#146;S Office of Technology Management, 200 Gardner Steel Conference Center, Pittsburgh, PA 15260, no
later than fifteen (15)&nbsp;days after execution of this Agreement and annually thereafter. Such certificates shall provide that the insurer will give the UNIVERSITY not less than thirty (30)&nbsp;days advance written notice of any material changes
in or cancellation of coverage. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">UNIVERSITY, AND ITS AGENTS AND/OR EMPLOYEES, MAKE NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT
NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY THAT THE PRACTICE BY LICENSEE OF
THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY. UNIVERSITY ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF UNIVERSITY, ITS AGENTS AND/OR EMPLOYEES, FOR DAMAGES, INCLUDING, BUT NOT LIMITED
TO, DIRECT, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
INDIRECT, SPECIAL AND CONSEQUENTIAL DAMAGES, ATTORNEYS&#146; AND EXPERTS&#146; FEES, AND COURT COSTS (EVEN IF UNIVERSITY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS),
ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, INCLUDING THE MANUFACTURE, USE OR SALE OF THE PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT. LICENSEE ASSUMES ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A PRODUCT OR
SERVICE THAT IS MANUFACTURED, USED OR SOLD BY LICENSEE (INCLUDING SUBLICENSEE SALES) WHICH IS LICENSED TECHNOLOGY HEREUNDER. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 - ASSIGNMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly provided hereunder, this Agreement is not assignable without the prior written consent of UNIVERSITY which consent shall
not be unreasonably withheld, and any attempt to do so shall be null and void, provided that LICENSEE may assign this Agreement and its rights and obligations thereunder, without the UNIVERSITY&#146;S prior written consent in connection with the
transfer or sale of all or substantially all of the LICENSEE&#146;S business relating to the PATENT RIGHTS and LICENSED TECHNOLOGY to a third party, whether by merger, sale of stock, sale of assets or otherwise subject to LICENSEE providing at least
10 business days written notification to UNIVERSITY and further subject to the assignee agreeing writing to be bound to all the terms and conditions of this License. The rights and obligations of the parties under this Agreement shall be binding
upon and inure to the benefit of the successors and permitted assigns of the parties. Any assignment not in accordance with this Article 9 shall be null and void. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 - TERMINATION </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top">This Agreement shall terminate upon the expiration of the last surviving claim of the PATENT RIGHTS. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top">UNIVERSITY shall have the right to terminate this Agreement if: </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall default in the performance of any of the obligations herein contained and such default has not been cured within [***] days after receiving written notice thereof from UNIVERSITY; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall cease to carry out its business, become bankrupt or insolvent, apply for or consent to the appointment of a trustee, receiver or liquidator of its assets or seek relief under any law for the aid of
debtors. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE may terminate this Agreement upon six (6)&nbsp;months prior written notice to UNIVERSITY and payment of all amounts due UNIVERSITY through the effective date of termination, including patent cost reimbursement
pursuant to Article 6 hereof. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top">Upon termination of this Agreement, neither party shall be released from any obligation that matured prior to the effective date of such termination. LICENSEE and any sublicensee may, however, after the effective date
of such termination, sell all products under the LICENSED TECHNOLOGY which LICENSEE produced prior to the effective date of such termination, provided that LICENSEE shall pay to UNIVERSITY the royalties thereon as required by Article 4 hereof and
submit the reports required by Article 5 hereof. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 - NOTICES </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top">Any notice or communication pursuant to this Agreement shall be sufficiently made or given if sent by certified or registered mail, postage prepaid, or by overnight courier, with proof of delivery by receipt, addressed
to the address below or as either party shall designate by written notice to the other party. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">In the case of UNIVERSITY:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Director </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Office of
Technology Management </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">University of Pittsburgh </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">200 Gardner Steel Conference Center </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Thackeray&nbsp;&amp; O&#146;Hara Streets </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Pittsburgh, PA 15260 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">In the case of LICENSEE: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Exagen Diagnostics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">801
University Blvd SE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Suite 103 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Albuquerque, NM 87106 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn:
President </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top">Any payments to UNIVERSITY hereunder by wire transfer shall be directed as follows: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Bank:
Mellon Bank, NA, Pittsburgh, PA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">ABA Routing No.: 043000261-UNIVERSITY of Pittsburgh </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Account No.: 0015510 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Mellon
SWIFT Code: MELNUS3P (international transfers) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Reference Code: Office of Technology Management </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12 - AMENDMENT, MODIFICATION </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top">This Agreement may not be amended or modified except by the execution of a written instrument signed by the parties hereto. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 13 - MISCELLANEOUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top">This Agreement shall be construed and interpreted in accordance with the laws of the Commonwealth of Pennsylvania. The forum for any action relating to this Agreement, including those brought against individuals, such
as University employees or agents, shall be the Courts of Allegheny County, Pennsylvania, or, if in a federal proceeding, the United States District Court for the Western District of Pennsylvania. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top">The parties acknowledge that this Agreement sets forth the entire understanding and intentions of the parties hereto as to the subject matter hereof and supersedes all previous representations, negotiations, or
understandings between the parties and/or its employees or agents, whether written or oral, regarding the subject matter of this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Nothing contained in this Agreement shall be construed as conferring upon either party any right to use in advertising, publicity or other promotional
activities any name, trade name, trademark, or other designation of the other party, including any contraction, abbreviation, or simulation of any of the foregoing. Without the express written approval of the other party, neither party shall use any
designation of the other party in any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
promotional activity associated with this Agreement or the LICENSED TECHNOLOGY. Neither party shall issue any press release or make any public statement in regard to this Agreement without the
prior written approval of the other party, except LICENSEE may make such disclosures as are necessary or appropriate to comply with its obligations under applicable laws, rules and regulations of the Securities and Exchange Commission and securities
exchange upon which LICENSEE&#146;S securities are listed. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.4</TD>
<TD ALIGN="left" VALIGN="top">If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable, the remaining provisions shall not in any way be affected or impaired thereby. In the event any provision is held
illegal or unenforceable, the parties shall use reasonable efforts to substitute a valid, legal and enforceable provision which, insofar as is practical, implements purposes of the provision held invalid, illegal or unenforceable. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.5</TD>
<TD ALIGN="left" VALIGN="top">Failure at any time to require performance of any of the provisions herein shall not waive or diminish a party&#146;s right thereafter to demand compliance therewith or with any other provision. Waiver of any default
shall not waive any other default. A party shall not be deemed to have waived any rights hereunder unless such waiver is in writing and signed by a duly authorized officer of the party making such waiver. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.6</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE acknowledges that UNIVERSITY is free to publish the results of the research activities of its faculty, staff and students, even though such publication may involve the PATENT RIGHTS or LICENSED TECHNOLOGY.
UNIVERSITY agrees to submit to LICENSEE any proposed publication or presentation regarding the subject matter specifically described in the PATENT RIGHTS for prior review by LICENSEE at least [***] days before its submittal for publication or its
presentation. LICENSEE may, within [***] days after receipt of such proposed publication, request that such proposed publication be delayed not more than [***] days in order to allow for protection of intellectual property rights. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.7</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">The term &#147;Confidential Information&#148; shall mean any and all proprietary or confidential information of UNIVERSITY or LICENSEE which may be
exchanged between parties at any time and from time to time during the term of this Agreement. Information shall not be considered confidential to the extent that either party can establish by competent proof
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
that it: (i)&nbsp;is publically disclosed through no fault of any party hereto, either before or after it becomes known to the receiving party; (ii)&nbsp;was known to the receiving party prior to
the date of this Agreement, which knowledge was acquired independently and not from another party hereto (or such party&#146;s employees); (iii)&nbsp;is subsequently disclosed to the receiving party in good faith by a third party who has a right to
make such disclosure; or (iv)&nbsp;has been published by a third party as a matter of right. The parties agree that during the term of this Agreement, and for a period of [***] years after this Agreement terminates, a party receiving Confidential
Information of the other party will (a)&nbsp;maintain in confidence such Confidential Information; (b)&nbsp;not disclose such Confidential Information to any third party and (c)&nbsp;not use such confidential Information for any purpose except those
permitted in this Agreement. Notwithstanding the foregoing, if a party is required by law, regulation or court order to disclose Confidential Information of the other party, the party required to make such disclosure shall limit the same to the
minimum required to make such disclosure shall limit the same to the minimum required to comply with the law or court order, and shall use reasonable efforts to attempt to seek confidential treatment for that disclosure, and prior to making such
disclosure that party shall notify the other party shall notify the other party, not later than ten (10)&nbsp;days (or shorter period of time as may be practicable under the circumstances) before the disclosure in order to allow that other party to
comment and/or to obtain protective or other order, including extensions of time and the like, with respect to such disclosure. In addition, a party may disclose Confidential Information to the other party to employees, to sublicensees and potential
sublicensees (in the case of LICENSEE), or to other third parties in connection with due diligence or similar investigations by third parties or potential third party investors in confidential financing document, provided, in each case, that any
such employee, consultant, agent, sublicense, potential sublicense or other third party agrees in writing to be bound by terms of confidentiality and non-use at least as stringent as those set forth in this Section&nbsp;13.7. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.8</TD>
<TD ALIGN="left" VALIGN="top">The parties acknowledge that they consulted, or had the opportunity to investigate and/or consult with their legal counsel and/or other advisors with respect to the PATENT RIGHTS, LICENSED TECHNOLOGY, and the terms of
this Agreement. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.9</TD>
<TD ALIGN="left" VALIGN="top">The parties agree that this Agreement constitutes an arm&#146;s length business transaction and does not create a fiduciary relationship. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.10</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE agrees that with respect to the performance of this Agreement or the practice of the rights granted by the UNIVERSITY hereunder, it shall comply with any and all applicable United States export control laws and
regulations, as well as any and all embargoes and/or other restrictions imposed by the Treasury Department&#146;s Office of Foreign Asset Controls. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.11</TD>
<TD ALIGN="left" VALIGN="top">If LICENSEE challenges the validity or enforceability of UNIVERSITY&#146;S PATENT RIGHTS or UNIVERSITY&#146;S ownership of the PATENT RIGHTS anywhere in the world, the LICENSEE shall continue to pay to UNIVERSITY all
royalties and other financial obligations required under this Agreement, to include patent costs and fees. If any such challenge is unsuccessful by LICENSEE, the royalty rates and any non-royalty sublicense income rate set forth in Article 4.1 above
shall automatically double in value, to include all royalty minimums and floors; and LICENSEE shall reimburse UNIVERSITY for all fees and costs associated with defending such action, to include attorneys&#146; and expert fees. The effective date of
such increase in royalty rates shall be the date of the first court order declaring any claim of the PATENT RIGHTS as valid or enforceable. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have set their hands and seals as of the date set forth on the
first page hereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jerome Cochran</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Jerome Cochran</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Executive Vice Chancellor</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EXAGEN DIAGNOSTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott L. Glenn</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Scott L. Glenn</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">President/CEO</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PATENT RIGHTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>University</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Case</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:35.50pt; font-size:8pt; font-family:Times New Roman"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Patent Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Application&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Filing&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Patent&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Issue&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Status</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCLUDED PATENT RIGHTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>University</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Case</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:35.50pt; font-size:8pt; font-family:Times New Roman"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Patent Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Country</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Application&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Filing&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Patent&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Issue&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Status</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>13
<FILENAME>d693329dex1018.htm
<DESCRIPTION>EX-10.18
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.18</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.18 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCLUSIVE LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement is made and entered into as of the 30th day of September, 2013 (&#147;Effective Date&#148;), by and between the University of
Pittsburgh &#150; Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with an office at 200 Gardner Steel Conference Center, Thackeray and O&#146;Hara
Streets, Pittsburgh, Pennsylvania 15260 (&#147;University&#148;), and EXAGEN DIAGNOSTICS, INC., a corporation organized and existing under the laws of Delaware, having an office at 800 Bradbury Drive SE Suite 108, Albuquerque, NM 87106
(&#147;Licensee&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, UNIVERSITY is the owner by assignment from the inventors of certain PATENT RIGHTS, entitled
&#147;Diagnosis and Monitoring of Systemic Lupus Erythematosus,&#148; developed by Drs. Susan Manzi and Joseph Ahearn of the UNIVERSITY faculty, consisting of certain patents and patent applications, and the UNIVERSITY has the right to grant
licenses under such PATENT RIGHTS; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties have previously entered into a United States-restricted Amended and Restated
License Agreement with respect to the PATENT RIGHTS, effective August&nbsp;2, 2011 and amended on May&nbsp;17, 2012, and whereas the parties are contemporaneously entering into a Second Amendment To the Amended and Restated License Agreement with
respect to the PATENT RIGHTS; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, University desires to have the PATENT RIGHTS utilized worldwide in the public interest; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, LICENSEE has represented to UNIVERSITY, to induce UNIVERSITY to enter into this Agreement, that LICENSEE is experienced in the
development, production, manufacture, marketing and sale of products and/or the use of similar products to the LICENSED TECHNOLOGY and that LICENSEE shall commit itself to a thorough, vigorous and diligent program of exploiting the PATENT RIGHTS so
that public utilization results therefrom; and </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Licensee desires to obtain a license under the non-US PATENT RIGHTS upon the terms and
conditions hereinafter set forth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties
hereto, intending to be legally bound, agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 &#150; DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, the following words and phrases shall have the following meanings: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top">&#147;AFFILIATE&#148; shall mean, with respect to the UNIVERSITY, any clinical or research entity that is operated or managed as a facility under the UPMC Health System, whether or not owned by UNIVERSITY.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top">&#147;COMMERCIALLY REASONABLE BEST EFFORTS&#148; shall mean, with respect to the research, development and commercialization of any product, compound or process, the level of efforts and resources used by [***].
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top">&#147;LICENSEE&#148; shall mean Exagen Diagnostics, Inc. and all entities at least fifty percent (50%)&nbsp;owned or controlled by Exagen Diagnostics, Inc. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top">&#147;LICENSED TECHNOLOGY&#148; shall mean any product or part thereof or service which is: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Covered in whole or in part by an issued, unexpired or pending claim contained in the PATENT RIGHTS in the country in which any such product or part thereof is made, used or sold or in which any such service is used or
sold; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Manufactured by using a process or is employed to practice a process which is covered in whole or in part by an issued, unexpired claim or a pending
claim contained in the PATENT RIGHTS in the country in which any such process that is included in the SLE FIELD or the MONITORING OF ORGAN </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
TRANSPLANTATION&nbsp;&amp; ORGAN REJECTION FIELD is used or in which such product or part thereof or service is used or sold. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top">&#147;NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES&#148; shall mean use of PATENT RIGHTS (including distribution of biological materials covered by the PATENT RIGHTS) for academic research or other not-for-profit
scholarly purposes which are undertaken at a nonprofit or governmental institution that does not use the PATENT RIGHTS in the production or manufacture of products for sale or the performance of services for a fee. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top">&#147;NON-ROYALTY SUBLICENSE INCOME&#148; shall mean [***] pursuant to any sublicense granted pursuant to Section 2.3 hereunder, provided however, that NON ROYALTY SUBLICENSE INCOME does not include [***].
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top">&#147;PATENT RIGHTS&#148; shall mean UNIVERSITY intellectual property described below and assigned to the UNIVERSITY: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">The foreign patents and/or patent applications listed in Exhibit A; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Foreign patents issued from the applications listed in Exhibit A and from divisionals and continuations and continuations in part of these applications; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Claims of foreign continuation in part and divisional applications, and of the resulting patents, which are directed to subject matter specifically described in the foreign applications listed in Exhibit A.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top">&#147;NET SALES&#148; shall mean gross invoice price actually charged by LICENSEE or its Sublicensee to third parties for LICENSED TECHNOLOGY and services or testing using the LICENSED TECHNOLOGY and services, less the
following deductions where they are factually applicable and are not already reflected in the gross invoice price: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Actual cost of freight, shipping and insurance charges or freight absorption, separately stated in such invoice; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Actual trade, quantity or cash discounts actually allowed, to include discounts to managed care organizations, so long as such discounts: (i)&nbsp;are in amounts customary in the trade, and (ii)&nbsp;do not violate
federal state laws or regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Actual credits and allowances granted for product returns, rejection for damages and recalls; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Rebates paid or credited to managed care organizations and governmental agencies with respect to Medicaid, Medicare or similar state and federal government programs; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">Sales taxes, tariff duties and/or use taxes actually paid and separately stated on each invoice. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top">&#147;SLE FIELD&#148; shall mean any and all applications of the Patent Rights in Systemic Lupus Erythematosus. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top">&#147;TERRITORY&#148; shall mean worldwide, with the exception of the United States. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top">&#147;MONITORING OF ORGAN TRANSPLANTATION&nbsp;&amp; ORGAN REJECTION FIELD&#148; shall mean any and all applications of the Patent Rights in Monitoring of Organ Transplantation&nbsp;&amp; Organ Rejection.
</TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 &#150; GRANT </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Subject to the terms and conditions of this Agreement, UNIVERSITY hereby grants to LICENSEE, to the extent it may lawfully do so, the right and
exclusive license in the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
TERRITORY to make, have made, use, offer for sale, import and sell the LICENSED TECHNOLOGY in the SLE FIELD and the MONITORING OF ORGAN TRANSPLANTATION&nbsp;&amp; ORGAN REJECTION FIELD and to
practice under the PATENT RIGHTS in the SLE FIELD and the MONITORING OF ORGAN TRANSPLANTATION&nbsp;&amp; ORGAN REJECTION FIELD to the end of the term for which the PATENT RIGHTS are granted, unless this Agreement is terminated as provided herein.
UNIVERSITY reserves the royalty-free, nonexclusive right to practice under the PATENT RIGHTS for NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES and to use the LICENSED TECHNOLOGY for NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top">The license granted hereby is subject to the rights of the United States government, if any, as set forth in 35 U.S.C. &#167;200, et seq. Pursuant to this law, the United States government may have acquired a
nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the United States the inventions described in the PATENT RIGHTS throughout the world. Pursuant to 35 U.S.C. &#167;200, et seq. LICENSED TECHNOLOGY
produced for sale in the United States shall be substantially manufactured in the United States (unless a waiver under 35 U.S.C. &#167;204 is granted by the appropriate United States government agencies). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall have the right to enter into sublicensing arrangements (without the right to further sublicense) for the rights, privileges and licenses granted hereunder. Prior written approval of each sublicensee by
UNIVERSITY, which approval shall not be unreasonably withheld or delayed, will be required for all sublicensees except in such cases where the sublicensee: (1)&nbsp;has at least one FDA approved medical diagnostic test currently on the market: and
(2)&nbsp;has yearly revenues from the commercial sale of diagnostic products in excess of [***] dollars ($[***]). Upon termination of this Agreement, rights of any sublicensee granted by Licensee pursuant to this Section&nbsp;2.3 shall survive such
termination at the written request of such sublicensees provided to UNIVERSITY, provided that the action or inaction of such sublicensee was not the cause of such termination. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE agrees that any sublicense granted by it shall provide that the obligations to UNIVERSITY of Articles 2, 7, 8, 9, 10, and 13 of this Agreement shall be binding upon the sublicensee as if it were party to this
Agreement. Each sublicense granted by LICENSEE pursuant to this Agreement shall include an audit right by UNIVERSITY of sublicensee of the same scope as provided in Section&nbsp;5.2 with respect to LICENSEE. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE agrees to forward to UNIVERSITY a copy of any and all sublicense agreements promptly upon execution thereof, but in no event later than thirty (30)&nbsp;days after each such sublicense agreement has been
executed by both parties thereto. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.6</TD>
<TD ALIGN="left" VALIGN="top">The license granted hereunder shall not be construed to confer any rights upon LICENSEE by implication, estoppel or otherwise as to any technology other than PATENT RIGHTS. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 &#150; DUE DILIGENCE </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall use its [***] to bring the LICENSED TECHNOLOGY to market outside the United States as soon as practicable, consistent with sound and reasonable business practice and judgment, and to continue active,
diligent marketing efforts outside the United States for the LICENSED TECHNOLOGY throughout the term of this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top">In addition, LICENSEE shall adhere to each of the following milestones: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Within thirty (30)&nbsp;months from the Effective Date of this Agreement, execute a commercial partnership agreement with a third party, or be acquired by a third party, for the purpose of commercialization of the
LICENSED TECHNOLOGY outside the United States; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Within fifty-four (54)&nbsp;months from the Effective Date of a commercial partnership agreement with a third party, or an acquisition by a third party, achieve first commercial sale of LICENSED TECHNOLOGY outside of
the United States. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">LICENSEE&#146;s failure to perform in accordance with Section&nbsp;3.1 or to fulfill on a timely basis anyone of the milestones set forth in
Section&nbsp;3.2 hereof shall be grounds for </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
UNIVERSITY to terminate this Agreement pursuant to Section&nbsp;10.2(a); except that for a single time, if a milestone in Section&nbsp;3.2 has not been completed within the time frame allotted
through no fault of LICENSEE and following the best efforts of LICENSEE to meet such milestone, LICENSEE may, on a one-time basis, notify the UNIVERSITY in writing that it desires a single six (6)&nbsp;month extension to meet such milestone and
LICENSEE shall be deemed to have fulfilled the milestone requirement if LICENSEE makes a penalty payment of [***] dollars ($[***]) with both notice and penalty payment to be received by the UNIVERSITY within ten days of the applicable milestone
achievement date. In such case the LICENSEE and UNIVERSITY shall negotiate a new time for attainment of such missed milestone (not to exceed six months) and subsequent timeframes relying upon the meeting of previous milestones may also be adjusted.
If LICENSEE fails to meet any revised milestone including first missed milestone, UNIVERSITY may terminate the License and upon termination all rights and interest to the PATENT RIGHTS and any other rights granted by UNIVERSITY shall revert to
UNIVERSITY. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall notify UNIVERSITY in writing of the achievement of each milestone in Section&nbsp;3.2 within thirty (30)&nbsp;days upon the achievement of the respective milestone. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 &#150; LICENSE CONSIDERATION </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top">In consideration of the rights, privileges and license granted by UNIVERSITY hereunder, LICENSEE shall pay royalties and other monetary consideration as follows: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Initial license fee, nonrefundable and noncreditable against royalties, of [***] Dollars ($[***]) due immediately and payable within ten (10)&nbsp;business days from the Effective Date of this Agreement;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Royalties in an amount equal to [***] Percent ([***]%) of NET SALES of the LICENSED TECHNOLOGY per calendar quarter and royalties in an amount equal to [***] Percent ([***]%) of sublicensee NET SALES per calendar
quarter; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">A share of NON-ROYALTY SUBLICENSE INCOME of [***] Percent ([***]%). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top">In the event that it should prove necessary for LICENSEE to license intellectual property rights owned by a third party in order to practice the LICENSED TECHNOLOGY in the SLE FIELD or the MONITORING OF ORGAN
TRANSPLANTATION&nbsp;&amp; ORGAN REJECTION FIELD in order to avoid infringing the patent or other intellectual property rights of such third party, then LICENSEE shall be entitled to a credit of such third party royalties against royalties due to
UNIVERSITY under Section&nbsp;4.1(b) provided that (i)&nbsp;in no event shall the royalty rate applicable to NET SALES in the SLE FIELD or the MONITORING OF ORGAN TRANSPLANTATION&nbsp;&amp; ORGAN REJECTION FIELD be less than [***] percent ([***]%)
and (ii)&nbsp;in no event shall the royalty rate applicable to NET SALES in the SLE FIELD or the MONITORING OF ORGAN TRANSPLANTATION&nbsp;&amp; ORGAN REJECTION FIELD from a sub-Licensee be less than [***] percent ([***]%). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top">All payments pursuant to this Agreement may be made by check or by wire transfer (along with applicable wire transfer, transaction, and/or foreign translation fees) in United States dollars without deduction or
exchange, collection or other charges and directed to the address or, in the case of wire transfer, to the bank, set forth in Article 11. Royalty payments pursuant to Section&nbsp;4.1(b) hereof shall be due within sixty (60)&nbsp;days after each
March&nbsp;31,&nbsp;June&nbsp;30,&nbsp;September&nbsp;30 and December&nbsp;31. NON-ROYALTY SUBLICENSE INCOME payments pursuant to Section&nbsp;4.1(c) hereof shall be paid within thirty (30)&nbsp;days after receipt of payment by LICENSEE from
sublicense. Payments under Section&nbsp;4.1(b) are payable on a country by country basis only in those countries in which there are PATENT RIGHTS with respect to the applicable LICENSED TECHNOLOGY. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top">Taxes imposed by any foreign or United States governmental agency on any payments to be made to UNIVERSITY by LICENSEE shall be paid by LICENSEE without deduction from any payment due to UNIVERSITY hereunder.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">The balance of any payments pursuant to this Agreement, including those specified in Section&nbsp;6.2, which are overdue shall bear interest,
compounded monthly, calculated from the due date until payment is received at the rate of five percent (5%)&nbsp;per annum, or the prime rate (as quoted by The Wall Street Journal) plus two percent (2%), whichever is
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
higher. Payment of such interest by LICENSEE shall not negate or waive the right of UNIVERSITY to seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency
of any payment, including, but not limited to, termination of this Agreement as set forth in Article 10. Licensee shall reimburse University for any costs and expenses incurred in connection with collecting any overdue balance of payments with
respect to Licensee&#146;s payment and reimbursement obligations under this Agreement, including the costs of engaging counsel or a collection agency for such purpose. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall sell products and/or services resulting from LICENSED TECHNOLOGY to UNIVERSITY and its AFFILIATES upon request at such price(s) and on such terms and conditions as such products and/or services are made
available to LICENSEE&#146;S most favored customer. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 &#150; REPORTS AND AUDIT </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top">Within sixty (60)&nbsp;days after each March&nbsp;31,&nbsp;June&nbsp;30,&nbsp;September&nbsp;30 and December&nbsp;31 of each year during the term of this Agreement beginning in the year of the first commercial sale of
LICENSED TECHNOLOGY, LICENSEE shall deliver to UNIVERSITY true, accurate and detailed reports of the following information in a form as illustrated in Exhibit B: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Number of product and service NET SALES for LICENSEE and all sublicensees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Total billings and receivables for all such products and services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Deductions set forth in Section&nbsp;1.8, each stated separately; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Total royalties due; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">Name and addresses of sublicensees; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">Total NON-ROYALTY SUBLICENSE INCOME received during such calendar quarter and total amount of payment due pursuant to Section&nbsp;4.1(c). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall keep full, true and accurate books of account, in accordance with generally accepted accounting principles, containing all information that may be necessary for the purpose of showing the amounts payable
to UNIVERSITY hereunder. Such books of account shall be kept at LICENSEE&#146;S principal place of business. Such books of account shall be open at all reasonable times for [***] years following the end of the calendar year to which they pertain,
and for [***] years after the expiration or termination of this Agreement, for inspection by UNIVERSITY or its agents for the purpose of verifying LICENSEE&#146;S royalty statement or compliance in other respects with this Agreement. The fees and
expenses of UNIVERSITY&#146;S representatives shall be borne by UNIVERSITY; however, if an error of more than [***] percent ([***]%) of the total payments due or owing for any year is discovered, then LICENSEE shall bear UNIVERSITY&#146;S fees and
expenses. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top">No later than ninety (90)&nbsp;days after December&nbsp;31 of each calendar year during the term of this Agreement, LICENSEE shall provide to UNIVERSITY a written annual progress report, as illustrated in Exhibit C,
describing LICENSEE&#146;S progress on research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales during the preceding twelve-month period ending December&nbsp;31. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top">Notwithstanding the above, UNIVERSITY shall have the right, on an annual basis during the term of this Agreement to inspect technical and other information from LICENSEE sufficient to evidence whether and to what extent
LICENSEE is: (a)&nbsp;practicing the PATENT RIGHTS; and (b)&nbsp;meeting its diligence obligations under Article 3, above. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall report to the UNIVERSITY the date of the first commercial sale of a LICENSED TECHNOLOGY within sixty (60)&nbsp;days of occurrence in each country. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 &#150; PATENT PROSECUTION </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">UNIVERSITY has or shall apply for and seek prompt issuance of and maintain during the term of this Agreement the PATENT RIGHTS in such foreign
countries as may be designated by LICENSEE in a written notice to UNIVERSITY within a reasonable time in advance of the required foreign filing dates. LICENSEE shall have the opportunity to
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
advise and cooperate with UNIVERSITY in the prosecution, filing and maintenance of such patents. If UNIVERSITY decides to abandon the preparation, filing, prosecution or maintenance of any patent
or patent application covered by the PATENT RIGHTS, then UNIVERSITY shall provide written notice to LICENSEE, and LICENSEE shall have the right at its sole expense to assume control of the preparation, filing, prosecution and maintenance of such
patent application or patent. If LICENSEE no longer wishes to support the prosecution or maintenance of any patent or patent application covered by the PATENT RIGHTS, then LICENSEE shall provide written notice to UNIVERSITY, and LICENSEE shall not
be responsible for such corresponding patent expenses that are incurred subsequent to the date of receipt by UNIVERSITY of such written notice by LICENSEE; such returned patent or patent application shall be excluded from the PATENT RIGHTS. Licensee
shall notify UNIVERSITY immediately if, at any time during the term of this Agreement, LICENSEE or any of its sublicensees does not qualify as a &#147;Small Entity&#148; as provided by the United States Patent and Trademark Office.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top">All fees and costs, including attorneys&#146; fees, relating to the filing, prosecution, maintenance, and post grant proceedings relating to the PATENT RIGHTS shall be the responsibility of LICENSEE, whether incurred
prior to or after the Effective Date. LICENSEE shall not be required to reimburse the UNIVERSITY for any fees under this section that have been paid to the UNIVERSITY by prior licensees or any other third party. Fees and costs incurred shall be paid
by LICENSEE within thirty (30)&nbsp;days after receipt of UNIVERSITY&#146;S invoice therefor. Additionally, Licensee shall be liable to UNIVERSITY for all of UNIVERSITY&#146;S out-of-pocket filing, prosecution, and maintenance costs (including all
attorneys&#146; fees and costs), for any and all patent prosecution and maintenance actions that will be taken by patent counsel after the term of this Agreement but in response to any instructions that were sent during the term of this Agreement
from UNIVERSITY to patent counsel relating to the PATENT RIGHTS, with the proviso that such instructions were approved in writing by LICENSEE. Payments pursuant to this Section&nbsp;6.2 are not creditable against royalties or any other payment due
to UNIVERSITY under this Agreement. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall own any new patent application, and any patent that issues therefrom, or new technology in the SLE FIELD or the MONITORING OF ORGAN TRANSPLANTATION&nbsp;&amp; ORGAN REJECTION FIELD developed independently
of the UNIVERSITY and UNIVERSITY employees and shall not owe the UNIVERSITY any fee or royalty under section 4 relating to such a new patent application, and any patent that issues therefrom, or new technology. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 &#150; INFRINGEMENT ACTIONS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall inform UNIVERSITY promptly in writing of any alleged infringement of the PATENT RIGHTS by a third party and of any available evidence thereof. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top">During the term of this Agreement, LICENSEE shall have the right, but shall not be obligated, to prosecute at its own expense all infringements of the PATENT RIGHTS in the SLE FIELD or the MONITORING OF ORGAN
TRANSPLANTATION&nbsp;&amp; ORGAN REJECTION FIELD and in the TERRITORY if LICENSEE has notified UNIVERSITY in writing of its intent to prosecute; provided, however, that such right to bring such an infringement action shall remain in effect only for
so long as the license granted herein remains exclusive. In furtherance of such right, UNIVERSITY hereby agrees that LICENSEE may include UNIVERSITY as a party plaintiff in any such suit, without expense to UNIVERSITY. [***] </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">If within six (6)&nbsp;months after having been notified of any alleged infringement, LICENSEE shall have been unsuccessful in persuading the alleged
infringer to desist and shall not have brought and shall not be diligently prosecuting an infringement action, or if LICENSEE shall notify UNIVERSITY at any time prior thereto of its intention not to bring suit against any alleged infringer, then,
and in those events only, UNIVERSITY shall have the right, but shall not be obligated, to prosecute at its own expense any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
infringement of the PATENT RIGHTS, and UNIVERSITY may, for such purposes, use the name of LICENSEE as party plaintiff. [***] </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top">In the event that a declaratory judgment action alleging invalidity or infringement of any of the PATENT RIGHTS shall be brought against UNIVERSITY, LICENSEE, at its option, shall have the right, within thirty
(30)&nbsp;days after commencement of such action, to intervene and take over the sole defense of the action at its own expense. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top">In any infringement suit either party may institute to enforce PATENT RIGHTS pursuant to this Agreement, the other party shall, at the request and expense of the party initiating such suit, cooperate in all respects
and, to the extent possible, have its employees testify when requested and make available relevant records, information, samples, specimens, and other evidence upon request. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 &#150; INDEMNIFICATION/INSURANCE/LIMITATION OF LIABILITY </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">LICENSEE shall at all times during the term of this Agreement and thereafter indemnify, defend and hold UNIVERSITY, its trustees, officers, faculty
member, employees and Affiliates (&#147;INDEMNIFIED PARTIES&#148;) harmless against all claims and expenses, including legal expenses and reasonable attorneys&#146; fees, arising out of the death of or injury to any person or persons or out of any
damage to property or the environment, and against any other claim, proceeding, demand, expense and liability of any kind whatsoever resulting from: (i)&nbsp;the production, manufacture, sale, use, lease, consumption or advertisement of the LICENSED
TECHNOLOGY by Licensee to its sublicensees, (ii)&nbsp;the practice by LICENSEE or any Affiliate or sublicensee of the PATENT RIGHTS; or (iii)&nbsp;arising from or relating to this License Agreement. LICENSEE shall provide this defense and indemnity
whether or not any INDEMNIFIED PARTIES, either jointly or severally, is named as a party defendant and whether or not any INDEMNIFIED PARTIES is alleged to be negligent or otherwise responsible for any injuries to person or property. The obligation
of LICENSEE to defend and indemnify as set forth herein shall </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
survive termination of this Agreement and shall not be limited by any other limitation of liability elsewhere in this Agreement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE shall obtain and carry in full force and effect liability insurance which shall protect LICENSEE and UNIVERSITY in regard to events covered by Section&nbsp;8.1 above, as provided below: </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:43.70pt; font-size:8pt; font-family:Times New Roman">COVERAGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:26.65pt; font-size:8pt; font-family:Times New Roman">LIMITS</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Commercial General Liability, including, but not limited to, Products, Contractual, Fire, Legal and Personal Injury</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$1,000,000 Combined Single Limits for Bodily Injury and Property Damage</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Professional Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$5,000,000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Products Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$5,000,000, to be effective on or before the date of first sale of LICENSED TECHNOLOGY products.</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The UNIVERSITY of Pittsburgh is to be named as an additional insured with respect to insurance policies
identified in Sections&nbsp;8.2(a), 8.2(b), and 8.2(c) above. Certificates of insurance evidencing the coverage required above shall be filed with the UNIVERSITY&#146;S Office of Technology Management, 200 Gardner Steel Conference Center,
Pittsburgh, PA 15260, no later than fifteen (15)&nbsp;days after execution of this Agreement and annually thereafter. Such certificates shall provide that the insurer will give the UNIVERSITY not less than thirty (30)&nbsp;days advance written
notice of any material changes in or cancellation of coverage. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">UNIVERSITY, AND ITS AGENTS AND/OR EMPLOYEES, MAKE NO REPRESENTATION AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT
LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR WARRANTY THAT THE PRACTICE BY LICENSEE OF THE
LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
PARTY. UNIVERSITY ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF UNIVERSITY, ITS AGENTS AND/OR EMPLOYEES FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT,
SPECIAL AND CONSEQUENTIAL DAMAGES, ATTORNEYS&#146; AND EXPERTS&#146; FEES, AND COURT COSTS (EVEN IF UNIVERSITY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, INCLUDING THE
MANUFACTURE, USE OR SALE OF THE PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT. LICENSEE ASSUMES ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A PRODUCT THAT IS MANUFACTURED, USED OR SOLD BY LICENSEE (INCLUDING SUBLICENSEE
SALES) WHICH IS LICENSED TECHNOLOGY HEREUNDER. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 &#150; ASSIGNMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly provided hereunder, this Agreement is not assignable without the prior written consent of UNIVERSITY which consent shall
not be unreasonably withheld, and any attempt to do so shall be null and void, provided that LICENSEE may assign this Agreement and its rights and obligations thereunder, without the UNIVERSITY&#146;S prior written consent in connection with the
transfer or sale of all or substantially all of the LICENSEE&#146;S business relating to the PATENT RIGHTS and LICENSED TECHNOLOGY to a third party, whether by merger, sale of stock, sale of assets or otherwise subject to LICENSEE providing at least
10 business days written notification to UNIVERSITY and further subject to the assignee agreeing in writing to be bound to all the terms and conditions of this License. The rights and obligations of the parties under this Agreement shall be binding
upon and inure to the benefit of the successors and permitted assigns of the parties. Any assignment not in accordance with this Article 9 shall be null and void. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 &#150; TERM AND TERMINATION </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top">This Agreement shall terminate upon the expiration of the last surviving claim of the PATENT RIGHTS. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top">UNIVERSITY shall have the right to terminate this Agreement, upon written notice, if: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE defaults in the performance of any of the obligations herein contained and such default has not been cured within [***] days after receiving written notice thereof from UNIVERSITY; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE ceases to carry out its business, becomes bankrupt or insolvent, applies for or consents to the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the aid of
debtors. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE may terminate this Agreement upon six (6)&nbsp;months prior written notice to UNIVERSITY and upon payment of all amounts accrued or due to UNIVERSITY through the effective date of termination, including patent
cost reimbursement pursuant to Article 6 hereof. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top">Upon termination of this Agreement, neither party shall be released from any obligation that matured prior to the effective date of such termination. LICENSEE and any sublicensee may, however, after the effective date
of such termination, sell all products under the LICENSED TECHNOLOGY which LICENSEE produced prior to the effective date of such termination, provided that LICENSEE shall pay to UNIVERSITY the royalties thereon as required by Article 4 hereof and
submit the reports required by Article 5 hereof. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 &#150; NOTICES </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top">Any notice or communication pursuant to this Agreement shall be sufficiently made or given if sent by certified or registered mail, postage prepaid, or by overnight courier, with proof of delivery by receipt, addressed
to the address below or as either party shall designate by written notice to the other party, or if in accordance with Section&nbsp;11.3. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">In the case of University:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Associate Vice Chancellor for Technology Management and Commercialization</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Office of Technology Management</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">University of Pittsburgh</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">200 Gardner Steel Conference Center</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Thackeray&nbsp;&amp; O&#146;Hara Streets</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Pittsburgh, PA 15260</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">In the case of LICENSEE:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Exagen Diagnostics, Inc.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">800 Bradbury Drive SE</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Suite 108</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Albuquerque, NM 87106</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Attn: President and CEO</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top">Any payments to University hereunder by wire transfer shall be directed as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="79%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Bank: Mellon Bank, NA, Pittsburgh, PA</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">ABA Routing No.: 043000261-University of Pittsburgh</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Account No.: 0015510</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Mellon SWIFT Code: MELNUS3P (international transfers)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Reference&nbsp;Code:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Technology Management, Accountant -</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">otmfinbx@pitt.edu - (412)&nbsp;648-2226</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">LICENSEE shall be responsible for all applicable fees and costs relating to any wire transfer, to include
translation fees, without any deduction of such fees from amounts due to the UNIVERSITY pursuant to this Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top">All invoices to LICENSEE generated by UNIVERSITY under this Agreement will be sent electronically, via e-mail, in PDF format, unless instructed otherwise by LICENSEE in writing. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12 &#150; AMENDMENT, MODIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement may not be amended or modified except by the execution of a written instrument signed by the UNIVERSITY&#146;S Executive Vice
Chancellor, or its successor and/or designated UNIVERSITY employee having signatory authority, and LICENSEE&#146;S President. In connection with any agreed upon amendment or modification of this Agreement pursuant to this Article 12, LICENSEE shall
be required to pay an Amendment Fee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 13 &#150; MISCELLANEOUS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top">This Agreement shall be construed and interpreted in accordance with the laws of the Commonwealth of Pennsylvania. The forum for any action relating to this Agreement, including those brought against individuals such as
UNIVERSITY employees or agents, shall be the Courts of Allegheny County, Pennsylvania, or, if in a federal proceeding, the United States District Court for the Western District of Pennsylvania. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top">The parties acknowledge that this Agreement sets forth the entire understanding and intentions of the parties hereto as to the subject matter hereof and supersedes all previous representations, negotiations, or
understandings between the parties and/or its employees or agents, whether written or oral, regarding the subject matter of this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top">Nothing contained in this Agreement shall be construed as conferring upon either party any right to use in advertising, publicity or other promotional activities any name, trade name, trademark, or other designation of
the other party, including any contraction, abbreviation, or simulation of any of the foregoing. Without the express written approval of the other party, neither party shall use any designation of the other party in any promotional activity
associated with this Agreement or the LICENSED TECHNOLOGY. Neither party shall issue any press release or make any public statement in regard to this Agreement without the prior written approval of the other party, except LICENSEE may make such
disclosures as are necessary or appropriate to comply with its obligations under applicable laws, rules and regulations of the Securities and Exchange Commission and securities exchange upon which LICENSEE&#146;S securities are listed.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.4</TD>
<TD ALIGN="left" VALIGN="top">If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable, the remaining provisions shall not in any way be affected or impaired thereby. In the event any provision is held
illegal or unenforceable, the parties shall use reasonable efforts to substitute a valid, legal and enforceable provision which, insofar as is practical, implements purposes of the provision held invalid, illegal or unenforceable. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.5</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Failure at any time to require performance of any of the provisions herein shall not waive or diminish a party&#146;s right thereafter to demand
compliance therewith or with any other </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
provision. Waiver of any default shall not waive any other default. A party shall not be deemed to have waived any rights hereunder unless such waiver is in writing and signed by a duly
authorized officer of the party making such waiver. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.6</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE acknowledges that UNIVERSITY is free to publish the results of the research activities of its faculty, staff and students, even though such publication may involve the PATENT RIGHTS or LICENSED TECHNOLOGY.
UNIVERSITY agrees to submit to LICENSEE any proposed publication or presentation regarding the subject matter specifically described in the PATENT RIGHTS for prior review by LICENSEE at least [***] days before its submittal for publication or its
presentation. LICENSEE may, within [***] days after receipt of such proposed publication, request that such proposed publication be delayed not more than [***] days in order to allow for protection of intellectual property rights. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.7</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">The term &#147;Confidential Information&#148; shall mean any and all proprietary or confidential information of UNIVERSITY or LICENSEE which may be
exchanged between parties at any time and from time to time during the term of this Agreement. Information shall not be considered confidential to the extent that either party can establish by competent proof that it: (i)&nbsp;is publically
disclosed through no fault of any party hereto, either before or after it becomes known to the receiving party; (ii)&nbsp;was known to the receiving party prior to the date of this Agreement, which knowledge was acquired independently and not from
another party hereto (or such party&#146;s employees); (iii)&nbsp;is subsequently disclosed to the receiving party in good faith by a third party who has a right to make such disclosure; or (iv)&nbsp;has been published by a third party as a matter
of right. The parties agree that during the term of this Agreement, and for a period of [***] years after this Agreement terminates, a party receiving Confidential Information of the other party will (a)&nbsp;maintain in confidence such Confidential
Information; (b)&nbsp;not disclose such Confidential Information to any third party and (c)&nbsp;not use such confidential Information for any purpose except those permitted in this Agreement. Notwithstanding the foregoing, if a party is required by
law, regulation or court order to disclose Confidential Information of the other party, the party required to make such disclosure shall limit the same to the minimum required to make such disclosure shall limit the same to the minimum required
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
to comply with the law or court order, and shall use reasonable efforts to attempt to seek confidential treatment for that disclosure, and prior to making such disclosure that party shall notify
the other party shall notify the other party, not later than ten (10)&nbsp;days (or shorter period of time as may be practicable under the circumstances) before the disclosure in order to allow that other party to comment and/or to obtain protective
or other order, including extensions of time and the like, with respect to such disclosure. In addition, a party may disclose Confidential Information to the other party to employees, to sublicensees and potential sublicensees (in the case of
LICENSEE), or to other third parties in connection with due diligence or similar investigations by third parties or potential third party investors in confidential financing document, provided, in each case, that any such employee, consultant,
agent, sublicense, potential sublicense or other third party agrees in writing to be bound by terms of confidentiality and non-use at least as stringent as those set forth in this Section&nbsp;13.7. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.8</TD>
<TD ALIGN="left" VALIGN="top">The parties acknowledge that they consulted, or had the opportunity to investigate and/or consult, with their legal counsel and/or other advisors with respect to the PATENT RIGHTS, LICENSED TECHNOLOGY, and the terms of
this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.9</TD>
<TD ALIGN="left" VALIGN="top">The parties agree that this Agreement constitutes an arm&#146;s length business transaction and does not create a fiduciary relationship. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.10</TD>
<TD ALIGN="left" VALIGN="top">LICENSEE agrees that with respect to the performance of this Agreement or the practice of the rights granted by the UNIVERSITY hereunder, it shall comply with any and all applicable United States export control laws and
regulations, as well as any and all embargoes and/or other restrictions imposed by the Treasury Department&#146;s Office of Foreign Asset Controls. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.11</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">If LICENSEE challenges the validity or enforceability of UNIVERSITY&#146;S PATENT RIGHTS or UNIVERSITY&#146;S ownership of the PATENT RIGHTS anywhere
in the world, the LICENSEE shall continue to pay to UNIVERSITY all royalties and other financial obligations required under this Agreement, to include patent costs and fees.&nbsp;If any such challenge is unsuccessful by Licensee, the royalty rates
and any non-royalty sublicense income rate set forth in Article 4.1 above shall automatically double in value, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
to include all royalty minimums and floors; and Licensee shall reimburse the University for all fees and costs associated with defending such action, including but not limited to attorneys fees
and expert fees.&nbsp;The&nbsp;effective date of such increase in royalty rates shall be the date of the first court order or date of issuance of a re-examination certificate (or foreign equivalents thereof) declaring any claim of the PATENT RIGHTS
as valid or enforceable. Within thirty (30)&nbsp;days prior to filing any such challenge, LICENSEE shall provide the UNIVERSITY with written notice of its intent to make such challenge. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.12</TD>
<TD ALIGN="left" VALIGN="top">Licensee shall mark all Licensed Technology with applicable foreign patent numbers in accordance with the applicable laws of the countries in which Licensed Technology is used or sold. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[remainder of page intentionally left blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties represent and warrant that each has the authority to bind the
party to this Agreement and have set their hands and seals as of the date set forth on the first page hereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">UNIVERSITY OF PITTSBURGH &#150; OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jerome Cochran</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Jerome Cochran</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Executive Vice Chancellor</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EXAGEN DIAGNOSTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ron Rocca</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Ron Rocca</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">C.E.O.</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PATENT RIGHTS FOR EXCLUSIVE LICENSE AGREEMENT BETWEEN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE UNIVERSITY OF PITTSBURGH AND EXAGEN DIAGNOSTICS, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Univ.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Case</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:18.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:53.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Application No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Application</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:39.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:36.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patent No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patent</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Issuance</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:29.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.90pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Country</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[***]</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top">Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SAMPLE ROYALTY REPORT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licensee name: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reporting period: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Date of
report: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalty Reporting Form </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:24.85pt; font-size:8pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">No.&nbsp;units&nbsp;sold<BR>(including<BR>sublicense)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Invoiced&nbsp;price<BR>per unit</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Gross&nbsp;sales</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Allowable<BR>deductions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Net&nbsp;sales</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net sales</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty rate</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty due</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total royalty due: $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name and addresses of sublicensees: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total non-royalty sublicense
income: $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Report prepared by: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT C </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SAMPLE PROGRESS REPORT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licensee name:
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Report date: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Technology title: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Progress Report </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top">Date development plan initiated and time period covered by this report </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top">Development report </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Activities, e.g., research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales, etc., completed since last report including the object and parameters of the development, when
initiated, when completed and the results </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Activities currently under investigations, i.e., ongoing activities including object and parameters of such activities, when initiated, and projected date of completion </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top">Future development activities </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Activities to be undertaken before next report including, but not limited to, the type and object of any studies conducted and their projected starting and completion dates </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Estimated total development time remaining before a product will be commercialized </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top">Changes to initial development plan </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Reasons for change </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Variables that may cause additional changes </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">E.</TD>
<TD ALIGN="left" VALIGN="top">Items to be provided if applicable: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Information relating to product that has become publicly available, e.g., published articles, competing products, patents, etc. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Development work being performed by third parties other than Licensee to include name of third party, reasons for use of third party, planned future use of third parties including reasons why and type of work
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Update of competitive information trends in industry, government compliance, and market plan </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>14
<FILENAME>d693329dex1027.htm
<DESCRIPTION>EX-10.27
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.27</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.27 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS INDEMNIFICATION AGREEMENT</B> (this &#147;<B><I>Agreement</I></B>&#148;) is made and entered into as of
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;], by and among Exagen Diagnostics, Inc. (the
&#147;<B><I>Company</I></B>&#148;) and [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] (the &#147;<B><I>Indemnitee</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
the Company values Indemnitee&#146;s service to the Company as a director or officer and desires that Indemnitee continue to serve the Company in such capacity;<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Indemnitee does not regard the protection available under the organizational documents of the Company and any insurance
policies maintained by the Company as adequate in the present circumstances, and Indemnitee may not be willing to continue to serve in his capacity as a director or officer of the Company without the additional protections set forth in this
Agreement;<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Board of Directors of the Company (the &#147;<B></B><B><I>Board</I></B><B></B>&#148;) has
determined that, on the basis of the foregoing, it is reasonable, prudent and necessary for the Company to obligate itself contractually to indemnify, and to advance expenses on behalf of, Indemnitee to the fullest extent permitted by applicable law
so that Indemnitee will serve or continue to serve the Company free from undue concern that he will not be so indemnified;<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, this Agreement is a supplement to and in furtherance of the organizational documents of the Company and any resolutions
adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>WHEREAS</B><B><I></I></B>, Indemnitee may have certain rights to indemnification and/or insurance provided by an investment
or venture capital fund with which Indemnitee is or may become affiliated (the &#147;<B><I>Associated Fund</I></B>&#148;) which Indemnitee and the Associated Fund intend to be secondary to the primary obligation of the Company to indemnify
Indemnitee as provided herein, with the Company&#146;s acknowledgement and agreement to the foregoing being a material condition to Indemnitee&#146;s willingness to serve on the Board.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the mutual promises and agreements herein contained, and intending to be legally bound, the parties
hereto agree as follows:<B> </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. I<SMALL>NDEMNIFICATION</SMALL> <SMALL>OF</SMALL> I<SMALL>NDEMNITEE</SMALL> <SMALL>AND</SMALL> A<SMALL>SSOCIATED</SMALL>
F<SMALL>UND</SMALL></B><SMALL></SMALL>. The Company hereby agrees to hold harmless and indemnify Indemnitee to the fullest extent permitted by applicable law, as such may be amended from time to time. In furtherance of the foregoing indemnification,
and without limiting the generality thereof: </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Indemnitee shall be entitled to the rights of indemnification provided in this
<U>Section&nbsp;1(a)</U> if, by reason of his Corporate Status (as defined in <U>Section&nbsp;13(c)</U>), the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding (as defined in <U>Section&nbsp;13(j)</U>) other
than a Proceeding by or in the right of the Company. Pursuant to this <U>Section&nbsp;1(a)</U>, Indemnitee shall be indemnified against all Expenses (as defined in <U>Section&nbsp;13(g)</U>), judgments, penalties, fines and amounts paid in
settlement actually and reasonably incurred by him, or on his behalf, in connection with such Proceeding or any claim, issue or matter therein, if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not
opposed to the best interests of the Company, and with respect to any criminal Proceeding, had no reasonable cause to believe the Indemnitee&#146;s conduct was unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Indemnitee shall be entitled to the rights of indemnification provided in this <U>Section&nbsp;1(b)</U> if, by reason of his
Corporate Status, the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding brought by or in the right of the Company. Pursuant to this <U>Section&nbsp;1(b)</U>, Indemnitee shall be indemnified against all Expenses
actually and reasonably incurred by the Indemnitee, or on the Indemnitee&#146;s behalf, in connection with such Proceeding if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best
interests of the Company; <U>provided</U>, <U>however</U>, that if applicable law so provides, no indemnification against such Expenses shall be made in respect of any claim, issue or matter in such Proceeding as to which Indemnitee shall have been
adjudged to be liable to the Company unless and to the extent that a court of competent jurisdiction shall determine that such indemnification may be made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a party
to and is successful, on the merits or otherwise, in any Proceeding, he shall be indemnified to the maximum extent permitted by law, as such may be amended from time to time, against all Expenses actually and reasonably incurred by him or on his
behalf in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify
Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with each successfully resolved claim, issue or matter. For purposes of this <U>Section&nbsp;1(c)</U> and without limitation, the termination of
any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>If the Associated Fund is, or is threatened to be made, a party to or a participant in any Proceeding relating to or arising by
reason of the Associated Fund&#146;s position as a stockholder of, or lender to, the Company, or the Associated Fund&#146;s appointment of or affiliation with Indemnitee or any other director, including without limitation any alleged
misappropriation of a Company asset or corporate opportunity, any claim of misappropriation or infringement of intellectual property relating to the Company, any alleged false or misleading statement or omission made by the Company (or on its
behalf) or its employees or agents, or any allegation of inappropriate control or influence over the Company or its Board members, officers, equity holders or debt holders, then the Associated Fund will be entitled to indemnification hereunder for
Expenses to the same extent as Indemnitee, and the terms of this Agreement as they relate to procedures for indemnification of Indemnitee and advancement of Expenses shall apply to any such indemnification of the Associated Fund. The rights provided
to the Associated Fund under <B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this <U>Section&nbsp;1(d</U>) shall: (i)&nbsp;be suspended during any period during which the Associated Fund does not have a representative on the Board; and (ii)&nbsp;terminate on an initial
public offering of the Company&#146;s Common Stock under the Securities Act of 1933, as amended (an &#147;<B><I>IPO</I></B>&#148;); <U>provided</U>, <U>however</U>, that in the event of any such suspension or termination, the Associated Fund&#146;s
rights to indemnification will not be suspended or terminated with respect to any Proceeding based in whole or in part on facts and circumstances occurring at any time prior to such suspension or termination regardless of whether the Proceeding
arises before or after such suspension or termination. The Company and Indemnitee agree that the Associated Fund is an express third party beneficiary of the terms of this <U>Section&nbsp;1(d)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. A<SMALL>DDITIONAL</SMALL> I<SMALL>NDEMNITY</SMALL></B><SMALL></SMALL>. In addition to, and without regard to any limitations on, the indemnification
provided for in <U>Section&nbsp;1</U> of this Agreement, the Company shall and hereby does indemnify and hold harmless Indemnitee against all Expenses, judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by
him or on his behalf if, by reason of his Corporate Status, he is, or is threatened to be made, a party to or participant in any Proceeding (including a Proceeding by or in the right of the Company), including, without limitation, all liability
arising out of the negligence or active or passive wrongdoing of Indemnitee. The only limitation that shall exist upon the Company&#146;s obligations pursuant to this Agreement shall be that the Company shall not be obligated to make any payment to
Indemnitee that is finally determined (under the procedures, and subject to the presumptions, set forth in <U>Sections&nbsp;6</U> and <U>7</U> hereof) to be unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. C<SMALL>ONTRIBUTION</SMALL></B><SMALL></SMALL>.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>Whether or not the indemnification provided in <U>Sections&nbsp;1</U> and <U>2</U> hereof is available, in respect of any
Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding), the Company shall pay, in the first instance, the entire amount of any judgment or settlement of such Proceeding without requiring
Indemnitee to contribute to such payment and the Company hereby waives and relinquishes any right of contribution it may have against Indemnitee. The Company shall not enter into any settlement of any Proceeding in which the Company is jointly
liable with Indemnitee (or would be if joined in such Proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Without diminishing or impairing the obligations of the Company set forth in <U>Section&nbsp;3(a)</U>, if, for any reason,
Indemnitee shall elect or be required to pay all or any portion of any judgment or settlement in any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding), the Company shall contribute to the
amount of Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the relative benefits received by the Company and all officers, directors or employees of the
Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the other hand, from the transaction from which such Proceeding arose; <U>provided</U>,
<U>however</U>, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to the relative fault of the Company and all officers, directors or employees of the
Company other than Indemnitee who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Indemnitee, on the other hand, in connection with the events that resulted in such expenses, judgments, fines or settlement amounts, as well as any other equitable considerations which the Law
may require to be considered. The relative fault of the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and
Indemnitee, on the other hand, shall be determined by reference to, among other things, the degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and
the degree to which their conduct is active or passive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>The Company hereby agrees to fully indemnify and hold Indemnitee
harmless from any claims of contribution which may be brought by officers, directors or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to
Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for
Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect: (i)&nbsp;the relative
benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii)&nbsp;the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee
in connection with such event(s) and/or transaction(s).<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. I<SMALL>NDEMNIFICATION</SMALL> <SMALL>FOR</SMALL> E<SMALL>XPENSES</SMALL>
<SMALL>OF</SMALL> <SMALL>A</SMALL> W<SMALL>ITNESS</SMALL></B><SMALL></SMALL>. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a witness, or is made (or asked to) respond to
discovery requests, in any Proceeding to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. A<SMALL>DVANCEMENT</SMALL> <SMALL>OF</SMALL> E<SMALL>XPENSES</SMALL></B><SMALL></SMALL>. Notwithstanding any other provision of this Agreement, the
Company shall advance all Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding by reason of Indemnitee&#146;s Corporate Status within thirty (30)&nbsp;days after the receipt by the Company of a statement or statements
from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be
preceded or accompanied by a written undertaking by or on behalf of Indemnitee to repay any Expenses advanced if it shall ultimately be determined that Indemnitee is not entitled to be indemnified against such Expenses. Any advances and undertakings
to repay pursuant to this <U>Section&nbsp;5</U> shall be unsecured and interest free. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. P<SMALL>ROCEDURES</SMALL> <SMALL>AND</SMALL>
P<SMALL>RESUMPTIONS</SMALL> <SMALL>FOR</SMALL> D<SMALL>ETERMINING</SMALL> E<SMALL>NTITLEMENT</SMALL> <SMALL>TO</SMALL> I<SMALL>NDEMNIFICATION</SMALL></B><SMALL></SMALL>. It is the intent of this Agreement to secure for Indemnitee rights of
indemnification that are as favorable as may be permitted under applicable law. Accordingly, the parties agree that the following procedures and presumptions shall apply in the event of any question as to whether Indemnitee is entitled to
indemnification under this Agreement: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>To obtain indemnification under this Agreement, Indemnitee shall submit to the Company
a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. The
Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. Notwithstanding the foregoing, any failure of Indemnitee to provide such a
request to the Company, or to provide such a request in a timely fashion, shall not relieve the Company of any liability that it may have to Indemnitee unless, and to the extent that, such failure actually and materially prejudices the interests of
the Company.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>Upon written request by Indemnitee for indemnification pursuant to the first sentence of
<U>Section&nbsp;6(a)</U> hereof, a determination with respect to Indemnitee&#146;s entitlement thereto shall be made in the specific case by one of the following four methods, which shall be at the election of the Board: (i)&nbsp;by a majority vote
of the Disinterested Directors (as defined in <U>Section&nbsp;13(d)</U>), even though less than a quorum; (ii)&nbsp;by a committee of those Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a
quorum; (iii)&nbsp;if there are no Disinterested Directors or if the Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to the Indemnitee, or (iv)&nbsp;if so directed by
the Board, by the stockholders of the Company; <U>provided</U>, <U>however</U>, that, notwithstanding the foregoing, any determination with respect to Indemnitee&#146;s entitlement to indemnification hereunder that is made at any time following the
consummation of a Change in Control (as defined in <U>Section&nbsp;13(b)</U>) that occurs at any time when the Company has a class of securities registered under the Exchange Act (as defined in <U>Section&nbsp;13(f)</U>)or following the consummation
of an IPO shall be made solely by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to the Indemnitee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section&nbsp;6(b) hereof,
the Independent Counsel shall be selected as provided in this Section&nbsp;6(c). The Independent Counsel shall be selected by the Board. Indemnitee may, within 10&nbsp;days after such written notice of selection shall have been given, deliver to the
Company a written objection to such selection; <U>provided</U>, <U>however</U>, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#147;Independent Counsel&#148; as
defined in <U>Section&nbsp;13(h)</U> of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If a
written objection is made and substantiated, the Independent Counsel selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within 20&nbsp;days
after submission by Indemnitee of a written request for indemnification pursuant to Section&nbsp;6(a) hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition a court of competent
jurisdiction for resolution of any objection which shall have been made by the Indemnitee to the Company&#146;s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by such other
person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section&nbsp;6(b) hereof. The Company shall pay any and all reasonable fees and
expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to Section&nbsp;6(b) hereof, and the Company shall pay all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonable fees and expenses incident to the procedures of this Section&nbsp;6(c), regardless of the manner in which such Independent Counsel was selected or appointed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such
determination shall presume that Indemnitee is entitled to indemnification under this Agreement. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence. Neither the
failure of the Company (including by its directors or independent legal counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee
has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or independent legal counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or
create a presumption that Indemnitee has not met the applicable standard of conduct.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>Indemnitee shall be deemed to have
acted in good faith if Indemnitee&#146;s action is based on the records or books of account of the Enterprise (as defined in <U>Section&nbsp;13(e)</U>), including financial statements, or on information supplied to Indemnitee by the officers of the
Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert
selected with reasonable care by the Enterprise. In addition, the knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to
indemnification under this Agreement. Whether or not the foregoing provisions of this <U>Section&nbsp;6(e)</U> are satisfied, it shall in any event be presumed that Indemnitee has at all times acted in good faith and in a manner he reasonably
believed to be in or not opposed to the best interests of the Company. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>If the person, persons or entity empowered or selected under this <U>Section&nbsp;6</U> to determine whether Indemnitee is entitled
to indemnification shall not have made a determination within sixty (60)&nbsp;days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee
shall be entitled to such indemnification absent: (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#146;s statement not materially misleading, in connection with the request for
indemnification; or (ii)&nbsp;a prohibition of such indemnification under applicable law; <U>provided</U>, <U>however</U>, that such <FONT STYLE="white-space:nowrap">60-day</FONT> period may be extended for a reasonable time, not to exceed an
additional thirty (30)&nbsp;days, if the person, persons or entity making such determination with respect to entitlement to indemnification in good faith requires such additional time to obtain or evaluate documentation and/or information relating
thereto; and <U>provided</U>, <U>further</U>, that the foregoing provisions of this <U>Section&nbsp;6(f)</U> shall not apply if the determination of entitlement to indemnification is to be made by the stockholders pursuant to
<U>Section&nbsp;6(b)</U> of this Agreement and if (A)&nbsp;within fifteen (15)&nbsp;days after receipt by the Company of the request for such determination, the Board or the Disinterested Directors, if appropriate, resolve to submit such
determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75)&nbsp;days after such receipt and such determination is made thereat or (B)&nbsp;a special meeting of stockholders is called
within fifteen </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(15)&nbsp;days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60)&nbsp;days after having been so called and such
determination is made thereat. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) </B>Indemnitee shall cooperate with the person, persons or entity making such determination with
respect to Indemnitee&#146;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and
which is reasonably available to Indemnitee and reasonably necessary to such determination. Any Independent Counsel, member of the Board or stockholder of the Company shall act reasonably and in good faith in making a determination regarding the
Indemnitee&#146;s entitlement to indemnification under this Agreement. Any costs or expenses (including attorneys&#146; fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination
shall be borne by the Company (irrespective of the determination as to Indemnitee&#146;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) </B>The Company acknowledges that a settlement or other disposition short of final judgment may be successful if it permits a party to
avoid expense, delay, distraction, disruption and uncertainty. In the event that any Proceeding to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee (including, without limitation, settlement of
such Proceeding with or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful on the merits or otherwise in such Proceeding. Anyone seeking to overcome this presumption shall have the burden of
proof and the burden of persuasion by clear and convincing evidence.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>The termination of any Proceeding or of any claim,
issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to
indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee
had reasonable cause to believe that his conduct was unlawful.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. R<SMALL>EMEDIES</SMALL> <SMALL>OF</SMALL>
I<SMALL>NDEMNITEE</SMALL></B><SMALL></SMALL>.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>In the event that: (i)&nbsp;a determination is made pursuant to
<U>Section&nbsp;6</U> of this Agreement that Indemnitee is not entitled to indemnification under this Agreement; (ii)&nbsp;advancement of Expenses is not timely made pursuant to <U>Section&nbsp;5</U> of this Agreement; (iii)&nbsp;no determination of
entitlement to indemnification is made pursuant to <U>Section&nbsp;6(b)</U> of this Agreement within ninety (90)&nbsp;days after receipt by the Company of the request for indemnification; (iv)&nbsp;payment of indemnification is not made pursuant to
this Agreement within ten (10)&nbsp;days after receipt by the Company of a written request therefor; or (v)&nbsp;payment of indemnification is not made within ten (10)&nbsp;days after a determination has been made that Indemnitee is entitled to
indemnification or such determination is deemed to have been made pursuant to <U>Section&nbsp;6</U> of this Agreement, Indemnitee shall be entitled to an adjudication in any court of competent jurisdiction of Indemnitee&#146;s entitlement to such
indemnification. Indemnitee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall commence such proceeding seeking an adjudication within one hundred eighty (180)&nbsp;days following the date on which Indemnitee first has the right to commence such proceeding pursuant to
this <U>Section&nbsp;7(a)</U>. The Company shall not oppose Indemnitee&#146;s right to seek any such adjudication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>In the
event that a determination shall have been made pursuant to <U>Section&nbsp;6(b)</U> of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding commenced pursuant to this <U>Section&nbsp;7</U> shall be conducted in
all respects as a de novo trial on the merits, and Indemnitee shall not be prejudiced by reason of the adverse determination under <U>Section&nbsp;6(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>If a determination shall have been made pursuant to <U>Section&nbsp;6(b</U>) of this Agreement that Indemnitee is entitled to
indemnification, the Company shall be bound by such determination in any judicial proceeding commenced pursuant to this <U>Section&nbsp;7</U>, absent: (i)&nbsp;a misstatement by Indemnitee of a material fact or an omission of a material fact
necessary to make Indemnitee&#146;s misstatement not materially misleading in connection with the application for indemnification; or (ii)&nbsp;a prohibition of such indemnification under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>In the event that Indemnitee, pursuant to this <U>Section&nbsp;7</U>, seeks a judicial adjudication of his rights under, or to
recover damages for breach of, this Agreement, or to recover under any directors&#146; and officers&#146; liability insurance policies maintained by the Company, the Company shall pay on his behalf, in advance, any and all expenses (of the types
described in the definition of &#147;Expenses&#148; in <U>Section&nbsp;13(d)</U> of this Agreement) actually and reasonably incurred by him in such judicial adjudication, regardless of whether Indemnitee ultimately is determined to be entitled to
such indemnification, advancement of expenses or insurance recovery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>The Company shall be precluded from asserting in any
judicial proceeding commenced pursuant to this <U>Section&nbsp;7</U> that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court that the Company is bound by all the provisions
of this Agreement. The Company shall indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10)&nbsp;days after receipt by the Company of a written request therefor) advance, to the extent not
prohibited by law, such expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors&#146; and
officers&#146; liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this
Agreement shall be required to be made prior to the final disposition of the Proceeding.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. N<SMALL>ON</SMALL>-E<SMALL>XCLUSIVITY</SMALL>,
S<SMALL>URVIVAL</SMALL> <SMALL>OF</SMALL> R<SMALL>IGHTS</SMALL>, E<SMALL>TC</SMALL>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The rights of indemnification as
provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable <B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
law, the organizational documents of the Company, any other agreement with the Company, a vote of the Company&#146;s stockholders, a resolution of the Board or otherwise. No amendment, alteration
or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or
repeal. To the extent that a change in any applicable law, whether by statute or judicial decision, permits greater indemnification than would be afforded currently under the Company&#146;s organizational documents and this Agreement, it is the
intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and
remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent
the concurrent assertion or employment of any other right or remedy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>To the extent that the Company maintains an insurance
policy or policies providing liability insurance for directors, officers, employees, or agents or fiduciaries of the Company or of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to
the maximum extent of the coverage available for any director, officer, employee, agent or fiduciary under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has directors&#146;
and officers&#146; liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take
all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>(c) </B><B><I></I></B>The Company hereby acknowledges that Indemnitee may have certain rights to indemnification, advancement
of expenses and/or insurance provided by the Associated Fund and/or certain of its affiliates (collectively, the &#147;<B><I>Additional Indemnitors</I></B>&#148;). The Company hereby agrees that: (i)&nbsp;it is the indemnitor of first resort (i.e.,
its obligations to Indemnitee are primary and any obligation of the Additional Indemnitors (or any insurance carrier providing insurance coverage purchased by any Additional Indemnitor) to advance expenses or to provide indemnification for the same
expenses or liabilities incurred by Indemnitee are secondary); (ii)&nbsp;it shall be required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and
amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement and the organizational documents of the Company, without regard to any rights Indemnitee may have against the Additional Indemnitors (or any
insurance carrier providing insurance coverage purchased by any Additional Indemnitor); and (iii)&nbsp;it irrevocably waives, relinquishes and releases the Additional Indemnitors from any and all claims against the Additional Indemnitors for
contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Additional Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought
indemnification from the Company shall affect the foregoing and the Additional Indemnitors shall have a right of indemnification and/or be subrogated to the full extent of such advancement or payment to all of the rights of recovery of Indemnitee
against the Company. The Company and Indemnitee agree <B><I> </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that the Additional Indemnitors are express third party beneficiaries of the terms of this <U>Section&nbsp;8(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>Except as provided in <U>Section&nbsp;8(c)</U> above, in the event of any payment under this Agreement, the Company shall be
subrogated to the extent of such payment to all of the rights of recovery of Indemnitee (other than against the Additional Indemnitors), who shall execute all papers required and take all action necessary to secure such rights, including execution
of such documents as are necessary to enable the Company to bring suit to enforce such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>Except as provided in
<U>Section&nbsp;8(c)</U> above, the Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that Indemnitee has otherwise actually received payment of such amounts under
any insurance policy, contract, other agreement or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>Except as provided in <U>Section&nbsp;8(c)</U> above, the
Company&#146;s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, employee or agent of any Enterprise other than the Company shall be reduced by any amount
Indemnitee has actually received as indemnification or advancement of expenses from such other Enterprise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. E<SMALL>XCEPTION</SMALL>
<SMALL>TO</SMALL> R<SMALL>IGHT</SMALL> <SMALL>OF</SMALL> I<SMALL>NDEMNIFICATION</SMALL></B><SMALL></SMALL>. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to provide any indemnification in
connection with any claim made against Indemnitee: (i)&nbsp;for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid
under any insurance policy or other indemnity provision, provided that the foregoing shall not affect the rights of Indemnitee or the Additional Indemnitors set forth <U>Section&nbsp;8(c)</U>; (ii)&nbsp;for an accounting of profits made from the
purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section&nbsp;16(b) of the Exchange Act or similar provisions of state statutory law or common law; or (iii)&nbsp;in connection with any
Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (A)&nbsp;the
Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (B)&nbsp;the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. D<SMALL>URATION</SMALL> <SMALL>OF</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL>. All agreements and obligations of the Company contained herein
shall continue until the date that is six (6)&nbsp;years after the date upon which Indemnitee&#146;s Corporate Status terminates and shall continue thereafter so long as Indemnitee shall be subject to any Proceeding (or any proceeding commenced
under <U>Section&nbsp;7</U> hereof) by reason of his Corporate Status, whether or not he is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement. This
Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially
all of the business or assets of the Company), assigns, spouses, heirs, executors and personal and legal representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. S<SMALL>ECURITY</SMALL></B><SMALL></SMALL>. To the extent requested by Indemnitee and approved by the
Board, the Company may at any time and from time to time provide security to Indemnitee for the Company&#146;s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral. Any such security, once provided to
Indemnitee, may not be revoked or released without the prior written consent of the Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. E<SMALL>NFORCEMENT</SMALL></B><SMALL></SMALL>. The
Company expressly confirms and agrees that it has entered into this Agreement and assumes the obligations imposed on it hereby in order to induce Indemnitee to serve as an officer or director of the Company, and the Company acknowledges that
Indemnitee is relying upon this Agreement in serving as an officer or director of the Company. The Company shall not seek from a court, or agree to, a &#147;bar order&#148; that would have the effect of prohibiting or limiting Indemnitee&#146;s
rights to receive advancement of Expenses under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. D<SMALL>EFINITIONS</SMALL></B><SMALL></SMALL>. For purposes of this Agreement:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>&#147;<B>Beneficial Owner</B>&#148; shall have the meaning given to such term in
<FONT STYLE="white-space:nowrap">Rule&nbsp;13d-3</FONT> under the Exchange Act; <U>provided</U>, <U>however</U>, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company
approving a merger of the Company with another entity.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>A &#147;<B>Change in Control</B>&#148; shall be deemed to occur
upon the earliest to occur after the date of this Agreement of any of the following events:<B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any Person is or becomes the
Beneficial Owner, directly or indirectly, of securities of the Company representing fifteen percent (15%)&nbsp;or more of the combined voting power of the Company&#146;s then outstanding securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>during any period of two (2)&nbsp;consecutive years (not including any period prior to the execution of this Agreement),
individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in
<U>Sections&nbsp;13(a)(i)</U>, <U>(a)(iii)</U> or <U>(a)(iv)</U>) whose election by the Board or nomination for election by the Company&#146;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who
either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute a least a majority of the members of the Board; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which
would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more
than fifty-one percent (51%)&nbsp;of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the Board or other
governing body of such surviving entity; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> the approval by the stockholders of the Company of a complete liquidation of the
Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company&#146;s assets; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> there occurs any other event of a nature that would be required to be reported in response to Item&nbsp;6(e) of Schedule&nbsp;14A
of Regulation&nbsp;14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act, whether or not the Company is then subject to such reporting requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>(c) </B><B><I></I></B>&#147;<B><I>Corporate Status</I></B>&#148; describes the status of a person who is or was at any time
(including, without limitation, any time prior to the date of this Agreement) a director, officer, employee, agent or fiduciary of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise
that such person is or was serving at the express written request of the Company.<B><I> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>(d)
</B><B><I></I></B>&#147;<B><I>Disinterested Director</I></B>&#148; means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>(e) </B><B><I></I></B>&#147;<B><I>Enterprise</I></B>&#148; shall mean the Company and any other corporation, partnership,
joint venture, trust, employee benefit plan or other enterprise that Indemnitee is or was serving at the express written request of the Company as a director, officer, employee, agent or fiduciary.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>&#147;<B><I>Exchange Act</I></B>&#148; shall mean the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>(g) </B><B><I></I></B>&#147;<B><I>Expenses</I></B>&#148; shall include all reasonable attorneys&#146; fees, retainers, court
costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements or expenses of the types customarily incurred in
connection with prosecuting, defending, preparing to prosecute or defend, investigating, participating, or being or preparing to be a witness in a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding.
Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding and any federal, state, local or foreign taxes imposed on the Indemnitee as a result of the actual or deemed receipt of any payments under this
Agreement, including without limitation the premium, security for, and other costs relating to any cost bond, supersede as bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement by Indemnitee or
the amount of judgments or fines against Indemnitee.<B><I> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>(h) </B><B><I></I></B>&#147;<B><I>Independent
Counsel</I></B>&#148; means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i)&nbsp;the Company or Indemnitee in any
matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii)&nbsp;any other party to the Proceeding giving rise to a
claim for indemnification hereunder. Notwithstanding the foregoing, the term &#147;Independent Counsel&#148; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest
in representing either the Company or Indemnitee in an action to determine Indemnitee&#146;s rights under this Agreement. The Company agrees to pay the reasonable fees of the Independent Counsel referred to above <B><I>
</I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>&#147;<B><I>Person</I></B>&#148; shall have the meaning as set forth in Sections&nbsp;13(d) and 14(d) of the Exchange Act;
<U>provided</U>, <U>however</U>, that Person shall exclude: (i)&nbsp;the Company; (ii)&nbsp;any trustee or other fiduciary holding securities under an employee benefit plan of the Company; and (iii)&nbsp;any corporation owned, directly or
indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>(j) </B><B><I></I></B>&#147;<B><I>Proceeding</I></B>&#148; includes any threatened, pending or completed action, suit,
arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding (including one pending on or before the date of this Agreement but excluding one initiated by
an Indemnitee pursuant to <U>Section&nbsp;7</U> of this Agreement to enforce his rights under this Agreement), whether brought by or in the right of the Company or otherwise and whether civil, criminal, administrative or investigative, in which
Indemnitee was, is or will be involved as a party or otherwise, by reason of the fact that Indemnitee is or was an officer or director of the Company, by reason of any action taken by him or of any inaction on his part while acting as an officer or
director of the Company, or by reason of the fact that he is or was serving at the request of the Company as a director, officer, employee, agent or fiduciary of another corporation, partnership, joint venture, trust or other Enterprise, in each
case whether or not he is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. S<SMALL>EVERABILITY</SMALL></B><SMALL></SMALL>. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or
enforceability of any other provision. Without limiting the generality of the foregoing, this Agreement is intended to confer upon Indemnitee indemnification rights to the fullest extent permitted by applicable laws. In the event any provision
hereof conflicts with any applicable law, such provision shall be deemed modified, consistent with the aforementioned intent, to the extent necessary to resolve such conflict. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. M<SMALL>ODIFICATION</SMALL> <SMALL>AND</SMALL> W<SMALL>AIVER</SMALL></B><SMALL></SMALL>. No supplement, modification, termination or amendment of this
Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall
such waiver constitute a continuing waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. N<SMALL>OTICE</SMALL> <SMALL>BY</SMALL> I<SMALL>NDEMNITEE</SMALL></B><SMALL></SMALL>. Indemnitee
agrees to promptly notify the Company in writing upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to
indemnification covered hereunder. The failure to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise unless and only to the extent that such failure or delay
materially prejudices the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. N<SMALL>OTICES</SMALL></B><SMALL></SMALL>. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given: (i)&nbsp;upon personal delivery </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the party to be notified; (ii)&nbsp;when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next
business day; (iii)&nbsp;five (5)&nbsp;business days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv)&nbsp;one business (1)&nbsp;day after deposit with a nationally recognized overnight
courier, specifying next day delivery, with written verification of receipt. All notices and other communications shall be sent: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(a)</B></TD>
<TD ALIGN="left" VALIGN="top">To Indemnitee at the address set forth below Indemnitee&#146;s signature hereto. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(b)</B></TD>
<TD ALIGN="left" VALIGN="top">To the Company at: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Exagen Diagnostics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">1261 Liberty Way, Suite C </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Vista,
California 92081 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Attention: Board of Directors </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. H<SMALL>EADINGS</SMALL></B><SMALL></SMALL>. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed
to constitute part of this Agreement or to affect the construction thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. G<SMALL>OVERNING</SMALL> L<SMALL>AW</SMALL></B><SMALL></SMALL>. This
Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. E<SMALL>NTIRE</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL>. This Agreement constitutes the entire agreement between the parties hereto with
respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. C<SMALL>OUNTERPARTS</SMALL></B><SMALL></SMALL>. This Agreement may be executed in two (2)&nbsp;or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same Agreement. This Agreement may also be executed and delivered by facsimile signature (or other similar electronic means) and in two (2)&nbsp;or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the parties hereto have executed this Agreement on and as of the day
and year first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>E<SMALL>XAGEN</SMALL> D<SMALL>IAGNOSTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Name:</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Title:</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="68%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INDEMNITEE:</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Name:</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:450pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE TO INDEMNIFICATION AGREEMENT] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>15
<FILENAME>d693329dex1029.htm
<DESCRIPTION>EX-10.29
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.29</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.29 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS EMPLOYMENT AGREEMENT (this &#147;<B><I>Agreement</I></B>&#148;) is entered into by and between Exagen Diagnostics, Inc., a Delaware
corporation (the &#147;<B><I>Company</I></B>&#148;), and Fortunato Ron Rocca (&#147;<B><I>Executive</I></B>&#148;), and shall be effective as of the date prior to the date on which the Company&#146;s common stock commences trading pursuant to the
initial public offering of the Company&#146;s common stock (the &#147;<B><I>Effective Date</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires
to employ Executive, and Executive desires to accept employment with the Company, on the terms and conditions set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual promises herein contained, the parties agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. As used in this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Cause</I></B>&#148; means any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the commission of an act of fraud, embezzlement or dishonesty by Executive, or the commission of some other illegal act by Executive,
that causes material harm to the Company or any successor or affiliate thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Executive&#146;s conviction of, or plea of
&#147;guilty&#148; or &#147;no contest&#148; to, a felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any intentional unauthorized use or disclosure by Executive of confidential information or trade secrets of the Company or any
successor or affiliate thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Executive&#146;s gross negligence, insubordination or material violation of any duty of loyalty to
the Company or any successor or affiliate thereof, or any other material misconduct on the part of Executive; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Executive&#146;s
ongoing and repeated failure or refusal to perform or neglect of Executive&#146;s duties as required by this Agreement, which failure, refusal or neglect continues for fifteen (15)&nbsp;days following Executive&#146;s receipt of written notice from
the Board stating with specificity the nature of such failure, refusal or neglect; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) Executive&#146;s intentional, material breach
of any Company policy or any contract or agreement between Executive and the Company or any successor or affiliate thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>,
<U>however</U>, that prior to the determination that &#147;Cause&#148; under clauses (iv), (v)&nbsp;or (vi)&nbsp;of this Section&nbsp;1(b) has occurred, the Company shall (A)&nbsp;provide to Executive in writing, in
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonable detail, the reasons for the determination that such &#147;Cause&#148; exists, (B)&nbsp;other than with respect to clause (v)&nbsp;above which specifies the applicable period of time
for Executive to remedy his or her breach, afford Executive a reasonable opportunity to remedy any such breach, (C)&nbsp;provide Executive an opportunity to be heard prior to the final decision to terminate Executive&#146;s employment hereunder for
such &#147;Cause&#148; and (D)&nbsp;make any decision that such &#147;Cause&#148; exists in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The foregoing definition shall
not in any way preclude or restrict the right of the Company or any successor or affiliate thereof to discharge or dismiss Executive for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of this
Agreement, to constitute grounds for termination for Cause. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B><I>Change in Control</I></B>&#148; means and includes each of
the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) a transaction or series of transactions (other than an offering of the Company&#146;s common stock to the general
public through a registration statement filed with the Securities and Exchange Commission) whereby any &#147;person&#148; or related &#147;group&#148; of &#147;persons&#148; (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities
Exchange Act of 1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;)) (other than the Company, any of its subsidiaries, an employee benefit plan maintained by the Company or any of its subsidiaries or a &#147;person&#148; that, prior to
such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act), of securities of the
Company possessing more than fifty percent (50%)&nbsp;of the total combined voting power of the Company&#146;s securities outstanding immediately after such acquisition; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more
intermediaries) of (A)&nbsp;a merger, consolidation, reorganization, or business combination or (B)&nbsp;a sale or other disposition of all or substantially all of the Company&#146;s assets in any single transaction or series of related transactions
or (C)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) which
results in the Company&#146;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of
the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#146;s assets or otherwise succeeds to the business of the Company (the Company or such person, the
&#147;<B><I>Successor Entity</I></B>&#148;) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#146;s outstanding voting securities immediately after the transaction, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) after which no person or group beneficially owns voting securities representing fifty percent (50%)&nbsp;or more of the
combined voting power of the Successor Entity; <U>provided</U>, <U>however</U>, that no person or group shall be treated for purposes of this clause&nbsp;(2) as beneficially owning fifty percent (50%)&nbsp;or more of combined voting power of the
Successor Entity solely as a result of the voting power held </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
in the Company prior to the consummation of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
foregoing, a transaction shall not constitute a &#147;<B><I>Change in Control</I></B>&#148; if: (i)&nbsp;its sole purpose is to change the state of the Company&#146;s incorporation; (ii)&nbsp;its sole purpose is to create a holding company that will
be owned in substantially the same proportions by the persons who held the Company&#146;s securities immediately before such transaction; (iii)&nbsp;it constitutes the Company&#146;s initial public offering of its securities; or (iv)&nbsp;it is a
transaction effected primarily for the purpose of financing the Company with cash (as determined by the Board in its discretion and without regard to whether such transaction is effectuated by a merger, equity financing or otherwise). The Board
shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control of the Company has occurred pursuant to the above definition, and the date of the occurrence of such Change in
Control and any incidental matters thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended from
time to time, and the Treasury Regulations and other interpretive guidance issued thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B><I>Good Reason</I></B>&#148;
means the occurrence of any of the following events or conditions without Executive&#146;s written consent: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) a material diminution in
Executive&#146;s authority, duties or responsibilities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) a material diminution in Executive&#146;s base compensation, unless such a
reduction is imposed across-the-board to senior management of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) a material change in the geographic location at which
Executive must perform his or her duties; or<SUP STYLE="font-size:85%; vertical-align:top"></SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) any other action or inaction that
constitutes a material breach by the Company or any successor or affiliate of its obligations to Executive under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Executive must provide written notice to the Company of the occurrence of any of the foregoing events or conditions without Executive&#146;s
written consent within sixty (60)&nbsp;days of the occurrence of such event. The Company or any successor or affiliate shall have a period of thirty (30)&nbsp;days to cure such event or condition after receipt of written notice of such event from
Executive. Executive&#146;s Separation from Service by reason of resignation from employment with the Company for Good Reason must occurs within thirty (30)&nbsp;days following the expiration of the foregoing thirty (30)&nbsp;day cure period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B><I>Involuntary Termination</I></B>&#148; means (i)&nbsp;Executive&#146;s Separation from Service by reason of Executive&#146;s
discharge by the Company other than for Cause, or (ii)&nbsp;Executive&#146;s Separation from Service by reason of Executive&#146;s resignation of employment with the Company for Good Reason. Executive&#146;s Separation from Service by reason of
Executive&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
death or discharge by the Company following Executive&#146;s Permanent Disability shall not constitute an Involuntary Termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) Executive&#146;s &#147;<B><I>Permanent Disability</I></B>&#148; shall be deemed to have occurred if Executive shall become physically or
mentally incapacitated or disabled or otherwise unable fully to discharge his or her duties hereunder for a period of ninety (90)&nbsp;consecutive calendar days or for one hundred twenty (120)&nbsp;calendar days in any one hundred eighty
(180)&nbsp;calendar-day period. The existence of Executive&#146;s Permanent Disability shall be determined by the Company on the advice of a physician chosen by the Company and the Company reserves the right to have Executive examined by a physician
chosen by the Company at the Company&#146;s expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B><I>Separation from Service</I></B>,&#148; with respect to Executive,
means Executive&#146;s &#147;separation from service,&#148; as defined in Treasury Regulation Section&nbsp;1.409A-1(h). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i)
&#147;<B><I>Stock Awards</I></B>&#148; means all stock options, restricted stock and such other awards granted pursuant to the Company&#146;s stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise
thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Services to Be Rendered.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Duties and Responsibilities</U>. Executive shall serve as President and Chief Executive Officer of the Company. In the performance of
such duties, Executive shall report directly to the Board and shall be subject to the direction of the Board and to such limits upon Executive&#146;s authority as the Board may from time to time impose. Executive hereby consents to serve as an
officer and/or director of the Company or any subsidiary or affiliate thereof without any additional salary or compensation, if so requested by the Board. Executive shall be employed by the Company on a full time basis. Executive&#146;s primary
place of work shall be the Company&#146;s principal executive offices, or, with the Company&#146;s consent, at any other place at which the Company maintains an office; <U>provided</U>, <U>however</U>, that the Company may from time to time require
Executive to travel temporarily to other locations in connection with the Company&#146;s business. Executive shall be subject to and comply with the policies and procedures generally applicable to senior executives of the Company to the extent the
same are not inconsistent with any term of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Exclusive Services</U>. Executive shall at all times faithfully,
industriously and to the best of his or her ability, experience and talent perform to the satisfaction of the Board all of the duties that may be assigned to Executive hereunder and shall devote substantially all of his or her productive time and
efforts to the performance of such duties. Subject to the terms of the Proprietary Information and Inventions Agreement referred to in Section&nbsp;5(b), this shall not preclude Executive from devoting time to personal and family investments or
serving on community and civic boards, or participating in industry associations, provided such activities do not interfere with his or her duties to the Company, as determined in good faith by the Board. Executive agrees that he or she will not
join any boards, other than community and civic boards (which do not interfere with his or her duties to the Company), without the prior approval of the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Compensation and Benefits</U>. The Company shall pay or provide, as the case may be, to
Executive the compensation and other benefits and rights set forth in this Section&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. The Company shall pay
to Executive a base salary of $440,000 per year, payable in accordance with the Company&#146;s usual pay practices (and in any event no less frequently than monthly). Executive&#146;s base salary shall be subject to review annually by and at the
sole discretion of the Compensation Committee of the Board or its designee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Bonus</U>. Executive shall participate in any bonus
plan that the Board or its designee may approve for the senior executives of the Company. Executive&#146;s target bonus under the Company&#146;s annual bonus plan shall be fifty-five percent (55%)&nbsp;of Executive&#146;s base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Benefits</U>. Executive shall be entitled to participate in benefits under the Company&#146;s benefit plans and arrangements,
including, without limitation, any employee benefit plan or arrangement made available in the future by the Company to its senior executives, subject to and on a basis consistent with the terms, conditions and overall administration of such plans
and arrangements. The Company shall have the right to amend or delete any such benefit plan or arrangement made available by the Company to its senior executives and not otherwise specifically provided for herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Expenses</U>. The Company shall reimburse Executive for reasonable out-of-pocket business expenses incurred in connection with the
performance of his or her duties hereunder, subject to such policies as the Company may from time to time establish, and Executive furnishing the Company with evidence in the form of receipts satisfactory to the Company substantiating the claimed
expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Paid Time Off</U>. Executive shall be entitled to such periods of paid time off (&#147;<B><I>PTO</I></B>&#148;) each
year as provided from time to time under the Company&#146;s PTO policy and as otherwise provided for senior executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f)
<U>Equity Plans</U>. Executive shall be entitled to participate in any equity or other employee benefit plan that is generally available to executives of the Company. Except as otherwise provided in this Agreement, Executive&#146;s participation in
and benefits under any such plan shall be on the terms and subject to the conditions specified in the governing document of the particular plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Stock Award Acceleration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Subject to Section&nbsp;4(d), in the event of Executive&#146;s Involuntary Termination or Executive&#146;s Separation from Service by
reason of Executive&#146;s death or discharge by the Company following Executive&#146;s Permanent Disability, the vesting and/or exercisability of each of Executive&#146;s outstanding unvested Stock Awards shall be automatically accelerated on the
date of Executive&#146;s Separation from Service as to the number of Stock Awards that would vest over the twelve (12) month period following the date of Executive&#146;s Separation from Service had Executive remained continuously employed by the
Company during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Subject to Section&nbsp;4(d), in the event of Executive&#146;s Involuntary Termination within three
(3)&nbsp;months prior to or twelve (12)&nbsp;months following a Change in Control, the vesting and/or exercisability of any outstanding unvested portion of each of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Executive&#146;s Stock Awards shall be automatically accelerated on the later of (A)&nbsp;the date of Executive&#146;s Separation from Service and (B)&nbsp;the date of the Change in Control. In
addition, with respect to Stock Awards granted to Executive on or after the Effective Date, such Stock Awards may be exercised by Executive (or Executive&#146;s legal guardian or legal representative) until the latest of (A)&nbsp;three
(3)&nbsp;months after the date of Executive&#146;s Separation from Service, (B)&nbsp;with respect to any portion of the Stock Awards that become exercisable on the date of a Change in Control pursuant to this Section&nbsp;3(g)(ii), three
(3)&nbsp;months after the date of the Change in Control, or (C)&nbsp;such longer period as may be specified in the applicable Stock Award agreement; <U>provided</U>, <U>however</U>, that in no event shall any Stock Award remain exercisable beyond
the original outside expiration date of such Stock Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The vesting pursuant to clauses (i)&nbsp;and (ii)&nbsp;of this
Section&nbsp;3(g) shall be cumulative. The foregoing provisions are hereby deemed to be a part of each Stock Award and to supersede any less favorable provision in any agreement or plan regarding such Stock Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Severance</U>. Executive shall be entitled to receive benefits upon a Separation from Service only as set forth in this Section&nbsp;4:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>At-Will Employment; Termination</U>. The Company and Executive acknowledge that Executive&#146;s employment is and shall continue
to be at-will, as defined under applicable law, and that Executive&#146;s employment with the Company may be terminated by either party at any time for any or no reason, with or without notice. If Executive&#146;s employment terminates for any
reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided in this Agreement. Executive&#146;s employment under this Agreement shall be terminated immediately on the death of Executive.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Severance Upon Involuntary Termination</U>. Subject to Sections 4(d) and 9(o) and Executive&#146;s continued compliance with
Section&nbsp;5, if Executive&#146;s employment is Involuntarily Terminated, Executive shall be entitled to receive, in lieu of any severance benefits to which Executive may otherwise be entitled under any severance plan or program of the Company,
the benefits provided below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Company shall pay to Executive his or her fully earned but unpaid base salary, when due, through
the date of Executive&#146;s Involuntary Termination at the rate then in effect, accrued and unused PTO, plus all other benefits, if any, under any Company group retirement plan, nonqualified deferred compensation plan, equity award plan or
agreement (other than any such plan or agreement pertaining to Stock Awards whose treatment is prescribed by Section&nbsp;3(g) above), health benefits plan or other Company group benefit plan to which Executive may be entitled pursuant to the terms
of such plans or agreements at the time of Executive&#146;s Involuntary Termination (the &#147;<B><I>Accrued Obligations</I></B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Executive shall be entitled to receive severance pay in an amount equal to twelve (12)&nbsp;multiplied by Executive&#146;s monthly base
salary as in effect immediately prior to the date of Executive&#146;s Involuntary Termination, which amount shall be payable in a lump sum sixty (60)&nbsp;days following Executive&#146;s Involuntary Termination; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) for the period beginning on the date of Executive&#146;s Separation from Service and
ending on the date which is twelve (12)&nbsp;full months following the date of Executive&#146;s Separation from Service (or, if earlier, (1)&nbsp;the date on which the applicable continuation period under the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (&#147;<B><I>COBRA</I></B>&#148;) expires or (2)&nbsp;the date Executive becomes eligible to receive the equivalent or increased healthcare coverage by means of subsequent employment or self-employment) (such
period, the &#147;<B><I>COBRA Coverage Period</I></B>&#148;), if Executive and/or his or her eligible dependents who were covered under the Company&#146;s health insurance plans as of the date of Executive&#146;s Separation from Service elect to
have COBRA coverage and are eligible for such coverage, the Company shall pay for or reimburse Executive on a monthly basis for an amount equal to (A)&nbsp;the monthly premium Executive and/or his or her covered dependents, as applicable, are
required to pay for continuation coverage pursuant to COBRA for Executive and/or his or her eligible dependents, as applicable, who were covered under the Company&#146;s health plans as of the date of Executive&#146;s Separation from Service
(calculated by reference to the premium as of the date of Executive&#146;s Separation from Service) less (B)&nbsp;the amount Executive would have had to pay to receive group health coverage for Executive and/or his or her covered dependents, as
applicable, based on the cost sharing levels in effect on the date of Executive&#146;s Separation from Service. If any of the Company&#146;s health benefits are self-funded as of the date of Executive&#146;s Separation from Service, or if the
Company cannot provide the foregoing benefits in a manner that is exempt from Section&nbsp;409A (as defined below) or that is otherwise compliant with applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service
Act), instead of providing the payments or reimbursements as set forth above, the Company shall instead pay to Executive the foregoing monthly amount as a taxable monthly payment for the COBRA Coverage Period (or any remaining portion thereof).
Executive shall be solely responsible for all matters relating to continuation of coverage pursuant to COBRA, including, without limitation, the election of such coverage and the timely payment of premiums. Executive shall notify the Company
immediately if Executive becomes eligible to receive the equivalent or increased healthcare coverage by means of subsequent employment or self-employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) Notwithstanding anything to the contrary in this Section&nbsp;4(b), and subject to Sections 4(d) and 9(o) and Executive&#146;s continued
compliance with Section&nbsp;5, in the event of Executive&#146;s Involuntary Termination within twelve (12)&nbsp;months following a Change in Control, Executive shall be entitled to receive, in addition to the severance benefits described in clauses
(i), (ii)&nbsp;and (iii)&nbsp;above, an amount equal to Executive&#146;s target bonus for the year in which Executive&#146;s Involuntary Termination occurs, which amount shall be payable in a lump sum sixty (60)&nbsp;days following Executive&#146;s
Involuntary Termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause, Voluntary Resignation Without Good Reason, Death or Termination for Permanent
Disability</U>. In the event of Executive&#146;s termination of employment as a result of Executive&#146;s discharge by the Company for Cause, Executive&#146;s resignation without Good Reason, Executive&#146;s death or Executive&#146;s termination
of employment following Executive&#146;s Permanent Disability, the Company shall not have any other or further obligations to Executive under this Agreement (including any financial obligations) except that Executive shall be entitled to receive the
Accrued Obligations. The foregoing shall be in addition to, and not in lieu of, any and all other rights and remedies which may be available to the Company under the circumstances, whether at law or in equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Release</U>. As a condition to Executive&#146;s receipt of any post-termination benefits
pursuant to Section&nbsp;4(b) above, Executive (or, in the event of Executive&#146;s incapacity as a result of his Permanent Disability, Executive&#146;s legal representative) shall execute and not revoke a general release of all claims in favor of
the Company (the &#147;<U>Release</U>&#148;) in the form attached hereto as <U>Exhibit A</U>. In the event the Release does not become effective within the fifty-five (55)&nbsp;day period following the date of Executive&#146;s Separation from
Service, Executive shall not be entitled to the aforesaid payments and benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Exclusive Remedy</U>. Except as otherwise
expressly required by law (e.g., COBRA) or as specifically provided herein, all of Executive&#146;s rights to salary, severance, benefits, bonuses and other amounts hereunder (if any) accruing after the termination of Executive&#146;s employment
shall cease upon such termination. In the event of Executive&#146;s termination of employment with the Company, Executive&#146;s sole remedy shall be to receive the payments and benefits described in Section&nbsp;3(g) and this Section&nbsp;4. In
addition, Executive acknowledges and agrees that he or she is not entitled to any reimbursement by the Company for any taxes payable by Executive as a result of the payments and benefits received by Executive pursuant to Section&nbsp;3(g) and this
Section&nbsp;4, including, without limitation, any excise tax imposed by Section&nbsp;4999 of the Code. Any payments made to Executive under this Section&nbsp;4 shall be inclusive of any amounts or benefits to which Executive may be entitled
pursuant to the Worker Adjustment and Retraining Notification Act, 29 U.S.C. Sections 2101 et seq., and the Department of Labor regulations thereunder, or any similar state statute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>No Mitigation</U>. Except as otherwise provided in Section&nbsp;4(b)(iii) above, Executive shall not be required to mitigate the amount
of any payment provided for in this Section&nbsp;4 by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Section&nbsp;4 be reduced by any compensation earned by Executive as the result of
employment by another employer or self-employment or by retirement benefits; <U>provided</U>, <U>however</U>, that loans, advances or other amounts owed by Executive to the Company may be offset by the Company against amounts payable to Executive
under this Section&nbsp;4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Return of the Company&#146;s Property</U>. In the event of Executive&#146;s termination of employment
for any reason, the Company shall have the right, at its option, to require Executive to vacate his or her offices prior to or on the effective date of separation and to cease all activities on the Company&#146;s behalf. Upon Executive&#146;s
termination of employment in any manner, as a condition to Executive&#146;s receipt of any severance benefits described in this Agreement, Executive shall immediately surrender to the Company all lists, books and records of, or in connection with,
the Company&#146;s business, and all other property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the property of the Company. Executive shall deliver to the Company a
signed statement certifying compliance with this Section&nbsp;4(g) prior to the receipt of any severance benefits described in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <U>Waiver of the Company&#146;s Liability</U>. Executive recognizes that his or her employment is subject to termination with or without
Cause for any reason and therefore Executive agrees that Executive shall hold the Company harmless from and against any and all liabilities, losses, damages, costs and expenses, including but not limited to, court costs and reasonable
attorneys&#146; fees, which Executive may incur as a result of Executive&#146;s termination of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employment. Executive further agrees that Executive shall bring no claim or cause of action against the Company for damages or injunctive relief based on a wrongful termination of employment.
Executive agrees that the sole liability of the Company to Executive upon termination of this Agreement shall be that determined by this Section&nbsp;4. In the event this covenant is more restrictive than permitted by laws of the jurisdiction in
which the Company seeks enforcement thereof, this covenant shall be limited to the extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Deemed
Resignation</U>. Upon termination of Executive&#146;s employment for any reason, Executive shall be deemed to have resigned from all offices and directorships, if any, then held with the Company or any of its affiliates, and, at the Company&#146;s
request, Executive shall execute such documents as are necessary or desirable to effectuate such resignations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain
Covenants</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Noncompetition</U>. Except as may otherwise be approved by the Board, during the term of Executive&#146;s
employment, Executive shall not have any ownership interest (of record or beneficial) in, or have any interest as an employee, salesman, consultant, officer or director in, or otherwise aid or assist in any manner, any firm, corporation,
partnership, proprietorship or other business that engages in any county, city or part thereof in the United States and/or any foreign country in a business which competes directly or indirectly (as determined by the Board) with the Company&#146;s
business in such county, city or part thereof, so long as the Company, or any successor in interest of the Company to the business and goodwill of the Company, remains engaged in such business in such county, city or part thereof or continues to
solicit customers or potential customers therein; <U>provided</U>, <U>however</U>, that Executive may own, directly or indirectly, solely as an investment, securities of any entity which are traded on any national securities exchange if Executive
(i)&nbsp;is not a controlling person of, or a member of a group which controls, such entity; or (ii)&nbsp;does not, directly or indirectly, own one percent (1%)&nbsp;or more of any class of securities of any such entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Confidential Information</U>. Executive and the Company have entered into the Company&#146;s standard employee proprietary information
and inventions agreement (the &#147;<U>Employee Proprietary Information and Inventions Agreement</U>&#148;). Executive agrees to perform each and every obligation of Executive therein contained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Solicitation of Employees</U>. Executive shall not during the term of Executive&#146;s employment and for the applicable severance
period for which Executive receives severance benefits following any termination hereof pursuant to Section&nbsp;4(b) above (regardless of whether Executive receives payment of severance amounts payable thereunder in a lump sum) (the
&#147;<U>Restricted Period</U>&#148;), directly or indirectly, solicit or encourage to leave the employment of the Company or any of its affiliates, any employee of the Company or any of its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Solicitation of Consultants</U>. Executive shall not during the term of Executive&#146;s employment and for the Restricted Period,
directly or indirectly, hire, solicit or encourage to cease work with the Company or any of its affiliates any consultant then under contract with the Company or any of its affiliates within one year of the termination of such consultant&#146;s
engagement by the Company or any of its affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Rights and Remedies Upon Breach</U>. If Executive breaches or threatens to commit a breach
of any of the provisions of this Section&nbsp;5 (the &#147;<U>Restrictive Covenants</U>&#148;), the Company shall have the following rights and remedies, each of which rights and remedies shall be independent of the other and severally enforceable,
and all of which rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Specific Performance</U>. The right and remedy to have the Restrictive Covenants specifically enforced by any court having equity
jurisdiction, all without the need to post a bond or any other security or to prove any amount of actual damage or that money damages would not provide an adequate remedy, it being acknowledged and agreed that any such breach or threatened breach
will cause irreparable injury to the Company and that money damages will not provide adequate remedy to the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)
<U>Accounting and Indemnification</U>. The right and remedy to require Executive (A)&nbsp;to account for and pay over to the Company all compensation, profits, monies, accruals, increments or other benefits derived or received by Executive or any
associated party deriving such benefits as a result of any such breach of the Restrictive Covenants; and (B)&nbsp;to indemnify the Company against any other losses, damages (including special and consequential damages), costs and expenses, including
actual attorneys&#146; fees and court costs, which may be incurred by them and which result from or arise out of any such breach or threatened breach of the Restrictive Covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>Severability of Covenants/Blue Pencilling</U>. If any court determines that any of the Restrictive Covenants, or any part thereof, is
invalid or unenforceable, the remainder of the Restrictive Covenants shall not thereby be affected and shall be given full effect, without regard to the invalid portions. If any court determines that any of the Restrictive Covenants, or any part
thereof, are unenforceable because of the duration of such provision or the area covered thereby, such court shall have the power to reduce the duration or area of such provision and, in its reduced form, such provision shall then be enforceable and
shall be enforced. Executive hereby waives any and all right to attack the validity of the Restrictive Covenants on the grounds of the breadth of their geographic scope or the length of their term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Enforceability in Jurisdictions</U>. The Company and Executive intend to and do hereby confer jurisdiction to enforce the Restrictive
Covenants upon the courts of any jurisdiction within the geographical scope of such covenants. If the courts of any one or more of such jurisdictions hold the Restrictive Covenants wholly unenforceable by reason of the breadth of such scope or
otherwise, it is the intention of the Company and Executive that such determination not bar or in any way affect the right of the Company to the relief provided above in the courts of any other jurisdiction within the geographical scope of such
covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <U>Definitions</U>. For purposes of this Section&nbsp;5, the term &#147;<U>Company</U>&#148; means not only Exagen Diagnostics, Inc., but
also any company, partnership or entity which, directly or indirectly, controls, is controlled by or is under common control with Exagen Diagnostics, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Insurance; Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Insurance</U>. The Company shall have the right to take out life, health, accident, &#147;key-man&#148; or other insurance covering
Executive, in the name of the Company and at the Company&#146;s expense in any amount deemed appropriate by the Company. Executive shall assist the Company in obtaining such insurance, including, without limitation, submitting to any required
examinations and providing information and data required by insurance companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Indemnification</U>. Executive will be provided
with indemnification against third party claims related to his or her work for the Company as required by Delaware law. The Company shall provide Executive with directors and officers liability insurance coverage at least as favorable as that which
the Company may maintain from time to time for members of the Board and other executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Arbitration</U>. Any dispute,
claim or controversy based on, arising out of or relating to Executive&#146;s employment or this Agreement shall be settled by final and binding arbitration in San Diego, California, before a single neutral arbitrator in accordance with the National
Rules for the Resolution of Employment Disputes (the &#147;<B><I>Rules</I></B>&#148;) of the American Arbitration Association, and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction. The Rules may be
found online at www.adr.org. Arbitration may be compelled pursuant to the California Arbitration Act (Code of Civil Procedure &#167;&#167; 1280 <U>et</U> <U>seq</U>.). If the parties are unable to agree upon an arbitrator, one shall be appointed by
the AAA in accordance with its Rules. Each party shall pay the fees of its own attorneys, the expenses of its witnesses and all other expenses connected with presenting its case; <U>however</U>, Executive and the Company agree that, to the extent
permitted by law, the arbitrator may, in his or her discretion, award reasonable attorneys&#146; fees to the prevailing party; <U>provided</U>, <U>further</U>, that the prevailing party shall be reimbursed for such fees, costs and expenses within
forty-five (45)&nbsp;days following any such award, but in no event later than the last day of Executive&#146;s taxable year following the taxable year in which the fees, costs and expenses were incurred; <U>provided</U>, <U>further</U>, that the
parties&#146; obligations pursuant to this sentence shall terminate on the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;anniversary of the date of Executive&#146;s termination of employment. Other costs of the arbitration,
including the cost of any record or transcripts of the arbitration, AAA&#146;s administrative fees, the fee of the arbitrator, and all other fees and costs, shall be borne by the Company. This Section&nbsp;7 is intended to be the exclusive method
for resolving any and all claims by the parties against each other for payment of damages under this Agreement or relating to Executive&#146;s employment; <U>provided</U>, <U>however</U>, that Executive shall retain the right to file administrative
charges with or seek relief through any government agency of competent jurisdiction, and to participate in any government investigation, including but not limited to (i)&nbsp;claims for workers&#146; compensation, state disability insurance or
unemployment insurance; (ii)&nbsp;claims for unpaid wages or waiting time penalties brought before the California Division of Labor Standards Enforcement; <U>provided</U>, <U>however</U>, that any appeal from an award or from denial of an award of
wages and/or waiting time penalties shall be arbitrated pursuant to the terms of this Agreement; and (iii)&nbsp;claims for administrative relief from the United States Equal Employment Opportunity Commission and/or the California Department of Fair
Employment and Housing (or any similar agency in any applicable jurisdiction other than California); <U>provided</U>, <U>further</U>, that Executive shall not be entitled to obtain any monetary relief through such agencies other than workers&#146;
compensation benefits or unemployment insurance benefits. This Agreement shall not limit either party&#146;s right to obtain any provisional remedy, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including, without limitation, injunctive or similar relief, from any court of competent jurisdiction as may be necessary to protect their rights and interests pending the outcome of arbitration,
including without limitation injunctive relief, in any court of competent jurisdiction pursuant to California Code of Civil Procedure &#167; 1281.8 or any similar statute of an applicable jurisdiction. Seeking any such relief shall not be deemed to
be a waiver of such party&#146;s right to compel arbitration. Both Executive and the Company expressly waive their right to a jury trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>General Relationship</U>. Executive shall be considered an employee of the Company within the meaning of all federal, state and local
laws and regulations including, but not limited to, laws and regulations governing unemployment insurance, workers&#146; compensation, industrial accident, labor and taxes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)
<U>Modification; Prior Claims</U>. This Agreement and the Employee Proprietary Information and Inventions Agreement set forth the entire understanding of the parties with respect to the subject matter hereof, supersedes all existing agreements
between them concerning such subject matter. This Agreement may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any
circumstances whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Assignment; Assumption by Successor</U>. The rights of the Company under this Agreement may, without the
consent of Executive, be assigned by the Company, in its sole and unfettered discretion, to any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly, acquires all or
substantially all of the assets or business of the Company. The Company will require any successor (whether direct or indirect, by purchase, merger or otherwise) to all or substantially all of the business or assets of the Company expressly to
assume and to agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place; <U>provided</U>, <U>however</U>, that no such assumption shall relieve
the Company of its obligations hereunder. As used in this Agreement, the &#147;<U>Company</U>&#148; shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this
Agreement by operation of law or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Survival</U>. The covenants, agreements, representations and warranties contained in
or made in Sections&nbsp;3(g), 4, 5, 6, 7 and 9 of this Agreement shall survive any Executive&#146;s termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U><FONT
STYLE="white-space:nowrap">Third-Party</FONT> Beneficiaries</U>. This Agreement does not create, and shall not be construed as creating, any rights enforceable by any person not a party to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Waiver</U>. The failure of either party hereto at any time to enforce performance by the other party of any provision of this Agreement
shall in no way affect such party&#146;s rights thereafter to enforce the same, nor shall the waiver by either party of any breach of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any provision hereof be deemed to be a waiver by such party of any other breach of the same or any other provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>Section Headings</U>. The headings of the several sections in this Agreement are inserted solely for the convenience of the parties and
are not a part of and are not intended to govern, limit or aid in the construction of any term or provision hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Notices</U>.
Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i)&nbsp;by personal delivery when delivered personally; (ii)&nbsp;by overnight courier upon written
verification of receipt; (iii)&nbsp;by email, telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv)&nbsp;by certified or registered mail, return receipt requested, upon verification of receipt. Notice
shall be sent to Executive at the address listed on the Company&#146;s personnel records and to the Company at its principal place of business, or such other address as either party may specify in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. All Sections, clauses and covenants contained in this Agreement are severable, and in the event any of them shall be
held to be invalid by any court, this Agreement shall be interpreted as if such invalid Sections, clauses or covenants were not contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Governing Law and Venue</U>. This Agreement is to be governed by and construed in accordance with the laws of the State of California
applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Except as provided in Sections&nbsp;5 and 7, any suit brought hereon shall be brought in the state or federal
courts sitting in San Diego, California, the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to
service of process in any manner authorized by California law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) <U>Non-transferability of Interest</U>. None of the rights of
Executive to receive any form of compensation payable pursuant to this Agreement shall be assignable or transferable except through a testamentary disposition or by the laws of descent and distribution upon the death of Executive. Any attempted
assignment, transfer, conveyance, or other disposition (other than as aforesaid) of any interest in the rights of Executive to receive any form of compensation to be made by the Company pursuant to this Agreement shall be void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k) <U>Gender</U>. Where the context so requires, the use of the masculine gender shall include the feminine and/or neuter genders and the
singular shall include the plural, and vice versa, and the word &#147;person&#148; shall include any corporation, firm, partnership or other form of association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(l) <U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(m) <U>Construction</U>. The language in all parts of this Agreement shall in
all cases be construed simply, according to its fair meaning, and not strictly for or against any of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
parties hereto. Without limitation, there shall be no presumption against any party on the ground that such party was responsible for drafting this Agreement or any part thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(n) <U>Withholding and other Deductions</U>. All compensation payable to Executive hereunder shall be subject to such deductions as the
Company is from time to time required to make pursuant to law, governmental regulation or order. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(o) <U>Code Section&nbsp;409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) This Agreement is not intended to provide for any deferral of compensation subject to Section&nbsp;409A of the Code, and, accordingly, the
severance payments payable under Sections 4(b)(ii) and 4(c)(ii) and (iv)&nbsp;shall be paid no later than the later of: (A)&nbsp;the fifteenth (15th)&nbsp;day of the third month following Executive&#146;s first taxable year in which such amounts are
no longer subject to a substantial risk of forfeiture, and (B)&nbsp;the fifteenth (15th)&nbsp;day of the third month following first taxable year of the Company in which such amounts are is no longer subject to substantial risk of forfeiture, as
determined in accordance with Code Section&nbsp;409A and any Treasury Regulations and other guidance issued thereunder. To the extent applicable, this Agreement shall be interpreted in accordance with Code Section&nbsp;409A and Department of
Treasury regulations and other interpretive guidance issued thereunder. Each series of installment payments made under this Agreement is hereby designated as a series of &#147;separate payments&#148; within the meaning of Section&nbsp;409A of the
Code. For purposes of this Agreement, all references to Executive&#146;s &#147;termination of employment&#148; shall mean Executive&#146;s Separation from Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If Executive is a &#147;specified employee&#148; (as defined in Section&nbsp;409A of the Code), as determined by the Company in
accordance with Section&nbsp;409A of the Code, on the date of Executive&#146;s Separation from Service, to the extent that the payments or benefits under this Agreement are subject to Section&nbsp;409A of the Code and the delayed payment or
distribution of all or any portion of such amounts to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section&nbsp;409A(a)(2)(B)(i) of the Code, then such portion deferred pursuant to
this Section&nbsp;9(o)(ii) shall be paid or distributed to Executive in a lump sum on the earlier of (A)&nbsp;the date that is six (6)-months following Executive&#146;s Separation from Service, (B)&nbsp;the date of Executive&#146;s death or
(C)&nbsp;the earliest date as is permitted under Section&nbsp;409A of the Code. Any remaining payments due under the Agreement shall be paid as otherwise provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) To the extent applicable, this Agreement shall be interpreted in accordance with the applicable exemptions from Section&nbsp;409A of
the Code. If Executive and the Company determine that any payments or benefits payable under this Agreement intended to comply with Sections 409A(a)(2), (3)&nbsp;and (4)&nbsp;of the Code do not comply with Section&nbsp;409A of the Code, Executive
and the Company agree to amend this Agreement, or take such other actions as Executive and the Company deem reasonably necessary or appropriate, to comply with the requirements of Section&nbsp;409A of the Code and the Treasury Regulations thereunder
(and any applicable transition relief) while preserving the economic agreement of the parties. To the extent that any provision in this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in
such a manner that no payments payable under this Agreement shall be subject to an &#147;additional tax&#148; as defined in Section&nbsp;409A(a)(1)(B) of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Any reimbursement of expenses or in-kind benefits payable under this
Agreement shall be made in accordance with Treasury Regulation Section&nbsp;1.409A-3(i)(1)(iv) and shall be paid on or before the last day of Executive&#146;s taxable year following the taxable year in which Executive incurred the expenses. The
amount of expenses reimbursed or in-kind benefits payable during any taxable year of Executive&#146;s shall not affect the amount eligible for reimbursement or in-kind benefits payable in any other taxable year of Executive&#146;s, and
Executive&#146;s right to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature
Page Follows) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>E<SMALL>XAGEN</SMALL> D<SMALL>IAGNOSTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Wendy Swedick</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Wendy Swedick</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CFO</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>E<SMALL>XECUTIVE</SMALL></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Fortunato Ron Rocca</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>F<SMALL>ORTUNATO</SMALL> R<SMALL>ON</SMALL> R<SMALL>OCCA</SMALL></B><SMALL></SMALL></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE PAGE TO EMPLOYMENT AGREEMENT </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>GENERAL RELEASE OF CLAIMS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>The language in this Release may change based on legal developments and evolving best practices; this form is provided as an example
of what will be included in the final Release document.</I>]<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This General Release of Claims (&#147;<B><I>Release</I></B>&#148;) is
entered into as of this &nbsp;&nbsp;&nbsp;&nbsp; day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;, between Fortunato Ron Rocca (&#147;<B><I>Executive</I></B>&#148;), and Exagen Diagnostics,
Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;) (collectively referred to herein as the &#147;<B><I>Parties</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Executive and the Company are parties to that certain Employment Agreement dated as of
[&nbsp;<FONT STYLE="FONT-FAMILY:'WINGDINGS 2'">&#151;</FONT>&nbsp;] (the &#147;<B><I>Agreement</I></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties agree
that Executive is entitled to certain severance benefits under the Agreement, subject to Executive&#146;s execution of this Release; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and Executive now wish to fully and finally to resolve all matters between them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of, and subject to, the severance benefits payable to Executive pursuant to the Agreement, the adequacy of
which is hereby acknowledged by Executive, and which Executive acknowledges that he or she would not otherwise be entitled to receive, Executive and the Company hereby agree as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>General Release of Claims by Executive</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Executive, on behalf of himself or herself and his or her executors, heirs, administrators, representatives and assigns, hereby agrees to
release and forever discharge the Company and all predecessors, successors and their respective parent corporations, affiliates, related, and/or subsidiary entities, and all of their past and present investors, directors, shareholders, officers,
general or limited partners, employees, attorneys, agents and representatives, and the employee benefit plans in which Executive is or has been a participant by virtue of his or her employment with or service to the Company (collectively, the
&#147;<B><I>Company Releasees</I></B>&#148;), from any and all claims, debts, demands, accounts, judgments, rights, causes of action, equitable relief, damages, costs, charges, complaints, obligations, promises, agreements, controversies, suits,
expenses, compensation, responsibility and liability of every kind and character whatsoever (including attorneys&#146; fees and costs), whether in law or equity, known or unknown, asserted or unasserted, suspected or unsuspected (collectively,
&#147;<U>Claims</U>&#148;), which Executive has or may have had against such entities based on any events or <B><I><U>circumstances</U></I></B> arising or occurring on or prior to the date hereof or on or prior to the date hereof, arising directly
or indirectly out of, relating to, or in any other way involving in any manner whatsoever Executive&#146;s employment by or service to the Company or the termination thereof, including any and all claims arising under federal, state, or local laws
relating to employment, including without limitation claims of wrongful discharge, breach of express or implied contract, fraud, misrepresentation, </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defamation, or liability in tort, and claims of any kind that may be brought in any court or administrative agency including, without limitation, claims under Title VII of the Civil Rights Act of
1964, as amended, 42 U.S.C. Section&nbsp;2000, <U>et</U> <U>seq</U>.; the Americans with Disabilities Act, as amended, 42&nbsp;U.S.C. &#167;&nbsp;12101 <U>et</U> <U>seq</U>.; the Rehabilitation Act of 1973, as amended, 29&nbsp;U.S.C. &#167;&nbsp;701
<U>et</U> <U>seq</U>.; the Civil Rights Act of 1866, and the Civil Rights Act of 1991; 42 U.S.C. Section&nbsp;1981, <U>et</U> <U>seq</U>.; the Age Discrimination in Employment Act, as amended, 29 U.S.C. Section&nbsp;621, <U>et</U> <U>seq</U>. (the
&#147;<B><I>ADEA</I></B>&#148;); the Equal Pay Act, as amended, 29 U.S.C. Section&nbsp;206(d); regulations of the Office of Federal Contract Compliance, 41 C.F.R. Section&nbsp;60, <U>et</U> <U>seq</U>.; the Family and Medical Leave Act, as amended,
29&nbsp;U.S.C.&nbsp;&#167;&nbsp;2601 <U>et</U>&nbsp;<U>seq</U>.; the Fair Labor Standards Act of 1938, as amended, 29&nbsp;U.S.C. &#167;&nbsp;201 <U>et</U> <U>seq</U>.; the Employee Retirement Income Security Act, as amended, 29 U.S.C.
&#167;&nbsp;1001 <U>et</U> <U>seq</U>.; and the California Fair Employment and Housing Act, California Government Code Section&nbsp;12940, <U>et</U> <U>seq</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the generality of the foregoing, Executive does not release the following claims: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state
law; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Claims for workers&#146; compensation insurance benefits under the terms of any worker&#146;s compensation
insurance policy or fund of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Claims pursuant to the terms and conditions of the federal law known as
COBRA; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Claims for indemnity under the bylaws of the Company, as provided for by California law or under any
applicable insurance policy with respect to Executive&#146;s liability as an employee, director or officer of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Claims based on any right Executive may have to enforce the Company&#146;s executory obligations under the Agreement; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Claims Executive may have to vested or earned compensation and benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) EXECUTIVE ACKNOWLEDGES THAT HE OR SHE HAS BEEN ADVISED OF AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH
PROVIDES AS FOLLOWS: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR
HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.&#148; </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS HE OR SHE MAY HAVE THEREUNDER, AS
WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>[Note: Clauses (c), (d)&nbsp;and (e)&nbsp;apply only if Executive is
age 40 or older at time of termination] </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Executive acknowledges that this Release was presented to him or her on the date
indicated above and that Executive is entitled to have [twenty-one (21)][forty-five (45)] days&#146; time in which to consider it. Executive further acknowledges that the Company has advised him or her that he or she is waiving his or her rights
under the ADEA, and that Executive should consult with an attorney of his or her choice before signing this Release, and Executive has had sufficient time to consider the terms of this Release. Executive represents and acknowledges that if Executive
executes this Release before [twenty-one (21)][forty-five (45)] days have elapsed, Executive does so knowingly, voluntarily, and upon the advice and with the approval of Executive&#146;s legal counsel (if any), and that Executive voluntarily waives
any remaining consideration period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Executive understands that after executing this Release, Executive has the right to revoke it
within seven (7)&nbsp;days after his or her execution of it. Executive understands that this Release will not become effective and enforceable unless the seven (7)&nbsp;day revocation period passes and Executive does not revoke the Release in
writing. Executive understands that this Release may not be revoked after the seven (7)&nbsp;day revocation period has passed. Executive also understands that any revocation of this Release must be made in writing and delivered to the Company at its
principal place of business within the seven (7)&nbsp;day period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) Executive understands that this Release shall become effective,
irrevocable, and binding upon Executive on the eighth (8<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;day after his or her execution of it, so long as Executive has not revoked it within the time period and in the manner specified in
clause (d)&nbsp;above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) Executive further understands that Executive will not be given any severance benefits under the Agreement
unless this Release is effective on or before the date that is fifty-five (55)&nbsp;days following the date of Executive&#146;s termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>No Assignment</U>. Executive represents and warrants to the Company Releasees that there has been no assignment or other transfer of any
interest in any Claim that Executive may have against the Company Releasees. Executive agrees to indemnify and hold harmless the Company Releasees from any liability, claims, demands, damages, costs, expenses and attorneys&#146; fees incurred as a
result of any such assignment or transfer from Executive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Severability</U>. In the event any provision of this Release is found to
be unenforceable by an arbitrator or court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the parties shall receive the
benefit contemplated herein to the fullest extent permitted by law. If a deemed modification is not satisfactory in the judgment of such arbitrator or court, the unenforceable provision shall be deemed deleted, and the validity and enforceability of
the remaining provisions shall not be affected thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Interpretation; Construction</U>. The headings set forth in this Release are for
convenience only and shall not be used in interpreting this Agreement. This Release has been drafted by legal counsel representing the Company, but Executive has participated in the negotiation of its terms. Furthermore, Executive acknowledges that
Executive has had an opportunity to review and revise the Release and have it reviewed by legal counsel, if desired, and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of this Release. Either party&#146;s failure to enforce any provision of this Release shall not in any way be construed as a waiver of any such provision, or prevent that party thereafter from enforcing
each and every other provision of this Release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Governing Law and Venue</U>. This Release will be governed by and construed in
accordance with the laws of the United States of America and the State of California applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Any suit brought hereon
shall be brought in the state or federal courts sitting in San Diego County, California, the Parties hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam
jurisdiction over it and consents to service of process in any manner authorized by California law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Entire Agreement</U>. This
Release and the Agreement constitute the entire agreement of the Parties in respect of the subject matter contained herein and therein and supersede all prior or simultaneous representations, discussions, negotiations and agreements, whether written
or oral. This Release may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Counterparts</U>. This Release may be executed in multiple counterparts, each of which shall be deemed to be an original but all of
which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature Page Follows) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed the foregoing
Release as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>E<SMALL>XECUTIVE</SMALL></B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><B>E<SMALL>XAGEN</SMALL> D<SMALL>IAGNOSTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Name: Fortunato Ron Rocca</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Print&nbsp;Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>16
<FILENAME>d693329dex1030.htm
<DESCRIPTION>EX-10.30
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.30</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.30 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS EMPLOYMENT AGREEMENT (this &#147;<B><I>Agreement</I></B>&#148;) is entered into by and between Exagen Diagnostics, Inc., a Delaware
corporation (the &#147;<B><I>Company</I></B>&#148;), and Wendy Swedick (&#147;<B><I>Executive</I></B>&#148;), and shall be effective as of the date prior to the date on which the Company&#146;s common stock commences trading pursuant to the initial
public offering of the Company&#146;s common stock (the &#147;<B><I>Effective Date</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to employ
Executive, and Executive desires to accept employment with the Company, on the terms and conditions set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, in consideration of the mutual promises herein contained, the parties agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. As used in this
Agreement, the following terms shall have the following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Cause</I></B>&#148; means any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the commission of an act of fraud, embezzlement or dishonesty by Executive, or the commission of some other illegal act by Executive,
that causes material harm to the Company or any successor or affiliate thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Executive&#146;s conviction of, or plea of
&#147;guilty&#148; or &#147;no contest&#148; to, a felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any intentional unauthorized use or disclosure by Executive of confidential information or trade secrets of the Company or any
successor or affiliate thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Executive&#146;s gross negligence, insubordination or material violation of any duty of loyalty to
the Company or any successor or affiliate thereof, or any other material misconduct on the part of Executive; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Executive&#146;s
ongoing and repeated failure or refusal to perform or neglect of Executive&#146;s duties as required by this Agreement, which failure, refusal or neglect continues for fifteen (15)&nbsp;days following Executive&#146;s receipt of written notice from
the Board or the Company&#146;s Chief Executive Officer (the &#147;<B><I>CEO</I></B>&#148;) stating with specificity the nature of such failure, refusal or neglect; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) Executive&#146;s intentional, material breach of any Company policy or any contract or agreement between Executive and the Company or
any successor or affiliate thereof; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>, <U>however</U>, that prior to the determination that &#147;Cause&#148; under clauses (iv),
(v)&nbsp;or (vi)&nbsp;of this Section&nbsp;1(b) has occurred, the Company shall (A)&nbsp;provide to Executive in writing, in reasonable detail, the reasons for the determination that such &#147;Cause&#148; exists, (B)&nbsp;other than with respect to
clause (v)&nbsp;above which specifies the applicable period of time for Executive to remedy his or her breach, afford Executive a reasonable opportunity to remedy any such breach, (C)&nbsp;provide Executive an opportunity to be heard prior to the
final decision to terminate Executive&#146;s employment hereunder for such &#147;Cause&#148; and (D)&nbsp;make any decision that such &#147;Cause&#148; exists in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The foregoing definition shall not in any way preclude or restrict the right of the Company or any successor or affiliate thereof to discharge
or dismiss Executive for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of this Agreement, to constitute grounds for termination for Cause. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B><I>Change in Control</I></B>&#148; means and includes each of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) a transaction or series of transactions (other than an offering of the Company&#146;s common stock to the general public through a
registration statement filed with the Securities and Exchange Commission) whereby any &#147;person&#148; or related &#147;group&#148; of &#147;persons&#148; (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of
1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;)) (other than the Company, any of its subsidiaries, an employee benefit plan maintained by the Company or any of its subsidiaries or a &#147;person&#148; that, prior to such transaction,
directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act), of securities of the Company possessing
more than fifty percent (50%)&nbsp;of the total combined voting power of the Company&#146;s securities outstanding immediately after such acquisition; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more
intermediaries) of (A)&nbsp;a merger, consolidation, reorganization, or business combination or (B)&nbsp;a sale or other disposition of all or substantially all of the Company&#146;s assets in any single transaction or series of related transactions
or (C)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) which
results in the Company&#146;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of
the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#146;s assets or otherwise succeeds to the business of the Company (the Company or such person, the
&#147;<B><I>Successor Entity</I></B>&#148;) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#146;s outstanding voting securities immediately after the transaction, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) after which no person or group beneficially owns voting securities representing fifty percent (50%)&nbsp;or more of the
combined voting power of the Successor Entity; <U>provided</U>, <U>however</U>, that no person or group shall be treated for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
purposes of this clause&nbsp;(2) as beneficially owning fifty percent (50%)&nbsp;or more of combined voting power of the Successor Entity solely as a result of the voting power held in the
Company prior to the consummation of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a transaction shall not constitute a
&#147;<B><I>Change in Control</I></B>&#148; if: (i)&nbsp;its sole purpose is to change the state of the Company&#146;s incorporation; (ii)&nbsp;its sole purpose is to create a holding company that will be owned in substantially the same proportions
by the persons who held the Company&#146;s securities immediately before such transaction; (iii)&nbsp;it constitutes the Company&#146;s initial public offering of its securities; or (iv)&nbsp;it is a transaction effected primarily for the purpose of
financing the Company with cash (as determined by the Board in its discretion and without regard to whether such transaction is effectuated by a merger, equity financing or otherwise). The Board shall have full and final authority, which shall be
exercised in its discretion, to determine conclusively whether a Change in Control of the Company has occurred pursuant to the above definition, and the date of the occurrence of such Change in Control and any incidental matters thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended from time to time, and the Treasury Regulations and
other interpretive guidance issued thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B><I>Good Reason</I></B>&#148; means the occurrence of any of the following
events or conditions without Executive&#146;s written consent: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) a material diminution in Executive&#146;s authority, duties or
responsibilities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) a material diminution in Executive&#146;s base compensation, unless such a reduction is imposed across-the-board
to senior management of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) a material change in the geographic location at which Executive must perform his or her
duties, provided that a relocation to San Diego County, California shall not constitute Good Reason; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) any other action or
inaction that constitutes a material breach by the Company or any successor or affiliate of its obligations to Executive under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Executive must provide written notice to the Company of the occurrence of any of the foregoing events or conditions without Executive&#146;s
written consent within sixty (60)&nbsp;days of the occurrence of such event. The Company or any successor or affiliate shall have a period of thirty (30)&nbsp;days to cure such event or condition after receipt of written notice of such event from
Executive. Executive&#146;s Separation from Service by reason of resignation from employment with the Company for Good Reason must occurs within thirty (30)&nbsp;days following the expiration of the foregoing thirty (30)&nbsp;day cure period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B><I>Involuntary Termination</I></B>&#148; means (i)&nbsp;Executive&#146;s Separation from Service by reason of Executive&#146;s
discharge by the Company other than for Cause, or (ii)&nbsp;Executive&#146;s Separation from Service by reason of Executive&#146;s resignation of employment with the Company for Good Reason. Executive&#146;s Separation from Service by reason of
Executive&#146;s death or discharge by the Company following Executive&#146;s Permanent Disability shall not constitute an Involuntary Termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) Executive&#146;s &#147;<B><I>Permanent Disability</I></B>&#148; shall be deemed to have
occurred if Executive shall become physically or mentally incapacitated or disabled or otherwise unable fully to discharge his or her duties hereunder for a period of ninety (90)&nbsp;consecutive calendar days or for one hundred twenty
(120)&nbsp;calendar days in any one hundred eighty (180)&nbsp;calendar-day period. The existence of Executive&#146;s Permanent Disability shall be determined by the Company on the advice of a physician chosen by the Company and the Company reserves
the right to have Executive examined by a physician chosen by the Company at the Company&#146;s expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B><I>Separation from
Service</I></B>,&#148; with respect to Executive, means Executive&#146;s &#147;separation from service,&#148; as defined in Treasury Regulation Section&nbsp;1.409A-1(h). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B><I>Stock Awards</I></B>&#148; means all stock options, restricted stock and such other awards granted pursuant to the
Company&#146;s stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.
<U>Services to Be Rendered.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Duties and Responsibilities</U>. Executive shall serve as Chief Financial Officer of the Company.
In the performance of such duties, Executive shall report directly to the CEO and shall be subject to the direction of the CEO and to such limits upon Executive&#146;s authority as the CEO may from time to time impose. In the event of the CEO&#146;s
incapacity or unavailability, Executive shall be subject to the direction of the Board. Executive hereby consents to serve as an officer and/or director of the Company or any subsidiary or affiliate thereof without any additional salary or
compensation, if so requested by the CEO. Executive shall be employed by the Company on a full time basis. Executive&#146;s primary place of work shall be the Company&#146;s principal executive offices, or, with the Company&#146;s consent, at any
other place at which the Company maintains an office; <U>provided</U>, <U>however</U>, that the Company may from time to time require Executive to travel temporarily to other locations in connection with the Company&#146;s business. Executive shall
be subject to and comply with the policies and procedures generally applicable to senior executives of the Company to the extent the same are not inconsistent with any term of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Exclusive Services</U>. Executive shall at all times faithfully, industriously and to the best of his or her ability, experience and
talent perform to the satisfaction of the Board and the CEO all of the duties that may be assigned to Executive hereunder and shall devote substantially all of his or her productive time and efforts to the performance of such duties. Subject to the
terms of the Proprietary Information and Inventions Agreement referred to in Section&nbsp;5(b), this shall not preclude Executive from devoting time to personal and family investments or serving on community and civic boards, or participating in
industry associations, provided such activities do not interfere with his or her duties to the Company, as determined in good faith by the CEO. Executive agrees that he or she will not join any boards, other than community and civic boards (which do
not interfere with his or her duties to the Company), without the prior approval of the CEO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Compensation and Benefits</U>. The
Company shall pay or provide, as the case may be, to Executive the compensation and other benefits and rights set forth in this Section&nbsp;3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. The Company shall pay to Executive a base salary of $295,000 per year,
payable in accordance with the Company&#146;s usual pay practices (and in any event no less frequently than monthly). Executive&#146;s base salary shall be subject to review annually by and at the sole discretion of the Compensation Committee of the
Board or its designee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Bonus</U>. Executive shall participate in any bonus plan that the Board or its designee may approve for the
senior executives of the Company. Executive&#146;s target bonus under the Company&#146;s annual bonus plan shall be thirty-five percent (35%)&nbsp;of Executive&#146;s base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Benefits</U>. Executive shall be entitled to participate in benefits under the Company&#146;s benefit plans and arrangements,
including, without limitation, any employee benefit plan or arrangement made available in the future by the Company to its senior executives, subject to and on a basis consistent with the terms, conditions and overall administration of such plans
and arrangements. The Company shall have the right to amend or delete any such benefit plan or arrangement made available by the Company to its senior executives and not otherwise specifically provided for herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Expenses</U>. The Company shall reimburse Executive for reasonable out-of-pocket business expenses incurred in connection with the
performance of his or her duties hereunder, subject to such policies as the Company may from time to time establish, and Executive furnishing the Company with evidence in the form of receipts satisfactory to the Company substantiating the claimed
expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Paid Time Off</U>. Executive shall be entitled to such periods of paid time off (&#147;<B><I>PTO</I></B>&#148;) each
year as provided from time to time under the Company&#146;s PTO policy and as otherwise provided for senior executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f)
<U>Equity Plans</U>. Executive shall be entitled to participate in any equity or other employee benefit plan that is generally available to executives of the Company. Except as otherwise provided in this Agreement, Executive&#146;s participation in
and benefits under any such plan shall be on the terms and subject to the conditions specified in the governing document of the particular plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Stock Award Acceleration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Subject to Section&nbsp;4(d), in the event of Executive&#146;s Involuntary Termination or Executive&#146;s Separation from Service by
reason of Executive&#146;s death or discharge by the Company following Executive&#146;s Permanent Disability, the vesting and/or exercisability of each of Executive&#146;s outstanding unvested Stock Awards shall be automatically accelerated on the
date of Executive&#146;s Separation from Service as to the number of Stock Awards that would vest over the twelve (12)&nbsp;month period following the date of Executive&#146;s Separation from Service had Executive remained continuously employed by
the Company during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Subject to Section&nbsp;4(d), in the event of Executive&#146;s Involuntary Termination within three
(3)&nbsp;months prior to or twelve (12)&nbsp;months following a Change in Control, the vesting and/or exercisability of any outstanding unvested portion of each of Executive&#146;s Stock Awards shall be automatically accelerated on the later of
(A)&nbsp;the date of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Executive&#146;s Separation from Service and (B)&nbsp;the date of the Change in Control. In addition, with respect to Stock Awards granted to Executive on or after the Effective Date, such Stock
Awards may be exercised by Executive (or Executive&#146;s legal guardian or legal representative) until the latest of (A)&nbsp;three (3)&nbsp;months after the date of Executive&#146;s Separation from Service, (B)&nbsp;with respect to any portion of
the Stock Awards that become exercisable on the date of a Change in Control pursuant to this Section&nbsp;3(g)(ii), three (3)&nbsp;months after the date of the Change in Control, or (C)&nbsp;such longer period as may be specified in the applicable
Stock Award agreement; <U>provided</U>, <U>however</U>, that in no event shall any Stock Award remain exercisable beyond the original outside expiration date of such Stock Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The vesting pursuant to clauses (i)&nbsp;and (ii)&nbsp;of this Section&nbsp;3(g) shall be cumulative. The foregoing provisions are
hereby deemed to be a part of each Stock Award and to supersede any less favorable provision in any agreement or plan regarding such Stock Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Severance</U>. Executive shall be entitled to receive benefits upon a Separation from Service only as set forth in this Section&nbsp;4:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>At-Will Employment; Termination</U>. The Company and Executive acknowledge that Executive&#146;s employment is and shall continue
to be at-will, as defined under applicable law, and that Executive&#146;s employment with the Company may be terminated by either party at any time for any or no reason, with or without notice. If Executive&#146;s employment terminates for any
reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided in this Agreement. Executive&#146;s employment under this Agreement shall be terminated immediately on the death of Executive.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Severance Upon Involuntary Termination</U>. Subject to Sections 4(d) and 9(o) and Executive&#146;s continued compliance with
Section&nbsp;5, if Executive&#146;s employment is Involuntarily Terminated, Executive shall be entitled to receive, in lieu of any severance benefits to which Executive may otherwise be entitled under any severance plan or program of the Company,
the benefits provided below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Company shall pay to Executive his or her fully earned but unpaid base salary, when due, through
the date of Executive&#146;s Involuntary Termination at the rate then in effect, accrued and unused PTO, plus all other benefits, if any, under any Company group retirement plan, nonqualified deferred compensation plan, equity award plan or
agreement (other than any such plan or agreement pertaining to Stock Awards whose treatment is prescribed by Section&nbsp;3(g) above), health benefits plan or other Company group benefit plan to which Executive may be entitled pursuant to the terms
of such plans or agreements at the time of Executive&#146;s Involuntary Termination (the &#147;<B><I>Accrued Obligations</I></B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Executive shall be entitled to receive severance pay in an amount equal to twelve (12)&nbsp;multiplied by Executive&#146;s monthly base
salary as in effect immediately prior to the date of Executive&#146;s Involuntary Termination, which amount shall be payable in a lump sum sixty (60)&nbsp;days following Executive&#146;s Involuntary Termination; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) for the period beginning on the date of Executive&#146;s Separation from Service and
ending on the date which is twelve (12)&nbsp;full months following the date of Executive&#146;s Separation from Service (or, if earlier, (1)&nbsp;the date on which the applicable continuation period under the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (&#147;<B><I>COBRA</I></B>&#148;) expires or (2)&nbsp;the date Executive becomes eligible to receive the equivalent or increased healthcare coverage by means of subsequent employment or self-employment) (such
period, the &#147;<B><I>COBRA Coverage Period</I></B>&#148;), if Executive and/or his or her eligible dependents who were covered under the Company&#146;s health insurance plans as of the date of Executive&#146;s Separation from Service elect to
have COBRA coverage and are eligible for such coverage, the Company shall pay for or reimburse Executive on a monthly basis for an amount equal to (A)&nbsp;the monthly premium Executive and/or his or her covered dependents, as applicable, are
required to pay for continuation coverage pursuant to COBRA for Executive and/or his or her eligible dependents, as applicable, who were covered under the Company&#146;s health plans as of the date of Executive&#146;s Separation from Service
(calculated by reference to the premium as of the date of Executive&#146;s Separation from Service) less (B)&nbsp;the amount Executive would have had to pay to receive group health coverage for Executive and/or his or her covered dependents, as
applicable, based on the cost sharing levels in effect on the date of Executive&#146;s Separation from Service. If any of the Company&#146;s health benefits are self-funded as of the date of Executive&#146;s Separation from Service, or if the
Company cannot provide the foregoing benefits in a manner that is exempt from Section&nbsp;409A (as defined below) or that is otherwise compliant with applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service
Act), instead of providing the payments or reimbursements as set forth above, the Company shall instead pay to Executive the foregoing monthly amount as a taxable monthly payment for the COBRA Coverage Period (or any remaining portion thereof).
Executive shall be solely responsible for all matters relating to continuation of coverage pursuant to COBRA, including, without limitation, the election of such coverage and the timely payment of premiums. Executive shall notify the Company
immediately if Executive becomes eligible to receive the equivalent or increased healthcare coverage by means of subsequent employment or self-employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Notwithstanding anything to the contrary in this Section&nbsp;4(b), and subject to Sections 4(d) and 9(o) and Executive&#146;s continued
compliance with Section&nbsp;5, in the event of Executive&#146;s Involuntary Termination within twelve (12)&nbsp;months following a Change in Control, Executive shall be entitled to receive, in addition to the severance benefits described in clauses
(i), (ii)&nbsp;and (iii)&nbsp;above, an amount equal to Executive&#146;s target bonus for the year in which Executive&#146;s Involuntary Termination occurs, which amount shall be payable in a lump sum sixty (60)&nbsp;days following Executive&#146;s
Involuntary Termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause, Voluntary Resignation Without Good Reason, Death or Termination for Permanent
Disability</U>. In the event of Executive&#146;s termination of employment as a result of Executive&#146;s discharge by the Company for Cause, Executive&#146;s resignation without Good Reason, Executive&#146;s death or Executive&#146;s termination
of employment following Executive&#146;s Permanent Disability, the Company shall not have any other or further obligations to Executive under this Agreement (including any financial obligations) except that Executive shall be entitled to receive the
Accrued Obligations. The foregoing shall be in addition to, and not in lieu of, any and all other rights and remedies which may be available to the Company under the circumstances, whether at law or in equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Release</U>. As a condition to Executive&#146;s receipt of any post-termination benefits
pursuant to Section&nbsp;4(b) above, Executive (or, in the event of Executive&#146;s incapacity as a result of his Permanent Disability, Executive&#146;s legal representative) shall execute and not revoke a general release of all claims in favor of
the Company (the &#147;<U>Release</U>&#148;) in the form attached hereto as <U>Exhibit A</U>. In the event the Release does not become effective within the fifty-five (55)&nbsp;day period following the date of Executive&#146;s Separation from
Service, Executive shall not be entitled to the aforesaid payments and benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Exclusive Remedy</U>. Except as otherwise
expressly required by law (e.g., COBRA) or as specifically provided herein, all of Executive&#146;s rights to salary, severance, benefits, bonuses and other amounts hereunder (if any) accruing after the termination of Executive&#146;s employment
shall cease upon such termination. In the event of Executive&#146;s termination of employment with the Company, Executive&#146;s sole remedy shall be to receive the payments and benefits described in Section&nbsp;3(g) and this Section&nbsp;4. In
addition, Executive acknowledges and agrees that he or she is not entitled to any reimbursement by the Company for any taxes payable by Executive as a result of the payments and benefits received by Executive pursuant to Section&nbsp;3(g) and this
Section&nbsp;4, including, without limitation, any excise tax imposed by Section&nbsp;4999 of the Code. Any payments made to Executive under this Section&nbsp;4 shall be inclusive of any amounts or benefits to which Executive may be entitled
pursuant to the Worker Adjustment and Retraining Notification Act, 29 U.S.C. Sections 2101 et seq., and the Department of Labor regulations thereunder, or any similar state statute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>No Mitigation</U>. Except as otherwise provided in Section&nbsp;4(b)(iii) above, Executive shall not be required to mitigate the amount
of any payment provided for in this Section&nbsp;4 by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Section&nbsp;4 be reduced by any compensation earned by Executive as the result of
employment by another employer or self-employment or by retirement benefits; <U>provided</U>, <U>however</U>, that loans, advances or other amounts owed by Executive to the Company may be offset by the Company against amounts payable to Executive
under this Section&nbsp;4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Return of the Company&#146;s Property</U>. In the event of Executive&#146;s termination of employment
for any reason, the Company shall have the right, at its option, to require Executive to vacate his or her offices prior to or on the effective date of separation and to cease all activities on the Company&#146;s behalf. Upon Executive&#146;s
termination of employment in any manner, as a condition to Executive&#146;s receipt of any severance benefits described in this Agreement, Executive shall immediately surrender to the Company all lists, books and records of, or in connection with,
the Company&#146;s business, and all other property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the property of the Company. Executive shall deliver to the Company a
signed statement certifying compliance with this Section&nbsp;4(g) prior to the receipt of any severance benefits described in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <U>Waiver of the Company&#146;s Liability</U>. Executive recognizes that his or her employment is subject to termination with or without
Cause for any reason and therefore Executive agrees that Executive shall hold the Company harmless from and against any and all liabilities, losses, damages, costs and expenses, including but not limited to, court costs and reasonable
attorneys&#146; fees, which Executive may incur as a result of Executive&#146;s termination of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employment. Executive further agrees that Executive shall bring no claim or cause of action against the Company for damages or injunctive relief based on a wrongful termination of employment.
Executive agrees that the sole liability of the Company to Executive upon termination of this Agreement shall be that determined by this Section&nbsp;4. In the event this covenant is more restrictive than permitted by laws of the jurisdiction in
which the Company seeks enforcement thereof, this covenant shall be limited to the extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Deemed
Resignation</U>. Upon termination of Executive&#146;s employment for any reason, Executive shall be deemed to have resigned from all offices and directorships, if any, then held with the Company or any of its affiliates, and, at the Company&#146;s
request, Executive shall execute such documents as are necessary or desirable to effectuate such resignations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain
Covenants</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Noncompetition</U>. Except as may otherwise be approved by the Board, during the term of Executive&#146;s
employment, Executive shall not have any ownership interest (of record or beneficial) in, or have any interest as an employee, salesman, consultant, officer or director in, or otherwise aid or assist in any manner, any firm, corporation,
partnership, proprietorship or other business that engages in any county, city or part thereof in the United States and/or any foreign country in a business which competes directly or indirectly (as determined by the Board) with the Company&#146;s
business in such county, city or part thereof, so long as the Company, or any successor in interest of the Company to the business and goodwill of the Company, remains engaged in such business in such county, city or part thereof or continues to
solicit customers or potential customers therein; <U>provided</U>, <U>however</U>, that Executive may own, directly or indirectly, solely as an investment, securities of any entity which are traded on any national securities exchange if Executive
(i)&nbsp;is not a controlling person of, or a member of a group which controls, such entity; or (ii)&nbsp;does not, directly or indirectly, own one percent (1%)&nbsp;or more of any class of securities of any such entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Confidential Information</U>. Executive and the Company have entered into the Company&#146;s standard employee proprietary information
and inventions agreement (the &#147;<U>Employee Proprietary Information and Inventions Agreement</U>&#148;). Executive agrees to perform each and every obligation of Executive therein contained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Solicitation of Employees</U>. Executive shall not during the term of Executive&#146;s employment and for the applicable severance
period for which Executive receives severance benefits following any termination hereof pursuant to Section&nbsp;4(b) above (regardless of whether Executive receives payment of severance amounts payable thereunder in a lump sum) (the
&#147;<U>Restricted Period</U>&#148;), directly or indirectly, solicit or encourage to leave the employment of the Company or any of its affiliates, any employee of the Company or any of its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Solicitation of Consultants</U>. Executive shall not during the term of Executive&#146;s employment and for the Restricted Period,
directly or indirectly, hire, solicit or encourage to cease work with the Company or any of its affiliates any consultant then under contract with the Company or any of its affiliates within one year of the termination of such consultant&#146;s
engagement by the Company or any of its affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Rights and Remedies Upon Breach</U>. If Executive breaches or threatens to commit a breach
of any of the provisions of this Section&nbsp;5 (the &#147;<U>Restrictive Covenants</U>&#148;), the Company shall have the following rights and remedies, each of which rights and remedies shall be independent of the other and severally enforceable,
and all of which rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Specific Performance</U>. The right and remedy to have the Restrictive Covenants specifically enforced by any court having equity
jurisdiction, all without the need to post a bond or any other security or to prove any amount of actual damage or that money damages would not provide an adequate remedy, it being acknowledged and agreed that any such breach or threatened breach
will cause irreparable injury to the Company and that money damages will not provide adequate remedy to the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)
<U>Accounting and Indemnification</U>. The right and remedy to require Executive (A)&nbsp;to account for and pay over to the Company all compensation, profits, monies, accruals, increments or other benefits derived or received by Executive or any
associated party deriving such benefits as a result of any such breach of the Restrictive Covenants; and (B)&nbsp;to indemnify the Company against any other losses, damages (including special and consequential damages), costs and expenses, including
actual attorneys&#146; fees and court costs, which may be incurred by them and which result from or arise out of any such breach or threatened breach of the Restrictive Covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>Severability of Covenants/Blue Pencilling</U>. If any court determines that any of the Restrictive Covenants, or any part thereof, is
invalid or unenforceable, the remainder of the Restrictive Covenants shall not thereby be affected and shall be given full effect, without regard to the invalid portions. If any court determines that any of the Restrictive Covenants, or any part
thereof, are unenforceable because of the duration of such provision or the area covered thereby, such court shall have the power to reduce the duration or area of such provision and, in its reduced form, such provision shall then be enforceable and
shall be enforced. Executive hereby waives any and all right to attack the validity of the Restrictive Covenants on the grounds of the breadth of their geographic scope or the length of their term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Enforceability in Jurisdictions</U>. The Company and Executive intend to and do hereby confer jurisdiction to enforce the Restrictive
Covenants upon the courts of any jurisdiction within the geographical scope of such covenants. If the courts of any one or more of such jurisdictions hold the Restrictive Covenants wholly unenforceable by reason of the breadth of such scope or
otherwise, it is the intention of the Company and Executive that such determination not bar or in any way affect the right of the Company to the relief provided above in the courts of any other jurisdiction within the geographical scope of such
covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <U>Definitions</U>. For purposes of this Section&nbsp;5, the term &#147;<U>Company</U>&#148; means not only Exagen Diagnostics, Inc., but
also any company, partnership or entity which, directly or indirectly, controls, is controlled by or is under common control with Exagen Diagnostics, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Insurance; Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Insurance</U>. The Company shall have the right to take out life, health, accident, &#147;key-man&#148; or other insurance covering
Executive, in the name of the Company and at the Company&#146;s expense in any amount deemed appropriate by the Company. Executive shall assist the Company in obtaining such insurance, including, without limitation, submitting to any required
examinations and providing information and data required by insurance companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Indemnification</U>. Executive will be provided
with indemnification against third party claims related to his or her work for the Company as required by Delaware law. The Company shall provide Executive with directors and officers liability insurance coverage at least as favorable as that which
the Company may maintain from time to time for members of the Board and other executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Arbitration</U>. Any dispute,
claim or controversy based on, arising out of or relating to Executive&#146;s employment or this Agreement shall be settled by final and binding arbitration in San Diego, California, before a single neutral arbitrator in accordance with the National
Rules for the Resolution of Employment Disputes (the &#147;<B><I>Rules</I></B>&#148;) of the American Arbitration Association, and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction. The Rules may be
found online at www.adr.org. Arbitration may be compelled pursuant to the California Arbitration Act (Code of Civil Procedure &#167;&#167; 1280 <U>et</U> <U>seq</U>.). If the parties are unable to agree upon an arbitrator, one shall be appointed by
the AAA in accordance with its Rules. Each party shall pay the fees of its own attorneys, the expenses of its witnesses and all other expenses connected with presenting its case; <U>however</U>, Executive and the Company agree that, to the extent
permitted by law, the arbitrator may, in his or her discretion, award reasonable attorneys&#146; fees to the prevailing party; <U>provided</U>, <U>further</U>, that the prevailing party shall be reimbursed for such fees, costs and expenses within
forty-five (45)&nbsp;days following any such award, but in no event later than the last day of Executive&#146;s taxable year following the taxable year in which the fees, costs and expenses were incurred; <U>provided</U>, <U>further</U>, that the
parties&#146; obligations pursuant to this sentence shall terminate on the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;anniversary of the date of Executive&#146;s termination of employment. Other costs of the arbitration,
including the cost of any record or transcripts of the arbitration, AAA&#146;s administrative fees, the fee of the arbitrator, and all other fees and costs, shall be borne by the Company. This Section&nbsp;7 is intended to be the exclusive method
for resolving any and all claims by the parties against each other for payment of damages under this Agreement or relating to Executive&#146;s employment; <U>provided</U>, <U>however</U>, that Executive shall retain the right to file administrative
charges with or seek relief through any government agency of competent jurisdiction, and to participate in any government investigation, including but not limited to (i)&nbsp;claims for workers&#146; compensation, state disability insurance or
unemployment insurance; (ii)&nbsp;claims for unpaid wages or waiting time penalties brought before the California Division of Labor Standards Enforcement; <U>provided</U>, <U>however</U>, that any appeal from an award or from denial of an award of
wages and/or waiting time penalties shall be arbitrated pursuant to the terms of this Agreement; and (iii)&nbsp;claims for administrative relief from the United States Equal Employment Opportunity Commission and/or the California Department of Fair
Employment and Housing (or any similar agency in any applicable jurisdiction other than California); <U>provided</U>, <U>further</U>, that Executive shall not be entitled to obtain any monetary relief through such agencies other than workers&#146;
compensation benefits or unemployment insurance benefits. This Agreement shall not limit either party&#146;s right to obtain any provisional remedy, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including, without limitation, injunctive or similar relief, from any court of competent jurisdiction as may be necessary to protect their rights and interests pending the outcome of arbitration,
including without limitation injunctive relief, in any court of competent jurisdiction pursuant to California Code of Civil Procedure &#167; 1281.8 or any similar statute of an applicable jurisdiction. Seeking any such relief shall not be deemed to
be a waiver of such party&#146;s right to compel arbitration. Both Executive and the Company expressly waive their right to a jury trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>General Relationship</U>. Executive shall be considered an employee of the Company within the meaning of all federal, state and local
laws and regulations including, but not limited to, laws and regulations governing unemployment insurance, workers&#146; compensation, industrial accident, labor and taxes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)
<U>Modification; Prior Claims</U>. This Agreement and the Employee Proprietary Information and Inventions Agreement set forth the entire understanding of the parties with respect to the subject matter hereof, supersedes all existing agreements
between them concerning such subject matter. This Agreement may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any
circumstances whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Assignment; Assumption by Successor</U>. The rights of the Company under this Agreement may, without the
consent of Executive, be assigned by the Company, in its sole and unfettered discretion, to any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly, acquires all or
substantially all of the assets or business of the Company. The Company will require any successor (whether direct or indirect, by purchase, merger or otherwise) to all or substantially all of the business or assets of the Company expressly to
assume and to agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place; <U>provided</U>, <U>however</U>, that no such assumption shall relieve
the Company of its obligations hereunder. As used in this Agreement, the &#147;<U>Company</U>&#148; shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this
Agreement by operation of law or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Survival</U>. The covenants, agreements, representations and warranties contained in
or made in Sections&nbsp;3(g), 4, 5, 6, 7 and 9 of this Agreement shall survive any Executive&#146;s termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U><FONT
STYLE="white-space:nowrap">Third-Party</FONT> Beneficiaries</U>. This Agreement does not create, and shall not be construed as creating, any rights enforceable by any person not a party to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Waiver</U>. The failure of either party hereto at any time to enforce performance by the other party of any provision of this Agreement
shall in no way affect such party&#146;s rights thereafter to enforce the same, nor shall the waiver by either party of any breach of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any provision hereof be deemed to be a waiver by such party of any other breach of the same or any other provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>Section Headings</U>. The headings of the several sections in this Agreement are inserted solely for the convenience of the parties and
are not a part of and are not intended to govern, limit or aid in the construction of any term or provision hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Notices</U>.
Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i)&nbsp;by personal delivery when delivered personally; (ii)&nbsp;by overnight courier upon written
verification of receipt; (iii)&nbsp;by email, telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv)&nbsp;by certified or registered mail, return receipt requested, upon verification of receipt. Notice
shall be sent to Executive at the address listed on the Company&#146;s personnel records and to the Company at its principal place of business, or such other address as either party may specify in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. All Sections, clauses and covenants contained in this Agreement are severable, and in the event any of them shall be
held to be invalid by any court, this Agreement shall be interpreted as if such invalid Sections, clauses or covenants were not contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Governing Law and Venue</U>. This Agreement is to be governed by and construed in accordance with the laws of the State of California
applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Except as provided in Sections&nbsp;5 and 7, any suit brought hereon shall be brought in the state or federal
courts sitting in San Diego, California, the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to
service of process in any manner authorized by California law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) <U>Non-transferability of Interest</U>. None of the rights of
Executive to receive any form of compensation payable pursuant to this Agreement shall be assignable or transferable except through a testamentary disposition or by the laws of descent and distribution upon the death of Executive. Any attempted
assignment, transfer, conveyance, or other disposition (other than as aforesaid) of any interest in the rights of Executive to receive any form of compensation to be made by the Company pursuant to this Agreement shall be void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k) <U>Gender</U>. Where the context so requires, the use of the masculine gender shall include the feminine and/or neuter genders and the
singular shall include the plural, and vice versa, and the word &#147;person&#148; shall include any corporation, firm, partnership or other form of association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(l) <U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(m) <U>Construction</U>. The language in all parts of this Agreement shall in
all cases be construed simply, according to its fair meaning, and not strictly for or against any of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
parties hereto. Without limitation, there shall be no presumption against any party on the ground that such party was responsible for drafting this Agreement or any part thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(n) <U>Withholding and other Deductions</U>. All compensation payable to Executive hereunder shall be subject to such deductions as the
Company is from time to time required to make pursuant to law, governmental regulation or order. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(o) <U>Code Section&nbsp;409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) This Agreement is not intended to provide for any deferral of compensation subject to Section&nbsp;409A of the Code, and, accordingly, the
severance payments payable under Sections 4(b)(ii) and 4(c)(ii) and (iv)&nbsp;shall be paid no later than the later of: (A)&nbsp;the fifteenth (15th)&nbsp;day of the third month following Executive&#146;s first taxable year in which such amounts are
no longer subject to a substantial risk of forfeiture, and (B)&nbsp;the fifteenth (15th)&nbsp;day of the third month following first taxable year of the Company in which such amounts are is no longer subject to substantial risk of forfeiture, as
determined in accordance with Code Section&nbsp;409A and any Treasury Regulations and other guidance issued thereunder. To the extent applicable, this Agreement shall be interpreted in accordance with Code Section&nbsp;409A and Department of
Treasury regulations and other interpretive guidance issued thereunder. Each series of installment payments made under this Agreement is hereby designated as a series of &#147;separate payments&#148; within the meaning of Section&nbsp;409A of the
Code. For purposes of this Agreement, all references to Executive&#146;s &#147;termination of employment&#148; shall mean Executive&#146;s Separation from Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If Executive is a &#147;specified employee&#148; (as defined in Section&nbsp;409A of the Code), as determined by the Company in
accordance with Section&nbsp;409A of the Code, on the date of Executive&#146;s Separation from Service, to the extent that the payments or benefits under this Agreement are subject to Section&nbsp;409A of the Code and the delayed payment or
distribution of all or any portion of such amounts to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section&nbsp;409A(a)(2)(B)(i) of the Code, then such portion deferred pursuant to
this Section&nbsp;9(o)(ii) shall be paid or distributed to Executive in a lump sum on the earlier of (A)&nbsp;the date that is six (6)-months following Executive&#146;s Separation from Service, (B)&nbsp;the date of Executive&#146;s death or
(C)&nbsp;the earliest date as is permitted under Section&nbsp;409A of the Code. Any remaining payments due under the Agreement shall be paid as otherwise provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) To the extent applicable, this Agreement shall be interpreted in accordance with the applicable exemptions from Section&nbsp;409A of
the Code. If Executive and the Company determine that any payments or benefits payable under this Agreement intended to comply with Sections 409A(a)(2), (3)&nbsp;and (4)&nbsp;of the Code do not comply with Section&nbsp;409A of the Code, Executive
and the Company agree to amend this Agreement, or take such other actions as Executive and the Company deem reasonably necessary or appropriate, to comply with the requirements of Section&nbsp;409A of the Code and the Treasury Regulations thereunder
(and any applicable transition relief) while preserving the economic agreement of the parties. To the extent that any provision in this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in
such a manner that no payments payable under this Agreement shall be subject to an &#147;additional tax&#148; as defined in Section&nbsp;409A(a)(1)(B) of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Any reimbursement of expenses or in-kind benefits payable under this
Agreement shall be made in accordance with Treasury Regulation Section&nbsp;1.409A-3(i)(1)(iv) and shall be paid on or before the last day of Executive&#146;s taxable year following the taxable year in which Executive incurred the expenses. The
amount of expenses reimbursed or in-kind benefits payable during any taxable year of Executive&#146;s shall not affect the amount eligible for reimbursement or in-kind benefits payable in any other taxable year of Executive&#146;s, and
Executive&#146;s right to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature
Page Follows) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>E<SMALL>XAGEN</SMALL>&nbsp;D<SMALL>IAGNOSTICS</SMALL>,&nbsp;I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Fortunato Ron Rocca</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President &amp; CEO</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>E<SMALL>XECUTIVE</SMALL></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Wendy Swedick</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>ENDY</SMALL>&nbsp;S<SMALL>WEDICK</SMALL></B><SMALL></SMALL></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE PAGE TO EMPLOYMENT AGREEMENT </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>GENERAL RELEASE OF CLAIMS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>The language in this Release may change based on legal developments and evolving best practices; this form is provided as an example
of what will be included in the final Release document.</I>]<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This General Release of Claims (&#147;<B><I>Release</I></B>&#148;) is
entered into as of this &nbsp;&nbsp;&nbsp;&nbsp;day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, between Wendy Swedick (&#147;<B><I>Executive</I></B>&#148;), and
Exagen Diagnostics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;) (collectively referred to herein as the &#147;<B><I>Parties</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Executive and the Company are parties to that certain Employment Agreement dated as of
[&nbsp;<FONT STYLE="FONT-FAMILY:'WINGDINGS 2'">&#151;</FONT>&nbsp;] (the &#147;<B><I>Agreement</I></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties agree
that Executive is entitled to certain severance benefits under the Agreement, subject to Executive&#146;s execution of this Release; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and Executive now wish to fully and finally to resolve all matters between them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of, and subject to, the severance benefits payable to Executive pursuant to the Agreement, the adequacy of
which is hereby acknowledged by Executive, and which Executive acknowledges that he or she would not otherwise be entitled to receive, Executive and the Company hereby agree as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>General Release of Claims by Executive</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Executive, on behalf of himself or herself and his or her executors, heirs, administrators, representatives and assigns, hereby agrees to
release and forever discharge the Company and all predecessors, successors and their respective parent corporations, affiliates, related, and/or subsidiary entities, and all of their past and present investors, directors, shareholders, officers,
general or limited partners, employees, attorneys, agents and representatives, and the employee benefit plans in which Executive is or has been a participant by virtue of his or her employment with or service to the Company (collectively, the
&#147;<B><I>Company Releasees</I></B>&#148;), from any and all claims, debts, demands, accounts, judgments, rights, causes of action, equitable relief, damages, costs, charges, complaints, obligations, promises, agreements, controversies, suits,
expenses, compensation, responsibility and liability of every kind and character whatsoever (including attorneys&#146; fees and costs), whether in law or equity, known or unknown, asserted or unasserted, suspected or unsuspected (collectively,
&#147;<U>Claims</U>&#148;), which Executive has or may have had against such entities based on any events or <B><I><U>circumstances</U></I></B> arising or occurring on or prior to the date hereof or on or prior to the date hereof, arising directly
or indirectly out of, relating to, or in any other way involving in any manner whatsoever Executive&#146;s employment by or service to the Company or the termination thereof, including any and all claims arising under federal, state, or local laws
relating to employment, including without limitation claims of wrongful discharge, breach of express or implied contract, fraud, misrepresentation, </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defamation, or liability in tort, and claims of any kind that may be brought in any court or administrative agency including, without limitation, claims under Title VII of the Civil Rights Act of
1964, as amended, 42 U.S.C. Section&nbsp;2000, <U>et</U> <U>seq</U>.; the Americans with Disabilities Act, as amended, 42&nbsp;U.S.C. &#167;&nbsp;12101 <U>et</U> <U>seq</U>.; the Rehabilitation Act of 1973, as amended, 29&nbsp;U.S.C. &#167;&nbsp;701
<U>et</U> <U>seq</U>.; the Civil Rights Act of 1866, and the Civil Rights Act of 1991; 42 U.S.C. Section&nbsp;1981, <U>et</U> <U>seq</U>.; the Age Discrimination in Employment Act, as amended, 29 U.S.C. Section&nbsp;621, <U>et</U> <U>seq</U>. (the
&#147;<B><I>ADEA</I></B>&#148;); the Equal Pay Act, as amended, 29 U.S.C. Section&nbsp;206(d); regulations of the Office of Federal Contract Compliance, 41 C.F.R. Section&nbsp;60, <U>et</U> <U>seq</U>.; the Family and Medical Leave Act, as amended,
29&nbsp;U.S.C.&nbsp;&#167;&nbsp;2601 <U>et</U> <U>seq</U>.; the Fair Labor Standards Act of 1938, as amended, 29&nbsp;U.S.C. &#167;&nbsp;201 <U>et</U> <U>seq</U>.; the Employee Retirement Income Security Act, as amended, 29 U.S.C. &#167;&nbsp;1001
<U>et</U> <U>seq</U>.; and the California Fair Employment and Housing Act, California Government Code Section&nbsp;12940, <U>et</U> <U>seq</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the generality of the foregoing, Executive does not release the following claims: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state
law; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Claims for workers&#146; compensation insurance benefits under the terms of any worker&#146;s compensation
insurance policy or fund of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Claims pursuant to the terms and conditions of the federal law known as
COBRA; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Claims for indemnity under the bylaws of the Company, as provided for by California law or under any
applicable insurance policy with respect to Executive&#146;s liability as an employee, director or officer of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Claims based on any right Executive may have to enforce the Company&#146;s executory obligations under the Agreement; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Claims Executive may have to vested or earned compensation and benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) EXECUTIVE ACKNOWLEDGES THAT HE OR SHE HAS BEEN ADVISED OF AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH
PROVIDES AS FOLLOWS: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR
HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.&#148; </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS HE OR SHE MAY HAVE THEREUNDER, AS
WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Note: Clauses (c), (d)&nbsp;and (e)&nbsp;apply only if
Executive is age 40 or older at time of termination] </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Executive acknowledges that this Release was presented to him or her on
the date indicated above and that Executive is entitled to have [twenty-one (21)][forty-five (45)] days&#146; time in which to consider it. Executive further acknowledges that the Company has advised him or her that he or she is waiving his or her
rights under the ADEA, and that Executive should consult with an attorney of his or her choice before signing this Release, and Executive has had sufficient time to consider the terms of this Release. Executive represents and acknowledges that if
Executive executes this Release before [twenty-one (21)][forty-five (45)] days have elapsed, Executive does so knowingly, voluntarily, and upon the advice and with the approval of Executive&#146;s legal counsel (if any), and that Executive
voluntarily waives any remaining consideration period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Executive understands that after executing this Release, Executive has the
right to revoke it within seven (7)&nbsp;days after his or her execution of it. Executive understands that this Release will not become effective and enforceable unless the seven (7)&nbsp;day revocation period passes and Executive does not revoke
the Release in writing. Executive understands that this Release may not be revoked after the seven (7)&nbsp;day revocation period has passed. Executive also understands that any revocation of this Release must be made in writing and delivered to the
Company at its principal place of business within the seven (7)&nbsp;day period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) Executive understands that this Release shall become
effective, irrevocable, and binding upon Executive on the eighth (8<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;day after his or her execution of it, so long as Executive has not revoked it within the time period and in the manner
specified in clause (d)&nbsp;above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) Executive further understands that Executive will not be given any severance benefits under the
Agreement unless this Release is effective on or before the date that is fifty-five (55)&nbsp;days following the date of Executive&#146;s termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>No Assignment</U>. Executive represents and warrants to the Company Releasees that there has been no assignment or other transfer of any
interest in any Claim that Executive may have against the Company Releasees. Executive agrees to indemnify and hold harmless the Company Releasees from any liability, claims, demands, damages, costs, expenses and attorneys&#146; fees incurred as a
result of any such assignment or transfer from Executive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Severability</U>. In the event any provision of this Release is found to
be unenforceable by an arbitrator or court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the parties shall receive the
benefit contemplated herein to the fullest extent permitted by law. If a deemed modification is not satisfactory in the judgment of such arbitrator or court, the unenforceable provision shall be deemed deleted, and the validity and enforceability of
the remaining provisions shall not be affected thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Interpretation; Construction</U>. The headings set forth in this Release are for
convenience only and shall not be used in interpreting this Agreement. This Release has been drafted by legal counsel representing the Company, but Executive has participated in the negotiation of its terms. Furthermore, Executive acknowledges that
Executive has had an opportunity to review and revise the Release and have it reviewed by legal counsel, if desired, and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of this Release. Either party&#146;s failure to enforce any provision of this Release shall not in any way be construed as a waiver of any such provision, or prevent that party thereafter from enforcing
each and every other provision of this Release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Governing Law and Venue</U>. This Release will be governed by and construed in
accordance with the laws of the United States of America and the State of California applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Any suit brought hereon
shall be brought in the state or federal courts sitting in San Diego County, California, the Parties hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam
jurisdiction over it and consents to service of process in any manner authorized by California law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Entire Agreement</U>. This
Release and the Agreement constitute the entire agreement of the Parties in respect of the subject matter contained herein and therein and supersede all prior or simultaneous representations, discussions, negotiations and agreements, whether written
or oral. This Release may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Counterparts</U>. This Release may be executed in multiple counterparts, each of which shall be deemed to be an original but all of
which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature Page Follows) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed the foregoing
Release as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>E<SMALL>XECUTIVE</SMALL></B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><B>E<SMALL>XAGEN</SMALL> D<SMALL>IAGNOSTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:&nbsp;Wendy&nbsp;Swedick&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Print&nbsp;Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>17
<FILENAME>d693329dex1031.htm
<DESCRIPTION>EX-10.31
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.31</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.31 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS EMPLOYMENT AGREEMENT (this &#147;<B><I>Agreement</I></B>&#148;) is entered into by and between Exagen Diagnostics, Inc., a Delaware
corporation (the &#147;<B><I>Company</I></B>&#148;), and Thierry Dervieux (&#147;<B><I>Executive</I></B>&#148;), and shall be effective as of the date prior to the date on which the Company&#146;s common stock commences trading pursuant to the
initial public offering of the Company&#146;s common stock (the &#147;<B><I>Effective Date</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires
to employ Executive, and Executive desires to accept employment with the Company, on the terms and conditions set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual promises herein contained, the parties agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. As used in this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Cause</I></B>&#148; means any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the commission of an act of fraud, embezzlement or dishonesty by Executive, or the commission of some other illegal act by Executive,
that causes material harm to the Company or any successor or affiliate thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Executive&#146;s conviction of, or plea of
&#147;guilty&#148; or &#147;no contest&#148; to, a felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any intentional unauthorized use or disclosure by Executive of confidential information or trade secrets of the Company or any
successor or affiliate thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Executive&#146;s gross negligence, insubordination or material violation of any duty of loyalty to
the Company or any successor or affiliate thereof, or any other material misconduct on the part of Executive; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Executive&#146;s
ongoing and repeated failure or refusal to perform or neglect of Executive&#146;s duties as required by this Agreement, which failure, refusal or neglect continues for fifteen (15)&nbsp;days following Executive&#146;s receipt of written notice from
the Board or the Company&#146;s Chief Executive Officer (the &#147;<B></B><B><I>CEO</I></B><B></B>&#148;) stating with specificity the nature of such failure, refusal or neglect; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) Executive&#146;s intentional, material breach of any Company policy or any contract or agreement between Executive and the Company or
any successor or affiliate thereof; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>, <U>however</U>, that prior to the determination that &#147;Cause&#148; under clauses (iv),
(v)&nbsp;or (vi)&nbsp;of this Section&nbsp;1(b) has occurred, the Company shall (A)&nbsp;provide to Executive in writing, in reasonable detail, the reasons for the determination that such &#147;Cause&#148; exists, (B)&nbsp;other than with respect to
clause (v)&nbsp;above which specifies the applicable period of time for Executive to remedy his or her breach, afford Executive a reasonable opportunity to remedy any such breach, (C)&nbsp;provide Executive an opportunity to be heard prior to the
final decision to terminate Executive&#146;s employment hereunder for such &#147;Cause&#148; and (D)&nbsp;make any decision that such &#147;Cause&#148; exists in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The foregoing definition shall not in any way preclude or restrict the right of the Company or any successor or affiliate thereof to discharge
or dismiss Executive for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of this Agreement, to constitute grounds for termination for Cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B><I>Change in Control</I></B>&#148; means and includes each of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) a transaction or series of transactions (other than an offering of the Company&#146;s common stock to the general public through a
registration statement filed with the Securities and Exchange Commission) whereby any &#147;person&#148; or related &#147;group&#148; of &#147;persons&#148; (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of
1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;)) (other than the Company, any of its subsidiaries, an employee benefit plan maintained by the Company or any of its subsidiaries or a &#147;person&#148; that, prior to such transaction,
directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act), of securities of the Company possessing
more than fifty percent (50%)&nbsp;of the total combined voting power of the Company&#146;s securities outstanding immediately after such acquisition; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more
intermediaries) of (A)&nbsp;a merger, consolidation, reorganization, or business combination or (B)&nbsp;a sale or other disposition of all or substantially all of the Company&#146;s assets in any single transaction or series of related transactions
or (C)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) which
results in the Company&#146;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of
the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#146;s assets or otherwise succeeds to the business of the Company (the Company or such person, the
&#147;<B><I>Successor Entity</I></B>&#148;) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#146;s outstanding voting securities immediately after the transaction, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) after which no person or group beneficially owns voting securities representing fifty percent (50%)&nbsp;or more of the
combined voting power of the Successor Entity; <U>provided</U>, <U>however</U>, that no person or group shall be treated for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
purposes of this clause&nbsp;(2) as beneficially owning fifty percent (50%)&nbsp;or more of combined voting power of the Successor Entity solely as a result of the voting power held in the
Company prior to the consummation of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a transaction shall not constitute a
&#147;<B><I>Change in Control</I></B>&#148; if: (i)&nbsp;its sole purpose is to change the state of the Company&#146;s incorporation; (ii)&nbsp;its sole purpose is to create a holding company that will be owned in substantially the same proportions
by the persons who held the Company&#146;s securities immediately before such transaction; (iii)&nbsp;it constitutes the Company&#146;s initial public offering of its securities; or (iv)&nbsp;it is a transaction effected primarily for the purpose of
financing the Company with cash (as determined by the Board in its discretion and without regard to whether such transaction is effectuated by a merger, equity financing or otherwise). The Board shall have full and final authority, which shall be
exercised in its discretion, to determine conclusively whether a Change in Control of the Company has occurred pursuant to the above definition, and the date of the occurrence of such Change in Control and any incidental matters thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended from time to time, and the Treasury Regulations and
other interpretive guidance issued thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B><I>Good Reason</I></B>&#148; means the occurrence of any of the following
events or conditions without Executive&#146;s written consent: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) a material diminution in Executive&#146;s authority, duties or
responsibilities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) a material diminution in Executive&#146;s base compensation, unless such a reduction is imposed across-the-board
to senior management of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) a material change in the geographic location at which Executive must perform his or her
duties; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) any other action or inaction that constitutes a material breach by the Company or any successor or affiliate of its
obligations to Executive under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Executive must provide written notice to the Company of the occurrence of any of the
foregoing events or conditions without Executive&#146;s written consent within sixty (60)&nbsp;days of the occurrence of such event. The Company or any successor or affiliate shall have a period of thirty (30)&nbsp;days to cure such event or
condition after receipt of written notice of such event from Executive. Executive&#146;s Separation from Service by reason of resignation from employment with the Company for Good Reason must occurs within thirty (30)&nbsp;days following the
expiration of the foregoing thirty (30)&nbsp;day cure period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B><I>Involuntary Termination</I></B>&#148; means
(i)&nbsp;Executive&#146;s Separation from Service by reason of Executive&#146;s discharge by the Company other than for Cause, or (ii)&nbsp;Executive&#146;s Separation from Service by reason of Executive&#146;s resignation of employment with the
Company for Good Reason. Executive&#146;s Separation from Service by reason of Executive&#146;s death or discharge by the Company following Executive&#146;s Permanent Disability shall not constitute an Involuntary Termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) Executive&#146;s &#147;<B><I>Permanent Disability</I></B>&#148; shall be deemed to have
occurred if Executive shall become physically or mentally incapacitated or disabled or otherwise unable fully to discharge his or her duties hereunder for a period of ninety (90)&nbsp;consecutive calendar days or for one hundred twenty
(120)&nbsp;calendar days in any one hundred eighty (180)&nbsp;calendar-day period. The existence of Executive&#146;s Permanent Disability shall be determined by the Company on the advice of a physician chosen by the Company and the Company reserves
the right to have Executive examined by a physician chosen by the Company at the Company&#146;s expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B><I>Separation from
Service</I></B>,&#148; with respect to Executive, means Executive&#146;s &#147;separation from service,&#148; as defined in Treasury Regulation Section&nbsp;1.409A-1(h). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B><I>Stock Awards</I></B>&#148; means all stock options, restricted stock and such other awards granted pursuant to the
Company&#146;s stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.
<U>Services to Be Rendered.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Duties and Responsibilities</U>. Executive shall serve as Chief Scientific Officer of the Company.
In the performance of such duties, Executive shall report directly to the CEO and shall be subject to the direction of the CEO and to such limits upon Executive&#146;s authority as the CEO may from time to time impose. In the event of the CEO&#146;s
incapacity or unavailability, Executive shall be subject to the direction of the Board. Executive hereby consents to serve as an officer and/or director of the Company or any subsidiary or affiliate thereof without any additional salary or
compensation, if so requested by the CEO. Executive shall be employed by the Company on a full time basis. Executive&#146;s primary place of work shall be the Company&#146;s principal executive offices, or, with the Company&#146;s consent, at any
other place at which the Company maintains an office; <U>provided</U>, <U>however</U>, that the Company may from time to time require Executive to travel temporarily to other locations in connection with the Company&#146;s business. Executive shall
be subject to and comply with the policies and procedures generally applicable to senior executives of the Company to the extent the same are not inconsistent with any term of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Exclusive Services</U>. Executive shall at all times faithfully, industriously and to the best of his or her ability, experience and
talent perform to the satisfaction of the Board and the CEO all of the duties that may be assigned to Executive hereunder and shall devote substantially all of his or her productive time and efforts to the performance of such duties. Subject to the
terms of the Proprietary Information and Inventions Agreement referred to in Section&nbsp;5(b), this shall not preclude Executive from devoting time to personal and family investments or serving on community and civic boards, or participating in
industry associations, provided such activities do not interfere with his or her duties to the Company, as determined in good faith by the CEO. Executive agrees that he or she will not join any boards, other than community and civic boards (which do
not interfere with his or her duties to the Company), without the prior approval of the CEO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Compensation and Benefits</U>. The
Company shall pay or provide, as the case may be, to Executive the compensation and other benefits and rights set forth in this Section&nbsp;3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. The Company shall pay to Executive a base salary of $295,000 per year,
payable in accordance with the Company&#146;s usual pay practices (and in any event no less frequently than monthly). Executive&#146;s base salary shall be subject to review annually by and at the sole discretion of the Compensation Committee of the
Board or its designee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Bonus</U>. Executive shall participate in any bonus plan that the Board or its designee may approve for the
senior executives of the Company. Executive&#146;s target bonus under the Company&#146;s annual bonus plan shall be thirty percent (30%)&nbsp;of Executive&#146;s base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Benefits</U>. Executive shall be entitled to participate in benefits under the Company&#146;s benefit plans and arrangements,
including, without limitation, any employee benefit plan or arrangement made available in the future by the Company to its senior executives, subject to and on a basis consistent with the terms, conditions and overall administration of such plans
and arrangements. The Company shall have the right to amend or delete any such benefit plan or arrangement made available by the Company to its senior executives and not otherwise specifically provided for herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Expenses</U>. The Company shall reimburse Executive for reasonable out-of-pocket business expenses incurred in connection with the
performance of his or her duties hereunder, subject to such policies as the Company may from time to time establish, and Executive furnishing the Company with evidence in the form of receipts satisfactory to the Company substantiating the claimed
expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Paid Time Off</U>. Executive shall be entitled to such periods of paid time off (&#147;<B><I>PTO</I></B>&#148;) each
year as provided from time to time under the Company&#146;s PTO policy and as otherwise provided for senior executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f)
<U>Equity Plans</U>. Executive shall be entitled to participate in any equity or other employee benefit plan that is generally available to executives of the Company. Except as otherwise provided in this Agreement, Executive&#146;s participation in
and benefits under any such plan shall be on the terms and subject to the conditions specified in the governing document of the particular plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Stock Award Acceleration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Subject to Section&nbsp;4(d), in the event of Executive&#146;s Involuntary Termination or Executive&#146;s Separation from Service by
reason of Executive&#146;s death or discharge by the Company following Executive&#146;s Permanent Disability, the vesting and/or exercisability of each of Executive&#146;s outstanding unvested Stock Awards shall be automatically accelerated on the
date of Executive&#146;s Separation from Service as to the number of Stock Awards that would vest over the twelve (12)&nbsp;month period following the date of Executive&#146;s Separation from Service had Executive remained continuously employed by
the Company during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Subject to Section&nbsp;4(d), in the event of Executive&#146;s Involuntary Termination within three
(3)&nbsp;months prior to or twelve (12)&nbsp;months following a Change in Control, the vesting and/or exercisability of any outstanding unvested portion of each of Executive&#146;s Stock Awards shall be automatically accelerated on the later of
(A)&nbsp;the date of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Executive&#146;s Separation from Service and (B)&nbsp;the date of the Change in Control. In addition, with respect to Stock Awards granted to Executive on or after the Effective Date, such Stock
Awards may be exercised by Executive (or Executive&#146;s legal guardian or legal representative) until the latest of (A)&nbsp;three (3)&nbsp;months after the date of Executive&#146;s Separation from Service, (B)&nbsp;with respect to any portion of
the Stock Awards that become exercisable on the date of a Change in Control pursuant to this Section&nbsp;3(g)(ii), three (3)&nbsp;months after the date of the Change in Control, or (C)&nbsp;such longer period as may be specified in the applicable
Stock Award agreement; <U>provided</U>, <U>however</U>, that in no event shall any Stock Award remain exercisable beyond the original outside expiration date of such Stock Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The vesting pursuant to clauses (i)&nbsp;and (ii)&nbsp;of this Section&nbsp;3(g) shall be cumulative. The foregoing provisions are
hereby deemed to be a part of each Stock Award and to supersede any less favorable provision in any agreement or plan regarding such Stock Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Severance</U>. Executive shall be entitled to receive benefits upon a Separation from Service only as set forth in this Section&nbsp;4:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>At-Will Employment; Termination</U>. The Company and Executive acknowledge that Executive&#146;s employment is and shall continue
to be at-will, as defined under applicable law, and that Executive&#146;s employment with the Company may be terminated by either party at any time for any or no reason, with or without notice. If Executive&#146;s employment terminates for any
reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided in this Agreement. Executive&#146;s employment under this Agreement shall be terminated immediately on the death of Executive.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Severance Upon Involuntary Termination</U>. Subject to Sections 4(d) and 9(o) and Executive&#146;s continued compliance with
Section&nbsp;5, if Executive&#146;s employment is Involuntarily Terminated, Executive shall be entitled to receive, in lieu of any severance benefits to which Executive may otherwise be entitled under any severance plan or program of the Company,
the benefits provided below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Company shall pay to Executive his or her fully earned but unpaid base salary, when due, through
the date of Executive&#146;s Involuntary Termination at the rate then in effect, accrued and unused PTO, plus all other benefits, if any, under any Company group retirement plan, nonqualified deferred compensation plan, equity award plan or
agreement (other than any such plan or agreement pertaining to Stock Awards whose treatment is prescribed by Section&nbsp;3(g) above), health benefits plan or other Company group benefit plan to which Executive may be entitled pursuant to the terms
of such plans or agreements at the time of Executive&#146;s Involuntary Termination (the &#147;<B><I>Accrued Obligations</I></B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Executive shall be entitled to receive severance pay in an amount equal to twelve (12)&nbsp;multiplied by Executive&#146;s monthly base
salary as in effect immediately prior to the date of Executive&#146;s Involuntary Termination, which amount shall be payable in a lump sum sixty (60)&nbsp;days following Executive&#146;s Involuntary Termination; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) for the period beginning on the date of Executive&#146;s Separation from Service and
ending on the date which is twelve (12)&nbsp;full months following the date of Executive&#146;s Separation from Service (or, if earlier, (1)&nbsp;the date on which the applicable continuation period under the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (&#147;<B><I>COBRA</I></B>&#148;) expires or (2)&nbsp;the date Executive becomes eligible to receive the equivalent or increased healthcare coverage by means of subsequent employment or self-employment) (such
period, the &#147;<B><I>COBRA Coverage Period</I></B>&#148;), if Executive and/or his or her eligible dependents who were covered under the Company&#146;s health insurance plans as of the date of Executive&#146;s Separation from Service elect to
have COBRA coverage and are eligible for such coverage, the Company shall pay for or reimburse Executive on a monthly basis for an amount equal to (A)&nbsp;the monthly premium Executive and/or his or her covered dependents, as applicable, are
required to pay for continuation coverage pursuant to COBRA for Executive and/or his or her eligible dependents, as applicable, who were covered under the Company&#146;s health plans as of the date of Executive&#146;s Separation from Service
(calculated by reference to the premium as of the date of Executive&#146;s Separation from Service) less (B)&nbsp;the amount Executive would have had to pay to receive group health coverage for Executive and/or his or her covered dependents, as
applicable, based on the cost sharing levels in effect on the date of Executive&#146;s Separation from Service. If any of the Company&#146;s health benefits are self-funded as of the date of Executive&#146;s Separation from Service, or if the
Company cannot provide the foregoing benefits in a manner that is exempt from Section&nbsp;409A (as defined below) or that is otherwise compliant with applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service
Act), instead of providing the payments or reimbursements as set forth above, the Company shall instead pay to Executive the foregoing monthly amount as a taxable monthly payment for the COBRA Coverage Period (or any remaining portion thereof).
Executive shall be solely responsible for all matters relating to continuation of coverage pursuant to COBRA, including, without limitation, the election of such coverage and the timely payment of premiums. Executive shall notify the Company
immediately if Executive becomes eligible to receive the equivalent or increased healthcare coverage by means of subsequent employment or self-employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) Notwithstanding anything to the contrary in this Section&nbsp;4(b), and subject to Sections 4(d) and 9(o) and Executive&#146;s continued
compliance with Section&nbsp;5, in the event of Executive&#146;s Involuntary Termination within twelve (12)&nbsp;months following a Change in Control, Executive shall be entitled to receive, in addition to the severance benefits described in clauses
(i), (ii)&nbsp;and (iii)&nbsp;above, an amount equal to (A)&nbsp;Executive&#146;s target bonus for the year in which Executive&#146;s Involuntary Termination occurs, which amount shall be payable in a lump sum sixty (60)&nbsp;days following
Executive&#146;s Involuntary Termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause, Voluntary Resignation Without Good Reason, Death or Termination
for Permanent Disability</U>. In the event of Executive&#146;s termination of employment as a result of Executive&#146;s discharge by the Company for Cause, Executive&#146;s resignation without Good Reason, Executive&#146;s death or Executive&#146;s
termination of employment following Executive&#146;s Permanent Disability, the Company shall not have any other or further obligations to Executive under this Agreement (including any financial obligations) except that Executive shall be entitled to
receive the Accrued Obligations. The foregoing shall be in addition to, and not in lieu of, any and all other rights and remedies which may be available to the Company under the circumstances, whether at law or in equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Release</U>. As a condition to Executive&#146;s receipt of any post-termination benefits
pursuant to Section&nbsp;4(b) above, Executive (or, in the event of Executive&#146;s incapacity as a result of his Permanent Disability, Executive&#146;s legal representative) shall execute and not revoke a general release of all claims in favor of
the Company (the &#147;<U>Release</U>&#148;) in the form attached hereto as <U>Exhibit&nbsp;A</U>. In the event the Release does not become effective within the fifty-five (55)&nbsp;day period following the date of Executive&#146;s Separation from
Service, Executive shall not be entitled to the aforesaid payments and benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Exclusive Remedy</U>. Except as otherwise
expressly required by law (e.g., COBRA) or as specifically provided herein, all of Executive&#146;s rights to salary, severance, benefits, bonuses and other amounts hereunder (if any) accruing after the termination of Executive&#146;s employment
shall cease upon such termination. In the event of Executive&#146;s termination of employment with the Company, Executive&#146;s sole remedy shall be to receive the payments and benefits described in Section&nbsp;3(g) and this Section&nbsp;4. In
addition, Executive acknowledges and agrees that he or she is not entitled to any reimbursement by the Company for any taxes payable by Executive as a result of the payments and benefits received by Executive pursuant to Section&nbsp;3(g) and this
Section&nbsp;4, including, without limitation, any excise tax imposed by Section&nbsp;4999 of the Code. Any payments made to Executive under this Section&nbsp;4 shall be inclusive of any amounts or benefits to which Executive may be entitled
pursuant to the Worker Adjustment and Retraining Notification Act, 29 U.S.C. Sections 2101 et seq., and the Department of Labor regulations thereunder, or any similar state statute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>No Mitigation</U>. Except as otherwise provided in Section&nbsp;4(b)(iii) above, Executive shall not be required to mitigate the amount
of any payment provided for in this Section&nbsp;4 by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Section&nbsp;4 be reduced by any compensation earned by Executive as the result of
employment by another employer or self-employment or by retirement benefits; <U>provided</U>, <U>however</U>, that loans, advances or other amounts owed by Executive to the Company may be offset by the Company against amounts payable to Executive
under this Section&nbsp;4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Return of the Company&#146;s Property</U>. In the event of Executive&#146;s termination of employment
for any reason, the Company shall have the right, at its option, to require Executive to vacate his or her offices prior to or on the effective date of separation and to cease all activities on the Company&#146;s behalf. Upon Executive&#146;s
termination of employment in any manner, as a condition to Executive&#146;s receipt of any severance benefits described in this Agreement, Executive shall immediately surrender to the Company all lists, books and records of, or in connection with,
the Company&#146;s business, and all other property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the property of the Company. Executive shall deliver to the Company a
signed statement certifying compliance with this Section&nbsp;4(g) prior to the receipt of any severance benefits described in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <U>Waiver of the Company&#146;s Liability</U>. Executive recognizes that his or her employment is subject to termination with or without
Cause for any reason and therefore Executive agrees that Executive shall hold the Company harmless from and against any and all liabilities, losses, damages, costs and expenses, including but not limited to, court costs and reasonable
attorneys&#146; fees, which Executive may incur as a result of Executive&#146;s termination of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employment. Executive further agrees that Executive shall bring no claim or cause of action against the Company for damages or injunctive relief based on a wrongful termination of employment.
Executive agrees that the sole liability of the Company to Executive upon termination of this Agreement shall be that determined by this Section&nbsp;4. In the event this covenant is more restrictive than permitted by laws of the jurisdiction in
which the Company seeks enforcement thereof, this covenant shall be limited to the extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Deemed
Resignation</U>. Upon termination of Executive&#146;s employment for any reason, Executive shall be deemed to have resigned from all offices and directorships, if any, then held with the Company or any of its affiliates, and, at the Company&#146;s
request, Executive shall execute such documents as are necessary or desirable to effectuate such resignations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain
Covenants</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Noncompetition</U>. Except as may otherwise be approved by the Board, during the term of Executive&#146;s
employment, Executive shall not have any ownership interest (of record or beneficial) in, or have any interest as an employee, salesman, consultant, officer or director in, or otherwise aid or assist in any manner, any firm, corporation,
partnership, proprietorship or other business that engages in any county, city or part thereof in the United States and/or any foreign country in a business which competes directly or indirectly (as determined by the Board) with the Company&#146;s
business in such county, city or part thereof, so long as the Company, or any successor in interest of the Company to the business and goodwill of the Company, remains engaged in such business in such county, city or part thereof or continues to
solicit customers or potential customers therein; <U>provided</U>, <U>however</U>, that Executive may own, directly or indirectly, solely as an investment, securities of any entity which are traded on any national securities exchange if Executive
(i)&nbsp;is not a controlling person of, or a member of a group which controls, such entity; or (ii)&nbsp;does not, directly or indirectly, own one percent (1%)&nbsp;or more of any class of securities of any such entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Confidential Information</U>. Executive and the Company have entered into the Company&#146;s standard employee proprietary information
and inventions agreement (the &#147;<U>Employee Proprietary Information and Inventions Agreement</U>&#148;). Executive agrees to perform each and every obligation of Executive therein contained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Solicitation of Employees</U>. Executive shall not during the term of Executive&#146;s employment and for the applicable severance
period for which Executive receives severance benefits following any termination hereof pursuant to Section&nbsp;4(b) above (regardless of whether Executive receives payment of severance amounts payable thereunder in a lump sum) (the
&#147;<U>Restricted Period</U>&#148;), directly or indirectly, solicit or encourage to leave the employment of the Company or any of its affiliates, any employee of the Company or any of its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Solicitation of Consultants</U>. Executive shall not during the term of Executive&#146;s employment and for the Restricted Period,
directly or indirectly, hire, solicit or encourage to cease work with the Company or any of its affiliates any consultant then under contract with the Company or any of its affiliates within one year of the termination of such consultant&#146;s
engagement by the Company or any of its affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Rights and Remedies Upon Breach</U>. If Executive breaches or threatens to commit a breach
of any of the provisions of this Section&nbsp;5 (the &#147;<U>Restrictive Covenants</U>&#148;), the Company shall have the following rights and remedies, each of which rights and remedies shall be independent of the other and severally enforceable,
and all of which rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Specific Performance</U>. The right and remedy to have the Restrictive Covenants specifically enforced by any court having equity
jurisdiction, all without the need to post a bond or any other security or to prove any amount of actual damage or that money damages would not provide an adequate remedy, it being acknowledged and agreed that any such breach or threatened breach
will cause irreparable injury to the Company and that money damages will not provide adequate remedy to the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)
<U>Accounting and Indemnification</U>. The right and remedy to require Executive (A)&nbsp;to account for and pay over to the Company all compensation, profits, monies, accruals, increments or other benefits derived or received by Executive or any
associated party deriving such benefits as a result of any such breach of the Restrictive Covenants; and (B)&nbsp;to indemnify the Company against any other losses, damages (including special and consequential damages), costs and expenses, including
actual attorneys&#146; fees and court costs, which may be incurred by them and which result from or arise out of any such breach or threatened breach of the Restrictive Covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>Severability of Covenants/Blue Pencilling</U>. If any court determines that any of the Restrictive Covenants, or any part thereof, is
invalid or unenforceable, the remainder of the Restrictive Covenants shall not thereby be affected and shall be given full effect, without regard to the invalid portions. If any court determines that any of the Restrictive Covenants, or any part
thereof, are unenforceable because of the duration of such provision or the area covered thereby, such court shall have the power to reduce the duration or area of such provision and, in its reduced form, such provision shall then be enforceable and
shall be enforced. Executive hereby waives any and all right to attack the validity of the Restrictive Covenants on the grounds of the breadth of their geographic scope or the length of their term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Enforceability in Jurisdictions</U>. The Company and Executive intend to and do hereby confer jurisdiction to enforce the Restrictive
Covenants upon the courts of any jurisdiction within the geographical scope of such covenants. If the courts of any one or more of such jurisdictions hold the Restrictive Covenants wholly unenforceable by reason of the breadth of such scope or
otherwise, it is the intention of the Company and Executive that such determination not bar or in any way affect the right of the Company to the relief provided above in the courts of any other jurisdiction within the geographical scope of such
covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <U>Definitions</U>. For purposes of this Section&nbsp;5, the term &#147;<U>Company</U>&#148; means not only Exagen Diagnostics, Inc., but
also any company, partnership or entity which, directly or indirectly, controls, is controlled by or is under common control with Exagen Diagnostics, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Insurance; Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Insurance</U>. The Company shall have the right to take out life, health, accident, &#147;key-man&#148; or other insurance covering
Executive, in the name of the Company and at the Company&#146;s expense in any amount deemed appropriate by the Company. Executive shall assist the Company in obtaining such insurance, including, without limitation, submitting to any required
examinations and providing information and data required by insurance companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Indemnification</U>. Executive will be provided
with indemnification against third party claims related to his or her work for the Company as required by Delaware law. The Company shall provide Executive with directors and officers liability insurance coverage at least as favorable as that which
the Company may maintain from time to time for members of the Board and other executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Arbitration</U>. Any dispute,
claim or controversy based on, arising out of or relating to Executive&#146;s employment or this Agreement shall be settled by final and binding arbitration in San Diego, California, before a single neutral arbitrator in accordance with the National
Rules for the Resolution of Employment Disputes (the &#147;<B><I>Rules</I></B>&#148;) of the American Arbitration Association, and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction. The Rules may be
found online at www.adr.org. Arbitration may be compelled pursuant to the California Arbitration Act (Code of Civil Procedure &#167;&#167; 1280 <U>et</U> <U>seq</U>.). If the parties are unable to agree upon an arbitrator, one shall be appointed by
the AAA in accordance with its Rules. Each party shall pay the fees of its own attorneys, the expenses of its witnesses and all other expenses connected with presenting its case; <U>however</U>, Executive and the Company agree that, to the extent
permitted by law, the arbitrator may, in his or her discretion, award reasonable attorneys&#146; fees to the prevailing party; <U>provided</U>, <U>further</U>, that the prevailing party shall be reimbursed for such fees, costs and expenses within
forty-five (45)&nbsp;days following any such award, but in no event later than the last day of Executive&#146;s taxable year following the taxable year in which the fees, costs and expenses were incurred; <U>provided</U>, <U>further</U>, that the
parties&#146; obligations pursuant to this sentence shall terminate on the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;anniversary of the date of Executive&#146;s termination of employment. Other costs of the arbitration,
including the cost of any record or transcripts of the arbitration, AAA&#146;s administrative fees, the fee of the arbitrator, and all other fees and costs, shall be borne by the Company. This Section&nbsp;7 is intended to be the exclusive method
for resolving any and all claims by the parties against each other for payment of damages under this Agreement or relating to Executive&#146;s employment; <U>provided</U>, <U>however</U>, that Executive shall retain the right to file administrative
charges with or seek relief through any government agency of competent jurisdiction, and to participate in any government investigation, including but not limited to (i)&nbsp;claims for workers&#146; compensation, state disability insurance or
unemployment insurance; (ii)&nbsp;claims for unpaid wages or waiting time penalties brought before the California Division of Labor Standards Enforcement; <U>provided</U>, <U>however</U>, that any appeal from an award or from denial of an award of
wages and/or waiting time penalties shall be arbitrated pursuant to the terms of this Agreement; and (iii)&nbsp;claims for administrative relief from the United States Equal Employment Opportunity Commission and/or the California Department of Fair
Employment and Housing (or any similar agency in any applicable jurisdiction other than California); <U>provided</U>, <U>further</U>, that Executive shall not be entitled to obtain any monetary relief through such agencies other than workers&#146;
compensation benefits or unemployment insurance benefits. This Agreement shall not limit either party&#146;s right to obtain any provisional remedy, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including, without limitation, injunctive or similar relief, from any court of competent jurisdiction as may be necessary to protect their rights and interests pending the outcome of arbitration,
including without limitation injunctive relief, in any court of competent jurisdiction pursuant to California Code of Civil Procedure &#167; 1281.8 or any similar statute of an applicable jurisdiction. Seeking any such relief shall not be deemed to
be a waiver of such party&#146;s right to compel arbitration. Both Executive and the Company expressly waive their right to a jury trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>General Relationship</U>. Executive shall be considered an employee of the Company within the meaning of all federal, state and local
laws and regulations including, but not limited to, laws and regulations governing unemployment insurance, workers&#146; compensation, industrial accident, labor and taxes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)
<U>Modification; Prior Claims</U>. This Agreement and the Employee Proprietary Information and Inventions Agreement set forth the entire understanding of the parties with respect to the subject matter hereof, supersedes all existing agreements
between them concerning such subject matter, including that certain offer letter dated October&nbsp;12, 2010, that certain Employment Agreement dated October&nbsp;31, 2010 and that certain amendment dated September&nbsp;9, 2011, between the Company
and Executive.<SUP STYLE="font-size:85%; vertical-align:top"></SUP> This Agreement may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will
be effective under any circumstances whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Assignment; Assumption by Successor</U>. The rights of the Company under this
Agreement may, without the consent of Executive, be assigned by the Company, in its sole and unfettered discretion, to any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or
indirectly, acquires all or substantially all of the assets or business of the Company. The Company will require any successor (whether direct or indirect, by purchase, merger or otherwise) to all or substantially all of the business or assets of
the Company expressly to assume and to agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place; <U>provided</U>, <U>however</U>, that no such
assumption shall relieve the Company of its obligations hereunder. As used in this Agreement, the &#147;<U>Company</U>&#148; shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes
and agrees to perform this Agreement by operation of law or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Survival</U>. The covenants, agreements, representations
and warranties contained in or made in Sections&nbsp;3(g), 4, 5, 6, 7 and 9 of this Agreement shall survive any Executive&#146;s termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U><FONT STYLE="white-space:nowrap">Third-Party</FONT> Beneficiaries</U>. This Agreement does not create, and shall not be construed as
creating, any rights enforceable by any person not a party to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Waiver</U>. The failure of either party hereto at any time to enforce performance by the
other party of any provision of this Agreement shall in no way affect such party&#146;s rights thereafter to enforce the same, nor shall the waiver by either party of any breach of any provision hereof be deemed to be a waiver by such party of any
other breach of the same or any other provision hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>Section Headings</U>. The headings of the several sections in this
Agreement are inserted solely for the convenience of the parties and are not a part of and are not intended to govern, limit or aid in the construction of any term or provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>Notices</U>. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice
deemed given as indicated: (i)&nbsp;by personal delivery when delivered personally; (ii)&nbsp;by overnight courier upon written verification of receipt; (iii)&nbsp;by email, telecopy or facsimile transmission upon acknowledgment of receipt of
electronic transmission; or (iv)&nbsp;by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to Executive at the address listed on the Company&#146;s personnel records and to the Company at its
principal place of business, or such other address as either party may specify in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. All Sections, clauses
and covenants contained in this Agreement are severable, and in the event any of them shall be held to be invalid by any court, this Agreement shall be interpreted as if such invalid Sections, clauses or covenants were not contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Governing Law and Venue</U>. This Agreement is to be governed by and construed in accordance with the laws of the State of California
applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Except as provided in Sections&nbsp;5 and 7, any suit brought hereon shall be brought in the state or federal
courts sitting in San Diego, California, the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to
service of process in any manner authorized by California law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) <U>Non-transferability of Interest</U>. None of the rights of
Executive to receive any form of compensation payable pursuant to this Agreement shall be assignable or transferable except through a testamentary disposition or by the laws of descent and distribution upon the death of Executive. Any attempted
assignment, transfer, conveyance, or other disposition (other than as aforesaid) of any interest in the rights of Executive to receive any form of compensation to be made by the Company pursuant to this Agreement shall be void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k) <U>Gender</U>. Where the context so requires, the use of the masculine gender shall include the feminine and/or neuter genders and the
singular shall include the plural, and vice versa, and the word &#147;person&#148; shall include any corporation, firm, partnership or other form of association. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(l) <U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(m) <U>Construction</U>. The
language in all parts of this Agreement shall in all cases be construed simply, according to its fair meaning, and not strictly for or against any of the parties hereto. Without limitation, there shall be no presumption against any party on the
ground that such party was responsible for drafting this Agreement or any part thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(n) <U>Withholding and other Deductions</U>. All
compensation payable to Executive hereunder shall be subject to such deductions as the Company is from time to time required to make pursuant to law, governmental regulation or order. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(o) <U>Code Section&nbsp;409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) This Agreement is not intended to provide for any deferral of compensation subject to Section&nbsp;409A of the Code, and, accordingly, the
severance payments payable under Sections 4(b)(ii) and 4(c)(ii) and (iv)&nbsp;shall be paid no later than the later of: (A)&nbsp;the fifteenth (15th)&nbsp;day of the third month following Executive&#146;s first taxable year in which such amounts are
no longer subject to a substantial risk of forfeiture, and (B)&nbsp;the fifteenth (15th)&nbsp;day of the third month following first taxable year of the Company in which such amounts are is no longer subject to substantial risk of forfeiture, as
determined in accordance with Code Section&nbsp;409A and any Treasury Regulations and other guidance issued thereunder. To the extent applicable, this Agreement shall be interpreted in accordance with Code Section&nbsp;409A and Department of
Treasury regulations and other interpretive guidance issued thereunder. Each series of installment payments made under this Agreement is hereby designated as a series of &#147;separate payments&#148; within the meaning of Section&nbsp;409A of the
Code. For purposes of this Agreement, all references to Executive&#146;s &#147;termination of employment&#148; shall mean Executive&#146;s Separation from Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If Executive is a &#147;specified employee&#148; (as defined in Section&nbsp;409A of the Code), as determined by the Company in
accordance with Section&nbsp;409A of the Code, on the date of Executive&#146;s Separation from Service, to the extent that the payments or benefits under this Agreement are subject to Section&nbsp;409A of the Code and the delayed payment or
distribution of all or any portion of such amounts to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section&nbsp;409A(a)(2)(B)(i) of the Code, then such portion deferred pursuant to
this Section&nbsp;9(o)(ii) shall be paid or distributed to Executive in a lump sum on the earlier of (A)&nbsp;the date that is six (6)-months following Executive&#146;s Separation from Service, (B)&nbsp;the date of Executive&#146;s death or
(C)&nbsp;the earliest date as is permitted under Section&nbsp;409A of the Code. Any remaining payments due under the Agreement shall be paid as otherwise provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) To the extent applicable, this Agreement shall be interpreted in accordance with the applicable exemptions from Section&nbsp;409A of
the Code. If Executive and the Company determine that any payments or benefits payable under this Agreement intended to comply with Sections 409A(a)(2), (3)&nbsp;and (4)&nbsp;of the Code do not comply with Section&nbsp;409A of the Code, Executive
and the Company agree to amend this Agreement, or take such other actions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as Executive and the Company deem reasonably necessary or appropriate, to comply with the requirements of Section&nbsp;409A of the Code and the Treasury Regulations thereunder (and any applicable
transition relief) while preserving the economic agreement of the parties. To the extent that any provision in this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner that no
payments payable under this Agreement shall be subject to an &#147;additional tax&#148; as defined in Section&nbsp;409A(a)(1)(B) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Any reimbursement of expenses or in-kind benefits payable under this Agreement shall be made in accordance with Treasury Regulation
Section&nbsp;1.409A-3(i)(1)(iv) and shall be paid on or before the last day of Executive&#146;s taxable year following the taxable year in which Executive incurred the expenses. The amount of expenses reimbursed or in-kind benefits payable during
any taxable year of Executive&#146;s shall not affect the amount eligible for reimbursement or in-kind benefits payable in any other taxable year of Executive&#146;s, and Executive&#146;s right to reimbursement for such amounts shall not be subject
to liquidation or exchange for any other benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature Page Follows) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>E<SMALL>XAGEN</SMALL> D<SMALL>IAGNOSTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Fortunato Ron Rocca</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Fortunato Ron Rocca</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President &amp; CEO</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>E<SMALL>XECUTIVE</SMALL></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thierry Dervieux</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>T<SMALL>HIERRY</SMALL> D<SMALL>ERVIEUX</SMALL></B></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE PAGE TO EMPLOYMENT AGREEMENT </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>GENERAL RELEASE OF CLAIMS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>The language in this Release may change based on legal developments and evolving best practices; this form is provided as an example
of what will be included in the final Release document.</I>]<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This General Release of Claims (&#147;<B><I>Release</I></B>&#148;) is
entered into as of this &nbsp;&nbsp;&nbsp;&nbsp; day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;, between Thierry Dervieux (&#147;<B><I>Executive</I></B>&#148;), and Exagen Diagnostics, Inc., a Delaware corporation
(the &#147;<B><I>Company</I></B>&#148;) (collectively referred to herein as the &#147;<B><I>Parties</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Executive
and the Company are parties to that certain Employment Agreement dated as of [&nbsp;<FONT STYLE="FONT-FAMILY:'WINGDINGS 2'">&#151;</FONT>&nbsp;] (the &#147;<B><I>Agreement</I></B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties agree that Executive is entitled to certain severance benefits under the Agreement, subject to Executive&#146;s execution
of this Release; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and Executive now wish to fully and finally to resolve all matters between them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of, and subject to, the severance benefits payable to Executive pursuant to the Agreement, the adequacy of
which is hereby acknowledged by Executive, and which Executive acknowledges that he or she would not otherwise be entitled to receive, Executive and the Company hereby agree as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>General Release of Claims by Executive</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Executive, on behalf of himself or herself and his or her executors, heirs, administrators, representatives and assigns, hereby agrees to
release and forever discharge the Company and all predecessors, successors and their respective parent corporations, affiliates, related, and/or subsidiary entities, and all of their past and present investors, directors, shareholders, officers,
general or limited partners, employees, attorneys, agents and representatives, and the employee benefit plans in which Executive is or has been a participant by virtue of his or her employment with or service to the Company (collectively, the
&#147;<B><I>Company Releasees</I></B>&#148;), from any and all claims, debts, demands, accounts, judgments, rights, causes of action, equitable relief, damages, costs, charges, complaints, obligations, promises, agreements, controversies, suits,
expenses, compensation, responsibility and liability of every kind and character whatsoever (including attorneys&#146; fees and costs), whether in law or equity, known or unknown, asserted or unasserted, suspected or unsuspected (collectively,
&#147;<U>Claims</U>&#148;), which Executive has or may have had against such entities based on any events or <B><I><U>circumstances</U></I></B> arising or occurring on or prior to the date hereof or on or prior to the date hereof, arising directly
or indirectly out of, relating to, or in any other way involving in any manner whatsoever Executive&#146;s employment by or service to the Company or the termination thereof, including any and all claims arising under federal, state, or local laws
relating to employment, including without limitation claims of wrongful discharge, breach of express or implied contract, fraud, misrepresentation, </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defamation, or liability in tort, and claims of any kind that may be brought in any court or administrative agency including, without limitation, claims under Title VII of the Civil Rights Act of
1964, as amended, 42 U.S.C. Section&nbsp;2000, <U>et</U> <U>seq</U>.; the Americans with Disabilities Act, as amended, 42&nbsp;U.S.C. &#167;&nbsp;12101 <U>et</U> <U>seq</U>.; the Rehabilitation Act of 1973, as amended, 29&nbsp;U.S.C. &#167;&nbsp;701
<U>et</U> <U>seq</U>.; the Civil Rights Act of 1866, and the Civil Rights Act of 1991; 42 U.S.C. Section&nbsp;1981, <U>et</U> <U>seq</U>.; the Age Discrimination in Employment Act, as amended, 29 U.S.C. Section&nbsp;621, <U>et</U> <U>seq</U>. (the
&#147;<B><I>ADEA</I></B>&#148;); the Equal Pay Act, as amended, 29 U.S.C. Section&nbsp;206(d); regulations of the Office of Federal Contract Compliance, 41 C.F.R. Section&nbsp;60, <U>et</U> <U>seq</U>.; the Family and Medical Leave Act, as amended,
29&nbsp;U.S.C.&nbsp;&#167;&nbsp;2601 <U>et</U>&nbsp;<U>seq</U>.; the Fair Labor Standards Act of 1938, as amended, 29&nbsp;U.S.C. &#167;&nbsp;201 <U>et</U> <U>seq</U>.; the Employee Retirement Income Security Act, as amended, 29 U.S.C.
&#167;&nbsp;1001 <U>et</U> <U>seq</U>.; and the California Fair Employment and Housing Act, California Government Code Section&nbsp;12940, <U>et</U> <U>seq</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the generality of the foregoing, Executive does not release the following claims: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state
law; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Claims for workers&#146; compensation insurance benefits under the terms of any worker&#146;s compensation
insurance policy or fund of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Claims pursuant to the terms and conditions of the federal law known as
COBRA; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Claims for indemnity under the bylaws of the Company, as provided for by California law or under any
applicable insurance policy with respect to Executive&#146;s liability as an employee, director or officer of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Claims based on any right Executive may have to enforce the Company&#146;s executory obligations under the Agreement; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) Claims Executive may have to vested or earned compensation and benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) EXECUTIVE ACKNOWLEDGES THAT HE OR SHE HAS BEEN ADVISED OF AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH
PROVIDES AS FOLLOWS: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR
HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.&#148; </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS HE OR SHE MAY HAVE THEREUNDER, AS
WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>[Note: Clauses (c), (d)&nbsp;and (e)&nbsp;apply only if Executive is
age 40 or older at time of termination] </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Executive acknowledges that this Release was presented to him or her on the date
indicated above and that Executive is entitled to have [twenty-one (21)][forty-five (45)] days&#146; time in which to consider it. Executive further acknowledges that the Company has advised him or her that he or she is waiving his or her rights
under the ADEA, and that Executive should consult with an attorney of his or her choice before signing this Release, and Executive has had sufficient time to consider the terms of this Release. Executive represents and acknowledges that if Executive
executes this Release before [twenty-one (21)][forty-five (45)] days have elapsed, Executive does so knowingly, voluntarily, and upon the advice and with the approval of Executive&#146;s legal counsel (if any), and that Executive voluntarily waives
any remaining consideration period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) Executive understands that after executing this Release, Executive has the right to revoke it
within seven (7)&nbsp;days after his or her execution of it. Executive understands that this Release will not become effective and enforceable unless the seven (7)&nbsp;day revocation period passes and Executive does not revoke the Release in
writing. Executive understands that this Release may not be revoked after the seven (7)&nbsp;day revocation period has passed. Executive also understands that any revocation of this Release must be made in writing and delivered to the Company at its
principal place of business within the seven (7)&nbsp;day period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) Executive understands that this Release shall become effective,
irrevocable, and binding upon Executive on the eighth (8<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;day after his or her execution of it, so long as Executive has not revoked it within the time period and in the manner specified in
clause (d)&nbsp;above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) Executive further understands that Executive will not be given any severance benefits under the Agreement
unless this Release is effective on or before the date that is fifty-five (55)&nbsp;days following the date of Executive&#146;s termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>No Assignment</U>. Executive represents and warrants to the Company Releasees that there has been no assignment or other transfer of any
interest in any Claim that Executive may have against the Company Releasees. Executive agrees to indemnify and hold harmless the Company Releasees from any liability, claims, demands, damages, costs, expenses and attorneys&#146; fees incurred as a
result of any such assignment or transfer from Executive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Severability</U>. In the event any provision of this Release is found to
be unenforceable by an arbitrator or court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the parties shall receive the
benefit contemplated herein to the fullest extent permitted by law. If a deemed modification is not satisfactory in the judgment of such arbitrator or court, the unenforceable provision shall be deemed deleted, and the validity and enforceability of
the remaining provisions shall not be affected thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Interpretation; Construction</U>. The headings set forth in this Release are for
convenience only and shall not be used in interpreting this Agreement. This Release has been drafted by legal counsel representing the Company, but Executive has participated in the negotiation of its terms. Furthermore, Executive acknowledges that
Executive has had an opportunity to review and revise the Release and have it reviewed by legal counsel, if desired, and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of this Release. Either party&#146;s failure to enforce any provision of this Release shall not in any way be construed as a waiver of any such provision, or prevent that party thereafter from enforcing
each and every other provision of this Release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Governing Law and Venue</U>. This Release will be governed by and construed in
accordance with the laws of the United States of America and the State of California applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Any suit brought hereon
shall be brought in the state or federal courts sitting in San Diego County, California, the Parties hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam
jurisdiction over it and consents to service of process in any manner authorized by California law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Entire Agreement</U>. This
Release and the Agreement constitute the entire agreement of the Parties in respect of the subject matter contained herein and therein and supersede all prior or simultaneous representations, discussions, negotiations and agreements, whether written
or oral. This Release may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Counterparts</U>. This Release may be executed in multiple counterparts, each of which shall be deemed to be an original but all of
which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature Page Follows) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed the foregoing
Release as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>E<SMALL>XECUTIVE</SMALL></B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><B>E<SMALL>XAGEN</SMALL> D<SMALL>IAGNOSTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Name: Thierry Dervieux</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Print&nbsp;Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>18
<FILENAME>d693329dex1032.htm
<DESCRIPTION>EX-10.32
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.32</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.32 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE RELOCATION AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
Relocation Agreement is entered into by and between Exagen Diagnostics, Inc. (&#147;Exagen&#148;) and Wendy Swedick (&#147;Employee&#148;) as of the 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> day of April 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Employee&#146;s relocation, Exagen shall provide Employee with the following assistance in relocating to the San Diego, California
area. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Reimbursement of Expenses: </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exagen will
reimburse Employee for normal expenses listed below. Evidence of expenses must be provided and must be verifiable. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">I.</TD>
<TD ALIGN="left" VALIGN="top">Home Selling Expenses up to a maximum of $30,000. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">Title Insurance </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Property Transfer Fees </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">Attorney Fees </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">Recording Fees </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top">Realty Fees/Commissions </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top">Legally required inspection fees </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top">Required repairs </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">II.</TD>
<TD ALIGN="left" VALIGN="top">Household/Vehicle Move up to a maximum of $20,000. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">Exagen will pay the cost of packing, shipping and insurance of household goods to the Employee&#146;s new location (either by reimbursing the Employee for the cost to rent a moving truck/van, or through arrangement of
professional movers by Exagen). </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Exagen will also pay the cost of the shipment of one vehicle, owned by the Employee to the new location or driving expenses to the new location at the currently established IRS mileage allowance, at the Employee&#146;s
discretion. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recognizing the Exagen&#146;s desire to relocate the Employee as soon as possible, Exagen will make the Employee whole for the
discount below fair market value, if any, necessary to sell her home in an expedited manner as follows (the Make Whole Payment): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">If the Employee has to sell her home for less than the estimated fair market value of $326,000, Exagen till pay the Employee an amount equal to $326,000 less the final closing price of the Employee&#146;s home.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Tax Adjustments to Reimbursements: </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exagen will pay a tax adjustment allowance, or gross-up, on any moving expenses or Make Whole Payment that are deemed taxable to the Employee. This allowance
will be based on an estimated incremental tax rate for the Employee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ron Rocca</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Wendy Swedick</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ron Rocca &#151; CEO, Exagen Diagnostics, Inc.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Wendy Swedick &#151; Employee</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">04/04/14</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">04/04/14</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature Date</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Signature Date</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>19
<FILENAME>d693329dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of Exagen Diagnostics, Inc. of our report
dated August&nbsp;4, 2014 (except for the effects of the restatement discussed in Note 3 to the consolidated financial statements, as to which the date is September&nbsp;19, 2014) relating to the financial statements of Exagen Diagnostics, Inc.,
which appears in such Registration Statement. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denver, Colorado </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;9, 2014 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g693329g07c28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329g07c28.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0K$4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!(````?<````&`&<`,``W
M`&,`,@`X`````0`````````````````````````!``````````````'W```!
M(``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````""<````!````<````$``
M``%0``!4````"`L`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!``'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2D&[&%KMWJV,]I;#'0-?SOZR,DDIJ_8&[FN-UI<T-:27?2V
MN%LNT_>'^8H'IL.&S)O8TF7-#]#IVT]BNH9_GV_U'?E8DI!^SFD/:Z^][7B"
M"_S:[VP/;]#\W]],>F@DG[3D#<"(%G_F.[VJXDDIK780ML%@OMK<!'L=`YGZ
M,%JBSI[6.#O6N>!N&U[RX0[\W56TDE(*<7TK38+;7R"-CG2T2=VC8_-^BU'2
M0Z?H'^L__JG)*2)@0=`>$G-:YI:X2UP@CR*YGZG=:MZP_(??CU4OQF5^FZO<
M3%N_U`YUI=_W&J3A`F,I#:%<7^$M,P)1B=Y77^"__]#U5))))2DDDDE*0S_/
MM_JN_*Q$0S_/M_J._*Q)21))))2DDDDE*59V3Z+8]*RV2\_HV[O\(&1S_P`)
MO_J,L3C(N-K6>@=I)#G[AI!AOM^G[V?I%S7U^:UW1L8.$C[:=/[&4GXX<<XQ
MNN(U:W)+@B95="WJJ;?5K%FQU<S[7B'"#&K5Q?\`BUYZA_4Q_P#W873_`%>$
M=`Z8!_W$H_\`/;%S'^+7GJ']3'_]V%+`5BSCMP?]-BF;RX3_`'O^B__1]522
M3.<&M+CP!)[\)*720Z,BJ]I=63#3M,@M((\GAJC]I;Z_H;+)XW[#LT`?_.?1
M[I*3(9_GV_U'?E8FR+C2P.%;[9,;:P">.=2U,";',,%A?63!Y$[.W[S4E)E4
MRLPT/V'TVEP'I^I8UFXR`>?=M;*S>A=?QNKYN172,AAH!+FV[`P[GEGLV/L?
M[?26)_C":UW4.F;@#H_D3_A*%+CPF608Y>D_^@\3'/*(XS,>H?V\+UO5;_LW
M3<G+@G[+4^_:T[2[TVFW9OVOV[]O[JH?57JAZI@6WFM]9KN-6U]OK$PVNS=O
MV5;?YWZ&U6OK!_R#U+_PI?\`^>WK'_Q??\D9/_AIW_GNA*,(G#*5>H2B!]5&
M1]V,>AB2YNUO_CF;H&[U.>_]!5[Z^_\`(V-_X=/_`%&4J?\`^<K_`*Y_[HJY
M]??^1L;_`,.G_J,I3_Y;E_[D&'_)9_[TW<^K_P#R!TW_`,*4?^>V+F/\6O/4
M/ZF/_P"["Z?ZO_\`('3?_"E'_GMBYC_%KSU#^IC_`/NPHX_S?,></^FOE_.8
M/\+_`*#_`/_2](SZ,BXU^FUND@S=94=2WZ/HL=O1LRN^[$OJH?Z-ME;VUVS]
M%Q:6LLT_<<B64U6%KK&!Q8982)@J7.A1M3E_5_`ZG@XME?4,S[?8^S<RPDG:
MW:QNSW[OSVN<JMO0^HO^LS.JMS-N*TM)Q-S^!7Z)]N[TOI^_^;6MZN/B%N.Q
MA:-LM#&G:!YN'M;_`&T;TJO4]78/4B-\:P//YIWN2N1T]0(.G[W9;P"@-?20
M1KV<OZR](OZOTYN+5:RAS;6V%[Y(AH=[?9M_>1^DX=F!AX>'8X6/QZ/3<]LP
M2-@D;O<KMM55S#7:T/8>6N$A2#6B(`$"!'8>"'&>$1Z`\2>$<1EU(IYWZL_5
MO*Z/F95]M]=PR`&AK`01#WV>[=/[Z?ZS?5W)ZQDXEU5]=(QPX%KP272ZM_MV
MQ_HUOUTU5%QK8&EYW.(')\TGTU6/:][`YU>K"1Q\/N3O>GQ^Y?J\O#@6^U#@
MX*]/]O$@ZGBV9G3LO#80QV1394U[M0"]KF!S@/ZRH?5CHV1T;!MQ[;67NMN=
M:'5@@`%M=>WW;O\`1+19EU6O-0:_Z189:=O#_P`[Z+F_HT:NNNI@KK:&,;PT
M"`FB9$3#]$D$_1)B.(2Z@5]KS_\`S;RO^=G[<]>OT=V[T(._^C_8_I?1^G[T
M7ZQ=%OZST^K'IM90ZK)-Q=8"00!?7M]NW_2K:%-0M-P8WU2-I?'NCPW?V4UE
M%-K-EC`]DSM(D2G>[/BC*]8`".G[J/;C4HUI,DR_PD/3,6S"Z=B8;R'NQJ:Z
MG/$@$L:VMSF@_P!58_U3^KF5T/[3ZU]>1ZXJ:/3!;'I^K.[=N^EZJVGYE-=I
MJ<'[FQJUCG#W0![F!W[R+7355N]-@9O.YT")*:,D@)1Z3KB_P?4DPB3$]8?+
M]7__V0`X0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`
M=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P
M`"``-@`N`#`````!`#A"24T$!@``````!P`(``$``0$`_^X`#D%D;V)E`&1`
M`````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#_\``$0@!(`'W`P$1``(1`0,1`?_=``0`/__$`-<``0`"`@,!`0$!````
M```````'"@@)!`4&"P,"`0$!``,!`0$!`0$```````````$'"`8)`@4$`Q``
M``8"`0`&`PP%"`8'"0````,$!08'`0(($1(3%!4)M18Y-'16=I;6%S=WM[@*
M(2*7UU@Q(R0EMA@X&D$RU39X&3/4-94F5YA185*20[-5)UD1`0```@4)!0,(
M!P4&!P`````!`Q$"!`4&(5$2LA-U-@<(,11TM#=!LU9A,J3D%346&''2<Y/3
M-!>Q(X2458&1H=$S4Y)#HR34E5?_V@`,`P$``A$#$0`_`+_`````````````
M```````-;_*/F>;17(>B(DGD\%1UF3.H1#N1C>\.K.GEJ4KD+N_0>E7F,%*%
M659:&&V.V-YTGQL65V+2_HE&-\EX,U!,(4PBR&D_*&.Q.S++J=PKNS#Y9`*T
MA=HL>J,JO^XV^TSJ6.L#:F*J35EA(U+A*4,U;BFQ<F>"64E(H<F_;<[L5J<W
M<4(EWYD5U7TIMMCE:FU%3^1RH.H1CC,[64K&&[2=:\8:QO%GAU5ORB1PY@WB
M,OB#TG5LY<B=3']=)G561G8M'@C5**.Q)&_+J!YGC7`D$6GKXN-L.+U/*W"/
MMC,[$UW/Y;!FF?M[9-&(A^Q-$+(UM#^W)W5X(:U#4UN#@20H/UR6NV1"A"O,
M/D#/*#LN$O$S>+-K+B:YP)^2RJ^*H@47L@FM+;W?4)3&HO)I?(5/7F+5*HC^
M^<)7MO0ZI"'/;<MS4)B-B#`(0IA\KMX/;-BOG+RHZXUMQ%,ZRD?!W-X+CHHV
M0<^)3J:E3V!11+-&&0)H\H>\Q9^:)`>M2DI'#5-O@\O?7I+QC4#V?[7!MVVY
M\R<S4558LNT(Q5V.)4MNE:QU95\=L:4G2V-6A%XF5X<ATJ*S)8N3JF-V/Z$9
M))FYZOL\%?K9P7L/8D#D=8=B5=P`O&WXQ.5IUGUCQ/LJU([.UD;BI2MSEL'J
M9[F+*[OT7W;G&)8W<W)K*W<4J9,4DVSN;JGT3Z9TU+$.VCY44SBXKEX_3OA4
M[/=B+K:K'E-93+0TSC4LC$&;9?$)Y+ZDGEEPJ:P)^@D=@+;X#JX5^I;WEO=R
M%YFQ"LD](<5N286?":(978MO.2OZZH5BM65,O(&2Q4W2ZW1XE,X:*F;Y&S;U
ME<3E7[S%'Q4R/\-@:V4EK]S_``%F:<JG1>P,QY^^#E1!F3Y10EM\YB09HL1%
M7:*#V1)5"WD"5QDQ(V)+""X\CMC:G,7HH;E_K!.6%\3LR6"8WSE=JAW*-7%;
M)R\;YW3['BA#T7\S2D'5F3RR:0ZTJD@CC4'(RZV2<3U'`#V1YB/%6;,T&N=$
MF00>P9E*4LC8'"1H34R=2W$$NA9NV$)RC?3&NZDT8I"F/.RI:TD#Y#[68Y?5
M4O92:C7Z,T^5UVS(')CNQ\D,5A<A3S0F?K8$@:2)A%%[.Y97.B50C<BBBL%&
MZKFTQ:*$96/S2=$CY?,'=:ON.#1RO.!$<Y8O<LA1U3K;AB1%@Z6ZB/:X^R2>
M5.D(S/8,55RWNA9Y3NVJ7DC.IO71X*V60FC^UD8S<DF-V?$T7C$)M*P<,TIK
MJO;`ED;98VXMM>RZPX!'[(:RYTF*>V=W+3-\-ES$X.ZUJ:U2%O*?T>^>@K"O
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M_6[*$QAV?H2U`N=M?6G!H]-JVK&Z9N<[5Q%;9?(/'X[$5T^A,%FT_EE<1=T?
MV,N=92.BMW>Z^D9Y2-D5NZG=#'UN^-,F]U(4RBAXIB\P./D/]LM%@P%XBNL:
MY72OB[5>=I'6S<58\BB-4H+!-1EO<LL./,2"42%2E6Z-J-6:@PJ[\W)BLFG:
MKS$PH9ONU@Q"+1QHE$ZD+)7K8\:H"B3)R\M<7U(<W!`8X%LAYSPK2)\/!:=.
M=G9/C;)G\P9G&.C3;."&-'*N^)+7Z_C!7%:KD**2<J;Y9:G03S):%V30N&I8
M)-+3FLN8D:M*YM#S)U,2@AR!CU5DJ&TIP<"5:DI2G3[I5!,(=J$;;Y9R3AO=
M<FB5K/4WN^IL<.KKY6)G%.Q5JCM>,G\:G:.;6;'TI;(CJ>#2)ADD,FB18UEG
MZ)EZ1Q;%1>ZE04M(T1PFBF'^UD@[\M(:TSZX*X]1[*6OU*.-.HY8M2-L5S&]
MVZZ4C\O8Y9H^G3`I,QPZ+H(TK/?5[UAKT1%Z:X*U4;F%Z;2BCL1G$N?<3L:1
MU7%:SI*[IT\6M5IEPH"VSZ'F]+&82ALUJJF0.$F<7RW6QMVWB\D=.T6%M9SF
M8>C+R<@U6Z8WSH*.UX>JO,?C,QXYUA<\CK&;[2^<T8S\A7BJH)M$)#+6FMG]
M8>G:'>/LRF:I'2;*'3*);HWMK;H>_.&[8HUU;RCMTZ<V*4QJY:'17;S.DDVJ
M;D8;2D6N6LEM#S]#!W6Y'5KJ+:*J9=&YS3.C_`T;.ZR:6R\S>71"RMC"5?@"
M<DI*0HQA<D<"]2,"$.REE:S<I8V\RVPX#K7MF()O7-UPZEUL5<"8!H[R+$XC
M#5-V6U(J4EL%60X5/K#%B]R.6GF)7/0I@=B=4&ZM%NGS**$5<]Y;;]1TM-;G
MK.W7^&*(\=3,=:8N@B];/+*:NEMV1N'RM]=CYA"),\J5*N,RTLE(20J2ITQJ
M3M=M#<F;8`A^A[*<WTW\:R'R-3.06%?DR)C4LMUNC[*SU@DL<FLHYAE0KD:9
MG;C:S9)<\[O9ZDEF0MJ/=W=C,X3Z$F[E;G9%%*/;"\P&#LM<<I9I7,-D<\7\
M6ZAM:R9FWJ'")1[9M=ZVAS#-$D4E<=<I,58L/52QB?\`*YM,<&5-A:A:UVY/
M7VU2ZJA1V)0K_EC&9K8L7IG>,OR6U%D.B$PF[!LY5^2=!F680R0REKDK@R%S
M]PDKE#E:^.9:<.36F=$9+LO2I3#NTPJRF$8,L@0``````````````````#__
MT+_````````````````````,69EQ/B%A4GR$HV;3FQ)&R<DS9N9.98M^CLF;
MM.LT9D,<)TBBU!7B2/I#85'VE"C85"YM<%B`IO2YV.-,)TWP33EA%W:[C1"W
MV7<?["EL@F4RL#CPV29FC\T?E[*0\31LEK8S)WI)8R6-L$?8)`2;((LROQ99
M*)(20^LJ-87IJ83@"GM1[*>%,,E^E](WNQ+"=H_R3L)=/K5AD@:*=DT*=\+Z
M>@%'8BY$>?:H6D:L;-#*P8U#:<HW4N:9W;]5!BH\D]8E5"GL?K7'#1@J.R5$
MRKRX[LCT)>D\'5S6E,OL0=J^G4RKJ"12N(S/WUY>X2XVD@DA\7A#5J\8:I$W
M))"I0%&N1*G&RG10*4PSJJ'V5R-9)&"VYU`]G2(IX6[L3.WP5^C+@WD+GE9H
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M8*F57SF;SZR+9>*3;W!/4:6>FP%*QP)Y=HZ9$'.9MK)7T`@C>[S-3%E![>4N
M=='#9`E5J=4>J?O*C)@I[6/[]Y:E=/\`"MH,?>G(E$V*Z_O>MGI:A<:5RYO<
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M1PP4:2<BT3I"4PI1ZD\NBH6:./<6BL_N*)-$DXC(>&#T2T.\`695U6T+[&<6
M%V)UDE</Y+7+X^=:[YHC[GHG9"B%19/ANQ25)H2*?D]J18EQ$:();J^TXC<-
MPLJ"6(H$;:5:$+8#F#VK,*NB3%`X//9(;F`8ES"_IHC&V]$Y$QYT9FYZ*;$)
M:M.82082H%/R)$F]!L<ZO"E[W7S";M4@HUKL1IC,89C(?K#GHBST+*W28V4%
M.L.=90H4821]+JFRA=4&A6=,YSKMG;.<D/.2SBE6D[LZXK*FBR3R4B]>.S+Q
M>L.O'!4Q%P%QJQF=+,=>ZIBD$>1S!,\.AEN/92L_+QN7N0?IKH47DO78$T]B
M*G[@'7,QC"=KG%BVM+)G'XK4T2KRWE[A#$MDUNGHZPFNU*V?HXM;84DCKA*D
M<_C[8Z.:IU;7!.\J&\G12GV3=9/L*7XLO`QB8I(X3U%?%V:V0X\C#>3)LU["
MG<*$\U=J,;..<N94T?\`HES%=XK*ZO:2"C2%*)2H1N!!2M(>3M@S0T4_(ZFN
MO+NA=1'58HK.\+YAZB`5P13<L.;7.MSC+@J5!,Y383'"9SNX5JLW:]HU+)HZ
M[-SRP99Y"E0NJTC5?DP_"@H4_(]B_<&:_?4]X,QL]L+:#<AIY(Y_958/#=4T
MNKMP<YG#&>%RY*G99?5SXX;IG/2/H'9-NL6K#FQX1Z;)=RT)JQO5"ED>GJ&N
M\U_#JR?HPU3B)09GCS.PHK"1))P=C6,LNL?:W1<IDA#ANO?L-G7T-6F=*@W)
MQF=MOYS;I(=/;5&P:XHS%XX_%.#$?`)?&;!K631(U"U2.MYS#L*"8[)XB:K;
MW)H3J43<N5(#4JI&K;ES8L4HE28](H.)W)I8I,7$J66.IY`-_+]8TVP_6U4]
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M9$$CCW!5\MK`RNMU,^KJ2N+$\O<+FC/8%>3N,J$N[S'2%:)<B0HG-J/,491*
M",*#<;"EX.Q.!E2VP[3-UL"13Q_-F--7;0F5>5,3;Y&T5=?;64SRZ(Z35MB*
M6825CCJ,K.\=3/JUV+:U1YQ^_>-\)<I12]%_<]B2^6TW,)=8-A3YTHIY:9'`
M%<I2UF2\M+VUP=5`E644FB=<Q:1-,?EC6LRI?&="I3-3BN))SV!2?O*94*>U
MET"```````````````````?_T;_`````````````````````````````````
M```````````````````````````````````````````````````/_]*_P```
M````````````````````````````````````````````````````````````
M````````````````````#__3O\````````````````````````````````AJ
M]G18T0EC5H';P4\VY>.;7NLZ)_GMD;YR#K!E<6G_`/6J97(OZ^;W`U#_`$G7
M#!_2?Z]W+9/$#-1!,H````````````````````````````````"&JF=%CD]W
M>4K=O$]&FY5S6A)Z)_CP='I7U=+=6G_QNF3MV>HH7&'_`/AS)K!_/_J;]^[]
MKJ$R@````````,%>+_,)FY$2@[90I5Q1!.T-B26@H>X0^0MN\ZJJKYXFKV1V
M3M.75'JQ25X6NRQM<<-+9N1LRL[^BPIPL.W,.3DQA0_UTN>Y].6:VI7`E56$
M0=(M(BZ/*F=9M#_"+^DS'"=7UR6M]QPZVW9TA;G''1<>:HBSQ&6IU7LS$H7(
M33RLJ,IADH1:NN[D;3[_`"EMM6TH!/(.WW#0M,OUKLM,*:O:ZB<IU'GZ;SU_
MD:%?9T^0KV/#"^0AM;G14I2(&QUD>YJLM44DW)-&3,RDXE78XW[3GKR[>$JE
MS19]YU6;(XYIU(K.M*3NJ?5"FL6*8PN="](_/4L)T=22M%2HM+LJV(T//T*U
M.,$84,EP0__4O\````````````````````````````````@'DIV?T=QSM?\`
M5^G[BAT?[\?])_>DISL?J]_K[_I>K[H_J/\`_-?U/W\$P3\"````````````
M````````````````````$`TAV?K%R+ZG\OT_.7:_[\?])]%M4_#'^@?ZG5_[
M`_J/_P"#^F=]!.9/P(````````8?JN(<:CL55MU2RN60.3,,3MB*TR^$+(^?
MI21%S3!FF\Q,A)3C$7C4Y-X['T7=B'31R[HWINX)-TB<TP$TIK154GQ,2IC)
M)E+YT8SO[E)H,Q2LN&98ZW=W9A7Q=<JB&8]#H^][G;Q]Y<$99KJM<SR$SDJ*
M*,T+.VT!#D-57M[!&9-&V"22MF-ELNFTS=Y,C4LIDHV<YU(W20+R$[@N8E:8
MI(SDN.C:V;9(V4HVQ$E*U-SN3@S(>A@L%B59P^/0&!L2*-1"*-A#0PLJ#M<D
M(D1&,YZ=SU)IZQ<M4G;['*52@PU2K4&;G'&&&[[[[!ZP!__5O\``````````
M``````````````````````@?D::037T>W4IB51>;XXLE:E'[6!KIJ>?R<J$A
M*IUS69Z:1]LC5&:'%X4[9C^3--</VN['XCIL3!/`(```````````````````
M`````````````0/2II!D@Y"8(3$I]B;X<2E&Q6U@;;*C\5C5N^5)_KR>>W:G
M9*WTTZ(W@N/]73'4U[]W_;8G,G@$````````*]/GS7==50Z\3D=0V]9=3ERM
M?=N\E,K>9OD-4ON&!!66S,6Z*6-6D.6$MV[NIV*TWSG77)VV<8_2+;Y+X3N3
M&6,)MT7_`&:M-L,+',F:-6O6J1TJM:7"$::D81[*T<E-"L>;.)KWPIA67>ER
M3ZLNV1M<NI3&I5KPT:U69&,**T(P[:L,M%*OC_?$YE?QA<I/VZ6%_ML:M_H!
MRP_T6=_F)_Z[-7];N8G^K2OW$G]1F%Y>G*OE3*.=O%6(2_DW?TTB,LL=\9Y+
M%9A:\PDD<?&XNK;#=BDKDSNKHI1*BR7)K3G:=;3/5,*USC].!4G.CE9@O!N#
MY5[W!=TR5;HVR7+TJTV97AHUJLR,845ZT8=M6&6BE9_*3F1BS%F*9MUWW;JD
MRQPLDR91"5+J1TJM:7"$::M6$>RM')30NQ#*32@`_]:_P```````````````
M````````````````"#N0I>3($P:X;_$^B\>,1G=NI8AG9X*Y*5,;EPZM7G$2
M7'A.-.]]93MF.Z]CTO\`KNQ8<M=B8)Q!````````````````````````````
M````"#J;+SH_7]G+?W'M+Q<#,&=2Q-/$L?1K66GB'3/#C6TSK=3LNM&L:1W^
M9Z-->_X7YR$X@````````*S?YBCW3PN]^<A/1]0"_NF[U"G;NG:\E2?/W@65
MX^5J35;<;R8N9I>6U[0[AI]K3]]SEI"@.I'T]D[QDZDY=W('CF?N^;KRE]H8
M.;/`'__7O\````````````````````````````````@?D:4I.KZ/:)$A*TW6
M^.+)NQ)Z2QUFFB9/R<J$]8KU)JM>W2;0Y`C+,/+-5&;1L@PO4V0E'L&CF283
M!/`(````````````````````````````````0/2I2DJ0<A=E"0E+J=?#B:EW
M)26.FV6)LUC5I>%9^\_7K6Q8=L<7N7VL8U3QO.I>-="L+]7#?<E/`(``````
M``5F_P`Q1[IX7>_.0GH^H!?W3=ZA3MW3M>2I/G[P+*\?*U)JMN-Y,7,TO+:]
MH=PT^UI^^YRTA0'4CZ>R=XR=2<N[D#QS/W?-UY2^T,'-G@#_T+_`````````
M```````````````````````('Y&E*3J^CVB1(2M-UOCBR;L2>DL=9IHF3\G*
MA/6*]2:K7MTFT.0(RS#RS51FT;(,+U-D)1[!HYDF$P3P"```````````````
M`````````````````$#TJ4I*D'(790D)2ZG7PXFI=R4ECIMEB;-8U:7A6?O/
MUZUL6';'%[E]K&-4\;SJ7C70K"_5PWW)3P"````````%9O\`,4>Z>%WOSD)Z
M/J`7]TW>H4[=T[7DJ3Y^\"RO'RM2:K;C>3%S-+RVO:'<-/M:?ON<M(4!U(^G
MLG>,G4G+NY`\<S]WS=>4OM#!S9X`_]&_P```````````````````````````
M````"!^1K>0YU]'DRE"2X%EWQQ9<-2#VBP'O0L]IY.5"ZI5VJ.LW5FD9)S8J
M1Z*2U:D[>/MYA6JI^(5,9+BF.)@G@$``````````````````````````````
M``('I5O(0R#D*80A)1[.-\.+@H,):+`:]EY^U8U:ERN/.G+LYMSR=L4DU+[W
M&]$<?VU*P5H1A<4O--)3P"````````%9O\Q1[IX7>_.0GH^H!?W3=ZA3MW3M
M>2I/G[P+*\?*U)JMN-Y,7,TO+:]H=PT^UI^^YRTA0'4CZ>R=XR=2<N[D#QS/
MW?-UY2^T,'-G@#__TK_````````````````````````````````('Y&MY#G7
MT>3*4)+@67?'%EPU(/:+`>]"SVGDY4+JE7:HZS=6:1DG-BI'HI+5J3MX^WF%
M:JGXA4QDN*8XF">`0````````````````````````````````@>E6\A#(.0I
MA"$E'LXWPXN"@PEHL!KV7G[5C5J7*X\Z<NSFW/)VQ234OO<;T1Q_;4K!6A&%
MQ2\TTE)4]G45K&%RBPIP[%,<1AK(OD$@=#25*K*5N;B-SSN[HD1*E>Y+C^K@
MM.E3%&JE1^^A))>YN^FF2'(99A'7Z'-,_1.1),3>8R@F"1X<<^%IRHZXM93T
M0Y+\K^PRW$Z-IV#3>VZG8ZXSU^CHR`@$OF30:F!L=E(),[.,0>X/*[2W<$D3
MDO>6&KH,^)X[+K"E+2H;$[K'HXQ.:K7!F%).BTXHL\TA.:6D6;$$T12J[W)7
M+)8M>U2MD9.T[M%ID;]#&9$F6.&K@R15`4XNSJJ<$1![:U(MTQW]$V5&D]_V
MT-PFP;V!W9D)/```!6;_`#%'NGA=[\Y">CZ@%_=-WJ%.W=.UY*D^?O`LKQ\K
M4FJVXWDQ<S2\MKVAW#3[6G[[G+2%`=2/I[)WC)U)R[N0/',_=\W7E+[0P<V>
M`/_3O\````````````````````````````````@?D;I@ROH]KEG)?.B^.+._
M<CV&82/0C)7)RH3</&K?!WAC>DYT>SIX@6O/.W9VHQ-JM=DZMJ3K4IQ,$\`@
M```````````````````````````````!`]*Z8TD'(3.&<EJ[2^''?)Y+#,&7
M9[SFL:MU\8/42IX=44A.WZO=^_LNB)GVU3X)U3X5$*S32<R.>9-(VY>%<*&*
MJ+%C</6M\>GVYD:E5>:3IJFKZ\1-6RQ?3O&TZ@Q<>7,ARQ3E*H4;+T9*I46L
MV3]X1)32A#(C-D@=[2&GJZXOJ)(W0B;5G5]'O4TM)?7C#.ZQFI[8F=6YUJM=
M`FRUVB1MQK:X1]N4GF&K\(7A*7N7_2$ARI-L/;2QMC_`Z[U7%J,UV_2];&N0
MC_6-S\=Y38422PIO@3#25SSX]\D:>8Q)]<;#VE[S'FOMG*/[L_=%FSJJPA/6
M(4)ZT_$)IA3\B84_$2_(ERJH.Q8]:<0D%/05VL4MS:EU8%HIE%H,HKQMA4%A
M!LN.M`XR2$HVEN*1)U"5F2Z)S\'KSTYJE:I--%,*(MG8E\@``K-_F*/=/"[W
MYR$]'U`+^Z;O4*=NZ=KR5)\_>!97CY6I-5MQO)BYFEY;7M#N&GVM/WW.6D*`
MZD?3V3O&3J3EW<@>.9^[YNO*7VA@YL\`?__4O\``````````````````````
M``````````@?D;I@ROH]KEG)?.B^.+._<CV&82/0C)7)RH3</&K?!WAC>DYT
M>SIX@6O/.W9VHQ-JM=DZMJ3K4IQ,$\`@````````````````````````````
M```!`]*Z8TD'(3.&<EJ[2^''?)Y+#,&79[SFL:MU\8/42IX=44A.WZO=^_LN
MB)GVU3X)U3X5$*S32<R>`0T1<MO.STXO<E[>XZ)>,*ZPMZD<H8UK)C],*&)E
M/*F7U;`[0URG8C*[D!B0IO23LI)G.RHS)IA&V^,:XVQKBS\%<I<4X]NJT7Q<
M<RR0LDJT5I,=K,K5*VG5J2Z\:(0EUH4:,RKEI[:<F17F+N9V&\%7C(NN^*EI
MC:9DB$V&SJ5:U71K5Z]2%,8UZN6F76R4=E&5CQ_F*%/\%RS_`-0C?^Z`=?\`
MENYA?]Z[OWU?^"Y;^ON!?^U;_P!U4_BMD'ER^925Y@#O=[)FEE=0+*7;:I=#
MLGV`FG9,B36FJM!(EP3NGB45V;#6@VL3NOC;4_!V%6G1G7J9ZU88UP3?.`KU
ML]SWY6D1M<RSU9T-E6C7JZ%:O,J0IC&K5C3I2ZV2CLHRY5B82Q==.-+MG7K<
M]6="RRY]:5':585:VE5J5*\:(0K5LE$RKEI[:<C:(.0=0``"LW^8H]T\+O?G
M(3T?4`O[IN]0IV[IVO)4GS]X%E>/E:DU6W&\F+F:7EM>T.X:?:T_?<Y:0H#J
M1]/9.\9.I.7=R!XYG[OFZ\I?:&#FSP!__]6_P```````````````````````
M````````"#N0J-0N@3`0F8/64S2\>,2S9N]7)G*>[)V[DI4S@K?_``R!NS*^
M)?5-*EW=?$3SMV5G[GW]X(5-*9:E.)@G$$``````````````````````````
M``````(.IM&H2/U^[GL'@>JZ\7!8F4^KDS8/6-/M6M9)\/\`WF6NSHAD_:&I
M]TOB+'HC9=^Z=AJ1A6G6&FDYDX@A1*\U;VF',_XZ4O\`A)X[#<W3+P'>^]YO
ME[*QUU"\9W5NN7YBTL"!HI0ZQ%^73^L3G/\`$OB'Z<Y:##/4UQ[=.Z)7F+4V
M/T]\%7GO2;[BS+10SJO8``%9O\Q1[IX7>_.0GH^H!?W3=ZA3MW3M>2I/G[P+
M*\?*U)JMN-Y,7,TO+:]H=PT^UI^^YRTA0'4CZ>R=XR=2<N[D#QS/W?-UY2^T
M,'-G@#__UK_````````````````````````````````('Y&MRMTKZ/)D30<]
MG%7QQ9<=T9$:E<KW)2,_)RH7=>[[-<,7MSNE)8$"$Q>8Y'&;-+,6FV<'0H]L
M2JR3"8)X!``````````````````````````\@Y6%`6:6Q^`/$XB#5.Y8F7+8
MK"G*2LJ&6R5&V%''N2N/QM4M*>7E,WD)S-SS$Q)FA6A>V=LXQKGH!*+"@,(5
MQM!-)Q$(@NF;R3'(>BE$E96!7*Y"IV+T3L4;3.RU(<^O*C<[3&B5+J:?OG;&
M,:YZ<`.?ZV1;UB]4/66/^MO<O$O5?QEN]8O#OY>_^"=Y\2[ET?\`U>RZG_O`
M<AGD+!(BUYL??&=]*:W1<QN9C.YHG,MN>VS?4MR9U^Z(\_5&Z-YFV-3TYF=3
MBMLXQMKC(#N`$#TJW*T$@Y"&JF@YKT<[X<7%&<=&I7']7E)O6-6I,.Y"J3+U
MJ.4D[GHS"/$F?5.U;[)\I]2L*4ZK?<G,G@$*)7FK>TPYG_'2E_PD\=AN;IEX
M#O?>\WR]E8ZZA>,[JW7+\Q:6!`T4H=8B_+I_6)SG^)?$/TYRT&&>IKCVZ=T2
MO,6IL?I[X*O/>DWW%F6BAG5>P``*S?YBCW3PN]^<A/1]0"_NF[U"G;NG:\E2
M?/W@65X^5J35;<;R8N9I>6U[0[AI]K3]]SEI"@.I'T]D[QDZDY=W('CF?N^;
MKRE]H8.;/`'_U[_````````````````````````````````('Y&MRMTKZ/)D
M30<]G%7QQ9<=T9$:E<KW)2,_)RH7=>[[-<,7MSNE)8$"$Q>8Y'&;-+,6FV<'
M0H]L2JR3"8)X!``````````````````````````P/Y.M+A,;(HQNK=/''>95
MIR'I.S9U!'VMI,8;+(@N<E,#=YBWV8E5LK0R+:E@4D>)"F,SEQ+5+FA.U':Z
M=\U*-)A[7D.7\F9KUI";Q.DCF5^MGO*HYBA\VIVP5:>SWRB+&;WW>EG!X.)A
MRJ'(Y9.6!(ER[[*=M$+8M\:3:&(^HK`ADCE1:5`K3Q>2QGPRR$Z:X\S]->IT
MGVW7]P3\>S>)6\02RY.Z8:$:;>,9C))E?93[FGXU>-C4^IF<8UQK"?\`DRFX
M;H\H"N39'<36\E3RXN1T;23$1J$I6S.'J[X<ZMQ9A1.BIH7]@9W=23C8@[J;
M=3;;JYZ)1'V,RP0@>E6Y6@D'(0U4T'->CG?#BXHSCHU*X_J\I-ZQJU)AW(52
M9>M1RDG<]&81XDSZIVK?9/E/J5A2G5;[DYD\`A1*\U;VF',_XZ4O^$GCL-S=
M,O`=[[WF^7LK'74+QG=6ZY?F+2P(&BE#K$7Y=/ZQ.<_Q+XA^G.6@PSU-<>W3
MNB5YBU-C]/?!5Y[TF^XLRT4,ZKV``!6;_,4>Z>%WOSD)Z/J`7]TW>H4[=T[7
MDJ3Y^\"RO'RM2:K;C>3%S-+RVO:'<-/M:?ON<M(4!U(^GLG>,G4G+NY`\<S]
MWS=>4OM#!S9X`__0O\````````````````````````````````@?D:QE2&OH
M\@.9CG[1/?'%E\PA(ATDG6Y!L9Y.5#)"'G9DBCLS.B$F.'M.K@8\&G;ML=+2
M[.KB0J;T2E,<3!/`(``````````````````````````!K8:/-8\LQL0ZD,7*
M6I43>H.5.6NC8F?24RE2ZJ37%<XYRFCVNBA2YK%6Z@X_/6W/-,V,WVVVVSG/
MZDNY+ZFRZDV5=%JK2JT(1A&$J9&$81A3",(PJT1A&&6$89(P?GS+WNF57KRI
MMZ6:K,JQC",(S:D(PC#)&$81K4PC".2,(]CL_P#FT^7)_%E6O_RR7_8`^OL"
M_?\`1+7^YF?JOC[:N;_5[+^]E_K,S*CM^M+YKYAM:GY@TSZNY/N\E,$K8]C]
MFQS,CS^Z19[+(RJ(3*,;MDA9%:0W&VFN=3B-L?Z.D?F3)<R5,KRIM2-6;5C&
M$81A&$81A&B,(PCEA&$<D81RPB_1J5ZDRI4F2Z\*TNM"$81A&F$81A3",(PR
M1A&&6$8=J2!\/I`]*L93-(.0IY3,<TY?[X<7PX\Z'22*:OAIE8U:VY>2%L@=
M7-+-B=]&S5/XPUZ(VW?9-E)J1A0D4&FDIX!"B5YJWM,.9_QTI?\`"3QV&YNF
M7@.]][S?+V5CKJ%XSNK=<OS%I8$#12AUB+\NG]8G.?XE\0_3G+089ZFN/;IW
M1*\Q:FQ^GO@J\]Z3?<69:*&=5[```K-_F*/=/"[WYR$]'U`+^Z;O4*=NZ=KR
M5)\_>!97CY6I-5MQO)BYFEY;7M#N&GVM/WW.6D*`ZD?3V3O&3J3EW<@>.9^[
MYNO*7VA@YL\`?__1O\````````````````````````````````@?D:QE2&OH
M\@.9CG[1/?'%E\PA(ATDG6Y!L9Y.5#)"'G9DBCLS.B$F.'M.K@8\&G;ML=+2
M[.KB0J;T2E,<3!/`(`````````````````&*]>6Q=*WD!)*ALN#05"PF58BM
M>-OT$D3T\N41)5S-?%4<)LU,YM21!XW(4R8Q6TKV\W"5;LTNQ."<:H]#SR?8
MCA?SNK-%/[L:%;JV,T)H4FQ&AU<G),ZFO]K3^IZY^E*U8C5I>"T,?..K")_K
M+"MU:QW<%*9QP6WID3;EQ5BCL=&IYB3UEKB\'9]@49ULBM>&T,YCL#"6XR%!
M%5K--8_:"I373J\J6M6Z&OD#D-5J2%:[5*CU=$KBC,T2(M^\%D"C_<SOC#L8
M_P`:CSZ<3HG->F-I=C2"]MMBR#'%`G6;DE[;?K;:%['9UQG/Z<XP"'>````^
M8_6_U=P+XEQ;T&A'J#R_X"P3NBQ^7EO.O''&N,-Z6OW\Q[0=>Y9=-\D/V9]#
M_'3E%^+:]1Y>X_X\QMO>V>8F/1;!/!F$-UV3R\MM?'(NG0/2K&4S2#D*>4S'
M-.7^^'%\./.ATDBFKX:96-6MN7DA;('5S2S8G?1LU3^,->B-MWV392:D84)%
M!II*>`0HE>:M[3#F?\=*7_"3QV&YNF7@.]][S?+V5CKJ%XSNK=<OS%I8$#12
MAUB+\NG]8G.?XE\0_3G+089ZFN/;IW1*\Q:FQ^GO@J\]Z3?<69:*&=5[```K
M-_F*/=/"[WYR$]'U`+^Z;O4*=NZ=KR5)\_>!97CY6I-5MQO)BYFEY;7M#N&G
MVM/WW.6D*`ZD?3V3O&3J3EW<@>.9^[YNO*7VA@YL\`?_TK_`````````````
M```````````````````('Y&H,N5?1Y/K&SI5DN^.+*_PPB#NEA;I<-7)RH73
M:2;,+0\,:M`3#M4>7<Q\W.W2Q@M#L\*4ZM,@-2G$P3P"````````````````
M`!A2@HKDI$$]PR%FY,Z2F9SMID!\42KZ>@+(T,<U7KF[,4<W=QV4.SVYQF%-
M"/+8F19/SJ4WG&G;%+%F-<[DTPS/Z>.#M8259(&R3*#'FN)'<T_OY9`3&XDC
M3%CVE4<HJ">:^/EJ=E9D2>FZ;O#MA'L3WTIW7[Y[]LAT+0ZBE^17"UD]0+;C
M+A.5[O,;6XQ0_B,HL1?'F_5>TU%`&.Q6B,YPRH5B)"LEAJZUWQS<UA1B1*N7
M*",:I2$R4A/J*67<69SH[&8\P*%A3@<QLC6T&+B4FZ`I9LVHB$?>=$6ZM?NE
MU.P3UNSR<;U>GHZV?Y00[X```'S'ZW^KN!?$N+>@T(]0>7_`6"=T6/R\MYUX
MXXUQAO2U^_F/:#KW++IODA^S/H?XZ<HOQ;7J/+W'_'F-M[VSS$QZ+8)X,PAN
MNR>7EMKXY%TZ!Z5;]D,@Y"F9C9S!XC?#BX:JCH.Z0[63Z[5C5J7UD(7N3PZE
M3XDW*3N?CB31$E,V1Y1X3X,1&FFDIX!"B5YJWM,.9_QTI?\`"3QV&YNF7@.]
M][S?+V5CKJ%XSNK=<OS%I8$#12AUB+\NG]8G.?XE\0_3G+089ZFN/;IW1*\Q
M:FQ^GO@J\]Z3?<69:*&=5[```K-_F*/=/"[WYR$]'U`+^Z;O4*=NZ=KR5)\_
M>!97CY6I-5MQO)BYFEY;7M#N&GVM/WW.6D*`ZD?3V3O&3J3EW<@>.9^[YNO*
M7VA@YL\`?__3O\````````````````````````````````@?D:@RY5]'D^L;
M.E62[XXLK_#"(.Z6%NEPU<G*A=-I)LPM#PQJT!,.U1Y=S'S<[=+&"T.SPI3J
MTR`U*<3!/`(````````0UR"?Z4B].S=^Y%/438:6;&](KGRR=.*5NB"EH(=$
M)A;-(L+CB4+LTR!=J4A/:S\&D.Y:C*(TDXM1L3N3"FG)VL8N"<KXWQJJF2%U
M)<%,.[18EGW3):TKVM+)A<HB$6)4O.+#?:BJ;U7?G:/.Z*J(]*T>[PECQJAL
M;UJA3N3J2FSH7H(TTL=*YF?$**<'9FIY$+:16TTW<V>>\?C\-LF2P)EJN421
M7SBY1:0"#+4TP7HZ]/1&-#B0M0E.>/#6P@DAUSV):,M23"<M.3,A"<T_,R>/
M<$1\=K,JGD<3/.,]1<?..$B;9BZR)_KB[*UN&8.N;RH5T*9I<A?JRCVTB;E+
MJO-=VK+8RUPUF=]5?J8T'MRP;_!+Y``!K@\USD#;/&3AI+K7I.2IXC8*&>5)
M'6Y^4L+')2T3?+[&CL<>NJT2-`Y-!YIK6XFZ:;&$[]GMG&VO1G&,CHL(W-(Q
M#B>X;CM,VO4L]KM4N56K5:-*$*]:$(QJTPC"F'LIA&#\/$UZSKCP[?=\6>75
MKS[+9IDRK5K4Z,8U*L8PA&B,(T1]M$815C_^;WYDW\22/]BU)?,,:X_+%A+X
M@O'_`'R?X3+_`.8C$_\`H=@_];^(_G/G"^9&BW3*3.1+>L*+6H,')#J9I@LI
M228M3E'$&&)X.4>7J:7OG'6TVUVQT].,XR.=Q=T]89P]A>_K\LM]V^O:+)99
MDVK5K;+1C&I5C&$*U$N$:(T9:(PB_>POSRQ!?N(KEN:T7/8JDBTVF7+K5JNU
MTH0KUH0C&%,R,*8>RF$8+R(R.T\````^8_6_U=P+XEQ;T&A'J#R_X"P3NBQ^
M7EO.O''&N,-Z6OW\Q[0=>Y9=-\D/V9]#_'3E%^+:]1Y>X_X\QMO>V>8F/1;!
M/!F$-UV3R\MM?'(NG0/2K?LAD'(4S,;.8/$;X<7#54=!W2':R?7:L:M2^LA"
M]R>'4J?$FY2=S\<2:(DIFR/*/"?!B(TTTE/`(42O-6]IAS/^.E+_`(2>.PW-
MTR\!WOO>;Y>RL==0O&=U;KE^8M+`@:*4.L1?ET_K$YS_`!+XA^G.6@PSU-<>
MW3NB5YBU-C]/?!5Y[TF^XLRT4,ZKV``!6;_,4>Z>%WOSD)Z/J`7]TW>H4[=T
M[7DJ3Y^\"RO'RM2:K;C>3%S-+RVO:'<-/M:?ON<M(4!U(^GLG>,G4G+NY`\<
MS]WS=>4OM#!S9X`__]2_P```````````````````````````````"!^1K&HD
M-?1Y`E9CGXQ/?'%E\V0D0[><[D)XQR<J&2*WG9E+=F;9$3'$C3NX&/';;ZQT
MM+LZ[$*L(LICB8)X!``````````\3)3X$D>8XZRQV8FYW8=W%=&\O+\2VX3'
MN*$UG7."9`I7)TJE3EN4FIM3]B]S"2CS=--M<&F8V#^_I&KWX>0SY4,G_7@3
M1',YK7+(:\KLIV62QEU<C2<=8AK>6I<N,3ILF;XZ2DBDU1N2GR?MG^3.NF=\
MY_1TY!#TP```-/7GJ^SQFOVM<??OCB`[GEEZA8,WC(UX./Y@\#8MW?.U(J;`
M]-WGDX+C[FU]^-WI!*.%YF^GN,]W3]2+LN7G'6$_'R=>#Z70\R7H6````^8_
M6_U=P+XEQ;T&A'J#R_X"P3NBQ^7EO.O''&N,-Z6OW\Q[0=>Y9=-\D/V9]#_'
M3E%^+:]1Y>X_X\QMO>V>8F/1;!/!F$-UV3R\MM?'(NG0/2K&H9I!R$4'LQS3
MJ_WPXOB8\V';Q35\3F5C5K;AY(6[NSGB;$F&MFZ?QC71'J9LGRD[#&4F332<
MR>`0HE>:M[3#F?\`'2E_PD\=AN;IEX#O?>\WR]E8ZZA>,[JW7+\Q:6!`T4H=
M8B_+I_6)SG^)?$/TYRT&&>IKCVZ=T2O,6IL?I[X*O/>DWW%F6BAG5>P``*S?
MYBCW3PN]^<A/1]0"_NF[U"G;NG:\E2?/W@65X^5J35;<;R8N9I>6U[0[AI]K
M3]]SEI"@.I'T]D[QDZDY=W('CF?N^;KRE]H8.;/`'__5O\``````````````
M``````````````````@?D:QJ)#7T>0)68Y^,3WQQ9?-D)$.WG.Y">,<G*ADB
MMYV92W9FV1$QQ(T[N!CQVV^L=+2[.NQ"K"+*8XF">`0`````````*C7YAIG:
M7CE%QX+=FMN="R:#E&Y);BB3+="M]K#+UVW+U4E&ZZ;;:_HSG'1G.!I'INNJ
MZ[UOS$DN]+ML]IEU+)+C5A-EU)D(1C,HIA"O",(1H]L%!\_;SO&[+FN"9=UX
M3[/7K6FO",9<RM4C&&AV1C5C"F'R1:$?4F&?!&,?]P-7_5!KS\'X2^%[N_RT
MG]1EW\5XH^)+?_F)WZ[:GY*#`Q,_F/58:TLK2UF'5E=.AQC<W(T6YNFL<;]M
M=#-TQ)6V^F-OTXQGIQTC-O4E<ES75<F&IEUW19;-,KVJ9"M&5*J2XQA"7",(
M1C4JPIA\D5_<@KXO:\[VQ#4O&]+3:*E6S5(PA,FUYD(1T^V$*U:-$?T+P`R(
MU```#3UYZOL\9K]K7'W[XX@.YY9>H6#-XR->#C^8/`V+=WSM2*FP/3=YY."X
M^YM??C=Z02CA>9OI[C/=T_4B[+EYQUA/Q\G7@^ET/,EZ%@```/F/UO\`5W`O
MB7%O0:$>H/+_`("P3NBQ^7EO.O''&N,-Z6OW\Q[0=>Y9=-\D/V9]#_'3E%^+
M:]1Y>X_X\QMO>V>8F/1;!/!F$-UV3R\MM?'(NG0/2K&H9I!R$4'LQS3J_P!\
M.+XF/-AV\4U?$YE8U:VX>2%N[LYXFQ)AK9NG\8UT1ZF;)\I.PQE)DTTG,G@$
M*)7FK>TPYG_'2E_PD\=AN;IEX#O?>\WR]E8ZZA>,[JW7+\Q:6!`T4H=8B_+I
M_6)SG^)?$/TYRT&&>IKCVZ=T2O,6IL?I[X*O/>DWW%F6BAG5>P``*S?YBCW3
MPN]^<A/1]0"_NF[U"G;NG:\E2?/W@65X^5J35;<;R8N9I>6U[0[AI]K3]]SE
MI"@.I'T]D[QDZDY=W('CF?N^;KRE]H8.;/`'_]:_P```````````````````
M````````````"`>2C9XM7<<2^&^*]E?W%!S[KZI^NG9>"\I*<>?$O!_%V3N?
M@W<.^>+=MOX#V'B?=U?<^ZG$P3\"&,O+&P)I6-<0B509X)9W)7R:X=U^\]X:
MT#J4ZPNY.5M-TU.&?J+RS=4)RV*3]7DE45C!Z<[338O.N<=."8)(N)'(U<'<
MMX_:GT+$-NBIYDUC$,<9?7*/1EG:G)Q6J6LJ:H'F'H=]%B=/LK4.+>N)U;-5
M6A>A2@PE6G(8+3:WN1M<T+Q2MBT9R[0J8N4RX\1JYF!II;=?`UK)-[+C3#:,
MEN/?1AEDFJ3?:O7+K-FB!<TI(]*U&2W(]>VXWV0P^LF5+3-8UOD<RW"#64;8
M<%K>1LC]FB69"U5/(*GL\N),[.;*%#_+6YK<;8AUCHSW!2Y)&M8I;VQ<TDXR
M1DTY(L+VE&2AG""```5*_P`P3_BEX^?8#)_O$+&H.E_[_P`4>#E^\9UZBON3
M#GBJ_NVB<;09,;0O)A]HW5'V:W5_9IO&7>J'[BPMXN9[N#1G3I]\XD\++]XN
MU#&+6(``-/7GJ^SQFOVM<??OCB`[GEEZA8,WC(UX./Y@\#8MW?.U(J;`]-WG
MDX+C[FU]^-WI!*.%YF^GN,]W3]2+LN7G'6$_'R=>#Z70\R7H6````^8_6_U=
MP+XEQ;T&A'J#R_X"P3NBQ^7EO.O''&N,-Z6OW\Q[0=>Y9=-\D/V9]#_'3E%^
M+:]1Y>X_X\QMO>V>8F/1;!/!F$-UV3R\MM?'(NG0#2#9X=(N19OAOA_BM_.3
MGVOJGZL>*=:K:I1>)=\\7=?7#K]R['Q;J(NOV/=N[X[KVII.9/P(42O-6]IA
MS/\`CI2_X2>.PW-TR\!WOO>;Y>RL==0O&=U;KE^8M+`@:*4.L1?ET_K$YS_$
MOB'Z<Y:##/4UQ[=.Z)7F+4V/T]\%7GO2;[BS+10SJO8``%9O\Q1[IX7>_.0G
MH^H!?W3=ZA3MW3M>2I/G[P+*\?*U)JMN-Y,7,TO+:]H=PT^UI^^YRTA0'4CZ
M>R=XR=2<N[D#QS/W?-UY2^T,'-G@#__7O\``````````````````````````
M``````@?D:U)WBOH\D5(CEY9-\<6774@B&:3S<M0Q<G*A>TBW9C,D$9U0DMJ
MMOT4&/7>3-HV65L[:I%^46$*@F">`0C:U*LC-PQINBDM-=BVIJG-<V,D\&78
M;E6LKJ:=QZSH"NW4=@?DPEBGL2;'+L,X[)3NCU)/U-3;G$F"&1&-A\:6NU7*
M<^N-DV\FC,L?*XD;=&85:$[@Y49>*Z0K"4JIF<&"0IE+8F=W(].N5(D6$B,Y
M>WIU9I9BK7)H)I^1WC;QTA*)`PLR^06?*X^QM[<B.C\ZLZ93=JDBAIEZV=-K
MU+"Y0ZNBI_?")&MSN8I.-ZRI,20D48.2)R22R'L6.JXXR2M?,MU\KD#RH7/J
MYI];94]2=%$<R91HI?$D.1.ZM23'T*PPO&FA17Z$B7'=4W8I?Y@!)0```*E?
MY@G_`!2\?/L!D_WB%C4'2_\`?^*/!R_>,Z]17W)ASQ5?W;1.-H,F-H7DP^T;
MJC[-;J_LTWC+O5#]Q86\7,]W!HSIT^^<2>%E^\7:AC%K$``&GKSU?9XS7[6N
M/OWQQ`=SRR]0L&;QD:\''\P>!L6[OG:D5-@>F[SR<%Q]S:^_&[T@E'"\S?3W
M&>[I^I%V7+SCK"?CY.O!]+H>9+T+````?,?K?ZNX%\2XMZ#0CU!Y?\!8)W18
M_+RWG7CCC7&&]+7[^8]H.O<LNF^2'[,^A_CIRB_%M>H\O<?\>8VWO;/,3'HM
M@G@S"&Z[)Y>6VOCD73H'I5J3ML@Y"'$(CDFSO?#BZJ=S89I$M5RC>L:M0Y6D
M+M)`^9G).Q2'0OQK8MMV,V+RD[IKA'@\\G,G@$*)7FK>TPYG_'2E_P`)/'8;
MFZ9>`[WWO-\O96.NH7C.ZMUR_,6E@0-%*'6(ORZ?UB<Y_B7Q#].<M!AGJ:X]
MNG=$KS%J;'Z>^"KSWI-]Q9EHH9U7L``"LW^8H]T\+O?G(3T?4`O[IN]0IV[I
MVO)4GS]X%E>/E:DU6W&\F+F:7EM>T.X:?:T_?<Y:0H#J1]/9.\9.I.7=R!XY
MG[OFZ\I?:&#FSP!__]"_P``````````(=E=TL<8LF*54GB\\ETHDB9O<W$R&
MQW5W9X&P.[JJ9FB2SYS.7(2F%C=%S6X:D&Z84;[^&J/U,9U+P8'ASN6E3MBZ
MW4,G+FT-S34'8[,D)\FA;TC)?X#)W*5,D<DD)+2$KEDF\<?(8O1)6\LK1W.5
M:E::I,Y4$=H30EN`V1'[#UEA#46X-SW`98?!IU&'DI(4^1*5%L+!+$[2[:MR
MUS;#-W*(2UI=DIJ54H(/;W).;KO^OG74A[\```&+?)GD5BCLU3%6-G6O]B7=
M.5\,AR-+%)A-DS$V1J'R&PI].WF*P)"OE\B;(E$(P?V#:W:Z*W5V5(46#4Q:
M@U8F)A"E'DIO>WG!OX^6O2<AI:S*8MB=4K%,,A$1G6D]L.,64[)R9I8<'D?K
MPE:X#M5T24K)$K8'9B>5)C;''$LY8D4;Z:$"CMA'M<OC[S%C5]6"\LR1<FC+
M$\.ULMU,L;W")VVOMJQVC)UBM;"LADGKJ2W5\Y-F\PQOE*PMN%SJ0R[I')4:
M5A9LE2",&;@(``!`G*BXG#CUQHOZ]FB/;RQUIZGK%LELCFI9YA3PX0V*.C\B
M1KLIC"U)+3NI0ZY6&EYZY*3!AFO3G7&,DPA3&$&O>675?4(;&6IM$$@GW)""
M6_62V50Q'::Y`W<PV.P:0NR>.$?JR?X:8:RTJX,V*Z?)&4SY3-C27ZE%MABI
M0G=<'G0G)_L1/_>=MA96MHSMJL6<N:R@>(W#"S:Y2N[+,8<[SBSK)N.Z6*SF
M:R8:L(2F/QSRMJ5N@YB5<8O6M1Y3B=MN6L4X4;"CL;VQ+Y0/R-:D[Q7T>2*D
M1R\LF^.++KJ01#-)YN6H8N3E0O:1;LQF2",ZH26U6WZ*#'KO)FT;+*V=M4B_
M*+"%03!/`(`%'SG#RQY7L'-'E1&(QRAY!Q.+Q>YY"PQR,Q6VYG'X^QLZ-"T;
MIV]K:&QU3HD:8O<[?.-=-,8Z=LY&M>3O*C!.+\%R;YOV[9DV\*UHFU(UH3IM
M2&C5C"%6&C4K0ADST,R<U>9>+\+8MFW3<UOER[%"SRJT(1E2Z\::T(TQIK58
MQ_XL7O[XG,K^,+E)^W2PO]MBT_Z`<L/]%G?YB?\`KJW_`*W<Q/\`5I7[B3^H
ML7^0[<]QV_"^3OTO6S8UKG1:PH"CCJRQY>]3%>S(G.&J%J]&WK7M4K4)DJE7
MI@S8O7;&N=_T]`R3SAPO<V$,:3[FN*SUI5WU;/*KPJQKUJ\=*M",:T=*O&,<
MN:EIWE9B*]<481D7M?,^K,MU:?-JQC"K5J0HJQA"&2K"$/\`@WZBK5C```J5
M_F"?\4O'S[`9/]XA8U!TO_?^*/!R_>,Z]17W)ASQ5?W;1.-H,F-H7DP^T;JC
M[-;J_LTWC+O5#]Q86\7,]W!HSIT^^<2>%E^\7:AC%K$``&GKSU?9XS7[6N/O
MWQQ`=SRR]0L&;QD:\''\P>!L6[OG:D5-@>F[SR<%Q]S:^_&[T@E'"\S?3W&>
M[I^I%V7+SCK"?CY.O!]+H>9+T+````?,?K?ZNX%\2XMZ#0CU!Y?\!8)W18_+
MRWG7CCC7&&]+7[^8]H.O<LNF^2'[,^A_CIRB_%M>H\O<?\>8VWO;/,3'HM@G
M@S"&Z[)Y>6VOCD73H'I5J3ML@Y"'$(CDFSO?#BZJ=S89I$M5RC>L:M0Y6D+M
M)`^9G).Q2'0OQK8MMV,V+RD[IKA'@\\G,G@$*)7FK>TPYG_'2E_PD\=AN;IE
MX#O?>\WR]E8ZZA>,[JW7+\Q:6!`T4H=8B_+I_6)SG^)?$/TYRT&&>IKCVZ=T
M2O,6IL?I[X*O/>DWW%F6BAG5>P``*S?YBCW3PN]^<A/1]0"_NF[U"G;NG:\E
M2?/W@65X^5J35;<;R8N9I>6U[0[AI]K3]]SEI"@.I'T]D[QDZDY=W('CF?N^
M;KRE]H8.;/`'_]&_P``````````,-K7H9OLN\8'/$%1M,.L2LI9`)1'N4K8L
MC*64K(.V.6IEB5"NV:CT=@.S3.(]NJ9#F=?J;'>[N'BG;97($J0PFG(@6Z.*
M-CWN9=TV:4DGK606)6M?,:^M;#LO>;PB8612-OQZUJQ=FE&D>IS&J\A?9,B]
MJ4[H$",Y;I(#U*IKP>FQLI$(]C*^B:ND<2GG)BTY3IX8LY`6W&ILS13;=I/6
MQ"*PND:IJ!L;GQ<S;*D#A('ATK]>[F[E*E91"9Q3I-3-LIMMMA&/9!DH"```
M118]01VR7NMI6L7O$?F51R=UED!E;!EIRYM"]^B$@@L@0GIGQJ>FES9'Z,R9
M20I3'I]\=IJ2>5L4I3D'%A!+?PW*C;]6ZV!\B[^KZ)5I'6F,(*SCB3CRNB+V
M@(=O&98J=GF8\?Y59S4\V:LVV\?7,<A9U1VN<=TW1YT+SH33\CWE>\6ZWK61
MQQ\CZA_-;H.YV^\U[$W`YF-CL#<;TE>TQL(V/92,B-\W(5.IZDM"4L6JRVY&
MM/3$8U([`L@4LD00``#C+42-R1JVYQ2)E[>O3'HEZ!:04J1K4:HK<A4D5I3]
M#"%*9209MH87OKMIOIMG&<9QD!&J>D:H2-"=D209D2(T3VUR1O/2EGIGALD+
M$RE1EA>VJ0D'Z/[6Z,,5(T:4)Z=268C:--4).=$F,$X#E&T[59JJ+K-J^B>I
MT,3-R*,8)942<AI0LSNAD3(B)2$%%I34;%)6Q*Z("C=-RT+HE)6$8+4E%FZA
M)("!^1J?"JOH\5LT'/>-;XXLJ.Y$05KL7<G*/DY4*O5WVC[O(XLD;R8_L1A>
M8^Z*3547+3;/*9&X*4!2!23!/`(`%`#GK_CKYC?;]*_1[(-^=._IO9O&3]:#
M$W/;CZ?X63_9%BD+T4VLV_EV_P#<WEW]I59?V#5#`/41ZDVKPDC5BVWR*X`L
MWBIVM!8_%&KB``!4K_,$_P"*7CY]@,G^\0L:@Z7_`+_Q1X.7[QG7J*^Y,.>*
MK^[:)QM!DQM"\F'VC=4?9K=7]FF\9=ZH?N+"WBYGNX-&=.GWSB3PLOWB[4,8
MM8@``T]>>K[/&:_:UQ]^^.(#N>67J%@S>,C7@X_F#P-BW=\[4BIL#TW>>3@N
M/N;7WXW>D$HX7F;Z>XSW=/U(NRY><=83\?)UX/I=#S)>A8```#YC];_5W`OB
M7%O0:$>H/+_@+!.Z+'Y>6\Z\<<:XPWI:_?S'M!U[EETWR0_9GT/\=.47XMKU
M'E[C_CS&V][9YB8]%L$\&80W79/+RVU\<BZ=`]*I]2)!R%VPT'-7>;X<5&QQ
MT%:X9J];9K&K2?%R'!MD;^;8!.^">P\=5E-BHS9/E%E'J6B*/4$IX!"B5YJW
MM,.9_P`=*7_"3QV&YNF7@.]][S?+V5CKJ%XSNK=<OS%I8$#12AUB+\NG]8G.
M?XE\0_3G+089ZFN/;IW1*\Q:FQ^GO@J\]Z3?<69:*&=5[```K-_F*/=/"[WY
MR$]'U`+^Z;O4*=NZ=KR5)\_>!97CY6I-5MQO)BYFEY;7M#N&GVM/WW.6D*`Z
MD?3V3O&3J3EW<@>.9^[YNO*7VA@YL\`?_]*_P``-:EH<G;2K1CY\.93DTO*N
MG[4H^NJ>T<FUG;FZ*F7=`Z-2(5CX=DYN+?6^.36TCG([*U45DY.3DC)Q)?1M
MH31V(POCGJOHV'<T*Z<K0KUIN2GGF9M-)2ZRGB$L.S\U(.+]47^H<7MCV]5F
M>0R^)OMJ$,2!I:T1ACENM9#%!/9'N"DB$T=D6T.LY8AG==06:-KTUR)%*HC'
MGXA]9%:)>T.V'1J2J]US<L;C#4"A(H,-SMIL3MDOHS^K^@2^8O;@```UB<LO
M-BXX<.K@WI&RXE=4AF)4.CLX//KZ)1=Y8R&>4+7Y`U%F+GN=1I3W_8Z.*<[E
MZD;:ZZXUSUL]/1CJ\-X(Q5BZI:YF'+GKVJI(C5A,C5K2ZNC&M3&K3IUZM-.C
M'LI['-W_`(OPWA>M9:E_7K4LU:="M&I"M5KUM*%6B%;YE6MV4P[:.UC9_F!>
M&O\`Y8\I/V>U[^]L=+_1?F?\)3OWDC^*Y[^K7+OXGE?^"=_#98<._-!X^<V[
M'D=6U5%[?CLGC,(43];FQHM&V-M4L*1^98Z?A`J8YI)S#5VC@_I_YO<LO7)>
M=L];IQT9Y7$F#L2X1KV27B.ZJ]EKSX5HRX5JU2MI0JT0K4:%:M11I0[:.UTM
MP8JP_BBI:9EPWE5M-23&K"O&K5KU=&-:F-7Y]6KVT1[*>QL>',N@``!J:\X7
MEE=W$"@*AF]"O;!'Y9.>13)6KNXR*,HY6ETBZNGKKG2HI,VKCB""UIKS`D.,
M'=/3J5U]<8_6'9\O<+R,9XPN?#5IM5>1(M.UIKU80C6J[.1,FPHA')EC4A"/
MR1<GCC$4[">%KUQ!9[-5G3K/LJ*E:,858[2=+E1IC#+DA7C&'RP5^O\`G/>8
MW_YKUK^Q6-?[0&F_RO7%\4VO]W+_`.;/7YB[Y^&[+^\F)0HKS@>?DMO_`([P
MB66-7;M$[#Y%4#6LK;DU2,+6J5Q>R+AA4%D12-R3KMST"W+-(#\DG:XSDLW&
MNW1^@<7S"Y#W3@O!][XELU_VF?/LVRHJ5JE2%6MM)\N5&F,,N2%>,8?+!UN!
M>=%Y8MQ3=>'[1<DB3)M&UIKU:]>-:&SDS)L*(1R98U(0C\D5QH9E:$``!CWR
MW>GF-\4^3<BCKLYL$@8./=T/3$^LJ]4U/+*\M5<21<V.S2YH32%K<YMRTC0X
M@\G?0TDW37?3;&V,9`AVP4+T7);E4<B2&F<P.9.QAJ5.9OM_>\Y*8ZV^Y6FV
MV>C6T<:XZ=L_Z,=`]"['R,Y6S;)99LS"]->M+JQC'O-LRQC5A&/9:&&K5SDY
MCR[5:9=3$5%2K,K0A_[>R]D(QA#_`,ARO[R7*?\`B^YD_P#J]Y*_O2']']">
M57PM])MG_P`A_/\`UGYE?$?T>R?P%W?RY)1)IKP-XCRV9R203"62*A:Z=I#*
M94].4CDC^[+(^D-6.KX_/*I:ZN[FL-VSN:H4'&'&[YSMMMG.>D>>ELEU)5KM
M4J7"BI5F5H0AFA"M&$.W*W/9J]:99[/,KQIKUI=6,?TQA",4M\C4^%5?1XK9
MH.>\:WQQ94=R(@K78NY.4?)RH5>KOM'W>1Q9(WDQ_8C"\Q]T4FJHN6FV>4R-
MP4H"D"G^=_O!/`(`%`#GK_CKYC?;]*_1[(-^=._IO9O&3]:#$W/;CZ?X63_9
M%BD+T4VLV_EV_P#<WEW]I59?V#5#`/41ZDVKPDC5BVWR*X`LWBIVM!8_%&KB
M``!4K_,$_P"*7CY]@,G^\0L:@Z7_`+_Q1X.7[QG7J*^Y,.>*K^[:)QM!DQM"
M\F'VC=4?9K=7]FF\9=ZH?N+"WBYGNX-&=.GWSB3PLOWB[4,8M8@``T]>>K[/
M&:_:UQ]^^.(#N>67J%@S>,C7@X_F#P-BW=\[4BIL#TW>>3@N/N;7WXW>D$HX
M7F;Z>XSW=/U(NRY><=83\?)UX/I=#S)>A8```#YC];_5W`OB7%O0:$>H/+_@
M+!.Z+'Y>6\Z\<<:XPWI:_?S'M!U[EETWR0_9GT/\=.47XMKU'E[C_CS&V][9
MYB8]%L$\&80W79/+RVU\<BZ=`]*I]2)!R%VPT'-7>;X<5&QQT%:X9J];9K&K
M2?%R'!MD;^;8!.^">P\=5E-BHS9/E%E'J6B*/4$IX!"B5YJWM,.9_P`=*7_"
M3QV&YNF7@.]][S?+V5CKJ%XSNK=<OS%I8$#12AUB+\NG]8G.?XE\0_3G+089
MZFN/;IW1*\Q:FQ^GO@J\]Z3?<69:*&=5[```K-_F*/=/"[WYR$]'U`+^Z;O4
M*=NZ=KR5)\_>!97CY6I-5MQO)BYFEY;7M#N&GVM/WW.6D*`ZD?3V3O&3J3EW
M<@>.9^[YNO*7VA@YL\`?_]._P``()7<<JP>/IU*?4#J]H>1IK>?:+<N>%125
MP/:(BT05J4,AC;E`OC*MNC$?0DDGH3B#BSDA:K&^%?6/V)I['\N?&NGGZ%63
M!I)%$TD0W!ZTG64\O/9J91*W.91%J@3Z]JGTHHA4WNQD-8&YM3F(N[:HD3:D
M(3:E%)B=-!3%,;&RMD;96F/,J0I`T,;<B:6Q$3KC4I*@;TY:5*1IC'1^J625
MKC_VY!#M0```4NO/"]HD^?\`#K2?]I+>&P^EO^0QE^VLVK.98ZC?YO"?[*T:
MTIJ8&K6:6[/R!_\`&M:7_"W(_O9JP8[ZI/Y_!O[&TZTEJGIR_D<5_M;/JS5O
MD93:4``!H+_,._X6.-W_`!DQW\-7*`6YR)]5<*_XGR=H5CSE]-<2_P"'\W(5
M1QZ*,()BXV_XI^(/_&3Q"_$K5HJ+GMZ58I_PWG+.M#DQZE8<_P`1Y2>^B4/.
MQNT``&-'-'_!URQ_X:+V^ZV5`F';!\]UM_[.0>\DO_V"QZR7?_(6+]C4U8/,
MNW?SML_:U]:+FC^Q_*O>^5][.WA?_P`.M8_V;1CR:O#^?MW[:OK1>FMC_E+)
M^RJ:L$[\C6HUXKZ/)"41R_<F^.++KD@B&1N>;EE,7)RH7L];LQRN01EK0DMI
M#?LH,>BE)CE&RRMG9N2+W!$F0J/Y'],$\`@`4`.>O^.OF-]OTK]'L@WYT[^F
M]F\9/UH,3<]N/I_A9/\`9%BD+T4VLV_EV_\`<WEW]I59?V#5#`/41ZDVKPDC
M5BVWR*X`LWBIVM!8_%&KB``!4K_,$_XI>/GV`R?[Q"QJ#I?^_P#%'@Y?O&=>
MHK[DPYXJO[MHG&T&3&T+R8?:-U1]FMU?V:;QEWJA^XL+>+F>[@T9TZ??.)/"
MR_>+M0QBUB``#3UYZOL\9K]K7'W[XX@.YY9>H6#-XR->#C^8/`V+=WSM2*FP
M/3=YY."X^YM??C=Z02CA>9OI[C/=T_4B[+EYQUA/Q\G7@^ET/,EZ%@```/F/
MUO\`5W`OB7%O0:$>H/+_`("P3NBQ^7EO.O''&N,-Z6OW\Q[0=>Y9=-\D/V9]
M#_'3E%^+:]1Y>X_X\QMO>V>8F/1;!/!F$-UV3R\MM?'(NG0/2K4:VR#D*<:B
M.28=[X<74DPZ&1N):KBMZQJU%A:0NC\@?54Y)VW0[%^-.A;:Y&;%Y2;)-4Z-
M.>>2G@$*)7FK>TPYG_'2E_PD\=AN;IEX#O?>\WR]E8ZZA>,[JW7+\Q:6!`T4
MH=8B_+I_6)SG^)?$/TYRT&&>IKCVZ=T2O,6IL?I[X*O/>DWW%F6BAG5>P``*
MS?YBCW3PN]^<A/1]0"_NF[U"G;NG:\E2?/W@65X^5J35;<;R8N9I>6U[0[AI
M]K3]]SEI"@.I'T]D[QDZDY=W('CF?N^;KRE]H8.;/`'_U+Y_B$P^#+-\J3_F
MV)R9T4QS'B$P^#+-\J3_`)MADSE,<S2A+O+/YY2:83*3(_-#OJ.-\FF,LD;5
M&6AVL!*U19G?I"Y.S/%6TI';*%+W",M:PI`5N601J9HGQO@HOK=37O[HO_`%
MDNZRV:]N7TVV7C5A'3G0O";)A7C3&,([*K)K0J40C"K1"M&FBGVN*O2Y<;6J
MWVB?=>-Y=EL%:,-"5&PRIL:D*(0C#:5IM6-:F-,:8PA131['G_\`E:\^?_ZM
M\B_^_K)_?&/T?Q/RO_\`RR=_]K/_`(#\_P##W,7_`/1Y7_ULG^,V2</Z2Y`<
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M=;?C?<SYUXOX?6MH5YZO^&]YAW<.U^DGOG>^\']7N79=CGMNT*Z[`F*88*Q7
M=6)^X]Y[MM?[K3V>EM),R5\_0F44;32^9&FBC)33#F,98<CB[#5YX>[WW?O&
MS_O-'::.SFRYOS-*I33H:/SH44TY:*(ZI/\`+XS#^)EF_92?^\@:*_--#X%^
MF_5%#_EPC\8_1/K+V%;>0[,*]M2H+,_O$LSO]%-RU!;?@GT:'M_CWT4V5%K#
M]7_$O7];X7X]ZM=S[WW=3W7M^U[$[J=GMR..^?L,;84O7#'X4[MWG9?WO>=I
MH[.=+F_,[O+IIV>C\^%%-.6BB/4X,Y*1PAB6[<0_B3O'=]I_=]WV>EM)4R5\
M_;UZ*-/2^;&FBC)33"Q-XA,/@RS?*D_YMC.N3.O:F.8\0F'P99OE2?\`-L,F
M<ICF/$)A\&6;Y4G_`#;#)G*8YD9W3"IA;].VS4W<6:/?2A6D[KOQ_P`9/=O`
M_7:+.L:\8\*\(;/$_#/$^V[OWE/VW4ZG:E]/6PR9RF.97N3?EZY@G3IT_P#>
M;9M^P)*)Z_T4'Z];LM-=.MU?I)VZO6ZO3T=.>@:RL_5#"1(D2/P/3H5(5:>^
M44T0A"FCNK,L_ITC.G3IWXPHTZT8T=T[*8TT?S+]_P#+XS#^)EF_92?^\@?[
M?FFA\"_3?JC_`"_+A'XQ^B?66][B_44PXW<=J7H/^IIG]$-=1B`^MGB!\=]8
M?5QM);_%O`NX/OA/?.RZ_8=\4]GT]':;?RC)MHFPGSY\^BC3KUJU';13&,:*
M6FY-2,J3*E=NC5A"G/1"BE_O(LF:O-?QY&3#FM;N3>_%MVR22E8Y[OH4P\FZ
MB?#U>6.4E1IL0E-Y+=L>8]%*#'&-Z%Y=F]*N7H4R%1_CDSO]81CF3OXA,/@R
MS?*D_P";89,Z*8YCQ"8?!EF^5)_S;#)G*8YE?^^O(_F%WWM<=U_3ZS1CZ6I^
MZSGU:^CP]Z\`\33H2/"_&?7AI\5[#N?3V_=$W6ZW1V>.C]-_<N^>4,`X;EX>
M_#'>]&=,F;3O.R^?&$:-#83.RCMTLN:"D\=\G8XVO^9?GXA[MI2JE30V&T^9
M",*=+;2^W-HY,\44_P"7QF'\3+-^RD_]Y`[K\TT/@7Z;]4<9^7"/QC]$^LMF
MWEV\"IAP'9K>:/79FM?Z59+&9%WCPL^"^`^KC":R=S[+Q"8^*=\[7M>TZR?L
M^CJ]7;_6%`<Q,9PQ[B2;B'[.[II29=39[3:T:$(PIT]"7VYM')GBN[`N$XX*
MP_*N+OW>=&;7KZ>AL_GQA&C1TYG9GTLN:#9!XA,/@RS?*D_YMCALF=V-,<QX
MA,/@RS?*D_YMADSE,<QXA,/@RS?*D_YMADSE,<S4IY@OECS#G9:5>V7])S-5
MGJ)`'.#>"^K9\W\5\2D6K_XIXEX[$.X]CU>R[#L#NM_K=IC_`%1:'*_F1#EM
M;[TMWV-WWO,FK+T=KL='1K:5-.RFTT]E%$/TJZYBX!CC^PW=8_M7NG=YM:O3
MLMKI:571HHVDNBCMIIC^A@I_E\9A_$RS?LI/_>0+H_--#X%^F_5%2_EPC\8_
M1/K+*'AAY0<PXA\CHIR`^F5FL+U8C4UCOJEZEGQ/OWK@VIV[OGCWK7)>[>'=
MAU^S[D9VW3T=;3HZ15W-#F[#F38+JL7X?[EW:=6KZ6WVVEI5=&BC8RJ*.VFF
M/Z%C<NN5\<`6R\K7]M][[Q*JU*-CLM'1K:5-.UF4T]E%$/TMVOB$P^#+-\J3
M_FV*8R9ULTQS'B$P^#+-\J3_`)MADSE,<QXA,/@RS?*D_P";89,Y3',P\YU<
M7YAS4X\/="^,,U:>,2VOI3ZU_P`_,N[>HDR9Y;W'P+HBO;>*^%=W[7OFO8=I
MVG4,ZO4S^[AB^H8<Q#<M_=WVW<[34F[/2T-/0K0CHZ5%;1IHHIT:U&:+\?$-
MU1OVX[VN7;;+O5GKRM.C2T=.K&&EHTU=*C-I0ISP:;/\OC,/XF6;]E)_[R!I
MO\TT/@7Z;]49X_+A'XQ^B?67X*/R]<P4%X+_`+S;-IT')S>GZ*#]O<Z@H_J]
M'TDZ_P"OV?1T_P"CIZ?TC\+$_49#$>'KZN'\';'OEFKRMIWO3T-.K&KI:/=J
MNE1331I5:<\'[.'>0\;AOVZ;Z_%.U[K:*DW0[MHZ6A&$='2[Q6T:<^C&C-%9
M=\0F'P99OE2?\VQF3)G:&ICF/$)A\&6;Y4G_`#;#)G*8YCQ"8?!EF^5)_P`V
MPR9RF.8\0F'P99OE2?\`-L,F<ICF5CXW^79F$>CK`P?WH697X&RM;/WOZ)#T
M_>O#4)"+O'8?28?V/;=CUNIU]^KT]'6ST=(U#A_J1A<5PW)<GX-VO<[')D:?
M>]'3V4NK+TM'NU;1TM&G1TJU%-%,>UG6_.04;ZON^+X_%>S[W:IL[0[KI:&U
MF5J^CI=XJZ6CI44Z,*:*:(=CNO\`+XS#^)EF_92?^\@?K_FFA\"_3?JC\K\N
M$?C'Z)]9;IN$/'"8<-N,\#XZ^),UC^I+U:+QZX=H?$/$_I)MN=VGW?U?[*4=
MR\%]=>X]?OQO>>[=MU2NT[(O+V(+TA?M_7W?>QV7?+9.GZ%.EH;:96F:.E15
MTM'2HTM&K3131#L:,N2[HW/<MT71M=IW2RRI.G1HZ6REU:FEHTUM'2T::-*-
M%-%,>UEAXA,/@RS?*D_YMC\C)G?ITQS((I8F:MD@Y!G&0YK2X>+W<78K<U*Q
MQ'"TK>LJN0X5DKF`I[4SDK;=!L7XTYEMSB9L7E)LEU(1ISSV3.1C')D3OXA,
M/@RS?*D_YMADSE,<S1)RK\F&8<F^3%S\BOIQ9H3]+SU"WCU/]0SY)ZO>J%25
MU5G=_6#UQ8/%O$?4'OW7[BF['O?8]7?LNU,O/EESHARYN&UW)^&^^;6V5I^G
MWC94:4N5+T='83::-E3I:4*=*BC)3&G.8?*:./+ZLM[_`&]W3966K)T-AM:=
M&9-KZ6EMI=%.THHT8]E-.6B$"?Y?&8?Q,LW[*3_WD"Q?S30^!?IOU1P?Y<(_
M&/T3ZRV(^73Y=$PX!R*]'_Z0F:V/II9:A9^Z>!GP3U:^BI=;2WO';^+3+QGQ
M[Z4NKU.HE[KW'IZQW;=!5&<S<?0YC7]9+[^RNY[*QU)&AM=K3HS)LS2TMG*H
MIVM&CHQHT::<M$+DY>X*C@.Y+3<_VEWO:6JM.T]GLJ-*7*J:.CIS*:-G33I0
M[:*,E,=HOB$P^#+-\J3_`)MBNLF=W=,<QXA,/@RS?*D_YMADSE,<QXA,/@RS
M?*D_YMADSE,<S6;YBGE\S#GT92YGKXS5/]$!UA&]'@Y\[]8?7Q/$".KT^)PW
MPGPKU4Z>G^D]OWCH_F^I^OW_`"WQS#E[B&O?WV9WRFS5Y6SVFR^?6J5M+2V<
MSLT**-'+3VPHR\3C[!T<<W%4N7[0[K1:*DW3V>T^;"O#1T=.7VZ7;I9*.S*U
MM_Y?&8?Q,LW[*3_WD"^?S30^!?IOU12WY<(_&/T3ZRFCC;Y*$PX]<AZ:OKZ=
MV:7_`$1RU?*?53Z/SV#U@[]#93$NX^.^NKUX3V7K+WCM>YJ>MV'9]3'7Z^M?
M\R>=L.86'JEP_AGN=%IJ3=IWC:_,JUX:.CL)?;ITTZ62CLC3D[C`'**.!K\K
MWU^(.]:5GKRM#8;/YU:I'2TMM,[-'LT<M/;D;[O$)A\&6;Y4G_-L4/DSKGIC
MF/$)A\&6;Y4G_-L,F<ICF?_5O\````````````````````````````````@?
MD:E2+*^CQ*U(<L)TOCBRJT)(C$4EV^BM#R<J%:@5[-4S>6%H2$H%Z<L\QS)/
MW=F0LO9Q:TZQS2I$AY,$\`@```````````````````````````````!`]*I4
MB:0<A-TJ0Y-NKOAQ5+-SHQ%([JL5[5C5I.59"N,O+LLE9.Q!!>GB;QHA==]B
M\I]D^$R9*:<3F3P"```````````````?_]:_P``,+IX\O,BY<MU2S9^E44J'
M?C@NG\0VC4LD]<%S.R4=@G-<^U73:(OT;?E2BN(06SGD-A2K";L']2K4E&;$
M)3""?9\K'"B+0M^6/7`1?/I7)MULR<.9S2OSJ\+V]MM2M8"[R-LHNPI,Q-YZ
M2/2)PE5:H&60:+LI,:;GN6QY&"M#==<0F,(96V`2^0```&)O+F92V'Q^FBF-
MQ=(]#YCR)K""W'+V7<]$X16KY%E[T4*-'].H2'1-))YJF9(\J=BC25*!(\FF
MICB%6"3BR8>UB5.Y)HW3+EG5,GN*>1NH8HFI%+14@SR!F,'D>>2<XB5EKYC5
M7TR[2<J;K6R'H8]%Y0J:U[DL1MZ1[5&KR3FK0M*1"<T6S"LS%1M<0$Q=,T-C
M+MH7%^^V$UE(B6N>+,,B+"J9MA;:8>VZMTI/QLN([MN8GR4?KDK;8OJ[9E\O
M;@```\C/W&2M$#FSM"VPI[F+7$9(XQ-F.UWW)=Y*B9EJEB;#="C"C-RE[H44
M5MC7;7;.-_T9QG](#60P6#*$D8X`S6.VM-WA]OM"]%\HE$JFSGE.SU\DXU6+
M,K9M5;#WYS6P^D7NIKYCD?;5'AZ%L0,;@Z[,AQ&G>"R-(S/K.RNX@J9*5'+A
MBDE-D:K,"OZ>QJ/N#Y:4@NE"NB:YLBTTCOJQ9<P+TF<A:6M!+=4"PIUV-4M3
MXD<&\LS=*D3Y$HBRW!````#4G;-CV;BJ?,-L4R8S>-W[Q]F,Q1\;X2VR&1L;
M,IU;JWA[[QM8DU:-SPF8+:;KWL4\Q'VKD@7J'IR<5K,F-QA"20FC.^LV9+L-
MNBPY)S7A$2E4?MN%MB^E^2349"ET9?D=8GN5<V'QW2--ADOFY'@LD6NV'AYU
M2.6AQA"9K<F],7J4H5*ME$HHR-AX(0/R-2I%E?1XE:D.6$Z7QQ95:$D1B*2[
M?16AY.5"M0*]FJ9O+"T)"4"].6>8YDG[NS(67LXM:=8YI4B0\F">`0`,.K9?
M)&Y\J:.J1^=Y/&J:F=179(L+8P_/\),EMUQ.15,7$88JG<6=F1_1JTE=/,I=
MTC(G4EX>"D2M49J9HTYQJ3[(L5XA9UJ.K)Q?5.\SE)K*?YCUS5#!Y.3)G<DR
MW..L>C_)7Z/3Y6>D7E)+$;#4D.0=T<UFBG+PG:DSIDT\Q3NK/A.?]#;:)?(`
M``#%OF9-YS7?'V1RN`J7!L<$DRIIME4A:46C@Z0ZII'=-?1N[YXWD'8RG(50
M.G'=]>,*C<ZE(,(LJM\]4G.,DP[6.<NDC-#+RLZO'VU)VV<6B>.$-G%@R(RZ
MIYX]#;4?+*4Q^$QJ,6X?+3+'BSC<$54[=DW-CTF4G&MB,QOPGW6J-EH]GRLM
M.+^'32B*_)>K(3VRYID+FF53A-(T4SPK[%^==$[$IFC<>J2S-TA*7&C&N=NT
MV.<5K<:>?C4_<W341[4^`@```!J%B5F6XLIGBQ;I,HF2ODM87*>$UO<=:.,F
MD/@*=H<[:=HYR#K[2H%#R?&&!-1]7%.+FB6)6]*[$D1Q.N5J#L*%N5</K)ES
M,JN-2]W3W!R1C'K!(YA"<?1#8-?RQ9<#K<D9=6F>QZ2(W+PM>]DZ'021J76'
MF.2^--F^\<0MKDUJ6W!>JT[3$HCV09H`@```!@1(GY1*^0O)F&6[8,QJVOZT
MIFL9G5K@P3B058W$1UX13_-KVMXZQ/;,5,E<7D*!`B7DN6%S8P$I$&V2"MG4
M[*LGV0H8YT5R1Y$3R5\"L7K#[AKR8RR#-R>QXXC@4A88#,IE(N.&DVDTGDIY
M*4MK3>"2Y5A,0R[YQJPJ$*LT[K[FDEHH3&$,M#<&)?(`@>E4J1-(.0FZ5(<F
MW5WPXJEFYT8BD=U6*]JQJTG*LA7&7EV62LG8@@O3Q-XT0NN^Q>4^R?"9,E-.
M)S)X!#$3D?)Y0AM/BM!<NC]&ZFLZQYI'+.D<=<'..*SG1%64D=JMA:R<,J]K
M>86AE\U3:=D>C5)53DYHD;5J9L6O-3*"8=D6(<KL.SVV'72W-\UF6T%K'S/N
M"M64?/BYI(S7V3UY.KWX7M-WP)WE?BV[E8L99)I9DXAZO5R.7:9)3'-JCM#F
M[.=(3_R;=Q+Y````1K<[W-XU3UKR.LF;61V0P5K.GNOH]LE.7:OTW:HNZ+HH
MS;(D^VBA9JZ/Q"<C)1>V-S.TZNN<9S@"#7TWSAR:7'A4[Q&XYH]1B\JRLIZY
M+2J4V$O<"F.N6?C^\RU1>^&V0NKG$Z@=8G="1F;#36M,VLR$Q_.1G)MM2DNJ
M6'UG9,<0#VH^*6.=&+<<+6@2ZTG!VK,A_L=WMF6UY`UT0AI*.(2N<29\D<R7
MN#O(D3I)DJ-\6&.[0UR%*WJ-2LI=2M)1%EN"`!__U[_```CZT*IKBZH4[UU:
M\,89Y"GS4C+A'Y"BT6),J49^BMN<T1O3HK:GMH7%:*4*]*82M0JB]#DYI9NF
MN^!31V.];HHSH"F;!Y.SVOCZ?9(TOLAP4\R-*D_7T**R_+"MW12:6FVP5LH-
M,W5*,:]=0:<=L89N'I`````'XJ4R=8G/2*R"52142:F5)5)6AZ=2G/TV*/(/
M(-UV+.).+VSKMKMC.NVN<XSCH`1%`*`J*KXOI`X1"&1GKY$XN+LP5_LC(<(=
M#UCPO6N3N7"F5R+5DQ)G7+5VV^&Q!DAK2YQ_14Q'7-[0FF*7B""4Q)*9,24G
M3IRBR""""]"B2"2M,%E$DE%XUT+*+TUQKKKKC&,8QT8!#]0````$2IJ-JYNL
M:56PRQ-N8)Y8+0TQ^RWAE*U0DV>RL!#FF84=B,^FNS++E;&0['E(G!6G,=$B
M7?9*2IT2F&D&$TI11HD;<E(0MZ1,@1)M,%ID:,@I*E3EXSG."R$Y&FA16F,Y
M_DUQC`(<D````!%L]I>MK)D$%F4IC",^>5<YN+Q6D_0]=LF\$<7AK5,KQM'9
M(BV)<2&Q]:E>Z=R;3=CFIU3]!*U,H*QU`*4F83E=H2?OIH:I(),3EJC"RN\:
ME'[$;J--3-=-<Z:*#$Q>V^NO5UVV+UST?JXZ`_8!PE[<WNI&B9S0(G%,4M;G
M$I.O2D+""W!G<$KNT+]"E&AA>BUJ=4)*I,;C'7(4$Z&:9UWTUVP'-``'C;"K
MN!VS#)!7=FP^.3V"2MO-:Y'$I8THGQA>4!N<;9(7-J\DY.;V9FNNY>W5ZY1N
MNN^F==]==L`8H%&V)FCK%A*<]HHCHF)BZB5J3)4\LJ=#HG*0:$R%^RN?UJE(
M6E+QA8K4J%YNVF-SCS-_U@'L@`````!#D(H"H:V(E#9!H.R1N,3&2.$T?X.@
M1D;08Z9.YA)SM*&V**2SV>.NCNH*R>LPVEI$ZQ6::J/*,5&;G;$TQ2PA0(6M
M(2@;$21N0IM=M4Z)"F)2)"-=M]C-M24R?0LDK78S?.V<:XQTYSG/\N00Y8``
M``"*U]+5LLM-NNXB-)&BVT$>VAQT^8^EK?WV%&+T[EO#988FZ$LNC92Q/VJ5
M.Y%*O#3C##T.R8_?8W)-/L]B1&QI:F5+A"SMC>THM=]S-4;8C3($NIAF>DPS
M"=*645C??./TYZ.G/^D$.P`````1K9]/5G<S0SLMFP]KE:2-R=AF\55*N\HG
MR(36+KRG*.S"&R5J4()%$)4RK"L;)W%L5)5A6NVVF#.IOOKL.Q[Q*@T((0%J
M#C7-2WE8+*<G`M)LO,,[+)!BG?=,F2D%J#R\YQODHLO7;&<XZ.C/0`YP``X2
M1N;T&ZXU`@1(C'-;LXN1B1*0FW<'#9.F2;+UVY.FFRM;LD1DE9-,ZV^2RM->
MGHUUQ@.:`Z>01Y@EC&[QB5,;/)HU(&Y8SOT>D#8B>6-[:'`C=*O:W=I<25*!
MR;ER8S8LX@XO<HW3;.NVN<9S@!XJ$T_7U?0A@K6.L16:_AZ=O0PJ)/9IDE;(
M:U-*+5O:66.FR#9R<DC0T),9*0I]SS=$";.$R7L4I91!8I2:``````(C;J+J
MQDL"9V<PQ%L89=9:)M06@I:"=$C99I+,F5I&95.V'J[LD@?&I.LR40ZF)\.V
M$NFB7*G9)C)&2:8I):F5F8D^Z1C:6QF2&';*3$K4@2MR<Q1OH65N?N0D*)+V
M.V+)TUSMG'6SKKC'3T8P"'9@`#__T+_`````````````````````````````
M```````````````````````````````````````````````````````/_]&_
MP`````````````C6TI-8L9CO>:LK5):,O.-.[K'W::I:[8"TJ1&H6J#W66J&
M.3FHC56Q.B1$40W*]SURDKMN[H]52U,&'[;YA<'>(@AGJ&#OR:,LM#<>>1-O
M9>G),B>JPK_DG)G^/0L[1M;T+PCERMD1PE^=W;L%:8DIH;RCTQBK*P@O)-#(
MM!>"URM&^:M0U^Z.#O3$,JZ7M>4#TU;J;`VM$JP-&QH0IU^&YOCJA(Y0`TC)
MZU;W?.BC4XW8C33<"CL?G0MRRFU%%M1R>5MBLIY3%CE5U*FMLEQ4_B#J>XP2
M%V2QO<2F6C!%%3DA<(I/4!AR=:U-R]&?MMH:1U,E&FBAD&"`````````````
M```````````````&,MR7O-JCE4'Q]#:V359(K(JBK)'8"29MB%_8)%<LS:8!
M%71CKS=I5JY;$V23R)N+?5>7!O4-Z=5NH)3*R$JO<@F$*?:\W67+R-6;*8<S
MMD;4)X]:NW(0JH9/H[Z*_7%3QOGZ2`2U,Z-VS8D(C)LK-./=8_CO:W*MH0J#
M%>$*C71-N*'7YY529UXI:<FXG5+6NRFC$XF#Y$I19R2)-;0S5\L?TSRFQ,M(
MB_&+'MTU8-\-I7A1:0T_?&BE4DT_GLBC+0RUCCQM(8\PO^S8YLFSXS-;QLS/
M1):9Y:-G-"0MRV.R<DY04G<T&3^R/TU,WUT-TVQC;.,=.2'<@```````````
M````````P-L;FJZ4M))BVW!2CM$X^GJ>5VO5[\US9EDBN<DQ:QJ[JO2$2MH+
M;&U-64XE$LMR-^$DFKG-O4I%YNYBLDY"M(()HS/42CET1$XE:SHX0/=5+Z3O
M>HZ-L.*-TFZS>F4W*OI\V+RZ/R1QCS:<_,>L6NMJ6&:^'I]^^D+$.,]9/L=D
M4=B1K7Y"L=7V12%898G"2/MRS]-##SVY4F(1P-"OB%@2=ID4DV,U.-QI(5%>
M+D;:EQKINNV3+#"]^JA/P!0R$!``````_]*_P`````````````@GD-#;>L"!
M;1&H917\45O2[5',5=A1R4R9O=H2<D5$O,9;T\0ET)=VI7(,F%D'+REVIZ=%
MD[5/V2DPE4F)@QLEG"V26"3."I?.HRDTOBJJ5J>^6^$1Q]C<=T8Z3L.92]MS
M5#"ME#YB-:2B'SYQBRTM4H/P6G+1+ND[9*:B5BGL3:54=CL5N<C+;B4@A:9X
MMJLJKAL$3O[:]NB"+R*K=++W0/DJ0H%C0?(&=S6V/VAJ)(K0G:%M_9X49RI[
M1,,SMN.M?6[74;>VJW)164J=7![4/93G6\*DT0V='1W/5.,GD<M,D\WF9SK(
M7]V5]?H2]Q0(DY1:=,G*(T+*+$60P(````````````````````````````8L
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MLL=EJ1LT,4FY_28=MMM_I!':D(```````````````````&O*9<6K_M[Z:6FU
M+/IPACL9(WFQ%[@M;3Y!84,<Z[FJ*<T6@6/SE:YK0Z12`2%-LX."9&@;%+RX
M&&;]NE+-V*U)IAD>BFG$E_E$,O8M/*&=/87(2_Z3O&4K5FKHIB\9(I(ZBT;#
M"8ZGUUT7JD*F.44E*-5&83[;N;NL7=EJ7@M%@4]C^[BX.QNT[FK>[4=CVU$W
M^+7;#;@E4=;+6L<N#/VT,K%[KE$VLL,125OC$<7*DZE%E2K*1_TM-HL)-+VP
..O/SD4_(SH!``````_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g693329g07q40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329g07q40.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[1"R4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````7P```),````&`&<`,``W
M`'$`-``P`````0`````````````````````````!``````````````"3````
M7P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#A4````!````<````$@`
M``%0``!>@```#?D`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!(`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2DDDDE*26=UOKO3^AXK<K/<X,L>*V-8TO<7$%VC!_)8CCJ.
M,[I@ZI7NLQC3]H;M$N+-OJ^UGTM^S\Q'A-`UH46-FTF53I75,/J^!5U#"<74
M73M+AM<"TFM[7-/T=KFH'7.MXO2:J66N_6,U_H8C-KGS8[1F]E?O]+>YF]+A
M-U6O91(JVC3];\3-S&X6&QS7VOV4Y%PBL\[G;6N]3\W]#7^C];_@EHY/1,+,
MK+<S?>\C2USB'-/[]0;MKI<W_@V+"Z-TCH-'UBMPJK;[LWIS&6FNQH%0+P-K
MVO:UN_Z?L9_@UH]7^N'1>DY)P[G67Y;6[GT8[#8YC8W;K8]E7M_?<A&$CH19
MW^C!B$S`GF.$Z[?HTV/JW?D7](J^U/-E]3K*7V$R7&I[Z=Y/\K8M1<_]2NI8
M>9T=M-#GF_%.W+#V.81;83>_Z8]WTU7/^,;ZM@D3D':2TQ0\Z@[>P1CCGMPF
MQNR8S6.'$=>$;O4)+'P/K7TCJ&+;ET&T4TV"JPOJ>TAQ;ZGT8W;=JUF/;8QK
MV&6O`<T\:'7ND8D;BF2P7__0]522224I))0MMKIJ?=:X,KK:7O<>`UHW.<DI
MY7J3!UOZ[XW37`/P^DXS[\EIX-M[?1J8?Y36.9;7_P!<4_\`%_>]G3<KHF2=
MV1T?(?CN![UDN=4[^4USO56;]6.D=2ZU3E]?;U'(Z8_J>0]X90&'=6PEE.YU
MS'N_1^^IFW]Q$Q<?)^KGUVQV9&59ET];I-;\FX`.-U?\VUWI-96YS-M==?\`
MQZL2`HPL7$;?UH?-_P!VQ@ZB5;G\)?*V/J//3>H]8^K;]&XE_KXH,SZ-O'/Y
MNWT?^N/L3O!ZU_C`8R-^)T"G<X\M^T6CV\?GM_\`==+ZPEG1OK?TSKKCLQLN
MNS$S#P):TOH<\_RO;_VPK'U`Q+&]'LZKD#]:ZQ<_+L)YVN)]%O\`F_I&_P#&
M('8Y/WH@?X1],_\`HJ&XCV/_`#?T4/2?_P`HG6__``M1^1BPQD5=#ZKU+I76
M@<>OJV:+W=0<"6V8T^JZG=7[_P!)[:G_`.B]:_U%M=-LKI^O_7K;7!E=>)2Y
M[CP&M:QSG+5Z75B=5JR<_+%62,L[/0?ML;537/I8]C)>UMWTK\AO^FL]/_!)
MLI`'A(N,HQNO);(<7H[F5_W.O^,ZV/D8^32W(QK&74V"66UD.:X>+7M]KEP7
MU*^M'0>C]-R<;J68W'N?F76-8YKR2P[6M=^C8_\`.8Y7/J4VFCZQ=;P^E/W]
M%J+'5P=S&W.^FVIVO\MO_6ZU+_%VS%=T?+-[:R[[==&\-F/9^\G<(B)@V1Z#
M^[+5=9)B=OF>FZ5UGIG6,=V3TV\9%+'FISVAPAX#7N;^D:S\VQBNH=(QV@MH
M#`)DAD1)\=J(H35Z?BR/_]'U5))))2D',Q*,W%MQ,EI=1>TLL:'.82T_2;OJ
M<RQO]ER,DDI!@X6+T_$JPL.OTL>ANRNL$F`/Y3RYSO[2#U+HW3>J.QWYU1L?
MB6"W'<'O86/$>X.I?6[\U74D;-W>O=5.)U7'Q.L=3'0^H4-NPVXXRS[GL?Z@
M?Z%>RRFRMS6[/56Q33513712T,JJ:&5L'`:T;6M_LM67U'$SZNJT]6P*VY#A
M4<;)QW.#"ZLN]5CZGN]F^NS]]6C3E9M>W*;]FI=].ECMSW#]RVUNUK&?OLI^
MG_IO\&A9VU_8Q1,@9@@F5^G3T\'Z/K</.KZ4S*S>OC'<<9@K&3<USC]JLJ<U
MF/34QSO2;BX]NSU+&?S]W_!56^KE?L/H>;:S-O\`JXX4Y;@;+,/)>\MW^[==
MB8KJMC?S[-G_`)\79=1QKK.FV8V$*FV%@;6RU@=5`C]$^K_1N9[%R]GU<ZE>
MZG[/TVGI>4US769U.0=NGT_3QF?1W.]S4N.8.A.W1@S#+&0,;E8L@1^:5_O<
M&3_U'_M';^KMN!6_-Z5@8;<.CIUH9[3(>73^D=INW^S\]SUSW4OJU]6:NJCI
M^/T+[;>^KUY.597H7.W_`,[;_P!^6OCXO7NG]2ZCD8V'5D5YMP>PNNV$!LQ[
M?3?]+<@]3Z1U/.ZC3GW].IR6_9A7;C.OVM;9N>?;8&>_:T_NI#),71D"3K2I
M2R'&!4N,2-^C_)\73T3_`$?ZC9^K'2\+I+<IU72QT<7%FZ<CUQ9M#MOY]GI^
MGO5W`Z[CYV=EXK&%C<1XK]5SA#W$ENVMOTOI-5'$Z#3D85V'F],KPZ!8VYE5
M-[G^H\-+9>\-K<S;[4+H'U2HHKJR>I4C[;5:;*@UY+6`']"WV[6/V_20,I$V
M=?$KA+/>.,0#'4R,O3]/YN'#_B/_TO54DDDE+.W;3MC=&D\2N6QNE]=K8;A2
MYO5*Z["[,LR2YEUCI%;/LS=U?H-;_-^IZ'H^Q=4D@1;'DQ"9!)(X;JOS_O//
MUX_UF)+?6M9CESWC>Z@Y`#:R&U.L;6_'_3Y3M[=C?T-=:0J^M#6UW6Y+6.K<
MP/8[TQ46-H_36VN:SU?TV=^X_P#1UKH$+*I;?CV4N8RP/:0&6C<PG\W>T_F[
MDJ\2M]BAI.9K7YGG*7_6,U;/M&^VQU?JU!^.;MH!.79AD?H6?F,:R[^O^C3Y
M/3OK':6NWO<[[)96T/LJ+6V6OV[;VMKJ;;LQ?\(VO^<3U_5;+QL>NK%N94YN
M,RFQU9=4Y]N_U<BUUU;'.]S&,KKWL?\`X13;T'K7ZH'98BB/4BRT-_G/5?MK
MG=8_T_T;'^M5_P`6A1\6O[>2JE'(=/W_`!_NI+*/K0QN0RBQHKI=MQ`/3W65
MO<WW.W-V,?B4?HJ=W\Z_])<B66?6#"Z#DW55G-ZD"3B8[RPN`<6L8VU]9K9;
MZ?NM^E_P>]`=T;ZQ/I]-V>UIK;8UKF/L!L]6T7V>J\_S>VEOHT;/4]!&MZ1U
M@="R,'$S/0S<AY+;G.>\5,<1OKQ[(9;_`#3?9^Y8].A\PO\`'9EQB7'=9!Z?
MTI:?XKD](ZM]8,?ZS8W1L[/JZIZ]#K<QE=;&.Q'-:7;'NQ_Y>RK]+_I/S/S]
M'ZS]4ZG5G=,Z-TJUN-D]2L?ORG,%AKKJ&]Y94_\`1O>_^7_YFJOU<^K/7^BV
M5TMRL,8/N]=E-!;;82U_IOLR';G/>RU['>[\Q-9]5OK!?A8-^1U-EO7.FW/M
MHRC7^C<RP!KZ+:V^F[M])3'@X[N-`=MY?O<+,.+AZMOZK]6ZC?F=3Z/U.UN3
ME=+M:UN4UHK]6NP;V.?4S]&RQG\A="L7ZN=!OZ8[,S,Z]N5U'J-@LR;&-V5C
M:-M==3#N=M:MI1SKB->'V]5T;K5__]/L-WUJH;]J+G/&27_H-C;35)LNQ_T;
M!C;/9Z6&_P#6+:_\/9:BNZC]:QZC?V?436UQ#@3M<6>\M9[]WZ9ME5-'_%9-
MW^BK7SJDI=.O`M^U^BOMOUH%)L..TM:6MTK/J.#WV!U_I^I[?L]`I_0>G^DM
ML4\/(^L5_4*&Y=8HHJ!=D-K9[7D5,V[;WN/\YD7/_0L9^B^S?I+?]+\Y)(::
M_+U3]K]"8/4OK&/LN)?6'7Y+8<ZRLM?6[:+<BZUC'^G9BXKOU=EGZ+[3D655
M_P##(N=;U[[5F.H&2+*MWV2JMM1QW5BH;'V.M_2V7693OH,L]1GI_P`WZ/J>
MO\[)(Z7^C^Q'3J_1%5GUDJZ=E.8U]]A<?0LM+!:U@;0QSZ<;TJO4<YWVNYC,
MFS\QG^"L476?6%GH_9&Y5N-5>VVY^2*1<^DN92[&K8UH]NS[1E_I/0ROZ/5_
MP:^>4DM/ZJOM?H1KOK;BTU6F<FW)V[Z'!K_3,^H[W,;B-J^FVGTM]E?Z+^D^
MHK?5OVU7GG(PG7/HKK8?1`8:W/?9Z3W;=GVE_P!GHWW/J9;^E_1+YP22Z_H]
M5?:_0_VKZTW@4FL8UA-3'.;6'-#'.J-N5ZUEFW=Z;KF_8_1?_-_SW\VD.H?6
MKTFVOQ6LW.+'M%9+FL'I#[9M;>_U';K'[<-OYE?\\OGA)+3^JK[7Z%^W?6IC
MRYV,.`YH<T;'!@9O8YS'N^Q>HU]ES[+/M/O9Z-7J?X1L#KG6LNVIC&56-R7;
M0X,(],;679%^EMC+L?%W?9-_^'R[*_Y:^>TDO31^56OB_P#_V0`X0DE-!"$`
M`````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``
M```3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#`````!
M`#A"24T$!@``````!P`(``$``0$`_^X`#D%D;V)E`&1``````?_;`(0``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("
M`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`7P"3
M`P$1``(1`0,1`?_=``0`$__$`,4```$%`0`#`0`````````````&!P@)"@4"
M`P0!`0`!!0$!`0$``````````````P0%!@<""`$)$```!P`!!`$#`04""`\`
M```!`@,$!08'"``1$@D3%!46(3$B(Q<8)0IA4C.45M@965$R0B2TU":6MF=W
ME]<Y&A$``@$#`P($`P0%!@L$"P```0(#$00%`!(&(3%!41,'82(4<8&1%;$R
M(Q8(H4)28H*2P='A<C-3D],T5A?P\70VHK+"H[,D5&2T-77_V@`,`P$``A$#
M$0`_`-_'1HT=&C1T:-'1HT=&C1T:-'1HT=&C1T:-'1HTUVM[7E6$58UTUV\0
ME&KGU)62#V756,O(/C)*+ECXB,9(NY69D!01.I\#1!9;XR&-X^)1$$IIX;=-
M\T@5?^W;SU7.3\NXWPS&G+\HS$-G8;MH9R:LU"=J(H+NU`3M16-`32@)TS%-
MY4U7D+\,9Q:E6%]*+1%Y:-$DHJ;84O.&CEPNV;,Y>.DD(2<F[U(E:*JLX-(J
M`E;D!P]<-$%6@ND$NTN:"U.X>+>`_0:_#\=5/$^Y.+YUMM_;BZ2]&T--=,DB
MV]J&)`5U81R27#4+);KMH@$DTD2/$9?1IO"3'=NBGC799#2M$F'9`.E.R>EW
M*)1@WY4BII/ZK3:Y+Q&>5Q5`Q0,!4(CLMXA]1\XB8QB2RAF'[5G9O/<13[`#
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MK=&/:_/V&092YY-6?>5N31:R\:S@4"'0:J.D4_J/N*PI`)"B8QA;6XA,TLJE
M5(H`?'XTTM_";[=<QXS=<EY+R+%W&/L+JWCACAG1HI965RYD>%PLB+$*JA=0
M6]5RHVBIOKZL&O:VJSN"Z2-HY">Q#6&H"+.:Y%L<J1.`?PSN<7@W40_.D<![
M*%5//IF[A^GZAU%V"UN<C-X&2G]W_OUY]]G"F4YS[[\FB_T,N?6R[?SL?%Z;
MT\^L@.K,>I37H+1T:-'1HT=&C1T:-?_1W\=&C1T:-'1HT=&C1T:-)NY6V!H-
M1M-ZM+]&*K-,KDW:[%)N#D30CH.O1KF6EGJQU#$(1)JP:*',(B``!?V]+6\$
MMU/!;0+NFD<*H\RQH!^)UQ(ZQ(\CFB*"2?@.IUD,X4^U7F7.<R<"MW(J^2W]
M+W*S4-+I%,J#J.KK2OP"\A,A`5Q&+F"0<>\5C*-<[#%,#JJO#G^D*J97N;Q$
MV^<DX-QZ+CV5M\1;#\\L((G=JDENFYJBIZLH9J4'6E-9EB.3Y:;*V$U[*OY1
M>22K&*4*[31:FGGT[GQK3IK1=[)Y3;ZSPNV^^<=[Q+T'4<SK1](C)>&CHR5=
M/8.FJ%F+=#F92S"3;*)O*L@[,7LD*@*I$\1_;UD7#TQDW(L;:Y>V66QF?TR"
M2*%^BFH(/1J?=J]YQ[V/%7LN/DVW:(67I7]7J1U\QIM_4?RNL/+_`(2Y]HE]
ML"5EU2M2]GSO4),J3-LNZLM<DSN8I\\:,46S5!Y+TF5B7BP$23(*RYQ*4`Z>
M\]P47'^27EG:Q;+)@LD8ZGY6'4`GR8,/NTTXQE7S&%M+R5@;CJK_`.<IH>GA
M7H?OU)CF3OC7C!Q=W#=5Q;F>Y]G\Y)UQJZ5321D;B[;_`&NFQAS*=P$LA:'S
M1(P`!A\#"(`/;MU#<>Q;9K-8W&+6DLJAO@O=S]R@ZDLG>ICL?>7LA^6.,M]X
M'0?>=4A<6=OY>(^H'E9S9TG4GSW9KLPL]DRVY_C-+CIB/J^=_04B)F'Q(ZLL
M$95^XL3*633%\FY*#%!N*0@0W;K1,SA>-)[AXC`8_'(MD&19P"WSLWS4))KT
M0J.AZ&NJ9B9[V/C&6Y#,L:Y2XC:3>J*I81KMC+D"KT`^4L31:`=-6,^J7D+?
MME]=^9[UOUX7M%J7-L$C<+G*M8YBH,/3]*N\<@X<MX=BQ9)HQ5>ADR=R(@(D
M2[CW-W$:KSC$VN.Y9>XK%V^R`&,(@)/5D0]R2>K'SU8N-W\]_@K.^O)*S,I+
M&E.Q([#X#5-<SS3]B_L0@^1&^<=M5AN'W#7CV:>(A-?"DIH5S<Q,7]W90OU+
M6-E9*0O$I%NV*JS))U%Q3)21;H%7<J>2IKGD<;PKV\LK8<@L7R&;DBWLH-$4
M?"I``)!4$AF-":`=-9_R#F61BP/)>5I=+:<;QD,LA;:&EE]-2=J`]-SFBH*_
MK,HZFM)L^KOBM[(,'M=&M>H;U2;AQIUVL2^NWND.&!U=&9Z)>8*.E6'WDTM4
MV$@UFW+MXD+]RA*NB]V1T3I``IFZJ>8RW!<EAF?#<;DL<LS*P`:J4;JQ-&()
MIX;1WZ'IIS[7X:^Q^$QV2BMHK6PR<0OI8-M)5N+I$D;U&(&Z3K20FA!7;2@T
MD/=URNY68'KG#W.^-&OO<K5V96X04R=*,@7[!]+JVC/H&OO9)25@)QV@VC3S
MZHG^G)Y"0YA\#F`H=6#VWP6"REAR&\S-@)Q;!&'4@@;7+`48#KM'?4]RW)Y6
MRN\+:8RX6-[ARI)`([J`>Q\_#7Y_1S[]/]X=A_\`FTC_`*O?7S]X/:W_`)1N
M?[P_WVN_RSF?_,$'^S_R:LCQ'*.>]-X[URLZMR!H=[Y#QMWLDG-W5%HFM3)R
MEOFCS\?@G!'&9QLDF[C'X-O,6[)J;X15#YCCX=5#(WW%KC+3366*EBQ+1*%2
MOSJX(W-_I"*$5[D]:=-3]I!EHK**.ZO$DO@QJU**1UH*4)Z=/+4V:*UN+&G5
MQEH,G$3=V:135M9IF!:J,8B6ED"?&YDF+%5-,[%)\)?E%'MXI&,)"B)0`1KE
MTUNUQ,UHC+;%CM#&I`\`3XT[5\=240D$:"9@9:=2.Q/GI6=(:4U__]+?QT:-
M'1HT=&C1T:-'1HU2C[Z>0:F.<%)_/X1ZJWN7(NQQ65Q+=JF95XO6OE3G;Y\2
M90-Y(/8%@$8J';N(28`'ZB'6C>UV)&1Y/#=2J/IK-#*U>VX=$_\`2.[^SJI<
MTOGM,'-%"3]3<,(EIW^8T-/NU`CV3<`'>+>H3C"6!0=-M$X9J5^UVQQ%]G*Z
M,IKLFR7UUVT=(@"_TD;ILPT=I*AW^)DS`QNQ2=PM/#N4KDN?YKUB#:9+<B@^
M48/I"A\XP13S.H;D>%-GQ2P^G_XFPV.#\>F\_CU^[5_W$?;X+E]Q*Q[95T&#
MYKK.:LPN<6DF8T<C:$V[BL:17025`#'9QULCY%D'E_QTTP']@AUE>>QLN`SN
M0QP)#03':?';7=&WVE2IU=\;>1Y/'6EXOZDL8/XCJ/QJ-4'>E9U)\1>=O-OU
MZ6N0>_2(3+RT9VG)$`AY0E$D%D64ZD1,132=7G+[/%29R]_\BR)_BCUJ7N,J
M9_C'&>6PJ-Q0))3PW#J/[$BLOVG5(XC7%9K/<??]17]1/L/Z/E*Z=3^\%Z58
M[M&\6N">:*!(7[D1IT9-R4$@4XN#Q[*695*@MW9A\4R,)RXSCA4![B!1ACF/
MX@4!%E[4V<5L^<Y1>"EK9P$`_$@L]/B%`_O:<\YFDN(L9@H#^VNY@#_F@CK^
M)_DU/7G;ED!A_J-VW'*L(FKV7<86-#B5SHIH+/&E7CH2'+(NDDA$@/9(S07"
MX]Q\EE#&$1$1'JK<8O9<ESW&9"?_`$LU]O/P+$FGV"M!\-3F:MTM>,9"VB%(
MX[1E'V!:::;TNU",T'U%YI0IHRI8>[Q_(FH2QD!`%RQEEU73(9^*(C^@*@U>
MG\?\/3[W%N'M>>WUU'_I(V@<?:L<9'Z--.'H).+V$9[,C#\68:S\1UUUSU86
M*Q\!^6E+E9GC+;=ZIFX3]HH*#-U.:#1(1R>).I6DW,^QB'$!HQ:/%_5QKUXT
M?QAHY8@^1SB4;ER3!XOW9M;/)8++Q19F&-1+`YZE02=K`?,E&)VR!61Z4Z=Q
MB?+L.98H/;[,7RK@1D+>\N%3YWFLDD8^DZ*P=(YI8U!<CO'(BAJU78?Q?YD\
M;>8E4<VKCWID/=6\2#5*PP`HO8.WU1=RD!T6]AJ<TV834<D<P'32<@B=BY.D
M<&ZZH$,(9%FN/9CCTXM\M9-$Q_5/0JP_JL*@_96H\0->B,=D[#*0"?'W*R1?
M#N/@0>H^\:SU?WB2RQU+Y#^O:Y2Y7)XFI2ERL\H1DFFL\/&P%ZRB6?%:(JJM
MTE71FK0P)E,H0IC]@$Q0_7K6/:6![K$<NMHJ>I(B**]JLDH%?AUU1N=7$=ID
MN,W,M?3CE9C05-`4K0>.I>__`*/N`?\`HOR0_P#;^C?_`"EU7_\`I%RK_76?
M^T;_`'>IC]^L%_\`<?[)M7`\9N0]$Y78=1.0&9-;$SH^AH3CB";6Q@QC+`DG
M7[/-U-]]Q8QLI,LD#&DX%<R8$<J^2(D,/B81*6@9C%7.#R5UB[QD-S$0&VDE
M>JAA0D`GH1X=]6>RNX;^UAO(-WHR"HJ*&GQ![:??J,TZT=&C7__3W\=&C1T:
M-'1HT=&C1T:-9/?9-%:'[#/;5D7#');NWHR/'&E+61Y<Y"-"RPM3O3J%9ZE.
M60\*B=%.1.#)O6(@B"RGB5^!BJ=BB<H[KPY[3B?`\AR+(6QE-Y)L"`[2R`F,
M+7PZ^HU1X=M9GR%+G/<HL</9W'I_2IZA>FX*QH1T[$_J_CJ6E[]7_LXTJF6G
M/KU[4G%IIMS@I.MV:N2V/(FC9J%EFJC-_'//CGBJE1<MU1*)B"!R=_(H@8`'
MJ!M>:<+L[B"ZMN#A+B-@RL)34$&H(Z:E)N/<DGBDAEY06B=2"/27J#T.F\_N
M[^P62#JO)/A'HZ;B-NW'[1W]@C(=ZJD9:,9R\F\JU^K;=,O8X)5B]UP7"IA[
M@9:9'L/8.W3OW:L(9;C#\ELZ&VO(0"1XD`,A_M(U/[.F_`KB2&WR&#N/^(M)
MF']DD_\`M5^XC2*]I44'#KVI<)N=[`5HVF:1+PE'UAXS4-YBK5EVE.M;UZ4W
M@EXR&2VULFW2$WBH>&4$?'MWZ<<)D_>#@_)>+OUN(5,D0/\`6JR@?9(IJ?ZV
MN>1)^5\GP.:44BE;T9/OZ"OW'^375X[PX<Y/>GR(W>0!62S/A0W"@5%)X95=
MJVME:+)9Y#%8G2,+;Z5W<FEJGVP]^PB4ANPC^O2>6D_=KVRQ&+7Y;W)'U'\]
MC4<U_L^FAUU8J<OS3(7S"MM9((T\MY[_`'@[OY-6W>U;_P"NOEW_`.CTY_TE
MCU0^#_\`F[C_`/XE=67DG_Z#,?\`AW_]4ZBEZ9K_`%;*_43EFC7:2)$52F!N
M]@G'YRBH=)C'[+H:QTVR!?XCM\Z.`)-T"=U%USD3(`F,`#(^Z4B1<QS,CFB*
ML1/^R35;Q.;QO&N`_G^8N!%C+2WDED8]:*I8F@[LQ[*HZLQ"@$D#4QN,^(GN
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MB2,?JGKU-/"OX`CIW.GA]_1"*\K_`%HI*$*HFI=)E-1,Y0.10A],Q\IR'(8!
M*8ABCV$!_00ZCO:PD8'FA'?TA_\`#ET[YB`<SQ0'MZY_2FM-OX)2/]#:K_W>
MB/\`J?6-?57/_P!1)_>/^/5_]&+_`%2_@-*!DQ91K5)E',VK!F@!@1:,FZ35
MJB!SF5."2"!$TDP.H<3#V`.YA$?VCTDS,[%G8ECXGJ==@!0`HH-?5USK[HZ-
M&O_4W\=&C1T:-'1HT=&C7B;R`IA(!3'\1\2F,)2B;M^Z!C`4XE*(_M'L/;_@
M'H^W1JFOUS>NO:.-G(SE3RFY+7#+KMJ7(*56>0ILU>6F58UIG8[5-6^Z,U'=
MNJ]9=MF[AZ>+;,D4"*%3:LA*8P!XEZT+EO+L?F,/@L)A[>:*RM%H?4VC<0H5
M3168=MQ-?$ZK&$P4^/R.7R=Y.DES<OT*@_*HK1>OW#IY:N6ZSW5GU2Q`>N#:
MLP]KMCYT9);,IB\4TQJX0T_/9*2ML=<WBEBJC%A<747'QM1>UMZZ?7>(;SQ#
MN)%+Y7*BP'`G<##HLO+\?>\&@XQ?V\[9&`UCD`4H*,2H-6#`!"4Z+VIJK1X"
M>WY+/G+>=!;RH%="#4F@%0>W@#^.G$]K?'RE\U\QK'$*)O%2JG)">EDM8QA*
MVQUI4BA:4LRS&YKRDY7*W8"P4<[K<D[2**H`=PY(F!"'\#>,)POE</%,_'=7
M"N\$D3*Z)W*]P16B]&`[D=*TU%\MR.!OK_&\'GRB1<GO8WGMHRLC$I!0R.65
M2J``T&]EW&H7<00%;ZL."%AX'X5::IH]DK]WV32]$FK[H]QKC^9EXV1,9-*-
MKD>VE[%#0,]($:Q[<[M<SIN!_N,@Z$#'*(&%SS?E$7*,I#<6D#18^&$)&C``
MCQ8T4E14]!0_J@:G>-X5L'8-;RS"2Z>1G=Q7YB?MZ]O/QU)?FEB5GY(<5MSP
MNF24##VG3Z'(U:#D[.O(-H!D^>+-E$UY5Q%1LO(I-"E1'N*+98_?MV*/4-QW
M)0X?.8S)W",T,$H8A:;B!Y5(%?M(U(Y2T>_QU[9(X5Y8V4$]A44J=4^<5>(6
MF3/$=IPTLFLU"J97QN<;*SM.WTT'DY3KMR'L-TN<W5DJ\G:VE,7L%(X_'LJ+
MR7%P#-J_MC=-FF91)@LJ*W)>16'(N8OGDLV;$))$S1R$+ZAC5`48@L-ORFO<
M&O;IK!K:R_?:^@PLE[&/;OCMP3<3]!'?9*)B5B7?T:UL&.Z=B0LEV%B%1!)I
MLZ1A_NNHQU,UP?V5\7]CJT<D:/K[RWV.!N%[;1S4!10<29+)D6B6-!XD@4!,
MF>8E4TP```YNW5Z;D7M3DF^HN^-W$5T>I6)@%)\:!94%/[*ZO&/O\M<RFRPO
M.,7?,M1T>-Y!3S"%C4?'[]28X9>KBTT'DHCRUYV\C8SD?RQ20%2GP;)\=6KT
MU86SMLA,QX33*%E)AQ&QZBI8MLTB8>+B1.L=-!93XE4(WD7/+.YQ7[M\9QHL
ML.3\U2/4?X$`F@)'S$LS-05(%09S%X6*VRPO<UETN<Z5^1:JNU>I^1*U\^M*
M4KTK4Z[/ML]<>_\`-R\\==#PW1<GSQW@S>WR#J2TN4LL>HC+OYFH3L')QA(6
MDV]@NA%K5@ZBWU?QD`?$/$Y1-V."\PQ/&;3,VV5M)I8[K:*)MIM`<,"2ZD5#
M>'\FE>48*[RTF/N[6]C@:U+-N<5`[&OE04ZUU&7^0'O/_P!Z+Q8_SZ!_U:NG
M_P"\?M/_`,JW/]\?[_4-ZV<_YUQWXI_CU;CP#IG+2D9+:8WF+OE`Y$:([T:2
M?UVY9RJT6A8JDGK-4;,ZRZ.SHN?I!)M9]M(NC@+18WQ.T_XP_H1.D\DO>/7U
M[#+QK'O;60B`96-27W,2WZ[]-I4=QV[:MV">Y>S8W>3ANY=Y&^*FT=!\O3Q'
M?[QJ<8J)@8""H0#CV[$$Q0,/?]G8HCW'OVZKU1J9J*TKUUY]&ONO_]7?QT:-
M'1HT=&C1T:-'1HT=&C1T:-'1HU5K=WR;?V^8TWD%/C0=\.K*T@P4-V34F%+U
M<GCLB'E^GU1XJ-4$P!^HD)U&.0,M"#_JC3\377FO,RB/^*OB*RN1&W$IE0'M
MZAN9V-/ZQ1&K\%&K2NI/7I344=!LUJVZ7D\=QZ9>P%5:.5X?9]MAUOA6K;=,
MY4I7-\L?@4R;[3Y%N)T7LFGYMJLF;R$5)$2((M9&:8F&%J+_`#F\O@/C\?#[
M=9IG<AD^875QQ3BMV\&,5BE_D(S0Q#L]K9-_.O&%5DF%4LP:_-<;42!/M`XL
M:Q9\:P6B\:*,]F,HR^0FVENR"H2*K):1CU&T`%7D31RCLCJQEC082:2RH&<R
M(.9/Z@2JF.LJ2/REK,T-NEJA,2'JH-*]J?;X_'K76(_Q&^VO)LEQ+A6$]O<,
M\O&,<\BSV,#%2RD1>B^PFLNS;,K-5Y=\V^C%G9:U+Z]X@Q<G32WCB7RFX$6R
MO32`M-!SF1F+&=4Q$%"D(NYT4M?>*+L%T@=%=QB"LB()&_R@"`!&2M:5CWVL
ML#`]QU_33\=>?<P_M3:7.+7,^UW)N$9:"8;;JT9Y:]#W:[$3%E(W[X8VF.W^
M<*#4RY>8B[)[?^*MCAK(-SBIW`ZG,1=Q.V2:*6J.DLPTEXSL9VJ+5DDU/.-U
MBN12*BB5,5?$"$`/$';-NS%L0^Y2@Z^?3O\`?K7;JZM<A_%3[89&SO\`ZNVG
MP,4B3[0IF1[.]99:!5"^H"'H%4"M-H[:N:Y)_KQVWD/_`":T[_P5-=3=S_PU
MQ_F-^@Z]8<__`/(G-/\`^3=__CR:RR\3J-@4]E'U^B\!^1/(NQ?DLRC_`#$R
M^4T!E6!8IIL1;07PUJSQ4;]QC#'.98WP@H(*E\A'L'56LEC:&KV+RMN/4$C[
MM?FW[:8#V_ON,B?D/L;R'/9#ZB0?561NQ`5&W;'2"XC3>G7=\M>HJ3JWN`Y#
MY)P.XE52XYYQ2U3/&&CZ[/,_Y)7"PV!&ZLY,D.NWE+@_?VHUM?(1;AA4V)$D
M2^*9@<)F*!1$PFEQ=QV%HCK:,NYS\M>OV^/PUZGQ_-N*>R?M=C<MQWVRR>/M
MLAE9%_+[B247*R;&5YW:<SNJ%+>,**A:,I%"36H]7GFXLW/(O+::S>XS%<KB
M;=*OY(RM!BGAE8^A#36R<A)!#*M54D9YR\EO'Z,@@Z4*7_DB88?\PWY#ZMHF
M*@=%K\*?Y=>7S[US9'WJ_P"I]WQ^[FQ]O016*S=8]MK].`[[-I`E:2>FP4=@
M.XJ;Q?\`:(S'X[]X_IQN'W+^DK^K?[%^4H?4?BW\T_P3\=^I_&/#[G^*?]H_
MD\/+Z;^!\/E_%ZGOS!MN[Z8U]+?2OANI3MY==>Q?^N]U]#]5^X-W]1^ZWYYZ
M?K"OH_5_3^E7TJ;_`$?_`)JM*[/DV;NNO__6W\=&C1T:-'1HT=&C7K^9'Y00
M^5/YA+Y@CYE^42_XP)]_/Q_P]NW14=J]=?-RUV[AN\M>SHU]T=&C1T:-0EY;
M\07/(65S/2\\T9WC>[XU).I#/]$:PC2P-`;OE&RSN%L$,Y5;%DHXRK;ND!SG
M23!9<BB*Z2ZJ9F5W9_4-%*DFR=#T/?[CK'_='VKDYW<<?Y!@<^V(YMB79K6[
M6-911BI:.6,D;TJOR@DJNYPR.KNI7U/RS=9B+1:<@-PB[,W*W4:/J]CM)<9/
M$SS=1`$3#9K"[L]MNJZPG#Y/[%>UU$PF$BB2J0B3KM89V%)YZCR4;:_:>_X4
MU.XCCO-;JU6+G/,(;D;2K1V%LUE'("*?M9'GN+@GQK;R6JFI#(R]-2'AHJ$K
M\;'UZOQT7"Q$2Q;LXJ$B&C6.CHV-;$!%JU81S--%LT9($*!"$3(4A0#L`=.%
M"J`J@`#P&KW:VUK90065G!'%:Q(%2-%"JBCH%55`"J!T```'8:A/S>X017,&
M(ICMCH,SEVAYTXDUJG;(YD:6CQ0EU(QP\93,0C)0KMQ\3J'05:N$'B"K10#B
M`'`XEZ97U@MX$.\K*O8_X]9#[P>T$'NG9XEX,_-C,[8,Y@F12Z4D*%EDC#Q,
M:&-2C+(C(:D5J1J*^@^OGF3R$B(&@\DN;\9<,NB)N/G'4+7,9J\).R#J.0<,
MT%@EH\D*<'Y63U8I%79GR)%%/D.@J8`$&LV/N[E5CN;RL0->@%=9CFO8OW<Y
MQ;66%]PO>:*\XU%,LC1Q8^&*1F0%0?43TSNVLP#/ZB@G<8V-*=[6O6/<IK8L
MVU?!.1G\CULER>E912$5\Z"[S<;&4V#DZTD^4F5[?",G+B0A)(4E`,Q[^7D;
MR[F#QZEQC&>.:"?844*.E>PIJ0Y3_#MF+WE7'.3<']P?R5L5BK>QMP;/ZF1$
M@CDB#>H;F)26B?:08O,UJ>CE4WB'R[0"Y16M\Y7NL4ZWYQ?J.O5GF0QD"W1D
M;?6G\%&SZCQG;'"ZQ8%R]!Q].7X_G\/#Y"=^_2JVEW\XEO-R%2*4'B*5^[4_
MAO:OW4B.5M^4^]+97$W6/N;<PMCUB`:>)HTE+"Y8GTBV[8*;J4W+6NF.R?UQ
M\P\+JGX/DWL!3I=4^YO)C[,PX^PCU#[G(%0(\=_/,7B1>"=<K9,!`5/$/$.P
M!TWAQEU;IZ<-\52M:4U3^,>PGNWPW&?DW&??=+3%^HS^FN(B8;VIN-9+MVZT
M'\ZGEJR'CMG>RYG19.`VW<#[Y<'5F?RS"YK4N.HP1\"XBX9HRKGV:*?OT%R,
MI!BZ<_4"H!S_`%8D[`!"]Y*VCFBC*S3>H]>]*=.G36_\#P/+>/8:>RYES/\`
M/,LUPSK<?3):[8RD:K%Z4;N#M97?>6J=].@`U'CA)P@D>*%BV^[6G36NIW3;
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M\G)Z:L&6/Z^NTFI-9"1#3;K$6Z+M,(G!_2E2CF3)-=8R`"58'"JIEH&&!G2!
M7M9OJMU6>I6A\ZFM>GPUX<XGP2+,0\.BR7MORI?=`7YEO<Q*\EG)%MD<U^LN
M$G2:+T]@6&-`S;:[Q*[,[M4+2O8)/6+,[=*LN3#/2B:19YC><OG<C@J]QQKF
M-P3V8?(U;.I5>F%E[;:YJ!:((1SAI,2#]5VJ!#',?Q64523(%HG(D]3<2PVT
M0*/`>9/AU)U9\#R'WSOK_CF4NXN1)R+\PF?)64EE%%B8;"-I&$-K*;823S21
MJBPNEQ+(SMM+'H[>;&;]D],JN07"3L^XZ#=+)@O(*UZ)2%LJJ!*Q5;B%?F6V
M%5A!O`4)C+)7)2R/V;MZW>.%UP*T^("$0%0AP-DD6%RSLY1B1M%`>NT=!WK0
MG7<-Y_$%A\7Q3*W62S&0S-S@\I/=6_T5N(8+@1.,;"!%:K()S,Z-(DCNP]/;
M0)N#=&QRGLUS8)*1K%EU+6I@>(E/L]@96#-J4,'"[K9K%&Q4S!Y^T@J?$I3D
M[G]>47?BS4,]5>.`-\Z:J?@W(,V2C)*%W/I`FH%`Q/8=.I`_RZ<9"?\`B)X^
M+FXQ^3R.4N_W4@FD62TMC&F3EF2.2.V$4$8DDMHM\WIMZAD?]<,FV->&QO'L
M?KF>:[9Z,\VN[)GBJ3#Q3;1<J5>WN&GI>;3&UWK-:Y8,KR:6FDXFOD43/$+0
MKIBD[.15(5$P\2BOD5CE92Y[=U->_4@$`]O"E-,4S/O[C\!RG)8&;,WH,5NB
M+>68:YCEDD'KW-I$]A8/((X@0;=K9XUD(9"RU4<C;8;EA>,`WB%ILWS7O%%F
MIW+J_7HC6,BIL/HEA:2+A0VDO64+!U",T56EM43>2B'VF+$JJ3<$%U$OJRJ\
MS)=R03JIE:,D"C**FO?XT^[RTUYA;^YF8X)S6VP]YS*\Q,L]G%$E[8V\=U*K
M,?JV6.*WCNS;J.I7T(#N6,1R,AE#=Z3K/+VD2.MZWD$)J4@WRASQ2SS+&5BQ
MVBQVO:QC,#%"^UNM2BS7.XJ9>QIIV52,#=F5!NP,W5^`J1BG,/TK=QF:6%7H
MFQ5JHW%?'PZZD+K'^ZN'N>4<IXM:9"5<8V$MK-9;"U2^OK")-]_#(RVB2,IE
MD'R1A$B*/Z80[CK[="MGLACFF<.[$ZU>/@]<"Y:9<FF447[[.9(B]<G-G^!I
M/:OD>B6.%+!Q"B2[V3=1)G;MZN9JH\(1J=53[(V2I'7<`]2:"NWR7H">@[GS
M/?II3-Y7W]MXN/39&3*)8Y3ZB\N%L;<22V08UM<8&BQ]W+&(TVM)-);F221C
M$9E$99I<)[7NO&GU\W#<MJ8R^HZS0*?9;%$P<K"D@K3._6S1V.?0ES80$<U*
MC*(C(M$GZS=FBX%J3S52!S\HC:>+XV7,9#&XV[N/3,TE"YH-J]22:T%0HZ5\
M:5UZ`X!/R_'^WUG=<TGEN^0(DCU>-8YVC+L84F2-$7U0FU6*QH30%U#[M4(7
M7FK[G\CX\43V&W[7\H;8_H-_0BHOC[*T"HQ[A.)DG\XG%-7$:%/8W!O"//L*
MX)?'959HC/XUU53=U#%W.UXW[=9#+W/$K2QN#D(HB3<!V(J`*FNXK45'\S96
MH`[:2N<SRZPQT6?NGMQ;,P_8E2"%)H.IZ[OA6H\O#6KG$M'+L6,Y'KI8E6`+
MJ>8T+1RP2ZPN5H4MWJL39@B5G(HMQ<*QH2?PF/\`&3S$G?Q#OVZPS(VGT&0O
MK#U`WH3/'N\]C%:_?2NM)MY?7MX)PI&]%:A[BH!IK/*;E;[-_8%R)Y61/!36
M*%@V,\4Y1>K1+><J-6L$EJE@:2-DCHX[F6LM.NQQ?VMS5'RZ1$?H&#!@9HFL
M11<RC@^L?D7#>*XG!2<GL9KK(WZ[CM=E$2D*3T5E_5W#O4D[J4'35)&3Y!FK
M_*1X:XA@LK1]E67<9'%:CX#[.WW]+)/4MSNL'//C0ZNFA1<1#ZWG%P>9YHJ,
M&B=C%S3I",CIF$MK&)57<JQ"4W&28(KH?(9,)!DZ%($T132)4.=\8BXOF1;6
MDC-831B2,MU(!)!4GQVD=#Y$5ZU.IOC69?-8[UYT"W<;E)`.VY?$?`]Z>&K1
M>J5JPZ.C1K__T-_'1HT=&C1T:-'1HT=&C1T:-'1HU"KV!/)FN<7M*T2`U#0\
MOFLV@)*T0CW/IN,@E)ZQ'9JPU;@[*Y?PTJX<5M>=E&YUT&IVBRGB'94O8.F.
M1J+621970J*C::5/8`_#X:R3WON+O&^W'(\_8\AO<=>8^W>:-K9XX_4EVE(8
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MBGD*"A#)JG[CR<I]/?M"F2A)![`5/4&GV'^33_"?Q)YIDXU/F[C%+B[KD+V4
M]TT+00Q011AY2LD=_=V\DFYXUCEBGDB8'<$92CM\,G[3]BD#118J!RJI5>_:
M+MBN>ZA;4&\'7G6-9Q*MH*N*$2TK7\MK\MI$C*(/?N*:DQ'E03(D"3$YSB4.
M3E)VIM10&9J$]/E!H.Y`)/V_=I&X_B5Y1*;0P6F+L\5?9#(FUO;@".%L?9N(
MXC2[O[&-[MG$GK*;B((H7;"Q)I+U[S<O&7>O6S\P-JI-<-<*]`2[V$KM-D2'
MK5]>/+#^.9V\C5F4S;SQ49:73UH=<"O7HHI?(JF8Q!('5MXICI^1Y#'8]F$;
M3/0MTH$%26[_`-$&@KWUZ)X#R[D&9]O;+E/*L=!'E721MML=T4R!V$4D0$L^
MT2IM-/5DIU(8J1K)W7>;V4<G-C-M_M'6Y"[<C6IEPOF?'O*X"&@<0K<<L=)Q
M\3MLYML-)*-14(1%1!(@/9!-JD,C(/"B*0>EIN-7F%Q_Y;PEK.V+I22XE8M,
MQ^'RD#SKV%3M5>^H6#-0Y*X^MY-!=R%'K'`D9]%:=B>H+M]O^&FM+5R]L]6H
M^V<),2I^!SDA5.7F6XAH-5L2\\QK)\[K^N6*5K4-"R=4CX.98G<5QA$IJ*)(
M/DTOW_B((%(!QQNVX+-=8WDF2N,JBSV$TJ,M"WJ-$H8D,2#\Q/<@GQUH=QR%
M8+S$6D=C(T=TBL&[!`>P84Z$>6JG<#Y.CZ8.1_/#(>0N6:+*Q6M6_P#F+@<_
M5X9)U&75NVD;FO6BA)R+N.;.(V=B[,T1<N&IG)HV08NFZJ8JE$H7O*X?_J+B
M.+Y#%7\*R6\7ISJS4*=$W&@!Z@J2`:;@00::JUE>_NED,Y:WUI,8IY?4B9%+
M!ZU^7IV->GZ?#5CGH&XR:1A'%6ZW_5J[*5"S\@-")=8>N3+5>-E&U#AX5M&5
MN4D8AVFD\BG$]).I)TBFJ4#*1YVJP?NJAU4/=+-6>4S=M:6$RR06D/IEEZ@N
M35@#V(4;14>-1X:GN&8ZZLL;<3WD92XN9FE*GNH;M4>!(ZT\/AJ]KK,M6_1T
M:-?_T=P,-RBXW6+37&+06\9)+ZZTE9R"<9G'W^LNKRE-UE-XM8H<U82DC2XR
MD&C'N#NVX)"JW(@H8Y0`AA"2DP^6BLQD),;.MB5#>H4;91J;3NI2AJ*'L:CS
MT@+FW:3TEG4RU(I45J.XIYCQT^_4;I?1T:-'1HTG;3;JO2(HD[<+!$UJ'4EH
M"!3DII\A'LU)NU3L=6*U$IKN#D(I(SUBEVK)HB`BHNZ<)ID`3&`!5A@FN7].
M")GDVLU`*FB@LQ^P*"2?`"NN6=4%78`5`_'H/Y=?C"WU:5LMBIL;8(A_:ZBS
M@)&T5UH^;KR]?8VDLF>MNI=BF<R[!&<)"NS-14`OS%;G$O<"CT-!,D,5P\3"
M"0L%8CHQ6FZA\:5%?*N@.C,R!@76E1XBO:NE"8Q2%,<YBE(4HF,8P@4I2E#N
M8QC#V`"@`?J/26NM1IB^97$>Q1=UF(?DEATS"9VR:2=YE&.EU!Y%UF*?2Q8)
MC+2[U*4.T;Q#N<,#-)UY"W.Z$$BG%00+U+R8#-QO;QR8BX#RDA`8VJQ`J0!3
MN!U([TZ]M-OJ[1A(?J$*KWZCIY:<;+MEQK=(62L6.Z7GVK0,;(J5^8EJ%9X*
MVQ\?*D:MGJD-)N89V]2:/08O45O@5$IQ25(?MXF`19WN.OL?(L5_9R0R,M0'
M4J2.U14"HJ"/MTI')#.&,;JP[&E#]QTFZ-R"XWZ1;9_*\ZUW)+I<ZX225L%%
MJENK$U,1Z<1(A$S2KF%CGBZITX>7`&KTQ2&!JZ[)*B13]WI2XP^2L[:.ZNL=
M+':O2C,A"FHJ.I%.HZCS'4=-)QO:/NMXS&:=U%/T?IUQYGE/Q2KM#K.BSN\X
MC$YM8IZ6KU0N3Z_5!O49FR5MU(LYJ)K\TI(A%OI2%>1;I-=-N<RB)T%`,`"4
M>E(\'EY;B2SCQ4YN8U#,@C;<H-"I*TJ`:BA^.N3-9".-O4C]*M%[4J/+PJ.O
M;3OU.ST33*G!7&D3M6O=)L+4DM7++6Y"+L5;EVASJ$(_B9./5=Q[M,%2G*)T
MCCXG`Q1["`ATQN+::UFDMKJ!HYT-"K`@@_$'J-+`0SQJP"O$>H[$?:--;)\K
M^,<+I:>,2V_9#&ZVK-Q=:2S5Y?ZTA=U+!-&8DB(1.LJ2)98TI)'DVY44`2^1
M05B``=S!T^3"Y>2T-^F,G-CM+>H$;905J=U*4%#U^&N#=6PE$!G7UOZ-17\-
M2!ZC-.-)RO6^K6TT^2L6"(GS56QR%0L@1+YN^^QVF*1:.).OR8MSG!I+QZ+]
M$5D#]E$OD`#``]*RP30>EZT3+O0,M12JFM&'F#0T.N596W;6!H:'X'RTH3$(
M;Q\BE-XF`Q?(H#XF#N`&+W#]#``_MZ2KKK7"@K36[.:<)79R,FS5J??5:P!&
M/$7GV>R1B35>1@Y`43'!M)L4GJ0JHF['3^0/(`'I66&6'T_5C*[U#+44JIK0
MCX&AZZY#*V[:0:&A^W7?Z2UUHZ-&O__2T=3'#>MN<(,:3Y2U9]NTML&ZS]9;
M/=T+!81&;O<[OH]AY!U.EO("%B[I&7)/-9"Y5UX\!)[-5E)1^^3:(KL_X6BI
MGY1D_DPKC&+!"K4AK,841%A9ZDJ4]01.!4))\JEB&ZP0L56WZW@-R7<BK?*'
M)8L%\0:;AYJ*^6FA6X>M-`B96>S+D_QIR#.[U)[HK>J5C.UO;)GM`P]YF^/U
M^WU_/;"5O$M7,D_L.>-WEQE3-89O$I69TJ@7Z@$E%WJY[Z5XX[O#7<]S$(MC
MRPA7>422LK.O7H%<B):L6,8!Z5`^/9/)N*72HK;MP#GH-H'RD=:U%2>E*FG7
M7Q:GPTNCI2OAK_+C"59^XQ9835G-GVZ.JR=3W>VN8IQ%S.4L+CF]P=.9>L8@
MC7XJIF;*56?;ECTWZ*R0RCD_75IG[8>M]#@KGTT:L>V(MNA4&JR%744:7>TE
M1(AW;2#L&OC6<U$$EXO5:-UI1CXK4$]J`=1Y^.E3K_%2!:P:$JOR*XWC=6^E
M[C=>4332MUAV58F%M&TN]/,D@YI2_P!!U&":5C*9R3?1Z,*\K<>W5EDW#E`R
M<B@!Q1LLVQD9!B;KZ8PPI;E(3N`C1!(1L>,EI``Q<.QVT!JITH]HX5*7*[M[
MEZMWW$T'4&@7RH-=J)XK1U5V+"(C4MVXY6XU:TGB]=<WO^@<@9U?>9O+<TH%
M$J5%S&D9Y*1",!+1=RY`U]*62?(R:J<Z]E`6%$TB"103?---8Y)[/&W2;X;A
M)$2!?1$DCNSR.X.X%(6VD;1L"TKMKH-JPDA$LZ%1(A!+'=0`44#L:L//K7SI
MKO[SB];5Y5ZE?;]HN"LGKW7,YU9!*M:U9Y#E+#9;E&*U%E-XI4\.9PS)N^<:
MPA!O',JNC(&.O`RYP.@X!)L)$L;D)1AK*VM;2Y($$D?S1*+<R22L1*TQ)IZ=
M0%!'1U[BIUU-!6YG>250-ZMT8[]JJ/EVC^EU^XZ5N(X#<Y;@!J-4US;:W6^1
M>N</Z_6)JTS=S9NH_'\8A<PE:3EKJ;<,IMV6)@'[!A)SMEEF[A1LXGY.7,W=
MKHMD#$1R&3MH^3V4UACG?%07Q8*%-993('DIT%2"52-2*A%2H!)U]AMYFQ\B
M3SA;EXJ5KT4`47Q\NK'S)TE]XRG0-AB,P;6JW\#,JEF3+CZKDM*IFV359F)K
M+:QI=7G7R]'W-OFT9>HJL7+1&U.C:_'PD&JP1<`W-]8J]7;)%6QM[:V$EZ88
M,E/&3/ZKO$&`D:-E&^'U"A9$,K.SN&I7Y0H)UQ<123)#5X$8%"H#4JH8'HVV
MM"=H``IX'OIY\>XN:E&4CD#7!Y;(5.^V.[:2_P!3AZ-8JWL[JLOKEBM#K&<P
M>J:_J=,1VJ0FJ-4HMA/,7"IX%X2/DT&Z8&CT&1@C[_,V;W.*F&#+VJ1QB,NK
M1!@DKM(8XHW](!V)0@;QN4D_,6TXAMY%BNT:Y'K,6J00=M5`4$D`].XK3OY:
M:-KCNN73%<$RP^L\(\HK[3CO_*K*M!RJ\N+O>I?*!@*I&;KLF'V^:IU44BDU
M\SB6A$6D4=PR1&5(_?RO_-6J:KYK^PM\ADKT6.1FE-UZDB2)L02;F,,4JAFK
M20FI:A.W:J=20@L,[6]O$9X5I'M#*:DB@W,I(\1]W6I.DYQXX<1[:Y9XTKO,
MC-Y?'(O4^3=RPZ<X_7^H06@3<_H%#QB.GZG7(*+KT[1F;*A.JY=7$BUAW+M1
MLSEFQS`EW7*DME,^QMKII<!*M^T%NDPF1C&%1Y2K,2P<EPT04L!4J>_2J<-B
M/52E\/1$CE=K`,2P6H\?U:-V\"-??C'&2E5/FAG5@SO=./CZCU^2E96CU%ON
M3._['9:E`T2:HTBG!1A:Q&W=B\?Z4C,REL3);9:KR$M]:\6B0DUEU&R>0R]Q
M/@;N*[QMT+IU`=C$4B5BX<;CN*$"/:L7[-9%7:H?8`"M#;JMS&T4Z>B":#=4
MGI0T\0:_K=2#Y5.I&\L<*MVDZEM4K4]JS3/KC8.)U`I%/A9*]*5>ZL<^@-QF
M[GR(G9ETE!3+ZG42YU]6!@0GFS242:N2'%P@`%2(K%X3)06EGCTGQTTMNMZ[
ML0FY"[0A(`.H#.C;WV$K4=CWHK=022S3-'.JN8@!UZTW$L3T-`105Z^.H)L.
M++.*HT-89;<^'M]PB[R&E14!4KMR-<P&'9AK-N>TJ'C;7D[W*:-G=6N5OAJC
M3'!B1K%"K.8R?D7SI@X14>N5^K$V:]2=XH\;?19&,1DLD`,LD2AR5D$CNR*6
M8?,3(&15#`[0--A:N*,9XVA->A8@!C3J*`5-!VZ4)Z:[4UPVI\A/P\9"<F..
M\5>$;GR-L'*V40WZ=-H,U5;_`,O:1<E*L(BHK,1[&@TV$F*ZY,]4C?IK2[`P
MB#A5RX'E,_,J2/+B+IK<QP+;`P+L#);.N[R.]RKB@:L8\@!KDV2D!8[E`=[^
MI1S7JX)'V@5!KU!UR+CQ.@'#*SK0V\<03XAKDSJE;PD9GD78HFJ<?+]8M2E5
MD[MA</'1[BMW'5&N=(0*:K)!_%K0]D9N0;.#-W[E17N#..&@#XR^_,(%C::D
M"EIT6,?+,2=RQE]]"58,A%150!]>T?\`:#ZA/3<M3YS\I+=U\S2G2HH=="7X
MHSS6P/(^]<A.,L_*WW3)Y:@6R1W26C-)R#5V7*#4-3UZ.Q.GJ1D/#W;8K#&V
MZ`KKQRM(PKY@M$),G:9VJ*2:O*9N)HT>WQ=VJQPC>HA!CEB-O''$96J2D2E7
M<`*X;=N4U)I\%HX+@W"'<W?<:JVYF:G:I-0.I%*4/34/ZY'7"PJS/T7T*7(B
MATYG396:/,WBL:?K'+RZ;]E=^ID]O5:T%]77=;9U(F?.(^0=,RR%9BDK$2.B
MY9^FN@S0G97MHMFZOY9+)N`HC1QVR0R(PA9`VXMO#*#MD;9O=%(+%ILN&7HW
M[=5(K5AN<NI!8$]``.I[=:`FNKD/Z8;5^._CO]6T/\/XU]O^[=XC[]_M"_YI
M_P`TOYP?>?N'UG;Z[^Q/P?R^/\:_LOX_I?W.J%^<0^KZOY(U=]:=:?1>GZ?I
=4I3M\_J_T_GK74O].VW;]2.W_O-U:_X*>737_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g693329g12o97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329g12o97.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[1+,4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!=````2@````&`&<`,0`R
M`&\`.0`W`````0`````````````````````````!``````````````$H```!
M=``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````$"\````!````60```'``
M``$,``!U0```$!,`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!P`%D#`2(``A$!`Q$!_]T`!``&_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#I/J-U+.R,G*Q\B]]]88VQOJN+RUT[#M<\GVN78;F\R/\`<N&_Q?\`
M_*.7_P`2W_JEM/ZGT!UY>_J72S+W;R7U[]ONV-W>O]-N]V_V_P!A*()&@MI_
M#9@\M$SD=SKOU\7?YU"=8=?7NE,H%?[9Z<QP&UNRVL-$-:T;6FWZ+7^_9_UM
M2=]8.E$OCK6`T1%?Z6HZS])_Z5OYOYJ/#+L?L;?%'N':26&/K#@&9ZSTT$`0
M6V,YD[MV[(^BY6<#JV+F9'I4]1P\IT$^CCO:Y\#\_P!MMG]KVI<,NQ5Q#N'3
M25"WK_0:;'56]2Q*[*R6O8^^MKFD<M<US]S7*(^L7U?/'4\,_P#7Z_\`R:7#
M+L?L5Q1[AO76&JI]@:;"QI<&-U<Z!.UO\IRQK\OJ?V><IK:74-%EKR',J+CN
MH8Q_IVO<ZGU6?:+6>_\`5[*%*_ZR='LW4C-I9KI;7DXX.G[N^[=[O^+5*SJ_
M2'V'=U/'=4^&.;9?CNW,^DYMA]=N^OWO]FQ.$9#]&V+).](Z_4.KTK+L?NIN
M+6;&U-I81M<0:P_?^Y[WLNV;/\&S\Q:2YOH67TUV4RJK(HS+S6T`4G%!:6"S
MU,C9CWV6>]MGI_HF?HUTB/">*J"KE[?3>M_T7__0V/JEB47NRJ+@7U9F+LO9
M);[76NH>P/9M>W=5^ZM-OU.^K.+D../AFIU8$.KON:X-/TQN;F,^FWV*C]3"
M?7=.@;CB">(^T.)*ZBYSO7L#7#D:>[^SQ_*3L<I`:$B_%H_#XQ/+0L`U?1R3
M]6>C'3T[7,((=5]HR2X,G8X/_7MG]OZ",/J_T`O!]/)V@QZOVS(+1[=NKQE_
MNN]):!]X<ZISA6!+]Y.FN_;[?ZW\VG;D8S*G!VZ'1N(@"8_-_P`U'CG^]+[6
MYPQ_='V-1GU6Z$^'L%[MI]KFYF28(!9H1D^>U"H^IGU:Z;?7GX6(:LK'.ZJS
MU;G;20:W>U]KF.]CW?26LV^JK]"UKCL.TP`=?'1.ZUMV.YS-1,#SU\DN.?[Q
MU\5<$?W1IX/.W?4/ZI4AH9T\008!ONDD1QNR6I\;ZK_5]I9330YK'`[&UY=[
M1!]SG,:S-/L=])=#>`XL_0OM!!&YC@T`&.=UE2%M+=!BW.#9@^HTSJ1^=>D<
MD^LY?XRN"'[H^QSV?4SH,`V4VE\;26Y65$#AO])^BFM^H_U9N:&78UEC6DN#
M7Y.0X`D07`.R/I+:=98V-M3G2)T+=#^ZZ7)"RPO#340T\ND0/Q0]R?[Q^U7!
M#]T?8X='U)^K&#D4YF+AFO(Q[&OJL%UQAT[?HNN<UWM=^<N@0[OH?VF_]4U$
M1]R>_$;VNU<$:KA%=J?_T=;ZK/R*&9EV)4VW).$YU-=A`:]XL>RIKW>WV;_9
M[W(AZC_C,:V78N"`T:F6=O\`T)4_J8PON>T-!G&[ZS^G?](+;?U7HH<X'*QF
M/;H6>K0V".Q'VCVI^,D#2,9?WAQ.?R(_H\/68[N$WJ/^,MP!;BX1!X,LU_\`
M9E,WJ7^,MPW#%PHU'+.Q+3_VI_>"W1U?H>A.7C2-2/6H(_\`;CW)J>K]$8S:
M[)PYW./\YC\%SG#_`+4^:?Q2_P`W#_%E_P!\V>'_`%I^T.*.I?XQ6@F_&Q6C
MAI9Z1U_E;\I3&?\`7U[0\8])TW,,4<QYY?M:M=W6.B[I;E8@F/\`#TM_K>T7
M.29UGH8.Y^7B=X'KT.'SW7L2XI?YN/\`BE7#_K3_`(SDC/\`KXV&_9J@V8;`
MQ_"?^Y?M]R&[J'^,K<=F+AEL^W<:YC^5MRMJVW=:Z"2T_:L+VND_I,?P/_=G
MS2=UOH^H;?@D>/K4-/\`Y]<EQ2_S</\`%/\`WRN'_6'[7`_:_P#C&U_5\'3G
MZ/;_`-"$[.J?XR7@EF-@N`T,%G/_`+$K<_;'21QE8A\CDT_^E4AUCI`(/VG$
M<!^]D4G[_P!*EQ'_`#<?\62N'_6G[0YW3,_Z^GJ.,.I8>(<)U@;<6.:'M#O;
MZM<7V^YCC^XNQ63A9V!FVBK&?BV6MAY%+ZGD-!;[OT5CGM_S%K(<1XODC=;<
M)K[.)=PGA^<[_-;_`/_2U?JOC5Y%>;0X.+,G#=78`X-)#K'5.#'_`."]BL_\
MP/J^!I@VP.S<F3\FRH_4O?Z]OYP&/+0R-P`N)=_:_<78EKK&02]S'#L600?Y
M34Z$Y1&A(\C30Y"$9<O"QW>-'U"Z-N._`MV`D#;<^?\`I.VJ;OJ#T`-<1AV2
M`2/UH>']9=/70"YLM?XZ-<WCCW/>=JL6"TUO_G/HG]SP3_=G^^?\:3:]F';\
M'E&?4OH]-98RC(KJ<07,9EF"0?:2UKOWDA]5L`V?I1D%T[F$9-DZGZ3GO_._
M?756"W88W^'(_P#10WJN&6AP>-\@C\^Z-/Y,%KO[:'NS_>/VE/LP[."?JGA!
MS3&5/T9^VGCW/VCW?O.W(5OU&Z'8?4NQ;GD#5SLJ3`^:ZQXMEG\YH[^1X.0+
M_5>X#WP">]C#I_Q#`U+W)C](_:4>S#M^#R7_`#$Z)ZA9]D/,`>M9(D2V7;MB
ME7]1.A$EMF&_=^;LO>!$3[O475/K?`:/5T/=]OC^^P;DC6_:&_I(@$S9;\='
M@?\`5)>]D_?/^-)7LP[?@X'3_J;T?`S\?-QL:VJ^BQKF6?:9B?8Z6;O>US';
M-BZ]4F.MAM;MWTFAHU,@$3O-K6O<KJ7N3N^(WM=E/MQKAK1__]/8^J3<BTY5
M6/8<6Y^*:Z<@MW[7/M<UMS*W;6V>D]RJV]!].U]=OUSM%K'%M@<;)#@=KP[]
M<_>6A]2P1D$D1-`@^,9!\U<O^I^7D7VWMRJ6-MLLL#78S7.`>YS]K['G?9MW
M?3<C#).`]-:^`/YN7RPR?=<?!#W#9_2X/^Z@X/[$K_\`GTL^^S_WL1:/JS;D
M;CC_`%ONMV1NV>H8GCC,\EJ_\R,S:&_;,?3O]E9/^=N5O`^K-^*+Z;,AK_6:
MWW55&B`W=_A*'-_2>_Z?\XG^_E[C_%BRXXYS(">'ACU/'_Z\<EGU5RV5.K/U
MELL+C(L>R_>WC1CFYS?#]U2?]6,IP`'UA<R)U:W(!,@<SU!WT=JWO^;[YG[1
M9\/5MC[O43'I9QG&;+'%XD^VVX#;[?&ST_I?F_SB9DYC.(3,*E,1D81J(XI\
M/HC_`(38CB!(!C0L6;Z?XSA_\VK_`/R__P"AD>7_`)L57/U8RK[+37]:+ZA4
M_P!-S&-N#0X-8\[=V:YW^$71_L1^0&6^M8P1HT&VK_MRH.:FQ^A9#'V.=9MV
MO(JE[WAS-E8#[&N?_.;O4^DE]XS]A]D6S]WY;]X_\YY2WH;*;'56_72RNQAA
MS'&P$'S'VQ0_9-'_`,^[_P#.?_[V+<R/J9EY69D9=>72P7NG9;C>H1`#/:ZU
M_P#)_-0S]1,X@?KN,(\,-@X\?TB'WGF>P^R#8CR?PVA>>0-"_P"=^;]+]!#T
M#I%[.HUY&']:W]0%#FNOQ8<]KZW'TRQXLR;6MW;O99L_1KN5S?0_JU?T?+NR
M+<AEYO976&UT^D!L>'2=KG,W.WKI$?>S5Q4./;:.S']WY/WO;]R7L5?N>N^+
MA_N\7S_U'__4V?J@^C&=DY-]OI4LQ#;98[A@KM>2_P#JMV;UH?\`CE_5<:?:
M+'>8HL@^>JS_`*H-9>_(I<WU&C%VO9M!T-KGN;M?N99[%T_[%Z=_W&9_VUC_
M`/I-.QF%>H$^1IH<AQ?=H<%=7'_\<SZL?Z>S_MAZ#9_C$^KSWES.H9%;3PP8
M\@?YS'.6S?TOIE?M.+[G#VEN/6X3_*=30_:JM'2\+:U]F,20Z'`8[N`'$0RZ
MC_U'_P!!2`X_W)?:/^];)]WN'/9]?^B6.#&=1R"\\#[.T<:\N8UJE_SLZ%Z@
M!OM<XRXG[-49'TOI`+7=T_I`T=AN[:?9*W<B?S,=R@_IG2(VC"/9T_9*XB6^
M&/\`2]R5P_</VC_O5?K.X<QOUMZ/0'/&7<P"`YXHI!T^E]`?G*#?\8GU?!D]
M1R'"-`<8?P8M?]G=&!;^I.$C=/V.O0"3K^K?2T^BHW8'3W5GT<(EYD0_&#)T
M/%E>*]S/ZVU*X?N'[1_WJOUG<.=3_C(^K;&[7Y=UI_>=00>/^#V-4_\`QS/J
MQ_I[/^V'JS^S<,>X8WO\#CN<S[OLO_35YG1^FO8'C&:`?WJ*&G_,LI:]`G'^
M[+[?_04CW>X:&!]>OJ[U3,JP*<HLNN<!6+*G,#G#WMJ;8_V->_;_`*V+I5EC
MI&#6^NRO':'L>QS2*J`00X&=U=>]JU$+QW\IJMKZ_P"*G]972W__U=3ZFLNL
MMZA71:<>ZS'#*[PT.+'.=L;:UCO:_P!/=O5P_P"+S/))/UAS23J22XDGS_3J
M'U"Q[7Y.7;M<*O3:P6QIOW;P&S]+;M79C[1&NPGQU'X>Y.QSE$>DU]&A\/Q@
M\K#B!WE6XZO'_P#C=YW_`,\.9][O_2Z7_C=YW_SPYGWN_P#2Z[']8\&?>4OU
MCP9]Y3_>R=Q]D6W[,.Q^V3R%?^+[-8Z3UW*LTC;9O(_K>W(9[E,_4++,_P"6
M+1/@VS3^K^MKK/UCP9]Y2_6/!GWE+WLG[WX15[./M^,GE/\`F)F1'[7L^.RR
M?_;M!_\`&[SO_G@S/O=_Z778_K'@S[RE^L>#/O*7O9/WA]D5>SC[?C)X[_QN
M\[_YX<S[W?\`I=+_`,;O-_\`GAS/O=_Z778_K'@S[R@C*>>W:?H6<?YB7O9.
MX^R*O9AV/VR>=Z;]3.H=+SJ<UO7<JYM;QZE%@+F6,)VNJ>U]KV^[=]/;^C76
M(##9<`20&:$B'!QB'-^GMV_YJ.A[L[NQ=5L$^W&JHUYE_]D`.$))300A````
M``!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````
M$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`+@`P`````0`X
M0DE-!`8```````<`"``!``$!`/_N``Y!9&]B90!D0`````'_VP"$``$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("
M`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`70!*`,!
M$0`"$0$#$0'_W0`$`"7_Q`#S``$``00#`0$!````````````!P0%!@@#"0H"
M`0L!`0`!!`,!`0`````````````%`0(#!`8("0<*$``!!`(!`0,%#`4%"PL#
M`P4$`@,%!@$'"``1$A,45Y?7"2'4%196EM87&%@9&C$B5=68,B,DM@I!T5*2
ME)5V-W<XV%%AD4(S-'6U-KA9)29X<42W8E-S)SD1``$"`P0#"@D&"`L&!@$#
M!0$"`P`1!"$2!08QDQ5!(A-3TQ1450<749'1,I+2E!9687%2(P@8@:%"LN(S
M<S2Q8G)#HR1TI+34-<%CL^,X&?#A1"5U5_&"=C?#9$4).?_:``P#`0`"$0,1
M`#\`V@C?;&^T"!,8**W#"S+#2N\Y'26KM8-!DX_P'UQ%2BI!*?\`_&^VK_GZ
MC0\\/YTG\`\D>(%-]M+[0S#R'7<X4[R`;4+H:()5\A+;"%^)0/RQW\>S9]I8
M'S09G-?;`@8BF[NJD3\/OAP"C$U>Z5ILH8$N;KX\B2<?%'1)AK#9@+Q!&>Z\
MAYEQ:,NMC[3+W";U7G1Z#_9F^TZQVW(K\O9@P]FBSU2,\*4M7N`J60I*5.LA
M:E+;4VI20XTI:[%)6A2A?2WVP=;$=N(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'
M2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$=8/'_D[
MR&Y#\I]UZDN&GI*A<=:"FU%4;:$''VJ+^L1F&M<?7:MAZ]F/_`LS"7B%*(G!
M55_R5W+0S:?*'Q<O>/K(<6XXI)$D">C\5ORZ;/X(ZN=GG:EVC=HO:QGG*&,Y
M,=P_LWPX/JI:YM#Z.>!M]#+$ZI1X)QJJ:4NJ;YI<5=0D<(MJ_?GBAU2,H7,+
M8<!08T*M4JP:!H]UN%5A&4QU?1?BMB7F#A;6+""Y;C0)FQP42<Q(/LLMK-^#
MF%.Y6MOO=7)3=>4E(`1=G^&<<^P#"*3`.V/,=!E^F12X+49?I:FH8:%QGG2J
MRJ:;J$M)DA+KS3;J75I2"YP+965%,XW&ZSQ]EATA#I"/_]#5_J(C\R\=B'LH
MYZ1@>??'YR.?6UB4EK;`R#6''$LF1TO0+4*0P2A"DX?0VM2'D)5VI2^RVOL[
M4XZRLF3J#\L=D/LCU]30?:$[/%4SA`==J&EB9DI#E)4`@@$3`,E`&P*2DRLC
MW$=24>[$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.
MD(=(0Z0ATA#I"'2$.D(=(1JOS;WD5QPXI[OV[$-NDVZ`I1D3KF/':P01+[5N
M9`U*U9#LC=]"W\RFP;#&LJ2CM7AM:E8QGL[.N095PE..9APK#7#*F6Z"Z=`2
MTB:W53^1M*C\\<?S5BRL#R]BN)-B=2AHAH?2>7)#*?\`]3JD#\,=5O';66]P
M-*<\O9D;$W+LB?WW5-7U;:VC=MR^P+([<Y./V[J^.<`DX2YN'*LCD)0^2=)E
MQ"5I>3E+)6&49PVI'9]!QJNPA>*91SW186PC!W*A;+[(;2&P673,*1*Y><IE
MH(LTB9MCY_@M!C",+SAD*MQ>H7C+=.AVG?4ZLN%+[(DH.3OR;JFW`;;$D)T$
M1ENSN7UYWC[+CC,YKBR35>Y$\X)34O%`">C5%A3]0VA-S)%.Y$V=*X]Q$G#I
MI$;1[8^DY"F7`G4,.YRA?=3G6H,M4F%9_P`>%<PE>"84EZK*3(I6TE(73)ML
M5PA<9%TSO`D6QGK\RUF+=G^`JH7U-XYBRF:0*3,*;>42BJ4)6I+26WS>$BDI
M!C@49R'@]F>V7U?QLLMLE[[JCC[P[@N.4!-V21L"ZY.N<>+JAUVIL3Y94</<
M9Q4<A]+RTI0?,(8=+RO];/5W!X(O#NRZOQNG:115%96JJ5)0$WDBI;L7=`-Q
M(,I#S43"91C2O&V:_M2P[`7W%5=+142:5"E%00KFJ_,"B4A2B`9FQ2P"J<<7
MLEU\4MA62V;5H.V]U2?(A40B,M^K=V;VW-.[4!HP<16(AF?VGKN^6\^OV0V8
MNK,K8`9.,$>B(U%G2,.MM>,)3%YS&:6&G$8GA]$,"=>G3NTS%,&B@7K@:?90
M%75))5<6N_+SA88ANR$X1BE5CF8D8H\YBM0L!MIVH<<>31-H;0TMX%:DN\,]
MP]8TM-Y#2*L-(*2%"-5/9T7KA)>Z%IDO?/(;D=)\MIG<]ZBR81W>G-#XOG6-
MCD1=(75D01$5ZQ9U(Y%D5H:%8=87CX/6WG*3,=N7\=<TSK29IHZO$T81@E`G
M+J:5LA7-Z&^$FF0IU0*D\-.\5D'SI^;N19DFJRO6TN&KQ7&L17F)56X".<XA
M<*A4N):24I7P%VZ$`B5R5BMV/35!P(E?')%#*F2FRC73UJFIZ9L#[;KS;+:V
MA2)HX]\,%.&,90.TI##:LJRE&,J5V_"GGE/J2I:4`@2WJ4I\82!,_*;?ELC[
MJVTEH$)4H@F=JBKQ3)D/DT1>NL49(__1U?ZB(_,O&^_LO?\`?VXW?Z7S']2[
M-UD:_6(^>.P?V5/^H+LS_M;O^%?CW0]2<>\L4Y18H([A1I(X8K.,9=)*>;''
M:PI24)RX\ZI#:,*6K&,=N<=N<XQU:I24`J6H!(W39&1IEU]Q+3#2ENG0E())
MW;`+3'/C.,XQG&<9QG';C./=QG&?T9QG^[C/5T8]$?O2$4Z"Q'"7PFRAW#!6
MAWRA$/-J)&9+R^D5Y]A*LNLM$J%<PVI6,87EM79V]W/9:%)*E("A?$IC=$]$
MQ\LK(R*9=2TV\II0962$J(-TE,KP!T$IO)F!HF)Z1%1U=&.'2$.D(=(0Z0AT
MA#I"'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.D(=(1UZ\XN,]LY;W+B
MGJ>7K[$CQFKVW)3</(TI=DQ#$R[6OJA+-ZKH`\:!(A3\N!:+U/().4SX;8C,
M8AS+GB>&G/,\IX[39<I<PXBV\4X\NF#-,+MX)X18X5PD@I!2VF29Z2HB4IQP
MS-F`U&9*G+N'.M!6`HJB]4[ZZ5<$A7`M@`A1"G5!2B-%P;LHB\3@-%<<.8W'
M'D!Q!UU&UNF%P&SM,\I8'%PDWB)'6]I`C+-0K5&)ND](N$DTS9%9'4^.(K)#
MPI:\(;SV+5B05G!S',LXW@V9*U2ZH+:?I%7``'4$H<0;B1*^THR)L!2)G1&@
MG)[>"9GP/&LN4813%MUBK3?426E@+;6.$49E#J!,"TA9D(AGBGPRV!#\[]D[
M4+/KTYP_U3MKE+L[C,['RHRY,'?7("0I]'WM`%5[N9)BHC4]FIMTB@\K2E"W
M9AQ8Z\MY4VG<QG..%U^3:.DI%*]X7VF*>KWIN\#1J=X(A6A2G)M%4N+D=PQ`
MY2P1=5FK$L7I:EI[*=+75YIBDVBL6Z*:M;*2!+FS[-4T-R:U73(1R[8BMKZ4
MY(^T<V&&'KL.N\A:UQ&?@YB][BKFJ(,RCZWH%MI^QJR9>#TG8UY=KZ^21$5U
M\MEI>$I,DF%9^#NZY!UV*8)B67\CX#45ZV32JJ^<+#95P:7G4J;($TW[P2;$
MJF!,Z0`>,9ZQ!>!XQGEFJQ*BHL.Q)JB+]1453=*VW2(;<;>;X=9`9J:R2V*4
MDI4E(?J4$FF"5UVI@;WRMYA<0^2DQJ33_&>F<?Z/NZ,JC,#OK3NX[_R!#M5*
M&H2:C6EZ7.DH!&I-5N22Y-:B)!]UF0R.E((WB+<QOO8EE_!,K8UE_#,?5B+M
M>MD@!I;33(97?*P'9*+JY!!N)D$SFLR`CD&7L3PW->/Y-QG#E852X;3TU0FF
M#%92U"ZM`;2TIM@4RE(53TUX*5)2KBK@N(G.(PX>[BY+<(M24KB)=>.6HIBQ
MTB[;&<+ES><7'RG31(FV=P7/:4,[G7\LX781"6X2_#I;'4M3I>$I6C&,.IQC
M>S4YDO,6,5>,ISCP+CC;0X(TKJB%-L-MRO3`M*)SE9.(O`\[HR4BGR7BQPE&
M*,OK!2YBU$T[_6'E/-SIUJX0$H=24IE-8(*;%".^-5BKZ;`W4U3L,FTNQ#E@
M:K2I,+%@<@63&XYZ;;ALO_"*XAJ0>0PHG#>64O*PC*N]G&.OETQ.4[8^W'$L
M.&(IP@U[.UBR7@S?3PQ:"@@NAN=_@PLA!7=NA1"9S,HO/58W8__2U?ZB(_,O
M&^_LO?\`?VXW?Z7S']2[-UD:_6(^>.P?V5/^H+LS_M;O^%?CW0]2<>\L:Z<F
M:0;=J3!)AZG:KC8ZS;4V:KQM:;UD>"Q.LU.VPHY5TKVV['6JC9Z:Z/-NBD">
M*X<V22.4)X#XR#!8;&Z9=32M<%3N./(<O)">"("KJQ-:7E)0I$E$$3O`D*3(
MIO)^B]F>-LX)C=<:S%J2CPVJI.!?6\:U*BT7V'"FF=H&7JAFH!:2M#ET-%"'
M&G;[;BF7=<).O<S)NRN,XBI&E0DD1K".LK=+ND(JNM!QN[./6;A*4*0G;\=-
MQ(CFG$7SO#L0%>=0VE#/9)&J#>5#+9S*X^4W"VRHMA5Q:;H`>I[Y05+*@.!X
M>P(1(2&_5=,?2*7$>QFAPQ*S5MUM<VFM6R:FF<X8J7AN+<W15(:I4M.*&(G"
MY+555:225_U9@/(%EN$=R0U[BA-2,_MNPQ%KV-4ZG/!1MPIKUD.C6MB[%`CX
MV'DGI*'8@G9K4V(C!YF"PUNN,)(<(1+Y??7A>1CE(*7A7:A;;CJ$J`6B]^M<
M`"3,!,VKEXS$Y3)OS,;N#U'9MF';ZJ:@PBGJZ3#7WVE+IZ@,I6:2C4M;B`AP
MNANOYQP3=QP)"BVEM5($(3\RNN.72.V8BG;3'F3L72XJ=-CSJ'-[#S!P:-^*
MJX4HO.UM9P4C8J0W:*TN9(:F\!R<FTI2$R862VG+5468P5O(*PM80"06U.74
MA^Z#]:TDJ1>;OF_)2A,7TW@:TN9.R)4J.K12N,L.U+C25)JFJ3A73A7#J1_4
M:UU#-26*P4R%4W",LJ`4:9X-+3V3Q2#FHR.:DR/+))L`-$@7Y,R%Y4<@=M)9
M'D8Y!8XGCOX4KPD.NH;[>ZE:L8QG/-VPL-MAQ4W+HF92F96F0)`MW)F7ACK7
M5*8555*J5NY3%Q10F\574S-T7B$E4A(7BE).D@&R*_J^,$.D(=(0Z0ATA#I"
M'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.D(?H]W/N8Q^G/2$836MEZX
MNB#'*=?Z3;&X^01$GN5JU04Z@&5<864W&&*BSRDC2#@S:G$LK[KF6TY5C'9C
MMZM"DJ\U0,0>&9FRWC0>5@V8:&K2VX&UEE]IVZX05!"KBU75E()"3(D`F4HR
M5N8B'>[AJ4CG,KP[E'AG#+[V&,/9?RGNNY[V&<#N=_L_D]Q7;_)SV5F/#$HF
MLI%2NU39G/0I.Y.>[N2,_!(^`QJ;J:)O>EH>[TB8F=3!T$K9.RK_`*_V0==2
M\2F(#=>SYZ^@`6"G&PX01<M$VR[OQC+[4V@:1;\E6C.'G'&$8A?0%`E-V9,Y
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MS;9L#7_'O`NQ[R"742ERTJ1`MO/8>';R4\E*,-6HIWDE#MW>@G\>@$@:=/SQ
M\VRCV0]KV4LR9<S8U2X!65%)5XTYS9VJYJ[P6))H`VJHK*/![M95)53.%]]=
M*E:@IM/"N!(N9@5Q;Y#KY0;#WF:!21PMKSVEK&JJU_D2?7&(T_7^KZ;6K;"G
M`R_%NVOWH%$K`%Y&>9*A%DQ^$J<;&6XK#-X9=*W7.#F+/P6`>#PQ+N=DW:0Y
MVI9ES\ZS1)I<5J,,?4PSB[C*6U4M%3,/MK2Y@50:I'"-+X-27*4N-2O(:4HA
M$BT7A%L2)Y?7#D=<.1>UYR&"B:O7]<Q?QG@'I.7JRYB4N5RHM^'8UY$"@T`6
MW$C?!4?&D*?=894HHG/:EI-$LJ#A67#+<M_$?DCD6!=AN8J/MCQGM+QCM(Q=
M^B0RPS1M\.R5N,%QRIJ:6K`HVTII$U"D<`TRLK*4DNNFQ`[(>MF.RD?_T]7^
MHB/S+QOO[+W_`']N-W^E\Q_4NS=9&OUB/GCL']E3_J"[,_[6[_A7X]T/4G'O
M+&KO+G8UYH>K0(;4YA(.X=K7:NZOUD6%!Q]F/C9232?9[G98^O2J'(N;D*-J
M6IV*>8#)0H<IZ+2R[C"%JSA"-2YGG];#-:6-`6OL0^R8WC5:^0DR*#9A1CJ=
M3Z7J"\HOY>,3M,L4*N[Z]Y4TM5$+B7QC66F2V)1SQF\9#<1647B]>T#MM2F;
M)3([3<;/[%B[_L2%B:FB_1P,=)5"FC2I]0)^/3XN:8Y<]O144LZ.BVBU/0X;
M4@N20VY%NM$5A*,RY)[XO.I=JPCSMT-A:5:=6YCZ;1:P7J>0M4=N5Z!W%8?A
M7;5-M$!*7P_79\36@$1AU4D<I!DX<_,F.N-RZ4/2*1A9_)FZ6'>?$2I5C9K)
M5-V%I"5N>R,TZQZ)CAS;K%W#0T8XF9-OL#.FD"BQ5]/\HA*ZX%+NI)0IGNJ0
MWG%8KN&-A8;D9?[#%<HG8W1%Z%G=&XFFZ7!S*ZJVY>9D'2NO]E1-1?77KA9B
M&+).S5R4PSX3.1<`Y95ESRC+C6*12(0.OESE>.M<V?1N8]CNEHG[+QUS.&4^
M#XZ$5^#'VMM"F4BRQ$17W-33TM!1/D]AD$`LS!LC*BD`H0\6^MDG#M1;`[MD
M2YO'8%BHUZX]:\IV[E_6;8[5119"@V<;6*(^_:PC;A6P=R;!OCWQ9BYR$DT4
MUTP:OYKKL0,3<C0!O(WQ5O-,TA$:P&^[QL/D&]5JGM2%,JLUL^6I<92ZV+3I
MAN(U/$Z`UINR$W:-8!1I"9F&[E.V%J/;-P6J#5%6H!EH9)P^2WJV0(LC.-WV
MG>.H=*?%R-V([<=Z[:V37-:ZEL,91JZ[)0V96*8E;?,1M1\E3!6*8HFMZ9:[
M<T,6VL<ET+`SO:QCMPLW!`1$XG/2X$U^&(9UE6G;/):6J]PQ73KX%&'XV8#=
M*M1]\4>0PZ-D.O&:*DIQ_#H$@\*?9BVF@X?QW759:I%8HF?:1Q$C:"FZQ6ZM
M<=;1.JA=Q638$=:Y6`^+M'JLYQR:W1.&U>UU>*M>8^@T;D%BRM/.@C#DA0C@
MN7DF//-`H2BCY)<E-Y#:NUCL+7N+;K4JV\;N0>^R8>"!UG.KK@U,"U=+T"7V
MNWM"O/R::?5J]=W#+9%5<9ZS*>PL6,28XTC+B&[',=[0:])$VY*Q>F*^56-7
MVB[U@NWG[+AXP=AG5NUEZZN]F/JV&3+3)!'UD$VW0T?$M'2!D.+X*4K(?%\H
M0E%WN?.%^?$<J='S"P=O^%-BOG%1]@#F)F!A]5<HN.>HP5GUB6@F"Q!MJ4K<
MZI-I93+#@C&&\-8=RZEYL;(`>&,BT=R^V-;[CJ.D[/K.L(ES9\YN.MC6*E7.
M5G$+N&N[#MAL:@LU14*N=@)<2IZI//(D)?(L44@=YEDA)Z$!.H2CL2Z12'2$
M.D(=(0Z0ATA#I"'2$.D(HY&/$EH\Z+/:R^#)!E1YK&''6<O"&,+'):P\PXT^
MUEQEQ6.\A25I[>W&<9]WH1,2,8:FG9JZ=^EJ$7F'4*0H3(FE0((F"")@FT$$
M;AC4*1X&\=9B-@8J8A[O+B5B+C82`3)[/V`:J'AH)=0>KT7$>46%:(8.!(HD
M6X/@/`ZLK87XN7$D$X>US3-&4YV?+_XT2$?'JCL#[.:RFP^DK*.N>9I6D-,W
MZZK5P;;7-RRAN;Q#:6C2L%'!A))2J^5!QT+C'<W"'1-7UK=+-KG23=FNT3&J
M.JM7CY:T`9D3VXJ\UQBO1RJX2V=%QDC%[-EF'VVDJ$SAYM\IDC`C:<6.4S24
M**&[?!X_+'&<Y]AV0L*RUC6*9<R.*K'&6BMAA#CZ+Z^#JF0R@LD*;0M%=4)6
M`"WODN.H<#20-44:U@ZG\9XX[@;LZT'5PT:1BI.NS6Q41$Y*Z_W/4(NG%5MN
M8A;*^"B>AM?Q%I)[I&!E"ODMJ%\4B1RO#=2"0:=1(^<Z#N6'P3_V:8^3^[-!
MA.U:=_L$Q2J?IEA;:V7:P-NN4F)4R*93(<;>*0ZW24]<N2[A0IU):O.U,ZZ6
MU=K!X)B*#]GWO*74'*5"'+#78KQ&QS8E9KEOUV#',2$E$ML'PDG6ZZDHA\=&
M`R2)Q@B0+%*=<R@4(WLJ95DO#Y/&?Q[D;%7E;*RV$4C/V?,=>4AVG;4DNU*$
M766:BC2@+6B2FELLWUJ0`VM=4V[4/-.K44PGO73DK??:L4NZC<=>4T'#4O>&
MB+E(<J8>F66XM6DRLP4571M04.3Q+UJL:?XJB^7K)O1;C4L7.F>6J0/AI7E*
MOO.$XFW1]GM52JQO#UNNTCZ!2%:47`I147G!=4IZK,I,":`VF[-4]['WC%\+
M=K>T&DJDX'7H99JJ=PU:4E=\I0$AALWTI8I!.=09++BK\D_E1@/++76_>4FV
MI/<`'$_D4%<MG:DT17>&DS:Z['0,QQ!VEK7DI9GMK3VQCHNWOCZK*L5<%!L+
M4JE1&)R`<:!\7*\*$1NY<KL&R_AS>&KS#1*I:>IJ%5J4**A6-.TJ0REL%$W0
ME14W=LX-R:Y2WT:69:#&<?Q)>(MY>K!5/TM,FB4I*0:-YNJ67E.$.$,E2+CE
M\$\(W)$R1=CTP]?"H^Y0Z0C_U-7^HB/S+QOO[+W_`']N-W^E\Q_4NS=9&OUB
M/GCL']E3_J"[,_[6[_A7X]T/4G'O+'$XPPZXPZZRTXZ,M3@SCC:%N#N+:6PM
MQA:L94TM;+JD9RGLSE*LX_1G/2$4GP1$]UU/P9']U]H]A]/D0W=>9E"%F2;+
MN/"['&I$MQ3KZ<]N'G%94OMSGMZ0B@<JM7>&)"=K<`Z&;)*F#!'(>.6,7+JR
MG*I4EA0^6GY)64XSE]6,NY[,?K=(16OPL.2>B5)B8TB3;#<CT2+X(KIZ`'LK
MR\"@QQI1"0W<N*RIK"NXKO9[<>[GI"+0U1Z4QY-X%/JS/D1*C0_"K\2WY(8O
MR?O%C=P3'@$J\D:[7$]B\^$CW?U<=B$9*AEIM3RVVFVUD.8>?6A"4*?=2TTQ
MAUY2<8RXYAAA",*5VY[B$X_1C'2$6P:O0`:SW1(.(%<E2VCY-P:-"87)',O9
M)9-/6TRE1A;1&?$2XYWEI7^MC/;[O2$?AM>@)(X23D8.'D)(#+2@)`V,"*."
M4P]Y0SD0M]AQ\;++^>^GN*3W5_K8]WW>D(^@X""CB6S(^%B0"VHP6%:*#C@Q
M26H8'.<A1+;[#*'41@><]K3&,X:;S_)3CI"+BXPPZMAUUEIQP9Q3HSCC:%K'
M=6RX.MUA:L94TXIAY:,J3V9RA><?HSG'2$6-ZHU0C)JB*Q7GU23:VI%3T+&N
MYD&G#U2KC1N5C*R4VY)KR2I+G>QE_.7,_KY[>D(QRZZHU_L""L5;LU<%>BK>
M,!'6M,:Z3`F6:$!)CG7*W/2<&]'R4K6)82,;!D8YYU8<C%J<");<%=<:4A&=
M.@A/X3AX,5["1WPTX=':<PD0G#:214X6C/8.0EE&%H_DKPG';C/9CI"+214Z
MJ8Z4^76J^4^=Y'@UXB&CGW3,1^&\`>5..C*61Y#AI.&>_G/A=W'=[.S'2$5.
M("!P<;)XA(C$E)8'Q(R&(T/RX_`F!TBX-+\'QRL#)$:PWXBE=S#2.SL[N.Q"
M/P>O5\4_,H+!PXTFI1:\R(\8$R?E4@]D@]63&V$D94:_GOO9[W:XOW5=N?=Z
M0B\=(0Z0ATA#I"'2$.D(=(0Z0C28FF\\XN=,*@]PZ0L\',627FO@ZZ4Z4C%T
MR!-L,T5%T>"54HH4BT#PM??`'3*R!`Y9"QW?$9RIW#Z.4"IRDXTA+N&U3;J6
MPF:%@WU!*05JODA,U7C<2"!,2-DHXZ:?,S;BE-U],MM2R9+01<25*DA-P`JD
MFZ+RC,R-ELQPM0GM#7&IU15TXLC//Q<"[7APH38CZ`9EU^MYM`!YQ(J,D1H0
MITVF.,P-XI#L?&K?%:268T.4YDX%N[35Y%Y4YJ;M3)5T@`Z20B\F<@%+DHW4
MDU2C-$EWGZ*<A(`.:=[>$_``5R,IDA$P)J`3,'SX;K)1H=TT@]:P=AE2;,=`
MQ4DJ)F-6@5MP<2%$CK+$AO(NL]/G.D9&?G`PQEA!(S+^`Z9WC3N4B^E"J:J%
M.60)J4)ATJF5$I)WB4@"805&:CP<PF"V\S!E2A44W#ATF029%L)T25+?J49R
M*P!)(ORO3Y-D5+G18`H,O76R=8TB:^*E$?FP'7PWZRS<G+/.O[+BD!2^EKO/
M24(+49,)F$DFY<!QXV+_`*2`A!3CJ%%4Y594ZFLH7W6N$<NFT*N74\$9I>0D
M$K"BXFXK>JWJYI`-*QC,CR6U4E8RTY<1,6%-Z\>$$BTM1%P@(5>%J=\F1,<T
M]1N;[X=<!@MR:\','UK5X*>L:HV+"2]L%X2U0]XN#M3*U-9$310+4G%R\,H:
M6@8QZ5C,L%1"07W&LT9J\K!;RGL,>*"^I24S)DW-!0B]PR;H,EH7-+B@A4TN
M7P#%7:;,10REG$&PL,I2I1`M<DH+7=X(S(FE2)*0DJ3)2+I(BLU?2^;41;J[
M([5W#JNUTV9<NC]\K$'5\QTI2$$9L"Z#'ZTL;57C<6U,?DL!N3*G!!%/)&[S
M3.,^)@BVOJLKNT[R,/PRH;J4!`;4I<PY*[PA=3>-R<E%(;493D3HE?14^86W
MFU5U>RXRJ]?2$R*/.N!M5T7I32%%8$Y3`TSQ>*IGM#!(DJ"D-NZ(D\OUT``.
MZ$P,EBXQ=E56PV)>PD@Q]'B:3.@(M!1KP4>F-CNX.,%XQ#N<E-/9W:G)RW`\
MC#JM,EDE`4+A3>,DS*U+2;H2"J\JTJD!O2,+=/F=#?!+KJ91N2OE)OA5T35(
M(2@B]>DFZFP)F3OIU<E!>T1R'#-1-UXOI)(@S6;$0='WQ+D5/YE)80(R"4S7
MGAYP#XM+#*R@E@#+4PES&</!XPRY:AW)H4X7*:O*0L79%NU,@2%;[>F]>%A5
M-$M"K1<MO--UL(?HKQ2;TPNQ4S(ILM%V1M`DJ>E-D4=*+]H*K9T5!WV,TXQK
MD.T"-3]R@.PYB5I;L*Y.//0(),Q%V5FS!RC&()UPJ.8%?=*2<T,VR*I!EU2G
M)_,7':1RIYZ6]ZA5DEWKN^(24W2/K!)1(`N$DJFFC"LS\[;;J44_-+^^4F?F
M2G8"0;P.\,TR,[P``(5OEUQ..1Q__]75_J(C\R\;[^R]_P!_;C=_I?,?U+LW
M61K]8CYX[!_94_Z@NS/^UN_X5^/;#MC9U1TKK'8.WK\>J,I6LJ=8KS:36T)>
M(:A*Q%%2YZ0AU.->62#[`N6QF,*PM]]2&T_K*QU/X=05.*5]'AM&B]5/NI;0
M/XRR$B9W!,VG<$S'NSB-?38505N)UJ[M)3M*<6?`E"2HR&Z9"P;ILC^?-S"]
MN3SHY,76<?H6UK;QPU5B0>^*%"T[.E4^=!BFWL>1O678T#F/ND].$L-(R7W#
M!X[Q.]A@5I"E85W-RSV2Y2P&E:%9A[==B-W?N/)"TD[MQM4T)2-R8*O"HQTD
MS3VQYPQ^K>-!B+E!AE[>-LFXN6X5NB2U*(TR4$>!/AT:^WKSG^^ARQ_B+W!]
M,>N6^Y^4OA?#O9F?4CAWOOG/XMQ/VE[UXV`T3OCGMO,?:9(GM"-^T=G5^O2;
MV0_=>3FX8P:POIEXN#BZI"O)MZU$6.?DY5H<(9M#KY)"T---K6K&,0V,81D_
M!SAX7DRC>-0\&P&Z5DE.]*BM6\L2D`E1L`%I($<@P'%\[X\,3*,]5K`IF.$)
M<JWP%&\$I0#?\Y2E`)%I)(`!)C;Z<UO[2"MV*P4N8]I7O9FX02+2\W'#[QY(
M$1<R-4-`[!WU,E1,\J;9&=:''U;-P.>^A&<2X><=G@YPYUQAK$,C/L,U361:
M0TR[MI8I@4E=0VPD%,IVEU#G\A7ALCE[V$=H-.^]2/=HE8*I`60.'JB%!%.Y
M4*(5>E8&G&_Y:?!;',K6GM&<6P^O)]IONAR.B-HP^HYJ<8Y![Z-^"[/:+OKG
M7=0(=C8VUG.EPUDM5Z*:;?&<>4(W!E*+0PMP9MUM#(_-T/>X=+?53J>2GF].
M)H0VZXNTI$E)0V#(RF5INSDH@<(S^'W&^\:JX%%2EA2N<5)DM;C+2+`LDI4M
MTB8G=X-5Z4P##^LCO:+;8J!&P*U[1+?0-(3NFV:D9L5EY#;_`(4=J)J=+D;D
M9M69&S/%%0NOE('%`6^M+CS!YB6E([4+[)+$!DC#:I-%49*HS6<U0]=33TZC
M>6X$!E)N@*<M*I"PI3.=HB*PQ':!BU*JOIL^5HHA6+8OKJ:A(NH;4X7E"]-+
M=@1,VA2I'08S"Y4_VHE-?H,+(<^^0#%ON]VU[1'ZW+<@N14,W6IG9FS+IJ6`
M9D[&])/UTDR.M]!D?A(`8AV2'`2DMH<AE)*AM>FJNS^J%6XC)U&:9IEQR\*>
MF5>2TTAY4DRO`%#B;JB`DJFDE)NWMBKH.TBD-&TO/-;SIU]IHI54U*0E3SSC
M"9K)NDA;:KR02H)DH`B<LB9U[[2(BN@VYKVD^]DP,F?AP%@K>7),*WN5INET
MZY&31%!+EF;:`8(S=A1E#/C(8R]C']*QY5'8-UE5^14O*ISD:DX4"V3%,47K
MZT`!P"X0;A,P9R_)WJ[FXG".T-=.*I/:%6<`563?J@N[P:'"2V3?!%\"1$I_
ME;Y`5SQ6M/:421U?AU^TKW&!+V<4XZ)8/Y';Y!:\DS9:]4JZ@\:0L@5E`EI^
M<M03/P:N,^$6B,N!H9?DD8!71S$<AMH><]QJ8MMJ`,J:G-MQ2U2(24E*4H4;
MUZZ1)1(0;XR-8'VB.J8;[Q*I+KB%*`-34C>A:4)F"H*"E%:=X4W@9H`*Q=-I
MTA0?:<;WH%!O]8]HEO"/$O;XV40LIR,W[B<AHA^=;K#UC-'&GGAR(6.L)\>&
M2MEQ3C;\J+C"%)6M3>3%Z[(.#U=;25&2J52F0=\*:GNJ(2%W02FQ13>4)V20
MJVP3U\%PKM&QN@H*^GS]5I0_+>FIJ+R4E11>(O6I"KH,K05ILM,JBIT;VC-T
M+BT07M,]Q/Q4N#>;*)8E<DMW9K/Q)HC^W(N0FGKBS<'J(--DSVE9AM,2Y+((
M:CG!9)U:`G'7&%36Y'I4N<-D2F#B"A)3S9B]?6&2!<N<(4W7T&^$2*KR`"H`
M&M+A?:!6.-)8[1:HMK#B@KG-1<N-\,"J_?X.]>86+A7,)NN$A,Y7F0TY[4B,
M<@D/>T4W62B3EQHV3=!Y$<C%8KPT9/V0/9,M)#2,A&2#`>K:?'0]CE&GF1R_
M@NS1^$,Y?\=IK$C%>SY8>(R52BZ@D3IJ;?$I26T@@$$NK*VTR)%YI<S=D3F7
M@/:8A3"3GRK-]8295-3O0%+#JB"00&D!#BI@&ZZB0G,"R25)]HW'E1\;^)+O
M]Z8'J5ZN5VB$[MY'9.J,;J^Q<AJK?8X9#,\0FUV&/G>+MN&`$!RK$FZT%AMQ
M"3$J;RMUF1UI6Y[C48:+C:$*X"FDLNIIUMD[W>)*:IDJ*O-!5,;VW`YAV?D*
M0WWA5I=#;BW$\-530&55*'``%&^H*I7@E*?/(3(@*F(WY".>TMX[:HB-O6/G
M_ORQ0$O;T4[$?7N2&]\3D8:5:-TUR*)G8F7GHT^":F,:1DWF63&F"TN8>%=:
M;*"+::WL%]Q,;Q%S#6,FTB'DM7YJIJ>Z0$,J-TA)"I<,D$@D2DH$I6DF.Q]K
MM$R_A2<7J,\UCE.7>#DFJJ+P)<>0"H%0*9\`H@$`SFD@*0H1HU]O7G/]]#EC
M_$7N#Z8]<N]S\I?"^'>S,^I'!O??.?Q;B?M+WKQMUQ.]M1SRXS7Z%G)_=U_W
M]KW$H,Y<-:[KMLM?FIZ%SEMHT2#MUJ<F[53)-L9.5!O`DX&:(PE3XQ+7?9<X
MUF/LKRACU&ZTQA3-'6W3<=80&[JMPJ0BZA8GI"A.6A23(CE&6>UW.>`5K+M3
MBSU=07APC3ZBY>3NW5JFM"I>:0;L_.2H61_0`KO)S4]CXO@<O!YET?316FG-
MY%2KK2'#XNF!U5VW2[1P0[KO=FX4(9Y@D5*LK08RMG^5CKIN_@.(L8^O+9:G
MB8JN``W"LKN"1^BHR(/@,X[KL8_AK^`(S*EZ6%&EYQ>.D-W+YF/"D3!'A!$>
M#OF=[='FYR7O-ASK#:-OXW:=3(O(IM'U5,+J=L9B67_Z$=:]CP'D=QDY\UEM
M"BFQCAXQM6<H9'QCOK<[>Y7[(\J8%1L[0P]NNQ.[OUNB^B>Z$-JF@)&X2DJ.
MDG<'37-G;+FW'JU\87B#E!A5XW$-&ZY=W"MT;\J.Z$J"1H`W3H3]O7G/]]#E
MC_$7N#Z8]<P]S\I?"^'>S,^I'"O??.?Q;B?M+WKP^WKSG^^ARQ_B+W!],>GN
M?E+X7P[V9GU(>^^<_BW$_:7O7A]O7G/]]#EC_$7N#Z8]/<_*7POAWLS/J0]]
M\Y_%N)^TO>O'9C7X;FO/:UC]A-^T_P"5F%F:>&V.;$A;-VO)#5R>/A-/6$>"
MM$RQO)"(&IQD1N<`B7FR!T%Q@PCY&8MT=0SI'`7W\J,U[E"<@X?(5):"BTR+
MR0IY)4E)8WRR65!"`9*)">$!F!]/I\/SB_A;&)#M)Q*:Z0/%(<>5<4I+*@E:
MA4;U`2\DK<(FE(*N#*9$Y:1JSV@C=IK\/CVC_,2,AI?R1Z:D+;=MV5FP4&/D
MYC;]3KLE?ZNK<LBU6@KW;M1Y36W'#U(F8F?BC$*;=*\B1KHQ+)BF'G/<;#%.
M)L2$(84EP@,K4&U<"+Q;0]-T!.\4VXDS";T;*L%SP'V6^\/%4M*M45J?0IL$
MO(07$<X-T.K9DR2J3B5MJ$BJY&./!<M(E5C,M'M-.?D'`UZ9WK$/R3KVS!#<
MOZ1U!9=U*%5$6CE+5'#9"YU*D2N`_@IV4CPR?(6C3&'#L(9SI<RV[P*:?(6$
M+>6AA4OJB)/O)8TII5R"%N(O7PA2A?*4D(F=9RDS.P755/:/C:&4KJ$S(=!G
M3L+J"+JZQ$RM#:[MPK2#<"U)*Y)NZM><[O@:A3@OM1N24PFVXFGI2M0.W-QR
M=[B&(B&Y#SP`<+5_K=&3:K%>QN.LD#6@DE")DIDE(CSPB$H(?Q&OR@':ME79
M_0I+=V2E,LALWC3I)4O@=XELU"5.*D;J!>`5,@;`P;.RF*:H3VE5Z@N\2A+K
MY=%WG!`2CA]^IP4Z@TF8O+-TE(%XQ["/<T9"/V&S/^U&Y(T2YTG;W*_585/M
MF[-F^-+IXIZ@5M2QSITE7=VV!,.B6<6W'N999D(H+L<=;D2W?)A"MUPY62NC
M+'9_1/4KM-2/%:&&M[SM[@DI`4PF<K5"U*U6`H2+RDQC36;UHK4O]I5>S5M5
M=:REM;[N^YFQPRUE2:A5V=B3(*0BT\(HW4JO;PG,7!E[B(SVI?+.S6"F"\C$
M(A*S=MXG+-F>.5G$A)\64FCMQ1=7JL#882P1$P',&GI`P*20,I69%D4.0P\)
MED(I'7.S[#FV733[Y2&!(5*2I)"0R5K4E25H4A*;TP%>85*1MFBS7PM53M=I
MF*.5#::G>H4^9JIE!*P5&H"$)4%MK2M2PF14//"4+O)]*YYC6.9J(OM*^6Q<
MA%G'ML6YW9&W0M12`0G,"B<376&]D.;L<;8M$!FXN6B?CU`99A(P1+:RG<NK
M>8QHK,GJ8;J59%PX(4!-'!LEX$T:ZN?!<!YBKG!-JO36LS"1*1N5AF=Q4NTB
M.T/%"XF9X2^\&"!6-TA'"\XL<1?+SB+OU:!*\9S$?;H=YW:BU3=]J->TRY!V
MT2G6%P!,%&\@-IMR4U5YR\,UO5UZC7P]L3`1M>V564E33#@:S4`('2P^O^D#
M/.[F%'*.)XE28:<A4;:G43O&G:DE:6[[K9!920IM4D$&[>G,"P@:&-,YUP?"
M*W%>\6N=#+DK@J'9J0IT(9<!#R@4.HFX"+P3*Z29A1Z_/MZ\Y_OH<L?XB]P?
M3'KFON?E+X7P[V9GU(^>^^^<_BW$_:7O7A]O7G/]]#EC_$7N#Z8]/<_*7POA
MWLS/J0]]\Y_%N)^TO>O'TCGQSJ;4E;?-+EFA:<X4E:.1NX4J3G'Z,I4FXXSC
M./\`FZ')V42"#E;#I?V9GU(#/&=`9C-N)^TO>O'=W[)3VXO(6M[SUWQ]Y;;`
MEMQ:DVA/PU"@[Y<'&3]@ZVM<^8/$UF5D+<ZAN3M=4/EB6AY3$L\04(T]Y8T0
ME+#HQ/RCM'[)L%?PFMQK+=&FFQ&G0IQ3:+&W4)!*@$:$+`!*;@`,KI3:%)^O
M]F7;!C;>,T.!9GK%56'5*TMH=7+A&EJ,D$KE-:%*("KY*DSO!4@4GW`]=4([
M<Q__UM8FFG'G&V66UNO.K0TTTTA3CCKCBL(0VVA&,J6M:LXQC&,9SG.>HB/S
M,)2I:DH0DE9,@!:23H`&Z3'8#[,N.D(OG[QM&DP#(XG-KEG/)SA7Q'_#73+1
MA+GA$(;<[BLISV9[.S/9UD9(+B)'=CL3]ERFJ:3[0W9FU54ZVG>=.F2TE)ES
M6HMD0#*/6ISQU-$[ZXO7C2,_-3M=@-N6G3.MY^:K#H+$^#`W3=^N*]-+BG9(
M*2CT%.1D@ZWCQAWF^Q6>\G./<ZYQE#$7,'Q^DQ5EI"WJ9M]U*53NE2&'5)G(
M@RF`;"(]N\VX8SC6`5F$5#JT4]2III100%!*WFTJD2")D$BT&.F7\KUPQ\^_
M)[_/&J?5;U]0[_<T=4T/B=Y6/E/W>\G]98AZ;7)1CT?_`&:?@/+1Y4O%<G=_
M2<4$>[%F2<?<=+FQXDFP^V,_'%&C:V<&8/9)>0VME:L.)6K"<X[<XQUF7VZY
MP;6EMS`J1+A$P"AX$CP@<).7RQB3V`Y)6@K1C%:4`R)#C1`/@GP6GY(KI?\`
MLV'!FB@_"D]RDY&4V-(+#$^$9>[:?KP+YR7?*X\;RPW6X8[A>'Q?%91WLK[[
M?>3CM3VXL;[<\V5:[C6`T3BP"9!#JC+03(.&R1D?GC(>P/)U,DJ5C->VDD6\
M(TD$@S'\V-!$Q\HG&4"_V:7B:Z.(\%R;Y:.">3OJ`=%N&M%C^22C4ADG(CC6
MM<M^3R+,T5W^YGNO)+=[>W#J^]@5VZYC!4%8%AUZ=LT.:1*4_K-(D/FD/!&P
M.P;+!"2G',3E(R^M1H,YR^KW;RI^&\?"8LA?]GAX5&2;I!_,[DR7,+?9\9\O
M:6IGY-1,=,1\4/XKKU!45E\&?'%&1VY[S1B&F\=CB48Q8GMSS`E(0G`<-"+;
M`AR5LYV<)N@F?SGPQ<KL(RVM16O'<4*[+2Z@FP@BW@]P@$>`@>`1;QO[.=P5
M8;:'#Y?<B&6CV,1[+`VQ].MMFC2<P0%@%IIK7N$D,2$^$ZSAK&,I=,96GLRX
MC.,7GMXS&HS5@N'DSGYKFD6`_K-(%D8T]@65D`I3C&)!,B+'&]!,R/U6@FTC
MPQ>T_P!F^X<7`8..3RPY1VD..&:G(\!-^U7-C`"3I!H[$P&+C7130HTR5#$(
M00A*4D.".8PI66E=VB.W;,+:E+;P/#DK4)$A#@)`T`D.6RBYSL%RRZA#;N-X
MFI"3,`NH(!.Z`6[#\HC(V?[-CQE'D5S#'*7F,Q+.DNF.2C-WU\U(N&/.1SSQ
M:S4:X22LEUZ($6IS*N\I0K.<Y[6T=VP]N6/%`:.`8:6Y2EP:Y2MLEPDI6GQG
MPF,@["LNI<+J<>Q4.DSO<,B<[+9\'.>]3;_%'@$<2/[-7Q@;&0&CE!S"0(@Y
M<H@5%TUXD9$FLI!RY%#&-;8:2<LUM+V7L8\3+J<+[>]C&>J]^>/E5XX#AMZ4
MIW')RE*7ZS1*R7@LB@[",N!-P8[BMR<Y<*B4YSG+@],[9Z9VZ8X!O[-#Q6#2
M,@/DORZ%0%A6`TC6[7#"1,+6AQ>!DM:T3AC"W&DJSW>SM4G&?TXQU57;KF%=
MZ_@>'&>F:'#/Y_K(M3V#990$A&-XH`G1)U`ENV?5V6QP-?V9CB<P%F-8Y(<M
M&8[)!Q>0&K3K5L+)<H!F*DRLBHUGACRB1B\Y&?7W>\\/GPUYRCW.KCV[YC*^
M$."8<5R`G<<G(&8$^$T`VCP&W3%H[`\KI1P:<9Q,-S)EPB)34+I,N#E,BPG=
M%ALBI<_LTG%EY93KW)KEZZX:T8R8XY<-<N++9D6,#2#12U:URI]HX;&&WDK[
M<.HQW5=N/<ZM';KF`70,"PZPB6\<LE:)?662.CP1<>P;+1ODXYBAO`@_6HM!
M$B#]7;,6&>D:8_?RTO%KRD8W[3?+WRP-\<D0OXX:Z\I%)$D"I84@9_ZM?%8?
M&E3GR6UISA2"'EN8SA:U9R[]<P75)V%AMTB1%QR1!`!!^LW0`/F`&@0[ALM7
MDKVYBE\$$'A43!!*@0>#L())'RDG28H2?[,GQ(-8\F,Y%\L"QN^ESR<FS:R?
M8[Z"9(Q"_"=UDMOOI,F"W<9[.W#A3ROY3J\JN3V\9D2;R<%P\*\(2YX`.,\`
M`^8#P"+%=@65EI*%XQB11X"XV1I)T<%X5*/SJ)W3%N_*]<,?/OR>_P`\:I]5
MO63O]S1U30^)WE8Q?=[R?UEB'IM<E#\KUPQ\^_)[_/&J?5;T[_<T=4T/B=Y6
M'W>\G]98AZ;7)1NI7.(E,JGLQI?@P);[P9KA>V)OCNFWGE0KM];I=ZYCKK,D
M8DMN&:@?A@&,M#Z1<Y`\F;PAM.6E)3E.>*/YDJJC/;6;54S0KN;IJ;@"N#OM
MT=X"4[TB4">^GIMCF;&5J*FR(YD]%0\<.X55-?)3PG!N512;;MV8"R!O9`2L
MC2O\KUPQ\^_)[_/&J?5;UROO]S1U30^)WE8X9]WO)_66(>FUR44;O]F*X1,F
M"QSW(3DFU(&H?="!=L.HVS"VQ<)42X*,O6&'R$#I7C+F4)SA&,X[>SMZ=_N:
M.J:'Q.\K#[O>3^LL0]-KDHK/RO7#'S[\GO\`/&J?5;T[_<T=4T/B=Y6'W>\G
M]98AZ;7)10$?V8[@^(.867R'Y("B1RLHD"B+'J%D<!6&VG<I,><UBEL56&GT
M*[%Y3GNK3G]&<=._W-'5-#XG>5A]WO)_66(>FUR45`_]F#X4%M>.+O[DP2SX
MCS7C#SNI7FO%&><'(;\1O5RD>(P0TIM>.WM2M.4Y[,XSCIW^YHZIH?$[RL/N
M]Y/ZRQ#TVN2BI5_9D.&LDT"RKD3RA/8`CVFXUI5DU44T'%%EFGLH!1G6+B!X
M\HXDEY.&\8;6ZXXO':I2LYM3V]9F25%.#T`*C,R2[:9`3/UEID`)^``1>K[/
M^4UA`7BN(D)$A-QLR$R9#ZJP3),A9,DQ1O?V8?A*.XEHCD%R58=<\+N-O3^I
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MF]^36)JEU>P6R(R],ZNPU\*5R)+F`/%RQK%E_#?E8:.]E"T+[/T*QGW>L]+V
MZYEK*FGI'<)H>"=6E!WKFA1"3I<EH,8WNP+*=(T[5-8EB'"M)*QOV]*1,?S7
MA$>FR`*?.@H0TE6%DF1$:40O"<)PM\@-EYU6$IQA*<*<7G/9CW,=?"'TA#SR
M$C>A1`_`8^]-$J;;4=)2/X(__]>,-)`R4AN#6;,3E:3V+O6Y)EQM\<=YE$1*
M#2Q+XRRCHUMPM@8):VFL/MN/.)2VWGQ%)QF()E;'YQ,A4]559URJW1$BI37L
MK!!2DC@W$N$I*EH!4$I)2D*"EJ`2G?$".SSCP7).>USU)%FRY,L%7;BN%K_C
M'RIXL=7TZVFY(*-BE3EJNDN/%MNR3KC;14D04E3JLO\`AOY<;1D9_6(MW?\`
MQNF.U79X]5J^V/E&DJ:Q;S-+6%IF\MQ80R*%U:4(X5^I<2@%:E!+CRW`5'A+
MKA4D>J'?O_H:"_VU<;/_`'%ZLZY/@_[V]_9:G_#.Q[`8I^[-?VFG_P".W$U=
M1<2,=6<95^#=J@JN4SNV7*:M<_KIFL/2<I$QT\MFLPMCH-,A!`3J4&;!0KD3
M4G!ER&&!C'7H%A]1WE3677.>KJ,U4[KR3AB06T.%4@2-^4N+42%F\J:P;LR`
M%D7;ID.'MT^7GVVE)KU%*U("9D`[P*2@`%`D))E>D";@)5,3,@@4_B<U4X*F
MUO>AA9D+LJ#VI#SU>M-3M=Q&M]#H,Q/`,/-)JT[%>0!5.IR,@L`B/[GB8=RE
M*5O)0K3<JLP&I<J:C"P$J84T4J0I""AQP))\Y)F5+2F\%:);@G&VAC!DLH8:
MQ`E270L$*2I=]""0/-(L2E2KI'A\,37K7<'&RC4*GU6N;3JL?70HH)BJC6"1
MC8"6-BCB3_@[P(\@*#+DG$K&>:<?R.LIUQA;A:W",NNKC*[#<<JJNIJ'Z!PO
M%1*RD%0!$IS,U`;DA.5LD@"0&]1UN%4]-3L,UB`T!)(40DD6Z`0"?E,IV35,
MS,1O6N.?&/9,G-3E/V!(W$E;;T7++K&PHR1%$C"U##KAA$0P^6H:,11%8J;.
M`_`4)6WB0F%M.DF.O1=11UE(4BJIEMDBR\DC^&)!BIIZ@*-.^A8&FZ0?X(L$
MYQKXI52;CZC:K/9(<J!J9]K=1/VC$3`DUR;L_P`&VDB4.(C0H&1S;64Q]?DF
M$JRMNN1@,;A`P*\-DZT9]$2)JF(XUZHL[+]7W"Q)VNV"@P^46?90$W(VYRV3
MZF(-]H4AQKRQ^5N4!,/Q_D:$#K/E9+#*,H=:;:&<(G%6YM>-Q4'-N3;C<;8K
MPO7462N-D4H7;&W)-I<>;VBX^"D)5#OXRZ5X+:7$X:SG#RT-JI"+9GD3H7#3
MS^=R:T2T-'P$J0M5S@<88C[4W&/5@I[M.QEMNQ-3(J@>WLR7A]'A85V](1EE
M+V51-AID?B;:(:??A_)/A@$`\9^0B,2."51JY0%MQ1(")-H1QP93B4X?;1E2
M.W&,YZ0C.>D(=(0Z0ATA#I"'2$:5O?ZGY3_\U(/_`-]%>ZY0/]1:_P#BU?X%
M<<?/[@O_`.0'^,3&ZG7%XY!&I/(6O:VF+94V;M=-KTN0L<(JD1)-`.4%&2#D
M[?:*U'!/CXAY=^6LB[&X'@;R=@ER.!466[@=A#A**PB`]G:MX^5A^R5*7V[M
M6'V,>`%KZ`D`61I>7@)W;-E&F`):K0-<JP8R).:,-DD$L"8'</BC9L=A&<./
M^&_!`>"+A$5SBH&[8+#&;+V%.".5B)DWB0)$P2'=C]"3%?OY2JBJ,@8<5*^_
MK-IIQZ/SX++(KPH#PCB<)0MLA&-Q=7X?1*3).O;BF*?10+/L@XNM1KY0L.SL
M&G[,%DC)Q+@<8]#FIU^W$$"#QYHQB<PDT.\8EU#P2E(1\)@>*%-^-IDAN;:I
M:=>!DC6@:48C_&.*GX393347,2*-?`%$7!$5+S$#D(XEB2::!$`*9PAH+OK8
M1M#.<2:+97=9'S=HO)4WJ4>LQU3FFC*ZV2Y#TRZQ-]K$9/!OULN+FVP+#5H,
MEQQUC#CI4&(1C*'L.J<3A$OT76PM%+D"Q[%/S2CXN#ALLR[5=98&CJVR0/#-
MM8@X"&=?(&'*<2L@A3Y#V%X2M>6VAVV:0B2>D(=(0Z0ATA#I"'2$.D(B_=_^
MI?;W^R^__P!5);K?PO\`U/#OV[?YXC4K_P!QK?V2_P`TQF-4_P#2];_\`A__
M`"X;K7J?WFH_EJ_A,9V?U+7\D?P1_]"$M<NK8V%1'FVF'W&;E5W6V"9(2&&>
M6W-@K0T1+GYP#%,.*QV+)>_FF$YRM?ZJ<]1$?FRRRHHS)E]:4)4H5S!`4M+0
M,G46%Q>\;!W5JWJ!OE6`QVK\<F9QSVM.F9Z?B<09MMM;UB1%.6<.VR`S*Z!8
MXE3DM*BAQR_A`XJ)=)RV^.V]X3R%YRXE:7G,C1FXB8E;';GLW1B"OM@Y+Q'$
MJ3@'ZVJ4]P9?34+2#1OMS<<2E&_4IM2Y*0E5U25;X*"U>J3?O_H:"_VU<;/_
M`'%ZLZY/@_[V]_9:G_#.Q[!XI^[-?VFG_P".W$U=1<2,=;A>UN)TFE4H9HRT
M'9IXNKS2@DU^M'KBL6'7"YG4K?Q?"O!.)LN>I8+83211S5,-L,MR/@,#I6US
M5O#LP)(:1BK8X0N@&\H3NN2=-XH%T)623,B=I1,F1XLY7X-=4XN@6>#""1=2
M97FYM[T*M*DB0D#*R]("<;0ZXU_I*Z4^F7^LT;#,;8806Q0KT\/*M3OD,]2G
M:CA,KF1-)*,RY39!8&,K=('<&RE3*UM^$[U`UU7BE/4U%)454UMJ*3(B[-*[
M]D@);\7M`,](!F(F*6GH'F6:IFF`2M(4)C?6HNVST[TW=)$M%DC$+UF7XQS@
M=BV9`Z6(:+KE9=V:2XJ+JL<66BW%S)<@=&(=M[,)FS3X#B#S75NLN%,EC,/.
MK+'6(+C.,8J6N!57.%J0$I[B971\R9;T:!;+29W;,P_A.$%(WPDR9RW3I/SF
M=ITG=T",\HUOU-KB`FGZ;K&ZTT&/NE[IQ-32"*"2-*4^FS&P"#0*F9:E,0L7
M=:_7<R$9W6A73UR#1;[36#'"%:]36U5:0JJ>*U@:3*?R3,IF6@3)D)`6`",[
M%+3THNT[00CP#1^`:!X;-V9TDQ94;,T%ON7I]?LM1G9%_8H8T15P;*Z$Y$2<
M8[0X#>^7TB0EMDHT7Q*Z_&N.J4V@PGQ/`[KHK9/AZML;$?%I8XIZ<O>6;)2H
MN!F'#JW>2K62*J1&^-]LM-JF*V7X;DH98I:[V*S4>0+RZ("4^ZL-*R',80WV
M2='A%;7L%ZE0%[Y0NVSW@05*G*Z$IOIF5*&FR<:%3B5+2.\%4+NV)M,I;XJ"
M0+9DFXJQ(.BV,;L6Y^&DB(?!39!M@B)[9$;%75$A7MDDQRKGB!GYVL/WA,T&
MP[/L&CP7D4,VI!Z77!`F1&LL1K:@MM&6<96%$4R0>#O@7T$J2%)2924;4W@5
M3E=&D@D`ZRL>PQ)`X<RX2X3=5))(41.8'G72$RG>.B<B1*T/J+CGMNGK*AJ<
MV=73I^ME.2:P;?6):2E]72>&X(K,C+(B+%(,1SXS@_E.%K:,86ZC+CJ%K[8B
MJIGZ-TL5"0'0`9`I5I$Q,I)$Y;FD;HB2IZAJI;#S"B6YD3D1H,CI`.G=T>".
M<>YZ2TGL"3UR%!%TDR;@ZG9R"HN(-<IQQ<V1;H2OPX(D8\9Y+9B`:%(O.(:!
M90X&'A:W590E*<&F,T6F0YI<=`(6!GLWEYP.RS$9$PS+];LL(<6V?9B:L7-I
M$L\5!.XKT$?&G+-+_D)1'$H:\4A"65I&$;'5VPQ-KA@I^"(=+B9##R@R7@CH
MYQU(Y+PCJLB20P9K:?'85A.5MIPM/8I/:G*<YI"+UTA#I"'2$.D(TK>_U/RG
M_P":D'_[Z*]UR@?ZBU_\6K_`KCCY_<%__(#_`!B8W4ZXO'((@3>,>PH!<ZK6
MU;OAT!3K9(PKTMK4G94L-9!I&IKK\)$Q8"V)'#4^^MW+J6GF,)6,V0MQ#0[F
M>@A$&@IL1E@ODDQQ1H;\A3([8EIHEY,U^'7LSNP:W!ZV(U]&1[4J*NZ9=>>#
M5&NS;(K.34P@3H;36&W!@Z_AA&.QE]F7IJFU3/!MT)N062F.D'Z$"'4ZK5K[
MDV,8BYR7:KQC%5/S"7#"[*D=DY+2/A,50R\YRK+\,(N5P3%V*9.C)[AQ%7")
MO(-42>[C7KD5.1#>PXDR<L(M@N+U><8*LL5;)*0>DG17!!8E.4D*D79,S(;#
M\,(^]>$U_85AK,18N!0&O8B6+'"DINZT:HN-Q`V*/:I@)U`L=4CFO"9<AQXI
M7E;X+;#A^&>]XOA,/OPPC?KJD(=(0Z0ATA#I"'2$.D(=(0Z0B+]W_P"I?;W^
MR^__`-5);K?PO_4\._;M_GB-2O\`W&M_9+_-,9C5/_2];_\``(?_`,N&ZUZG
M]YJ/Y:OX3&=G]2U_)'\$?__1BG38X).U]=,R!;P+"KC`9:?8CU2BE'MR+#D4
M*Z&W+P3JA3I-#+#SB"V7&&7%.)[RD80J'5H,?G`R.U3O9QRPW4OJ;;-<S(A'
M";\+!;24AQHW5N74J(<24I)4)E(![0>/.3D>U\UF(;Y2UY'?7\"QY!QL@B(8
M/UI+S*XT4@^>LCN1V39-Y><I)2A;BUN)8&[_`).UD9\]NR5HCM9V>%]/VS<M
MLOE0",05=05J7P850N.%"2IUXR"EJ)DN5XJ(0U/@T^J/?O\`Z&@O]M7&S_W%
MZLZY1@_[V]_9:G_#.Q[!8I^[-?VFG_X[<35U%Q(QUSA;O`%C:'&3_#&4`EY<
MF+`+A(:G1DP!5H/9@4Q*S*QG&JTPPZY*Q@8V3QD>$PX08H<MY!0SXZ>9*PLJ
M75+9S*DMI!(*ED%2FRD">^T`DW3:9)FD%)!CC*:^2:=#N!D+40"`D$)"P2?R
M96@"8T35(D$$1)];Y)+4%%1-6X];!K@#V9MD`<V(C(B#9=!UG:]G>("BLXFV
M/)920B1XU'?0,[D\]25MI?:RP[HOX*`I3C^,LK79.1*E6NI:MO2M`)59,74V
M$@S&TSBI5<;:PMU"9D6@`?JU.3$IV$@)MD;RI$`B1^ZI<8:_55H*?X_P.(U,
MH/E,0[5ER,%'+>CKG:;4$9'3%1C5MV""3'OCNN#CD!$RDZ*WXZ7B"FF,%7A-
M/3NE"*Y*DR/T9FU*4D241=45$VD*"4+,I`%6:FQ%YY%Y=&I)L\-EBE$&:0;R
M0F6BZ2I(!F2!%M6Y%#-PDH-8.'=IJI4GXP1`,730G((]UN+B8.U$S'PI!UJ2
M/@0MAVJR`>.*">HVO-HF6VU"R:VV=]W+=,%IYOC=.IK3:0%2)44B0*A>+80H
M@J$G%*:)FF:M1O&Z@I/#84\ER<K`2)@)!,R$FZ'"I((!F@!P"2I)S>O<H'S`
M8**^H:[P]L=L5AC68W-0DAX>*-B8:5D2+7@K$:A(E>G1G,`AD=])AAKQ3:6<
MLCO/9Q.9>:0MQ0Q1DTZ4A4[R9F9`NRGYPM)&@)E;-0$7IQIQ2$C9[H>)(D4F
M5@)G.7FFP`Z29V2$XHC-[`S]IM$7L_BU8B2ZML.XZ]J]ED*U"6&,DJ2BS1=5
M%NZ#Y@5DT.L3#<ADJ4;`1(*$CTH><0XE3R1KTX4IJG8<HL=0$.,H<4D**2%W
M2HHD#:H2DDJNS5,3%A58<1X5YY%5A"[R'5(2HI!!3>NA<SH2=*I3(3(R-H34
M?6[4K-*5J)$XNV!#M@/J$;\+V_7,4Q##Q5YMT!7K=%8>9$.,^,%=@&EE2PCK
M3(C68<E*GWFPL*<##7V6WW58\B2$K,D.&\2VA2D'2!=4JQ!!)-Y-@*K'/VG'
M&FTX0N:BBU2!(!:@E0T'?)%J@9`73:96[#:3N'QVIZIIS64IJ8MZ5F$$568#
M!#-\$&6D(6*EGFPF1L97+PD0,1A*VTJ:0XEK"G$(2XJ'Q2FYK4\$*Y-0+J=^
M"2+4@D6S\TDC3;*=DY"3P]_G%/PAI%,&\=Z9;A(!L\(`/X91^;,ER(E\GP=9
M15[98H-LN[CQKCB7WIS6TI5C*K5V6456P)>.E,V:1*`>RYAX4H+.&6'?'=='
MC8WH@6&V@S8+8Y$9XP1PCM2D&08:7DF@L/QXA>TZ?7)%^.;8HY;D;D>$N3TR
MZEAWPE2L5(`K<2D=4BJOX81N9%Q47"1XL3"QH$1%@M^"%&Q88\?'AL]Y2O"%
M#$;:'';[RLY[J$XQVYSU2$5_2$.D(=(0Z0C2M[_4_*?_`)J0?_OHKW7*!_J+
M7_Q:O\"N./G]P7_\@/\`&)C=3KB\<@B`MST_<\\3%R^FKE%5:;CX2>B^RS2<
MJJMX)EG8UP>5768^&D(^7EP/(<H9?D/*F&&'7D-C8>>24PA&*7#5^^)Y,<H#
M:F&S029,@,]$Q+59N,=DTZQ?;=*AZ?"QT5=`H8B$LPX@4JA2/)9<=;KKA#.7
M,5LA&!%5+FZR8+!@;,K;Z'`QS7K8H"HBU\)`LF4Q(0*!3:7-VU^<EH]0KP#[
M@Q`@#:"4%/GOJ9<Z60B2+;K_`'K8T214/=HFK3TQ7*NV'.,6"WKCZ9)Q#<?+
MS,"!KX'`=8LHDY;(=/BSI9#4FF*D20L,J9:0E]9"*&PZHW=)VVSR$=M!X&MS
M`UH^!V$6BS!R,&9*TJXP\7GR`&/1!/ABSMJCU,I80(Y'M54,M*R3Y"2<6LA$
MH5"IWB.N=FL-AGO%A)";N3\)71K)89L,**EFM?"P*ELS`HK(A;.:G(%J&:PL
M:/=F'F!5*;RM;E(1+?2$.D(=(0Z0ATA#I"'2$.D(B_=_^I?;W^R^_P#]5);K
M?PO_`%/#OV[?YXC4K_W&M_9+_-,9C5/_`$O6_P#P"'_\N&ZUZG]YJ/Y:OX3&
M=G]2U_)'\$?_TH4ULA3FQ:"A"$NK7=:LA#:O(>ZXI4Z!A*%?"8Y<;W5YSV9\
MH:=8_P#[B%)[<9B(_-GE<*5F;+J4I!4:ZGD#=M/"HLWX4CTTJ3]($3$=J?'.
M/(`]KGJ?RQ)C)Q=S63(`2BJE\,Q4DG6DR))14TBEF&0J9,$\1Q#CG\V\5CL(
M6G.7L+7>SY[=F[';?LXI7*7[8^4P_?#ZZTJ6A9I^$;7S%U*VW>;*4WPB%I4"
M=ZI=CBAO[RO5-OW_`-#07^VKC9_[B]6=<HP?][>_LM3_`(9V/83%/W9K^TT_
M_';B:NHN)&--X>T<RLBQD8[K:I-O(EXJ/D[3:Y6N%OOQCLO8!IJRMU^G7&/%
M':3&MQQ@L6E];PC;BPUER#J,GKY(XQEN\M8K')720E`4`#)-U-Y:"3;>!5(`
MR"@E`-P0B'<<DE/-6P9@%2B#,35>5)*A*0ND)G,3*9J(O'XJ%\Y?SM@@RYG4
M-;@:P_>Y2MV,21E(T(N(JD9<)6+>M,:VBS29\ZE^OQS9`1G:-@U92<8BT,=T
MQ2HI,NM-.I;Q%:WPR%)(!(4LH!"#O0$[XD*%MV7ZR>]BUBIQMQQ"ET*$M%VZ
MH$@$)"E`J%I*K`"#9.?F2WT9[JL_D.[,1S6SX<8:-=CBOC"0E%1>"8EDM(5#
M8J3L#9/A5J.<;;>Q**DAB7,%J'2)C#"GW&-;$48*&UG#W"5WA=\^<K;U^\F4
M]%VZ0)3O;Z0.>A5BI6@5K8";N^\V4[)7;JIRTWKP)G*[9,B=K"N2;@)MR&8*
M*ET1$BJ*'!>C!C7Y'`;V06A")IMV'8)<)[N$+*0L9*LXRXE2,9QF$B6C4?X<
MY?Y@^\NEKQ/JC9!;J6975B`4R>=31CHS(6'I8E2&<[E0Z@=QY;F&X=3^'T.K
M4.\U6R$7(V<Y6]^XY!I#V<MQMI734O3FL$BO2N'M?NU%!N/+5EK#<-<L22D+
M4PI,,@=O#JI#^E+60B?M9/79^I`N[$%."N*LIS/#$*K*XMN3R*-F034E5H@I
M6:;@_P`7$;\)+S+^3=GE?\YU2$2!TA#I"'2$.D(=(0Z0ATA#I"-*WO\`4_*?
M_FI!_P#OHKW7*!_J+7_Q:O\``KCCY_<%_P#R`_QB8W4ZXO'((I33@HYC)4@8
M*`+AX8?))I#(K&'S260@V,O/K0WXQ9A#;32>WO..K2E.,JSC&;DH6LW4))5;
M8!/0)GQ"T_)%%*2D340!\L575L5BPRMJK$$]D:;L<##D)#1(J8E9B/CWDQ[D
MB)$(.RT60RO`:Y:08%P[V=S)#[;?;WUI3E"*-^]T@45HXFY548(A,TI@Q^PQ
M#(KR:VXMJQ*:(<,2TXF`=;4DW.,Y\E4G.'>[G&>D(_5WFDML+)<N%6;&;/D(
MIPA=@B4L(E(@)Z2E8U;JB\-I/C(X=Q\AG.?$990I:\)3C.<(1]@W6FR98L?&
MVVLR!YRLH!"!GHHLLQ>(H>=R@49@MQXA6(0QHSL0G.?)74._]FI*LH1DW2$4
M$=*Q<NT0]$R0$HR(?(113L<8.:T-*1);L?*1I#@SCJ&3XT\=Q@AE6<.,O(4A
M>,*QG'5ZVW&R`X@I)`(F)3!$P;=PBT'=%L6I6E8)0H$`D66V@R(^<&P^`QAA
MFV]4QSQX\AL[7H+\47(1\FP9=*V,]''Q+H[$J$>V_)(6&7&/%M((;<PE;*G4
M87C&58[;(NCD-VMJZ.+)CY#9-!`/#[_E81MPKPI8OA@*E7/*1GY%#S'<BT*)
MSWDX[!\9<S^ICMZ0C\,VQJR.<;:D-E4`!UYN)>:;,N5=%<=9GA5'0;K:'Y%"
MEMS02%/"*QC."6L96WWDX[>D(O-=NE.M_EGQ3ME9M'P>@)9_Q=GHN;\A1),K
M(CEF?!I1/DR#QVU+9RONX=0G*D]N,9STA&3=(0Z0B+]W_P"I?;W^R^__`-5)
M;K?PO_4\._;M_GB-2O\`W&M_9+_-,9C5/_2];_\``(?_`,N&ZUZG]YJ/Y:OX
M3&=G]2U_)'\$?__3A'7*35[!HJ(UD(B17<:R@!B28R5'/&KF@DB-GC82OR@-
M;^4X=;[JN^CMQV9[>SJ(MW#(Q^;++(>5F3+Z:9M"ZDUK`0E8O(*BZFZ%IMO)
M)E>$C,62,=F_$JK3M-]JEI&OV@Z`+L0=G1B4'K%=;JL+$85K*8Q%1`<,+%0T
M<.V+`I$SC(K&&587C/;E??[,K8DXV)[H_P#&Y':7L@PG$,$^UID?#L6>IU8F
MBJ/")89##;?]1=X-M+:4-H`2UP9'!I"2#X9QZQ]^(7F@QCR494T#MOC[*FN8
M]Q`D7#[\UI*2TB0O/ZK(<9&!O$/N*[$MLM*4K.,8SGKDV#D"L<!TFFJ`/E*J
M=T`?.20!\ICV7Q0$TJ"-`?8)^0!]LD_,`"3$T=1<2,=9T7]<P-4*7"\LZ(%$
MDU:O3$)+FS<E>>RP05GUA3+%-XLUQ@).0MU?FW8HDE44$X'@>3M3<?GQ6B0C
M\<J7B67W'$N.82I1O*G(!`*"'"D!*%!*5)*DIO&\2$!=AF@P"*'&4(4A&(@;
MU,IS40H7`22H$D$)4J0NR*RFT24)F8=V!-36K+--\C:BQK^*'F&;6Q5Y.%$'
MMM^I$+;F[2,W*LUX%)D+5I6&()D4K)'#>8"6T\`PIA3K^CSS"&Z>M2SAQ+ZU
M$(*B2$HF-R^9*E,"PE)MOF<AM<VQ);],IRMDPE.^``FI4CNW19.W<!T71*9P
M*8K^V0HO6A1O)&MTNECUW$@W+.76R3^+U(JKY<,%>9*7G`(V=9AI20L<>6H!
MZ;=AVS2PPF4J*\F*)VQB6"@U"U89?=6JS>H2$IO`W0`2FP"Z%W`HVDF2KHU5
M4&+*X%":^XV@6VJ45*D1>)("K2;Q3>*18`++QXWC=YIBH2'L'*G7P-ML$A6T
MU>9!3"#1,H]*DLN-A`0C6OXW%G?:/KCZ?#3()2X/)9;*;92)VR=.?9=2Z5(P
ME99ND2)5.=H!"BX9:1^22"F8.^%RXTF-J;NG$4AV8M`$I3!.]N">@RM$PJ1\
MW?[*ZXJ>\H2R2<EL79P=PKTDKQ8^MCQ==`Q54)CPT,1[4K&4>#/M"T&Y(\H,
M>4#@E26WVAA$*4$F.K:C"W64(HZ$M/)TJFHWK3,R*U!-DI`7I6@J4=]&[3,U
M[;JE5-6'&S^3)(NV"0F$`JW9DRG80$^;$;[Q=M4??\R]?W+7=?8C:5%228^>
MLT^T-'9`;VB)(&G5%D,^H/A6=B:9(^%9-@M4>FJ.OH#);'><$RT%9AK-+P%;
M1EQ1622$IF0>#EOYA8NW%;U)2%7S-296XZNEKG7P[2U-P!(`M,IB_/>R*3>O
M)WQ!NE`L,[([8A-TSD7:]<6OE57URT]*.!5R<JN$5BQ1$S#;`>N%DBQY"(A8
MMYU`-,I\Q&IPR<E"/`D`G6EJC"'NMW:6`M5%/44V#V)!"DK-]*OJBD&2E$3O
MD*-FE,P1.0U>8XNXP\R]B>^5*2DBZ1OPHZ`#YH*=.@R(,IFNK:^1$T@]$7R7
MU5.B@1%6MA;D?B$6F+UW9,SCL'/$Y<I9D@+BVU\54@&:6<\VTJ(=9[2D&Y-`
ML569<,B,+<"I?2/G6?QP)`@B02)A0-ERZN\4V-`R->@IGX!HM_B3F00;5&4B
M+;UY."FG;SEZS=(N*YFZZ*"%JI@IDD)%Q4+/TC.'F@2Y`N?8K4T>RN$BWU%2
M);[31<2L?'CJ8\IP<%F:Q'+27FGE8(O>K!(O%25#3(IO`2G9+1(S-@NJPNT.
M.J9>:3BJ=\D@$)"2-SSKI,Y6STB7A-Y.\,Y+M2^HK+*@6B-:2Y2;)ENXJL+\
M/#C/B11[#T]FVP\<$]'18A#"GOA,,9/A-)\=E.<83V\=:6TBJ;<*?J0L&4@;
M`=%U1(-FX3(Z"8FW$K4PM`5]84D3G*V7A`!'S@3&D"-.5O;Y!;GG(GE!K^/`
M-:J(^NHF1&=E2(<6W2SEO*1*3%HJDY8+TI%?@):"BI5W&>T4!\XI""@SQUS_
M`#_+J@P7<*65S/"$&[>DDI24I2I(0"9+4D6`S0DRD1$\TQD<*$8@D)LN"4[L
MU35,J2HJ(&\2H[F^(G,&JL3NUH:9E[=1^3588@IZ/V7/&5:]26`7PE0FQ+-!
M`+@U6^NV)NHQ=0.LL/`G#^084J13C.</>"R$[:Q7X&XRTS6X8;Z+H"DV6!*`
MN\$J05$J"E`E6@RL)*@>H\60XZ[2UV]5>-U5MLU%,B0H)`!`(`TB=H%TW*>"
MY"1S1$'.<MJ%7+/$`T,;+3T/36L/V6SWV(*@9.<#73XTQF-GZ]79V'9B6'&\
MR+PRS/*6&GU"QU!79=2Y,8,HMDF8*US"2A0`&_(G>NJO$6#>W24WEC28TI`!
MQ1(6`-"$R)"DDD[T67;R2D:3OKPG=3G.ER-F.[2G&[[NJO79Y%791BAPAHPJ
MJ\N,);CIH\B";H%<?4A5C6M+);[R"'QG&E8_F<)2O5KJK"7*9+-!1%MT*)*C
M,DB9D)EQ4K)62E/QQLTC&((?4Y5U86W=D`)`"P3T(3.V=NF7BC;_`*A8DXTP
M6TIS2%ADTY[P47RTD;3)OH2M:8^`HW-AN6M4F5A"59;%AHFMF$OK]W#;#*E9
M[,8SV<FG+%&&Y;]6'!`'A4Y1$(`_E%20/"3$!IPYU8.]37%1^0(JYJ)^8))/
MS1N?UQF)^(!VGQYJ>X+G3+5;I274#2V'TC5D)F&Q&2Y3QPQG?F29"+D)!<?E
M`^6GA!W!FRT*['\NH2E&)>@QFHPVFJ&*9";[AM49S`E*P`@3W03,C<D;8CJO
M#6:UYEU]2KJ/R;)'YY@F7R"4]V<1WCA/J_R8$=5KVHI<9!V2OQQB+<((>*%:
M8U^*DGU%`P8KATGY(4XU@HKQWW!>X&\IT%@<5K=]Z*^:OJ*>2EI41<F"4&8T
MJ,A.V0D+TUB2RI1U!@%&`GZUZ82H`WK0%:=RTRLF9DIDDS2`!D,]Q'U;98>(
MA)8JU."0M514!G0Y"(BC'HYN9D)-!I947!!NOSN(^=E8S)WN$J!FI!2E9+*<
M*S!U-2Y5/NU#@`6LS,IR_!,F0^2<AH````EV&4T[2&4$E*=$Y>&>X!XY3.DS
M,S'`5Q!U:3F%<3(7(,JN2DM.01P$M&#%Q4V;$,UR!DPUI@\H:=U_6@@P*ZSW
M?)8IH%AUMK)*,OJUXRQ2A\,]1Q\$=5P2[D+7#I\JP_`[$S'H9%??CX4!B,$+
MQ"_":*^`NH5\IL%3ZQG#:\"\^EY?E?E59PB_U#BMK&E6FH6^)?M;TK1VW1X!
M)\X@@1L-Z#D(EX(MEL%A9K!4E-R,T0IQ>72YV1>,(6ZO#.&:3A&R?2$:KM\1
M==L62;L@EBO@BYRT'VYZ"1)5TBJCRLI-7"?/:^+9]6+BY6))DKW).Y#DD'#)
M(<;)2A);#!#<][PUI8;84TT0EL(O25>D`A(WP4"#)"1--TR!2=Z2#$#!:4.K
M=2XX"5E4IB[,E1.]*9$36HR5,3,](!$G2FF*E,O3#\F],&*L)%F(G$/%!N,R
M?QL:K\1*(>87'J996BD5MBMCOLI:+'A'7VT.X??=(5`Q+QS2FHX&:-DY.3F;
M21*2'E[@\FB4'$/@BC*2]01RZ^2$`,N+5#0TG*O!,I[16#YLXKPE/.H4TA'X
MO4-<<+'-4=,8<"(A,QK#7P(-&QT74T6-RE5X>'%A&8AV&I<M9%24=A]AXE,B
M$$\\\]D5K&$(R"G4*!HS1#4+Y<YAZ/KD.TY)%JD"`H2JP@T+"PHI;R/*L1@R
MFR#<H<6YE4A(EO\`;WGU8Z0C->D(=(1$V^RF@=%[H-?[W@!ZFV,4]W$Y4OPA
MZ?,/.=U./=4KN(SV8_NYZD,(25XKAB!I-0V/&L1I8DH(PZO6=`96?$DQ(D$&
M]'PD,`1A."`8J/#?PA7>3AX81EEW"58_E)[Z,]F?[N.M1Y06\ZM/FE1(_"8V
MFTE+;:3I"0/Q1__4U^JA$B):*V7#Q+<_+BS\.1%P3H),FU-2+,B,X#$N1H:V
MS)!N1)2EG+#2DN.X7W4YPK.,]1$?FHPARJ9Q;"W:*C%16IJ&RVT4J6'5A:2A
MNX@A2[ZI)NI(4J<@9D1V,\"HC9,5[2'CLYM:M6>KVV6LADD\';:W(5>6-"Q2
M+1&BRBP9,$`LM).8Y:5F+2MPI]MQ;KCCV7%YR-"3C8ENQV7^S_19IH_M-=G"
MLX855T>,O5"W"FH86PXI/-:A"7+CB4*4%7""X02XM*E*4I=XGVCV.OQ-LKT[
M5I\3!\%98:4K\T"IQUG!L3,A/QTB)EYA;3[6"`R5H[R%)6GM[<9QGW>IAEYR
MG>:J&52=0H*2?`4F8/X"(]O'FD/M.L.IFTM)21X01(CQ1#\9:-DZ\%8KMWIM
MGV0#&MJ&C=FT9$+)F2\8/EY,<[>:<3*1$_'W-0C;;9KL,+)19Q.%%H^#DOXC
MQI%;%%6*+U+4MLK5:6EW@`3*=Q8!243F0%E*DC>F_*^K10]5TJ0T^PMU(L#B
M)$D;E])((7N$I"DD[[>SNIA`>J:)%C<1(^E.1#("0HV/0PW%;L3X8D/+*G(I
MIMS%C\1&8^42RXTO&>_C`0B.W*`Q4LTV6OI]+K4Q=S]/1*C5F,M65J1V*%@7
M]';F*@`3CI(2!,UU?BX,<Z49M@TD0W$DON@=IXUWD6W4Y;RA;;K:<X[!QO";
M+7TZEUJ8;0'1*C5F/LD_5)<12X%[2FZ_@C7L5&P=2!:U]L)AN,AXAZNE1L8Z
MMDEMZ4#$-J460E!:G\9(`9=SVN(PKILM>GGU+K4PY^GH=1JS&-$0&C2I2OS)
M.CM[O2-6=BW()]RJ;7S@)N'+G#(\);/PMA@Z*9<LIZ<AD)>$<:+=;4WE"U)R
MV6OIU+K4PV@.B5&K,3C]>$?YMMV>BJT>]NJ;*7TZEUJ8;0'0ZC5F(LNK^I]A
MRF)JVZ8WM(R7D<2`H@6F;.A<.B09,X1&LOLP4A&LOI9;M$J*YWTJ\HCY0T-[
MQ!"GV7*[*7TZEUJ8;0'1*C5F*./9U)%V&-M0&HN1+$]$FER`1N83<;R<&'R,
MC+&OEAOSCH$DX2?-R3BLDM/9Q\+2"<=B3S$O-EKZ=2ZU,-H#HE1JS%97UZ:J
MSMD?@-!;9CGKC4*Q0[2XC5UU>5/U6FQ<E!UN,E<DJ?\`*UQL/+/"^4+[2GF,
MH0ZXM+36$-E+Z=2ZU,-H#HE1JS&(`TS0,:3.F@Z.Y""FV@B.*LIK,3NQLRP/
M1DG\+CXF2D6-)$D,](96LEAY2V"\//(?0XA]Y+C9:^G4NM3#:">AU&K,9I6C
M-34^@RFKZWI'=$319D"1BY""&UW?\H=CY2*;@S!FSW'UR@J<Q#*!T9:?0MI"
M$]S*58[>FRE].I=:F&T!T.HU9BQ#Q6F171GFM/<B\J%."D6DOQ&Z"V%%`0*J
MNSXPQ<^^.^,[`/DC/CK1D<E)YJG4+<-*6ZV6OIU+K4PV@.B5&K,5,X#I*SPX
M,!9-#;FGX:,KQ]6C@)F@['DF0823:J;9PPF3#7G&"'G:1&O^5)5@I!;*R4N8
M?((<=;+7TZEUJ8;0'1*C5F+C="-0;#D<R]RT5N*;E,*J#K$@[K:^"F`D4.5L
M$U4RXP@!X5R*.B)&TR"L/C9:>>;*6TZIQKNHPV4OIU+K4PV@.B5&K,*J3J6E
M6@VZ5K2.Z8^T2(T\&;,*UYL`TD@:S3H]FG&7$GOE,Y2?.BH*SGN]J'<N*3E.
M7GO$;+7TZEUJ8;0'1*C5F)**N6SKLVY$T2@S="8*3AM[8NS$08;$8*[AM+Q5
M8H8$K,62>L`W?5AIB98A(]*L>+EXE*?)WB::AI2'*NK0\1_-M7C,^!3A`2E)
M\*"M6Y)/G"BGZRH!134RF@?RW)6?R4`E2E?(H)3NS(L.>Q^O:J!K]&L70,RM
M176B:K)!S#RSR9^,D`G@9IV?-7E!$K)V%)+SL@4YGQBR'W77%9<6I6=1=94+
MK#7!=VIOWP18$D&:;HT`)D`D"P``"P1LII64TO,RB\Q<ND&V\")&\=TJMO$V
MDDDVF([C+#L;6@@E9ME1MFSX>+82%%;,J"X65FI&*%;R@!S8=4/E8>=;N&64
MMLE%0K$F#)/H6;EN,2]@$?<6S15RE/T]2VPXHS+2[P2"=/!J`4FYN@+*5)&]
MFN5XZJ':JD2EEYA;R$B0<3(D@:+Z20;VX2@*2HS5O`;HKOKPC_-MNST56?WO
MU;LI?3J76IB[:`Z)4:LP^O"/\VV[/15:/>W392^G4NM3#:`Z'4:LP^O"/\VV
M[/15:/>W392^G4NM3#:`Z'4:LP^O"/\`-MNST56CWMTV4OIU+K4PV@.AU&K,
M/KPC_-MNST56CWMTV4OIU+K4PV@.AU&K,/KPC_-MNST56CWMTV4OIU+K4PV@
M.AU&K,/KPC_-MNST56CWMTV4OIU+K4PV@.AU&K,/KPC_`#;;L]%5H][=-E+Z
M=2ZU,-H#H=1JS#Z\(_S;;L]%5H][=-E+Z=2ZU,-H#H=1JS#Z\(_S;;L]%5H]
M[=-E+Z=2ZU,-H#H=1JS#Z\(_S;;L]%5H][=-E+Z=2ZU,-H#H=1JS#Z\(_P`V
MV[/15:/>W392^G4NM3#:`Z'4:LP^O"/\VV[/15:/>W392^G4NM3#:`Z'4:LQ
M^IW:$M6$-ZTW6MQ6>Q"5:PL`Z5*S^C&7BD,#-8_YUK2G']W/0X6H"9KJ67[5
M)_@AM`=#J/0,4!,?>]NOQHMFJYVL];!24?+RM>FI:#D+[>RH<T.3C828'JDE
M8*S7:*L\5#AK*),TV993Y&2R(,HAHNX+I,.#BF'P_6D$!20H-H!!!4+X2I2Y
M'>FZD(.^!4JZ4VE-37%`>9+-(""4D@K6000#=)2E$Q:+Q*QO2$IF%3UU$Q)1
M_]77^I0S%CM59KQ1X\4-/6"&AB)0MUM@6-8E)(8%X\EY[*661PVW\N+4K.$I
M2G.<^YU$1^:G!J%O$\7PK#7:A++514M-*<40$H#BTH*U$V`)!F2;`!,QV9\)
MJ##ZV]I-QIJ\03*OY9EBRY%N;?AERHIQ53N:D-F!P9!@L1DF,0,2V(Z^Z4TR
M^C+^&G5*8:R-?K$6;L=H^PS+U%E?[3G9CA5&ZZJ3BU+#I:+B5*IZJ04EHJ2W
M>0$+#:E*<2E:2Y<62VCUK\D=^T3BWHK9_('93Y#5,U=5R['*,!8:5(RQ7BL1
M\'78E)#C(RIFSSYPL<'AUQMK)13>%K0CM5CE&!X/69@Q>@P:@2#55#@2)Z`-
M*E'=NI2"I4K9`R$>SN.XS1Y>PC$,:Q!1%)3-E:I:3N!*9R%Y2B$IF0)D6B/%
M#M/^TL<[+5;Y*1UC6M-:JI7E#Z(*L+JAEXF68_+JE#9L-GG95EJ6ED-Y[JW@
MP(P96,8[!TY[59[48?V$Y2IZ9M&(5%5454M\L+#:9[MU"4F0^0J4?ECJ7B7V
M@,WU%4XO#:2DIZ29NI*"XJ6Y>65`$_R4I'R1&_YC'VE?RGU!Z)XKW_UO=R&1
M>)JM<?)$?W\9^XVDU/Z4/S&/M*_E/J#T3Q7O_IW(9%XFJUQ\D._C/W&TFI_2
MA^8Q]I7\I]0>B>*]_P#3N0R+Q-5KCY(=_&?N-I-3^E#\QC[2OY3Z@]$\5[_Z
M=R&1>)JM<?)#OXS]QM)J?TH?F,?:5_*?4'HGBO?_`$[D,B\35:X^2'?QG[C:
M34_I0_,8^TK^4^H/1/%>_P#IW(9%XFJUQ\D._C/W&TFI_2A^8Q]I7\I]0>B>
M*]_].Y#(O$U6N/DAW\9^XVDU/Z4/S&/M*_E/J#T3Q7O_`*=R&1>)JM<?)#OX
MS]QM)J?TH?F,?:5_*?4'HGBO?_3N0R+Q-5KCY(=_&?N-I-3^E#\QC[2OY3Z@
M]$\5[_Z=R&1>)JM<?)#OXS]QM)J?TH?F,?:5_*?4'HGBO?\`T[D,B\35:X^2
M'?QG[C:34_I1O&Y[2/VX(]<F[6<3H&-@:UJJC;KL!DC0XL-43K:^UK:%@C[$
M^*ZK!C[$07J&7B)%+#;JAYG#`Z<.8=\1/$AD;LG4\S3HYZIYRH<82`X3-UM3
M22D&4K0\A:9RFB9LE*.<'.W;$EEZH6F@2RW3-5"B6Y76G4/*"C;/>\"M"Y3D
MN0M!G%K>]J'[9QVY5ZF5ZU\;+@[8K98Z4S9:[11LTR(GZQ3J+>9%BS66:&A@
M:V(Y#;&C$L$F>$.Z2XXWA?\`-JSU>,@]EPIGZEYFO:"&T.75+WY2M;C8NI3>
M*C-I4P)D"1E;%ASWVMFLIZ-AW#7E..K;OH0>#2M"&W"%K5="00Z@`FPDD3LC
MD)]IS[:Z.EW8::E^.\`4!457NP+FZ1$@-U6IAQVRIJP2]@;6M1@N:M":DG2S
MQ6FGC<($PVRR\^XVTHG(796XR'F45RTJ=X--U9-]9+24A-DC?4\V$DD)MF2`
M"8+SWVO-/%A]6'-J2UPJ[R)!"`'2I2[9BX&7"H`%4A(`D@1B(OM=/;!R(%YD
MX>U\?9T.CQ^IY%;D'J\F579F]VQ,K.:W:K;`<:Z_WYV+AGG,N2"8\<=66VG7
M$.NMMJSJ[..S-M=&VZS7(6\IX;YT"Z6%!+MZ9_)*@-[>)M(!`)C71VB]JKB*
MU;+V'.(8;87O6E&^*E*E,W)">^"2=]=`L!,S&1[,]J'[;'4U:M=IMA&B4Q]1
MW$#HXMJ/UY'%$2MVF*G2[O`)KRUJ'`F0K)5M@19T>AI_RTL1UTA`^1QB76L-
M!D'LJQ&HIZ:FYY?<I2^)N$`-I6M"KUDTE*FUI5,700`534D'+B.?NU["Z:IJ
MJH4'!M58IR`W,EQ26UINV@*"DNH*9&\02;LDJ(S68]H5[<"M(MI5HG^,E:BJ
M-L>'U=:9B6JL.D&+L=F$TS(5(K+0?EDD5`6R,WK"$QYK([C3S"25Y[N&<=_5
M:R9V3OFG33MX@XXZP74I2LS*4EX+%L@%(+"PH$V&[IG9N.9P[8F#4\X7AK;;
M-0&5J4FP+4&"C022E8J&RE0$I7IRE;0B>T<]MG+P^)VM6;C+:(M^:@X.-+AJ
M>`D>6)GMWS7'L5X0J69BPQQF-D03S;OE;@SN`?Z6A"V6B%,W+R3V4M.<$^UB
M#;EQ2B%+,P$L)J#,"9F6U`B0(O;TD$B9&<.V%YDOT[F&.-WP@%*=)+ZJ:PJD
M)!U)G,@W=\`0#*U#>TW]L])``2D'<^+D]'S,S``U\J,JT3A-@@+*_I`*,O42
MW()`?=JF)3D54A"$N(;E12)%Q+P2,"%J8RJR'V7(6MMVGQ%"T)45`J.]4GAY
MMJE/?RIGB)300D24;R9X49X[6W4-N,5&%N(61<*4^>@ACZU,R-X#4L@SDL%1
MFC>JEB.T?:V^V%U'6KA:;/;N/!0-$(I0EF%@]9$2$G%OWMAQ^'<,$<C!<`Q6
M,I0UB3)4S%&DNX8`),>;?0ULX?V<=F>)5%-34[%<%O!PI*G0`>#\Z1F9G=NB
M:DBU:4@@G2Q/M'[5,)I*JMJ7L/+3);OA+2B1POFDB0DG<OF2%'>H4H@@:I_F
M,?:5_*?4'HGBO?\`UR/N0R+Q-5KCY(XIW\9^XVDU/Z4/S&/M*_E/J#T3Q7O_
M`*=R&1>)JM<?)#OXS]QM)J?TH?F,?:5_*?4'HGBO?_3N0R+Q-5KCY(=_&?N-
MI-3^E#\QC[2OY3Z@]$\5[_Z=R&1>)JM<?)#OXS]QM)J?TH?F,?:5_*?4'HGB
MO?\`T[D,B\35:X^2'?QG[C:34_I0_,8^TK^4^H/1/%>_^G<AD7B:K7'R0[^,
M_<;2:G]*'YC'VE?RGU!Z)XKW_P!.Y#(O$U6N/DAW\9^XVDU/Z4/S&/M*_E/J
M#T3Q7O\`Z=R&1>)JM<?)#OXS]QM)J?TH?F,?:5_*?4'HGBO?_3N0R+Q-5KCY
M(=_&?N-I-3^E#\QC[2OY3Z@]$\5[_P"G<AD7B:K7'R0[^,_<;2:G]*'YC'VE
M?RGU!Z)XKW_T[D,B\35:X^2'?QG[C:34_I1OS[/K^T6[IN&]:-J+F)7->RM&
MV79XBGQVS*5#$4Z=HL_9)$2*AI&R!.2YM=F:8V<^A!>6V`BPFG5DY>(2U@=7
M#LY]B6%TN$5>)99??35L-E9:<4%I<2D$J"3="@N6BU040$R$YQS?(_;KBE;C
M-'A6::9@TU0XE"7FP4%M2R`DK!44J1,@$BZ4@WM]*4>QOKK+':./_]:#=?H,
M<OE);CC1XV0<MU;0!(EO30XH!BYD)(II)%;6W8F!Q7\I<6L!234I3G+&<.X3
MGJ(.@Q^;'+:7UYBP!%,^EJI-:P$+474I0HNINJ4IDAY*4F1):(=`$VR%2CM+
MXI%S9?M.N-&9YZ-=+8-)%;^"1=L!`,L,UJ]_T=@7<9IUH8PR2IQ.4,J3'HS^
MJRA*L.8ZO8(*VR")3W)_[8[9=D[M<[]JGLQV@XTIY*E)'!IQ!*`!3U>]"<26
MM\2,[$D,C0@`A4=^'M?]16K??L^]TZ<I!$.+:MA6'1D!"OV`PH"%;,7R`U<6
MG,D6$#)%,#X2+GW4,.Y[W9[G7TGL\QBDR_FS#L:KDK524[;ZE!`!5+@'18"0
M";?"(]7NT[#7\8R1C.&4RTI?>+"053"?WAHVR!.YX#'CS_`/YL?*?C_\^KEZ
MM^NP?W@,E=$Q#5M\K'5'NCS#TVD])SDX?@'\V/E/Q_\`GU<O5OT^\!DKHF(:
MMOE8=T>8>FTGI.<G#\`_FQ\I^/\`\^KEZM^GW@,E=$Q#5M\K#NCS#TVD])SD
MXLF?8;<M,.NL9V/QCP^PLEM]G.S['AUEP,IL$M#K?U?=]M8IKR&7,9QC*'58
M0KL5G&.LW?OE*0.S<3D9?S*-T3'\[N@$CP@3BSNFQ[K"B]-?AEQ?AL^>+H+[
M!GF>:,.:%;^/!89;#10A8M_MQ`Q0Q#:76"!WVM<K:>8>:7A2%ISE*DYQG&>S
MK$KM]R8A2D+HL0"P9$%IL$$:01PMA$7#LDS`0"*ZC(/\9?)QS_@'\V/E/Q_^
M?5R]6_5/O`9*Z)B&K;Y6*]T>8>FTGI.<G#\`_FQ\I^/_`,^KEZM^GW@,E=$Q
M#5M\K#NCS#TVD])SDXLC'L+N99-CE:NW9-#XDH>$K\^6M5VMV!5!60^S1T>E
MEW&N\N+(0_5"<NIRA*4I4WG"E95G"<RNWG)B:=JI-+7\&M:DCZMN<T!!/\[H
MDL2_#&,=DV8"XMKGE),)!\Y>Z5#B_P"+%[_`/YL?*?C_`//JY>K?K#]X#)71
M,0U;?*QD[H\P]-I/2<Y.'X!_-CY3\?\`Y]7+U;]/O`9*Z)B&K;Y6'='F'IM)
MZ3G)P_`/YL?*?C_\^KEZM^GW@,E=$Q#5M\K#NCS#TVD])SDX?@'\V/E/Q_\`
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M$$K6-Q)*E66F-9?9UG12T.+QUDK2I1!+KLPIQ*6UD&YI6E*4'=(`&X(S]?LK
MO:Q%."%N\G*J6Z-8EW$4E[?&UB7/C(1"F5UZ=R\[27%$&DUZ4*"6M>5>((80
MTKM00]A>EWO]EJ0M(RX^`47".;,C>A05=_66`*`5\X2=($MXY+[1"4*5FD$I
M<OB;SWGW2DJ\S24DI,](4H?E&?,U[+'VL@Z1TL<E:8PD1^"*$PSNK9C6!2JN
M8^?6B1^Y04^`17C"G7`5I[%"*<5X64X5GMH>U[LL,YY=?,PH?N[.A8DH?K?R
M@`%>&5L7>YW:,)2S2FR[+ZYVRX9HEO/R23=^CN2BQ8]D5[45*8I&.0-#RF#D
M827A^]NG9R\QLK6FJ>Q7I(/*Z)G+!T&/KZ";$=3V+';APT(RE(S6$YN^?LSF
MX=A5,UI4E7]79M"K]X'ZRT*X1R8W;ZI^<8USD//Q#23F1!"%)4GZYZQ2+ETC
M>:4\$W=.D7$R\T1].>R.]J2]&NP[W(2C/13X@0)$>[NS:#@A`<;)4*9CAB6%
MT539#0,KJRM$,X7A7AO0$>I/9D1CN!VS=F0<#HP&H#@),^;LSF0XDF?";H==
M!\(<7](SJK(F?U-AI694EN0$B\]*0+:A^1;)3+1'@+:/HB*D#V3/M4HF':@(
MKD528N'',$D!@8[=NT`6AC0;;)7X0@50M%:<&<8O,P3,I[BDX^%'E%?]OV+Q
M:OMD[,7'2\Y@%0IV1$S3LF8*`V09NV_5@(_D"[HLBY&1^T%MG@&\S)2S>O2#
MSPM"RY.Q'&**_P"6;VFV+7$^S+]J?;AY\=CDA5\CQFQER$FT3NK9C*'[M4QZ
M?&@3;>&*2OQ<1`='@F@,J[J1FX8+#3;>!&.YF>[5^S*C53J5E]Z\NG%V5.S8
MVN^2G]9NE;A5X2M4R;QG:C*':%4)>`S.+H?O'ZYVU:0A(5YFX&VPD:`$)D!=
M$N6R^R$]I]<HJ6@[7OC7%AB)YF''G(^6V]L8T:9&@'T%0HTJV]K]6)`:-+:;
M>:;>[Z$O,M.=G?:;4FQCMH[-:5UMZGP2J0ZB]=*6&@4E5BB).V$BPD;A(T$Q
M;4Y!SW6,NT]5F%IQA82%)4ZZ0H),T@[RT`R(!W0#I`E%'X!_-CY3\?\`Y]7+
MU;]27W@,E=$Q#5M\K$3W1YAZ;2>DYR</P#^;'RGX_P#SZN7JWZ?>`R5T3$-6
MWRL.Z/,/3:3TG.3BG+]@US.`%)..N''<($(=XLPPO8%M&%$%&;4\0220]KE#
M+`[#*,K6M><)2G&<YSC&.KD=ON3'%I;;HL14M1``#39))L``#MI.X(H>R3,"
M05*KJ,)&DWE\G%*W["GE^\N+::OO&MUR<$</A6V]DV=;DP"RT.^\;%(3KS*I
M$1E@MI:G&<+0E#J%9SV*QG-3V]Y.'"$T&)209*^J1O3;8?K;#8;#X##NDS!9
M_7J.T3\Y?)Q<OP#^;'RGX_\`SZN7JWZL^\!DKHF(:MOE8KW1YAZ;2>DYR<4!
M?L)>8@!`0AUYXWA%R3BFHX8O8UI&(/=0II"V@F7M=H<*<0I]&,I;PK.,K3_R
MXZO3V]Y.6E:T4&(E"=)#2"!\YX6S0=,6GLES`"`:ZCF?XR^3BO\`P#^;'RGX
M_P#SZN7JWZL^\!DKHF(:MOE8N[H\P]-I/2<Y.'X!_-CY3\?_`)]7+U;]/O`9
M*Z)B&K;Y6'='F'IM)Z3G)P_`/YL?*?C_`//JY>K?I]X#)71,0U;?*P[H\P]-
MI/2<Y.'X!_-CY3\?_GU<O5OT^\!DKHF(:MOE8=T>8>FTGI.<G#\`_FQ\I^/_
M`,^KEZM^GW@,E=$Q#5M\K#NCS#TVD])SDX^'?8?<Q]?-.7V8LNC%1-(0NWRB
M8V[6YZ15'5I.9DY(#+NOA6G3<C!*\)*G&TJ<[,94G'NXN1VZ9-Q!:*!JDKN%
M?(;3-MN4U[T3^M-DS;8;-R,C/95C]*ZU5+K*6XVH*,E+G))F9?5Z;+(_H?==
M18[T1__7A;69CL=L>@2#&7,/1]UJQS:F2AP74K#G`24K;-,QD0):,M=N'G?Y
MIKL[R_U<9ZB)RMC\VN5GET^9\NU#9-]NN84)*"2+KJ%3"E;U,I3O*WJ=)L!C
MMFT39IVV^UWTS-3<^S/MES<23`K"NL3?8N*KLEJ*0F(Z%B9R".D(A``2Y%S.
M!V'%);<6O.5.J4IYS(T27&YF9F/E_@CN!D/%*_&/MD9+KJ[$!4(6\A3-VI;J
MD-LKPY;B&FW&E+;"$E:B$))`)))625J]+7,,GR/2+Y/D<J?X6S]#*P'!PLO8
MI<C.=Y:[3AL"$@`9*8DG\YS[C8[#KF<=N>SLQGKDN%M+?J'VFY7U4S\ID)'Z
ME>E2B$C\)$>M.:0HX*^$(4I1=9D$@J)^N;T``D_@$:K_`!L<\W^\_P"'7??J
MWZCMC5OTJ?VBGY6.!\VK.KZK4N^I#XV.>;_>?\.N^_5OTV-6_2I_:*?E8<VK
M.KZK4N^I#XV.>;_>?\.N^_5OTV-6_2I_:*?E8<VK.KZK4N^I&OYVD]7R)4N:
M3K/DDHJ>/E)*8?3IKDDD@XJ>$&%GTK*^K_);`4TZ"P4\*TXV*DUAI]IMMUM"
MDSC=1C[26DH=I`$)2E/UM+(!))39PDB4WBD*(*BDE))!,]5>%/+G>PZKM42?
MJGMV[.V[.6]!EHF)B)H@)$6M0D77XO7^^DQD*$Q&1C1/'S?Y3HT<&C#`(>27
MM<*(?0$*A#2%NJ6ZI",96M:^\K,0_AF(5#SC[BJ;A%J),GZ<3)M)D')"9MLL
M\``C8325:$I2,/JI`2_4N^I%X^-CGF_WG_#KOOU;]8MC5OTJ?VBGY6+N;5G5
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MA\;'/-_O/^'7??JWZ;&K?I4_M%/RL.;5G5]5J7?4B/\`8$!6MF1XT;:-=<@E
MLAN9>$=C=#<A8PH9[+X9'C,E":Y0\V]A02,85C.,IQG/9V9[,XW:*EQ;#W%.
M4ZZ6\1(S>IE`B1&@N?*8QN4-4Z+J\.JI?L7A\NXF([(TGK@I\1U[7_)13(\O
M&SCX&-%[Y3'R)\2*P("HX9.J\8RTVACO*0UEI+BU9[_>QA&$[Z7\>2%`+I+Q
M04@\-3S2%&9E];_#.6YNQC5ACZK#AM5(D$_4O6RT3WD3C"R[$##Q,&!K[>B0
M8:-!B@DJXY;U1E(D<*T&/C*!]8L#HSAEG'N-H0C'_53C'9CJ'=PK$'G7'EKI
MRM:B3_6&-),SI=)\9C.*6L2`D8=4R'^X=]2+G\;'/-_O/^'7??JWZQ[&K?I4
M_M%/RL5YM6=7U6I=]2'QL<\W^\_X==]^K?IL:M^E3^T4_*PYM6=7U6I=]2'Q
ML<\W^\_X==]^K?IL:M^E3^T4_*PYM6=7U6I=]2'QL<\W^\_X==]^K?IL:M^E
M3^T4_*PYM6=7U6I=]2(KU9:5H1L/_P"Q-UN]_:ES7_1^/^\BO#[SXG\T_P"3
M:\=\G(1V?KM.=UQ'_63CJ6Q7"*Q1PZ2F+*1L?KV!N'PN?CT1H4-/5D5<J"I/
MUZ_YEWP_R(E3XV.>;_>?\.N^_5OU$[&K?I4_M%/RL;_-JSJ^JU+OJ0^-CGF_
MWG_#KOOU;]-C5OTJ?VBGY6'-JSJ^JU+OJ0^-CGF_WG_#KOOU;]-C5OTJ?VBG
MY6'-JSJ^JU+OJ19;(:#:Z[/5>8UWO=V(LD+*0$JTSQZWZPZY'3`+\<<VT\C6
M_?9<6,2K"58]U.<]N.L]-AV)4E33U3*Z8/-+2M,WZ<B:2"+.%MM&B,;M%5.M
MN-+PZJN*20?J7=!$C^1$,L:4UD/*Q,RC6O(]1\&EQF+>?TAR%)<&!>P#AZ,4
M01K5TLF/7B/1A+;SCGA8[,-Y1AMG#<D7<>+3K/"T@;7YP#U,`3;OI<)*=ND#
MY])G:,.J`I"SAM45IT$M/S'R3NSE%.+HK5H3,(P/K7D>G%=8F!X=;FC>0#ZA
M6)P$>/D&'$OZQ=9-%>&8RA3#Z71W677&'4.#+RSUF769A<54J4]23=*2KZZF
M$R@D@B3EA!,P1:"`H$*$XQIPIU*6DC#:N2`0/JGMT`'\GY/X9Q=7-34%P$D+
M.O\`DBA9$E99=L]G1F_6)`.0M1M:.DR!'VM8(0A;:JF&ACOH7X3:5=G:K.%8
MP\)CEY*BND(`0)<-3R(;"PF8X7_>*GX28J,,?!F,.JY[[^:>_**2?R?XHEX)
M1BA/'^@Y"A(J-I7(R.CHZ+7#23F>/N^C9N5"^&')YHA$N3K?.`)E9V4,/'^`
MZ4Y&-)#2MMKK9%9CA6\ZYS12U+O`</3A*24W970Y:D"T(F$A9*R"8#"ZA*4I
M3AU4`$@3X%Z=AG.91I\)TRLB:Z0!#:_C3(FO:_W^D$V01)*9+X^;Y?2.^F)B
MH?+8B4:R9;'8<9B$.K3C'ZY+CKJLY4XK/4/5T6)UKB77U4U\)E8_3C\I2K?K
M?"H@>``#0(SIHZM`D,/JI?L7?`!]#Y/',QF?QL<\W^\_X==]^K?K5V-6_2I_
M:*?E8NYM6=7U6I=]2'QL<\W^\_X==]^K?IL:M^E3^T4_*PYM6=7U6I=]2'QL
M<\W^\_X==]^K?IL:M^E3^T4_*PYM6=7U6I=]2(UW-:5NZ?VLWFB[I'PYK:](
MR0=H'>$<"QA=7E$Y>,D#]>C`@"M=O><>><;::1C*EJ2G&<XD\%PBL1C&$J*F
M)"I:-C[!/GIT`.$GY@)G<C7JJ>K32U*E4%2$AM4R670!8=)N61W)]1<?98__
MT(9U@D]S9%#'C#9^/.-M]=CV#*M,M5VR,YD984%?P'//X4-#RCC1"DLD.X4T
MTM6%+QE&,XS$1^;;*G.%9GR\W2OU#3ZZUE`4PZ&7A?<2@\$Z=ZVX0HA*U32D
MF:@4S$=L>B(F!@_:Y:7C868MDX4Q9/\`[F.O9+<A<LV9S7UD6>S9946/BHN8
MEF1E,8=*"&9&?S^MA.5]]2LC5CJ9S\[=T_ACM_D.CPZ@^V+DBEH*VLJ'4O\`
MUZZI074\.:)\K#SB4-MN.!-P*<:0E"M,BJ\3Z@>2$P)`:[B)DYF4?$CMOZ`(
M(9A8.:LLJXVG>6O<92#!5V/E9R4?[5>XT,.\[G'Z$^YGKE6"-J>K'6D%(4JF
MJ!OE)2/U#FE2B$CYR0(]=L76END0XH$I%0QH!4?U[>@)!)^8`F*[Z_Z)^P=V
M?PT\CO55U;L>KXZE]JIN5C)M.FXNHU#_`"<:^2\\X<^`N-VYREA1QE]\P5CB
MWO\`,Q(9;'-''2I\W6#CX[;>"DJ6E.<X>6TE2OUNS.&QZOC:7VJFY6&TZ;BZ
MC4/\G%B29*F1TM%6+=_)V<#F4R`I>&^(V^H)]F,+=%2R,`3":Y#>#*:C/+!'
M'\95XJ)!;V$-E#1Y`;8]7QM+[53<K#:=-Q51J'^3BH1+3:!DA-[OY,"B,"H!
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M'U_T3]@[L_AIY'>JKIL>KXZE]JIN5AM.FXNHU#_)Q9K#NJDSD%,0[`>^X8B3
MCBPAY>,XX<E19"+)?86V/(!O#:Q&>2^&]E+B<86G"LI[JOU<YQTV/5\=2^TT
MW*PVG3<74:A_DXA-<XAZTBV%_9W)O(8MLC;'\`#<:.4H<83'BD5UTRL%,,51
M(;L02B`7AO'@8[F9`KQL$MK2VBNR*OC:7VJFY6&TZ;BZC4/\G%KA"W(47R5.
MY.5IK9(&$R")+C/R0DLHEW%MM$FPIA>OER45'+CV&FVQ%//^"^C+Z'$Y=?0[
M38]7QM+[53<K#:=-Q=1[._R<?2)(]#(X_P!=7*98S`30F!E\5^02L*=;+AR$
MR"I)[7#]@>,:0"0E/BFNH7E].'<.(2Z@BNR*OC:7VJFY6*;3I^+J-0_R<4L1
M(3D:2\WG=?)A<&+,2!,/$9XG<ARW%092D/!P$[-26OS+!(M1V'RQ?*VRV)1\
M<CQEE^7,@DA4V/5\;2^U4W*Q7:=-Q51[._R<<0F2ARX%3V[^59L5$V>ESYT.
M_P`6.0+;<T'4)^-EUPIDB+KEB40+-`PPH)/8]EIYE+N7VG_*2,.-CU?&TOM5
M-RL-ITW%U'L[_)QM-]?]$_8.[/X:>1WJJZ;'J^.I?:J;E8;3IN+J-0_R</K_
M`*)^P=V?PT\CO55TV/5\=2^U4W*PVG3<74:A_DX?7_1/V#NS^&GD=ZJNFQZO
MCJ7VJFY6&TZ;BZC4/\G$-:;WK216]H>+![D5Y1N6^E-^3<=>01G=:>)"RA+_
M`))K%_R4G'9^NRYW'F_^LG';U*8IA-4HX?)VFLI6Q;4TXW#X7;1\HLB+PO$:
M=(KYMOVU3A_4/'=^1O\`%IB9?K_HG[!W9_#3R.]5747L>KXZE]JIN5B4VG3<
M74:A_DX?7_1/V#NS^&GD=ZJNFQZOCJ7VJFY6&TZ;BZC4/\G%IG=XU*3B#@(U
MC>L"<2SE`LL+QBY"DO!NX4E:598*U.IMUAWN^&[A.6GO"4KPG67>XZAL>KXV
ME]IIN5AM.FXNHU#_`"<0K(3HQ=IAIT79?*&/B(PN;)(K#7&[E"Z#)8FK(?.M
MX))<IGC.*@!SL"1Z'4O"-LL--OL$#)R,IL>KXVE]JIN5AM.FXNHU#_)Q'ZV;
M/%1LGBM<@>5JI@P`A#"K'Q?Y!S$:Q+$V@V7P:ALS5IKPT<'#F^1H$8\-:^YV
MY?2WX+0[8]7QM+[33<K#:=-Q51J'^3C*4RDJE!*D[OY2#%F%QSQ!`O$_?CS2
M!P_#2^,$#-ZWFQ(_RQAK#2E-)3CNJ6XI*WU>-AL>KXVE]JIN5BFTZ?BZC4/\
MG&2DV]!D/"@*O_(V/,AXVLBY)BN+_)EEB1D:Y;Q9Y4I)^4T<J6-Q,5YAR','
M6;X1+)3CSWC.H&\G;'J^-I?:J;E8;3I^+J-0_P`G&"QXJ&8E4/*[LY?RR"+-
M69DB41Q\Y/QLX/%0(-B&-@(N0;HI.`QYYZ8860XI#B\^28[^'<^'EIL>KXVE
M]IIN5BNTZ;BZC4/\G%R)E)L@(=/UX<FTRXA#Q0\HGB1R#:8PZX:T6RT1#AT,
M2.D`QFQTL8:)2[A;*W>]G*UI6VV/5\;2^U4W*PVG3\74>SO\G$I:\V7#TYF2
M:L-EY&;!<,R-Y.7/\7]^BD"88(DG5K2B+U(,)EPMHUI+O8WC'?8_F_#8\$8=
ML>KXVE]IIN5AM.FXNHU#_)Q)'U_T3]@[L_AIY'>JKIL>KXZE]JIN5AM.FXNH
MU#_)P^O^B?L'=G\-/([U5=-CU?'4OM5-RL-ITW%U&H?Y.(?Y";TI4AH/>`#$
M)N-M\[4&RPV7#N.W(&,"0Z32YIEM9DE):Q$CH\5*UXRX^0ZTRTCM4M:4XSG$
MC@V$U2,7PI9=II"I:-E33DV+3H`=))^0`D[D:&*XC3JPO$DAM^9IW!:P\!YA
MTDMR'SFR-S.N,Q/Q_]&'M4YD/K-U^S%.*;/,N-=CF.QJ0(2[\)RHL<Z*^)%2
M4-)'"F,E*:>'9+&<(:6IO#J.]WL1!T&/S<Y0-3[U9<12*E4+K64"Q:@;[B4%
M)2VMI:DJ"BE2$N(*TDI"DSG'97Q)AY>$]J9HH2S6\>Z7%5H)<N,B'$,1(`<\
MBB687,;&Y%((%E(E$6,*\(8G#+KXK[?E#`Y6'V&[V2"ML@[L=H.R&BK:#[66
M1&<5QI%=C7.EFI6AL-H2Z*1]-Q%TE*VPVE"FW!=4I"T\(VVZ'&T^N3;=:F+3
M1C0ZZAE^PP\W3;O``$/M"#34UKNYP%^C*X5(/-O(BA+,96T1SQG<<R(T4I["
M%Y1A.>0X>^VQ5)4],,J2M"B+2E+B%-E0%DRD*O`3$R);L>S=<RMZG4EH`NI4
MA:0=!+:TK"9[EXINSW)SW(L`O(74*499L]TB-;3;.?#/JNTS!==V8%]/ZKR<
M1MH?C\2X"'TK;;D8YPV*,[F5BE/M=US.5>$8@#-FG4\T="VOK$G\*9R/A2JZ
ML:%)!LC&G$Z+0Z^&G!I2YO%#\"I3'\9,TG<)$5/VA=!>?'3_`*2Z7^^NK=DX
MKU;4:M?DB[:6'=/9]-/EA]H707GQT_Z2Z7^^NFR<5ZMJ-6OR0VEAW3V?33Y8
MUI<VH>@1QL;ECQRR://.2(3Y6R8%R..CGLUH?`4R`AY$ICR1N-D3FT"2+#"Y
M"0;:<0J.'4$0V3BG5E1JU^2&TL.Z>SZ:?+$ZU+>NGHFLP459N1>G[+/Q<6''
M2MD5L*A@NV,L%E(KD^4`')C`QYLUX6"7QV$8''>=4VUVMI3G+9.*=65&K7Y(
M;2P[I[/II\L9#]H707GQT_Z2Z7^^NFR<5ZMJ-6OR0VEAW3V?33Y8?:%T%Y\=
M/^DNE_OKILG%>K:C5K\D-I8=T]GTT^6(HA]Z:2:WEL27=W%JMN*.U1IF."DU
M["J2(\N0B[?ODF3`%-5+X&(,CAI@1Q]I"LK904RI>,8<1E4@YAF)'"J)L8>_
MP@J'B1P:I@%#`!(EH)!D=V1\!C0;KZ`8G6+-:S<+#(!OID2%OS$YZ1,3\$QX
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MC5K\D-I8=T]GTT^6*9>TY%3[!R.8W'IIYJ+K`K\=FVT1T0J1$KX#5B.P5WV6
M1@S;8,Z4XQY$X06`\L8<N*6IMX=LK%.K*C5K\D-I8=T]GTT^6*(?:%B'08[G
MFEQW*()(C'&A3[)KEX0,=L,=J48"?"8BWT*()9<<0M]!.?%?4K]1E#0J*[)Q
M/JRHU:_)#:6']8,>FGRQL1`;^TN+!0@T[OK39LV/$1K$R8SLZE.-%RK0;+<@
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M^_M.%0YX]=Y`:4BYEUGN`GG7^FGCC.96CQ%9&Q8&D^,IGO):<7AUMEW*7%LO
MH3EER,V3BG5E1JU^2)+:6'=/8]-/EC7YW9DD45)]_FAH>.`,L)A038MNUL83
M$UM_,JF-CF'5AQ_E,I#.K$)=(>RIF2_6&4R.TWEPFNRL4ZLJ-6OR0VEAW3V/
M33Y8Q%S:NS\LXAT<R^,J'G(=:%6P>R:Y88#,5+QS>%,PIV)D@V51!()4A;JD
M!I*RE:T/)5X+;96*=65&K7Y(;2P[I['II\L9[&[=D1[96RI3EQQME:9'$QWP
MS$B6ZFPTU*"_!Y#<JHR161,,FD(.)3EC#"(U#C8V,J\-;W:Q39.*=65&K7Y(
M;2P[I['II\L6EK9M@4)9LN\UM`#F2LK72*ZPW9M7F,U2+98,;M$?@]V,%5.>
M5X+3Y&M\5#C;XS#SCBF\$B%MDXIU94:M?DAM+#NGL>FGRQ4O;.DT'LR`O,WC
MXI+4'2XQ^+?M-%2$?+`QH*;I8\.Y()5'?#$L,XI@%+;W8PZO"21U*3X==E8I
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M,U%-EO8-=2T*RZ($*V5BG5E1JU^2*;2P_I['II\L4HNRYE#Q+!G-C0SX#`IH
ML:6S9]7#RQKF3\-QI\PGX,<`9<Q&?SI+0R<=][L9:<:3WB%4V3BG5E1JU^2*
M[2P[I['II\L9]KG=,+&2!Y&S>4?'VRCD,/*'8KUWI42$,4^L!QA@,!PORX0.
M+;;(:[[\@<\:MSQE>"G+8S#9.*=65&K7Y(;2P[I['II\L9/?KS7]T52QZJU<
M0N]_'V(/IUANE=:=-U]3JO8A<Q%KG7[ZD=ZH2UCAH217D*#"),DR9!T=+[`X
M/E1HNW1TKV&OL8A7#@N"4%I0JQQ:DF:$A$[X25#?+4$I"09$JNI5K550W7L/
M45&>$X5)0I2;4(2H24;_`)I4`;$`E15*8";RALOU"1+1_]*#]>K2W?J.XN/,
METHM]:6J*C@"I60DTIF@E9CP8L$Z+-DC#<8\-H=DD=UY:L(0ZVK.%XB#:"(_
M-CEI5S,>`+-,MX"M8/!H0IQ;DG4[Q"$J0I:E>:E"5H4HD`*23,=JO&E]POVK
MFBBVZH14(<F>PY7HXB.(`R5%(U[8V'Y)*WK%:T2&29MDQ+A#1[K2WVUIP@=2
M%#M7L)"5M@"R?_CPQVX[,W5O_:[R(^,(514:WYLH*"B\V*)X%=KU0%WG0X"M
M+JDE04)-D%M'L24I*4Y4K.$I3C*E*5G&$I3C';G.<Y]S&,8ZE(]EH\__`"T_
MM$O#WCO<YK7.LJW<.25KK4D3$S\I3#XJMZU#D02/)I``&\RJ9$BP$"/(6GQH
MZ,*CG<I_FRE8SVX^R9<[%,S8W2M5U<^U0T[B04AP%3I!M!+8E=!\"E!7A3'Q
M?,W;CE3`:MV@HFG:^J;44J+9"6@181PBO.(\*$J3_&C3C\U'0?N9V_TU0OJX
MZY-]WNN^)VM2KE(XG]X[#_A9[7)Y.'YJ.@_<SM_IJA?5QT^[W7?$[6I5RD/O
M'8?\+/:Y/)P_-1T'[F=O]-4+ZN.GW>Z[XG:U*N4A]X[#_A9[7)Y.'YJ.@_<S
MM_IJA?5QT^[W7?$[6I5RD/O'8?\`"SVN3R</S4=!^YG;_35"^KCI]WNN^)VM
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M&TJ4K&,Z-5V'M4+B&:W/%&RZI)4$K0$DI2)J4`IT$A(!)(L`%L2=%VZOXDTX
M_A^0J]]A"@E2FU7TA2K$I)2T0"9B0-IW(K[!_:+;C4X(^T6GV9_(2M5F+$A#
MY.Q3]GE(:"C@;,XVU7#3Y>1U`-'B"6!UY"07''$H+4O&&LJSG'5C/8G35+J*
M>GSW1./J*@$I2"HE'G``/3)3^4)6;L7U';A5TK"ZFI[/L0;ITA)*E$I2`OS"
M5%D`!7Y))MW(ML=_:1IJ7FIFMQ/LY-YREBKF8--@@8ZZEFS4$JSS4+6JTF9B
MQM2NG1BK#8K)'``X?;1Y6:>,PUWW7VDJR+[#FVFFGW,[T:6%WKJBB257$J4J
MZ2[(W4I4I4M"4J)L!C$WV[/.OO4S60JY52W=OH"B5)OJ2E%Y/!3%Y2TI3,"\
M5)`F2(N`G]HPMYX6)('V:/(,R.5&DS&)`2T29`68@-N`>+E<%LZA6QF-%9M<
M6MQ_O>$A,D+E2L8(9[^-78G3(66UY[H0X%!,BD3F;TA+AM)N+D-.]5]$RS([
M;JUQ`<1V>8B6RDJ!!,BD79J!X'0+Z)G1OD^$1;)_^TERM35:T6GV=&[ZTNB%
MQ8%X1/W@F&533IQ##D*%:TR.IALUTN8;);4*V9X*R,.)RWA7>QVY&>PU%3S<
MT^=J-SA@2W=1>OA,[Q1)TW@F1F1.4K8PU';N[2<ZYUD.N;X!20Y>5=X,JD4A
M<VA=*@1="I$S$H^2/[2;)B&62.+]G5NT60IL"#:K>`1>2&#*K6)0R'CHRQV0
M5W4Z7X.!D9"Q1[#!A26AWGCAT(7E3S>%53V&H4AAQ.=J0H=64((18M8"B4I/
M"[Y0"5$@3("5$BPQ17;PXARH:7D.N#K*`MP%4BA"BD!:P6II22I("C($J$C:
M(R)[^T/W\>28AB/9A<CV)@JWA:]&BGIZ::DB+](P0]HCZ.P"O3J2G;>?63&I
M%F,2G)KH+J"$MY:4E><`[%J-2"ZG/U`6PT7";HD&PHH+D^&E<"@4E7FW@1.<
M;*NVRN0XEI?9WB(=+H:`),RX4WPV!P,[Y00H)\ZZ092BBC?[1?;YJ4CX2']F
MCR#EIF6C7)F+B(VT29TG)1#4)`65V5CP!=0NEF1K=<M<7(*?;0IK`4D*_E7A
M$,J7<OL3IFFUNNY[H4M)5=*BD`!5Y29$EZ0-Y"TRTS2H:4F5C?;A5NNMLM=G
MV(*>4DJ2D$E12$I42`&9D!*T*F+)+2="A.M7_:'M@-M"OK]F%R00P<)2I`)Y
M4]-):,`V5(JB-<FBN9T[A!`E_EDY%A'$9RB5(QEL7+J_U>K.Y>CFI/O]03!<
M!WHL+0O.@_76%L6K'Y`M5(1D[Z\0DE7=UB5U26R+56ATW6B/J;0X;$'\LV)G
M'%&?VB6\36.V&]F1R*E\?%=%X[8RQRY^/B4Y#P=B;M_]%T^[_P#:ZZ_9XP[$
MA_W3(<B*]XGAD-*7<YV*TC/ZW/E"GZRY:D#?WE)N6O>=>2I-W3-*A*8,6M=M
MU:^9,]GF(K/!\)82?J[J57[&?,NK0J]HNJ29R(C!K5_:=(VBSA=8N_`O:-.L
M@"!'3J]:MGL5Z<#;/$8/!<+B9?5P9XZ#026WFLK;QAQEQ*T]J58SG;INP5VL
M9344F;Z=U@SDI#14DR,C(AT@R((/RQH5?V@FJ!]5-6Y,JF:@`$I6Z$J`(F)I
M4V")@@BS1&._FHZ#]S.W^FJ%]7'6?[O==\3M:E7*1K?>.P_X6>UR>3A^:CH/
MW,[?Z:H7U<=/N]UWQ.UJ5<I#[QV'_"SVN3R</S4=!^YG;_35"^KCI]WNN^)V
MM2KE(?>.P_X6>UR>3A^:CH/W,[?Z:H7U<=/N]UWQ.UJ5<I#[QV'_``L]KD\G
M#\U'0?N9V_TU0OJXZ?=[KOB=K4JY2'WCL/\`A9[7)Y.'YJ.@_<SM_IJA?5QT
M^[W7?$[6I5RD/O'8?\+/:Y/)P_-1T'[F=O\`35"^KCI]WNN^)VM2KE(?>.P_
MX6>UR>3A^:CH/W,[?Z:H7U<=/N]UWQ.UJ5<I#[QV'_"SVN3R</S4=!^YG;_3
M5"^KCI]WNN^)VM2KE(?>.P_X6>UR>3A^:CH/W,[AZ:87U<=/N]UWQ.UJ5<I%
M?O'8=NY6>UR>3CM^]G_[7+BY[0@HZH4!VQ:\W!#Q3DS):HV"S'CRY\4,IMLZ
M7ITS%F&1%LBP''DX>PA0Y[*<^(Z(VUV.9^:YR[-\P9,2BIK0A[#%*NAYN92"
M=`6"`4$[FE)T!1-D?4,E=IF7,\%RGH%+9Q-";RF70`J[NJ002E:03;(A0TE(
M!$=I77S^/H<?_]/6Z+RWB3CLNMGNM8/#RZU%NI8DW&\$-]]N.?4R2ED]:>W#
M*\MN82YG&>ZK]&8B/S/TET5=*5I<*.$3,-F3A$Q,(,C)?T3(R,K#HCLEX`1`
M4+[0_C"%'5J^U4/,N<2Q&;#=9=F5H)JMS=P:%EB"KS6(<G&>UKL85C+N'%=]
M7;V8R-?K$?/'9W[/-%3T'VD.RQBEPO$:1CA%J"*P@N&]3U1O(DTR.#5^3O3-
M5XWC.STJ^U>LVU:Q[/GDDYI&-FY?:%FK59UO5XZMCD$V`C&U=@5+6L[\"-AI
M46F59K-J-<'6UV.-.H2M*DJ3A6/HO9\UACF<,$5C+S;>&-.*=6I9`0.";6XF
M\39=*TI!G8091[&]HU3B-+DG'UX2A2L06TEM`3YWUKB&E%/RA*R0=PB<?SX_
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M'^+*#7(\L/<S-/451Z,/P^><'W5MX?,"=]Z].\'(_P`64&N1Y8>YF:>HJCT8
M?A\\X/NK;P^8$[[UZ=X.1_BR@UR/+#W,S3U%4>C%&#P)YI2;+A$?Q@W28PT;
M)1KKH]$FW$-GP\B5$2H:U)&SA)$?)@O,.I_2AUM2<^[C/5R\_9*;(2O-5`"4
M@VO(T*`4DZ=!!!'A!BT9.S0J9&!U%A(\W=!D?$1*)LU+QH]HII<]J1IW%/:Z
MB&;KK:_(^%]8V(YOX=U78G+/5\92UD7.0523N?*6^WM>;_5PI&?=ZBL2S7V>
M8JVINJS9172TZWO7VQO74W5[IMEH.X?#$UA&$9VP5SA:/`7;W"M.;Y!.^945
M(T$63-HW1X(FK8=<]I]LBCW+7TIP_NL57=@URLUVX)A]6W]TZ754Y>CS,7--
MF6"P3SD/)Y(U[&H=:`P+&J:2YA(J<N*5U%46)]F=#5TM:WG"F4^RXM2+U0U(
M7PM)3)(3,2<5*]-4Y;ZR)K$'NT'$:*LH'<N%-/4-H0NZVN9N*0I*IJ<5)4VT
MSNR21/>VQ8JK0O:@TU>Q7H/BGL%HO:,'5J_:#R=/SI<@D&DZRL>L*J["FOK6
M3!GPPEBQ+MD#J0ZN:`$>7E3+2AW,M1C/9G5"A#V;*2[3K6I`%0@";CJ75WAH
M4%%-R1LN*4!:;PPTW>%2*Q%;.`J"ZI"$N$M$F3;*F473>FDI"N$F+>$2E4Y"
MZ9"))]JI(2]RFI;A]:)4FXNVAU81>GKLW78'XSU/3](::A:F#.AU9]BH5K1T
M`U7420<AB!*&P<%X)[(A0VB*GLN0W3--YPITI;"!,5+5Y5Q;R]\L@KWZGW.$
MNJ3P@-Q4T%252.U.TA3U2^YEP+6X5F1:5=3>0PC>H#@00A-.WP=]*N#(OIDN
M2A@,WK#V@D_)[KF#N`\[B3WS*522N1S-#WFDP1FI2,-.CP4.8YLITMVL2]G@
M!98Z.DER(CTD.,\A#>08_`FZUC?9^RWA+2,]L7*-*P@<-32-\*25*'!RO!"B
MA*DW2$E0F;R[T>ZC.K[N,ON901PE<I"G#<>_FRE02D\-.Z5I"U)5>!6`9;U`
M3EDX-[5.P6C95K.XC6KR_:];<J5N81I"=<857RX'9$5+@PY19)4Q!+F9G:4C
M.NOBE-D,3+`;@K@XXC0V-9FN[+V:>AID9OI[E,N^@\Y1.\%-$%0$DJNI:2V`
M004%04"I15&T]6]HSU5B%6K+TEU3=QP!DR*+KH(!*BI-Y3RW"4J!#@3=*4I"
M8NSQ7M3D3,K9(CAI8X2R2%VD+^'.9U)L.V%P-CEM+N:-EI&)&V+:+I%/3,]6
M'<GRTR<.;/SDVA@R3/,R(&@?&FJ[,.#;8<SFPMA+0;*><,H"DA_AP%%M*#=2
MO>H0DI;;1-+:$WE$YE8GVB\*X^UEE**@O%T*X):RA98YN5)#CBTWE(WRUJ"G
M'%R4XM5U(&/0\9[5>!VO`;BC>+&P6;-5JM+TFNQ[FI;217(>JRVU)G;>(./B
MWSG%B@1,Y-K!!0AW&!(AA@9'9EE+G6=W$.RY[#G<,7FND-.XX'%'G#=Y2PR&
M;Q.Z2D7E3%JR5'21&JU4]H[.*LXPW@2A4MM%I(X,W$H+Q?NA-ZP!1NID;$`)
M&@&+A''>TT*\@EX3AI8EG0Z-(0@TOC7^XIP9F4XKVY+]0DD5^P7^8I@]J$D8
M1R*D#F8ULML-1@PBQ/+3\DXG*GLU'"-.YS8NJ+ZBGAV$F56C?B\E`7<(4%I2
M572;JE!5U$ME.)=H8+;B,KI#B4TZ0K@W3^Z+FV;JGBB]9=4L(O72H)4F\J>.
MV^E>TEN4(F$-X26>/\BJTIKZO2<7K/::9&K:RDM9U/4C.NHC$C<9*-+@XBFT
M2&:&-D1SY[QH]+CT@]ETC#VQ38OV<TKO"HSM3JFX'%`OL26Z'5O<(J200HK<
M7-*2EN2I!`D):-6<]5C1:7E8)^K4TDI0Y-#2FD,\$F;I%T(;0`I04Y-()69F
M<+;JXL>T`WIL"2V/:.(.T8B:E0H<(QBO:\NRVBLP\8-&)DY66L\C9K;9K#)I
M&\<Z3EI(^0,(6I;KRL=W"97"<W9`P>B;H:?.%&II)41>?:LO$F0";J$I$Y)2
MA*4I%@$0V-X)G+'<0<Q&JRZXA]24@A"%2-T`3)6I:UJ,IJ6M:E*.DQ%'X?/.
M#[JV\/F!.^]>I+O!R/\`%E!KD>6(KW,S3U%4>C#\/GG!]U;>'S`G?>O3O!R/
M\64&N1Y8>YF:>HJCT8?A\\X/NK;P^8$[[UZ=X.1_BR@UR/+#W,S3U%4>C#\/
MGG!]U;>'S`G?>O3O!R/\64&N1Y8>YF:>HJCT8?A\\X/NK;P^8$[[UZ=X.1_B
MR@UR/+#W,S3U%4>C#\/GG!]U;>'S`G?>O3O!R/\`%E!KD>6'N9FGJ*H]&'X?
M/.#[JV\/F!.^]>G>#D?XLH-<CRP]S,T]15'HP_#YYP?=6WA\P)WWKT[P<C_%
ME!KD>6'N9FGJ*H]&'X?/.#[JV\/F!.^]>G>#D?XLH-<CRP]S,T]15'HP_#YY
MP?=6WA\P)WWKT[P<C_%E!KD>6'N9FGJ*H]&)MXV\;^>/&'?FH>0<;QPW=7E:
MAOU=N\G)NTZ>C0TUJ'/:>MH,J:D7/@P<O5LF!G]N,I4$^ZE6,ISG'45CN:<B
M9@P?$L$5F:@<-4RIM*0Z@F^H;PI$_."[I3_&`B:RW@F;L`Q[",9:P>I0:=]"
MR92W@._!^12+R5?(3']+[KHW'H!'_]2&]6)>5L[7*1TJ60J]U!+"$'+BUJ>S
M8(_#242;;)"XY2E]F,/X;7EG/Z^$J[.S,1\VF/S;Y2OG->60V"5[0II;XHMX
M9$M^`HH_E`$ITR,I1VK<>YB3E_:W:9Q+Y.\OC+,B-(;EGTGS([^-;SIQ0LM,
MH8&3/EBF'.-I-2GNOL);RG*DXQG.1J7"ID=V.W'9Y7U=?]L3)7/@L5#51<(6
MJ^XD\Q=6I+CH"0\I*EJ`=`DM-V1(D3Z;N6_NZ:SC'G1T-_\`SAKWKD-!Y]5_
M9G_^"N/6_-/^B5'[1G_C-QKYW%_X"O\`%S_>ZX[,>&/GTCX(=Q?^`K_%S_>Z
M3'AA(^"'<7_@*_Q<_P![I,>&$CX(H9/X3;C9!R(&')E6P2UQ@QSCHX1$@EAQ
M03!A#+;KS`KI.$I<6A*E)1G.<8SG'9U>WP9<0'5$-3$R)$@;L@9`F6B9BA"I
M&Z-]N3T?AEN1K8[&\KPJ[%P[,GKF=E,2ZX25LA+<A%R"JH)FOCC6U#`@Z(]=
MNF152KA`S;3`8I.!ELI4VEP=R=#N6UO/NEJH0BX%)2)$7S?)1:20VD\&$DE2
ME)O!1!(4,-VJ`:%Y!WV^-L[LTR-@`*B+TQ()!D19,1?JXCD<N=CWY]-,%K*B
M8\$L%`SADJV#$SEF`-F%OMR(R5%6ZNL1\AA.'%?!A)*!O!?P.0X3CJ58!P2T
MT_#%^1(-@3-24$)D1H0LJ3.6_2DJFF\D)-BIG-RZ$V66SL)F?PB1EN$RMD9[
M!]Q?^`K_`!<_WNH.8\,9Y'P0[B_\!7^+G^]TF/#"1\$.XO\`P%?XN?[W28\,
M)'P0[B_\!7^+G^]TF/#"1\$1GJ9"_BS-?JJ_UI[Q_P"KGSU7_P#YNI#$R.'8
MM_\`2TW^':C7IP;CMG\Z[_Q%Q)G<7_@*_P`7/][J/F/#&Q(^"'<7_@*_Q<_W
MNDQX82/@C'[:+8RJK9AJF2U'VHBOS+%9/*;0X,#8'HXEN&,);>'*:6P-(J;6
MO"FG$Y2G/:E6/<SL4BZ9-53*JTE5*'$E8&DHF+P%HM(F-(^<18XEPH6&S)R1
MD?`=S\<0;&,<HXN94.>YKRS5P2PB8:(4P;#34E5F<9?DR'"6GBA1Y@Y:'!P0
M<B90(TZ.X1)%N,$>5RCBLO.4\T!]NJ+9\"DA>X)6$@6%2IB9"@EM(4FYC":D
M.6E!:O?*#+\8'R"V5DR9&]G>I8_;0,5.HVV="R4P58SI"'57O$7'1\&<VP\W
M$(<?%%-<P!(9(PUXV'%)&4TCQ%93GLUL5<PM;S1PI"TL!L`WY7BH3WQD2+1*
M<MV9D)Q5@5`1_6+I<G^3.6@6"=NF<I[DHE?N+_P%?XN?[W49,>&,TCX(=Q?^
M`K_%S_>Z3'AA(^"'<7_@*_Q<_P![I,>&$CX(CG5:%_%0[]57^L7='_5SYY]@
M?\W6Y7D<YT_S+'^':BU`/!ILW5?GJB1NXO\`P%?XN?[W6G,>&+I'P0[B_P#`
M5_BY_O=)CPPD?!#N+_P%?XN?[W28\,)'P10RC,BY&2+<6K#$DL$M$<\XG&6V
M3E#N)$=<PMMU&4-D93G/:E6.S'NXS^CJY!0%I*[43$_FW8`6B8LC5/$!R^8#
M`;<LFOI,^`D5DC%N1T@.BQA$IE`'<3(P,C%,N$@@R*G!0\I0/XPX2WBG74$.
M+Y,7\J*4X13U"4K2!*:3<(D=Z3,R)$BK3(J``!`&D$5\D7E-D@VZ1,2/R6:=
M%N@?ASHEKDTA^9\B?U6^VV'7W(#!D38!QR3G6HQ5C'E'AYT@IED8ETY+&6FL
MY4RR*KO*6X^E.@@Y?(9X05(,UWI%!EIN%,T@&>]G/=*MP"-@BHWUV[N2L/X9
M_CE^"*>5C>2,B''KC9BHP98%ZA),D7(&',S-"&A9_P"%J\7)KQ+,#3$G(/1B
M5D,A(2*2R2MK+HZVD)O:=P!"W.$9=6E3*@+?-<*DW5`3!*0`NPJM!2"`H$FQ
M2:HA-U:0;UMAM3;,6BPG>[FD'<(`L99W+4(:-<1#:ODRCK3!1JA1VIEOX-KC
MI@2)2;FWER>&'71XU1;I*15)['6VDC-NY5EMS*E.65J<'"U*4AI2IDIM7;=2
MFR<B;H%Z>DE1`M%IYXG<03>`W?-W2?E&FS\$]!F#7_UG*9E,;'9@/$PN-5#N
MP+#PBLM+`;^$ACQ%GR[;CPQR<YP4A]M)&5J3@5A+:5O1=:<.FWS`N2MO7I>&
MP@B6D?DD&4O.5.S.D.6WY?)*?X[/Q[O@$2)W%_X"O\7/][K2F/#%\CX(=Q?^
M`K_%S_>Z3'AA(^"'<7_@*_Q<_P![I,>&$CX(C+=:%_4UMO\`55_JROG_`%<_
M)65_YNI3`R-M8/;_`.J:_P"(F,%2#S:HL_(5_`8[:.D?:8__U8(HSP[%UJ#Q
M99H`C5G@5EFQLN'`2(@J947))(,[(I5'0IC+/>4V61C+`Z\8<<QE"<]1!T&R
M/S79?6VWCN"K>><;9%6U>6AQ+*TIX1-Y2'5[QI0$R'%[Q!WRK`8[-.&4!3:W
M[3#CA&4N4J4N'B;D"),JBS]ELE3^%'ZO=E(Q#R-L@H67PAV'P&Z^CQ)!C!3C
MBF2LMJ2PQD9_6('RQVD[%,.P3"_M1=FM+@571O,<,XI:J5Y]ZGOFGJI<&NH:
M:<M;X-2A-Y%]2BATI(0WZP>2$'"V77<1!6.'BY^#D]P<?QI*&FH\25BI`96\
M]>*4.='',OB%L*4G&<H<0I.<XQ[G7*L$==8K'7F'5(=335!"DD@@\`YH(M$>
MS.,--O4:&GFTK:54,3!`(/U[>D&PQ7_9JXY^8'2GHKHO[AZMV[C?7%5K7/6B
M[8^$=54VJ1ZL/LU<<_,#I3T5T7]P]-NXWUQ5:USUH;'PCJJFU2/5BW2_&[0S
M45)NPO'C11DRU'FN1(ANL:0,$5)H&=4`.60W7UK'%?*PA+BTISE",YSC&>SI
MMW&^N*K6N>M%=CX1U53:I'JQ`L5QSE&9"*9E^.7#^0CA:T<B3?%U=7HU^3MP
M<)&B!D^7YCI'R2!E+"DPM+#<9A](KK#2W65CN>5UVYC77%7K7/6BFQ\)ZJIM
M4CU8CPSC=M4IF;<BN/G#@$X1BFIK[4WJ*E#1$VTTX^;?,R;$4S8Y."GCGLCA
M1KC91H`8>"7G62B$CX<IMW&NN*K6N>M#8^$=54VJ1ZL9D=QPDL-PJU<=N-GB
MCR5H/DF:QJW5Q"9"/);GSJK!G*M,7'9#Q%(,C(]]\-2G"R`R"<J9:>0TAMS&
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MGNMM(2E.,)QC&)'%,;QE-2T$XO5`<VIS^M7I-.T3^5NFT_+$?AF$82JF<)PR
MG)YP_P#S:-Q]P#\G<$2_]FKCGY@=*>BNB_N'J.V[C?7%5K7/6B0V/A'55-JD
M>K&&7_0^DZY5S92J\8=-6FP-D1P\;`LZGI/9(OFR`PGAE%MPB<1,>VA[*R3E
M)>P$.E;V&"5(2.ZVYC?7%5K7/6AL?".JJ;5(]6(=3KJ`2$IW/!+3A9BY(-N/
M89HFOPD'5[$:2N2L)63(+.8,O$@_'^#$D_TWNDO-Y[V1"76VW,:ZXJM:YZT-
MCX1U53:I'JQQV'6@8,.HJ&X':%/G6Q9`M4$W6Z&6&1Y'`%3+`(-@>I\,VJ1/
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M*W(-2DL"!L(::1C/=;;0E*<83C&.M[$<;QE-0V$XO5`<`P?UKFZRV3^5NFTQ
MIT.$826%SPNG_7/?S:.-7_%B6?LU<<_,#I3T5T7]P]:.W<;ZXJM:YZT;FQ\(
MZJIM4CU8?9JXY^8'2GHKHO[AZ;=QOKBJUKGK0V/A'55-JD>K'&[QMXZ-MN.8
MX_Z47E"%KPC&JJ/G*LI3G.$XPBON+SE79V>XE6?^3&>FW<;ZXJM:YZT-CX1U
M53:I'JQKP)K>H2DT(S'\)=.#P9,$1*D&2^L*K&D1THS%%&MU=Y,A5P'"I`A\
M=E'E+;'D:5'(;PM;@Q.$MN8UUS5:USUH;'PCJJFU2/5C&Y:I1$%8YD-_V>VJ
M)FJ,V&SQ\/:(FG:^PE4)$9/3&3,M$,5*7L"4R#<8HA6!0G\K&?;2/A\O+8C[
M;F-=<U6M<]:&Q\(ZJIM4CU8XV:]!D1\C*M>S?UWAL6,D3`8=ZL:W&FCGQ,2+
M[+#Z2Z.,*$X0-'X0AIE1CKA+V$IQX?@.DUVYC77-5K7/6AL?".JJ;5(]6)`1
MJR@/UXB2QPJT^+)-FRPPX3FNZ20X1Y#,QHL&VZ"JK`DC8N$:2]EHE*WQ(EY*
M5G+;'P\XU3;F-=<U6M<]:&Q\(ZJIM4CU8L1.JHM5*"E([A1Q_P`7.1ML'$!P
M$E0:BQ&XKIY`;<A.S!XM;*(@$`A.$%K\1MW+3;&&.XX4XVTMMS&NN*K6N>M#
M8^$=54VJ1Y(LS%1A2"3%Y]GCJIB.`"&?5C%6U^[)R9BBZ\Z1%PHYM%B!7BUP
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MC<OKC,<AC__6A;62/%V1KYO(SIN'+O5$9#8>F1GR^_/`)\F9(KC!-A8=?[>Z
ME8#;AJ<Y[6$J=PG&8B<K8_-KE5(7FC+:"T5@U].+H+@*INHWH+(4\"=`+25.
M#2@%4A';UI(21`]JUQF!E"Y(XD-D4=)4G$*@7EC(J%X\E:&BF82$B18P1C*6
M1/(?*V5C-H4Z2\6HG.+F)7T2%DX[F9*9JJ?[7/9>Q6/.N/(0!>6WP1*>;5=T
M)0&FFTH2F2&^"X1)0E)6ZMXNR]./(F+`FJ!"Q4H,@R/.W#Q_8*&<RM*'FL[R
MU[G*%*;4A>,=N,?HSC/7*\%<6U5O.(,EBFJ):AR/6O%D)<I&T+$TFH8_X[<9
M+]2VKOD@!_E$C[]ZP;3KN//B3Y(V.84G$CQGRP^I;5WR0`_RB1]^]-IUW'GQ
M)\D.84G$CQGRP^I;5WR0`_RB1]^]-IUW'GQ)\D.84G$CQGRQKH%7;(\95V"^
M*H884I8"1K&:O8`*S:[!9(GR0B6HP:1+`E"O@EB,;<7\(LH\L()QX:,,-I?K
MM*MZ1^)/DBG,:3B!XSY8M3U?O[>!6&.*M;.['?"-FOK$?CQ5XPH_#Y0L`]Y1
M*MQ8Z&6W&7%NK.,2I*5`C..J0,VE6](/B3Y(<QI.)'X_+%8[5K9AB!?SQUKX
MA3E8?)LD,F;E9=3%I:M@\&P)#S@TN%'NQ!L&E^41E]I#[;&&T.X0XK*.FTJV
M7[Q;\R?)#F-)Q(_'Y8NU(I\M)V.'B;IH",@H<MEY$E9`Y(MX`:3'3:S"!!1?
MC(9*^0)$1##LF%##(),\M[B,-9$4Y3:5=TC\2?)%>84G$CQGRQ/WU+:N^2`'
M^42/OWIM.NX\^)/DAS"DXD>,^6'U+:N^2`'^42/OWIM.NX\^)/DAS"DXD>,^
M6'U+:N^2`'^42/OWIM.NX\^)/DAS"DXD>,^6(?T=IW6A-+FG'ZF"XM.X.0HZ
M59(D,9PR)OW9@HZ/U3,8[&AV4IQ_=[,>[[O4CBN)5HJF@'[.;4^X-VG:/@B.
MPRAI#3.S9'[Q4;IX]SY8F#ZEM7?)`#_*)'W[U';3KN//B3Y(D>84G$CQGRQ3
MEZ;UFP(4^Q2@"'F1WG61_*Y-OQW6VU+;9[Z"'EH\5>,)[<(7G';[B<_HZ;3K
MND?B3Y(<PI.)'C/EC7^7DM?0[\NW]FS8LRB';J1+K-?C#"I,P"U1\`ZLN-$E
M)2&"/S79:PMB2#+12GV,#D/=S*6',8;2KND?B'DBG,*3B1XSY8LD_:]=UX>`
MD2.,>SI`":@US10T-"R\E8:UA=OS7`A+/#-E('AE%Q;3T@I]POR5E#"TJ<\/
M'C]-I5W2/Q)\D.8TG$CQGRQ1XV1I5\N8%CN..Y)'XO2@<9,D"4XPYAA3XWEQ
M.`FH>R2TA*G`A=F7`V&%DI>5X*T(6V_AEM*NZ1^(>2',:3B1XSY8F77%>U7L
M862+;U#8:@F.=:8R%=!B(J64[E\\4AIX`::/P(\,_'J[4+<[^6W&U]F$K3TV
ME7=(_$GR17F%)Q(\9\L25]2VKOD@!_E$C[]Z;3KN//B3Y(<PI.)'C/EA]2VK
MOD@!_E$C[]Z;3KN//B3Y(<PI.)'C/EB)-*:<UH13IEQZI@K6G;>_F,*R1(8[
M&AM[['&81[AF,=C;#24X_N]F/=]WK?Q+$JT5#8#_`/,,;@XAOY(TJ"AI"POZ
MD?KGMT\:OY8EOZEM7?)`#_*)'W[UH;3KN//B3Y(W>84G$CQGRQB5SU_K.HQ*
M9)C5Q]F?>)\C8CX')"W$/+%+(:(DBSI<,&)B?$&PVZ6\YAIE3J<J_5SG.&TZ
M[I'XD^2*<PI.)'C/EB!#KEKB+G519O&+:14=AFCJ^'(&`FI89@RX5?XQ$QLB
MR\1&YBCJ\Z2**0A]:<Y=>SC]5Q*6G&TJ[I!\2?)#F-)Q(\9\L<,+L;35C;:)
M@^-6Z#P<E'A/%-U+Q49*`<!&<9`R';C&)/"BCL)R\VYY*E++BLN]OA)=KM*N
MZ1^)/DAS&DXD>,^6)`K'U5VIJ&)%TI9HP:6EP`7VIL<X26AP9*L$6`,Z4A1)
M$\]LCRMG`;PZ,+\E6K*WEMX;<PBFTJ[I'XD^2',:3B1XSY8L,V=28@8E;/'6
MR'F"2.MPUBI>EA6RF[TY!IF$Q9)#6/A&4HXLPX:<(A&,J!#>7WT.IRSAM*NX
M\^)/DBO,*3B1XSY8Q@'9>FY.1<"`XQ;U('&CI(PN130S?(&BXY:4.Q;4BBSK
MAR"VUM/H=S@I*6W&L=G?0K*T-I5W'_B3Y(<PI.)'C/EB^"6K4IYT*(SQWV>`
MW)K"P0Y/U\R(?"Q(6A^IM,8%3.&]LD.4QF0>&(6(O$(E1K674)[BJ[2KI?O'
MXD^2*<PI.)'C/EC+9@77<6YA3>@[J:/Y4`+E#,5-*DGG"IB<B2<``CD%,F8$
M9BFY#O\`CH95&NK=6XVM"&GZ;2KND?B3Y(<QI.)'C/EB/3+C18E@!,IQ4VD3
M(RYN$1#=4$1:(HZ*>,D6`95R28G@BH[RT>-RZADH1E6$NI7E7D[9)`]=I5W2
M/Q)\D.8TG$CQGRQFU9*U/9K0!4_J)OM?.(<)06?:(21B()O++`Y;2(6:^%R`
M+:X_'R`IBEQBR!!AU/-D/M&C/!X;2KND?B'DAS&DX@>,^6)V^I;5WR0`_P`H
MD??O5-IUW'GQ)\D5YA2<2/&?+$.\B-/ZV"X_[S,%J@3)(FG=FDCNI(D,J:?8
MI4VZRXG"C%)SE#B,9QVXSCW.I+!<1K58QA*5/[TU+0T#Z:?DB/Q6BI4X7B2@
MR)BG<\/T#\L;9]<>B;C_U]<X19K<U$.1K#14BW*1ZP!B&FGV"#4%M*%8>9?S
MAAYIY_"4J2O]56,]F?<ZB/GC\T5`:A-=1*I6PNJ#R+B2`0I=X700;""9`@V'
M08[-N#DC>97VD7&HW8,+%04\[,FX2)$1$/##O!)J=RPT8\Q#8\`@M\CQ>^\[
ME3R^[C"L]F$]E[*@IQ%W1..TW8149@JOM-=F3^9:%JGQ%3J]ZVVVT"GF]5)1
M#=A457IJ5-1E:9`1ZT^2$.)8-=1$,>]*L!R.W^/XY#T).S=9EFVU;SUXK*@9
MZN2$5.1;_:GW'1B67<8[<85V9SURO!'5,UCKJ`DJ335!WR4J'ZAS2E0*3\Q!
M$>T>,-I=I&VU%02:AC02D_KV]!201^`B*W[/U#_;V[OXF>2'K6ZMVS5\32^R
MTW)1DV;3\94:]_E(?9^H?[>W=_$SR0]:W3;-7Q-+[+3<E#9M/QE1KW^4A]GZ
MA_M[=W\3/)#UK=-LU?$TOLM-R4-FT_&5&O?Y2(UVEK6"H,"#,5V`Y$[#*(F6
M`"X:`Y,\F\GAQGP?)2)LJA`>PI=Q];*([#++*D-(?*(:;RZWW^]TVQ5\32^R
MTW)0V93\94:]_E(B1!D/ER<!7J/F+DV"DU1SDDC?/*IBGRK*:3#V14[!6"7O
M,3)R-=^'I949Y1F,;<3@-]U;2'\(#77;%7Q-)[+3<E#9M-QE1KW^4CAB<%2$
M:X2?IKD_7I$-JOD'14SR?Y8_SK$F1`1\XN$DHR:DHV4>JL@5)^.PZX(04&`P
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M4Y=?=RIUU2W%K6J1Q3%ZM-2T`U2_NU.;::F.EAH[K7B&@"P61'X9AU.:9TEQ
M_P#>*C^?>X]S_>?_`)TF)>^S]0_V]N[^)GDAZUNH[;-7Q-+[+3<E$ALVGXRH
MU[_*1@FP:#J76T2'+S\YOIYJ0DO@H$*-Y,<@G9,PO$;)2[J`@3-R@NGY&C(D
M@AY+'BN-#,N/K3AAIYQMMBKXFE]EIN1ALVFXRHU[_*1%1UKXR1=L`I,I:^2P
M=AF)&LQT&,UN7EK+BS";4^()'2H\C`;&EH\&!9,+PP\<:X*,E]"VTK6M&4]5
MVQ6<32^RTW)0V;3<94:]_E(HP;EQSD)"1`8D>4F$10DV:9(N;RY*ICL,0-;M
M-F,4P]C<"G2LO"TF58'\)M?CE@NMI_D][IMBLXJD]EIN1ALVFXRHU[_*0.O7
M%J(CS"IZX<EH(\"-S+DP$AN+EPY,?!Z@'Y<5X;X-V'(11[DA!CY.'9'*=>>&
MRE24=[.$]-KUG$TGLM-R4-FTW&5&O?Y2,FJ,AQJO=JC*55+OR(E+')#^5J$5
MNGEY'!QPWP=*26')";E;Z#!)=4B(=;2RT2\0M?9E+>6N\XEMBLXFE]EIN2AL
MVFXRHU[_`"D3M]GZA_M[=W\3/)#UK=4VS5\32^RTW)0V;3\94:]_E(?9^H?[
M>W=_$SR0]:W3;-7Q-+[+3<E#9M/QE1KW^4B)M+:&HY5/F7')S<Z5)VSOL?&!
M^1_(<1O+8F]-C"-*4T)M%EI;ZVF<9==SC+K[N5..*6XM2L[V(XO5IJ&P&J7]
M0Q_Z:F.EEL[K7B&YH%D:=!AM.6%_65'ZY[^??XU?^\C-K/JK4M.!$D;#;-W@
M"'S$1`"/?:0Y,D)=EYXYJ-B!%J&VBZ@5)A[Z&_&>RV.WE6,N.(3[O6CMBKXF
ME]EIN2C<V;3\94:]_E(A.6L/'Z'@56$F1Y+D!,A)D3V8SD3ON5,B0DTR,OIS
M\LS'[Q(0!F(K<NP^8VM6'1VUX=6G#&<.YKMBLXFE]EIN2ALVFXVHU[_*1CIF
MW.&(C8&?K4Y#ODRAD0%&QR-J<V!Y`Y<V^>R"0.-(6H)68_PHQ]]9.<X80.E#
MF5]UYCQ:;8K.)I?9:;DH;-IN,J->_P`I&=U^1XSVB9+@X2]<AB"H^)D)>1>*
MW1R_B@@6XT8HTH%9,O>@$DRS04<4XX,/AYT?`V4OX:6Z.AZNV*SB:7V6FY*&
MS:;C*C7O\I%R=!T:R;+@YG>0[CL/6Y:VD>#R*Y%.N.0,3$U2<<D,!(W%F2$'
M+C;B(MEPI@=KOI=;<4VZWE'5-L5G$TOLM-R,-FT_&5&O?Y2+(>?HB+5G!Q?)
M]*!52>9M8>^N1TNNN"Q,Y\`ER$T%"[DD9)L+!/\`.]YAA]2&,XRXE"E)0JNV
M*SB:3V6FY*&S:;C*C7O\I&,1^S>'\DNQJ&V7R)\@JI!8<Q+N;:YGHBV2P3AH
MI\=M_-QRZXZJ6,:%9QW,>5/O,I8\3R@?+K;%9Q-)[+3<E#9M/QE1KW^4C/(E
M''^>J3-QAK/R)D`#&+(1'Q^-\<I`IPYJK1Z)B13\&2FSP7(TM<.^R0V,=D4K
M&7DL.-MEX6.BFV*OB:3V6FY&&S:;C*C7O\I&/3<_QVK;$27.SG)0`.4*4"X2
MC?O)&3Q%FIG[36U!GC0VX)(Y\EN1I<CEQ`;12F61\N.80GW>J[8K.)I/9:;D
M8;-I^,J->_RD?,1<N)$[)L0\9M'?[T@1(B1"&7MN<U@6TRATKB$&`?*/M(P@
MI2Y/.6LH=6C*.ZI2NQ"5*PVQ6<32>RTW)0V;3<94:]_E(MQ=]XL1<41(SEPY
M+P90D<W+OP,CN#ETJ:Q'$M&'1Q#*`-A&QQBY:&"7("LL$N$/!Y2M+?>5A'3;
M%9Q-)[+3<E#9M/QE1KW^4C*J:;QKV!9P*=4;OR%E;`:+DYT56[.7,:'&BI&E
M",J/FI:_@P7E'B0[S6!V"7B5*[%I;RSA;J6V*SB:7V6FY*&S:;C*C7O\I%UY
M":)I,?H/>![$YN1Q\'4&RS&6SN1?(.3"6Z-3)IYM!D;);/+CI`52T8PXP0TZ
MRZCM2M"DYSC,C@V+52\7PI!:I9&I:%E-3@VK3H(:!!^4$$;D:&*X=3IPO$E!
MQ^8IW-+[Q'F'<+DC\QLC<WKC$3\?_]""J'$!V"\4R!D6W78^;M==B#FF'GQG
MG0Y*7#");9(%CY<IAU;+RL)6V(4XG.>U+3F<81F(C\UV7J)G$L?P/#JE)53O
MUC+:P"4DI6XE*@"E#B@2"9%+:R#:$*.]/;#QLU=6M0>U3X]4VJ`&QL4Q*N'8
M%D).1E24$%T^Y)=4I^2@8%YE*TLISAI&#&D8_DE/=OZM[,^$3/3..WW9IE/"
MLE_:U[.L$P>G<:HTN*7=6M:U7E4U3.UQED@&0D!PB96AU<[/5%R%K\Y8M43C
M=<,F@IFO35%OXJZR!&2=G+:UG?JQL.0AZP!,Q$]%%62P1M8>``00(^RHHE&%
MXPGMSCD^#O-,X@UPR4EI:7&S>)"1PK:FPI124D)25!2I$&0,>P6*M..T+@:4
MH.(4A>]`*CP:TN$)!"@5*"2E,P;2(I8.GSEEAHFQ5_DKM27@YV.#EX>5`B]`
M$!2,9(#ME!&B/HTAE+HY([J5I5C].,]5=J&F'7&7L%82ZA1!!+\P180?KMR#
M;#CS:'6L6>4VH`@@,R(.@CZJ+K]6ET^\)M__`#+H+U']6<]INJ*?TG^6B_FE
M1UF_XF>2A]6ET^\)M_\`S+H+U'].>TW5%/Z3_+0YI4=9O^)GDHBO;TF=I6L@
MVRU[VW^?%G6&,KF$UNI\?94T<J504XR4^&YIL-U836!%87X/BO=JDX2VK.?<
M"LIC_P#XBG])_EH<TJ.LW_$SR48&QMJ'(DR(%O?G(G-@#D#(TR(33./;N&'0
M=>-[&(*1/,:@=J1\7@!]L'!8L@^,J05[B_)D.%(<\I^J*?TG^6AS1_K-_P`3
M/)18XS>(<FP:_G;/*6+S'#BGF,3U.XPP;Z8@A%9:(FPD2>N1DS45#S-A?C3W
M`,E9"/AST.I2AIEQ]SRFZHI_&_RT.:/]:/\`B9Y*-DJW4;/::[`V:-Y!;F1'
M6*%BYT!!,'Q^02D*7!8D!4D(9TH^TA]+!"<+PE:TX5V]BLX]WISVFZHI_2?Y
M>'-*CK-_Q,\C%Z^K2Z?>$V__`)ET%ZC^G/:;JBG])_EH<TJ.LW_$SR4/JTNG
MWA-O_P"9=!>H_ISVFZHI_2?Y:'-*CK-_Q,\E#ZM+I]X3;_\`F707J/Z<]INJ
M*?TG^6AS2HZS?\3/)1#^C]<W!ZES2V]][9$3C;_(1K+0\-HM3:W&-^;+8=)5
MDK2Y+OCFNMY>=QA6&\..*PVAMONH3(XI64XJ6@<*IS_5J?=?Z.UX'AHT?PS-
ML1V&4CYIG?\`W-\?UBHW&>/<_P!U$P?5I=/O";?_`,RZ"]1_4=SVFZHI_2?Y
M:)'FE1UF_P")GDHPVXAN4()P^X<G=M0H#4<=*D%$5O2#XS$7&EQ(,D<2X)H4
ME#`H+LV.IY2^[AIC*WE=C++RVW/:;JBG])_EX<T?ZT?\3/)1@!FQM?@88S*\
MR]@17E$4Q-BXF8/2,0H@$J8D:ZQY,B3T$*I\YR8BR1_)48R5WVE=K?=]W+GE
M/U13^D_R\.:/]:/^)GDHI<;-UX7<&=<8Y@;2)MI\MBNM0/Q*U*[DF3>FCZTH
M')'V=51RDXF8U\=Q2G?"1E':M6$*2K+GE/U13^D_R\.:5'6;_B9Y&/F/VGK&
M2$--$YIWG`T:Z8&_DF%T?'NJ<CF\NE-!#'Z"&(D4-CI<<3D=#J5M-.K1E26G
M<H<\I^J*?TG^7AS2HZS?\3/)1=(NZZ_L2JXN*YFVZ4+L!<6S6A&1./KLP85.
M$#Q49D.+5HSX59R:N50C"\M(3AE[*U9PWE2NG/*?JBG])_EX<T?ZS?\`$SR,
M33]6ET^\)M__`#+H+U'].>TW5%/Z3_+0YI4=9O\`B9Y*'U:73[PFW_\`,N@O
M4?TY[3=44_I/\M#FE1UF_P")GDHB72NN;@]3IE;>_-LBIQMK?K66V(;12D*6
MQO78[+A"LDZ6(<\8QQO+KF,*PWAQ:L-I0CNH3O8C64XJ&YX33GZAC=?XAO\`
MWVY&E04C_`+_`/<W_P!<]N,\:O\`W49;<`%Z_C')BY\I]F5V.:$E#E/R,9H)
MM2Q(6.(EY<A@=&CG"2&XZ,$<?>\-"NXVGMS_`'.M'GM-U13^D_RT;O-*CK-_
MQ,\E$=_6#0'!PY)7,38OD3SLFT-*.UO2J`&G8I]84LER2=X_I$"R(XT[AW+C
MC?8AEU6?U&G%)<\INJ*?TG^7AS1_K1_Q,\C%N9OVGF9-PD3FK*_"TT^W$DF@
M-<;W2Y!42R^6E@XX31RU.B0S!REK6\OP`\$XRI2/&3WW/:?JBG])_EX<TJ.L
MW_$SR,9?#R=3LRS9"$Y?VV9Q7TI;/E0F>.90L.@T\J+[I$LC2*A0FWI&.6PO
MM=3CQ<(2KW5M]YSRGZHI_&_RT.:/]9O^)GD8M@-YITI&RLO%<O\`9TM&PA$4
M+*%Q5:TS)MBNSD>Q)Q*LX!X_D+='/#*:RVZWA367'FV^]XCB$9<\I^J*?TG^
M7AS1_K1_Q,\C%I=V1KIH>#E'N7NST#6(\J$AS7*7J)*'R4QI,ZZV\ZKCMC,>
M"7&Q[I+)!&6A2D,YRTM>4].>T_5%/Z3_`"\.:5'6;_B9Y**@'9NL)!V3;"YQ
M6-Q,.LIJ1+ROCNS',NB^(HII$J]I%N-)=1X2\Y2TZM2NXK.,9[JNQSVFZHI_
M2?Y>'-'^LW_$SR,9"#(UM=:3;HKEAL)ZMG+LA+,E%P6AWVI)VK^49LSH8X6A
MEE2;\:."Z0]X3;B\B,K(QVL)RYASVFZHI_2?Y>'-'^LW_$SR,8X/?Z$8(?,A
M\M=JF#QDU`U:3*#HFIBG@):R+-S#@'('XYN%"M/Y&>6XXXE+`R<96\MM*L9R
MY[3=44_I/\O#FE1UF_XF>2CDQ9M86=J,;7S&GIQ#CX4W%"$A\<37L'`K<D`#
M1`2-&K?:E0"A,9;[J$DLE9:1C"7G&DJ<\I^J*?TG^7AS1_K1_P`3/(Q^D;&U
MV*W+OE\T;N,W!DN`R#I49HEA&2&T9=RR"M[0Z,2_BL8<=:R)XZ7F67G$94AE
MY2'/*?JBG])_EX<T?ZT?\3/(Q605OHEN=K?P!S(N4X=8?(B:R$(!Q_(F34R:
MF`A2PHK.B_A5IIYN53WG<M(2@=U2UY2UWU8<\I^J*?TG^7AS1_K1_P`3/(PW
MK0[0]0)6A_7YM:4G=M#&ZQKL$1#:+4F0(MP)$7+R)@X&G(Z2=K]3KQ!4O+*&
M?9?1&A/>$M+V6L9DL)JV$UC=7LEA+-.0ZI0+]EP@@`EXB\M4D(F"+RA,2G&A
MB5,\JE<I=IO%Q\%M(DS;>$B;&@9)3-2I$&Z#*V4;B=<<B=C_T82UP*4=L.AA
M`OE"FF7.KBADA`NRAHY1$X"T.^)&,1LR](E,NKPIMA`9:GEXPC#+N<]Q40;0
M1'YL\L-.OYER\PPXM#ZZYA*5(25J2HNH`*4!#A6H&T)#;A49`(5.Z>U'C"$"
M-[4KCP5&REEE`I6=ER\+M=IF[E+1YX<)L"#G(5=@G*I4G3&X:P1!8W]':,#2
MMM7@F$)_7ZO9EPB)>'_QX([:=ES%.U]K#LZ=I:NJ>8>>=5.H?=J7$K2S6-/-
M\,[3TY4&WFW$;Q+C8*3<><&^CV*=2D>S$:-[SVOQ1XNS.9C8/*6`XOG6<LF>
MD:AB]4<0>X/G.OOF30FL;M"7%`!!\AXQ!LA`1T>1(F.+<,>?=5C/7*\(PW,.
M/M\%19?77I0`D+X-PW):`74*1.0D$I<4H)$@D`1Q?%\6R[E]7"XCC[5`5DJ*
M2X@7YZ2&UA6DS)+:05$S428@3\4/V>__`,D,'_T:^]3?4Q[@9T^"'/Z3EH@^
M\;(WQNSXT<E#\4/V>_\`\D,'_P!&OO4WT]P,Z?!#G])RT.\;(WQNSXT<E#\4
M/V>__P`D,'_T:^]3?3W`SI\$.?TG+0[QLC?&[/C1R4?*_:@>SU<2I"_:/P*T
M+2I"T+3KU25I5C.%)4G.FLX4E6,]F<9]S..GN!G3X(<_I.6AWC9%^-F?&CDH
M^OQ0_9[_`/R0P7_1K[U-]/<#.GP0Y_2<M#O&R-\;L^-')1\I]J![/5"4H1[1
M^!0A"<)0A*=>I2E*<=B4I3C36,)2G&.S&,?HZ>X&=/@AS^DY:'>-D7XV9\:.
M2CZ_%#]GO_\`)#!_]&OO4WT]P,Z?!#G])RT.\;(WQNSXT<E#\4/V>_\`\D,'
M_P!&OO4WT]P,Z?!#G])RT.\;(WQNSXT<E#\4/V>__P`D,'_T:^]3?3W`SI\$
M.?TG+0[QLC?&[/C1R46"M^T>]G'5(XF+A_:.Q#0A4_:[*\EYV@/KS*W.T3%P
MG7$K7IOO):=FYTA;:/T-MJPC'N)QUF?R-GBH6EQS)"[P0A.AS0A(0G^>^BD?
M/&)GM`R$PA2&\[,W2M2M*-*U%:OYKPJ,7_\`%#]GO_\`)#!_]&OO4WUA]P,Z
M?!#G])RT9>\;(WQNSXT<E%IEO:2>S;GV/)IWV@],FAL>'_1Y:-UE),?S1H,D
MU_-&:5>;_FY&,&(3[GN/CM+Q^LVG.'N!G3X(<_I.6AWC9&^-V?&CDHL*^??L
MLW6(X5SG)JYP:('4)$CKJNH5L1@JWVREC1S*M&9;"'64RAS*&\)3EQ&%=G;C
M&>J^X&=/@AS^DY:'>-D7XV9\:.2BI%]H1[,`$YR3"YWZX#DGG%.O2`M=U..<
MZZJ3"FE..%M:/0^MQ4Q&C%YSE6<Y)';=_EH2K%/<#.GP0Y_2<M#O&R-\;L^-
M')10O<]/97$C!AE<X-6EBQ[#@P(Y=5U$4T(.[(_##K(Z"-&N8:;>E\^5KPGL
MPHG^=SVN?K=5]P,Z?!#G])RT.\;(OQLSXT<E'.-S^]EP%\'>0<Z];Q^8A0JH
MI4=7M4@+C?(RQ3AD@.!Z086(VT6$TON-Y2G.6T]N,XQU3W`SI\$.?TG+0[QL
MB_&S/C1R49E^*'[/?_Y(8/\`Z-?>IOI[@9T^"'/Z3EH=XV1OC=GQHY*'XH?L
M]_\`Y(8/_HU]ZF^GN!G3X(<_I.6AWC9&^-V?&CDHL5=]I![.2K1Y$9$>T=B&
MQ2IVT6-U+SM`?7F3N%FE[;-N86O3?:EIV9FR%-H_0VC.$8]Q..LKV1<[OK"W
M,D+O!*4Z'-"$A(_GO`!&-KM"R&RDH1G9F14I6E&E2BH_S7A)CXG_`&B_LSK8
MR,/:>?E#LHX;KKX;$_"ZMF61'WQG@WGAFI'21*&'7@R'&E*3C&5-K4G/ZN<X
MSB]P,Z?!#G])RT9.\;(OQLSXT<E%E3ST]E<@1\!'.#5J(\IG#!4>BJZB0`4S
M@X232V2$G1N!2$MR(##Z>^A7=>:2O'8K&,]5]P,Z?!#G])RT.\;(WQNSXT<E
M%IC^:WLEHN0,EP>:.IVI4\\B2)DUU74I)^3"D,MOK9,)T>\0*RM#",8::4AI
M/9^JG';GM>X&=/@AS^DY:'>-D7XV9\:.2C(Q/:"^R_`>6^#SQUX&XXK*W,BP
M6K!T+=S(.2RGLM-:20UDA4HZHG+G9W\OJRO.>][O5/<#.GP0O^DY:'>-D7XW
M9\:.2BB5SS]E8IAT57-W5*AGSL2;PZJCI_+#TEB+.@\2#K6=%^&X=B%DR0\.
MYQESR4AUKM\-Q:<O<#.GP0Y_2<M#O&R-\;L^-')1RL<^O9:BCY$%YSZS&"RW
M+,J!&K6IF`'&YYI3$WAT)K1Z!7<RPZUMD94C.76W%I5G*5KQE[@9T^"'/Z3E
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MM*QV\Y3GN)[*IR#G0$$Y&61X#PMOB?!\1BA[1<C*!`SPR#X9MV>-HCQQO_QT
ML?'79T:?M71^UZWOLR01F#G=I@7^/V/,H_G6SGZXX4`6['T2/<+;P6J!C1(B
M-;?SXR`T*5WL\7QJGQK#W$8?BV'.483ODM%LMCP7I$3<,K.$45JE9>CE>#5>
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MA(E!D8RU(`0<_9&#RA\_]L**XCW.WMQS[)&`(S/FG!\%=)%.ZX2Y+3P:$EQ8
M!&@J2DI!W"08]?L\Y@5E;*F-8XTD&H9:DV#HX1:@VV2#I`6H$C=`,?S&K]L"
M[;3N5BV%L>TS=UN]ME"IJR6>Q'OR4O+R9KJGB"2RB%*5GM4KL0A/=;:1C"$)
M2A.$X[[45%28=2L45#3H:I&TA*4)$@`/`/\`;I.DVQY[5]?6XI5OU^(5*WJQ
MU14I:C,DG_Q8!8!8`!&'];,:<.D(=(0Z0ATA#I"'2$.D(=(0Z0B:]#7VE:\N
M,]+W^GPMV@9'5^VJ\#%S=:B[2T%>I?75C:U5/CA2Q`K`GP#M-$,260A>7,1K
M9+>&WDN*8<B<9HJJNI6&J.J6R\FH942E91-L.)X5)*9DWFKX`T7KIF)3$W@-
M?18?5U+M?2-O,JI7TI"T!P!TM*X%4E:+KP02?H7A(SD=^G^07LY\1CHX^@+*
MX033=]P6&WJA2VPPK-=^3K-OU-95/-RN;*0Q3N/"E0A;;<NR^VZWY/&K!>5F
M7SPQ&"9Y#@4K&470[3J_6.$E**:XZF4K@OU&_$T$&=YR^/JX^ANY@[."V4MX
M$J99?3^J0)+<J0II<YW]Y3S29+!$KJ+BCPD01K'87#&LS?'V5V30;/L.+IU)
MMZ-S0,?4@*VJYVNPF-QL!",%HV"ZQ*1-*A9`F28FEH!DBI1I++K/D>!FQIFO
MHLU5#6--T-8VPMUY'`**RJXA(FI4N#!!6H!)1-20@S!O7BKC^&XADRF=R^]B
M%$M]#-.YSA*6PGA'%D)0F?"$*#:2I8<WJE+`!%VZ$R56]U<!(N6U^.=I2>/A
M0F:4=?Y4ZHPIDP18!]8VR@;!?K0+UR>B'XTJRQ=>M\()(LOQS$X<<P<&7'C^
M3G1[^$YR<:K"C%4ATE8;2%J`"2ZAQN\;EZ827&5E)"BVE!0I*S-,I3XWD%MZ
MB2O!U%D!LN*+22HK#2VW+HORNE26WD)4"D.+6%H4E,E8O;-I<)9>[UF2KU`L
ML32HCB.#0YN!D=?5-95CY&LZZC*^9;D.UVSP!4'''7WRF;=EW3)<_NH4.PP,
MV0TF/V*7#LVM4=0V_6H55JQ+A$J#JY)IN$*KF_0H*(;DV$!*$_E$J*3?UJO%
M,CO5],[3T2D4"<++:DEE$U57!A(7O%(*9KFLN7EFPI2$A0N*OLK@56;9H@Z7
MU==;U6->1FQV-GQY%:%@3-K%2%6K<#0526'=G3@PSXMU1/6=UY&$X"%-"B.X
M8T+AU%:B@SC44V,(;Q!IFH?4V6B%E09`6I3DOJDD[S@V@/RBE;F]*I1938ED
M*FJL"6YAKSU-3H=#P*`DOJ*$(;O3=4/UG"/?Q4J0UO@F<7$/8_`=RM#UB3J6
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M]IQU)0)BG2E!6T#>(5>=+IM$[G!HG))!R4S>?L_3P8U`^G+-7W20MF9GLB46
MA2AT;(6A@@JI'UY^1,<"/FJZ\Y@-:3&VX!;*G%@14._Y*6%K(P?.J%.7L40N
M2FKLW'`"$2"PH`3"5>=O?K)R"W'$WDJWG<=[/'&VKF#K;)2]>DRV2%+F4%))
MD5(F$[[ZJ4RAMLW5)M0>XN!`5FK<R+K&>^#P-P4+8LY$2NK:[+A2&NRK?N,O
M96E&Q"-EJ8<'CJ3=:Z)&RZL(R29`X7X`O<;=7D5A6<EL/M*Q!%Y5,XVDAY:2
M'`AD-/S#6DN(<*D;B7)35,B-<8QD(5##S>'*"4U+3J@IA*@6RMXNL2X65C;C
M82LZ5-@R$@8ZW)N3S-34O,9#CH_,M*2$GD"(`'BXD')Y;I60XN,$2@6.CALN
M]QAAK&&V6DI0G&,8QUSUEO@6FFKZE74@3425&0E,DVDG=)M)MCYI4.\.^\]<
M2F^LF20$I$S.24BP`;@%@%D6OK)&&'2$.D(=(0Z0ATA#I"'2$.D(=(1N3P/Y
MC;&X/<D*#NJBS<F)"AS<7&[/JPI#GP9?M:%2(^+56)8#.<BF..QOB/`.N(6H
M&1;8);QAQK'7%\X98H<V8%6875M)+I02TLZ6W0#<4#I%MBA^4DE)TQR[).:Z
M[)^/T6*TCRA3WTI>1N.-$B^DC1.4RD_DJ`(C^HW'GB2H`4G'O))`D1!CPB$I
M6E)`AC*"!GDI<2AQ*767$JQA6,9QV^[C&>N@"T*;6IM8DM)(/SC3'HBA25I2
MM)FDB8^8Q__3@*GR$K$6VK2T%&LS4W&6.$D(>'(CERX\M*A28I,?&OQ+?:Y*
M,G%M(:4.G]9]*\HQ[JNHC1'YJL$J:RBQG"*S#Z5+]>U5-+:;*"X''$K2I""V
M+7`M0"2@6J!N[L=E?!Y^^O>T:XMHV)1#=>S8I;P8L(?`V6O$D13%4NJ1I/R*
MUDER66'B<O-,X:4@$9IE(HC3`X[;#=[$KZ)>&.T/82O,2_M*]E"<RY>7AM<@
MJ2EI;+[*E-BGJKKEVH4I<BJ\E-TAI"4AIE#;3:6T^KWDU3:AL&GTFFWVJUN[
MU">W%K`6<JEO@XNRUN9%;L;)38TM!S(IL7(L-DCMN)0\TM.'$)5C';C&<<PP
M&IJ:.IJZJCJ%M5**5TI6A12I)NRF%)((LLL,>SF-TU-64]-35=.AVG74-7D+
M2%).^G:E0(-HG:-,8_\`8/X.?<SXI?P[ZA^A_67WNS7\3XA[2]Z\8?=7*_PW
M0>SM>I#[!_!S[F?%+^'?4/T/Z>]V:_B?$/:7O7A[JY7^&Z#V=KU(?8/X.?<S
MXI?P[ZA^A_3WNS7\3XA[2]Z\/=7*_P`-T'L[7J0^P?P<^YGQ2_AWU#]#^GO=
MFOXGQ#VE[UX>ZN5_AN@]G:]2'V#^#GW,^*7\.^H?H?T][LU_$^(>TO>O#W5R
MO\-T'L[7J0^P?P<^YGQ2_AWU#]#^GO=FOXGQ#VE[UX>ZN5_AN@]G:]2'V#^#
MGW,^*7\.^H?H?T][LU_$^(>TO>O#W5RO\-T'L[7J0^P?P<^YGQ2_AWU#]#^G
MO=FOXGQ#VE[UX>ZN5_AN@]G:]2'V#^#GW,^*7\.^H?H?T][LU_$^(>TO>O#W
M5RO\-T'L[7J0^P?P<^YGQ2_AWU#]#^GO=FOXGQ#VE[UX>ZN5_AN@]G:]2'V#
M^#GW,^*7\.^H?H?T][LU_$^(>TO>O#W5RO\`#=![.UZD/L'\'/N9\4OX=]0_
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MO4A]@_@Y]S/BE_#OJ'Z']/>[-?Q/B'M+WKP]U<K_``W0>SM>I#[!_!S[F?%+
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MA_3WNS7\3XA[2]Z\/=7*_P`-T'L[7J0^P?P<^YGQ2_AWU#]#^GO=FOXGQ#VE
M[UX>ZN5_AN@]G:]2'V#^#GW,^*7\.^H?H?T][LU_$^(>TO>O#W5RO\-T'L[7
MJ0^P?P<^YGQ2_AWU#]#^GO=FOXGQ#VE[UX>ZN5_AN@]G:]2'V#^#GW,^*7\.
M^H?H?T][LU_$^(>TO>O#W5RO\-T'L[7J0^P?P<^YGQ2_AWU#]#^GO=FOXGQ#
MVE[UX>ZN5_AN@]G:]2'V#^#GW,^*7\.^H?H?T][LU_$^(>TO>O#W5RO\-T'L
M[7J0^P?P<^YGQ2_AWU#]#^GO=FOXGQ#VE[UX>ZN5_AN@]G:]2+!:N"G"(>KV
M1]CAQQ69?9@9AUEYKCUJ-MUIUN.(6VZTXBH)6VXVM.,I5C.,XSCMQUFILVYJ
M54,`YFQ`@K3_`.H>\(_CQB?RME@,O$9<H)W3_P"G:\'\B-@=+^[IW4W^S2B?
MU6BNH;$_]2Q#]NY^>8F*`2H:(#1P2/S1'__4@:DPP=CN=1KTB\^/'SUG@(8\
M@7*L$L!RDJ("4\/E`<@O#[3#ZE([!W\][&.QM?\`)S$'08_-9@-"QB>.8-AM
M4M2::HJV6EE/G!+CB4J*=ZNT`DC>*M_)5H/9UQ`IE3UU[4O1]&IX-I``K%L(
MC3F[@821,O3&-?6`D\AT4^CZ]E(;"O*$I6$5&I>&>2XGQ'$=S/61H2<0#IG'
M:CL;P/!\M?:PR-@&"T]6W34E6I"A4J472YS-XK)2NEHW&](!:<9"D*"A>4F1
MCUG;K_[IK/\`VTZS_P#/.N485YU?_9'?S8]F<2\VB_M+?YT:`>URY3;MXJZD
MU;:='VH6ISEFV*5`3)A5=KMC23%-5J2D$#(&LD7*BCY\K80KOMH2Y^KV=[LS
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MXQ7M!//-$^BW5?T.Z<X=\(A]]SM_Z]H/8F/5CL)X$^T!Y;[_`'MN(V1M9)R:
M>WKQ4)B-HFMHKPLV)5\Q)^/D6GXR1XF(`;N][^1W<]G\K/5.<N^$1VO^S=]H
M/M+[2L/S949JQ&F==I'F$MW*=MN0<2Z53N@3M0)3T1V)?7IN?SC27S<H/T0Z
M<Y=\(CLQ[[8_QZ/03Y(?7IN?SC27S<H/T0Z<Y=\(A[[8_P`>CT$^2'UZ;G\X
MTE\W*#]$.G.7?"(>^V/\>CT$^2'UZ;G\XTE\W*#]$.G.7?"(>^V/\>CT$^2'
MUZ;G\XTE\W*#]$.G.7?"(>^V/\>CT$^2'UZ;G\XTE\W*#]$.G.7?"(>^V/\`
M'H]!/DA]>FY_.-)?-R@_1#ISEWPB'OMC_'H]!/DC'9CD'O$+1U&O;&RY'%AG
MOJ0S(O*K&O5#+^/5NHT/8/#%S3O#:\8*>(PWV?\`9*5C./=3CKQ1[%_MT?:"
MSM]KE/8]CV,X<O))Q?&J>XBB90[P5#38@[3CA1OIA=.U>.E0!!TF.\.'Y!RY
M489A=4ZPX7G4,%6_5I7<O2&YI,O!%=]?N[?.3(_-K7_T/Z]6O?3'>.;]`1R#
MNQRGT9[6*A]?N[?.3(_-K7_T/Z>^F.\<WZ`AW8Y3Z,]K%0^OW=OG)D?FUK_Z
M']/?3'>.;]`0[L<I]&>UBHMDUO/?YL/*APVW#H27*CC1HN9<I>NY1$3(/C.-
M!R2HQZJCLR&`2%)=\%:T(=[O=SG&,YZN3G7'`I)4XV4SM%T"8\$]R+5]F&5E
M(6&V74K(,CPBC([AE,3EX)QU\^RPW/R6CN(L`19>0MROF)796]2HXJV0M1F;
M#&)!W?L."DAS;-+PLI)SK4K*Q#TFG+^4J%=.=8;SY.AAMJ2QC-N*TM:JGIE(
M2A*4&U(,RI"5;NCSI?@B%R[V>9?KL-15UJ'%N*<<`DHID$.*0!8;9W9Z-).Y
M*.QGZ_=V^<F1^;6O_H?U%^^F.\<WZ`B<[L<I]&>UBH?7[NWSDR/S:U_]#^GO
MICO'-^@(=V.4^C/:Q4=*7)_VK?.K5F^=BT"H[A`'KE</AQXM@S6NKSB6VC*S
M"2C^'2WJ=XKV<EG.9QG/Z,9QC]&.HBN[0,R4]2IIM]JX`D_JT[J03^,QW/[(
M/LC=B^<NSW`\Q8YA=:O$WU5`64U3J$G@ZEYI,DBP;Q"0?";=V(%_&<]H;YYX
M;T5:K^AW6GWC9GZ0UJTQ]+^X]V`]3XA[:]#\9SVAOGGAO15JOZ'=.\;,_2&M
M6F'W'NP'J?$/;7H?C.>T-\\\-Z*M5_0[IWC9GZ0UJTP^X]V`]3XA[:]#\9SV
MAOGGAO15JOZ'=.\;,_2&M6F'W'NP'J?$/;7H?C.>T-\\\-Z*M5_0[IWC9GZ0
MUJTP^X]V`]3XA[:]#\9SVAOGGAO15JOZ'=.\;,_2&M6F'W'NP'J?$/;7H?C.
M>T-\\\-Z*M5_0[IWC9GZ0UJTP^X]V`]3XA[:]'K:T!>[-M'AIJ/9-U.;E+??
M>.M/N%HDF@PXYH^?L6O0I:6,;`CV!@`D$G%+7AIEMMIO&>ZE.$XQCK[_`(!4
M.U=)@E6\07G6V5JE8+RDI)LW+3'CUVF8+0Y<SUV@Y>PM"DX908M7TS(42I0:
M8J'6FP5&U1"$@$FTFTQ*VEO]3FIO]F=$_JM%=2^)_P"I8A^W<_/,<)H?W*C_
M`&2/S1'_U81UT,T;L&BAONK89+N-8&>>;R.E;+3\V"TXZA1<?+")6VA><XRZ
M*2WC./UFG,=J,Q&F/S8Y::0]F/`&7%%*%UK"21*8!=2"1>0XF8_C-K'A0H;T
M]K?&[75>U;[53CQ4ZR2<7&C'#N8=D"8\A_"VZ#:8]M&$1L!7&1FT!@-=B%LN
MNJSVN+?>ROOYO9L<0/E$=O.S;+.&Y3^UMV=8/A3KBZ5*IS6I"C,4=0@"2&60
MD!*$[TI4K2HN+O3CU1;K_P"Z:S_VTZS_`//.N4X5YU?_`&1W\V/8#$O-HO[2
MW^='4I[==R$:U+QQ=LK!)-<;WLTY/C!Y4DPB$16Y!4JP*I+PZDDN@X<2C.'$
M9PK./UL?IQ!5/ZL3T7O+'37[>"J%'9?D=>*(4K#!FVD+P3YQ:%)7\($VC?%$
MP+1;NC3'1"G'`:2!M=@R/N>OO1-4KP]8HOPH`818K5(1+,987GK$J,-;3F*D
M\OR(Y*F@`T9:;0L0E"\BJCK9G3+<_P!L>>21]G:JIL8Q(MXY3N,T;*6*3A$J
M4]4+;"'B7N#4/JUWGDK(:;!2@*9="N".)A$<-HR8IYQT9M*PPIU<P'<8I)@P
MC\5.#2U2C6YV-;9=`=4Z9$CS1[X*I!]AUQ;#33@B7NP.^R>[*(2G<[$Z2LP1
M^II<6J:)=-=J4!24E#J7*=`=0`4&:FQ4O+:+RT*46TH4R%R9L#Z>)`'Q6+BE
M;IGC1]@UYVSQ=F<K4=7I'6S8C+\Z*@BOBHGP[":=C+65,N*0*TI:6LD*0V2Y
M:`9"9M_V>6-!P=C5/LEZC..U#Z<29+[;Y80RNB"074@LI#J7E+WLTJ(;25)2
M7"E+JLNB:WPFFG[<4;?-QUY'P]7<U"->A8(`=4-)6-@&?&)7CXZ$H7%0N73&
MG72<^"SW4+46^CNOO#IT6:/Q_P"R)JBPOL(KUXP\_F'&J8<Y9YN@MM(3P3CP
M0Z"952IMM7G`I2]ZF0)>6F3E67'\"8F=<2!.\@[3#CFQ;#3IX=7`8/&:D3ES
MYZV10XF2'&6"$PW'LX<P\5@W+CZ@5M90D1X"?Q1E=I_L\4=>H4]?F2KHDN-@
M%:6$!:0M9>7)*6U@74H#29WEAPJ<-.I-T8#Y)Q%5(5Y6)7?C40X_,9M+:QZ*
M[*C#I@Q'X5N#4@5L(E?P\Z\RZZ]W/&:9QGPA\.>(FLK/.MCCW`]C!J<-(J\Q
M)HRISAP12EQ(X)):#4DA)/"E25*5*^E(-QJ]>3ET),\,RF;1B?JE\B',71PF
MGY`<DYIYVC"6FA$(CYMU=MAQP)63I\5.#X4TR9G!LOA>7&$!,9>J)3MB8H*W
ML/=;Q<8CA&(,JY\54UPN.DTJ7Z15QTFH;"''*9NJ1-*7).5`45(##=_>/V;#
MU5)O/*HBC!D1]->E=8.U@$MPEXH.$<,VRJ.%)>,>(*>?8&RE*UK6I2U8SG^[
MV=6F.TWV4%X.X[VIN9?96W@:L0IRPE1)4EHIJ+B5%1*B0F0))),IQOUO.-W5
M*T9\;0EBK59OR""B!I"V!-G0[[#$#-K#C'T+CI7R9,E8<`-.$I8=4*PIQ[#;
MW<\!VJ;L]^#*.Y-*JE2Z#5H4IGY-.D6Z1H$[-W19I$?-*YA2"+<+*8TA7Q"*
M)86*E)5EFT2-CC]@NDD,09[K5A-=KQD(`)A+B&GF4Y,<\-Q[R5*G!&[OJ[-.
MG\49CLU/!E/"J-\3!D`4[NBV?\&Y/3&!RUGYY0(U/#"U]I*S.8KD^FWRS<U8
M#BLSL76'I"$*8:0JDB91,3J6PG6F14X>([5H2&.YWQZ@,V[XQE2WA*N$)>=3
MOA=$AH)M^EH%NGQG33C2/M#)F#94=`<<JC+$"R!#S0!=JD2P'7A8=$(`A\P^
M7BWBVWCS')!W+2F!7`4-CX/0YXBWU,]*I1<4X,E5BWU)_`/#,Z`?!+PSME$@
MNF\ST!V-#</QU(DFHZ*^*CV"=@,QADGFT$#2[DXA9JS0Q55-ELEIEG#JF"G^
M[XQ.&LI<I]59YWXHP`882B:G@F9GYLY2LE^&SYMP1BT]!\V`Y*MN5RX4*;`^
M*1;%M9DF8B!:1<3X39+0AT$ANGSAAD9#6.9KCRFWGQ?Z%"Y1V%.'$9:J."MF
M#I\G_G&1"\+*5WVEA5ZR4S8"G3:+2`KPVJW)">SVO6+D+1ZH-L,X63O+$&`U
M:Y$)H5@,Z=0PE,B4*P$.*(P.^1C*D(0VE*$YQC^YV]8S*9EHC1>+1=<+(DU.
MP?)N1R6/_==U;_\`IQ?_`/Y"U;U^9;[-7_\`T*1_^XLS?X+%X]/,(_T3`OV5
M+_\`TXN?7OA'+HU.OA',""M.PY/7(>K+=2GQ<%TJ'N+\@#.1!8-7A^V.!$KX
M@/PP))6`8Y:W#Y-#[CI333:16!\NDR3(PM;;"7RXEW\HIE(VFVV<I"6@;ATD
MV0M2<<;>JETJ65T\IH"I@B218`D"<U3TJG,@"0$SA-;MOM`)9(+DOK30-?\`
M!B._,#2$G:%/O6)VNBF#1\4]'6:4'Q#-3CJV##5^*MC&,I88+PG+RLRVL%3.
M[4/*MLD!HGI,P+96@>,C1&NT_F9=TKI*9.]MF5>==!D)*-D["=S<"M,9C&.<
MV`Y"/3(L:!EH=9%/;F75*MXDPTC`E<"NY,&*,ZS'9$68W(E`H*>4_A*TJ7^A
M`>,2MDD*NE\*DJ7FRW;L]WP`R_\`.-A'O`E2;PIE(FF?G3_)"Y;DO.(F9_FQ
MA55J?)H`:R-:^+T'1==@6&#3K.F:FAXL.MFB.;)M$YM:2LA1,))C0\S9$$(8
M>>`;(SAYXH[(N#U*&ZRN.8>2CAP\M\I-]2R9SN@(`M$P/EEN"<K8UV6<72'1
M2JIFZ4*'!H;`"2+ZBX5&1D5:"1.TE5V]9$SZ2#Y#LF3A.\I*M/C.P%%$@HRM
MKCR6!9Z-K8@5\E7SAX*#+>19+0T^:.PI&6A!W4-H]WM2C5JS0D(%&E4[RIDS
MT$[T:3H$@?"8W\/3B@4X<16@BZ@`)EYP3)9G('?*F0-`%D;"=:,2<>9?G+_O
M7;B_\6KO]2*QUQ[%?WU?\E'YB8]*?L[?_P`0Y7_:5G^-J8NE,:X762*H\%<?
MK4H4XVM2[[<H\T24C3&V*-%*7F(CW@I1R*95<AS,^!@0]\A+B,H=80XED?.U
ML1P4R'0\VJ8OJ$C9<$Y"V6_G9)1(W1.0SXTKMLPRKQVOP;95?0$2I:9:5(6F
M=4Y+A%A38<(IRWON$:2B2II<4DK<^[,]PH('E9>I1VU@BA=GA'Q%7FCA_(Y#
M7DI.069"!,.'P<<@6$K\5)Y&=0^W(M/R3#;Q$AX7C(N>.!DN.,(>$G9A)E:@
MJ$P3,FQ(,C.<U`$JE.+<+1VWM.4E'B]3A+C2\+4EQ]M)O(JT-.W'4I-Q-YUY
MQD+24J94AE:D-T]ZX;[%5O@18"I4LV];NJ.')Y1`L3F,@FHH6!.M0X+$9$%N
MAVZ5**C8%QPG+QSB,882E2UK?2IERY+>`.%14_4(-^<I"03>T`[XS";;?&39
M&A5XE]H##FJ5EC`<#K)4\E.7W2XIU+"E%;B0JG;2%NA*+K0.^)`"4$+3P)C>
M`4-<UMJL'(*V5`*?D!L/J&K02I6$'5>&A#\#-1D.>E):@H%QM/C#/.-%O^(D
M5>.ZPNY?14R+E0NF"S;)()3)5LK-T).D3!,[I$7FI^T)6X*E0P_+U)C"Z="I
M3>5P;IYL5(F5N(WMZJ!-U:4J;1=+H,UX$$%PZ4]5LR$SR!2,Y,Y^.F!A**@D
M:"?U]@]MNN(6,0R\?';/?^#G'R%]TF'&R8D=IXC`HVLA.$39X1RHE/?R")RN
M3WNF<G-[,FU(O2!5=3R!Y_MF",5%/19>+H8_JTU54E.BKN$O;X$)71#A@E`F
MBH6&2XM#9=<OQ,QPZ/@[$.-5[U7IG$Q!9JIRER<VZY!@4NCCSJ9QO-K`CPS9
MFXQ,T^WX+1..R7]SR9D-AE[.5X(IMU(9<2N\FZ;38$HO3WT@20N4@?/_`"0D
M`Z#='VS4]=ASCF*T%31\"[PZ9(:`=74U):X(\`I:DMT[E,DWE(_=[>%6\M:-
M>MF$T4R_6LK64<;$:_?F"7*E&23Y1)X4,KN^2CF/FD%%.D(QV][*W%Y[?[N<
M=1M4IA50\JE04TY4;H,Y@;FDD_CCZ+EAK'F<OX2UFBH0]F%+(%0M`2$*<_**
M0D)2`=R21\T>[SA__P#\^N./_P")VM/_`.+(KKM9E;_2\N?V>G_,1'Y\.VK_
M`/E;M:__`'#BG^,?C8;2W^IS4W^S.B?U6BNIW$_]2Q#]NY^>8^:4/[E1_LD?
MFB/_UH1UTR81L&B,1Y;@![]RK#()S+)I#P1CDV"@8MIB-8*D7W!GE)6E`[3C
MRLI[$)4K.,9B(_-EEE#SF8\OMT[Q;J%5S`2L!2BE1=2$J`0%+)29$!`*C*20
M3(1VH<7QAV/:D<=G0;3;+:`7-2;@IETMJ[M-Q3HL#?HN6K3EA2"""8S79^/+
M%QD/)(.5MJ4.22TI+Z\C4N$3+1..VG98TVW]J_LW4QB]964ZW7"E534<Y=04
MLU:'&.&NI0H,O(<;^J+C4TDMNNI(<5ZK=U_]TUG_`+:=9_\`GG7*,*\ZO_LC
MOYL>P^)>;1?VEO\`.C1CVI?$C:?,RCZIUCJ*4U_$62!M4]>SB=CSEC@(1<)&
MQ`M?(9%,K-/NQ[LJH^S#*0TL5MG+*7%9=2I*4+A76RXD)!E;'PO[2G8UBW;A
MD?",JX-C%/15--BS=65O)6I)2BGJ62@!`)O$OI()LDD[LHZ6OP&>;ORVXK>D
MK;G_``_=:_-5?2$=)/\`MZ9Z^/\`"=74>K#\!GF[\MN*WI*VY_P_=.:J^D(?
M]O3/7Q_A.KJ/5A^`SS=^6W%;TE;<_P"'[IS57TA#_MZ9Z^/\)U=1ZL/P&>;O
MRVXK>DK;G_#]TYJKZ0A_V],]?'^$ZNH]6'X#/-WY;<5O25MS_A^Z<U5](0_[
M>F>OC_"=74>K#\!GF[\MN*WI*VY_P_=.:J^D(?\`;TSU\?X3JZCU8?@,\W?E
MMQ6])6W/^'[IS57TA#_MZ9Z^/\)U=1ZL;C\,?9H<M.-<UMB+GC..MD?M<7K6
M087$;2V6,R&S%E[('REU1NA,+<<?69VXQA.,)PC].>WLPYJKZ8CL?V$_9@S'
MV2T68Z7$\RT56JM=94DM(=`2&DN`@WP--\2EX(WP^S1R7_8NC/2[?O4'U3FB
MOIB/O?=]7]/9\2O)#[-')?\`8NC/2[?O4'TYHKZ8AW?5_3V?$KR0^S1R7_8N
MC/2[?O4'TYHKZ8AW?5_3V?$KR0^S1R7_`&+HSTNW[U!].:*^F(=WU?T]GQ*\
MD/LT<E_V+HSTNW[U!].:*^F(=WU?T]GQ*\D/LT<E_P!BZ,]+M^]0?3FBOIB'
M=]7]/9\2O)#[-')?]BZ,]+M^]0?3FBOIB'=]7]/9\2O)%CD^*G)X_4E1UPB(
MT,V;6_JEP_)*V]L'(I/U<V6HSIOA,XT!XJ/A)JMK;:[<_J*<3E7N8SUY0]E?
M_P#KISSV??:73VZ5O:)A-1@XQ/%JKFR&:@/7<18K6D)O*%R\V:I)6=!"52TB
M.W%%VE4%+A^'T:\->*V4-`D%,CP=V<OGNV16?9<Y-_L?1/I=V!Z@NO1KW`K>
MGM>)437>]A?5-1Z2/+#[+G)O]CZ)]+NP/4%T]P*WI[7B5#O>POJFH])'EA]E
MSDW^Q]$^EW8'J"Z>X%;T]KQ*AWO87U34>DCRQ9[!QZY"U:!FK-/!:(`@Z[%2
M$Y,GYVOL@A(45%".G2!BF!./A!3J!A&%KREM"UYPGW,9S[G3W`K>GM>)4.][
M"^J:CTD>6.N3V26N]D[=X;5TO51^D+5%US9F^HN7*(V7>P'0924WMLFSC!/J
M`TG.0RW"H*<#D&$L'/N*C3A"'4,9(2WC>Q')=775CE2BM;2E24"1!_)0E/XY
M3B,P?M.P["\/:HG,,?4M*G#,%(&_<6L:3N!4OG$=F?V7.3?['T3Z7=@>H+K1
M]P*WI[7B5$GWO87U34>DCRP^RYR;_8^B?2[L#U!=/<"MZ>UXE0[WL+ZIJ/21
MY8ZD]Z>Q@YF[SV_?]H0EEXQ0L;8YIEIF,E=F[5<.&<@8F-KI/BN":`<86AXF
M)6XC.,]OAJ3VXQGMQB,K.S+$*E]3R<29`(2-"MP`?[([4]F/VW\H9$R3A&5J
MS)6)/U%,I\E:'&`D\+4.O"049V!P`SW0=R(H_`%YQ_+KBCZ2MO?\/G6KW5XE
MUHQZ*HY]_P!P[(W_`-?8MK:?RP_`%YQ_+KBCZ2MO?\/G3NKQ+K1CT50_[AV1
MO_K[%M;3^6'X`O./Y=<4?25M[_A\Z=U>)=:,>BJ'_<.R-_\`7V+:VG\L/P!>
M<?RZXH^DK;W_``^=.ZO$NM&/15#_`+AV1O\`Z^Q;6T_EA^`+SC^77%'TE;>_
MX?.G=7B76C'HJA_W#LC?_7V+:VG\L/P!><?RZXH^DK;W_#YT[J\2ZT8]%4/^
MX=D;_P"OL6UM/Y8?@"\X_EUQ1])6WO\`A\Z=U>)=:,>BJ'_<.R-_]?8MK:?R
MQZ<M"T6:U?PYU3K6R/Q9-AU_Q[JU+G2(0@LR&?F*Q0A862>B2SP(HXJ-<,"7
MEAQX4=U;64Y4TA6<IQ]IP2E50T^$42U!2V4-()&@E`2DD?(91Y@9_P`?8S7F
M[.V::9A;5-B6)5E4A"B"I":A]QY*5$6%20L`D63%ED2GI;_4YJ;_`&9T3^JT
M5U*8G_J6(?MW/SS'$J']RH_V2/S1'__7A'71S$7L&B291^(L6.N58.)D\G/Q
MF(Y@2;!(>/S)#`RA,?@-MO+GCMC$+:[O>2TYG&$9B#H-L?FRRS4(I,R9?JW:
MC@FFJYA97?+=P)=02N^E#A1=`G?"%E,IA"B)'M6XS1X\3[4KCA%,REID7HTM
M()H]QMIMQFX1\:EW%IB$5)%QP30@`L<EA8H@SIPK`[J/#)<PK*47L_K$#Y1'
M;CLQIFZ/[6'9I1HJZMUQHW%"IJ%5+K932U(2WPBD("4)1<+;:%.MI0H7753D
M/5/NO_NFL_\`;3K/_P`\ZY3A7G5_]D=_-CV#Q+S:+^TM_G1>K[!;#EIBC%TZ
M=B8R*A;C!2MF!*5(`ERU=93*B6*+<.$;D$R`Y8A[!`PF&@L8/!:4\2XPM;28
MJ)*)/Z0ATA#I"'2$.D(=(0Z0C6:7IW((RS2YX=FJXD4]:]=F`I#L$L"T97JZ
M.XBW-F0ZJ4=)PR+`[*N9;BF)TL=+L4P\HO&#SAL(1LSTA#I"'2$.D(=(0Z0C
M2"=U]S<*LW(-4?M_7F*S=ZF_%Z.?CVGZR;J^P,:[!9AI0J`D=?[`22G.S@2\
MR;CLO)+,B9A+HZ`WHMD4NL(ND]6^<RML7A=8V%H]G2LW*6]VFIGHN;(V#3(H
MK0M:AZ8,V!'U<:%F'HWD2%(2I?ED@_E=?)4WA;CBV!@J0LB^Z-IG*2$>H;F[
MM@5B>9K<%MZ%LXM<E\2[=O>L5QI,]I^>/=(U;22T3^OZB),0!SK3S`TCGPY!
M3&7C%,1Z$;7=(0Z0AG';[F?=QGW,XS_=Z0B.M5:CUEHZF":[U#1Z[KNC@2=A
MF0:M5H]J,AA)*U3TC9I\D8-K^;9S(3<L0]E">Q#??PAM*6TH0E")%Z0C'[8Q
M-DU:R#5E`J[&1`R[$"@V8+KP:IAX`AN-P5/`1%@.A1_+%([Y;(!KHZ?UTL.J
M3A"D(C'6%:V_"31I&Q++$3\6Y3J?%L>1R1)1;EKAAWP;)-Y":K%8B01+*IIL
M]>$MNOH+)=:PO`[3"<(1-W2$.D(=(0Z0ATA#I"/E>5X0K+:4J<PE64)6K*$*
M7V9[J5+2AQ2$Y5^G.$JSC']S/Z.D(A^NP]R@-+F1&P),.:M@-=MS<G*`FER#
M)K*WIIV*>66:!%NNF?`[@^",)'9901A:64X:PCK/2_O-/^T3_"(Q/_J'OY!_
M@B[:6_U.:F_V9T3^JT5UGQ/_`%+$/V[GYYC%0_N5'^R1^:(__]#7BN.23-A@
M7H8(F2F&IF+<B8X+,HDP^20<PH$(3,&2%-8)**PA#>0WFBN^K'A+2YW58B#:
M"(_-+A:ZIO$\.<H6%NUJ7VRVA/"7EK"P4)3P2DNWE*D!P:DN3.\4%2,=K/$^
MR[-N7M2-`6K;-`EM;VR=L)IRJ[+A[!!=R!\4+@.Q(C,;*FYZP8&+?8=QG+;Z
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M)"J\V%F`KCK]I["0JS",*,.Q.>$99S7:Z7<WC:^#21F'8^/?9D1X5[!J5^0>
M$@ACRIUPUFMD(^$U7G"F-FQ_K,TWDUNNUH:KF/19[S[UF$?I#=GDK.ZS2@PE
M1LL&U85L,!AM*9(<!_6PWXR6UG@A%1)5OFN*Y?':_==+G^4R@;.O&K`JPC-M
M0S!9+3TM;?(J2=AFP$Q,='^()')1'*(+D%(\+.1G&UG@A%8BI<LB*[)Q%@M&
MMYXUZ9UFW$RD99[71):/@XB+PYLZ6+E:W0E,2,]9IEGP8T'R%J/$8(40ZIW+
M*0WDQN"'SQR"07,[.:^X7==*C]C:&[.,D*=DV\+;E!W\E0Y":O`N$J(#R\E3
M3J!DI'PV.E7CX7)*60C;/JD(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.D(QB
M[O-#4RW$/K2VRQ6)]YYQ6>Q+;3446MQ:L_W$I0G.<];%(":JF`TEQ/\`"(PU
M!`IWR=`0K^`Q8=/CO!ZEU<(2WEH@775)'?:5V=YMYBM1C3K:NSMQVH6G.,__
M`*=9<2(5B->I)WI>7^<8QT0(HZ0'2&D_FB/_T=>*X`/*V&!BR\%*%DIF+`)2
M#V>7*',.8'>P'WF24^59;<SX?:VYCO\`9^JK]&8@Z#'YI<+IFJS$\.I'K_`N
MOMH5<\^ZI82;MAWTCO;#;*PZ([.N&=(K6N/:G:=I=/-G)&LPEW=1$&V5`#4\
M2,=K"3D\N2C$8E(0I7C&JQEE';EG&,(4I2DJ5G(T`'$2T3CM1V*X#A>6/M99
M-P/!7ZAW"V*U0;4^$!XA5`XN;@1O4JFH[T>;YI)()CV-7BI!WFJR]8,*)CLR
M#3#L?,`I85)5^=C"QY:N6:)\J:?%3,5F?!&D`U.-N-I*&;RI*L8SC,W2U"J6
MH;?2D&6D'0I)!"DF5LE))2?D)CVLJ&4U#*V5$B>@C2D@S2H?*D@$?*(C^'VI
M)0_A5_:52M,%:@V$)+G*Q2[=;-<6%++&%/V"#LM;CK"Q6XPEU"L8`GW(^2'<
MQE&$$->"61MN4"')O4%0VM@Z$J6A#B?XJDJ*2HCZ384DBVPS2-5NL6B358PM
M+PTE*5*;5_&"DA5T?(NZH&RT2)OWUPZ__:LG\T[?^X>L6S:SBAZ2?+&7GU-]
M,^BKR0^N'7_[5D_FG;_W#TV;6<4/23Y8<^IOIGT5>2'UPZ__`&K)_-.W_N'I
MLVLXH>DGRPY]3?3/HJ\D/KAU_P#M63^:=O\`W#TV;6<4/23Y8<^IOIGT5>2'
MUPZ__:LG\T[?^X>FS:SBAZ2?+#GU-],^BKR0^N'7_P"U9/YIV_\`</39M9Q0
M])/EASZF^F?15Y(Q#85UU_?:#>*-\:I^!^.=0LM3^'(^I6]1\-\8H4V'^%0<
M?`K/:9'>6>,UCOI_71CW<?IZV:.EK*2LI*OFR5\$XE=TJ3)5U0,C;H,I&,%4
M_35--44_#*3PB%)F$JF+P(F+-(G.-&)3CRX;5#Z(%S2W>!3CPQX%4-FE71U#
M%0%K@U=;JXK`Q($*&`Z*-C#R6`6F76EK3EK"U*=SRIO&`BI16+RQ3*J4J*IW
MT6K*BJ\;"2039-1(-L]R./+PPJ852IQ]\,$797%'>RNW1:`+-,A(C<G;%V-T
M7Y=#ZVB5<RM\#+UI(GRD7,CP6S"I\TTFLPM:#)/DYR5FG"WP61I->?'2^V\B
M9('6CR;*FG+$XM==KG/=BE/#@`IFV$@!960`E*9`[T62E<!G>M%589>;HF]O
MU/U!)!DX5$W`D$DDS/G$SG.^1HL-L/X[`6!]MVW<M-L6="15QZF)"D;&<1B.
M5'%-LCX>+G#2S51TN>^\-F0</;2.[V.MO&H:D&[T8TMA!339<81;.86WIF/`
MD`3``-T"T6$))0<:\(#RPM_''ER!$KBY2(E](DD&9$R;#:"H!8NQ.CE'1-=C
M#.:'(##T&3,X>E(^"OT9*FP<Q!:_C/BNW*CO9F0X2.D*-DEI'E3KA'E6<F++
M+\I,+QC%;JWUIRO2R6$V$H("DJ<-Z4I%1"Y&R0EO0E,DIS'#BIME"L?J9I)M
M`6"00@79BVZ"F8MF?RBI4U*MQ6E+2X;6&1.<W(0")COC038"Q(_9>)61678(
M"2JD,`#(N2L./&1,:F48>(>P\2O+@Z,84.G+*,B<4I@BH*LI4A<5="02W(;U
M0620`J9-P@"0$B;#;&)6&U!73W<R50;3>O2"YG?)*``9@`"\"3,F8W+(N86C
M64EP&9OF%O>PQ$3(5B6-BI"(VFO)\M`2<U,D3#!KLR^L.4,/DV4L*<02P(P(
MW_,NDMBE"XU8J;KW!9:I4.*2I((+=@4$@`BZ)@`&<I$DFT`J2K*,-$V@YCM0
MIM*TJ((<M()582H[I$IS``%A("AQ5[0X\7/5>TS7,7>UGLE?NX5T)FCZS=15
MRN0FC(E$,[""=VH8"(J,D_$O./QI3SH_A*4K*T+\6CV*J<:>8;RU3(94T4!(
M4@RG(WID7YA8"Q)0`,QNV5:PX(<:><QVH6ZEP*G)8G*R4O-E=)29I,Q+P6_;
M6F)<@N5=G.:^[Y:/DXQP-F#^*>RT1,07FL,5E@Z/9D9Z7=,0PETLU3$DN0:)
M/<8<(\;#+J2FTFTI;#65J9*TJG>O-S(O7I&21+<3--TA,P)3%VG,'%*47,P5
M!218+JP`;MV=JC/=,E7@52)G(SO8.FX`I^#<O/)[<E]%A-@:IV(/&3$%LC`+
M$GK)]\MR,CUOER$F)#64G`JR6G"2%*6$VZ^HDA;KSF)6)/)2\*3`:=E2VG6Y
M@MSDZ`)F0`)2)R,AYQ`NB0&5-`THM<YQ=]T)<;7(A<IMF<A:2`HR)$SYH)F2
M2<,J/'$&IT.9H:>96_Y,.3!'6&6=`W\A^`M3&R:5LA=TAG"R##VITLZIOL/+
M<)=4K,F0^E27W2EE;=3C2ZBL;K/=BE2I)M`4B2D<$MJX9`"Z`H$2`\T"1`3=
MUJ?"4T](Y2C'JDA0L)"R4JX1+E\3)MFDBTG23.95>OM$TJ12+<+9\\S]\V)C
MXQPM@FH6;KFP7A+(J(%JD;D>9>08E9^3X:L)`=4^EYKR525):P3Y227AJ\33
M54Y8]UZ5!N*2DI4C>WBHS%EDBJ\)2MG;=NI3?2X<JE>X7W@J5S6E1"DKWUT)
M$C;NA,C9HE*V\5<9>FIT\>#8?YR\A0UPT:`$\="PNT`#I\L)B595)3V"9N1C
M7GGVI-+*D##"I6R(PZ]XQZ7#G",2:072,J4A"B3)1;(2#*Q,D@V2G:3:HRDB
M2!55`ZO@IYBJ1=`T!8O$3M5:1;.5@%@$YJFHU]ITT-.V0VQP_+3<=0(<NFX;
M)%(@*A>AEPD!MWXMF%TH%3+[`V(:$G*VV8SV,I2MUY;N&VS,(+1:QB1:80PY
MERG<3P3*3>6C?*9O`+-FE252-MD@)E,TFKV'\(Z7D8X^@\(ZH22JQ+LC<^9)
M2"+/EL5)0HY'3,N4HY$;SHY'P<?D>/#@HX.$O!*(48:E/5F2R^?)>62\V9/S
M642S[Y!&5B/N/HC_`"+/D3@%R,2;%PKRG2+7,E1)0)DKO"P`!(2G>``6B17>
MWP755"X2JYF&I2F0`$EV23=-I,R5'?$DV$F[=WI1)[-2B6XC6X)G(K9MAD->
M7#-P;E+33+;-.S)GB$F9041Y().LK?)?6$[CX0<$Q7RS8U@=A)#;X^BJH<+E
M:I.",H0\W<DA:4W18+-*=%OF@WPE9)D0=H,(N4B58HZI33E^:DJ,_GW=-GG$
M7"I``F",+O&J6K0,-$5_EGN2@UJ-UI4-=Q=;K-2O`L8TJLQ)T)(S9S8S@?EK
MUHC)!;)24>`0UC#;K!#90XA`VU28AS<J<>RY3O/J?6X5*4B>^(4$BPRND3&D
M&T%)25`ZU70\X`0UCE0TR&DH"4I5*P%))T3O`VZ#N@S"2,QI%)J%(E8>1'V_
M89A%?OQ%]C&IC7%Y(??*)UE:=;9CIDE!3;4B**%:?Z.IMD9;(,7&AX[<"J>>
MU:JJJ:IMU!PQ*2MG@S)Q'&I=FFRP[V1M,RI:ORI#8IJ9BF6VH5ZU77;XFA?%
MJ;D;;;%6:)!*$[DSM;]<.O\`]JR?S3M_[AZX_LVLXH>DGRQ-<^IOIGT5>2'U
MPZ__`&K)_-.W_N'ILVLXH>DGRPY]3?3/HJ\D/KAU_P#M63^:=O\`W#TV;6<4
M/23Y8<^IOIGT5>2'UPZ__:LG\T[?^X>FS:SBAZ2?+#GU-],^BKR0^N'7_P"U
M9/YIV_\`</39M9Q0])/EASZF^F?15Y(?7#K_`/:LG\T[?^X>FS:SBAZ2?+#G
MU-],^BKR1^XV_0E9PEN0F7G%>XAD>FW0A]U6?Y+;([%><>?=7GW$H0E2E9]S
M&,YZ;-K-UL`?*I`'CO0Y[3;BU3_DJ\D8'89*8WE'%4>"JUH@-;3S:HS8%OO5
M<E:4;-U8I"VK!2JC3;.'&7;R^Q!Y5'F29P$8*&$4M\!\HI"<-;;*&\*<35.U
M#:ZU%K:&U!82L>:M:TDHDD[Y*4J45*`"PE)MUGE+Q%"J9ME::15BU+24DI/G
M(2A0"YJ&]*B$@`DI)5HV'QC&,8QC&,8QCLQC'N8QC'Z,8Q_R=0T2D?_2A/6[
M*B-B4)A#1#ZW[I5F4,"R1D,4\IR<!0EH:7CO_J$40YE78@EC^>85G"T?K)QU
M$&/S9Y707<RY=;"%**JY@22M3:C-U`DEQ&_;)W%HWR#ODV@1VE<9HV?`]K7J
M9ZR5N7J<A*7HZ13!3]F"N4R$S\0+``I$A:`9*53.$8*`=QDIQ[QR,8PZXE*E
MY3C(U^L1/3..V/9C38C3_;"RDYB>%O4=0]7+7P3KZ*EQ(YF\C?OH6X'3>0KZ
MQ2KZ_.4`HD1[!YJ:AZW#2UBL,I'P<!`1A\U.34L8Q'Q4/#Q8KITG*29Y3C0H
M,?'A,+=>><4EMIM&5*SC&,YZEVFG'W6V66U+>6H)2D`DJ),@`!:238`+28]F
M'76V&W'GG$H90DJ4HD```3))-@`%I)L`CR?<L/[3K&UJW3E1X?Z2AKS"PII@
M`^V-O2,R'"65T4AP;X0@->UQV'G,5\GPL/#$&RX9;[3F/$#'5C.,]B<N=@CE
M13-5.9L54RZL`\"R$E29B<E.*FF\-!"4*`.A1CK;F7[0E/2U3M+EC"4U#2%$
M<,\2E*I'2AM,E73I!4I).Z@1I3^9_P"=/F:XF?,[</KOZY3W!93ZUQ'TV>0C
MB?WB,U=2X?XGN5A^9_YT^9KB9\SMP^N_IW!93ZUQ'TV>0A]XC-74N'^)[E8?
MF?\`G3YFN)GS.W#Z[^G<%E/K7$?39Y"'WB,U=2X?XGN5A^9_YT^9KB9\SMP^
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M`)T^9KB9\SMP^N_IW!93ZUQ'TV>0A]XC-74N'^)[E8R.H_VE'VA=[LD34JIH
MCB?*S\V1D8`/%6VL&UG+;+A))1LA(;V$C8N,CPV'""RRGF11!FG'GG&VD+7C
M!5=A>3*-AVIJ<9Q%+"!,F\T?D``#!)),@``220`"2!&S1]ON<Z^I9HZ3`</7
M4+,@).CY222\```"5*)`2`22`"8V&B?;3>V(FY<2$C>)'%5\J0CBY@`QQBT"
M0!\2)4[+?\R8-I,Y*CUDL`R@4^2GQ'FRU-G00V9`?+H:VWEPCG9=V9LMEUS,
MN(`!021O2H**TMR*!3%0(<6EM5F]<-Q4E`@<B:[4>U)]P--92P\DI*@;Y""D
M)4N86:D((+:%.)-[?-B^F:"";'*>W)]K?#AYD#N*?%;R-.J'MWK?#CKI)H;U
MB-!5JU$V)S$9R-,4V0+5;A&2KL<K&)1J,,06H;`_><QE;[*.S=TW49CQ"]SC
M@+;@^M*E)";:86%2%)"O,*@4WIV1B=[6.TYA-YS*=!=YJ:BQ2E?4@(45;VH-
MH2M"BCSPDWKMV9C!9;^T)^T]A)L*MR/&?B^W/26T[9I./B1ZGM,\T[:E'+JX
M%II@C(&^BE$2<69=8MOO)[6'EF(PTXYV+[NXWV,9"=:<>1C]?P2:=#Y)4T`&
M7`LH69L"PAM9\(NV@61'/=MN?V'FZ=W+-"'UU3E,E(#A)?:*$K;$GC:DN($]
M!O6$VRD1'MOO:YJ(DA7.+'$D1V'F-CPDC\(YLD6T,_J,19VQI/)$CR7%'<JU
M681CQII"E1#CCC;;)+CCK:%:)[*>S<)0KWBQ$A26E"029\,9-B0IB;Z]Q'G@
M`DI`!E)#M6[3BIQ)RKAR2E;J3-93(LB;IF:D"XC=<\PD@!1)$ZG\;+VO?B1#
M..*O$C+\Z30`HEA+L^I\T_9P9\E3(Y#..367&Y$^)C'SB1UX2]&`-Y*-2./G
M#F:=U?9M)P^\6(R0'";$V!H@+/[KH"B$@Z%*-U%Y5D7GM3[4`6TG*F'7EEL`
M7[2702@2YSYQ`*BG2A(O+"4VQ4P/MIO;$VB-`FJ_Q&XKRD%*-"$1]@&&M7Q=
M+&.LM]J0A34^YR41#Y$?G-8SB<.^/AOR</!.<^2D#//6O=EW9G3N*:>S+B"7
MDD@I-V\"$MK(N\VO3NNHLEI)3YR5`7,=J':G5(0[3Y1P]3*A,*"C<(*G$3O\
MYNRO-.6ST`*\U22:3\;;VNR'A6B^+O#Z*0?4)>_1ALZ=+P$3,5"`AYBPS4Y"
MS,WR>`B9H:,KU>//>2*\\Z@$$@CN^"RXM->ZSLV-Z[F'$E%+H;(2D*4%J4$I
M2I*:4E,U*2D3`%Y0$YD"*'M2[4$A)<RMAJ$*;+@4IT(2I"4E:E)4JJ"5`(2I
M9D20E)4;`3&L/YG_`)T^9KB9\SMP^N_KD/<%E/K7$?39Y".*?>(S5U+A_B>Y
M6'YG_G3YFN)GS.W#Z[^G<%E/K7$?39Y"'WB,U=2X?XGN5A^9_P"=/F:XF?,[
M</KOZ=P64^M<1]-GD(?>(S5U+A_B>Y6'YG_G3YFN)GS.W#Z[^G<%E/K7$?39
MY"'WB,U=2X?XGN5A^9_YT^9KB9\SMP^N_IW!93ZUQ'TV>0A]XC-74N'^)[E8
M?F?^=/F:XF?,[</KOZ=P64^M<1]-GD(?>(S5U+A_B>Y6'YG_`)T^9KB9\SMP
M^N_IW!93ZUQ'TV>0A]XC-74N'^)[E8?F?^=/F:XF?,[</KOZ=P64^M<1]-GD
M(?>(S5U+A_B>Y6'YG_G3YFN)GS.W#Z[^G<%E/K7$?39Y"'WB,U=2X?XGN5A^
M9_YT^9KB9\SMP^N_IW!93ZUQ'TV>0A]XC-74N'^)[E8?F?\`G3YFN)GS.W#Z
M[^G<%E/K7$?39Y"'WB,U=2X?XGN5CZ3_`&G_`)SX4G*],<3E(PK'?2FH[@0I
M2>W];"5YW8O"59Q^C.4Y[/\`DST[@LI]:XCZ;/(17[Q&:NI</\3W*QW$^S8]
MOOKOF)LB!T%O37X&CMO6UU0%#G(B?>E];WZ=SE*AJNRJ5''EZA:)/"LHCQB'
MCQY!UOPD%()='&=^9YZ[':W+%"]C&$UIJ\,;M<24W76T_3,B0M`_*("2D6E-
MT%0^HY![:,/S77,X+BM$*/%7+&R%7FG5?1!("D+/Y*3>"I2"KQ"3Z'^OBL?;
MX__3@R@8&S>Z5@U8[8>;;6\%N%JR@5`WPR%XZR5I(%4D=+7;E><.MYPGM_73
M^G$1'YK\N\%[P8%PY2&>>,WKWFW>$3.]:FR6G?)LW1ICM4XS-N_BPZ5*R/$9
M#.M3S\7-UYLY,#:0&*!8X[$W#NERDNP^&V6"Z!VC/9:;<"4TO^D-OJS>S/A$
M3(-NY';?LQ2Y][W)+RF60RY5*4VZT%<$^@4;Z.%;*G'`I(4A34T**0IHI5]8
MEPGOR]K;5=I;%X&[DU1IE\8;8.W"J%K>,>,DT0XBHJQWZN)M@!4@XVZVR+-5
M(8X%["L=BVB5)_3G'7TGL]K<,PO->'8MC$]GTB7'523>,TMJN$`6DI64J'RB
M/5WM,8Q"LR7C%!A:@*VH"&P2;HNJ<2%@FVPHO)/SQXN/P-^>?[!UCZ1X_P!Y
M==D^_/L_Z74ZE4=0^ZO-7@IM9^C#\#?GG^P=8^D>/]Y=._/L_P"EU.I5#NKS
M5X*;6?HP_`WYY_L'6/I'C_>73OS[/^EU.I5#NKS5X*;6?HP_`WYY_L'6/I'C
M_>73OS[/^EU.I5#NKS5X*;6?HP_`WYY_L'6/I'C_`'ET[\^S_I=3J50[J\U>
M"FUGZ,/P-^>?[!UCZ1X_WET[\^S_`*74ZE4.ZO-7@IM9^C''CV'G.U3JV$PN
MK<OM-M/.LXV5&Y=;:?4\AAU;>`^^AMY8[F$*SCL5EM6,?R<]E>_+(,@KG53=
M/^X7N2GXICQB'=7FK1*FG^T_1CY8]A_SK*0IP:'U60VA\D92V-F1CR$DAD.A
MECJ4V&I.'Q2V%M.(S^LAQ"DJQA6,XZ'MRR"FQ554@R!_4+T$3!^8BT?)`=E>
M:CH%-K/T8IHSV)?-^;!8DX8+44M&E>)Y-(1FTX<\$CP7G!WO`+%&='=\(AI:
M%=U6>ZM.4Y]W&<=7N=M^0V5J;=J*I+@T@L+!&[:#;HMB@[+,TJ$T\V(_:?HQ
M4M>P_P"=;ZGTL1&JWE#/9')2ULR,<4._AMMW+#^$"9RT]AIU*NZKL5W58SV=
MF<=6GMQR"FZ5552`1,?4+M'A$5[J\U6V4VL_1CF_`WYY_L'6/I'C_>75O?GV
M?]+J=2J'=7FKP4VL_1A^!OSS_8.L?2/'^\NG?GV?]+J=2J'=7FKP4VL_1C)J
M=[&?VBU`LT1<*D%K**L,&2HF/,S?8*09QEUET4H4V-E(DV*EHR0"?<'*#+8?
M%+&=6R\VXTM:,X*KMI[.*VG=I:FHJ5,+$B.!6/E!!!!!!`(((((!!!$;5%V;
MYSP^J9K*1=.BH;,P;X(T2((*"%`@D*200H$@@@Q/T-P*]L?7RQRX>Z:\"P)/
MS5E$`18M=.08DG/Z><X_G-BUY^FNP(T,QI=S-;"C4#)C8V,[&Q&&,XPK$*[V
MD=D#R2EQNH)*$I)X-Z\0E[G`FJ]>*B]]8I1-Y2K5$QR!G`.U!A86UB-.`'%+
M"9HNA2F.;$!'!W0D,?5I0`$H3YH$4QG`'VQIT:S$DWRFJCV*;'ZY0PW=J:.K
M.NHNAKUH'KUU\>L-$/T)-/=6PN%6M48\2XLUQA9JE$9JGM)[($J*TLO7BX7/
MU3OZPN<(7/._67[;_G``)!NV156!=J2DW#B;%W@PWYR/U8;X(-_J_P!7=TM^
M85361>MBU37LX/:R3\Q#V&0*TJF?@-M&[UAIN,^J*"EX_;4FU7D2UU8DH.@Q
MQGPC,NU*,(.:RO(II@31+[3A",.]96NU'LI9;=:0Y6<$Y3"G4DI?4"R+TD$%
M9$DWU!.ZD**00+(POY8[1JAUE]QZBX9NJ-2E02TE0>-V\X"&@9J*$E6XI20H
M@D3CEK'"CVO")B2&A+1J[$W1;G4IDV5-(U4;,*O5>U?&UNJ6PF?D:(7+3EFB
M-?3R16I,IYXU#C[[N7,D..NKI4=H'9*&FENHJ>!>:6``E\#@U/%2T!(6`E)<
M3,I``D`)2`$9&<&[3DN$MUU+PK;J5WB&BHN):#:7"HM%2EI;,@LDJF29S),7
M'\/SVO.<&X<EM,OYE*_K^JRSA*=.DO3%=U;-1UCH4/,O$:]<=F`J]/0X9B$D
MY=\<@1A;WB9:;RG%WE=DF]D:P!*W%)D*@75.I*7"D!=A4DD6:`2!*9BXX#VF
MJ*B:NC*E):2HE+)*DLJ"VPHEF:@E0"I'=`)T1D:^%WMK'2&R7MDT@A3<Y9K)
MX!-GUV0"[.W(V.D;-)%1KU-<CC")8N*94YXK2\)QWTHPE+KJ5X>\#L:`(%,^
M-ZA,PV].Z@$)`-Z8`!W#X)Z!+.,*[6+P4<68("EJD2V4WED%9N\%*9(\%DR!
M($SC^5]FW[6V:";C9*R:]?CF6K@P,"BW4D4,0:^ZM9TK;1`1A*NPR"'+:P83
M%999PAIA':\RELA2GL[K7:CV3LK+C8J`X2@D\$Z22V[PZ"256D.[Z9M.@S%D
M:-1ECM*JF^!?KJ<M26`+R``'&>;K``;$@6M[(6#SA)5L0!^!OSS_`&#K'TCQ
M_O+J:[\^S_I=3J51QONKS5X*;6?HP_`WYY_L'6/I'C_>73OS[/\`I=3J50[J
M\U>"FUGZ,<;WL/.=H[3K[\+JUAAAM;SSSVRHUMIEIM.5N.NN+#2AMMM"<Y4K
M.<8QC';GJH[<\@$@"KJ9_L5P[JLU>"GUGZ,<GX&_/+]@ZQ](\?[RZIWY]G_2
MZG4JAW59J\%/K/T8?@;<\_V!K'TCQ_O+IWY]G_2ZG4JAW5YJ\%/K/T8X7/8?
M<ZV5CMO0^JVG"W5,"H<V7&(62^EAXI3(Z5!XR\ZD8=QS*4]N<-MJ5^A.<XN'
M;ED$A1%54D`3/U"[!.4S^$@?.8=U>:A*8IM9^C'-^!OSS_8.L?2/'^\NK>_/
ML_Z74ZE4.ZO-7@IM9^C#\#?GG^P=8^D>/]Y=._/L_P"EU.I5#NKS5X*;6?HP
M_`WYY_L'6/I'C_>73OS[/^EU.I5#NKS5X*;6?HP_`WYY_L'6/I'C_>73OS[/
M^EU.I5#NKS5X*;6?HP_`WYY_L'6/I'C_`'ET[\^S_I=3J50[J\U>"FUGZ,/P
M-^>?[!UCZ1X_WET[\^S_`*74ZE4.ZO-7@IM9^C%RAO8Q>T'H4Q%7F""UW#S=
M,D@;9#2P.R@4'1<K72FIB/D0UH#PM!0)8:'6\XSC.%IQV=6.=M79Y6MN43M1
M4*:>24%)95(A8ND'Y"#(QFI^S3-]%4,5C"J=+[2TK20Y:%)(4"-[I!$X_H7T
M2?>M='IMI(;0R_9:I79]]EO&4MM/3,0'(N-H3E;F4H;63G&,=Y79C'Z<]=0J
MMD4]54TZ3-*'%)]$D?[([V4SA>IZ=Y0DI:$D_A`,?__4A76G=^L:@=YU#"?C
MM5>\^[CM;93\.@=KKF/!([4-X]W/\VY[F/Y*OT9B#HC\VF5I',V7`5A(Y_3V
MG0/K46FPV#=L/S'1':%Q;N35Z]JWI*=#M#5IB7+0IJ)>$:G`XV'87KJ>-D8"
M,B)Z)A"(,:.GS#,K$:&;';(<=RC*^]E:KV97VY2TQVM[*\;3F#[762,09Q45
M=&:DALI#J4-#F3RELH;=;:+24/*=);2@(2M2RF],J/I^Y:M2C^NJPS"P<E99
M5S;6LT!0<0_""R,BZJQL8\$4BR3%?A&EI1VKSD@QA'=3GL5E78G/*L);#RZ]
MLNI0#2N[Y5ZZ-[NW4J5XDF/7W,S3KV&H:9;*W5/M@`2!.^'TBD>,B("^+^YO
MN[[2^<O'SUZ=1FR4=<4?]Y_RT<2V)B_5KGI,\M#XO[F^[OM+YR\?/7ITV2CK
MBC_O/^6AL3%^K7/29Y:'Q?W-]W?:7SEX^>O3ILE'7%'_`'G_`"T-B8OU:YZ3
M/+0^+^YON[[2^<O'SUZ=-DHZXH_[S_EH;$Q?JUSTF>6A\7]S?=WVE\Y>/GKT
MZ;)1UQ1_WG_+0V)B_5KGI,\M#XO[F^[OM+YR\?/7ITV2CKBC_O/^6AL3%^K7
M/29Y:(?V1IZUS>)*Q7'3&X*TR6#5J^_+-[&XXUX<-4?8S78#R60*W@G`DI(R
MME<"2K#G??23AA&.\Y^M)4J7:1MMIO%:`H2I:M\FI,RXE*2#_5[1O$D#<(G&
M%67<54I:SASMY02//9_)*B)?6_QC^"(>K]#JM,LQ%G%C]A-R8Q7UIG`G<@N*
M+$"U'.)E0B)I^L"[Y!@0J44]8GUY;0,U&-GJ9+:PV:.,^UFJ'7:FFYJO$,-#
M?!7)A%3>NS20;YIRHJ%T"\2579H)*%*2:(RYBJ'.%%`_>O7O/9E.T:.&E*TV
M2E.W2`13USCC#(AQ1*I3]W.1S1CU:CWXK?G&R29'EI=^S1+\2#V[V,!1,'R)
MQ[:64H\?!;"_#2ES#W?VW<1JWWS4/8AA:G"H$S;J+2"DB?\`5YD"Z-W189R$
ML3>5L2::#**"HN`2_6-:+1QUFF):JVA;?%WDVXPVG=UR=FAG(J%LC.;WQA)2
MJ1`J9C`@UF8!V^P8U(OP=Q9/RPMQK'\X,\VVEM?8YHOEU^B%`K$\/#`)(D*J
M:;RDJ($V"/R0-$Y$S)TC,G+N*I>6_L]V^H`'?,2L$N-_\&)O^+^YON[[2^<O
M'SUZ=16R4=<4?]Y_RT9MB8OU:YZ3/+0^+^YON[[2^<O'SUZ=-DHZXH_[S_EH
M;$Q?JUSTF>6A\7]S?=WVE\Y>/GKTZ;)1UQ1_WG_+0V)B_5KGI,\M#XO[F^[O
MM+YR\?/7ITV2CKBC_O/^6AL3%^K7/29Y:'Q?W-]W?:7SEX^>O3ILE'7%'_>?
M\M#8F+]6N>DSRT/B_N;[N^TOG+Q\]>G39*.N*/\`O/\`EH;$Q?JUSTF>6B*Z
M'![>5>-W(9T#LU]UJ]UQ)3#=BT*EP-U6J->K;9?4]NQEEQQP=2'<996ZC"',
M8RK"\*0F3K<*2:+!QM:D$F5](M^N<T?U?\%LO%;&I3X-BRGZY(PYR:7`#OF>
M+0>-\!B5/B_N;[N^TOG+Q\]>G49LE'7%'_>?\M&WL3%^K7/29Y:'Q?W-]W?:
M7SEX^>O3ILE'7%'_`'G_`"T-B8OU:YZ3/+0^+^YON[[2^<O'SUZ=-DHZXH_[
MS_EH;$Q?JUSTF>6A\7]S?=WVE\Y>/GKTZ;)1UQ1_WG_+0V)B_5KGI,\M#XO[
MF^[OM+YR\?/7ITV2CKBC_O/^6AL3%^K7/29Y:,.F(B\7)-OUH[I>_DRKM<4)
M:*_&WWC8JRP\';`SX\,\R-3OA\V,:DFFG_)'GF<-NJ:5W>]W%8QD9PX,NM/(
MQBCOH4%"8J93!F/_`$T4.!XN01LUR7\IGEHB@_B-:)$DLIW1_(IAPV-KD63Y
M%LGCV%EUFL0AT*`XXX/N9#[KQ"Y,@TGOK4V0>^ZZI/\`/.I7+IJ*A&C$L-\Y
M9\RI,KZKQE.GLE()3*T)`$[`1A]W,5NI2:!^0"?RV?R1(3^NM^6=A/SQ9G^+
M-@D)-<1/ZLWJ=.2-GG[ZW!@;+XZ5Y9$<U*+63%X@XK>3)1U:AV+9'BE*<RZI
M:_(5..)RD1+>45;S926*_#4@,A%J*E1L`!7-5-8HD$S`LO*`\Y4[%99Q5:2E
M=%4$%1-CC0\,A8]H'XY">@2%<8I>C!F6V<UKOF"CX<C,U)6*Q;*XKQL1&B#@
MQ,<,*>^=M@6$#J\>S$M=@#B4QSJEJ\H:>3E*4V+JGEHX(UV&!%R[YM7NDDF?
M`SO&?GSO#\DB+_=S%K]_F+]Z\#Y[&X)#^=T?)H\,912`F-7P]N%BZ5;<QU9E
M9)-X,L&Y^+ABZU,B'#_"K=I.?Y`,YB901ZPA#D>6J0^A+@B',]JF^]'UK"Z]
M:''L5H00)"ZFI`E("4N;Z+)R\)/AB]O+^+-3"<.=D?"MGEHG5J$W"^TT^QQ\
MV<\P\VAUEYJT<>G&G6G$X6VZTXC>N4.-N(SC*58SG&<9[<=:6R4=<4?]Y_RT
M9-B8OU:YZ3/+1R?%_<WW=]I?.7CYZ].FR4=<4?\`>?\`+0V)B_5KGI,\M#XO
M[F^[OM+YR\?/7ITV2CKBC_O/^6AL3%^K7/29Y:'Q?W-]W?:7SEX^>O3ILE'7
M%'_>?\M#8F+]6N>DSRT/B_N;[N^TOG+Q\]>G39*.N*/^\_Y:&Q,7ZM<])GEH
MLME@-QXKD_ESCWM!IO$+*Y6ZNR:`RAM&`7\J<7AK>+CN4H3[N<)2I79CW,9S
M[G6>EPI`J:<[7I//3TGPC_\`MHL<P3%@VX3ASDKI_*9\'[6-[=+?ZG-3?[,Z
M)_5:*ZR8G_J6(?MW/SS'T>@_<:/]DC\T1__5A#79R8S8%%DE%@@)C[C6#E'2
MCYPL8$D2;!?R7(DQA0,D."-AOOO.#O,OH;3G+:T*QA6(BW<TQ^;'+50*3,>`
M52GFVTMUK"RM96E";KJ3>6IM25I2F4U%"DK`!*5`R,=H?%Z5B9OVMFJY2#GH
M.RQ1=U84',ULV2D8,A#>HBF5L1QTO(RAY3,>\VH;*UNI3E;.>XR.CNL-Y&I\
M(@$VSCM=V65=#7_;#RK5X;7L5-$NMFEQE2UM$;-4"$*<6M:@@@HF2+4F2&TR
M;3ZJ.1Q$I%4.#LT/%?#AE3VEJ2;7%*,:C&'X]S8=>A)8PR6?0Z/$QT%%3#TB
M42ZE33(XBU+[$]JD\KP0-KJWF''+B7*=Y,Y3MX-2@`!:2HI"0!I)$>QF+E:*
M9IYMN\IM]I4I@6<(D$DFP!()42;``8NWQSW'YDP_2A!_N7K%S7#>M#JE>6+^
M<U_5AUB(?'/<?F3#]*$'^Y>G-<-ZT.J5Y8<YK^K#K$0^.>X_,F'Z4(/]R].:
MX;UH=4KRPYS7]6'6(A\<]Q^9,/TH0?[EZ<UPWK0ZI7EASFOZL.L1#XY[C\R8
M?I0@_P!R].:X;UH=4KRPYS7]6'6(BPQNW;Y,PXEAA];5:5@#RD`@SD;N>I'0
MYAKDI\!MAB28L:Z$04N:_H>&T+RO)7\UV>)^KUF7AU(TZIERM<2\!,I+*PH"
M5Z9!,P+MOS6Z(QHKZEQM+K=$E31,@0Z@@F<I`BS39\]FF,+W+6KENW7\AKV^
MZ5<35RYRD6@M<9M^`C"T'ZZO-;V-`.>6K@'T-BHL%3%R0G*?YP?"T=J>]WL8
MA2X<2`,3)/[)7EC)SJO%NS;/VB(T!B.$6AE!G2-9I9K=;!^+-]!&B.3FN3JY
M3EQ<EN>+I%KAW7:B=Y!`1;&QK9"Q@A#SU?P*UD=`JG(YE0^PK"V$+2VNJ="R
MHI`+#@)4`"4@3G,!221I`(.Z(PC$GUI*TTB"@)!F'FR)&8!GX"09'02#X#&T
MD9H[-`K%^R7JN08C+)MV%Y(VRS63=%%97%;$I4Y!6H>VCGN4P**KL<*/4`12
M6D-M"?!XR^\E+CY;S^%%'0.K2VWB*E.*(``:422;``)S))T`1E765J$*6YA]
MU"1,DN(``%I).X!&<Z=I\OHUO:CE*U,:\]>]B26SMGR%FY`A6-Y6P)BL5IFP
MS)6)$%8595,1T8+(O"#-"!LX(QY.RR)@=EIS*@-P;15-6CZE5MLK+;;019NB
M44YY6R43A]B=/UB++)V^"PS^:,Y&Y"2YK0CX=7UR6Q(`1\H`\-OVAOM&QDO/
M)JL5(B.-"J02!)V=:8T=Y&5-O'YP.C.7<]SK85@S:2L*?>!2H@SIW+"$WB#X
M"$[XC2$VFR,`Q5Q5V[3MF8!'US=H)N@BW05;T'039IC*(W9>S9ELMV'U1!2S
M0$B?#G.1NW:R<V'+Q1*PY2++6+%.I'D8TQI31#"\X=9<3E*TX5C..M==#0M%
M(<Q!224@B;*Q,$3!$SH(M!T$:(SHK:QR\48>%`$@R=09$6$'Y1NC<BY?'/<?
MF3#]*$'^Y>K.:X;UH=4KRQ=SFOZL.L1'&[>=O,-./OZ8`999;6Z\\[M.!;::
M:;3E;CCCBX;"&VVT8SG.<YQC&,=N>JBDPXD`8F23_NE>6!JJX`DX;9^T1%+C
M8VTE&EQF-1PV9$`(*2.C\;:K>30HZ2>D1XZ0+$Q$^.,$>_$%H9=6E+;JQ7L)
MSG+:\)KS*@NI7M%5PD@'@E2)$I@&=I$Q,;DQX1%O/*V\I&S]^`"1PB)@&<B1
MX#(R.[(^",<AM[62QEM@5ZF4.>.>;2\R%#;VI$H6ZRL$"30ZV."&^\MM<;*B
MD85C&<98):<_D.(SG.[A+#*2MZJ=0D;JF'`-)&Z?""/G!&X8Q-XF\Z;K5(A2
MO`'FSN`[A\!!^8@[L6NM&[HJECVO:)+4D*F.N=FB;,.K.TX5G$6!#:]J%4*Q
M)/$0C;#:O*:T\]WDJRA+*TYSG&>]C&1].&5#&'TZ,15?:0I/ZI5I4XM8E;X%
M`?/%C*\09=K7EX>+KBPH?6)L`0A-OX4D_-&<1^Q=I2PB#XK44-)@NK(:;,C]
MM5PT1QP0AT0IM!`T2XRM8Q;"VG,8SVH<0I.>S.,XZU%T5`VHH<Q%25^`M*!M
M$Q83NBWYHV4UE:L7D8=-/A#B#HL_ABW2VW;Y`$B!SNMJM"ER#>7@!9;<]2C2
M36DR</"*=$8,C6726TS-BCQ,J1A6,%'#M?\`:/-I5>WAU(\E2FJYQ24Z2&5D
M"PJMD;-ZE1^9).@&+%U]4V4I<H0E1T3=0)V@63^521\Y`W1'W#;9V!8T/.5[
M6=8GD#^!E]<-N6J2B&,%#M%C9>4#&OX;\H%?0ZCO=G?;6E6.W&<9Z.X=2,RX
M:N6B>B\RL?)NGPQ5%=5.SX.A"I>!U!_@A.;8V#6!QR[+K*LUX4PT2,$)G-R5
M2)'*D3WVQ08\=X^-';?--)=2VTTG.7''%82G&<YQCHUAU)4%26*Y:U`$D)96
M9`6DF1T`6DQ1ROJF0%.T(2DD`3=0+38!;NDZ!%>G8FU%J+0C4,0I8!;(!R4[
M9KBE!'$,!E#AEIQ$9R,6^-(#N(;7W5J0^VK&,X6G.;.9T&]_]R5:)CZI5H$Q
M,6Z+#XCX(OYW6V_^W:#(_6(L-EGXQXQ&K.Q^-\_LJ]S&PC]?[!K4S/35/GI<
M&D;VJM5@Y4^EP!]:`=F`HJE,ES1<A#F-,$GE$.RR1@A1QBQAF$,XMYMAO6AU
M2O+%><U_5AUB(U6UUP&N,)-UV-M<I9K>NATF8CY.N53;$719-Z2O6XS-HA34
MDL>3LLA$4X$*&3"P<,A#;(^&#3VR7)!Y3S-YHJ`(2X<14&U$@'@E2)$IR,Y$
MB8GX)CPQ05E:5*0,.!6)3'"(F)Z)CY961*9O$JE4AF(*GZ?<ZZ@RQ18HDE*\
MIJ]5#+).F.T,5,`9-A5Z#DK`NQU'68M<5'K?=[T$0<.,VTX4Z]U>SA](^5)8
MKEK4$E1"65F0&DF1,@-TFP18Y7U3027J$)!,A-U`F3H`GI)\$5\KP^JT95=4
MPMJUW>7*OJ0R/`KJ;?R>BB`9N4F+I+24&+;GYF`RQ8RY&VW3++0R\I1(FXCU
M/-D&`1KHUB*&A=5<:Q!2ER)D&5DR2"29`Z``23N`$FP1<NMK&Q><P\)3,"9<
M0!,D`#YR2`/"2!IB_P`[Q"+G9RZ3JM?[`BW+W:Y6X345$;BUB-7V)63V%2-K
M=V&@WM6$Q\.RSL.@`R[RV$))E3W2GY1T]TLA:[.;8;UH=4KRQ?SJOZM.L1&Z
M0ELW$(*,+C2X[V!AV1\.N[/KV'7<,MI;PX[AF!99\1>$]JNXA*>W/N8QCW.G
M-<-ZT.J5Y8ISFOZL.L1%1\<]Q^9,/TH0?[EZ<UPWK0ZI7EASFOZL.L1#XY[C
M\R8?I0@_W+TYKAO6AU2O+#G-?U8=8B'QSW'YDP_2A!_N7IS7#>M#JE>6'.:_
MJPZQ$/CGN/S)A^E"#_<O3FN&]:'5*\L.<U_5AUB(PG96RMJU_75^G933`S$;
M"TNTRL@\WLJ'(<:"CX,XLIQL=F$RZ0XEAE64H1C*EY]S'NYZVJ&BH':VC:;Q
M,E:G4`?5JTE0`W8UZNLK6J2J<7AI"4MJ)^L3H`)B:M=09=9U]1:V?C&#J]3:
MQ!FXQE&<8+B80$`C&,MK<;SC#P^?Y*E8_P"3.<>[U%UKJ7ZRK?1YJW5*'S%1
M,25*VIJFIVE><E"0?G``C__6U?ZB(_,O&^_LO?\`?VXW?Z7S']2[-UD:_6(^
M>.P?V5/^H+LS_M;O^%?CW(3$1%V"(E(&<`%E86;CCHB7BSF4$`R47)#.A2`!
M@[F%-OBF"/+;<0K&<*0K.,^YGJ6;<<9<;>:64NH4""-((,P1\H,>\3C:'6UM
M.)"FU`@@Z"#80?D(B&@8O=E`":@:ZFH[9KH/\U"GWFXS])O<5#LX2D2&F98.
MG;`CMAR`K><MMRC_`,"DN,-MX+P65E\YZ24O"ZM1=?+E.\?."$)6V3ND`K;+
M8.ZD7P"3=NID@:*48A3)#;(;>:&@K6I"P/`2$K"R-Q1N$B5Z\9J-3\;-]>9F
MC^F@KU6=.;81UHYJ?^;%>&Q+H#>M_P"7#XV;Z\S-']-!7JLZ<VPCK1S4_P#-
MAPV)=`;UO_+A\;-]>9FC^F@KU6=.;81UHYJ?^;#AL2Z`WK?^7#XV;Z\S-']-
M!7JLZ<VPCK1S4_\`-APV)=`;UO\`RXT/<X(Q3P`D:[I):Q0F8AL=&>3,FG+;
MT(VH((U"D:B3X1F8+#48ZION)=`9PA2<K<?<>Y9[UN7UKVL+RKT_ZL-"K2/U
MNB\2H>!1GN`#C9RVT4)0<.WHE+^L'2+`?U=AN[TRTILW3-!\)9>-J1E)D-7L
MG0@]^EKM5'`>0TS$3%=9EX#7D$3#DRWU;GO6#*D:\97@E]*5,H(4T.AA#;7<
M.YG:74BK1B$G2TE"YTX*575.*!">$`3^L-@TRF223%6LOK;8-.JDFV'"I,GR
M%)F$`@FX2KS-)T`R$@!%A.]GA7I!4CE_3!OA2F8%10Z.31?@J762QS(-W&5Z
M96]E^-<9SAAQ2U.,(<SAO*.XSX65O.#S=R[BJ9I*B#S;Z8(5_/:#.T;LK9S,
M\:\KLK"@K#S=(39S@_D2N_S6D2L\&YN2D*&X@GP=:OU,#U&MRJ;1A@X.^1)'
M).0R]/@QM@^,,8VJ:'U$-.`X%>*/97Y.0WDAJ2(R[E3JDNITW,Q(<>I*E6)#
MG#"RIL\V\TE-TV%TI,Y)-H,BE,I"R-EO`BVU4L)H?J7DA*QPYWP"KPM#84)6
MBPB849S-L?4-P_>@;#%V0#2[*RXF1+DV`3^1A,I"$D$PI4"AJ1A9'3I,?(A!
M!&N^`.\A;",NNIRG+;[[;IW,8=9<85BN]4`)BFDH25>L4'0020)D6V"V8!!&
M!!MU#PP^:@29%\E)FF[:DMR(`T"4K39(D',*MQ^NM/C'(J&UBA++L#7ZR\05
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MV-R,*C2XQ@>6L<LZXY(A:A:)D5K79GQV$O\`>;!$RXT.EM))7CW,YF33A?`X
MD`5**E3II@F24Z"[(>:"9><9%4[J9'<O\.4EVB)"4A*9/D$":CI#<SYQ`GYH
ML3*:IU$7PK`AB)\D'0P7B6.&MD"=@_DA*3+3<;=:2BB3[`S$UJ:092T1&MI)
M2VM+C*#D(<[G=;;;18YF93H8"\8,FUH4)4P3:A=],RET&PV>&[,3M)BY&`(1
MPTL-&_2I)F^38M%Q4@6R+1;X)VRT141W#C,9.:[L#&E\+D=8Q+4+6W'N2DBO
M+P3%FOMN'1-O)U$@R9P+.;&D'64/.Y98[&O#0G*,Y71>9.$:K&58J+CZKROZ
ML--UM&]'"R$TMI!($S;,VP1@(0[2O"@W[*;J9OG1>6K??5S.^<4;3X(^J/PX
M:U[)PTU6]%QS,O`/95&R+_(5YPIL%:BGGX-UQO3C/CU\@R3.>4$K&6,9.=:0
ME+"&&657F/GJ'&G\7);6+1S>R>@*_6^<```K3O0=))-U+@0HU(6SAPOI-A+U
MLIS(_5>:3.S1;+0`!98#@X'6S&)$#3)#L@R`;&9.D>3LK(%/!2&1L&,//$ZC
M6ON/,#88QA&4X0.K+*,);SW<9'LT*?2I"\4%PD&0I0!,3EH=^6?RFTVVQB:R
MZEE25HH#?`(F:A1,CIM+?_X%@LLC]JW!T*F1>(JO:6>!:Q2+A0,NIY/3&5?`
M-WBQX27R@7ZIL1;!H\.QD81;8Z$#,.+0E'=5V=*C-*JIPN/8HDGA4.?NH\Y!
M)%O"SE,S(G:;8JSEY-.@(:H"`&U(_>%>:L`&S@Y3D)`RL!($??V(`</23N-(
M,XQ*Q;,26C'(XGO9'18X6V/N(*SIS)Z7S+!`#F*5E[.&3,NECX9+?>(6]Z5W
M6T[6L29C^K?Q2@6<+*Q*B-%HDDS2`!;[N-WEJV=YPE^O/TDKL^JG:I(.FPS4
M)*))_9#A46Y2K13(+4R:XS:(6'C"30N0[[B&SZ])1TQ"3JHE>H$13APLC&(P
MM*&FFU!.O"(PV,[EO%J<RHYRS4NXE?*%*,C3[B@0I,^%G(@_*;P"C-0G&16`
MGF[M.W0A(4D"8>W0009<%*=@LT2FF0!E%K3P)A?@)^ND:/0=&OOQQF<R'(]\
MPY@Z)96Q'F`RCVFE2,>X,A2>ZAAUMGM8'_4_HP_A93FQSA0\,6DL3T4TA(VD
M$<-(SW9B=IMWQGB]VV^!+!P^;=FE\DS&@@EJ=GSRL398(SL3B:^)B3__`-&Q
MA3LI2*-0'7S.0;Y#@T!KV3ITS`9!0K3V&!I%Z5H<80:_A&5'/C^(]A;F<JZU
M%8^DE/\`[L0`ZMRRGE-3@6E4_K=$EJ"1^2#(61L[%L(.'),VT(M>G((*5)E]
M5IFA))W2)FV,1B>"\3!S50L45HI@2;I3,8S%23?)$_))7P.>J2CW)=:M09^$
MG!"/#PUW_<90PREK",,MX3LN9J<>:J6',7FT[.8YL+)B1E];9/=\,S/28UV\
MN-M/,5",.DZV``><'<,Q/ZNW_P`A+0(N3O"T5Z&+A%Z/1X!TO+3A1S?)F98F
MG9.4#-$9.Q-,:H:DFCXC)JGABT.),R]EW+[KR2SDE6#,R@XAW:PFE(2!S479
M`@RN\+*1E(B4I2D!=1=N]WD%"D;/,B22><*G.1`,^#G,3L,YZ9DWE3I(CA$)
M"RE;E@]*J6_59S%BB6B^3$H6SB5P]5B,/DY?U&L@E'C5`564*<[N5J=5G&5.
M*SU<YFE3B'FU8J).(NF5,!9O[!];9YY_%X((R\AM;*TX?:VJ\/KSIWMI^KM\
MT?C\,6&#X#!@5,FM3>FF+.5)UF/@9:;D>0Q22%'!6:$N*K)"!_5&\)79M5AA
M,.MO,8RXTV24GO*642X[E=S:I=0'VL4X-*7"H)%/N%*D75'A9J3=5*1TR3]%
M(&%K+*$,<"Y0WU%`227SI"DKO`<'))O)!!&B:OI$FL`X&Q$2.\S$Z27%OE$I
M(.D@.3$@/*R+:;#&VGR(X]&H/'(`^'(EA_#><_J.([R,I7V*Q8O-;CA'"8J%
M)`D`:8$#>E$P.%TW21.+TY::0#P>'W23,D5!F=\%2)X/1,`_^<2CIWC=8]%6
M\BYZ^U$.')%194$^))\AG):,7!%*#=^"$L%Z;40R(*3&AJ'4VZE\=D(81MQ(
M+#8J='$L:8Q6F%+68G-`4%3%/(WA.V8>TD$SF)$J*B+Y*HW*'"7,.?-12T("
MBF[(OS%WP2+5@!`E*T`!(-T78VD^-F^O,S1_305ZK.H'FV$=:.:G_FQ,<-B7
M0&];_P`N'QLWUYF:/Z:"O59TYMA'6CFI_P";#AL2Z`WK?^7#XV;Z\S-']-!7
MJLZ<VPCK1S4_\V'#8ET!O6_\N'QJWZK]5O3=!0M7N(43NN0;'2K/N)4^X/J0
MQ]#.,_RLH:<7C'Z$JS[F7-\(&G%'9?(P)_@FZ!^,?/#AL2W*%J?RNGDS_`8?
M$:\7R3B)':QM=C:[`RD9/QNLJ25*2\478X,QJ0AYBX7B8CZZ=;!8B3$8/CXY
MB&B!A36\+)5(9;84S3G5+2-N(P]*U/+24EU8`(2H2*4(!4$$@E*E%:R4F2;D
MS-S>HJ5MKK%)#25!0;0205"T%2R$E0!D4I"4@'3>D)3;U%Q(1__7U?ZB(_,O
M&^_LO?\`?VXW?Z7S']2[-UD:_6(^>.P?V5/^H+LS_M;O^%?CV5<G>0-.XK<?
M]K\A;[AQZLZKJ!]D)CV'DC%3LGA3,?7*P"0XV\T/(VJR'"1HSBTY;0^4C*_U
M<9ZY5@.#568<9P[!:.RHJ'0D'2$C2I1'@0D%1^0&/<W'\:I<NX+B6-UO[M3-
M%9&ZHZ$I'RK40D?*1'\Z7E=[5OF[RVN$Y-6W=UWH]*-.+7`ZGUE9):DT.NQ#
MKCOD<4Z%7R(XFUOBL.Y2HZ7<,+=SE7ZZ4=UM'=K+O9WE3+=,TU3X4T]5@"\\
MZD+<4K=,U`A`/T4!('RFT]%LR]IN<,S53SK^+O,494;K+*BVA*=P&[(K(&E2
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MO3ILO#.KF-6CR0VYC76]5K7/6C;[C[`S.U]?7NW7KEW;]>3,#;==PM0J*]E*
M58[I#2%L@8_:\E&Q4_<:^UDND4VQ-2H"'BQFI1T9\9#G?0K*.,XT\UAM;1TU
M)EII]E;3JEKX+>H4$*+()2A5BUI*%&1*00J5MO,,OLU.+8?6U=;F]^G?0\TE
MMOAS><25I#Z@E3B;6VUA:1,!9!3/P;)HT+!**4C/.*>=<%FMA1KD`'R-JC<K
M87*[L2IU.&$I\U:)JHUUZ+#HUB*MA\Q*KB7'4PAT3B+$=P&<;`G&7[H/NDB1
M0T;QIER3>;6M16E*5JF7$I:2A%^5]#G"*%Y">3#`62N7ON\2''DW15HO+N.H
M0D-J6I"2`VI3RUKN'ZM38;!NK5C^=.5]BUQD%CG99YBG#5:!O$IMX+<D-&5B
MX0N(^/M&Q8.F50VVEVJ`MNOX=N1AT!R_:7,3P[?DHO@NM)=S;5J%4[CON@VF
MI+BFPR6%%:%3*6U+6$!"D.*NKFBQ#9-Y4P98-CL!]MKW[?52AM#A?%2D(<3*
M\Z&T%9<2MI(4B2[5N2NID1/)&-+Z_+))@1N;]]^'8.HG24])/;YAOBV?.QW(
M38VDB?BFZ)DUV2`<KFN,7`8<AP=14+/`*\I;1W7R<)Q6N2E+RLI,\"MP!(%.
MJ\$FG;?W\Y2(4YP)(!DMM>])L3F3@]"LK93G>JX=#2BHFJ3<*DU+K&\E,D%+
M7#)!(FVXC?#28XDM:B`W6[P37,.^O#5ZJ5R9^`5[HK'PY57YVPVN&GI*Q60&
M[R-8N,;K6$KX,Y)Q==038B1)X8;`8I`LCD7=;Q!:Z2D>.6&0I;JDWN`7=6$I
M0I(2DMA:"ZI2FTK<DT"VI5Y25(O:#F&I17UU.,Y5)0VRA5WG*+R"M:TJ*U\(
M4+2RE*75H;FZI+B4A*5)64R81H2C-IE,D^T&L<">#$.3*JY*;GJTQ*#9Q/;#
MU[$0+<K5;[+5RPV"T6EFC61M`!*F(VEV4XAYQU<.^\YH)QFL);"<EMK0I5V^
M&%I2=ZVX526V%)2A'#M;X34\T@``.`"3.`48#JE]H+[:TB90JH0I8WSC8$T.
ME"BM?`.BZ9)9=5.9;*C=;7QVUY7X'9<G!>T4FKK)4^A[>M4%%![FCHSX;F*'
M+:2KE=K*'(^=MQQDK.R=LMY;3+0K>#H^%#=;<8:>((9QTV.UK[M"AW)"6FW7
MF4*)8)NI<#ZE*M2@`)"61,G>J6H$$@)-]5EZBIV:]QKM#=><:8>6D"I`O*;+
M"4HL4LDJ4IXR`WR4((*02H8O<]6ZHI^P54T+G1MJ_0<Q(T-5<NM0VA!K9%B[
M7O\`O&I[`#-U]ZRD$/6*D5JKM21"$%#,EI=28QG,:4&0[L4V(XE4T?.E91IF
M74I<O(6TJ9**=MY)2JZ!=<4LI%A(D4'?I4!K56&8735II$YZK7VU*:NK;?3(
M!RI=94%)*YE3:6PI4B`9WT[Q22=%MW3VSM67^9JT+R"M-QB1Y.T-1LQ6=MR]
MKBG`(6\6JIA99L<6<$'-)-$KJ#&RDBA8(8);<P.TE:<=<OPAF@Q&B:J'<%;:
M<*4S2IE*#-3:%G>D$ID52E-4B")F.#8]48KA.(.TC&8GWF05R4A]2Q)+BT#?
M)("IA%Z=U,P1O1$0_7/N'SK[*^?5H_>G4GLO#.KF-6CR1"[<QKK>JUKGK0^N
M?</G7V5\^K1^].FR\,ZN8U:/)#;F-=;U6M<]:'US[A\Z^ROGU:/WITV7AG5S
M&K1Y(;<QKK>JUKGK0^N?</G7V5\^K1^].FR\,ZN8U:/)#;F-=;U6M<]:'US[
MA\Z^ROGU:/WITV7AG5S&K1Y(;<QKK>JUKGK0^N?</G7V5\^K1^].FR\,ZN8U
M:/)#;F-=;U6M<]:'US[A\Z^ROGU:/WITV7AG5S&K1Y(;<QKK>JUKGK0^N?</
MG7V5\^K1^].FR\,ZN8U:/)#;F-=;U6M<]:'US[A\Z^ROGU:/WITV7AG5S&K1
MY(;<QKK>JUKGK0^N?</G7V5\^K1^].FR\,ZN8U:/)#;F-=;U6M<]:/M&ZMR-
M+0XUMK9K;C:DK;<1?+2A:%ISA25H6F5PI*DYQVXSCW<9Z'"L+((.&T\OV:/)
M%=N8UUQ5:USUH[GO9:>VAY%\==UT/76_MI6S;O&Z[V*-JMG'V/.'6F>UGBP'
MC`#7NK6N86?8QHZM$/)?.BE/O`D`>4898;*RT\CY;V@]EN"8WA5978-A[=-C
MC2"M/!)"$NW026UH3),U"Q*Y!05*9*9B/J_9QVLX[@N+T6'8[B+E5@3RPA7"
MJ*ULWB`'$K5-=U)M4@DI*9W0%2,?T!.NF\=U8__0U?ZB(_,O&^_LO?\`?VXW
M?Z7S']2[-UD:_6(^>.P?V5/^H+LS_M;O^%?CUE\_-"T_E%Q^^SUL&2L\51MK
M[-U17K273Y`"+L.(X*\P]C93'FRD5-Q[+GPG!CJSXHCZ>Q/N)QGL5CGN3L8J
M<`QDXU1(;55T].\I`6"4S+93:`4G0HZ"(]O<X8+29BP56"5ZW!15+S25W"$J
MD'$KL)!&E(W#'5A^63]GYYP.5/I#UGZF>OH/?SG/H>'ZMWEH^<]P&1>.K]:C
MDH?ED_9^><#E3Z0]9^IGIW\YSZ'A^K=Y:'<!D7CJ_6HY*'Y9/V?GG`Y4^D/6
M?J9Z=_.<^AX?JW>6AW`9%XZOUJ.2A^63]GYYP.5/I#UGZF>G?SG/H>'ZMWEH
M=P&1>.K]:CDH?ED_9^><#E3Z0]9^IGIW\YSZ'A^K=Y:'<!D7CJ_6HY*'Y9/V
M?GG`Y4^D/6?J9Z=_.<^AX?JW>6AW`9%XZOUJ.2A^63]GYYP.5/I#UGZF>G?S
MG/H>'ZMWEH=P&1>.K]:CDH?ED_9^><#E3Z0]9^IGIW\YSZ'A^K=Y:'<!D7CJ
M_6HY*'Y9/V?GG`Y4^D/6?J9Z=_.<^AX?JW>6AW`9%XZOUJ.2A^63]GYYP.5/
MI#UGZF>G?SG/H>'ZMWEH=P&1>.K]:CDH?ED_9^><#E3Z0]9^IGIW\YSZ'A^K
M=Y:'<!D7CJ_6HY*'Y9/V?GG`Y4^D/6?J9Z=_.<^AX?JW>6AW`9%XZOUJ.2A^
M63]GYYP.5/I#UGZF>G?SG/H>'ZMWEH=P&1>.K]:CDH?ED_9^><#E3Z0]9^IG
MIW\YSZ'A^K=Y:'<!D7CJ_6HY*'Y9/V?GG`Y4^D/6?J9Z=_.<^AX?JW>6AW`9
M%XZOUJ.2A^63]GYYP.5/I#UGZF>G?SG/H>'ZMWEH=P&1>.K]:CDH?ED_9^><
M#E3Z0]9^IGIW\YSZ'A^K=Y:'<!D7CJ_6HY*'Y9/V?GG`Y4^D/6?J9Z=_.<^A
MX?JW>6AW`9%XZOUJ.2A^63]GYYP.5/I#UGZF>G?SG/H>'ZMWEH=P&1>.K]:C
MDH?ED_9^><#E3Z0]9^IGIW\YSZ'A^K=Y:'<!D7CJ_6HY*'Y9/V?GG`Y4^D/6
M?J9Z=_.<^AX?JW>6AW`9%XZOUJ.2A^63]GYYP.5/I#UGZF>G?SG/H>'ZMWEH
M=P&1>.K]:CDH?ED_9^><#E3Z0]9^IGIW\YSZ'A^K=Y:'<!D7CJ_6HY*'Y9/V
M?GG`Y4^D/6?J9Z=_.<^AX?JW>6AW`9%XZOUJ.2A^63]GYYP.5/I#UGZF>G?S
MG/H>'ZMWEH=P&1>.K]:CDH?ED_9^><#E3Z0]9^IGIW\YSZ'A^K=Y:'<!D7CJ
M_6HY*'Y9/V?GG`Y4^D/6?J9Z=_.<^AX?JW>6AW`9%XZOUJ.2A^63]GYYP.5/
MI#UGZF>G?SG/H>'ZMWEH=P&1>.K]:CDH?ED_9^><#E3Z0]9^IGIW\YSZ'A^K
M=Y:'<!D7CJ_6HY*'Y9/V?GG`Y4^D/6?J9Z=_.<^AX?JW>6AW`9%XZOUJ.2A^
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M&^_LO?\`?VXW?Z7S']2[-UD:_6(^>.P?V5/^H+LS_M;O^%?CV<;K_P"Z:S_V
MTZS_`//.N485YU?_`&1W\V/=/$O-HO[2W^=$T]1424.D(=(0Z0ATA#I"'2$.
MD(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0AT
MA#I"'2$.D(QVX?\`I*T?Z.S?_EA/6>E_>:?]HG^$1B?_`%#W\@_P1BNEO]3F
MIO\`9G1/ZK176?$_]2Q#]NY^>8Q4/[E1_LD?FB/_TM7^HB/S+QOO[+W_`']N
M-W^E\Q_4NS=9&OUB/GCL']E3_J"[,_[6[_A7X]F^\L^!"4*27V>3QNZM-X)]
MW]?_`.M[!@ZH%W$_];.92P#X5_R([V?[G9UR?"3-VL0/.52O2_`VI9_$DQ[J
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M4E*A0DH-I!^<)$?_T]7^HB/S+QOO[+W_`']N-W^E\Q_4NS=9&OUB/GCL']E3
M_J"[,_[6[_A7X]P%LK$7=*U.569P1\&ST:3'$/!/Y%D`\OMYPQ(Q1J,*=CIB
M,(P@@,EOL=&):0ZC.%H3G$S3ON4K[50U*^A0-MH/R$;H(L(T$$@V&/>!]E%0
MRXPY.XH$6:1\H.X1I!W#(Q%0=XV/1Q&XO8E`LUSQ'K6-]8VM1(>=`F@&LI:`
ME)RCM2$;=(6R'IQWC`HJ+E8YAS]9HK"%>$U(*I**J45T=8VU.W@W24E)W0E<
MBA21N%2D*.ZG=.FFHJJ=(154RW)67VP""-PE$PL*.Z$I4D;AE8*CZ]Z_\A-W
M>A'9OT;ZMV2[TREUS?K17:+?1ZC5.>K#Z]Z_\A-W>A'9OT;Z;)=Z92ZYOUH;
M1;Z/4:ISU8?7O7_D)N[T([-^C?39+O3*77-^M#:+?1ZC5.>K#Z]Z_P#(3=WH
M1V;]&^FR7>F4NN;]:&T6^CU&J<]6'U[U_P"0F[O0CLWZ-]-DN],I=<WZT-HM
M]'J-4YZL/KWK_P`A-W>A'9OT;Z;)=Z92ZYOUH;1;Z/4:ISU8?7O7_D)N[T([
M-^C?39+O3*77-^M#:+?1ZC5.>K#Z]Z_\A-W>A'9OT;Z;)=Z92ZYOUH;1;Z/4
M:ISU8?7O7_D)N[T([-^C?39+O3*77-^M#:+?1ZC5.>K#Z]Z_\A-W>A'9OT;Z
M;)=Z92ZYOUH;1;Z/4:ISU8?7O7_D)N[T([-^C?39+O3*77-^M#:+?1ZC5.>K
M#Z]Z_P#(3=WH1V;]&^FR7>F4NN;]:&T6^CU&J<]6'U[U_P"0F[O0CLWZ-]-D
MN],I=<WZT-HM]'J-4YZL/KWK_P`A-W>A'9OT;Z;)=Z92ZYOUH;1;Z/4:ISU8
M?7O7_D)N[T([-^C?39+O3*77-^M#:+?1ZC5.>K#Z]Z_\A-W>A'9OT;Z;)=Z9
M2ZYOUH;1;Z/4:ISU8?7O7_D)N[T([-^C?39+O3*77-^M#:+?1ZC5.>K#Z]Z_
M\A-W>A'9OT;Z;)=Z92ZYOUH;1;Z/4:ISU8?7O7_D)N[T([-^C?39+O3*77-^
MM#:+?1ZC5.>K#Z]Z_P#(3=WH1V;]&^FR7>F4NN;]:&T6^CU&J<]6'U[U_P"0
MF[O0CLWZ-]-DN],I=<WZT-HM]'J-4YZL/KWK_P`A-W>A'9OT;Z;)=Z92ZYOU
MH;1;Z/4:ISU8?7O7_D)N[T([-^C?39+O3*77-^M#:+?1ZC5.>K#Z]Z_\A-W>
MA'9OT;Z;)=Z92ZYOUH;1;Z/4:ISU8?7O7_D)N[T([-^C?39+O3*77-^M#:+?
M1ZC5.>K#Z]Z_\A-W>A'9OT;Z;)=Z92ZYOUH;1;Z/4:ISU8?7O7_D)N[T([-^
MC?39+O3*77-^M#:+?1ZC5.>K#Z]Z_P#(3=WH1V;]&^FR7>F4NN;]:&T6^CU&
MJ<]6'U[U_P"0F[O0CLWZ-]-DN],I=<WZT-HM]'J-4YZL/KWK_P`A-W>A'9OT
M;Z;)=Z92ZYOUH;1;Z/4:ISU8?7M"*_59U_NYYY7N-,_4QL(;Q7,^XAOR@^#$
M"8[ZO<[[SK;2?TJ4E/;G%=DN;M;2@?MF_P#82?$(;1;W*:H)_9+_`-H`\9B@
ME`;[N!+<!/U,W6>LGELKMD=8I*LRUYO8;!#3SM.5&U>3M55@Z-8&4>#*OO2)
M)YP"WPDB">-Y8BYM=)AQ+S-0'ZX>84A00V9>?-00I2TZ4`)"4JDJ\J5TVK34
MUP#3K!9I#YP44E:Q]&22I(0K0HE1)3--U,[PGWJ(B2C_U-7^HB/S+QV8^R'H
M4W=^>.H38L0AZ,H0]PO-G-9;RMN+B`*E,1`1!.?Y*&C;--QX>,]O;WB<9QV]
MG65@3=1':'['.7Z_'.W[)]12,J52X>BIJGU`3"&TT[C22?D4\ZTW\ZX]L_4E
M'N/#I"'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$
M.D(=(0Z0ATA#I"'2$6^7EHV!BI.=F36(V'A8\V6E9$I>&Q0(V.&=,.-)<S[C
M;`HK*EK5_<2G.>D(A%?*#2&#YF(:N?C35?<DF):)S!V$(P$J'&),E0RE2<4"
M((5&B`D.$)>=;\G;%?4YW4L.Y164(MI?+CCT(#,'9V(&_F``)D9<%F(L'PG'
MLBN)'4W(`/Q3)$8^X:X@="2L,]I+B&_<6K&.J2A&2.<B]--&W2-7=&<G:\4^
MW=&&8:Q$_`+HTT!77V'WA8AX<E]N:DFA^X.MY65][..U+;BDI0BDA.3.C;.8
MQ'5G8$983RG2VAAH@25+PXH%>4&.N%)`2`(")VH4\4^ZT(PT\TZXZAIUM:JR
MA$KUJRQMIA(6;`RMAN<B!)D<$IT/,@.,4VA66R4`EFBJ<&=7X3BF77F/$QGN
M.+3V*S2$9!TA#I"/_]6`:K\4_AP'X[_&'XM>,W\)_%7X-^'/)_%;\7R'X7_H
M'C>#WN[XGZO>[.WW.WJ(C\U.$;'Y^QM[G.RYB_S>YPLIB=WA-Y.4Y3LG+<CV
M+>RA^P]]4TW]DOX:^-/B@?6O]97D'UR>5^&KX,^,/D'_`-+^+/\`VGD/P1_]
M*\3Q?_W?E'6_3\%(W)WMV>G_`/'_`(TQ[0?9)[BO<^N[H.&VI>1S_GMS:-Z6
M\X:[O.!T\%S?^KWK_P#.\)';!UL1VVATA#I"'2$.D(=(0Z0ATA#I"'2$.D(=
M(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I".`KR;R8GRWP/(_`>
M\K\J\/R;R;PU>/Y3XO\`->!X7;W^]^KW>WM]SI",4&^KWR9KR/XF^2>49\'R
M;X$\F\K[V>WPO"_FO*._V_H_6[>D(X2?JV\I)\L^(_EGEJ/+/*?@'RGX0[8_
MP_*?%_G?+>WR7L[WZ_\`V79_U.D(^9GZL_(#/C#\1?@OX=BO+_AGXO\`D'QE
M^-,9\">6>7?T?X=^.WD7DG?_`*1\*^#X?\_X?2$6<#ZE?A:6^#/JQ^&_(P_A
MOR+XK?"7P?W+5Y!\)>#_`$CR/P_ASPO$_4[/+NS_`/<=(1F4-\5>Z#\7_B]W
I/@Q?P9\#?!O=^!_*L>)Y#Y%[GP9Y;V=OA_S7B_\`]72$9!TA#I"/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g693329g17c99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329g17c99.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0S^4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````/@```&0````&`&<`,0`W
M`&,`.0`Y`````0`````````````````````````!``````````````!D````
M/@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"F(````!````9````#X`
M``$L``!(J```"D8`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``^`&0#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2DDDDE*0[[Z<>IUU[Q76P2Y[C`"(L+ZWUOR.GUXM$NR++0Y
ME+=7/#6N+]/Y'TTCLLRS,(2D!9`T'BVJ>O8.6[TNGN^TWGAD.8`!S98ZQHVU
MM1K.F593?U\G()Y;+FUCR;4UVW^W9^D7*?57I'4F]6KR;*;**:-V]UC2R9:Y
MFQH?&[Z2[A`&QJP\O.6:!EEC6M<->FOWN&3SF#4[I'UC'3J7.^Q9E1LJJ))#
M'#<?;N_XIZZ-8=[?5^M^,!_VGQ76._M%]?\`W];B07\N*$XCY8S(CX#_`-&4
MDDDBS*22224__]#U1SFM:7.,-:))/8!>>XGUWZN[J]61>^.D7Y#JFU[6B&^W
MFS;O_1-NJL^FNF^NG4/L'U>R2TQ9D`45_&SZ?_@/J+G>I?5UU/U#QW;",G'<
M,NT=XLTL:?ZE3JM__$J;$(U<A\QX!_%9,F].@XGM.K'+'3<EV$_T\IE;G4N@
M.]S1N#=KPYOOC8LCZE=>R>L]-L.8X/RL>S:]P`;+7#?6[:P-;^^S^PK_`-6^
MH?M+HF)E$[K"P,M/\MGZ.S_.<W<N7^KH_8OUVS>EGV4Y6[T6]O\`N11_FU&R
MM`1],XD>J.OV?,HG6)Z'3^#W-CV5L=8\[6,!<XGL!J2N4^J/4^I]9R<WJ>4Y
MIQZMU6,WTV!S=Q]79ZK6>IMK9L_/5OZ]]3.#T&RMCHMS#Z#?':1-W_@8V?VU
M9^K/3OV=]7L>AS=MKZS;;X[[!O@_U&_HT``,9)&LC0^FZ3K(#MK_``:'U%ZW
MU+J]&6_J%OJNJ>P,(:UL`AT_S;6(75/K#UK.ZT_HGU>:QCZ/Z1E/`(:1]/Z0
M>UK*W.V?S;W^HJW^+'^BY_\`QE?Y'JAU.WJ/U4Z_GY;:M^-U,6>G;V#GGU='
M?Z2FS_!_N*0Q'N3``L#TQZ+.(B`.OC6[;Z7A?7%V8_J5&73D'U?LUSG@>]C'
M-:^ROV,_1-_D65O71?6SJ&7TWH5^9AO].^LUAKH#HW/8QWM>'-^BY-]6^I]&
MR,"G%Z?D-L=2P;JS[;)YL>:WP[Z95?Z^?^)C*_K5?^?&*,69Q$H@:B].%4`8
MX[_2(XC7[W5RNG'_`!@=1PJLVC/QA5>-S`]K0Z)V^[;C.\%K])Q?KA7=<>JY
M=%M1J<*14`"+9;Z;S^@K]OTUF?5SZW_5_!Z)B8F3DEE]3"'M].PP=SC])K"U
M=!TKZP])ZN^QG3[C:ZH!SP6.;`.@_G&M3I\0OT`"]^%=&M/59\U;.O>I&^CT
MIB==^W=NW?1V>IL_1_N)+2247%X!>__1V_KK9?U;KN#T+"VNMJFQX?\`0WN'
MJ#U/I?0I9N_ZXKUN#_C`NJ?39DX3J[&ECVD:%I&UP_F5+H'0>IL^L>=UKJ=8
MK-NX8[=S7&'&/S"[^;I9Z:ZI2RF(\,11X1Y^KJL$;LFQ9_!XG_%]DV8F1G]!
MR=+J'FQH[2T^C?M^ZIS5+Z^5/P<_IG7JAK18*[([[3ZU;?[7Z=6<OH'4Z/KC
M3UG`K#\:S;]I]S6Q(]&[V.(W?H_TO_&+4^M.`SJ71[<+<QN1;!Q0]P;NM:=[
M6,W?G/\`H(F0]R,NDAZOKI)%'@([;?\`<O.]=+?K#]:^G=.I._%QZVWVGMM?
MMO?_`)]/H,_ZXNWL_FW?`_D7+?4OZN=0Z9;DY?4V@9#V,IJAP=%;`.[)_<J;
M_P!;74O!+'`<D$!-R$6(@V(C_?71&Y.Y>+_Q8_T7/_XRO\CUOUU5]6ZD_(M8
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MCU4%VCC6QK"8_>V`+D>GU?XP.G856%CXN,:J1M9N<TF)W:GUF^*UNCW?7%^<
MUO5L?'KQ-KMSJR-TQ[/\*]-G$W(\0(U/S)B=A1^QWTDDE$O?_]+U5))))2EB
M]8=_EOHS'?1+[G?,-;L6TL/ZSUM?]B-5HJSV7;L,$..\^W=7[&NV_P"#^G[$
M#LQ<Q?MDCH8RKOPSC+A=Q5LW,^SM%=3?5RK-*:1W/[[_`-REG^$L0,:_K-S`
MV[&KQ7<.L-GJ?-E3&_\`5W(V(W%;9:UCM^2"/7<_2P_NSN#?T7^CV?H?]&BN
MXC(>FXWUD.&O\&2L'"&,U[WN-N3<=U]Q_./[K?W*F?X.M6DDDET1$"H[/"8=
M[,C.S&=0ZID8C*WGTMEK@#[G[F_G_1AJO="R,G]ONQ\3,MSL!K2;'VDN`]OM
M^G^=ZOL]J'T!G2V]1ZB<Y^.\%_L%T:'=9NV^NUO_`$$JVL;]9<A_175/)I<&
M5UZ,#M@&[1OH[/6]WM>F#IYN;CC(>W+<^YZA$GW>&Y;C]U76<GJ74NIY=?3[
MK*Z.G5$O]-[FASF_SGT"/?NW,_ZTNAZ%U#]H=+IO<9L`V6_UVZ._S_IKE>E8
MO1C0\YF9>W*+CZK:&VP!^;ZD4N]WTUH?5%GI9N8W#L]?IY/M?[@09_1>VQK/
M=Z?\YL1%VRX/=&7BD#^LOC%\7M_I8_3^A^Z]4DDDG-Y__]DX0DE-!"$`````
M`%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3
M`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"
M24T$!@``````!P`(``$``0$`_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`/@!D`P$1
M``(1`0,1`?_=``0`#?_$`*D```(#`0$!```````````````)!P@*!@,%`0`"
M`@,!`0$`````````````!@4'`P0(`@$)$```!@(!!``$!`4%```````!`@,$
M!08'"``1$A,)(105%C$B)`I!(W:V-R47MQ@Y$0`"`0,#`08"!@8&"04````!
M`@,1!`4`$@8A,4%1(A,'<11A@9$R0A6A<H(C-`BQP;(S)!?1X?%2DL)S=#:B
M4[,E%O_:``P#`0`"$0,1`#\`W\<-&CAHT<-&CAHT<-&N7NMVJ6.:M-7>]V&*
MJE2KK,7TU/S3M-E'1[;R$1(*JR@AW*N'"I$D4B`95990B:93',4H^'=(T9Y&
M`0=I.H[+Y?%X#&WF8S5_%;8NW3=)+(P55%:=2>\DA5`J68A5!)`U4RI[Z8,S
M,^)4=:YT,T9)>G7*TJZ<7:J5'1$<T\`2-ON$Y:ZTP&'I<09TB59PU;OW;A99
M-!HV<+'`@:B7]O.=MLV^3PZBGTFHZ#[=5CC/>KAO+)UQ7M_>_F_('KMA"36Z
MHBTWSSR31+Z=O'N7<R+)(S,J11R.=NI(L&M54RO'`&P;J1RH]<$6\T"2<M-7
MQO%)KF4,#&%HL%/LXQX#1-02%D)7ZA*G#N_4$3,5$F5K9)1_B#O/AU"_4*_I
M-3J?O_;[%\G@`YQ))DI2#6,230VJ5KY8[:.54;:"0)9O5F/7]X%(15VX3K#[
M3#V-M]9J3.SRFO>?\83%[I%`DI>3EHNC6>)0FY)X6+5E7+Q<%FY*1(IF4`P*
M.&D@V*Y.LHV34Y&P(;+)?*QD_+R(2!7L(_V:H?B&.F]I??R/V\P][,>"YS&O
M<V]L[NZ6\R"1VV%RQJ!;R@FH+)+&)&=HU.G2\F]=<:.&C1PT:.&C7__0W\<-
M&CAHT<-&CAHT<-&E2^W6O3>1=?J9B>B*OIG)=MRE%S%9QS`M7,E8[[%5*LVI
M_9D6<<T*<_R%<:.4I)=97M1*=LDD`BNL@0\1F%:6V2&/K*6J%'::`U^SMUS3
M_-%87F>X/B>,X5GEY!=9)'AM8P7EN4AAF:8*H_#$I$S,U%!15!,CHI5QZLM2
M]C8O:ZFY3LV-[]C.D8W;VQ>QR=ZK$Y31FU)JHSU895N(8V!E'/)IPL_F2+K&
M22.@V2;&,<Y%11*I%8FSN5NUE:-E10:DBE:BE!KG#^6[VQY];>YF(Y)D>/WV
M.P^/6<RM<PR6_J&2"6%8D654:0EY`Y*J454)9@Q0-JAXV:_272K[XS"X^W;!
M[9D`*CB+5JVW684(/4&P6B8N-)2;K?P*H'W(U.4/Q$JW7D5)Y\O`!^"(D_74
M?UZYKS4`RO\`--PY(15L7QJ:X<^`FDN+<`^!_>H1XAJTZ5TU#DKKI31PT:.&
MC1PT:__1WVR#]E%,'LI).D&,=&M'+^0>NE"HMF;)FB=PZ=.%3B!$D&Z"9CG,
M(]"E`1'GI59V5$%6)H!XDZ":=3V:QVXH]W>VDMMOCW(U\L#=KHSE#8^Z8MB:
M@M2J(S/`U9N2M-T#/;LC66MG5D:!$9-@9IZ89`1="FJF(>(W;R_[[VVP4?'[
MNTM8F/*(+-)6;>Y!8[B0$W%?,8W0=.G0]NJSMN79"3+6\LAC&!FNGA4T\W0#
M:U?`E@?MK2FM3FUBV6VFMN;I+`U@4K&8X/'%GL6.95*$A;$<UHK<<K/1T1]&
ML,9,1#TMB/'#'&\K944RNA.0`4*4P4EA!8ME\<F3BWX]IE605*^5C0FJD$;:
M[NA[M6'>?,?*7/RC`7.P["14;J=*COZZ7AZ5=[<B;OZY7-YFJ<86+,F*<A.:
M_9)IE%0D">=JUD9$GZ9-NX6NL(J&CEBG"1BR@W;)E53BBJF$RIU#"V^XW&+3
MC.9@CQT97'3Q!E!):C*=KBK$D]S=3^+PIJ`XGFY<WC#-<T^<CD*O04'B#3X$
M#X@Z;W.S<56H28L<Z]0C82OQ4A-S$BY.";9A%1319_(/7!Q^!$&K1`ZAQ'\"
ME'B#'&\TD<4:UD9@`/$DT`^LZ9V(52S'H!K/[ZD=EMF=W\C[0[596EZTMBZD
MDLF-L*19<88VCK-7#3TL2^!6DLA1E0:W61B:36"QZ*S1Q*+HO%I$J[@BBI"*
M!9G/>.<>XVN"Q]G:?_<N@:60LQ)4>4T!:B[WW'H!3;TTB<9D7.Y*^Y)<V-MZ
M\6^""7TD]98BP=D]6F_83M)0,%+"I!(UW'HPW7V2W/H>P<WL;?6][DJ);:+%
M5=PWJ-,J01S&:A[`[DDC(TZOP"+P7"[%(W<N50Q.WH40`1`?GN9QO$<<NL3%
MB+8QI+$[-5F:I!`'WB:=O=K=XAF;[,V]_)?,I>.;:*"G2E=<!M![!=TL^;G6
MG0CUL1=0@)W&172&6\[W%C'2[*N/XT6+6R*HEF(Z>A(*NU.6E$XMP<\5*2CZ
M6`R;5`A$P,OLX7BG'<7QV#E/,'D:*<_N8$)!8&M*T()+`%AYE4+0DDF@Q7^:
MRMYEY<'@(XQ)$H,LKU*I6G0`=_4#K6IJ*``G59-7\,>XJ6R[:=I:%L1AW+"J
MF6B:^Y$EK;`0QE+O0:1:8"(G[;462]$K356@1)@5<%"/EH:4>!'*`1)1;L(:
M.CRWM1E$OI(^,W5K=;75)!(QW%!Y13U7`#-TKZ9\6U6?M\DO)<_R3W`Q449O
MOGI,;)<2AO\`$P6CHIDMPKE!$6!"$!&=HZO73F_;)L!E?6#1?*^:,)V5*I9&
MK$QC-I"SRT'`6--HA8LEU2NRY#1%FC)B&<_-1$HLD`JMSBF)^X@E.!3!#\&Q
M5CF^38_&Y&(O9R"3<`2M=L;,.JD'M`[]7-R*^N,;AKZ]M2!/&H(J*CJP'9\#
MI3^NSCW_`.S>%<?YXQ]MOK;'TW),.M-P+.U4NDQUA;M$))]%')*,HS6V98-W
M'S,>H(`DZ6*)!`>[J(@#SEU]J\-DKO%W6"O3<0MM8J[%2:`]"9P>_P`!I=Q[
M\SR%E:WT>0M%CE0,`4-0"*BO3MTQ#4W&/M^KMMR$OM]L3@R^4U_B2TQF.V6.
MH2NLY:%R^XD8!2J6*2.E@JFD5@V,:A()K$55=I"=8@BU4$`,12SUYP*6"U''
M\3=17`G4R&1B08J'<H_>MU)VT[.P]1J?QD/($DE_-KR!XBOE]-2"&KVFH[*:
MLI](WT^X/E?NC"'V?]5^0^I>.3^\?MC[F^I_7?%]J_;WWE]M_P"E>#P_3.[]
M;V>3]/R&W\:]+=Z-SZ]*TZ;=VVE/O;MN[S5KNIY:]^I.EYN^\FROTUI7[*TZ
M>%>O9K__TM4WN>V$#7KU]9H>L)'Z?:\L-6>$*B)3]BRSK(8.&MI\"@&*HBNT
MQTRFG":A?B19(@AT'H/'?V[Q/YORO&QNE8(29G^$?5?M?:/KTO<IR'Y=@K^9
M6I*R[%\=S^7I\`2?JTF78[UX25+]#V('QZPY:Y<Q--M-G[PU\!@FTXW*:RD?
M;HM^V*D)FZE7H\O!JR)3=HHEKAA,;\@@-AX;ER7'NA?DS`X^X4VR>'[O[A_:
M<-3]?2MDN.O#PFWMD3_&6X$QI_O=2_V`FGP&M!GK?V##9_277S+3N0"3LCZB
M,:O>EU#=SD]\HIU:=;7+Q,3'.BK+2T*H^(4WQ,@Z3.'Y3`/*IY?B?R3DF6QX
M2D2RED_4?SI3X`@?$:=<)?#)8FPO-U6>,;OUAT;_`-0.D,>O-N?1;W7;-:D.
MR'@L?YQ1MA\>1IBF1CUTD@-F3$YF[@P)-W!(FA/YB)*8H#U?'.B'\PIB\L_E
MC?\`Z;VWP>>7S7=J5$A[_P#VI*_%PC?#KI/PBG#<PS&+8;;>Z7U8_"M=U!X=
MKCX*/HTR[WL[*N=?]#[?6H"2(PN.P<PVPQ&=OYW1*M-,7TCD9TFGWD$K9>H1
MZ\8HK\?$I*)"'YA*()_MCAAEN46TDJ5MK5?6;PW*0$'_`!D']DZG>89+\MP=
MR4/[^;]VGC5NTCX+4_&FIT]9VNG_`%B]>F(Z`_C?IMNGJ`_R9?TE2=CW[QR,
MR5LKME)!V$#YZNQ;MG$&^'P)'E#J;IW#%\RR_P"=\KR%XK[H!*(T\-D9V@CZ
M&H6_:UO<?QXQF&L+/;1UC!;]9O,WZ2=*;_;&?XNVQ_K[&/\`;UKX^>]'\=@/
M^@_]I=*OMW_!Y;_N?^4:JKLI:]B?3_OQM?F5E17-AQ%N<SR<M3,A)@L+2*G,
MA2;J\,W,;*D3!JVNF-;@[6*>)>&)\]&AYBCVG26)N0VEK[B\&Q^'Q]_'#R*P
MC`57)`JJ[`6`!;8PVG>H.UNA'<5KE[9_C;<JEPNU;G)6LJV\K$[8K@HVQFH&
M-(W):FTU6A%:$:T(>MW9;3C).!\:XDULS!6+5+4&DL49ZFO!<5G(9);H#VWV
M*0I4^C'SBK:1M$@Y<+/&J2\?YG'0BQ@$O*AR7$LWQ>..#)X]XXQT#CS1L?H<
M56I[:$@_1IL]M<;@^/<-X_QG"7<<L5E;*C$=&:0^:61E-&!EE9Y#4#JW34/>
M^/\`\Q,[_P!088_YFHG&;VP_\UQ/PE_^)]2_,?\`QO*?J+_;75,_73[>=`L`
M:4:^X=RIFB2KN0:)3WD5:(5#%V5IM*/?+66=DDT22L'2Y&)>@+1\F;N074(`
MFZ=>H"`,7+N`\KRG),OD+'&![266JMZD0J*`=A<$=G>-1.!Y3@+7#8RVN,BJ
MSQPJK#:_0@4(Z+33@=6/8)JCNC,6Z!USR.]O,I18V+E[.W=4>]U(L>PF73IG
M'K$6N%;@D'@KN&:A>U`RAR]O4P``@/*_S?%<[QU+>3,67I+*2%\Z-4BA/W&:
MG:.W33CLQC,MZOY?=B793=0,*5K3M`[:'5S^+VI/7__3:)[IK#>]QMZM6_7U
M@D(.2NM(^HWB>:6E5<E,+<++`MK:P);BMF<J<8RKXYK"CU80:JF,WESD`IN_
MH-X^W45KQ_C&=Y7E-XMI:1KM^_M!VG96G5G8`=>U:]VJYY8]SE,SA\%8%#,C
M>LVZI4$"J[@.M*`]._<-6DL^$_W`5RK%AIEES1H_*UFU0,M6)^(<0[KY62@I
MR/<14K'+E+A,H_+O(]THD8`Z?E,/(.'(>U5O-%<0X_*+,C!E.Y>C`U!_O.XZ
MF&AYHZLC38XJ10^27L/[6H,_;\9+G<-Y`VR]>.5#EC\@8VO4U>X2.*NLX8+/
MZV_98VRHVBW3DC?RLDGD=!O&0$3*+INX7<`4`*8>2ONM9Q9&VP/+K$5M)X@C
M'OZ@O'6E>M"ZGKT(`U%\&FELVRO'[LCYBWE)'@0>AI]%:,/UM?6]\-9E<"Y[
MT8]A559+*.,89$A:-<SMB^,SU*L6`V3*9$K*I=ASH3D:E:&B_D$"BF8A`'\P
MAS%[83)E<7R?B4[=)X2Z?02-C'ZCZ9'PUEYBAL;O!9]!_<3A'_4;_4&'[6N)
MWI68>RKVMZ;:R4>0;V3#&*:#5LT7]\43J1BM8O",%E:S*JH]BA"DM&-VE8CV
M9U$Q[7<P4#@!!'FQQG=P_@O(LU<(4R-Q*T$8[]R;HQ_PN9&/T)KQF47.<IPV
M-4UMK=/7?P-2"`>[K1?J8ZU%6$`"O3@````0TF```=```8K@``'X``<I:+^]
MC_6'].G\]AUF/_;&?XNVQ_K[&/\`;UJY<_O1_'8#_H/_`&EU7GMW_!Y;_N?^
M4:;I`5:N[C;'6C)=N@8BX:^Z^-[/A_&$-88YI.5;(F49<4V68+V>+D4EXR8@
MJRU;)5U@<Z3ALNX*[63/U(`!0]O)(]^M[%(RB`D1L"0=_P")@1U%/N@CZ=*F
M'AC]QO<>[Y=*@DXGQ[U;.QKU2>^?RWUTO<R0J!:Q-1E9O6=6J-)!]S/K_P`6
M:90]'WQU"=/<!WF"RQ5X:2J-+<DAJJTDI)A-/XNUT5@U(DI69)N[AO"]CD##
M&.VBYA*BCXU2N>A/;OE5]R*6YXKR`"[M)(&(9^K4%*JQ/WA0U5CY@0.IJ*,O
M+L-;XB*/D6('R]W%(M0O16#&GW13K4]:=&6M0=7Q]L&17^8/24YRU*,$HN3R
MA0M3\B2,8@50J$<_NMTQ79'C%$JHG5!%HXDS)E[A$>TH=1XK<$M%L/<B*Q1]
MR0S7,8/B$210?KIJ>Y1-Z_$KV<K0O"C4\*LAIJ2_57J]K/=_7QK!:KIKM@NW
M6B9HK]S,62SXCH$_/2K@ENLC<B\E,2M?=R#Y8C=$A`.JH<P$(`=>@!S2YQF<
MQ;\LSD-OE;E(5FH%65U4#:.@`8`:S\;L[-\#B'>UC+FW0DE5))IVDTTT?'V#
M\+8F<R3W%>(,7XS>3*#=K,.\?4"ITQS*MFBBBK5O)+UR)C57R#954QDR*B8I
M#&$0`!$>)5UD<A?!%O;Z:95[-[L]*]M-Q--,$4$$-?1A1*]NT`5^S4H<T]9=
M?__4T$:$Z)[*PGL5VEWJVNI\55WMV"RM,/1:-NK-M=M&5NG$F;43GKDG)A'K
M4O&U<9PQ!6,3S)/C]@&[#=MH<HY/AY>(X+C&#G9UBVF8E64$JM?Q`5W2,S?1
M0:4,1AKZ+/Y?-9$(&E\L8!K1*]_@:*OUUT_#E7Z;]9_,L:$[-4/W#X\WDUTI
ML3/XCMIJN;-Z9KA5Z\YC_K<*\QEDH$*_,RC!W,]E40:6!+PE/\Q*]P?!0OQM
M.QY3A[KV^N^,9:=EOXRQ@\C,#0B1*L`:>8LGT*?#2?/A;Z+E=OG+(+\J\>V8
M$T)Z4J!W]B']G5\?:1@B$V>T^R!@CZW4HK)=U6B'N#65HLD)6EK'EBK2"$]!
M5FON)QZS07EK,S;.8L0*)A(@^.8W0H"8%'B&>BXYR+&Y*XDVVVXH_B4<%30=
MI(J&`'4D#6WRIL;-C?RJ^R-O!=7C".W$LB(99AYD2,,07<D?=4%J5(&J*>F#
MUU9_U4M>:<S[714>QRG9:GCW$./R-K/`6QRQQI3XF-;.R+2->>R#1)LLA6H!
M@W1.<JQ$H;J8!`Y3"W>XG+L5G(<;CL$S?((\DKU4K61V)[&Z_B<D]GG^C6EQ
M3!7^,:\N\LZM>R!$%#6D:*`.M!U-`/V0:U.GV3#=5Y$2C1`H&7=1SYNB43`4
M#*KME4DRB8P@4H"<P?$?@'*O0A71CV`C3D>S68+UI:K;:ZBU7+VH]KAF./LQ
M;.S56L!+37[96K:;%>#*Q'34'D/)3M6M24F6.L;UQ,)0]:17%`7,LY%<IP39
M+"#][J<IQ?)[O#Q8.=F9(7#DJR[`6'7S`5KV#Z?AJ@,FO(+,?Y;X2X$/)LRS
MR23QG=\CCUHD]V:#I*Y/H6B]-T[;ZA87I+T97/>3IJ^FL<8)Q3KILA@",L-B
M5Q;&/9:OQ\G3*9)3DA*Q$$N]>W#"-EDI5LB]_6.'I)=19T90_P`PH!@-S<L+
M3VKN\=80SW=Y8WD<2J_0L'8`!GZ+*/,:GIM[>S3OA<+GN&8VSX]Q['6LF`M4
MV0KNVNJ#O<G;N=B2\C]2[LS$DG7`772;VJ>SFYT&.W^<XUULULI=E;6I[BK&
M<G$2DW,/FR#AB9U%HP]DR$*MC>Q+UPR3?RTYX(I-RJJW8J&.HDK,6W).$<+M
M[I^*":\S4B%!+*"%4'KWJG0$`T5*M0`M36W/B.1<BD@3.&&WQ:.&,49W,Y'<
M6ZBGU_LUH0T#V=:M7O/?K^O.M6NU4C'EC4_VBBZ3559B+KL8U@*'?*=)'9)2
M<Z\:,&J,77((X)E45`Q_&!"]3"`"E<,S=KBN56F9RTS"$&4NU"Q)='%:#J:L
MVF+/X^;(86\Q]H%]5U`4$T'1@>WX#2M]?:K[_=:<-4+!>.L":Q+TK',0K"U]
M:RV:K2<ZHT6D7TH<TD_:9BC&SE?YJ04Z&(W2`"]`Z?#J+OEKCVKS.1N\G=Y.
M^%Q,VYMJL!6@'0&,^'CI=L(N:X^RMK**ULS'$@4$L:T'05^G3`]0+G[B9K-D
M0PW*Q-K]4<&GA+`I,36/)"(<65*<3CSFKJ""33)]I7%LXD>A5A!F8`)^)B_C
MQ4S]O[?QXYVX]?7<F3WK02`A=M?-^!>M.SKJ;Q<G)FNJ9:WMEM-IZH26W=*=
MO=V_HTW3B'IBU__5W\<-&CAHT<-&ED;@/B*;N^M2`?F[89U=<\32P*#T04F8
M6CUL:[U$?AYTI)T`)_Q[E.1=X?\`&XU3V;F/UT&N>/=.8-[Q?R]V,W\&]WDY
M#X;X[:(Q?7O(I\3IF_)370^H2S+E\<=L65>J40G><R7%-PUQKC5L[\#F:>D[
M4EK!8G29%C5K'E;.J5:7F%R@@W2[44_*\7;-UL,TWI@*@W3'L']9\`.\_P!>
MD_EO*OR"&&PQ=H+WEEV"+2T#4,C#H996%?1M8JAIYV&U!1%W3/'&_AA'"J.*
MF=@G)^=<WK+.1'S:=RCD613\3FP2Z"!DV</!LA.J%<H57(LHA"Q"1S),FYS"
M8RBZJRRGR"'T@S,VZ9NK'Q/T>`'<.[7GA_$4XU%?WE[>M>\FOW$EY=.*-*X%
M%CC7KZ5M""5MX`2L:DDEG9W:=.9].6LH.'[W#Y%S=LG$[(;W;&X)@:O>I1+'
MQ:SE^Z,VLL*]QN;67C"M%RV!NW:03*.8@BFBFW*F582_F#M`JE%*KSW*W-\\
M:AC3J?'7YG<4R]KR#F?N):^X'O7R/"V-M>N+409&Y17K<7*R)M/JJ%B5(MJJ
M$`#D=10+:71C(>23;]SN,\/[&Y;V8UFCJO)O[7:<D35CL#1@W/4RKQCI!6S'
M!-G*H9`.A'IN&:+7YYN"PE3.D0QR[=A+*<@T<-PTMIMZD_#_`$]/AJQ_9K.9
M_P#SMON.\6Y_EN1>WL=N[337DLTP4&"J,#,?*XN=L0:-4]1=Y"E02.2W&R3L
M;L]LUL)7M<<F9`J./M1\4S+RP!0KK:JPTL<_55#.K8V.A6Y2.&1M#J96>1S1
M-3O`Z,$H9+XF'O\`%[+<W5U<K;2,(X4ZT[R.W_1]6HOW8S_/_<7W#YU8\!Y'
M?VF"XMC)&E^5N;B`320FLZD0NF^=I#)%&&J"MLQ3J>KB=%,_ALEK%C;(;YZ1
MY;6L:-0R!T,`KDNU6!..E7;HA0`J"M@;`A*D3#J!$7Y`Z\F;"Y^:M8I2?/2A
M^([?M[?KUU9[,\W_`,P/;OC^=FF#Y18_0N?'YB&B.S#N,HVS`=RR`:M[S<U:
M6O_6W\<-&CAHT<-&E9>S6NQ\\&LR]0R!&T?9B#R^C+ZZL92%L\JVN\VDX@$I
MVJ'=5^#FV4&DX?JPZYG4H",8/A!%RJD@JJLE$Y10WRI20+=!_)T/4]*CH#3N
M[>FN;_YA;""]_P`O7Q6<CL_<*'*A\6KQRNMQ(#$)(28XY%C!<V[%YML7EV2,
MJ,[K9''5VW+N\4VC[U@[&>$)4C<$)BV2&4RY)(9R!`(>0K%`JT*W2<IKG`3E
M1D+&U^6ZE`3.N@]=J)[UU`D@6-N\[MWV`#^DZ?\``Y?W7R]O'!FN'8[#W`6C
MS->?-=>S=#;0Q@$'J=LMTFRH%9>NI(Q0RQ;&V2\L("86L&6&CEHADZ;MJ#IK
MDF4[`.$6\>MI:/BG2%%6/Y1ABQ;=&M%#RA'EZ>7F6(1!G"M67\1/;_L\*=/#
M4_QJ'CD&0S,-C=&?DRLHNY)@PNG_`-QF#JC"W/F]`0JMI]_T!][4Z<SZ<M'#
M1K-OH+$ZOQVP>Y:^P%HUTGFSNXMQK+/*S>(1+&/"WG)AYHD4;*U>AHY1T=-5
ML1U],5<#_+3\H@443&6\<+87%YZ[1GS?B^)\1_1K@'V4M/;>WYW[NOSG)X">
M-[M?16]"#8WS-Z9?3^=BC0D@QA_19_NKOH-A)7F<,P]D^7YC1:2Q-.NG>(+<
MTJU4H"JT=2XFP.,90K)>64>1]>)CAW`Q^1"M'KM%F_.DLZ-X_@Y[R%^+09.<
MV&T_NS0#L!IV]FVE?`Z]8^&RA_F`Y1=^S-UBIIFQ4XA@MJK;I(;.-2Y9(OE6
MC6[].214E(9_+TDJ!".JV+].'5*L[O-NR.>H[,+FT2Y[U%X9J^=18QK!-PY;
M1B%N<Q^&I0[R<<.T)!R=190`*"YD^T#D5$=:TBLBCFXN9!/N.X*&_3Y>WMTH
M>VG'/:E\1D9.6\_SB<J:X?YE,?#DMJJ"0@G*6#[I"PE<ECTW%:5#:N-ZD(,U
M6S5LI'85N*&3-7';QN6,L1VMH@Y*)F47[QU03/8RVU:L%=R[NH+.VTL9@4Q@
M61:'5(5$[<>;N'4I/="!]]IW'J#7NJ"!W5K35J?ROV0QO+?<&#B&77(^W#,-
ADNV:-DD#,;;<DT,(:0P%TG,8)JL190ACT_#C#KM?7__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g693329g21a42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329g21a42.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[1&:4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!=````2(````&`&<`,@`Q
M`&$`-``R`````0`````````````````````````!``````````````$B```!
M=``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#OT````!````5P```'``
M``$(``!S@```#N$`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!P`%<#`2(``A$!`Q$!_]T`!``&_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#H_J1GY-HSZ\JZVZJMC'C<Y[W-GU-_I_2L]T?F+I/4Q#)_6=!/T<C@
MD#33W?27&?52W+JQ>KV83F,RFX[?0?:0&!_Z38ZQSO;L:Y!-G^,,"3UG%TY_
M28Y_`8Z?C@)#Y@->I:')92.6QW<B>+Q_2?0ZG,UK;O\`88)>'?@^SZ?]E$7F
M_K_XP(!_;.-!X]]/_O,G%G^,(@$=9Q(.NMN./_==/]G^O#[2V??'[DOP?0?M
M57J&K;9N!B?2LVS_`,9L]/\`Z21RJ@)(?'_%O\OY'\I>?TY'U[)W6]7QG,AP
M`9?C,.X':'2[%L]B+]J^M[70[J;#)T`R<3Q\?L+OS$#A_KQ^U0SCK&7V/?N>
M&L+S,`20`28_J-&]#9DUOK%@%@:=T!U;VGV':[V/8U_]3_2_X-<+]H^N$?\`
M*=<SI^MXD1/_`(1_<5=MW^,%VK>LXD20`;<>=#M_T"/L_P!>/VJ]\?NR^Q]%
M;:USRP!T@3JUP'^<YNU37FYN_P`8(,'K.+XZ64'\F.D+O\8)):.LXLCF;*!^
M)QT/9_KP^U7OC]V7X/I"2\\IN_Q@,>2_JN'8TM>W:;:.7,<UC_;2WW56;+?^
MK_1I)>SK7''SM/O"OEEY4__0VOJGAXV31G8][/5IRJ&-OK,PX&RVIS/9[_H?
MNJP[ZL?5)NIZ?C0)/+1H#9XY'\C9_K:A_4T^W)D:"FOPU_37'\_V?YZV+'YL
M.D6`!KG:;^=Q8-Q]/Z/]E_\`VTG0E(#21CKT--+D`/NV/0'0]/%K5_4CZJ^F
MTV=+K]2!O]MHUCW:,<YG^:Y2'U(^J,@_LNO_`#;O[UJAT``M=/?^8/\`WY/N
M'[CO_`/_`":?QS_?E_C-KAC^Z/L<NGZK_5]]<OP=2Y\_S_9[MOYRA9]7/J^P
M.9]C8`(&N^(G@M?D,\%I8SOT.K#].SCT/WW_`,M1M=>"2UKH!T^CW/\`P;7I
M&<[^<_XR!"/[H^QJ,^JGU;<T.."/=K(];PV_FO<WZ/\`*03]5OJY9CEUN`QT
MO=NW^J1[7.8S^<L:WVL8Q:];CM;N8[=&O\R?^J<UR#67_9_8UV[?9QZ7[]G^
MC+G)<<Z^<_XRN"-_*/L<C_FC]5?3+OV;02.^UT`_^Q#F_P#33_\`-'ZJ03^S
M:#'\EP\?^'=X+4#LCTR=K_O;Q_FM_P"H3[LB##73\6^?\EJ''/\`?/\`C)X8
M_NC[',9]4/JIZ3K1TVDEI@.#7Q!]KOH7.9]%W^D26H'6^@[<UV^1MDU^(_?V
MV?YM:2/'.OG/^,KAC?RC['__T=GZIT7VX^=7BW'&R+J&"N\-:\L<;+6,L]-V
MUK]COS+$;]E_6>/^7[):2X#[-C1+3,_TC=](_N(7U6N=CXN;>VE^0ZK'8]M-
M0#K'Q;<?38UWMWN_,5H]>RO_`"AZF!KS/<N=_P!ROS?^@GX^+A](&_40_P"[
M:/(\/W;'9(WV,A^E_59U])^M]MCF-^L=@VM#B?LF,>2YL;&7._<1?V#]<?\`
MYY;/_8*C_P!*JH>M9+M/V!U0Q_6,:>67[?I(U7UCS*M&_5WJ6TZD&MKC(#6-
MAUMUGYK%)^L[1^S&V?U?<_XTTN+T7ZT&HD]?L=[G@'[+4.'.:>+?W_>HV])^
ML#2[?UJT]OYFH:G1O^';^<IX_7LH5@#HN;J2XGTVZ;G/<6GV?2K_`,)_Z,2?
MUG*=K^Q<X$_%H$?U',^D@>/M'[,:/U?>7VY&5?1?K,6@CKUFTQ`^S5&/F+D!
M_1_K.:MU77[*Z]SP6?9J720Y^YV^R[\Y6!U_+9M;^Q,X^>P._P`YS@YZ$>NY
M;*(;T/.M&YQ(8P3[G.=S^@^AN1_65M'[,:OU=[R^W(A;T;ZTN88^L5FW_P`*
MXYF?AD.2'1_K2X?^**PC_P`*XY\NV0[]Y3_YPY6TM/U>ZH9[D`_])UVY+_G#
ME$0?J]U0SXAI_P#1R'ZSM'_%QI]'[TO\::S.B_6H5N/_`#ALV#EGV3'Y.C7;
MFW_O>Y)./K%E[37_`,WNIAKM22UI,CW?SCK7.;NVI(_K*VC]F-7HO<_;-__2
MWOJ4`W[4X:%U59)GN+;!^\W;[5LV/I+3.2X`$@G<.YL_>QW_`$8_U_PN%]4\
M2O.Q\W#RFB['NQVL=5);-;K+O58YU<6>_P!RL.^HG0A]'I9//Y]G9W_AYGTF
M?Z_X-.APUJ2/(<7_`'46ER%_=H4!UW/#^E_A.YCY58+6,M#_`%;7"2X@SM]2
M&PVAKO[?_;W^#5S>?'_I?^IUS+/J+]70Z+.DN>TD-D66M`U]UA_6[';/Y"L?
M\P/JC_Y6#_M[)_\`)IU0_>E_BC_OVUZ^P_QO_079QG13]+\^S\[^6_\`X=!N
MNHDSD;=1(WMC4G_C5DT_4'ZJEDV=,]VYW^%R>`YVS\_]S:IN^IW1]I_42=2>
M7S!/_'-_ZI$\'>7^*/\`OT>OL/\`&_\`07:JM9L:&V!V@@[AK_X,S_J$)A'V
M8R\M`?89#A^^_P#X2W_J5G-^IGU>?66V]/!!T(+[6Z?];?9_U:J#Z@_5O9N_
M9GNE^@LO.@=^C^E?5_@TO16\O\4?]^KU]A_C?^@NRUU9K)%Q(&LAPCCR:W_J
M4X-6W2\F(UW-[:_FC^2L7_F%]7#K^S"/[=W_`+U.3M^H7U:,3TPC3O9=S_[%
M.^BA4/WI?XH_[]/K[1_QC_WCMM>PT/(M);(D[AI!'G7_`.>[$EC-^H7U;!)'
M38<`0";+^_M=_P!J'M^AN21]%?-+_%'_`'Z/7>P_QC_WK__3V_JA4_(IS<</
MLQS;0VL7U';8`^RUGJTO=NVV5[O8_P#?01_BXZ*+'"S(RBT%P&U]9<8\=].U
M7/J0/=:8YKKU\?T]JV+'-#GN%0T<_P#PD'^4?H)T,DHCTFK:/(0C+EL?$+J_
MS>=_\;GZN$$MR,YT&(#J9_Z502'^+KZMDP,C/F8^E5SX?S/DNA+@TEK:1'#A
MZI&G:?8C5MQ(8[U'`QMB'D"="TNENY/]_)^^6U[./]P/-T_4#ZOTN<YMF6\$
M1^E^SV-Y'`-7L=JB_P#,;H(V^^YVTQ)KQNWNE_Z$;OI+?:W":"YMKQ&I<`Z>
M?WMWYSBELP=8L<=D$-VN(@>[]'N/\O\`-2][)^\KVL?[KSX^HW0?HE]PVR)-
M>-)_>DBG=_Y!"M_Q>_5VQ[K'7YC"2):PT,:"8#0QC:MK%TFS!+738_:X0XEK
MC$^_Z4^U.&8+3HYWM)&S:XC74APGZ'N2][)^\KV<?[KS/_C<_5S7]8SCMYAU
M/_I)(_XN/JX.<G.XW?2I[?\`65T[&X+=K_IDB6A]3G3I^[^=M:[VH@?A:`-J
MCM^@,"-?%+W\O[Y5[./]P//T_P"+GH^&'9%&=FL%E;JGP^N'5W---C7_`*#W
M-V6;OZZ2Z)MV.<=X8&BJ-[FBES6QN;)<#]+=^[_A$DO=G\W%KM?@KVX?+PZ=
MG__4W_J.V++S,[JZ3\/TUK=/N6]Z0]9^YSFM<3+W"8=/T6[9\/SVK!^H[PZS
M(`_,KJ!\OTMKUM/KQ'/L#JVPVPD]P7$G7G^<U?[?YSZ:4=FG\._W-"O'\TPJ
MJ)!-XYU`:Z/[.B1QI.KCQJWTWQ),_N?VD`C$&V:*FP-"T"=-O[O]G8C'(@AA
ML.I@'U'<\/\`=O\`S91T;>J_V4<^HXG_`(IXU]WN]K?Y2<X\ND.+!SM;4^.T
M_28[\QJ@<APDN>1`!@6NG\T<;DCD"/YPR=0/5?S+7!L[_P"3_KZB6BM67V40
M07N@ZD"MX$@0'?02^S:07NU$2*WZ?#V_]4F?E%Q<\N<));H][1,<-:U_M=_Z
ML3G))<`'DEQ'#W@:0/W_`-Q^]Z6BM5WX^X_2.V/H^D_Y_F;DWV;7Z9@Q(].S
M@1I]%.W,<UYLW`%PU#G$M$^[1CG^WZ"/]JS()],]M-CN_P`TM%:K"G';6\,=
M:=P`<7-(TW-X]C?<W\U)/]HRW!P?5$`%I@ZN!KAO_221TKZJZO\`_]7=^H1+
M;>H$,-I%5<5B)=K9[?>6,_SG+JAD60V.G7M!Y$T"/D,A<S_B^KL]7-MVGTRV
MMH?&A,V':"NT2B=-FG\.!^ZX^GS?])"/2CZ#AY;2GBK]P_YI14DFXABG]P_Y
MI3Q3^X?\THJ8F!**D3W8U>TV%K-YAFXQ)@OVZ_G;&N0*LW!MM-3?I!VR.23+
MV_FS]+TK-O\`(0>HC#RV-WU,R-K7&O<2'-<Z&S6TLV-MU^FYS-G]3U52-)&3
M7D5MLI#=H80:]M0;^ALV^J'/V?X2UG_;?TT0/-CE,@T`3Y!W17428&HT*7I5
M^"C+VAQ8WU#([QI`]RH9?3LK(M==7DY..\@AK*[&^F##-OZ,M_,=5N_Z]=_8
M"]T?2KYVB>Q26=3AY=++:79KRZY@:UUAW6"&EGJ4>_;79^?_`,8DE]5/_]D`
M.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`
M+@`P`````0`X0DE-!`8```````<`"``!``$!`/_N``Y!9&]B90!D0`````'_
MVP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__`
M`!$(`70!(@,!$0`"$0$#$0'_W0`$`"7_Q`#]```!!`(#`0$`````````````
M!`4&!P@)`@,*`0L!`0`!!0`#`0`````````````!`@,$!08'"`D*$``!!`(!
M`00#"`D,#@@%`0D$`@,%!@$'"``1$A,4%1<)(1:6UE>7UU@BU#555AB8&1HQ
MTB.3)#1DE=4V.`I!,C-38].4)>5VMF=WV%%Q5&4G-SG984)B)K=2@:*C1$6E
M*&@Z$0`!`@,"!@L*"0D#"@8!!0`!`@,`$002!2$QDQ05!D%1DM(34]-4558'
M89'1(C)2E!87&'&!H>%B,V34"+%"<B-#HR0T=+)C-?#!<T2T9=4VUCCQ@J*#
MLR8EPN*$12?_V@`,`P$``A$#$0`_`+$$]I7SL"*'+9Y+["6Z,\V^V@M<*>*I
M;2L+2D@$Z()"+9SG'V3;K:VUX]Q2<X]SK5\(X,-L]\Q\#V?Q/=OC#K;R.T^\
M2M*@1:X):9C;2MM25#;"@0<1!$>@SV6WM,[!RMD);2N[6(EG<$'"/6&O6B%`
M1$QU]@(]0@\NB0BF5Y!C[7&.E)?7@1+(I0JEJ;89R.OQ,MAXK-A?E;>W'T3_
M``I_B@O'M;J*S4C7EME.N;#!>9?:1P:*ME%E+EM`-E%0@J"B&PE"VR2E".#5
M:W#6R0GXJNRA]7K^;3/L,M^C(+$@#%8.(=?:9SWSY%\8-EH5IQ3R\*<3E:6\
MI3GO*3UDQ[NQC=G9G*YP`8Q'&F(%*3(]TR)=VK4"RWHU#9"\J%*;D1(\=YYU
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M_K41^9>-@'LM)0Z)Y\\<B`'LL.D6:P1;V<8QG#@,O1;3&'LK3GW%8=$+7C';
M_:J[%8]W&,]7&S)Q!&W^7!'L1^$^J?I/Q!]FSC"[*E5+Z#W4N4E0A0/PI)^`
MX1A`CW,=;./O!!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!T
MA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA!TA'_]'%
M_K41^9>,\/9C?T\N-G^NQO\`LK8.JT>6C](?ECV`_"O_`-P/9G_6N?[,]'M@
MW!8;?4]6WZR4"-`E[O"U:7D*I&2L/<+#&G3S`JU1HYT'K^*F[K+"N$]WOCQ@
MKI;J?L48QG/>QT-VLTU17TC%8LII5.`+(*$D)GA(4X4H!ELJ(`V8^[M>[4,4
M54]2("JE+:B@$*4"H#`"$`K(GL)!.U&!U?YV[TEXYI87!O=5G+#DZ_7)HB)3
MF`R%/O!6)VUA2D5-1I8,+(0)$$UA3`<Q.1@SA[8I4LR4E+;_`%SVJ=TMK(7K
M72MI*5*3/QIIFFP04D%05:.%2&UFS:2V4S(Y5G6B\W6YHU8JEJ!2DR\62I*M
M`@@@%-D8`M:1:"5.!4@I\+Y@\E@)92!^$M^M];<,U]AN9@CKE79%`EZG1H$U
M$?7KMJZ(/E6Z*VI<C+%2.:ZZT%G'?#:4C*EV4:MW(MN:M:&6GP'/%4$*$VP5
M":D.D"WY*`GA`58E&>"\YK#>[;LDZMO.,S;\9-M)\<@&25M@D(\I158(&-(E
MAE-.Y1<A+Q"%2"N(MXUX0XT&]$-VTF=D#'5C6G3D?/"RT#FH59^-P_7-G2!,
M:\DMY3SU8E,.LMMC)4]CU-PW/2.I1ZQM/)PSL60/)>*2%6U3\9I(4)"0=;D2
M58+S%]WM4-K5H!UHX)6K1)\9D*FFPF7BNJ*<),VG)@2PRCBUN?D)MFC6(W<.
MJ&M:VL**A3:V473=BT\:=*E:#59F9')HMR9<DHENE['DYBMK2Y.Y+F&X3$F.
MPP`>&XK$UANVZKN?;3=5X<.T;0/CMKLR6L)-M!`5;;"',"`$6^#*BM"I95PW
MC>=>PM5YT/`NBR1XJT6IH25>*L$BPX5MX5$JL<($A"TS[K7M;DJ"YY*LZO@"
M"#D63T?*3$!?G8F/*9U-K27JXTTS74RQ^8]S9]QED21K6,.HB:\0(&&5)+;[
MW.QOXO75-DO-GB)4Z]5_WNE-F5OT0(N&-@BG8^4UK0[%*^?"-F)S&#8VYS<K
M'N8:?4VSY/#.<N.-./.(1:/2$'2$'2$'2$1:\RDY!TFX3=8BO3MEAZM8)2O0
MG@OD>F9R/B2RXF*\`5;9+_I`]EMGN-J2XKO]B<XSG&>LBD;:=JJ9I]RPPIQ(
M4KS4D@$X<&`8<,8]6XZS2U+K#=M]+:BE/G*`)`P8<)P1K;<Y=\UH.ICQT_PO
MFI'8P]7/LLQ-UP.YE43MDJW=9ZH5^)A8V+LLJ;<VRQ:]&RD=B74(/('%H<D!
MF!_,]=L-7-5W:@K9UG0FB+@2$J*`Y@4A*U$DI`1(N*2JQ,I2F2%$RCD=/ZQ-
MLMH>U=6:NP5*4D*L":5J0D`!1*_JTJ3;D%%7C@)G$JD>9')IUF3<@N">QQT1
MMQ@*TM^R3=A:?7&25FLX4O:!XF!UG,/R<)7ZO3WS"7`GB5J+DXM@5!C9>7V\
M=O5JXP4<-K8P9M*7XJ4XPE)")J=3)2E+``4!XJ7"JR4R-]S6&^9'@=6'L#B4
M^,HC`5*FJ26U3"4H),B9J4@)M!5H9'6';VR84+5]D%UA*3T1;ZQ!2%MK5<KM
M]D;)59J=<A7"%OES=9J1P$!7`C"\OM&PC-A?(9::7%B860X)Q]0TAFH?90Y:
M0A:DA7BX0"0#XJEIPX_%6I.TI0PQU3#BG6675(LJ4@$C#@)$Y>,E*L&+QDI.
MVD'!$,7R7VLJ49AQN*>T5D>]N[V$N1)=+$KP[E6(D,PM?9EL5A]9EBND<(VX
M&PEC"$/OI94OW/$S9B[#U8-X[9J]]Q34:-M5\"F;7/1\-;:M$3T-3ZW7HZOJ
MDXPFX3TP"<^3('R;.1''0@<`)4^UY=PK.'\,S"&$ODGMAMZ6B1N.-H*LD'1:
MI>CX6-D)B3==18B9YSWOAF'TZMP[L@@2O+"7^[//,2A*.P!\)@@I*$975:4D
M9RM5^:EX0BMRLM"QDE)5XM[S!,&<:$R27$OO^`+EYV/?<4TI66FE*RGMRA&>
MU.(A#]TA%7[IM%QI>J[O:M?P.;-<H.$=.@(),'-6=1YJ'6490FNUP@6>G,LL
M+6Y@0-Q!#_<[B,X5G'6?==/355X4M/6/<'2K5)2K24R'Z2II3M3.`8S&%>3]
M334-4_2-<)4I3-*9%4S^BF2C\`PG8C6U=N6W/B&K%@D:QQ=9FK!'2%>"A8Q_
M4^XW!IRER-\UO`N;L6J.F2#8_$E7[%,ON:VPV_<:_B.\X:^^,TXA?;4VKNJ+
MC["'[_LLJ2HJ/"LS2L-N*X#")&2DH&<S#+EJRD`D$<=4W_K4VP\MBX[3R2D)
M!:=DI!<;3PV`DB:5+.;2+S=FTI1`,]EFH;A9K[KNNVNXU`NA6:3Q*MR]1/:F
M6384B,FY*)2R6W.0T&4DDA@%#R_`07'94YG(!\F#Y>1*X>\:9BDK7Z>FJ0\P
MF5E8E)0*0<%DJ&S+#)6#QT(5-">RH*AZJI&7ZBG+3RIS09S202)&8&UL33YJ
MEIDM554[9^ZSY2R+M6KW!8>)C]JF1PD?"S8$I)F5)G5I=.A19"3D"`#"+`[:
M9X!!*&4L2+L+YH;#;.5-]849D?9'8.[0]C,5L.M1$K5P+'JF*LDLUK_8H;S@
MMFA9OW]N5"9>/=J<^%7Y=Z&-7)/E!CQT>L\13)\D.TT],(Z=E[*WM!5@2=H.
MMV;"=(4JT6=F")KLX5+A2(FP==@U>OFAM3\.A$]):\L\F0^$Z\-E,C&.*P\A
MEIQ&8A#I3;QO<O8D?`6[7P":))N7]_%UBXUR(Q$(@Y(:)K,)*1LE<I>3488[
M&GE)D4"X#E8\^.=9;%<08RVA&1_2$'2$'2$'2$'2$'2$'2$'2$?_TL7^M1'Y
MEXSP]F-_3RXV?Z[&_P"RM@ZK1Y:/TA^6/8#\*_\`W`]F?]:Y_LST>ZCK:1]Z
M(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D
M(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(__]/%_K41^9>,\/9C
M?T\N-G^NQO\`LK8.JT>6C](?ECV`_"O_`-P/9G_6N?[,]'J^]I-RS+X3<--Q
M<@(0(*4N5?C8FOZ^C9)"G0";S<YL"L0!9["5-^;CH!R27*$L=]K)(P+C25I6
MM.>O(.HVKB=:M:+LN9U932K45.$8PVA)6H#:*I60<,BH&6"/MSKWK(K5+56]
MK\:;"ZEI`2V#B+BU!""=L)*K2A@F`1,$Q^;/N#DCOO?]NE;UN7;M^V)9Y@QP
MTH^Q621)'86YG.4C1,4AYJ(@HP9&>XP&$P.*.UC"&FT(QA./>>[+BN>YJ9ND
MNN[66&$B0"4@'X2KRE$[)422<),>@]ZZQ7[?=4Y67K>K[]0HS)4LR'<2D22D
M#82D`#8$5-Z;F?OO)_Y>5_C>MEP;?%I[PC69S4<>O='PP>FYG[[R?^7E?XWI
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M*B$*`"G7&T3,@`HJF;-D]7JY<3U^T]Z53M[FG9I@DX3-2YA:UA`*TVBAEIUR
M29DE($@#:&1IO`"R1C=T`,WU@JTT1%V&G(F!KLC,00\U0:-I6_V`$J[9M@5=
MAPQH?;13*2)!8CADA`/@@LF'$CC9T2==6EYJXFZ)4[U@I*E`*LN+?;2;%@J)
M*F1@2"$I<"EE*051TBM0*AO/&EZP*-4P'`L)02D+;;IW%#A"X$`!+Y$U$%2F
MRE`6H@17-KX=WR$F^4%>K]NV-;#^.TW0J]%/BZYFP`=BS-\L<'#1\0EMVUDS
ME3DB(J2*E@5+!.CS`8]7?+'=*!;)SJ;6ND=9U???IV&T5R'%$%U)+26TJ45>
M196`0$*\9*@I0DE02NSKJO4V\6JC6:FI:RJ=7=ZVDC]4H!TNJ2D)^LM()"BM
M)L*24I,U)*D!4GLW!>V0=ZWA30]Z0\@QI_7LY:H^7-=8@UWJUQ.+_(Q-#B(L
MRXNOX+O]/U5.S];?#<DGI2'S'$Y%90<YD2PQKC3NT=T52[I4DU3X00)JX-!X
M,%Q1"!@;6ZVVZ"$A"[:;1*1:R7]1:UJNONB1?H4*2G*TDFR7'/UI2T$EPX7$
M,N.-E)45(L*L@*-F8D^SWEQYXL%?((Z-KT1LA-;L5LMU+-U]'0VO,Z6QNQ.P
MGD7J^5]M,\1`"'-XJ3[H\Y'I&;(EDQC)8^5X@UX064K%S!3RF+24(7PA4[P_
M`<&.#;5XH44GA0"VN9#964JEFJ[/70^I!UA<33IJ`A:UH+24M9OG!=/".IDJ
M04.!,G$2"G0V%)B(P7"MB3W1K[2\ER8#A)2WPVP9>P39$$ZJ)I.=>6^7UG(`
M'$DWD"/DB9#95+L(H^6R6FU0X84CWLYD/*"Y3NMBT756WJBXRIMI382D*PN<
M*@.@B2"1)I;9,Q.VI2/S+2L)O4Q*KWNZZ'-9%)<>0ZI:BG`WP2RR09N`&;R'
M0,('!I0N<UV4S+/L\ICTC!QF.0,HTY*4CBI?#Y62U]/0-3A87D@1%#3CI-UG
M[A%U-Y6JR)IAAP?!B9&<+P^P(*EP0S`^(->6RAQS0Z2`[5M@!Q*EE5,"4^(E
M!7^M"29V;*!(J5)2;6P/9V\'6FE:P.@J9I'"HMJ2@"I("SPBG$H_53`LVK;A
MF$IFE5F!R7"B>JT77YJ[;7ND-&R=-V',V%^*U^3+XHMWU]Q:UURA>UE;7)+8
M5<$B;/,QMLEX!AEYULQ,M7W<*%[%OI"S$:W-5#CS5+=[2G`ZTE(4Y+A$.U;M
M)PJ)-J)2DH0X2`18<'C8K6`[J2_2M,/UE[5`:+#REE+95P3C-(U5\$N;J0%+
M2MQ"02#;;Q856<:.0VL9W0VPL4?WZ3ME&(KD!9HZ9.C)"GG&1]@$R6,HNI2,
MP=9*V[A.,X\M+L@2/=['%"H:<:6YT-R7BW?-%G>;(;4'%(*00L`I,C)8`2KX
M4%2=BT2"!RFL=VU%PWB*$5[KJ2TA8404$A8GA05%2/@6$KV2D`@FC/3<S]]Y
M/_+RO\;UM^#;XM/>$:+.:CCU[H^&#TW,_?>3_P`O*_QO3@V^+3WA#.:CCU[H
M^&#TW,_?>3_R\K_&].#;XM/>$,YJ./7NCX8/3<S]]Y/_`"\K_&].#;XM/>$,
MYJ./7NCX8/3<S]]Y/_+RO\;TX-OBT]X0SFHX]>Z/A@]-S/WWD_\`+RO\;TX-
MOBT]X0SFHX]>Z/A@]-S/WWD_\O*_QO3@V^+3WA#.:CCU[H^&#TW,_?>3_P`O
M*_QO3@V^+3WA#.:CCU[H^&#TW,_?>3_R\K_&].#;XM/>$,YJ./7NCX8/3<S]
M]Y/_`"\K_&].#;XM/>$,YJ./7NCX8/3<S]]Y/_+RO\;TX-OBT]X0SFHX]>Z/
MAC)_BQS;Y(</MFUW9>F]EV>+<B)`5Z:IQDW)F4:[PJ"6WI"LVZM.E*CI.*E&
M4J1E?<22*M6'QG62$-NIY_6'52X]9J!^AO.A;5:!LK"0'&U2P*0J4P1WCB4"
M"1'1:MZY:P:K7BQ>%V7@X`E0M-E1+;B9S*%I)D0=N5I)PI(.&/T"OSHFDOO-
M,_\`IS?G(OWVQ_Y9?@7^]?YX?_1_;?X+KTT]0+UXQ/\`C>C,1^M\_P#0_P`I
MQ[O>O]T>8K_`])XQ]3YOZ<?_U,7^M1'YEXSP]F-_3RXV?Z[&_P"RM@ZK1Y:/
MTA^6/8#\*_\`W`]F?]:Y_LST>G7VKW'L'E3QEA="25G+IH5_V[3FG[(#&,S!
M4;BNP]KMK>6HT@P!DGS3L`EC/:ZCNI=RK';G'9GR)J3K$YJG>M1K`U2I><IZ
M=4D$E(5;4AO"0"1*W/%L2C[5=I-S-ZP:LN70Z^IMMUY$U``D6)KQ'!A*9?''
MG9_1W:)]:"V_-C#?'#KR=[QEX]5V,LK>1Z\>QZ[^F7MPGPP?H[M$^M!;?FQA
MOCAT]XR\>J[&65O(>QZ[^F7MPGPP?H[M$^M!;?FQAOCAT]XR\>J[&65O(>QZ
M[^F7MPGPQ4B_8J\9F#9*.,YM2\<7#R1T1*(EM7"Q#0,G'3Y-8(!()D[*(*@A
MR;&RTPGO_NI#C3K/B,OLN.;,=N>LJD-N(U+;4E8!%EXJF"FV"`E!/DX3YLB%
M2*5`6?9-=$R#?KP(GC0D8C+9ELX!MX)3!$UD?[$7CC)O,C#<V#O.$3)L`.`]
M0(%D]^6"G$5W(C8;ERP0IPN5=2@;[']TISE;?>2E>4VU=N^L2`5'4Q%D("I\
M*N5FS:G/@Y8!CVL1V(J'9'=9Q7X[CEY*,<Y;>R<6WL1U_F2N-V"7PE\UI=HX
M>TNTI8#VL`F#W+.Q,-P+D4*"]9T%G+Q*.X;PZRAQA2<*<PO+:5+Q4>W76,(2
MYZEM\&6^$GPRB+%FW,D(D/%PR,CL2G$>R6Z9E.GG;4Y2L)G.<L4]O!M1U1/L
M4.-4V(,8#S:D<H-?E6`62=<Q`9Q_H<MX$I\&/*MK1Q8SI3.6V'&VU)(<SAMO
MO.9[G1WMUUC94I"]2VYI`G)U1`M"8!(1(&6,$X,9P88E/9'=2@"+\=PXO$3A
ME@P8<43:M>P*U!<`&I.M<N+!+AN,M/Y=#UO"/>%AY;[26R,)N.<L$)=%<2IM
M78M"D9[<8]SMQ'_Q"7Q3**']4FDJ[KJQM8OU>+",,5CL?NXSE?3Q_P#(GPQ(
MOT=VB?6@MOS8PWQPZL^\9>/5=C+*WD3['KOZ9>W"?#!^CNT3ZT%M^;&&^.'3
MWC+QZKL996\A['KOZ9>W"?#$3NGL`J/5(F/DF^2UK-4;<M>5;+2];Q#.&V[Q
M?ZS2WC,+3;7,J7'-3ZB$H[,8<4UA&<IPKO8RJ/\`$'>%4ZZV=66198><^N5^
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MOL`J14X<.4:Y*VHU15MH-:RRO6\0RE#=TO=<I[Q>%IMKF5+`:G5/I1V=CBF\
M)SE.,][&51?B#O"J>6T=664@-.K^N5^S:6Y+R-FS+N3G%I[LBH&TA0OEXDJ2
M/(3^<H)V^[$L_1W:)]:"V_-C#?'#K%]XR\>J[&65O(N^QZ[^F7MPGPP?H[M$
M^M!;?FQAOCAT]XR\>J[&65O(>QZ[^F7MPGPP?H[M$^M!;?FQAOCAT]XR\>J[
M&65O(>QZ[^F7MPGPQ%K?[!/3="BVYJW<M[3"Q;IC4>@QW5`I2,F/,D/M,Y1'
MV8MY.7&A5YQG*<)[<=G;VYQC.13?B!OJL6INEU296X$S(#Y&"8$\*!LD12KL
MANQ%FW?;PF9>0GX=ON1`FO8Q\6WIQVOHYSN>>:#$,0XJD5I`923")H=#0)*K
MMA!K[7H%Y;F&^\EMIQA><]TAG*\WVX:S\"'QJ0DHF1]8Y,2"29C@\`\8`3QF
M8QI,K1[)KH"[!O\`<"I`^2C9)`V>X?RG&(>1/8B\:CW&V0><N#7GF'BV&@Z9
M627'Q!Y!V,)+80Q=5J>$&+97AQU.,MMMHRZK.&\97U:5V[:R(25+U(`2"!,N
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M[V8<6R]JHREU)D07E@@[1\3'%P=C]VJ`4F^WB#]!/AAS_1W:)]:"V_-C#?'#
MJW[QEX]5V,LK>1/L>N_IE[<)\,'Z.[1/K06WYL8;XX=/>,O'JNQEE;R'L>N_
MIE[<)\,'Z.[1/K06WYL8;XX=/>,O'JNQEE;R'L>N_IE[<)\,90?BM1OX8'?^
MBU^*U]R!_N;^&'[^_?W\#_N?^%ZH];'>9)_YAS_RCY7%XL7TL?<CR!ZL,\Z5
M_P`I9EB'D^?^EW,4?__5Q?ZU$?F7C/#V8W]/+C9_KL;_`+*V#JM'EH_2'Y8]
M@/PK_P#<#V9_UKG^S/1Z2?;+;^MG%WAXUO:CQ-<G+30]N4-V*BK8/)E5\M5@
M'L%4+Q(L0TK"23B6@)UUQOPBFNQY",J[R<92KRAV=:O4FM6L"[@KWG6Z2HIU
MVE-E(6+!2X)%25IPE`!FDX)XCAC[0]JE\U%P:HU%[4K2%OM/MR2N=DVS8,[)
M2<2B1(C#*/*A^D%\M?DCXW_!_:/TL=><?=XU0Z9O3=T_W>/6#VP7[T51=YWE
M8/T@OEK\D?&_X/[1^ECI[O&J'3-Z;NG^[P]L%^]%47>=Y6#](+Y:_)'QO^#^
MT?I8Z>[QJATS>F[I_N\/;!?O15%WG>5BNY7VV&Y9QU3TOQDXA2+SDN5/NNET
M+83SCTT:XV\5)O+7M'*GC'WFDK4M?;G*TX5^KCMZSVNPNX6!99UFOA*;`3@=
M8'BC$/Y?$)Q:5VM7NL@JN:@)G/R7<>W];#L'[<[D#'FGR`''WBN"9*GM2LLZ
M'4]FB^EI0>28F!)*5;8VNVU)'@RHZ2!WGTN.#NY4IO*<K7WK2NP35M:4(7K!
M>Q2E)"9N,&R""DA,Z>8!22%`2!&.<A%7M<OH3E=%#A,S@=PF8()_6X9$`B>+
M8A+CVX&]$NH?;XX<2VB&CHV4:(9I.QF"&I6'&\G$RS1#6TT/-2L:-C"&"4JP
M^UA*>ZO&4XSBH]@^KQ%E6L=[E,B)%Q@B2C-299O*R=D8CM1'M<OH&T+GH9X/
MS7<8Q'ZW&-@PW,^VIW$/Y7R_&7B,,H#!.(YP:D[('>C<%NX)>Q&/,[50['8\
M[^Z4>`IOPR\Y(1W7LY<S</89<2K5K6:^#:E.;C!M2P"T,WPX,&&<T^*?%P1`
M[6KX$I7/0B6+`[@GM?K<&W@V<..)-6_;O<DZBS(CUS1W&2)9E9!$H<T'6MGL
M,O%LQ47!"J2PWM=+++84'"!AM(;2E*!QFT]G;C.<XS_8!JO4ELOW[>JBE,A-
M=.9"T5'#F^RI2E&>R3%8[7K[3,INFA$\>!W:`XW:`$2/](+Y:_)'QO\`@_M'
MZ6.K'N\:H=,WINZ?[O%7M@OWHJB[SO*P?I!?+7Y(^-_P?VC]+'3W>-4.F;TW
M=/\`=X>V"_>BJ+O.\K&43OM`_:0[)U]$6Z0TWQ3KM+2KCYM%$R?C9@Y#`-PV
MR"C5SY4:-L68E78Z:N%9!'/4P*Y@,66#4ZXQDME>.?3V7=G=WUKU,B^KV75E
M-2S9!8(\5E0>D>`2)I0M13,X5(5@59(CL6;_`-?:VBIZX7/=J*10IW`I2G<3
MKDFI@.$R4H)"I#`%H)(M`Q.A/:$^T[/@JO9PM*\1"8"Y,CNUZ4:QM7P#%$@S
M4XAAQ"MCI(#?35JX;*9P\AM/@,H8QG)Y`H;^$OLM[-4.OL+OR^`\V9*$Z?!A
M2GB,/CJ2C!/"2?(2I0RT7SVA.-TSS=SW86G1-)"GI&:5+E]9,>(E2\,L`"?+
M4E"FFS^TE]I13JX=:+#I[B(%'!0=ELW@-L[;.DRJ_5(VJ3,O)"1L?L,HM>1H
M6Y!FNC+2@T01LEXIEAL,E35RG[)^SBJ?13L7U?!<4M*,=.`%+*T@$E@#"I"D
M@^239"22I,[-5K#KY1TKE94W3=B6DMJ7C>*K"`A2B`%DX$K2HCRDBT5`!*I?
M9GVE'M'H*0DP#=5\/%(A8[8,G*'C#;F(#%'UI,(K]B2VE%Z\](NJFE*'92(R
M_P#9MY4[EI&4*6:[)^SIU#:T7Q?/C*;`!-,"2Z"I/[&0\7"9D=R9G(]K%KTR
MZMI=V77XJ75$@OD`-&RK\^9,\`L@XL,L$Y-GGO[3_*YL5G3W#@F4JMJ@Z5;H
MAA[:JBJQ89VY'T5D>0*7L5$.:"%-Q!BGS0"C`L""K(0ZXTME3MGV7]FDFE&^
MKY#;C:EH/\/XZ4H#F`<!:!*2))4$JF0"`9ROZ9[0"74HNJZU.-N)0L!3TT*4
MLMX27`D@*2J:DDIDDD$B4Z83S?YU.MW6.SQDX;L3]0J%(G=@4!5:W$-+"U]R
MC2UTUV#.")OB*K8EHK%,R-'CH,-2(2^B.SX)#[X_6S/9MJ+.D7ZS7R6777$M
MN6Z8BUP@0Z4G@+:/'7:49)M`<)A"4JC#3?VO,JM`N2[14,-H4XW^O"@%-J<0
M#X]A1*$2`"E240V9*)3$E-YH>T(TG/NP6.-?"ZGG%$ZX9:.B8_9R(Z=-WE=G
MZ;6G%2@&QUM%%GRM848<\8I"AQ6TNN+\5]MMVR.SG4"]F0\K66^G4@.8%*8F
MD4[?"*$BQ,`!<DA.`F8`DDD5U%\Z^W<]F[MQW8@S9D07K*C4.\$@@\)(DJ3:
M43B3(G"0#*RO:&^U"CQX8J5T-Q2C6)\FLQT4MYC:12B9BWV,>J041X47LR0>
M:?>FR4M/OJ3@$/M3DA]KQ&O$Q$]EO9FLN!N_KW44!9.&G$DH25*.%@;`F!Y2
MOS4F1E?5?7:&V6@[<MVIMJ0D87CXSBK*4^*X=G`3Y*?SE"8GRA_:%>U$G0ZU
M(1VA>*:PK5&5J0CR2!]IA-#D6O5Y&WXB&D5&;+8P)+9IC32WD_9,,$DM,K=P
MOO\`<J=[+.S-E50A=_WM:;4H&1IS.RZ&21)@S%N<MD@$@2E.AF_>T)]NE=;N
M.[K#J$*$RZ)6VB\$JFY@-@">P%*2DF9P-\3[2+VE<C682YGZ<XAUNK3U2JUV
M$EY_UIM9;KMT;'56SGXB-V3)V#+<@Z6RUE30CK;*WF_$4A+B%*K<[)^SA#[U
M*B^KX74(<6V0DT_E(G:$RP$X)$X2)R,IR,6V=8M?':5BM5=%V-TKC2'`I2GO
M)<E8FD.%6&8!D#(XY3$<++S9]IQ:XJ4C#=*<56,U:Z54AUL5C;#'GK)3+"C8
M,5$QTT9?'*R<V8'2TE%926E(X;Z&GG!C'4-)FF[.>S6D>0XB_+V)<:<3A-/@
M2X@M*)2&;0D7))P85"8"D@F+Z[R[0WD.C0UVS0M.R]A()6`E179,THF?&\4$
M!12HRATBO:'>TSE[E9*./I_A\U*U2NU*RRIK^-L^A%`W2=(J\,U'2K&PWV)9
M]JSBN1QBQO$&`-:=:(=;4.3X-ISLK[-VJ1FL5?-\EIQ:T``T]J;:0I4QP$QX
MIM)G(J3(@&TF=#-_:_/UK]"FZKK#S;;:R2IZS)Q12F2K<E>,"E4IA*I@F85*
MN=K>U9]I!I>IQ%UOV@^,,;7YQLIV-,%%V-()(0"=%1A_AN"[96,]D&1FAF7,
M-N+^S<[4]Y*5*QG7;V.=G=[5#E+17_>JGD8YE@8P2,=/LA)(C77OKCKS<=*W
M67C<=`EA6*1=.(@'$[L%0'Y)@$QC9^D%\M?DCXW_``?VC]+'6^]WC5#IF]-W
M3_=XYCVP7[T51=YWE8;93V^?)^;'2+,:2XQ28R%.K2P=5]FDM)6\(2`\K"'=
MK*3A3@1CK2L_V6W%)_4SGJXW^'W55DE35^WJE1VG&!L@\WVP#\(BD]KU^*E.
MZ:$R[COP<;M1'V_;D[_:?#*;X^\6D$1\<W#!/8J^T<.#03);L@-7VE>MGM37
M0CG</#Q_[S'<::4VVG++.47O8+JW):?6"]9*5:/CT^%1$BK^6\LC`5>402"3
M:,X/:Y?1E.Z:+!@Q/8IS`^MQ`X0,0P2&`1T*]M_O5>0E+XZ\4UN1@/HJ->74
M=FJ?CXCQ,+]"@OJVQEX2$\+'E_)-J2+Y/.1O#\OG+758["=7@%@:QWM94JT1
MPC$BJ4K1&;R*MFT?&M>-.UAB#VMWT2";HH9REB>Q3G+ZW%W,4L$I8([)3VXN
M^YQEEB;X]\6)E#`XH;:Y6J[0D2/)AJ.4P&X69MEXIX-.),E"FEK4VXV0XA6%
M(6I.8:[!]76"2SK#>R,)/BN4X$S*9`%,`#XHP@3!`(P@05VMWROR[HH2<&,.
MDX,0)+LR,)P';.W#,GVT^ZF[&':V..O%@6:CX@&$`+"JNS0%B!1BP51V6%A;
M68>21'M1C#0[G?RIAEO+;?<2MS"[I[#KA-.JE5K'>Q9*BH@N,&9,YXZ<B1F2
M1+"3,SD)4CM9O@+MBZ*$*[@=&+%AX6>"6#:B?1?M]N4D*&F/B],<:0A$OF%>
M"S7=I=BRY$TB1D2WEJVRIQ\R0D2W7WW5Y4X\\ZM:\Y4K.<X+GX?-4W56W+[O
M0JD!Y=/B```'\-@````&```#!%T=K]^`2%U47>>Y6'#](+Y:_)'QO^#^T?I8
MZH]WC5#IF]-W3_=XGVP7[T51=YWE8/T@OEK\D?&_X/[1^ECI[O&J'3-Z;NG^
M[P]L%^]%47>=Y6#](+Y:_)'QO^#^T?I8Z>[QJATS>F[I_N\/;!?O15%WG>5C
M8]^,]=_O'4__`$(_QGOWK,_SW^\?W;_FG_@OWY_">N<]5*#G#W_-.8XT_5>?
MY'UG=\GZ$>5/6:LYNU_R7GOYWUGF>5Y'_J^E'__6QH"",D3!(^/$)///)8"!
M!"8=*,,,*=2P,((,PE;Q!)#RTH;;0G*EJSC&,9SGK41^9QAA^J?9IJ9E3E0X
MH)0A(*E*4HR2E*1,J4HD```DDR$;"/9V5&UTOV@?&B(N-8L-3E7;80<W&6:%
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MK!'P$37I$R/6HMNS6'QCC0AFV'$K`A3W7%MY:;2]V7MLU\YU39%,<-[#.S[F
M%1EU^&*7F/9R>QVB*U4K5G1/+@B-MS,B\.A5S>BBXO$8#4Y,AD]J?M$2B0,:
M`M7:ZS%*DG62@G`%XQ)E1@4@]MFO?.J?(IB?89V>\QJ,NYX8?;;[,/V0]4L5
MKK6>/O,^<,J4A&,ENQ)]K':DX,^,8+*N,*/89*"DB:O7Y=)T3).O,,$!R$0=
MWV?+#Y(4]MFOG.J;(IB/89V>\QJ,NYX89[5[.KV*]371F2M8\HS7]DUM=EI>
M`K58$"2HHDY<X2;;*E3Y,**A6JTU139(\TU]B-;ANX<@EP?OK0]MFOG.J;(I
MB?89V?<QJ,NOPQFE4OZOY[+NZU2LW*%I&W\0]MKT+9HG!^S[7''8C9Z-&E0,
M&QY;+18)?E2D>(RZE+C2^U*L8SC..H]MFOG.J;(IB/89V>\QJ,NOPQ(?T=;V
M9WX$[4^=NQ_K>GMMU[YU39%,/89V>\PJ,NOPP?HZWLSOP)VI\[=C_6]/;;KW
MSJFR*8>PSL]YA49=?A@_1UO9G?@3M3YV['^MZ>VW7OG5-D4P]AG9[S"HRZ_#
M!^CK>S._`G:GSMV/];T]MNO?.J;(IA[#.SWF%1EU^&#]'6]F=^!.U/G;L?ZW
MI[;=>^=4V13#V&=GO,*C+K\,5_MKV"'L]*=4HJ1A*WMII\O9FCZJ\A_;UH?8
MS$7'<FO:5,-I94K"$O8@IEU+"_U6'$H6GW4)ZS+N[8==*JI<0Z]32##Z_J4S
MFAEQ:?\`U)$]L3&S%FM[&=1V&$%JGJA-YE/\PY*2G6T'9VC@VI#:BU4?U?3V
M=3?ENY!;J1Y)EH</N;LMZ?*#L'(E&6!NQS'@,LR;:2$I3V)2^G#F,=_&,]:\
M]L^NQM3=I,)F?U",)E+#\6#X,$9H[%=1A9DQ5X!(?Q#N`3G(8=O#\.'''#/]
M7O\`9RJ8>%57MS9&)[_F!\[IMN6"/%<:><\9K*_#=\1UE"E=[&>U2$YS[N,=
M3[9]=YA7"TMH8CP",$0>Q344I4@L5=@XQG#LC/',3@;_`*O=[.5I2%M5W<S:
MVLDY:6WNFVH4WDQ6%F90I*\91DM>,9<[/[IG':KMZ'MGUW,P7:61E^P1L8N]
ML;4!V*:B@@BGJP1/_6'=G'L[.SM[,8V/^R)]E(((AYNA<CBF203B&F8G;ALN
MHR"@Y38E;L4E'MPUC.1,Q%810GU&J$R_AD:6CT]F5E9;1/MHUXG]=2X^(1\,
M1[%-1)$9O52(E_,.8I2ECQ2F/@@=]DC[+',1&3V=<<J28^1-LH#&&]AVYV2$
M14&HV?D#"XM4@DQB.3*6'[!Q"5X23EQ]>$-=][`=LVNXQ.TF01M2_()?!@B3
MV*ZC'"6*OTAW;GM[9G\.''$=)]FE[(`SQFTQ')R7-?$A)]49ZQKPF1)'LIF%
MQYY`TL8'D5]XT;"U8*RR\IW#?<PMQUC#E*>V775/DN4@D)?4(^"7>P14KL7U
M'4#;9K""9X:ETX9SGY6WA^&+3UY[&3V5VQ+/*U2HUWD2W)5F,42:[);'V%7Q
M!PS/1#C3,>_)M">=;.:-9<SY?"V\8;QXF4Y[F,R>V;78SF[2&?\`<(B!V*ZC
M)D4L58($A_$.X`93EAV9#O1<CG]7R]G0[E*G8'=#BD)[B<N;KMR\I1VHSW$Y
M4O.<)[6T^YCW/L<?]'4#MGUV&)VDR"('L6U&.$LU9/\`4.^&.C/]7H]F_E.$
M9K&X<HPC+>$YW+:N[AM2D+4C">WLPC*VDYSC]3M3C/\`8QU5[:=>,?#4L_\`
M0(BGV)ZB2EFU5+^H<\,5WMGV#7L_JC4(PR&A-Q-K-V5INJD,D;DMA`JX>^[I
MH]5LC7EEN>%XI499"U)7V=J"%X=]U6.LV[NU_7*IJ7$NN4L@P\L280#:;8<6
MG#W"D?%@C&KNQS4IBG06V:N1>:21G#LI+>0E6">R%'X\..+03_5^?9W)\?NP
MV[4^:2(@KN[NN./,H`&>#!0_V._LR0A"7&FL*[<-MN*2GL2K.,Z_VRZZF4W*
M3!.7ZA&"9F>^0"=LB,T=C&I`M2:K!.4_XEW#($">'#($@;0)ECBN+/["GV:D
M!)1515KWD+/$3QU:%]'Q.W)K(38TC)%QK,J[B:EH@:4"JP[!)L@@'SID<`C+
MJF,8>9P]4.VC7<*"P]2VQ/#P")X<>'N[.W%![%-1%(+:J>J+9E@SAR1EBP3E
M@G@VHQY;]E'['5DA@.<UOR2K)),3(SK*YJXV;$2[$QA#S;QS-FCBY"K/L$#M
MMNCY0:K)#A0X:,9D'D!YN>VS7SG5-D4Q9]AG9[S"HRZ_#'>/[)_V-A(<I(MT
M;D5F/BY&&C//MVJ[G"F/SJJXV`Z.J*;D'F1,O6L+&7"$,]K;F7D86QCQ.GML
MU\YU39%,/89V>\PJ,NOPQ.@/8H^RMDAX,P'3O)$L"P`44T(X/8$H6..J^6DV
MJBARK8\LX="%P1,:0_(8,980AIG++*GS5($4]MFOG.J;(IA[#.SWF%1EU^&(
M,KV3'L>QF:V1+:\WY`L6BM2EHCE2^TULKP#$VTNH.L.I&L):7"3C1,OA994Z
MR<.I/@../*PSE[;-?.=4V13#V&=GO,*C+K\,.2_9&>QQ2(B0Q3>0+D<\6*&-
M(LVV]NA%.E]B6_`(;'RA64.X6AQ&>QQ'A+7E.&T]_I[;-?.=4V13#V&=GO,*
MC+K\,.4+[''V1-@L,U`15&W:7B%BBY%R5:VI*+BI!^-.E@9.+A3,'^#/&BYB
M^\CR*B6R,.8PVI2DJQA[;-?.=4V13#V&=GO,*C+K\,-]@]CU[)ZN9OR3-+\G
MGG->U>0MLBP)?#G"Y>/!LA-9:$@H]<\W)/2LH2+EX5DID3"FEI0XILCO,)>V
MS7SG5-D4P]AG9[S&HR[GAAEG?9/^Q[K[Q`)VL>2BY@`26)EX,:[3CTE#NPN7
M6CP#L^DT@*.;/9R(E++[R5E]C2595G&,O;9KWSJFR*8>PSL]YA49=?ABQM<^
MQ3]DIM*PG5RJT#D"DN/C7I,EZ?M>Q*NRVPTS6BFDK:L,=&EMNG@VP-\9&6^^
MZSE:\X2G",K>VS7OG5-D4P]AG9[S"HRZ_#%V?HZWLSOP)VI\[=C_`%O4>VW7
MOG5-D4P]AG9[S"HRZ_#%%_BLZC^]\S_Z9_XK/W;+_P#*/[W_`*GW9_AW]UZV
MOK%>?GH_QS._)'UVW^C]'%%/JI<_%+_P/,?*/\OYOZ7TL<?_UZKTP%D_;6MV
M/'"'PW<Z\:M<A)1<0.MN-DAY%T=,A-'1D2R66V+EH?!!##;A"T(RM/>[<:B/
MS@ZC,E_7+5=`<;3*N97-:VVTR0M*R+;JT-A2@FR@+6E*EE*2H3G&RKC@*-&>
MUIU)!Q[BLP\!>Q(F%%R!&0[<?'-:X.(P$W"0IAL1".)+)=<?%84A+93CN5MM
M.Y6VFIN5M$L5H?ECV@[-6FZ7\86J-!3J.94U<&VDV6VPA`H5JLAII2FVC:4I
M2VT$!+BEVDI65)'J?WW$^G3M&17I.7A_-[K$QZ2@C?1\J-X6L=H/]HAGAO>#
MEWPNXO['/>;4K']GKK;H<X)-ZKL)5*E.!0F/K&L8C[%WDCA%7:BVI,Z@809'
MZMS9BF]LVJ,U%:XVNRA'+>U`&5,VREV2AXDK1%1I:;!$PD16GW`XI+:IN9&?
MD3DM^(G+0D4XK.,J<:QG'S_[%3[CYXO9E]K>W7S12U@Y#B15<I5ECZYR]+'N
M+4D^Y&RTL=!S582$%3ST#3P&*W)X(D&A;00HMN,7(MCOQ3P+3A$J5&1YTY_]
MBI]Q\\,R^UO[KYH?S-X0L7L>1H\J-RY#A(NRR$$9?L/3K\$..-19"W1QCP":
MLF:0?-R4=B*'!\'+_F#`E*SCS2$8C/\`[%3[CYX9E]K>W7S17%QY1:IAIQT=
M8'+.2N\13X>^4IJ5!E@3CJ!<*5KFU2\\$^FK2MEBDQKUU'A)4,0`LEJ;%0&\
MA+CX^%,_^Q4^X^>&9?:WMU\T;&/5#_O0W!\-?]&=,_\`L5/N/GAF7VM[=?-!
MZH?]Z&X/AK_HSIG_`-BI]Q\\,R^UO;KYH/5#_O0W!\-?]&=,_P#L5/N/GAF7
MVM[=?-!ZH?\`>AN#X:_Z,Z9_]BI]Q\\,R^UO;KYH/5#_`+T-P?#7_1G3/_L5
M/N/GAF7VM[=?-!ZH?]Z&X/AK_HSIG_V*GW'SPS+[6]NOFBE]]:H\O1X)SUE;
M9?[VZ.-['<)N/BMI\UR(U:-XR4^CD]CX_C>(TK_Y'4I5[O9V=;2YZZ=6\,S8
M'\+4XD;5,Z=OO]R-?>5'*G;_`(I[^88_._OV^Y%T>J'_`'H;@^&O^C.M7G_V
M*GW'SQL,R^UO;KYH/5#_`+T-P?#7_1G3/_L5/N/GAF7VM[=?-!ZH?]Z&X/AK
M_HSIG_V*GW'SPS+[6]NOFB@9J;;@WWF""N3Q#C#A"LB!6(<J2(!C9O8\1.'Q
MX3(JT23<.S0&BUI9=7E8\T#E';E[':S_`.Q4^X^>&9_:WMU\T-I=N&8CXZ69
M<Y4OB2!]H#\EF4(38AV:S'PA#DH[!,1)3BHPLZ:2QAU+N<I2WES&%>ZC$Y]]
MCI]Q\\,S^UO[KYHCGK$U@#*V,:"F>3!EJ<:J$Q.A1:V&I,SWSA9"K\C8'AQ5
M%-K%B8G"7$DI4:V*PEMAEY?A,JC/_L5/N/GAF?VM[=?-%OTIN%ODX9"15SY'
M1JP07S7R;-*EUU#GA*B>XV*+(QC1S^'6I="\.9;2WV)SC&59[>ZS_P"Q4^X^
M>&9_:WMU\T6IZH?]Z&X/AK_HSIG_`-BI]Q\\,R^UO;KYH/5#_O0W!\-?]&=,
M_P#L5/N/GAF7VM[=?-%-;WU1Y>D0;GK*VR_WMS<<F.X1<?%;3YKD+J\;QDI]
M')['Q_%\1I7_`,CJ4J]WL[.MI<]=.K>&9L#^%J?S-JF=[O?[D:^\Z.5,W_%/
M?S#'YW]^WW(N7U0_[T-P?#7_`$9UJ\_^Q4^X^>-AF7VM[=?-$&GZLJ&GHNNB
MW#?,J?(O0F?&9M;[$8@"4EG8XX@>35"N!E&5\0=PXP?O(RT&A.5+PX\,V^S_
M`.Q4^X^>&9?:W]U\T4$7L"AE1KF;Z3R8AXL49BR^8L)8IU:4B'EB3HF5#FR@
MT01;[+L4&6&MEU;N#B!AV\>=6.V[.?\`V*GW'SPS/[6]NOFB1AW^J&JE%-S?
M+!H4"3CXD8U]1F!))Z0]`I0<T4R"^*##MO6,=O+Q3C#G:T0O+6&6DNNL^^Q4
M^X^>(S/[6_NOFB71:D2T7#S(<YR*?"F8VBG-,CVKQI$%RZ6IVL.C28N8ML<-
M5<P,\8;VOJ=:'84E;:'E--.,_P#L5/N/GB<S^UO[KYHKPJ_1@^(5R8-Y$1\#
M*5.P62>+D[L"P3$C15E/JS0:(DB-3B41,*CGC&7%NC(=C^XIO#KJ\,=,^^Q4
M^X^>(S/[6_NOFA[7>Z>V/@W-BY8/!.DCCC$C#3CF'/,=C:<N(>AALI<;(;=P
MM+?BX;:1AQ>4X5V8C/\`[%3[CYXG,_M;VZ^:'4">@Y*T3-<%M'(U;</"O229
M+WS#)8EI`(V3%D(.#RXP@6:-90`A;61'W\$>.G",>YVYG/OL5/N/GAF?VM[=
M?-##9K?Z`#OS[#?*>1(I55D+,()F<='=M+@E@(@`XB(:8ASSL2$LMI#[#>6%
M/^$ZE*FL._L?49_]BI]Q\\,R^UO;KYH0S>QX>#RT(\OEL3,)%F7)&,"*)-3&
M%0;2$F,/R`,<4&ZSY]S##2V\J=+7WL"M$.(<;0S_`.Q4^X^>&9?:WMU\T6+0
MWX784VJ&BK7R8BL8AB9G!=I.D*UEIL9V$2D<Z/EHD:3C29(>P,O!-OM(<(;9
M(SE*,-8RXS_[%3[CYX9E]K>W7S1;_JA_WH;@^&O^C.F?_8J?<?/#,OM;VZ^:
M-17H+_OB=_H>^@ONA_\`WC^X_=W^$?\`[O7DGA?[M'^(6L7R?H]R.(X+^]7_
M`"5G'_ZOTN['_]"C]>O.#7ZCD,NACO,7"M/-/R$F5"`,N-302T.G3(+;IL2&
MVI.,NE,I4Z.C&5HQE2<8ZU&+#'YL=6EK:UCN!QM:$K36L$%:U-(!#J2"MU`*
MVTC\Y:05($U)$P(VJ\>V#U>U?T;-21M7**L]H$F5CU6R6JU!Q>&*1.P&`#92
M[0M?LWI!68/)'ADBHPD=]I365,J;SU4V05MRQ3'^:/;CL[;J3^+W46OJWZ5;
MU74\*0P^_4);E2/,V%.5+3+]O]5;LK;$D+04$H*3'J7WE&#3$IHF-+<D&1R=
MUBX<<BI:5@CTX;U?M)Y/EY6$-CY03.5MXPK+3R,J1VI5VI5G&>LNE:FT7LM(
M!(I3C`4/K&MA0(/QB/L)>*`M=VI43(U&P2#]6YL@@_+%5;@M8VIK-'Q0NF>5
MNU(%^JD3DA/:HN^V+.2%-NV**AX6LL1I-]B@32"HM<G)&/*/8\@/'M(\-YTX
M=/6+G[_F,Y%G>1DYFUY[N5<WT52C>)R0-=S!7%KFF/'7,HH&>$1;=T&66D$J
M8IV(QV5@A+0ZTN+4=:"$G%O%!M!CQ)+C7FEXPSU.?/\`F,9%G>1&:->>[E7-
M]"AK;%P\:G^9XN<H$"6FAQ%I+?&VSO%\BLV4NJ3<]+4&=")=`4+,1,A&CLH(
M4M(Q`Y7=[6Y5*(=UGSWF,Y%G>0S1KSW<HYOH<]*;E@MW[%S4HG3?*&H5L2`F
MG):_7F^;IB8D*XP$RJ*E*:P^'99.`>4.II2E+>E13\.=U.0,)SEQ,9^_YC.1
M:WD3F;7GNY1S?QF/ZKJU]\]B_._MKX[=,_?XMG(L[R(S1KSW<HYOX/5=6OOG
ML7YW]M?';IG[_%LY%G>0S1KSW<HYOX/5=6OOGL7YW]M?';IG[_%LY%G>0S1K
MSW<HYOX/5=6OOGL7YW]M?';IG[_%LY%G>0S1KSW<HYOX/5=6OOGL7YW]M?';
MIG[_`!;.19WD,T:\]W*.;^#U75K[Y[%^=_;7QVZ9^_Q;.19WD,T:\]W*.;^*
M6WYK6NCT:"<1(W]2E;JXV,YP]M?:1*.X3R*U8.YG#9%R=;2ZEMW.6W,8PMI>
M,+1E*TI5C:7/7/*JW@4,_P`K5?LFABIG3L(_\<1P1@7E2-"G;-IS^88_:.<>
MW]*+I]5U:^^>Q?G?VU\=NM7G[_%LY%G>1GYHUY[N4<W\'JNK7WSV+\[^VOCM
MTS]_BV<BSO(9HUY[N4<W\'JNK7WSV+\[^VOCMTS]_BV<BSO(9HUY[N4<W\8_
M3<SF"<=9<U9R"EGF,FN*8K^T]S'N'BP\QL:.F5PCI5@C@3C,`TH`R/&?>$<D
MVI\7PNQ*5KRS]_S&<BSO(9HUY[N4<W\-[EKPJ-CI4;3G)A"#S[4,N"E-F;7"
MN`8-;CX9UF7>@@KI+"N@R\I*Y99RT8O.6&>^CQ'UI$ZG/G_,8R+.\AFC6'QG
M<HYOHB_KAJKQ!\;&:/YGE3X,;6)8^*78MCX4"W:4I4&S*E1FVI=(9X8B<+(9
MRE;J$X[,)5W5]R,^?\QG(L[R&9M>>[E'-]%MT,B!O=BDX3WB\DJ6+&`K*3-7
M^_[/KH<R[CT3G#$",WLF1/*2PB3_`&=9#8F$.([C>'<^)EIGS_F,9%G>0S1K
MSG<HYOXM[U75K[Y[%^=_;7QVZ9^_Q;.19WD,T:\]W*.;^#U75K[Y[%^=_;7Q
MVZ9^_P`6SD6=Y#-&O/=RCF_BF-]:UKK%'@EHD;^I2MS\<&<X>VQM,A'<(Y#Z
MN'<SALBY.MI=2V[G+;F,86TO&%HRE:4JQM+GKGC5O`H9_E:G]DT,5,Z=A'_C
MB."-?>=(T*9OQG/YAC]HYQ[?THN?U75K[Y[%^=_;7QVZU>?O\6SD6=Y&PS1K
MSW<HYOXA,_6XN+G(N!C83<4T_(/PN7)-K:^WV*^,`=*.AR[KDRW;C!AY&`C!
MW#ECE8%;*:PAEEY1+K;*F?O^8SD6=Y#-&O/=RCF^B@%;4A8QMMRVZ7Y5QP.8
MQV8=L$-?MH354990<2B.;3*2VP*N>^;),8$RPRV$I[S3ZF^YX:&WWYSY_P`Q
MG(L[R&:->>[E'-_#D-LB)(9DB<:(YHMMBR,5'Q[3UBV6*3((D_>XC,D[@[:H
M@4?&@NV+O/N+(4II@(I:DI4SE&6?/^8QD6=Y#-&O/=RCF^B>1JVI>*A)<"A;
MP\"6!HY9(QFX-LBG1#EJM+U>F!2V??6ZP^[4PPGC2?!=<[&<L9>P,R]E]N,^
M?\QC(L[R&:->>[E'-_$`?V`/'9@RI33?)I,0?5YFQ3147L7<ATA67(VTG5P`
M"2BCK-#Y3B=#!5)#K<>9=2%A2G&4=B>_.?/G\QC(L[R&:-><[E7-]#DN_P!<
M0,@W&F>:+XSI`S+6!Y/;7F\8)SW/$(CB=GBG-)96VYES*6W$);2E65=KB$YC
M/G_,8R+.\AFC7G.Y1S?PYQ5GA).R3D0K6W)J-BXJ%,D`)24O6X!#+'(QATR/
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M1C>6\+&<QTSY_P`QG(L[R&:->>[E'-]%T>JZM??/8OSO[:^.W3/W^+9R+.\A
MFC7GNY1S?QIW]#B?WZ5_HC>A_N[-_O3^_?=#[J_P[]_?X7KR7PJMI/\`B%KR
M4X^]B^CY/<CA^#3MJ_DY>4K%W\?TO*[L?__1JC3KT*-M;79-AS(8B1[A`OD9
MBPH^2,\9F08<![(^5-C8\X;,@EKQV72&,.,=].'$9SA6-03($Q^;_4E=`WK?
MJTY>1=S--:R3P:4+5,+!1XCBD(4FW9MI*TS1:`4#(QLZT%)-2GM>-7OB^*V`
MG8`N``7'P7FXME_6QAQ,<.B,E)D$5IF2+?5EE!"EH=6OQL)?RZG%34K39`D)
MC\L>U/9_4IJOQE:L+:)%.+P%A,TD(!H5J*$A"W$I`6I1*0LD**K<G+0'J1W[
M!A60S1L)(OS`P9VZQ$OO0%AGZI+HPSK':!*/)V"KR<//1RLN,XPO(Y+67&\J
M0KM0I2<]=<[RV!>KJ`DJ%*?*2E8^L:&%*PI)^,';QQ]@KT90^;N:65!)J!Y*
ME(/U;AP*04J'Q$3&#%%';AC3]:64&/JVE^4>VJPY5GI63L=,Y0;S26#9B+!'
M1T+518([9J'9%),"S+2)AV'VV@,B"#J2M<@VINWIBKXFE]&IN2B=$4G'57I-
M3RL5>/8-A%P<&<SQ:Y3"S4S5;M+YBICEER'!``M%9K=9L$/3C)0"SS,B#B?=
MD90+$D;'!CJ,BTMA(/64VA+2]7Q5+Z-3<E#0])QU5Z34\K$`D[]R";L%J@('
M@UR6EL1.S7:169H_G+O^!@;/6U60N'`OQ$B48^F#B"XEE$DYA*3&16%90X_A
MS*$+:7J^*I?1J;DH:(I..JO2:GE8G+5].*W+*:F$X\<MW0JULR!I5EO3?)/D
M.5`L5FVV28B:S?XML:]N9)@W8.+5+R"BW0FHT1EY*G''78M$HTO5\52^C4W)
M1.AZ3CJKTFIY6,Y/4-1_OYN?\H_D/]*/4:8J^)I?1J;DHC1%)QM5Z34\K!ZA
MJ/\`?S<_Y1_(?Z4>FF*OB:7T:FY*&B*3C:KTFIY6#U#4?[^;G_*/Y#_2CTTQ
M5\32^C4W)0T12<;5>DU/*P>H:C_?S<_Y1_(?Z4>FF*OB:7T:FY*&B*3C:KTF
MIY6#U#4?[^;G_*/Y#_2CTTQ5\32^C4W)0T12<;5>DU/*P>H:C_?S<_Y1_(?Z
M4>FF*OB:7T:FY*&B*3C:KTFIY6*8WSH^F"4>"=:FMOK4K=''`;."N0F_#6L-
MF\A]7!O*2R9LLAE!"&7U9:=PG#K#N$NM*0XA"T[2Z+VJE5;P+5-+-:DX*:G&
M*F=.PUWQB(P&8)$8%Y732IIVR':G^88_UFH.-]L;+O\`X8QABY_4-1_OYN?\
MH_D/]*/6KTQ5\32^C4W)1GZ(I.-JO2:GE8/4-1_OYN?\H_D/]*/33%7Q-+Z-
M3<E#1%)QM5Z34\K!ZAJ/]_-S_E'\A_I1Z:8J^)I?1J;DH:(I.-JO2:GE8QJC
M!7"AK.7(:JY+1P\+-C14)EKD3RQ-)M(AS%K0'-"1STK&R4?'+EH,(9WQFO$$
M1(X))2R*AMXB=,5?%4OHU-R4-$4G'57I-3RL()(2R@KG$)TGR.=S"P;I+*L<
MJ.0CS<Y8466C0;</%O@WLT;R;P5DD#$$]]SO,Q:\]S"<Y4EIBKG]52^C4W)0
MT12<=5>DU/*QTS"IJ+:\NSHOD](S(IP0$FP)R<Y*O0J'7&@,2#T1.B6<Q,R&
M*80XEE]+#8[[6&W%.,YR4@-I>KXJE]&IN2AHBDXVJ])J>5BP=>UB.NMIG:_,
MZ_Y/Z_!AQ/,BSUJY&;\2!/+7B+4AB*6!M4EE;C&#G$OX4YCNK9SX?B)[RDM,
M5?%4OHU-R4-$4G'57I-3RL73ZAJ/]_-S_E'\A_I1ZC3%7Q-+Z-3<E#1%)QM5
MZ34\K!ZAJ/\`?S<_Y1_(?Z4>FF*OB:7T:FY*&B*3C:KTFIY6*:WOH^EB4B#=
M:FMOJ4O<O',;.">0F_36\-F\A-8!O*2R9LM]I!"&7U9:=PG#K#N$NM*0XA"T
M[2Z+VJE5;H+5-_*U)P4U.,5,Z=AK%MC$1@,P2(P+RNFE33MD.U/\PQ_K-0<;
M[8V7?_#&,,7+ZAJ/]_-S_E'\A_I1ZU>F*OB:7T:FY*,_1%)QM5Z34\K%=VS7
M$-7YRNQ45!;_`+$%,2L$!(3`O)/D<D2,&F))T(TY&`K_`"R>[7!6/-F^?7&,
M*9=:2,\0[EUMF=,5?%4OHU-R4-$4G&U7I-3RL4"1/&0RP\V31'*L&.?BBY5^
MQQG)?D3*P3&&91L>/CDM>_@2S8F9L`AI`PCT8P]Z4>2RYA`*'Y1AI>KXJE]&
MIN2AHBDXVJ])J>5A4%*R+\9)R1?'WEZQY21@0Q!A>1G(9TPD66]ZZ#I-T28O
M]>(;8AUV%YQ:6DOY\O'OY<4P^E;#;2]7Q5+Z-3<E#1%)QU5Z34\K$[CH%<F]
M#-#:PY)>%(PFOI*1*+Y.<AHIJOGVBVR<#;8B1Q*7T7!CU,AX])Z51ZSL%Y>0
ME[`0JFSG&F*OB:7T:FY*&B*3CJKTFIY6(8Z:3'CUXJ8TWR@&;EJT?/2C47R&
MY7SCD$0)<"X$2+-6/,CY9(F*^,F4820V,ZUAS#9;8S.%%):7J^*I?1J;DH@W
M12C]K5>DU/*P[*<:\JT<WI/F$Z,^6(.RCU_<@6C\-O\`V)#Q,8]L]!HF`U(6
MI65H\)3>$YPOOK2WEIBKXJE]&IN2B=$4O&U7I-3RL+*T$B;FY>//UGR9AH\*
M+,(C)0GD'RG;8GI2.EI<5P./1(6B,-&%DXP-A\1V0'`RIUW*%I2C*'E#>]7Q
M5+Z-3<E#1%)QM5Z34\K"6P1L]$YOR`=,\B99VK5<Z<K30W*WD;E=SED68F&B
MZT.\BU.181TA%LMF.K9*.P-EWN]UQC&"E-,5?%4OHU-R4-$4G&U7I-3RL1R>
M/L$245'@<?>4\R;'C2JS'A.3?);$,Z9&N/#-"P\OBQNMR[<D8UA##J6VTK;7
MA_/8QVN]-,5?%4OHU-R4-$4G'57I-3RL67K>NAWJR2D--ZVY3:X``!=,9E+E
MR.W<E)/:+5BP!T9A=Q2P2RCTSY2%(;?<0,Y%NH4M3N7&QVF*OBJ7T:FY*&B*
M3CJKTFIY6+P]0U'^_FY_RC^0_P!*/4:8J^)I?1J;DH:(I.-JO2:GE8U'^]J.
M_P"TS_\`0[][7\Z[3]SO^T_=C[O_`/>WW4_A'7D;.'/-1_B-OR$8]KR?)^AY
M'T8XW-F_.<_D;'EKQ;?E>5]/R_I1_]*E-;>-C8M!\OYOS'OUJW@>CQB33_&]
M.`>%Y(,(R.,++[_9X;31##KB^Q*7$*SA6-0<1C\VFJUOUGU<X.WPF?T\K"5*
M7/A42LI2I"E*GY*4K0HF0"DG"-IO'WPG?:V:?-1($R#TA<HXLS)D*S7WQ3,:
MV.$=%Q%#3,\(.'W14NBJ9(\!P1UI;2&FU);3+)FILRV1_FCVT[/+"OQB:G/I
MJ5.K<K$J5::#)2K,5I*>##KJ0F20INRNP6U(*$H00D>I#?U>AK49HV`L(#,I
M#R&ZPTF@/Y<2T0EC66T"F<+RRMMS&$$,(5CL5CW4]=?<[SM.+U>964NII3(_
M^XT(^P=YLMOF[FG46FS4"8_]MPQ1VWJ!FCVF.$USQ`$VU5%5,PZ5DP;J#63&
M[:188@2'A!$RTLX]Y,>MC2Q9CWE7$9?R"RE;?B.*Q;TW>G/5?)X(JT1=O-4_
M+X8HZ<B]S^!JHFL^S_@''K(Y/YV;%36Q(]#-$R/%TXJ!#C+`/9VB9Q+\K)RH
MA!BHAA*O))=:8\//V;3=Z<]5\G@B=$7;S5/R^&%-=JF\7J_79JR<)M;L2,M)
MS*96KQUVDVY6"BAIRKQ]=P:8_.%QF3[(R],>(MEQ]F+&9%-([<+=#2TW>G/5
M=X>"&B+MYJGY?##]5P9J?V_#Z_E.$!]8IH$L>%<]DD%%GPCC)(3#U;5`Y*GJ
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MNJ[DT[9%*F><,;>R^WW8N?\`%STE\GL-^VR7V]UK--WKSU7R>",_1%V\U3\O
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M&[-$CA`B'F39B67)+D"$KB<CI9<ASR8UAMQDYW[')"WLN,+QE",)[5M-7ISU
M7>'@AHB[N:)^7PQ:WXN>DOD]AOVV2^WNFF[UYZKY/!#1%V\U3\OA@_%STE\G
ML-^VR7V]TTW>O/5?)X(:(NWFJ?E\,4UO;C[IH.DP;PM"B&7%[EXZ"*6EV1[<
MCG\@]8`EM9[QN<=U\0A:,_V>Q6>SW>MG=%\WFJK="JQ1&:U)V,8IG2-C;$8%
MY73=R:=LBE3/.&-O9?;&W%R_BYZ2^3V&_;9+[>ZUFF[UYZKY/!&?HB[>:I^7
MPQ`['HNCL3T/$US35??CB"H5^2L1Y)SX"`%RCK=CCDBL3P1T?(!P;.7QBEI?
M9=)=:8PRO"GG1VF[TYZKY/!#1%V\T3\OABC/0#<,&Z99.&A1@_D<F"%U>4E9
M-1BWI$MH(/T$'B6LP1C@KP33B2!6DL/N./.*0&V^^,TU>G/5?)X(:(N[FB>^
M?##T%5(XI<D\]PUD0P6Y.,!C%/65C)+@!681)<Y(#I-\VT@;TP\K(@S!*T-1
MSF<NY<=PRU.FKTYZKO#P0T1=W-$]\^&)5%:EAY`&(DGN/,"*J1C:,X?"OG28
MI<%)2UL)C+FT3(F3+'GFZ]6ALEH0T%C"GUM)0Z^TYEUN--WISU7R>"&B+MYH
MGY?#%>O4TH#$`<=Q7B71?>G.R]CB(_%M,EB9L>T&Q$!&Q)T>3)A169&O!IDU
ML/M&/I40V.O+/8I_$B^KTYZKY/!#1%W<T3WSX8?%U*-0/@Q'#*6)9?*';:%]
M]$6)(#,NH\-[QF<S96'_`"SK*W5.*\LG+3K:$)6O&<JC35Z<]5\G@AHB[N:)
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M,SS<D0,>AR!7&QKJH61,B2WY,26*RORI3Z`W8U:'%JR\CNM-WISU7R>"(T1=
MW-$_+X8M[\7/27R>PW[;)?;W33=Z\]5\G@AHB[>:I^7PQJ2]ZM>^]8_]#KWJ
M_P!L[_-[[U_W3][_`/Q_M_\`X]>1<X>XP_XC;_\`-MQQF;L<6/Y*Q_Y=J/_3
MHR@Y>3>J6H=L5U_%LKN6&S67B0W'O2X?A(+''/BWR!E+[,+0@D=2T]N,.MYS
MWL:@XC'YL-7"L:PW$6DH+F>,R"P2DGA$RM!*VR4SQ@+02,`6G&-E'$6%)@/:
MC:/BY&>;L4L/=&<RIHU>A*P$.2NA2JAHP&(KTM,10XT=%Y':[J'$+;6E3;C:
M7$*[:FO*;EBF/RQ[/]CU"[=OXK]1J2IO%-56)K/UBDLM,(2K,W++:&V7'&PE
M#=A.`@@@I4D*28]7N_ZW7;<7HVNVN!A;/7Y+=8:9&"L,6#-0YZ1]9;0+82;&
M23!(126"QVW486A7=<0E6.S.,9QUUSOO4PO5ZG>4V\FE,E))2H?K&A@(D1@P
M1]G+S::?5=S3S:5MFH$PH`@_JW,8."*,V[IO%5M,;ZH>"G&O:]/35"G9=F4C
M-8Z^FGKD78X9F,8`EY&NRPP<)"U064?,PY&$.&FE`-,NL-MEKQ;T[??3-5EG
M-]%W1-U=&T^31X(IR4U?NAVI5DZ+]GMQ*BK:7&S+EDA%UW55O$!F!AJ9F)!\
MT[8==L!19KI\\I);#\L\MR.%'<&%;+6:/.G;[Z9J\JYOHC1-U=&4^31X(2U?
M5.]O,;`D[SP+X6B0%977W:A#0=/J#UGOP9UBAW)W(10IMA!B"(&FX/P^@D9+
MBI7+*0T'LHSX[3M]],U>5<WT-$W5T;3Y-'@BV^.VKP=E$6R9W)P4T7IJKDQ=
M&E-<1CVOM<2T^]Z7BCB+9'6,C+#$SB1ACFQL9;-KM=6.IY3*4F>'DG,:=OOI
MFJRKF^B=$W5T;3Y-'@C)W\6;C?\`5^TC\U-#_D'IIV^^F:K*N;Z(T3=?1M/D
MT>"#\6;C?]7[2/S4T/\`D'IIV^^F:K*N;Z&B;KZ-I\FCP0?BS<;_`*OVD?FI
MH?\`(/33M]],U65<WT-$W7T;3Y-'@@_%FXW_`%?M(_-30_Y!Z:=OOIFJRKF^
MAHFZ^C:?)H\$'XLW&_ZOVD?FIH?\@]-.WWTS595S?0T3=?1M/DT>"#\6;C?]
M7[2/S4T/^0>FG;[Z9JLJYOH:)NOHVGR:/!%,[XXY<>P:1!/A:(TT&\O<_'$1
M;PNKZ0.ZH20Y#:N`/%4XS!H6H<T$EQEY&<]UQEQ2%8RE6<9VET7W?*ZMT+O>
MJ(S6I.%U>,4SI!\K&"`1M&,"\KKNQ-.V1=S`.<,?LT;+[8.Q%S?BS<;_`*OV
MD?FIH?\`(/6KT[??3-5E7-]&?HFZ^C:?)H\$'XLW&_ZOVD?FIH?\@]-.WWTS
M595S?0T3=?1M/DT>"#\6;C?]7[2/S4T/^0>FG;[Z9JLJYOH:)NOHVGR:/!%`
M3>C!`''D0W#CC18/!60\.I=#UW"#2;$;,[(0L)93WI`F%.LD#&UA83N136!'
MY$OS/;X26TSIV^^F:K*N;Z&B;KZ-I\FCP0V.Z8>=C8TUGA#QBCI9\ZT^D:NY
M6=?SB!8J/CX5JMOCV]N&@0'C925*+>4TX"WG++21_P!B[%F9:=OKIFKRKF^A
MHFZ^C:?)H\$1Q=%,+/EX6/\`9N:#8.B1:H^[+%O:V57G")UIPN7!CBSM90"9
MXBN"HPV\L1Q;&2%]SQ$]W[)IV^^F:K*N;Z&B;KZ,I\FCP1;M'T=19R>/'NW"
M_C]0J^R$^N+,8@-<W"3E2TJB,IP:-'4N-"@FFTE$)2C#QRB,M95WF4HQAYIV
M^^F:K*N;Z&B;KZ,I\FCP1;'XLW&_ZOVD?FIH?\@]1IV^^F:K*N;Z&B;KZ-I\
MFCP0?BS<;_J_:1^:FA_R#TT[??3-5E7-]#1-U]&T^31X(IO>W'+CT#28-X+0
M^F1'E[DXZ!K=%U?2!W5B2'(/6`!XJG&H-"E#G`DN,O(SGNNM.*0K&4JSC.SN
MB^[Y75NA=[U1&:U)PNN8Q3.D'RL8(!&T<,8%Y75=@IVRF[F`<X8_9HV7VP=C
M:BY/Q9N-_P!7[2/S4T/^0>M9IV^^F:K*N;Z,_1-U]&T^31X(A,]QWU0W.Q4;
M7>+N@'H9]V)>D[)(:WU\XR(-B45Z?CUQ*(L"19*S!,YR"4UYU"CG6VWF$,X<
M>2T[??3-7E7-]#1-U]&T^31X(H)S7!=?"4=-^S^X\V@)J.R4LJMURB1$P^:5
M(DIC8L6G,U*]&^9P(2*T4MPUL9A3+I*G<-N>`-.G+ZZ9JLJYOH:)NOHRGR:/
M!#R'JHI[$HLGV>/'`/.9..&AF")#5.$-Q;V(!N0DY0P&@2;CJPEGGN^`P-A:
MD`8;3E:GT+Z:=OOIFKRKF^AHFZ^C*?)H\$32*T-5Y&*ACB>)7&Z&/>`I#DU$
MF:ZHQ&1I`RV.A7MH$QD%OQ&8NJ">;%\5E&?$+;[,E*9<'<:=OKIFKRSF^AHF
MZ^C:?)H\$0(G49<8S&23O!KCE.-#U69D;'`1U'UK'23D^S:I`*%!B)E3DV.G
M!%0&;/?&0">KS#B6$O\`>7CNM.WUTS5Y5S?0T5=?1E/DT>"'-W5S21L$,>SJ
MT&^ZX2PCR!$CID(D4=>%(?<<>:I,B&5EE;67,=U;>5)=0G">U*U=-.WWTS5Y
M5S?0T3=?1E/DT>"'(#3T(]99EF2X,Z#CZVS"E+@$LUK5LA)2DZ`5+K3YN4:B
M&H^-CYP)H)MEIT9#@CKKCBG'\8\%#3E]],U65<WT-$W7T93Y-'@AJLFCRQ1;
M]BN<-^+AIP58/)UVX9KZA9CY>V.6(D6(B9KPWQ3L1S<#EEXE_+8*5*[Z\+;S
MGRZ(T[??3-7EG-]#1-U]&4^31X(:Y_5$X"I(4'[/CC',NCC3:7IKQ-7"Q<D9
M&-I:BW18LRHAR<6+92%I='0XLE8["7$D*;<0WX[3M]],U>5<WT-$W5T;3Y-'
M@BQJ%I"H3LXXQ?>%?'>@P7HDHAA\&%U[<I#TDVJ`4$,7D6C0P;*3&Y`]M2&<
MD^"Y&Y4ISN$,]K3M]],U65<WT-$W7T;3Y-'@BX?Q9N-_U?M(_-30_P"0>FG;
M[Z9JLJYOH:)NOHVGR:/!&I3WI53\&:]_0Z]Z7W%C?YJ?@S^]OYO?P+][?_1U
MY%SFHX]?^(V_*/E^=C\KZ6/NQQ6;T_$(_DK'DCR/-Q>3]'%W(__4Q\JQ4@#9
MJX;$#LERH<[$%1@A#CC0Y4@/(#NA#ONM%!.MLO$H2E2DO,JPG.<X6C/V6-1'
MYI[H=J6+VNM^B:2NL14-J;2HD)4L+24I)"DD`JD"0I)E^<,<;$N"0-^$]H_Q
MY?V6X<_;92X.2)Q<G,,ST@:TJI6`,8@N5;/DW#'\M!]W*WGEOJ[O>7G.<][-
M:,#B/TA^6/93L"IM8F/Q-=G2]:E.*OEVK4M2EN!U:AFSR4J4X%K*C),IJ45F
M4U$DS/K1Y+)HRV=+)V4FIJI.=U1_IQ-YQ#YJN48UQLO(/I;$_P!L3E/I/P?"
M\;W/'[G=^S[O787'G4[SS+A,YS4V;$[7UC<Y6<.*<Y;$X^UM[FF`N\U91F^<
M"=N5GZMR4[6#'*4]F,4]P2&J8JP!O:3I/L^;55V:PXB0"N<MJR&FC+@;8(]8
MSPA@KJ!!*_"U:,.;?2MMQ\DZ4$6WG#0I"'+DM:MJ\/WT6K>K7G4/?:BM`K**
MS"U14AJ+V=!UC4P^]<4B673\?!J*S[SQV8^&:=ECI"*$4>5+J\RM^4<:C&4E
M99>,;:B39EK3_O#]]"WJUYU#WVH<=JVVIU4^'=U[J?V?%\C)2W+@2A\2>LP7
MH.%FF-4I@I\LEPI+LD#7Y@^VL2I'@`YS'""G-"^,G$<8EK3_`+P_?0MZM>?0
M]]J+STP1Q?E-;5XW=-:X85G9;CDZU8HB$+T?(QC;8MCEQ8(X9X!XT4;TQ7&`
MS%B)(+R"X0H=1!"FLON1+6K:O#]]"WJUYU#WVHM'R_`S^\<1?VK37ZWI+6K:
MO#]]"WJWYU#WVH/+\#/[QQ%_:M-?K>DM:MJ\/WT+>K?G4/?:@\OP,_O'$7]J
MTU^MZ2UJVKP_?0MZM^=0]]J#R_`S^\<1?VK37ZWI+6K:O#]]"WJWYU#WVH/+
M\#/[QQ%_:M-?K>DM:MJ\/WT+>K?G4/?:@\OP,_O'$7]JTU^MZ2UJVKP_?0MZ
MM^=0]]J*>WDQP>Q2H3T4SQ3P5ZX>/&'?1[>HO,>C<[_UGB9\3RV/$\CF'\?S
M7;^Q^6\3O_8=[K9W0-9\Z=X05]G-:G'PN/-W98]F<I=V4L,8%XKU<S=NRJBG
MP[&+@L7#-S^3'W(N'R_`S^\<1?VK37ZWK62UJVKP_?1GV]6_.H>^U!Y?@9_>
M.(O[5IK];TEK5M7A^^A;U;\ZA[[4'E^!G]XXB_M6FOUO26M6U>'[Z%O5OSJ'
MOM1C[/E:<8<?9K]9X$'.?N]\(PEO4(L4IN+F=B^7!DFEV14J*79X%%6PPXP@
MEH8E<@I_+:,,HZF6M.U>'[Z%O5OSJ'OM0VY.UAZ)C7L4_P!G]F?4?:E2@.#=
M2LPJ(D<&(;JS8Y:C3#DRAAKI;J\YPMGL:PVOPDK2XE+6G_>'[Z%O5OSJ']U$
M1?MU.,,DHZ,U/P(`4(!47T2DDO3KT<HZ06TY:8L9:;L(X>['"(SX1+2%#M.$
M>[YA8N6"TM:=J\/WT+>K?G4/[J+DH9_'*0L$DQL.E\'J]7V@G'(HJ`D]-RSQ
M)B\Q2FV"E.OI>1EE#I*<JP.A"U-^YGL[N5I:T_[PG_[T+>K?G4/?:BWO+\#/
M[QQ%_:M-?K>HEK5M7A^^A;U;\ZA[[4'E^!G]XXB_M6FOUO26M6U>'[Z%O5OS
MJ'OM14&\!^#V*9"^BF>*>"O6_P`>\.^CV]1>/Z-SOS6F)CQ/+8\3R.8CQ_,]
MO['Y;Q._]AWNMG=(UGSIWA!7V<VJ<?"X\W=ECV9REW92PQ@7DO5W-V[*J*><
M,8N"Q<.W/XI3GW(M_P`OP,_O'$7]JTU^MZUDM:MJ\/WT9]O5OSJ'OM1!K!^*
M?B=B!:S%\(4P#C\.N6E99&IC"TC)E5.609((YD3F/>Q`#X;C7T9D4O'E=I#+
M#(O:6EK5M7A^^A;U:\ZA[[44`]9Z+#CI*.UAP'G!4QCI6?0Q&I/3C\DY)..`
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M%TEK3M7A^^A;U;\ZA[[4.#EAUED5LEC4_`-+SI`B51Y-KTZHD9C/V)REO,.X
M#6E*496WE+BU94K",I[.U:4M:?\`>'[Z%O5OSJ'OM0YPDKI5R<E43=(X/-0?
MH0M$&2RG1@Q#T^,=+J">F`6[K+KC(Z2`\HA>&"9!;2\97V8[V4(2UI_WA^^A
M;U;\ZA[[4-]A-UFVQ?40%3]GP02S69![7F5O:I89)M;MD):B`ILTF7=6N,$K
M/A**>P"-EY[O.MH;SV"8B6M6U>'[Z%O5OSJ'OM1&Y^8K+;BA*]K[V=CWE!9A
M+DL:5J7RLL6PK+$.L`'WU,%@L'KQXJ\O]N66,]Y2%.?N?$RUIVKP_?0MZM^?
M0_NHM/7TCQ]DI\EO9-%X*UB!Q&E/,KKL_J&P.(DE8KBXP!DI\2-?,;;21*)+
M(<$%PIQEA#36$)R^5$M:=J\/WT+>K?G4/?:BYO+\#/[QQ%_:M-?K>DM:MJ\/
MWT+>K?G4/?:C63W=:_\`Z:/_`$(N[^I`?^6O_P"G_4?_`.'[PZ[[^._O?\3^
ME];O_P#U1R,Z#;9_D/H_5<G_`.F/_]6A*9#,6.X52O%.*9%GK+!0Q+J''V5M
M,2DH*"\XAX:,FR6E(;?SG"FPBUISCM2R[GL0K41^:NXZ%N\[[N>[7E%+-15-
M-*()!`<<2@D%*'2)`XPTX1L(6?%.S7A_0(W6WM)N,%:CX27KV<2C4D9%STU)
M3DJAR1KUP?`-*(E=>:P*%Q+P?E#&QLQ:%LM/IP[E+_BLLRT25MDB7C#_`#1[
M3]C6KE+JM^)WLLNNFH7Z;Q[:FWG%NN`K8J2A2E.4="I/"-<&XE'``I2L!9#E
MM"-S'M\:#>]H>SZG*)K2E6W8EWG]M:O;@J;1:Y,6VU32P)$^4.1$UZ`#D)>1
M6'&`O$NX997EMAE;BNQ"%9QYG['ZRCN_71BLKZIMBD13NVEN*"$)FD`34H@"
M9(`F<9`CZM=LE#6WEJ-645W4CC]8M]FRAM)6M4EA1DE(),@"3(8`"8\.GYOC
MGQ]2#E]^35N?XE]>V7KKJ=UKNWTEG?QZ>^H>NW5&\O1GMY!^;XY\?4@Y??DU
M;G^)?3UUU.ZUW;Z2SOX>H>NW5&\O1GMY!^;XY\?4@Y??DU;G^)?3UUU.ZUW;
MZ2SOX>H>NW5&\O1GMY!^;XY\?4@Y??DU;G^)?3UUU.ZUW;Z2SOX>H>NW5&\O
M1GMY!^;XY\?4@Y??DU;G^)?3UUU.ZUW;Z2SOX>H>NW5&\O1GMY!^;XY\?4@Y
M??DU;G^)?3UUU.ZUW;Z2SOX>H>NW5&\O1GMY!^;XY\?4@Y??DU;G^)?3UUU.
MZUW;Z2SOX>H>NW5&\O1GMY!^;XY\?4@Y??DU;G^)?3UUU.ZUW;Z2SOX>H>NW
M5&\O1GMY!^;XY\?4@Y??DU;G^)?3UUU.ZUW;Z2SOX>H>NW5&\O1GMY!^;XY\
M?4@Y??DU;G^)?3UUU.ZUW;Z2SOX>H>NW5&\O1GMY"*0X%\YHEALJ5X8<L(P5
MTZ,C&B9#CKM\)AR2FY(2&AH]MXFGMMK.EI@]@05K&<N$$O-M(PI:TIS6C7'5
M%PE+>M%W*4`3(5+)P)!4HX%X@D$D[`!)P"*5ZC:YM@*7JG>($P,-.Z,)(`'D
M8R2`-LF47]H3@OR`KMGL)7(/V<G.?8%5*IDF!7(VI:$W9"'Q5V=E81Z+G3'F
MH*$R9&B1(YS*V,O9PMPA"N[GN]N-)?6MUSOTS*;DUXNEBI#H*BNH94"B2II&
M%4B24F<M@X8Z#5[4R]Z:JJ%ZQ:A7Q44A9(0EMAY)2Y:20H^1,!(4)3QD8(O#
M/#%:G*$ZS[++VCPS43!`)O8)>F]QRSEIGT0,[&G8'E10:\D`1<W)A2?F!PQ/
M$S%>62(PV8XMG4#6E0-9/M!N,VEG@R'F193:21,&U,V0I,BH^7:M$I`/1JU5
MHCF)1V9W^+"?U@++JK:K)&!04G\XA<[*9V`D)2%DI[Y3AOC)9#D+[*CVC+8G
MIBLX&8E-/[K>RNNL,T:/M>'%"##K'L!B*S+R`CG?>%279G1U-('CPU9AO6A5
ME(=[0[DM65S(>9\K]848_P`T6D)4,!LM`S)6J(=U5H@HECLROZQ;3@4R[Y'Z
ML+PA7E>(M23A%IU0D$H3$>EN%=F?B:2U&>S#]H&++1\E$N7XAO0.\QV;*&-:
MH<Z8][ZS)*=17`Y.I"G@M`NCFDC/G#O>DW,@N>D+K6M327:HN:_W,6BD\&,X
M8-DE"@FU)*;1"RE14"D$)4+`MBQCOZI(6U1!KLXOM+J5I+I%.\+8"TE5B;BK
M(4@*2$D*(*DGA#8/".,YPWDW#06Z_P"RE]H8S#(DCLR:C]3;Q18R8G,%<D1V
M(^11&'0D>?BPG0>7<.QA;>!P"5XRK)*6&Z6=9TA"R]VB7+PMD2D\Q9"K2)S&
M!1%D.2\885)&Q,UOZJLVFTT_9E?G`VC:M-/!9397*RJ:D@VBV#-!\5*C^<$A
M9-<.R7<UO$![*'V@X:&(*&$M2I'3N^RGCIX:WZ]*FI2)4RXVT,Q)4N/LHK;2
MT=UHL\56,8PUEQ%+.LX`J.'[1+F)*U%$GV!))0X$A6##)PM&>RE*MN1N5&JU
M,33YMV8WVE-A(7:9?)*@XT5%/C[+8>$L$E*1W2&.,X2S;9$PN4]F5[1UYHNZ
MQTI$)9T9MM;$12&:G$>E*KD5((11L@=>$'89.<,RL>+6TK*77\*;Q=<UK;LM
M!O7RXYADA4WVIERVJ2]D`!NS-,L*YC`,,6&]46@NH4[V=W])3X4@!AV26@A,
MVY6@22Y:DHJF$$8S,0QYX6[%=#I"W_9=\\VY",F->F7<:*TMO<$.Q1L-#R?K
M%BQCY0"Q/"BW6:<"0)AD8,F*:9??P2]X[8@UU.M-&E56/:!=!0I#@02^P2DJ
M4.#,A9PH3:F25!9(39$BI5I>J:UBC)[-;Z2I+C96$LO"TE*3PJ9J*YAQ5D)`
M2A2`%*MFU8$M-X:26"26XOV5OM#,QRA)X89^5TQO)V80^IBO9K4FM8*`HQ)#
M9+<FDUG(ZV<I6RIO^VRVSC(UH%E)=[0[EX2TDF3[%F4U6QA!.*S9,YXP<4SE
M+U58"BEKLROS@I*$U,O6I^+85@4`#Y5H2(Q$8R!RL7$B/CH^:?Q[+[V@<$@Z
M.A8:MG3NE]V8;#M\M<Q@1QWR')<(4HFSQLB+$1.?"<\E+9R\L.6P6T$&8UD=
M6MD'7^YED**E!+[&%"4$G!9)%@@K7A\9&`*:LE2JG]6*!*7B.S6_$)(`22R]
M@65@8^$D;8(0C!XBIJ*7;80F#;TX0;)GXIQ&@_9I^T!HDQB;K#[#UKT/N>6#
M]!M54X.X`D8=CYU:RB[:V(8`M"6_#'60AQ6<>"A&9=&ME$R].^=>KF=9L+$D
M5#(-JV"@_FX`BTE6$X9$;).NO_4]^IIDIU?[/;[8J;:"2Y3ND60A06,:\:[*
MDX`96@3*0&+OYOCGQ]2#E]^35N?XE]=%ZZZG=:[M])9W\<CZAZ[=4;R]&>WD
M'YOCGQ]2#E]^35N?XE]/774[K7=OI+._AZAZ[=4;R]&>WD'YOCGQ]2#E]^35
MN?XE]/774[K7=OI+._AZAZ[=4;R]&>WD'YOCGQ]2#E]^35N?XE]/774[K7=O
MI+._AZAZ[=4;R]&>WD'YOCGQ]2#E]^35N?XE]/774[K7=OI+._AZAZ[=4;R]
M&>WD'YOCGQ]2#E]^35N?XE]/774[K7=OI+._AZAZ[=4;R]&>WD'YOCGQ]2#E
M]^35N?XE]/774[K7=OI+._AZAZ[=4;R]&>WD'YOCGQ]2#E]^35N?XE]/774[
MK7=OI+._AZAZ[=4;R]&>WD'YOCGQ]2#E]^35N?XE]/774[K7=OI+._AZAZ[=
M4;R]&>WD'YOCGQ]2#E]^35N?XE]/774[K7=OI+._AZAZ[=4;R]&>WD'YOCGQ
M]2#E]^35N?XE]/774[K7=OI+._AZAZ[=4;R]&>WD;Z?5ALOY/+S_`/\`.7ZL
M/YI3_P#YE_)Y]S_Y\_\`=/[_`/\`!=>(=(T'/F?^=N&\M/U7&X_J_I^3W8\W
MZ)O3HY__`)"X#R%?7\3B^M^AY7<C_]:BZ&$Y)7FF1S1S46Z?:ZZ$U)/JD4LQ
MSA4P&P@YY4.0'+):$4YAQ617FB<83^QK2ONJQJ<&SBC\U^KU.NKO^XZ5NH#2
MW*QE`6;<D%3B0%G@RER29S/!J2O!XA"I&-I'%Z+F(?VF_&4";?=(,:E<KPX0
MS)-DJ0]$7AUU9#TQ>=B2AKKQBW7,OO2:U.87CNH2CNY54@@N((\X?E^$Q[7]
ME-'7T'XI>R^FO%:E/I</E!85(M59,RY55BU$JM&TIXDSP`)E/U/;_E#H4O1L
MG&UN:MQHNZP\L5VO/UT:8DLNZRV@RM(3]KGJQ7VU#MN*>7Y@X?&6VU81E3F4
MH5UMSMH=%ZMK?2VDTI\95HI'ZQK'82I7<P)/>PQ]C;S6IM5W+0TI:A4#Q4V9
MG]6YBM%*>[A(C&W>=0W3M2VP]NK4?R[T^[$14+%@0U4M7'%VMNRT9/G3S$X=
M`%\DV(68E#"G11G$%#OLO!#J86A>'4Y:MZ/H^G:7<U/W>+N>U'1-1WV.6B"Q
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MH)RQ\L9NV%D1TC19]U7%2MM5EZ)2\^B&.<C]_P`L=-14N6EEDA\S)9"!4JSE
M+[ZLNY:/H^G:7<U/W>)SRHZ)J-TQRT3+C95-]:5?N4QL6+Y9[YL-W"JK9:KC
M9>/(U=K)L(5;9>9=IE;_`!F)&-@1[)/7,IUU+2$N($8""POR8`+`S1])T[2[
MFI^[PSRHZ)J.^QRT93^M:^?5FW=_'W&__F!Z:/I.G:7<U/W>(SRHZ)J.^QRT
M'K6OGU9MW?Q]QO\`^8'IH^DZ=I=S4_=X9Y4=$U'?8Y:#UK7SZLV[OX^XW_\`
M,#TT?2=.TNYJ?N\,\J.B:COL<M!ZUKY]6;=W\?<;_P#F!Z:/I.G:7<U/W>&>
M5'1-1WV.6BF-\;0NY%(@FW>.6Y04)W/QP?P^5.<>EM+<&Y#:N)9$3@+>YCV"
M)!YI([.<HPUAYU.75MM86XC:7104J:MTB^Z4_P`+4XDU&S3.B>&G&`8SLR&`
M$R$8%Y5E0:=N=UOC^(8V6>/;_OMG%%S^M:^?5FW=_'W&_P#Y@>M7H^DZ=I=S
M4_=XS\\J.B:COL<M!ZUKY]6;=W\?<;_^8'IH^DZ=I=S4_=X9Y4=$U'?8Y:#U
MK7SZLV[OX^XW_P#,#TT?2=.TNYJ?N\,\J.B:COL<M&/<L!NV30GPJAR>B'5M
M>*Z_&3^@.\Q+C2>PY2)(BT2/*.099BAG[XRR^$8D_P`X)!Q[*W<89[<SH^CZ
M<I-S4_=X9Y4]$U'?8Y:&]R&W:]'QP*X#E6J6!.M1Y,^W/\:!Y(]<]'04<$&6
M$+R+9C%1\*-'K4AOP<=BR?$;\%W"7<-'T?3E+N:G[O#/*CHFH[['+1'G:]RD
M-+.8,SR?;A,@58<'R;W&4>9>/B>^_.2)9@/(V,9$:F2,,(P,TE:<-,=CBW,/
MD(<:/H^G*7<U/W>&>5/1-1WV.6BVJ-,;KK%@D)>RZ\Y'WQ@X(A@6(EC.+48%
M$K=S#J6\`U%;_9\3&7`',Y\;Q5(P_A*%)^SRY&CZ/IVEW-3]WAGE3T34=]CE
MHMOUK7SZLV[OX^XW_P#,#TT?2=.TNYJ?N\,\J.B:COL<M!ZUKY]6;=W\?<;_
M`/F!Z:/I.G:7<U/W>&>5'1-1WV.6BF][;0NY%)@VW>.6Y@DIW)QT?P\5.<>E
M-+<&Y!ZP)9$3@/?!;V")!YI+#.<HPUAUQ.75MM86XC9W104J:MTB^Z4_PM3B
M34;-,Z)X:<8!C.S(8`3(1@7G65!IFYW6^/XAC99X]O\`OMG%^7!%R>M:^?5F
MW=_'W&__`)@>M9H^DZ=I=S4_=XS\\J.B:COL<M%5VR:W+89AH^-U=R'@HU)#
MKKD.Q+<>$-^6)J=@JY4<P7"\FJ\\D7!,TW+#NO8?-'E14+P^IE##`[1]'T[2
M[FI^[PSRIZ)J.^QRT5C(5O?YDT9/1X?+.$(-!HXBQX^5XNE1>7JE7E1!LLS$
MRW(.1BQI&QGDO&D]C*VGG,M))04VRRAN='T?3E+N:G[O#/*G8NFH[['+1UQD
M3R:21B3F`^38Y&6/#2!$E\97XV,0I06'E#*FN1)8\D0H8/.$OFB.]Q:\K2C'
M>>P\T?1].4FYJ?N\,\J>BJCOL<M$I@_7W'@-AR=.Y%V%2).-D_2A9O'P&3,2
MS7I"#E`3EPW*B.C51TBLIDEI`XP^1WATNY4Z2K)'31]'TY2[FI^[PSRIZ*J.
M^QRT<)4/<TA72(-=*Y0),/HH5,>E5V3CTT_F2#9G<(MHJ`>3(+@DZPY,>82X
MRX@I]P-A)9!3324):/H^G:3<U/W>&>5/1-1WV.6B,#Q'*3-E=DS%\FFZ^S(C
MOQ]>C0>)[><!^C6!C_-2,CR$D75F&&/%NI2I#H;"EM9:80AI#*8T?2=.TFYJ
M?N\3GM1T34=]CEH^S$'R(DXZ,!+!Y,-$BFG$(-&=XT`$%OO(C7(=O*$\FWAU
MYK;\8X2/VMK<(6XI)*G6N\G,Z/H^G:7<U/W>(SRIZ)J.^QRT67(2>Y#SVI!6
ML.1;2&F)4=40Q,<=AX4@>38K25"/,-<EL&.-Y*@7G,OK?<.'3(/MA$!H4K"F
MCZ/IREW-3]WAGE3T34;ICEHJX2H[]#9K0(J.7KT+`9@UNC2%@XVG2D]F,+@3
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M)+RB`;-"R*5,&MQCC#<;(#GOE9E7Y.$'B6@V!E.K+=-#:%0C+JWV4(RXG4&0
MQF0C\V6K1>1K#<;M.E1=;JVEX%AL@(6%E7"%;0;"0DJ+BG6TM@%:G$!)4-I7
M'0PR1]K1IR0+\1O$A;8*0#!=F`YM40"?JAPP:&P1'V.UB#-QB7\M)&0<\EA*
M<)3V)QC&*T`!Q$L5H?E^./;#LUJ'JO\`&!J95/`I#E4VM*"ZEW@T*NXJ2W:0
M\^D6)V0@.J"`)"0D(]3>^WIX<[1CU9C8B7G$;K$\C'3LV978HE6=8[02_@N9
MCX"T&!8;%RM:,H`([[B4HSA.%96GK+H#13>H>6I+6:F92`H_6-8@5)!W0_S1
M]BKR+@5=Q:2E3F<8`24CZMS9`41WC&-V[N/V=Y;)KDGL&DZU#V:-4%^]0.O\
MKKY6;$BN4^QL29%E@X@/0:#%/5FSVP%2I9EK+L>00,WAYK!&4/8_!W7SRHR*
M.7B]PEX\U9RJN1BL8WC$".J$@V+*U(D6E+J*4"7[0#:,C)'2D%6X]P^8I^7=
M'N2$E-@0H[4@0XTHC#/BJ)RA"75J4X.Z^>5&11R\.$O'FC&55R,=49Q9B:[[
M_$,S<8VNE@"JV+Y[G;?W54EENE0RAC[HA_0F&X1#]*B12GL2B<#&QZ&E$(>%
M9'2TX.Z^>5&11R\.$O'FK.55R,.$'Q?K2(AFVU(&CC5*KQ5?$F9"O\U;X[2"
M(G7U0U=`BIMS;>AR:R2(%4-30^#/'2AO+67GU]BW?$2X.Z^>5&11R\.$O'%F
MK&55R,?0N-6)[4]V9J15(F:Y8N[.`WY_F/?;;!TXZOM.FBG0I<=I$"*`@(Y]
M#+I@;)`[#HHR&%+;83A.'!W7/^<J,BCEX<)>/-6,JKD8LW5%6/X:U(ZLDDZF
MCT6V4S<YZP[IY>60F=M-B&#I="E;2[)V/0@.<J*6J!!?0/A`;11`J$-H=)QX
MK@[KYY49%'+PX2\>:L957(QDP;<MSQKHC$C2-'1[Y[J&063=_6L5TUYPD0)M
MH1M_C^VLEUPP]AE*485G+KS:<?9+3C+@[KYY49%'+PX2\>:LY57(QT"7S;Q[
M48^#4-#F,S40Y8(9X3D'9R&I:!93'+=FXQQG0*T'Q#2)<3*B6LK93@IG.5?L
MB.\X*Z^>5&11R\.$O'FK.55R,?*]?MN6Z&`L=4J.AK/7I1M;T9.U[D+9IJ&D
M66WG!W'0)2-T"2"6VA]E:,J;6K&%ISC/NXSCIP=U\\J,BCEX<)>/-6<JKD8>
M?36_?DTT_P#/C=/^7KIP=U<\J,BCEX<)>/-6<JKD8I??4QO15'@L%ZYU,PUC
M='&]2%C;HN!3BBD<B-6K"94T[H0-*6"#$MMNN87E3+2E.)0ZI.&U[2YV[LSM
MZS5ODYK4_L4#!FSL_P!N<0Q;>*8QQ@7DN\,W;G2L_P`PQ^U5Q[?]S%T>FM^_
M)II_Y\;I_P`O76KX.ZN>5&11R\9_"7CS5G*JY&#TUOWY--/_`#XW3_EZZ<'=
M7/*C(HY>'"7CS5G*JY&#TUOWY--/_/C=/^7KIP=U<\J,BCEX<)>/-6<JKD8Q
MDF-?D3Q*F7JSI8?,F=X:`(OE!8`<O3<M:-LGP3T>H?CYB0$EH^SW*T)C4BNM
M9R0RXC*'5AXPTX.Z^>5&11R\.$O'FK&55R,()34Q`8<35I>!U<%Z.D;<4`(?
MRRN`LPN6E8*O%33N2R=`HEW7X:M1XKF&L.>&R`2K+R%LNIZG@[KP?QE1D4<O
M"W>'-6,JKD8;5\:MAAD3!]B%KY%;4/51(R,/Y1[!9$BV*\SE"#)F6D]"'$3T
MU*2Y:G5%.J9PVEL5#;:71TOK<'=?/*C(HY>%N\>:L957(Q;M'U]M+7UHD)R,
MJE/DYN>C2&71+3RAV)8F_)L.0J2B8N/D^/[N8]+3XX_C*&PVVI;^/$PK.6N[
M'!W7SRHR*.7APEX\U9RJN1BW_36_?DTT_P#/C=/^7KIP=U<\J,BCEX<)>/-6
M<JKD8/36_?DTT_\`/C=/^7KIP=U<\J,BCEX<)>/-6<JKD8IK>\QO15(@\%ZY
MU,PUC<W')2%C[HN!3BB4<A=7K"94T[H0-*6"#$MMNN87E3+2E.)0ZI.&U[2Z
M&[LSMZS5ODYK4_L4#!FSL_VYV,6WBF,<:^\UWAFS<Z5F6<,?M5<>W_<Q<OIK
M?OR::?\`GQNG_+UUJ^#NKGE1D4<O&PX2\>:LY57(Q3LY2;HF4AYVQ:]U*S(,
M6X27ABY3DI>Q'B+&79XN<B8W)3N@V"IUI,Z&TT``4X2VRVM(PZ$MMCMM.#NO
MGE1D4<O#A+QYJSE5<C%*`:`L<Z"F2U<B@!$*#=`Q*5KE1=IRNY$*G9(.QG,U
M>)T4)46YP@X>60,3@;(\?/84=@=9@F.[/!W7SRHR*.7A;O'FK.55R,2H3C[;
MVL38@\)#9)<E8>6GW!>76R`ST&1Z:\6#B35&<?@W$-$"5]A.4O8^R$>=;1W6
M7.[AP=U\\J,BCEX6[QYJSE5<C#\-29P(:E"$5G5)!-2CZJBL2:^6%\B9IT)Q
M5GJ]/)=/K^BH4B34>K8Q@`;ZN\LITQ*4*6\XK+D<'=?/*C(HY>'"7CS5G*JY
M&*\#TT/)K$KP$;J`^5LMGIVUV!XWD\]B6LTCJ^5R_&SC,=%<9V69&,8GA<K-
M=8'[N7T*:[[:,K;RX.Z^>5&11R\.$O'FK.55R,2.'XY;)$0<R0$++O=^6%0I
M7*[8`>(<>5E3)M`08T5QV$9$<'"DF6,=Y.>\RRTO"4J[,].#NOGE1D4<O"W>
M/-6,JKD87XU%=4R8<(J/IKL[!QT;)BQ97*&PFR@@CT[.KC)\J+-XU$+,\>2.
M*"&**9>0EEG`C&4MM>'B>#NN7\Y49%'+PMWCS5C*JY&";A#/?,S>)\'1K)VM
MWR[02N3Y1R#,?5T@VF5,E)"347QWP]!10\ZXL5Y&7AQ!U"^&E+;BB<O1P=U\
M\J,BCEX6[QYJSE5<C#;%:1DJS'PI4?5]<1D0X&T2PXCE+;1(BR*4_)2Q$V6A
MKCPS'R3TD++90ZMK"1_)M,);0A++64N#NOGE1D4<O"W>/-6<JKD8D4!I:]UN
MPQ!@%5J;DK"Y8D@8<WE)?2X]`0I\04WA%:=X\>C1X_$M%^*I;`[2LO$NXROL
M\)+<\'=?/*C(HY>%N\>:LY57(QD-Z:W[\FFG_GQNG_+UU'!W5SRHR*.7APEX
M\U9RJN1C45YBS?>B"_H>^8_G%(?SF^]'\U_N%_WC^^/X%UY)DQQB_P#$/-'D
M[?E>5]'%]*.(F_Q:/Y/SCY6UY/D_2Q_1C__0H_7J'W;[2F1BY(!]^V5X=HV&
M/;BI853\L(SX\9)NFQS4>>UA?:T\LAA#2\84IQ&,95C41^;'5M+B]8;B0T\Z
MVXJL9`4TO@W$S<2)H65("%B?BJ*T!)D2I(PC:WH$:N`^U?T4#7GI8MP.T,LS
M\C/SAUCG9*<54K*]DV:F#+1<FRY-R(=$2[Y>0?9;4GN9SXJ7.JT87$?I#\L>
MW?9\S=E/^+S4.GNU;RU(J2'5O.J?=6[FSYM.NJ?J0IPMEL*L/+2"+,[85'J/
MWH[+LR>B78(&.DI9.ZQ?*!2TH3"QSZLZOVCAW!,F'#SY(N$,94I.4B/=Y>,)
MSA.,Y6GK+I#91>P=6I+>:F9`"C]8UB!*0>^(^P%XE87=I;2"O.,1,A]6YL@'
M\ABC]YT36>Q+-'![ZUWQZ-M!E1>3&!6KD1<:\>32X6UP62EC!M:VB?$AQKI8
MXK#R\)[KD@Z%A>5.-C81B\'=O.W\DCEHR;==S=K**Y***E-<\344^C0#$+QJ
MK5:GVG*]09"%Y7W`)NW1A<]J.+?@HF7>U\4/=(IR<:IS0N%*,Q''+CR@%BFI
M&)1/!W;SM_(HY:%NMYNUE%<E#E&Z6XGU>;LQ<?3>,<3/3%?D=5V=2N96P4'N
M0L;2BVS*H6T16U.`EP%'AW26\)2V7&C`X+;4UD9+S:Q=W.W\BCEH6Z[F[645
MR4-%NU5P^")LLC=:3QO%-S?9J=N,_-<L]JM&(O$,/7O??*6>R/4Y)#/DFKE$
MMSKI9&`^^:(V?G*_!3AP=W<[?R*.6A;KN;M917)0WV[C_P`+AD"1EHU=QK91
M8LRL,T*QRKVPE$SAL5N/DXH_$/3>PUD9E]./`)RI#3N>^A*7,=["Q=W.W\BC
MEH6Z[F[645R432K\?N*M;EAQ:_J?BJY(V'(I0T(;RAM]C&G?_O>G6P9YFMSE
M(E(^42]=BH%WMP,YAUU\%C/>;=9:5%B[>=OY%'+0MUW-VLHKDHJ6$X_<#WV"
MHF*HW&0H.UMO1`X:.7^SVFE1U$&]%&C19#50'?;C8XL-QY\SQ5>.<O#BGUKP
MQA$V+NYV_DD<M"W7<W:RBN2B;6G0/%2(HL+`'5;CA3Z55[[&[&2PWRKL3P\G
M.3P>O8Q<9)N6+6\X_*QM_A0*['K#;['CAB1FALI49C+RQ=O.W\BCEH6Z[F[6
M45R49,TJZU#15'!I-8=X]5.EUP>R3@[<YRDLLLD9@ZP6F>M$D99;=KN5E#NR
MP#R[I"R"W5,J'?3GN(9RE$<'=O.W\DCEH6Z[F[645R47K%6G:4W&1\Q%TW69
M<;*!CG@%)VK;6TD"%M)?'>PV]I5MYOQ&EXSW5I2K'ZF<8S[G3@[MYV_DD\M"
MW6\W:RBN2BI=^2>VE4:"P32==--^NGC:I*V-HV4A>2$\BM6*$;RVYJ`9*67B
ML(0XOO94TVI2\(<RG"%;2YV[OSMZS5/$YK4_LDC_`%9V?[8[&+;.#!CC7WDN
MMS=N=.U_,,?M%<>W_=1=/I7</X":T^=BT?0QUJ^#NWG;^21RT;"W6\W:RBN2
M@]*[A_`36GSL6CZ&.G!W;SM_)(Y:%NMYNUE%<E'!R9VZRVX\]2-8M--(4XZZ
MYMJSH;;;0G*EN.+5IC"4(0G&<YSG.,8QCIP=V\[?R2.6A;K>;M917)1CA)05
M*L4,5(RE0T;/P*H@QJ1/(Y)7R6C3(PY4E)O%RA?JY(8DG,>N%]]DM]3CS*9Y
M*VG$X>;SU/!W=SM_(HY:%NMYNUE%<E#!FM:G#KH<,BF<<F*C&3C@HP8_(>S>
MA!K/L8@-`[7GFM8JPQ-31$"WD5O#Z58<3WVTX7E*NEB[L>=OY%/+1%NMYNUE
M%<E$3(U!H:.<E;))TOCF)&/0L`\ZV?R>LL77H>&I#$JD*0::;UP`R.V*IDQT
MHHA;BU.LNJ<7C*%]C@[NYV_D4<M$VZWF[645R473KNO0](GEG:WU_HL"PVD7
MP"7(K>EJE9.=&\JV6RHM1&J#S2&AA8%2FE+SW&^Z[V?9.+[RQ=W.W\BCEH6Z
MWF[645R47IZ5W#^`FM/G8M'T,=1P=V\[?R2.6A;K>;M917)0>E=P_@)K3YV+
M1]#'3@[MYV_DD<M"W6\W:RBN2BF=\R>VE4>#P32==--^N?C@I*F-HV4A>2$\
MAM7*%;4VYI\9*67BL(0XOO94TVI2\(<RG"%;2YV[NSMZS5/3S6I_9)YL[/\`
M;'8Q;>+!CC7WFNMS9N=.U_,,?M%<>W_=Q;$A:-H1(^2Y2IZICAL=_'CF[@L8
MS6<MLNDK2E;VFD84M(["UYQCMSW$*S^IC/6KX.[>=OY)'+1L+=;S=K**Y**9
MDMC5R2L,!9)!''0J<D9".K$&6GD5,J9F)6)*>FX6$4(-JW$;,GQ9IZY`%E]M
MYP=W/FF<)4C#B7!W;SM_))Y:(MUO-VLHKDHJ2P:UTN:VX<?5^.\?*EQ)`#5H
M:Y,SOO@\@B.29(O`'G:R,["GX1[O/D-MY?R([V][",ISU-B[N=OY)/+0MUO-
MVLHKDH=T:>U#'KL`.-5<>D/11K$U91S.0UU.5'2$5FOF(*F1Y'6Y;33H?H&.
M=>:?3E.4I;RZC*7L^(L7=SM_))Y:%JMYNUE%<E$YB7*U"U^J`!P''U4$8'$!
MTYPKD-.E#2(5!L9TQ&I@'GM6*:,8@)V0>\50W:GN9PT_E3*$H2X.[N=OY)'+
M0MUO-VLHKDH@4M2]42@+8,E4=$CLPT!*Q4:HCDK>@2X^'F[D^9*2,4Z7K9!)
MB)6]'^$HW'CH(.2@;"U91X6%B[A_K;^11RT+5:?]7:RBN2CHSK#2IT)#EJU]
MQY/A9`X1J"DU<G;X:U(F-E?N5J.E54)UX_'F7TJPEMU:,XPA6<92A&4K%W<[
M?R*.6A;K>;M917)1,LTVI52P.OKI^DX&>NN)BOK&(Y*W<4VR.&2)$7,1@K!6
MM_-D/MRLPL=QH;.,LONX1W4JPG&%B[C_`*V_D4<M"W6\W:RBN2AG/B]7V=5C
MC#ZEQY=S<H!=>G8LKD1;HYN<K!$P0<^.)%$ZQ&87%%2S)#"B0FDIRMIX;#N,
MM+;0X.[N=OY)'+1-NMYNUE%<E#+-ZCTE-$JDY35?'$EV0+.AU*#Y$W5@1PNY
M/ELNQ^0XG7+(+.2W(\IH1'AI2(E)#8WA)4\G+@[NYV_D4<M"W7<W:RBN2B74
M(/7NKK`.J@U3C569Z4@C$B,1_(.5R;(PA#-9+DS4X?U:^5)CNL1T0ZZ^XIU+
M??:<QE"BUJ(<'=O.W\BCEH6ZWF[645R49`1-RV//-E/0=;U',,@EY`,>C-RV
M`YD8U(PQBA'71M..MH(2*8TYE&<]N$N)SG]7J.#NWG;^21RT+=;S=K**Y*-2
M/C3OWMB?Z(GC?=HS[N_>W[@?<G^&_P!V_@O7DJ37GJ_Q#S1Y.WY6/Z.+Z4<-
M-WS$_P`GYQ\K:\G%]+']&/_1I[5+\J/LW7RH21D(F5<N5;%"D8IYH>1%=-EA
M`\K$=?E8,=+N4/Y3V.FB-*QGL6\VG.5XU$?FYU075HUJU<-#4N,U:JYE*5MD
M!:2MQ*9I)<:3.1(\9UM)Q*6D34-E7%N(EH/VJ.D`+/:)FW71%T[;O+SD8#'$
M+LF*;/-.8%>`F9M,Q&DQ;8I+!CRV3'D/]A++9"7.VILDK;)QVA^6/:'LJHJR
M[_Q:ZCTUZWL_6WX*PYTXZA*#PV:O`V2AQT.(+8;6AQ12XH+DZA+@5/?U[5_D
M[.<->,L'R4K=7BKI-:RW#2B0:S-FEQT7**LL7::8\DHT!#A;&!AK&M]/<QGO
M+;3C/N9SUY0[.[A:UGO]RXGZA33513.`J2`2+)2O`#@PE,OCCZU=HNL3VJ>K
MAU@8IDO.T[[<D*)`-LEO"1A$@N?Q1YB-A?UAZ1VN>B5V-P.X_7"4:C&81J2F
M;3;WY!F&8.?DTQ+)J1&R68UR1?\`,.L)5AIYYMI;B5*9:RCS7[OMT=8JG)H\
M,>"?>-O?JU395>]B!F>W0J4@)7PC_9R\:C&*HZX_7,E66YODP[BPHJ,3Y,UU
ME1C:!XR$%%81XF4#C,X9:PAO.4YGW?KIZQ5.31X8CWC+WZM4V47O8:#/;:T>
M1=<?D/9W:$/?<CW8S+YFR=J%/-B$!O`D^7=?.6X,46T0XMXAO*"'2%J?6M3V
M<N=1[OUT]8JG)H\,3[QM[]6J;*KWL2`_V[\1)PSM=.X!:-(@29&0E#8=6R-H
M)C9(B3*J1I#$J&V4AB5BV"Z%"."A$I=#"5$B9'::\NUW7N_73UBJ<FCPQ'O&
M7OU:ILJO>PB-]N95)*2D9B0]G?Q[.DI98CTD47>=BD*+("92PR6ZAYQ;7G5-
M-IPZ]A.'7^ZG+BEYQC.'N^W3UBJ<FCPP]XV]^K5-E5[V$)/MN*&:N36;[.'C
M@8F:-8D)8<JX[`(!D"!YO-C;25'O*6"Z+F;6X0L?+?@.+>=[Z%)>=PM[OUT]
M8JG)H\,/>,O?JU395>]AS-]NC5I*.B8J3]G;QUDPX()N.BO25QOIY0@;<K<I
MW+*9`OQI!WQYG8,R4\I;JED/GN+=RM6$92]WZZ>L53DT>&)]XV]^K5-E5[V&
M=WVV6O7L2.%>S;XV)]+%!FR/A6Z_,9*(`<C7AE+RQEO*6_,1+#JVT]C;SN%K
M<2I;KN5O=^NGK%4Y-'AB/>-O?JU395>]CLM?MO:G<QX`.<]GSH=P&NDM.BA!
MW[8<<P8(SXSR(26R%X+TE7UR*VC'`G%Y'?+$'<=2OP4XZ>[]=/6*IR:/##WC
M;WZM4V57O8R*JG]9MVM1ZW#5&K\1-2Q=?KX#,;$@>L&^&J'$8QV(2X;(-%GF
M/*SG*G'GW7'G5YRI:E*SG.7N^W1UBJ<FCPP]XR]^K5-E5[V)*S_6(>47(QT;
M7E+X@ZVE9J,E*_M50L;>K"V_F.T?8XC<<EA;DH@,3#3XM&4SW,+\P^IW#(R'
M27&6ETJ[%=7[C"JVKUF?2TI*F9EM.-]*F1BF<;D]H2FJ202+]/VYZQW\YF-#
MJHPM]/ZZ0=4/%8(>5C`&)$MLDR2"H@').Y>W5]H!K]I2[9P3U!'/)/)C\1@^
M[`)>==6(57A'SAZ]"SLC.E06'+9&K3)-CKCW&#&WD/J9SW\:&E[)=3:Q5FGU
MNJB)`S+!2G"%$`J4D)"O$4+)-J:2)3P1TE7VK:^4+:EU&I5*)$^**E*E2!2"
MH(22HI\=/C`2DH*G+##_`#7MK?:/5S,CF;X`ZFCV8P8XI\Q[=\2J-(Q'2/HD
MP2*DVK$Y'3DHW)Y2/@,)T@MQUQM*&U9<1WK+79;J,^&RUKC4FT0`,W,\(F"1
M9FD2PVE`"0.'!%YWM/[0F5.I=U&IDV)S.<ID2#*0-J2E3P602J9`E"USVSGM
M+6U1J$>SUU<4J6/M$<'Z.W5&2F,/TUVPCV%TU4=82DQ8`I-6-::**RR*8ZAM
M`[CJR!TNT)[,M0U6_P#[I4"R$DS8(\NS9E-(F3;3,"9`G,"1E=5VD=HZ;'_T
M.F-HKE*I2?(M6IR5@'B*`)D"92)F)T/%>UOY:*CW@XOV=^DUPM4KM7V`O">0
M:EP/O1LX!;=/E!R'KCF)L=:EX[4.'`!FE%"+;BQ'FVOLPUN9"NR?4Q!9"M;J
MH*6ZIL#-S.VBQ;219FDIMI!F!(DC&#+$;[5M?'B_P>I=(H-M(<)SE,N#<ME"
MP;4E)6&U%)23,2.(B?7(>U>Y40LBO7!OLW>/C17A4Z\E5QC>D:9'D9E)J.@*
MH[)^3M9$48:B9OXB5QI"UOBYD&7B!VT90YB&^RG4QZG%4WK=5%@J4F>;J&%*
M5*5@*9RLH40J5DV2`28EWM5U\8JC1NZE4@J0A*I9T@X%*2A(F%2M6EI!3.8M
M`D`$&&4;V@G)TJ5AHX;V96BD+G)$`:LP;/(8&.CY^<MSY<@F:@$M7,15G,+;
M.<44:T\4Q&CA+4XH9`CRFZ%=ENI*4..*UPJK*$J*OX=7BA..UXOBG:!D5$BR
M#:$[P[3NT$K;0G4BEM+*0G^*1XUH3!3XWC"4R2F82`2963*=UGVH',R`G96V
MU/V9&C(R?I0$HN>DX?=D>R9!`P],E[@9Z>9'M/['AZGS"SF$E(RH[$F$IC#K
MQP'CPKLOU&!:"M<ZD<(0$S8/C%2P@6?%P^/-)EY)2NU*PJ0=IO:&0\4ZBTQX
M,$KE4I-FR@K-J2L'B24/."D69VTSEJ?;K>T"4!9Y3\0W528RFVBP4RR2+FX6
MF@8RR5:3ID-.1ZBW)=#!2`Y._P`6TE]A3HS^7G<M.+2(9EB^>R34T*80=;ZF
MVXVE:1P&$I6%J292F)AM1D<(D)@6DSQ1VM:]*14.#4JFX-IU3:CG``"T*;2H
M3)D9%U`F,!F9$V525)]N7[0=Z:K]?`X(:@FI.SVG--B<5S=\;90,3_IR=K26
M968K\_)0]>CG;!5Y,-$A(/BQ[A$:4A+^<CO=RGV3:F<"^^O6ZJ0VVW;5:8*3
M9LI5@"D@J-E:24I!4`I)EXPG5[6->R]3,-ZE4JW'7+";%2E8M6E)\8I)"$E2
M%I"E$))0H`X##-9_:_\`M$MF0E)AL<$]2`)M-BTCL&H^)O2O`G6%L,O&_:FP
M$#+6<,A;4K!ZHDVS\=S#L4^$6(6E@]A8V+E/V;:DT+M4Z-;JE7!MOMK_`(=1
M"9C-UDD)(P*=24["P4J3-!"HA[M(U_JVZ5LZE4J2XIE:`:E`*OVZ``5`X4M+
MM;*2E2524D@*[![8;GK<,)A+![/C2II#A%VKS0;^_P"(C9EDJ)!DHRW1@ZV;
M:%,`O&P;13S2$*;S)Q;:RQ?'%1E[&/[+-2`FWZX55BRE4\W5*2Y63.S*4R$G
MS5$)5)1E%_VH=H%HH]2*6W:4F6=(G-$[0E:G.0*AYR`5)FD3C&+<'MA]NT&M
MM-[?]FWH)FK2EF"9R+(;0D[1&E6AJ(K&Q(G$@%$RTRC!H,)+1I06248P,RK(
M[.480\RG8T'8QJO>;BFZ+6JI6L)M2X$)\6TI$_&`GXR5#!\.(B>KO3MJUNN5
MI#UXZH4J&U+L`A^UXUA*Y&S,CQ5`X<?P@Q1<=[?9<<2DM'!K3)3K`\Q'QV#=
MB;"?9AX>P1#<#-PD2/W4,"14M%)<:*;[N5%8)(\92_'=[^U]WZZ>L53DT>&-
M'[QE[=6J;*KWL.L+_6#3*VQ("US@QI:`$E07HV0#A-C[+B@R@B7@R#67!`'A
MQO\`.+X*%E*PG"REY<R[E>77<KCW?KIZQ5.31X8>\9>_5JFRJ][#X-_6,+&&
M!'Q8G!_1HP$4P:)'CLW6\-X&!DGVWI*-2M+.'5Q<DTTD8@52E#O@8\HXA0O[
M#T]WZZ>L53DT>&'O&7OU:ILJO>PWR?\`6'):9`:C)/@WI$L!IT=]0SE_V$E!
M1`<B]*`$2&6^XN3?C2BG\"K)RZH5@E]AK*&2'FUO=^NGK%4Y-'AA[QE[]6J;
M*+WL("OZP2^6=%RJ^"6CF)>%;0U$S(&P-BQDU'MH)=+3@68C5B2;6</._JX=
M[<H;:1G/<9:2A[OUT]8JG)H\,/>,O?JU391>]B;'?UD^^21S<F;POTJ_)-2Z
MYY,AF[W9!V99Y4=@@MPML=!#V2QH@05]"U*;?!%:%<2H9M#6'N^W3UBJ<FCP
MP]XR]^K5-E5[V(9C^L'&842K\1;22E&#1H12E[#V.M1`4,!&140&ZI;BLK$B
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M[]=/6*IR:/##WC+WZM4V57O8S*_'(L?X%PG_`*+?XY'W1/\`YQ_@7_<_N)_"
M?[O_`/#K0>JS'.U_\T9CB'D\9^EW,4=CZZ5/,4?\J:1\H^7Q6+R?I8^Y'__2
MHR@K>:O=*<'!/E"&[;7%L1L4AUR3D7D3`:F@8UM@H%]9Y:\8;9PA]E>7%8[%
MHS]EC41^;#5Q2T:PW"MJG<==%:P0AL$N+(=3)"`%()6HX$@*2;1$E#&-J'&^
M8/L'M4=`3CX[[,3)6(9=8=?GJW9U&P@=0LD8\6J>IUCM55DBE3X)R"W`3,M^
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M"FQQ%7CPR0ZYQVEK"Y(S1\F\X.D<%]E`L8:\0XPAG&5^0/;WKCT?=N3>^\1X
MV]WO4GG]Y95GD(K'\T5[&]NN5ZY&<@N;,74)Z#M%D<L$Q.:EBFH6)JD3490[
M)T,=H-BT2DN:N\QHPD5$`2<L^\ZZORN!QB7VI]O>N71UVY-[[Q$^[WJ3SZ\L
MJSR$1L_V7GL18^WS=,>Y-<W\R$%5H.TD&^7JC$86BR/81#0\>LSC",<1)F"/
M,%^+EA$<@,EMU92<8<[CV]ZY='7;DWOO$/=[U)Y_>659^[P]5KV3_L4K3;:[
M1`.3G-9FW624A(`6$*]Z2G`K!95Q_O>AY$X'C";$M.2@Q_CY*;(=C@V&'5%D
M#]W&%/;WKCT==N3>^\0]WO4GGUY95G[O'RG^R6]C=?K+KJHU'?/.B8G]D%@1
M<>(DW5X#$#-R?O6=!@[%(RG'X&-;D"0;/DE"@GCAU-QIJ<.Y>:;:=>WK7+HZ
M[<F]]XB/=\U)Y_>659^[QG-^C!\!_E<Y??#[3'T`]1[>]<>C[MR;WWB'N^:D
M\_O+*L_=X/T8/@/\KG+[X?:8^@'I[>]<>C[MR;WWB'N^:D\_O+*L_=X/T8/@
M/\KG+[X?:8^@'I[>]<>C[MR;WWB'N^:D\_O+*L_=X/T8/@/\KG+[X?:8^@'I
M[>]<>C[MR;WWB'N^:D\_O+*L_=X/T8/@/\KG+[X?:8^@'I[>]<>C[MR;WWB'
MN^:D\_O+*L_=XAU[_JY_#35,`!8Z;N[F)&R<GL'3-++<9V5JL/"XB\[IU[5I
M%65Q6D(XA14<U*8-"RI:FFI`4=Y2',-]S.32=MFM%XO+8JKKNQ3:67UB;3IP
MML.+&-\B1E95LE)4)B<6W>PO52[D)?H[UO5MU3C2"4O-IP+>;!PI8!P8%#8"
M@#L1;DG_`%;_`(?S6<JF.1_.F65E;KF52>X-8'YRX\5'GO+SDK1KN<K=.B17
ME9_54Z,TO/V3:,XUK?;=K*U]5<=T)^!AP8@1L/[2E#X"1LF-D[V':M/SX:_[
MY7/SJA!V0=EG;2D_"`<8$+@OZNGQ2C6S&H[D_P`]P&I$:1"D&PMUZW%;/#F"
MRCY<0Q#&D6TE#2AQS[Q+:\*0^Z\M:\*4M6<T+[:]87"DN7!<ZBD@B;#AD4@!
M)'Z_`0``#L``#%%3?8EJZT%AK6&^DA0(,JE`F%$E0,F<(4229XR23CCD]_5U
MN*A$EB:(Y1<^7YA*>ZF6>W9KAV22GN3;7=P<O2*BL)\.S22>SO\`9W9`G'ZC
M[O?@=M.L"6^"3J_<P:\W-W)?F['#R_,3N4[0E4KL4N!3I?5K'?9>E*T:E%J7
MC8)\#/\`/7NU><9X^VOV._`5Z'*"MW+'VB,U7W<O2L@&]N'6=PC'A@[+L=B9
MG,1L5I^;Q-CP4WKF2*,=$:*<:60.O&%.D83@UVT:P,.)=8U>N9#H$@I-.X"!
M*S($/S&#!\&#%![L5N"H:6S4:R7VME1F4JJ4E),[4R"R03:\:>WAQQU2'LB.
M`<S&@7(CEK[26?B)-$E2F;`;LBJMD)C->(BY]$.6#8M%Q]D%@(F6/9\FVX*D
M9DE&2<8;'1YGHCMFO]I(0WJ]<R46BJ0IW`+2A9*I![&1@)QD8#$N=BUPNK4X
M[K)?BEV`DDU*2;*3:2F99G92K"!B!PC#$?(]ES[,R($.C!><GM$G$*$I9I$%
M&W9+>3P),D#---2*YQK%"*`#=;'=;>RKP8_#;:UJ:[$9Z'MGO]2PM6KMS%8G
M(YNY,6ISP\-LS,]N9G!/8K<*4%M.LE^!LRP9TF7BRLX.!_-D);4A+%%N4CV*
MG!O:4O+5RF<SO:&6(B,CB/37>VW6P8Y@5TT.06`LJ:T&`-(9,,F4E*:'R^G"
MUY<=[JEHRND=LM^B1&KERX#/^77C`D/VVT)?`)1/L8N,S!UGOS""/YI.(DD_
ML=DDGX23%GK_`*NYQ:<<EWG.4_/YQVP#F"3SJ]X:[6Y-B2.352`TNM6DLJDA
MSLR9.7D/96EW)#G>QGOJ[9';1?X#0&KUS`((*?X=SQ2)2*?U^`B0E+%(;0B#
MV*W"HO%6LE]DN`A?\2GQ@9S"OU/C`VC.<YS.V8;7OZN'Q")'"$(Y)<ZR!(TJ
M<.CAGMPZQ='`-LV'DV0P)E>C5-BE6!)#F#G&\)67A:O%ROO9[;@[;M9$J6I-
MQW0%*"03P#DR$>0#^OPA,A9!\G8E%H]AVK2DMH5?U\E""HI&<(DDKG;(_4X"
MN9M$>5,SG.(AL_V!O&^DP\#:HKE)SS(FD;*TY612Y#=U$==`%O&S:_K22-`?
M&TX(6+)@5G84JD-Q+G=:64YA:7&G7FG,F[^U^^ZIQZF<U?N<-<`\H@4Z\);:
M4Z`1PQ!!4VB8EAD,1`(M5O8[<C"6JE.LE]E[AFD@FI3,6W`V2#P4P0EQ8!V+
M1V"0;/Q_5[^-B4>&GEO[0O#>,R^<(QOJA81C-@E<3L]G"<:6[.V;FTX,,_[2
M5CQ7.\Y]EU@>V6_)S]6[EG@_U=?YHLI_;?FI\4;0P#!&;[&;ED1ZT7[(VO\`
M6D_G*M*_8_G*\96V<)PQC_?/8;\"3C8"I7;DS[0*UCG76.IL.S,[/UM,Q`UP
M6;$TE`S(TWI'OM+BT%@C+)984RD3*4MN+0RXEN\QVVZR4JU.4UQW0VM0D2EA
MQ)(G.1(?!.$D_"2<<8]5V'ZM5R$-5M_WR\VDS`74(4`969@*9(&``8-@2Q12
M(_L1_9)^82%+[ZYLUV14&_(9`DI/7![C83!Y8:BW#*SQSL$4@530Z"<.>8\/
M`[R>]G#C9#;.7[>M<NCKMR;WWB,'W?-2>?WEE6?N\$;[$SV04MB56#R/YGNL
MQ4K'0V7\D5%*9$^5;KRP41+6>+WFCQR'+6`VA]+?@+<(QA*U82O*7MZURZ.N
MW)O?>(>[YJ3S^\LJS]WB7K]@3[,-M%1(5N#FU@"["5<R#/S9M/);6W;)*3B`
M&R`EZ%3+M/!R$;V%)2,OP6'<$_9"LEO#O;WKCT?=N3>^\0]WS4GG]Y95G[O$
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M]E@#L.NZNQO3F89<+*Z0T$`/:=1,M,>5GD5I]PE^1T`!A;;<NOP\^7P_GN)R
MYV>'V*R]O>N/1UVY-[[Q#W?-2>?WEE6?N\1R.]B#[)TU`R2]V<ZH,T].7XN.
ME\T;#\J`J0E(D23C2H[C7(Q)0$G*PA0PJL$]X@AK#2$Y<=92X]O6N6+1UVY-
M[[Q#W?-2>?WEE6>0A\J7L(O927F1BH>K[ZYJ24M+*'PV"J2H`&0TDF1(;>9(
MV1XUB1@3R53X#BAUO^:2.<P[X7ANI5E[>M<NCKMR;WWB'N^:D\_O+*L_=XR"
M_1@^`_RN<OOA]ICZ`>H]O>N/1]VY-[[Q#W?-2>?WEE6?N\17\4#6GW\O/_I7
M_B@?=.`_\M/OY_-G^?/\)_>'\"ZR/6>OXIG_`!_/<2OK?-\KZON>5]*,OU.N
MOCG_`/E_1_E)^H\[R/K?I>3]"/_3QMC&4DR4>.L(Z200<(RJ.C',,R1Z77VT
M*"CW<AR.&CBL*\-I7EW^ZXK&?#7_`&N=1'YGJ1`=JJ9M3#CJ5.)!0V9+7,@6
M4&RN2U8DFPN1(\56(['.!,`BN>T0XS`MT:]:^;>L>36X+81R9">=;)J]GRW)
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MB1/O)5%08S2=`*D&9=Z+RP8SYEEE!2'V61E/%NM#K9]2]"4NZJ/O$,RJ>EZC
MO,<C"ZD\K=63UU`I,+O+E-%6VV6.%CYMAK3.C<-!6NQ"PC$1BTS$9Q[>CTF.
M0"D//D.O*4,$$C#F<8<$2\SZEZ$I=U4?>(9E4]+U'>8Y&._4/(_4^P=AURE4
M+=')2!N>V9-1,_Z0U'QOK!@EJ'HH]D9%O*T:,Q(24[[VP&V,%LH/%99:'RX2
M@8F.<*9]2]"TNZJ/O$1F=3TM4;ECD8SV]5MX^LANC^(N._T"]1G]+T)2[JH^
M\1.95/2]1N6.1@]5MX^LANC^(N._T"],_I>A*7=5'WB&95/2]1N6.1@]5MX^
MLANC^(N._P!`O3/Z7H2EW51]XAF53TO4;ECD8/5;>/K(;H_B+CO]`O3/Z7H2
MEW51]XAF53TO4;ECD8/5;>/K(;H_B+CO]`O3/Z7H2EW51]XAF53TO4;ECD8I
MC?.M+H/1X)QWD+N`U*MS\<&<,E0N@D-(<)Y#ZN'9+3D+1PCV2`'G4OLXRO+6
M76TX=0XUE;:MI=%=2JJW@+FIA_"U.)51L4SIEA?.`XCLR.`@X8U]Y4=0*=LF
M]:@_Q#&PQQ[?]SL8_P`L7/ZK;Q]9#='\1<=_H%ZU>?TO0E+NJC[Q&PS*IZ7J
M-RQR,'JMO'UD-T?Q%QW^@7IG]+T)2[JH^\0S*IZ7J-RQR,'JMO'UD-T?Q%QW
M^@7IG]+T)2[JH^\0S*IZ7J-RQR,8_6"Y$0#SZ)'=')QXJ,6<XID6C\9C#$!Q
MDSL>`L4H",SIMPLT&!SK<EXQ8R7%)&D8_*<*45W$3G]+T+2[JHY>&95/2]1N
M6.1AH5LIO,?%V3.Y^4C@AQEOB1'\:YXZYE!F:R)`G2Q+X"M()D!HHTB1':2O
M"<X\1KONX;:1EQ+/J7H6EW51]XB,RJ>EZC<L<C$2QN.C@'GF`;KY)^GSH:HR
MLBV+J[C7'SYT5+YRU7E'8.TC'F.M`H\SEO#RNZA+"L,]_+XF"6?4O0E+NJGE
MXG,JGI>H[S'(Q<="E%;(LDG"UKD'R(\_#@.DDR4OK[0T,&Z,I4.KPXX^0X_L
M^D,/)D&5J2SWO#PC&7.[WF^\SZE'_P#24NZJ/O$1F53TO4=YCD8N+U6WCZR&
MZ/XBX[_0+U&?TO0E+NJC[Q$YE4]+U&Y8Y&#U6WCZR&Z/XBX[_0+TS^EZ$I=U
M4?>(9E4]+U&Y8Y&*:WMK2Z,4F#6[R%W`:E6Y>.;.&2830*&T.$\@]8#LEIR'
MHX1[)`#SJ7V<97EK+K:<.H<:RMM6TNBNI35N@7-3#^%J<2JC8IG3+"^<!Q'9
MD<!!D8U]Y4=0*=N=ZU!_B&-ACCV_[G8Q_EF(N7U6WCZR&Z/XBX[_`$"]:O/Z
M7H2EW51]XC89E4]+U&Y8Y&*=G)B1A)F(A2-\<D3'9BY!T@0D.F<;E,L39$S&
MP;CIPI>E1)<``,J4;>R\X,GQ@/W8/AX1;3SDY_2]"4NZJ>7AF53TO4=YCD8J
M(G:U./%Q!63<7)4.-Q!DRI0T_JKC:55Q*_&%/846_,,Z./J:XW$;'>=8RV2M
M+J<,BMXS).L`N,^I>A:7=5'WB(S*IZ6J-RQR,.@VY8$P62RK>O*1IL.1B(GP
M%:PX_2"#R)?%:9'R/Z%T7*L^7'(LPK+BG<MY^Q6MO#C*<.99]2]"4NZJ/O$,
MRJ>EZC<L<C$M'M268^E$@[OY+.1EP%KA4-F(UYQU-R$NS2LG#X#(AX[1SLRF
M2ABP'5R(XXCSXH_B/J3EI@M;#/Z7H6EW51R\3F53TO4=YCD8ATAM\06/7+D[
M9Y;_`.;]AT6AK#,U5QX"G1)W8!>8&/DLPDAI%B8!&B4$JS(X?98-8!\1U#+K
M25=,_I>A*7=5'WB(S*IZ7J-RQR,=,+N>BNL$-07(;D=@=A,U)R;<1JW0;HP1
M:)PT65R8J+T$\*X:?,ME+4XVIU#[R5YRO+CB,.,^I>A*7=5'+Q.95/2U1WF.
M1AY<V/!G+`:]?O((D.0S'E**-IG&=@04!PN=C%RA[9>D\/@-1<K`.LJP2VRX
MZA2'QL/CYP[TS^EP_P#X6EW51]XB,RJ.EZC<L<C$E.MY(5[K&OW-W<IWY2T/
ME#Q\PC6F@6ZDP8!/HK<@)FU&:+&AI$P`Q["WFXYTU;8V?$SCN]O3/Z7H6EW5
M1]XAF53TM4;ECD8B<1M04YF*0G<7*B,?.'%=A@"==\:$9)C7S9:&C3P"1=-O
MQF(LPZ'(8'<R\A*L]S'9C#K?>9]2]"TNZJ>7AF=3TO4;ECD8>*U?`;E+P4+'
M[VY+8D32&6F<R.N>/30428\1$#,L.3*=%D0RR_+SPA*L!D/^$(0VM>4Y=90X
MSZEZ%I=U4?>(9E4]+U&Y8Y&,B_5;>/K(;H_B+CO]`O49_2]"4NZJ/O$3F53T
MO4;ECD8U(>AI'\*Y_P#H=^AOWM5ONC^%?\VON_\`X/[E_P`#Z\C\*CFZ/\1M
M8UXO,\KR>[Y?THXK@E\Y7_)6<2,?G^3Y7<\CZ,?_U*2UP,HS8=#$0AAQ95SJ
MXZ$$Y$P,M3TX"VE)&3TK!PPK*NQ?C8RUW>WOXRGMZU!Q&/S::KME[6;5UD!)
M*ZZG$E6;)FZ@>-;\66W:\66/!&UC0<R9*^UET>.7,3<NF"LX$,-[X8ZJQLI%
MH30YJ3*B'VZ6=(UU[`DI)D9PMAS"<=_N80UA&&T5MSX1%HDFT,?P]R/;G4"N
M>K/Q@:C-NUK[PIZE+2>%13H6C^#=6ILBF6MDV7%K,T*EALV4A(2/41OZ&183
M-&PZY*9B$F[K$3F1K\D]$3`W@ZQV@1VAR(_[,,IS+7<7E/\`;-J4G]3/76W.
M[P(O5T(2J5*<"A,']8UC!QQ]?;T:X8W<V5J3.H&%)D?JW,1BD-O3L/IZQ@P9
MS7,J[AE58BQDSFN9:SV>/!+S8(R$BZZ\\ET03,S)"O2$AX>7TY:#BW,YPI;K
M*%V]*JYA2Y),5Z,3SZIRABAYKD?78I%!Q[T^;2)"]5C8]NS7Y:=MD38:_%Z\
MI]7M+HLD-@(V*,EY8VV#0_A!FD,A2ZT#$O-N.M)4THKF-+DDPT8GGM3E3#S:
M-^U*GWJQ5>;@^</H"$E:7`@6L%6QB5V2;OI$1$UL2$K[T,(<4S*6B?$C&7$N
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M<HJ+"X[+9Y`:^]_;V.6.I'DRN8=^H;3N$]7K4.4Q"PDD<XN/7E6%A#G2K@;;
MZ%*:(6*MQM66U)STTJKF%+DDPT8GGU3E#%\>I,3Y3=U?.;.=1I57,*7))AHQ
M//:G**@]28GRF[J^<V<Z:55S"ER28:,3SVIRBH/4F)\INZOG-G.FE5<PI<DF
M&C$\]J<HJ*8WSIL46CP3N-C[B?RK<_'`?N%;&F7VL8+Y#ZN$R\EM?N8('P]X
MC*_U6W4I7CW4XZVET7FI56\,QIA_"U)P-IV*9T]X[.V,$:^\KM2*=LY[4_S#
M'[0\>W%S^I,3Y3=U?.;.=:O2JN84N23&PT8GGM3E%0>I,3Y3=U?.;.=-*JYA
M2Y),-&)Y[4Y14'J3$^4W=7SFSG32JN84N23#1B>>U.45%"31`4$LILASE88\
M*HQSR<9=Y0R0,`BIS8</,'Q8N"4)D6HUJB,%*PVO/>8G(_*<]K^.ITHKF-+D
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M]PG8\R^VG!?(/6`F7DH7[B2!\/>(RO\`5;=2E>/=3CK:71>:E5;HS&F'\+4G
M`TG8IG3WCL[8C7WE=J13MG/:G^88_:'9?;BY?4F)\INZOG-G.M7I57,*7))C
M8:,3SVIRBH@UAHB8>;BH$&S<A)DJ1*@TN%L['GAHIB/E)5X"0):DEM.L$&5\
M,=PXH?/A=@J4_LGBNL-.SI57,*7))AHQ//:G**C'D[8FNQV$"7C'+6$!>CG)
MEDR5FIDRGE#1\@K`;@MH(>8K)!)2D"*!9P_Y@DTID4="RUM-N-**YC2Y),1H
MQ//:G**A]1?J,^+)'>:YFYBQ)")C&#?&N;S<AF877V6I##+'C.@P[3EF'\1T
MK#+B&VB'E-X89\5;2BN8TN23#1B>>U.4,3.+&"D`(&0#.Y-9CY\"DE!('O5@
M?,!>MUG+KQ0DP.*RX##>]H<%TTS+Q*5(91X2DH(6VTMI17,:7))B=&)Y[4Y1
M40QVW5\5F%.ERN3<<"969>TE.E;,<9-C$1EFD:JTPR`><"Z:J6;!=.%=0I"7
MX]2<HPIU:&53I17,:7))B-&)Y[4Y14+DV:DB#8):)YB8CGS$89(")MF&G'I)
MU3KSKC2U#*R0HU3RW_"P]W$X\5Q2<+ZC2BN8TN23#1B>>U.4,.4?*569LDQ7
MPYOD\2U#Q1DB+(KNTFPW.RD2;*AR4-6$'%C,6`QE0#?EW`7B$%*)1X?V/V>6
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MDDPT8GGM3E%1J1][[?WWL']#OWO_`'7)_N?WW_U@_AG]TZ\C<,>*1_B-KR1N
M?T?HXHXO@!QJ_P"2L^4=U^E]+''_U:(H[P@]UJ#YYDC'@LVB`=-/AS\14L$&
MB5$447%RF<IQ&R`[&%+9?SG&&7,87_8ZU$?FNU?6RW?UR.5+SK=,*MDK6VO@
MW$IX1-I3;GYBP)E*_P`U4CL1LMX>Q]'C?:6<;6:"1`F0SEC?(>,K0^QP88PQ
MV$N7AFB1VU$D6T%1D4D5UQ*CY09UU:GF24H<\L/4WY:,7E#\O=CVA[&*:X:7
M\3_9FWJZ[3KHB^LJ4R*U+:EEFJDI**\&H1:;X-2@77T*42M#H2O@FO5YO^!!
MLY>C8*2?FA@C]UAI??KUDL51F&\,:RV@4CR5BJDI"V"-4IQA.%Y'*:RXWE3:
M^\VM2<]=<[RV!>KJ`DJ%*?*2E:?K&AA2L*2?C!V\<?9R\VTO*NYM94$FH'DJ
M4D_5N8E)((^(Q0^Y$06H[(!&AZBYK;8@'JL[,R$YJ;>/)"SFA3A-ACHB$K0T
M43MN+`.<(BTRDD>0J08]'#@,-^$\[(#(S;TQ5\32^BTW)1=T93<;49=_E(Q_
ML6XLQ#&O'!N*_.U4E>JWL^P+A)7>O+#,_7TZ[J%3L#<?(P=(L^P)QERSV*UC
M0([[XPH:9+*,X==:\9;$Z8J^*I?1:;DH:,IN-J,N_P`I$BMFRXNE[!L%6L/&
MOGB37(:7HT-#6R`WER/FLV*8OST5#PP\5E[:4;1R<IL$ZR,0H.R&9CA<N$2&
M`DCE-L-,5?%4GHM-R4-&4W&U&7?Y2$C>\M?O$#AL<6O:H.RQ)#3*8E=GWX%(
MM!NF0X7IDAN3Y(`H'@FGIC&5DJ7A&$C/]F,K:4C$:8J^*I/1:;DH:,I^-J,N
M_P`I"<C=D(U)L!-<//:GDBN&@-*D6[OOQ#.`I6LIFP76T/<A&^Z<F3=2"4V^
MH<4!27,D$MO)2,MIBKXFE]%IN2AHRGXVHR[_`"D3?:]RI>I%(-M.G^9T[5W[
MF)58V6J.^>1TL:^1)5W4\S5I!V-GMJ5F.%7+V78Q,(AI)[BT2D$2VWEYS#C;
M#3%7Q5+Z+3<E#1E-QM1EW^4B[='4B`VUKJ*NUDK');54R>7*BF4JW\B>5L=,
MQWH^0?$8>6S8[I5)5Q@X9M#J%J!:1GO9PVIQ&$N+:9J^)I?1:;D8C1E/QE1E
MW^4BW?Q?J']_MW?E,\D/I6Z:9J^)I?1:;DH:-I^,J,N_RD'XOU#^_P!N[\IG
MDA]*W33-7Q-+Z+3<E#1M/QE1EW^4@_%^H?W^W=^4SR0^E;IIFKXFE]%IN2AH
MVGXRHR[_`"D4QOG1%(#I$$\U.;E6M>Y^.`N<%<C>0IS6&SN0VK@GE)8-V@0R
M@A#)"LLO83AT=W"76E(=0A:=I=%[U2JMX%JEEFM2<%-3C%3.G8:&#;&(C`9@
MD1@7E=U.*=LAQ_\`F&/V[W'M_P!Y%S_B_4/[_;N_*9Y(?2MUJ],U?$TOHM-R
M49^C:?C*C+O\I!^+]0_O]N[\IGDA]*W33-7Q-+Z+3<E#1M/QE1EW^4@_%^H?
MW^W=^4SR0^E;IIFKXFE]%IN2AHVGXRHR[_*1CB4#'A#X>=U9RU/=2P<>L2$Y
M!\JBGR(Z(GMAQ4HJ/7*W2#&5++CZ?&F``F.`OR2+`-AG[!IQW+3%7Q5)Z+3<
ME#1M-QE1EW^4CH<;BUP\;-":BYC8P<?:!GJ_*<A>1@%O`#KD=$/M2K\*)M65
M$>#EI"34TSX1CF5LL94WXI"DB9G3%7Q5)Z+3<E#1M/QE1EW^4B%MWS7)!T[#
MP^E>?I=GA6ZL_-Q'K3Y"85'O6H))4:W,FQ>\Y9`KXL:EIPA'=<?9:<1V(5W7
M<,QIBKXJD]%IN2AHRGXRHR[_`"D750JM3;Y8Y>#]YO+^E!107FFY_8&]N0]<
MCIQU6(Q6!X!E&Z3SR<CHD,X?40T)W%H[K>'>QS+33%7Q5)Z+3<E#1M-QE1EW
M^4BW_P`7ZA_?[=WY3/)#Z5NFF:OB:7T6FY*&C:?C*C+O\I!^+]0_O]N[\IGD
MA]*W33-7Q-+Z+3<E#1M/QE1EW^4BF][:'I`E)@W6IS<RU+W)QT%S@KD;R%-;
MPV;R#U@$\I+)NT"&4$(9(5EE["<.CNX2ZTI#J$+3M+HO>J55N@M4O\K4G!34
MXQ4SIV&L6V,1&`S!(C7WG=U.*9LAQ_\`F&/V[W'M_P!Y_P"&,1<GXOU#^_V[
MORF>2'TK=:O3-7Q-+Z+3<E&PT;3\949=_E(KZT:M@XB=@H"`B.0%B=DY""Q(
M2CW)[DY%P,="'RCPLZ8U,"WZ;%7-5Z*&<.\D;F.9,1A#+17F76FEM,5?$TOH
MM-R4-&TW&5&7?Y2*`D;32J^PV_>M0<U(R,RTP6JP16].1,W567WIOR,`/Z1F
M-NU>0S(RS[P.!VL!>*@U]2<X2PTDMV=,5<_JJ3T6FY*&C:?C*C+O\I#P%-54
MUJ4(;T;[0%#(<E%1P#)&UN0T?(2:9)<"AV2P/,;SC!`XH'T^E;CJR,K;;#+R
MZAI;&49:8J^*I/1:;DH:-IN,J,N_RD3:/J8LFU$GC:_Y)HC)2+U^8[@KE-R0
M&FH@RW6LZOSP,I&JV%D'**A'@9.>6*:4[EMYKS+03"\DIC3%7Q5)Z+3<E#1M
M-QE1EW^4B`/RT'%BUXZ?U'S$8!E:M-6&:3#;TY:S!]>>C+2971HXP8RVP@0R
M94$3,FVN1*C'4`9RXIGLQVYG3%7Q5)Z+3<E`W;3C]I49=_E(<W9:DLAX/]3G
MM`21G3!1QVP]D<EE2.&B48QD@V+-W4":)A@AMW#G=2ZVAI*%Y7C+J4=1IBKX
MJD]%IN1AHVGXRHR[_*0\Q3%/E;!-1GJ]YE1D5%19)@LO-;JY0QI,^>`;),&`
M0<*]L[))K3@P+:Q7O$QEY9+>'&V&,X(RTQ5\52>BTW)0T;3\949=_E(:+(-Z
M"1L+R>G^5DV_3JE)6*"%#Y+\H4JNLH-8B86-JT4;BY/1'I>4$:;)PD<DU:,.
M]F$.,XP0IIBKXJD]%IN2AHVFXRHR[_*0RST_#P2W0,:$YY2LP&'-N'MQ&X^2
MTC!+/@4K8)$AK&%M@@66&-DL(;"?RVQDYAU)`[;C:'_!:8J^*I/1:;D8G1E-
MQM1EW^4BS]>URI7Z>(AWJ'S%H0K$41)(E]@[[WY"BE+:3776@V&H_>4R\V^6
MS8<^'A_P59=!+;[O?'<PEIBKXJE]%IN2B-&TW&5&7?Y2+G_%^H?W^W=^4SR0
M^E;IIFKXFE]%IN2AHVGXRHR[_*1J4][,;_VFP_T.O>S_`#MM?W-_[3]VOYP_
M][_=7^$]>1>'7YJ/\1M>0C'M>3Y/T/(^C'%<`CSE_P`E9\M>+;\KROI^7]*/
M_]:E]8X[VR=>I\%\CO7BIX\`4B3%)?[9X#'@CE0A`DR,^Y_:H<$=:*0K.,M+
M2O"<XU$?FVU4PZTZMBPI7_Y"GP)*TJ/ZY&`*:*74DX@6U)6#A00J1C;OJ&*D
MH3VK'&2,E9=V>('6`I,NH"=C!BVB(.\E=V,"GB2'VHD)UY8XV6\YPXTSA;SI
M1:B32:FP`X@`S\8?YH]RM3Z2KH?Q<=EU+6UAJ'4@?K+#J$J!9JU2;2ZHD-I)
M*$%.`I3-:G7BZ^[M#]OE?KUJ_P!GU.7O6EUMNN[O`;:U>Y!7*BV.8J-KA5GR
M)\6<N)L,`9'R\<LR,.>&=RR\C+C#RVU=J%JQGS-V/T='>&N;%'7TK;](NG=M
M(<2%H5)((FE0(,B`1,8P#'TL[9*^MNS4:LKKNJW&*Q#[-E;:BA:9K"3)22")
M@D&1P@D1X=/S@_/CZ[_+[\I;='QUZ]LO4K4[JI=OHS.\CT^]?-=^MUY>DN[^
M#\X/SX^N_P`OOREMT?'7IZE:G=5+M]&9WD/7S7?K=>7I+N_@_.#\^/KO\OOR
MEMT?'7IZE:G=5+M]&9WD/7S7?K=>7I+N_@_.#\^/KO\`+[\I;='QUZ>I6IW5
M2[?1F=Y#U\UWZW7EZ2[OX/S@_/CZ[_+[\I;='QUZ>I6IW52[?1F=Y#U\UWZW
M7EZ2[OX/S@_/CZ[_`"^_*6W1\=>GJ5J=U4NWT9G>0]?-=^MUY>DN[^#\X/SX
M^N_R^_*6W1\=>GJ5J=U4NWT9G>0]?-=^MUY>DN[^#\X/SX^N_P`OOREMT?'7
MIZE:G=5+M]&9WD/7S7?K=>7I+N_@_.#\^/KO\OOREMT?'7IZE:G=5+M]&9WD
M/7S7?K=>7I+N_@_.#\^/KO\`+[\I;='QUZ>I6IW52[?1F=Y#U\UWZW7EZ2[O
MX0R'/3G-+,-BRO,_EC)BM'1DFT-(<B]P&CMR4+)"3,-(-LDW%UM!T1+@,%BN
MXQAP<EEMUO*5H2K%2-3M46R5-ZKW<E1!$Q3LC`H%*A@1B*201L@D'`8H7KSK
MHX`E>MEXE,P<-0[C!!!\O&"`1M$3A=^<'Y\?7?Y??E+;H^.O5/J5J=U4NWT9
MG>17Z^:[];KR])=W\'YP?GQ]=_E]^4MNCXZ]/4K4[JI=OHS.\AZ^:[];KR])
M=W\9#::YN[PLT-+)W'[27G3KN='LM<'BBX7D#N>Q`&UJ06ZU.D.0K<WXK9<*
MMI+BGLR2.\T]^QC.K:[CFCO75.Z:=UK1>HMTOM%M4PJG920H2L^-+$J9P6<8
MPJ$\'27'K?>E8T[IKM!O:F>#B0DI?=4"@SM&SCF",=K$?),I&SH[EU:I.+F#
M7/:O\[J\:-'-'Q,7,[LWN64:Y*!0I#<<ZJ&,,"1+5!3\AYQOQTC2SPC3`Q(V
M'\$)USFK;#;C:!V<70M))!*66`!(J$_&`,E^+9,IH!)4E5F4;=K68.MO.*[4
M;X;4`"E*G7B3:"3+Q9B;<UVA.2RD)2I-J8>SN4%A;V$B)&]L9S0;UZU5798B
MS.;<Y)G2A<VR_47F80*/%6SY<^2"D)IE+3R/+C.1;#KA:O.I&9MIU?9S+A3V
M8W8:TN`6.!I@`DA<U$G&`0@S&$A2@$^+:-Q>L$KP+*.UJ]!=X:*K?"U!)4"B
M20`,!(+@D1(%"25>/9$)+YB;*9JA^$>U(YOYNL+7\N&/!\@]\2<!/V/%=D)%
MUNJ19#<&0]'CVP`:"0V9)C9)9EL2^'VF(]X0G*1JQ0FH1/L]NK-5+P3IV`I*
M;0'CF:A,H)<P),BC@Y$K"DX2]::E-*[_`/Z5>V>(;QA]Y25+LD^(FRDD<($M
MR*Q,+X6T$H*529/+*S1\82>;[6SG!/GAPRW45^$W=R&AW9B='IE<R0.'-2S!
MHL<`]L-N8;'4\.M3D0L%2LI=P0KK']7&5NI0GLWNI#95Y2F*=5E)6J1*4D$G
M@[!,C@7;&*49?K)P;"W%]J=[./!.!*7GTVE!M,_&4DR'"A83,84%!G.<21?)
MT_$T:(/[8;F\1%L^C<`%O[JY`1[DBIZ3F\$+0OOFL",/!C@#+R3X#H"GW3<M
ME-MH$<L"X$\$E1[,;J#F&8X&G,L"?@PS*C@G:D$323:&0;_9#JDCM:O8M[!X
M5\?G*[A$B`D;!3,K(4`$F*6OEG<8ZDS9U3]K%S>LET&C-A%0X16^=^0\*3(0
M,A!HH\:0T0E4LY[\XM^04TZCNX;+:':*2"PX^6-E4^K=*NK914]G-U(I2IL*
M(88*@%!7"$;'B&S,>:5%-L@)5BUFLBVJ"H=I.U&]7:P(=*4E]Y(*DD<&")6O
M'%J1$O&LVK"2I2<&9#GISFEF&Q97FARQDQFC8R3:&D.1>X#6&Y*%D1)B'D&V
M2;BXV@Z)EP&"AG<8PXP2RVZC*5H2K'7(U.U1;)4WJO=R5$$3%.R,"@4J&!&(
M@D$;()!P&.!7KSKHX`E>MEXE,P<-0Z<(((/EXP0"-HB<+OS@_/CZ[_+[\I;=
M'QUZI]2M3NJEV^C,[R*_7S7?K=>7I+N_@_.#\^/KO\OOREMT?'7IZE:G=5+M
M]&9WD/7S7?K=>7I+N_@_.#\^/KO\OOREMT?'7IZE:G=5+M]&9WD/7S7?K=>7
MI+N_@_.#\^/KO\OOREMT?'7IZE:G=5+M]&9WD/7S7?K=>7I+N_@_.#\^/KO\
MOOREMT?'7IZE:G=5+M]&9WD/7S7?K=>7I+N_@_.#\^/KO\OOREMT?'7IZE:G
M=5+M]&9WD/7S7?K=>7I+N_@_.#\^/KO\OOREMT?'7IZE:G=5+M]&9WD/7S7?
MK=>7I+N_@_.#\^/KO\OOREMT?'7IZE:G=5+M]&9WD/7S7?K=>7I+N_@_.#\^
M/KO\OOREMT?'7IZE:G=5+M]&9WD/7S7?K=>7I+N_@_.#\^/KO\OOREMT?'7I
MZE:G=5+M]&9WD/7S7?K=>7I+N_@_.#\^/KO\OOREMT?'7IZE:G=5+M]&9WD/
M7S7?K=>7I+N_@_.#\^/KO\OOREMT?'7IZE:G=5+M]&9WD/7S7?K=>7I+N_C?
M3ZS]E_*'>?\`_G*]9_\`.V?_`/,OY0_NA_/G_O?[H?X7KQ#HZ@YBS_SMP/D)
M^JXK%]7]#R>Y'F[2UZ=(O_\`(7#^6KZ_CL?UOT_*[L?_U\<8;)N)B*S')$7(
M8D@<@(D&HUX!9N"FLBI-9F$KB'1%/]W#B2DY&4CMP[C*.]UJ#BC\T-#PXK:,
MTH0:GA46`L(*"JT+-H.3;*9RM!P%!$[7BSC97P>*NYGM&^-+M_;JK<][XEI2
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MX<%J]S-C)#>Q$+-<-X!T`VR5G1'`.7N/=4[':^)US=!I?+#JH=(S1LH\R'4D
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M)P^O#WA>%C*UK'SRHRQW\."U?YG3Y(;V+]\WP]_`S5WS1L?%#J+6LG/*C+'?
MPX+5_F=/DAO(/-\/?P,U=\T;'Q0Z6M9.>5&6._AP6K_,Z?)#>0>;X>_@9J[Y
MHV/BATM:R<\J,L=_#@M7^9T^2&\@\WP]_`S5WS1L?%#I:UDYY498[^'!:O\`
M,Z?)#>13N\RN)F:5">CJ?K5HCUQ<=\N*8U4R.O(&.0&LLRC:G,51OO,NQF'D
MN([?V5O*D=BN]W<[.Z5:PYT[;JWRG-:G]L3AS=V7Y^W*6T<,8%XMW#F[=FC8
MGP['[(8N&;G^;M1<7F^'OX&:N^:-CXH=:RUK)SRHRQW\9_!:O\SI\D-Y!YOA
M[^!FKOFC8^*'2UK)SRHRQW\."U?YG3Y(;R(O:RN-JH]&*92M(JD,K(\PF=U>
M['I4QY$OP$`'BZ[GFP3%R/@8\=X$UIIKOJRP]G&&U+6L?/*C+'?PX+5_F=/D
MAO(HJ`#`8;MN+$'Q6/>4,0W2U`:>.&9P0B;B%B/S;2M49<&\>`:.2YAM926W
MW6L)PO"5.=3:UCYY498[^(X+5_F=/DAO8=XS,!YBJ(E*]Q)Q'>5@<W50^H;&
M]-)D8\R$:G<5HKU?"11$98`!CGD))#8?$=(2TE>4IPZVM:Q\\J,L=_$\%J_S
M.GR0WL5_'25C@6I)V6UYPWO+#T])KAF`-93D1/CP,C*/+@!Y9M^CPT`P[``%
M--2+K!)BW6AG'QVWGE(&<6M8^>5&6._AP6K_`#.GR0WL3=HR/\,9PJC\-\+=
M3&*DV`=77%]8F$J"1,#P62Z"&V60XT02Z,^8MMO#@S+2V>Z^X\PM:Q\\J,L=
M_$<%J_S.GR0WD7]$%\3_`$3%^F:9JC,OZ."]*Y&U&/Y?,EY9KSWE^RH8QX/F
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MD)ER5B^+A<(F!DVX`<#3YB;`N=P!;T1#\FZ1K$:(4TLYV%6^EOPT8[C^$_8M
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MC"UK'SRHRQW\3P6K_,Z?)#>1KZ\2B?\`8(?^A'X_W#3_`#!_[%^\?N)_`O[7
M_!==[_%^>K_$_._:;>/ROI?+'(RH^+1_A_F_L]K%Y/T?DC__T**H<4)/7BF0
M9["R09FUUV*-&:6:VX0)(RX89+#;D:%)2*%NLO*3C(X[[V,Y^P;6KL3G41^:
M[5ZC9O"_[CH*ALKIWZQEM205`E*W$I4`4)6L$@D30A:O-2HR!VP<>M:U357M
M2>-58ID21#P;D@)*M#D2,S*9>>,KEP;<+:+F8X/*FG4CIQV"OR`?>3G+1;O;
MG"*FYVVYXYC_`#?Y?Y3CV_[.M5[GU1_%?V8W5<5&IB[RKA`"MUR94Q5`J"G4
M),B$@>(IYN8-EY6$)]9>T*>==:B_&PQ@L=98N6KMMJ4@<VXL`:TTV?CK/!LR
MGETY-Q!2IL4D*3P/E!#L820VVI*EXSCH:&I32U`6XDJ84E2%@8RA:2E4MBT`
M;29X`H`G%'V(K&%5#!0A0#J5)4DG%:2H*$]F1(DJ6&R2!&(^VMB[J/F(F5J5
M]D]#+"JYE?FJ!>=$VZ^Q9%R?L$/*EV0?8%9@IBM3HT7`Q208]$:8Z.0Q,END
M>"6,VTSDFZ7UJ5FCK3S6PH.(!([J%*"TG;"DC#BF)$V4WBRD`5+3C3FR"A1`
M/<6D%"NX03\1!`J1VR;Y(A(7Q>7[C-FAX!UITD3C]<&8JQ6QNP:K/9F;,-ZO
MLMOPQ,17;.-F/C6(I(Z)QI/??4PEY#0UX<2G*-[^)TG1<8K<+WL(E;)Y62=:
M0IWDEKF%LI!&"TL,\=MHN@1HP_H8X*/(=9K*W3I%^0:)9*?0Y@-`6%,I8)<(
M24&T->'$IRC>_AI.BXQ6X7O8[ZY:N14')0#Y?,`">AU1NOHFT0TWQPN)9#"J
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M/F\V/\4NHT->/$IRC>_AI.BXU6X7O8/QB-3_`'ZL'S>;'^*730UX\2G*-[^&
MDZ+C5;A>]@_&(U/]^K!\WFQ_BETT->/$IRC>_AI.BXU6X7O8J/=F[]>3U-A0
M88NT2);&W./\R\.+KC8[CK<57-\:WL,Z>M.*G[@T5"19!3RO_D994K^QULKJ
MNNM9JG5NH0E)IJA,RXWC53NI2/+QE1`'=,8-X5]*XPVEM2BKAV3@0O$EYM1/
MD[`!)[@BW/QB-3_?JP?-YL?XI=:W0UX\2G*-[^,[2=%QJMPO>P?C$:G^_5@^
M;S8_Q2Z:&O'B4Y1O?PTG1<:K<+WL,M@Y`4,J-6U7;5*1DEYD)SS)NL=CEMK#
M:+9<D!&O_M7*!"C0D+::)6T2@9:\.98>PGPU-#7CQ*<HWOX:3HN-5N%[V,:A
M-D;1:@6!S>1&)"?9DJT\Z=G3%O"$,C@:W:HVQLJ0%J1GRQ$S/246?]BVM"%1
MZD-88:=RUU.AKPXE.4;W\-)T7&*W"][$UD-L3+AI+XFZ"%@.@FO-1;VH-@!)
M9F2Z](C>6%D0J*H\:"'L!R'1O&482.PPUWUOK2KQ&AKPXE&4;W\-)T7&JW"]
M[$`1MS=$4UY!K=T!9DO`.QL=*EZ-O\29''((4X/9+2ZU47QY5.8EIQEP2-`&
M21*$#NI\H(.0R2T->'$IRC>^AI.BXU6X7O8D"MM;*P4-A&\8)<9@@5TYMW1N
MRDRSV,L+:,\E(L4UN/##9>':>8&6"^XM1#B'2<H:3AYH:\.)3E&]_$:3H^-5
MN%[V,F?QB-3_`'ZL'S>;'^*74:&O'B4Y1O?Q.DZ+C5;A>]@_&(U/]^K!\WFQ
M_BETT->/$IRC>_AI.BXU6X7O8J7=6[]=SM.A@H<RT2);&VM!3+PXNN-CN.MQ
M5=WKKBP3AZDXJ?N#Q<)%D%/*_P#E994K^QULKJNNM9J75NH0E)IJA,RXWC53
MNI2/+QE1`'=,8-X5]*Y3MI;4HJ#[)P(7B2\VHGR=@`D]P18\SR"UX1%2#$':
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M:3`5S![0UX<2G*-[^)TG1<:K<+WL1]C8NP_1&6)'D`])2R;O49AA_&I[Y$CM
M5&.D"7[375+A-6QSA#\S$/(!PMY#N,N-^;1D=><,I:&O'B491O?PTG1<:K<+
MWL=T1N+;CGF7)K<54#\%)K,>P)IC9\DLGLG)C(A$F1[Q(AE.78'`']Q93W'O
M&QE.<9QGIH:\.)3E&]_#2=%QJMPO>P\8W%>7'8Q1FUHEY@!I@LT<'6.T8E^9
ME&)*5<P)DU.M#FXN'<AW@V7>\.:MTMEQ_"&VEI&2T->'$IRC>_B-)T?&JW"]
M[#I>-M3TL.-FD[O,JY239Q3R2-+VV0']'OO*77VW%F:U.=,,!;<4E]:,"-N(
M2UCN94VZX0T->'$IRC>_B=)T7&JW"]["([:MFP8P?#[M6QGP:D(=&RFH-A2`
M1F!(<-BWRC+C=#&]&R4E+B>(,VTUY;#+KW:EM;B%,M#7A+ZE.4;W\-)T7&JW
M"]["1W;>P<+>=$WA#MJ=E02<,'Z,V,>,S%X)!S)1HOEJ;%$,J4+YG##KJR%I
M=RC*\Y1GN-M#7AQ*<HWOXC2='QIW"][%Y`[4G)FJ0U=UM"66VWLF$#CEVRR4
MNZ5S7D(<R&V$=;[!8+?%5+-EC@Y%.5^C8A9$N>XI*/#'9R^8-*;N2PKA+Q>;
M0RG"4I6A3BOHI2@JLDC\Y8"0,.$R2J%URG1P="TM;IQ*4A24)^DHJ";0'FH)
M43@P":@R_BF4/[_V[^C+^*[^^XO^:?X6_<K^?7\*_N'^!ZR?6&KXIO\`GLZQ
M'RO,Q_5]S'W8Q]"4W&+_`)3-\8\GSL7E]WY(_]&DM<#/F[#H88JG4$EW.KC#
MK8!3*/H??G`6FE,QBXJ=1(NI<7C*6,@F8>S]AEA[M\-6H,Y&6./S::KM./ZS
M:NL-%0=774Z00CA""74`2;+;H69XD%IVT<'!KG9.TSC;%`QOM1>.3\:W8AP9
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MMV]5W\LG>0?I4="^IE;_`)ZH;Z-^GN]UW6=K(JY2'O&W;U7?RR=Y!^E1T+ZF
M5O\`GJAOHWZ>[W7=9VLBKE(>\;=O5=_+)WD'Z5'0OJ96_P">J&^C?I[O==UG
M:R*N4A[QMV]5W\LG>0?I4="^IE;_`)ZH;Z-^GN]UW6=K(JY2'O&W;U7?RR=Y
M!^E1T+ZF5O\`GJAOHWZ>[W7=9VLBKE(>\;=O5=_+)WD'Z5'0OJ96_P">J&^C
M?I[O==UG:R*N4A[QMV]5W\LG>0?I4="^IE;_`)ZH;Z-^GN]UW6=K(JY2'O&W
M;U7?RR=Y!^E1T+ZF5O\`GJAOHWZ>[W7=9VLBKE(>\;=O5=_+)WD'Z5'0OJ96
M_P">J&^C?I[O==UG:R*N4A[QMV]5W\LG>1RQ_6H*)G&,XX87'.,][LSC=,/G
M&>YC&5=G_AO[O=QGMS_T8ZCW?*WK.SD5<I$C\1EWF4M57\LG>08_K4%%5G&$
M\+[BK*L=J<8W1#YRK';W>W&,:V]W'>]S_KZ>[Y6]:&<BKE(D?B+N\REJK48?
M[Y/)QRS_`%IVCX[W;PNN>.XGOK[=SQ'V",K2WA2O_#;[%.7%83VY]SO9QC]7
MI[OM;UH9R*N4A[Q=!A_^J5&#^^3R<<?TI^B]O9^)?<NWMQCL]=$/V]N593C'
M_EM^KE6.S_KZ>[Y6]:&<BKE(>\7=_56HRR>3@Q_6H*+G';CA?<<X[>SMQNB'
MSCM[4X[/<UM^KVJQC_KSCI[OE;UG9R*N4@/Q&7><6JK^63O(^_I3U&[,Y_$N
MN?8E&'%9]<\1V);4I*$N9SZMO<0I:L8QG]3.<XQT]WRMZT,Y%7*0]XN@ZJ5&
M*?UR<6W]7'S]*@HON_\`^%]Q]SO8S_XT0_N93CO*[?\`PV]SNX]W/_1CI[OE
M;UH9R*N4A[Q=W]5:C+)Y..7Z4]1^[E7XEUS[N/U5>N>([N/L>][N?5MV?VON
M_P#5T]WRMZT,Y%7*0]XN@E/U4J)?Z9/)Q\S_`%IZC)]Q7"ZY)SW4J[,[GA\?
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MKO$K;J[K3Y3C<P4;`*T'"$GSDE0'YQ&"??ZF=KFK6N-4F[4)<I+V4/%;=E)<
MA,AM:3)1`PV2$J(P@&1EN:Z\7QY4C__2I76K#I.QJ`,QX_CD76JL,^5#3(E>
M*[.@-M^6CU1,\D]_OJQW&<@FX=5V)\![M\-6HC\VNJR%NZSZN--VN$57TX%E
M-M4RZ@"RC@WK9GB3P3MHX.#7.R=FW%"N1%8]I1Q6!A!I\4)9:,K:LAMED9-L
M^/B;U!28V"K-2->.K!CI"(<%%P+%#B)'81A.$N>*A%3<K;<A^</RQ[3=DEV4
M5U?B>[**>@:J$,$F8>6^M86AJK:<3:?I:,E"%MJ;;X-A#=A"9`*MI3Z&_:N3
M>XXK@/OZ+X_Q%AGMPWV)K&KJ;%5,9\JR%^LN[5NEV9$(@1;9;4HFF3,DH=UK
M.'67L)<3G&4XSCR5V>-78YKA<[E\NH1=C*E.K*\"1P2%+3:G@E;"9@X",$?6
M_M$7>R=3;[:N)E;EZO-I:;2CROUJTMJLXI$(4H@XP1./`]^:N]HU]3'?_P``
M93]9U[@^T/4?K11[L1Z7^S'7_JK5;D>&#\U=[1KZF.__`(`RGZSI[0]1^M%'
MNQ#V8Z_]5:K<CPP?FKO:-?4QW_\``&4_6=/:'J/UHH]V(>S'7_JK5;D>&#\U
M=[1KZF.__@#*?K.GM#U'ZT4>[$/9CK_U5JMR/#!^:N]HU]3'?_P!E/UG3VAZ
MC]:*/=B'LQU_ZJU6Y'A@_-7>T:^ICO\`^`,I^LZ>T/4?K11[L0]F.O\`U5JM
MR/#!^:N]HU]3'?\`\`93]9T]H>H_6BCW8A[,=?\`JK5;D>&#\U=[1KZF._\`
MX`RGZSI[0]1^M%'NQ#V8Z_\`56JW(\,'YJ[VC7U,=_\`P!E/UG3VAZC]:*/=
MB'LQU_ZJU6Y'A@_-7>T:^ICO_P"`,I^LZ>T/4?K11[L0]F.O_56JW(\,'YJ[
MVC7U,=__``!E/UG3VAZC]:*/=B'LQU_ZJU6Y'A@_-7>T:^ICO_X`RGZSI[0]
M1^M%'NQ#V8Z_]5:K<CPQL*U9ISVB6NM2ZZU(Y[-3?ZA-<"7QJ*O=)*ME`V2Z
M;M)FXM;!D&K$S7I\.*(G&SJRPAP4-LIH.K,LN//9=:<#XN\+TU)K;RKKR&O5
M':?+<VW`EQJ35C@Q9M))LR=.%4BITD`2(5Y!NNZ]?;NNF[KI/9_5V*8.67&W
M."=)>X3A3;DH"U-H"200&@+1M`IEUSKOM2K0S(D1OL[-YU2:G/!--(A`;&+!
MU&7#FPI<1.FJ^#!1^-4UDC`RO/QS!)JCB$"NJ(0D-EK&'3.]GK'!I<UVI'&D
M'`%62I8((/#J*CPJA/Q5$)LBT+/C$QFU2>TJHMK:U$JFGEB9*5R2A0((X!(`
MX%!EXR`5%1LDJ`0!'6'6?:E(S.%RGL\=^3,K)A6]AHHMNUK#D7;C;N2TZ^/?
M(XF&+3?*_`17)@YJ*`><&P%*0P)V'5-9(!>E3W9Z0RAO76D2VDHP"S,6$4HF
MV01P:E&E3;4`;2%K1*<EB4I[2K;SKFHE4IU07(E9D;:ZM4G00>%0E-6H(02F
MRMM"YRF@S?)?M/"K(;9I7V6^PSI"PS.MYZXDLPMUC3)N7U+O*Y<@ZC+A."#I
M!CIF7V+<R#+&00,?F9>RXZA(BW>U&*$:@)ITT[?:"T$(0ZE&%!"0\PBG6#/"
M0&T!+8!38$AXP$92G^T5Q]=0[V;+*W%-*<()!46*A=2V1+`E1=65.$A5LS(L
MSP5UH_7GM']`R,HBF^S.W;,524V;;K^16;F+.S.20;E:./%K-KTC(1M7@F#7
MXF3X_#$1IZ1&EA'E,EH:R\"UES.O:MU%OE+9JM>Z5-0FG0V%(DF1;34H"@"I
M1$Q4$*3,VD@IG)9EK[EI.T"X5O"C[/*A5,NI<=LN+"L#BJ52DDA*09&F!0J0
M*5*"I30)H(J@^U.83/8F_9][TFL$4&C:^K(C,-.1$1'0],U#:M/-B6^,&@WF
M[_$I`NATW'#$+%5&V)`Q7C/M-.#/UNUG9ZHM%K7.D0>&<<69A1*G'D/302K]
M6J:$MJ(G::M)D"0H4LT_:6@.![4:I6`PTV@!5D`-L+8DX`/UJ?'4ZA)LV';*
MIJ`(-BW)/M1+U$[+BYSV:&W'/6I'W:-L)C<596R(X>[:IA]2GJK7=A4HB'W(
M6%:?)<5AY9;JW&\Y0RKN8P:7V?T;E"XSKY3_`,.4%(FF1L.EX6L.$!2B`,%G
M`<)PQL:M[M'K&:YE_L[>.<)6%FUA`6R&38P>*2D`DX9X1@&"(]=H/VIUP)LC
M[/LX-NUL.U.SA$M58F-V`51G7S=*[AT+!=E8FW95/EH.@['B65,9?RR_FL#I
M;2.RZAH:_2N]GE,AM)UXIUJ0$@+);#@D\S4*\=(&%3C:S.4QPIG,B:L>J/:7
M4NK=3J"^VE145(2I7!&=._3)FA1.!+;J)B<E<$)600$O-B#]I]-5_9]6;]FC
MN-R(V93=AUEXFR@VFU6&O2>Q:UR#@RK)$3Q4*&]DJK(Y&2\="-N-J\E56D1*
MW'EN.GJML*[/V7Z"I.O=-PM.ZVH!-E"5!M5.H)*03@7FZ%+(\IXER0`"(KJ#
MVCOTMY48[/JC@JEEU$UKMK074U"2I*B`?$SE:6P?)9`:F22N-5?YJ[VC7U,=
M_P#P!E/UG7D/VAZC]:*/=B/%GLQU_P"JM5N1X8/S5WM&OJ8[_P#@#*?K.GM#
MU'ZT4>[$/9CK_P!5:K<CPP?FKO:-?4QW_P#`&4_6=/:'J/UHH]V(>S'7_JK5
M;D>&#\U=[1KZF.__`(`RGZSI[0]1^M%'NQ#V8Z_]5:K<CPP?FKO:-?4QW_\`
M`&4_6=/:'J/UHH]V(>S'7_JK5;D>&#\U=[1KZF.__@#*?K.GM#U'ZT4>[$/9
MCK_U5JMR/#!^:N]HU]3'?_P!E/UG3VAZC]:*/=B'LQU_ZJU6Y'A@_-7>T:^I
MCO\`^`,I^LZ>T/4?K11[L0]F.O\`U5JMR/#!^:N]HU]3'?\`\`93]9T]H>H_
M6BCW8A[,=?\`JK5;D>&#\U=[1KZF._\`X`RGZSI[0]1^M%'NQ#V8Z_\`56JW
M(\,'YJ[VC7U,=_\`P!E/UG3VAZC]:*/=B'LQU_ZJU6Y'AA^JWLU?:=TBS5VY
MU+B1R,@+34IR*LM;G8VC2K$A#3T&<Q)Q$H"]AO/A%@'C-NMJ[,]BT8ZLU&O>
MH-73OTM3K'1+IW$%*DE8DI*A(@]P@RB_2]G?:-15-/64NK58BJ:6E:%`":5)
M(*2,.,$3CW*_CR;!^3HC_P!,#\>3[CE?^8/R=?=/]\?P/^Z_X;KU,]5*+GH_
MQ[,<?[/C,6+N_)'N1ZR7AT<?\$SS%^UXG'C[GRQ__].@:@?*15LJ\I!A#24U
M&V*%/B(XT1!X9\H')#$1X18+F4MFC%%MH;<:5G&'$*RG/N9ZU,?FJN6IJZ*^
M;IK*!A#M<U4M+;0M-M*W$K2I"5),@I*E``I.,$C9C8_PAS>,>T6XOL7^K"U"
M;$F?+M18L0W#)=`][UN>:.<%;<=3^SDO/);0C*!A!T-BBM,"#CCM5(24K;!!
M'C#'\,>S/80N_5?B4[+$:PW4W1UR'2D(0V&YHX"I(40"<:BH)`DAM`2TTAME
MMMM'KHWM]QM>_P#&_37^WL/UU-T_65O]*]_8,?:R\?(I?ZAK^V(K?E)K&'V1
M(Z7'F-C["UWY.\20D,JG2T7&P5HL,A7C#HRKW4>1D@/2@4LB#=9"'QA27BW$
MM*4A3J,YPV*9U]%2MJ1X)%HC#.S:`)$@<4P3.4A,[!C*=?0RIE"\'"*L@X)3
MD2`<.S(@8\,ALQK;!USQVO!\8&)RRY1T26J]8:K4C6!J_:AY&-P&]=(H28D9
MZIP,W32KFPNSN9;-&,+\"-8$;2AIO+BG;.':B[@$9.:CN&D-';`EK6=N[;-M
MC[TP!#13]KJMCE8>:(>J.NO\_,$L!'R/I]MFKH?E7&PXT@\^7+))9?'&86!3
M$QE.QRYT@Z>X$_.S<>WEL5T$L^HV5E4DDH<@C.&(9$8[:`5"8#?2]@X`3P\M
M=ONH<96ZD80@#YH\<I`=9H5VE7@F12RWB5Z^V.+A+0;>%J2P*;4QCY$A]WO,
M-,B-/NN%-.,83XS:T82A#N?RPTG"&!!V>PR=5],M1!E=)GJU/,#ST;.04'8(
MV1:P(`83!)>'GV6<C3#<:>DE*V\CX[N,J2A$,D.=G'6+FHB".L-C',LU:%MM
M1\6EV5OWTP<A'P9\67'BN1Z)*-1(YG4L)S)L`(9>8<\=33:QW'TH1((WF?QQ
MF(`RRQ-ZE)&*"EPH)2A=<[/</*DY(=PH!F+A_>9B7F&"V$)R@@5AX;/C,X\3
M&7F>^D80V1?./C9)(1ARXV"*+Q%ARQP4OK39@BXEDT-PYEB0/147H5)*V&',
MMX:*=01A&5,*=1E*LI&&U#N_S)X[,MQ?9>3'#9NO8M$5$JI=Z#EGXI=FDJ8U
MDP*2K8*X$MRUQ+X&6)+(;K;R<9<PAM25Y2,(Y&<P^/XHY+S=ODBWA<QJL@M4
MRZBFDC2CSS3!T>U*5^.1(@H0*^XMUA3B>Z.XE/><QA&4C$3AC/YNZ%B)J5!F
M)6RQE>BZFFXXV`[5)8RER$;V1RW!H]^*:D+`J189E&G%-O1S*>XI.<+SXC.'
M$HF'V'YA:!F*Y%6;%O.`$E8T.50&95+4](B#&Q,;-MX-8BH>390MJ,EAW7,H
M<<;1A>>U7:E7=2A"2L\T>.EP0]FNWDB2<'B)RQ/CMU6V-/,UZ`A#[(5,N>/"
MM-($)@P/,,(RKS"\.MMY;2[E3:4C.4(4O<Q-`H(!$8M,V83(+#;9;;H5]$:9
M<D`GSPD2!TK6X^-BE.CM(4Y@IYGRC+[;Y'@C*R]A(PCC>.7FF]?JN;<Y(R9!
M%+<K;)(4*Q&R\G-/VJJ9N$4+`Q(DLJ4>.]&+82Z,2R*0VX8(K*/!*'=<S':"
MH9I*2M4/U#UJSC_-)3AF`,)!D02#(C&D@8K56T[45-*F?"M69XOS@#@D9X`1
M,$`B8.(@E7"\N-%6@CRE4M)UC?0EYTA(=;L,<T&,)L.L:O.+**L4;"B-#!6R
MU,MJ5XF<N-#%+:PYY=S&,.494)I+E]I0$-)0LI8YAYP.U2+$4#49\*:(`J-"
MF=B'%,Q5A"@RU(DX:%6S&IRG#DB4XC#"5L]]Y$0A@&YV\8'(@B8.V`;",!//
M#&L2U)O31(Q#,BU%9:Q@6N%CF*4>[X2?+./8RXV\CM[XY"6IE"'Q?,OCJTP,
M2_=)T=DMB7*963J_;`V?*00QADF8ZA^CMK'"9&"4I#SF$M/]]G#2EY?8PXD8
M=R%:^7&CVGQFGIZP)8,DJ/`CFL46Z2+#EEV&#-2=8KF68J"/D&Y`F.@'W775
M,)"'[4-N/I=7AOI(PAFA.;7'&?D&(L&Z2GG#Y`@"%0JC7IYN?PPOP4&Q#X-<
M,9=$,)0XT/XJFGGUM*RAO*>ZI21A#QCEOI-^",L\;.2\I`1HYQLC*L5J:"$&
MCX_,.I\YE<V)%9EV\C3PI&&P,%D8'<RXIM*6W,H2A`YR[T2WEACWTR"Y!WWE
M9?C45>RY>!1?(BK6&%64:J+3#9RU7K@&:0AHIUQ#7BH2E;[2F<)&$-97-?C<
M.&`:B^&%L2=E'J02AJ5>L8?FG;/FI$,-N$UL9E:(Z7;7A_.%9SX:.\C"^^UA
MQ*$*R>9/'D1)GC7&;;>`:$<*%(UQLT%\=<BO#,<.3B1IX;0))[^<H:20IKM4
MA?;V8;<RA(PA-8>:O'&L>;3+768:(#CB910S>NMEK<="'>*$\9E[-02%X1!P
M;@[3BG4-./X[F%]O21Q0AV5RTT>J+*GQ+%*R%=CTS.)*<$JEF\L"_!3>KH(X
M7`!,6-.R3V2MOPZFU`B%-+0I].%^*RIO,2A"">YF\<JV20))7TM1`4E(Q)[,
M=2;]+O!&12,J,2Z/%U<LAY"5*:PC+*'?%P^TM'>:7A?4R,([Y?F%Q]@@&926
MNA@,:[9JI4UEE5&XC^6F+PW:,51!(;\"U(MLS)M//%0K#.?#>;1ES"&G6W%)
M&$6IK_;>O-I+G$4.QMSZZV\`Q-)1'3$?D)V38>("Q_G:/`\PEU`[B<J:\1*'
M&EMKREQ"DXB4H18_2$'2$:1?_9%Z\J_]51P7_`(__]2BZ%"!V6\TRN2+CC4?
M/VRNPASK/>\9L.5F`P2G&NZAQ7B(8?5E/8E6>W'ZF>M1'YK]7:!B]-8+CNRI
M4135-8RTLC&$N.)0HCNR)E&SSBW2J?KCVJ.D*+2HR<C(JLW`8%_WP21QQTA(
M/T*7D7I+RDK5*A+U_!(YS6'(XH=YT8A#G8^M"D)16CZQO!LC\L>U793<=R:L
M_BUU'U?N&EJ&J.EJ[!X9:U*6LT;JRNRXQ3N,V@I,V5H4I"PJ2U)*0GU@[V^X
MVO?^-^FO]O8?KJ;I^LK?Z5[^P8^RUX^12_U#7]L1RW=.7B!@PS:1>=;4LWM>
M1V;&\-H:</R=$8CXN-+(E8P4=TIE1+&<*[REO/L8PIOLRKK5B-A&/U9ONTR`
M(M[/*CC;:&7;@3'H-:>A!7)]M#Y'AUP0D$GR8ISF6TI2TT,20EM7;A]WNX6Z
M^*$=]9N^]B9,/!/('BO88OQTL'"1<BI,LZ<+&%.R@01@SS@K+;TXZ.RRVL5U
M\$%"W'5F/.)0@9;4(X6^[;8C]B>B1.3G'VNL/3UC7&4:<1&"3^8D9R>4^!,#
ME)=E2%UP$="TFM.`M+)&SXJ5H7W%/BA$2BMA;F+AX%Y?+7CT<>_-S8@,C&`Q
MI<!8B_1\2U$04RMF-3Y-H*9<RX\L9\1Y\<O#"5X<;P^I"++K=LWG(3H@#^Y>
M/5I$?US/R!,=1WB5VUP]3):8"_0<6AFT++A13FT,.LX'*9?7VY1VYQX*D(AE
M,VG=<5J!L-DY/:PL##GOG?>FH46"54[&S,L52%H9\:0/4`W6X<"T'EO98;*R
M^8,M"&RBDMN/X?%##"]ZU;AAK1'RQ7*K1^:JW,F2M@K<R'7I?P:F5,1H\>/&
MRU?CZH:RZ%'RHR$^87E91#N5>,EM:<,(0LK=ZV?!PEB-V'R/U#(%9AU)`<`B
M18!B))M4?5S*79@<%PI!,P-D88Y8\9Y<C!SI?>\YE*V1@DH?!"S7TGO(F,G(
M\[D'KC8-D*B[S2X)<1"QK`\9LUV#%EJC+%R,+3\BXCX7$%*)>%=!=:7V.NY=
M)5A`0MZG+":AA52@FF"TE8&,IF+0&$82)RPCX1CBT^'5,/)IU`/E)LDX@J6`
MG`<`./`?@V(:)K9&U&`:M8XKD-Q[`K<C7:[9LS-JF!V:]8H1`"H7,O&3C5<B
MH[R5RGNPU2VG\>4RK##"7&\8<5<K6@Q5U#/`+;LK(L*$E)^B023XN+"9F4S(
MF46Z1WAJ9ESA4KM)!M),TJ^D"`!AQX,`G@G#V#>-H(G#67>0?&3`+KC*&66R
MQ7Y=TG*4QY#QHS4E'8R0T2Z$RTC#F?LL]BLY[S;:<7!&1!+R&WY>#F8J$WYI
M6.OY#5(KM1LXBH":D8<NR5L;):"H=ROO-'GW^9"?E0FD(:&PQ'#Y2PZTA_J<
M&U"$8=OY`IB9=F4WMQC1*HE'Z\)*#!2S`<1/0+$VS.QTM&&2658)],4V;;<2
MLAKPF8]W"?V1ESJ!+:B8Y"6C=BI"JF6/?_'4FCGV"N1=@S!QJWG9=1301TG!
M!S)1$E"134\R.>.(@IM3KC;HR$O^/VY>2[D(2JMNYBHZ*CVN26A&)DB/!F)F
M3C11Y05G!EK00)D`A2%1@=9(J),>!@LE"%$2)B>YEI9P?<?%"&U>TMOON$C0
M?)#BJ<TS8766CC"7RR<@,"+E'8UWT82/'/$>5EX]]UQK.,"`86A:W%H68I@V
MH0[W"][LCW8]=6W9H$@,"GO(DAI=_),G8[RU%'@1[$<?'@CP\:*79H"0\TUG
M#KRT#/.-M"H8<:1.#8&&(AN$O>[Y",:EHKDKQB?`.FY)T8J2"=&0F!5*3N!H
M]I*I,)U4H%A,>+YA:?#=;22KPLK6RXB/BB85@WW;BXB'*,Y'<>$)?#<+Q)O/
M"1C$V8389HAM4>J0#98>K<?`*2#W&$*)4?%NH<+2ZDG"6"$=D/?=H%%"M3_(
M;C&?&9GSVK3&H-#PI4$U8WHT>$C125"NMNGAJ9$)>*6^EQ]Q7@=F'&E)8-J$
M,+5^WCZ``E"=]<5(^+]#122&GG%$5OTM*3UIJ3$&B4&?2!,AMF09`7E@WF22
M)@!;*<L-MK:?8-J(AYM%GW.1',5FA\C>.-?F1Y65#D5R68Z1-BX>:#`C*9%P
M^16@XAB>BIUHG#22(YQ!#2F6E,K4E2UN[$PFKFQMUGJ'%E.0W&!4E+2\U!Q`
M41YU1*I8>*G9B/BG8^1=&.4<V!$/D/)4EK/E15.(2YC&<K?%"<1V;V?N2/DX
M`S/(3BM*UHK:-Z?7,OD"/O5VD@LR;`P09+!2!A)RM-D9C2U9R4_APQ'C.9:9
M*4^A^2)DULG:2ATRJ.0''<H0^O=D<RH\2.!>DSYRT5V&EA)4UI"26FYN.4"2
MSCO^*5'+\-MI??&=G!M0PPD.N>S$GAI.Y+<;23"FFDL#-MQJ1XR2=$.CH23@
MXIPJ:DAEG6>68&()*.>9\HC#3:$/O97T^*(AWC=F[#&F"39[?W'I^J0J@)N5
M%AG'#IIZG08D58;*:(\UW&I`V4K+[[ZTBM*0$@@-25*PE>28P;4(CJ;KN0</
M$8YOKC9"V&:C"8^1LC`3,<.;LHITD6";!5,$H9E93%<>C6\C>6-=:]%^&\E&
M'6L*8-J)A8_>=CO0DG&3W)#C-(E2]?N<(W@1H`B.19"**7)P*R8MTR5R9$QV
M.X<>(\K.2@G.U*DI4AIQ@VH1)=>[9OCUT?1L';7'S-7AF7VYZ"KDV\NQ,EV6
M9,8U\:/(%(9CUQ$K%(&6VGW'GU$][*D=S"'$MH1$96PEEKEE:>?KE@A)]@=?
MAD/0DJ!*M,.>(\UX;S@+[Z&E^*.XGL5G&>\A6/U<9[(B8>^D(TB_^R+UY5_Z
MJC@O^`1__]6CM?#)-OM(#6MUM!=OK0RG&7_*O(2_,A-*6T5B.F/+.IPKM2YY
M0KN9]WP7>SN*U$?FQU;:#VL5PLJ40E=:PDD&R1-U(F%6';)VCP;DL=A?DG:M
MQTUS#:N]J/QKJ\'DI0J#HXEQ1<LY,.*>35+5'([CSE?KRAFD"1[24L]PGN=W
MM\P[G.>[4W]8@?2'^:/;CLVU9H=4_P`5W9C=5`5\%:2HVG"X9YM4(QEEFR`E
M"19DN4OK5DX/5)O;[C:]_P"-^FO]O8?KJKI^LK?Z5[^P8^PUX^12_P!0U_;$
M1GD742K>/48\?2L5N!EQZQ"2>9.P"5KWN1Q$8R0VIB4?<60.J4FP0E=YL20Q
MA0B<*8QVX?8U8^&-A&-\/4IM3DBI?`Z`'?A[&V"3EC:+,>Z4)*CQLH5*UIHN
M`3&GL1K5A>;2E)K#"5,K:0MEQ+PPT_`8C\L10K65H:LKWO3X$UB#9@FE#5VU
MRNU6I`PZ%`GH*H#`,Q\=)0K\`3[P):6-9$48^(E8S+27>\I3C;XXF)*_7[M,
M$-V.0]G_`%]^TR,QDV;49MV"CU/DODI>.FB"Q8R28D)-Z<>.)PZ[A;BAU-J4
MYWB'/#CXX1T0VL[#"Q@H!?!NDRL?-0>"IR,CKT#'(AYN;IL"/+0@;<L=8FY`
M(N3)*`><3Z.:#%:PWC!"&_&??'".BJT"YP:*:UG@Q7P)8RFSM;L%AK^Z'*ZU
M78*03'1TG7FVAUS<TVW+LRSSV$,%F*<P&\YE:7W&\=3\<1MP^L5O:;C=>"-X
M8P!<"35R,R$3ZZ\QK\"8W8:M?&Z[(.X(G!+DXU9D84&2\T,AMZ.=PG(XZT(=
MC!MQ,(:I0[O(8;@)7@U3:=!#P\+$U]ES='O@@ZTRZ_,OR;4<*/%Q[D"V*N.&
M\,F-#&+&<DWWDI?RZ2VX^.$=YU:VE8`MC1V.'%3;L4U7*I(@$V3;,H96#K+6
M1QF*G#D.MLL+@W:^F.)0+,PSV2H)TEO+([[:G"")^.(A[K,/N894Y*,\1]:U
M*4;V?$O*4U9HY\RXT<V!NF+`4PY&R26:7E)ZA$9%R]*@/>FC4.`+RIXAX%$$
M*2HA0/>@0""")B40N=HVVD5R.@8#A+K`FHUX^B&U^@%[$1#HB(V*IV9`F$CI
MZ-+(#0[5K1<)8(+*(ID$?.''6AGE):<<OU-545KSE35O*<J%&94<))VR=D]T
MX8LT],Q2-(8IF@AE(D$@2`&T!L#N#!'>=KB;/)!A)?@#5WZD+->GFGQMS@2T
MBF='DEJBS'1'XN(\FRA3+)2U)(-0@;O->%XJ$,N6/_-%^%<O"W^NI!+>X51]
MN.5;(>XQ+M7V`FGLP-UK42S3JI)NH'E[<6R:D"T'H;D6FAF14M+))2CLP2A\
M<1L]R%QU<OMAAKG'$\&JM!+E+"1:&WBMC0-@:D[2@^<AWKFXS&O520S+RE:/
M.>?4T4(:Z_*X2MU_S)SHL?'$PS@ZSLU8`FJPQPGH]D9EL:\/D50E[55XUM(E
M<?-7'8D)GTV7,N5JR'SHC;[3[*TLFLH='2PYXKD_'".R"I=I<J]M;E^!<'4$
M.P;LTS4ZUN`&4Q;ITZX1@TW3)(V.8JHZH:T`EKFBTDM+CO.`)*)8++\/#,=V
M$(*]K9"H^:5`\`X2GE5\IV#KCTM<@I!B:KPE\C:W*,#@95!2$:T=6H<@\?*E
M+82K`[[.#&'\N*?'".<33]B)L4D6O@S`R`T!;9J-I4Q,;R4,6N+/DKJ1-S#K
MI-<60W4,E%ML0L<J-2X,"\RON]F$^%/QQ!^".$;2IU-F)01[.T$")A69F/A+
M$-NROO'%CR#(*I7RL<EMMY`Q<A*2.!5ONLNMM-K<;0A164=1\<3#WLS65B.K
MQ2*KPVB+"5ZJ8@*-BY?::(-NOSMD.=B]C4VN2(LL8X,O(,PV=B28!B<&E,G'
M.N/%N-MN/CA$25I.<?KDT1'\$-85^?&/@[57(XB\-2@?GF-AP@<H"Z/''P([
M4RO7\S*G]YHI@-Z0'6A[#R#7,)G9QPB3K@;TB+K(I7L_X$PCT"`)9VP=V0X[
M,=%>^!BX$5@5QR&<>L\<-</&DQ8I]W$<V_W'%+:?<6A$?'"$4'KNQ15I=CF>
M`]4KD*F/LY(UVBMH1,Z/$O0M*S-U`%FBY57GK"9+7"*8B%-)/BF&6/*.8(PA
MM2!GQPAUE=8WF;$AK/,\6Z29=XZLV(]B,C)0F/\`(SL+:&J57:[%S;>R(R/:
MQ.ZM$PY@IW`Z2"'!'24BX$<::3[L(88FJ2]Q<&B)/@Q$52/C@R3FI._V$W8J
MP):>EI.OK##'[L82.24QDEXHP,LG`XY&'G.ZTXVZ\^.$.)NM[A*>]Q^4XNU!
M_P![Y9P\<LB)*:EX6'&O,J2VG!\=MN3?,E/`M!TNRI#A#*EDNE-N)-8;CGIP
M;<(RRB^-&B1&22`=;`1KLT4+,2:O.33,D2>V.&TTN1)1+*(>>9'"9:4A3BD=
MUO">S*<=4PC@+Q7X^A9'\IJ^!82+&2\,RTV]*X8]%3[#+$R"Z/Z1\!\>2\NE
MQU+B5=XC*G_[LM;BIF80O3QLT<VJ*4UKN'83!%X/A6!WY4<2),])14N\1'!,
MR#8@;ATC`@.%9;0GS?D!4O>(D=E*(A#<OBKQZ=&2$1JVOEQ^(PN&S&FNRIL8
M[%R`R@I`$B-+D'@21Y$16&B$N-J\=M"$K[V$([J<([W^+V@2)+TP[K"OYE%1
M8D,2<E4BT1(QH`(T4(/+K:.1Z9RQ$BI#PX7XSGDUN,95EIUU"YF8185!UK1=
M714A"4"N`UF+E9LVQR(@*B5I,G)%H5@V2?<+?(>620R$TG.>]V=UM.,8QV=1
M")STA&D7_P!D7KRK_P!51P7_``"/_]:D-=MF/;`HS,>XXR>[<:RV"ZRV8\\T
M8N:"2,XTU'QLR>ZXA[*<I2P&6\K..Q#+JNQ"M0<1C\V6K*'G-9-7VZ=134*K
MF`D@*)"BZBR0$(=62#*02VXH_FH69).TWC8VC'M2..Y3$W9YL4ZRENLJM]ZE
M-C3<0^'&WF'EZ\1:).L5;!7H*>C"QU(%;+#;<0O#)A2<^+FIKRT?I#9GL[<>
MVG9FA(_%?V<.MWA5U#+CZR,XJG*QULI:JVW&2^XPQ:X)Y#B"&PXT%`V'G1XY
M]5>]ON-KW_C?IK_;V'ZZJZ?K*W^E>_L&/L3>/D4O]0U_;$0ODON;6VI&J*UL
M"T7ZO/VN0G18$>@&#B%G^B(\>1F"93))`S6(Z*$RA:G,J[&_$]W]7K"IZC@"
MH\"VN?GIG+X(R7Z?A[(X9Q$O-59G\,8DB\TN.Q\([8XZ]<GI""&EJM7S),0V
M/<&"L-MB[%,1T`5WI1#B)84.J'>::PE7@*9[,YSA2<YRM('F5-N/GC'T>.>5
M&[,-]AYQ<<ZTR(Z;<>512CR-@@@BQCP!QQDCK9<$F<CQ`FY;!1+T@FPL9C'&
MTJ'D<M$H9<4X&4AEI`G_`%&FR?SPT>.>5&[,.H_,KC[[]Q=?S5UY052?=M@U
M.D'+&;'#1%?E27RQTO6*8!E9$"*CT*#5E3BUYSC*DHPG+N<HPT@>8TVX^>(S
M`<\J-V8;('G%QNL<38YB-O'*=8M5AXV;FFUY:\V*)(RE(B%]X9HYUQ.8DR^"
MID'%=U@%3#[;SB'DMMNM('F5-N/GAF`YY4;LPEE.=G&V($#D3+ERKS&R4C,Q
MD;(#.`EC'D5\REA2J6?+2SKS;J';['X''=0V7(+4MH-HAY.&E-('F5-N/GB=
M'CGE1NS'2/SWXND1<S*8V+R=;Q!R4'&$@/$AHDR7)VKG6E@R-$Q)*](Q8086
M$E%-*4RPR0T?E68E2I%+2!YE3;CYX:/'/*C=F,V-2-5O<]`A-CU._;P$@)]Z
M;8"8G[)F,E4K@)^4K9^2`VV2T(;5(Q#V6EI<4EUGNN)SE*L=1I$\QIMQ\\1F
M`YY4;LQ9'JI3\H^U_AFY]H]-(GF--N/GAH\<\J-V8/52GY1]K_#-S[1Z:1/,
M:;<?/#1XYY4;LP>JE/RC[7^&;GVCTTB>8TVX^>&CQSRHW9@]5*?E'VO\,W/M
M'II$\QIMQ\\-'CGE1NS!ZJ4_*/M?X9N?:/32)YC3;CYX:/'/*C=F#U4I^4?:
M_P`,W/M'II$\QIMQ\\-'CGE1NS!ZJ4_*/M?X9N?:/32)YC3;CYX:/'/*C=F#
MU4I^4?:_PS<^T>FD3S&FW'SPT>.>5&[,'JI3\H^U_AFY]H]-(GF--N/GAH\<
M\J-V8/52GY1]K_#-S[1Z:1/,:;<?/#1XYY4;LP>JE/RC[7^&;GVCTTB>8TVX
M^>&CQSRHW9@]5*?E'VO\,W/M'II$\QIMQ\\-'CGE1NS!ZJ4_*/M?X9N?:/32
M)YC3;CYX:/'/*C=F#U4I^4?:_P`,W/M'II$\QIMQ\\-'CGE1NS!ZJ4_*/M?X
M9N?:/32)YC3;CYX:/'/*C=F#U4I^4?:_PS<^T>FD3S&FW'SPT>.>5&[,'JI3
M\H^U_AFY]H]-(GF--N/GAH\<\J-V8/52GY1]K_#-S[1Z:1/,:;<?/#1XYY4;
MLP>JE/RC[7^&;GVCTTB>8TVX^>&CQSRHW9@]5*?E'VO\,W/M'II$\QIMQ\\-
M'CGE1NS!ZJ4_*/M?X9N?:/32)YC3;CYX:/'/*C=F#U4I^4?:_P`,W/M'II$\
MQIMQ\\-'CGE1NS!ZJ4_*/M?X9N?:/32)YC3;CYX:/'/*C=F#U4I^4?:_PS<^
MT>FD3S&FW'SPT>.>5&[,3FN0/O=`4!B9GISO$N$^=L<EF4/3XB&D>`DG+3.<
M#(\+M2GL]S*E9_L]8C[W#KM\$A&"4DB0[VW&6RUP*+'"+5AG-1F>_M1IC_\`
M9%Z\G_\`54</_P``C__7HW7YPL9?:1)'&^C08^W5LXR1R0Z)@`429"?(-R4Q
M&S#PWE66\N>(@,I2.[VX9=SCN*U!,@3'YL=6WV:76*X*JHJ."IVZUA2ES*;"
M4NI*EV@APIL@$S#;A$IA"O).U#C9&1<-[47C?%Q1-C=;`E1`R`[59)FSR\,^
M+5[6,S#9+FJ[75@`AQ[3'E@Q\&"#CJ1AHIW&<X34WY:,'YP_S1[:=F5)24/X
MKNS2DI'JE26W+*DOO.ON-%-/4@-6G662A"4!%AM'"MH00$NKPA/JKWM]QM>_
M\;]-?[>P_7573]96_P!*]_8,?8J\?(I?ZAK^V(:]\6"?K.:3*0NTJEK5K,I*
M!&HMX;TA'S_F0FLMH2$,C#SBHD9I]["LNL--NJ;4XO*<=Q>K$MJ,^*R@;+NW
M`MJ*.WGH4B5FSF6*8`9X[$7!K4/&0PF#`'6H>>.>.E`"GE#>*WAYQ_PVG$8Q
MA?3XH0V$7S9<G"6F#`Y-<=TVDAI^,BR67@(LZ'D$"6&"/);'*+D\AJ1:@&EA
M8?$D$X0.^G*B,=U73!@D(88ZP;UMW&&F'^2/'`N2%)CP3AAWAWW3T2$>#B+<
M&#'<;?$DIB=?_84MM$-J#?PVGQG4I=PP;6&&WM0D.V5M-F%;L$9R`T!(1"82
M:3#>'(#8D+&7#U>%E'Q\DFJ'BF+-@R19=<:6C&!QR&W%,X2ZI"&#8$3AA7&W
MK:HTXI\;DCQQD8*2.G"WXZ7>5+RP#Y!#KP4;&XB):!Q'Q58CBP,$MD8===2M
M2G'1U=KKK!M88B.(M_VY*-6UV,Y'<;1WDS1BJNP3+0<^U#!.>8]ZD9:?1+T2
MH_$U$AMGE98=$(6IYY(^6FTM^$P;43"*#V1L>3*F0R^3&@R!PK::Y7RT.`Q#
MDHQA;IC%;64HL)N:"@Q314O/A"J;(4I"%$N*02SE@A#\;=-RN'1KL;O_`(XO
M1JZZ.,@`<T!,M9KVB*02D:-*)*(!CX@W`Y#RF^X40Y]BZC([*%LJ8,,X883F
M7';\7B.9>Y)<=F3#R\G>6/P,6X3"6&38+K3L4P,6&6ICT9)"(P0O#@[K#F7,
M90E:'6F#:B,,<9FR[)(D!FHOD_J".):F18J=`+8CULF)&D))!T=#225#A0QT
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M^*CZK!^8+DI?`"3BRREGM.-N/N--,^&^.A+ZB&#:B(6P5KWA+2-9%SO?0)XK
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M26AEDJ[_`'4-,-9[7Q0AVC[)?P)"^PDYR5U._B:K5A@]='AD`L%4*8G7IY5/
M)EPS"3O6!8JMB/6V03@L%!PP"GW@PE=[)#!L"&&&D.W<D'#8(-_D!Q<>(L4G
M,N,-@#23PST=#R46.6#72_&6R_)C15CBEK&(<=?P87E>%N#]UK#!"(W,V;?<
M/!6$%_E=QX9E[!FL@4R5D"0U+#M<T'!UJ.8<`C`!E&0M@NL>2KRX^6W6DD$9
M2^A'AMAH18-JV%M.-P@8/?>C(YV,K+PLZ256I><;'NL^]=<T8PLZ+-;C@84A
MJ%P@@1Q#1+ZXYW+;B/&2GJ<&U$0Q^_'<V;*).?C-\>\5&Q5G7\;7H=H1O#Q5
MI*K!<O+2^5NOD.>1LJIX0X)"5-=H;(W;V)>[,P);43M;<<BK-O\`61*2%?Y+
M\928ADD2-6_-(;):C)$C)Q\>$\J*D8\13I<:XRKN96A\A*'.ZM.,(4A@VH0L
M,V!LT9Z)1'<B./18T/!Q@DJPN6#E)Z9E!:]&C29SJ0UAA,$RML02AG&6FFN[
MEE"4I=>RTVP;6&(PPFL=XVOB4@)-SD+I"OP!C`4.X$*4@O*YN3$KR)-EZ0%#
MD0$2467+(=%6M[#+@127%,M8;42I+N0A-2]C;K-5$NV#=^CN[+!1-@DFF(V5
M0/%BK@&YF=$CY1T!N'5"1U<`4:T<X1E#IKA'>4VUX33<X-J$(;7L3>(4CX5;
MY.\406:\HPFU!7!:_P!CCQI$-Q3*9`.0'R*4#7P3?-*7EQ8Y3K3CB?"[$*C!
MM1,3,R][AC9^,B#-SZ*QF<<K9U:%Q'3/F[)%VTAR.K.!"&!20G6)^3%6P.\,
MI_"U86O&>S*&FYP8<$1AC('5X^VQH^33MD^JR)ZSGE1#]8:(&PT`V;("LLFC
M.CI:RX_'#B%9<0ZK.7BGFO#0EE"G8,MB)C4M_P"R+UY4_P"JHX+_`(!'_]#'
M.#</9FX=V*&(-E&I2/<C0Q,R"2RST%LJ#&&5$OBRJ2'R,)2C(SK9&%9QX:DK
M[,XU!Q1^:*[U5**^B71M*<JP\@H2FW:4L*%E*>#*7+15("PH+GY)"I&-I7$J
MW;#O?M/M`6O9],,HEJF+:Z2_!&AW*/7Y3-:M"1BVA;S*S$NVT_G"D]J'$CK6
MA2DHPO*\JK09N(/TA^6/;'L?OC66_OQ4]GM[:UW&Y=][O52E%I::E!LYO465
M!-4XXX`<(P$()!(2"53]9>]ON-KW_C?IK_;V'ZZFZ?K*W^E>_L&/LY>/D4O]
M0U_;$,/(<::*CH3%?X\0W(*5'#M3X49.3U=KP<&21'"0^$9,M`CL8I$^/+.,
M$8P\T[Y-M[NI=QWD=:L?#&PC'V*HMO-M%/1,\"-30D1"U@N/9L\7LRC*F:^V
M9-VDC-5`C@H`%\2,(-D\R1;;19(SB)9S/8X2VIIQ\<(X0]/N(,V5(9X(:UB7
MGF9&;"8$VG252AL]D2E0J%2!K,?X3@^8^2D&77?*NI';C1DI[<.M=U/NPA=5
MJ!=R&92QR7"C3U9O(8TL?"2\?LN!4])V`!H-<,P8J)KSA$?&2K$8$.]VR#_>
M<&REUO#"4.9?'".`].MC:7!<<$*2X",*;;`B6]S4UY>;A/!10#T7#N>]UD@5
M;L=4X9N0D,K9:2IG]BP5AC#CL_'AA"<*LW:&7&L0G!S7"7S"'2+=%1FSZ-',
M,EY6D"*DW&TH<&2W@*'8(RE;!3RTKSW.QUIS*XA'>-1Y4H&PL27`?6([CD;9
MI5Z!:VG0CE6&8S6[=&P(9HV:P.)D6U*BV8UTLC&<"#RG?PT_A@AM+XX0SR^M
M+?+'/GB\)]/LDUQ(0E4Q-6*I6C,P"^[.JL+B9MN7@RH5;Y@T$O\`9(TKL4E]
M]Q;S[`S67QPAZFJ=<(*3AQ(7@]0K@*D"KV`VY%;<K-68CK.F-9E)1[$3*QED
MF(X^L60LM##[9)2NYV/LOJ4I>$O@,(`J-<A2Z[;`^$.O`)U9LW`RS"MH5D.R
M5ZNT6+I\3K.5$MH(4@F>;F8^(*99"PR.X*XP'AY;6$N/JGXX0W!46T.PN8R8
MX24T.8:'CK9$1E=V5!0@[YD-::?)Y@)":#&D(\:09+"'>2E\E(YP(9`S6%--
MKPY!^&&W'<F@6V)5$)KW`S68HTTO`4VEO:E3%Q7XTH=WTGE\=N$8;.8DQ!V1
MG6Q\8RT[AMU22L-)0E@VX&.$A`6^.L%T3KS@K!&QZ:3FIQ=ELVRZK$XN478H
M:LG354M54E&<NNQ()<2$$3XAQ@KR1'/"6YX?AJ=R<(^)U[*EA3M$<X4ZE#CG
MW`9!N,C;O`D1YS%?],5P5ZT.!PH+8TC(5*QN9!$?<4IGSY7<<)\%YWJ=G'$?
M%$B,H]XD;E7#R.'U`=C;X_+M[&L3FS84"V:^P[?9`-4PB8'$D2[R[.P4A[XT
MA",1N`GE/LJ)<+RG"X^.)QQ&VZ)=8R5JK@_!/5Y\V)"Z\)+OH6Q:;"!05LC:
M&4N1("K#C$K+CC4RP3TG""^')/ND@OOXP3X#Z^^^$P^"%L3K4Z"(A;$/PBI4
M)8*4095:)'UW95?G27Z.3"2,4,`:>2%6XVFPF4`1KWE5IE16%B*PTCS+(;CC
MXX0B>UG;/>X)'-<%]5"LFW"6*E:X)L&KD`!C5ZNSBZC916T#PD>5(2LPL9KO
M94.]]FOQT-=J2&V#;A$GU?4;S76XL&P\4Z+7<5%R6E-?IJ)]="`Q.R"ZX8[W
M\L6NRXIRRFX=UXIM>#`B)``-[S7F5MXP/PPBL)&J['2T]A7LX-3&5V>;KBIR
M'-W-KD0S$C5YR8A(&2D3GX,B,EG!*S(((#;RRAYE+JV%$*7E+:$(D@%4M;C,
M]"&\'-7M1$_.*3(J&V]4<QLC7X3PY&-7-DKC\2%F%E;P:66RT\*,TRLI)+HJ
MRF^\0^.&U"HJFRTF-B8!X?:V!G4#&*+A++:X+!,$MFXSU&E5CR!!$6LN(EZ7
M',E"(9"$CG12'V4%/H>RA<_'$?%#R)!R94^5!W/AG36*0T,V[$RD7=J+8G"Y
MTB-AGCVQHLE^/([SYE;@`U/K:'3AJ,\X\[A#3+"8P;<3.(L3KVQV[RS5HX4:
MPB5UH"E$UJ/.VQ6IZ3#,7F/@9,&"-%3&8K)]3KQB&&3D-Y[H[>6!TD(>0UEM
M883QQ:3T)<RXZ>#5Q&UXQF1:BERPTGLRMFPDBM90S9[)83-;\*1"B(B;EG$"
M/X&9,1CRJLL,G..LOCPP$5K8J3>IXQF/DN!.OS`@(BNV)1.-XU9J">G:V1`/
MU^J1+2:PR;E4,!40TN)>BF([)33*&W<MI45T^.$<KG4=L1L3'"0O$S6-P:*D
M8]9<?(6>`CA8R1>&OD>S(,%2UY?6:X$4J%RXVVTTX^*2^,E6>_XH39QP^&&R
M8I6SS7-FG5S@KKV)DRVH>1K9=NV=49H6['9N%!K9L>?$0QT6W3>YKJ%?D"TX
M()9*6$,QG)*L986^.$/X]8N$+,3$<KBO3+'75O8V3'B(N%2@XXR[@`5V#`6#
M#EV:P0=4>"'A22275J+P]Y\MIIQ:6B7)%\<(DJ@;9X8;8W$>.CR["BR5FQ-0
M&]*S$*BJC#1-8K%5QAT+$:J0-G8S!(@H;*$(BT0/[X3GRO:Q;,(KEFE3<>9`
M-QW`#4\'(&U<G$N,?MO7P`\4)*%VI9=;#,C(DTU]MDQ319#Z([`["9-Y(^'G
M%DY:?'#X8E1P&Y4/4$FO<0ZI*/UQK5JUS,QNB)+3$AE0Q,U;XFKC$23Y<6S2
M9.7(BAU+=?8-'>[S;#HB$M*8H1F_5).>F(5L^RUI51E7)"<8S!+E@IMUF."G
M)$*#/>/CT)#\>;@QQSG&$97@19.6,N.9;RXJ(1IH_P#9%Z\J_P#54<%_P"/_
MT<=Z\$/)S\'&EH+<%D)B-")0!E&#ECEFLL/("RXT^W@M3;F<-]Y"T]_L[4YQ
M[G6HC\TEVL-55XT%*\E99<?0E01*V4J4`0F8(M2/BS!$Y8#BC9IP^HU>UK[4
MO3E)JA4X9782_LIBB;,D!$\X,?KHV4_SJW&)2"T6APY25(1C'<[.[G[+&>KB
M0`XB1P3'Y8]INQFX+MU7_%CJ;<5T.U"[MI[P(;+]CABE5$M?ZP(DD*FH@@`2
MQ'#./6[O;[C:]_XWZ:_V]A^NHNGZRM_I7O[!C[2WCY%+_4-?VQ$#Y0P%:FQM
M?O6AG990438E&BA:UL/HDL^365##QX4]%,#$DSL`Z6ZC)&'.X&.TE2G,K(4(
MTYJQ&P,8A6'5>IJM8;^W9*OR9DAS&HR*>L56L(DH+;(FSR5XB&,SXDC"5!`3
M8,B"M+V)1+S8A0^'^_@9M1I$X80ACCM'WMJP567H/*R2>-$JNNVK;8E+A6I-
MX4>BP<G,CF3,PT3'S#DX*T_)BOH,402-EUIETAEIH9LPG@A\F([2T3`1,N_!
M<MXX<.7L=L<J\`^$7D=^VJH,=)CDB'O-D2\1DJB#3@8B^^2M;\@3X.5LDLA/
MCA#/=AM52T"V-+0G,*!J50CR;&])UD44`PNMNUIFN&"1I,1'L3,2Z+%U.,()
MC!LB/R+1+['AF,NOLNL,(5[#I.L8>6LD0%7MV1YU"L(02[?+O0$+`35XG:?)
MS@LZEL&GR>)M=<CH09IDOPA6?,.MK\1`[&36DY[,!@B9@U?3]NL<"W;=,[B9
M*L]D0B4BY[-7EX6/(D):>BO>?:$+>P',TO,'*'..-^*:A,0\T[VY(RK+,0B-
M)>U1;:;36+3&<@1L0E@G*I`Q%5NF;#96C-C2-ALMAA[%&LQL*R_2QB=9"'Q$
MA)-+>SG*<#9;:01A<RA#!+1&BI:PV",G(KDS+1=ZU&?&6"H2H]9EH%N)G;3"
M'QT^M=AD4156L!<?K=`3R_`:82$^.R2_CMB>UAB(>:Y7-.R+VNJ]8]?\EFY9
MNP@4YFS6RTXM)N2:]=;"U4IFUO6DM*YMJUD;NDG$S'H]PYI/F<-O)>%DG&F'
M#$Q&Y(.L2A=3D0*3RKDHN5P1;(YAF<JXLT)#U^:M(T<&:P'$IPH20D`C)*,C
MR"9`:4%4I0SOC9&&*;41M[</NU*'K&+AL8%3R81&675`<C6YO4BI.98KAT['
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M(V(&F;#&-D%.>E'E#UIDB"3E@T9MZ1[`6F/!<4A"B!5]3(F(AZIE-UG6=COQ
M#<;R@:36'[-J!FQNW!R:CY!,-*R`+5GG`QJT.$5"3+E;<PQ/2+SC(\P4H1[+
M/V+R4(40ANGQ9.1(@ZQS#F91H9D)L679`8C21GH:+HJB\1V4Y@I.2)08P[.8
MEV%R3[J"52B'RFU".(G%AA`U4-2K`&9&B>8`.1'HLFS>*1'AV),;:,2]AKT@
M<_D-2G\BF1;D,B%90WY-\<=([:6H\`CIAA$T@*SJ>J$IP1$[E$#IY`NT41$G
M;8.7,6=7AY25@5M4T6*=K<I;%R\LLO(X[SJAB6,N/$(>$(9:B$5-"1VBX!FR
M`5'3O)%8]A`<U8XJPE1(!`D-Y[6]J('&!/P0$VV6TU%0[1,@I]^0]%#BYP^H
ME"RGPPG%B'$:D`CJ7$33?*4XZU4LJ-$%!CXF;*K\?!;HL%['>ES+?%^^"JS-
M>MX3`0I+JVV!,-1,>,\LXJ.P8VXB'R+D=?X76*9)U#?\+'%V6/?C'&Y2K/K<
M/7:J.JM$'V`SR4[(HL4]3HU3;F7_`#[:VVTL=_&7U#29PB)UFH:.@(NL6",U
MIR4%DHV4CAHV`4U4<M.F/0,%#-0A9RU#"/!UR%KS@Z7\*2>(^:4Z(M4@V.X*
M!.*!ECA1)UW2I-7&FAZCRR;KPEAL420&"/6(U;.8V/C1R%R$08MO$C"EQUB:
MB^PW"F<AK-;,RG"#,*88GNPR(+TA/6F49-K?+:;ES+:7,#(G(&`"J+YEFLKL
MVL6%](8*;BX>J'QN<NCCI27YC+IC3)4@^X\MAG@@<42(?&E:_.6*NFU_D,J(
MCHC7UY:LQ'O;EG6Y^>K4B[*RA!S3Q"5S>*^6(&<21AXOS'8(VI*2`$&,,1#P
MEC4<@^+:H>N<D)25"OE5>C(:1E&(-YHZ"IP!$</&(AL%SL/&D`4A+"&V<#%3
M11#GE5DLF^([&'%"()K@'2%(U_AOWD\@ZI"8K98(E4P%4)O#R.1%4-BRY&$$
M3`10=BFG&J=@8%&6SG,$NH;;$SF3R@E$PZ)E]=24@>2%3N4[(]7B0(>&GG#:
M@\ZI\HO%H:'@X:RB%UN&R`*ZL8)L/+<$X+X#B$IP^HM,X<4(R4;XN:OVU3X>
M0-L&UO0,S5,1304F?"`2$A'+A8&L"3$HX]7291X]^N5*,2UG)'EE8:\TEG!!
M13K\3D81<HVA:@Q/CV!Z3M!:Q/>FH2'<E6!JZP]2EUEV!?7#QP`;)ZQ'JH,X
MC!F24M.]KK6&W4,K:3A$TU_0(G7,.9#1$A/2;)\R=.$%V*35+2"BSTCMN-)*
M6TSE`;#0R$,M8QW6D)PE/V.,8Q$(T_?^R+UY5_ZJC@O^`1__TJ1URWAW85$:
M4.26ERY5=O(H9I\:63A<V"G(XLC%(<E`"7L9[J'ADJ(:5G"F\97C&.M1'YLM
M6$V]9-7D<$I<ZY@64J6A2INH\5*VP7$*.(*0"M)PI!4!&T?CF#-B>UHU&3/5
MXFJERU_S(M0!]TA]@R<<*FD34:VU)6R%--9F2U.1RU>8>\$DE&4O+:1XF,=5
MH^L1^D/RQ[8=FM/7,_C`U1=O"[5T;SU>I8974MUBT)S1U`"ZAM2@XJ:";:K*
MU@A:D)M`1ZL-[?<;7O\`QOTU_M[#]=3=/UE;_2O?V#'V-O'R*7^H:_MB%VUY
MQ$$Y4RW=U5/4`Z);!!;%N8K3H5R""-BBCH=IR>F(0H7.`FW&5NAO8<;29W\X
MSE*.L*GI*JJ*Q2TKCI3CL)*I3Q3D#*,A^JI:6R:FI;;M8K2@F<L<ID3E&*\D
M^3(&B=SVC%-"@PU=J(D5.JF2U8RT@9:'K`Q;&)8S'E%/(3YE3^4K=P]G.7VF
MG4Y6B+VZ*J,FO>QCZ5NOI.GRB-]%OZIVC5*K%S8NRN5.I-C21T^0?%RGOHHD
M&]'Q'E1`A8UQB-EQ8U6$H#P[G#0S78^ZZI2W<K[<#=%[=%U.37O8:5NOI*GR
MB-]%I^OG1ORSZH^<6H?RQU&A[VZ+J<FO>PTM=?25/E$>&/F=\:,SC.,[FU/G
M&?<SC.Q*AG&<9_L9_P`\=-#WMT74Y->]AI:Z^DJ?*(\,??7SHWY9]4?.+4/Y
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M2I\HCPQ\]?&C.W"O7+J?O8QG&,^L2G]N,9[,YQC/ICMQC.4X[?\`JZ:'O;HN
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M+'30][=%U.37O8:6NOI*GRB/#$YKEJJ]P`5*U*R0-IBT$N!KDJY,1\V`@ME#
M3CHJC(P@H=)+3;R%*1E7>3A:<YQV9QUB/T]13+X.I86VY*<E)*3+;D0#*,MF
MH8J4<)3O(<;G*:2%">U,$X8TQ_\`LB]>3_\`JJ.'_P"`1__3HR@X9S>J7@GP
M?+YMM<P_YAU;+'@^F`_%\=YHD)QIGN=O>4EYE24]N<+3G[+&HP[&./S8:N<'
MZPW%PUG@L]8M6C(2X5,YD*20)8S:3(8;0QQM5X\L$M^UATD0Z!%,"&VX=Z)E
MX%F6:@;3&#4B<C&YV&5*S,_AT%LF/=`Q@<E;3*P5,K[2&WU9K0%!Q%K':'<V
M8]MNSA"Q^+S4=TT[*6'*N;;C(6&7T"D>1PK16Z\"@*0IGQ%E*2T4*_6(<)]4
M^]ON-KW_`(WZ:_V]A^NINGZRM_I7O[!C[$WCY%+_`%#7]L0@WM<-W54:MITG
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MFK0G!'EG49D)G:(!(`P_(,/QF7PRB"0)3,B8CL+MCVFIAPR)'CEI`>.1(0#I
MS@MSC")9ZO'PT4Y(E!QS6VWPF3FIQN3:3XABF4(;92UDO'BO8C!$_!%F:OV!
MSI*V'3P-R::U16]5O1LZO85T@[&(Q*P)X4%*&1!$3$JV+:,D0QLJ*.R^M>%/
M#X(SCNY;;43E@EW81G`R\R0VEYAUMYE>.U#K*TN-KQC.<9RE:,J2K&,X[/<S
MU$(ZW"Q6GV1G21VR24.N#CN/-H??0PIE#RV6E*PXZAE9+>%93C.$Y<3C/]MC
MM0CBLX)H9!CA@K8CC>'6RED,H&6UEK+^'$/J7AI3>64Y7C.,]G=QV_J=(1\2
M>"O)B4&B+5'9[L@E)+*L@J\+#_=,QA><C9\!6%]B^[]AGM_4Z0CZ.:$8HE`A
M8I2PB,B&('(:?4(4EMMY0Q*6EJRP1AIY"LH7V*[JL9[.S..D(Z!)B(/?)&!E
M8XTD)UE@P<0X8E\1\@;SC#)+3+JW&'7Q/V5"5XQE3?V6.U/N](0KR2/@A`>2
M&<%N,N$H%RZW@A8[3C;3I"&.]XJF6W7D)4O&.[A2\8SGMSCI".Q*DKQG*5)5
MC"E)SE.<*QA2,Y2I.>SM[%)5CLSC^QGI"&I-@@5I<6B;B%H98D"7E)D@E):&
MB<C8E2'%8>SA#$9DUG!"\]B6<NH[^<=Y/:A'U4_!(<\)<U$(=RZTQAM4D&ES
MQW_.X89[F7L*\5[T:1W$]G:KP'.S^T5V(0H(DXT5+2RI`$9#Y2@65D%L,I>-
M0EY:PVE..)PX4E`[F<MX[5XPA6>S['/9)!&,0QQS6>"TWXKAHC;7?6WXBR&4
M-^(VI:7$=]2\)[[:FU85CM[<93GM_4ZB$=29:*6VRZB3CUM$--/L.I-&4V^P
M^SDAAYE>',I<:>'3EQ"DYSA2,=['N>[TA'=YT/N*<\V+X:!_-K<\PUW$"]SQ
M/,J5W^ZD?N?9=_/V/9[O;U(!)``PP)`PG%'0N8B&RO(N2D<@W)'E,"+.&25Y
MKR69/RWEU.X=\QZ.QDCN=G>\#'?[.[[O40CNQ(`*6MI)HBG&U*0MO!+.5H6A
M:FUI6C"^\E27$93G&?=QG&<?V.D(Y)-#6CQ$%C+1WVF^^E]I2/$?<PRRWWL+
MSCOO/9PA./U5*SV8]WJ0"<`$1,#&82-3D(\2\$S,1;I@R''2!&I`1PEAMHM\
M!UQYA+V76D-'"NLJRK&,)=;4C/V2<XQ$3"MHP-]24LEC/*7AS*$M/M.*7AEQ
M3+V4X0K.58:>1E"NS^U5C.,^[CI"%/2$'2$'2$'2$'2$'2$'2$:1?_9%Z\J_
M]51P7_`(_]2D==8QG8-$PIQIE.;E6,9=?<2TPUC,V#VN/.K',2VTC'NJ5EEW
M&,8[>XK^USJ(_-GJQ+UEU>FI(&?,829`?K482;*I`;)LJD/S3BC9_P`9;@->
M?:K:.G8^UBVV(=M@;<43'#S`$5%-JH4N7*0D7#S,#6EP8H=A*-6H1@-H9M]U
MS*,N94IQ531FM!^D/RQ[5]E]]-7]^+?46OIKW1641J@&U(2ZAML9FZIQIMMU
MI@M)2\ITEM#24!:E$%1)4?5QO;[C:]_XWZ:_V]A^NJNGZRM_I7O[!C[(WCY%
M+_4-?VQ!NFLTNQBP2+@[LAC#!*5@O:X@[M,F?N&?JUG6/)JI==L#PP),C60T
MK01AILICQF<]]"W$]83##C]H-J;$O.6A'>MJ3/XIQE.O(9LE:5F?FH4KOV09
M?'&-<;IK1P\=*@3!7)"P9E9[$TX](:]W\^EA`,R%*08;+!U'D$82$B)#R2KM
M[AIC;I2D(<?7C&1HZHXRGR['*19SYGS'LD[O(9E:"T8]/6"5*F^4KT?,#03(
M40FD\@&TP3L2W)#EKBS545U\0:3&+8Q@=A+#8S["BFNPLA]];1U1QE/EV.4A
MGS/F/9%W>1-FM::.8$G0&?QB6PK(4\9+L8UGN?O.$/&521PL,KU8^>BTCR=*
M`*:2,ZRAHKS+R<8=.-61&CJCC*?+L<I#/F?,>R3N\BPH-_7=<CZ!%1:=T+C]
M>VB2LT8B4TKN*0,)5)56VU=<>4?C7(Q#S#*+<Z^AQWQ7NUI*,JRCL[M]JDJ6
MFZIL*IR'4!)_7LX)+0N?UGT)?'%IRI8<6PLI>'!KM?4NX?%4GS/I3^**\(UG
MHXJRDVEY7([$@5!P-<<'8USNT.-3"UJ.E8J'!0$'K0='ACAS#N%YSG*GW$MN
M.Y6XTA:;&CJCC*?+L<I%W/F/,>R3N\AOBM2:,A?0:`'^2G@0PTH$XR10=[NH
MEQ):%(BRTS.&M>CIEGEFN-R&5E8>PLQK"E)5C/9B='U/&4^79Y2&?,^8]DG=
MY`[I_CZXU)M8%Y#(3*-QZ'DKUGN@QAAV,E2I<0H,&1UB9'C/I(*RWGL9[F1L
M>#W?"6ZEQHZIXRGR['*0SYCS'LD[O(EQ%3TH4)`B.`;VRFLS#TW#O9U5NIUY
MDPAR`=?;+R1K9YN6$(77&,/-&)?00TM]I[#C+[K:HT=4<8QEV>4AGS'F/9%W
M>1%ZSJ7C_4LCYAQ.0J$A!L@1K1>MMVFL1(H8.(Z+3$L$ZU<:C7(,3'8`XSA#
M@2OLF5(5A.<3H^HXRGR[/*0SYD_F/9)W>1TP^H-`P;)K0">2&%R<=,14L^_K
M[>3[DJ!8!;4',,&MKUOY5?FV+F?W5);2IA;B'&<MN-MK2T=4<93Y=GE(9\QQ
M;V1=WD?8G4''Z#A,UZ*8Y'`Q:BRS7$"4'?`ACI!F#U*>?E1->,2KY+)<J42V
M^M]1"27U.9<RK".ZT=4\8QEV.4AGS'F/9%W>02FG>.\LR&R['<A0%!)IZ$O0
M.O-[UQPANCUN/JD(P2B"U['CN"8AXUM+K&$)84YG*TH3GN]UHZIXQC+L\I#/
MF?,>R+N\AP3K;1ZV\,DIY#/M-GMG,-8UQO9I#'E@/180J'/5\LS(3(;CRW!\
MNY%?,)<*6UXR6%,-'5'&4^79Y2&?,^8]D7=Y#:!J+143.1=BB3.3\=)1-AS:
MAO#I>^B0USJC1Y)13P,AKHP;RKD@PIU8:$H"<P0^VME33SC:FCJCC*?+L\I#
M/F?,>R3N\CC&:8XY0<TW.0,-O>%=3%SL8Z`%JC<:XLG-CHR-?R\DZ(;K`ON2
MYD,TEUQ]M3>72DX6YA:4I1B-'5'&,9=CE(9\SYCV2=WD%0TSQXH5K,N=3`Y!
MQ<V:VAIU;NL]U3`;;6;E';!*:%"G=9R@XC1UQB6#5);PE+*D*:'PRPXZTMHZ
MHXQC+L\I#/F.+>R+N\BR[<+JR\`H!G1=TIPV=+D^-&Z7V^*ZX+,W"O7<F.>P
M1K0UKP/3E4CU^(VEM_N,93A:4..)5<<HJEQ256Z<22!]>SL`#C.Y%"*MA`4+
M#QF2?J7=DS\R*T<TQQP<C<Q>(??Z1?./F(RK7&]BGQUD.#.K0"^?KTMR.2ET
M7"TK'RT\E[/C87XR4.)HT=4\93Y=GE(KSYCS'LD[O(<6-5<=1GTDL5S=3)"1
MA&DOLZAW$P^T4-`>]U4N*\QK)IT"9?%['_,#J:6.9CQAO!7[O31U3QC&78Y2
M&?,<6]DG=Y"^G:^T-K]ZVFU"%W;'R=TJLG5IHT[5.])CS#,GW%.G>`=0E);?
M8<:3AAEK+08C&,,#,LL82VFMJAJ6W6W+=.2E0/U[.P9\9%#E6PXVMLH>`4"/
MJ7=D2\R$MYUAQ\V+)%2-JB-^F^/[XEL1[&N]_!1D:79DV!TV4`#%H;:,3(<G
M9S#037<NE`D9:2PXA@89EJWHZIXQC+L\I%>?,<6]D7=Y'?;=<<?+O,ES=BKN
MZ"RC4$H>;;U!N0=O]U6-ZUY<P\UK1)ZGQII]2V'%OJ6.A*&V\I0TUA$Z.J.,
M8R[/*0SYGS'LD[O(D]/BM/4(4H>L1&X1,F^\=HEPC2VXWTJ$H=ED+/%#,"L:
MY$#$\P?,%Y?4TVCQG2%O+PIY;BUUM452VHJ"Z<S2H?7L_G)*>,[LXH75L+2$
MV'O*!^I=V"#YG<A@E]?\>YFV+NI%9W2/.$$6TR16%JO>PX<N9<F6V9,N6"Q0
M5#GOBI%%R+E>,^#Y`5/V2!VDIMZ.J.,8R['*17GS'F/9)W>1V:_I&B];V,2U
M047O8N7`P]@-R:U;N^08%R_&O1"_+C8UTPTPWD`AS&6D82RX\XLA:%$K6\J=
M'5'&4^79Y2&?,>8]D7=Y&0/K>JGWIVA\R&Z?B!U&CJCC&,NSRD,^9\Q[).[R
M#UO53[T[0^9#=/Q`Z:.J.,8R[/*0SYGS'LD[O(/6]5/O3M#YD-T_$#IHZHXQ
MC+L\I#/F?,>R3N\@];U4^].T/F0W3\0.FCJCC&,NSRD,^9\Q[).[R#UO53[T
M[0^9#=/Q`Z:.J.,8R[/*0SYGS'LD[O(/6]5/O3M#YD-T_$#IHZHXQC+L\I#/
MF?,>R3N\B:5^P@68%4C'#S@PZ2'!LMV"L66IG9<:0VM2DQ=JB8:36/G#N.Z]
MAG+2\XSA*LY2K&,5YE;"["R@F4_%4E8[Z"H?%.<9#3J74VT!0$_SDJ2>\H`_
M)&F'_P!D7KRA_P!51PW_``"/_]6CM?%(!OM(-<*`!;#M]:*<.E7C1HP-`\R$
M\HJ1(CBP)`<`=*.^\MA]AY#>,Y0XA6,*QJ/@C\V.K;R:?6*X*A;S;:$5K"BM
MPJ"$A+J25+*%(6$)E-10I*@`2E0,B-GO&:0B)7VM&JI""GH*S1)-_`4)-UJ0
MD)6$-2G5SK;N`9&4D),TS`KZ%,N+4[A.76U=QME'=9;J;!"VP3AM#\L>U?9A
M54-;^,+56JNVO8JJ)=>DI<96MQI7_P"/(-E;BEJ59(*220+0-E"$R0GU>[V^
MXVO?^-^FO]O8?KJKI^LK?Z5[^P8^R=X^12_U#7]L1U;O?V$*#$$:^V71M=F-
MC61#R;XJ/;BYZ1+BT`5ECQRP#GQF0+`6RX\MC"EYPI*/#=[^$XU8E&PC'2L6
M_D-+MC.S'(GCV)YXN2FAAP,QPDA[WXQ\I.'$@R4>9DZO$A1?FUK0XVZAAU[N
M'+1X+[<X-D1&&)5*RN[<G)D@N1NH`*R<W28V+SEVM%O*L<W$PD20$HC-66R>
MU/VE\A^-RVME;B'F$>'A.%8S&#:A"5-IWJ\S!EHWUH`.3C6#6K;#&R,.[$2>
M(Z[V`Z5E8]P,5R3@4M4E<,PTET@I(J7B$DI<?\,W+!$PV!37($"#\:4Y+:,=
M/BX^[2=F.?&C5A,`2L)4W=?D`A,PL:1%^@S1)$@O)*S/,,F83W%>,QY%@VHB
M!%OWD*\$XODOQTD1C9L:+R[A</E(WE(TYN;%'C1/!,GI=$YD1IH1DH=W/CXP
MKN9;RE]@VH88X(MFZPI(*)-Y.Z)65,NR3T$AQ4(20^(W,0ATBR0L.OQX+SD7
M7'U,`+QY?*77N^_@WQ$>68-J)AW"FMYC1^PVWN0VHR9%RYV\6GJLX`%=>K@$
M9+/Q8L)("KKD8Z2B.)BB,9?4P7@AKO\`AD/)RV2E\4(YQT]N[-CGP2>0VGCP
M@1E&@"-AQT60PF4K)?O;](2+M?,CRX]V59<,>\NKQ7FQ\X;6TE#K2GQ1$-[,
MQO7$S6TC<H-%GQ^#R920!RQ".D3L#)`K><1A0PKK@8L>?(8]&$-O-MM--BI)
M4:M:TO/BB<$(L63?CUXN@`O([3K#5<>I0,E3IZ*8KTC$NC#S:+64,_*5)HT0
M>T^`/D`M7I@-#PY+K?>;RD1I@EBPPA.5GE`:\1&P?*317OF?S68\R$<9@#%1
M,I!3=H<OX\6VS`8.P^^PE@7N%C/.)3'/MY2*ZKS#3!M0^&)-#S'(8BO7T>7W
MOH<>6=L2P=?VP7T<7$B@0#@ADJ'+U]K`:G)5^%/2T>K,AG(AK/F6QT#$(%:8
M(1&5VS>LY$!.PO*+0[-AJDI-YM;042%BO2,:/%PHWDR\'QTC*F&Q,J/*O>9C
MW`&<H6+A;+F.W'3XH1*I*3W>=.W&3A>16HQ*\ZYF)JD:H:)>76Y%Y:6UMS7?
M@WGI,X<QMMI6%.HP/WG\.)[<=U#XHB/D;)<@D3R$F<A-$&1:&X!#\<G$8J2R
M4&K/I-2<L1P66V;`Z[W%MYSE;:,M886TMMQ13!M0PPBL$]R&;'&>B^07'<*-
MD(&7D(^0+2V_(2F7[-:&8TR)PR&\$X$!%/P@J24,F(R6DEM;#RLM.JG!M1,-
MT]>]T#UV6S7N1>@4OQY]B4Y8[&5'/YCFX:<CXHB.D(V+A`.X.,4D\53N&%Y%
M4TTZZ\3C*D*C!M0AR&N.Z@O3TE)\A>/TKEZ(JD9$@`Y%@XV'L<U>:U#H..`)
M:G9P5DOWR(C4I?.>P0^Z(VEH9][+R6#:B([XF1W\VZUZ6Y(Z,?9%5!2A3334
M&\3Y(298+M(QI3<=%LNQ)$44D8=UH<-]MMQK"G<.X42\P;`B8<*9:]K2K:1C
MM^:9E#BYRNRHJ(0R*D%-4B6O$ZT`%@[%;B1SYR:J;#`K;F!!TER3#W@H'1V+
MR^*$<(J<W(-4&&);D3ILZPBNG#$S&,0@[K\@]E0D='&,(AF1D%B&S(2'&6X]
MA]Q[#*.XG+JD.,&U$1&,6?D$\)B,-Y&\>(VV-$1\L9'QY48ML"`;EX\IL$PH
MR',P@N6@4%C.DJ&:020C)0C3#2'!T3@VC*)CHC;'O4:DVG$YR;TZ3(ER$T/#
MW,5BOC"0#+]UGZ(.V,"BMK2KWKV,-@)XHU@D593;R5N]B%*1'Q0AX07R*&@;
M'#-\C])25B-DY=R"G34U]HJMP<IFUO0)!X(4**#)."(DH-EEO(R<94WE;CQ"
M>\@A\4(8;+<>00$'8;6CD'I.*A(:!CAI,U(#<S$4VPRPL^EJ5M#L559G*(/!
MCT9W'EFBBL^5,\5QW#S>!IP;41ABQ9B<V>5-2[</R!U;`B'5R28*'."CI8.K
M6U>O28T$FJRCXL6++"P5Y?&F)&,,??,2$Z-AQ8K1#:2(P2Q88F&!NP;O+S;X
MXGD9H;$J2%!OUE$`N+$37<DV"F!J>E42(-@6ZU-*CY\(7Q%*R^Z^VAK&'&EK
M88-J$<:?;=KSJJK*YY!:O=A1Y09-SCGF@8:5<2Q=[,>;'!LV&DQTHW@^B^CA
M&E.CA+\<<A]M64.-N(?%".)UGWMY4D'&_P#C\!+2660ZZ\T:(5C$ZVJ3>*8)
M;<A,MHC/#@<M8:4EQ]2TG)\=*W!4@L$(3S<WR7`4\<QOSCHJ--C++)#X5&$-
MN#1;<;@BN2L4*T_*E22!9*&E$FJQDI)##6$--H<0XXVP;4(0UW96TYV0@'Q.
M1&E3(4:>J^;4&D`@&=>#9V)=;'=HU(Q]<'>JR7M9@@1T<DUI;G8._P"(^E]]
MB2RA%\\;K%9[/KMR1MNS*GMJ4:L$E'9M]+":!A'4@#1XY`"6&(B'806'))(\
M5*4.^$I7A*=4I"L)@PC6'_[(O7E7_JJ."_X!'__6Q?ZU$?F7C/#V8W]/+C9_
MKL;_`+*V#JM'EH_2'Y8]@/PK_P#<#V9_UKG^S/1[5-SP,Q/4`U5=#S)V&LSM
M,V!"Q"%,LOSY^N;E`WK%7%+(QEF.)MS%?<BDDJQE(_G?$4E24Y3GH[L>::JT
M\,JRRXA;:CYH<0I%H@8P@JMRV;,H^[E>VXY3*X(3=0I"P/.+:TKLSV+5FS/8
MG.*<W79$VRETW8&O],-\CHK(TT4/!MS#$(XP^DF)R+'/"RG>>CIM%GB6V"TD
M`/O1;@1#)+3&?%4WC/L.TKSC#Z2EU)PCY01L$$2((P$$$$@B+[+K50VAYI4V
MU#`?R@C&"#@(.$&8,C%-&5FRS[H\F5[/>HJ,D(1\5^3DMETA146Q(BS63XHD
M)40'(DLOHE>Q3+2D-O\`FRD.*94CL>M_'%S#$HQ2;!!2]@ID9P]IQFM7#3SP
M96'L-9@FI`,/(A40&95'99Y1$N\J%9PM[+C+.2<BNY;1D/&5Q$PQQ5<L\;',
MCC\"ZZ#[XIV:`L@@FQJ:V$-!ICY&!:E#!4M+3(XFJE%L`K;1VJ[Q*,+1EOO8
MP^.$2-JHG/@2$EGA36T3&7#0'H@>^UMD@Y-7B8:4HY)4V9&Q0;C:C+Y9`V5-
M8,]'$,OJ;<RDUW*7QPB$3]&NCTV"PK@3K.?@PHF:G&2'=BUDEV.NC#=:=C,A
MD2,8*^3B4S`LM+7@%ES+@@ZG'4);SU/QPA7;-=&S,G:*XWP"IDY6GYURJJFY
M38E+BQ+52)G.2+)/LQC,=(&0@ZY8]U[R+B'7C%H4XK#:G/&0P;<1AA^G:#<+
M!994Z5XPPA>6+/,SV)9NV1H>9AP425L,&\ZZFT%FGH<NCC2_L6`E+<0T]EH?
M'[&W$^[$PPR-?M\S0I22NO"*+*ML-4O?,,%6;M5XXTVUAVJ[P8E7@"!')\^/
M-CJ2VQ(8D&7'EJ?F,-"M9<0IUM\)A#7'U.YK4\8Q[/ZHQ<0IROM-PYFR*>#,
M-,'#/)G9!I^*S*A,K@<R\FUX+8Z'CD$83A:$O.Y1.#;PQ'Q18$X!<B,ERIW#
M&%LU[FHD),V6C8D%&#S2(E8I+0LA87`)//8*43A3;1#KSCCB5J1XF$*7A\!A
M\4?9.$O3]B7A_AM5Y1R4G[LQ(VY&SH)H0-AQDV7AYQV&(";-DH^R2L='-$MM
M.LO)?["%,HRRE"8^.)B+UJ)L!44:0YP,BH,JMSTD=$P*+U68YW-FGVJ[-6B=
M$.R(S'/YD3A0?W:+YA+AT<\[XWB?J3/NPA"!$7L<T1F,]GO38U@>O$0\J_G9
M=+\0)Q5@J\]'QT,8J'"5*`,DCIDGLMI;0LH%*</((82VX^.'Y8=Y"FSX33\O
M6.$%7R?)1\N1--A7FLP$L783K#FO'99.6F.\)T>)23*L$J0Y@EEUI#3P[BUJ
MQ'QQ&QW812]&FL8-D`^"%;E$R<ND$V#D;O1U./,G1J'K'922737(]UB3PVJ,
MRG#2R7TH'==3EM&6$L&W".]F,M"SJ_*F<!8P1V"CCZP/)E[/J<E(P561:96>
M::C4QT=)RI<4<J*$D%A--9(6\6@;+6<L=BY_\T/BB/6G7UE;3(&Q?L\->60M
MRW%BH4]M"GBER]=L\FRY9;.\DV*:3'&R`K8KY&%O/%O%"]];7?8'[T?'$Q9W
MJ\$G(J9D`^)U0"`O@T29>(*>Q%X)EYR`N$;@7,U'/$1.95L"(IL4:.M8>5.J
M;9;[W<8PER?CB,/QQ%H&`GKALB!#L?!H6M0\62\-,6::V96S(@0&X(`,FK"Q
M#@PI3%PDV)..)'6UYALGPN\X]A""F.\^.$-4)#VZ)(BH@K@3!I.8@#;$B7B;
MY7(^'])TB2.&JD3A"69QN/ESHJR8>::=->\-Y\EI"R&Q7'\/CB8FT/1E$%V!
MZ5X55:N2)\>^^`>-9*;+)EIZ'&D+3!!S+T=D57D$V6"%4,:\MI8Q9K&4LH6A
M];;_`,T1$']4DFS6:,_"\+Z4#8YR7E'+]$VV>K=O;K&(A4)FJ2R9P&9@AIQ/
MFF!W!@V!4-#-@X[%"+&:PN(F)Y)ZUFHV<'IL!QCUV31)*'O]6M$^\Q#K%(J4
MA.V[8`,6'%KMS,DXB\7127I-IU&?"D#VBU*?PXZ@)/NPCHG:189$B#1GB12)
ML!O7%!B3/'E:]!N`SS,5*UJ6KT?E,P6XQ5:;7)O(PV<LY=?#<.%1GN.XRXGW
M80C!8O!6O[I&!\(8%<%(U[,1$Z].V1!0(5MC8]Z#1'0<Y'24%D.&#2E9:FEO
M#J4RH?&4M=TMU;8_#$?%`7`7+&(]*."M/(Q`1DFY"I5MJIO1\62U$)C\#1X#
ME?:PB0FF@A`1WVFDYS%M-MDNBI';%P^$PC(V#T'IIE$)->J6GQ,V*Q"FL=V(
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M;(?;P8L+)4K(90IJ/CF"9`M2&&'W4YM#2&L?DI133(\9Q>PA`.%1[NPE.-2B
ME*9J4!&+65(I6II`4^KQ4)V5K(P)^#94<24@J,@"8IW\3R._#4K^A?\`B>?<
M9'W._#7[I?OK^!_VO^&ZW7K*YS8?XGGF/9\S%B[OR1JM!(YR?\/S7%L>?CQ]
MSY8__]?%_K41^9>,\/9C?T\N-G^NQO\`LK8.JT>6C](?ECV`_"O_`-P/9G_6
MN?[,]'NHZVD?>B*R/U!13;";:Q0YRN6"4>05,G4RXW"DLV&0:$;`8E;3$U.=
MAX2V2PP#+;#9,H,8^AAIMK"O#;0E.<B\:M+**=2D+92))"T(79$YD)*TE2`3
MA(20)DG&3&&J@IE.J?2E2'29DH4I%HRE-020%&6":@3(`;`A1ZM@?PKV-\/;
M%]N=1GJN;,[@15FJ>.=W9@]6P/X5[&^'MB^W.F>JYLSN!#-4\<[NS!ZM@?PK
MV-\/;%]N=,]5S9G<"&:IXYW=F#U;`_A7L;X>V+[<Z9ZKFS.X$,U3QSN[,'JV
M!_"O8WP]L7VYTSU7-F=P(9JGCG=V8/5L#^%>QOA[8OMSIGJN;,[@0S5/'.[L
MP>K8'\*]C?#VQ?;G3/5<V9W`AFJ>.=W9@]6P/X5[&^'MB^W.F>JYLSN!#-4\
M<[NS!ZM@?PKV-\/;%]N=,]5S9G<"&:IXYW=F#U;`_A7L;X>V+[<Z9ZKFS.X$
M,U3QSN[,'JV!_"O8WP]L7VYTSU7-F=P(9JGCG=V8/5L#^%>QOA[8OMSIGJN;
M,[@0S5/'.[LP>K8'\*]C?#VQ?;G3/5<V9W`AFJ>.=W9@]6P/X5[&^'MB^W.F
M>JYLSN!#-4\<[NS!ZM@?PKV-\/;%]N=,]5S9G<"&:IXYW=F#U;`_A7L;X>V+
M[<Z9ZKFS.X$,U3QSN[,'JV!_"O8WP]L7VYTSU7-F=P(9JGCG=V8/5L#^%>QO
MA[8OMSIGJN;,[@0S5/'.[LP>K8'\*]C?#VQ?;G3/5<V9W`AFJ>.=W9@]6P/X
M5[&^'MB^W.F>JYLSN!#-4\<[NS!ZM@?PKV-\/;%]N=,]5S9G<"&:IXYW=F#U
M;`_A7L;X>V+[<Z9ZKFS.X$,U3QSN[,'JV!_"O8WP]L7VYTSU7-F=P(9JGCG=
MV8/5L#^%>QOA[8OMSIGJN;,[@0S5/'.[LP>K8'\*]C?#VQ?;G3/5<V9W`AFJ
M>.=W9@]6P/X5[&^'MB^W.F>JYLSN!#-4\<[NS!ZM@?PKV-\/;%]N=,]5S9G<
M"&:IXYW=F#U;`_A7L;X>V+[<Z9ZKFS.X$,U3QSN[,'JV!_"O8WP]L7VYTSU7
M-F=P(9JGCG=V8/5L#^%>QOA[8OMSIGJN;,[@0S5/'.[LP>K6/S[B[3L5:,_V
MR/?_`&=OOI_LI\1B0:>1WL>YVH4E6/U<9QGW>F>JV*=F?Z"?\\,U3QSN[5X8
MYU/5=&I<F5.PL2639#1,QQ-KL]@LEXMZXKQ6R,0J;;=9>P61J"02REU(*"DB
M)=QW\-X5G.>HJ*^KJFTLNN`,`S"$I2A$_.L("4VI8+4IRP3@Q14U.LNMH)>(
ME:4I2U2VK2RI4NY.7<BPNL.,J/_0Q?ZU$?F7C/#V8W]/+C9_KL;_`+*V#JM'
MEH_2'Y8]@/PK_P#<#V9_UKG^S/1[=]@W^HZKH]LV1?9A,!3*1`R5ELLNH.0D
MEA1,4,LHI8T7$"2$Q+G.(;[@X88Y!A;ZD,L-..K0A6]HZ2HKZJGHJ1NW4NK"
M4B8$R3(3)(`&V5$`#"2`"8^\%55,45,_653EFG;25*,B9`"9D`"2=H`$DX`"
M3*(0+R/X^&,BOL[RU'A)K];$';?V+4A25&W$)^1J<<X&5+,EL2=D!%=="&<0
ME\E#2\MH5W%=F6JY+Y25`W54X`HG]6LB2#)9F!*220%'$"1,QC"^+I4$D7G3
MX2D#]8@&:Q:2)$SFH`E(QD`D0I#Y!Z#D',M`;OU`<[@=\O+0>RJ82Y@4427D
M"2<H9FEJ\N.!7SWUK[.ZAD$A><X2RYE-*KFO=&%=U5($Y86EC"2`!Y.R5)'P
MJ`V1$IO:ZE>3>=.<$\#B,0!)./$`E1^!).P8CL_RKXY5MZ.'.W'1SBI6#N=F
M`$K$LFYF/U[7T%:+%<)K(E/1.$LQL+&TJ52IUQ"4.EA."-9<*[K.;S.K]]/V
MBB['0`M""5"P+3BD)0F:[(FHK1@V`H*,DX8M/7Y=#`!<O%HS0M7BFV;+:5*6
MJ29F20A6';24B:L$2RL;UTI=7X(2H[=UI9#K/DY%=C8:\5J0E)IZ+%'.E1HZ
M+'DER!1<2(6TX6RAO+HJ7$Y=2CMQUCOW3>E*'55-W/H0W*T5-J`3,D`DD2`)
M!D9R,L$XOL7G=M26TT]>RM:YV0E:23*1(`!G,3$QC$\,6KUKXSH.D(.D(.D(
M.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(.D(KN][6HVMHR2F;?*'!Q4(P
MDNP'QE;L]G&K,?E&'ERUI<J\-,XK$,.+E1#QI_EA6!6W'W'$LMN+30I:4":C
M@^`G\D<[?VM=Q:M4M36WQ5.(I&$VG5H9?>2RC'PCY8;<X!H)FM3KMAM"`I:E
M!"5*%A)4E:4K0I*T+3A25)SA25)5CM2I*L=N,ISC/;C..JXZ$$*`(,P8Y=(F
M#I"#I"#I"#I"#I"#I"#I"#I"#I"#I"/_T<7^M1'YEXSP]F-_3RXV?Z[&_P"R
MM@ZK1Y:/TA^6/8#\*_\`W`]F?]:Y_LST>W6_Z]I>TZN52MA5\*U5(^2KDK(U
M^3R1F+DR:I9(BVPS,H,P\RB3BT3D&,LD%_Q`CV$J&*:>&==:7OJ.MJKOJ$U5
M$\6Z@)4`H8P%I*%2.P;*C)0DI)\9)"@"/N_5T=-7,*IJQD.4Y4DE)Q$H4%IF
M-D6D@D'`1@4""1&%<=[,/B;%O1'EJ]=\QD)=,VL&`<V/;<PJ(AO6MLU6)K-(
MZ)!L@?6+%:N)67XUAUIR5<;9:DGS0T9%5U"M?-8EAV;[5M;5@JX-%J?"H=+L
MY2+MI`DH@V`26PA1M1S0U(U?"FB*=RPART$\(NS9#2V0U*?U5A9F@2MF065)
M\6+):X$<1&GAGO4K!O\`D_>3D8<V;MYX#3FOF==B5M],:=8B(_).8S4M:!DG
M<M9<FXV%%#DE%BM^#G`];M8Y$"]%"=O$E`/ZSA+6$)G*;KBDB?B*6I2+*C.,
M_P!5K@M!6C4S%B6%<OU?!V<%J4Y--I4?STH2E=I(E'76.`O$BF9'Q5]1#PS(
MU0E:(V&)<MA^CG*O,Q%XKYH)<8[;7(\XIN`V3-@C&/-.'!!'98'>::;90W+V
MM^L51/A[Q*CPH<F4-SM@MJ!!L3`M--J*0;*E)FH$DDTM:JW`Q@:N\)'!%N5M
MR5@A:9$6I&275I!/C)2J0(``"^F\+]-ZYN,I?*`Y=:G92X0&"AI`&TD23M79
M;L>Q;?/&!O6(>:)M1]VL^T)(V959G)YLQY@#.$-XC@L,45.L]YUM*BCJ^"<8
M"RI0*`+7BMH2#9LA`0EI*4<$&R`5X3;5.Y2ZNW=152ZNE#B'B@)!M$V1:<6J
M5J945J=45\(5S(1BL)E;GJ[M_P`O.U_XGT;]#/6MSNGZ+8[[W+1L\W=Y\[WF
M^3@]7=O^7G:_\3Z-^AGIGE/T6QWWN6AF[O/G>\WR<'J[M_R\;7_B?1WT,],[
MI^BV.^]RT,W=Y\[WF^3@]7=O^7G:_P#$^C?H9Z9Y3]%L=][EH9N[SYWO-\G!
MZN[?\O.U_P")]&_0STSRGZ+8[[W+0S=WGSO>;Y.#U=V_Y>=K_P`3Z-^AGIGE
M/T6QWWN6AF[O/G>\WR<'J[M_R\;7_B?1WT,],[I^BV.^]RT,W=Y\[WF^3@]7
M=O\`EYVO_$^C?H9Z9Y3]%L=][EH9N[SYWO-\G!ZN[?\`+SM?^)]&_0STSRGZ
M+8[[W+0S=WGSO>;Y.#U=V_Y>=K_Q/HWZ&>F=T_1;'?>Y:&;N\^=[S?)P>KNW
M_+SM?^)]&_0STSNGZ+8[[W+0S=WGSO>;Y.#U=V_Y>=K_`,3Z-^AGIGE/T6QW
MWN6AF[O/G>\WR<'J[M_R\[7_`(GT;]#/3.Z?HMCOO<M#-W>?.]YODXFM:A).
M"#?&E+A8KF\Z2I]N0LHU2%,%:RTTW@)A%/J]4CU#)6WES&7&''N^XKM<RGNI
M3C/.H=4"BG0V)8DE9![OCJ4>\9=R+S:%(!"GE+.V;/\`^E*1\D2+JS%R-=\1
M[1_5EDBN94A6*'L>>*X:`6>>GXD0.":-VQ5*9.[$J5EM6I?,S33<_#1ERU)8
MXG+CV1\.&1N4H[R76E*[-S4B\&'-64/U;"$WFI*4DE4F5K2VM*'I)\510\VN
M0GXJL.(RXUO76[GF]9EL4CZU78E:E`!,W4(4ZA2F?&\8!QEU&&R2I!E@()L7
M?N\JC.:QT_2ZE(661.YQE,:IU7/4;P,S4%`[`UC9;O-[;:4Y)QKHT30-=114
MNI]EQ3B"$CI3C.7,9QIF=7ZVH%_H<6AG1[*U.E<\"@XEH-B0,UJ<4$I!D,9)
M$HLZX/-7UJT;BHJUYIZ_F5TK+S/UC2:AAPJJ4$*0066@IQ"@9A81MQK0U;R`
MI-&X'ZGX\:-J.[=^[`Y-:"N]YK<389+7->G:E5=OW-O5,-/W64L=RC*^&$]L
MC8(,<''QQ4H3E"2"7LM#,//HV53J2Y=>F6KUO>GIZ2EJLV+I2ZL+>4DJ"4(0
MVI<@D%2E*"0!MD@1X/N.Y[LU&[#J?LWN>NO"\ZJ];M?0T[4<&'$JO-W-FBYX
M]E*!453:`A"G"$A2U$(2I0V'6/EG:*7L>B\?:7Q8V[L+9!?'VM;LG*K$W;1<
M*[0:V9//TE==L$Y;MH05=F+'#3P&1R%1)<@(YG]D9><;^SZII-6J9Z[JB]']
M8*9B[T5:J=*U(J%<(I*0L*2E#*E!)29BV$G8(!CST;\<N^HH;BHM7ZIZJ31(
M=*$KIQP:)\&$J4X\A*E@ID;!4#C!(C,.I3D]/1C1E@I<M1SEC1[SD1+RE;EB
M&7BP62B@U%5B8F0%O11+BAG5)<RTMUO*FE.-92O/.U+++*REFJ2ZF9PI"@,!
MD#):4G",(P3D<,C@CJ&'''4!3M.IM1`P$I)$QA'BE0F,1D2)XB1ACHO-@-K,
M*%)`-"O/DW#7E?6@M#KC6`K;?ZS59)U"67AUX*8CIIU;"LJRA+R494E:<90I
M3-)><4A9,@VXK!MI0I0^*8$^YM1+RRV@*3*=M(W2@#\AB8=8\78.D(.D(.D(
M.D(.D(.D(.D(.D(__]+%_K41^9>,\/9C?T\N-G^NQO\`LK8.JT>6C](?ECV`
M_"O_`-P/9G_6N?[,]'NHZVD?>B#I"#I"#I"#I"#I"#I"#I"#I"#I"#I"#I"#
MI"#I"#I"#I"#I"#I"#I"*2Y)7NZZRT'M^^:VIM@V#L:MT"R&Z_I57@S[)-62
M\+CWA:E&CPT:P084,[8"!\E*2C*61<..K[$(5G&TN2DI:Z][MI*ZI0S1+>2'
M%J4$I2W.:S,X`;,Y;9D-F-7?5754-T7E5T-*MZN;946VT@J*W)>(F0VU2GM"
M9V(U8ZLXD[UXE;0X3S4[,QN\Z49KJQ\,MU1NOM)S<?)P54V%#';2%V5L:91=
MKTFR08N[*FXU)S#PL0.+FUEOJ[J",L8\@7AK'=.L5!K2TTTJDJ@^FM8+CX(4
MMM0:+3:;"+*BPL%*`5D\"D8TSC@KOU=O?5VOU6<=>35TO`*HGPVPH$)<3PH>
M</"+M#AVY*40D#AU*.`RA?[/G3FX1MV*A=K52S1FK^`-"V/Q>XUV:RAR"8S:
M,==MMS1L?LFH&ECM"R(E0X\4.E5=9([A#39K\F.E:%(<:1;UPO6ZG;I#UV53
M:ZZ^'FZJI2@@EHMM`*:6`<!54K?<D9&0098C#4N[Z\WE8K&5"[;G:=I*59PI
M="WE2<0<1X.G:89)$Y++J)S!$8H:EJFOR>,?#BM[KU-S.UWM?CUQTDHC7.T.
M/N@=_26V:]N:5D7`[+KX:Q:\HTV)`'50>';8,@[>VBO2!\@\V6EMV,>[N=75
ME?6:W:U5%T7A=;]P.UQX1NI?IN!=`PAT!U8)2@$I#M.>$!)2#L'B;K:I;RI-
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M'`V4)(MA87*0E;#@"PKS@L!4YVL,X8-M_P`U8K_B;I3_`/,M"ZN4'U[G^A>_
M^%<15?5I_P!(W_\`(F+-ZPHR(.D(K3<FW:%H/5=_W1M&:][VO=9U>5M]MF,"
ME'NB0\0,HA_RL>$T^;('D9PEH<=E"W7WUH;1C*E8QTA&K;8WMB:'KS85/!D]
M,6\73*MMUO2NW=K%6*$L$EK&[7[7I&PM<9!JNIV=H5N^UZXQKC#:"HVR*-#*
M'.&*!8?8825V.K&J?K12WRFBKPF^:9GA4,*2`'4`I"R'2L!)3,S!3+%XTIRX
M_6C6L:K5-RJK:`JN>J?X);Z5$EI:@HH!:""5!9$@0J8P^+BG:UE]IY3=-GIA
M>4&D]G:,ERJ!M7:$=EB4H>QXY57U51#-H2T+,"URS"WFOW]RCA..9&(@?>^[
M(L$"@34@D=Q_KF[PIZ2EJG&**MSAE.#A+-@*4!XUD$DE$YV5*LE0D2A,Y1TM
MWO5552MOU='P#RL/!VK:D@GQ;1``"Y2M)25!)F`M0%H_#_:M:-A+?,Z[L>M]
MP5W8$9B,7'U26(TB*Y:&Y;46=XCJKUD=W2BDJ<&UXX.\^V;)A.8--&$:P\\\
MA.<*,R1QPVQOM=./4LP',A:TY"+I6;)QMKMAOSU-I`M<IB>6`,:=I>;L@)6R
M6K@N*F?2S#1K<=%'R$8\O"21F\*1E:$C&U'I$0=(1__3Q?ZU$?F7C/#V8W]/
M+C9_KL;_`+*V#JM'EH_2'Y8]@/PK_P#<#V9_UKG^S/1[J.MI'WH@Z0@Z0@Z0
M@Z0@Z0@Z0@Z0@Z0@Z0@Z0@Z0@Z0@Z0@Z0@Z0@Z0@Z0@Z0BN['MK6]1GDUNSV
M^(@I7R0DB2F2<=&CXH*1Q,>BB)Z;6UB%KJ)E5?.2#YX@?)RPWD,8<4VK&*"X
MA*K)5A_R[T<[>.MNK=T5XNV]+X98JN#2M5LE*&TKX2PIUPC@V0YP3H:X5:.%
M+:PW:*2!'\\B^/B4MK5O;3:4.I?6TO.SZ3A+B!6?,%*;5F<[%I&'^S<SCW$(
M^RSV8]WJ.%:XQ/?$:\]HW9Z`DG7NYI$&7\;38;(M*E^MV!A.T,)P1CMK[:=+
MHU17K^T;TT:%7UVBSYK=PI.TF9^V6&KV^8L-Z@W#X=,6*-1I5RMR'[-(MGR@
MZL,*?84UE]K+%I*TI38+B0-L'#M_%@V<,>.M7=:;EN.Z%:OWGKU<2:`U;_`5
M%+7!Y]UBI<>JFBIL(2*9PLKPNI=?00@N-E'")X/%#:FC(6Q<AK#M[6N[.-%>
MJ-)>UO8[<;,[/J\E(4#7^N8--<M3$Q#R>OK//4YDOL=0D^*NU5B,+=4Y)`&D
M^*X1+5&[65"&*)'"/+4`E"05*)Q`!(!))V`,>U'BS6'LY3K!VGU6LFIFM^KJ
M:.F<HG'0:MEYZGIJ5O@'D*951U#[%OQ@ERFO*A8M**JFF?="U.Q:[Z>MMHXQ
M<69*Z[<XA@:CT!7HJOA[:]>]8E=<;,`>I+.O!)IVT;<XW[+U<"4_.QS+C#3D
M;,>(ZXM#)+)#:',Y:;DOEVJT2F['57BC!P00LN8!,S;L%0D,)\7`(IOGLKUW
MOK43LKNN]+TU>3=VKE.AGAQ7(=:K$BD%*'%&ON2NI4*MI2L)735.,A#K;B4K
MC,:B<9=KXWEJS<AF_P`K.MJ%I:NU6J:ZJ\9K(V`05+MP^+G7P)")U#4`2]?2
M(%6B7P905D*56ZM]`S<8#W!5XN;NMN@.$I*!(B6$$8")2$L6T#\$>3KF[+=<
M6NT#5G7"K[0'4ZO7;<S5,S0M-T1;2M?!BJ9"D7?3I-*I-.PIMY"6G[1<2TFE
M8DRK++;?\U8K_B;I3_\`,M"ZVE!]>Y_H7O\`X5QYVJOJT_Z1O_Y$Q9O6%&1!
MTA%8[CU)K_?^J]AZ4V?$IL6O]D5B4IMPAFS"`B'XJ9$RT]Y<X)UHV-D1\.(?
M&?:4AUAY"'$9QG&,])'!,8(`X<!PB-=^Z?9B&[]T]:M";>Y<[HV;K[-$:A-.
MIO\`$4ARTZ_V#',M)@-CV^7U_&:WCMO$4Y`:&XT8N/CS%,%GJD)`\MT$N-[#
M576LZJ55+7T-WA=8EV;JE*G;9Q%E`L?J@N9MKFLDA$@E(4E?(:UZJ(UMHZN[
MJ^O**-34FDI3(MO8P^HV_P!842%A`"`D%<RHE*D5S<_982T)J79EHJVW]@[3
MY43X^X[@),R<U':]U_/[1W;II.B]E3@-?6/9Y>ND6FBMI=%27/F(BIEM*@"(
MX%:QD<U7O4M16U3]%2EBD6LE+97;L`X;-JRB8&(>*,$IS.$]+0MU3%'2L5M4
M'JI"`E3@38"R/SK-I=DG&1:(G.6#!%*T;V:NWJ;<:S;*-9>4]4IFFHVMR>A8
M.<O7"VJ[NI>W9]$_3]IV<4S76H+?HXW5TSJ@:'BY&,G!9XV9>[[F66LA#9=B
ME:IWG;%55<"U9)M62K",0D,.';Q#9BY4NO--VJ>GX5R8%FT$X)X3,[6.6/:B
M[+=P^MNP8[:LM:M-[_L=BW5:N/MUO:S^0W'$,AZR<;WXV3U99*[)0^OT`X-`
M+A@42`Q`[81:,E9PA?A#>9V8N^YK9!U@38EC#+N/NC!+9Q3V-LV<`UMYA$TW
M.2J>+A6\6V#WL<MG'(3V%M;.Y%=S.%\7G,J1V-X4YNN@]]Y2VY?P7L^"!AM+
M27`A,$YQA*F_.]K3;W@KQTT?<LO^8,/^@<[G=[IE^CA(F(C/+SZ',O\`2H[O
M@$_AP3D8L/WX['^1^1_\J_?C_/6H?^8_R/\`[\^Z/_??W'_PG6%FU#TD/YBQ
MY"_JN.^#Z'EQE</5\R/U-KRT_6<7_P#O\F/_U,7^M1'YEXV3>R1HLU=N>6F'
MXL5]T"DJM=XL9K3??:C(B)J<R&.^3GMQW&CK!)@A8S^KAPI.?^GJXR+3J!W9
M]Z/9S\'MPUU]]O\`J4[2M*-/0YQ4O*`F$-HIW4))[BGG&FQW5B/;EULX^YD'
M2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$'2$(Y"0`B0#I65.#
MC(N,#)D)*2D"60@(\`)E9)AQQA*VQQ`Q!VU..NN*2AM"<J5G&,9SU4A"W%H;
M;05.*(``$R2<```PDDXA%*E)0E2UJ`0!,DX``,9)V`(80;W2)./S+QMRJLA%
M):2^J3!L,07'I86AMQ#V36#'!L-*;>0K"N]V9PO&?U,XZO+I*IM?!.4SB7)R
MD4D&>U(B<6TU-.M'"(?06Y3F%`B7PSE%:W6O\;+'*^^?847I:9FV@7P4V&V,
M4LR49`JP4G:GV$2LKA93+59C<&R.>QS'D1_'?[6T9<5U0*!]Y6"B6I6#\PG&
MH)3L;*B`-LD`83'.7MJQJ7>]8+RONX;MJ;P"`CA7F65N!+=IQ*0M:2H!NTM:
M9'Q+2U"4U$U5N#5O&YO7DG`0C?'+5EFM<)8877MGG*OJ?((4F<6F5D'HJ(L<
M29$3+2)66264,D=Y"WB<+7C"W$KZI1==34I=32T*U+2,-ELJLSGCD#*<CCVC
M'+:T=GFJ%5J]>%W7-<]RW=>KU.ZW3O*HZ-:6E.**U*#;C*VUI*U%:T%!"E*)
M/C&U&*4OJ:<@/-L`;EX*1\=B7IEVJA-JU_KMF08A(N**/A)<Y$:%"Q)"EH.!
MS&FBL#ML#LM$L*3E2VGJ$7+>J\#=`M0"Y?5*.%,P1@3C!$B,8E'B^H[,=;Z;
M.&Z*]]4$L"I8>9+MVT]M*6DJ*2O@VVVRL$H#2T(38"$K19-I*WB[:4G++J_;
ME=@=B<&*X7M^)HE5TX>YK:K2]<"FJ"?4[)!XEV<$QX.Q3-<UFOMK@@U#/A)3
M'Q;KX:6!2&S-[JVAZZ+\9KJZ@J33,@\(ED*;=L*2I%FW*:$J)L*.`E)(24JD
M8Z^Y-2;YN\ZQK<J=666*UEAJE%/1(04<`&^"#JQ8#XIVD);938L<&W3_`*M'
M!KX6LAN'^RT:/U'I6,W7Q*3G05_=VR((?`7*TQ]QW/93]Z%;(,V:U([)1ER&
MLM5W8//#B"B"K`LHZR&DHCEB"B]HK66[Q>MY7HY==XRK&0S,*0@H80&`V&I-
M^4E;!;))-IHV3-=I2NF1JS>.B[MNYN\KOM4;Q>`*'%I6^LU'"EV;ODK0^'`D
M`671:'B64IV1<8Z?3=*Z#T?HV"V5&;!9UAJRC42/LZI:+=,M(M8@HN!9FV1!
M#S4LBR#C2,LM-N/)90XVUAQ?9A2N'OVJJ;TOB];U=HE,E^H<<*9&2"M159F0
M,(V3(3PF0CMKCI&+KNBZ[J:JPZ*>G;;"IB:@A(3:D"9`RP"9E@$S$\VW_-6*
M_P")NE/_`,RT+K#H/KW/]"]_\*XSZKZM/^D;_P#D3$GME3BKG%9AIE1J0\N+
M>QY`QT)[#R@RQ&G?%:]U61LEY=;2K&4>,VC*L*QCNYM4U2Y2N<*U*UW1/9!^
M64CW"8J?814(X-R=GN&6P1_G[\4FQQ>HPPPS+5FV.T\*P*P@X>V9!)=\L>])
M*(+;CX\0`PPPQ_*GWG65..XQA.<]W&,=;0W_`%:BHEABR2<%B8PB6"9)$@,&
M'!&O%S4H2`''01LA4MF>P)83CP?)"]7'2JJQ)OL3UJK\E*D$%$&TN1;K"&BD
M(#!@SF!&V#FO25<@8H./$==R[AL9C*$H2VZXVJC3=0.#!9;6VD2DL6L&$J$Y
MC`I14H@2F3,DD`Q5HECQR%K2M1G-!LX<`!V<*4@)!,Y`2$@2(5B<>ZD+-RDV
MY8;W).2L1/Q"XV9L:9>$!;L<?B+D38N*D`'Q0)!065(RXC&,/87GQTN]B>[:
M?O5]^F-*IEI*#+"E,E&6$`F>$3VYRV)1=9NYEFHSE+CA7AP%4P)X"0-@RVL>
MS'$CCQ3R'2G,6"_"X/\`-Y.9CK4]&CO+,*&+<=&9`%&1"O#NL+R,N/P(H-1#
MBQ\M.92M&LG&?"AK1,./)$GC7'8+*38<F+.;S:I$IPYXB4DY%LPE)[I<7V!L
MS)(S3*!$-Y'<2AWQ$L#880ANC.-E$B4Q;`<Q?41L.^AX&&1;SQX?'=!:CE,E
M`!(%:D!U",(;0@CQ<#H3W&/";RI.4X1?``;<<"%'M.$O-`B#AM/&$O&%NMC,
MH90X460I;Y1*THQE;BU96M6<JSG.<YZB$*^D(__5QRAO0WI0+WP^D_0OCI])
M>AO*^E/+=F>]Y+SW[D\?M[.SQ/L>M1'YH:',<[8TEPN8VO'X*SPDOHVO%G\.
M"/8;[)'\1[U76'\5?WP>_P`[P/K8]:/HOUO]O:YZ,\_Z*_S/[S?&[_DO17[B
M[_;X_P"Z_$ZSJ?@Y&SY>S/\`RQ1]F_P@>PGU4O'V39QIZ:,_S[@]([-BWP?Z
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M,[5G9G;\:<3_`/7<T19EFOC>3PD_*%J=GQL<K,]B5C!"R=_-]>AI'T_ZG?>9
MYB,[WFN]ZM?3GHR.\/WL]W_[$]^WO>\#TEZ*_P`[^B^WSO[E[_5+/KCPB.!S
MG.9'%]99M&=K\^Q:G9M^);\GQI1+OJQP:^&X#@,&/ZN<A*S^9:LRG9\:SY7B
MP\R/XC?JZL7G_5QZL?6O_GCL])>]KUI>DJ7X7HSP/W/XWF/0W@>0_</D^SP_
MW+XW5E'K3GC-CAL]S?!BM<%)>/XK<[7C3Q^-*+[F@<V<M\%FO#8<<N$FG%W9
MV96<$L6"<5T7^;8\EGS_`*KO#\*L>)YSWQ^EO![L5[W?->/_`)Z[GEO*=_Q/
M<\KW?'_8>WK-1Z[6S8SB<U8K,MFU+8QSQ;.+#&(OU5L"WP%F2<<YRP69[.UC
MV,>"$=`_-W>NZB>\'T7ZQO*L>\3R_K)]Y'C^;D_1_@>D?_#WTUXOE_1?FOV;
MN>B?1_N>0ZKK/7+157G=K,IGA/J[>Q/%X]G':E@GPEO\^*:;U9TC39O9SR7B
M>79V98_$GBE/#*Q9_-C/>^>@O0@/OB\YZ/\`?GKGR_D>SQO3OK"J_O6[_;__
M`"?OF\GYC^#]_KD*7A>%5P,K?!N8_-X-5KX[,Y=V4=*]8L#A)V;:<6W:$OEE
M/N1,^L>+L'2$'2$'2$'2$'2$47OOP_>[7._Z[>WWT.?^17<]\?@>]*U^?].>
M+]C[WO1WB^'X/[O]+>2\C^[/`ZVUT3X9^6:RX/\`;^3Y:)6?I3E/\VQ;M>+.
M-;>7U;'\Q]9^QQ^0N=KZ,I]VW9L^-*,2J5W?3`_GOSBO]T@^Y[]O0'H7S';8
M?$\S[WOV/R_F>]YGQ?W%W/*^6_<O9UT=5/@S8T+^=Y%J?YN*ULRQ2\;RK7C1
MI&9VDVM*XT^59E/#CEL3Q_F^3+Q8R=_<_P#_`+#_`-'/^&?O?_F'_P#XW6@P
6_8OYW_+_`/CQNO%^T_RO=Q<M\L?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g693329g31f69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329g31f69.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0ZN4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````0P```&0````&`&<`,P`Q
M`&8`-@`Y`````0`````````````````````````!``````````````!D````
M0P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#!$````!````9````$,`
M``$L``!.A```"_4`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!#`&0#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2DDDDE*220,TEN'>6O%3A6^+"8#3M,/)_DI()H$]D%G7.D5
M7.HLRZA:R0YNZ2"/S=/S_P"0I-;D9K9LWXU#OHL:=MKAXV/'NI_XMGZ7^7_@
MUY:VB]]S:6UN=:\C:R#N,\:+U?"9=7AT5WG=<RMC;#,RX-`?K_60W:/)\U/F
M3,2CPQAVZW^C)P>O=`Q\;$?U/IV_'S,;])ZC7N)<!]/?O<Y;?3,O[;T_'RCH
MZZMKG`<;H]__`$D+KU@KZ-FN/'HO'WC;_%+H-)IZ-AUGGT6D_%PW_P#?DNK-
M"`AS$A`",90XI1'R\?%I)OI))(ME22222G__T/55PEO^,3*9UEV.**CTQN3Z
M!R(=NV!VQUF[=L^C^D^BNH^LG4OV9T/+S`=MC:RVH_\`"/\`T=7_`$W+A!]7
M7?\`C?G-+2<@W?:_/TOYC_SU^G4^&,:N8W(@/-AS2D#4#J`9GR'1]+N]7TG^
MC'J[3Z>[5NZ/;NC;[=RYSZG_`%KR.NORJ,RIE&1C;2&UR):=S72'N?[F/:K_
M`-5.I'J?0,3)<9M#/2M/)WU_HW.=_P`9M]3^VN4@]!_QBP!MQ^HNTG0$7_\`
MD<MJ$(`^Y`CU`6/\'=,YD>W('TDT?\/Y7T)<GU7K]V5]9ZOJW1CUWXY-9RG/
MWR"/T]G\V]C7,95L]C_\(NGR<BO&Q[<FT[:Z6.L>?`-&YRXC_%YCV9_4>H]?
MR![K7EC#X.>?6NC^JTU-3<<1PSE(6`*']Z2LALQ@/TCZO[D?F=6_ZSYE7UQK
MZ$VFHX[]LVD.]36OU?WMGTOY"U.O]>Q.A8/VO)!>YQV55-T<]W,?R6_O/7)Y
MG_Y4*?['_GE&_P`9^/>:NGY@;OQZ'O;8.P+_`$W,W?U_3<U2>W$SQC82B"?$
MK?<D(9#N8R('DT^I=<^N/5\6JEO3ZZ<7/<!0SA]@;^D_PEC';/\`A/38NM^K
M74.JYV)8>IX0P;:'^DU@W`.`:UVYM;_HL]W[[U1Z)U7$^L'6#G4N`JPJ6LII
M<0'A]ONOLV?2]FWT5TRCG+<<`C_TD8(DREDXB;/`/ZT8?^A\?"\7U?ZX]=Q_
MK#?T;IN'5DNKCTP0XO=-;;G\6,;[=R;_`)Q?7[_RD9_FN_\`2RJ,>QG^-*QS
MW!K1,DF!_1@NZ^V8G^GK_P`]O]ZDF8Q$0(`W$2LVF`E(R)F14C&APN;]OZY_
MS=^V_8Q^UML_8X,3OV1&_=_->_\`G$EK;V;-^X;(G=.D>,I*'B'[HWO_`-!9
M:/<[5_Z$_P#_T=K_`!FY[W?8^D4@N=:?6>QNI.OITMVC^5ZBF/KBX8`Z?^P,
MK[,*O0V>[Z&WT]O\S^XJ_13^WOK[E=1,/QL'=Z1Y$-_5Z"W^M[[UZ`K$Y1A&
M$#'B('$=>'U28("4Y2F)4">$:7Z8OG_^+//=3?F=(N!8X_IJV.T<'-_1W-VG
M\[;Z:M_XS,!QQ,3JE0BS%LV.>.=K_=6?[%K/_!%2^LA_8/UWQ.KM]M&5M=;'
M'_<;(_\``MMO]==IUOIXZETC*PM)NK<&'P>/=4?\\(RE62&4;3W_`.C-$8WC
MGB.\-!_TH/-_7#K[;/JACVTF']5:P0-8;'J7M_L_S2W/JOTP=+Z%B8I&VTL]
M2[2#ZEGZ1X=_4GT_["\Z^KK+^M=1Z3TFT3C=.=98]IXVE_KV;OZSME2];3<P
MX(C&.YD?^Y3A/&3D/81'_=O`9G_Y4*?['_GE==U[(95TY]9K;?9DD44TN`<'
MO?\`1ECOS6_37(9I`_QGTDF`-A)/_$J[U+ZU8V'U?'S\W'MLPBU[,)S`(`!#
M7Y6U\->Z[W-9[_93_P`:AD!E[8CJ>`+#/A$X@T9S(O\`<C^E/_!1YG^+:IE#
M+NE93\?/J:#J3L<\#78]NVVG<[^4K7U%^L6=U#[1TOJ9W9F%Q8[Z3F@^F]MO
M\NI_YZED?XR?J_70Y]'K76Q[:MFV3_*>[VM5;Z@]*SOM.;U[.K-+\XGTF$$$
MA[O7MLV'_![MGI)QXO;E[HVK@,OFM=$0$XC$?[]&X\/BY'4>EXW5_P#&+D8&
M47"FV"XL(#O;CML;!<'?G-6]_P"-G]7O])D_Y[/_`$DL+J'5,;I/^,:_.RMW
MHU0';!+O=CMK;I+?SG+?_P#'*^KGAD?]MC_THG3]VH<%UP1V6Q]JY\?#?'+Y
MG?\`V7C?LG]DR[[-Z'V:9&_9M]+Z4;=^W^2DJ'_._I/[&_;46_9/4]+Z(W[N
M/H[DE!PY.Q^;_GL_%#N-K_P'_]+U"G%QL>?0I95N^EL:&S'CM"*DDDI%=C8V
M0`+ZF6AOT=[0Z)\-P6=]9<W(P>E[\1WIW/L96QP`,;CX.EOT0M98GUOHMMZ*
M]]0EU#VVD>3?I?YNY([,/,DC#D,;XN$[?,ZM6)BTO-E5-=;W?2>UH:3\7-",
MJ>'U;`S,1F57<P,<)<'.`+3^<U\_NIK++\T>GBN-5#OIY/#B/W<8'_S_`/\`
M;?J)6O&2)`,3Q7K'AZM/-QZ.IYCL>JM@KJ/Z[EAHWF!_1*K?I;G-_GO]'7^C
M5CIF?TWK&&[[/7NQJSZ1KL8`W0`ANSW-V[2KE5%./CBFEH96P$-:/]?<Y<9]
M4L'JF3@VOPNH'#K%I#J_2;9)VL]^YY"%FVO.<\>;&!'W#E$^,1J_1P\,8<<H
M>GU.[CN^K3.I7XM6'13DXC?4MM]%C0`-ON%@'\M0=]<NDRXULOMK88=:RN6#
MYES5SEV+F_M#K6.ZTY.2W'E]@;M+P'4/=[&_R%N_5SJ_1Z>@U5VW5U.J:X75
MN(#I)<?H?G[TK)W+#CYK).9A<</SGBD/W)\'!\W#Z?TVX_/^KEV$[JMK:7U$
M[76/K!?N`_FRTMW^HL\=?^J^CGX!94XP+G8[-GWB5A]2.'?A59F!@OQ\!F01
M?+BX/,""&N)V>W<Q=!UOZP]%/2CCL(O9E5.;6VN"&$#]&+&SNK]R7$>Z!S<Y
M"9,\<.",97PR,<QE^E'BX)<#K_Y)_9_J[:?L$>K.UOIQ^_MC:DN5^R9W_,6(
M='J>KL[^CN\/W=_Z5)'B*_[Y/_-?Y#W_`/"_=_NO_]/U5)?*J22GZJ47_0=Q
MP?I<?VE\KI)*?>^F^E^TAM_8V[?[O2]3?S_@/4_1;_\`BUUZ^54D`PX/E/\`
M-[_Y'Y?K_6?JD\'^*R_J]'V6R/L7\Y_WGSZ?#?YS=_A5\U)(KS\\?EZ[_/\`
MX'_=/TKB1^W,K^A3L_P4_:_\'_2?Y'_J-8.;Z7VU^[]B;MQC=ZD_]=]/]%O7
MA"2##D^7_(_,?G^7_P!B/TXW_DC_`+2_S?;^C?\`JE<F[T-UD_L.8.Z/6XC\
MS;[=W_%KP])+[%9]H_S.W^5_[A^A?T/_`#*[[/2_X7;.[_M[T?\`P-)?/227
M\&'_`,+_`-S?R_ZD_P#_V0`X0DE-!"$``````%4````!`0````\`00!D`&\`
M8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O
M`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````!P`(``$``0$`
M_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!
M`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#_\``$0@`0P!D`P$1``(1`0,1`?_=``0`#?_$`-\`
M``(#`0`"`P````````````D*``<(!@,+`@0%`0`"`@,!`0$!````````````
M!P0(`P4&`@$)"A````8!`08#!`()#@\``````0(#!`4&!P@`$1(4%0D3%A<A
M(A@*-1DQ07$R(S,D-"928D-35"66-Y?7.+@:.E%A@F-$9&6%U396UE=G61$`
M`0($!`(%!0<(%PD``````0(#$1($!0`A$P8Q!T%182(4<3(5%A>!D:%"(S,(
MP=%28G*"DR3PL9*BTD-3<X.STS1$5&1TM"4U-C<8..'QPN*416565__:``P#
M`0`"$0,1`#\`?XV,&)L8,38P8FQ@Q-C!B;&#&5;'KATBU*W2]"L&H7&#"WP1
MWK>5@@L;9T[9R,<8Z;R#.=D#AL>R).$S(],(<S\S@/"*B*GN;8%5+")IG!`<
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MLQ>0]JNNE9DBN8YKED=G08`H>F?+!\ZZ?L.Y>7200?W_`!_6[!,-FI#)M6M@
M<1Z2=B:-"'.H<K5K.(N$TMYC#P%#>([36%EQIM9\XC/R\#\.+1\L]V^OG+[9
MN\5)2EZXVYAYQ*8A*75(&LE,23!+H6D1)R'$XO';+CN<38P8FQ@Q_]!_C8P8
MFQ@Q-C!B;&#$V,&*TS0\=Q^'\JOH^RL*9(-<<W9>/M\J]3CHRKR"=;DC,;`_
M?K&(DR:1#K@<**F$`(5,1^UMB?)#+I"H&4Y]67''.;Q>=I]H[H?8N3=&^BW5
M)34+4$(84&5RNK6<DI;5!94>`$<>OCC:+?)ZVQ=-C*G:)*[6!RP)$UU&'DE+
M#*.)@J3B.4;1YD`>KA()."*IJ</"=,X'`>$=^VJ"VY01"7J^I#ZF/YUJ7;VX
M[E>J2QTMFJW;_4J1ILAM9><+D"@A!$QG!"@J$"#-&&>/8.87A;=6\.XGKN0'
MBDC?('&E$A;M(*O.H*OK=%U>*8V1XJ_\17GE',R@L<RW$;Q1-Q;QW[;9D+2R
MTESSPD1\L,\?T3[,HKO;=G[4M^X'R[?F+;2MU*RJ<KJ$,(2\HKB9BIP*)5$S
M1C'/%,:[I]M6=&NI>7=\`I$P[=6!2G$`*=S,Q*\*S3][V<2CR0(4O^,0VQU1
MA3N]HA[^6.,Y[W)JT\FN9M<\`4)LM4F'67&E-I'NJ6`,30C4%Z+HVTTUQT!B
MNT</4N6=IG`0.@[LT2C9G38P"!1`S9Q+F3$-WLX=BE$*=H]8C[^?U<>>0]E7
MM_DSRRM;@(>39:5:@>(6\V'EIZ/-4X1[F-9;2,-K$V,&)L8,?__1?XV,&%0;
M1\P_DZOZRY7'2>*<5N-(<+J6'"SW,";2ZNK(K48^RD@)>VLYE&TIU9>0-&HK
M3#9$&/"9CP%$IAWJ#82GY+T3VV&ZXW)\;D50ZX8[DLQ3$)(EGA'NDQ\["`J.
M=-0QNM=L]$-G;*+AX4U4RHS"`48>;D<X1\SO=F&G;:>S$JEF/2@B#7$M?F3U
M(L^@Y=01K*6.<F@BS39D^C'CB)-*`ES!$G+=0R/$!5"&$#`@:<,&H8%5-X:<
M3RP"I8B:$01&$81!SZ#A]O:H:=+$-:4RQX30RC"!A'CG@+G9][JN1.X/,9\H
M&;*!2,;9,P^K6I%A$4IO8V3:2K\JYF86=3D6-FG9]^C+5FP1222XE43()7R1
M>`#$,8S/YD\OJ/9C=GK+76NU%OJDJ[RY8A0`4F!2`"%),1Y#A8\M^853O1=\
MH[E;VZ6Z43H2I"5%44F*23-`@A:5)/1PP<3958:6%\=4^ONWY7[G%`[7%$Q+
MCG)N,%Y?&;W.4M:U,AC(1SMB@;*5O(F2F7JJPDQ78"A=..+"50>,7$MQHNTE
MDR@B#3HN7EJ?Y=5N\[W6/H<BK1;24I2N!"&YH@J[SD8PR*0,NG"0WG>*'=>\
M:+E966-JNLZ])ZIG<>0D::M8)6AI2`ZV`E!4TZ5-+*@'$*2(8L"]]SG+M3[P
MU-[>C#'F*UL83Z=917O#EA9_45LWF<3+Y`<(-7:-E2KQ2)2R())@+`2@W'<(
M"?W]O5'L&VU'+:IWJJL>%>V5`($FF970@?%FX&/'CC?5>^:JEYET6R4VYDTS
MK`7JQ,XBE2I0.$(I^'AC=^OK7CB7M]805S!D]![8)"5E25J@8_A739K/WFT*
MM'#[D&KAR59.,B6#-L=9\_.DHDT3X`X%%544E.4VAM&Y;RNJ;9;H)2$S..*\
MUM$81/623!*1F3V`D=1N_=MKV9:'+O=%$IFE0A/G.+()"4]60)).0&9PL_J-
MUR=X?6CB^DTUEI!H&.\/:HIUJQQ36C\Q'7_)D?!*,+JB5N\N.2X"5>5M1@@V
M55EB0T7'.FZI#)*`"A1V8URVGR9L[HLM[WC6*N95*I322I*5`@$10RZA,"<P
MI1ATG(XJGS;W'NG?]ALVQ+]91;[7N>I2S2M(6H553HE-04DRJ#;4J$EQ:VVT
MA*@)TE0.&(^VGJ$U2Z@,271759IE9Z8[GC&\I8VC:XR;V6%:6!A'5>!FNIQ5
M5M";UY%P#)I-M4&KM&4DVC\04\,R?@B!^!WI9-NV.NHV=M7LUU"ZS/-!/<[Q
M2$E28`GNF(E24Y1C'*T>R+C>Z^T*1?=NIME13KTDM)5%)0A*8%(^*B!@D15D
M..!7ZMN\1KIQQW"LIZ'=+^F[$F:)6J+P`4V.>QEY=WB?;.L2UK)E@5<].R!`
MQ"QHI*2>'#PD4=S5`-X&.`F,PMN\M-J5NS*+=E_OU12M+*@LB21)U5-IA%!.
M<![IQP>XN96Z:+>U5L[;VVV*RH0VE:8K4E1!0%JCF$Y1Z\?6^L2[^7_R_I/\
M&;]_/#L>IO*'_P!^>_.?N6/7K=S?_P#G+'X?_FP5GU\UP?5V^N_PX0_QL]`Y
MWX=.ESW1^M>J'ESIO3?-O7.#R#^^>_JOW_O[_#_![+WT3M?UR]$^FE>J^I#Q
M,4S2:<TWFR^?W82]G'/##]);C]5/2?H9/K+H3>&F[NK'YN:/#[:/;C__TG&>
MY#J.#2CHCU$9J:R72K-!X_DH&@.B@51=/(UV%.GT5=!`Q3<P,=9)MN[5+N$`
M0;J&-N*41#J=DV0[AW39;443,K>!<_6T=]<?*D$>4XYG>5[&W=KWN\3`.,TZ
MI.UPB5`_-D84W2[=K\/E^G6=E8-VODY?+WQ7))G3X9!OBHHHXI.B7<;<K%&I
M21[5QF'?RZ@F^T&UB#O5OVRIM>H!;Q3^#XY:GSGN?*?)PZ\5W]2'E<D%5TA-
MU4[X^,.]+P\I.CWNN/O8:7[4NI1;59H(T]91E7IWUQ8U$F.L@K.'17;]>[8U
M74ITM+R9R@7@?6M"*0FA((;RIR1/N[('F#8_5[=]ZMR$PI]74;R@)'.^D#L3
M$I^]P_M@WX;EVC9+L5`OK9"7/UQON+]]22?=POV**G;P^8M!)N@O#8LU@S**
MZ`.5Q:Q[UMJ+4W/5TS#N;"VBM046Y(B3V%103`H;@V<0(WGR4,3-<+6,^DC0
MX=N;!'EPG3'9?/(926V\HZH`K<R/9'63G]WGQS;@R/?:YBO'MYR;<'J4;5,>
M5&QW:R/UCE33:0=7B'<U*+F.<0*'ALF1Q#_"/LVKI14CU?64M#3)FJ'G$H2.
MM2B$CX3BQ=54M4=+45;Z@EAI"EJ)Z$I!)/O#"M7R]./IS4)J%UI=QS(D<D:9
MN=[GZE57"AU7(,+-D&8/DG)#5@JH4A4T(*&D8-DW$`]C9T9,`(4-POWG+6,V
M6S;6V/1+^3992M8ZP@:;<?NE!:CVPP@.3%,]?;QN_?\`6I.I55"FVHC@F,RH
M=@3IHC]J>W')9D_O06+_`+E"_JU/-I%K_P``[A]VY_2!C%=?]0-H_F:?VMW%
ME?,[X\O2]:T?YP90CJS8PQ?<+_!7=@*!U8B-E[>I0).N'F13!3P6-F;T]ZQ%
M4Y`3(H0B?%QK$*:'R&K:05&Y;0MT-W"I906S',A,X4$]J9PJ`SXGHQ)Y^4=8
M*/;%Z0P7;=1U1+J>($TA25=AD*8G@2!TXW9HCU4XE[D.KU]J#H\XT84K3MA*
MO4W&>,IQ]$M;BROF5VP2^4+6O6`6"59HUIG&)USFDTCQ[P$05;JF`!`$MN/:
M-_VU=ZAF\T#J&4&"')26G/MT+X&(XB,1E$`XTFT7U\SN>5?OIQM2-J[<M#=+
M;4KE^5JJ\!VNJ4I\Y):;0W2*!$"1,D\<'`VTN+.X3^AIB(@?FE+E*SDI'0L8
MV0D0<2,L^;1S!N*VB.,01!9X\51;I"JNH4A>(P<1S``>T0VLBZTX]R!IVVFU
M*<+B<@"3^^ST#%<V7&VOI"5:W%A*?!',D`?,(Z\-?^KF*?\`R=CW^&E;_P")
M;5[]'7#^(/?F%?6Q8/QM'_&VOS2?KX[#K,1TGK_58WH7(=5ZUSS7I/3/`YKJ
M/4?%Y/D.6_">-Q^'P>]OW>W:+I.:FCIJU8PE@8QX0AQCV8SSHDU)A)",8Y0Z
MX]6/_],F?S,^>YN3)ILT74M":EYB[RI\N6FNUQ!:3F)M%%Z]I>.X9I#,D5GL
MBZD)D991%$H&%1=LGPE$0#:P_(FT-H5?-TU*DH:91HH4J`2DD!:R2>`"90>P
MXKQSZN[CC-@VE2MK=?JG@ZM",UJ0@P2$I`,251([4QZ,=&U[Q3YI@IOIP3[1
MFJHV)6V*DL,$K2Q+&NW-0$:F6E%AU05Q`<%BF@"^$83;Q,/M'>.T=7+,*NIO
M7M$MWI`U&M-E\Y//'YS[+&T',IP6X6OV:W?P09TI9,I)98</L<L5%\LWGJ0I
MEZU)Z+;HWDZ[)+N29=JM<LK=U$3S"P00L:9D*(=PSU)%=G*],3B%5D3%*H3D
MU-Y?8.VSY[6A%336+=-*I*T%.BM2#%)!BM"@1Q$9P/*,:#D+=W*5[<6T*M#C
M3K3FLVAP2K2#!*TD0$".XH^4D98T%\S#@J0=8DT^ZN:<WY&V8-R":HS=@8@9
M.2:P-P59R]2?*K%WCX-<NM?*#<1W>&M*G'?[VVFY%79M-SO.VZI0--6,3!)X
M%2(A0^^0HQ^YQN>>]J>-GL^YZ,$5=NJ021Q"5D0/WJTI]\XZ7O`Z_6-C[0V(
MK;3'B#*?UTU^@Q?(,%DW9XJ#7A&5KRQ"@J7VF4B)%J$"Z``WE.Y.4=P^S:/R
MTV>MKF17T]4CY&TK<421Q4%%+1]T=\>3$SFAN]OV:T]50JB[=VVT(@?BN)"G
M(>013Y3@K/:[TR(Z2M"^`,2N(TT=;E:<TOF22+M"-)$<BY"*6UV=E*`4I3KN
MJRM(IPR9S^_RL:B4=W"``OM^WY6X]V7FY!<:?5*&\XC3;[B(=B@)O*HX8.QK
M"C;6U++:`B#K;(+F4(N+[[A/WQ(\@&`$9D_O06+_`+E"_JU/-F_:_P#`.X?=
MN?T@84%U_P!0-H_F:?VMW#%VN^^PM0T[VBLNZ5`Y.M.8G#/#V.,8V.'C[%$7
M:]W;Q&<.SDH&3;/&<E%0Q$E))T"B1TRHLQ$=WL':M_C:FWJ;JJ)];=8E7<4@
ME*@KH((S!&.TYS;R<V?LFK-OHD5>YKDXBAM],H!0?K*F*&P4$$*0V)GG(@B1
MM4>.`8Y@^6XK$#1ZM>-(>=[WBO4G2J[%O%E7TV\\FVBZQT6(R3VKST9TV[8V
M=R\L)A;N`>2*#9+A(*!?>5!X[;YT7-MEJV;RHVKC;U"5:RA(<@>)4F&FX!U%
M(4>E1..)8Y"&VV*SJM.YJAK>-/2MAVH!D0^^E`U%A+806DK7&`1DE,(I48DW
MUV+^XCG/4@;,NDW5:X<2V=].1"';VN7*@A;[!7(R><4RSP=Y1;)D0?6F@V5%
MLV6DP$5I!-Z7F>)PBHY<Q>;&R[18Q:]Q[<`39J[X@S2E13.DHCF$K3$A/Q2D
M@9$`=3RGWK>;]Z8V[N9/]?VY0"EP`*TQ*3,!`3)4(%0`"@I)XQ)$YJ$TN8WU
MF?,69;T\99>6IA1+J:/=R[JER;"'L22M4TB5FV1G(R$G$3K)$AY.%1*J!VRG
M$D)BAPB(&!B67<%=MCDI07FW);-6VJ`"P5)@NJ4DQ`*3P.6?'"\O>W+=NKGE
M76BZZG@U4H49%2*BEA!&>>6>>"T?V9[MZ_\`5VIS^4>B_P`U.RZ]N>\_XM0?
M@E_NN&+[#-C?RW\.?K8,9\,6._A1^#KG;3Z4^@_P[]0ZE'^<_(GD;T^YKJW2
M.E^8^A>]S'(>!S'O>!P^YLM/3M;ZP>LDC?I#Q7B(0,D\^I"6,99NB:,.G#-]
M#TGH7T#%?@?#:''O222>=#SI>F''/'__U-^Z,5![B'?KSKJ;<\E8L4:8%;"2
MC.04,[A5&M20<XDQ.^B^(RR0C,/BO[4@(&*!7A3*E`/L;6/W/#9G*&T6%)*+
MC<)2X.GO0=<!\@E;\F7;BNNV2O>7..^[@4)K9:T%IH]!(BV".,8G47&/`CR!
MOO:N&+%83N[D:RG;N[WFG;6C'">-QQG$*S*Y".W:E19$;%:)X:S*S*EO3:NW
M):2NQG.(YBF-(N?$-N,4#C939$-Z<JKYM9PQKJ2;2CF?U9KMA/,CR=F6*W;W
M)V7S:VYNQM)%OKDAMXC(1^:63T9(*%_>]<3AFG6W@%MJFTE9\P2)&RK[(F-;
M!'U===,BZ#2YLV@S%(DMP[_<96J/9JB)1`W`4=PAOW[(O:UX58-Q6>[`D)8?
M25=J(P6/=22,/7<UH;O^W[O9U@$5%.M`[%$&4^XJ!CA&#MU1EWUW:B.WUHYM
M\:X>XGTC3F3;_88B065,R5K3K(JF5+BVD6HH@=NG-2C:.@C)F-Q<*NXIB;]P
M6OWJNDVC9=Y[GI'4BONB&FT$<9M/320>F`*E_7Q4W8HKMX7G8^U:^G6*2R*>
M<=FX&5V9*8=$I"6R,^!X8]B/M3#%SL*!YM<MV?S/6-G;M=%JU:H49PY<N%2(
MH-VZ.F=\JLNNLH8J:2*291,8QA`"E`1'V;6.MA`Y!W&)^.Y_2!BN=X6EKG[:
MWG5!+*:))4HY)`#3I)).0`&9)X8T_J/[IN-,*:NL2ZB<\8CRS:=/+ZMY"J^F
M:>J\6S/&Q#1I*QD+8L[IQ-@681=GELF/4'C&+(E)1[N-K4<B[%LX&22,11[*
MY>W+?;-SN%OKZ=MRF4E+;;A(+D02M642D#N@&4A1)!E*8GC*??%OOV_J+FWN
M:VUBMD4Z'Z6Q0;BB6*4U-V6DG-5806:,B4BD:+DAUXBV,@_,C=OVO4J2FJ&E
MEW(US!@N:"I"="<5?FY84C<DUF+#.NTHR+CS.!*"Z[<'RJ9-XIHJB`%'L*/D
MAO-ZJ0U5IIV*:/><+@5`=)"4B),.`,/*,-ZLYX[$8IENTE6]45,.ZVAM04H]
M`BJ`&?$QR[<4IV"=+.<0R+J=[AF?Z<ZQ_-:G'LP-"KS]@_A7LK&7N\.,G7VV
M)0$D7G8ZJ2,V2-1@U%C&5=((KJ`'@B@LOL^;VX+3X&P[+LM2'V+>!J+!!$R$
M::$S#(J`F*X9`D#C&&OY1[?O2:[<>]K]2>&JKFN+;1!"DH*BLJ(.8!)2$@YD
M)F($1@>V?=3^,]'/S&.6=067B6-2A4LS%I,$J<4WFITRUITA5FJQ8,XYS(1:
M*Q0DYE$5!%<G`EQ&#>(;A[.SV&OW-R4H;-;"WXQQ41.J5,$52E&)@>@&&6.+
MO6X;=M;GC7WF[%P4*:4))0DJ,5LH`R'1$8+Q_:4.W1^XM0O\F4#_`-^;+CV'
M;WZZ/\*?T&&+[<MA_J]7^`5]?&O/K=M*'P;?'1RN5?1'U$],?"\GQ?G3S)S?
M)<?0?,_*=,\?]EYSBW>W@VYKV=;A]9O5.-/Z5T=3SS)+"/G2\>R&.I]H.W?5
MCUNG>]#:DD=,SQFE\R,81Q__U7OZ9C#&F..?]/,>4:A]5Y?JGDRI0%7ZER?C
M<IS_`$./8\YRO,*>'XG%P<9N'=Q#OE5-=6UDGC*QUV7A.M2H1XPF)A'&!BEI
MJ:;PU.VW'C*D)CY8`1QW.T7&?'$7/&>.,CIL$<AX_I%\2BCN%(M*YU2!M"<:
M=V5(CH[`DXP?%9G<E0("@I@43@0N_?N#:535M;1E9HZMUHJXR+4F,.$92(XP
M/TM-4A(J:=#@'"9(5#R1!QC'N4YHR%@'2^I/X?G0IUYG,@8[H-;FFL;$/QB$
MYV9+SG*Q\PQ?Q0\<5'JHEXT#@0#[R@`@`AJZYUQ+14E9"R>/OD_E80GTF-[[
MDV#RO=N>T*_PFX*FXT=*RZ$-K*-9T!1"74K;)*$J2)DJ`C&'2-AU7$N+:/*O
M+!3\<4*KV*206;RMBKE-K<#.2J;E=-V["2E(B,9O'@/'B15E0.<2G5`#"&\`
M';:OU]?4M(9J:UYQE/!*EJ4!#(0!)`RRP^6:.EIU%QFG;2Z1FH)2">N)`$8G
M,]N+"VB8DX&KFBAT;59F&7QU4:=5&U9HCI$NIC/\96($+K(*LHXB;?3W1KT#
M$TV6=DX8Y4[.Z0<`,3#J%8`8%W1R(^%W"N?97;&JUT6X>>D+5(<XRRQEB3F<
MOAP@MX`\TK_6;#LBM/:U$H"]5S8`6Y`!0M-,Z!'4<20:Y:3\@P0R#JO$-W#I
MKSKILULX>F2XYI:,OB>IR[;'3JF7RB0C6`2&'@H:08QC2K.#RL0>'814BV31
M+P%(GP\!2@!0V^T%<X@I?HG'&7$P@4F4@$90*3EEVXZ3E+S,V'S;VO45^QJ5
MQ.WJ%\4>FZPEE*"VTTM*$-`J2&TMK0$@0`A`"`Q0]"?=M6&U'97Q-5--N#<>
MY5P'6W60KQ=R8`Q748>!AXH*XZ<RS"Z,8I%\19H6SME!.!4A+PG'BWE#?M'M
MV7VHGHZF^UJF0DQ"WG"@@0CD5GK'$8U5KYH<JWM_;QV+3T;=-N"Q4BJFL=73
MMM,-M(TBI8?CG`/()R$`%9Y9\^][R6E(J\VO7:MJ`O-7KSM5K+7ZGXKYVELP
M2'WG+B1DK!%/FK8Q!`Y16:IF,00$"[A#;0&N:!A(K\Z/RU`^^,+I[Z9G*:>O
M<MELW#<+33+*7*NFH"NE3#I+BW$*"89Q4@1!!`Q9$QGGMSWK"\EJ_M,1A:R4
MMZ_1B)JU6C&-;F+RYMC9BW0;5"2C9*"=V9Y;48Y!($FI@4-R9"*D-RP`IMM6
M;]7T].E-/<ZAME)@$)<6F!XP"00!'CEETX8PYU\FZSE^OFLY?:16U0O34XMN
M+P?@/Q<LE)=\1"!#<I)3!8^3[V,@(Z]^V"!(Z3E])$M6J=*NB-6.0Y[2=0$*
M2Y%0VXBR$DR._>N4A*`FW)-CJ<(?>;?!NN[$P]*5GX57Z/"G1]+KDH$4U76[
M5O=+9'ERHK'K6!2JCP(6E:E$'CD@F'1@HG!I/^'_`,X="PK\-O2?4CQO*E4]
M->2\+FO,?1>E])ZCQ>[OY?F^8_!</B^YMZ]+UNIX_P!)/:\L-2=4T.J:,W9"
M/'*$<67]9-E^J'K?Z2HO4OPWB?$=W0T99M3A#AE"$TW=A-EC_]9_C8P8FQ@Q
M-C!@7W=\H]GMNC*PS=29J/Y3%EWIF4W#=$ICJEB*R[=-Y9X5,OM.G&-)072O
MZE%`YOM;0ZY)4S$<`<_(01'W(XJY],*QW6[\E;G769DN5=JKJ:O(''386=10
M'VB5E9ZDI)Z,:OP[JRP1FC%-<RU7\D4Z.@YF&:R,JRF[-"Q<C4Y`4"FE(*QM
MGCU`\=(Q#L#HJ<8`FIP>(F8Z9B'-E14-*1,5A)Z02`1Y?R>3#:V;S9V'O;:=
MMW=;-R4:+>^RE:TN/-H6PJ'?:>"E"1;:HI5'(PF22D@GQV">N^<&H5[%,G)4
M3',B4"6/-/*F:6"7B5@2%:,PO'R"'%S<BV4.0;0\1Y)D7A/'HOU#^,UQJ4Y4
M=UDE+1XJZ2.I/Z+@.B./5PK;UO5H6_:U4[0[><$'KC+*ZM!A%%N0L><M)(\:
MXG3:$%4Z*A1G9MNKT2I8SH#2C4:$:UZK5Z'=M(N+:"LH!`.1PX=.W;MTJN^D
MY62>K*.7CQRJL[>.E5%UU%%5#G-G2VAIK3;3!`&.LM-BM.VK'3V.QT2:>UT[
M12A"8F'$J4I2B5+6M1*W'%J4XXXI2W%*6I2BL]VE\'ZH\GX,R#,8,U@.M.];
M896>1DM5$,.5/(Q9F<+3ZDZ4L(R\_+Q[IF91@Y0;<L0@IEY?C`>(Y@#5TC;K
MB!I/2`)3'*,<L?F%]$/8W-;=&P=PUNP^<JMN6MN\+0NG%MIZW4=%/3*+VH\X
MA28H4A$@$!)-&*CBD;9C#-9=0/<TQY(WR1S-E:,TZ).++<V56:5>2N\=%7G`
M,_-^!58-5\U9'3JR!T!11.?QB("(^\<0V\.)4'5!2IE!)),.,%-DY>3\K'$W
M+:V^/:!]*?;=1?G+WNYO;:2]4HITTZZE**FUNNPIVBI*3H`HE23.$DG-1P6/
MMR:MM(=%T&T*OVG)V.J9(42"L[7)-/L,E&L)YU*O;!./7SHL`Z,#ZSELS5V1
M1$6R;D%2*@@.XQ#)EF,/,MLE+BA-$Q'7$F$.N(ZN'#HQ;;Z-?-[D_8^0.W:"
MZ;JMM$_;Z=Y-93O+0ATN%UU2SHJ,[VLE04DH"Y@H(R4"D!WU'KX<R%A>@9KT
M\Z7;QB'3;6]0;V/RD9_9YRR0U]F7#&&5CI%C$R<Q)-*\@PAT7T>99'P6YG$@
M1L)Q.D4I82TI,5-M%.4(E1.?$#,Y=/#KQ3;F8[LW<FQMN[XY=\JZVS\L*7<J
MDUTSSCS=6X4MR.):6M26@EL.,S)E1.ZEHF*0`836OW!M%BVE9UCN'>M,E0.:
ML4VV"I\-2$H-XPH\I#5YJI3V-QBNIM92FNV,ZHS*T3!J8[=5H8VXH)`(S'GV
MELZ3:8DC+[4B$(]4##WL7(YW_2(Y(GE2]MZFJ47.WWRTU#5.W2AI::9;;(-.
MFH;U$N4RDNEL-C3)0ILGNA$<8:]*,X_49<KR,]R_J5ZG^7_ROG_1;S-S/C].
MX?%Z/Y@_2#AW>'R?Y7][[=L4JO#S_I6K'[V$/>FS^'"(]4]]_P"0O0\/40](
M>-T>]/Z-\3/&3CIZGXW#S=+Y;AC_UW^-C!B;&#$V,&/SICZ)E/H[Z.>_3'T3
M^;*_2G^SOV__`#?%M\5YIX<.GAB/5_O6I^;^;5\YYG`^?]K]EV1PO%IS\M_$
MG']-^I6ZQYK;=3]-/5?SWQ=0#^*KS7^@OF7?^*Z3[OC;OM;:42ZC$/#1CTS=
MGF1R\GP8_._EGZ.]I[?AO8GXSQ:-3P'CO%^=EX'7_%=?^;_'A-AB[;=X_1C'
M@=?FKG\1^(6_.?S;\6;\XW>WP/U?ZW?M\/`X\.>8OAP/'A[O9UXP9V].7]++
MERWP1\'J`XXO@4ZIZ:\7ENO?\U]5_#>>-V[Q.'W.0Y;[>_:)1PD5#2XCS(PX
M=,?R0PA/H[R>J5XD]1H>D5?W6F\#\RS\_/GXO[+HTM''PQ-R_P`<6=>#X'_'
M\I'\3TQZG\8^[Q:#_'1X_P"]WE?[&_PO>XNF_KMO2(>*7\W&!X1GZ./9_LQX
MVC)[<M_0]1)_"?P&;UCXTO\`:<>[H>3I\-VX$SFKRKZV3W4OJ-^K^87O*^9O
M6;J_YT?A]0?*?Z#^8OW7SG[+OXMH7=[T=",>B:''LRC]E\.*D;Y]%^OE9XGV
M$>,\2N7Q'I#5X_PW0_%=;[+6^-PP;V._HEI_T6OXN5_H_?\`"9]A7[S?[?3K
M]L_RMI?\#_2?-_8_]V+TTW^%"/[L?V:?,_L+@>'\CZ^R.%[I+R)U&W\Q]1+S
M'29[JW3OB-\'E.2=<YY7Z9^]G6/"XN7Z)^7>)NY;\)P;0ODX".C[D_P?4^#'
MYUU/H/QE\U/8%JZ#FI+Z6EEE5'0D^3U81AX7Y:/F=Z&"`?H9]2W_`*5Y?]*O
M_?GE_J7F[^4WT[Y__=/3_P#4]LG_`&_MF^&;WO\`ACBQ']2?Y*.GT9Z%_P#+
0:,^O_P!?X.?]AT/Y/C__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g693329g37c05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329g37c05.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0R<4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````-0```&0````&`&<`,P`W
M`&,`,``U`````0`````````````````````````!``````````````!D````
M-0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"?\````!````9````#4`
M``$L```^'```">,`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``U`&0#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))#JOHNGTK&V;>=K@Z)_JI*2)*!NI%@J-C18>&$C<?[*FDIA==5
M14^ZYP976"Y[CP`%D8GUHP>HWC$P).0Z=IM&UL#Z3_I;G[?]&K/7&-RL&SI[
M2#?E`,8W<`1)GUG?G;*]F[^7]!87U>^JC\/J8RKLFJW[,3M922XR0YGZ60WT
MTM6KFR<P,V.&*(.,U[DOW?Y1>BOZ5AY;"W,:<C=R7DP/^+8#LJ_L*C]6WVUG
M.Z;98ZUN#=LJ>\R[TW#<QCC_`"86M?D8^.SU,BUE+.-]C@T?YSED_5RRC(LZ
MCF4O:\7Y3MI:0[V,'IL=I^_[TJZKYQ`S8S$5+U<7>4.']+_#X7:20K,K&K=L
MLN8QP_-<X`_B5$9N&XAK;ZR3H`'MDG[TJ+/:=)-(3I*4DDDDI__0[WZV]2_9
MO0,N]O\`./;Z57]:S]'/]AOZ1<K]4Z<CZN_6*GIV1(KZMBUV`'M8&FS:[^HX
M7U?VU9^OO4\;]K=,Z;DN(Q*G#*RPT;B1)8QNW^HVW_MU4/K;]:.E=0=@9W3'
MV#-P+M[=["T%IAVKOZ];%:QP/`(UIDNSV_<:V28XS*]<=4/^FZOU]K.#E]+^
ML%39?BW"NV.[9]9C?^C<S_KB["JQEM;+:SN98T.8X<$$;FE976\:OKGU:N;2
M-_VB@78_FX`7T_YSEA]*^L@J^H+\HN_3X;#B-_KZ5XW^;794HZ,X1'Z49<'^
M-\K)8A.1_1E'C_Q?F7Z`T=9^N?4>LD[J,#]7QCVD@T[F?R=C;G_]?2^H?_+/
MUB_\,M_\^92U/J1TP=/^KV/N;MMR?UBWQ]_\W_X#Z:R_J'_RS]8O_#+?_/F4
MG2-C*!M$1B/\&2R(HXB=Y&4C_A1<L,Q>M]0ZUF=8<Z^W"L-&#A;BT`N<^FD;
M6EKO:]M>_;_UQ=9T/ZI]+Z-:S*QV$91I%5KMQ+23M=8]K7_1]S%D=6^JK>I]
M=NS.D6_8<C&`=;>!+79)/J;=H^@_T_?<_P#\#1^A?6#K%'6!]7OK`QIRW-+L
M?)9Q8`'/]VV&^YK'^_V?Z/TT)$S!,):`:X]JK=;C`&0F0O7AC/IQ<7J_[QS.
MI],P^J?XPW8>:PV4.H#BT$MU;7N;[F0Y;U'U$^K5%U=]6.X65.#V'U;##FG<
MWEZY_JV)F9G^,%U&%E'"O-#2+PW<0!7[F[9;]);N']7_`*R49=-U_7GY%-;V
MNLI-4![0?=7N]0_21F2(QK)P^@>GU+H`&4KQ\7K/J]+M5]/Q:L@Y+&Q:=P+I
M_?<;'_\`3<K*22KDVV%))))*?__1Z?ZL8>3F?6/JO7<NI]8+O0Q!8TL)9,;V
MM?'^!KJ_SWKHNK]/;U+IF3@NT]>LM:?!W-;O[-FU7$D^4R9"6U57^"MC`")C
MO=W_`(3S?U"LS!T,8>;593;B6.K:+6ELL/Z1A;N'N^D]BYG*Z%U0]>OZ$RA_
M[+RLYF4;0QWIM9#WO;ZD;/YNWT_I?3J7I%CME;GC7:"8^`69]6'%W0L5[G%[
MGASG.)DDE[RY.&8B4I`?-^![L4H`G'B).D3+B_JQX8\/^%QNH````(`T`"XC
MZLG,P.H]>FA[;\S)#<(6-<T/._)/J>X>ZFICO5M=^XNSR,BO'J-EDQPUK1+G
M$_18QH^D]RR\Z^SIV%D]7RH^V%FRBN9:S<?T5+/WG.=[\A_Y_P#4K3!.HRC^
M]7X*SD"C=<`,I']V%;_]XX^+];/V36<3-Z3FUVASBZUK`[U7N)+KY=Z7\Z[W
M>W>ETVCJG7OK/3U[)Q7X&#A5EE%=H(>\N#Q/YOYUN]$Z+UG(QAE8UV0[+?\`
M9OM5+[MTBQC)OQ_TFUVQKQ[=BMX_6NM/LP!;7C!G4ZWFC;OEKVL]1AMEWT'.
M_-8B,D0#PQHD5=VP8\\#&%F5`CT`?*1+@CQ2C_6X7&ZM=F=-^O+NJ-P<C+H;
M2UGZ&MSI)9L^GMV^U:3?KO<YP;^Q,\20)-9@3_90<#J'5'4=-=DVBQEV9Z8(
M<\/(#G[VW>[:]G^C8KW7,YN3TC,NC.P785;K6/&['WOAS*F;VG](W?\`F)PG
M&7"#'H(W:[%F$@3&1CQ>OAD/WH\;T*2XS.P^MX=N!B].S,FW-%+\S);?<^QK
MS2*F^AM<[^;OLM>S8@Y?6LGJ>0^SI]][J,N_$QZ*J;#4X`5NS<YK';@RJ[^;
MIL>D,5Z@BFP<M:$&WN4ES/[(S/LOJ;>I^MZFWT/VA[MD3ZOJ>IZ>W=[-GTTD
MW@'[W\OM3QG]U__2]527RJDDI^J3$:\+G/JW]O%-HZ>6.Z6;7_9W7@M>T3[O
M396;&VU;OWWU+YY20+6S_P`YBKBOU?S?\Y^C?S>CVO\`.?\`4^!^GZA4,D#(
M.[+@^F7"`6_G_9VR_P!O[WN];_2INH?LV*/VALCU6^AOX]7\S^TOF%)%D/R2
M^7?]/Y?^J?UGZ;ZE^Q_5J_:'I^KML]+=,[=OZ>-OYOI_329^R)P-OISM/[/Y
MXVC?Z7_6U\R))+3\\OYK>/\`?_0^?^M^Y_U-^C\;_FI]J_5O0]?UFQMG^=]_
MI[?S?](M+J/V'[&_]H;?LLM]3?\`1G<WT]W_`%W8OEY)*.X\^BL/RR_FNO\`
M-?)_A/U#^H_M'\W[=Z.G[WH[O^H]54</_FUZU?V/T/4^TV^EL_[D;/UG;^;Z
MGHKYL23QL?FVZ,IW'R[OU4DOE5),7/\`_]D`.$))300A``````!5`````0$`
M```/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B
M`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`+@`P`````0`X0DE-!`8`````
M``<`"``!``$!`/_N``Y!9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`#4`9`,!$0`"$0$#$0'_
MW0`$``W_Q`"O```"`@(#`0`````````````("0`*`P<"!`8%`0`"`04!`0``
M````````````!P8!`P0%"`()$```!@$!!P,!!@8#```````!`@,$!08'"``1
M$A,4%@DA%1<8,4$B(R0E,K<X>!D*0C-$$0`"`0($!`,$!`D*!P$````!`@,1
M!``2!08A,1,'06$442(5%G&!,H*10F(C,[,D%PCPH;'1X5)R0X,VP7,T="5U
M)AC_V@`,`P$``A$#$0`_`+_&Q@Q-C!B;&#$V,&/-W&X5G']4L5XN<RSKU3J<
M/(3]BG)`YB,XN(BVRCMZ[6X"J*G!)%,>$B93J*&W%(4QA`!HS!068\!C6:SK
M.E[>TG4M=UJ]2VTBTA>6:5_LI&BEF8TJ30#D`23P`)(&%XXG\GV#]3-Y:X?T
M[FEGF3)E1X:+<9)AR5BKMX6+0ZR;LJ2)9LDS:%HR.(=9"%:@W?OC$'C.S;$7
M>M\?U&8A8A[Y]O(?S\?H'/VCF.=-G_Q2[#[HZ]'LWMRTS[GF+%#>1]"`11C-
M+,!U.I.42K+;)DEE(.8PQ"2>,H;UI4Q!EZ%?16;8=]EU2334ZIQ;IF9%G'.%
M4N5SZA`1T@S@:0HW3`I4E8QN@[,!"G7776XEC^S`C?I*LWF?Z!R'U?77#5U_
MM3L_>-C/9[XLGU@RCWC<2294)%*V\2.L5L5X!6A5).`9W=ZN16\;TS::PYU1
MZ8;#;)R\Q.F+-:M4Q[9+,\5D)\N.K*P6DZU7I)^KN%VI`ECU2E,`%(F"W+3*
M1!-),GBWJO4C)]U3PPIOX:K[5=,E[J]K=1UB>_M=K:X8+2:=B\WHYT,D$+N?
MM&+(P!Y`-E4*BHH9UMDXZBQ-C!B;&#$V,&)L8,?_T+^QC%(4QSF*0A"B8YS"
M!2E*4-YC&,.X"E*`;Q$?LV`*\!SP8\S6KQ2KH5X:G6^KVPL<+<)`U:L$3.E8
MB[!86H/!BW;H&PN0;J<OCX>/EFW;^$=U^>UN;;+ZFWDCS<LRE:TYTJ!6F+44
M\$^;HS(].>4@T^FF.;FYT]G86E1=VNM-;6_2!9C6',[%H6%ZB8BZI56D*JZ+
M).$C)ME#`8B0@)4S#]A1W"VURT+7"V[FW'-@IRCZ6I0<_;@,\*R"%IE$QY+4
M5/U<\>EVL8NX#36]#1^6,)VS39%+Q<AD'-S:'J=?A%;1$P;R#;O9@C\^199J
MY7&5>5:FD@%WZZ#5NLM)F9]$EPG6%1.LEK<RVSRQV[M""`6`.53PYM2@\//B
M/;A1][]`N-Z=N]=V'86AFU+61';)218U@S2*WJYB?>,-L$,K(BL\Y00+0R9E
M51X^/%/-86U+HY>O&<,27I/#KR8+#U?%$](SLL><EHR:K;-:]D>1T0:IE9(K
MNE`9E%T=9TW%,RG+34`]CX?=VYBEN861&XJ2",WT$@5'$<J\\<F?P_\`\'.N
M]N>Y=GO?=6[-.NH-,,IMXK-I6:1Y(WB5K@R1Q=((KLW30RYG`!?*#F?G=L@T
M+&L*:QY&N]0H%>(L1N>>NUEAJK"D74*8Q$#2DZ]8,2K'*0P@45.(0`?3TVS[
M6SN[Z4065K)--_=16=OP*"<?0>YN[6RB,]Y<QQ0C\9V"K^%B!A?'CFL%&R/.
MZT,TTJTUFRL<GZJKF6(7KD_%SA7%+HS-C4ZU/*C'.W!F[6Q/FLBY:B<"@JW$
MIRB(#Z6I=.U#3Y)!J%A-!(S&@D1D)`\F`/CCGSL%9I<:EWHWBJ94U?=EUTJ\
MWMK14MXI:'B%E=9G0D"J%6%01@_)W*&,ZO(J0]FR)1:[+(II*K1<[;H"(D4D
MER`H@HHRD)!NY(FLF(&((E`#%'>'IM>BL;Z=!)!9RO'[51B/P@4QT')=VL+9
M);F-7]A8`_@)Q\]IF?#S]TV8L<L8U>/7CA%HS9M+W5W#ITZ<*%1;MFS=&5.J
MNX75.!2$*`F,80``$1V]MINHHK.^GSA0*DE&``',DTQY6^LF8*MY$6)H`'6I
M/X<;&(LBH)BIJIG,0QB'*0Y3"0Y1W&*8"B(E,4?M`?4-L,@CF,9-1[<9-J8K
MB;&#'__1ML^6K4I]*^@34!D1BKR[5/U<^+**`%`RA;;DT351K(I`82I\RN1;
MYW*[C[RF!B)=QA$"C-^W.A?,.\=&LG'[.DG5D_P1>^1]X@)][$'[CZ^-N;-U
MO4%/[0T72C_YDON*1_AJ6^A<(,\3E.OOC-\AV---&2C/VU;UY:2\8Y`;H.VZ
MB187*T;592W$@Y)P9-%+K*M.QULA.2!3*%-)M!,.XW&=P]Q+JTWYLN^UZQ"F
M?1]1EC-/QH2X3,/)E,3U_);Z,)SMQ8W7;W>]CMV]S"#6=,BE%?"X169E^Z>J
MM/RD^G!9>>VN+Z?LN:#?)+58I=U-8-S+`T.^I,T3&5G*JG(N,@UF,<KI\D&S
M0R458X\QE52D.:83(`E'^*.=H)QK.F[OV-<2`17=JTD=?Q7ITV(\^,;<!^(3
MB1]XX3HFI;,W[;QDR65XL<M/&-CG`/EPD7_4IBR+6K'"W"N5^VUN0;RU=M,)
M%6.`E6IN-K)PLVP0DXJ0;'#^-N]8NDU"#]Y3!LCYX);:>:VG0K-&Y5@>8930
M@_013#TAFBN(8KB%PT+J&4CD585!'D0:XK9:!V#;7)YF-9VN-5\:9QKI>2)@
MK"#@RQ3M%)=Y%2N/!FX`Z?-36@W5<@[)(&*)B&,>SHJ>@B8@/+>#MM/MAM?:
M83+?:@?43^V@(DRM^4&:-?\`2(PBMG(N[>Z>[-W,^>PTX"UMSX9J%&9?*@D/
M^J#C+X(_ZR?,]_<I7?YIZJ=O/=O_`&QVO_[%_P!5:XKVB_W7W7_]BOZRZP!K
M>$QEKSU!>3C.&M29L>3+GISR(]P?I5TN+W.4JK*,DK)>;EC;'3(L#"2D-+ND
MHRS1<2G(`R4105>'>NY`BPJD*&QW1K6H=M]E[0MMI1)`;ZV$DUR$5V>5D1J!
MF#+QSDC,"0@`6@4X4N]=:L;VR[J[JW+(]UK&GS&RTNQSE0;F>1K:S4("I8M.
M8\].%!*[A@*"PKH?\4&E[0_98#+&-:[+L<RKX;9XROTP-MGYJK3TD^<5R9ME
MDC8.>7>C#O9&;KY2H=,=!!%F8R8(@8YS"JM:W]NG<FDP:1KNH+<0I*),V1%?
M,%9:$HJ@K[QX$5K0UX8Z"[<]LM,V-I^D3/(TVY5T^.&ZGS'+-*`AFE"4"IFD
M4E0JK1#2E:G"6-2FF7#NKG_8;E\*9VKKRTX[F<#0DP_AV,_.5IPK(5_$:,E%
MK%E:\_C9-(J#M,#"4JH%.'H8!#TV;VA:]J>V^RR:KI$XCO5O64,55N#2T/!@
M1R\L+W7]O:3N?O:VE:S;&6R.FJQ7,R\57@:J0>'TX;52?!3XU<>7.HW^J87L
MK"T4:SP%PK;Y7+V5'J3*?K,JTFH=VHR>6U9H[3;2+),XI*D.FH`<)BB41#9<
MW?=K?-]:W-E<ZHC6\T;(PZ,0JK@JPJ$J*@GB..&/9]H=A6%Y:WUKH[+=02+(
MAZLIHR,&4T+D&A`-"*'QPQ>O8!QA5LAN,I0<$HRNCI"S-G,FF_=E37;W"T2]
MRGTG#,JA6K@'ECFEW`"H4QDQ$`()0#<,*FUF_N+(:?+*#:C)04'XBA%H>8HJ
M@>?CB=Q:79071O8HJ7!S<:G\=B[<.7%F)\O#&YMM7C88FQ@Q_])I7GMU,XY'
M5AH:TO95F9%E@VCVN"U*:@&\!%JV:2D8XDZ_@:S!E@VP&,>0-`0<XB4IP,`)
MSB:QR\!0X^A.T&@WOR[NW<&GQJ=6EC:UMRQR`'*&=LQ\,S(?I0@<<<\=XM?L
M?F39VW=1=_A,4HN[D(I=BJL5C7*.)KE<>0<'E@2O+7Y1M*VHZ3TE9]TJV'(3
M?4)I4S`%KA26K'<M5HB3JDDK#3CU-[,*G5!T9A9J5&)IM%-R:C1^]#?O,)3R
M/MSL#<&B)N/1MP10'1M1MLC9)5=@XS**+YJ[&OM5?JC7<KN%M_66VUKFWVN1
MK6F78=<\+HIC;*6!8\/M(@H>8+?79%UM8XK^O_QIY.CJ.S1LY<O8'C,N8@*B
M?B4>6AG"1V3L;E9.12(JBO)2C)LT./"0PI.%$S@!3&+LC]JWTVSM]6$ETQ0V
MUX89O)"QBEJ/($GZ0",/;=FGP[SV+J5O:J)!=68EA\WRB6*A\V"CZR,*RTJ>
M2%K4O`98LNO)0A,EZ=J3,:5H=%-8[=SWT@A%5#"RC5-$4G9TXNF6Z"=N#IB!
MA+'NC`<!3,)6!N'8[7/>&'3$3]AO9ENSXCIFKS>7%TD`_P`2^WBN]M[[6V[,
MRZO))2_L(&M`/'JK2.#S^RT9/T-[,'WX0]-">FSQY8<2D(@T7=LSH.<ZW@S@
MA"O%W5^3;*U!)P&X5F_18Y90Z9D#CQ(N.;Q%*<QR[0_NMKOQW>FIM')FM+4B
M".G*D?!Z?3(7-?$4\*8F7:?0/E_9&DQRQY;RY!N):\RTO%:_1'D%/`@^.`,\
M$?\`63YGO[E*[_-/53M+N[?^V.U__8O^JM<0_M%_NONO_P"Q7]9=8[.K#Q5Q
MVJK79D;-NC'(@:8LI8AC(&>R#E&+9NY:IVS5')R:-M81*,6R69*P%BCJ@NSD
MK)*-%'Z(NW[+F1QG9GBJL:VUW/>STY-L[FT:'5-N1TRJ].I'3D$)!4A!Q2N5
MEK0.!0"(:]L^+?\`W8UT;46&T@T2*![B\*]16UAF6>*&.,^ZLEO;F.>>92S)
M)-"N7/G.-K:%?('J_H>KYCXT_)#58!SFV9K,C/X?SA3$FB$3DV*AX6<L17$R
ME&M8V"?,IF$K$GT<HU9Q:I'L>9@\8@\,<Y=GNW9NVKS;3[ZV/<.-*60+-`]2
MT19E7A4EAE9EJI+#*P=6RX86T=Z;EM-SKL+?=M'\8>,O!<1\$G50S$D``<51
MB"%7BI5D#8`;5?B;,F:_]@N;H6!\^2>FK(K[!,`^C\K1%:2MCV,CXS$R#J5B
MR0RLO"$5)-,R&0,?J"\L#;]QOLVF&W=1TS2^S,=YJ^CK?60O&!B+9`29:`Y@
M#]D\>6(?N/3=5U7O8UIHVMMI]Z=.4B94$A`"\5RL0/>]M>&&KX<T`>1^AY7Q
MS=,A^62ZY3HE5N=>G[?C9[A=G#-+W7(N3;O)>J.98F0'YXY&<9)';F6!!44P
M4XN`V[=LO=3WAL>[TZ]M;+MW%;W<D3*DHG+&-B"`X&05RGC2HPQM+VAOBSU&
MRNK[N/-<V<<BL\1MXU$B@\4+!B14<*@8=-LKL,_$V,&)L8,?_]-ZOC&Q%DW-
M7D=U^>0?--$O-/:N;(YPUIZ:9"I]AIK][CTCQ!BRL,;#V-A'.$R-,>4N!;=0
MD0R:RTF]#BX^/>Z=^:E8:7LC9VS-+NXI6$?7N3&ZN!(14J2I/^8\AIX!5PE=
MAZ7J&I[ZWKO35[.6(&3T]J)$9"85-,ZA@.!1(^(X59\.8U<X!B]4NF7-^GV5
M53;)Y2Q[/5N-?K"<$HFS"WZ^H3BH)[SJ)P5J9,GAB>H*`APB`@(ALL=N:Q)M
M_7M*UF,5-O.K$>U:T=?O(6'UX:&X]&BW#H.K:+,:)<P,@/L8CW&^ZP#?5A;W
M@9L&8&VAYIA;.6/\CX]NV`;]::-&,LC4Z?JSF5HLJZ[KK;^&<S<<Q)-1<>^E
MY"-3.B94$4V"9=X)BEOF_=Z'3&W8^J:3>036EY"DA,;JP$@&1@V4G*2`K&M*
MECXUQ!>S\NK)L^'2M:LIX+VRE>("1&4M'7,A7,!F49B@(K]G"+\GZ%=3R^NW
M*7CU@L474^CG..NFA:G'&065)LX8UKE!3K]UL5AA6EO08%@42,*;=SQ"B1WJ
M*IY6OMD2CQ*`(MJPW;H`VCI^\YM1B^9[32)+01EUZK29D56*$YN+IG!RD99&
M/(84FH;/W`V\-1V5#IDORI>:S'>F4(W26/*[.F8#+R;)3,/>C4>.+NK9LW9M
MF[-F@BU:-$$FS5JW2(BW;-T$RI((((IE*FDBBD4"E*4`*4H``!NVY49F9BS$
MEB:DGF3CJX`*`JBBC%63QIJ9ATZZC?+(=;%ESALE:A-3,#7=-$==Z;9J_!Y`
MFG&1-3D@ZN3)Y)1K1.9QUCZ"E49V>?M#*)(Q8$`I^:Z;%5<O=;4[&ZVUVWAL
M;V&:XCLV5E1U8HQCMA1PI)7D>=.1]F.5]/UK6MF:CW$AL-*=MVZUJBV^E12(
MX2:9FN29VX5-K:1GU-U(."PK0'.\:MMO%OEF/HZKKK#F>_'GK<K%Q:6.U2LO
M=X*@,;03--TG[#)2$]E!X_FW=*:];?9)0SU1)BO*-F/,!HW650;IB.):=IHK
MZUMY]&WOI4Z,BL^:0HRL0"P(&<\#4#-E-*5`QO-F[HB[;:)'MK4]F:R=1$TL
ML]RL(<WUW-(TEQ>.U5&:XE+2%5++&I6-#D10.OIKI6I_R(>3K&OD-RC@*WZ7
MM.^FW'DA4L2U/*<8_B<@Y)>3\#>F#>1!D[:1CHS=*5O3B27=E3"/3;M6C1`7
M1U'#@NWUR[T'96PK[9>GZQ%J&M7TP>9X2&CB"M&:5!(K2,*!]JI9CE`4'<Z'
M9Z_O;?\`8;WU+19=.T33X&2".8%9I6=7&8KPH`9"Q/+@JC-5B-%ZLKEF#2]Y
MS9O5E&:5=16=\=16&*_5B*8CQM:)UM(2$YC!"!.#*P-X9U!*&BGBGZ@@+"<@
ME$H@!O3;;;<MM-U_M-'MQ]PV5I?-=L_YZ55H%ES<5KFXCEPQJ]QW.I[?[NMN
M5-N7]YIXL%CK!$SU9EIP/!>'CQK@VXSS;761DH^/-XN]?3(K]\T9&>.L72Q&
MK0'3A-`7+DXP8`1!`#\9Q^XH#M%).U=M'&[_`#]HQR@F@E%30<AQYXED7=6>
M66./]W^N+F8"I@X"II4\>0\</HV46&YB;&#$V,&/_]2_QL8,38P8^18)(\-`
MS<PFESU(J(DI)-#<(\X[%DLZ(EN*(&'F&2W>GKZ[4)H"<8FH7)LK"]O%3,T4
M+N![<JEJ?72F`C\8SYS+:&<"S4A+.YV4G8NX3<Q+OW:KYZ]F)3(MP>28N72Y
MU%5#MGBIT0`1'ED3`@;@*`!8M?T"?7_2<([^%^XEO>Q/;^^N;Q[B[N(;B621
MV+LTDEW<,^9B2258E1QX!0HH`!@O<@9`KN-*TZL]C.^403508QD1#,'$Q8[+
M./3"G%UNKP;,IWTW/RRX<"#=(HB/J<XD2(HH6\[JBEF_M^K#AW!N#3MM:;)J
M>I,Y0$*D<:F2::5N"0P1+[TLLAX*B^;$A59@!V<+K.::<,YGUF9=]J#.K^GK
MTW%-,2>*SE=QN2=?]+0L=UU$XE]XG9>;5:2=P?MBD]S59"5/A8L&O#CMF16F
M?](10#V?RYG^H80>^]=ONV.R=[=Z=W]+Y\>R-O86P8RPV?5;+:6<(_S)9)3'
M-J$J`==HR%I!!%0"=&.LC(&+D,ZXRNN7+1G6P%TPN-3.-K#E<;VN[C,G4[&)
M9#+.('*]R)"3DG7XNR1XN&*<<)&P1S9=8JH++J"6S%*R+(,U3EJ*UY@<N/\`
MPX<//"![*=Y]P[5&^]JZ]N^[U[4?E8ZW9S7_`*HLE[;V0;4-.)N!%*\4<Z9X
MA#1.BDCAL[M0C<?:S=:4[8=)S:VU+3*P@]9N-\@R^,/8D\GN)6GW"KXN"Y5]
M_>U'LZ#1W6)B6=M#.6,>07;=FLJD5V=9$JJUQ9ISTP<GOJ2.?L\>/F/Z\,G;
MO>GO7J&I=HX]7T?;$>G;UTR[DLNEZUI+:X@L/51/=%I`K022&,O%$.HD;,HF
M9T#.+6!,^ZGY.DZ*9?)^0FUJA<@:U'%$CI&+M^4(^\/&;*T71G:(W(BZ5I;P
MEKK**K5HG#1[A!9JFS(8KA-0W`(8X>8M#5_<S#Q->8K7CRX\,*KM[W"[HW.W
M>R-[NG<(N[34=\&T1TN+Y+EE6>Z6=+PB<1W$(*QBWA=6C$8(D5B%(*[6]G1A
ME321J3NB<=KKTORVG7'ELR)5;*T[XTU#>+R$!/UZCUY&RP4J1]<X%Q:GC4R\
M=QE1,*B*HE,8J?"P>W\YFW1I=A\,MYX[F9(W%Q"LJB,N#(RAZ@,$!]ZE0*^>
M.L+G?Z;PT/=;1[;W3HDVF6[2I)=VTNGK/)1UC6*3.>L,X!91X%30U&`DSIB#
M6OA2RZ2L3Z8M2>I6^:@H_"5VU=9G@\QYXR-DF`R+.X$C<6Q),4A!RLV(,J=E
M2VW>5CEHX1(U6=*LS"<!;@<C'TG4MK:I!N/4=>T.QAT<W26<+0V\<31+<&5N
MMF"\7B1$8-Q(&;A[W'UJVG;ITN?;NF:!KE[-K"VLEY,)IWE65K<1+T2&/NQS
M/(X(X#-E/->&MLM:SLEZK,@V>RZ;<GYUD<>9_P`YZ$L`XHH.*LM26);-'149
MB2Q:GM4<97YU2PQU<H^2>0_B*S,RI5""V'C;+F51)N'.T[:]CMZS@@URPM%O
M;.TO[B:26$3*29EM;4LN4M)%4/*B<:\&%"<85_NF]W!=3SZ'>W36-Y>6%M"D
M4O2<`0M=W>5BP5),I6)VJ*$%3RP<_P!(^8_BSN;VOR@]_P#R![%\8?Y2S^^]
MG=N>X=^]W_(?9?M/O?[=[;S_`'3G?G\'(_%M$OF/3?B'0ZF@>CZ.;J_"O=SY
MJ=/)TL]<OO9J9:<*UQ+?EZ_^'];)KWJ^M3I?$_?R9:Y\_5R9:\,M<U>-*8__
MU;_&Q@Q-C!C&KRN4IS^7R>6?G<WAY7*X1YG,X_P<O@W[]_IN^W8QY;+E;/3)
M3C7E3QKY82SXWR9S;TV[(:<'5+F-&3W*M^/AF5S<PL%;R#6XY6P.CS+>G0%.
MDK5&7:@L)@RZ:"TC)5]\[?)N5#)M@.*2>%!U,IZ-.E7A6O\`+^VO+'$O\-*[
M[BT77(^VTME-V4?5KLZ;)J:2PW<*&9NH+:*V>X2ZM$DSA6FFM)9)1(Q2(-E5
MDU52K2&1F".2'RTGFQ-C.$J<A9(IG!QCR!!-GW&OAB';S-ACHZ'4+RQ?I=<Z
ML9&_*"34,ATP[75R]0=0UFH:5X</'+S^OC7V\*8Z<TI=-3<5NFXYS+O41R]!
MYD6)&BHO6.G1B29$C/#JKU7NPF7U+%.GCCJ#^G'D8O\`J-[1Z#Y3K7QCWKU/
MM/ROPNNU^CW?MOOG+ZCI^J_!R^;_`,>/:X_3]WJ4Y\*^W%CN+^[7I[5_>5Z/
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MKM'V;E_LWN7.]VZ7I/TG_9N]-VUE/2=3W:9^'M]O"E?/V86FW/\`\H?,_P#\
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MGYC-7CT^KR_*YXT&G?)7J+?X7Z/K^NGR=/+_`-5TSZBE.'4Z=<_CEPQ':&8F
#&/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g693329g39n30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329g39n30.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0ZR4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````;````3P````&`&<`,P`Y
M`&X`,P`P`````0`````````````````````````!``````````````$\````
M;``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#!8````!````<````"8`
M``%0```QX```"_H`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``F`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#K+OK9G=0ZQD]#^K6-5=DX6[[7F9CG,H8YI]/TZZZ6OOR'^IOK_P`"
MS]'^>LJGK?6/K%G9'U:S;7]$ZQA>H]EV%833<6`-++-[?M%;/TM-]7IV?I*O
M]%8Q<[]5:&_\Y\WI>;U+*Z5D6V65!^+8VLVWLM?--K[*[V.]3U'6X_[_`/UQ
M=YTWZF](Z;UMG579F5E=3>'[795S7.>-K:;'[&5U>IZ=>QG_``:()!L=%$`B
MB\A]2?K!E=,Z];B=6O>VK*+V91R+)]/)J_PMEMN[_1.QG^_W_H/]&M+)S^I=
M<^T?6,OSJ.@8L486%@O?5D93G/;3ZI]-]>VMU[_>_P#,KK_X[?SOUS.'F]8R
M^H=-:78-SQ0[*`'I/R6,_3^@YOTV^GZ?O_PMGJV+K>K?7E^#]3\#J?3,>K[3
ME$8[:7`^E2ZMK_M#?2K+/H>AZ=%>^O\`P=BM9M`,@C4I#A/]3_T)JX;,CC)L
M1-C^LAZO]=/K?T&^J[JW1\=F!<2*VU7%[P0-YJ.1'I^OL]S6NQJV6_Z1:?7_
M`*[5X/[-QNET#,S^L"MV(VQWIUM9<65T6Y#AO?\`I++?96QOYEWZ1FQ<A]=!
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MP.^S5.;DC=7Z]S'8WJ[_`-%=_@_0_3(-'^,+K%_7']);T;]8J%K#BUW"RQUS
M`TUAV011C8V,W_#W_I_^#_2>Q7S]1^C-ZAB=5S^I9F7D4V5'&LRKV$%S'^MC
MU-V55;_TGN]-<]T#_P#*MU#XY7Y,=)3HX/U\ZYC_`%AJZ+]8>G58KLBQE332
MXDL-WMQGZFVO)ILL_1.LK?7Z?_6K*UW:\U^NW_Y1>B?^@,_^Q=R]*24I))))
M3__0[;KOU(^KO7;SDYM!;DN`#[Z7&MSPT;6B[;^CMV_O6,]18F7]1LW&N.+T
M%K,:G)8VC-ZK??9=EF@G]+CTUO;LIK:T?X-[/6_X-=I3E8]]EE=5@>^DQ8T<
MC5S/^KKL9_7KL_<4VW5.<&M=N)W#342P[+!/\ER=$F)NMNZ"!(5?V.#UGZIX
MN5]6!T3`:VG[*&OPB[@6,ETO</\`N1NMKNM_X>RQ8/1?J3U88UG1^N447=(N
ML^T!U=SQ=3>&>FVW'+*V?SGT'^__`,@N]>]E;'66.#6-$N<=``%%V14V]N.2
M3:\%P:`3`'YSW-&VO^1ZGTTX9)<)CN#KJM../$);$:.!3_B^^J=6!]A.%ZE9
ML]9]CGO%KW@.8WU,BM]=KV,;8_;3N]'_`(/>N;ZSTGI&7]:^F_5#TW8V%CTN
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MU?\`J5CV.-+,JRS&Q[;6V9#[@<9K7/QLEM$&O[+EU6,?_-,]>O\`GJ+$>OH?
MU,^U4Y>%CYEV5DU,ROM./?F&UM63+69-]PR&V_I_?[/Y^S9;^B_16+>K^KW3
MJ[/4;ZFYPVV2\N#_`-,[.L-@=/\`/9#W>K_P?Z'^:4!]6>FM#FUFZICVFM[*
M[',::_5?F5TPW^;91===]G]'TWU56>A_-)WZOQ6_K*Z.3U7%^IG5LEW4NI46
MV7XQ?C6W!][#4_&>-M+FXUK/TS[LAOV3TF>ID>HST5JXG6^GL-.!6+_M`>:#
MCV[GW,V"ISK+[+GV/M8VO(Q[/6]6_>RWU/\`2[)Y'U;Z9DE[[A8Y]C'UO>'N
M:XAUWVYAEFWWXV3[\7_0*&7T3I5EC&9CGV/RK_4(?'Z6YC&NK)VLVU/IHP_T
M7H>A_A?]-;ZB_5^*CQ^"JOK/TZR267UAEXQGFRLM#;(=8\/<[VM;377ZEUGT
M*V)V_6;I[O1BN\'*(^R`UD&YI#K/5Q]WTVMJK=;Z?\_]#]#^FI]28Z%TUQL;
M#W!V6[-L:XDM-KV>D]IW#:ZAU3MOI)G_`%>PK<%G3[GVVX=;/2;186N'IP&M
MJW.9ZGLV-]/(W_;*O\'DH_J_%'ZSP?_1ZQV+@EM+3FD65DC)?D56S98+666.
MQFY!_0^IZ>;1B_9_YMF1DV8O\S<I9&/A?9]SLIA8S(N-S:Z[!O)R;/M#+W43
M<QK;WT?\%OI_T-J^?$E/KIOO_58--?EV_K/O]N-T@LM+,RMK06.M%M3B#5ZG
M3[<>I_J>[T/LM=.*]_\`ILB^]_Z:K(5K.;BV=0N?DOJHL'HMV9#0^LTAN4*[
M+O3?Z7INOLM>SUW_`,[CT,_1VVXZ^=DDM?'\/ZJM/#IW_K/T'C8E9H%.%GM;
MF^H[TLFRISLG8^BX8_KU6>F_]6IL8ZG_``5WV?\`?M3&GIWJFRS(G'&2P6T%
MMVK_`$6BI[K(]3^:VOI;_1%\^I):V=]OZMJTH;;_`-9^D.B4-JR<@LR:LA[@
MS[0&UECV[?48/5]WNNMR?M5UOJ^__!JMC8S&48/VG-;:]E364Q4]GJ.;=C_:
M+G[B][+\C+;B>S_M/^E_G?IU_/"2BG\S+C^73^7VOON/CX'V9@KRZBWT,>QC
MGUV3]F%FXXSO5]WV-_\`-]0N_G_\)U5/9BX+:B\YPLHW5AM3:K&T^HT5_:7U
M.HW_`*O=4[%]%C/U>C'KM_G:[,A>`I)JY]]>SI/JVUT6.])SA;G6[7A[<08M
M0KPZF^[,=ZF/]FW6[/2_IGZ;[=^C1^KXW3W9N:_.S&UUFBX6U"IYO%1II-UE
M5K?TOIUXM66RMF,ST_6RKO\`M72OGM))3]`Y&'ANLO?7U`,H(LFJBEQ8-XQ&
M].])]+O^TEC:;&?9_P"D76_F;+$S*>B.MQ'LR&UVD5_9*]EK@'LR2^[TGV>[
M=D7NHJ?^?7B56>G^JV6+Y_224__9.$))300A``````!5`````0$````/`$$`
M9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0
M`&@`;P!T`&\`<P!H`&\`<``@`#8`+@`P`````0`X0DE-!`8```````<`"``!
M``$!`/_N``Y!9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!
M`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`&P!/`,!$0`"$0$#$0'_W0`$`"C_
MQ`#&```!!0$!`0$!`0``````````!P@)"@L&!00#`0(!`0`!!0$!`0``````
M```````"`0,%!@<(!`D0```'``$#`@4"`@4(!PD!``$"`P0%!@<(`!$)$A,4
M%187"B$B(Q@Q020E.3*UMG>76!D:TY97AWBXV%$S0S0U=B<WUSH1``(!!`(!
M`@,%!0,&"PD```$"`P`1!`42!B$Q$T$B!U%A,A05<4)2(Q:!,Q>1L5,D-`AB
M@I*R@Y-T)756&*%RHD-C5"8V-__:``P#`0`"$0,1`#\`O\=*4=*4=*4=*57@
M\O7F<UWQX[36\+S+%,[MTI:LC@]1C[Y?+!9WL8V^=VN[508=U2J^C67"IV#F
MEG5$Y)S^*FX)^B8@(#VKZ:_2[6]UU4^WS]K/%''DM$8XU0$\4C?D';F/(>W]
MWX(/K7#/JA]5]IT;;8^FU^H@EDDQ5F$DC.0.3R)Q,:\#X,=_[SR"/2JV6Q^=
MWR7[`5PT)NB&50SDQC&A\<J,!33)"(`!?A[0X:S-]0*0._8"RX`/?N/<0#MW
M/6?2+HFLXL=0<B4?O3.S_P"5`5C_`/@K@>U^LOU`VG)1N!C1']V!%3_(Y#2#
M_ETR'->:7)O,>0%-Y-Q^QZ!:-?ILLG(HV>^W"RW)Y/,%#D"8K-G=SDJ[D)BM
M61B4S5^U.L`+(G'L)3@0Y=LS^K:'/TV5H7U<,>LE6W"-%0*?W60*`%93Y4V\
M'[KBM0U_;.PZ_=XG84VL\FTB:_.1WD+#]Y'+,2R./#"_D??8UI;<0>3U$YC\
M=,QY$9Z/P\-H$$5S)0:K@KE]4;7'+*QEMI\FH"3<RCRN3[1=N"PIIE=HE3<)
MA[2R8CX3[+H,OK&[S])F^987L&M8.A\HX]?#*0;7-C=3Y!KW_P!7[#A]JT6N
MWN#XBG2Y6]RCCPZ'T\JP(O8<A9AX(IRG6"K/U7H\Z/E6D>'E'C>._'ZT)1_)
M;262$O-V6,,V<O\`&\]!R4R<H!%TG#5"XW=1`[:.34(<[5@1P[,5(YF*BG:?
MI)]/$[-ER;O<X_+10&RJ;@3R6]/@>$?JWVMQ7R.8'#OK%]2).K8<>BTF3Q[!
MD`,SBQ,$5_7S<<Y+$*#Z+R;P>!-:/,?*5YC=5DB4+(-TWK5+&5@X<EKM#S*O
MZ';ACP5(DX>F1A<]FK(=%%9V0GOB(^V8Y"@8/VAUW;/^GWTQUT9S-GJ,/'@N
M!RDE:-+_``'S2*OP]/CYK@&N^HWU4V4@PM7N<W)GXD\8XEE>WQ/RQ,_Q]?AX
MJ[!XJQY..>$>63',%[H;C>[!)Z!*6QEJ<>XB;O#1Y+Y88JJQLM%.F;!Q'E4K
M$8T=HIG2*;V711,'<1#KRM]0_P!!7M>PBZRD`TZ+&$,1!C8^VI<@@D'YR03?
MU%>MOIO_`%"W4-;+VEYSNG:4N)@5D4>XP0,"`1\@5@+>AJ1/K2:WJCI2CI2C
MI2CI2N;?7.GQCY2,DK76XZ22,D56/?3L6T?)&73360*HT<.DUR&625*8@"4/
M44P"'Z"'2E=)TI1TI7Q,)*.E6XNXM^RDFA7+YD+I@Z0>-P>1;YQ&2305FZBB
M8.8Z2:*MUT^_K172.F<`,40!2OMZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4H
MZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4K_]"\!R.Y-8;Q+R^9V+D#H<'G5%ANR(/I54ZL
MC-RBB:BK6OU:"9D<3-HL;XB)S(L6*"[@R9#J"4$DU#E54`GP*I6<SOR"N87,
M?08_!_']6;IC-6M,VG6*LK5&*<]R/U*0D%?AV23=U%I22="*Y,)3),X(RD@D
M8ICJ29TS"DG&]7`@'DTWO5/#3YM%*3(;+?8Z]:--MXLTY-UHG(9+0=:2;"15
MZ^3^6FM<@>PRC;]QCLXYZ^=KJ&]**:R@B7I8TY+Z4P/CSY.>?7$NT-'N;<CM
M30:0KX$Y'-M"L$Q>L^>?"N2`_BI2AW)S)1D>JY]@4%UV:;*22)W!)PD<`,"]
M2*@_"KS?CDY>\1/,+F2^D:3QZQ=_R0RF*C*3JU4O.?TZ]OX*+E5W\C$25'GK
M5$RDXKF5H?H.UD&JB@'8OR.$%@5$J;ISE,+=;C7PM!K]MDP0%N16.5T4M:W(
MA6`+6%K^MO%8;/T6EV,RY&QT^+D3A.(:2*-V"WOQ#,I(6Y)M>U_-5S//?XV*
MOP\UJJ[KAU90K6!;D[>QKFJP[4&]?S34XQK\<\K\0@F4J$97;E#)J2,8S((E
M;K,Y!),J39)NF7UC]'N]9'9M;D:C;9!DW&(`0[&[2Q$V#'[61K*Q^(9";L6-
M>/\`ZT=!QNK;/&W.GQQ'I<PD%%%EBF`N57[%D6[(OP*N!90HJOGUV:N(5:E_
M&5Y?#5-1TWAA:9,Y8;4V;K5,J;KJG%%&_P!3BB)7F&9IBL(`YLE&8)/Q[)@4
M$Z^<1-W,`#Y[^O/6OS&OP.TX\?\`-QR(IC_]-S_+8_<LA*_](*]'_P"[[VC\
MML=AU/)D_E9(,T(/^D0?S%'WO&`W[(C5F#R&\Z\Y\?\`QWL6PW%1G+W!^1U7
M\CSP[KV7^@7]9HHI'Q_I2'XEK7(G]'<P^`/2T9$$"^MRJV16X1TKJ.=W+=P:
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MH]Q]*Z3J>E:I-=K4Y9#6,TQ`#RO]I^Q1Z(@-E'VL69JLG+;S$^2_R&/YZ.Q>
M)U#(\28JN&_V[XV,+K(29FA6[AXH&D:?6(U"S6-V>-*<SAN08N'.W3`PL`,4
MZIM1N:W0*H]?6H:Y6_;?4K*\1F[IJM9N$8],H_2E;';H6RQ\@L4%SJ/$W;QM
M*-'JI5_6(G`IS`?O_7U2I6'V5*)PB\YW.CB);H(MFU"T\BL<(\;IV;+=BL4C
M:W:L.*I2N?HR^39Y*V4Z6:MC'^#*FX7BRJB`KLER@`!6]4*@UHG\?-VSODYB
MF;;YE$J:8S_4:PRL]?<JE33>M2K&4:R4++-TE5TV<]7)AJXCY!`#G^'?-54_
M4/I[C*K1%C:H\/+#Y8<W\9^;PR:<,TTCD'I#1^IE^7J/U&4>WCV2A6CV^WUZ
MT*H\C*=&/%/:002]#N:=D.V;'2(D[=LZ$VJJK?\`95)20Y;>4GRU[[7<8C->
MT2VV30I1ZG!Y519]SF615J(116=R,E+0-><QL(E7JM#IJ&6DI<7\A[!1*9==
M=4"JT\FKEE45)A/_`(J'*B.S]29@N1^'6+26\>HZ5H@Q-UB*X[>(H%5-&1-_
M=L5'"ZSA4#)(*.X5BB8WH%4R)3&,1:J<Q]E0.53;>:G`G5)VEU'3MFX[Z1FE
MDD(2T4F/L\O$L6,VP=B+Z.L%1,Z<U&RQSAP`+`1RV>,'A#$6+[A#$.*I6!J1
MC0O+QY<?(G&5_CKFCRW.I(]8*UM-:XH9[88V^:0V9`@SE[5=I"J'F+%&12X/
M"EDD8M2'KP$6[+-@3$H%7-4XJ/-6O/"G4=CX>>-DU9YL5T_'U+)K_I\XU7TJ
MQU9FSC,MG5HR\_4TJ^933YM`,U+99)A(R,@H@\!9$QA3`BB)CU%6V\GQ41/D
M;_)ED#.Y[)O'C'(M6B!UXU_R8NL$1RY>'*;TF<91GT^T,V;-0]/8DG8FRIU2
MF.!8Q(2IN3+U()]M1]M/%GYUN7].;;??9#4YE2R-/J&`@]PY"JP5XDVBK8YV
M)F=-LMF`U+!=,PI-F<D2'%%,0_A)H&*8:6-5Y*/%1G,>0_D&X(:Q-T5#8N0V
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MZ"4>YNZ]5"@?"IK.,_F^RW@-X@N+N:5-9IMG+UY`[,2/HKZ2>/*YF#!?D#K1
M*K,ZY*-W)'S9NG`BV7C:ZU63D7D>5`3'8,UVSL];^*B5NQ^RJT6[<U.5O)6Z
M2U\VG?-/NDW*R"\@5HYMLPPK,(*YE#`QJE0BW3*L5.);@J8$FL<T;($`QA]/
MJ,81I4[`?"OTQ7F]R\X[6%A9<9Y';!1GT>X17!A'WF>=UF1!%R+LK2>J$H\?
M56QQQW(B<[9^S<(',(B)!$>E+`_"M!;PT^49MY),-GC7B.AJSR(QYS%1&K04
M&4[6#L,=-)O#5C0ZPP<N73EG&3ORYPW>-155^"D&Q^PE07;`-0:M,MC]U3(=
M5J-'2E'2E'2E'2E'2E'2E'2E'2E?_]%N?Y`_+B>Y)^071:`A+.%<TXPN'&+T
MR%(Z.>/1LT29$^J3ZC,IA;I3<A=R+1RRH=SG91#0AQ`4_2$35Y185('^*?@=
M;M.S<FN1<[%-GLWD50HN?T)V[12<?*Y#57-M>6R5C/6)C,I9M!4=%C[Y0*<6
M<JX2*82*JE$*BY\`5>!ZE5NLVG\A'%J_C7D[UU:L1J,1$ZY6:-LIHYJDT0:)
MSEIBE(BVOFZ;4PF`\[;JT_D7`J@14[MVJ;MZ!(88GUJ\GX11^/?N,SCODZQF
M";/UFU9W")NN/W%F03F2?MI6LR%FJG=`!]L5F]^J\4(*"'J31,J`"`'-W#UH
MXN*O<>1CB@RYI<.]EPCV6PVJ7KQ[%FCUR($+&Z;4Q&;IJ@N!43!HVDY%M\N=
MJ_KZ6+U?]IN_8=NZ1V)^K=FU>WN?RZOQE`^,3_*_CXD`\@/XE%:5WOK2=LZM
MM=-8?F63E$3\)4^:/S\`2.+'^%C67U(1[Z)D'T5*,W,?)QCQS'R+!XBHW>,7
MS)8[9VS=-U2E50<MG"9B'(8`,4Q1`0[AU[[1TD1)(V#1L`01Y!!\@@_817YX
M.CQ.\<B%9%)!!\$$>""/@0?6E3X_[1:^.FVY7NE'4]-HRJ\5ZZQ;<RZC9O)_
M)9!%R]@GZJ0&4^56".!9B[*`#ZVSA0O80'MUC]SJ\;=ZK8:C+'^KY$+(?B1R
M%@P^]39A]X%9+2;;)T6WUNYPS_K&-,L@%[`\3<J?N875ON)I\7*'D1R7\Q?-
M.%:U>M2LO)VB8/1\$R",.*L90:4"QG1U'[DOJ;).3,VQY:S32X@D44U#B9%D
MV;HH:EH-)H?IEU65LB=5CC7W,B8^LC^G@>MKGA$@\^@\NS$[?V+>]@^J?;8E
MQ\=FDD?V\:`>D<?KY/I>PYRR'QX)\(JA;R?C2\=.:^.[#F](@196;6;>G'R^
MS:>5N<B]KL;=%3V8B&^)(5TPI%8%RJC&-1`AC@91RL4'#A7KR9WON^?W;;-E
MS7CUT5Q!%?PB_:UO!D>P+']BCY0*]@_3_HFOZ+IUPX;2;.6S3S6\NP_=6_D1
MI<A!^UB.3&FG^;?QA;/Y*Z=Q_B,9NN;U&1R&S7B4G$M%>6-BC*QMR:U%B`PJ
M]>KU@`\A')P"JGM."MTEA.0OO$[B8-'(O6_*;7J7'"<5H7'3'LYQ#,HEO#4G
M,ZC!U&$01;-&SAXE#1Z#)69EC,T&Z3R>FUT3.W[D2^XY=K**G$3&$>JU$F_F
MHY_,EP(RKF9P\UV9DZE#EW''\[M>BX_H;6.:)VUG*TN(>V9:C*3`%2=NJK>&
M\>I'N&:ZAVJ2[A-X5/WVZ1RT-24V/W5F3=1J]6A3^,5<WEH\;$C!N7+A='..
M1^I4R/26#LFR9OJ]GVAG;-!]P_J;G?WQ=81[$_BJG#M^GJ&0]*M/^*JC'F<W
M.Q;UY+>5\U.NW"K/.M0L&&5:/4544;0M=Q>1=4`&D>FJ`?#MY.=AGTHJ0O[1
M=R"QP[^OOU0^M34645+U^*)3860Y#\K+\Y3:'GZKCE-JT094@&>)1MWN:\G-
MJ-#"?^&D*]%9%5$"B(^HH>HH"(&"J/Z"KQ_4JM5GE_DUYY%4GR5IV*.;-6[G
M6^/>6Z'-G;@`'=RK"7O&6E<NP*V0[.AB<T:I_J98133(/K#OZ"1/K5U/PTUG
MP3VN?J?E5XGJP'Q"@S]ANU4F&B!TR$=P%@S&Z,Y/XD%3$(HWCB"5[Z>_J];4
MHE`3@4!#UJK?A-30?E/<O+"E8<3X35:9<,JXI6R;GK3)DL8B<\]?34I7<S@Y
M(Z*I1,W@AKTI)*M%2F(HJZ8N.WJ12,%344'J:AN\$>$57?O)K@4'>(]E,56A
M?5NNR$(_1(X;2TCGM;?RE00515*H@LBSO"D8\534(=-9!L=,P=C]PH/6I,;*
M:TR^I59JE?\`E?8W6XNX\2-ZBX]HUL]PA-,S&WO4D`2<2S"EN*E8J6=PJF0"
M.%8_ZMETQ.H/N>V9(A>Y"=BT-7(_B*JZ\9MIG>.?(7%=VK;UTQE<ITRGW8IV
MAU2'=L(2::.IF(7*B=,[B/G(8KADZ1[^E=LX43-W*<0ZC5PBXM6C9YQZ3`WS
MQ:\JW+N'@9E]7*17[;7921:M72\.K"W^ES;J1@Y`45EV+MQ&QYR`=`Q/?*;V
MSC[9C=2/I5E?Q"LR+J-7JO`_CX>*OC#9.+5+YL[;0JMM6BZO,WPE%A+["LK)
M2\XJ](NT]G?="HS35W!RERD[!47KT9)PFN+5JJV(U*@J1=1:0%6W8WL*GKY&
M>./AAR@S6>S/2>/^:-6LK'O&T3;J?2ZO5+]3)%P@=-O/T^UQ4.C(14FQ6$JH
M$,*K-R)`3<H+HB9(U;5`,1\:R^^1V-2G';?]JP:9?$E)+'=2O.;N)=)($$ID
MM/LDC!MYI%`%5OAT9ALR(Y(F)A,F54"F_4!ZA5\&XO4[WXN=BDXOR&7Z#:K?
MW9:.+]_;RC4YEA2.>*OV5RK!XFF15-+XUJJ@=,ASE.!47"I0`!/Z@J*@_I6@
M+U*K5'2E'2E'2E'2E'2E'2E'2E'2E?_2@&WVSN[MNNU7)^*IGUMUK1[.],L<
MBBPNYZXS,JX%51--)-145G8^HQ2%`1_4`#^CJ%7QZ"GM>/+D'Y1<8;ZI'>..
M,VB:;3*U1>ZTSR3CO$[ZFT70)84*:YL"4GF.C!6#NDPDBM#`#3XL$E@#W/:'
MT5\U0A3ZU,*OS3_*`5:K-T\:VQLLHW41(^0X=4@SINH=,2%=HD<YVX8F<)&'
MUE!1$Z0F#]Q!+W*-?-1LGVU&_P`A>'GFMYPZ:MKW(7C-R$T+1FU=AJL-AFLE
MKF;)$KT0J_5BHQE$0D%2*Z8C5=\X.84&HJB=43*F$3`(T\U(%1X!J0#Q6>$/
MR(Y)S*X]<AMDRBMY1GV67UK;9PEHTFE2EDD8QM'/4!2AX&BRUP<E?*+.P*5)
M\+'_`"1$PE+Z1,`JC,+$"KV74JM5GP_D`\/QXU\W9?3*Y%%99KRA:OM2A3MD
M2I,6>@).D6NK0I?0BB3XI2>=H39^WJ`"3A``PB4P%]G?1OLWZ[U2/`GDOGZ\
MB)K^ICM>%OV<04_Z,UX@^MG5_P!`[?+L(([:_8@S+;T$M[3+^WD1)_T@J"[K
MK=<=JW#^+?(88O-<FH5U5X\O))BRK,Y$7!\8KJ2=8PZ4+%S$%6DE"'&%0AKF
M5JM+J)"F,A\SCRG]8-">CS?_`+P";<1:&5<AOT(EE9!X`G'E6;^+DEP@-^/%
M[6Y&_IS_`'=7TYE[#$V.OZ^`C*Y\DP'PRI_"%DL7(MRYH#?B+7#NO,U>I:0'
MD1RFX\\3*5]PN1FMU#)ZJH=PBP=65ZH,G.NFB15W+"KUN-0?V:UR:")RG,UC
M6;MP!3`/H["'2J@$^E5T>1?Y47':HJOX?C+@N@;*^2*H@WMNA2K+*:<9<?<]
MM_'Q;=I;[?,L4_V"*+IM"K'$3%[D[`8U+U((?B:9>;R5>?SGG4+$OQYXV15`
MRN8@9A-Y::OC<;&U.2K*D6L68:AH_)*:FJ3,JJQ:YO=^`,FKZ3AZ"%$2]Z7-
M5XH/C53#JE7*T(?QA$_1XW)PWM^CWN2^GJ>KT^GW>U4S5'W._8/7V]KT]_U_
MR>W]74AZ5:?\552/-[QMM'''R1\C"S,6Z;5O:[K,\@*)-'!<[*PP^KR;RS3Z
MK)=8.YCPMY=2L<NG_P#"4:_M#VC)B:AJ:FX%."_'>YB4'BKSB>UW5YZ.JM`Y
M#4)?+OJB8708P]>O:,_$3]&>3DHY530C8>259/(LRI^R2;F1045.FD10X!1Q
M<5HM&71(B9R=9(K<J0KF7,H0J)42D]PRQE1$"`D!`]0F[]NWZ]2JS6:EYY^5
ME%Y9^0Z\V+,9YG:\_P`GIM5Q"MVN+=_&PUC/4'<[/6>1A'1%%&SN&3NUNDVS
M9PW$6SU)`'*1CIK%.:)J\HL*D/\`QE.!UNNN\R/.NZ03V+S+((FRU3))!^U5
M;IW;3[5%O*M89.#,LF*<A!T:I2$@V=K%`"?-)!`B1S*-71$PJCGQ:F"?D,V"
M1F?+-R0CGRA3MJG"8;7X<H"J(I1SG",XM*J9O<54(!AE[*Z/^P"%[&#]OJ]1
MC#ZU5/PBF'\(-;YBXUN\?9N"J5\=[](UFQU^-C<WRZ.V*TR=8<MT9.RMFU$D
MZ?>4)!J@UB2N5E0CSG;$0%0#D`HFZ54V(\^E3W07-K\GTT2S.;'MZDQ.0ZGQ
ML[PKIT3++%464.4'D<EET$5H=(I@(4HM$3>@H"8!,(F&OFH63[:9[RDSWS[<
M^&E0J7)?!^1FB1%.F)6=J$8[X^4W-8F%DY%B*#YP>2JU'I23@QV"`))_'N5O
MZBD_>?\`=3S504'H:37+?Q_?*;IRZ`N./C/,XI<Z9#3FI:)1*Z@W]?;N=>"C
M9V>N8$2*;N82Q9O_`&!W,';I8U7DOVU=>\L44X@O$QRL@W9T5'<-Q[1BG2C8
MQSMU'$<K7VBYT#JIHJ&1,HB(E$Q"F$O;N`#^G53Z5;7\0K,"ZC5ZM+C\?O\`
MPB^)7_?S_P"9K9^I#TJR_P"(U,GU6HUEZ^:2*<0WE(YF-'1T5%%M20E2F0,<
MQ`;SM0K,VT(85$TC`LFTD"%4#L)04`P%$P`!AB?6KZ_A%/H_&$_Q(YS_`,-&
MH?Z5YKT'K5'_``UH1=2JS1TI1TI1TI1TI1TI1TI1TI1TI7__TX,N7&>/,EY4
M\DLP?,U6*]`W;6*D#=4BY?[-!7J=CV2Z(N55UEFCMD@FJ@J*B@+(G*<#G`P&
M&-7QZ"ILOQF>3==Q?G#:,>N$JTAX?DSG?TC7'3Q9-L@OJ%/E4[%38I5RX620
M3--PKB;9MB?N5<R2[5!,!.J!1"HN+BM!/J56J.E*.E*.E*H?>?\`\D='Y7Z7
M7>-6-I0EAS'`+/+2$WIZ3=F\7N&EJLUX*5CZ;+E!1<E$KC0QVZBR2A49F0[J
M@4[=HR<+>O/HWT;+Z[@3[W:%TS\R,!8O(X17Y`N/](Q\@'RB^/#,X'C3ZV=^
MP^R["#0:H(^OPI&+36!YRVXD1M_HU'BX-I&\V*JC&NCUVVN$T^_QI<K%^&?-
M'%-M<O%&U.:6(M1T]$IU?9=9G=2A`6Q9PBC^]V:OMG1)=LE_09['(=_Z.M0[
MWUT=HZMM=4JWRBG.+[I4^9+?9R(X$_PL:W/Z?]D/5.V:C;LY&().$WWQ2?*]
M_MX@\P/XE%:?3=PW>-T';1=%TU=(I.&SENJ1=NX;KD*HBN@LF8R:R*R9@,4Q
M1$IBB`@/;KP,RLK%6!#`V(/J#7Z&JRLH92"I%P1Z$5ED>4?F/>N:_,S8=+LL
MW(/*;7K?8J)CU;6<KFBZEF=8F'<7`-HUBH!$F;V?3:_,Y(P%`RT@[5,(^D"%
M+`U]"BPJ;#\8[A!BVVV3<N3FP5&`T*3Q^9IM,RNN6:/0F(*OV67:25AGKN[A
MG[9:.>SC!JU8(1"I_6#,RCI4"`M\.JD%1<D6`JZUHW_Z]OG_`-F6C_,C[J56
MQZBL>?J%7ZT4_P`:S_#!JO\`KEUW_.\?U(>E6G_%3X_)KQ<X3\E..,Z?F\_A
MJ-0L\1>ST)M2DVRJEKRJ2>HD:*OZM87;9ZBY6F!(DB>'7:R#256(@46BSA-L
M*=345)!\5GDXOP/LW-'EC;N/7`V6F-<ID0:6FHK5-2KZ>4L&5$BCM6BEONL>
MTD;>M`1SF6>)M61"@I(/A61,+)NH=5NA&KU["YJ::,\!OFCDJ:VQR2Y84B&Q
M\S?X)6BO^3F[/,X:L"%((M"T2,HS^(42,"12D2*S!,3`4#"0H>H%C4>2^MJ?
M-Q-_%IQRCR\5;.7>TRFTK,E4G:F7YO&/*#1'"Z1@$64];W3]U=+'%JA^HE9)
M5];OV`5#%[@:MJH7^P5:8I5)I^;U.O4//ZQ`TNE5.+:PE9JE8BF4)7X&(8I@
MDTCHJ*CT6[-DT0('Z$3(4._<?Z1$>JU;K.N_(WH$G3?*CKEB?IJD:ZQGV,7^
M%,IW]"T9'9S"98JHA_"3_A!,YJ[(/ZJ?O*;]P?Y)8GUJ\GX:9)XO.2L1Q&Y[
M\:=WLKOX&G5J^&@+T^,8X-XZC:'"2V=VV:=)$*<7*-=@[2M(@GZ1$QVA?3V.
M!1`*JPN"*U36SEN\;H.VBZ+IHZ12<M7394B[=RW7(55!=!=(QDUD5DS`8IBB
M)3%$!`>W4JL5^W2E'2E1H^8[_#!YH_ZFI/\`SO#]4/I4E_$*RXNHU>K2X_'[
M_P`(OB5_W\_^9K9^I#TJR_XC4R?5:C67YYK98LUY3.93PJ!FX(Z5&Q(IF4!0
M3&@*-4X(Z_J`I.Q7)XX5`+V_:!_3W'MW&)]:OK^$4^'\83_$CG/_``T:A_I7
MFO0>M4?\-:$74JLT=*4=*4=*4=*4=*4=*4=*4=*5_]1<?R3_`!MVVIZNZY_9
M57GDQFVBMH**WM"*:F<&H-^BF;*N0MU?MVJ!?@ZG=XEHS;+.3`8B$VB85E`-
M(-R=1-74/PJJ9#S$K7I>+GX&2?0TY!R+&8AIB+=+,9**E8QRD]CI*.>MCIN&
M;YB\0(JBJF8ITU"@8H@(`/5*G5Q_@C^4!`1U/A<_Y[46U/[1$-T(Y'<\HB(B
M10LB""1BDD+]0EY*$4BI<2I%!=W"F=(NUE.Y6#4H"(RO5LI]E237#\E#Q@UJ
M&4DX.WZ]H3\J"JB==J>13K"555(0IDVX.;VXID$0ZYC>D#"\]`"41,(!V[KB
MJ<&KX?&1YC]8\F/+33*-2>.D)G7%[-,O<V&6N4[892;T="XR5DBXVC-I%['I
M-JBS"U1J,LH$,1HLHF5@LN64."'P[@#>C*%'KYIMOGG\MI,JA;)P@XWV7MJ%
MDC?EN\:!"N1!3.JQ*MP.OG,`^;J%%*\6:.6*$FN7O\JC%Q1(/QK@3L?07T@^
MG!V,L':]Y!_W?&U\>-A_>.#_`'K#_1J?PC]]A<_*+/YP^L_U-&MBR.H:#(_[
MQD6V1*I_ND(_NE(_^8X_&?W$-A\[71F?@)\4I=;L$-S?Y"UD5<NJ$L9Q@]+F
MF@"TT.Y0SLR1M"DVK@H@ZIU+E&YB,$Q+Z)"81$YA]AF9-UM'UB^HGZ;#+U/2
MSVV$JVR'4^8T8?W8(]'<'YC^ZAMZM==5^BOTV_4YXNW[S'OKHFOCQL/$LBG^
M](/JD9'RC]YQ?T2S1+^6GB6;AQSGV+-HN-/'Y]:9(NJY1V*F1J-"OR[J2;QC
M`J92>EG4;"E(P9`,`'$(SU#Z@,!S='^G'8_ZGZEK,Z23EFQK[,WV^Y'8$G[W
M7C)_QO[*YE]3.L_TKW':X$<?'!D;WH?L]N0D@#[D;E'_`,3^VHV>MYK0:T6O
M!7RW#E)P-HD1/2AG^D\?%4\4NOQ3HSB1>QE?8MUL\L3CW@%R=.4I2S9J==0R
MAG#^.=F$PB`@'B7ZN=;_`*?[?ER0QVP<W^>EA8`L?YBCX>'N;>+*RU[L^CG9
M_P"H^F8<4TG+/P?]7DN;DA0/:8_'S'87-[LK5G;\E\[L>1\B=TS"W,UF-DH6
MMZ%59=!=`Z`F=0UJE&0ND2&$P'9OTTBKMU"F.FL@H0Y#&(8IAY=77!Z"G\^*
M/RN7_P`8E^O;UE1FVKY/J[*$0OV>N)Y6LR)):L&E/IRTU6P#&S;>+EF"4TZ1
M<I*,U49!LH4B@D.D@LD!M5&7E4R.X>:3G#Y/JIHO'WQ]<;Y[(JFG2[!*[/K[
MNU$F[17<W:QK]Q.'6M2,3`U7+6\K$-ET1%-62FGH@9*-.1?^FM[U$*%\DU4'
MZC5RKY'XU')K$X7@A/Y1=-FS6K7RH[S?72%)M=SJM9LA*M88*E2D9,LHF4D&
M,E)0C^87?ID=@10GQ**J/J#VP*$A5IP;U&M^4]OEPG^3N'\=$GKMMG-`QQGJ
M(1Z3A9-E/731+/989Q+.FZ2PM7Z4-7Z6T08J'**C<[IZ!!`JH^JAJ2#P34+O
MCU\C6Y^-W4+/I6+Q=(LZ=XK"=2N50T&+DY"`F8YM()2D:\1<04O`S<;,1+LA
M_852=>R)%U"JHJ@)?0J1`-3>-?RO.1Q&R!7W%3$W#PJ1`<KM;9>V;958`#W%
M$&BRKY5ND8WZ@0RRHE#]!,/]/2]1X#[:YA3\K'F"*B@H\<^-9$A.84B*%U!5
M0B8F'T%45+>T2J'*7L`F`A`$?U[!_1TO3@/MKIZ=^5WR.9S39;0.*V)V.NE5
M3^,CJ=:+W2YI1'N/N@VFIIS?F*"HE$/2)V"@`(?J`]_T7JGMC[:4KR+&RCSJ
M</H_F?P[@9Q+DIP^9/(G;,(ED&:VAN<LGTE[`NA&&8F53N"-8DHQ])U]1GZ#
M2+9:50]@)$$F85]:"ZFQ]#5/TQ3$,8ARF(<AA*8I@$IBF*/8Q3%'L)3%$.P@
M/]'4:N59@\6GY#-SXBT6M\>N4U1LFT8E4V[6(H-UJ[UD?5LVK;5+V&M4%A//
M&$/?*E$I$33C4%GT:\BVX&0(NX;$:MFU0:@R7\CUJP+_`,R+XM_D'SG[B:E\
MQ]GW?I3[.V_Y_P"OWO:^&^)]GZ6][T?Q._S+V_1^GJ]?[>JW%1X-39<E_(:L
M?,'FG@?&+AUQB6<TZ_Z$Q8WF[;1-G8VHF<1K9]+WV<@ZM2'<I$59Y7*Q'.'Z
M#EY)RR;@R(-S-4SJE.5>G"P))IU_F]Y=\=XKQL\EJ9#;SDLMH&BUBMU"GTR`
MOE3L=JL2DU>ZVC+%C:]&2;V15:-:\W?+KNO:!)ND@8PG`X%`1JB@W'BLX3J-
M7JT"/Q^N;G%N.\=>.X1<-\R&B:KEECU*$E:)=[]7:9:';:W:U;;W"2D7%6B1
MBG$_'O&]X00!PP!P@1?LB<Q5NY.I"K3@WO5CID]9R3-I(QSML_CW[9!ZP?LE
MTG3-ZS=)$7:NVCI`ZB#ELY04*=-0AC$.0P"`B`]5J%98OEBL!+-Y*>;<BF=L
M<K;D5H]?$6AQ.D!ZG-K550AQ$YQ!RFI#"5<._8JP&````[!$^M7U]!3OOQY]
MSS;!_(U7I?5+G5<_J]WR72Z`2UW6<CZU6X^8>(PUHBT'T]+N6<3'*RBU3%HW
M%PJ0JSA<B)!%51,I@]:H_I6B]5;O3+TR7DJ1;JQ<8YLX%HX?U6?BK"R;N@(5
M06R[J(=O$$G`)G`WH,8#>D0'MV'J56:Z?I2CI2CI2CI2CI2CI2CI2CI2O__5
MORS4+#62(E*]8HF,GH"<CW<3-0<TP:RD1+Q<@@=J_C92-?)+LI"/>ME3)K(J
MD.FHF82F`0$0Z4JM9RU_&*XG[)-S-QXX:):>+\]++*/5*@2&2TK)DG1@*HHE
M#5Z0F*]:JRB^7]8F*E,N6;3W`!NS(D0J(TM4PY^-1<2?XI7+%)ZJ2&Y+<>'\
M<'I]AU)L])B'JG<H"?W6#6JS:"/I/W`.SE3N'Z_I_1U2U2YC[*7C,/Q;J)0B
M)7+F/S1B8:E1ZK7YQ&9Q!Q=+9G]SOZD3ZCIDDYCXTJBH`0GJ@3F4+W$!(;L`
M7\?%R,J58<:!Y)CZ*BEF/[``37SY.;C8D33Y4Z10CU9V"J/VDD#_`-M+AROY
M\<#?%)QXF^-?BM2RZ3W&^D19V'0J#*,],9TX&2"K1:YW_2%WTXE?-":`]<I0
MT0=X[:0[E591=NW0(1D\[-]._I-LMSGQ[#LN!+C:2,WX2`QR3'X*%-F6/XLY
M`Y#PAN2R\/\`J5]8=9I,"37]7V,.3OI01SC*R1P#XL6%T:3X(@)XGYI!8!7@
M[\5'CXN/DDY-N%+RO8E\6I4FC=^0>@.7CU:5G5)5\X?-J:VGUU3O'%TT9^BX
M]QT90RS9F1T\$QE4TDU>\?4/N>+T;0@8@0;65?;QHP!9;``N5'@)$+6%K%N*
M^A)'GWZ;](RN_=A8YC2'4PM[F3*2;M<DB,,?)DE-[F]PO)_4`'1MK%9KU*K<
M!3ZC"1E:JM5AHRNUNNPK-".AX*!A62,=$Q$6P:D3;,H^.8-TT44DR@1-,@%`
M.P=>(LB>?*GFRLF5I,B1BS,QNS,QN6)/DDDW)^VO=^/CP8F/!BXL*QXT:!45
M0`JJHLJ@#P````!Z"J\_Y'O#LNS<5X/DS58KXB^\9I(RMB.U144>RF/W!XRC
MK&F<B!3*.OI&Q`PDRF4_ALV`R*G<H&.(]H^A_9OTOL,VAR)+8>>ORW]!,@)7
M]G->2?:S<!]E<.^O/5OU;K</8,:.^;KV^:WJ8'(#>GKP;B_GPJ^X?MJB)UZ[
MKQK4QGA,YZQ7!WEJ@70Y<L3AFY1[#/-0?N#"5A5WJ+Y1S1M!>^D.X-:K+/%V
M[LXCZ4(N3>*^DYTR!US+ZJ]/D[9UP_DHN6WQ&,D0'JXM:2,?>X`(^UU4>`37
M5/I'W2/I_9E_/2\=/F*(IB?1#>\<I^Y&)#?8CN?)`JS-SD\37!GR[/G&]XKO
M-1K>RILHJ&G=AQ.6INN4ZV-F;,&T(EI57@K$S1E9R/C&I6S-\C*QSX&:)$5A
M<(MVZ:/C#/U>RU<HAV>OGQYCZ+*C1DV^P,`37N#7;?6;2(S:O8P9,`]6BD20
M"_VE"0*C+IGXFK].S0ZNA<TFCJFHOFRU@8TS&%H^S2,:FLF9W'P\M-Z!)14*
M^>-P,1-XNR?IMCB!S-EP`4Q^&U9'W/NJSWFO"/CYB7&6T<4L1J!,HS>VT:TT
MN7D*J=,+D]7MU<=UN5N<G9I))^]G;J+9X*I'K[XCT'33(4@(ID2+6H7)-S4)
MS'\5K@,FT1))[7R^=OBE-\0Y8W3&(YHJ;UF$HHLG&$2BR!03$`$#.%.X@(]P
M`>P4M4N9^RORD_Q6.!JK420^W<NF#WUD$KB3M^-RS4$P'^(46;7#X54QS!_0
M;WP`O]8#TM3F?LI*OR!IWQ6.J15J+MENMD]S$R.ILZMG49A3R!>Z%%PIVZ+I
MG`;.YE&KJI1%-657!^1J\%*:0,Z.O')"FX<%6&U57E\/2H(O'%X.>3/D)K#O
M5R3$7@N$G%ZTK&CW>'>SK^^2K)P9LY;TFI,G<,\F(2,<)F1=RRSAFQ^(*9%L
M+E9)RFWI:I%@/VU*-_RF>A?[[%,_V'S?_P#2^EJIS'V5X-D_$[VEK%.%JAS!
MR^<G"E/\+'63,K958I8P(+&3!Q,QEBN3QL4[DJ9#"5@KZ2&,<`,)0(=:G,?9
M5:;DYQGV#B#M5QP+<ZV6M:#2W#0'J+9TG)0TO%R;1&1A;%7)=$"MY>!FHYP1
M5!8H%.01,DL1)PDJDG2I`@BXJ:_\8FZS5=\C,Q5V*C@T/H/'W18B<:%6$K7^
MXYFGVJ,D5D!25(JX:.H<R"1NZ9B%=J`!^QC$/45%_2K*'.SP!<,.9MBG]-K?
MSOC?M%C<.)&:N&9,8UW3K3..U/==3ESS)]\)%R$H[5,=5PYBGD(Z>N5#+.EE
MU#&,-;5`.1^RH.+3^*)R4:2)TJ5RGPZP1('4!-[::S?:?(F3#V_9.>+B6EY;
M)G/W-ZB@\,!.P=C&[CZ5JE[GW5WF5?B?:,ZDVJVW\N:5"0R*R9WL;E6?SMID
MY!N"QP5:M9NW2=/:0ZRB`%$JYX]\4AQ$!1,``)EJ>Y]U6/N#'BJX<^/INK(X
M?0W<GI4A%FAYS9="?I6?2I2.6%%1W'M9$C..A:O%O5FY#+M8=C'HN13(*X*F
M3(8*VJ!8GUJ*B(_%6X+HE7"=W7EE)',9/X8T19L?A2I%`#>Z"Y7F-3XN#'$2
M^D2BEZ>P]P-W_2EJES/V5['_`"KOCX_[8N9/^T+$O_3STM3F:\V4_%8X'K-@
M)"[ARXCWGNE$5Y2VXW+MA1`#>M,&C3$8-4%3&$H@?WA```0](]^X+4YG[*L8
MY5G\;DV7YOE<*]?24/F="I^?Q,C*"W&2?QM,KT=7&+V1%HBW:B^=-8TAUO;3
M(G[AA])2AV`*U"H(->_&MX3;CL.O;9>M?Y4(6K8]0O.ISC*K6[(XF#CY>_V%
M]:9EE'M93%;`]%HE,RC@41.X$2H&(00$Q!.>EJGS(`%)_P#\J[X^/^V+F3_M
M"Q+_`-//2U.9J47QV>-3'O&M4]/I.-W;2KI!Z=;HRV/5-,>5=_*Q2T3%'B&K
M-J[JU8JC-PD9N?U*'.V`3'_4`*'Z=5M:HDW]:D7Z52CI2CI2CI2CI2CI2CI2
MCI2O_]:_QTI1TI1TI4<OE'X5W;GSQ?-Q_HU_KV<R#K1*E;Y&;LL4]EHYU$5I
M":,>**A'!\8BY7DGK98JA!+V!`Q1'L80'=_I_P!JQ>G;_P#6<O#>=!`Z!5(!
M!;CY\^+6!%OOK1/J+U++[KUW]$P\U(',Z.6<%@50-X\>;W(-_NJN'_RM.^?[
MT^0?]3;G_P!+UW#_`-06G_\`+V3_`,M*X-_Z<]U_YCQ?^KDJTOP8X;YQP5XZ
MTW!<\32>JQ:1IF]7`[1-K)W^_P`HDA]0VN3`GJ.4%SH$;,D#'4^#C6S=N!C`
MEZC>?>V]GSNW;O*W&:;!OEC2]Q'&/PH/\[']YBS?&O1G3NJX'3M%B:7!%ROS
M2/:QDD/XG/[?11YXH%6YM>G?]:U6T5SMOJ=>OM2M%&ML8A-52Z5V;J=FAG7J
M^%EJ]8HUS#S48Y]!B']A_&O%4C]A`?2<>P]7\;)FP\G'R\:0ID1.KHP]0RD,
MI'["`:L96-!FXV1AY48?&EC9'4^C*P*L#]Q!(JG'8?Q:]>-/SAJMRDS5.L&F
M),U<3G:?:3S:<"+U<8@DP=BK\$>5)'^V#@4?X0K>KT?M[=>G(?\`>!UOLQ?F
M.OS_`)CB.7%TX\K?-QOYM>]K^;>M>5Y_]W3:>_-^6['C_E^9X\D?EQO\O*WB
M]K7MXOZ5X_\`RM.^?[T^0?\`4VY_]+U<_P#4%I__`"]D_P#+2K7_`*<]U_YC
MQ?\`JY*G=\17C2LOC;SW8*Q<=#K&CV#4KE7Y[YM5HF4B6C&&KD(O'Q\<X)+'
M.X6<E>R3M3N7L0"J!_7WZY%]2>]P=YS=9D8N%)!#CQ,MG()+,UR1;X6`%=D^
MF'T_R.@X.TQ\K.CR)\F56Y(I4!54@`\O-[EC_;4O/7-:ZA1TI1TI2)\EM#F<
MBXX[_K%=;&>6#,,3U70X)H5J5\9U,TJB3UDC&Q61A`KPR[V-(4$A'LIW]/\`
M7TH/45DA2L]*W6V2%FO%BEI69M4^YFK;:Y55S.SDA(3,@=Y-S\@JZ<E=2\FX
M7<*.%!46`ZZ@CW.`F[]0KZ*U],UK%*I6>46GYLRC([/:O4*Y`49C#"D:):U*
M*B&C*O(QIT/X2K(L4BE[9R]P.7L;N/?OU.OGKM>E*.E*SUOR=+Q5K;Y)8R#K
MSAHO*9IQPS"CW<K84C*-K2\LNBZ&W;OA3`#?%A3K]$G['$3@D<@?T=@")JZG
MI3NOQ5.-L]):WR$Y9R<<X1J54HJ6%U2071.#26MUNFJ[=+7\O6[>E1W5H"L1
MY'`=_P!J<XG^@]_VA5'/@"K4?-3G#F'!"AP>G;'3M6G*%+RJL(]LV<5J#L3"
MKRAC,"1+.S%E;377+,]B.\4*Q%!-R0XM5@4%(03]S:NK=3V';\R7`UF3CIF*
MO(+*S*7'FY6R,#QM\U[>HM?S;4.V]PUW3<*'8[7%R7PF;B7B16"'QQ#W=2.5
MSQL#Z&]O%T!NOE?RK,:1#ZGJ/&KFOGF32[6(D3:G/8,W?T>&B9Y)NK$2]ADJ
MI<[([AH]^#M$J1EFX&445(0I1.8"]9C%^G>QS\N77Z_>ZJ?8J2/:7(M(Q6]U
M4.BAB+&]CZ`GTK"9?U*UNOPXMCL=!MX-8X4^\V,#&JM;BS%)'*@W%KCR2!ZT
MHN]>2OCK@_'R@<K%&FB:WQYT-L5U':GC-=B+17H)-S(1D/%)6Q.;LM6E()Y+
MS4@=BFW.W.NV?LW+9V1LNF"9OBT_1=WN-UF==#08VZ@-C%.Q1FL"QX<5<,`H
MY7O8JRLI8&]??NN_Z+3:/"[(5GRM'.+B:!5=5N0HY\G0J68\;6N&5E8*PM3H
M\$V6-Y`Y75-=@Z9?J/7KM&M9RMQ6DQ$5!69]7I%JW?PT^:+B)VPHMHV;8.B+
MMO=7(N9(P"=,G<.^O[C5R:;89.MFRH9IHF*L8F+*&!(9;E5N5(L;"U_0FMBT
MNUCW>MQMI#B3PP3*&02J%<J0"K65FL&!N+F]O4"DLQCFQ@F][WR&XW9Y/OWV
MF\9Y**B]#:/&C5O&/'#\[IG(GJKU&0<K3"-4FVAHV6$Z+<S-^8B8@8#E,.0V
MG5=QI]/I=YFP@8&>I,9!)(`L1S%AQYJ>2>3R6Y^%8[4]NTNZW6\T&#.QV&O8
M"4$``DW!X&YY<&'!_`XM8?&OOY5<SN//#*I0]LWF[_(#VF2-"4>HPL7(VB^W
MZ<+[(#$T^H0B#J6E5B*.D2*KB5-FV.ND599,54_5#KW5]UVC)EQM/B<Q&O*1
MV(2.-?M=VL!Z&P\L;&P-C4^R=KT?5,6+)W69P,C<8T4%Y)&_A1%!8^HN?"@D
M7(N+M>M'E2I6;007?9^(//7%,P([8-WVHZ#@4.I4X1&4=ILHY]8V%)T6Y7>N
M-';I=%(@/H=NO[ZZ:(I@N8$^M@Q_I[E9TWY35]ET^5GV-HH\AN;6%R%,D:1L
M0+GY7(L";V\UKN1]1\3`A_.;;J^ZQ-=<`S2XR\%N;`N(Y9)$!)`^9`;D"U_%
M=GRE\G/'CAEK^=Y+R&A-6HK;4WB+2G:PO5(=UD#XB:L&WGWKBSH6D99DSIJ]
MC:!+BI&@HS(L57T'1,10WR]?Z%N^T:S-V6EEQYFQQ=X>;"8?B*CAPL2_$\/F
M^:UK@W%?7V/ZA:+JFTP=9O(<F%<DV2;@I@/X0Q+A^0$99>=UNM[V((-+IRDY
M6TSB?E9=GN5*TV^9^BYC49>7R6"@;8>`;33R/C(25DVLA:*^JK%2\I*MVZ*K
M3XK^(J43@4@^OK$=?Z[E=BV/Z7BY6/#FD&PF9DY%02P!"-Y`!)!MX'CSXK,=
MC[+B=:UOZMEXF1-@@CDT*J_$,0%)!=?#$@`K?R?-AYKC]OYWX?QQH.:VW9FM
M^I]QV%XC#YE@J-3&U[W<K(LNV0^F86@TJ0L:;F404?-RK*?&@Q15<HHG<%76
M23/]6IZAMMYF9^-JVAEQ<4<I<CGPQT7S\S2.%L/!M\O(@$A;`D?+N.YZ?0X6
MORMLL\65E'C%C<.>3(_@<%CC+7/D7/+B"0"UR`42EO*UB6=6VFU?DICO)WB'
M'Z#)?)J;H'(O,Z_!9G,2YD2KHQJ]UH5[T2+KSPZ1P,<LJ+'X4G<[GV4R'.7*
MQ_3O:YV-E9&BV>!LGA7D\>-*S2J/2_"2.,L/_<Y7]%N2*Q$OU)U&!E8F-O\`
M5;'5I.W&.7*B58F;[/<CDE"G[>?&P\M8`FE_Y)<U\EXT6/.,]FH71]2V'7_F
MZF98IBE1"\Z7;V$`W!U-S+:/<24'`0\#&(")E7TG(L6H$(H8#B1%<R>&T75=
MEOH,[-BE@Q]9C<?=GG?VXD+&RJ39F9C\%16/IXN1?-[_`+;K.OSX&#-%D9.U
MRN7M8^.GN2N%%V8`E551\6=E'J;V!LD3/R6YF%2WB>M&#\JL_M7'4<B-?LCN
M650S?37S;<KBK1LW?4EE!W>=J=T93TZT=%*HQF%`]+-8"^I0GMCDFZ)G_F=/
M#C[?738^=[WMS),WM`P)[DHD+1JZ%5(_$@_$/@;UBT^H&O\`RNYFR=-LH,G`
M]CW(9(5$I&0_MQ&,+(R2!F!\JY_"?B+4DKSS'8Q'Z]%X"]XQ<YVNV3<"I:(?
M+%\`8)WB2KJ2$BY5FF=>-?0D%XU-O$.CBJ4@D`K<X]_VCUDE^F.T?6R;E-_J
M3JD?@TOY@^V&\#B6]NU[L/'WBL8WU4U*;2/2/U[<#;NG-8?RP]PKY/(+[E[6
M4^?N-=3H?ELP3+,&;\C+MDG)J%SU'3;GC]L2>YI7V5GSK0*7)1\0Z@KY7I&^
M,G4,M,R#U1-@*1G'N"S7]WV>R?N?/A?3C<;#<'28FRP'S3CI,EI6*21N"0T;
M",AN(`+7M:XM?S;Z<[ZFZ77:5=[EZS8)@C(D@>\2AXI(R%*R*9`5Y$D+:]^)
MO;Q=<K/Y`./>;\8JYRQVAY:\.S:X(-5JG":7`)-M'LRDLFLYKC&"I-6DK4_E
M)"S1R0/&J*)SG38F^(<@W2(J=/$X_3=UG;^?KFK2/+SHB>;1->);>&+2.$`"
MGY23ZM\J\B0#F,CNVCP.O0=FVSR8>!*!P65;2OR\J%C0N27'S`#T7YFX@$A"
M;%Y7*-1J>;3]*X@<]\SQQ%NP?/\`7KE@,*A48:+DE4$FLQ8(B&T::T.OQ)S+
MAW7>P:!`$2E_RE42J9>#Z=Y>7D_I^!V73S[,D@0ID-S8CU52T2QL?N60_P"0
M&V&G^I.'AXOZCL.K[K'U0`)GDQE"*#Z,RK*TJKY]6C'^4BZS[!S]R_,-C/QY
MJ.;;KR)W*/J+&^6C,^/]$B[+,T6I2AT"Q4O>I>YVF@U&L&E"N4S(-7$D5Z<B
MJ0^R'OH>YBM9TW89^L&ZR<[$PM2TIC27(D*K(X]5C")([VMY(7CX/GP;9;:=
MVUVNVIT>+@9F?N%B$CQ8T8=HT/HTC2/&B7N+`OR\CQY%^1_XF..?93[R?:;D
MU\;]_?Y8_LM]G7/WT^]/R7Z@^D?HCYW\#_\`3/W_`!?S#X/U?M]WO^G7T_T'
ML_U7]+_4L#A^3_->_P"\/R_L<N//W.-_7]WCR^ZOE_Q`U7Z1^J_IFPY_G?RG
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M,DR)*-W1R`J(&HLE_(J?*-_(4\2SZ,(_<\F96'='2.H:%DL,W]632.0!$J)U
M8C,)6&%57M^T2NS$_7]3!^O:MQ4.#?94>7,3\H;!*S49VN<+J#;]-T=^R<LH
M;1-'A?HW-JPX72.1">2KKETK<KBY9'[&*P<-H9`QA`QW!BE,D=>I!#\:KM\,
M?&SS6\LNSS>GR/U!&TJZW*1LNO\`*30XQ<8!:2E9-1Y8UJTU,>)"_P!L,JHH
M"47%F2:-C^VFX68H"4X4M>I%@M:*G%CC'E/#W"J%Q]QF%^44JB1@MR+KB5:8
ML<V\4,\L%ML;T"E,_G['**J.'!^P)I^HJ*)4T$DDB2JT3<W-14?D8_X:EG_U
MOY/_`)U?]==^B/\`^]X__9IO\PKC7UV__0,C_M4/^<T_RUO<_CO')+O-7%A]
MM4>&IQO!),&QF:]:/C14Y5J<CLBB"RSMJ<R228E,*BQRE*4QA`!T['3-?N\2
MZZ_YX[3^7:]^7O\`@^/L/DGX"MUR7P4Z'*^RX_IXU7\R]K</8^8>?M'@#XFJ
MK5>KEP@/QE-%=6EI(-(ZT<C8FQT4K\R@%7IZFM9]#_%QZ*OZMX]S:H:5,0``
M"J'$RH=P4]0^A)I\:;Z\X2X[*7CP2LEOX_9D:Q^\(R?L]/A7G""#*@_W?,]L
ME6$<F>K1W_@]Z);C[`75_P!OD_&K-#3>6_&7Q:YGM9F1Y>8I_$C%R4NNHHG<
MN;7H]ASJGUG-JBT:(C\0Z<VB]S$>Q*FD!E1]\1*4PAV'@S:=M]]0,_5<^,4N
MRGYMZ!(ED=I7)]`$C5F\^/%>@EW2]>^G.OV_#E+%K(/;7U+RM$B1(!ZDO(RK
MX\^:K10TTY\:?.#A7RI7H_(*BTS4Z;&9!S8N.X99;,YC;IJM]>N977;XR?38
MI-Y-@O,O&]E19)&]2!JZ`B4Y3=NN[RQ+WOJ?:>O#+PILK'E,V"D$J2E(8P!#
M&0OD'B#$6/K[OPKS_%*W0.W]2[(V'G0XF3$(,]\B%XA)-(2T\@+>".1$H4>G
MM?&I!N2SU@;\CCAD.QK-5L\4Q-`^)FEU"JU<+<]KFPDK[AN#PXQHV)SI1`*S
M.@`KFD/EHA^X$A#3-$C_`."':/TP$9OYO^?;\?`-#R'CSQ$7XK^./N??6\=@
M=/\`'CJ?ZJ0<'\I_J_+\',K/Q(OXY&7\-O/+V_C:I8O('S2P/B90Q3Y18SJ=
M[Q2ZDBH*5LE?I%,NF>.)N6<S#AC39QG-W6&E0FRI5HST`&/,U!,R1B+BJ!B)
M\YZ9U;<=CS+]?VF/#M8KL%:1TD"@*"ZE48<?FX_BOZW%O)Z5W?MFEZSA6[%J
M<F;4S64NL<<D19BQ$;!I%/+Y.7X;6M9K^`V+G;QRR?R";7PPRS5H&;@Z[J/$
MKF=;:\>11C4+UFEM<R/"^7K<ZV(S?2D6A;*JH^.FZ11<N6CA,7#8RBK=4XFS
M_4-WL>F:KM.PUTR//C[+"1K7]N5`,X,IN`>#VN"0"#Q:P8"M>[EH=9W?;=3U
MVRA=(,C69SK>PDB<G`9&%B1S2]B`2I');E2;PCV/E+MO$CCQR'\0G-A*0>6Z
MKIYN'%+5B).WL/>,]CM=I,K&5U*25$ZR]:5KT0LXKZZ@>N/^&<0[OV5FK=N3
MJT'7M5V3=:7ZE=5*C&D]W\W#X#1R&&0%K?Q<F`D`_%=95N&)/(I^Q[?K&BWG
MTO[<&.5'[7Y.;R5DB$\9"W_@XJ3&3^&S1-8JJB03;Y-0/R4^+#32@`M=;\>'
MZ.0EF"]XH'[V@[8<CN-*<QFH2#BW%DT$E3@"@O$TBE_>1`0TS4QC_`OL+8']
M^<T>]Q];"2#P?C8)Q)'IQ)/H36[[>0_X_=<78?W`P3['+TN8\CR/A<OS`/KR
M``\@4[3\@YK3G'B\V56S"P":8W+&W6=@[$H.#7$^GUED]"+`Q3"+_P"W[R=$
MW80'X8%OU[=P'7/HPV4._P"K&/?VC%.)+>G#VF(O]WN"/^VU;-];UQ6^G>U.
M1Q]X2P&*_KS]Y`;??[1D_LO3*YOA%S,TF.\<?*'BUO6;4/FK@7`O&JE=LWUT
M5U7+FC3D%86T7*.FZM<MS0TA-C/3<1(_',6_N.68G3>E71`Q=JB[7U?!?O&@
M[!IYYNJYFXG>.6'T$BLI(!Y(;+QC=>+'PUBEC:M2FZAVO81]#[%US=8\/;<+
M2P))%/>YC96`)'!Q=N4B-R47*W#\A>G%>.CEGR0UKF'R,X9<^>.6(P'(.AY3
M1=#GM'H=:ASC=JO1[-67M`CKH^1E+5$V?Y2^U<DW7%6[ALE$K*O"E:(.A5$,
M)W?KFCUO6=)VCIV\RWTLV1)&L4C-_+>17$A060I<0\)002X"_,5M6>Z)V;?;
M/M.]ZIW30X:;R'&CE:6-%_F)&Z&,2&[J_$S>Y$00$)?Y0UZ3[2O_`/2OQ]_\
M(,U_HKM_7V8/_P#"MS_XFO\`SX*^'8?_`-^T?_A;?\S(I2/R&H""K_C1NY(&
M%B80DMNN;S\J2(C6<:63G9:;?N)6:D"LT40>RTFO^]PY4]2RQ_U.81_7KX?H
MM---WO$,TK.5Q)5%R390H`47]`/@!X'PK[_KE##!]/\`,$,2H&S(F/$`79F)
M+&WJQ/J3Y/QIDGD!EV<#S)\%,QLQT$N.<=5,S<HN9?W_`*:9:"21H`2\A.&<
M')$)Q\=WJR[HZ@]B-$U#+`*(=AVOIL;3=8^KD6K!.[:2467\1CM)Q"V^:Y_F
M@6^)%O-:CW:58>U?1R7;$#0K%$;M^`2WCY%K_+8?R2;_`+H-_%6J+A4*U?ZO
M.TNY0S.PU6S1KF(GH20*<[*4C'9/;<LW)4SIG,BL3]![&`>O/6-DSX>1#E8L
MI3(C8,K#U!'H17H_*Q<?-QYL3+B#XTBE64^A!]0:K]<A>&?/:G<ZN2',[QI;
MCB<Q/7UK3*'N^,:2H@XEXJUU_-L_EV%4!25@Y>&2%_5UX.=;&5E(-VV1ER)E
M$S-0!-V72]HZ?D]1T?5^]ZG+6&$O)CSQ>`4:612_AE;P_N1FR2`E"?Q"N);S
MJG=,7N6^[9]/]QB/-,(X\B"7RP=8HF">59?*>W(+O&P#@?@-,3_XQW)'[<?:
MC^1_C[_/A_/#]I_8^CF_T#]^?E_T7]9?*?J3M]_/J/\`N;YM]1?#>S_%]WX;
M^!UMW^&.C_/?J/\`5F;_`$A^D^]^,^Y^7OSX<N/^S\?GX>W>_BW+S6F_XJ;_
M`/(?IG](8/\`6?ZQ[/X![?YBWM\^//\`VGE\G/W;6\WX_+7_T+_'2E'2E'2E
M'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E'2E<W;Z;4-!KDI3[[5*W=ZE.-_A
M)JK6^#B[+7)AKZBG^&E(29:O8R0;^L@#Z%4CE[@`]NE*ATUK\?#Q<ZK(/9=M
MB$YE4K('55=.,ET*UUN/]U0AB%.RJ\N^L=-B2(B(&(DSCFZ/J*'<@@(@-+"I
M<F^VD)0_&(\;22R*JDKR2<D3534.V7U&M%1<$(<#&06,VSINX*DJ`>DPIJ$.
M`#^TP#V$%A5>;4\'$/![XP\'D6DY7^,%9N]B:>T))C8IBQZRD91'TBDN%7NL
MK*45!RFJ`G!5&*24`X]P-V*0"K"J<F/QJ5E@P8Q3)I&Q;)I&QS!NDT8Q[!LB
MS9,FJ!`30;-&K<B:#=NBF4"D(0H%*`=@#MU6HU]?2E-'YF<,\RYSY4UQC8;%
MH,104[''VE_&Y_+5^#=3<G$$6")+*2,Q5K&\*SCE7!U2)M3-@.H("J*@%*`;
M)U?M&?U+8MM-9!"V9P*`R!F"AO6P5U%S:US?QZ6K6.U]4U_<=:NIVL\ZX7N!
MR(F52Q7\-RR,;"]["WGUO2#RGBUQJYP%7HFP[5RPW/)JFG$),L8TO;G!<OE$
MJ\5B%>1L\!0Z_1GEH:09XU$[=!\Z7;E.3N8ANYN^7C^H.TQ9LC,UFJUV)L9.
M5YXH![HY7Y<&D:0(6N;E0#]]8:3Z<ZK+@Q\+:[;9YFLBXV@ER#[)XVX\UC6,
MN%L+!B1]U*SRMX'8_P`N\>K7'^ZSVA9]C%:28-R9SCDG5:56I9I!'A5*G'R;
M1U3ITZ,933PB8QK5B=FW2]PWN$5]*/M8[KO;]GUK9S[G%AAFVDE_YLP=V!;E
MS((=?+\OF+<B;>"/-\GV7IFK[/J\?29<T\&ICL/:@*1HP7CP!!1O$?$<`O$"
M_D'Q;C;7XZJ-<LOPO(IG?>3(U+CO9:E;<Z*VMV<)/0F\Z/&'S1:QF/E*K"R(
M9Y\I3^6(N6YDA.(J.BN52IJ$^K'[MEXNPV^RBT^!^9S8W26Z2VXR7]WC_.NO
MN7/(@W^"\1<'Y,GHN'EZ[3:N7=;#\K@R(\5GBORBM[7/^39Q%Q'`$6^+<C8C
MK^:?`[)>>6>U#+=OM>G-J349SZG)%4F9JT*:>LJ,?\KC)Z<>RM,GWA9"&8N'
MJ;<6)V*8DDG)52JE,F"?S=6[?LNH9N3L-3CXYRI4X7=7;BM[E5`=19B%)Y<O
MPK:WF_U=MZ9K.YX.+KMODY`Q(GY\8V1>3VL&8M&QNH+`<>(^=K@^+</JGC#X
MV;G@V9X1L3K3-$+C"94LFV*;MS1INU!(B1J@Q+"Z!`P4,1PFR9Q[1($WK-VD
MX%FW6<E7<(IK%^O7=^WNIW&?M]8L$'YK^^A5"<>3UORC9FM<DFZL".3!;*2*
M^/9?3S0;C2Z_3;5LB?\`*#^3.S@9$?I;C*JK>P`%F5@>*E@6`-);>_$S4-OK
M<%GG)SEQS$Y(Y-5IZ,L$)FFB7?-HV,>/HAJ\8,75PM%%RFJ:!:Y)%D^53^*/
M+-U1%50X]U#`<N0Q/J-DZF>7-T'6]9@[&1"K2QQRD@,02$229XT%P/'`CP!Z
M>*QV9],\7<8\.#V'L^US]9&X98I9(@"5!`+O'"DCFQ/GF#Y)]?-.?M7"^FVK
MD-E7(\VI[9!6C%XE2MY]3X*R5)//(FJ22-=;VVL+0\K19:;>QEZ;U=H2545D
MC/3@7NW7;B!!)@,?M.5CZ78Z/]/Q'Q\IN4CLK^X7'(H_(2!08RYX`+Q_B#>:
MV')ZGBY.\UN^_4LM,C$7A$BNGM*AXATXF-F(D"+S);E_"R^+>/S2\??'?GA"
MT6/VJ,GV$_FEE:V6CZ!17T3"WF`,1TU=2<&A*3$%8H]U6K"9BB#UFX:+$,9)
M-5(4ETR*EN=6[GN^H2Y;ZJ1##/&5DCD!:-O!`:RLI#+<\6!'J0;@D5:[9TC1
M=SAPTVT;K-CR!XY(RJR+Y!*W96!1K#DI4^@(L0#7U<O^!&`<U6U'>ZDVM]8T
M'+I7YWEFRY59E*1K&<ROQ3-\#NLV4C22:?PY"/0<I)O6CQ%!RB59(A%0]?4>
MM=PW/56RUU[12860O&6"9?<AE%B+.MP?0D$J5)!L21XJ7:.EZ3MJX;;%98\[
M&;E#/"_MS1&X-T>Q'J`0&5@"`0`?-(ZMXP:!H-EH=@Y3[]R+YB1N7SR5EHF=
M;C8J&AE,;8&1#)15BG*/FN>T)K=[`P0442%::6?-UT5E$E&XI*JD/DQW[,PH
M,R'KVFP=8^0G&22!9/>*GU59)9)#&I\&R!2"`0UP",6?IYA9V1A3]CW6?M8\
M=^<<60T?LAA^%FCBBC$C`7%Y"P()!6Q(*J[[PD:;+LD-R$IG(KD5QWUV%SEI
ME0S&.VBI%JUAI;.RS5I;1]OH=[I5SKL\NTD[$\.@N!$%4SG3,(F]HA>L?INU
MMJ]7+I<K28.;K7G,W&9'YJY54)22-T900JW'D'S]IK);KJ*[7:Q;S$WN?@[1
M(!#R@=.#1AV<!XY(Y%8@LUCX(\?8*Z?C7PPRWC19-,T:*G-`U/:MF>QCO4MS
MV.?C[1IEM;0;4C."@1=P\)6JY7ZO!MDRD:QT5&L6Q4R)%.4Y4&X)?/O>T;#>
MP8&#)##CZK%!$4$*E(D+&[-9F9F=CZL[,?6UKF_T:#J>NZ_D;#/BFGR=MED&
M;(G8/*X465;JJ*J*/`5$46L#?BMD:L?C-RNS<M&'-5YM')!KNL,+UC7Y6/N5
M$0@8"HO5)HIL_C8)3,ET3TY".L+MF1)R=P\]A7U&<F7`%NLI!WS8P=<?JJZO
M!.H:Q8%).3../\PM[OX[J&N++<?AMXK%3_3[6Y'9D[:^VSQN4N%(DC"JAY?R
M@OM?@LS+8W:Q_%R\TJW-+A'F7.S/H?*]BN&HPF?QLL,Z_K>=3U=K[6SRJ!V:
MD.[L+B8J5D?K&KRC90S,K59J3NZ5%8JW\+VL=U;M>?U'-EV&LQL=\QEXAI59
MB@\\@H5U'S7'*X/H+6\WR7;.HZ_N6#%K=KE9*82MR*1,JASXXEBR.?EL>-B!
MY-[^+>'H?CUX^;/QCK?%/<T[EM-#IB+,E/M5^GF1].K#B(9K1<!(P]RK,-6C
MH24%#K"S35.W.9VU`2/?B@.IZ[V%W3=:O?3]BU)BQ<R4GFD:GVGN;L&1F;PS
M?-:_@^4XV%K.=T?1[;KV/UO<"7+PH@.#R,/>0J+*5D14\JOR@V^8>'Y7-T:H
MGC#5I$<RI@\]?(%8,EB6#6(B<TD-MKL4DE"-B)D"`=WFK9]`:&$*FF3V44V$
MG'+(M0*A[IDP$#93+[\,MVROZ/TR;)F+&40,?F/[PC>1H^7Q)96!/FUZQ.']
M/#B1IB?UINWUBJ%6(Y"K\H_=,B1++Q^`"NI`\7M7?W+Q_DD-BTC:,GY9<KN/
MDWLDA7)#4JQFMNS^7HMA<UJL0M-92T56].S6_(U:T?3->9,_F#0X&!%LF04S
M$(0I?BQ>Y%-9@ZO8]<UV;%BJPB>5)%D4,[.06BECYIR9FXGXDF]R:^[+Z2)-
MKG[;6]EV6#-ELIF2)XFC8HBQA@DT4G!^"JO)?@`+6`KQO^%+Q`_E_P#L!]/7
M7V?N;]\_O)]<2O\`,!]^O5Z_O9]T/3\=]P?5^ON>Q\O[?M^%]/Z=7?\`$3LO
MZS^L^_%?V/8]CVQ^7_+_`.@]KT]O[K\O^%5K_#;J_P"B?HGL36_,?F/?]P_F
M?S/_`-Q[WK[OWVX_\&O_T;M.J\P^*&&6AI2=EY)8=EMQ>HLG256OFH4VL6!-
MC)'.1A*/8B7EVKZ-AW9DC^V\<$2:F]!OXG8INV<UW6>Q;?';+U>BR\C%!(YQ
MQ.ZW'J`0I!8?PBY^ZL#LNT]:T^0N)M=_AXV40#PDF1&L?0E68$*?XC8??2Z5
MRRURXP45::C/PEJK,ZS2D(2Q5R58SD%,,%P$47T5+QB[J/D&:P!^U5%0Y#?U
M#UB)X)\6:3'R87CG0V96!5E/V$&Q!^XBLQ!D094,>3BSI)CN+JRD,K`_$,"0
M1]X->WU:J]7*1=[I,Y;+90X6W5J6NU#:UM]=ZC&S<:^LE/:7%"2=5-Q9X5LY
M5D().RM8=TJQ%TFE\4DW.=/U%*(]?1)AY<6-C9DN-(N),6$;E2%<I8.$8BS<
M2P#6)L2`:^:/,Q)LG)PHLJ-LN$(9$#`N@>Y0NH-UYA25N!<`D5S<)L^6V34[
MQB4'=H:2U?-H.LV6\T=NHN,S6X.XIKK5N0?%.@1L*4FBW$X%34.=,ATS*%("
MJ0GORZO80:_$VLN*RZZ=V6.0_A9D_$!\?%_B//FU[&WSP[;73[+,U$.6C;+'
M1'DC'XE5[\"?AYM\#X\7M<74_KX*R-'2E'2E<E1[[1]-K$?=LXN%8OM.EEI1
MO%6NG3D99:W*+0DN_@9<D=-P[EY&OOETU%N6JPI*'`BZ!R"/J*(!].7AY>!D
M/BYV-)#E*`2CJ58<@&6ZL`1=2"+CT(-?-AYN'L,=,O`RHY\1B0'C8.AXL5:S
M*2#9@0;'U!%>'KNP9G@N=6?6=@N,30\[IS(K^PV:9,N+5FDLX19M&Z#5F@ZD
M923DGSA)NT9M$5W;QRJ1%!)14Y2#=UNLS]QG8^MUF*TV;*;*B^I\7)N;```$
MEB0%`))`%ZL[3::_2X&1L]IE+#@Q"[.WH/-@`!<DDD!54%F)``)(%)YQ]Y,U
M'D<WM#JJ4+=*.A6#PJ@*;7B>AXW]31=B))J0\_3"WZ$ACV:$=$B%A,JW`3(=
MT_>(G[J?J^W<Z')T9QUR,S$E,G+^XGCGXE;<E?VV;BPY#P?7S8FQKX=)V#%W
MRY#8V%F0K'Q_VC'E@YAK\6C]Q5YJ>)\CT\7`N*<9UA*SM'2E'2E'2E'2E'2E
M>-8YQM6*]/61XSF9%I7H:4G'4?7(.5LUA?-HEBN_79P-;@FC^<L$RY2;B1JQ
M9H+.W:YBI(IG4.4HW8(6R)X8%959V"@LP102;79F(55%_+,0`/)(%6IYEQX)
MLAU=E1"Q"JSL0HO944%F8V\*H+,?`!)I'N.O)++^4E%DM$R9S9UZ]#W*RY_*
MI6^F6>A3L=;:>X19V6'?5RWQD1-M',0_6%LL"B!?0X342'L=,X!D]WHMAU_+
MCPMBL8F:)9!P=)%*.+JP9"5(8>18^A!]"*Q6BW^N['AR9VL:0P)*\;<XWC8.
MALZE7"L"I\&X]01Z@TO76'K-4S9SY%.`;.Q_23KFQQ20L(++-5(Y3?\`+`,W
M?-W1V2T8[<?5'PC.63=IBG\(JH1SZP[`3OTJMC]E.S;ST&\@TK,RF(Q[7%XP
M)IO/,GS9W$.8@S;XPDHVD6RBK1Q'G:?Q2K$.9,R?[@$0_7I5*XW(=>S;>\WJ
MNNY!;(^\YO=F3B0JUKBTGJ#&89M)!Y%.5D$9%JR?)>Q(QZR)BJI$,!TQ#MTI
MZ>*4CI2CI2CI2CI2CI2CI2CI2CI2CI2FW<HN5>4</LY-K.TIW]M0&KT&DS8J
M1F-\TAE5D3)&.66N!Z/`S@5.`,J!4`?R'P[0SE5-$%!44(455`OXIQ+1R1XU
M;.TTW")'3=%R1)VW69NDB+IE5*FY:.2)N&K@@&['34*4Y#`)3``@(=*I28:_
MN.38'`P%GV&\0]"@;1=ZMG%?DIGXL496[W5\,=6:\V(R:NUA=R;DAOW"4$D4
MDSJJG(D0YRJ4J_2E'2E'2E'2E'2E?__2GBS_`)>\,*;S#\H>B\CKWGSJPR.N
M9QQ]I&42<:GH6C6&N8-ES>OR\12\S91\Y8I9M:="MTLB8$&OL.G93IJF`K<1
M)VG-ZUVG*ZST#"T>',(5QI<B28'VXE;(E+*7E)504C1#Y-P+$?B\\.P>T=3Q
M.T_43/WV;`9VRHL:.$CW967&A"LL<0#,P>5W'@69K@_A\?9Q+O&]\:,UHO%'
M&\4@:YR0Y3:AR+Y443%]7?2D=GG"GBK9+^HYK2FN1M765L1#MUWK=E'5N-52
M<+2[U=NY=,E&ZH##L>)I]]G9?8MIM7?1Z_'QL22>$`R9V6L=F]DO\OFQ9I6!
M`10RJX(J?6<S==?U^'UK5:A(]]LLC*S(X)B1%@8;273W@GS>"0JQ(02[,K,A
M4TZ?$-PYL2G+GD1Q0O>E\9K\_P`SXS0>F1MWJ.):%5&-)V32Y^289M5+?"K[
ME/+S]18UV%5EI!FDYCY)\@[0*@^;>@YU-?VVIZK'UO2=BP\#/A2?/:(QO/&Y
MD@B4&5T;V%XN68(K$,JD&Z-<`;'J-QVV3L^]ZUF;#7S/CZ]91(F/*@CGE8B)
M'4Y#<D"J7905=@P"NMB2AGCIB.8%]W7FIR&D-*XTN86Z\MIC']*598II_P`=
M<8WB]4(3*(N6R:2/R`5CZC6E'R;Q-)"21GSG7277!P)7!2)9;NTO6</4=5TJ
M8&>)8M:LT5YXK(<IVF(F'Y>[M:Q)4Q^"!Q^4DX?HD7:,W<]MWDFPUYBFV;02
MVQYKN,1%A#0G\S9$OR`#"3R&;E\UAWV9\[[9FN+<\N1G):%Q:R2/'+D/-\:Z
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MYK\\]*YE<H.#V;1?&JQ63'Y*B.$=W#.-3K]`RJE66L#:)I[?J^YURU.="T%1
M2=C(:!B8Y[#(.Y!E*O':B#-J1)6<_5>GX'5]!VS.DST@R5D'Y?W8FDF=7X*(
MV$*"./Y6>1V5R%:-5!9B1;Q^V]SV':^Q=/P(]?)D8K1G\Q[4RQPQNG-C(IF<
MRR_,D<:*T89ED=B$4`^PES)Y;SW`#E5M1Y_`JMK'$W4^4N;76Y#G=^GJ)J5;
MX]M;%%ISF8UMCJE9DZG:KC/I-$F3MY+2<<V605];4Q52@WMGK'6X>Y=>U0AS
M)-=L<?$E1/<C62)LDJ>,K&%@Z(MRP5%8@BS>/FNCM79YND]DVQFPH]GK,G,B
MD?VI&CF3&##E$@F0H[MQ"LSNH(-U\_*XOQ>8UO\`A7%;$L]U&RXT^HL/C5$7
MI=:S_.+E5KK7Y>PL@M-D3OMKG=2M]?MC\'\TH51:.AH8BSKW%@(4I@2#"=_V
MFFV_8=KFZ^#*&6V5)S:25'1@IX+[:+$C(+*+!G>PL/OK._3O5;O3=;U&#L<C
M$.&F)&8TCBD2168<W]QVF=7-V-RL:7-S8#Q39?(Q#\G=.Y>\%./=2N6!-J+<
M-KG^0E$B+=E6AS[^$E.*N8FLKB0UR1A]HK3"\5)Y>;BT^7Q<:PAU2.Q9J+.E
M2ME05SW2)=!@=:[=NLG%S#EQ8JXTC)-&H89<O$"$-`QC<1H>3LSBW(!1R%M>
M[W%V'8=HZ;H\7+PAARY;9,:O#*Q4X</,F8K.@D0R2+Q150\N!+$*;K*7D+S3
MUK6[=Q;PE_QV1O?'V$K)^4?)JS9]H9LI87R]LW-EJ678QC[;2G\[+V-G4CLW
M$V[D[:JVCO=,0R95SI(]8O\`1>K:W6XW8-NF:</-=_RF*DD?O&.,A7EGF,05
M5+W"!806M>]@366&\[9L]GE=<TSX(S,%$_.9;Q2^R))`72&"`2EF8)Q,C/,0
MMR+7(%<Q5O(S?,;S[F['\OJS3)C7N$-JSFJ*K8@G-Q]>WQSN%6B+#AD=4JY8
MW4_-UNY7!:;:,Y%I[[]NQ75.L0113.4GT9'2,/:9O5'ZUD2KK=M'*_\`/XEL
M<0.5R"[*%5D3B64V4L``?)%_GQN]YNJP>WIVC'B?::>2)/\`5^07).0BMCA$
M8LR2/R566[!2;CP"`X/*6'DQL$O6+IK-QXCY_6I^-E'=AQ2!S'3+E9<_&0K\
MLXJ\<;4ONW!1=SLD#831R,T9&+81KE$'@,S%[-U3878OT.&+(Q==B[*:=&`6
M=I8D62S`.?:]EBBLO(I=V8'CR_>%9O6I]0)Y<?+V>5K(,=U);'6*61XKJQ0>
M][RB1U;B)+(J$<^'[IHX*<F-/VS%MGT[D#(Y2@US3?\`=<XA+KF56ME%I%AS
M3%9)&LN;ZO%76]Z')MOF,_#3#@5`D/:39$13%,JJ:ICNW:'`U6UU>!IDR"T^
M'CRLDKI)(LLXY".Z1Q@V5D'X;EKF]B+.F]@V.WU.VV&[?&"X^;D1+)$CQQM%
M`>!DM))*1=E<WY6"V%K@W:L\\CFWM?'SQFY.2%5R"L:GRRW&O9349"U)6R'Q
M#(:SI=YOK3/=&U17ZB>SZT+'9_5V2\D=.08(.)9^0B9VZ)BAUL*]'U+=SWV@
M3(R9-?KL1IG"<&GF:*.,R10_*%Y&1V"W5B$4DAC6N/WS;KTCK_89,;%CV.SS
M%A0OS7'@262012S?,6XB)%+V9078`%13F-&WW:>%G&B\:GR<M.<\A-"7MU9J
MV,UG'Z3(8NG>[=?CP=:I.<JA:;UHS=!U(7!TNLO+`L";:)*HN9N<R/MC@<'3
MZKM.^Q-?H,>?"PA&SSM-()_;2/DTDOR1Q&P0`!+7+V'(7O6P9^ZVW4NOYFR[
M#DP9V<942!((S![CR<4CB^>24`ER27O8)=N)M:FY93S*Y0H\P\%P*_:;P[WQ
MKL=9TB?UJD<8XRW'L7%-I3*J6?@K%9[L^T*Y1,_4)V67;PYEY9C7W3Y\[3.Q
M1$H>R?.;'J^@/6=QN,/`V>&V+)$L,F44XY9=^+*L8C0JZB[V1I`J@AS\1@=;
MVOL0[3I=+F[#59JY4<K31X@?EAB-.2L\AED5D9B$NZQ%F8%!\#ZK[EERWY`9
M=J7)OCK/<?<$XCYTST>5I^D[12KIJ-_VNN94691LNBQ=>@KOG5:S_,I1W"/"
MQ!W3B3E)!)L5R8C5%0J:EM.N=;TVPU^AW<.;F=DG,0>*!TBC@:;CQB+,DC22
M@,.=@J*3Q!8BXN/V;L^[UVQ[#HIL'"ZQ`)626>.2:3(6'ESE"K)$D41*MPN7
M=@.1"@@%<_$U3I:H>/7C2XL(%/9M%J,KMUC=^T9)5_+;K;+!KQW:X'.HH906
MES2(`F,(@F0H?H```8CZC94>3W3>K#_<02"!1]@QT6&W^5#_`&UF/IIBRXO1
M^OM/_M$\1R&/VMD.T]S_`&2`?L%.RY$Z>CB6`;ALCA1)-+*,BT?1Q,L!#)B:
ME4^8L::8D.`E5,JI'`4I.P^LP@4`$1[=:36]CR13+_'/Q7S.M^.;BGFVCYA2
M+:M-X-3K/?(F\5&OV@)*Q:?&_<.WL;`E-L9%*55+.VUTDM[HJD.("`=R]NJ5
M(DW/FHX<;TS1.%O%WRX?RS3>=LLGX3\J]1=XW6=AKMMTJCQE?0S6M72[X#6&
MM<TN@3%=;L=$L*39@Y4E'Y&2CU?WF*BJHB#[:J?)6_QIY&E<F^1M-N7!#AYE
M;+C=@&M\BL+G=(N=\OM'LJ^25NSTJ$I[FT9;AF6PUVJKJ>MDA9[,Y<%8O9P3
M1T.D"A_BUU/655+#R?A2L;OR>Y$8%!<:^.4#&9AR`YY<CY*U0U<7;1-@S/$(
M&OTA(\U>=HO$&%AMUIB:-1:_(,$U8UO)F?S3Y0R;-4AA]LB@`-S\*YG2.0?,
M'AKGDG8.0TUB/)W1-;OF<8WQ/RK"LVMV,S5MVZ_N[$D:LVV;N>FZ/%L:'$Q<
M:E)+2@)D69L6KY1?U>A`IU+`^E<7;^07D,XIZ'Q>FN44EQ4U#(^2?(+..-5H
MK.)4G2J/;L=ONPB]CZ)-UVT7.^6AGHE.86!H+:4,ZC8Y\HF=)5%)(IE?:>:6
M!O:E2QKGXLGC7/G5^3+>HU!MP>Y)<@<MF@IS*3BQGLYS>-KUGS6;3B+%8IU\
MO:K_`%VT,VZ`)K)-Y"3/[;9(@"!>E"/2WQIMC+GSRP"!P'#["EQXS+EMM66V
M'E!J]GV$\M7,:XB\>)VY+QN;PUQA1M,#-:/L+YN^1B$(U.2A2'DF+M=SZ6S=
M1112P]?A7]S+GUR9MG%GR!::SNW&6\K\,)F?=YYRFKN9Z$_XX<A:K3,_3T"]
M14%3HW8&4TO::PJW7A5)"(LSZ)4D'#<6Y'9"F.NI87%)C6N=OD]MG`70_(F-
M&XP4^E5KC_%:%G^02]&TZ6L&BO:Y(U9WJ&I2CY+4HEQ3LXDZVTLCBJQOO/)%
M5D6/>/%!*8Z2SS5;+>U/_P"5?+FV0<+P]HW&A>!?[1S5U"@,\Z&QQBDTPKN*
M1L:RU#;=1EH%-Y'+2$75,P;BV,0JZ*A7DLW$A@$HB%:B!ZW]!3B.6?)FI\2<
M0LFR6F'F+8Z9OH"J4;/ZT"9K3IFEW:8:5J@Y[64U"J`,I9K%((I&5]"@-&P+
M.3$,1$P=*`7-JA9YW$\@=_I/%S'>2UWXP5.H\R^6/'3*;3QWR*@W:8O=9J[*
M_,-?M`+[+8M&>15H&G0.?E1G7+.MM8UXHH""/I17*=6E2%O-OA3C.<'.#FI@
MW-K`^+/'6F81L*O)FF7:2I%2L])T6'LN?25981<>G<M%TN)U=6!>9U'2J\G-
MR)&E7;/0BH8T>BH9V[3>(JH`""37=7[5>7V<\CO'CQSUF:XH;"7D+/:@[T@R
M&'7N+GH1[A4#9]+E-(SF2D=EDH*NMXV%?UJ)9I.X5ZZ;2RRKCXHX.$D4E/%B
M:[[&N?0IY'SXU'DT2ITYCP>Y*;YE\VM3XZ4C?GF99['U^SYG/EAYVRV%TYM]
M\K5H:()HI.4T7LH?VFZ2?J*7I0CTM\:;`PY^<L@KG'_$;`GQVS?EQMV7V;E#
MJ%IV!67KV*\1^.T_<G;+,(:YQ:5B@9C0]=?LGK>';QQ)"'(:28NUG(_#MSJK
M*6'G[*^G,N?7)>V<7_()IC2[\9KP'#";G76=<JZ[F6@R'';D-4Z90BZ!?(N#
MH\;L3*75M57%NK"G?Q%J?1*LBX0^'*Z3(*CA2PN*1%?R.>1R=X05_P`A,;GW
M'.B9)76.+)/<ULU3T!W?>1\Q=+S1\XO<UG;LNC$99!17ERM*[*E?-?G3Z70;
M)R#HR+5V@3IYJMA>U6..JU"O_].W5XT\)MV2<<&DULM"1IN_:IJ>Z;1J;*0^
M125@C;!JFL6VQ-&#J;AG<JV6.G4EHTBA472B?K`W?L/<`W7O>WQMEO&BU>89
M=-CX^/!$1R"E8H44D*P!_'RM<#Q6C=`TV5K-"LVUPA%N\G)R)Y@>)8--,[`%
ME)'X.%[$TBFQ#R(POR'7?>J'Q5T3DG7->XG9WCN?2E`L=*B(VGZ!2M.N5@D:
M[I$K=;+!I42E3#>UMWJLJBVD?29+^$@J?XD$LKK/T3;]*Q-/F=A@P9\;8R32
M"17)>-XD4-$$5O<=>!4(2OKY('&^(VOZ[IN\YFZPNMS["#*UD4$1C>-0DD<L
MC%93(Z^W&P<,7`;T\`GE;EO&+B_)?(.0W.FS\I*%;WFC\@+W3[NZW)H2E$Q^
MRQ=&KS>$C:72TD;U(Z*T80$O;99O`HOX5%(M=C43KN2.C_#C]'?MIH=EI>HP
M=?S(A@X4+QB`\_>4R,6+O_+$1+!$,A5R?=8@*5'*OG^GFI[!J]YW'(['A2G/
MSIDD.0/;]AQ&H41Q_P`PR@*SN(PT8'M("6#'C7<>*`VTY?@K'CKMG&C8LST+
M.7FM7'0],L9:`OF>C7>^[';;B*.:S,->I>S6@\@RL9U`6=1K1NV0:D3,X5$Z
M1S_)]1?TK8;A]WJM]C3X4XA2.)?<]V*..%$_FJT:JEBMK!B223Q%B!]GTU_5
MM=I4T6WZ_E8^=`9GEE;V_:EDDG=_Y3+(SO<->Y4```<C<$M$L_"KD))^+_$J
MW9<1+HVT17,2)YC\C^.3N=K@.=4B9;=[G?K]ERLC(OR5.8>.*?8FB"B2ZZB#
MLK(P)@HL*21MDQ^U:6/O^UG@VWL:MM8<+&R0K6B(QTCCEL!S4<U)!`N.7FPN
M:U?(ZEO)/IYJ,?(U'O[9=J,[*Q2R7F5LB222&Y/!B490020W'Q<V%25<.)RG
M*RUDK^7>.R]<**(VABO7\];LVX_8\VLMB+)(@UKT;3<AO%KEY8OP3YR\-(+I
M(M$CD.D)O=4+ZM%[/#DB.";8=VAVN86L%27(F*K;RQ>:-`/("\023X/H*W_J
MLV*9<B#7=%FU&$$N6>+&@#M?PHC@D=F\$MR("BQ'J:YS@5B5XR.#Y;;+I>>O
MH#7>1G*3;];=0*[V'?61?.XN=?P&*U=1[&R3^,*FC48P%VB9ENZ9Y0XG]`F$
MI;_<-KB;*7K>KP,T/K<'7P0AK,%]PJ&G>Q`/XS8FWG@+7JQTO49FKA[-M=A@
ME-GG['(F*DJ7]H,5@2X)'X!=1?QS-[7IET]Q,Y&1WA#F./Y,ZF)_D??B-KYK
M.>Q$Q"L+/-2&A\F&&L['7&$G\W5A7,Q]"R4A'I%!^'ND3*0BAU?20^TP]CTC
M_5>+<G-5-'#>.&1E8HHCQ3#"Q''D%]P*Q^7Q>Y`'D:E/UG?1_2&72#!=]]-:
M2:)64.QERQ-.H/+B6]LLH^;S:P)/@S(8;I,EJV?L;;)8[IN%&4>/(QIGVN1E
M4A;HR918IM4GKF)IMIN,,PC7:A3@T*#T5#H$*<R:8'`H<QVV"FNS7QDV>/E^
M`3)"79"3YL"Z(Q(^/RVOXN:ZKI\^398294FJR,/R0(IPBR`#Q<K&[J`?W?FO
M;S87ICD8!=,\P%H?%!5_"<6>#E=KPE.(?#P>E\C]6DIY=PD4JHB5T\SG+VZ9
M1$H>I-94#!^Q,W6V2?ZA]-,=/278;9F^]HL:$+;]@EE)_L'VFM/C_P"\/JCD
MO^*'6Z=5^Y9<J8M?]IBA`_83]@I(,UE^2O";:>:==+PVV;D?7N17).R<B\9T
MS')O*C0C[ZYI=*A7F>Z:[OF@5.3SEK2I"L$;H/%6SQ%8BRRB*7M$**F2SH]%
MVK5=6G_J?%P9L'!7&GBF6;D/;=V$D0CC<2EP]RH*D6`)N?&+U\O8.H[;ML']
M*Y>?!G[!\J"6!H>)]R.-3%*9)4,0C*6#$,#<D"P\I%IW!KE0;`+!NLE5*WJ7
M+V[<[<)YOZOB=9MK-E79FD8E*1L94.-E8NUC&+C)1&ET*/0`'CTHI.7J:Y4"
MJ_V;UY/`[;U[]9AU$>1)C]:BU&1@0SLA++)."7RG1;D<Y"?E7R%M>WS6Q>QZ
M?V3]$GW,F-'D]HFW./L)L='`5H\<@)BI(]@?;C`^9O!8-QO\MY6\$Y`Z'N+B
MRC-\5MWX\P\1%,5(>;W<,PC5[%/.#N$WT5'U>BZ3=9])G%E(FI\8Y*V1<D.)
M2"4Y?3USO<:;"U*P>UV'#S968\EQ_=/%1Z$O)%&MSY'$7(^/BNE:7=YVX;(]
M[K>;@Q*HXMD>R"S&]P$CED:P\'D;`_#S4$S'-O(/(^,20X#9SQ:T_,K[7*+K
M3+==9N-BS0D=J,G9+C<+5(4G`_E-U<O;4[VJ?LH$DYJ50BHZ&@E'Y"_%N%&G
MJZX^=TQ._)W'.[!CSX;S0G'A19;Q!41`^1=`$$"K=40NSR!#\JAJXVFO[P_T
M\?I6!US(Q\V.&89$TC16F+N[F/&XR$N9V>SR.$1(RX')BM2'M+&GG7"GCMQO
MO'COY-[=5I#"XW)[5E3:I858@K[C,(JNTJ/+I8O]I+5XQ&[.F9Y6.D&4@_=-
MTDP<JE0<_M)I;0'-[5N]YB=UP,3(7+,R3%\A>0E+.?:M!S/M@\&5E4$GB+KZ
M[RLXP>I:+09G1MAF8S88A>$)CMQ,(6,>[>?@/<(YJRLQ`'(\6]&D7O@]R)B_
M'[Q"H-\R%7D*KQ]YBP^^WCBL^N$%H<LTXX-W.K1\-AD3:;?)LH/3Y_,J==V#
M<K1P]&/>BV5:H'<H)-@5V/$[9I).Y]ES,/9_DAFZQL>/+"-&#DVA+3E$!:)9
M7C8W"\EN&(4EK:QF]/WL?2.KX6;J_P`\<':KDR89=96&*#,%QU=R%F:))%'$
MMQ:Q52RA;R#X6A%W?+-OSG'N!5OX0UR8SJ>AZXXNM(PK(6EIN%AB)Z**V0I^
M,72XR31M#G707-(ND4TS@L8$@$Y!`VF;<R8FPU.=L^X1;:=9U9@DF1,4164W
MYSH@);R.()]//@UO&F6/,UNWP-5TN73P/`RJ9(\>`.[*PMP@D<@+X/(@>OCR
M*B5TV@^0K7/%U6>$>5\1-*Q5UDV'4+.]B?VNQYTSG=ILU96A*TO2<11CKY*H
M/*E990!L=CG)->.;&B&SN-:(K'<IB;H^!F=+UOU`G[7L>RP92Y.7))"$60K`
MK<F]R>\8LZC^5%&@8\RLC$!37,MAA=XV?TZQ^HZWJ^1B-C8<<4Y=X@T[H50Q
MX]I""CG^;+(Y4<`T:@EA4V^9:1H]5?\`%+&Z[Q1U"`RNP93.,+=>[A/9W#/,
M!-F-?915*JETJ%1L%VC)62NY61$D/E<PLDT!5(0]XI7(->4Y^#@Y"=BVD_8L
M=]BF0I2-%D89'NL2[H[K&0([W/-`38^GR\NNZ_/S\9^M:J#K60FM?&8/([1*
M<;VE`C21$:0,9+6'!R%N/7YN*=>6&B;#JO`3?LKPFE6._P"BZ7&5*EMJY574
M"SF5ZM,7RL%T-9LXLLC%0Y3I9\E)@0JJY/=5,0@?J;K5C6VK:XO2=R');F[I
MU48Y]Q-X":#@[M>'0KK+6^9MHRBCT;*FR+<8YI*-,OS30=7T31G$4@V$6C(J
M,>V4,1,7"Q4C`52E5L/B:2S=?'[:*?X^:=PER9K/[-*;-R4QR4Y2:E-N(6/G
MK9'VS<Z]JO(W;;D63E&X+M9!.!40.Q;*/GH1RB+0A7(D,<RE_-ZZ'R9MIKD;
M4M!XGPO`'<]ROBT0S=X;R"14R^CY!F.F2T.W=PFF1>QS.B1U_I4IFDFJ1P[+
M'PBZDB9F9B`+)KF*(T'CS>N.T;..5'&;E-P[Y22.3:%S:A:%P9><3-R=Y,[J
M+S5(C4U9ZD6J2VR`J^@6FDIVDFA2M<5:.O:<MU6K9191P8O=)-13P01Z>:Z'
ME<ER:V&.X0\OJEQ&U!*:XQ\D[)?+IQ>G[1E/WCF\ML=!M-"&Z0)8B^2U$6MT
M,C+)O6T">4!\<R@IB=(Q3"*@L+B]=,6L<@>?7(;`+YJ&"7KB]Q/XK7YON==I
MVT/*0;:MUWZ*A9B"H#][4J#;+I&9W0LF/,NY$%'<FLZF'ZJ`$;E3(95%3P`?
M/FD'M7!/>M*\E&R15CKH1_CXTS1,(Y@:$[5EXE5IJ6PXKG,)1ZUC:L$W=&FU
M*\]T"%C[=-IOD#Q[LL&DB!BBJ0@OC2XX_?7Z\D,))3/(EJG(W:/'9.<\L<U/
M#L<JF9S%*H&*;-8\AO6:R=J/:(UU0MEM]22KZ-E;S#5V669F/^K=-),XG.X*
MFJH/BP-C3C^9U#V?DKXUK!CN7<?;)B=VVUWG^9.<B?2&:)S.3Y7*[+`1EUG)
M+Z(LTM0$$T<@8O)'X%C(.#M0=D;G(=PFHW%5!X/K3J>554H-9X-<CJ*JWC*I
MF$%Q2UVGF9I(%"(KM%CLCL$(#-%J8%`&/BH%($R)=C=TR`7L/5:H/45%WX7L
MUT#9*7EG.?;X:6B7$'Q/Q#B9Q;K-B`AGT1E.;4JL,]9UY1`QU0))[OK4.Z<Q
M[LQ$79JTQ:]S*-W1.J"I-X\"G?>4'/-9MU(XH7W)\SL^Q*<<><^!\B;_`)M2
M'$&6Z6;.*"RO,=-)U*-L<O!0U@L,5+V6/?MF2SM`IU&ON>XF*7N$J:B/C^RF
M*6JF<VMQ\E/"KF+KG%[6(/COEGW8B,ZQ>%F,EG+=D9;M66M+BM;W9)UI45$-
M+3<G]B5DWT9`.YI:N1%88H@5X^<."DI\:EXXD`^:D)I&$WN=\H&\<G[[3UH^
MDT;B_C7'OC]97KN*=-+`6Q6FZZ;LLG#1S9\Y?Q+V*F5(J-7<N4&RSA(132,H
MB4W:M1OX`KT)O(]-N'E"HFRS%9=)8;B?#.Z5>E6I9>-%L_W#8]8@36V.9-`?
M*RB7R;-<^9^ZJ9JDFJ9^4I51]LY!4^'WWIC=LX*;YI7DMV2-L%;;L?'QJ-]P
M+ESI+Q:0A?9T_8,/SN)I%8QL89JZ5FW->?:!"1ENFB/FP,780P(^YW6*0]/C
M5;CC]]?ZY)X,G3/(KI_)'9?'E8>>6-ZEA.05+-Y*E9]A^R3V17[.)>SGLK!U
M1-EMU5&!2L#.4:NDY=DIZ>Z8(E$YS+`DJH/BP-C3D.9-&V7DMXTK+D.9<>;3
MBMXVIS1\Q4QUQ(9FE-Y9E\EM$%$7";DS5&RR&?M44\?8.Y3X%B_<BW^+(V,4
MZY%$^GPJ@\-ZUUO-_CC9]"SGA;QWQS/0<Y%5.67&J1U&-CUX:/KM+XZX+\=<
M#1[AH_?M%G;%:6J,'%MVK5%=3TJB;TE`@=U`?4FN]_F>Y.?SA?8#^1*__P`O
M_P`Z^6?S>?=*F?2GP?VU^LOG'V\^6?/?@OJK^X>WQ_J][^+_`.]_LG5:I86O
M?S7_U+_'2E'2E'2E'2E'2E'2E'2E'2E-!YJ_SI?:R`_D4^TWW>^X4/\`/_O+
M\3])_;GY#9_G7L?!_P!I^;_4/RKV_1^[V/>[=;+U7^EOU";^KOS/Z;[+<?8M
MS]WDG'U\<>/._P!]JU?MO]6?IT']&_EOU3WUY>_?A[7%^7IYY<N%ONO35O%A
M[GIY4_>+ZL_GJ^\4#_.7]:_2GQ/SCZ#A_L]]O?HO^Y/L7]NO3]+=_P"U?_.>
M]^O;K8?J#:_7OTSV_P"D?RK?DN'.W'W&][W.?S?F/=_O?A^&U:W].+__`))^
MJ^[_`%E^:7\][G"_+VU]CVO;^7\O[7]S\?QWJ6?KG-=,HZ4HZ4HZ4HZ4HZ4H
MZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4HZ4JN%S^_F]^\UQ_GF^H/^#?]
M?P'U1_+S]-?6GTQZ8'Y%_,7\O_\`RE]COK/U_/\`Z?\`[7\)Z?=_9Z.J?YJF
M+?#\56'JG]+?2U:^AOD'T3\@AOH_Z3^7?2WTM\N;?3_TU\G_`+I^0?*?9^#^
D%_LWPWH]O]GIZK4*]_I2CI2CI2CI2CI2CI2CI2CI2CI2O__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g693329g57y14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329g57y14.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0OV4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````#H````I@````&`&<`-0`W
M`'D`,0`T`````0`````````````````````````!``````````````*8```#
MH``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"5H````!````4````'``
M``#P``!I````"3X`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!P`%`#`2(``A$!`Q$!_]T`!``%_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P`O2?KWU_&>/V@UG4*[`#M+&T6ZC]&YEE3?2V_\95_UQ>@T9#<G&IR6
M`M9>QMC6NT<`X;MKHGW-7`=*^HG53DQG-KQZ&B7?I/4(<[71M?TW_P`C>RE=
MU74W'QV5,>_;4T#U#!<8_/<(]/\`Z"E('U8VOUO)&+A#(.K&6-#V]W!WL<QO
M\OW>U<YT9CV?63'KL).VQQ:#(,!CO3<YI^C^C<MNWJV$RM^3=[K,9QJN+`2/
M:=S'4UN/Y^[=_P`':N8Z-=;F_7'&S;'O>[UGUN<X1!;5;MIEOL]K/W/T:>+$
M2*Z%80#(&WTM)))5V=22222E))))*?_0M==Z]]8,/JF+<S)%>-E5M9_-![6W
MC]':-GM_GJ_3=[W?O^FMCI575>HF;\FK>"',(KLF1^_&0-VW_1I#%Q<FL.R&
MLMJ>TL=78`6N!.YOM_>;^\C8F!3AMV8SK:ZN-AM>YH'[GN<7_P!G>I,F/+Q@
MX\G#']*)%_XK'"4>$B4>(]#;F=5I;BWOQ18RZZEX+K*V.8WW@O>Q_J6W[K&O
M+?>SV?F?SB%T'$KLZ_A7,W--5CG.:#[=:[&^[_.5CJV&_P!9CF>UFV&O&@$'
M1O\`45GH'3MG4\:]QX+B&P0)+'-W*<CT'KHQ#Y]--7M$DDE4;*DDDDE*2222
M4__1W&9VYS:O2;J1+X&[B3[D=F?5:=NP-#'$[A]+;!L:.?SMJRV]/ZH?^TSR
M/(M_\DCOPNIMMW'&=`B)+8(']I7+CW'VM8<0W!^QNEWJ;VD>F+3MO=+G1[:W
M:?N-_-6CTRPOS*XTK:2QK8(^@'5SO/TO:S\Q9./3FAQ-]#SO(DR`/F`_Z*TN
MCLM&95NK<TESG.!(X@R[;N=^<Y,E5'4;=U\=QH7I4DDE69E))))*4DDDDI__
MTB.ZEU$XUF72=U+`2(+2(:8=[BWZ3?ZJLMZYF578ME+7,HR:ZW;_`-&XZU^I
M:?2V6;=KV/4.G8^&[I;/M-'\W4'Y#6[2194#Z[_3=NJ==^CWO_EK(9FU96:T
M"Y^/C.I=;5:&GVXX>U[*6T4FO:[:[W_I/^#3#=@6=680!ADD(_S9ZG7AGZ(C
M;]&7Z3KU]6MRB;+;&M<26O8?T0Y_1ZLK8RS^NQJL?5W+;9]8<2L9`<[W%U4.
MW?1<)W[6L=6L6ZR]SK_LV<RYP=H<H"MS7$_H_3JR+6-;CTL:UE/J66>LMCZM
MA]75NGU%KO2<YSF/@;737ZGMM9OK=OM?>_\`0N]/T_22HC6RL`$C0'0G\.)]
M%2223UBDDDDE*22224__T\;)Z9;F=6MPJ>K8S\I]9=6;B^MPGW^@'>FZG=?Z
MKOYJVS^6KN=]6LW"8+Z:7'#R'5MOH87W68X:-ESV9-;;*OLO^A]3W_Z5>D.N
MN@CU'1\2JN5DY;&M-=SFN+@"9)T@_P`I31QD$$&BPG*#H1OXH.GY=M_57=,K
MQ:STRM@%&;7>7.],-8VL6XUK';_4W;?49:L'ZO==KS>N8M<!E->==7BULTK#
M37>WTV,VM97L:SU?8MYN5E/J:YUK]QF8<X<%S?%&Z=DY+^I8['VV.:2Z6EQ(
M^@_\V4#AT)OQ_P`7U+H9ZEMO<?\`PR/M_P#=/2)))*)D4DDDDI22222G_]3N
M'*MD\#^M_`IG93O6MJ=;15Z9&UKS[BUS=[7F;*O^I53-R;/T#:[:W;\BNLOJ
M`=[7,N>X>YUK/\&K$IB$3([1!)_P6H!9KNR=_1X^/_5HO1_Z?B_%_P#U-BI8
ME[K>E4WWO`<ZLOM?HUH]SI=^ZUNBN=%<UV?B%C@YI+BUPU!!;9J$^[@3_5*1
M\P'B]8DDDJC:4DDN;M^N=++6@XXKQWV74B^ZUK-ME&XO;?2UMMU#7-HR=FYG
MJ>MZ%==3_7]2I`6IZ1)<Y3]<Z+K*:F8EGJ7ANQALJ!W$.>^MVZQNW]&QWHO?
M^CN_F_T5BTNB=99UC&?>REU`::X:\@DMMIHS:G^W_@LIC/\`C&6)*?_5L=8?
M7_SBS`Z-S\;&+08D[6V[E0^K3PW$M@`1U=A\.:KW=EJ]2P/6ZO9E@`N=36P%
MP)(V[]VQP^CN:[WK/Q.C9-6*^MMGL?E>N]A$$NVN;4YCY^C7+TI8)2R9=*$Q
M5_X/"T,1`RSEW$/P1=2ZR_&^KV%TW':7YN;2Z3'\W4+;!ZD?Z2W;Z=?_`%RQ
M;7U&ZC=EY&-1E",K'+@XQ&]I;9%G]?=]/_K:Q,CI64;<2T.'J45&M@#26BHN
M<X56.<=[[-[GOWK:^J&.^GKC;+A-MGM!&C0QK+/8UO[^_P!SW*YPUCEJ=JK]
M'AX?^DS`@RCH-[XOTOFV_NOH:9P):0TPXC0\P4Z2IMEK"K/C6]A/CZ9'_HQ0
M?AW6.<Y[Z2X["'>C)FMV^MSMUCMVS_!_Z-7$D;53GGI;C<^XFGU;.;!6X.!F
MK=M_3^W?]GKW[?I^E1ZGJ>DB5]/;)-Y%A_-+=[8[Z[K;-RN)(6I__]DX0DE-
M!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O
M`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#``
M```!`#A"24T$!@``````!P`(``$``0$`_^X`#D%D;V)E`&1``````?_;`(0`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("
M`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@#
MH`*8`P$1``(1`0,1`?_=``0`4__$`0,``0``!P$!`0$````````````#!`4&
M!P@)"@(!"P$!``$%`0$!`0````````````,!`@0%!@<("0H0``$#!`$"!`,$
M!@0(!P<")P$"`P0`$04&!R$2,4$3"%$B%&%Q@0F1H;$R(Q7!0A8*\-%2<C,D
MMA?A\6(E=28X@I*BLD,T1!A3<[,U155E1E8G-]+B8Z-4A#9V&<*#D\/3E*2%
ME;7%9J9'*%=G=W@Y$0`!`P($`@4(!0@$#0(%`@<!``(#$00A,1(%009187$B
M$X&1H;'!,A0'\-%"<B/A4F*2LC,5-F,D%@CQ@J+"TD-3<[,T)355DT6#H\-$
M5-,F">+C9+07)__:``P#`0`"$0,1`#\`]LLB%-R(M(_@L>*66QVH`\^\]>_H
M/L%ZZ=KXXJ:<7+B^[2BE7<0TTGL"$@#HJR2!;J!8V`_JGPJ\3.=B2KA3%85Y
M$U;ZZ(XXP@)E,*+T=Q/1:'VN]:2%#P%;[;+K0X-<>Z<_*L2[@#V&@QX+)'#>
MUKS6"&(GDHR>''IEMP$.*BW"0+?&.X>WX!"DUI]]L_`N/'C_`'3_`%_ES[:J
M6TE\1FEWOM69A6E:0*U65BOPD&KJ@TZ5:2OPBXZ_JJ^N&.:M4$VOT\*KVHA%
MJ(#5?!!!Z_"A)K4YJ-?!Z6'E_BJ@5PXGBOD@?&]Q5U#FJ@]2A+N+>%AX?J\:
MO&2*&2!XT0BJD7/$_&_2_P!IZ7_34F%`@P4LKI^(JN`5[0!CQ4(];WJ\*6N0
MX%0R>OPJE,5;E@ODFWXFU7C(*SB5+*Z7'WC_``\:J@S4%:NQ*E?Y()_4:`&J
MN)H#T+7#DG)'(N.1BZ>QJ]_&U@G]`ZFNEVZ(1M#J8KFMQD\1^FJQSI&;3$S+
M>-2.Y+SR6S8VZ.`IOYCK6PO(2Z$OX@+`LYM$X8,JJS_<!I#>-R$?:6V?D?0`
MJR1T=20!;J3<@]/C4VS77BL-O7O!8N^V8CE;<@8$>E<[>5<DS(=BR`X(ZXJR
MI:^H3Z8N#WV-R+GPKJ+=I`(X+@]SD#BUQ-""L3XG*JS4EYR*6W68RE*7?X#S
M'=8]"+^/G4[VAK<<RM;#*9GDLQ:%C_D+;W@XY"AE48IL'U-.?OV0`I"D@6LJ
M]_OM2.,-!+C507-PY[]#,.E:WY+*)`6DJZNFQMXD?;]U6/?3-4AA)IT!5/#O
MD8U2KV3WDCK]JNH^VLF`]PE9'A_BA;>\4<A8B5PIREHF;<2X\,),F81*OWU*
M6P^I2$%0-U-2@#U\EUC3Q.?<03L.`-"MK;3LBLKZUFS+=3?R>5<O)Z)?J/"]
MDH=7<?;W'I;[JPG!V-5NXM.EI/1[%Z\_R74.(]D&"]464KD?D)8Z6^4Y")VF
MQ^-J\BYO!&\OK_LV^I>P\G4_@K*9>(_UKK%7+KJ4HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41?__0]<V"]]7L]V0-IQ7/^@%3H':B?.EX
M574]HO\`SF'!2D7\[VKKSL.]MKJL7.'46N_9)7GO\6VIQH+M@/75OK`6:\7R
M)H.YP%OZ/NFF[A(4P\["C8+:,1/^J?#*E,,J5`D3'&$O.625%M7;>_:;6J`V
MEW;N`N;>6-M<26.P'$XTK3HJ%D,GAD']7FC>[H:X8]6%:>92V1AO2HB?J8PC
MR%-),B/WAWT'5(!<:]1(2E90I1%QTJ:*0-?W'597`](Z5DXN;WFT=],%A=AZ
M5I&VQ<NSZAB/O!,ML$E*TKNEUN_@D.L&POT[['QKH'-9N%F^$@:P,.W@?.L`
MU@G;)]DYK;B+)9F1F)<=8<8D,MO-+'@IMQ`6D_#P/7X&N,,9B<YC@0X'%;&H
M(J,E&H:X45J5544`FY)-$7W8"Y/^%ZKDK*\%`-69E%\7\?OJ\4S)Q5U,E\7'
M6WB/\+?JJ]%"4J_C;I544%9\.HMX_M\[_&F*<5)K\2?/S^'A5[5=U*`HW_1T
MZW^/^.K@<E>T8*"?"WVWJ^E.U2%0^E*<%'45JOP_950K3FI11"C?[S;[ZN`X
MJX"E5*R569>/C9L_X?KJK<7!'BC'%:H;>H/39X1XE9!(5YV2/#RZ5UMI4,97
M*BY*Z_>R=JQ'BY`Q6PQY"G0"IQ-@JWDH$6ZULY6^);EM%JF'PK@.KC59FYLE
MP\GH4!2>UQQ2F7$@?YG>+^1L.E:;:8WQ7DM<EN=W>R2RC-*DKCSSAZ46!(7V
M*"EN!H*`\.Y0Z7'ATO7?6M2X8KRO>0/#.&)*UCQ.R+P\2<PP%)<E`!#O=VJ;
M(N+_`+I"KW\ZRWM#B"3DN=CE?$U[6C-8LV/*.6<=<=4XM1)45*)423XDWN2:
MAE<&C#)36\;I'8^\5BA^4N1*[B24I!%O$7Z6O]M8))<:K=LB#&8YJ_H0",(A
MP].X*4!X7-R/.M@S]R"HFC^L4":SEEMY%47U%I$IMUE00JW<%`DHZ="%6\*1
M/[VG@5)?0DPZQFWZ%6+DL$MK-.P$HNMZ2X4I/_K9)5W6\P0*QGQ$2:!TK:6]
MSXENQ_"@7K/_`"?FRS[-,0R4A/H\B[ZU86L>R;#%Q;I7CG.PIOL@Z(V>I>V<
ME?\`8HCTR/\`6NH]<DNM2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1%__1X3M\G;&%%3>8G-J^QY=_NN%?97=C<+BM1*5QQVZ"G[H*NXWF
M'?\`'OMR,?M69BNH(4E;&1ELK38@@I4V\BQ%O'RJ1NYWC35L[O.5"_:K)PHZ
M!OF6Z/#?YH'O-X8?C)U/G;=C`:6E7\BV+(C:M=="!VE*\'L3>3QGSINDJ2V%
M@'H14OQPF-+J%DAZ2!7R.%'#R$*$[=X0_JTKX_NG#RM-6GR@KM?[?_SXL!N4
M.#J_N7T-C%2W`VR>0=&+IC%8+*1)S.LO)><03\ZENPG/EL`B,3>LNW%H'A\+
MS&?S3WAY#F/+7M6-(Z[8"R:,2-Z1@?*,0?)3L7=_@?WB\:[[JS3_`!SF<7R?
MKL9"9#F8UC/8AE_#?6&\?#Y#!9J5CM@;R#JDK<0ER*U<$@=$UCW>SB[E\=DP
MCD<,B'&M.-6@@#AFKHK[0/#\,N:.((%.JA(<3Y%N;J^[8#;6U?RQ]UJ:TRT_
M*Q,]AR%E(C;O^C<?AN@+]%9-@XGN;)Z!1KGKJRN+,CQVC030.&+3V'IZCBL^
M*5DP[A.KH.!'D5VUB'H5Z@I'7K\*N5IR1PFWV?'[?\54*JRGE4`W\O"U&YJ@
MHODD>)Z5)3&JJH!/4V/0FB+X)M]WC^O_`!4PR*HH"B;$@?</Q_"KNA5"E%$7
MO^G[_*WA86J_CUJ\!0EG]/G]G4^=7-S!*D:%`-7JA*^;^=4IQ5M5\+(\5=!U
MZ]?'[AXU<J9J4)\2?T#QJO0KP%*R/]`]X_Z-7ZO._P!E7,]YO:DE-#NQ:(\E
MYE>'R&6<]<#^*5)23;^H"/*U=S81B2./#@N&W&7PI9L>)6EFU<FR,7D\;+D.
MK1&7D8[:G#<)[77D-7[NO0]];^.V:6.:!C1<A=;@Z*2-SCW=0]:WBCS$[-H\
M,I6'4HC()N;D=J1>WF#VUSI;X%TX]:Z]C_B+-G0`M!.9M2&1_F$<=H2TAQQ/
MRD_,D%21U4+`VKI[26@94YKC-VM!*)`>&*YG;+*<QTAYA0[?2<6@_>E2@?+K
M6QE=2E%R<,&LD="QCF,D9+92D]/,^'7RZ>0%8,KZBBV<$`C[Q5MPVG"5@DDN
MK"4_YRB+5"T5(`6:X@X\%DF;>+`CL>:&AW?>1>MDX:6`=2AMM+WO=3,JQXSR
MVLO!<;7VJ^M8Z_87;$?<0:Q&N(D;3.H6RE8'02`Y:2LF[-K&2.>9GI0X@G'Q
M7P2+=R'HZ76U`_!3:P:SI(G/E$C<J+#VZ9K(/">,:^@Y>M>HO\H=MUKV<8A+
MR>US_>'OA(^^=%ZG[37B7/((W^4'_9L]17O/)9!V..G^T?ZUT_KCUUB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(O_]+SE->H>@O<=/\`
M#I73M)*TQ`Z%7HL.4ZD$=R?`CR_HK)9&XBJQW.:"5=L)#WHEF3%9F,_Y"NYM
MP?\`*0ZV0I*@!XUDL:=.ES00L5[6EVICB'*IPXK3'^CF2H@4J[;<UHN(;/DD
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MRCS&HX+K(9VW$39HQ@>'0>(\GU'BKQ[DCX?`G^BL97T-`**"XJYZ$D6ZV/VF
MJ%7M%!B,5"_$U>``K?(OE73K\/+X_P#%544$GQ\O/[J(H:C_`(?&J@=6*K3(
MJ"OHD^/X'KU(\_QJZF`"#-2:K]!T'4=>A_PM50KQCD5`6;=/C]_^,U>."OX*
M$?&KL**PYK\)%[?&JH:*"LDW24FP-[_'RZ"JC-*<0I8B]5XE7@T4!X$MK3YJ
M21X_9?\`750:$=J.H6D!<T>?,-EE[-D&TJ6W'<2EQ"OZO[EE="+>5>B;1)'\
M-&>*\XWV*0W4@KW2M!.;6?IM997Z]G69+`)!LI12L$`7N>AZ]/A706N,CEP^
M\"ELWO8@K=+V^;<K8M(P[9='\>$TAX%7@YZ0;=3XBP#B:TFXPADSGT76['<_
M$6<8)QHI#D75N].30D`+_B?/>]P4GPOXCK]U36DU0Q4OK?"3#%<:.6L>J#F\
MK'2?44U-<*E)'DKYR+`V'[U;V3O1M/4N&@`CN)F&F!*P,M"B"5?N@W^-['J*
MU[@MD5&PCHF9B)%0D%*7>]0\AZ8[NOV7`JZ#&5HHK9AX<#W$\%?>:-W%I\@+
M6/QLF_Z*SY,B%;9@"-AXE8GES?0S4!-[)_F$2_PZR&_'R`L:U[G$2,QPJ/6M
MUX6J"3ITGU+>KE@L1H&N2(24E;FF8-:RCH%*$7M'2W0V3UK<PES8I#^D5JF1
MM,MJ>F)M?IY%Z#/RA9#LKV<8EUY/:O\`WB;\FWV)GQ0#^->&<\$NWZ4N&/AL
M]2]ZY-:&[)&!EXCO6NH-<>NK2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1%__3X!Q,8PVH6`-^T];?XNM=NV-K:%<X]YHKQAP&^Q([!=0L
M.@\Q^BLMD8Z,2L8D\2JLSCU(5T2"//\`X+U*(R.Q6%V"N>+CX[Z$I4VCX$$'
MQZ_9;SK(:QKAB%CN<ZJFD:VPET*BN.1'C>SL=:FEB]_ZR"@V(-OA51`VO=)!
M5KG5%'@$=>/K4![7_0?2X["Q634RXEW_`%N`TEYY23>TB9%^FG2$J`L0MTBQ
MJTVX!J6-=3I'M%#Z5:75;0/<T=1]0-1Z%MCH/OW]XG$6"8UCBGF7;.--9@+0
MY&UG4):H.NMK;:;9[TXJ5];'0I;;24K[;)6$CN!M5UQ(;@L\:UA.EM!6-IH.
M@5!/I6/#:LMP]L=Q+1QJ:O=B>G`C@MVN&_SV_??HN0QYW?8=5Y<P$5QE$[$[
M9J.&Q\J7&"QZWI9[5XF&R;,Q;5PAQQ3J`JQ4A8Z'$-G8S`A]H&GI87-/FJ6_
MY*E/CQXQSU'0X`^G!WI7J>]C7Y@?#WOETM_+::7M4Y`P##*MUXRS4IEW-80.
MAM"<KC9+:&6<[K<F0HH;E-(2IM=D/-M**`O37=@^T(?75`[)W7T$<#Z#F#F!
MD1S"7`X2#,>T'B/2.(R6]ZO`V^S]M8:O4(D^?Z_+]/A1%#4?M_150K@.I0E'
MH>E^AZ?'[*KT=:H350BL=GEX>%_#[>M[6^VJ]@2AJI-:P>OC^KX^'QJYH.-<
ME*&]."@DU)@`JG@O@VJF)*M-*+Y5>QMX]/#[ZO5JEB3<]3T\KG[!55<,E!4;
M`'P_5^%,E>.*@D];V\;?\=4K5,UJQSOH^6S#2YN*0"I*%^I8=2@@GI;Q(/E7
M5[+>Q,`CD=BN6WRREE!?&.U<C^<=9D(PDR'-7Z$J*\AYMUU78TLH798O>P(3
M7=VD@)!:,"%YAN]NX1.#C1S2L.<.\TSN-IS6)EOJ7C'I(4E7>H_3+6KM6>I[
M?1/B1Y&YJ6ZM63#'WEK]KW*2S=3_`%)/F73$S(7(&GN9C&Y!MZ0Y%40IEU*O
M4'8LD!0)-QY&M!0VTXC+>ZN[U,O;4RQO!<0N.O(6*?B;3L&/R+3@D)G2/],%
M`J0M16VKYO$*018UTS2U\;",J+S>5DD-Q*'>\'%:X;/#5C^_M_=45%/;UM?Q
M'3[:P9VZ<0MI:2>,!7,*@\?K<<V%]:@0&F%&Y\+K(Z=?L%169)G/119=ZT?#
MCK*OO-R%+>6EOJ>MU#S)ZW^WK6;,:N-%?:0C2*K%[V.7*V#$,+)_CY&+?XFS
MJ2?C_DUA&,NEC'2X+;@Z+>9W0T^I;M\CI$.-C8[KOJ)Q^OXJ.I1\`414E20#
M\%*(K?B@B<>%2M-$T^-&WH8WU57HG_*)D-2O9SAW64]J/]X6^)`^U,^*"?MN
M:\&YY(=O\A&7A,]17NW)K2W9(P?]H_UKI[7'KJDHB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41?_]3SZ8O(_5O)0V>[Y@;@WZ?I\*[6.36:
M!:.6/0*D+)\2Z`T3?R\SXVZ_MK8MK@M<[BKT@,!Y-RD*\//]?W5E,%<5CO)!
M5?CQ$)6E*"4];]:F#5$7550=;]%2"E0[U?\`!]_G5S@&D$*RM<U]I0D!;KR>
MZXO\1X6\/OJX#,N"IT47U"1CI$@M.-I'<;`$`]#8=!:P-&!CG4(5KM0"O->K
M0$Q4".P.YVQL$`W)Z]>EO.LLVS-(TC$K&\5U:G);,^UCE3>O;%RYI_+FCOR(
MV0UO)1W,C`2XMF+L>ONNMIS>M9)*.B\?F((4TKH2VHI<19:$J%YL630202M_
M#<*=AX$5X@XA8[YW,D9+&>^TU^L'J.1^M>^70]TP_(ND:AOVNNJ>P&[:Q@MK
MPRW``ZK%[#BXN6@^NE/^CD"++2'$_P!58(\J\\FA?;S2P/\`>8XM/D-*]AS'
M4MZU[9&L>TX$`^?%72KP/^`%1@55P4(FF!5Q(4,DV-NE@>MO,?AX556J36;`
MBX(/2_4=//Q^-7M%3T*1HQJH"B/#X?T]:D`XE7G/%0Z$CB%:OFJ@45A[%\+5
MVC[:JE%*J)O?XW/4?'PH%(!@H*B3T)_P_"A*J:<%"4KM_;>JM%<PK<L2K/V"
M>R]`FMJ[+(9<-R/"R2>I/0"U9]M$YDC'#B5@7,H<QXX`+D_SQ%U_9,3L>/7,
MB-SFD2?3(<0"EU-RDJ`\/F%>B[>Z2/PB6]TKS'>&PW$5PS4`[%<?\LA3$AX.
M.=JF5KZE5[%"C8W\".E;]PI4DKC(&ZFT`6UOM=YB?PF3B:[/?<>QN3FMM-J+
MBE".ZHV+9"B0$O`?I^^L&ZA$\+GCWPMOM=XZQN1:R'\%YP^I9*]V&F0)DN+M
MNOL)),=*)WII`*T*'>T[;H5%I5P3\#5NVN>8S%(>\,ED[_:,,C+F$=VG>^G4
MN:^PLOK6MM]KJ"JU_AT\*R)FG$$+#M(6L#7-*IFEXY",C/6$V4&0+"W@2?P\
MJLM6`2.('!37KB&1CI*N5V!9+SA2#U)'2_3Q_IK)T'$K*A(H`L<NN"+M."=4
MFR$3F>O0)ZK`^RUC6&>[<1'AJ"VGAE]I.!GI6RW(&17EL?ZSJ@%NML-@IZ7#
M;:$7\3T(!^ZMU,`(=(XK26.M\^MXQ^H47I._*':;9]FV#;;_`'4[]O0OYD_7
M122?B37@O/(#=^D`_P!DSU%>\<H5.S,)S\1WK73VN.74)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB__5\Z>GN.8-O*-RF5NSD>@J">U1
M;<9]2T@`@='4I(-O,5U=CJMVRMD%7BE.L<5JKC3,8RUPT<5F9K(L/?3EDCM6
ME*E)(M8D`D6MT(K=!X.DM6K=$159`PTQJW:HBQ'QL#8CI>LN)P\BQ)&'@KD0
MOM4%)M8'IX'Q_P""L@=(4%#151Q*7T)7;NLGI:X/AX=.GC4A`(JK!4&G!4>>
M]Z4;]\I-O`D=#X6%1/-!FKVC%4+&S753V5(NKYAU^/4?A43''6U5>RC35;Q:
M1BX\S$19BX?U"^Q(4D)[E"UQ<?HKKK.-KXF.+:X+GKEY:]S==%DYK`QY;`]*
M`MGL\5+24_9X'K;K6P$+7#".@6$Z0M.+ZKV,^P.)E8'LV]O\7,AP36M(*FPX
M"%_RM_.9B1@C902?3.#>C=GEZ?;;I7D_,`8-YOPP]T.`\H8T'_*!KUKJ=NU.
MLK<GWB#^T:>BBV\4J_\`1^J]:C)9N0(XKX)L"?@+T5%+N+!M8V^P]/\`AJX`
M8X8JX!2ZE#KVWL;7'QZ]//X5>W/%2@<%+GQ/^'2KT/I7R:IB<LE0FB_.M7JP
MJ5<7>_P'3P%QUZ=;7ZU17`*"38'[0/Z;U=DK_8H)/4U0"N/!4S*DYA/TSW;^
M^$$CQ_HJ5F$C1]FJLE!\-U.A8?V7$9G)ZOFH>,=5'GOQY"$/K)[@IU"@E24V
M-@+@5NK>6*.XB?)[BTD]O/-;S,C-'D%><7FJ!FM5Y0S>%G9IV9.<F.&4X)*B
M$!]:E)8>/<E""@6^7H`FU>FV\K'PQ.8*-(7B>Y6\MK>7,<LFJ0''%88V_%G%
MO%N;(94EUM+G<R^B0VI*_@XV2DV(Z]>AJ1[FEH)."CMI#&[PRT:NHJ'J4Q&$
M>9G0EJ"F74R&5GK9YLA25"]Q<6HP-TN%,"K;F1[I&O!`>"MWVN9M<G:1C'ME
M47LG)[XBX:&2NS:5+:];M)L&4(0"HDW*CTO4`@>V0Z,&=*V[-UB=:M$^,IJ*
M`+63D?'ZC.CIE8B<U]1)6M2F&KV8239)"3X`V\+FUZS:%["U^?2L2.9C9FNM
MW5:<QT+$.JPX>-S$AF1)3ZLE"0@$V"@F_P"OYJCMXVLE+7'$K-O"^:!KV-P"
MN78%-X]E78V#W>!\1U'3KUOX5ES'0TX*:Q89*8XK5_;M@]++XN.P;R1.85VI
M'EZJ>MQY7K17,M)&-;[U5UUO`!`\N&%%L5E<BY*QD1)(%V4*\?ZP;!\[UNWO
M+F-KT+16T+8Y'D#BO4!^3\5GV9X<N7[O]XF_#J+=!/B@?JKPGGFO\>DK_LF>
MI>T<J4_@\=,M;O6NHU<>ND2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1%__];A`MYB%'R.5A-M>MCT*?BEQIMY/KMK"F2MEY+C3J0L`E*D
ME*O`@CI7>N(8V61@Q;DN7;5SXXW'NG-=@.$O<Q^6U[I,'&PON]]L\/@'F-&%
M&!?YZX#C[%A=!STJ/AC!Q6Q;'QGKF3@ZWJ^8;FQ6ER5Q<;(BRE.K6Z64I-UC
M(;ATCI'4<2,'5H*G$APQ&%<'5`P%:917\<]LQHMW$M`=B*$Y85:2*T/YIJ>A
M:R<T\,<8XG;LL>`MQS6Q:..V3AO[8G&'+.1'.Y2",G@DG'36U(2"VOT6>Y*@
M?MKH9=OT!O@SM>=-33+R'&OEHN=M]^=)(YES8NCCK0$^]_C-PIYS3BM=4'(8
M]U3,IEQ*D$H6DCN2"#;HH721<>-8??8:$8K<ZHI&U8X*MP9KKJNWL6$'P%C^
M@7Z5(QY)RP4;F#J4W-Q!FH'8I23U)!2;=>M7NBUC!6AY:55M7U#_`%A*U@D)
M(MT-KCX`U);VW>!*AFGP(6XF@R51(C<$-J!'1([3=5U$_K-=39.TMT46@N@'
M.+JK:+4=%W?=8V9BZ1KKNS[#B-;RVR,:W$DQ6<IF6L4QZSL+%17WFG\C.>)"
M4,,)6\X39"5*L#L+B=MM`Z5_`8#K^G%:YC/'G;$PC4<>&72O6-[->8]3YU]M
M'$V^Z?B!K6._LM`UF?J!;=9=TO8-1CMZ[F]3=8D6E-#"S\>IMGU0'5Q_36H`
MJKQK<HY([Z?Q"27N+P3Q#B37MK6O74+N;5[76\8:`"T!I'13#U4IU46SE^E8
M`PJ2IR:T4!:_'MZ&]E?'[Q]U5SQHJ@=*E5GQ^/V^9M^VKP,112-"@DFUOA_P
MU?0#M5Y%,E#)JAZ%83TK\)Z7^`O56Y*TFJ@J78_A<>'E]U_.KJ8(!52O=\2?
M^#R^%54E%"4JUNI\[V\Z8$$<4S1;3J6%2BTX(Z!=;O:>T`>/7SH""0RHU)6E
M:JS<KO\`J>//TB<E&5.(LMA;S9=0;V)6@*^5/3QK80[=>2=_PR&=/U*"2ZMV
MG29!KZ%0-EV)AC5YZX,EAN=-BO(C=0`''$*2VKN%[A/C61;6SW7<8D:=+3ZE
M#-(UMO(6$:B,%Y=_<+K6T:]RAF6LK),R5D,M-R*9H6I9?$J2XXVI2SU!`/;V
M]`.VWA7I[2'10F$49IRZ%X;>Q&"ZOF7;M4I<37I!)6.8>F;EO&Q8W6,/CY<N
M9(6VA00API::)^9U]5K--)3UN?'[ZBG?I%7NHU8VWP>*\QPQETQP`IZ3U+J=
MQ[[5HNLXC"Q,[CV9KJ?2>EKDQPXA;R@GOZ.(_<`Z"_E6FEW($N\-WI7>6G+K
M8HXQ/&'.K4U"W8A^W/C#9,,Q`F:MBWVTL?(E41I*&UE-NYNPNA?=UN.M:=VZ
MW43ZB9WG71CE_;)XM+[5A'8N8ONN]I^/T"/.S>INRV&&BN0<<5KD,)1U4?1*
MKNM@`@6*B!]E=!8[F^[:&R''I7'[KRZS;2Z:U)T_F\%QKV3E:7J6:#,^"Z^R
MTL?QVA=:$@GJF]NH(^-7S;BZVEH]E0K[*P;=058X"HR5^XSGW3-GBMP'\FU$
MEJ`3VS5>C\U@?WEV'CT\>M9T6\6LX##+1W6J#9KNU>9&,);U*5GZJ,GFHN6C
M.L2XGRN!;*PHILH*NDCHH=;BU'V_B2-E:06K.9=:(3&X$/62,KD/HV,:V0H-
MK4ALK5_5Z`&_E86\:SWOTA@6);MUF0\5ZNORBU)5[.<*I-BD[_O1%O#K-BFO
M%.>_^_R?[IGJ*]8Y1%-F9_O'>M=.ZXU=.E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B+__U^(FAX-&6AOHG)_U9Q!+_>!8IM<@WL+UZ+90
MB5A#QW3FN0NI"QX+#BK=W_9\;@V#KNLLML-)NF0^VE(4I72X[@`2;UCW]S'`
MWP+<`+*L[=TI\:<U5U<([K/QS4B-E)3B\:TH*CJ>6M88"S_%C(OW=C3E^X#]
MU*[GI<FI]GNI&-+9'=P9?4L#>K*.4AT3?Q/I0K-.XP$A2,G!4%Q)K8>0ZW92
M#W=04D$_O`BMM<,`I(P]TK3V<E:QR"CQ@L?1<].@R&FVNQ25$@%Q"5!)'7J"
M/.L-L\C'4"V)C#FYJ^#NTB/#9]*-&?F)6Y]0'XK?H>FD-^BMM:'$N%:B5!22
MD`=H(4>ZR<SXQS6BC03UA0"&I(+J-5>USDR:X[Z9Q&(+HL1VLO(!(\+@/];V
M^(J:#<7.-/":HIK4#'Q'46R/&&VS=ISCD!2\)@V66I3D9^:51TN/,L//1827
ME^JR)D];7I-]Y;;]50NI(-;NSO'RO+2&M`R]BT][`(8]37$N/F^M=G/;3L6<
MYD<T'2M+W'CSCWD/CZ$,GA<UG-,1E=EG1<1$8$G6,-C<0[@3L,K*/,R)$LSW
M_IWX\HA<AM:'"J:_F,%M*X1.>)*!U78-)^T:G`#"A:*C``=&KL"ZXNF1R:0^
M.KF.IB1GI!`Q)XAQ`P)KACU>X<Y[R6J;[MFER>)Y.N8^3D6<EL>2:B0L*=BW
M)W'P6<QM:,9!R&8Q\)S.1V6%EI4R3)4VAM3SJEGNK07_`"_'=645RV]!E%:<
M1IK@VM`30UQH,R*+=VN[R"^FM7V+FMPJ<!5U*$TJ1B`*"I-*+H#C-OP>680[
M'F(:6M((8E#T7DD^(4E1*;C[":XB6RN('$.CK3B,ETC7,>`0X*HF?"4`D2X]
MOL>;42?,=%'X?A48C>,V'S%2Y5QQ7WWA5RD@@^!!!_95P;U&H4@`H,5#-5Z4
M=P"_/V>54&76K,NQ0E'I8&Q_9]M55!FI0J)\3=/@;V\:J!TJ3UJ&HW_P^VA3
M(47P%--J2Z^OL9"TA1/]8W`"!]IJK078#-4KABK=Y=Y7@:=I4T8R'ZTH1E>A
MZB>QH^DD*5=:D]H"`FY)(OY=:R-GVE]U>L=*_N5QZ5CWUZVUM7D`:J+E5J7(
ML7=N4FY^>D_31HJC',".MMY"N[U70\XZB[CO<IP"Q`L``*]-N+0VMB66XJ>E
M<':W[+O<@^=U`,*8><K;F6K#9:4F/"D(5&/9Z+275H()2E*@E!4.T*-_*M`P
M2QLJYO>XKI9'1O-&.[O#%:=^X_VG_P!MI\':\.YZ>3A^D9+);+K<R,E:7`P\
M4J!2LBX"P#8'J#6VV_=6:3#*.PKE-^Y<-V]L\1I+Q&8(SHL[>VG@S6<>T,QD
M(T=&;#:&Y##S2`\VMH=H2#U[T@FX(\16GWF\F82QM2SI[5O^7MH@B;XCF@2\
M:YK:G;M:BLLI4TPW8"PL@$#ITL+>-:.UG+C0G!=)<P!HJ`J=KZ$XUH%PI2DB
MW[1U!\NM2S?B'!6P`M%7<5IM[P-DP6(UC)OSE-.%41TA"PFWS(\R;W!)K=[1
M&\D`9+0;]+$R%Y=3)>4;F=Z+,RS_`-.A!27'%.&PLVE2E$)\+=!\*V.XT+J!
M<WLK'-8*U"U0R^'0^NS*BV0>[N0;&_EU!%:*2(')==`\L!KBJQ@-]WS276QC
M<Q*=BH*"(LAQ;S)2D^':LJM<"W2IH+R\M"`R0Z>A5DM+6Z!\2(:EM%J?N;PF
M2C,8_>L8IA2E)3]9'27$!0M91;"0M([O@3TKH+;?HGM:R[CH>D+3S[`]CB^S
MDQZ%[2_R>,GA,Q[*]>R&ORD3,9(WS>5,NH)("OK8@6V00"E2#X@^%>8<[OBD
MWU[X7588F>HKO.5(Y8MI:R84D$C_`%KJ37(+I4HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41?_T.,V%DIBZ5,R#0#:WFW"@#Q"?ZH/P%J]
M-A<&VCGCBN,D:3<M:>"UEE-2,OE%(:0IQ2W3U`))N3^-<T\.FE(&.*WK7-BC
MJ3P63<7@)V(CH:G,R417E-K=0P$AXI2?!L+4D$FY\>EZV<4#XFAKP=)6MEE;
M*2YI&KK6Q>/R<&-JWHQ<%DX.+[@IE68SK,N0I:D#O>C0D8YH1VUJ!^4.F]K^
M/CO&/:VW[L3A'^DZOHIAYUHWP2&<O=*TR?HMIZ:X^963*0T^4O1RE25&X[3X
M&_4'KT-Q6*X!U"TK);48.P*OG3L1#RNSX/%Y#(O8C'S7FH^3R4:/]4_$Q[B%
M">XS&"V_J'U1.Y*&[_.H@>=9=M$'S1L>[2TFA/0%BW$ICBDD#=1&0Z3P_P`*
MS%OO$^,PV_1\?H>%R^*U^?A,7FL=!V;8L1F=B:Q\LK$2=L2<7$@MX7(Y.-V2
M_P"7J;#S##[?=XWK+=9L^(TVS'!E./2,">KL4/Q8\$OF<,^`^E>U;$Z#Q8VE
M,7T&P]+D.-%UU16AI*DV'1:;$I"A_5^[K70VEB!2@[Q7*W^[!NNN#`NG?!W&
MVJQMEPN[<F[@W@I6D9R!'BL8B<WAW)DC&/QYT/(P<F%J=RJDH=;<:6PE2%)4
M@`6(-;"X8]\9:R,.D<TBA&&5*$>@@T"TUBZW;*YSI]%NUX-:]XG`U::Y<00"
M>Q=G\2MCEC++E:/L."SV6?DO/9F/CG\4SF<3BFF(C$26YB,C.QB)D1E:FV5O
MM2G%I4L!325!*%<E+(-KB$=W$]D5!IKJ+2XU)&IH=0YD`M`Z#Q'<1O;N$I=:
M3L?)7O4TZ@!0`Z214#`$@FAI45P6;=1XJ=<9=GYC*[0[(C=[*8D^"Q@&7WV[
MK[X\1G(.S7&+V`4MYD.>(Z&XTMYNX:6L@BBTG&K27FG16@%?(:+;6UB_%\LL
MA=UC3Z,_2K\9CNPUY(3L%B8<6,\$8Z7$D2LN_DFEN!#;\AAS#MO0Y)*DAQOO
M?"%$]JW$CNK7E^L1EEP]SCF"`T#RZL1T'#L!64`6ZP^)H:,J$NKY*5!ZL>TJ
M3RN6V"%)QD7$X1.23()^JE-3<=!BX]D*0CU'R^A,J0LA5PF.RX;)-[=.Z2&&
MVD;*^68MID""ZO81@/*>RJMDDF:Z-K(JUS-0*=O'S`^13;6UY2*4F3&6XT0.
MJ%`]3^\%)=#:T@#P%B?Z;391/'<?0]:O\5PQ<W!59C?L&I2&ICX@O+'RIE!;
M"3X#Y5O!"%V4;?*34+MNN`"6,U#JQ5?&BXNH>M7''R,2>E3D.6Q)2DA*_1=0
MHH58'M<2D]R";^8%Q6(^*2,T>PA2L<UWNN!48^%@18^=[]?A8#[*MP5]<>M0
M;W-OZQ\!5N*9E4Q^+_.LG'QR7.V'!*9$LI)'J+![PDJZ?+TZBLN-X@A,E*O.
M`5-/B.#:]T+!_-L9O=X,[4XCGHL!D-ON(600A"@D(*3;N*C]OQ-;K9@ZT+;E
MXJXK5[JP74;K5N#:8K2G4>#DZ=GPMB&J7(EJ#2'GD@]EU?*4W(+8N!U)/A76
M3[F)X35U&@+E;+96V=P7-;4N^@6U>'X-BX]Y&=R&6EF18.^@RZKT@LJ[@D)"
MR#8USLN\E];>.$$5^G!=)'M+&.$KI"'++V.QJ@PEN0A+J4E"6U+M<)M:Q!Z]
M/.M9-+WJL-"MDR(!M'8JD9S50I7\PUYW^7Y)@=X+1(:=(ZE+B$D7[C\*DANL
M/#N1J85;)`*ZX#I?Z%;[_);4)3>*W-DP'P`@25GN9=`Z=Z5]H"DD_B*F_AI-
M9K0U;T*SXX-I'<@AW2L3\I\IX;5\0_D8.086PVTXZ'&WDE(2$=US8DB_P\:R
M;2TDD?21M"L2]O(XV%[7@M"\_'NK]TF0Y!D3,:P^M&+9?("PX;R"WT3<=/D"
MOTD5TT445G'A[ZX:XN9MUF`/[@'SKE+MF8,U4E:G>BU$#K=1)-R;_"]:NXEU
M5Q70V-N&!O=6,T`K>^8DI`/:+5@YE;8M`&"^76@XX0M(L?`V^`Z`7\JKIQH5
M>WNM%,U\O8IE;22`"L&P`'@?*JF$''BI&2'4>A>YC\A%A<?\O?6VEFY'*7)I
M_`Y*%;\*\_YD;IW-P/YC5UNTG59@_I%=HJT"V:41*(E$2B)1$HB41*(E$2B)
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MLI8E26UICMOI0ZGO;#BDM(*W`%D%+04.J5*':;$7)Z5U=EMAETN?E5<I?[LV
MVJQOO4^GY5NIJOMUQ^M0ES\H7V`ZA+K#CS?8'B\4(82Z\IA:?IVRDWL0%D$`
MWL*Z*#;8H036IX]*Y"XYAFF<&L92N1.`SS4WF]PUKCF.8F0DEK)=G:QB(12Y
MDNQ0Z!]JR`PVX3T+BT=/`*\*GDN(+1M'N[W0,3^18D&WWFZRE[&_@UQ<ZH;U
M]ODXJE:#D.3^9MRU_5="UJ1_-<WE&(.#A0F?J\E-ER'`TVZY,<9"&6HZ"5K=
MLVVRD*6I0`)&(Z^>6.GDI';MQJ>CIJ?9Y%O8MEM;?\/O2SNPH*T)Z`!TGI\N
M"]4GL]]I<+VX:R[,V/*Q=KY0V*$Q&V+8H["FHV-QS7:^C6\.]9B1)B,R^YQZ
M8ZVT_,="24H0AM"?.M]WR7=I6L9J%JSW0<R?SCY,`.CM*[7:-HAVQA<6-\=P
MQ(P`&&`]9Z^RJW.<;^4);L%>/S+6;]@[1<GN4>[M%_/SK0@G-RW>'!4R3#4X
MKN5<`)'2X2D$BQ4D!)4K](J5C](5A!."I+T4)24BRPH*"AT0.J2%+(3V]3W>
M!OXU*UX)K3@K7-5,=Q[;@6BY'>%)(!*5?,#^ZI/5)M\/VU,V4M-580"**V\K
MK[+P(4T%I6WV*"AWHLI/:0M-E`IL.O2LN&Z+>.-5&^(.X8+6_?-#VG!O)V#C
MS/SM9S</YF&V777<+,[05?2SH'7TXS@L.YH623<H4+BNBM;R"YC,%[$)(CTT
MU#RX5\JT5]M]PTB:QG,4XRS+3U$?4JGQC[K&7\K$TCF2%&T[97@PS#V!'JM:
MUDI2E*83%FR)/:WBISSB+MK"W(D@*`2XE:7&D:_<^7'1L==;:3)!GI^T!^C3
M,#B,".NJLV_F+\5MGNS!%<<'"ND]1K2A/#$@UPQJ!N%(DHC1W9*K=J&RI)N#
M<J_=*3>Q%O"N88TO<&@8KJ:BE5)17DXG79V7?NE^4VZ[<^-NTE(ZV-NM3.;X
MUS%`!W10(UPCB>\\53^+^))NQ19&X;*XJ)'R3RY,"(JX?<AI^9I]WN':VA\=
M4CJ2GJ;7%5W7>F6KQ9VK:O;F>`/0EAMKYV.N9L&$X5Z%:/(/'*=BR:F<9DGL
M:B*X6HKL3L!*PJWJ&R"#V?'S-9VW[D8(6F6/43G58MU9^.X:'EI'0K$V[3ML
MTG%0IC>VSLGZ:V4JC3DMJ]3N58A(::;4"/+QK/M+VUO)9&FU#33,?0K$N+>X
MMXFN;<EV6!43";U*A*;C;/%<B)<2`Q)2#Z![A:Y</0*\/&J3V+7U=;N!HKXK
MMT9`G;2N2OV)D8\D^I`D-R$JLH=B^X@$#PL2+5KW1.'=>T@K,8]I)+'56FGN
MGS^6@8MU]K%+ELMI4IQ+225^"OF`NDA2;>1O71;*QH(H[%<YOT\C(W'02`N(
M_(?+6=EOY3#O9C(M8QXK8^D>=L60I(2ZV%+2'$@%1'7K78AD`:"Y@U]*\[^)
MN;B22-DSO!Z#ZES]Y6UW8U)<R>&1_-,>D%QQJ-=4EL7ZW:3<N`7_`*MZU%_!
M-3Q(N\SJS71[48&TCE.E_H6H4S,JDR51WFRPZA90MMQ*D*2I)L0I*K64#7..
MDU.H1BNOCBH!IR4S"(]4=UO$>/GXWO4C,U*X898JX'8J924):"1V]5'S\`.G
MV5/HUY*%O=-2H\?&+4>SMOT_>\>O3KX6J5L15SI%[?/R*6#']@>NMDDD<G\D
MGK]N2AUYOS4W3NSQ_1M78;(:V+3^D5V.KFUMTHB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41?_2X]9W+RXSRI[:"/FZ!0L0`;>?3QKU&:5S
M27@+AXHVN`!*S7K>;2O3$3)-F7'$+>*N@^1(Z)O]IK<6TW]4UN][-8$D1^(H
MW*JU<UHO9+?I.0<)6$//.7ZDD]Q(`^VN;M]4E\YY6ZG`9:M:,Z*HC0LIN&Y2
M)LYAR)B8[W>\\\DI2IM)O9!-PI2AY5>;*2ZNB]XI$%9\6RWMPUAJ\K+.LXAO
M/[OA->PS7=CL;(9+K@!+:6V2''G%J%_W4-G[S6R@C$UW%!$.XU:VYD$%I+-*
M>\0NP_MDY,TSB?>%1-FCXJ3A-RPF3TO-'*H@?38Z'FF0AG)M/34J:BN0Y+:"
M5_O%M2TI!-A76O$>D,;(6OU`YTR-:+B'&>21\KH`^'26G"IQPJ,."R!D-VQ_
M*7*.L<&ZKM>+@876@\C:N5)4:.J'@]1Q#;#>;S\)IHOJR3JRA,?%1T-N.R77
MD&ZU.BTLMZ6ZV6T3G7#L:"F'GPJ>DX`8K$M=F:_P9;V5OP;!05!&H]?'2`*T
MK4Y9K(G'?LDX,]R')63PG"6U<H[;'AQ?5R/)>8TYEC7\/E4+1ZCVSS<KL+(<
M^H:)4Q"C,+FN%22>T!5L"]N;:RMF7=Y&QMS7$![G$]0JT`]9P`QJNBMF32RF
MTM7$P@8=P-`'2>\:#HXGA5=\O;/[.>)/;#B6TZICUYK<9$-N+F-[S2&GLU.0
M$CU8V,CHM#P6,6Y<^BPGN4FP=<=*0JN$W/>;K<CI>=%L#@P9=I/$^CH`736>
MW06G?'>F.;CZAT#LQZ2<%MPA*QXJMU*B#:_4>=@!XGRK35PH`M@.U?BW$HZ@
M7/5-S]GC^R@Q5>H*G./%7<3>W[/NJ\-R51@I%9O?Q^/V_=4H5KNA23BRFY`L
M0+`^/]'Q-2`=*C/:J>J42""$GR/RDGP(ZW)Z]?A4@8*U&:IC3$JG/0D3$]A2
M+];!9Z*-_"]B`3\/MJ9LIC-0J%NH46F/N7XF<VW3L\Y'0S_-,?.2<:P(\=E[
MT76.]V.F8VPMQ(D*8)`-VT*2.ANM)ZW9=P;'-$QQ.AS34U.=<#3JKV]BY7F#
M:_C+29P`\5IPR'#$5Z_-VU6JOMR]WVQ\=9O&<-<Y3I3FF.RF(6M;EE0OZW6T
M%P-1X>:DN*4Y)UU2?!U?>[$/2Y9%F\W>-@CF\2_V]E+@@U:,G=8_2\U>W%:+
M8.8IK)[-OW1Q-L"`''WF8\>EOGITZ:`=OV<0QL\W$89HH>Q24LS)2VB%LO0V
MPE32$N()2MN4?`@V*>HKS)UPZUBFN/\`6G`=IS\H7J(C%PZ.(&K30_3J5^;?
MGU06$8+%D,MH9#;JV[)]-H7`;3VCY2?#IY#XUK;&V$COB9<23AV]*S;F<M`@
MCPC`6.\>RAMPOOC]T=UK^%[]@L2>I-;.0U%`L(4;4E85Y9V9I^=C,:EQ*E.3
M&4)0#?K<7-@?`5N=KMRR.20]!6ONYFN<UG&JA9F##DXIH3&T+"60?F`!N4`#
MK]GE5\,CV2.TGBI)61NC&H<%C#%ZIGHSST_5<F4D$D0I!*V5?!`23<`GS%K5
ML7W4+P([F/RA:UEM,TE]O)CT%85Y2Y1AXPN87DO$+Q(5=L9%;17!4I70?ZP;
M(0%?\H"L^SL=0$ME*'#HXK57^X,BK%N$9;PKP^G:N)?NQQ&K.;$<EILZ+(CS
M6%.R1#<0I*7A8`K],J"5+2>O2QM?XUT;&2FW`E:0\+BI76[=P+K=X=&X<#Q7
M.#);1L6!F.IB2E)2E7S1GQZL9T&]TV/[E_L(-:UUQ/"XZ7+I+>"&9@UMPZ50
MY7]@]]5Z>P01K>P$$(R4?M;CO.$=%%W]Q:2>MG!?[:C<+2\_?-\.;I6PB^+M
M,87ZX>@JQ\]Q3LFOMF9""<WCOWDRX1]10:\BXT+J`'Q%Q6++MT\(U-[[.D+8
M07\,QTN[DG050<<AX$A84@I-E)6""+>((/7I5L5>*F>1PR5_8I#*NU*K%1M;
MH`.M9\0''-8LE0:<%[7/R0V4L>Q+`-I\/]Y?(ROTY&'7E_.`T[R\?T;/4NVV
M#';F_?<NO%<LMTE$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B+_T^(N*Y#C9>&UC-J@*;>'R(S4!/CX65,@6"56O<J:4#8`=A-S7HL5^V5H
MCN68_G#VCZO,N1DLRQVN!V'0?85E]YI^9K,:'B);&0@H2FSL-U*U%/:%)2Z@
M'U&U=>J5`$>=JVIJZW#8G!S.I:]K@V9QD:0[K5LZC@1KZIN2R*>QYU:O10K]
MY*?$$@C^L:QK:$0%\DGO*:XE\4-8S(*\<OL+LK&M0H"Q]5*6&BEL'OLOIT`%
MRHWL*RY9RY@8P]XK'CB#7E[SW0LX\;:@=6@LH"FF<UE%1DY";(;<6C&M27+!
M+JFFGW`$)/>X$)4H6[;%0L=K8VWP[!_M79GH^G%:B]F^+<30F)M:#II],%L;
MH/!>\\U97':_INOYG+9`."*Z8+,O)NY:8Y-4EN2PPRQ'./C"(M`"7/W"%+6Y
M95D;$V[71F6XE$<+,W..!]7FS6*)_#<(HVZI'9-`RP\M>W+H7HR]F/Y6^C\0
M8R+MG,^-@;)O,HMR4ZRRXB1B<204K'\_GLK6K/S^X!)80\K'MI!!^HO=',[C
MS+X0=;;+W&'WI2.^[[M<6CK(U=3>.RMMI\<MDW+&APCKW1]ZGO'J'=[5U@P^
MO8+7&)$7`87$X2+*E+FR(^'@Q<<P_+<;:95)>9AM,H<?4RPA'<1<(0E(Z``<
ME)-)*097N<X"E2:FGE70,CCB!$;`T'H`"KB%I`(0GNOT'D!]@!L.GV]*CHKC
M4*&XZ;GKU%Q]IMUN;6%J455)N.$IO<$V_2?'K]M7M'2%4854GWDWOT\/Q^%7
MT&%%0GK3R\:*G"JI\BZE`"R2.@L3UOU(-Q:U3-4=5(^AW*/<.X7Z@CJ/M'7J
M*OJ1C5%^+*6@?&X^8`7-Q?K^FQJHJ[!55,1JT;:5+3D@]'PC,E>8SS_:IMYR
M%%3]-!Q\7O[2)$]XFQ_JMA1\;7E?=NM`/!H9R`U@Z"<7$]3?60%9X#9Z-?A%
M74[L&`'E]0*YK>Z+V^8;8C+=P\1J"W,1D9V#:MW2\?*8<*PTZZD%;L62Q;N2
M3_I+J1\PM7<;/NCA&V.=VIPH''('Z%<1ONS-E<7PM#74):.BG3U$?6%>OY=/
MNFE8EW*>WCE*6L;)@XCIXYS$U94_D,=`0ZX_J<J0I1]5W&-?Q8"B25Q^YH'M
M;:%:/G+E\R^'N=F/P2?Q`.O)X]3AY<ZK,Y.WIS6OVR[-)6@Z"<Q3-A/4,6GH
MPRH!TL1.<EN.SY)4>]:G%=P-B224HZWZ`5RF@-&AHPR7:@YN<K*W+;4X;&J6
MVZ!*DN!J*GJ>^0Z0"H@"Y2RB]NGE6;96GCR-J.Z,2L"]NO"9W3WC@%IOF\Q-
MD\EX*'->45+6'^Q2N@2.T`VOT))KIM#&6;RP9+2-<_XN,/-2<5GG:,TQ%QSE
MW.J&`!UMU"0!XGP-ZT\,9<^M.*W<T@:S356OH6Z1FP[]4\A`!(2%*`)L3:W6
MYJ>Y@)I106TX%2XK7GW$[KK65AY&/E&HDII+3R`E_L45!3:Q\I-_V&MIM4,L
M18YI(6IWB:"1DC96@BA7`O>]BPD?/9*&TW;&KF/)C*"BH(;)``!MU2%'I]E=
M@Z?NM;(,:+SJ&VU/>^$T8#@%A_8]!Q^?CF7C'6G%*!6$$CN)\?.UC6+-:,E&
MIAJMS:7S[=P;*VBPQEN/9###S;K)*D@V04]1;P[5=+_A6O?9&A"Z.&\8_26N
M6/,;MFR:/.^E9E.2,<E5G,=-NXT`3U]-2KK;N/A6$RXGM'Z0ZL?05GOMH;EI
M);1_2%D6-+TO>P%+8_D>67U*VPE+;BSX]4@-+!(\P#6Q8ZUN^&F18CF7-KD=
M4?6I6=HV4Q2P\T1*B@W2\SU^7KU4D$D=*J;5\9J,6J]EVR04=@Y>S'\D4*'L
M2U\*OW#DKD4&]_\`W(0_C7DW./\`WI_^[9ZEWG+_`/VYOWW>M==JY9;M*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7__4Y$:UP7G\RZTE
M&/>6%$7/9VVN?'J0*]4M]GGE(I&5PLVY1LS>N@7!/Y:/N&Y3ELKXVT[-Y-*F
M5/.2T>GA\<TTE!62_F<H[`PZ._MLE*I'<M5@`216SDVRWVQ@FN[UD0Z">]^J
M*D^9:S^(NNW&.&$O/9AY\O.5TUXD_(ZYCW:<EKEMK#\?XV(RCULID<E!SDN6
MOU$!34+$ZOEWOJ7@E1452'8S=A;O*NE176Z\O01-=XKKB7H:'-\I<X`>:O8K
M8X=SE>6M8(F=)(/F`))]':M!N0_:_P`3<5<R[=C-#S<[<\?@-CG8'7\O+BML
M0I2\0H1)N7Q^+0].6CUY[3@B]\EX):(6#W6(W=IMMN1#>>`63/`(83JT5ZZ"
MI[1@?.M/=;G.]TUJ)0Z%AH7`:=7#I(IZUU6]F7Y:^W<A89O9.6V).C<;Y7)Q
MM@:@F.B-O&SJAE3,-F(TZ77,/CV4!PID2V@H"0LL-.!PN-XFX[Y:;:R2"VTR
MWI./YK.T\3^B/*1@LJUVVXOGQR2DQVH'E=V"F`ZSU4!7?KC?C+C_`(FU^+JG
M'&I8;4<%#;2E$3%1&V7Y2TI2E4O*3SWS<K/>"!ZC\AQQU9\3T%<#=7ES>R&6
MZF+W<*Y#L&0'4!1=3!;0VS/#AC#1QZ3VG,GM60KF]^I_ROB;'Q^RL;&BFH%#
M[CU(L1UL/A\+]*KUJ^G!?'J`>%[?B.OV>=,S14Q4%2[D^?\`A]EJJ!Q.:>M2
MZE>(M;_"]74HBA6O]]@3^%78BE%;0&N"^%J*1?PZ>?CX];`>)-5`J4)H**3(
M!)5X^8'7\?,=:D!HK5`4ZE)N+A1/2YN4CPM\W@+>=ZNH2J*U,QDVE2&,3%F1
MA.E/^DZTI2ENM1O24\\Z&TV4+MV"2JR23XUFP0D,=,]AT`5[2H9).\(VN&HJ
M_P!;GHX&%!BMQ8WU+;3DEP?*M]<8N+0T^H]J%)CI<"19/7QZFM:UM;B25Y)H
M33C2M*T[5F5I&&B@P6E',.S177G6DJ(<Q$,9.>E02W&3'^N3!2XW)?<:;[E$
M.63>P3<FUQ?LK"!S(Z\'&@[:57+W\[73T&;6U/12M,_8N2W/4)S`[=CN2-*R
M*\1L&'S[;<CZ-Q*9&-SF-;BY7!Y:,DD][.0CGYK=S?J,+2K][MKK;%WQ-L^T
MG;J86\<BTU!'TZ5Q]ZUMO>BZ@?I=KQZ0X`%I':/)4+M[P)SKC>?^(M.V_'M,
MPLN\PO%[KC(Z5):Q&U8=+;6:C,I4IQ8B3'%(E10I2E")):[CW=U>:7VVR;=>
MW,<E2P&K2>(.5>O@>L+T>ROVWUI#*!1Y'>'01GY.(ZBJML4?^;YZ.5IO%Q*>
MY*#U2IY0)[B?`]J;?KK*M3X,#C]IZQY8_'N&D^ZP+47,Y1N9S82%!(QS"4FQ
MO;YDGH>OCVUNBW38`=*UI<';B>@!5;D[9Y2XKJ8KMDH;/6Y"5=O6P^SI6':Q
M#54K(NY3I-"N9V:]W,K6=ODX66'?I,>XXT[(;*B5+"CT4E*KD6MU`-;UMFQ[
M`3F5R3]XDBF<W0=#<,%SR]QGN^VC(9U^0AB=(Q:BXF/#CK6VV4?,+NE*OG=6
M#U'A:J2W3-O:&LBU'I58+27>'N?//H97`?6M)Q[@\EELLEO*ZY)AQWEA+1/J
M%Q140$V!0.I/WU@C>7R24DA(!6Z9L4,$=8K@$A9J1NRL0F`O(,SL(F<$F,N4
MA;3+O<`;`GY>X@^=;9MUX>G75@=E58;+.*<O#"UY;G3,+*,7)IS$-*[M20M%
MPX"%=P(OT/47K8M/B-K6JQ3:^"XACB"L.[WI$7+H4XE!C2A<H<2.BOL5]EQ6
MMN[42#$4*VUG=OBP>*A8/$.9KCO;-8<2A!/I26_F;58FUU"_;U^-JU@#H#1P
M-%MM39Q5A"RQJ&Z3'$!"U^JP"$A*R5H4D>5B>G4?=6SMKIQ'4L"XM6@]#E[2
M/R9WV)/LDP+T=I+*'.1-_4I"``GU#/B%:AV@#J:\JYU(.^2$##PF>I=SRR'-
MVMH<:G6Y=6:Y)=`E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B+_]7U,\"_EV>V[A"%%><T[&\@[2B/'$G/;IC<=E(C<IL)4Z[AM?>C.8S&
M-*>%T%8D2$)Z>L;F_HFX<S[C>.++=PM[<'`,J'$?I.K4^2@ZEYU;[5;Q"LU9
M93F78CR-R\]3UK>6+%AP&&H<&-&AQ(Z$ML1HC#<>,RVD62VRRRA#;:$@6"4@
M`"N=<YSR7O<2X\3GY5LPT``-:`!P6OGNPY:'"?M[Y1Y":?#&5QFM2X&N&P4M
M6RYTHPV"6TT5(]8PYTY,EQ(-_284:V>SV7QVXVMNX?A:JN^ZT:G>>E!UD+%O
MKCX6TGF'O@4'WB:#TFO8"N6_L$]CNLHPN#YOYDPQSF=RB6<EJ.I91WZC#P83
MA9DP\UE\<N.W]7D'E)46F7G'HWHE*EM%P_)V6_[W-"Y]E8O+7Z:/>,P36K6]
M&&9SKE3-:+9MJCE9\3>,#FEU6@\1A0NPQQJ0,J9U7:"X5=2OE(ZA`Z`"XLE(
M%@D`?LKA%UH`HOU-NI'2YZ>%[6!_IJE5114J'F#X>1MTM]GC>U*DX)12SBPG
MNM]OZ.OC?SJHQP*NX54O\RC<^'^'PJ\89"BIGQ7P3V@]MK]/V@W`Z57"J#!0
MBJ_CY>9Z>/V_?05X*VHJ5"6I1`*18=/&XO?_`(JN#17'-4)KB!@H*^XA:E]I
M+038`WL2H6O;IX5>.`"H<LE(+D#J`"+'IU_Q#R^)J4-KFJ>I4UUXG[SX?$?X
MZD#<@A-.U8ERDDP^1,8^XVU9_'/MH4!_$"F@25&_<2"A5KBW2X\*W<3->W/:
MTX!RUCWZ+^,N`Q:5/[=R/!CLX;'1'O\`G"6J0E"+$E`2T$75V@@%3J@`D^-C
M>H+/;GZYY'BK!1275\QK8F--'E:L\O1TS-:R4%3R?J]A3!UY.15WDLO(+\PE
M`_>4E+G4C[/.M[:'OM_-;5U/,%S]Z`8I!]M]&5\Y7&KF++99OD!UMUM^(7HZ
M(N1AK*E1Y"XLEY#<QM2S_$0KY2%&Y3X5TM@3&(P`"%QM](UURYSP6X"O1@?I
MFMT_RY>5F]/Y?R7&>4DK1@.4L5(R&&:4?X,?<=;A/S5(3?Y4'+8!A]"B`"MR
M*R/A6FYOLC+:QW<0[["*]A('H-/)5=3RS=Z97VSSW79=HQ'G%:^1=7M[VF+K
M,*=/*1=:B`;#JXHV-NHN!?XUS%G;OG+&XKJ+FX9;L>:"JYZ[&O/838Y.\OI<
M>AY,%12GJ4,W^5:2`DI/:D^9\:Z(-8^,0MI4+F7OEBE=<N]URMW=^4,=D-:E
M)B2$_4F.I-E'M<0HI/[PN%=`#445N62"H5UQ>,DA.DXKB?O,LO9_*NK47G7I
MTI:EDDDCU5$7/D+5N3W0!QHN.95[I'$YN.*I^IZ+@MZRT6'FEI8B-J4X^L,>
MNZ$,I*W`$@$)!0#<^0\CX5&862-JYE:*;XF6%[6-D+0>/0L2>Y[5M4U:=C96
MF,EV'BI+)2^\REM3RFTH<7\K:6PIL/`V-A<5K]RB;''#*(P)`<AZ%OMAE,\U
MS#X[GPD4!.?6L>\[\OX'>.+=>@PXL>+EL8TP7%,-I0\%-=RW%.+3=:E]Z^V_
MFD"HMTW"&YL(PW]X*'LHMAL>T7%AN4[WNK$:CM6EVD^Y_;]&G*AOD97%!PH,
M=\DO-I![?X2RKX#P-<W:<R7-F_0_O1=!7;7&Q074>H=V2BWGT?FW$[]&CES&
MRXJI``!4CN;[U7O\UST'XFNRL]UBOF`^&15<K=;6^U<=+P:*N[-#,=M3KD<3
M(*OF<3VW4VD^)MVW'0U)<1T%2VK5!#6N#M+E;6'U_&Y$A_6LBAE])"G8*U``
M*\TJ1>XO6/%'&XCP7T/0II9GQC\=E1TKVG?DL,2HWL<U]F8WZ3Z.1>00I(\"
M!/B`*3]A%>7\Y`C>W@Y^&SU%=SRVYKML:6&HUN76:N46^2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%__UO<&I0\!U^VNA.5%QHP7P235
M:'I2JYQ^_?&RN3LCP3P/$DM"'MF_M;;M\<EH/IU75RS'D/-J6YW)^H8R4ME/
M\-:5/%"38D$=CRJSP(MTW(LKH8&#M/>/[+>.1*T.]%MQ)8;?KH9'%Q[!W:_Y
M1\H"W"UN.F+CHS2H[$1$=AMIN/'67&8[;:>QIMI7I,_*$`6`0+>`O:YT=TXO
MD>X.)J:U/'Z?3H6]A&AK06@4&0^GT]*N?U+K""#<I*P;&Q"2D&ZO`&ZA;X^7
M@:Q"TTKT*8G(449*DH[@H=0E)[CVV^<J%AU*KI"+FX`ZBU^M!D"K:XTHI03&
MGE/-L.MN*84$.A#J%%I:DA80ZE));7V$&Q`-C5^AP`)!`.6&85P<#@OPJ_R_
M']-OM'W&@%,ABBA^H#^[X>7QJA%#0*HH<5\.+[?&P^(%_'[:N`)*M)4O<FZS
M<(3UMTZF_06\.IJ3+#BK3TDJ`XX#U4H>(Z>`3Y`?>*O`Z%0DG%4YZ1Y=Q[+^
M`/3]'A?]E2-;B,,4R5-+KA)%[`GR-^[X'X>'2I@T9JTN*^"/E!N>O3P^/VGS
MJE<<"E,*G-85W/8L)@=_U?\`G\E,*))A9%$=YQQ+;+DH-BS:K`*6H-W(NH$'
MPZ7OOK2"6;;[@1-+G@CMHM3=3PP7MKXSM+2#YUCQG$2=@Y.@Y&`XVG!0&9"!
M)[E+/<\T\XEQI(_A*6PZ4J`4%(-OF!\*S'2"#;W,>#XII@L3PW3[@V1A_!:#
MBM*?=GR\]B-FP6L:P&E16),EQ:@KN><F//%F5-[05I[G/4[4`FX%_N&YVBT+
MH733>\1YAP"Y3F'<3#/%;VU"`2?*:`GM6A6RO.[1NZFYKJ>B%8R,H#Y4O265
MW!'2Q7,<ZGR/W5NV1AL0(&.:YF65TUPX.=QIZ/K*I>MYC+Z#F-;W2"E7\VX_
MVZ!F&VTJ4A3J\/.9D2(;G:0KTIS3+C#@/12%D'Q-3W$#;JRDC=DX$>=;C;[@
MP74,C?>H#Y0NX/.6X8R>W@\5B9#<N%D&HV1^K;7=#D-]`>8>!N24O-*20;];
MUP>UPO:U\DC:.%13HZ?,NUW>Y8XQPQNJTT->K\JQ7L&QXZ9B$8Q"6W6&VDM$
M'MLJR;'KXVZ]>M9T<+FO<_I*P)KB-T89P`6C_/$7!Q\,\UC9:(&3=:6IM+;G
M8M:K`D(*?FN:VEM"Y[JEN"YO<Y8XXZ-?20KE%M,;.XC)/R);#C\9Q1['4))(
M!/B?(CK?SJ.=DL3S5O=5EMX,L30UW>6>_;UMFLZY(RN1S,-F7,<AN(@&0"M#
M3O[R@4=1WK`%K@CI56,=(QK6NH:XJCY([:=SYHZT;0+5[W%956=FSBZA*43G
MWGPE`"4-]_=VA(\`$)('VUB[E30(ZX!;CEUIUF:E'$DT7-G95R\=.<:<[G(J
MBH'SZ&_G;[:X^?4QY'V5Z1"!(P$>\K'Q/';6Q9D2$.%$93J5K1VGNZK!4!\+
MWK!BV\3S!W"JRW7KH8M-,5VV]NG'NILZCC6TXM@*::`)=922M5A=5UI)\_*O
M7MEL[:.TC:(QDO-]YO9VRO<'E7ER/QH8[;T_&('TBD*+D<)N``#<C[A63>6(
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M69XCB87./`8JY[V1@ND<`T<2J!B),*2]-R+63R&1>R<@.MHD3'U0(<-"4)BQ
M8&-]01(W:E)4ZZ$EUY1)40`$UESLD8UD)A:QK1P`JX\279GJ%:#@HH])U2!Y
M<YW7@!P`'T)5RLQX[`46(L1A2UN...,18[+CJW5E;BW7VV0Z\I:R5'N4?F)/
MB:PWO>\]YY('2<!3H'!2`!I-`,?:OHJZ$!/7[3\U_/KY5;3I5U0,BOBX%_Q/
MG\/,CK51G54KG52RG?3*2JU@JR+WM<WMY_\`!4H`-0%:'``%0O7"BH%0">TJ
M5=77J;W-S<%1'2K@VE,$J2,UC;8>3-0P<ER!(S$5V>VKM=B1W6W7(Y-R1)*%
M*2P1_DJLKSM:MG;[9=3M$@B(8>)&?8L.6]MH7%KI07]'0H&)W/%9M'K,/(#7
MQ*QU4?*_07/D/WOL%7RV$D.'%7174<PJ'8*MS,OBH$9R5/R$2&PVDN..RI#3
M*4(`)4I164V2!YFL=L$SG!K(R3V*5TD3&ESW@-Z20J'/WC6,?9+V7A`E(4?X
M[7:E!L0MQ17VM@CKU-SY5/'87+S7PS3L43[NW:*&5N2PQR)EN+]X@QV,@Y%R
M\Z$\I_$(:4AQTS4"R?INI[B#\I/:0+]#>U;BQCO[-SBSNL-*UZ%J[V7;[QC6
MOH]X/=IG7J5M<?07G>/MNF-O.Q\S`ERDF$ON;?C1$-=R$@J`4DJ0LD'PMUK)
MOWTO;9A;6)P&/"J@L6ULKEP=29I.'$!<BMG1/V/?LQE\F$_3X%A;K!25.--I
MBW*6P;D*>*P5?NE)_P`FU=BUC8X&-9F[V^Q>:3.DN+V:27W&#U9>58FA^NG:
M,:IQQ+\E>2QLI:^_U"5OK9DI2H^/J)#@"AY&XK,PT.`&%"%B,:X%CW&KBX'S
MD++V]:,Y'V+;(L=HAEUG'9<-=A\,@)+;RDBP%A+BJ5]RB*I92!\#6N[%MYH7
MQ7+RS[)KYZ^T*#DN9\O$UO3,:R^J3+@:KA\.\\ZOYFD86,G#I'@J[JDP+G[3
M>M<RS8UTM10:CZ5;N&ZRA[6L-3I&/5T>97ZG?94+5%9F2ZKN$?U$MJN%*6NY
M0FZC<DFP_P`51&!KI=(%`I/C7LM?%/1DM2MFV3);+DUSI;A<=<5VI2"2E".X
MGM2.I\ZV#6A@#6#!:D%TSG2SG%2CF"BSXRFY[*70H6[5@$B_POUO4YB8]M'B
MJL$YB?6,K"6>U)_"37)V**TLW/J,)!L$@W)[03<=*U,]LZ%Q='DMQ!<,N&!D
MH[RP_N,-K/-*#@LZ@$6\#?PZBM=<-$HH<UT.VUMR.A:L[3HC@6M;D8+:*OF^
M4GI;Q!M<$VK37%E6I(P776]V#0!V*F./L3B,%E67Y6/]>,%CO;L2.A!O8_=5
M]A%%!("Z.K56[D?)&0'4*Z.Z;R7J34./%A.,PE-H"0R2ENQ^`ZCPKM[>\M]+
M0P@47'7=C,\ESL0JIO/)\9.)>CL.LK]1M8[@M*NG:1T!OU-7W-Z!&:$**SV[
M1('4-5I9DLN63(R4A]L1''5%0[@0.Y5OC;Q-<W)+@9''NU73MCU4:!BO9=^1
MX^Q)]A^`>CD*:7R;R.4D6M_[48=[$>(KR/FXM.\R%N7AM]2[K86N;M[6NSUN
M77ZN86Y2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%_]#V
MZ+<"O,VMU`/2ND#<ER`:H'<3T_4.M_VU<`:55P'%<Y??UR7L?'$-<S5'W865
MS6LZ;A$Y1LJ0Y`CG+9_(ROHU)4EP3)2'?3"DW"&^\W"@F_=\FV<-U$?'`<UD
MSS3@>ZP#R#UKD>;+V>PC)MG:9'QL;JZ!5Q-.LY5X"JR[P;S-AMNXJUK8LOEH
MBLR=<8G9IEDN+<#\=Q^%+4ADEQ_L,R&M(*OWE`]564:U^Z[3-%N$T<$1\(OH
M.C&AIT9$+9[3N<5WM]O<22-\3PZNIY0>O,%<F>=_<9N7(^^[!)",RUBL).9B
M:/!AY#(Q<=A4QYL9"Y<O&17D0,G.R[`?0XX^A:U>HTELI2W9?H&U;/;[?:Q-
M;I,CAWR0*NZ@>`&%`.C&M5YQO&^7-]>SD:]$;@(P"0&T(Q(&9=B#7'$`4I1;
M.^V[W%RLGD3JFZHE1<TTIM28RH\I*7D.(0&Y)6\KO8LVY8-E5[&X"A8C5;SL
M[/#,UO2GTP71[#OKI9/A;P%LPX8^?'U'R+J.)#JX+4E'1*VPL$$7L0.I*;6O
M7G1C'BEISJN_`JT.X+!6V\MY+!N*9QD!B4H*4CZJ4XY]/W)-EAI#?SNA"NA-
MQUZ5O;;:(I0#(\CJ"U-S?F+".,'K.2MW+^X%[&8N,]%Q:<GDG.SUHRG5LLJL
MD^MZ)2A:FQ<?+W$BWB:FCV!DDCPZ33'PZ?*L>;=A'&TMCU2=&7UK&N4]W*VD
M%UK"F*MH^BXTZZN6R'E)2$]I;:;6@A04".[X'I6?%RNTX.>2#QR]JU\G,3`*
MMAH1A3-89V/F_D">N1DU961%$]:$F#"<<9988'RM,QBA0=;0!8J6"7%&]U=;
M5O;?9+&)C&>"#IXG''K6!<;K>NK)XA%>`PPZJ45J8C%R,OW2B'4OR5N..=O<
MHO+6HK!4H]20KIUZ=?#X[!Y9&`'4H`L>*!TU74.H^DJ_FFMGQ,=)3E'X#;`)
M3Z/:%-BUP$J5?TP1T)%C;SMTK#T6LKJ>$"X]*SQ%<Q-KXI:!]/(M*^<.7=G;
MR*,7`VW(/(9<4M]MF4OTU%"KMH=4E7\9*5"Y2?E)'6];.WLK9C"?!`7&;WN=
MUXPABNW$#-:^3^1-QSZVFYVPY602M*4)3+=0E14L=B0VTM*?D/1(``'WGK.V
M"!E=,06ADO+Z:@DN''J^GH72SC'^R/$&,@[%MTAV1FOHXCSDK)+]:8TIYD):
MB1/5!;@J<2Z4I:CI]58Z$KL*YN[;/?.=%`*,K3Z4S\J[_;Q:[5"RXNW$ST!J
M<^H#H/4,5E+W#<D8"+D=#V30R]`P&]ZHZUL.-8?3&=?G-1EOL/RN^SRI782T
M[\J2$H1YW%:_9+.Y\.[@O2'2PR]QU,@3D.K);7>K^&-]C/:X0SQD.%:&M*@G
MKS!7.+(:\K'<69G89"BRO+SY#$9UAXR"^H+=22IYI2PMMQMA=U`V(2":[`O#
MKIL0X"JX,0>'MKYW9O?0$8UQZ5K[QU$5E=UUZ&W=:G<S!N`;&R9*+J!(/2WA
M4[W!L<KCP:58R,%UO&&XE[1Z:KHCG\(Q(Y'RR;#^#J&(6H+2"`1E\ZE"C\%6
M:4/LN*U]E(1`PG\\^H?6NI,+7;C(VG^J'K=]2YSP\*Y.VAV`Z%):C9*4EYL@
MW0AJ6YW-V_JJ)-K=+&LZX.@O*XN:/7="/@:5\C0KGY1SJ&S&P44I;CQVT+<0
MW8!2U#^&#;Y?E'6UO$UCQ"@,A]XK(N/Q)F0,PC;G[%B_%LGN#JT^!)3?SOY]
M:RXQQ*CERTMR5T=UT7MT`)-9`6$UA+@TJVLE%2\E?RW!!"@?/QZ?::@D:'!9
MT=6%M%@+;]/6"[,@(*7+DE`\%>9M;SZ5J+BV(JYHQ726-V*M8\U6*B(ZTN0L
MM$]-PW2%+;Z'R\QTO6(T@@MD9BM^UQP?&\45J2=68CJ4]$*%(-S86Z`F_@/`
M"H_!:#4+*;.YU`[-4VT1EP(>4&5@_O!?:?P-^EA5.ZW#(J3$J@[%ZCT1;<3*
MN*N"`/5*B+]!U"C4,]2PALA4T5`X:F!8!SO]HV&E,O2GG(R5%81ZBR!XD$"Y
M!-JT4YN`VCGDM6UB\$FK6BJ]R_\`=^)CTW\NG677R2M'*_*+%R2;I:RD()/7
MKX&O.M_>7[@XNST-74[8T-M0!^<5VWK2K8)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB__]'V`Z%S1JNZPV)./R<62AU*5#L<^<7`\4^/
MC]]>A7NRW-H\U:N%M-PM[M@?#)4$+-V/<8DM^NVXA:>VZ1<>77X^=:234#IH
MMBUNKL7F8_-@_,$WSVT^Z#'<>9O1-+W7C79>$\;G,"_/Q\E>QX;..2]XU=W(
MPGW,NUCI*H\R,ZVIM;24AM=_F6GKTFV;DS:&1L<QW@N>YSM)HXG`AN.&G!M>
M.>/!<KO3'W$Q:6M/X8#=0J!F*]N+L<NKBM'^*_SHN(L#HKO'V_0]LUF$^I2P
MS!P$1R.W_K+TM#[.1PJ'9Y>3*DN*"70M``'P%;W^U6P3W$=S.Q\5RW\[4X94
MX5'`</6M=9[5N\=H^VM6,EMZ\"UI&->@=/JZ%E)GW[Y;;=%P>_\`#'!KHX]V
M#<)VIX/EG:%+_D*LUCS"3DWLKB\"XWGF'<='D^H$R%-6195VFW0I>Q9O#;UA
MGM&ZH2:`FE*5I4MJ7`5J*EHJ1CP6)/`^R>(9X6,F&.`)-:`T!P:74-31QH#@
M,PM[T9_FWA+!O<]N:UQ3S3H+4/'Y7(YCB_)J5GAC9;;;S>;.'R^9S..RT24A
MY+C7TTEKY>B9C@\:OO!=QBVD#P2RH%-->)T.`TGJ!QZE(R*?;WF\?%&8M6+A
MB14T&MN8ZR`:=-%GOBS\R'CKGO'_`$_&6\\?C(Q4-1\KJ^4<7KVTXN4XWUB2
MM;V69$GEQ*P4]T5,QDD&SJK$UJK3:MGG<YS9Y'O:<1A5O:`W#HQHM[)NT[=#
M9&LCU#"O'L-:'R55[Y_,[GLT>"'H28DA*7&I4G'8V=]'Z/K+<97',AA8#SK*
MDWM=-[VZ&];J"WL8'.TS`LX`N%?+BL&9UQ<!@J`>-`:>2H5*CX"&S93[LV5(
M[?G5+DN(L3U4`T@-(`)Z6(-9'B8=UC0.H*K+2$9N+G=95O3N-L3.7*<;FS(#
M$Q:77XD*2TB.J0">Y]"'6GBVZZ".\I*0H@>=[SBZ<RE65(4#]K@D+],CFM/`
M$4]N*DO]UF.46DKR^46ED_(%OQU*Z$&W<64CP'D*N^-(S:%8-HB-*S/('8LE
MX>%'PL1,=AIQP)2!ZKH05$`6-BE``O\`=6'*YTSM1("V44386:6XJS]Y@;-L
M&*E8_"+AP7WFEI;D.O/*[5*!`*FT-#NM?PO:LFV,$3@YY)\BQ;^*[N(71PN:
MUQ&96AF0]KO+4S(.+(QDL.*4XJ6O(!(4I1))*'!ZQ/X&MF;VV(KXF'85P[^6
M-U+S@PU.>I7UQM[:]XU;:\1F\]C(.0AP9#4GMCOL2W&G6EI4VZEITA'<V4W!
ML2"!:QK&GNX'0R,9)WB*+)LN7;^WNHIYXFEC37`@XCMHMF-KTU_:=GQ^4RL#
M(IQ.*4B6TV(SRWWY;;8;^=HH+:&NV][$DD@V-8$;_"@,<;FF0YXC!;RZL9+B
MYCEE8?"9B.))[/IV+6SE?'YZ9*G/(QVQQ(L5IQN$7<+EW&5);;?0E"'Q"=C,
M1E)<("4D(\#TK:6.EK&MJTFN-"%H-U@N9#(YL<C0`:5:[R<"`/,K?W'=<3&X
M6AZ1C,ACI,TLP(4R(6934QA"5_4R7@A^.A/K^NR$DDCM!/6Y`JZ.U>;U\[V.
M`Q[/6DMU&S;(K2-S2X4!%#48UXA6W[3^/7=@Y#8S,J,]]#A%HE(>*#Z`?:2Z
M\HK/:0L-M(N?A<?946Z3>!:O`/>=@K]IM_B;Z(G]VSO=5>'M6[<#'M[)M&Z9
M-IGU&@K&:U<@I0IR`$Y"86R0E0;;5FR%*'0*21X@U@PR&"&!IS`+O73U+HK:
M-L][=RC$8,\V)]+O1U+1S$ZFO)[CNV>9'IXY[8]A<BJ;N$>B<M.6VEL7-PE%
M@+^0K9W#@`QF;J"JY,P&6_O+@8,U&BUYVMA+VQ3_`%5]Z6YCJ03X#L(2/&_0
M=OW5-&P$-KD%K`XMEF-<2XJ3]5#7;Y`!(^4C\363@I&,U5Z55@I)8NGS'Q\_
M\1J04HK6Q'Q!7)4LJ"SV$=;GH;=>GZ!5AQP64]E!J&2IN1Q@>9("01XVL+@$
M?KM4;XZA7V[]+NM8OS>JQ9`47(Z21?M(2`H?B*P9+=KLVK<PW+FY%8TRF@.2
M`HPY#C!*39/6U^O0]+6K"DM'GW'+81WX:1K"ULWO1][Q0?E16')L=L$]S755
MO'XBM)=VUY'5P%0M_9WMG)1I=1RUVD[1E<:\6IS4F,Z#\R'O42;CQZ*Z&Q%:
M5UU(PT?4%;H0QO%6FH4*;M34Z.HN._,$V2/C<=;GSJU]R'M-2JM@T'!>Z'^[
MV+#GY<FMK'@KEOE0C[?^=(/6O/\`?#6_<?T0NHV[_EA]XKN%6G6>E$2B)1$H
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MQ(K@^8MJ,<.@D@MH<.@C36O46T72[?)#=2^)(XC,`@TXZJ=>#O05Y5W,_!R2
MBB9QUB%DD`NX\R\6DGS*$-O=B+@_97G%Q"^,G1?O;VT*Z*&(MHYDU0JW!V"?
MA\=)P^"E[)JF+R+\9<O'X_:C(B.NM/E?KR,<K)(,@MH("06BL`$`_,J\]IN-
MW!&Z/XUQC.=-3:^08*RXLF3R"5\3'RC*H'KI59RX@]T',O"6NR]-XYY@W37&
M<XK)8+9L&]/^NX^GZODE'ZQ3>J9[^88TSI10WVNQH[#M@0%?,0K=6/,&Y6)+
MH;P?"-;4--'`.Z@00/)BL"_V^&Y8_59'6X4[N#NPEM*CMJK,W&7+WS=9V<B9
M;8X&Q*R,MS$YMB')QTIZ+(EO24O+Q^(;6SC&Y4I]Q[LC#M;6ZH7-<?+S'?,N
M';E<733.\ZGEI#:.XZ2-.660[%NK;:88[<645I6W`H`[&O;4D^M9RU+F7WO<
M=X^.O3N;-YD0(X2VPQ&V>=F$62L@MB!EI"Y)4A7RJ2&%!)L#;H*V5K\U(HG&
M*7>W,<.$K=7I[PIVE:ZZY-:^DC-E):1G$_3Z,/,%F;#_`)FGYBFHI#4[?,K,
M:9)!&>TU*%'M'@I]>`C%0MUN%G[ZZ.U^8C+BG@[IM\SN@.;ZFE:B?ED6[:R6
MVX0MZZGUE9&Q7YU?N]Q1#>?7JF4";!1<P@0L@$7%@XU<]/A?K6ZCYVNLS8V[
MA^BYP]16O.PL=A%NERT_I,:?8LRZQ^>ERFU89W4-7?4?WG$8M!<1_FH6\HBP
M^PWK)9SN_P"UM%1^C*1ZPH7;'?1U\+>@?O1GUA9DP7YX");K7\VUG%ME9`6D
M0Y,?YK#YO]60H$7\K@UE-YZM0!XFSW([',=ZW!1'9][%=&YVKAUAS?8MC--_
M-WT+9UM,S(.NXY3G8"Y)5LB"DD@$=T?"RDWM?Q-KUL;?FVPN*%NWW@_Q6'U.
M4+[3?8<'OM2/OT]BV>USWX<8YY*5L[9I$5PB_9+V(8P$]"4(.6Q\!PJL>@L"
M?*M@.8+(TK:70'7$?8593<AQM]74\+).5]V&(QN,3E,6O5=@9]!,DG&[SKQ;
M+0[BMDN/3VO2D``63V+4219)'42P[OMD[M!=*QQ_.C=[`5;._=88_$;9L>.I
MX&'EHL>H_,<XH,=Y3V/V2-*99*O0O"DM.R4K"5QTR6G4%*`+E+G8I*K#H+WK
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MJT[\R_VB\DQ<JCA\[DXZPRXF1#R&LN8L').AZ8](=E3I##3CCQ)6XX`>WX=*
MW&T2MW-Q(NFN+3B:.&%,L1P45UHV]II;N;45H",ZG$X\3U++/$.GIRG'V&D>
MBKOFXYG(/A0)4EZ>TF6ZE=NA6%ND&ME>W-+AQX57.V-H'6P!Q.-3VKGSS`PQ
M@=^S\%MM3;+<SY4?#O;;6HW'_+436XAEK#$XG,+F9+<?%W48&`=[%C7ZM*[%
M!!2?`?;]WA4P?7+)2!FD4X*MQ<@%)]-0(M:Q\`;#PZ_=4K7<*(8Q4$#%04O*
M5(`OT*^@'F/"_P"N@.*D<*MHKB0SW(!(\?V6\?QJ>@(R6,.[455*G8M+J24H
MZG_PJB?'7$*>.6AH2K;?QB6C=35OA]_^.H'1TP4_B$BH*I$C%-O)6AQH*0>A
M24@@BWF"+'QJ)T=12F"O;,1QH5AW>.%]3VN.M,O',H>5>S[2.QQ-_P#-M6MN
MMKM[AM',%5M;/=[FW/==5JTXW/VJ9C'R%/:V^9D4]RO065=X`/1(-CXBN9NN
M7Y6&L!JU=3:<PPR"DPHY>U/\@K`S]:_+UU_$9*,N)+C\L<H%;3@(5VJR<$I5
MU`)"@.AKS'F*%\&Y/B>VC@QJ[S:)F3V;9(W5:7%=J*T:V:41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(O_T]IBVIMT&Q`"NMK7'7[/MKZY
M<WBOE-XPQ6T_&?:ZQ'3?_(_0;'KU/G]IK67&%5TNU@$-JKUY\T[`\H<,\@<%
M[HEE>L<NZEDXF&=>](&!ONL,*SN'7#4ZE38RLB-&,YA2P?FPB46/=8\MNUE'
M>M+7MS!8>PY'_%=Z2NF;<268U-/=(J/O-QI_CMK^K3BO!/M&<V?7\_D<=-C8
MR/,Q,Z3!DQ3A,0D1Y$-];+K)0J$KYFW&R#?K?QKP2^VZ-DLD4K7:@2#WG#'C
MD5ZE9Z'P12QOJ"`1Y4QFUY#.O-0_0A1IDE=FY#!3CT%12D$*2U>(F_;_`.M>
M)K6OM8;>)S^\6`9''UXK+:R1\@%14^19N:X0WO%HPVT940G<?+6V\PY_-6L@
M$E1"D=S<=AM()2;BY_"N0GYLVF<W%A;ZQ,VH/=T]N-?8M\W8-PC;%/(UOANR
MH:K93A[@3?>3>7--U'7&L*G*;2M4#"?4S6F(C\N&P[+6P^M_'RHK-V@5]KJ%
MMJ"3>XK@N8N:=LV;8KV[N?$+(R*T%3WB&BG>'$CB*572;-RON.Y;E;VL)C#W
M@TU$@=T$FO=/`'@:K8R7PIS7QQFTZE/V+ZR/C,M)A3\=`CX3(X:/*7,D%U,&
M4Z]"EQX]F'"M*&64)-[(!KS,\V<I[Y;2;C'9!LKHP0\E[7$4%*@!S2<10U->
ME;^78M[VN<6DDNIC7D$#26UKPJ0:>0+*$W6^241VSJ4;`N/H_?1F_K5QE^!`
M2Y"6I\'N^^N5CW+E\R._B<DP8>,>FO\`E8+;.L]R(!M&,U?I5IZ,50QJG._\
MPE;#DN&N,-KRDB,W#>D)V#*-RI\=E?<VE<3*8F1CTN7-RI?:H^!4;5FG=^3'
M0LLH.;MRMK<.+J>&PAI/Z3'AWF\RB_AV^ZW7$FQVDTM*>\:D#J<VGE*R/B-%
MS6099.S^T#3WT.E!D?32M"G.HN+K4E$O"0TN6N+`NB_A>M)/OT%L]W\,^;%Z
MVF51=,!\HD=ZEGQ;/),&_&<C6Q[/!<?2T>M94P_MMX+V=V,C-^U!$0NE*'7F
M->U6`RUWW[_4>U[9XDD@'^LA)5Y#K6QY?YSYT^/AA@^8SY8R\"CI97UQ_I8S
MYE6_Y7Y>-N]\O*+6$-X,8W]AX]2WEXN_+E]L>0Q;>39X4_EH[!=*<ON\5?<J
MW_DD[.XT+>5AX5]^\EQ<PR;5!<W.[B1VD8Z68X9X-7SOOEGL;;R2./;=+:Y:
MG_Z2RBG\N[VVKD*]/#;1B#<*#$':,BEMM-[62,@WD'$CIYK)K9WW,^^;<\L\
M6)U.E@]E%@Q\K[+=-U>`\5Z''VU57_\`J8G#64L<-NW(N`4JUDJG8;+,I)/^
M2_B8KYNGI_I/QK5L^9N[0.I+9V\@['-]3O8KI.0=J<*QRR-/^*?6U4S)?DVZ
MSL:D(QG/6?QT<A7>U*TC'RWS<'J9+.?A`V4/_6^H-2R?-F8-=XFU1UIPD(];
M2H&\@1-=2'<'@=;`?456=:_(-XUD!<C*\^;7*F.E:EN,:7A66;+<NUVH7EG'
M/40@64KN!)-Q8=*UD/S3NY'DMV:*OZ3W'U`8K)DY)C8T@[I)AT-'M*R(W_=X
M?:WM$25"Y!Y%Y-V!3BDKQTW79,74IT!02$D.(6O8<3-;O<CNAI4%?UK=*P[[
MG+>=U<#&V*%O0!J'I2VV&UL:Z[A\G:`/4M>-_P#[K'PG.@37.-?<]REKN1/U
M#D1G<M;US;8(6M1,5IYW#O:?*[$7[5J^92KW`'A6'_%M[9&7%T,CNQS:^4..
M?W5D_"6A=DX-\A]@R[5SLU[V#;W[&MPVKB+DC,X+:MIFSXRL%GM>$M.*S6N9
MF'WKRD*/D&VYD=3..BR6W&5H_A/,.`*6FRS[U\LYF[AL#MP>PLG=,Z,M)!H1
M350\10U!H,#D%Y?SFYUG>S0AHT-C#P1Q'V>NI=@?71>@?VZ,,Y#0<;&D>FF5
M_+V4+!M<*2PA)^WNZ?=6UW>K+HD'NU]JQMB`DL8@[W](]2YA^[C7AB>5<HV@
M=OU+$>0;6\;*;)/E;^$*Z#;W&:RB<N7W&/P=UN6CB`?8M3[NQ5A5O`^'4)/V
M?`5D@%IKP5C0#AP529S,<_*Z0VL6\_']?C4PE%,<U4PNI5JG&7^YT.-*[DW!
MZ=;=?M^VJM-78%1EKA@X*YV\MVH2%`W`^_\`4#:LD2D4"B,(/%1QE&G.T?N_
M&XM^OP%5\0945OA4XKX?*'TVL+'S'QZ?A5'$.[55H+>&"DE0$G]U1\+VZ7ZV
MJW2"A=U*FO0S8]Z>H/B?#I]OE4;F#H56N(R*I;D1+:@;`C[1_P`%1EM%()2X
M=!7J4_*9;0U[0<.&TA`.^[PH@"PN9L6Y_&O#>?!3F"2@_P!4SU%>S<E.+MBC
M)-?Q'^M=+ZXQ=:E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B+_U-V7\4E,JQ%D]]O`WZ_'R/6OKHG"O%?+[X>_3@LW<?@Q%,B]D@@7\NM:
MZX%<LUNMO&C2.`69N4-7E[[Q9G,5@Y!B;9CFV-CTV>BWJ0MLP+@R.&<024]J
M);K2HSM^BF7UI/0FM),PZR"!0X+IWM$UJYGVAB*=(^E%XK/=OPWGY&Y<E<L8
MW'1T:^_M$5W/8YA;+,S"9G8/KERDN8XK$OZ5W*0GR%I0I"`I(6H$B_E7,^U2
M"ZN[V,#PRZI'$$YX=%5T_*^Z-;:VNWSU\5K:!QR(&6/31:4X##RY<T(89<4R
MRH*><ZMI9Z^/JFWIK!\/.N!NI&PL=JS7;QCQ'#3FM_\`3]H,72X>MY)4F?Z:
M$%KZI1<<:LJZ"TX;^HE""3]WAX&WC^\;:UVXRWL+0TG.B[.QW,MM66TIK3*O
M0M^?93NVM:/ONR<N;%-9A8'@_0\WM2/66PE[*;-D(XQ6$PL%#KB"^^\XZ2I"
M>JN@/0D5X[\R['<+[;]NV/;XB^]W"Z:P8$AK6]XO=2N`-#CP!7H7*>YVMK/>
M;I/)IAM;<GK+G8`#MQ\M%F+$9Q_:2K)9.2],S$HOY;*27FP.^;D(\9DJ#B``
MX/J%/K"K?-W@UYK?6;-O'@V[:6[>ZT=0-?50+8LOOBOQ9#65U2>T_0K)N#A(
M';<63=)^V_[O6U_&N0OI7$D<5N+2A`-5FW`XU)]+Y>AMX"W2]K?;XUQUY.^I
M`*Z*!@[JSAKN)0I384D'ITZ=;`V-:ATAJ!5;J)@H,%L#JF&27&OX8L5)M\H`
ML".M=MR/WMYLL?\`6M]86LWS_D+@@8Z#ZET"X_1&AZ\S'*4E2AW%-A;J`.I_
M=M;XU^JO+6[VUOR_:M;(-08/4OD+<[.23<97.:::O:KH9PV.EO\`JKAQ5K[@
M>\L-^)-[@%)'A7GO,/,#3.ZEQZ5OK"P<&"D:R9A=9Q[W8DP6+*(3=+:47(MU
M"@$W\:Y,[G)*YC8G$EQZ5L70",$N&2REC-/Q(^81$I/:D72I0[;$V(N3U(-9
ML4#I'.=(*G3UX>E:Z>Y\.@;3-9!Q6%AMCM;;4$A':"5$DD=.A(_HK>V=H"T=
MW@M)/>R%Q`(IV?E5UQ<>AI8*5*N?(V('@/&U_&MU;6;6T(<5@OD=(0"JZY#4
ME@*2>\JL;=!8>)\3\WX5M)+=WA84-5313[R\P_O"W?";K[R>4<LZIN1B>-X6
M-XUQKB>]7JYV)CF9>ROE*`I).-ESUQ+C^LIQ/B"*^@?E]MS[/EBQ:![SG2'M
M<</\D-/EHO%^>-R@?O5Q$78-8UOD:/\`2)\P7QQSSS@^,\/.;RLEV3-^=S'Q
M(J75J+;C86P`YV!KL(-B2H=:Z:]VYUX]I;@.)6CVW>8K*)['DNDX`5R.78M,
M^6>0Y_)FW3=ER#(84]VML,!7=Z,=O_1I4JP"EDDDGXFMA!;LMH60L.`6#--+
M=3R7,K:.=PZ`%A^4CN*DI'CW#X^7^.CE+&0*J@.8TN.7)-CXGI^SQZ5#H)-5
M*'N&%%.1VU0E!25E201=)/D;#I?[*O:"SBKJZ_>"KJ)\>00@*"7`.H)M_AXU
M.'@\<5887M%1DHP0]^\+*3]AOT_`=*`'R*$GI4VQ)4C]XD@>*3U(M5P*M/1P
M501,;*AY$@"QN+?C:U2-=E51/`QIDHSI2M)%AU!`^V_AUJIQX*-I=7`*WG4*
M5=*>H!\/,V-1.%:*8&B]1?Y3X(]H>&!-[;WNX_\`QV-7A//W\PR?[IGJ*]HY
M'-=AC_WK_6NE5<6NO2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1%__U>F,S`_/W=J2/'P-_$??7UG4KY[DMFN*NC`Q?IRBPL!8_;>UCY"L
M:45%%+"S20LPX+*K96EM2B`!T()O\#^BL"1@<*%;>"8C"JXJ_F#^W/%X3>I'
M*N.@,R-*WI#4/>L:6B8<>8QD(V37)6W&2'&6UN0TO%Q`]3TR\A/0=>?WG;62
MM%T6U;2CQU<#]?%31W4D$@ACP)-6$=/%OEX=>"X`\CZ;.T?+9#!JCRHL!K.9
M;&P7WVOIUKDPEMO+1)9"O4;?=B3&5I[DCN"NEQ>WC>^;3X,KWAITZB/-]`5W
MFT;D9FM&O'2"?+]1PZE:#.R[1`C,NP\BF3'QOI+]!YM"G&56Z*"D@.M7*0D$
M+"K].MQ?CI=LLYB[7%1Q6SGW>>WFCA><#D5D72-JD[TXK7IC3R(*WV)<_%HD
M.)0^Q%"5./0UMN!7JI4G]Q0(M;QL+<CO.VMVF/XV$UEH0UU,B>!ZNO!;`;Y$
MS3#=RZ87$5SH5UZXG7../>GY`,LJR2X7TD)E_P"I,&%!BIC-LN/WLXM]P*=-
M@.VX!N037ROS1'%X[886GN5U$BFIQ-<NK`==%ZOLFX-N8A/%,UT3J4H:X#!;
M1:^@.=A4?#M_&_A?\>M>9WL!.K2,5W=C<!I&HX+.^O\`8A+8[1;O`"A:X(L3
MY>=<==VSM;CP7407((:M@M6;1\GRCRO?KU'46%:.6(M(6ZBG!%%L+K*6VRW<
M=>A_'IX`>8K;[-=OL;F.1HQ!JJ7;63PO:3@0MB]>R#G:RRTXM+(0"N][$CI8
M6(\Z^CF?-B]MMNCMMO<YS@S'7T\:4)KZ%YD[D^WFNGS7(`!=AIZ.M9XUHI4A
MON)58@_-U/CU/VWO5=NYEO-U:R2\N3W<2*YGZ%0WNV6]EJ;!#B5F_!`'M!38
M$@]+>0\!X#PKU#8[AMQ&'4P.74.A<)N3"QY%<5D^&FS5QX$"]_/X6^-KUWUJ
MT"A;6G6N5N":NKT*\<:FS8^T$V^"2>@'W6KIK5I/:M&[WBKCBH!4#X]+_P"`
MZUO8AE5&"I)Z%H/^9'[ET\$\&Y/7M>G"-R+R?!RFL:PVRX43,7B'8Z8^P;*E
M;9]2,J%&E)9CKNE0D/)6F_IJMW7*&QG=]Q$\S/ZA!1SN@N^RSRD5(Q[H-<Q7
MF.;=[&T[<8HG?UR>K6TS`^T[R`T&6)'0O,=@\^]-?E/Y";)R&4GS)F1RF1GO
MNR9N4RF2E/3LGDYTE]3CTF;D9\AQYYQ:BI:UDDDFO?[)L,4,=O"P-C8*`#``
M=0X=B\$NQ-/-)<3.+I'8DG$JL3XXEH[DJ(6+6!)(Z>'X6K+<`0H(G",Y*RI*
M'&W%(=197QMXVZ5`<\<EMF/#FBBDT!*U#H+FXN;'P!^_X5:IB`1@%%^F0;GI
MX?"@`.00$TS4DY';LHCP'EY6/3]M4+12M%,U^`5L28SB75*2"`>MQ4!!!64U
MXIBIO'Y:1&=2VOYFP;'NZ]"1\;W'6KF/(-#DK70M>VOVE<SDJ*Z$K!2VH@>!
M`!^/3I4Q+3C58)C>"110>_M47`04D6%C?K85;7C50N&-.*^H\QU3GIH[EE1L
M$VN3<CP%C56N-0.E5T4[QR5\XK`KE.L-%AV3*DJ2AF(PVMYYQ:KV0EM`4I:B
M?("LG2UH+GX!8DDCG.T1XGZ="]/7Y9^#G:][7L7C,C"<Q\IO==P=7&="0XA+
MLJ,I)4$E0!(KP3Y@.8_F*1T9JWPF>HKV_D1LK.7XVS-(?XK\#VA=`JXE=DE$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+_UNM4AJQL1T!L
M?V5]7L-:=*\*<W,%3<!@(6GSOU^'3I;\>E12&OD1C,1@KJ:06AZ@MTMX&QMU
MOX]+5C&E2L@"A6'>8(^%V+6LGA,[';EX^8PMIQIP)40LI(0\W<'M<;5U!_`]
M":G9")&ECQ5I&*U]_,&-U5HX&H[5YVO=G[?LECUY'(Q8\N?!#+#YE,MK?=5&
MQW\")*^4H'K0X92RL'P""HE:EIKS[F;8G1"0M!,9]GT]JW>R;LV3PB"`\BF/
M2<P>WUT&6*Y99;7<UKDE&50')6-E'^,XI*O1?:01Z[4ANY(2A2K7\B"0:\IO
M=N>P%P:=)XKLA<P7K'6\N%RW+I!X$+)VMZ+D,UZ64TDS499'HRHL-Z[,AY]Q
MI+O\N;>2@!4V2E?=#6H(1,2"@'U@$+X;=KR.R:8MUC'PKL">`'YQZA]K/3GE
M4C4OD+P^&8@M&'93C]8X=BZ:>T7*O[?A=GPV<R;L;?H)8GXW"3$>BC,QH32V
M\FW`*T-VR[3+25+B]MW`.Y!)[DCYH^:ME_#KK;[ZQM@[:#5KY&XEA<06:OT"
M2:.KAD>"[_Y>;M%;7-QMLMR.\06M/'.I'HKU8K=S5YY!;2KN!/:DW)N""+@@
M6LJ]>+7\#AW@,"O>[.X!TBJV%UMT*+9N#T!\?W?L/A7)W<!(-%T]K<C#I6P^
MJN?.E('0@$G\/\5<]<6Y&(&*WL%R"MB-;'J%OJ.H3<&X!-P/&_PJ^WMV.-2X
M!Q4SKHBHX+/NL))4T.EA;P^P#\#X5O+?Q2\-%*+%DE8&D\5L+KUPE`'2Q3>W
MX7^/7I7I^P1.D#6Z?0N/W.X#23J6<<(/]%UZ]+W\!X6/W=*]FV%IB\.,#)>?
M[E)KU.65X">Y"1]@M?R/3K8=:].LF%X;J."Y*Y.+NQ7ICPHI2#_6MX?'S-JZ
MRU!J/,M*\4)5L<K\JZ;P?H&;Y$WB>(6)PL9;S49LMJG9>:4GZ7$XMAQQKZC(
M3'!VI'<$@74HA()'6['M%YN][%96<=7N.)-:-'%SCC0#\@Q*PK^^MMKLY+VZ
M>0QHK3"I/``<2?\`"O+Y[N,KRQROLC7-O);;F/=W5"TX+54%XL:7K$9:OY%A
M>Q[YF7GFBJ0ZD@++KBEN!+JW$)^B-DV^PV^T_A]EBV(XNXO<?><>LY#H``X+
MPO?KO<+Z\9N%^*-E'=;P8T>ZWVGI./%:.H;DP)(?:![0KY@/@?'X?&MH`Z-U
M0M:`UXTE9!@Y-#[(6%CNM\R?$I-OV&LYCPX5"Q'P4)4>0TQ/:*%@!1'[P\1T
M(!^-JJ0UPQ4;0^-U1DK.EQ96-<4I0+C!/18ZV'D3;PZ5C.:YF8JU;%CV2`4]
MY0&IB7%=J3T-[CS^/]%`X&BE+*"O!1UK2A)4?+I8GH?UU<2`"C*UHI)[TUH[
MD@=Q/D#T'GU^RK201@,5*PD.H[)6_-066RL@)/4WOU_PM4#N[4K)816E<%9T
MK.$)],+/<D]+'P'Z.AK&?-3+-9&@#&BKN)R,^2A#;*5+[NG6Y`Z^-_A5T;WO
MP"UTK&ZB25L/QGQ[F-QRT?&8EID3'0E<B7*46XL)GNLIUU02I70>"4@J4?TU
MG%[;=AD?G],%B:9+J86\.?H'65OCJR^+.#H\A+#D3;M]2P6I4Y:F7$8]Q2`%
MMM("E"(VVKRN5D>)K7217FXEM28[;@.)6WMSMVT!YU"6\IB>CJ^F*[3^P;8$
M[/[?HN92X'52MQVLN*2GM3ZB)3"5)0GR2GH!7C?/D0AY@?&!0"%GJ*]4Y.G%
MQLK)0:UE?ZUNI7&+JDHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41?_U^O\]DI<)\C?H/*W3RZ7Z5]5L.`HO$)6\>*BX]!-Q8W%K?C5LAS*
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M&9Q[3K5@D0\CZB`A24+2D"Z0>E>1[SRE)M[3;FVD$8'=U`@EGV2>T+Z$V/>Y
M+BUM9IG`2.8TNZC3'TK;'49;;R4*2M/2UTE20JQL!;K\PN?*]>;WNQO&L@4I
MTKN+;=&U9BMF=2<02GKY)MX>=DVMXUQ]QMDC2X47107[<#J6R&L!-VC_`%;"
MWA\+_8:M@VMSQ4A99W$9`K8?5&TGL7UL`"?#QM^-=-MNVAKFUC)6ON=P+@0'
M@!;`8#L#;?8L74H`HL01TO<*%TFP'Q'6O5-JVUOP['02C630LH00>JE01YCV
M\.1N[YQD<U[>[P-5F[!I%D*42GH+"_7K]GA7J>R;8^.-CI10T7*WMTUSBT'!
M95QKC0[>Y02/,J/4V[O"Q/2]>@V48`8,EH)CJ<2,EBWECW1\4\-@8K(YN-FM
MQ=2/I=/PDJ!(RS*5,O/#(9I3TQF)@,.TVPI;DF4X@=B5%`<([:]-Y9Y5W+?C
MJM(O#M6^]*X'3V-P[SNIOE(P7*[OO>W[6YK9Y-5T[*-I&K[SJD!K>ESJ=55R
M11R)LON+Y/1F>3,S-RVOX5]65U379`<BX1W(J>>7#GQ\.XEM+&'QS;A3"0\@
MR)/21())0TW[W;[1:[#MC+>PB:'D`/?3O.Z:G$XYX&@R:`!4^8R;C-O.XZ[N
M0F%N+6Y-!X4'0,A7$YNSH*ES%KD??-&S6'"4KR6-#LB$5=%!Q/<I'Q41WBQ^
MR]3V+C!.UY]UV:QMTB%W:21C]ZS$+D%D(2HLE^+(;*'67%M.(6++0M"BE:5#
MX@BNC(!7(0N)IP*M*6I[&J]5HGTK_,GKT'GX5`ZK#49+8,`?W3FKAQ.6;EH2
M4N`VZ'KU2?"Q\#XU+'(#D5%+`6YC!7*5-OLE#@"PH6Z@=;W%9&86%H+'5"M/
M(X,!??#44=;D#PN?T_"L=\5/=69%-J'>5"EF;&`;?;*V^EU)%S]G4#SJ%VMN
M!&"R&Z3BTXJ21-3W=H<";?U5]#;IT)M:]6ARO-0`2%0<V\]*;4EMP"P(!OX^
M5K_=4,KJC`J6)X::D8JRX&`E2)25/.I[21T!)4KSMX6Z_?6*R%SG8GBIIKAH
M:0*Y+?#V]<;<4S?YEF>5=I:P.*P["'H^+;=#,K+.E"U]G>`J4ML6[0VPDN*4
M?$6ZY,_Q4$<;;:#5(XY\`L*U^#GEE-[<:(FC+B[J''S8JF[=O>$A9[)*XZ3,
MUW`+O&C@/*9F2V4A0]9\H>6MKU`>B0JX'CU)`S65$;1.0Z3CT5ZEKI-!N'NM
M`YL/#'&G6L8IV.2AQ3I>*PHDK[BH]Q)N25?O%2K_`(U*)B"*'!2_#->*:<2O
M3_\`E82_KO:7AI%BDJW?<P0?BF9&ZC[*\*^83M7,<A_H6>HKV;D:/PMA8W^E
M?ZPNC=<.NP2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%_
M_]#LKD&@3T\S]W4U]3M.)7C$H%5#@(LOPZ`B_6WX4?DK8QC2JNDL?PKI'12;
M_$>%_A\:QM6-%*YF!*U&YECK8R,9SJ$K2L"][7O<D=+7-JV5N>X0N1W5NFX:
M3UK![#"G'@D=2M02+"YZD5,T8UX+6.RH%NUH_%6I[?IG]G-NPL7*8R?$(D-O
MI`>0X\@`OL/H^=B0V5GM4D^'0W%Q6JOY2*M%".O$+L]ILHW6S1(VM?/5<W/<
MQ^5_E75S,YQPES9L04K<3%;=CP]@Q[8N4LO)>2XW-;:0+>JC][^LEM-ZYB\V
MRVO02SN3=!.'D=[#CVXK.#;W;R70DO@ZAB.UM?2*]BXS[Y[:-TX_;<R?T[S;
MT"3+8F8XQ)L'-XP-O>BEUTJ08CR)`6579DN)"3:N+W+EJ:)I>8JC&H(^@/G6
MPM=[9([0]U"?-7V=E*K#NFYO>N+LZO.:=D'<:^ZZ%Y3#9!M;V)S`[@IQO(8Q
MQUEWUG`BPD-=CR1X+(Z'SW?>5;7=H'6]]:]C@*.;V'V&H776.\F`AS):MZ*X
M+I?PU[S-5GF+`W9I[1\MW);69SBY.OOK'0&-GD1FF8Z5VZ)F)BJN>U/?XGP+
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M?&48JS.XP'IRDN_08'#%S,['EW&2M!9QF%QZ)$UY/JH*/54EME)![E``UZ3L
M7)F[[O*R*TMR>LC`=I^AZER^Y<R[?81N?/.!3SGL'M6K^8]X_-_-+SN.XVP^
M7XQUF3&;:=R.39@RMK*9/J)'H8UA$@Q92T)[O47+:0V@CY$FSJO;>7/E-;V3
M6W7,-P'NS$;:@"G2:X]8IU8K@;_G6[OGOAVJ-S(^+SB<>@>VOFXT#7>#XD!M
MW*YZ3/S69EO?79&1EY[N4R>:R)(4J=L>6?4Z[.)4$J1";4(++@)L\0VMOU&*
M:WMF1VMG$&6S!0`"@`ZA[?4M"VP<XOGN7%T[L22:DG](G'_%K0==%:^-^NP?
M*;2U`MM+99M>Z4_*\M)2!X&P6.HK83@2V2TO?@W($^Z0%FO:L@G"9IF4M0$'
M*#TG?\C^+86/B!92ZU5NSQ(J4[P6QN7^#.'?8<N>'N"T<:]M+F3A-VQV<O*0
MM(!0F2HE3R!XV[[A0^-S6\MI/%BQ]X+F;V#X6[)'[M^([>*ULF10MM0='RD=
MI!\QX7Z5(YO`Y(QV-1F%BW)N3M<F"7%[G(:E?.CX`DWOT/D*U[R^!X<WW5MH
MM%Q'I=[RO?#[6Q,8;6EP))`)"CX'I>_P/6LR*X#@#58DMH6DBF"O")D&9'0]
MO7P(-[W\O`5DB0'-:]\+F&H7S(`"E)6D*01T[A?I]_QJCJ5ZE/&-5.E6'F68
M(62V"%];]M_A]GVUBR!O!9K212I5EOQ5N*_?<2W?H!\/.]Q:L)XRQ-$\6,84
M[RG8DF/`6A14"H'IWJO?I^BJM<&TJ<5$YKI`:#!7))VEY33:&PH7Z`WN/PL*
MR#<$X#@L1MO4DE4U$F7+>'<M=B0?.WGX_&K&N<_$K*CC8`33%7SBX/K=K:O%
M5O'X^/B?*LZ-E:!5>X,"]3?Y6D<1?:;AF0+`;MN1M]\R-7AOS#&GF.0?T,?J
M*]:Y)=JV-A_I7^M=%ZX9=<E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B+_T>R^25V`V!\?+\*^IF4K5>,2X4[%+X]T*<MY?'KU/P_157C`
M*D9%0K]B)"V0D@=$V^WP^WPK$=[Q6:VFFE,%K[SAKBY&+^O902J&KU%6!_T?
M7N_$#K6;:29M*YK>[8Z1(T>Z?0M=='@-Y'88$9WM`4\%?-_6*!W!(OYDBLTF
MC7'J6AM(Q+<1,.1*Z1:E`3!A-)2FP#2`+>'@GP_`5S]T\.<O1;9FAC0!@LF8
MY7SC[;?:>EONZUK)10++::JQ>2.#N,>4(4AC:M9A.R9+;J%Y.&VS'R%WF^Q;
MJEEEV/*=]-(`4^TZ4V%O`52.XE8WPR0Z/H.7UCR$+&N+*VN3J<RDGYPP/U'R
M@KE]RQ^5+KF:+\K2MABO-J]12<9FH$:,\!<J0A,MAAZ-(<'AWJ0P35DMGMMS
M^\C+">@`CV'UK`-E?6YU6UP'CH)+3YQ@?0M)MM_*SY%QGJHC8*<0$DIDXJ0S
MDF>A-E*CP9+S8'B2GM!L:PY.6=OE'X=RROE'K`5OQFZP^_:N(\COV22K-PWL
M,]P>B)0_J<K:L"M3WK!W$R,IC69:P4D*DXR/$BA:TE7:I*TNI)%[D=:UMQR%
M8W@+;B&WD(XFA]-*CSJ2/?MRB=J$<K6GH#O4:A9BQG'GOEPBHK",MDLBPT4-
M($K38$CO5="$(>D,X^/,"3YK6I*?$E0-:*?Y2;&\D_#,`_1>?47'U+,;S7NS
M*?A//:W\@6QVB1_>C*;3'7&C1Y!*&TRH&GOQ3'[%E+A,K*Y63"4M5K7*`!\*
MR+;Y3\N0:72O<.QP'GPJJGFK>9M38;4UZP:>P+-LSVX^X'E.,S`Y5Y2G0]>5
MVKDX*!+CP$RR`KM3.C:Q'C1I[858]DEYQ*5"X2"`1TMERCROMKQ)#:E\@&9J
M[S%Y-/(%B2W',%\`V:Y;$SH!]C<_*Y9FXZ]I'%/'ZXLHPW\_D8H/\6?Z;<)9
M(/:%PVPM3@:4HE(+G8HFZDJKH62L@;HM(FQMZ12OGR]"B9M41<)+N1TTG7@/
M-]9IU+;+&08L5"&XT=B.VE"&TMQV6V4);;%FT)0TE*>U">@%N@K#E>75JXGM
M*VS&-8`&-`&6`IZE<2D@H-QY>%OV"L>N/4I2:X+`6]0FV=DQ$Y">U;A+2E`#
MQN?'\:W-J[7;N:>"T>XQ@3124QR7YNC$G.X*?B;]L]N*7H+I('\=*+HL?@H@
M?\=60`1O#A[I.*Q;IAF@?#]L##M6M2LD.2=%R6KYM*6MOUI*PT'``Z\8ALA2
M;FUU=I;7]_P-;'P_`E$C/W3EHFR&^M'02X7<>773Z\EI'FG767%L>DH%I2DJ
M!200H&Q%NEK$5+*ZAP"QX""T5.*L&?)2\A;#[/<%`I(4/(CX=/C6(X@BA&"V
M,=006YK%&33)Q$@OPUK]`J[NP'H/B+5@2:HC5N2VT99*VC\U<F#W5:TI"[@I
ML#UZ?T=*EANB10J":V'D65,?L4><VEMUP!7@#]GW^5;!DP>`M8^!T9JU73&P
M>/?_`(Y2'KCS-_'KX7-9`A:[%:^>6<C36B^)VMQ'VE(:0&S;I8#H?PJV2W:1
M08*%CY6'434+$>:UMZ+*LKO*`>BAX&QO]O@*ULT!:<1@MM#<@L4^UCT&,WV@
ME?2Y'E]GAYVJH8#0<5$'N,APP5T8K''N;!;OX7)M<^'V7K-BCR%%DUH#19+Q
M^,NIL(1=?2UA\1:P^/6L]K!@0L.22E:E>H+\MC&NXOVN8".^.UU>T;3(6D^*
M?7ELJ2D_:$VKP/YB$'F26G^QC]17LG)$9CV&(.S,CSYRM]ZX5=<E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+_]+L?EW3W`#[>OWWN?CY
M5]3QC$]*\6G)%5(XY9#PMX$_T&KWCNE1QDU\JR5BU=R.MB+@?I_;:L*0&I*V
M+#4+]V/!LY3&OLN-I6AUI:%)(!!"DD$>!\JLAETO'2H[FW$L;FN&!"T#V+#9
M/1-F]:.E:&V9'KPWK*[%)N"4*(MX7L1\*W3'A[0Y<%/')97-*4H:@K<7C/E;
M%9^`S'D+$>:VA"'656N%V2"47(*T$^%:J[LW`ZV#!=CMNZQ7#&L>X"0<%LAB
M74.A*T'N"@""/@2#TK2S@BH.:WC,<0<%<2UW%O.P\>@\!:L57J5)O>I."J2"
M**0>'7X=+_??SJ]I5M0*J44+^']/[*O!HF*^TFPM?_#]HZU2N93$TQ7XL=WB
M;GXGK^WX4KD51W:I18[?.P_"I0>-%;0*62.Y?XW-A5RH:*OPV_#R`M_A\:QG
MNJ2KVA5,]1;Q^SQ-_(7J`=)S5RP]R%%(1$E`=8\E)!L?!5S\?"MO8NP<WI"U
M]\W4QKN@JW]N=D-X*-G(-U/1&`IY">I6V@=QZ=+D)J2'"5\9RJM==@MA$[1B
M!BM2-U6EQ<7DK4EA+K:DMYR,ST2%=$*==;3:Z5@]K@/E8_;6UCJ*P2#LZUS5
MUI<6[A:FG!U.!^F:PQML#&9\?VAQ*4-JE75D80`[H\M1NXM*0"2RZHGP\_U2
MZ*MIQ6$\]XO;@#F.@_4L42L,P[W!;2?M(`!J!T0)-0I&SO;C56GD]1CR$J[1
M=)!NE0^/P-JQWVX(ZEG0WQ&!S6.I>FKAN=S=TI)O:WX^(`\ZPG6Q8<,EL6W@
MD&)Q57QN,=3VI23W"W6]K5)&TA02W`%<,%?T!W+0SV!U7IVZ7*OLZ6!K,8Y[
M<%@OFA<,1BKK@RI:R%.GN!^^LEKG<5A2RQT(&:J\['1YT5)4`7.MS8=/AUN2
M;W\ZN<P/&*PH+EPF()P5HLXBS_I`6`(Z6L/P\C>H61"I"W\;FZ=85]8W%I;2
M"I-U`#K8=/NN+5FL8`H))LPLQ\>ZS_-LHTM=A'BJ0XL$#^(L6[$=>EKBYJZ1
MWAL)XJMG";F<:O=::^7H7I5]C<54/@/&,JL"-CV(@#P`,AFU?/?/SM7,,I_H
MF>I>X\KL+-IC:?SW+<&N+71)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB_]/L9E4%3EKG]/2W6WW5]41X$KQ685)"D(I[7$@$>(/Z?\57
MNR*C9A0!9&PYZ>/D"?#RK"DR'2MC$<"K[90E;02H`]PM:L!V!P66!W0"K0V/
MCW%;"VM$AEM87?Y5H[@#\;GKXUD17;HZ5*P+G;H;D$/`5AXC@C%XO)(G15K8
M*5]P"%N%(%P38%9'E60[<:L(HL"+8H8I1(UQJ%LAAH0A1VV039M"4@GQ-@`2
M?'QK2S/UN+ET$;=(`Z%7"KXG[`/V_?TJ"@&*OR7Q\?M-_P#CJA*J:<%`*._]
ME_A:KZ@*U07FNT`_;_A>JAU<%0X8J7";FP/Z1_QW\:O3%?B@15*U0U4@_>]O
MQ_;4K<L%;6@7PS?NM^!JXGNFJI3)71`1W`?#M\/QMY?&L.0T."D:,%54,`GH
M>O4]/^&HB["H5U*+'N\X_P!2`\E(Z@=Z1X]4]?#\:V-C)1[:K'N&ZHW!63"`
MD8KZ5X7:6VM"DJZ@A0(5TM]M9C^[)49K7Z08RTC!:0[4W)XOW>=&?:5)UC/*
M=6Y&6D%E<:2I0>;2D_+ZD<JZ>%TVK:L<)XVN^V/0N/EC=874K:5A=PX$'/RA
M8)WQIS0\M]?#<5,UG*`26'$74!&>-T_-X=[5^U7QMX=>ATKHJ//N\4;!',3"
M#4T[IZ1]8R4HAR)DXR)T):76G4A22DBUCU^((/Q%JG[KP'-."PRQ\;S'(,5(
MKCE70I^X'J/P\ZM+04+:9*G2<8AU*ODO<??^WK4;V5S"N$I:J.UBFXSU^P!*
MB#?KTZU$(@T]2K+*9&&GO+(.+TG*YJ*_,QL)R8Q'N7RT02BP[NH[N[PM5[G1
MM(#G4JL&,7$@>61$AN:E/Y/-CW[XSJ6T*[5$H-DD&UK_`!JX=16.]Y(J005>
M..U"3/CM.QLA"07$CN:D.EHHZ"XN.\DB]4,N@Z2TJ2&!SPU[7M[.*@C2LLQ*
M4I493Z$J[0\PDN-*\^Y)`O;IY@5DQ!I[RVL1GT$&,GLQ"O"%I^23Z1<C]J'+
M=J21WD#XCRJ?6P9%7"UN'D5;2JV`TG#HA1VV41PT\@@K('F.MR?ZUP*PYWU%
M:K?6,`C#6AM"N]WLG45\%8XJ-R-BV%-_L$AH#]5>!<]_S!+_`+IGJ7KG+E?X
M8ROY[EMM7&K?)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB__4[$99PA9\P!]GD;V\:^J8Q6J\5F-'%4B(\5O)L/ZP'CY7%QU^%ZE>.ZL>
M,]Y93PR?D\!XI`_7_BK72G*JVT0&E7_%![$G[+5@/KBLD<%56D^'X?IJ(D4Q
M5V/!3[:!?J/U?\%0DFF:J,U.H-@+=*L.*N40*'G?_A^(_`U0CH55]`WN//KX
MCP'P/AUJA%*(OT`#I;I_A]MZ9YHH3UNW]O\`AUZU4#$]"H30*22;$_?\/OJ0
MXJTUP47M"_O^\V^WR^VJ#!,U++8/P_&WWU4.IDGDP7PU&)7T3]E_M\_U54O[
MI05J*%77!8(2"?AY_?\`=TO:L1[A52#!5!E'S=I_']-1O.&"J%;NSQ@MA0(Z
M*"DG\?\`%>LJT?B"K)!@L9-PRW$<`Z*;)N+>(OX_96S+ZN'0L-\?<)XK`G,V
MGIVW5Y"V&^[)XY*Y$90'SGL'\1KIU)<1T'VVK.MWZ'Z2>Z5H-S@\:'Q&C\1F
M/;TA:&0LHC-8N=IV;`6IHN?2*=Z*;)%E!-_F['!T(\B`?C6<-,FJ.08Y?E7.
MN<^$,GC]S/L6*M57/U+9G=:GE:\=)=4J&XKP2#8]H)^(-8D!?;SF%_N')9]Y
MX=U:"ZCIK:,5GK+80X]]*2?4:>:;>9>'[CB'$)6"#8@]%5LQ0XA:KO--#BJ,
MJ`F_</Z?M\Z%JK6J@+QA<O9-[^5K_;Y5;H5I"R1QOG\KJ+^49C1OJH^2AJ:4
MP4W"747+3H%O%/<1]O2L>:T\8-J:4-5?;SR6SY#&VH<VA'M5%=@YN?)6RM$H
MJE2%++`0Z$%:U$]$6`[1?QM85DMA:T`X+%%LZ1Q#M1).5%E_7>*'F0S(E/%;
MO:EPL-I(2A7C8JO\Y23\!4;I6"HHMW;;,&EKG9]`6:,9A6F6DQU1PV$(\.WH
M;=/Q)\:@=(:U!6]BMP!I+:45-=P$F0^I<<!"D*/;TZ>-O/Y3^BI!*`&U.*C\
M!Q<=(P5_:YB2PC^,+N>"C;Q/P_36)/)4BBV%M%I!U9KM5[.8R(G"D!I'@=@S
MR_/Q6^T3XUX7SPXNWZ0G_9,]2])Y>&G;FC]-RVHKD%O$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?__5Z[9%Q4AU26'H[RB>G9)97<>'
M0I7;PKZLC[HQ!7B$IU$@$$]JEX$=]I97(0E*4J!4>]M0'VD)4:J]S2*`XJV,
M$.J1@LK81QMY`2RXA9)'3U$#I;RNH7Z5KY<"3P6UB((P*R/%97V)`;4>T`J(
M2HV'VD#I6N<X5S65Y,%4&@0?PZ_H_P"&HWFH(X*M.*G4*%NI\K=/UWJ*BK3)
M1.X$DW_2?VW\:I1,:K][S]E_/X_C:E$.6*C)4DC[?AX?C?SJBN[5$%B+?;?[
MK"K3TJJAN?ND?"_[:J%0Y*0N0?'[_P"FK^/4HU-M]?"Q'Q_7^VJ$*X*92D$7
M-6$XT5ZF&6D]XN`?A]I-CU^ZJ$X&B*NM)"4"WB?VDUC..*N'0IJ,GO<!/AX>
M?E>HWG!78!4_86;QU&W46-_(="*DM7=Y6ORKQ6-BU8."W15P1:WRGRK;UQ"A
MI48E8XRK):?=84+H7WI-_@;]?MO6<PU:"M3,-+G-7.;FS2'=7VYO-P&RW&F/
MF0@H!2@%:_XK1`\`%*O_`)IK-!UAL@]\8%<M<QB"26%P_#=4MZND+]VKCUW(
MZUKN\1X]T$-&0XE/SMN(4IOU3YE"RW\Q_P`K[ZD+F2R:/MM-1V+%C;)%:B5M
M?">*'J.7F5T:U;9(PPTH`.,0Q],\1=:%-CHD$6(MX?=60:LHX**`&7\%W`8%
M469KF3B/J97'>4D.%*7$H46U=;!04+BQO4PHX5!57121DAS#VK(V#TV/'C)D
M3PAQQ7_DU6*6[^1'F:L<_$Z<EGP6+:!TV+CP5X1,/CHSJ%Q6&ED?,I*4B]R;
M]>A(ZU:7%WVEF,@B8:M8*J]L=`A=9;["$.=+#M2"/@1TO>U02.(-`5F1L9[[
MABK]PJ&9844)*.T6'2W=:W0$_96)*2TYK9P-:_(4"J#T<W5\I2;]56Z6/2]_
MA5H(\JO+3BH6-CM*DA(NHK-OLN;7^/QH]Q`Z`J1M:7=)64(&(88`6XD*)(()
M`L/T@]:USY2[`+.:T!=8O:<$#B&&$?N_S[-V_P#MS5>-\YU_C;ZY^&SU+N]A
MI_#VT_/<ME:Y1;E*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$7_];I*WLN0D-)CY#DS6H*T@(]56(G+DKO?YG!CM9F-J([NMCY=>M?50:U
MF+;:0CM^MP7S@VZ>0`_<FMZRT^QA"N_"RTMF,&>2<'F7%N`OL)9GPW7P#\S3
M:9NIQ"V"/,F]O.K2^M:VLC1Y#ZG%9\,U"P#<FO/81ZV#UK8W28$3)S(\')Y&
M!CVG5(2)T\P%060L@A:G0AB0M`2;V0E:R/!)/2M7>3NAC=)&PNIP%:^WTX+H
M;<L-!+(`.DTIZ@3ZUG?6I>-T';'F(NT:XB<ME_'8B2AIZ7C\_E'V'%'"PV94
M=M+DTLMJ5V.!*[))2#8D<[>.=N%HP26TNDN!<"0'-`^T:'+L6<R:""?1X[-9
MP;T./0.O!2[N-7%V"/F=RQV9QFJR9)1E/2P\J(XE]U+I[XDCZ!8*#+"4=H"A
MVGQ%P:O;+JMY+>RFC?=@=WO`C#I%?S50"1DXDF#A;DX]VF/4:*J[^>,,7B<C
M/TN=L.>=A?3H;]/"YZ'`2\\P7G&YV0R6&]%@L*(03W743<)[>M1[>=XEFCCO
MHXHP:U[[":5X!KZFO9AQ4UT^UC8YUNYSW"E,"!4])(X+6].ZY]924X)HH58'
M_G9`()\;>KCVNZQZ5T@LX^+_`$?E6J;=W+J$P#];\BKD?9,BOL]:`VUW>(,R
M*H)))`%U%H*_"HW6S!723YBLALSS0F.GE'Y%<\:8^Z`LMV23^]9#B>MK=6'7
M#6,Z-C:BM?IUA3AU3B*+(6JX([#(7%49"%)94MIR.VVXE3O:?30XEYQOM0L]
M+WZ??6LO;GX5@?AGQZ.KK4T;=6`"M3U;9#)8I^-,AS\8XVB5&E,%M02\CU&5
MH<0IUAQ+K9!LE9*0?F`K*:=4;)6D&-W%0LD;(Z1FEP<TX@CZ!2KWR*/EYG_#
M[JD'>H`KA3$E7BUHVWB.U*.`R"&'F6Y#)<:2TMZ.Z@.MNM,NK0ZZAQ!N"D&X
MK!.X66LL^);J!H<<CT=2D$,M`=!H50E*,=:F7T.,NMDI<0MM25H(/4$$7!K*
M'>`<W$%6U&7%16YL5)LIRQ%O$$']`M5/#?GI2H53:R$,V3]0V%6Z!1[>GC?J
M!4+HWUKI*OJ*45:@.LN*LTXVNXZ=JTJ)N.G0$DWK&E:X8D%75&0*E\ZE184.
MU0/;?YA;S/QM\:NM3WLU1^1Z5CAMHJ6L6/4'[1]MZVY=1HZU`,:*R-I@+"4R
M$@]!95K'JGP^/C67;/J--<%A7;"1JIP6MO*>OM[%KTE"F^^7%!?CFP"N]LW*
M1\0M`(^^MC;NH^AR*YS<X/%A);76W$*Q=%V>`]HK^IY!*"J*)#/I.`$K8>6M
M8`"@?W2NWV6J5T#A,)6E:VSG8ZU?:R#*N?05CF)#E:YFVY#*5JBEVP=0"H*9
M*K6)3X*`/A6>`'M^F:Q6!T$K74[H.?4LW+E0YV-2Z"WW%(-["W<1U/4>-S4-
M"#UK?:F/C#N"M-Q<OO`B/A;9/SH)ZCQ%O`$'SJ^C?M!8CC)JI&ZH4U%>G05!
M8[E]RK=3X743?JJYZ?"E&G)7,,L9RK593P3<K(>BEP!85VE0`\`3UO\`8:Q9
M"&"HP*VL#72$#@LS)PS;$9IQE(20E-PGITL/'X^-:SQB7%I6Z\(-:"%`6RI5
MTGY@H6)'P_XJOJJ$5P4#&LLM9%M(N!WBU_*QOX].M'DF,E6L`$HH%D]Q/<PD
M)/6W[+?=6L;[Y*S#D%U&]I0(X>A`^/\`/LY_[/:KR+G/_O<G^[9ZEV^PU_A[
M:_G.6S-<HMRE$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+
M_]??UC*8-M;8CXK$,25K_AO8W<,QAX[:`BQ;=_F'^OH7=8L2KPN+$^'U8&.H
M=3R>UM?4OF830@M`C;7J>6^>N/I6PVD8/=IV"DYK7-<V+94-"2EA,'.L;'#;
M?:18-.3IV,G(:':ZDCQ/P!(Z:^XN+1D@BEN&->>FK2>P5'%;ZS9=/@=+!#(\
M=3RX#RD$*\LAR5LFE2--FY+C6.9\)<W';9`5E]U0WD7,LG_F9,CUL%B<'C)P
M8;<L8<II*NPJ4D>6M-O\1\6&WKBQU"PCP^[3$TQ+G"OYPPR"R'7\]L^V?):4
M<*AP)DH:Y?9#6FG$&A68<EN.E/X$;#CV=IEYW()Q.H8C4<-HCVUYI.;R3V5R
M+>(Q^.A[&YL&1F1HF+FNNRFFC#992D+=]5Q#2]63=6\K89HVB!I+R\R:10!H
MJ3HT`8@4)U$U--()6T$]K*QTK-7BD!H;HJ034T`U!Q.!-0*`4QJ0%:V<]T_(
MTIU>J3<GG-7#4*1$G.9?B+<Y.6;1)BAIMJ4%97(9;'F(ST:6TRA;*U7'4!52
MP<O;8`+J&W,E2"`V1@;G6HTM:#7,@DU6+/O5\28/&<S34'5$\DU'3J)%.!`%
M%K=`RN8CSE3=>YZEXW(*6E2I,I?+.O*C.I*5!+\R1@$N.^@2"5/&WA\Q\1OY
M(X)(]$^U.<T84I&[#LU^I:1KY6NU1;N6O/&LK:=IT^M9FQG+_,8BHC_^J.T7
M-*4WV);RVTZ](E)L>A5_;2`MYQ7D.ZY)OTOUK5G:=F+BX;-(P_HL>/\`AFBV
M$=]N36C_`*Y$X_I/:?VP:JJ8_<>3\@LC)[3QULK9ZN*QV,XQR,AM)%U=[V'A
MQ5H(^/<GIUM60++;V"K(IV'K=,!YB2LJ&XW)V#KN"0=7AD^@!9-PN$RN:A9#
M+,.:CCW,7#,V<[D!%P@CQTI!7+4_-R6-QBV$GK9I]2@#X6M6'<74-NYD<GC.
M:XT%*OQZ*-#G#M("V31*6/D+XVZ14DT&':2!YBJ3M>X\ORF=?5H.=XRRD3$Q
MW6\KEDXG(I;6E26/IH\N9C9;\/)/-QU]RG)+J+)/=W**DBL>&TLP^;QHI6ZS
M@"ZOZHS&/`"G4L*>YW)_AFSG@D8W,AIIV$@D'#K5[R)LB>H/R2T7"D$^DA+;
M0\_E``/;<]+W/QJYL;8Z-8,%N!D*YJL:9@=<V+8F\9M.=&MXZ1'>#.3==Q\:
M*F<DM!EJ7*R<J+&CQB%DJ5<KL.B:Q[^YN[2V,UI;^+*"*MH2:<:!H))5\+(I
M)1'-)I:>.%*\*DD`#KX+(V_[3E-0UV+J.-Y-PVP8!QER.6L5G^/\K(B1V%,>
MDT_DYTN%F4"PLRMHN]@!`LFU]3MUK#>7+[V7:)(KFM:N9,T$G,@`%O:#2JDN
MIWVT8@%XQ\1_-=&:>4D'LS]BUP6-*?>E3@YE&5/E#A6]%P^15)4D!#BG\@QG
MH16H+O;^!<IL3XUU`^.:&LT-('07-IV`L/K6J:;8ES@W'B>Z?3J"C(_D8`5$
MF%I"R$([H61]5=TW!"(",@`BY\;V%KD@=:K_`%C[4=?*WVZ5*U\5,`0.P^RJ
MJC4=;9[0M,BXN"')1!%CT[W6DU&7`YX>;ZU,&J9ANM*R,2&_F,+K[BWD%J5,
M?R`%PKP)@Q)CS1Z=#Z9Z_"HI,(W/$+Y13$"GM('I"L=(&N:UTC6DGK]E?4K=
MDYJ)R!ORL=A=QR<C<,-(1BI.$3D<BVQGXB$A]A^%ALUBV',P'EO!*WV`%H[>
MT]E[&K&ML;4NEA#;8C56@[E>DM-!3M/E6&R5EU=AL%T[XAAIIK@X=0<,>@D>
MBN.P>=C:?&U#U1J4V%M;+<1J4RB'/&+B^I'"I$V1E'9*U(E.O)M].L)*"*T<
M#[Y]]I-ZUUD2:'4W4<<`&]'6,UNG>!X`.@B?B*&G6:D^A8E9A9?L[UX]N3'4
M$K#_`-`ZZPI"@%I4'TEQE2>Q0((41;K6Z,D)REHX?I"JQ6AYP.([%9VX9C6L
M0J-CLIB(F3S<]"U8W5\/CDY#/9<)LE:VL>V+M1F3U<DOJ:BLVNXX@=:JVX<S
MW)G5X8JX6S9@:Q-T<2<OIU+7C-<#[CO+SLIG&Z9Q)#>65"-AH+V?V=U"@;IR
M.14B'AHCJNZZDQ/4`4.CJO$Y'\0OJ4^)('D^@^F*A_AFS-=J-BUS^G(>C'S^
M98DV?VX;;QXAK+)W38,[C5/(;?=_F[TR/&6XYVH1,PV4>E1XS#SA[`M%P%'M
M[DDIO=%>W=7.;=$/_2!HI'V6VR,\/X%H:1PP/G5'RVL[')QTG-:OC)APN-BA
MO8U_S+%N_29!J.9#SD>.A].0^A>BV6A1;-CW([E%))WUAN(E:R.Y`%S4Y!U.
MK/ZUQV[;7<6LSG6<;C9Z:UJW`\<,\.Q8UQN8DMRFG$O*)2XFZ2HD*05`*2K[
MQ6W(#A2BT#7OC>UVHK=?6>&][V&-A,E(UK)XO#Y:!_,8&;EX^6O%2F$J[5!$
MF.TZV'?/M)!MXUS\^]6$+Y8A<,=<,-"P$:@3TA=A!87$PC>^(MC<VH<1@?*L
ML8WC'^1+]!S,XA;ZDW[%.KBK3VCKW"0E"AXU@2;GXS=0MWZ>ROJ6UAM&PX>(
MVJNIC4Y2FB&\GA5I(L+Y-GITM6,Z\8""8I!_BE90;A0.!4!.D9)I*NQW&R2K
MK_#R$8W^';=P>%7'<(B<0\#K!5OA$<5*'2<REUMQO&/.E*DG^`4/@]1X>DI7
MC5_\0@TD&4"O3@GA4((S52EX[)8Y"6YT.3"<[`0B4RXPI0/4*`=2DE)2>A'2
MHXY8I23%(UPZB"KB"!D5T]]I*N[AZ&2;_P#/^<_]G-?8*\DYS_[W)_NV>I=M
ML/\`V]OWW+9JN46Z2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1%__0[B9+0N5)\.1%SG*^FOI24/#,9*5H"LH0D&[3DAQ;2U(4%'N]0$E0
M\?C]'17MC%3P;&8<*!LE/-2B\/EMMP>QS9=QBITGPZ^<X^=:\-L\B:EM4_5,
M+R%DW,/L<1N9-&I8O"9$;7D<7%F/8O'/18K/T>32C*.]K1=<[`%K6E04`#L)
M&P7$;+F2W'B,.&JH+0:`XG$89T[#@M!6\M[B2WBNB62-K5@!U.`-,!GCTGII
MBLO9W>=CTZ%'<?QN.E9P0E9\8_?\7D,U+8AX;$*E1]1Q<9K*.8*+D7<S$[8J
M)3+DAM2D*2JR4FM<;9LX)CD<(JT/AZ6U+C[Q(&K(XD&AZULGW4UL&:V-\:@=
M^("X@-'N@>Z#J'=!&H9UP7YLOMQY?Y:TW6.9M:FZ-)5M\&-F7\?$QW(D=[%N
M%3W:TW.1$E8]MZ*BX44EE*%D]O2Q./'OUG9W4NURZFNC-`7.CQ'9J!]!5\FQ
MWFY6T6YLDC)E:'4:'BGG!&?8K:QFE>XW34B0UA7GH6/*')*]?Y-V_"K6?5+B
M"TTMYMYF2CM*2?3)5VW()ZG,-QMES5KW1%SOSF-=Y\#@HX[/=+1NIL3RT?FR
M.'FQJJ1MVVYII[ZK9>/=]9?E.H2\_'Y)3E&YSA9<'^L,Y/75R9BBT@V4ZHGI
MXGI67!$YK0R&>$L'1'2G91P`\RAN;EU29[69I/\`25!/6-)Q[2JCAL?ZJ8KL
M;`\J8"*M"%OOY>!K&6A1E=G>$M2I[9?#11X$(1<>52^*_$/FA<>HN!]?M4L+
M!5M&7+&GB0PCSN%?0LC1,S+@>FPSA(N?@.N!#60,&%"F/`E+3I:DQG4L(>+B
MP`"TH=QL`:QGQAPU?$%KQPK4>G\BV'C21T:Q@?&>-&@^<8>A7R[R!A\!.;@P
MN.]XEXB4K%1F\KZ&$V-]$J:N*]*`QK<YB$J*@NK;'JQ$GTK'H>AUKK6YF96:
MZ9X@)-!5HZ!CBX'B<:5Z<U,=P9$\,;8RF/`:NZ[/'*H%.'NJ8SFM'$8?;8^G
MK:QN3G9-,V3+:3%>=_F+<$B(\S"^=M;$%Y+:`M#*&E>D1\RPJK[5['26[IFX
M:3T]/$])'22<>M9$EL60W++4TD+JDYXTPI7@#3(`>57KQ?'V[-:KC\Q/QT+(
MY;!8^+,V;^:/HBXA4F-)2PX,F^A3*D0Y\A`#B61W]BU=HZ5A[F^VMYG0>*6-
MD-&:<79?9ZQPK@LRR-P^UCDE`\=K:NKE4=/4>-%*<L<\<;.IF8?%R-3:S4W&
MKAP-A#FLL8_6)LIQQN$SCY3CN3+^/Q8>!2J4_&;>6FZV4)[J@VK:KUFF66=X
MC#JEO?)>`,2X8#43F`'4&1*P;_>K$N=#%-%XQ;35W:-).`&)P%<"2*G,!8;T
MG,<M(@RX$&=HG(L5R2H&<_J&(R#B5`]/H,EJN:ALI_>N5L*[5`)\4D@[::"R
M+FRR74L3@.#RT>4.!KY1Z5B0S;@01#)#*VOYK3YBTA9"0]R+CL=)>R/&^)ER
MDN7CK3B\UC7&%?,7!WMN/72;"Q6'5"UK_&.EH]S?#W-P;3I:01Y<O)19H=?L
M8YSK1CG]A'JJJ='S>7R:'#E=58PSX199?+\AAA*21Z@,K$)"KVO8JZ?"L@0L
M931=%S>JG^DKF332`^+;ACOITM4[@]CQ,1(>9V*-/#G>$-Q(07CPMM9;<:6_
MC<:&EJ:5<%"PI73PM>HYX)'C287#MS\E7*L4\+.\+D'L&'G`60-B>WG*8;&I
MTF!I&K9J"EC.Y#,[&UR'(CY_78SR6WRQC]9QTUN/,4Z\EM:%Q&KI45I4@IK3
M#PHY)/$EEFA)TAH\(:'$5S>03AB.\>@@J2=UY(&?#"-C@-1+O$.IO4&@BO`X
M98BBOO7]=S?(&#BRWI?T^RZSZ++S$2-L&9CLR\:U!R$W/0)\\0U)QR#DTI=]
M<QGTE*.]`)`.'/=1;=*621@V\HKB6-]XD:"!7'`TI4='%94,,EW&UU2)F=`<
M:4`)<":8"N-:'JR6GO+'OIP#&6GZ&A&U;]_+'9>(RN9UG%QH6$><6XM$A:,\
MI3TG/2NI0'D!U*4?*R\1>LJTV^*%WCVMJ/%.-"[*G`#[/908YBJFE<Z5FBYD
M<&95TYUX])[<Z+%^+Y5U7?$X?`<>XZ1JV]9IZ0T](W9.9AX;78K+16]F`^U)
M>.=G!M-F&4M(4I8NY9M)OM7W&X!Q:;8D=/=/H]BQ&66V1_B&3N]`U@D^H=JR
MQC-.T?4(TIA4?.;QLL[TW\_GG2G-9;.S$'TT+F/&8I;$!M0`9BLM%J.W^XCQ
M)F@;,.]J:RIS.!]5/2H+N>&3NF%SVMR:T5`\Y].)60M?AZTN.SV:WD\(M9*@
MTS!V"$KU24_O.PHR0D75T4X$)JDS[AI/X[2.UI\U2D#8'-&FW<TGJ<//0>M9
M+<PC&?P^3PKFTPL.EW'3(ZFLAD\<'2A^(ZS=ES,+4%2&RJZ1WAP+`*1<=-3<
M.T&KK-S]1QTM=AVZ<NU9[7`4(F#2,<2/;FN=7%V=A[2WN>0'(;S3;V"7!V7"
M+3AFXF4E8F2Y';CK@2F8TW&3UN/K2"TE#CZ"00OI6[M&NB=:L^$&!P/>PZ<<
M:CMP6MW!T<PFECO_`,.A#FX8X85!H6DTS&)&"QIL^I)Q;OU^*478BSWJ:3=2
MV#>X\+]R`1]XKJ&/U85Q7%75MX7>9C'ZEU3]K>[XW;.(846;RK@M/SN-GRL5
ME-;R$O5,&<_C%$!J&W/V!2\C(+Z0A:F8)945J25=PZ#S?F6W?;;JV0;6^:)[
M06N:'NTN'$M9@*=)!'GQ[G8[IMU8QZK]D<K26EI+&ZAP`+L2>-&D5ZP%-/2)
M#>1E(@83U,872J/,R.2;,E2$J6.Q<&#&E1G0NZ2'$24@`?NF]QDL%8H_%F#7
MTQ#1Q\I!'86K++Y"\AL/<Z2<?,`?6JK%EOW"%:OC7K@V<:?]/J>H"P]&=2D'
MXD^-1/B;B1=N'D^HA7U(^P*?3J4ZVAPI44ZVVA06I)0EZ,LV`)[FU?0]EKIZ
M"X-S5A(!`^,)\GY57'#NA0>P+0M+F.DQBW>Z6H;<AU*3UN2PZP;>=_*JGND$
M3-)ZR1ZPE>I4S8,5@)T!&<G;`F6_B@XK^1K1E3EH[#:$^K+*"SV/15+"1_IE
M=I2;)MXRV\T\4I@;;Z6N^WW0T\*5Z?)Y5#(R)U'O?73PQJ.NG0NAGM#DQ)G#
M./DP74O1GL[G%MN)"D@_QVP04K2E:%)(L00"#7FG.@<W?)`\4=X;/4NVY>>R
M3;6/C=5I>[UK9ZN36\2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1%__]'LSJ^]9(.2HLS8\OD`XV]]#+5+R<J(Y:,Z6VW2T_(0TI3O:+K/
M9<^)M:OIN>UCHTMMV@\<!T]@7@UO>/[S'3/=A@:DC+C0E9/SF9UQ.QXZ-@G%
MR1E,4S'QN24S(<+F61APN:/JPTE;$B)(2\H>!/H+[;VZX%NRX\!_CM`>'FHP
M`TZL,.L4\^*SIIH?'8R'$O;W3TNTU./"AKYBK_UC1X&Z[;!R<V=Z[>2XN+&8
MPBX[#$9&18D24F6YD):0B-DHLC#QFG.](#R'>U+B4@)<UMU=RV5N]K8](;<4
M:<ZM-#@!F*.-`,B*TP67#9-N;@22NP=;]YN6..9Z109\,*\%5,9_.>(LQ@]+
MT3&)QT!B-A7LU"B8C"PLA)E3),%C*S%S&6_J'5Q1(";]RCU2`21:H=-MN=M-
M=WCJN)<&G4XMH`:89<#PZ5>P2;;+%:6D8$8#=0`:#4D`FO',<>I9TS_(VRZ_
MR@K7L@Z^G2I+D=,><^HF0AAV$XXZZW*.4=:D>B_8D%ILGM*1U(-:6WVVVN=I
M^)C:/C@,AE6H&0:"*BOK6VDO)8;XQ.']5)&/'+IJ?4L:YKF+8SB<A*CXM.4>
M9R8C0EC!Y%,#(8_M=3(>$G(XN4["D1U)22V\V$E#@Z]#6SBV6U\6)AE+:LJ1
MJ%0>`H"*BG&N:Q9-RF\-[Q'J.J@P-"..)!H?(L![/R%EL^LQG\9D(7J-F[4=
MG2Q%!2+=#/TJ0HH/G972MW;[5'#WF7%?U_\`36JN+I\W=+7`4Z&4]+"I'"\8
M1]P^D9=#H<CI7E%+3B]7[XK,"2S)6IM[%X;'E"BMD'^J2$W`(-JDFO#:!SG.
MJ"0,W8D]I*ACVQER6AQQ&/NLPICP:%>4;7<5JR&=A+TO),87-*5,:#90^(>(
M0TB6F/':!0&5MJ;;^5#A`N$)4J]H'3R7!-L`UKGQX'/%V7M/M64((K8-E#G.
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M675()*W"]&QVQN-H?0DW(`O9-26_,&XO;X^JML[$.IW:=1+<E9-R_M;3H-M2
M9N!;D>O`.S5M[+[?\:[C'!IKN8PDEE1$:+_:7:,$YU#9[7WVV\A$4IM:;$=Z
M@/$7K-@WT:Q\5&'`C/0T_4?0H)]EC,=+5SF.'Z;V_6%8LW!>X;5L,TV=2D;/
MC<9Z@;=C[E!R;@9;[UEUYR;";F+NV/ZR?N\*SV7FQS25$K62NZ6EOY%C$;U;
M0@?"&2-O$/!\]158RUWG`Y]Y['9'77,.[ZSS:I360QKI^ICE)]!Q9B-(2\57
MN%'NL+V(K8/L@P:V.+AT8Y%:Z#?OB-4;X-)KF",_-FLI[I@.0MOC:\XGDS>\
M*[I\E#V,3AG8+D21BI*4K<3,C-M(;D,PF&5+47PM`:Z*`M>M5"RSBDF+;=@\
M7$U&.K@,:Y\`"%G7$-]/X;S>2CPSA3*AXD894XU`"OO>$;.]P%RAL.DY%O%Y
M33N/LU+V+*K$R)D]J@N2(.(QDC%*QLZ`UAYAQI<===)=:>^4A("B:TM[*V"[
MMHKEI?XT@#`*$1FA+JU!KC[HS&/0M[8QRRL+V$!L3:O)J"\5``%"`.O@<ES%
MPVNO0($:-A=>Q^=EEM;CK<K(+@A2F"%.KCSFP\S-;<;N`5"UP"*Z.W#88F%T
MNAM!B!4XY5'!1W4US+(X10LDQR+B!AT$8%7=K^7RJ)>*E0M%EP,S%R\+^726
M<JP^P[(;?;(8[4-ME(=`[%`DA25$$6-3/B;5U;QI;2N6*LCN)RTAUF6G[P(6
MZS[^X3\^B`RUA,)&*T)DY#)0&\DTTVHCN]-N,M#KI%O_`%Q-6Z8&6Y>"]SN`
M::8^58I-X^;2T,:.)(KYJ?6K_BX^;'EM1YLS!S82/E<FXN+*C]R2>JD0WWGF
MP`GQ'=U^SPK!=(UT;G,8\2=#C[0%FL;("!(6%O2!3T*??_LQC<CCYTO77)R8
M[Z`[/P^NQ9L]N+XN*:?-E,JMT'4(%^O2H*7,L<C6SAKB,`YQ`KV#ZJ]"ME9;
ML<V1]OJIQ#0XCVKCMA,@]L6>WF+J'&V0QF$QNP9;+1MG9P4:`E_%(DY24G^8
M/0X[46.WZ75L>HL**0!91M70[0[PHXS/<5D<*4J2*X95Q]"YO?SXCO"@L-#&
MFNH-TX`&M:"G'"AZE?V!VL!UMB?9P*4&[J%P0JP(4#\1^%;MS*XMS6CANBPZ
M9,6KKEPUC=>TCBG5X69T?";FUM4C*Y_%X]E!Q^6U[+&8W&<R<G(.8.5'>]:/
M'92AE$M#W:G]SMLNO-=Y-Q?;O<NMKY]N8=+7./>:]I!.D-U`BA)J=)&.!K@O
M0MOAM[6RA9):LD\2K@!@6NP[Q.D@X<*UPZ%&W=<7)9.&EI>0PF(7Z[F1^G?$
M+)XF4I($1EA"VW(V9A%:4@EQV.ML`I2E0L3=8!\4+@0U\V3>(<..6+3V`UXT
M5\[0][:$M9QH:$=&8(/E(\JM6+BIQDJ,78,PBW@XC+^BXML]0HPG`&2I:0.B
M>Z]9LDD>COV[/,2/.K!"2:^*ZO;[%<$'&Y1J2\I>>SLME;=A&R#6&=90JUN]
M+KD93_11OV]`?T5BODB<T4@8#7@7?712-B<QQ/C/(Z#3ZJJ=42T25OONW/R`
M0QZJ$6/RW@W3\IMU(0;>56BE*-;0=OUJ_$9FOT\BEPV'WVY"L-A\HS'4I]R5
M,5EOYI%*$N%MYIL,H5(;;)[BRI;C=Q?MN`15Q+00)WL<>`TT(XC/"O2*=&2B
M<P.<TNC:1UUK^7Z%=$_;#_,QQ>A&57$<D(V+.I:<AN.NMKA^LT8JEJ='=Z_H
MD=]BI-_`D6KS+FSPOXN[P@0WPVY]-,5V^P:_X>/$I76[+HJMAZYI;I*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7_TNM?&2HSS#.68]92
MDI;2Y$#B1%2ZR4J;+03Z@"?6:3W)/<""1XU]3WC#0QZC0^=>`[=&Q\;96.->
MBN&'G69G6X.4;U6"\W,"]4V3=-DPLE,E"5LHR\YJ?BXC[@3=Z/%CO26%(`2E
M?>%6))K3MA?$^XDU5$C(VD=8%''JK@>K);%T#2;9I!_"D>]N/YQJ/(*D==5L
M9QYR'K>@ZUF)687"9_G,O(XY]R5&7*08N.@_7(A-,M1WUJ#\I](*1V$E8_JA
M5M#NNWW%_<PLBU=P!PH:8DT).60Z>'!;R"]@M8Y'2G!Q(\@%:`<:E6GQIF-!
MCYC,[CNKRF(J\=,R@1%$QB2I^:X,?$AM_0ECL6W*R*9B%(ZM)C)`!6+C)W2#
M<76\5G9`:BX-QH10"I)K7@-)KGJ6)8OM8Y9;JZ/=()%.DY##KQ%,J!?>J9K2
MLUDLQL>TYK8FM8A0<GDR[.FNY/+-1/JQB\1C\>S(:G%Y\2\BRI/>\E"$)65=
M*K=P7T$$%O9P1&Z<YK<!I;6FIQ)&0HTY9DBBN@?;2.DGN)'^!0G$U/0!CGF.
M/2L9;1(U&/@8S^*V:4G(2\R^U!Q,C!8J1(G8E$:-(E3IA:B-Q$_2O24-H4M]
M"UJ4L!%D]U;.W;=NN#'+;#0&5+M3J!U2``":XTK[M`*$G%84W@-C;HF/B%QH
M-(J1F232F%1QSKA@L8Y?ZF2TJ*Q%9R[3[:VW&8;2<<M;:DK!20P+%7;_`%0#
MU\#6R:UHQQ!ZS58DT;G-H(]8ZL%<FA;%F\/'QK.,QN21"Q;V-B%Z++[9RH&1
MEQ8&3CK^N;:4MF'AV?42H)>47#V]GS=]85Y!'(7B0`EPP!RJ*D'S]8PX\$M)
MI8FL;'"[0T@5!QH2`1C3)HZZGAQ63\/C\_ALYO\`JF>B2$,PYO\`-\3/<G+E
MLS<;FG94"4E:BX0)(E-*40D%`01;P%8#Y(9HK*ZA(HYH!%*4+:$>9;*U;*RX
MO+2:,T!U--:@@YJYV&$O!EDAQYWL:;0L+">XA(0;@CQ6$^-^E1N=IUNP#5L0
MT4:.*S%PGH/]KN2F$*6(F&UAUG.9)R0$O-]D&0VZS#<5W)1_K;R;$W-D!1M6
MBY@W+X+:26C5/,"QM/T@03Y`L_;K;XB[:TNI&W$GL^M7#O<<<H\R(&&QCPCX
MQWZ]N7!RB%/.X[$LKF3'6T6:4X^_$B*4PTI2?G6$W'EB[>[^$;'^/,"YPH06
M\7&@!Z!4@$]&*MN6?&[BYT,>`J10\`"3VX#`=*I>5SR-BYME;E#P,U&*Q\IW
M)Y:._"?0\]CF6C&D_7-L,N.LQY_JAI:B5)LOJ!<U/#;&UV!EB^Z;XS@&M(=D
MZM1IK2M*$BBMDE,NY/NA"=%22*9CK[>*UUW['.L2(:L5F($?'$O.F!,QSR<G
M9]?J?)+;S,9IIAI5DH[F'%$7^;R'26$CW!WBPDORJ#5N'DSZ<5J+MLH<TQRM
M$>.!!KCU@@>A:YRMLY#A9R-C\EB9V4P:IJ`B9@QDEQFF"\L7FMJ>>]2S0!_=
M`-[>=;IL%LYCG`-#Z<:+1ON]P;.R.6`NAJ,6UP%>.:VMT/"Z2YF(CV6B17`&
MFW/0G8V(ZPI]W(I0%O+DQW`MQ#0OX%2`1;IW`<YN,EX('B`D8Y@D'(Y99Y+?
M6\5J9`Y\8KU@'&J^LBF1EY.3@Q9)@_RX/F8E2%!R3#<8F1)4)KM%W$J:D)"B
M!Z=^E_"D9;$R![QJU4IT`X$'T*1Y,[G1M.G3GAF,B.S%5C:,WC])XIP\3%0&
M]AY1Y(7DM+TK56D1I1GP&8$?$2I&5QKY4E[!1G9JRX%)3ZCH;;N!W*1S6ZWK
M_P"(20#_`)=@#B37WG$NJ#TTIY"M[MUD)(1*32F'#("F765KUH_"&[XC#9J5
M,R^N3,CA<3%=:;RTY6/C/Y%2E(FX['MR77ADPT3T]-;:PBRNVRA6ZNY(_P"H
M0L8\M>:'2,1@*$X8>58L$P)N9'4!&6K(XY4]BOSCW0(6-5C]EVO5M<EROJ9:
MH&(PV7EQ$PY\=+"F<G*0EYJQ2I_N:2``I:+]Q[;56=DI>^&.^D#0!4N:#4&H
MI4CJQZ%;XT;F`FU:*]!(]16'=TUS.2MT,B1L>*@8]MTN>@XMQIUMI;BB0KUG
M%MN*3?J>\7M74VLH%L-+"33H7)75I<OO`\W;6Q=&1]:GDZCRQ)<2O7=WT_\`
MECRWFXGK8:6ZOL[%EQ!E1G9*'5MMA74&_3RJ.2XM6EWBP/UC/&GKIU*46FYD
MZHKV(QG+NGUBN/E659Z]\QG'F>S&\9/'3F=9U3,9".[A\:_BDNKQN)R4Z.W]
M0'4*<<D+PZT)!!OV'H2*TEQ)90O>ZU81(3]IP=2I`R_QAYPMQ:PW<@BBNY&G
M$#N@M6KG$VJY)7"^89Q2BF=M#C&/E+4L_4+QD>-(;D,]SJVT]CKDLIOU_=-N
MO6L[;G1MGA=,.ZT5'17!-XB=/'/%"3K=@>Q8/E\0;[`R"/3U^9(C>NVD/1U1
MW$]G>!=80Z5(^7QN*ZIMU;G$2M\JX-^UWS'4-LXMKF*+O'PCEL)B./L=C\Z(
M^8;D-RD>CD52&HNMR8JG/I\>EQJ'DD]F<;96Z2E#/;Z1"U$*37C7,$%Q-N4L
MMO6,@C$4J\&E3FWW*CISP"]5L)(8[<,F;J)''[)&0R/O8]&6:PMMNL8O9V<K
MEX\>-DHV&"7<@S*1*DHQ[#KA8:%XYG):9+X"4%3B0>G05OK.ZEM?!@>2US\&
MY`N(Q.=#6F>'E6NFA9*U\CF!S6YX8#U^M:T93=..M,R<:'E<'E<<EU06Y*8P
M.0>CM]`I`_@7>_B6Z`(\P?#K71-@O;B,F.8'#I^@6EDO]OM9&LDA>WKT$CZ>
M13..]P>@G9T1=:0N3D'+)8+V-RT1(6E"NY/:_CG0E"$I)*E6ZWJQVT7,EOIG
ME[O50^T*]N\64DHCA)+CU.'L5:D<^:U_,'V):L6B2ASL4W&F/.%;RE=JFPA.
M/:N;GKTJT;'(&`->ZE.@4]95YW>U:\L=(W77(&I]2R-KNR(STIF=@\CD<9(8
M474+ARWVV4_P[%*5H;!_B(6H$"W3I6!<VOP\;H[B%KV'I`^G6LZ.5LU'1O(7
M2+VJ8^5C^*4&<\^[-G;/L61E>N^J1Z;LJ4W_``F5J;;*6$H0"D6\R3<FO+>;
MY&2;P[PP-`B8!PR"[7EUCF;<-1.HR../7P[%LE7+K>I1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB__]/JKQ4SFX^M-.M2<8A#ZRXVB1CY
M,ET)[W"E1<:RL1()#?\`D=!YU]679:7@$&HZ_P`A7@6U-F%M5KF@$Y$$GSZA
MZEEY+TT+59<4O)AQP.UI24][W;>R?66M*?L[B;>=81:TC(TJ5M*OKF"Z@X?E
M6O6^;=G!N2<2M;*VX;D]T1V)+[494J0RTTI[T5)=["EMH#Q5?KX5EP0QZ=8&
M-!T57-WUS,;TQDC"N`)IET8J_P#:LYD8FN,-(C($A<%!3V2%.*"VFPY\A*&@
MKN6W]AL:CCC:Z6I/%;"\FD9;-&C&G3U>16WEMEFMZ-$A_19%A<EN*PMPN1?2
M=[YL=U8NW-6]VJ](V[FP+V\/&I1$#/7"@^HK'GN'BQB:6.!-.BF8Z"3P5B;#
MLSJ,UBP%9!I,#%!M#3P87=3KG7L[77D^FX$7)N#]GA4\48TO)`J2L*XN2V>(
MU<*-XK,F@YIIQ+$B7(=8ZH<4A33KBP"3^ZAIMSN_"_2L:Y8:$-%2M[M]PUP:
MY[EGZ#D\>]*6&2HL%'<DKB.L]I90CJ4O,-FUQ<]/*M0^-X:*CO=JW+)(W..D
MX'JIEVJ[X2@[+9G*>"_X0C?*2HJ:2M3P1\>Q"U$V\C>L-P#6E@;QJIV`%_B5
MQ(6M?,?/^4TW9,)J>BN:O/R<QJ5E,R<W]2ZF"PF0J-!;:^DR..6TZ\]'?*NX
MGY4I-@#<QNCF+VM;&:TZUF0?#2,?))**`T%"/*KTX#]U.^1U[WJNRLZM#=W'
M&1HF#R.OMY%F4G(,2TJD,.NRLKD&W([N*5(4+64EU"3<B]85ULTEY=;;-<,_
M!A))'FIGU@>17ONK>""=MN\^*^@\G')9>QV^Y/6,<]'Q;RH\G:H[4*;-0J\M
M6-1(5+D,-.&ZT-S%1T!=O%";=!6PFVV"[E8Z9M6PNJ!PK2E:=0)[,UKA<N@:
MUD>!D%">JM?3@L0<I>X'E3A[%P9W&PP85L#S>&S\O+8^3-?9B28JY<:'$>BS
M8?TL:6XRL2`0HN*#8Z#H8;G:H;MT!E8'-8XD`DTKP-,,L:=JS+6Y8PS,+G"K
M>%,N(R*M3CSW![QRHWE<1ON.U_'S<;'@*QG]G(#T%J1C[OMNN21-FSWER6Y3
MEU+[@DAQ([?EK,M=L%H2^O>)KG48K&NI8W@-CJ&'#K58S.@9>;+QN<UW8,@P
MN,XD.X^2[(<AR&G`M#JEMQ4!1<1WW1TLD@>-;!ERQH='*P=JU-QMTSW1RV]R
MX$9@G#K68=49DX?+P)TM<ET,Y2-(?LM*T*QW:XJ6VRAY/IM2BMEE*%]A"4ES
MH>X6UEWIFA>QI%=!'EX>3.H[%FP12Q2-<7$]ZODX]AP&/;TX27+NT1=0<Y(Y
M0Q+[B&(.#AQ,+BYZBIO*97)PL;$*9"DK;4KOS@"B&RDJ22;)(K!C,D5A;6TS
M09`2:CA0G3Z"LR*#Q-PDE:XB,@8>0:CYPJ%Q-SIRUF]<P$+)Z[QDR[E&,A;/
MQ<)E!MN)P[3DA2V\5EI&9FG'M*GS2@]J/!]9`)ZUI';:ZZW=UQ+7PHP"1]DF
MF%0<SAZ%NYY(8-N+(7GQWNH`3PZ5.^YSE3*\5CB'3^-SKF3V#8,5EI^]Y3-1
MYD[&JFO+PTS'1XZF9L9T+Q4/-*9?6`KN*!9(((.7:-O9KB[FECI;ZB(VGW@&
M8'(_:()`/3T46,R.U\%G>)>`-1&575-,1P&!Z5='&'(&P<A:3+S6Z93#-Y"/
MF'L%CX6.QDF(T_BL9"@+C+"7)<Y])07^WN=<0%)L`+A53Q6\MN\-^&HX]XD'
M`%U?/CT*"?PRX>&\EM..?J6O/*6X:Q@-H9&8A;J7F0'DR,'+:C0U`.%(2I+C
MS?>D]O=8D"QKK;**4V]6.C`ZPN4W.ZMH;IC9HYB\?FG!8LSGNW;1D%XGB?"Y
M38WFW&W7L[L*G48%M3K3;"F(,:&MJ5D$,*42I?K,)[@KM]1)O6KE9)(2QC6$
MY5X=-?IT+H[>*,-$DSY&M(!`.=.@]'Y2K=RF^<X[W@\GCMDV:+$UZ4T$3,'!
MQ4"`WD(Z8>0R[S<68M*YI#45AU*@'25+=0A0/>:PWVC]30_27..)Z.\T8]II
MY`>A939;9A,D;'5:,*G,T)J.P8=I'2KPQ?)>ZZ+B8&LQM;PV<Q&*EOPW8CZI
MD#,.E#BW'`U-9<<9;<4X\I-UQW;%/PJ?0\.$D!!:6@^A1M;%('B8D/K1;<P]
M=QDJ+'G.1Y\&<MEAY^&N6EYN.ZXE"W&5+0A'JJ962F]@#:]JE-W.*-.DM[%A
M^#'4D561-DYFWKB#5]!1HV&UF0,VYR0_FY&T1<A);DN8]G4HF+&/$#+8JZF8
M^4?0L.%0*W$]O]:N%W>!UUNCHA(=9:RE,Q[Q-3CF:>0+I=LCA^$FGF:0QA-<
M<ZY>:A\I6I&$]PW/T+#;\\O"<?KQ.XB-B8<56#V%U7\R@3FLBP8Y;V$IA+1]
M2!=Q1]1*QV@D7K=SVTDEQMH[OCP5<37[)!::](PX9>58D0MF176HOT24`RS!
M#NC#!4#8O<=[@\J6VIN*X]<=>5!5,B?R3-I]&7C8J8".YTYU2GG_`$6AZJR`
M5+O?XUDVMHZ$$QM``U4-<PXUZ<JG`*%XMG$:G/KAAAP%.A8[>YEYL?RJI*->
MX[1+<=::4\<7GP;$]JBDC,!2;=YMT/6MLWX@1M:YPT?3K6.Z&TJ7M#O$[?J"
MV>RF?R,+96L2WK>+=#L"2U)=EL*6\MY,+&O-NPG'"TC_`)X<E.1(2NU:A,BN
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ME$2B)1%__]3>'6,KMC$4&'E<BUCV;I++,EKML4+N$I?'R@!9\/C7UJ]C7#$`
MDKYDAFO&81RN$8Z%D^#LNP.-R"Y+R29Z'(3+<A7T"_1>2`KJTAI33W</ZJDJ
M3;I]M8[HV88#3BM@RZN75J]WB"F.'U+!>4S<R9L64R<V4X_-+SO\5Q#:7%.!
M2A;TF41V$)N+$```'H+U,T!H:T#!:266:2>25Y)>7'H5Y;)O>5R<&*V_)@H#
M33;?9'BK:=/<P5$K2[,=6H)79-P$C[STJUD88XT:LNXOYYV,:2,!P4GF-[EY
M;#08[D6$V,>N$"AE<D.OE/JK"EW^1`'I_,1?J?+I56MTO)QQ5L]^^:.-CF`:
M:=.*M;+9U^?.1-6RAKU8S"$-(<6X$-M@IMWN-H)4JU_AUJ5AT@@=*QY9O&?K
M(H:#T+.7'F]XZ"F*U*Q;[RD+:20P_`6ZHGP*&GY,91Z_&P'QK'N(G/!HZBWF
MW;A#$&L?&21UCU56Q^.W+'3%K4K&99I)#BD=R,2/F42$=WHY5Y7;TZBW6M4^
M!P%`\9]?U+H&7T4AJ(G#]7_25]0-DPZ,>V]+;G-MJ]9"51HKS[@)04]40Q(?
M`^;J0FPOXBL1\$NHZ"*_3I6:RXA$8+FD=@KZL5H9@\WC>2>5LOG7)#@QN4V1
M&&Q3S\::RRWKV-<1CXKR3(CH"$OPV#(4GS6XHVZU'#'*3-,!4\*$?6ME+/##
M!%'J(`%34$8^96_L>=BX7DO*G&DMQ\!LHE0$%#L4.P4E,Z(WZ;J&W$H?AOI;
M!('<E73H:VL%71%KL7!:>62*5['-=^&X=GTQ6YR)L'(1L-)QDP%E,%AT.J62
M%K=C^L5I4I9`0&W@+)N;]#48!#GU'%8SW-<Y@8[W1Z>*MS>]=;V[2=@QD&8T
MY.^B$R*`ZE2CD8"D3X:.](6H(=DQDH/A\JC\:M<'#[)_P?E4\!:'-<V3C0X]
M*U4XRV!^%M6'EHDE#61*,5*-VR.R:6TM`E:5]H1-2TH^'0&LPZ71-=2O^!2.
M:\.D:'T(71C$C,LPVG4N,SRKTPJ/(*(00WT)6V^Q&>NM/AVJ38W\1:QU,IB+
MRTBG9CZ*CUK*8)6M#@X./0</-0%7+%=EEMQ3\5#:DL@)2U*#P-S<?,IEH^5O
M"L5X:"`'UJ>*E;J()+*+4KW1;$N6]I.@QDN%V;,5M69CMK1ZGT,!3L'%,NW4
ME"T2IBWE@$@!48'[H]&N9D=<%FV_=BEF(ZA[5>G!45Z+CY63E"06WUOQ,<UZ
M:G4LPHQ!<4VE`7V)?F%85Y%38K.FC8&T;35A7K6N\5SI7--:#T+%ON+R3;NX
MZ$M2G4E#&U)25M.]H2%:[VV<+93Y>%^E6,B(?;@=!]BGMY!X-Q6N8]JRKPMD
M0WKJF%-R%,JRLM?U*$7CM*$:&2EU?[R5J[?A;[>M3RQUJZHU=&"@<_\`$#:&
ME,Z*WO<QFD1=%1C827AD=LRL373+2Q)2J/CW$/3,CZ#OIA"EOQ8Q9*D]WR.J
MMU`(Q7F1K=#'4J>D?6LFV9%)*7O;72*Y'R</*K;X`XMUIY,F7,A,2(>':8;:
MBNMGM?EO!3@<D)*$]Z&D-]$JNE14+BPJ][G0L:QN#E61_B.J<E<&RNC>>>-;
MX^Q2&FM:U"&U-S;;#:/1^IDMMSI;+H92E"`F$TQ'`N+..D=":Q6S/#I#7(*7
MPFLM];AWG'#U+:Z;JVN9=]N3E\/C9#K;[4EIYYH-R#*;=2^7S(;4V\YZCB1W
M)*BE0Z$6-0ZGM%&.([.CH4`S)Z55)Q81*C1F4MA,GUE*4@=P2&TH^7O[CV@]
MQ/B;VJL>HM)=PIFK"0'-;TU6$_=;N\=6#X(U#&-I9DPX')ARSPZ%U<S*ZF\P
MI*KILM+4=/7Q'3X5J[+;WC>[J]F=5KM.D=@Q])*VHN:[<;9@H*U)Z<Z>I77P
M[LK:]'P,=>'Q,V#@)TUV+"FP6)#+^2);6K)SBH!V8^F7_$`<4I'R)204#M.?
M/8,,UP\O<)9<"X'$-_-'0*884S)S6$Z=Q$;<-#,APKTGI/;T`9*^Y638G3FY
MBL#@5N)D29CJ1B8H#\N8I*Y4ET)0""ZH#Y$]K:`+)2!5T=I''&Z,2.I0`8Y`
M9#R=.9XJ%TCG.U=:LUW6C(RDG()QN.2EY16&DX]/IH4H]WRH2Q\MOC>L\21-
MB;'C@%#I?J+@Y7"PE]M,)R5&2Z8KJ07P%"3V>HM3PCNNH"6E.,N!)/:KYD@V
M/A6.]L;G/TFA(P!RQZ?*KQK`%<JJJX-:&HN5@Y1Z8>_%Y6-&4@)4M^5,;B_2
M!Y?<01%D76%A*5I*>G0VJ*<%TD+XFC![2>H"M?/EQ5&-[KVN<:T-/*NEGM4"
MQQ)#*U%:U9W-J4H^*CZS8)(\B2+UY5S?3^,OH,/#9ZEW&P`C;VU_/<MD:Y=;
MI*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7__U=SH^MDX
M]J4G)/,J=<:;]-)5VCU766[BSB>J/4O^%?7#L#2F2^8!$XLU^)QI3S?6JE`P
MF24VIV/L$EI:<A(25^L[VJ,-M2BZ07"%+^7XFPJPD#"G!7,BE-7-FIWB/-58
MJ0E]<IY9>4I2W.JE65=7=<DWN3UH`:D`K%JZ@)H:A5"<B<B26WW0IU`"+V2?
M`#M'0#R-7&M10H`[4:M"@O>NDI2LCNL!;M`N+"W4&CM5<:*@)_-P7PA2^\`H
MN`1Y_95!7H5U*MQ:LK:2J07$J;Q$?(@.=4%Y++J#VI(`46'/EZ?IJDE*8DA9
M=D'!QI"'#MH?45F2)DWHA6Y_9B2RM24*!9FQW`%D@I40KT?W1^RL0M!^WZ%M
MFREE3\*0>T*D<B;PK6M`V#(F/E6<AD8#F+QQ[F@$S\NHP&'&RS(4H+C(<4[8
M>/I]>E85P`UC@".@>5;7;?Q;AFMCZ9GR>7BL2<7J8UW$Q\HB-D7&L<VW$::2
M'@I>5GI6TA``[[!N,AU1)N+6MUM4D,!#6L-*T]"FW>]\.+6T.(+J>56KR_L,
M$;!B,BWBWX2LK!?C9*>MN7>3-CN+6PL#L`0IR*Z4#H#9JI8H',G<=7==P[%J
M8K^.2`Q>&0YN-<<05FSB/?,3D--CXQ]242<0^Y&]9XNI*HR4I7$19:4I(2RK
MM'G\M5?"\2$AV"N^(APZ\5E'^=:[](ASTV@ZAY2GW6TH2EU"C8(*&TH)`\B5
M5;X<E<\/IVJOC6Y;4TJ#P'^!::9N/$QFY9^!BU?3Q&LF<ABD@D*3$G$2V.T]
MY%H[JE-CQ`**OA#FM?&_-;$2-F$4L;L"*>49U70?3LUD\SK6(R48R"F5$:<<
M+>0DMD/I'8^CL"PG^&\E0-O,5AR-9J.H#S!9+?%'=!/G*R-$G9".TX)!F)!"
M$]SDL/)0!8_.'`M=C?R_&L1T<9(+0WS*9KY0#JU>=:#YK8)>^<F;3L#"GWVV
MLBG6M?4TEMQM4'$K^B:5']4&[4^9ZCXN/%ZK+6(&623#3D%M)7F.VBCQU$5*
MW:P#"]:@X_'1)##BF(#,=1[1(2>Y*%..K2RXSV/.O$J4/(DU,YK9`:M.![,O
M(5IVRN:Y[@<3].D+6'W!S)"=KT%A0844M[8H+]-0[_FUX'P=4GIVU0,:9H'"
MN169:S.\"Y!`S'M67^&\M):U1]?:P6OYQ,'IEY23?Z:$"2L,.$#I]M2R1-+J
M8UPQ4;IW5RPHOCFK&O;3I</*PV&W9.J9IC-.QF)(>>5#2R_"FJ0VIEHJ]!J7
MZJO^0VJL66+2YE2<^C\JRK2<$O%/>%,_\"Q]H/*C.A.95^=C9D_$SX1=4U!,
M=<EJ?%;<7#*4^M93,GN+2S>Z24JM8$4N(R6!P.2D:`]U,BLB>V3!S$0,]R-F
MT%6Q;IEY4I9([O095*=DR4)^=2FFG9+G:E)\$,IM6`&$,()Q.)4UR]I<UC1W
M&C!;:2'D,)9*@I7J&]TM+=LGIU_AH6`;&K&@NK3ZO6L8\%1I4MES)LI0F[#4
M)YYTEI24H]1U#0*PM*4HNH@`FYN;6ZW$S6$1DDXZL%"YU)6MX4Q6GON,=*MK
MXT!)N6-T".ZX-B[J]NG3H+FI(P!*SL65"[\&?'"H]JS+PN@-Z4A-RI1R60'F
MD`!2"3:UR"1X56<ZI`>I0T(P688"5^H2V+DI()NDD^/^4#T'W5"\X5*J,Z!5
ME+12T74I;"T@J-P2E5NI`";5!7$`JZF"DW"OTF$%*1WN+4.VZ;FZ$]>I^%2#
M`N-5:>`4VI(5*0`!=3Y"NB57(4F_[PM8`58#1IQX*[B,%TD]KB>WBJ.+@_\`
M/^</06'5]L_MKROF[_O#_P#=L]2[78O^0;]]RV+KF%N$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?__6W48F%4.$@FUIC)N5=+(6%#I<
M`"R/U5]=$5-5\O:SI:#TJ;Q,I0BE/<1_JF>F$`W`5]&XD&QZCK^FHWC$GL5T
M+Z#3U//H*Q7#*E25$=1ZH\;?$VJC34J%V`'2JC+=+DQPGQ*Q]OZ/#KTJXYT1
MIXG-?,U7^MI`\`E/W=$#K5'9A&8AR@,DJ=7?S-A_A]E5'$J3@MB^)XC997(7
M:X<6>MO``=+^?[OZZCN#@!U+;[4P4>\]*RXA]'^M7`(2VT+$#ITO?K?P^RL*
MF2V@<.]7H6N/->8:S&Q:7IC`'IQ&%;+E`GH.Y;[\3'-+!Z$I0R^NWP4D^8K#
MEJ^9C*X#$^Q;C;FAL$DU,3W1[5E6%BVL/QQ@WG6TAW-YW^8D=HN&O0?;B)[O
M$I,9E*A\"LUF1"LCQT-HM;NS@8(NN0>U8@Y&Q2LW@=A+:#]1AF6\OCDBY478
M16MUM"4W45/0W'D"W]90J9X[@<,QBM-:2!MR\$=TC3Y\O2K9X:R[;6:,-Y21
M'S$%7HI4D$";&N\T1_5^>.'AU\3855]#1P6<Y@HZHQ:MEY4Q;4(%:&"%.>FD
M+:04D%?2]@#X_;5@8TFH)"@<ZC!48+6KE#'(;S&!V)III`6\Y@)A;3VI)4'9
MN/58$_NJ1(!/@>X#Q\;S1CV..1%/IZ5E6(#Q+&*5!J/5]2VRX!<&2UV=BU+[
M7,7+1(90E13:'D0I:>VRNH3+9=)^'<*UMR_0\X+>B'4UKJ\%>'-&5&D<<;3F
MVY+_`-6EE.-QP#SP4YDLDMF%#(`6;EEZ2%G_`)*"?*L8SD`X"M/2I([;7(T:
MCIKZL2M<>"-,<4_C5*D/)1A\8YEY*RKN[I*DA$=!*TN7677.^Y\>PU+'I9&U
MFD5*ONW.=K<'E;(8I#X;FNM2I`3?N=+@;=6>X@?*>P$`$7K)=PJ`M)"UX:\A
MYHM8.>/JSL7'BER"6RSM0;)0`JZ5Z_W`D&YO5F'CQ`C&A]BV%J'_``]QWL*C
MVK+?$(/]DI"E2KN?SF:"R$+Z_P`"&/&_;XW_`$5,_P!Z@;A11N!K6JV.UF''
M?CJ,B.T>[N_>`5W`CJ%`I-[_`(UK[EY!-'+*@:"*EJU;W_5-=;Y*B:/I45;N
M7R4%>3GXIIUM&.Q(7W.LA#A!$5IYAM;I;)*4)*>VP4E(LBNB.X\X`="S/!_#
M,Q&%?.K4R^`WW1I[,B!,V'49R%#L>A2+XR44FZ$OM%;V*R#5Q^ZM*TV\JJZ-
MDX)#Z.56O:VC2P$=:S)H_/&05)BX'D=H05NEJ/#VK%+=8QSSILAM&8@=[WT*
MW56_CMJ]`*5\R&D#NK%T/C.+01T_3Z=BN=$UPK$XUZ%GB4Z_$>,Q4F<8Y0W%
M2ZX2I#O>YZ@:["V5]JEI!N/'XU.P->T-TMU9K6O#F/U$G2M7_<AD6'=LXM=;
M9#*40-L[D%;BRM??K'>Y=R]BLI\/*]611.$@!=4X\!DLRW>WPI32F(]JL5.L
M;QM,!$O7)FS0<8'7@A.%V!6.:]="DAX.--SXI*NO4]O7XU-+;M<0'/HX*2.Y
M;&3W`?2OIGB+EQ8):SF_`>1_MC)!\NMQF/&L9UM",Y2IQ=M)PB;Y@LC<=<8<
MJ8;;]>RN9RF[R<3!R#<B<S.VR3+A.,!*TE,F(K*NA]NY_=[%5`^&$8MD.KZ=
M2.N0YCF^&T5'0%NL)#1=CA;:_E/R@*N2>X'Y;H\U#SJ/3@<5BUQ&"GFI,4RT
MJ4%@)6H]2DK!*CW6M:HW->64P5P(J5TH]L2VE\612S<-_P`\S03W6)_T[9ZD
M7OXUY7S8'#=WAV?AM]2[78Z?`-I^<5L+7-+<)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB__7VL^K[$(3<_)W*!N;`]B@#;PO<U]=U'2O
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M1"&BE"^T6`Z=*F9`'RRD2D8<"5@[E=P16EIKB8=3ZBH!X=BQHO4.4$//*5LF
M[JLF*RZ#LTPW+@2`A259(A0-_"KFVQ(_YA_G*UOQ]J'._JT=</LCZE5L1]9J
MLF&VXA;<["KBR/261W]S)$A*%E*E?*\WT/7JE59#6#1H!K12B025?3NN"W#E
MSVI6&QLAM5VID:+,0?#N;D-)?0JWS#JE0^ZK6^\3UK#E-&!IS6.<]`.PX+,8
M]I'=*"5S(0'0F=CW/K8J`>I27%L!!_Y*R*DE;6,TSS\V*NVZ8-N6G[)=3R%7
MKP/L0Q^?Q%U68S<%>,<Z_*'5!N7'41X%?K1O3'_L0UJ;@"1H>NQ'<:6\0HWN
MEV)60R>CZ.RZ2TN9+VK+L@GJVP5XW#=UC8MK<$LE)O\`,VD^58C&:YHV<!B?
M9[5)$[1%+*3C6@]9]BR[Q;B!B-+?R+B`E_+M+>0HW2H0HZ51XB%#_P!B>HL>
M12L5DG&0-X`K"F>:/[%6,0\H1)7<!8E(58GJ`5*'GX$"IWCW<<2M;"ZK'+6/
MGE=\UQD/_D>VJ_2]KPM_X/ZZM(_K,?85L;4GX6;M'M65N'0E6K.J_P`K-33?
M[V8=NM3R8G#H43\UL!/V?&:3I^6VG,**8&'ANRG$HMZLEVZ68L-CN(3]3-E+
M0TV"0.]8OTO6GN32I*V-LPR.8UO%8H]O>JY.4WGN6]L;2O:-^D.2V+@@0<.I
MU/H1XZ5W6TPI#+:&A<D1VD=>O7&8"!CF<5EW+VX11^XW!;(3HL6<VJ),CLRH
MSZ`VZQ(;0ZRXDILI*VW$J2H>=2"H&H'$+$K2BT[Y6U#'ZEGV8D='=B<_&DRL
M>RZ2X8SD9;29T-*U766F/J6E-W)/:NQ)L34T<GB=PYT4PJ6EXS"SKQQEGLIQ
MOBFY:U/2,7DU8=+BRI:W&X:"_%[U+)*EMQ'$)OY]OQJUK"R=U/=HH)Z%HZ20
ML#^XM;AV;C*_11B;A8^=N_6;6Z6Z5)&/QV#J5T'[B:G2/:LL\/N.#3V[)0JT
MZ:H]S:%&_>V#Y>=2R@:L5"XG4LWQU'TRI2$BXM\J0+"WV"L-XH0`Y2C*M%7V
MP6F`XVJUQ8A)4D'I<WL1<]:QC[U"%<,JA0^\*?82I*KFQ%E*N/A;QL15:8&B
M<05^-E"I%_FOVN+N#UMVJ)\1XT-:*@I7!=.?:O8\30^V]OYYFO'K_P"6:^ZO
M)^;_`/O+_P#=M]2[?8:?P]M/SW+8ZN76Y2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1%__T-A/J%*/C?SZ>)_X*^M*GI7RO)QKDHSCY2@@
M$]6R#^/_``T)P(XJ!U:$U5.CND!LCS6H_>"KK;IYBHVDU5S*@OXB@45#_P#&
M"OZP4/Z/'SJX''RI&:!XX44:8]W/,]2+,("NEOWBISP\_P!^J%V)JKHY*-=V
MJ#&D]CG7K\W7KY5<U^.2R=56@GH61\-LDF!'5&:`[7/$G]ZY*?W3U'6]2$-<
M`51MP^$.:W(J3Y(W=[#:-FWVE=LS(J5B(5EGN^HRSCL5+J"`"%1F7%.#[45A
MW)T1NIF10=I6SVZ3QKA@([K7$GL!K]2@\#8UN+,9?6@>EB\3'-K]/K)C):;/
MP[@%+5^%6,9HB8SBMW-<U>]W2`%L?S-)[86CL"PNZZ[:_@4-1D)-O,7-5MAC
M.>*UV^O_``K!O7[`L+R<J7)\I)!2ER>@=!8CT02@'IU%_OK)8VC`>*T#IB7N
M'#5ZEC7DZ/\`R[9\/-2I2F,WB&F'5*M83(30L22.A<BO(`^Q%8\9(>ZN1706
MTK3`&#WF^H_E67=0S7U>MG'N+[G,"512"3?Z8M%V*?/HE)+8_P`RK@./6J7A
MTFO"BCZEDTJS+25*[0MTD`]1X]+^!-@?+XUEO;W,EK+&7\=HK@2J6XMS4-NR
M,".>TXG+1\SC/(?2R2WE(J!X7]$N>D?*Z#XUJ&LPDC/`GTX^A>@"4/CCDI@1
M0]N2IV<G/;WRQELDU\[4N;C,+B[$K[8L9AF.MQ)('R+DK==-O\LU%;QD2S2'
MAAZ%6>0-MH6<<2?.MZ9*V,9A1CF/D8AX^+#9'0E*&FVT)^/]04:VIKQ6OFEI
M&^JM6#+"<3+(40JZ;?&P03;_`,*IB,6K"C?2!_35:R\XR`K,\:=>@C;23U\2
MI_"'S^ZJ$?UF(=1]BV=FZMK,>L>U9BX><0WJ;G<0D)RTL]3_`/(8G[:ED!+\
M%1Y&95O[/L.-Y6W[%:(_E8^.X[TK(LR-PR3\H1HN4V&SP9PJ'U=K8,?TU-`D
MCM<+JO%M-])<#7(1]EIQ[?R+>6P\&#Q`/Q7C`=72MUVGHC$9IJ*6D1FVVD,)
M8[`PED(`92T$?(&PV`$@=`/#I5`TX+#<\8BN*^GI(^LCMWL;$D7/P'X];54,
M_#<5:7=YHXK2CFS?,=N/(N'P6!D-SH6EQLFWDI\=:78SF5R;D)$B&V\@E"_H
M&\:@*(-O46I/BDU%!WIAIR`6Q$9CMW%PH7%;%Z!BW,/Q]@B]W(=RN8=RO;X*
M2W(B/-,W\+=T>.A7_=5E#O33=`:M=<&C8S^E]:P![A72K:^-AY)B;B1?['-;
M)/XVJYH_%C/4?8K[9U8)AUCVK+W##P_LHWU%OYA*21UZ?,V3\1YU?.,37H4)
M/?Q/0L[1R/3%^H-O&_GXCH*PGTPH<5,*T586X$LI'2P3T\A\UO.Q\J@PJ5>3
M@$0L?4H5<$MH!!O]AL1XT(P/0J5I10VO].H]>C2@3?QN"/AYU<<AVJC2NGGM
M5_\`A20_^G<U_P"SFJ\EYP_[R_\`W;?:NWV#';F_?<MD*Y=;I*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7__T<V(?4%>(`58_P"'6_6]
M?5]3FOEE[!Q/!3#SY"%V-[)_6;4<[`]BA+*@8XU4@S)/8T+="DJ2;V(N2;?B
M*M#LB%<&`ZG`XA334A(44JO>Y(((\;6"3X>!JH.)*L+'@=W*BJ,M[%C'H4V9
MQR@?^<+]`0OI`UX-D$OE_P!6WC\H35M7:C@-%/+5(VU;2IUZO)3ZZ^A4N'(9
M6L"RDDVN%`^/]-7MH<UD:9&BA`5VLK0A)(/5/9V]1<];^'B;`=:GKP&2@=B1
M58ZY$Q^R[%DL+CH,!Z3BL059*8^VN.(ZYA*6([(*W$J<6PRET]`1_$\;UBS,
M,DT0IW!CY>'FQ6SL)X[>&X>]X$I``[!B?6MC>)V%8[$R&9*$M3IDZ%WLK4DN
M(8;8;8900E2AYJ4+?Y57/&(Z`%E-N6ROTM/1ZE?O/$LMSM4:3T+,64Z!X`?/
M'`\C_DU9;^Z\])5>8GT-J*9`E8#$M:W_`%5J)/J%P]?,GP!ZGI>LH8-IP7.Y
MC7QS43>8$S:"(D!/?/QCL*3"8*DI+RXP2R\PA3BDI[G(;KB4]1W*[0:QG-I#
MK&8-5M+.?3>M:\T81I^GE4ABT;#K63R3&0QTB.QE(:F'5%;)#3C2BY'=)0XI
M5@%+387ZK'WU>SO!C@?IFLF_G9I?'J[]</4KEUAYW^=0;7)2Z.E[=!]I\^M9
M+G5:]:^#"6*G2LA<C8'+9;,83,X>(N:Y]"[B<DVTII*FVV%B5!?/>XCN3WR'
MDJ/B/E\O#74+90[@5V5O<M$+HW&A!J/:HW'>JY'';+'FY2$87TC+KC*'%,J4
M[(D.)C!0#;B[!MI2R2>MR*.I0T&"I-<!QC:'8K8+9,DIMA]`45=RDIZV%NU"
M>@\.G2H&C(J&[EHT@<5:L3(GZ"2"H``75UZW#:"0/N)^%2EN+%ALFI$5@SDG
M"[!L\_0Y>&QS\]B`WGFI;C2F;,*EJPZXP7WN()]4-+M:_A5'M(N&./N@'V+8
M6-PT6TC2[O$BGI4KG]LV#0=&8UC'174;QLV5DQ<'$NRMV(U(:C,N99Q`4XA+
M<4)5Z95\OJBZAVI525QP$>+W8#ZUEL+)'>)*ZD#!4GIZE?\`A>&9:=!U[`8*
M9#6]%D/938TS`ZAW.Y28PTVM\2U=_:F,$J0VA:0.P]Q4%%1.))`&AK>O'K6P
MM[\2ETA!RPZ@K:5H')>L*+>OS-VP+1<N6,),R#V-40391C0G'H2NI_K(J)UM
M$?<?19/QC7$>)&UQ[%(R]6YFVR6,;E]BW_(1'B&WHCBI\"*^V?%$D(3$CNH(
M\0X2*M-H-!U3&BN%W$R0%L+=2SIQYP3&UY3;V=2TRTPM*_Y6PX'79*D@$";(
M0>U#05:Z4%15X7'G2-K8VAL0\JMFN7R5)*VCVTHBP<`RD!"3*=*$I``2VQ"6
MD)2/`)3Z@L.E16G>?/CP'K6+>.HV(=?L6J7,FL;%LVPZ5+P.*D9&-BH>SIG.
MLJ9`CJFKPGT_=ZKK9/K?3+M:_P"Z:R:4DC<<O\"6\K&PS`NQ-/:L5SN-^1IJ
M66HIV?%-H4I26L;EW8+:E'LNHHCSFDE1(ZFI9F,EI5]**2&X;&?=![5,,<0<
MK%I*AE]]M<#ILLX=?#_W*7\JPC;PU(\4^=9XN\`1$VG8%4!PYRP4@'+[_;H!
M_P!9Y_W_`/N4J(V\(/[WTJ[XO+\)OF6]^HQ9>.UO78,]<A<V!KN'B3%RG%/2
MERHV,CLR527EJ6IV0IY"BM1))42;FHJ4``."Q'$%[CTE5UE=W'+];H(_1:A%
M`%;TXKJ#[4S?B.']F=S8_P#ES5>2<W_]Y?\`[MOJ7<;!_P!O;]]RV2KEUNDH
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?_]+*J'QWI25A
M0`'[I!!'4>7G7U6'5R7R^6DMU:34J<E/6C*7W([%W`LM!7=)3^\@**T#KTN!
MW>5Z.<*%8Y8:A4YAT^DEV]T!'9W>25D=4];V/0^-6-<**HP#V$=XE3+;JF_X
MJKE"BH`V)!-[_O`6O8U<'(P`C0"-2BN/%T$MCNZ6'4?+TMUL3U-5)JK!W"`3
MQ7U`2OON;'X^7Z/LM5[:K*<0:$*Y6EW-K6('0_:*E!4#\!2JJ#9_AJ42;)4A
M)^4VNH*(Z@$#]T^/CY57(T6.>DJ^M,47,_BCZBOXN8@H6CQ!;5*83X^%[#]%
M'^ZZG05DV7_-P"IQ<WUJ[^>I!_M'A&[_`.CPW?U/@7);Z0?Q]*H(?W?E6RYA
M)=/$W^C]9*P@EP=/LL?/]'Z*GKA1:1PHQ56+,*\DB2^XIL&6TMQPE0*4>LE2
MCYW"0/"K<-):.A48<&R./&I]:EYLI<AYQY:W%*4I2NXJ*C8JOX_=5PH!@K@=
M3^]B3FI9&:&%CSLP5&V,@3IOC:QBQ77_`+[_`"4>:12'H!69;M'Q$`I@7CUJ
MI<!Y_(N8G(3LCELEE9<R='[UY+(2YP;#3)7Z;*9+KH92M4CKVVO8?`5AP0%D
M8<YQ+G#BNAO[QCIVQQQM#6]&%>&/F6S,'.>ME(:>U(6?32M5DE02J2YX$#H+
M(N!\*N?&-)"QF3:I65^F*_-TV1$9A:.Y/^F7=?2Y`%K"Q^SK\*LCCK0]2I?W
M(:TCK5HP=F3_`"*:\[VJ4%J^5*@D$=[:$@$W)46S^-2NC[S0%@LN1\.YQZ<E
M!R/)>MZAIBLU+,P.M.^GBXS:D%_)Y#O"&(;*.WN4X\&P/`A([E'H*AGK$XEY
M%*>?L6QL#\2UK8JU!S.0I@:_3-63K^-FK4[OV\..JW#8E-JCXYQ'<QKF)<4!
M&Q<(*!++P;5_$\P"025*<*EK#("9)!5Y]`[%E[G>1:&6\-1"#C^D:YUZ.A;E
MZ@XVF$""$CT4'JM%S\@L/E/6U1S#&@"SK0TC!ZE>C,Q-DI*DWZ?+>YZFQZ];
M]36,6<:+)U8CI4)$A*<J%]X(%O`WMX^/PO0@^&114#AXN:J*Y:7I31!_TCCG
MC?S6+7\P+FK`W2TU'!3%^IP`XE57DAT-C5V$J^<_S)9`/^0U%0;_`'%RL>P&
M-P>SVJNXNIX`^][%8T.9V)>!/0LJ%_'^LW^/2]9SF@T6&Q^&*FD.$I84%!:5
M=R/E))"B#;P'P35*8Y*1KN@JXTN2$QV"DV!6+CNZ]!UZ'K>H2&ZC4<%F-+M(
MH5<T5:UI'?W7'9T/X'Q\ZQ7@5P62%4FE$%1_Y*O/KT!O4+J4'2JY+Y;40I8_
MY"_V@?#[*JX8!4)Q74;VGF_$40WO_P`_9S_V<U7D?.(IO3_]VSU%=SL/_;Q]
M]RV5KE5NDHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?_3
MO2%*0XYVV[5!)Z6'C?I<5]2L<*KYLECT5QJ%,3)H;0I/]>X)"O#Q%O&JR/P(
MXJ(QZFUX%2;<I(':I7:/$_U4W/GY)\O&HVG!7>!W2ZBG&746'<M9%NG:21U\
M2/'Q%7M<`*E8^BE2&BJ^%.I;=#T9^7&=;/>EQAQ3:TJOT(4CM4#5KM->-5>*
MX!S6E5C'RWU+N[(=>)%RI\J6LD]22I1N2?,FIXR<JJUT;/LM`*N-F2>MBA7=
M<=;GM\";=I`!^\5-7+%0/C%:XU51;DCTU(-_F6A7]86"`L&Z?W%7*_O%OMJX
M&IZU"6E7WH$IL;+B`ZM"&AD65E3BK)2IM*W$$W-@"XE/6JNKH=V*>SHV[@<<
M.\%<'.DI+NW02E:5H&"AJ!20H67)G+'4?814,>#`.M9N]%K[IA!J-`]96'VG
MB.TW/RV(Z_:+=?"I2:CK6HE:&MS4VEYYUE]3:;DN-=P18JL$.DJ4FY<(Z?,1
M\H/C:XJ@/!6L:*-!<I94U*1VNMJOUN0+B_V@VJNI3B!U:L(5O;9)0=/V;L2J
M_P#)IZ;@`?Z1E2%'H?\`)4:MD(\&7K"R[9I%S;:L]84;B-]V/K+JF%!-IW8H
M>LWW]WTT125!M*_4(^7]ZUA\:FCH6L;U*V\+A.YP*SKJ^5<_G<)+[RB%+)/6
MXLTP\XVD@$D'U'/ATM5LK>ZZ@X*RTE=X[*GC[%`W'+J=E]B'2IM?JN>1ZN+<
M;/6Q!`[3Y?LJUK:-R5M[*7O`::A6-F-F@:YKN2G9.2TS#84T@*-E+=<>]1QI
MF(WW=S\F0IFR4I!)\>@!(I(]L8#WF@4<$,LQ$43:DGS=95LZ3$RVS9;';3M4
M%:78#CIU/5G?2<;Q#$A:G$3Y;"KA[,2%A*BHB[7:!8%*0B%D)E>;B?#H'1V]
M:VINA:PLL;3O'[;Q]H]`Z@LR[5,GN3HD9X.)6A#1"2`$E2CT[?*]OUUF1@:2
M0<%AW+I'/#7#(+8G6I$N-"92X"?E'<I-B/"UK@=#<5A24)71VSGLC:"."OR+
M,'>FZB#\MNZX-QVWOY^=8S@LT/J6J+$D]V15=0(N+_#HD]/L%6$$-JC'5D.*
MJL&07LI";2009+:".M[J>0+CXU:\`1O[%,Q]96#K50Y1G%K,8!M2@?2@Y21V
MDW_](QC7AX$'N(K'L&_A2FG$>U5W1X$L`K]EQ]2L9N>D19"[A/R)_`E3=A?X
M=*S-.(JL,2`L<>I3+$KO]%-R4A"5FQ*0!=74D6ZU6F)J%>Q]:=BNOZT=T0(=
M<3U!4DK-C<&Q-QYD5%IP<:8K/#O=%5?D"1_#*;=X)3\W4KZ=>I[KVZ5@R,-<
MUF-=4=*J;4BX5T(L%CR\"`/U5$6>M75QR7RQ(!6\+>#7;U-R+JZGX=15'-H&
M]JMK7$KJ;[2UA?$,4CJ$[#G4_B'FK_H->1<YBF]O_P!VSU+N^7S7;F_?<MF:
MY1;M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7__4JL1X
MCJ"BX5<E#02H@E1ZD=3^\;=?"OIYIXU7S@^E`,:=:CS92%I:<46.YIDL]K2'
M$..DN+6EZ22HA3B"JQ(M=(`^VJ..%:XJ,^Z&-:?8H?:Z\I!<7%6$MJ0`ATI[
M^[P*@X4J)2/"XJN)Q)%$9)I:X4<*]*F<;-F0&E,/QX<UH+5Z:W'&D/M#R2A;
M#S9*4CR4%=:,<]F!H1Y%%+''(=0>YI/;[1ZE/)R,5Y8'T<ACI92@XAQ)42;$
M`)/:D6^)ZBK]8<<6X*SPG`?O`3V?E"K<*9':2H]JO*P4@];W\^WMM^/G4['@
M<%3\08!GE4^G)1C8)*$>-R2I*4]?.R%$^/E5_B"F`5A$KNZ6GZ>559B0A32%
MA0)4/C>X)\?T5(#@"HW,(PI194XPA,Y7;,3%6I`1_K+R[BX!:864$_*JP[B#
MUJY[OPW$9J6PA\2[8UV7Y%+\RQH&)WF9"C+6IM./QJUD*[PAYV.%K3U`(`"A
MT`Z7J)KM36DJ_<XFQ7+F1FK13ST!6,4RD);*^ZX!`_5>UA]]7ZJ#K6$]I)#2
M%^0I:'U'TG4+43^ZE=U@B_B$FX-4:X'$$*Y[-(&IIH%/OMN=UE$I/C90((\^
MM^HJ\YBAP56.:2H4_%*R>"RN-[D@S\=,B)5T^53[#C2%#_-4H'\*N+-;'-Z0
MI6R"*2-X&1!6->-<VC&N_P`JGJ3'^J*&D%PA(;R$=197&45V"7'AT%_%20D=
M2*K&>Y&3T461=QE[G.;C0U\BV!Q,EQF<V^R.]38=[>ZX2"IM8O<`@?*DG\*D
M.-1P6N:XQOU`#4%9^Q[2Q$<;C@/97,N)!9Q$`)?R#J5.+[77DE24Q(G>JRI#
MQ0T/#N)L##+(UITMQ?T#/_!UY*YD#Y>^XZ8^+C@/RGJ&*MS'ZS-GS&-AVMYF
M9/CJ[L5B67"O%8'N!(4PA82J;D%)_?DK3T/1`2`*B;&2YLDQJ[@.`^L]:R);
MAK&>!:BD9]XGWG=O0.I7\PM/>V0I7<DIZI)!!!`%K6-Q64,<UBXM54R,V<_(
M:^LES7E-H1Z?U;CKJT)\0$J<45!-JK1K?=&"D+G.]\DE9SU;:"K'LH):"T!(
M#?JNE8[18&ZW03T-8\D=2MM:W/X8!H".M9,BY?O"%!M2%D%9!"[=O0DI)*@?
M"]NM8[F9XK9,FJ`>-%#@YI"IKIO9/JK%QW']ULWNE24J`O\`9XT='@`,U;',
M/$).55>>M3Q,R\!#-P[]4T1W$`=UU+'51\@BL>9FF-Q.5%GVLOB31@9U4+E-
MV2C;\:'UW:;UEU[Q%DEW*H;5>QM\RFAX_"K+)K?`=I_/]BBW9Q^+B%<!'7SE
M6HQDDB"[="7`I32`GIU*EJ0GL7<`$$'SM606U<,5BMDHPX="FL5E(ZICC,QA
M]`;(2EQL(>!\E)=0A22V4J^^]7%CM)+2"I;>4:R'-(5_1WL8[-AME*DI\EJ2
MNQOU`(!)'4U`X/#'&JVC7QES0<%?>-?8+_8PM1"5K"^TWN4]"+*(-Q^DUA2M
M-.\LN-P)[N*J)=0"ON/[I4H`?)Y]4D'QM?\`34=#A12$A0X;@/U!"Q\B4A0Z
M=22/VWH\'N@C-6M-:KJW[0%=_#K"KWOL^Q7^_P"I:KQ[G;#?'?[IGJ7><N_]
MN'^\=ZUM'7(K>I1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB__U;;8D[*P^EQ_%9!IKY`L+QTM"AU!5;^'V$"W2XKZ3!G::NC-.Q>`>##I
MH)`7=JJV5R2%Q.Q@.LRAVJ'<"GJ/FLKN1<)418]/.I97G20`=2QVP.+JG%JD
M(>UQA9C+09,9T"RGX#R702``3Z3J65`?C43;@92,(/4K'V4]=4#FEO013TA5
M9G):]*-V\RMLW'R2V765"_Q*0ZD@7ZU('PG_`%I':HW"[9[UK7L*KD"+$E`"
M%E(<I1-^U+RPYT\?E6E!M^%JE8&'!CP5CR7!9C+"]H[,%4G,=DV>TQG(RE#H
M4*=Z@>1LDA7C4NEP]TCSI'<VA%7D@=BJ#(E,MA<QYIHVL0MTA%_L*_(_=5X)
M&+G!4=+;R5$0K152/.A(*&?K6O67_P"338WZCP(1U\*E:]E::A56&)[AJ\,Z
M1V^JJS!QA#R$K/@19J(KS,=Q]#W:E)"%*;2L!(*2M2@>OG:IQ0!VK$)!&XR-
M,;]+^GL5K\J9!9W;-F7):4Z)#3:BGH@`,M^FT+V-F@0F_G:]0/+6Z17@%69K
MI)GO.)U'Z>Q6HB0AN-Z2XS3M^Y8<3ZOJ)ND)""0KL[1;P(O<GK5U:"M5"0'.
MJ'4*HZ@PH_Z-:;]?F/V_U0$U'W3PQ4X+V\5';NBWIR)3:56Z)60#UZ?*/$5=
MV$I1KB=3&U5Y8_)*8B/,DMN^NA*?6?90X\T$J2N[*UW]-1[;$]>A/QJ=N0.H
MJ%T5":9'Z8*SLMJ&.S#STAM_Z=^3UDCTFW67ED6+RFB4]KJA:Y!Z^-KDFKJ`
MU!-6E3,E?%ISPR4C`X[G(<2F1NVU_0IZ"#!R<R(V6QT#0=^I<6ALCI9('2H?
M`!-/%>&]%5<;P4)%K'KZ2`2KXAXO%X&&B%AH3$)KO4Z\I(4J1(>5?N>ER7BM
M^4\;_O.*4?MJ0,9&`UC:>U8$[Y)W!TDA/1U=@^I3P==1Z2T=JE)42I+@#B5)
M5XI-S\/MJ['@4T-/O'!3S4]I`2'H+@6DN$NQY(2#W"Z`&W67;!*O'K<CX54%
MX*N$3:"CE/1<C]5+8,KN+:5H02\2JS23T3<)4;`?`?A4@=TC@K2TBE3@LM3,
M[@PEN(EAF4T@)`?8>[&[$>*5^F%6'VI!\NG2K&M?2N(68^>"C6!M>M79B<W'
M4J,RR8_86W+=L];CS02`@)6V8[22VXE9ZA2A8=?*HG,.-00LB&9I+`VF73CZ
ME4L9F&&LB\A82>X.A-UH)5=`2;66#>YZ?&U4<TEH4L4S1(ZJR7J<5&3RL:&5
MEI+Q%UH3=2`VTMQ1Z@CN[4UC3N+(W.I6BVMFT22M;6@*H'(RXF`VZ4Q)EOR&
MSK^,0TL%L+;]>;DUA"@E)[KF(%]1Y?:*6Y,L+7!H!U'Z>E8NZ$0WCFN>2/#;
MZ2[ZJJR_YQ`$6/%7.AM_4?.E4I]$<+#;KJDEM;A"1W=_6_V5D:7:BXM)6#XT
M>EK/$`KTE5W&P=F4CZE#<<0>X".\TM3[3S9ZW;?0DMD_C5"^/(G'S+)A;<GO
M`#1YZJ[VH.74N,'6_6[AWI"?'J+V';\"*MUQT*V`CG[N%5DO%JGQF&@XRXGR
M-B;A7CX&_P`:PGZ'.P-5M(R]K0"VA5:??<$;U%NJ;)\0M*!U\AW%(-U?KJ%K
M&ZL&X*1SSI-3BH4>:B/ZH5\RW>TA:$@I*`4A-S?[:JYFJF."M#P*])76[V6N
M%WA**LDGNVC8R+^0,AD@?H->,<]"F_/_`-TSU%>@<LFNUM/Z;EME7'+H$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?_6O3'<EXR:;#'R
M6N@ZJ6R`?P*KW%?4C+^-^;2%\V264C/M#S%7$YM^%0E"I#3J`L>:4N?J2HW'
M7\:F-S%2I6.(9B2&N!*B-9G6)Z"X8[3J/,O0D+3>WB0IHWM56RV[LQ7R*CFW
M+#IUT/:OLL:4]U=Q^,-_#OQK8/ZF1TJM+1V/AM\R"6[;@)74[5^#`Z&\E21!
MQ:0L=>Q'I&Q_S"E0O5/"M#]AJKXUY4'6[S`K[_LIIS@LUV-^'1F:\FUO*WJD
MU7X>VR``\JI\5<C-H\K?R**G1M<=-TRI0'_)FA:?Q"DKJHM+<\3YU3XN8&OA
MMKV445O0L4VOO8FRD$?NF[*_U^F#5XLXQ[KRAW"7C&*+*.C8*9BY0?C.NRU#
MM1ZBD(3Z:.X%75*NXW3TZ?&K_#:QI!=6JHR625[2QE*%?6Z<+9'9\WD,RSDX
M_IY$-RELRVGT^DOM"%-E20X7#9-QT\_"L:2!KS4N\BV36R,[P:#F:U(S)ZBL
M9/\`&&SZ\Y9K(1%A8)"4NNJ0D$]#VE![;_=>C+=PKH>L>>2`X30GT*$_B]K<
M#:7VL9(](!*5>C$;4H)L!W+$=MQS_NB35W@S#$46*3:&FE[F]BESCLZIP%W"
MQ0A*`D_2EM'<4W^:QDV*U7Z^`H(YAFP45CBT8Q3FO7_@516S.#26T8:9T'S+
M`;5UL.@#:UGH:E_$`QB58S(:ETS*J66A]"D)$"8ROMNLN,KM?R[0D7[;>9JW
MO<6%7M$AKJE9YU.,*?0L=P4A%[V6%`WM8WO;Q-7MKQ1T8H:TU=2^IKSI`4PF
MZD7^4]`L6\"2#:CRX]JL9$*XY*1CSG'_`.&XVXP4CJ00M%Q:_A8_JJQKB<PK
MG0N;4BA"G4A#E[/D_$7/0C[#;K5_E5H+FTJRBFXC*W74-M.J<6M5D-H!4I1/
M0``7)/V5=AT^="ZH-5D#/ZKFM98@'))#1G1TR&D!85VI4`2A=KCU$]PN!X7J
MYDC7@ECJT2:!\!9XH`U"O^%6ZU)DLJ"@M8^T**3XB]CTJ[5C0J'NY@JI#,2O
M50I#S@=0`$%/8A1)ZBY;">XW/B>M5[IJJ5DP.JE%FOB#9<BQLJC.>]1$>&]+
M25+5ZGR-AM2`5+*+!*_LZUC740=$6CBMQL]RYMUWW5`:3YE+<X9V3*W.0TAW
MLBN8G"//)(22IUD3WHUR"HI*43EBU[=:MLXPV*G$$J/?I7/NRT'NEK?17Z_2
ML=*S#,F'%9E8]EUUAKTD/-GTRIOU%K27$EI8*KJ\4J%[?&LL,HYU#F5K?%#F
MM:YF(%/\*C0=G>QJ[PE3HEBH#Z:8^TBQOU+85V*!/V4+&GWF@]JECG<P=PD=
MA5VX#=W(V19FO29CCS/:E!=4\X.WN[B.X'I>_GTM5KX6N:6@"BS(+US)6R.<
M[5YULQ#W)N9$:E*D-MI<NKY5]H/4`@EWL/2M6ZVHX@!=/'=M?&UVO-59&PX^
M8$=RY)'47;"74+O:RB$NFY24]//K5G@/;7!2MN(WTQ-%\IRF-QX?OD'E>HY=
M++S,@^F5J'<$E:5(2E-K@=P'D*:)'T_#](^GH5#+''J_%/F/T]*[$>QMY#_`
M\)QMX/I5M6S'O"5(\932NRRDI/R`V^X5XGSZ"WF"0$4_!9ZBO1>52';2TAU1
MXCO6MPJXM=(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+
M_]?TRMYK\MI*%N.^SG'Q0V@+4/\`=%Q[,6$*/179BMFR"^OPMW6ZVM6X_C6]
M<-SF_6*UAVK:J4-A%3[H4M_;G\L!0(;]KVO2%M.ED,1>)]*ERT.@"R%PHV;=
MF1R20`7&T"YM?QL_CV]Y?Q2?]<JG\&VBI_Z;#^J%=&-S'Y?4@I;9]H$2#$>_
M<E/\9\9-QG2$@A(:8W%Z8%`FUE-`@_9UJX;_`+[PW6>GWS]:C.Q;(XU=M<!/
MW`K@3(_+](2I/M>P/7H".-]$L.H'4_V@[0#W>-[="/$$5<-_W[AN\_Z[E:=@
MV+CM,'ZC5.-#V!NVM[8=>3W)*CW\<:*+6],64!G2;]S@3\`?'IUI_']__P#+
MS_KN5/X!L/\`XF#]0+Z_EWY?[I'?[7]8!N0>_C?2"1VB_P`P3FU&QOT^)I_'
MM^_\O/\`KN5_\$V49;7#^H%.-XOV"(2KT_;-JR`E7:0GCK2TDD*"24VS'5(O
M>_PJHW_?N&\3_KN5IV/9#GM4/ZC546\9[$T*4E'MNUELH(3_`/0!IHOX=Q`3
MF"?X85\UP#;J+U4<P\P\-YN/UW*W^`[%QVB#]1JJ,5/LI@NA4/V\X6*M16CU
M&=%U!J_IE!-RG-`]OS`B_EU\*K_:'F(C_O-Q^NY!L.PMQ&T0`_<:J@Y-]G(0
MV5\#8TCJ$I&EZF5(!L%7`S=@$A5SUZ"G]H>8:_\`>9Z_?<J_P38S3_I4/Z@4
MDM7LK<^9WV^85:KD'OT;3W%V">^__M:4>TH-_L%KVN+U_M'S&/\`WJX_7<K3
ML&P'/:(#_B-5-D/^R5IKU6?;;B9I\FHVA:*EP]+VO+V&*TDV\E*!/@+D$4_M
M)S'_`.;N/_4<J?V=Y?/_`+/!^HU49>S>Q1A79+]MT&"X+=R9O'&FQV@5`$)$
MU>=&/=6>ORH>6>AZ54\Q\QBG_6[C'^D<J_V=V#_PT'ZC5/(V'V/!*5(]NF."
M%#N0I/'^DD*1=8[QVY\FQ*#Y7^RJ'F/F,9[S<?KN51L&PC+:(/U&J*O,>Q^2
MLEWVZXI:PE`'JZ!I7<0TGM0A-\[?Y4*Z>`-^G4VJ@YCYB&6]7'Z[D/+VP'$[
M1;_J-7V,G[';$?\`J>,*$`]MSH6E]JNU*5?*/YX56LL>7G51S)S%_P":N/\`
MU')_9[8,/^CV_P"HU0%3_8J;E?MTP/1/<>[C[2CT[>ZP_P">C=5K6'B2>E/[
M2<QG/>KC_P!1R?V>V$9;1!^HU?/K>Q!SM4?;CKQ"E=@)X[TP"_2P*CF+"]^G
METJG]H^8O_,W'Z[E=_`=B'_M4'ZC5\6]AO4CVW:X>G<2./=)\+C_`-W5[DG]
M1I_:+F'_`,S<?KN5?X%L?':H/U&KY#_L/:*5H]MV`2L$%"D\?:4A8Z_*H$YQ
M*D@^1Z4_M'S#_P"9N/UW*T\O["X$':8*?<:OR3G_`&)O**Y/MYQ4A382`M[0
MM.<5VV%@D/9X.`!/6UAT_"K1S%S`W`;Q.!]]RH>7=@`QVBW_`%&JUYW('L!Q
MLE,;(^VJ)$;<4`Q->XYT0P'EK(2D?4(V9P1U+\O6#7</"]JK_:3F$9[U<?KN
M5/[.\OU'_1H,?T&JH*W'V$H`</MNQ_@"V1QWHI[T@"Q0H;'V]B1YW`L*H>9N
M81_[U<?^H[ZT/+VP`8[/!0_H-4>-R-[%XBUNPO;FVVOTU(6Y&X^T5)])SM"P
MI0V9-FST!\NGV4/,W,)SWFX/^.[ZU<W8=BC-6;3`#]QJD)W+/L*R,A<J?[>6
M)CQ2B.[+E:#H2@GT$*2VR[(>VE*$AM"+"Y[4W%R*H.9N8`*-WFXI]]WUJK]@
MV.1VJ3:8"ZF98U2['*WL.@O-"#[9I!+W1+^-XTT:;&'6UG94':)$9KXV6H4/
M,W,)SWFX_7/UH.7]@!J-JMP?N#ZE&7R?[$WG[J]LCBR+WDKXWX_81W#J$`2-
MJ8?4HDBUD$=?'QJHYFYA&6]7-/ON^M#R]L)-3M-O7[@^I0VN8O8PTIQO_P!3
M/*B(1VI[G./^-PAT'K=M+>YN.J2`>I*1:J?VFYA_\S<?KN^M5&Q;&*TVJ#]1
MJG7>?O9#'0&#[?\`(%H``-M\?Z*I"0OPLG^U8%E`'P%B!]E6GF7?\2=XN/UW
M?6I/X1M&F@VV*GW0K.S/NC]A6KQ',D_[<,Z6V'&DN&#QUQV76R\;(40[N\<=
MO>0#UN"H=/&J'FC?Z8[O<T^^?K1NR;.#5NVP@_="V^X1QGM>]QG%6E\O:=Q#
MKS>L[ICG9^,A['JNNL9O'JB9"9BIV.RT?&3LQ`CY''Y''NLO(:DOH2M!`6:P
MF\Z;QJ<UNZW0(/YY_P!)2NV/:R!JV^']4?4M@.-D:/#QN=P.@:_%UO#:QM.3
MP,J!`@1,?CW,S'CP)>2D0F8;KB5M>I-#2UK#:R\TL%-@%*BN+VZW![;J[G?)
M*X9N-30$CV8+*@MH+1A@MXFLC!R:*"I`/M"R+4"F2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1%__0[%1\1KSS@?FPW\J[?N'\UER\F>X=
MB!V,3WGX;+B22"E#*4BW3K8T!-<2HJG@0"KYA/PTH"&FPTT$J;1VV;92%%7:
M$HMVH"B3TZV\+6ZU('`X`H"1FIQJ%BGE%U3+3;H%EKCV9D74>X$O1UM*)5TN
M>ZYO>XJM:)A@2JTS'9_AJ8F9%HI;#1[I)E=[:Q8I3_,$36P`;_Y)'2QJO!*=
M"").4Z5,9EM*0D=J)$4.N=Q)!(<C26&T**FOF_A*%NE[^+RH2>A?CS>P("RU
M)AE*"D)`D.>H\D(5_$2VJ,AL"Z>B2LCH.HZU7J5,112"\UGXJ72N&^?F#805
M-R7'5V"E/CZ-R<P$7L4A;B3T'C:J!.U$;S-:642F76$N%MM/K*;858J4ETI0
MXI+JT+)/3M[3\?"U-3AF%4AM*@U*J[&Z/I[006TJ65**^U``4;E:T*!*NTA/
MA8FWPJFOR*E:@4569W"_85AI?;W$!2^J5W([[N]X"K6"A;M(O:QZT#\$QXC%
M1CN+*DI[O44`NQ`)7W?N_.5GI_$-[^!\*KJ!JJX+\5M49*2KM6M38*$A3GBD
MD]@OVJ!2D>:A=7V`"A<!VI51$[O'`"E$]P<*EDNMA12I*.T`DJ[.PW\C=1L3
M85770C%4PX*AO976W5EU+*(CKERIW'NO1'7"5+/<Z(CR$2#9?BZ%D]*:QD78
M)AFJ+)RH;6I<+**F-A!7]/-B(+BE(O8-2X`C!ELI-E*7'=ZB]R+5:7CI5<@I
M?'97.Y:0IG&:WG,LM#?J%S`1I.<:)591'I8^*K(J6;6%XH3_`,HVJ)UQ"PD/
MD:#UD*X->141D^0J1=VM2)LO'NI=:G07T,SH#T*6WD(+ALM;4S'.,IF1U6L>
MU;22`>O2KFS->`6FK>K'U*TC2<<%\/9_*EQM+3$AQA;=R^PJ&WZ*2/W%MS)<
M.2E7:?``_?5P<3A0JE<^E1A,S+@65S(@/=8(]=P$H!(!6M$=?9<V)[>Z]JN-
M26T.:IA4*+VS70VIZ6E)"OF#1=D]W;;TPE:D0R@'QZI/0'QJ@%#BKJ#IP4)N
M*L+<5(RA<24DM(BQS%;2@BX4I,F5D'5*[1_EI`^%Q:JDY]"IPS7P]#:?;=C2
M)DF2RL$+9=3&0'$$=4J6Q'3(+1[>VQ7<]:LK0TX)Q5G.:NWBE![7E6C=ZGG\
M#,FS1!D.^FA!=COEUUR&^4HN?E<:-@+)M>K:`5TC%"37&BB0\]@9#RHTC'L8
M[)LH4IZ#D(L=J:A`*DEUMQ/J)G11VV#K:EM$&Q4DW%,\U3)58YN&EL(2ZTA*
M.U(0%!-OE![B$V``'EX_?X4]2KBI5W8(2#=+OFH%7J^*N@38%7Q5TN!^BJ9!
M,:CK5+E;%#6GN]=`4+**U+![N@["5]0GY0`4VZW_`$,..2K0UH`J))V:""Y=
MX&UU7Z*'7N\>G<4?-?P'CXWZ`",>A-+J45JS]J@@*[%DI[3_`%0E1LH=H2!V
MV`*02>I(O\.EA?@0%<&T-5C;:,LSE,=.A)=_\ZCNM-]ZC9+R@I;)(ZV"7?F\
M;=*QY).Z6@XJ\<<%UE_)GVP3O;?R'I<F0V'>.^<]V:AL$D%G!;KC-?Y#C.D*
M("6OYULV19^'='76G<1\265QS]GL4U*^7'Z_35;R^SS;(^\<9[/M<4J5&V#E
MODS8(CB@KN7`V;8'-FQB;J^97TV,S++-S;_1^`\*Z9S=`C9Q#&U[:"OI6)&X
M/\5P_/=Z#0>@!;75:I4HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41?_]'K$PR"EE*,RMH(':LJ0D+[.T'M[TN-I[@5?Y%ON\*KATJP9XC!
M3S*LDR5^GF,>Z.H;),AM0*;_`.D*0XFR?P^ZU4`XU"H:8T!HIA,_8FPD-O0'
MU(3V=K;Z@V!W#M/<ZI"AWI(/VU3AB$TB@PI5?9V/96%'U(32Q;M#C#_K)40?
M-+:UKMT`N4)JN/!5(:0*9KZ.\YMDMF1`?0A)L24%*>])[A<K4$J`+AM<#P'E
M5:NZ2@`&945/(4@+;#L8@>"0KO[U`E5^RR^TJ-[?#M\?C5*GI32<:.4?_>#V
M_P"D9[%'J25FW\-!";@K'1=P/T#SJA=C0G%4T%1/[>1E`AP=5J6FZBCL*G/E
M':/5*`HD>1L#\:%XQQ51'7%3L?.0YET1\0MQ:;J!:CCUD+[NXK[V;+;44G[#
MU\:L,K&@EQ5?#-0`2KM>US-(B0\@YB)T"--96[&??0MM,ML?Z1QIR6TX'U([
M@%$$@7ZFHC=Q-+:D"N72>SI4_@2N#OPS09]7U*W7<9G.GISL8EH?*?J)#IDA
M8Z75]&EQI2"!862FW2]&W'B'2R-P'6"/716N@H,96CJ!!]55.X.)&1*!W`9.
M3!]9HI.IRH:IICD'UDK9S:(\9QXE/RGU4I"?*_6K;GX[2TV@BK^GJ_S4880?
MQ=7DI[5M-I+?LE66F=HF<JXV2ZGM*MOCEV*VXH=M_JM&AY*+%3V]>YUP)2.I
M4+=,$R;D&?UAI!Z8])'D!J[Z9*0""M8P"/TOI1;8ZOQ7[-MF;CL:?F="RTJR
M>QEG<(>2R*E$=!)@R<DY+]8I'5+C85\16!/%)-ENDT3N@G3Z*`^53-E#346\
M9'4*^E93Q_MZT[`+#^N:]JK(#@>3VX/&(4M:2%)<*DQ#WK!'[UR:UD^S;DX:
MV7KI6YXN<?74+)9=P"@="&GJ%%E*%.SN&99C2<0AR.P`V@PVTI2E`Z)"$('I
MA(`^SI4UO>;K8-#)K74T85HHWQVTM7"3O5^F:HFT:UQ/R,E+6^Z1KN<=0V6F
M7\_@(,F;$N%`&#D765S,>XD.'M<9<;6DFX4*VL6_61_?M,;NOZ8+'?:RM&'>
M;U8K6/</89QCGE29V@;CL>FRW_4<CXYV5&VK6VUK"K7AY)*,\VBZ@D>GDT(2
MCP1?PVL5S;S?NKAI/14?X5C/B(]YA"T\WGV<^Y#2VWYN+Q.`Y%A,][O=J&55
M'RRFD]JE.+P>>1BE%T=2EJ*_-6JW2ZB$F<O(&8*C\,FN*U`V//;=ILQO';=J
MN=U2<ZLH;@[/A<MK\YVP"B6XN68AO/I(/=W)2I"DFXNDU03`Y9A#'A6A"I'^
M\A8/S)[2".Y5_EZ7ZW[[$%0\/AY5<9`*552P&@XJ$KDI70]"$]RCVIO\J2HB
M]EJZJ!^RX^ZFMIR*MT=:I;O)1D%?8XLJZA7IA?[WA\P1UN/,7\:M+]()*KH%
M"*JV<MM,;+I].8LNN-E1:6E+WKQ'"/\`31GTE,B.\$"UTD?#J*H)`>&:J&@*
MS)6S9'%K"'53<C#2.UN3'C+5/:MVV5*8:^24E*?_`"C7:NP-T'QJGBT`JKJ9
MT*AM[69S:78;SLEA95_&"DM)N@%*@HO.(<!0>BD]M[]*B,HJ-(0"E%!7E9Y5
M9M=^X@$AU1(`M?O'<@?+_35VM_0/.E.*EY$S)+![)+;=[ILM;R3UZ]`DKN38
M'IX&YJ,.>:=[`I@J;*=F>F`U(;4Y<^H75K[1TM\J0FZ_^^%JC<<<U7-6W/?=
M0W<31Z@("KI44F]K]H;<0LV(^-45>DX*L>W_`)XY0XHRFZ:#QEGAK<[D;/X>
M'/E16G79&1&70YC,0`B2\_#9^C5D74-N)9#X*K*<6E+:40FSM[FX@=(PZPX`
M$%PP)'017RJV662&.1\9P#2<:'*O57->E?\`+_QJL%P[NVLIEJF1-2YZYDU'
M&NJ`N,;K&TN82(BX2%*LB#?K<B]A9(`&]F(=/,X5H7>P*.&/P8HXR:D!;RU&
MI$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?_TMO1G\<O
MM]#9LDVJW:0?3<1V>/1*D=_2_AW$5K];:5UFJFT/&;%(Y#DG6,`D+RO)&+QA
MZFV3GPX*W2FY*D)=?;6M0`\@HFK3,!6DOI5/"D)IX:M.9[IN-L8+?[RD3G>H
M#4''9J:%V/[HD1H#\8`>(N0.M6&^C:"#+BKA:S'_`%1HJ'&]Y^D*D>D9VQ);
M22KZU6,0I@J!`"DH3),JY'B2V"/U5$-RC%6B0^97_!3''3Z5>$/W9\:25-H<
MWJ5$4M21V/X'.I2E2KV"I`@N,-I3YDD"WF*E9?QDG\8UZ""K/A)J5$=5<<3W
M'\2S/]+O\1VXL4RB_#2>X]4$3(K2D@$`WO?XFKFW<9)K,**WX>88&,JJP^7>
M%I#J?I]FUQ]Y:NY33.;8<>6Y<J'<TB0I2K`_`@$W'6I!/#0T?7RH(Y1AI*N6
M)R%HL9-L5/;C7O\`^9R9+9*B"25>D4]W<!T)O:KC+$:X_3SJNB:E-)H%]N<C
MXU\+2SO6;C=P(*6L[)0$C]T_PW4J':4JL0>GCX5#X=NXU+1J/8JZIVBFIP'4
M2NJF*D,Y/V.0<ZQE?5$;C?<ULYAU:7RT<3DLRT9*EE:`LQEPU7-P?EJ"XTQO
MBH:`D<*]`56G4Q^JM:<5R5'(F6AI/TVZ8J3W*LE"U/MJ7;S`0I]-U#H0.E9V
MHAOO@E0AH_,4RGE;:.J$.,RR$7_U=\W(/=8V<9"EW[C;I>K?&<4TC"N:^3RO
MLKJ5ES$Y!1:6$DD)0;NW%T=S:'%H';U/[J;];7ZO&)X)I:,%+.<C9::A2'<1
M$6TH!!;E3X2T'N`4>YKL>L;IM:WE\:H92<"T45:4^UBLBZI[B>8M):;9U'=M
MCUJ#&0LLX_#[;FV\8U8!82WA(ZT8U0';>WHF_P`/*H-$1.IL0:[I;4>JBI6G
M%9TT?\RGW.Q4A\;EAMK@1GG(BXVX:6PR0Y%<,=]KUX$+4\L^IEUM2%K6\X?4
M20HW!%4<R8BD5T]OF</\H$^E5KI)!`-?IPP63<E^:%SD_&6VC3^)7'`@?QGL
M?G^^Y!N0T=A#=O,75X5C26!E!^(F:_\`Q&@J]LQ!&DD>58*S7Y@W/\Z4J2<M
M!U]2C=#>M8;'(;:[B2"R7UY1_H#T[E'I6N9R]MK3J(D+JU]\C]G2I#=3D$5%
M.P>VJH*?S">>S>.OF#9FB18M^EBF'!?KVI]'$I>38?`WM6T@M;>%I:QTH'#\
M20^MQ4+W/<:G`]@'J"LG<O=9OO(>&DX'>.2MHV;!3^T3<+E\E*DXR5V*!3]1
M`6EN,[V+ZI[D_*0"+$5D>'`96R.CU%IP))-.RI5`9*$!Q`6$SM&N,-+;@3Y$
M*R>Q*&'7'&4`GP3%D!^*D*OU(0#]M3/E!P`5NDUR4BO;I+%W(J69K15<A,9<
M-?4'XH=:<5;S*T?TU&'EM:9E7Z#Q4%?)3S:DI=CNMGP05CM3W'P;2\>YE2U7
M/1*SY]/&J^*X8ZE;HPQ7X=_G+-FX+Y4;]2Y'OX7-BYVDWMUZU?XQ/%6Z2I5>
MXY98)^@("KCJ_%\5?%27B#?KTJ/6^M:J\,5O9')Y%UY4Q@+Q\USM[WV'6%)>
M">B42XUPU)`2D)"NC@`LE::L+J9E7:!3$JUI_(&6PZTHS#;T5"U%MJ:WVR,>
MM:RE#:7'6U>I!6XKHD.@(N0D+*K`VZV@AI.*%N.`5'D\L9%E5D)F=Q_JHAJ6
MH@>:4MH<'S$=#W5;X[<>/8I#$:`4Q5%D\M9E0';C=BD*5<$M8Q_MZFW=W!)L
MD?JJQUPVF%:U5WA-(`XJ1/(&<D=',)E6PJY'U)*.MNMP`56^(-JH;EN=13M5
M!`TT!P"O;@23F<W[G^"(YC%AK.<D:#AW!=+A*H^W8S(_Q6R!<"&A\GY?`'XB
MI;&Z;->6[`,W>K'V*&[C#+:4UK@1CUX>U>JK\L?,N['[==BV%\J4[G^=N9\V
MM:@1W_S?;GLD%CNL2E8E7!\P;UM8Y!*Z=P-:2.'E!H51[2TMJ.`71&I%8E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+__T]F97&7(2&UM
MS^%MR[5@)>3D>.-A;2ORLZ'M>^;QM\UZY\7<.-74[0MH8I*:>!6-=FT/7=>8
M1(VCB?6\*E:BEYS8M+3A6FR2.WLE3=?0'%K^!"+6\3XU9\79N.@R,+N@4K]:
MN;#-P!HL:3=.X>RBBHZ?KB!<V3AWLE&"CX=#B)V-%NOPJI-B<V"O8JZ+G)KO
M.5;SO$_&#_S1M2F,J%^C6S9MM!`_R1-S*_'IXU'X6WFOX1'T[54_&-H:M("_
M!P7HTU00(>0QJ?$.M;4'38CQ[7&L@0H'QZ&AMK'`@D>4_E56RSEW`E1T>V[C
ME:3ZVV;C$6>B3%R.-EH!\^CVLM*58?;5I@LZ&DSQ3K_(I#)*:4A!-,/I523G
MMLXT05=V_<AK2"/E$3$I'_*_B##*N/ATJT06@Q\9^/7^15'CT)^&:#V_D4PS
MP3PQ"6CZG-;#-4+&V4=R<=2BGK\RL4<:4B_PMTJ0,LV#&0T[3[%>&7#S^'"V
MO4:J]<=K/'F!4DXAK%RW$!L-*GY+;)[B4M)"6PA,Y_)EH)0D6";"PM4P?"W&
M-[:>58TT<[21+&]M,>%%W]X$)V'\MJ?#9CQE?2Z5SQBVV6%2?IUK5D=VR#+0
M4\PU)3WF8+W3<>72U67KZ10R84!^F?8L1H%75&-0N&[6=R'=_"PGE^]&S3"4
M$"WR)#[B%!1^RW6IC-3-HKVJGAG/&G8I]O-9PFX_F$=)"0&Q+C/E!!5W7+<"
M45W!%NOEXGI5IG)K04PX%5\-M.E17<WGT@J&:D1AX_Q\9*DVO^]=:(45)O49
MN2#C(`.PGZE<V#5DQ4UW9<HDI3(VW'!-BDH>A+C=]R/`+'E]HJQUXT93`^12
M?#4Q,1HLKX#AKG;<XR)>L\5\A;=$<`*)VN:%L>0C*20.TIE1M>>8MUM?OM5K
M=PC>!X3M8_1Q]5588!7%M.TJ\,3[-_=!D%^C!]OW+$5*G''").#7AFRMU:G'
M%*_FZ(#84XXLE1L"2?C1NY,<2QL+W.Z`/\"M=;TQ>\#RA?>;]G_N>P*'G,AP
M-S#V,`J<<AZOD<Y&2D`?,',&U+;6@`]3W*`%^M2.O90!2RFK]VOJ5O@,)PF9
MYU@+/\?[KJ4I.2V;5=EUU3"U%/\`:./N&!B]]B@H=ARIZ<<X``?E4R0"";7%
MZQ7[D]F<>DU^U@IA`"*`5'4K=>V1"DI0[_9E]`*#=G*@&[:@H72IE'<+BQ%[
M*!(-P2*L;NC^+65[2K_A6--=1IV9*[DQHHT)O>`S$8QYVB3JRVH+[J%HG,XR
M+DR^KZ0EA4=;,H)!^90(_=L15';F=(<1C6GJ^M4^&HXL`JK%;V^"X[+:8R4F
M&J,M#27)?IO1WE+90\5QT(93(<;;4X4DJ*#<$6\:M.XO(KXE"JMMS7]T/IY5
MDGCK8.+7IRD<J;5OT7&]R/3D\?83!Y*60HH]3UHFP9?$LV3U(*7CTL+5COW&
M[#QIE:8Z=!U>05`\Y"N\!H9^[QKG7_"MZ]%XQ_+GW=@N3/=?R)J4E('J8_=M
M7QF`?%T@J_UQK%9G$KM>UDR%=:O^/<]I!NRT]#HCZV.?Z5&8#7&(DCH</:%>
MF0X2_*AP9"<I[O-LF2D@75K^2PTALDB_5./XYEMKN!;YE$BC+^T:*7$DKG=,
M;33_`"J*G@3$UCB%.LA:@<Q<?>T3#-SLGPY[OL;L48$KAZUNVE;KC<FV.]9#
M7]H=?P>0B35]M@"<=%23XD#K44UZP'5;RR./06EI\]:*1MN\GOQ^D'\JT><W
M;%A:T%U]782D+5/(:=MX*0XV\!VGR!LH?`547#W#WC3[SD="6F@:*!2[FW0E
MILE#2T*!2HJG/N)4"#>X*E`W'CY4\5XK5V':3ZRGAN%*-I7L5&_M2F(>^$8Z
MFRHWB2'''64BP!#"UI46.GE92/@!>]4UN%>\*HV-Y%0W!0#R2R"4JAQ&UI/8
M4KCA1!^(4A-E)^!!-ZM^)[Q;5M1].DJ0P/&-:^Q4Z3R-XV,)/B;?1.$WOX#^
M(D>'V4\<DTI0)X-*.)JMF/8IESM?N\X2CE,=UO#;'E=L79GM2TC5M8SN9+RR
M'%A#:%QA<D>)^VMOL(,FY1.H:-#B?U2L#<&.9;TH""]@_P`MJ])OY.&R;=N7
MLUC;9O>4R&8VK8.5N2)V1F9`I!;C-Y"%"PF-@LH;;;BXO"Z_$BPH[*+M--1P
MANS82D;^TG9<,EDCII\1P\V!\JCGU!S&NR#`!V?3%=5:RE`E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+_]3,W)GNHYF;>><S'YD6O;3'
M3&<0O!ZEO'N(;]>0A:2E+;F*XQQ&&4VI`(LMU*>[K>U>::8?]5:22#K#_P#Z
M@'J7:BWB+A5NGMT_Z1*T>SON>G9V69>Q[7E-DE-J4E.0SF<SV5?4$]`I#T_)
M/2.Q7B+V-O$`UFPVWAG7%9L8\C$AH!\X1\5NP`&94I/N(Q:;?\XH3?\`>+8E
M._9\I<R#5S66UMQGIH[J_P`*Q'LA!U-FK].Q24CW"-ODHB9]"`>G:[A7W_#X
MVSB$DW\!4@CDH"=5?)]:M'A<'BGE^I4-SF#,27"M&R1%`_NM)T]HBW3]Y2\^
MZX3]H*:M,>'>=3M(5S6`D.TU\A5:B<HS#V^K(@/`_O+.NK8OU-NGUTM%AX>5
M8[W,!H91YQ[%F,LY'$4@?YECCD'G;;,)DX<37X6K2(DC'H>?D3\`5O)?7(DL
MNM)"9+*2V&FT$$I)N3Y5I+_<9+:8-C+:::Y#.I7N/RS^6FT\V[7>7NXRW$<T
M<YCTM<`"W0TU-6DYD^9?FK\V;@TH-,#5L8A]Q"G_`.5Z\82W5`=O>X69Z0XX
M$IL"H'PKG;GF?<F!QT@T7K-K_=[Y7G>&V\]UB0/>9_H!=0^&(&O[GJT?/LZ/
MAMZ7CD,M;/\`VO\`<QQWPFEN;(0%L)PF-VO*:U.R,=Y+3ERP9?HFR5K!*;V<
MK\S;GNIW(7DD40B<`VF!<""<BZM109"B\W^??RHV7Y7_`-DV[;<2R_'P2N?K
MCU:71E@(#F@#'5[N8H#Q7?SV=976<U[3-FQN/XWP^L875=HW?`Y+1\/S%B^7
MHV3;E:WB]BF^KO.MY/*H@O9UG8B@Q@Z'HS92XE(0XV3Z"V5\FTZWO\0B0BI!
M:*9T[,<POF"<-^*[M`TM&0ICV%<2<U[EO9=D(X;3[#.4=9DOL/2VE8'W`[E)
M"V6NQ+CWH[%IV9[8[)6+J[.E^I\JQ"Z[?WAMS":?[1^7E#O6LSPRPT==MPZ0
M/80M3=E]S7M.G.R4:]QCRWK\IMQQI,>1S+K678C.H7V%M;#G`XF?(H$$%_NN
M.IK%>;J@TM:UWWB1V9A9<=L3D6GL9^4JS-7W3;M_G2&.,]3W3:/16D*C8+&S
M<K+C(6?X2)#^/PL=)<(_K=B+GR'A5ANI8]+9)FM=]ZGF!)/K63\(T-:7C2.D
MA86V;W/[!JNYYW1<UKFYXC8M<RDS$YC'Y>2U!DP9T!XQY+$F)*<;>:<0L?NN
M)2H>8!K'=N<S&EVL::\"2O1K/Y77NX;98[C%<0^#,QKVBAJ`X5%>"RQH?//(
MCZ#L&"SNT:MBH,V%$RNU8V9DEQ<`N<7E0EY"1KS.0EL*D&,OTD)25N%![1\I
MMBC=8IG.UQ!SV@9TKC7*I&5.I<US'R7<[`+7XI[29M>G3QTZ:U!&'O!='N*^
M3N3,PQ"EI_,1YHUB%*2E31QFD>Y_8H:E$)*4LC%ZZ(4E`/0$$_=69'N4KRP$
MO;%QTDD^9KL?.N.DLV-!I#63K+0/7[%?_)N_<UX[%NO8;\Q3E;9D1VG'7OY[
MHON\T6$AE".]2WY<#1LQ;M2#<K1V`=>X5=/<N`$AGFIQU-D``[2[V*R&T#J`
MVXU$X4<PU]*Y5[E[\MPGY')ZK*]U.\;QCPIR#+?B[/RE+PF12>YI]@Q-OBXN
M>XW<%"DO0T`_`BL=QN2W4^V/AU^T:Y<?>/:./2NECY3W#3'*+%PU"HIIX]A4
MUI>.VC?IZ\9K#6.ES4H;7Z64S^N:J'`YW$&.]G9N&9D+/:;I;62GS`N*B^/H
M07DC//`9=)^M:>2VTXZ1A]."W2QG'F;U+@#^6<I:/L&4[>6\AFQA]1Y1TW7I
M[N)=U#`1F<FQM4F+N^$<C)>CO)^D#?K+44K%DCYLJ2ZI:QO8X.!E(_R1Q`/G
MH5@E@^(TMH#H]I5FXO:O9;C4/*V+B3W792>RA05`1RSQP[C.\(/<3/C\1ID.
ME!ZI*`02.H/45C-NISB+-YZ@^GI,+O4L@VTG^VC'D^HA8FY!F<'Y/'/+XNX]
MYLP.3<7WQ?[9;5I.QP&T+O8/IPO'NKRU*`MT[D'XFJ.N+YS^[9/:.MX=Z!$S
MR&JO;`RA<ZX93JP]I]*L?5^-=EVIEUP[+J&L/-$)$;:)>7Q[[B?'U&G(FO96
M`46\`70H'Q36%-?WMNXM-E.X<"&Z@>K`YCKH.BJG%K%)WA.SZ=/Y*J]<]PAD
M!A<;(@;_`,?.9+$P);N7B,9/.E>QO/Y"<[%D8?ZG46F%-0HC"8B[NQ5*?0NR
M%`)=5<W=;IS&5LI@XMK0L-0=3AC2K1D#B1@1UJ,6C'2/:)6Z0<QB,0#V\>"P
MK$Q>[X[(1IR=7;FB(^A]47(R5*Q\H-FY9E,)FLAQAP="`H&W@0>M9>N]>TAK
M"TGH+:CTT]"HZWCU82BO85MK"]S6-P&%BMY;V*^UC-SF6/GRLO\`WJ!SN]=3
M+3F2QZ.45QG7GB`JS)"#W6L.HJR6ZO8('^-&PLCI5Y+]0KE[DK6GADSM"R]H
MV"[WW<K?;-M)?>S:M#:M;72TO=B\`"C03BX5IABLIZMS;I7*6)R6K<@>V7V=
M<-8Z=&#N)V.!Q;S#/G*4%R&.]O*:#RK'V>$MMYGI=+B'.O>"``<0;GN-Q%6R
MM(Y6&H+]6@M(H:8N)H>G2[LQJI=WY;N=AW&;;-UD,=]%0N8-+\'#4,6DL.!'
MVNK,$+`B?;%Q<]%R3SON?QC<QIF0Y`AL\0<A/X^4^E#BH\=4V2IB7%9=79)6
MJ.M2$F]E$6.-#?[W*Z47&U.AI[OXT;@[S'#JKZ%B.M;=N@QS%P.?=I3R5(/D
M*U6E\7;NA;R/1QRD)6M`?:><2AYM*CVN)2M+;@0NP("DI4!:X!K;Q,NB&N);
MJSH78@^0'+RA6.BA!<"]P;E@WAYU0'^*=N<;++D@AHJ"^P9*:A!6G]U:DM/(
M!4D'H;'I>LQKKX4)>P#M/U*)\-JYP`#B.P?3TK?_`/+AT]O6>:]RV?/Y-Y>P
MZAPSS!G\6E3TN;]/AHW#G*!R,L2);KBVRC)1X*>P`A5TG^KUZ_EDRM%Q+*&Z
M:'$'*FD=`X$GRK4;K$S3;-:\ZC,W"G4]WK:%Z8?RAN0=HY(]DNC9K;LYL&P9
M7&9_9-5;F["ZV^^SC=:<AXO&0L>\A]]QW$1HC*0P72ERQ/RI3VBI>699)=LU
M2.!`E>&T)/=!P][$=F0R"Q]RA;!<^&UM*-'G73JNA6O2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%_]765KVZZ8X!W)ROV]TILW_`14B_
M2M"Z.!E:U[5O&.D<!@/+Q549]N6C6`^DGK/Q,I-C_P!REGH:QI/":ZE'#RJ<
M%N&GCQ56A<!Z3C9")<?$=[S+C;MI08F,+6T04AZ),C/17V[CJA:%)5X$&YJ)
MXC<:.U@4_.-?."%>V5S-5"VG8/34+8K"\K\D:<EE.L3-&P(BM^DP[C.'>%,?
M(;:2`+"7%X]9E7L.I*[D^/6H&V-FX@4EJ?Z1_KU*)]Q+CI<2SIX*L2?<[[B5
MA2?]YI8"NG^JZOH,)5KD@)5"U:.I-K^1%7/L+)M23-Y)I1_GX('34%'X]/#Z
M>18TV+DGE_;FI#6>Y9WR0R^@MNQ8>WY7#PUI60E:%Q,-+@1U(4V3=)38BL<[
M;MAU5@>\4^U)(X>9SR%<+BY8YM)AG3#_``+GQSOK<;6LMA#%]4C(P9CKCCTJ
M5,6MUF0CO5ZDIYY0)#X)Z^)OXUS6^11-F@,3`UNFF&6:^M?[N<TD^U\S0R2%
MQ9<1NJ<::F.'^8K&PB^Q32QXW2;=".OV'X5Q]TT$.!R7V1L<+&R1N+<J+).X
M>X;?.*]'?U/5<]L6.QG)/KZ_EXF'G.QH4M7T:F(JLHQ&0N;+:;5,4/38`=4D
MJ"?FL*VW(&WQ37^YAY=1K6/H'.`)#CF`0#_C`A?/']]&-CN7/E]?!GXC;BYB
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M+,G;);,-V;E,C%1&BR(D.1+G)64$QP`YV]J>VL&W@MYFS1MC(#7X4Q[O`#&A
MX].2S7SS1NC_`!B<.NA/3TK(NO<_<B;&O![%!BZHY#Q_)D;/Q(^-U'7TP,=*
MP3$=N;E\PM>T/9V7AVF$R4O1&\X67&'4O!D^-6W.VVQDF-'^,8SFYPK7$!HI
MIKECHKPJKXKJ5TD3C+0:@,\`,JFI]N2QWS)LCVZ\M[_NCCF%>>V39\EEU2-;
M:DQ]?E?6O>L)>&;F/2)*<;+2?49[EK)0H&YO>N"<#&71NK4.-:YYY%?<_*=K
MXO(O+<HQ!MX\?(5LY[<L7J,K;MVU#+E#60E9'LUG&2RXX^N-B)>81.1ZQ2`E
M<=*XR%*44]ZW$I%U*`J_;WELT[_!#H^Z"2`0*UIGTX^9>6_.)KF['R/<.DI+
M,)R:85[L!X=N':MXH6L2\2I+&,EY*`TE5@W#FRHS:;GK9+#K:1<>/3K6V)MW
MFIA97ITCZEX$6DG$GS_E62<9K.0R38;G3\C,;([%MS)\M]"DKN%!2''%A04#
MU!J,F$#NQ,'D"J!I(J37M*\_FX85#'(?(\1'<V(6V;>EL-V'8J%ELF4)5TZ(
MLW8_"K3/0BN.2^D_@G-V?99F_;@9Z6M^M=X!IK;<>,0PD)5&85T3XW;2?,>-
MJRV3$AO>X+YIFCK)+CAJ/K6>,7K[9X`EP0A-ARPJ64@)Z%6J8J.%6M?H&K5=
M+)1L3G'[9_96'1OC]W+1[5B]S64A`4ANQZ^73Q'E:]6^(T]"E%,RJ>-='>#V
M]PO<]/TV^^]0NGIAQ4S8VUKF%6<?KB5?^3Z?>;#[.@K3W5^X=UKL1Q67'%U8
M%72WKJ%V_AI_@L)93TM_Y>5(('0FW=*-:^:YDK":YMQ_6<IHH^]-08:O\T*B
M9+6F^T@-@'QNGQ'X6Z5)!>O;0EQ]B/B%*45CO:DF6]);=;[FTN-)([E`**&T
MN)[NVP6G^+X&XZ5-))%.R2.:,&-U*@UIZ^D*6QN[_:KN.^VR[D@O8R=+V.+7
MMJVATN&(J"0:<#171C=722W=M3A;;#25+*B4M(4M:6^Y=SV)4XI0%[`J/QK%
M8(K=CH[9@9&7$T&53Q]`\RON;J\W"X?>;A</FNWTJ]Y+G&G23B?*KS8U1'I?
MZ*WV6'V>/2YZU&ZX%>\]6Z"`2J1DM93V*`9`ZVN$]3YGQ\ZECN'4JUYHK"T4
M!H%9$G6%%9[4=+]01TO?S%OMK+%Z\#/ZU#X(-2#BL^>UZ.QCLG[AW5M=J6/;
MER_C5.#L[B]EX7'VILH2?1]46._.)_T@2>\_*2+UUW*EYKAWL:CJCM)'XG#`
M5RZ</0HM\LFP[3LEP`-4M^!6F)`C>,^BIRZ^*]`'Y3*,6S[0L5%Q+\5Z/!Y"
MWV`ZF*XVXF+,AY%AB5#>""?2D1W4%*T*LH>/@03O^5(Y(]F@\1M-3BX=;3B#
MV$+F-X>U]Z\@U-`#V\5TPKI%JTHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41?_UL%XW9,S-E2(:LCJ$%45+2U2']TD2H3R75.)M&>=X[QR
M7UM^G=20H$!0)Z&N&?S#LM'!^Z0?KMK^WBO9++Y._-:[+3;?+C?7]%+*XICV
MQJX3GA"*#+W;4;%Q"5IAM3<B$(4"5.*?8DXT=B`.MDD_8:P9>:-@;0G<&.X8
M:G'UE=)#_=W^=\S:Q_+;<VBE:R1MB'_S'-^M7]@]1Y(VO&8_/:K"B;/K&69=
M?QVPXN&PS"D):DN17TEG,\M:]D4+:DLK;/\`JY!*#Y6)WEO_`%N*.XMHB^%X
MP.`K0T.=*8@CR+R?==KO-DW*[V7?(_A-Q@+?$8^I(+FAP'X0DJ2UP=V$8URF
MLAPQS!/8=CQ82<9,>;+4>9)<P\>)%4X"GZAP-\A;1(5Z`)4E"6'`M0"20"5#
M*;:SAP)A`97B6U]`/K6JF-FQCO#O&O>,@!(`?UF-"1?;#S*L0DKV_6Y*&\<E
MJ>XN8B$^]DQ]/>0VG^R&>:9C*[7B4?.05)L;`WNE@D!):UIJ>)R_R2K+:2"2
MGCS.93\T:JGL+FJX8'M/Y)E63D-RQD$$64<?/PF2(/S`V1,X?@J4!T-^^]ZU
MYBO@[O-@#.D.>3^PWUK=O'+`&MFX7[I,#0V\317CC\2\^6GF6HWO.X&R7%&(
MX^STO:I6RHRT[.XIT2(&-AB"ZF-C9C"4NXZ#CDO?4(;=OW-"W9T\37,\P1O8
MZUUZ:D.RKPT])/2OI'^[C=VK;SFBTMC+I?'#(-9;B&ND;DVM/>Z>@+3K%.@(
M;(O;L0;WZVM\:XR=M21Q7V[M#@T1O'NT'J4WM6IXG?8.*AY2;DH0Q&0&2C.8
MUV.RZMP-EKTW%R(TD>F4F_RA*@H`@@U=M.[7>PW%Q<6D4;G2,TG4"0,:U%",
M5A_,#Y7\N?-W;-KVCF/<+NWM;2X\=IMW1M<7%I86N,D<@TD&N`!J!BO4[^0!
MD'I&@^[/&RL]G<PJ!L7$,Z'$S&3D9&+A(.3C\@^G!PK;U_Y=CDN8QRS*5%/2
M_C<GMMBW2?=-LW)L\,;#$6$:`6UU5J78FI[N:^"_[Q/R@Y;^4^Y<J-Y<W"]N
M(+Z*<O-P^-Y#H3$`&>'%%04EQ!U<*$+DGR%[".#(_+F^YQYK;W,B=RS"7XR-
MA$?%*3CLL]'8AJQ<6#'B.P&DQTI##B5ME(^8&YKHH;V=MI';M=W-&?VL>OIZ
MU\_"&"247/A`&H.G'3AU5XTKFKI_]2-P)F6G_P">:*WF7)K,:/*D3LQG4/O(
MBIBAD*,')0^Q:?Y:P2I`2I11\Q-U7US[J>!X$4I`!P[3GZS@LQWA/;3X:,$Y
MX>;.JM#G+V[<4\6<"[5EM!U)C5Y.M3,+EH,W&93-M38JI^QXB#D5"6[DW)"A
M)B2UI6"HBQK5[E?7OA.F;<.$YH*]5:99<>A>C?*/;=FW+GW8-MWO;X)]JD=*
M7QO8TM.F%[Q4TK0::YTJN2.04VJ2\XT/X)<3V$+*Q8)L/G4I2E??>N=#I'C5
M*XF4XDG.J^X-RLMOLK3X3:+2.';8W-;&R,`,8T84:!A3/RK<;VEX+";!EMHR
M&5Q&-RF3P3.(R6'GSX4:7.Q4UV5.]67CI3[:WH,IPH1W.-*2L]HZ]*GL9'12
M3,,A#'@`C@:=(XYKY^^>T,0VCE32P4CFFTX95:S`='NCS+=B7(?8`5ZD@*;6
M/G0^KOZ@C]X&_4H^^LJ=E*%H[OT^M?.C9'EA`<:+)W!F6<G[%OF/DOR9:L>Q
MJ$I+4F2%ICHR<?/MH+?U3R>P/JQ2R0GH2FYJR-DA89"WN$D=I%*Y=%<5;>SV
MS;.Q890)FF34.(#M.FO;1U%PTY/B>GRMRJC]TIY&W1!'3H4[+ED=MP2+>1MX
MU37B*]"^J[:V:_ESEB4^ZZSC-?\`X;"%U,]U?NRF^VV?QY@<=QM#WE6X:M-S
M3DB5MB];_EZ<:]CH?HH0UKN:^J+IFA5^YOMM:QKH]DVL[I'(\7&CPR![M:U%
M>D47QSNEZ;2XDC,8=5SN-,CY58_`ON8V#1_8-RIRP=/F;1D('N@@8I.O;'R#
M,G!+&>TG7W2]%S;FN..PHD92%!$5,=2+W(4+D5N+W:1+=V5F)0W4":AO0T\*
MBN6:U$=WI;).&G##$US6Y?"N_/<P<3:;R3+P;.N2MHAS9,C"QYZLHQCW867R
M.*6RWD%PX"I:5F#W]Q91^]:W2]<U?0?!W4]KXFHM-*TIT<*GUK:V\GC11R.;
MFLC_`,M02;(O?_)Z'Q'E;XG]5:&:9YJ3V+8M;[K0%684!#5OE/2W0@`^1O;H
M#6LE.&*SXV@:6YJJQFTK5*%K!#R4'P!'^K,*'@>I^>H):_A`'[/M*K#75/CA
MK]@4&1!0X/W;@W\?/I<@>/3I5@)`4KA4$46@G_J@.4,DRG*:IQQH4S&2\CM$
M52LWN><@2VW=<W+8]1:]-J%J>0:4S+@:^Q*N5`I<?6BQ2@*5VT'+T,@=XEX\
M.&G)@([S&OXN&1=3R+E+O?S:S&/X8.Q/'H);_FU\JD1[E^>8BW`SP[QA)+3J
MF5!/)&P-FZ4-*[OXVCH`2>^W3KT-3GEJU/O7\@_Q!_IJ`<S$BIM0/+^19DXS
M]]'MXS6GX:9R!O>LZ1N[[<AK8M2;&Q95K"Y&-.DQ%PVLHC7FFIJ"AE*PL)'[
M]O&N<O\`ES=8KN=EK9RS0`X.#:5%,Z5/K6_MMTM)88WRS,9(1B*Y*^%^[GVJ
M35!MCF/55.*/8E)9S*5+638)`5B`2J_2P'C4+-CWQH/_`$R:GW2L@[AMY%/B
MF>=4)SW0>U]\*<;Y@U!20@NJ67)R4A"4EPJ)7`2D(2@$D]+6J7^#;V1I&US5
M["H_C]OPI>1U[0LV<';?JN3U?W%[CKN8@9'6LEQ_@,3C\S&<5]-,>V7G#A?`
MO-,*4A*U%<K47XZ4A-UK387K=<JP7=M9<Y^/"YERRT<W2001XC9.OHH>H+(Y
MAFA?8<H112!T3IY'U&56O8W_`#BO0!^3P^U*]E.&FM)2$3^7.=9R2FWSMS.4
M=DD1UJ/]:\5Q%K^"0!Y5Z)LC3'MMK$1BR-C?-&ROI7"[A0W<Y!P+W?M$+J/6
MV6&E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+_]?GY!E%
M"1<VZ?J'G]M?*$\53@%_17MEZZ(-)-`IV1*2I)22%=P*;'S!%K'Q\:ACB((.
M5%LKO<&OC<TNU`BGD74KV79-O(>W[!0DK"E:YL6WX19'7M*L[)S;:2/#_P`W
MS*+?`6KZ$Y1G,NRVH_,+FGMKJ_S@OQ'_`+S>V#;OFSO3V@".XBBD;3(@-,-1
MP_U1R6QT@A3J1W6*+&]C;J#;[_"NH+C1W0OGPJ=QJK.N)OXW(%[>)^WQ\:QY
M"2U31'&G!7YC(AD$!(*E>([03<'P(^ZL.4T:21@IP*UQ7/O\SK#K;X7TF>4@
M?2<FP(QZ@E*9NK;0HW`-Q=<,#J/&N/Y@JZ*%Y_/(\X_(OHK^[?-HYPW:WR#]
MN<?*V:'_`$EQ@QILTT/&R0/P`L*XF;%SE]][:?PH>P*!MNSOZMAV\FRTP\53
M6(RDR'DLH2EYI\]W>I;8[@I`%K^=9VQ[5%O%^;260L;H+J@5.!'3VKD_FY\Q
M=Q^67*$?,NVV$5S-\9'$6R.<T!KVO-:MQJ"UO5B5Z)_[MSR0YM>?]Y&%D"-'
M6K4>',NVS'DI?]9.,RW(L5UQ82M9'TZLLE(/3JNO0;;E^'9+.^\&X<\2-%:@
M8:0[H[5\`_-+YR[M\VY-C_BFT06IL3+I,;GNU"7PZUU='AC+I*N'FZ)_+^9.
M5812;1^2-W9'3Q2C9LDE(\_ZHJ*#OQ1T'!>;M>UD3"XK"N[;U&XZU<[&[BWL
MQZ<N)&^B8D-PW/\`62\D.>JZVZG^&4V(MUOXU$^W<]QJZ@4;I_S34%8HYMV+
M*\O>T?DF;$U]_'1,WAFF/HH$IS(;(V(.S8IR\6((D6(^IP1@M7<^V`R5$GH:
MQK9KV[C;Q@,<!(,\L,17/CEUA9?Q#HH7R1RR,>6.;5IH:.!:\"E*AS26N!P(
M)!P)7$-O$O8/'MXIYJ>TJ)(^F6,DTRS,:69*^X2FH\F4RVMM:B"$N*(`ZV-P
M,*^M7WO,$]KJ:V5QZR/<![5]A<J<PV_+7R*VCF&:"66S@:<!34?ZV^/B:9GI
MR6]GM(;;PVP[CCW)*7WLAJ[,M0+3T8L)Q^1:;MZ<A*'75.JGV\$V*#X^2?9I
M]O\`#E,@=5U,!VG.O4O#N>?FI:<]P;=96^U/MA;O<_4Z0.+M0#:4#0!YRLO\
MK;/(QVF[#,B3Y.+=B&$438[Q8D-J<RT1@^DX"%A3B7>RW];OM60RW:YS06@U
MZ>Q>7RW+P'`O('4KYX1W?'X'`\C;CLRI\R/B]"PTG'/*SSL5K9,KIN/VW)9F
M/&R<&8XTJ1/1+CI;2[W.((6KTP+=^!-!&)(;8N:'F0Y&@:'EH`(''!7F9\C7
M2M:2T-Z*DD5Q7()O=(W)VZ['MT7&*PD/-[=NLY6'>RT?.*8^KD1<RP@S$):,
M\1TY4M>OV%"RDK[KJZ=!#L;-ODDBG<V:K&D'32F)!S)^G!=WS!\T;S=^6^7K
M+:XI["2Q`B>YDM?&I$T!QHQFFA82&U=35FMM_=Q#_P!Y66]I[,_(S8#F5X8R
M#\S(OQ3E)RW%9/4V7I"F7YT'ZE;RW"XDK>3W)(Z]:KM5\-J9=_A:]=VV,8T`
MKJQR.`IE1<GM'+4G-AW=XO1";':I[UY<W67B'22P=X4<[5[QKEB#59*Q>'XR
MTC\M_EEG.['O"]:<]R.D2,C.A:IAE9=G*.:JQ&CM0\5_:ER,[!4ED%2URDK2
M?!)Z&MI\7=7.XVKXX8Q(W4`"YU*:79G3GY*+CRV%L4C1KT8=%:_5Y5LSP!R;
MK&B>U32]IQ>(W'-:+A<)EIT3*S\;!QN9F0GMJRX4MS'-9&9`CN?5R%)0GZL]
MR`"2E1*1QFZ>-=[]/9.CT3N?B0"6>Y7WJ5R'1G@MY;>'#M[+@$%C1E7O9TR^
MF"H7(WN&Q/(G#\?:]9F<D\>XH<@XK7W<]B<:Q(RK\IF/]8]BG&86QXUDXV:S
M(1ZA5*)'9U:4+5KY;-UM?QV4Q:YY`=D=!Q(`+J9YX4RQ74\M%UW'O5Q%MK)V
MLL+@T<X`QZ6`F9H(=5T=:MRQ^T,U5=4WU[5>'H&^Y;*;AM6M8;#S<MD)\[''
M&YK/1VLC/[TI=&X."$XI2T,-J`="0V#UN0)SM\5PYT4>TQC4"-5':12O'PZ8
M=HQZUIX+CQ/"B?.XW)(^V.-*5;4D])ZEB_C_`-P+G,ON0TN!@)>VZCQ_&P^1
MAY[7,AL3J(F3R$?!YJ8Q,=EQIX?<6'E,@%2@I1:3XCH-5);6C=I/B6\9G[H#
MCF!6E*D=OGZUVW-?)NX\G[E%;W.X-E)>X%K`[3[K75QH376,*84703-8[78N
M$S$UG*Y!+L/%9"2VI&VYNZ7&(CKK:D@98W/<D$=.M:>""W,D;3(W47#"HQQ"
MYY[GM%1'A3H7'?VX;1F)V(=_M)G,]+B/_P`G8B+$I+_TDO)9':I$YX,OMK"W
M,C/<:6ZONZ$*5VJ*R1Z9`UA>YK1]MW3TD-'8`*!:?YBV[;'=[>*UB9$P6MN2
M&M#07.@B<XTIFYSB2<R225LG,QF2]&<O&YF3]0J0LQ52V(#\<6+20'4H@)<6
ME0!_K=US4DMO%Q/>[:KA(;ES9&&<N,5<:`5(ZJBBY%<B;5D<)MD2-$BZPRW(
MPNL9&3VZ3ICA=FY#%0I4^279&`==+DB6XM9)-[GP'A746]G!()=3I,'4]]XR
M`_26>Z=XT%I`!%<AT]BLN-R'FDL)>+6L)<2CU2M&AZ&A84VWZGRE.M=P)4/&
MLGX"#\Z3_P!23_341N):C!OZK?J5V[KMTS!9'^6QHFKM)1KFKJ?;&B:(M*I\
M_5L2_D5J#VLNJ_CSI#BU)OVCN(2```+(;-CFN.N6NIP_>2<"1^<KGSO:6@-9
MB!]EO1V+O7[;TG'>PR;F"&XKFRY'VK8UY4*'#@)0UF^8^1>0\C])'B168<19
MQFM>JE3+3?IJ2%H*5I!KE+%I^!Y_FJ=#IO#&)+NX=`J223[PSK7C4+JMVDH_
MDJVH#IM"\B@`_%D:<J4QTGV+TL?D0Y67G/RZ^-LQ+EF8<IL>S9-M90TT6QDD
M8K(26O28C1&&O]?DO*LA`2>Z_G75;6P1PSQM!HV9XQ-2:&@-:G@!GBM-O-M)
M;26)D:`Z6V9+AT25<TX?HD+L;6R6G2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1%__T.(+7*.:*!_UAP7<5.6'U4M%D]B"S?N>0`2ON!^R
MWA7&GE+E^IIM_I=]:]S']X[YX,H!S]=_JQ?_`*:^WN2L^MMX_P!HL4E*6I*D
M+8GMJ>!#"E,%"'9CGJ+]<`$=BKCR\ZN'*/+P]W;@3UEWUJU_]Y#YW9'Y@WGF
MB_\`TUV'_*OVB;L7#O)^-R4YS(3,;RH]DO4=*2I$7-ZO@66$MA-DH:+^%=("
M0!<FU;R&RM;"&*&S@$<70.G#'&I)RS7F7,/-','-]\=UYEW26\W'3IUOI4-!
M+@T!H``#G.-`*5)71QUFSBK^9N/AT'V=:FS-3DN>(S*F(:4MN*6I2`+=.IZ7
M-R#?[JL<&NJ&!(W!IJ5IGO'-/+6'W38<#BMC:BP8.7D0X#;6,@!0CI=_@!3R
M6/5<(;(NHFY\ZQ9(V/;WB:#H)"R6.-:C$=@5%]YV&RN9]KNN9[([7ELQDY&P
M:GDWL-,<@%A<QV+DH4B1#C,Q&Y9])<Q?:.Y5D$WO8FN+WU@;;`AQH).LX4/6
MO?\`^[]<Q1\^QM)8T264S*F@RT/];>E<G-0@QGYLJ#DHK_K15@)96XU"^4MM
MN#ZAZ5*AI:*WWD-C]X6<[S8((5=LW+UCNEBV\GDDUEQ!#2`,/\4GTKT[YL_.
M_G+D'F@[!L$5C\%\/'(V1\;GO)?6N(E#*`B@&D]95S[7J^KY'7WH\G#Q<A&3
M-Q9>#DB=*4TU(46!,`C%I+:%=CO8XE9`4XR>T]XOT^V;#MVW7+9[:-WBT(J7
M$X'JR]"^=N<OG)S_`,];:=GY@W:.3;#(U_ALAB8-3:Z35K`_"I^UVKM+_=\8
M>I:E[E^===UN(F(=HX%G2'&T/S74O/Z]N.IJ82$RWG02TG*O7*1<=Y!^`W.X
MM:;6<-_-/J7F-L7"5NHK.?NX9&$YUY3B$%#[VV3LF2`$GMS:6LRFY%CW%N>#
M]]<MMS0Z-NK%;:6H:T'CZ%HMR=D<#'U%V3ML2=E=:9RN#>S4.#-F1)SD`Y1E
MA[Z61!D1I3;R?6"@$.(*K6[A>LZ>V$E&5#:@XBH](Q5]C?/VZ[@O(XV/DC=4
M->UKV'.H<QX<QPRP<".D*F/;3JC7`^=W/2\!N;&CXC!Y56;=&VY!#^)&-@%J
M=-@8O,9#)OR9?KO*<)19#I0+BUK840M;::*U\.LSG`9GB>G$G'IX*[<)KO<I
MKC<)"UI>2=+&,8W+)K&`,:.%&@#CF5IO['/;7"YIU;:<O_9_.[=,8A:S/SC6
M=VI;4.,7CG<@7Y;2I,"1)DOS\<I#9:2I12HI<^55ZELVOW?<=YCDN&Q?"2M$
M98&!Q#P\'%S'UP&.(7J_.VR;?R3R+\K]UV^"2:??;"=]RV=\KF!T3X"!'&Q\
M;6MU/)HX/-:8X+ICQ+[>,JV[E?[.Z!Q#A5XO^7QU.9F!F<]/D1YJI3SCCCZ5
M9+Z4-*QJ"`5D.+(ZH*0%9IY6$SJG=;HXBH=)YZ`-(]"\DN.8+JXC8QFVV+`#
M]B%D9IA]IH#G8XT)/2LZG@+9YD.1$SW&?MTS<-]AAR5&D8K/LI?=^H;=0TZG
M^RKZ@&PVEPJL5I<L"@#YQ8>3W-H8]SN`0*CO\?U,OI18G\3NBTEUI"<#TXT_
M)Z5K]@]BU+/YW_=SIGM?XZRV2SS4S"1L1%E8G%,9.-CX64D/QEJS,!&,CI,$
MR>[O<3WI5V]RCVBM<_E>-[_^XW)?JK74*UZ0:9X#S*]NZS`"L,>FE,N'D6+F
MO:.]CIR7,1^74Y$CY&1D2PO$\H8."R'`D)E*=@JV2"SB2X&0&4O>BIT)0&@K
MY14_\,OI'M+MQN\10$L:<!^=5F'&E<Z\:J?^*VIM+>W9&P@O+BSPW-`<!2I=
MCJPP&0Z`KAW#B*&<9IVR<C>T7<->QV@:5G8&%V#,;5DCB]0Q^,$:1$P&1.$W
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M38>7AQ)&0F-920Y&S\5\`JC=Q:038)^88KKFUFWZ2/XJ3^(@U/<!%-&9H0`"
MTCCGAG@O+G17#;!KC%'X'WB#[V7$Y_6J5AY7`>3]O$08_CSG;^Q4?E"-DW\'
MC\?`SFU,9EG%M.JR<X,1Y$#^S3;%D.@GU>_I8`B])6-FW2/\:5UPW20?"&B@
M/$Z^G,5K3)=!RY=7FWVN^>#+:Q-EL)XW"5SM3FO:`YD8#?WKA[FKNUS5]XG"
M>W+D+1--XMBX#E+6$Y^!C,5'D,:K$U_8FQ)P$Z.\G:LPO`/89R4PTMQR5WAP
M?6E*T`E0[MY"R2>\GA@DMC=/!&IT!J.-6.UU&5*C,5"Y:*X-EX%RYC]$;@ZF
MO`D'`$4^G:L!Z5!]FO#G(^'VG^T'.$C)O0,\Y"P^VXO5LEK&04WAWXBX[[>(
MQ3*GL@X'P(;:G+KDK21T!MJ9=@NA!_#S<1%CW,%0U]<7D`\>Z":N(!P&73W'
M-/S"O^<+MNZ[E9PQR,+S2,Z6^XP&NMSJ5#!2KLR?)<?(WO0]GN;U/(8J%LVP
M<>2LO>"C9H?$V/S\R&TX%(DIA1G8\V`'WFNY*7BEST^JD@*`(FM^19K:>.8W
M=K,6.!TAT@-1B":,!IAEQP7(/W\2L<WP)6D\>Z?\Y8<XXU+VF-ZW%<PONDWU
M[&Q5LR6G,MQ(Z$1O3#KL?ZL1];=?<0N9/0OL6Z0LM*0`!W5G3V%T9'L9!:AY
MP-'2YDDYZ>`\U:J+<=W?N=RV]OY9G2$-&(9B&-:P9'"@:*=-/*M@-:T/@/;A
MGG=,]TNVN.ZU@IFSYE`XZ.+8A8?%KBQ\AE$N9#38:I3<9Z:UW-LJ=>[G!VIL
M:QW;3>D.#K6W<`"35[\N/V1].M:ULL9D'A3R"IP[C<UCF1PGCG%Y(ZK[O^(6
MH.5C08[L#9^(<,Z^ZW$^F?:2_+RSR)`0)L5+O:0D-_N@`"K9;2UN98)I]NC,
ML;JM+;I[0,-.7=&6&/E6UCNKFWC?''<2!I&(,0/&N="<\508_MD4IY9G^XOV
MK96*M-E,KT[C_%R%CO)"$OS)<DPDJ0M7<4-W(L/`"V:`W`1V;@1T78`_;;58
MYFDK[X/;#_\`RE6!O7MV9<V:=,C>XCV6P&IB8CL3'[/OF,BSOIFX[<1:U-+V
M"8Z6B_'7Z=E*2D`)!^6LV(7)8'&QN79U+)HB,^I_G4'B,86-\=@.`H8S[6KJ
MGI^@9"=[(86K8/9-.B9!SD_B#"Q<FF7*8PDV5J?MHW?--Q\*\VP[)<C.Y_>X
M[Z&^PK&-6M2;N`7U.WMDDY9WLQ02.?-N9%`074U,<:XT)H",#BY;_>.YO>S,
M<X$LV^%O56LN0I@,`1A@%Z)_R4=.RFA>P_3M8R\K!2YN-W/<6EN:VY,<PR4H
M=Q[2681GQ8DI++):*4I4BX2!U-=%R[=&\VXW!AD9JE?0/`#J5S-"1BL[YCVS
M[+?K:RDBT20V-NPBE!5C-)(ZC3#JX+K36]7`I1$HB41*(E$2B)1$HB41*(E$
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M:8CN3BHDK<*$K4&6%N^N^`56':DW(K!=<6[*ZYV-[2/5FLQFW;A.`Z"SD>SI
M#33STHH[.?QTD^JC)1UH<^9-WP/$W'RJ*2!X>0J=MQ:$59,S+I6*^WGC>6/B
M<'@XX+1KDC,RL3R;LLB5KV1DXU&2@NPI\+ND-SV9&'QDI^4@HCJ:;2S->=8*
M>]2RIKNL`H5AW3FEI\)P<3T$#VJ>$.:`'M((KP./H7&SW=Y+,3>;]@V!<C8F
M&Y@Q$N"W]'.8_DN/C0H*<2O'2Y$I87(`CE2BV(X2XD]M@OIE[<QGPS6/8"<:
MU()S.'JZ5%.Y[92YKB#PS"WUW38,;,YSVJ:G%X[)M[)K&G9C)S\ZN<H8>=/U
M_'EV?#.-DLNO+<9#-DO%Q"G"2&U.ADI@M6QL^,8QI`$N0ZV-R6XWEUQ)MW+<
MLVG1\-(QAXZ6SRG'K#G&G53BI+9MSF9?6MC9CO8*<WE\2^A<7':5C</L\F+J
M[[.R0.W(XG&-EIQ+F+4CT!**"AM14A1((V.Y2V,MY:R[58S0Q-BC#VNE\0&4
M-I(YI(%&N=WFM.+<JTHN=MFR%LL=S.PU<=)TTHVM6UI4U'$K=3\B_?LBK\P#
M"8M_#9O$HV/BKE+!-R)CC[\*:F'!:SJ$%UZ-'].2ES!!79\UNQ5E$"]1W8?)
M;O:8BVO33LX%94<3(W!PG8[LK[0%OQ[\.YOW#[])-D)DM:K)0;?*?^INOM+-
M@.I]5HWKEML]P>59LF`J'5]BYP\K!<SC78T@7LSBU6/BI0S^+)4+^(LHGI6X
MGC(8'-&7J6*UPKB<:^E8B:VB5A^"][T1O&9S/PMAQB\8[B\#`BSI#"-@CR,3
M./IQXC^3/5QB6ZDAP*;B%+83W.$\FR:3^,!C[<B$`.$G`N!)+3C0$``C+/&J
MZH[9:?V7CW:+=X3N#KE\3K6CO%;&&1N;/6F@L>Y[F!K27`L)(`+2<Z?E197#
MZ=`Y5Q^;S+,5E["ZLF.Y)CMX]G(.&1N2D-HBH[X["2B2%MI0>VP':>TB^RV&
M4R;YS(XMI5\1IY'KU3YM`2?*#Y`SZZEMMN#*]DL`'H"VARO.\OB6<\_B-#R^
MWM;%&D*RBXKF5Q36).,CK,;U'W-<R<5YR<J:0.Q;?8IJQ4>XBO=^0>3]KYMF
MW**^YF@V^2#PBSQ`T^)XA>'4U21^YI!-*X.X+Y'YFY@O-A9:/M=HDNQ)JU:"
M>YI`(KI8_P!ZI`K3+CDIN-[^F4J1&E<8YV.7G6&5%&PMN);3)BM)DJ63AXA#
M("P%7^5M23T)KTD_)"`M?X/.UI(T-)P9^;P%)G8G,+D#\RGM:SQN79V$EH(+
MLJ]L8P'$X46$N,-HPG'7-VL;KL\ER#@L1EL[]4MII4B4M$_%9C&),:(@AZ19
MV:D*[`;`DU\_;'LE[O\`OMKLNV-:Z^F>\,!(:"6M<\]XX#!IS[%Z5NNZVFR[
M5/NUZYS;2)K2X@$D`D-&&>9%5T3@>\3@QUQEL[;E(AC-.M2"O7LY\@?;8+:D
MJC8DDW^H(#@],@J%T'R]+=\E_F&*'^%Q.%2,)XLQ6HQ<,J'S+AS\U^36G\2_
ME:=`DJ89#W32AP:<ZC#K6-/<;[@>+N0.#N0==U7:9&1S3NNH>;@KP>?A)]!&
M0@2W"7YN'B1&@EA2E!7>V7`$ILH]HKF^8_EUS?RWM4^Z;QM8BLFN#2X2POHX
MO#:4:\N/>Z!AF:`56_Y<Y^Y7Y@W>WVS;-Q,EV]CG!OA2MP#"XFKF!HJ!4=[L
M7.[V;9C.8[1GQABWW2-NDI>+O<">S!:P4_NA2O!9\J\"Y38'6&Y"N/Q3CZ&_
ME7VY_>KD`YHY!9IRY;M_^+.LGPXVIY73\O`VSCS!\G1<KR%R9.=0_NKFK+3,
MR/+6X+=5CIF)US-O*6P\XXV\X)D1PH[VRT05)K:P[,TSOO\`QGLE<*&E,FC3
MCQ-=.K'JPP7S4^]=X;8A32#45K@3CTT%*TR]:V!PN4R>K)3QN>"CQ7@<GA,O
MEH>38Y/P.URE8Z"W'C+D,8M>%E3XS\A^3VLK?DK:3].XHLN=BDG,_@'<U&9V
MDBHK3O4XYX9]1ZE%-N3WN:?$:]Q&-`>[^B:@"M*'"HQ&)7)'&;?R%D/S&L3P
MIKF_;*.(-"R$C:G-25G$LX/(R'^.U;AF\GE,?@H6)Q&4R,G:<H7$]\8(;=LL
M67W+5T6WQB&"%C<=(]`K3T+43G4'DCO'VK;'C+VX;]RKAY&>U3>-0U'&XYV5
MCI<39N$N/.4U9*:D0I03&R.VK8RN&"F'$BT=Q+:5("_WS6'`R&1LKI&:G5]G
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M4[92KJ`MA[C8VUM;W,L;""8R,23A7K*EMYGNFC`<*`UR&8_PK::-QEQ@J)#3
M)T#3W'1&CI>=_D&,0ZZX&4I<<6XW'2M:U*!)))))\:T[+:U[H?`W+.@^I9WC
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M#\F[**R_LHP4Q9N3R'O[5[D]&\A%`ZDD^=9W+3]>UQFM>^Y=-\]HFP\_W+6Y
M?"PGS@KJG6_7C:41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(O_TN,6@\G[5LNZP==SF?R"V'(LJ1_JZ(3<A,EB%]6IA;\G%(="V"VIMT!N
MW>@]JBD!1XOF'=]PVK:Y;NTDK*US??[PHXTZCQ'%?2WR<^67*GS"Y[LN6=^:
M^.QFAG<TP'1)KB8YXSUC20QU0&URH1BO0-C?8AJ^3T_7]GQ61RN?;SN`Q>;8
M1D<RRB4IK*06)R4-M1L7C(?JH]4)ZR&TDC]X5T$=O<7%M#*-SEI)&UV`8/>:
M#P:#3'#'*G:O%=VN;38MZW?:F\OVIEM;J6&KC*_&*1S#4/D<RM6X]S.N%,%C
MZ1[:_P#=U,G.X[BK;Y*LLV@9+(836=.SKDU,>Q:3,<8Y%GYB5Z)`[`MGI;H.
ME0?P=Y'>GD>/TJD>EQ]2P9^9;N6@CBC@:!_JFLB_X;&*@MYO4M7D+B['"WK2
M4-$E3NR\,\IXS&GLZK6G(XK5,KC'0D)N5)=4`!XU:[:2!W90#UM(]A"P_P"*
M2O<73ZWGK<#ZS5;3:YQQE,YJ^%V[`KAYK6\]C(^7Q&5Q\/8'6I>.E([V97H*
MPC<M@%)^9#K:'&[$*`L:QG<O3.TN\5E#UGMZ%7^+1`N'A/&/0/K5OY-K6L0I
M+.5W;CW&/K-OILKOFKX26M7@0F'G,CCI5Q;J.RK/X)+&ZHTD_>'JP5QW-KFD
M`'MH5\,8+'9'M3`R&MY9;H[VDXS:-:R2W@KJ%(3!R3ZEI-_$`U5VUW>!$56]
M1!]14D&X0M<TNEHX',U"N"/Q5F)'\9WC^1.:Z=TDXAR8VE('F\W'>:`L/&_2
ML1^V7C*N;;R^8^Q;INYVCQI?=,H,A44IV'#%?6VZ_K?%..QN<Y%X]CXV#EY,
MB%AXTC6$NS,@^B,F5)8:C/P%+!,-?<M;Q;:*2;FUZT^Z3.VRU-W?W+H;>NG4
M21B<ATU76<K<K[ISQNT>P<J[0;[=GQEXCC`)T-IJ=C04%151.!?=![9^#>8]
M6Y*3Q3A,.-?C;)".5U;6=4;W2.UG-<R&/=;QZ<=#9CLQYLJ8VEX*R+)4A*BM
M)``/,0?,+:[29KG75S-'C4`5!PH#WGBI7MFV_P!SGYP;V"#M%I9NZ9GNC`QZ
M/#KA^B'#K6*?<?[U=;Y=Y"R&V:UQS'3C'X<.&B)N3<-4J083?H)DS7,(^F82
MIIM(2AN8E*$D@]U@JN:N_F!N#+C5M+--OG208^9KJ>E>\<F?W$;%EF'<_P#,
MP?>`FK;,NTT.6E\L;"'=-8W#H7*KE3(\^[5F7(6O2"QB-@5,9U7$Q<QK\&++
M4E+"Y;`A24PG9+4-URS2):Y2T%*%]ZE`$>O<L[V=UV.RO;Z1OQ+FG70$-P>Y
MO"O`+X;^>'(>W?+OYI\U\G;$Z9VTV<L0B,SVNE+9+>*4ZB&L!-9#2C1A1:\/
M<3>X/'*BXV;I^0R6Q0LD=C0%O:ODLO,B>L'W4QU,9LR6HO\`J*V$E#/:U&>D
MM([4/O!6[;=6M9-$C/!<W3F10CC0C/'$YG!>6F%WAM:0[QPXG(4I0<:US&67
MG*W6]O438Y3&[1-[P;F&V%V3KCV5PLZ%%A.1+'8C""H45I$5E*L>^TM'II"2
MA8(\:TNRR1NYBYA;"\&,B(^4-^LFJ]_^8D;Y/D+\C9Y!WV2[FPX4_P#N#3T1
MK-G.D##2/:/RJ]C&H.+V?3-3Y&>C9V&RWC\S`5@>1>$]E0F+EFPB<S)<@;BA
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M#,R"]40D-,K8*U./.J4GS78"VEN_FC\S[>\?'9<Y[@`'T:WQ7NQ/&CB[$US&
M?1B:R1\C\D2V[3=\LV;JLH3X3!AG3`##`&F6'4M+]_\`>4-5VC-XJ-F\3O.O
M2=?>Q3D73\?B(>-ES9>-EL)4YL*<='<6Q!E_3K'H)>;(0H`=`:Z0<Z_,C?=J
M_AW,V^3363GZG-D(J:'4W`"H[P#C6A)%<5?MG*'(>TWQO]HV2.'<VQ%L;XQ0
M-K1KJT(!!CU`8&E:"G#:K@7:/[*:%C\F(N6D/R=AR[<=O'YAC&QVBK":4\7)
M#,C"Y9,EQ-@E*K([4E7QZ>=\F6[;G;MR:7N%+MV7W6_6OJ[^]J3;\X<B"@J>
M6K;_`(UQ]2RKQIL^L[7K$^5CX^7UZ&QLVX06\=)FM252<AA-NS&$R&45])I"
M\6\G+YO$O%"'I;4CTP$EL-]B3V0L'MC:?CG`'I`-!YJ>=?*AG%<8@:=:R5K&
M1=S>?R&.P^1RV4R)B^D^,MA\6_'1$0F,I,J-_.9V.D-0[O*21':"BM"EA/6Z
MHY;*X$+M-VUS`W@T5X?3-6ME8'-)A()ZU:&N<=X'2?<I"Y4R:,]!Y$?QV>R<
M;(Y#"Y.?K3Q8T38,:YCE9!]_.8^-*CZ[C!*^D[VN]A390%'N;3A065X+AEO-
M.WX2A)`J'9$BA`IG3IPJIWW,/A%\3#XN&=".@YGV*)POSIBVXVTR<7O>G9)*
M,$K^;8^3IFQ8=J'%0Z^[)SC.1_DS$],M?:4J3ZCD9:6P2SW)[JQ9QN-G)'%"
M^#0XYN=(#7_%PRHI8Q;3-,D@DJ!P#2/6KYTOW3<,ZGK<*7`W?@"0S(,;'Y'9
M(F=U?&9R7DIT5#OU>=>B8J.\C.RX^)+BQ,902J/;TP&^P9,0WGQHV.B95O0Y
MU:`\-6>/$`]:CF-N^/O22$#`5%0,\,,AGAVK0GDG&\5\B\@;CN6/Y>X;F3MF
MV#)9AUG([GJ\E];TZ0X\`DQ.5=8[[=P'R0VAY!"?`=`RZW1A`,9T_>9[6+",
M=N1@<>QWUK;WBK^7P_;)LVAXW+ZQF1CLUB9TY6`F17L8TYG-MA3$)!A;/M.0
M;4J%A20'7[*4FZ`4]P%EY+<7%E<"2-VJ@PP-<1E0!6Q-9'<Q@%NDU-<:#"F*
MSTUM\=F'BW9FNSY*8_I?63L'Z\YG)J<2CUPJ`AYQR$U&*3Z0;>6IQ*CWJ!%Z
MYR/=9'2F$[;<MSQ,;AAVT`]*V;K)NCQ!<Q:>IP^OV*[,]OO$^UXYC&Y_1\3A
MF68[D=65@:;"UO.2?5BB"X_,F,0&,I*FO1U$./J?+JPGM*BD`#/-^QX8QUO(
MW+_5TRZP[+Z="Q/A::G"0'_&[<L.OU+/6N>_KDCB'@3.\5<>:D_"T+6]/SVN
M:R_$Y5X[R,EG'RH,N,W*?PFWZ*C892$KEJ66&9;T@I^1JQ[`-5>7EU#;W$AN
MR0UI-2W&@'3CCAG5;O:K:%][8Q!E"96B@(H.\/I18>VGE3(:E[.-FP<=O)P,
M;R-`WF(^XW+UA$1<2!R!DL.PS/C/,JSKK67S&A-/L&%Z00L`2G%=P0NFWRFU
MY(L.]0.LYGG"N+ZTQIA0OI3CP7:\IVIW'YR[="*G3N\(X8B%S"[M[L;LO+05
M7<'\C*?_`##V'89VX);Y3Y'95;XB9CG?V.BLOE/'9H7<"]Q]-/8MW_>#+1\R
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M6;M?B*;<'16L%6O=KN-%`SN-=2I80"[2":"M2`>9^<VR7>V?-/YG1QVLCXH=
MQN;AP:W41%-)XP(:,3W96X-!)SI2M*-L'*F67"&;;U['P\)ZZH;DC,92;ISR
M9B5D*0ZQN6,Q"F$JZ]JG/3"K"PZUNY>:=IM+NTVJ?<(!NT\;WQ1.<6/>R,M#
MRUKAJHVHJ:<>TKR%NX61LG[G)(^+;6R!CI'QO:&N-:`ZFMH33"M*\%;HVW99
M6.C9QK0\AD<-D0M>,R6O;3HN=8R2&I4N$\8GTNQ(+JDS8#S0'@7&EBX*"*V!
MW2'3&TECIWM+FL:]A<X`@.+=194`D5.`!(J<0I(KVPGC9<1WT)M7&@>7#3F1
MPU<6D85-0>A;5\9Y@3N/\?/R4'(Z\IIR<T_`S\=J'D(7^MO*3]6VT_)81ZJ'
M`M!2XM*VU)(-C6P$A='%,YI;5N()!(Q.>DN%>PE2A[2X^'('-K[PR/96A]"I
M&R[GHS27(DG-XUV/(;<9D(F("8KZ5((=94EX*:>:4CH0H65X6J.VN[>Z87Q/
MU,'2UP_:`KY%*YKXS1XH>T'U%:O[7Q7[5-P=<8S/'O"V1E_O.._V=U2-D$^L
MOM(7-C16)B"MQ8\7`>X_&HX[K;+B>6VAGADN&>\UI!<W&F(!J,<.U7.;,QC)
M2UPB.1I@5I]S3[?=&XLSO#F^^W;5TZ_+P>Z?S#9EZUMF3<BO8]J7A'FO6QN1
MV%^([%;99D]R&&K=I/<"+6U&X:X+JR=:D-+I`7"O!N(H":YCAGQ6=9%DC+AM
MQC1N!IQ.&/GXKH+^8Z5/Z'Q9DVU73$Y"7CW;^/IY/1=PE=UP1;^/BD`^/4UQ
MGS1BU\JWYIBR9A[/Q`/:5]:?W-+KX?Y[<H1@@>/97D?;2U?)_P#37#K-.E&0
MD@>:P>AZ=4BOG6T;JA95?LK-(&.<!G7#LH/K5&2X?`'K?_C_``K,+>I8)?4X
MK&6?B^X79MBEX7B2-M\:+&^C0UF(V6;QFO-/R(L>0ZMM>5<CPG"TIQ25I8$A
M07<E-R17OWR_EVJ'EW;G;E&U\8?("![Y'B.PR/2#CP7XN_WPK6\9\^^<G6I+
M?$BLG@\/^2MVDG+BTC!5_D#4/>IQC!QFPO<K8-.-7+.$?>;8QNUYB&ZJ.MQU
MUYK.<=8R6B(]T)2%=I-[*\J]'DBY/E&BRMYS,<:.[K2.K2\XU]"^6Q_&F'7<
MR1Z.EM2:]=0LYM3,JUR+O\F1.?\`J_Y9I>5#N/<89,R,K`,0X?U*7H+C![6,
M@AU;8;[0^V`%%(N>#V%K!S)OD;!1IC!'50L[>GRKZ2YX)E_NW_*:9QJ^+=;Q
MA_QWW#Z?Y-59^Z2,AMNG[_ILK/;S#Q^WPMG<RO\`(XVM97^8LY;'<>-Y*'*Q
M+BM16\S);XKQ)]%N8EM3L9M20A9=6[W#YGVL4DCIB8VM).7:>"^<;.!U[=6U
MI'$/&ED:QI)-*N(:*TKQ/`'L*U]XZ]J;'$_(&!W3&;F["V+5GY=\1N&@2TX_
MZM['3L8\C)08>>V=F0ZE$U8_AOI0TNRD]W;8\G?<T[+=P364YF:QXQ[M,B#@
M03ZEMW;+N-I<$-,;G,)%6NP-.C4T&G;0]2[%:M[AO;IKN`1@N2(6LR]JA9#,
MHR2E<<;0['<)S&25"2-AQPR#\EQN"XT%K,5!"PI*`4@%78>$7,U1-!!&%?1]
M,%S@DT]TDM/8%H;^8Y[@_;7M?MRR&L<,3M0C[ID=ZU=C/X7"9;>(^6CX)*<C
MF9S\C7L]@\1CDQ)&5AQ5+62IP+6GHHDJ$4-C$R2.=\#/';]H``UI3#,@9\3V
MJ=LTI9X9E);05PH/65P-C25.@A1OU'G_`(>59DN+0LRP($X-5W(TO8U:]QWK
M1;;C/,KV3-J=;DBZ#Z6!TGQ4%)*1VWOUK@N1"1M>Y&G>-Y)^PQ?5']\5K1SO
MR,QN0Y8M?_\`(NED_4.1_;IQ)IF+US>-W;S.R9!;_(DDL\<[^]_(_P#>=*5R
M='P<"=B=VUR).9Q!VE*`^]'6XXL+-P@I;1Z`62!@8?#((&8=4`BO`@5'TJOD
M0N!.INNE>&FG1QQ5R9;W\^V\[,SM$[;=K7.A8`:_$.(XJE1@B%]1)?<6X96[
MM&0\Y]04!3G<IM(LA0))J^1TDC2TMC&'0[_!YU8&D.!H[T+9YCDSBW,^W7EC
MW`:I@I<[#9/BS,\A8K)YUTQ=C?D1)6[<>SG<BS+8S9Q&1DO:0]"8D-RWDB$X
MVVEM+?\``$<-N\NN)I7U+6C3UUU`@B@I0##$JLA`\*,"A)-<.@@X8X^9<:..
MOS"=0T'BO;N.,#PPYK&>W5.8@Y?E6+E=8VK=A@,O!:B)U^.K(Z;@$#$XU\.R
M6&'7G6@_(=4$I4KNJ`P$N:0\X&O;A3$94^G0I:<0J+@-]]OG+:.,>*8ZI&(R
M3TO$ZW$:'`VH:*YM&WS6H6LZKEMSW7C?D5W,Y]V*N8^ER3(@@E4IQYQMU14#
MGV[VL>72,J:=?3VJ*5LCF]Q],>/^!9/]I?L35[C)6R;K*8R6#XTU3.C6VH;T
M>*O9]ASF/B1)N>5.>^FCC'8IAU^S9`[U-K]-*N]E3IP]UO+FW)CMK4NG(J:X
M!M<L\Z^:G%36D;):.DD`9U<5U)P?LWXRX^TK8-:QV$:9UC-KQ,O8HF2FN3<=
MD'L*MT8M^>G(Y%WN7$=E+]/K8*6;"YKE[G<=V;"^2ZDT0-%2>Z`.NM>':MU8
M;2[<;Z"QVRT?/?RNTL8T%SW'.@'$TQ/12JH[/L[XRQ:)2<%QYKF'?>+*I,G6
ML5`QTU2XWJM-%<K#N,3&2V'W$W2H'YE`^)OB'^+X.DD>2.G'VE5+K+$"-OF"
M^G.")N.5BQB\KL^&BXC*,Y3^78O/YW%0\DMI+S:X.:CQIL=64Q<M+ZB\PM0#
MA"5$W2#1FY7]G+XKF$]1!IYA3HX*SX:SF80,#7J_*L>;_E$8#8=3T'+YG._7
M;ML>!C8R)$W#/,0TQH&<Q4K,G)8-V8N%)@28+:V?3*0DERXN`H"^_P!]=?\`
M+V_&6'12W?4\!5I'1CTYX++V/;6Q;_L_ANU.-PRG2:'5[%GK=N,<KRMPYPQJ
M6)S'\HR$_@;$;$J3D1F%X9+VT<R[WO0+C<-PPERYD.4T`M;;CZ&5?)\A4#C\
MSW\6Q\F;-9OB+I);>*,$84TM:YQ\NFA[5ZE\F+07_P`U;_F%SOZK97-U-I`K
MJ+S)"QHQ`%"_5V-P7HW_`"6.+-FX?]D\+4MLR>'R^67RQR7EQ+P3LQV`($[(
M048YD*GPH$@2&H<=`='I]O?>RE#K6TY.N[>\V"S?;,<UC:M.K/4#5QP)PJ<.
MI:#YTF\E^8N_7=X]A=.6/9I^S$&-9&TX#O!C`'4P)J>*ZTUU"\K2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%_]3S8ZY@Y6O;M#9DY3$0
MY^N9R,X^LR)#K3CF/EM/.-,K9C+;4XHH*2AQ3:KW!`J*[LIMPVZ]@CMGN;)&
M]F#3F6_E%%O^4MY_@'-?+&]MD#7VE_;S`]'AS,?C^KBO8U[#]@PV0]IN+QN4
M=2M[7]LW#$M-HEPV)S*Y.3BYF-*AJE2&"T6!FW"'$FZ1?X5P/+^T;3OW+VR#
M=+".X?8W@GAUBOAS1/<^-[<1WFZN.!!H00O=/[T\4^T?.CF&>VD<QM]8VSG4
MR<PPMA(/43"5M%@,?Z&+D-JRV3<FL39:</D$M3)$AN+.9C*7CT>N'(LE3HCJ
MN6[=H4HM]I^:MSN'*FQ;GS/L/-M[8:M[VYDK8'@N:`V9A8\.:TT<-+G::B@)
M)&*^<H=QN[?;[W;FS@6L[VEXT_F&K<>&>)%*Y')7B<4QG=#Q<G/2<%+R465E
M,4M68AX^5C)7I2(DH1Y&*E-ADR1'?6A`(*D.+[CW$6K6;Y\O-@WSG;E/GJ\?
M<1[IM,<S&,C>!%*R9CF%LS7--0TO<YNG1WCWR\!H%8=Q<W8MRV6:W@DLKIS"
MX/;JH6.J"W5A4\:@]5%(ZSJJ)N#E:S'Q$7`AI3TM,'`-_P!E&9H<0N%(E8]6
MON8]>.DY.-ZBT/H4VZA]?J=R5`+&'\T^5.:>:>7-JL.0^8SM&Z6^Y0W!DU/8
MU\48>'Q/\&I<QQ>)-%"UYC#'@!Q<(>7F;!9FYM]SV<2;6^&1@CCI'I<]N$C2
MPMTN!)[S2'-J7--0KSXWTR'%5MN'C1-JC90P([L!&W[KLVWHC_3S8TL(B9//
MY',3HJW&T^D^II_TGFG.TH([T#*^9NR\VWG(7,5A\M]]-MS?+&PVTKG$Z"R5
MCWM#I=;6NEB;)$USAI#G@G2!J&'R?8[)M6\M_BWQDVU$CQ&/GFE.G&A:7R%P
MHX@G2X5`H1P7UA.--:7N,?"9QK,Y7ZUC,(9Q>SZSQ;F<5,G,PI2VW4RIW'7]
MIFXT5"TR6%MY%*E/)0AP.MAT*W>U67--IR?8OW'<8;CF]FV1^,*L\%][X#1)
M2C&N$9GK2A%&XT`*U_\`#X8M^>Z'>[\;697Z(GF!X\,N.G$P^*2QI:X#Q221
M1U14'&V<]NNLY?8VE.IX\Q3\IQIF=A\QQWLB9,!A7TT=F/\`S_2N2-*:0K)^
MOW1U-X]2&NZRSW=H7PGR:=\Q^9.3=NW_`.8W+MK9<X^-,R1IMFQO<R-Y:QX_
M$+F:F8#$@Z=;:M<`MCSA;;IM^_SV?*7-\+^7'-C(;-;NDH2UI>W7'/`"2ZI!
M,1T^ZZI%3A[\PB.Y_N2PKS7_`+9N1]/<<N.XI9E(R6O**BKJ#?+6OXW/GX5T
MOS"@\;EG?P1DS7^J=2^E?[L>Y';?G3\J[IIH77W@^2>*2`C_`"S],%PSS23_
M`#!Y72RNTCSM?N%_'SM7S%9D>`T<:E?M]<R?BR5X4]5/8J2D=>OX#S'B?P\*
MRR5@&4DT&"VBXD4^]J+[49P,26IL]EA]2/42P\IAIYIU3?\`72VMX*[?,=*]
M+Y-D`VT%V+1<$'L[IIZ2OR?_`+Y]H;?YO-F&#[C9[9]>Q\\5?((PM;?<M"Y8
MTWA>/@N6>>./E9([=K64QDM$[,-[!E-=AX_=?YS$3I\O%X>:M$N1-Q[16R^\
MAQ#!0XI![>[WCXG8Y+R*3;-MEC!:X$4:0"=&DZ@XY:784XX+XG$6X,A<V\NV
MOJ1C4UH*U%*#.HX\%:^A<TZ1R+GMZSVJR9\V/K_%F%?S$:1!^CGK7K+6"ARW
MXC#[W8^P^6%!I1<3>X"^V]<?MNVWMES/>3W$8$$\+M)%",'1X'H/UX+W7=N8
MMJW3^[WL.PP7(.[[;O\`62,@APCGANG,>.#FEP<TD$Z2WO`5;76/)>[K);5D
MOY!QEIV0<=R,:;%?!QL_.;/,9>CN(>5CX&'*&H"V65*-TKDE)2%=R;5UMU:_
M$6TT#G4#V%N=,P1],%XEM=Y)MFY;?N44;'2V\\<H:\5:3&X/`<*BK210BHJ.
M(67M&]R&Z,(Q>O[#K6::R24J1]5FM5V^;FLFM:RM3CR$R79DJ6I:SW*"%*7\
M+]:X"]Y3E8"8G%_#WFCTD4H,EU&X<R#=]RN]PEMHK<S/+BR)A;&VM,&-JXM'
ME*V=SG%>Y[+E<O(C:?L<A<[*2A'<7B)L)AL2WG'FI$E^8TTF/$*#?N5\"!<]
M*]$BFB`8P3LJ`![P^M<28WXN\,TKT%<\O<3[8-VP.T,Y"4W%0[O^X:?IV-PD
MMS(L2DY_*,B'"=7*<Q,7'''RI?>D!M]Q;`"2HK"KB:,O)(<YI&HTIY:<2/+7
MR!5%`#@13J6Z&D?D_P"PP=:6_N>KY_:]HE2DJ#.M<KZ]H&%Q<`,J"T1W<AQQ
MR;DLY+^H`4@JCPVUI58]A3==VA[JZV$-ZB*JL=QX3FN:YOE!5P\Y:/H_M_T5
MG%<QY#.<79!U.PY'5=<R&1Q6_9?<FWL3CX<Z-C&M>PN&4VTIW$L1FWYK4*,'
MWCZKC;=B=3M.RP;/;RVUJ9"Q\KI*OI@2`*#2!7W1PXKT+YE?,S>/FAN^U[SO
M=M:Q7-K81VC1!KTED;Y'ASA(YYU$R$&A`P%!FM!^;<K"E;#AY4%IZ-`D\8\,
M284:0]]3(CQ9/#^BR&&'Y)-Y$AIMP)6L]5J!/G6^<,6#CI'J"\X9EY3ZRM6,
MS*:4I5@`"/,]!>X-KGK>K0VHKQ4H%,5T[S_(,G6?R^]$P3&2GPH^P>WK:&YT
M&.IH0LT9_NGY+UR$B:E;+CI_E1R3KB/34V+N'O*OD34)<]KBUI.DC$>56.:'
M/:2,0?8N-*5V/Q_XZKFI*+8KVL-,N\Y:?+>2%#"0MTVIA7=V%K(ZEHFS[-B7
MT*/@ZSE,2RIOXK`%B3:KV8N'TR5CS1A(SHO3)[$]:C:E[7>*8C,=<9S*0\WL
M4H//M27G7,]LV7R$=QV2U'B(D*&.>90%>FDE"$WZWK5W+M4[^WV!9$`I$TKC
MK[M_<Y[K-:]PW+>*PO)'(&IZ)AMURV%UF#C'_HL$C'XA]&,92R['C".\J0N*
MIU27%J<[EDD7K);#$Z)NJ,&HQKBK1.^*7Q(92V1IJ""00>HC)69A??S[O]+P
M<&=!Y:EYEW(Y5;#47.ZOJ6?$U,-EIU^*79F`7D4EQ4YN_I.I7\%"]7B"(MKH
M4+9'%[F@T%%Z/>/,OL&R<6\;;!N+,=C;<_H.H9K:(\2*Y"C1]ARNO8_(9AF/
M#=6ZY%9:R$AQ*6U*)0!8GI6N<!J<*854_1C0KDCS?,@RO?)F8\EPJ5H^@-;1
MBVP^V%)ROTFJ2U%ME:O5=4C%P92NUL7'<5'IW7T'-3-/*V[Z&8N#&@#]*1C?
M:NJY+;XW-&RL?[@<YQ)Z`QQKZ`NDF/V6+K<K7,$SC7_YAJG"GM^U:6F1*>1%
MALL</:CE1`C-EQ;29<:?E))D$MAPJ6FY-JX_YMW`MY>7MO&3+;40>DT'L7V-
M_<\^65MSOLG.V_W.X20/%W'$PM:UP-?%D=4&AS>VE",%Z8/RQLK_`#CVL8F;
MZ/H=VZ[@WV>IZO\`HY<87[BVWXW\+5TORVD\3EB)P_VTGK"\4_O0\L-Y1^:U
MWLS;PSM;8V[]1;H]YI-*:G9=-5T)KOE\[I1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB__U>&7(^A8":UFMF@^H9R<=D):6<7*1'A9":AI
MQ_UY*HB?4DON%-K]]K>5^M66UQ<0A[8[F0,<:D:B!E3(=G&JL=I.FK!AU8KT
M#_EESL=NG#FVXN7&B2W(N:P.RQ@\2'XK.RZ_";4MB0G_`%ABZL4LI4@@]]^O
M6N,Y)(BM]XL#[\-V[S$!H_8*^J?[U33N.Z?+7FUH/@;ER[`:]+FDRG'C1MPS
MR$+;G:]+PF"D/3,-R9M>F32A2%1X.P8_(1[`J[UR6]O@9]#;8L00E20+?U>A
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M"Z(%IKJ`ZQCZCZE9,P/8X.:#V@CTU^I:R>^^(K.^W3=)^,!<$39-%SK8['$'
MZ"#R1K<B>>QUMMY`1BR\3W)2I('4#J*Y/G"W,NQ[_%F#:2'_`.6:>SK7M/R3
MO38_,KY87=0-',-C7L-U&#Y*%<$<Z0F:>XD7'[#_`$5\H6C:1D#*J_>:\_>5
MXZ1[51D+:*A<VO;S/[?.LIS7`+4@OU@FM5JW[CO<CRMQ6[`T'0,VSK>*SN+.
M<F9F#%_ZQB6Y-D0'8T7)NN+1"CICP&E`M-(>[EJ^>U@/:_E=MMI>;7>SW#"Z
M1ER0`?=IH8:TZ:UXTP7Y<_W[/&M_F7RK,P:1+L+`3QJV[NZCS%JT/P\;D/F/
M=\;B8B=JY&Y`VW(Q<7C(OJ9+9=ESV2E+#<6(P7ERYTMU9/07(2D$FR02/8&,
MBB;IC8&L'`"GJ7PV2^0BKB2N^7LK_*=]P>CY_,[;SC'Q>G8/:-#R^KR-.QN1
M<V#:G(^9DXN0IR>_@(^1U_'>@J"+(3,?>[C\R46ZX4]U,:"UMPY_2XZ1_I>@
M*9L0`(FD+6G@.-,NI=6>"/8MQ+[;].E8C3=:S4^*[/3(R;VPJRFS9G(2W$-$
M26\>J&EAEE"5A*OI(C*.Y)[@2FXTES!O5TYVN4-%,FF@^OUK(9+:1"C(Z]9S
M6T6&PF,C+8QD'%KB/+8]9B$<1+@$LH*DJ*&G8C`!1Z9NFP4`!TZBM5/MFXL&
MI[2YO4:GS9^A9<5U;&M*-<JHCZ-UH+C!B0PL?*XR6GFE#J.CC94@@D?'RK7/
MBEC]^-P[01ZUDB9CJAC@2K>S6C:AM+<=K/:M@,VF)+8R,5.5Q,&=]).BN!V-
M,BF3&<+$J,ZD*;<39:%"X-Q>KHYI8^]'(X=A(]2AHV6H=&-5<:JE;6[A=08C
M3Y<M?UC2E#'X\*$B6?43Z2_2(*"TR4'JIPD?#KTKIMJW7<G.#9!XEOQ<:U'E
MX^48]*UMY:VPH6`-DZLEYCOSH=]UK<.<^,/[.[%C<[#Q_$<9F4K&9"#D6861
M<W+;2_'D*QTN8RS(#3;=TJ*7>WM)0`179OH&-%<,UJHA@[#(K<#B3AV-E^,>
M(6^2ORYLQONR+T71L/EN09W+&NZY'RD##Z?@L+B9LG"1MR:FXT(QL-I5Q#6X
MMML)4CUU%(QV7UO@US1JRKBJ.CD&KPY/(KUWK@C@K6LU(8B_EL3L]KL*6L*V
M/#;WD\LY/A10%S'XN`=S<.=_#*@@]RAU4%`*20JJNN[<@Z::>G$>L*C!,X5+
MC7H6FG/W+FH\+<H:<J%H3O'.I:EQ7F=1T_BS:M/RZ(#F-RW(&;W(9ES%2,AD
M(DZ%_.,W(27)+PD.K+A2VRHD-11R!Q>]H!!]"E+7.%*D8YK+O%TWVZ<X2M?P
MN^^V)_5\YM$S&_3;7D_;O"QVFR(N<R"2VM.].9#$Y&-BX4*4A29;L9MHLA*Q
M<JM64TQES`X"A.=**%Y>S6X/RX9^A:7<GM\7Z-M6Q9WBWBOCW!P3DMDX\QRG
M<ONKBLW#S*<MBDO,.JVUK#QQF<>PM!"8?<AE^R5@@$VN=1SBUK0UM1QJ55KR
M\!IKCCV+TA\/<0[%B>'>+XV)8U]C&8_C[5TLXO'/3`Y`1$U['>LPV[-;2%0X
MSB'`A2EK4JX[B#U.I+'.U.H,2359H>ZFFO!<6N97TX/W`\EQI:$*:D[C-R_I
MN@*2J/GBWG8X6E?0I,?(H/46K8VQ!C@/5[5KYA21RR\O8<'R-L.A:'K.!Q&*
M<RN1QV,ER<5C(,*0F,ZXV<E,6Y':07#&@H<<4HW^5O[*RYGB.)[@`*!1L%7`
M8FI75%QUE`;CLI#3#"$,LMIL$H9:'IMH`'0!"$@#[!7.YK9G@!P7!G=6V]G_
M`#$.99R-GU_4Y>O:AEXF)V'9\D8&)@96-Q[%QF.C*[861<=EY.?)1%CCT74_
M4O(;*%+<0*P-[MG7EA860E:SQ;J.I/$,)E(%.+@R@X5.-!BNBY=NFV%W>7[H
M'R"*TDP;3`R-$37&I%&M+P7'@`2NH.[X!&N\F<EY=>75E)>W;2Y.?26[+P\;
M6X<70<5A77O6=$B0UB]19D/$);#+\E;`20T%K\C^<=QXG--K'7NLLF8=!U/7
MZH?W"=K\/Y.[M?%GXD^]2XGB&6UJVH/$:M=%Z;_RGG/5]H>(5_\`M[O`^X?6
MQ;#\!7>?+#^58L?]?)ZPOD;^^VW3\];]M/\`VRS_`&'+I77H:^1DHB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?__6\TK4%U((2XM(4+$(
M+@"D_!7A<&L353BL[2,3@O0S^3]N6/CN;;B9L^'!C3>-\6MN1)DLQV/J]2V%
M.%98[W%H0'5#)E*1>Y58=37);"TV_,O,EK6A>1(/*:@__,7TU\W)F[]\AOD?
MS`.\;7QK(D<-+?#H?)9A=8M@XSB3=KC'+IS&0C9*6ZVW(E_V>S>+FJ?AOF`)
M)S&#R>Q03'<0CO2B8TA;R47[D%:3!RQL_.>U<J7-GO?,K+[F9AN/#F+-+7@E
MWP_B#0*.`+=8;4#(%]-3OE6_CVV7>([FQ=<0;>X,U1:@]M=(#Z%X<X8@D4<W
MK&-%B_'\":S.V/,0\_$B/.N8O)Y.-$Q>!S>%S+;L5"7HL,9]O8LEBLM$QY*!
M_!A0RKO1VDE)36NLKKFC:N19>;][Y8@DYXBL)'RPQ"/Q9)8VNHP21^)^\:P'
M2W66U#`'$`',%O+)OIVV'>]>P.FI&7L>W0UQ%''OAI#:D&K&$YU"R)P'I64U
MG;-GQ4KO<Q4O#(,!D9R%FV(9@R74MQ74^CBLA%GN,I7]0A<$)0MLI+SA[;];
MRON4^\;-8[_=65Q;.OK:"8Q2N)\+Q(]6@-+6D$:J.J,:56JD=?0[E=[;<6L(
MAMWO:R:.0/;(`Z@)JUK@:"H%'-%2`XK(O)&=RF(4]#QR)+3+;2E2G%ZQMDF/
M9/==$O8<?A)^J8Q%OF(D9%I?:0HH`ZUH]CY\V3G2?<1RIOT>C;KZ2UNVOMIB
MX21NH6`E\08#1VF2CVNS&+2%+NDK=A,$>]V%PWXB%LD;FL>Z/2ZH#G21,D8.
MMKGL(&>86&9\??%Y$ZYD=6UO.Y-]IY<C!8S9,7DLJ[$8>=B/N_R*`[F<B^E,
MR.ZT4^@$=Z".\VKH'\QQWMR^UY?-G?/AG=#<4NHVFWD934QX:V0A[0:N80'#
M"M`0K&3[?%(+>_W!L-R]FJ.,COO;4C4UI<TEA((#P"TD$"I!7.;WB1_;%QYJ
M&QQ-IT+0>'>5<C&;<A.9.'%UC;0#VR7)K&JZM"E[%D9$YE*&4JG08[)1(+A>
M'8`K)W>)DT?P\0)N7GNZ6N(:10]YS06L!I2KB`3E4K.LWELNIYI$!C6F((IA
M7$^1:P[G^;LB9P)I?MKX]XZ^HCQ-6US2=GY$VG(K"I#,)<>/+>U[7X\<.MME
MEI(:>EO!?FID>!CNK2:?:Y+6:@U6WANXDG10XY8^5=5REN3=NYFV*_C]V#<H
M)APIHF8\=/$*%D93DAPK=-U=1U%O/R\@*^3H(PUO=7]#.X0ACV`"F"H*GR";
M_'S/AUMT_"LT,K1:UND.I3):#>\5/=L&E2/$N8;),]WQ]":TY:_V?4_KKVKY
M5NI8[LSHE8?.TCV+\RO[_P!`&\U_+RZ#??VZ=E?N3-=Z/$]*Q#[>]NG:+S'Q
MUMN-R4C$3<%L^.FQ\E$R+^(D1%AQ32G&LG&<:?@DMN%)<2H%(->KY'A7K7Y_
M9X!>FK!^[SF;.:5-EZIOVRZYLICC$PI6PR(VZ8J/*BH9=^J>8SD.<9'>W(-U
M%H+4X$E7>$@58RWG+R_N.;7HH:=`4<[Q'1A>[*HXT5=T?W7>Z?'9M$G9>9-'
MSN*^DAA_'97C&$5.RV@1(#3^#_LDY&1(422LK=Z`!*$7)$TK-(_#LB3]X?6L
M)LT@)#YP?(?J6V>&]Y^YR27Y&I:-GH2&BTX,=E<QKBU226E)*I$I&S(:'I%7
M<@H)ZIL18WQ2R4G_`)63R8J4W;6_:9AQ7QFO>/Q[@40)&V<7O8![.9%O'>OJ
MVUX[)3'GI%VTNL$8_7W)<EIUQ'^E0E`222KR4-M\12,PFAX.'Y?6KQ=MC!<Z
M04'0:JWN4_S!>'=7X]=S6F8+;I6U"5&Q<;"YJ%%@J=4]$E.F=)R*)68@L!+D
M;M6I)=5W+NED@7$%QRLQD@E<`&5Q`-1YL%='O3'U8RI=3Z=*YUQ/=CN.X:SR
M%R%L6YX6'MF+V'3XFB\4LQH5]S:R&2]'88L[*2X>1SS$:/B'?41+;4RAE]E(
MLH+]%4TEG%"S3&RC-)\BL9</D=B[&H5T8+\MCVT\[)SNY[/QWN>AOY[(+SD#
M.8/D9<N/M:LX[*GSLTWA):,JUKI5*<N8A2E*"OM0E*4VJ!MP\`#`@+)ICDLY
M9'VA\SXV5C<;I_OF]P4!J4)#45.U2T;<W#8AQ@MII0:RNON2$!-D]5IM02-X
MQA6EH'2K)VSVR>^'!0)$_%^^-O*PHC+GK+V'4LWBB&GU(2M!1`S&WN.A]SM!
M2EM7<?(FU5!B=4&+U)@*4)HM'^;O8?[Y>:\]%SFR;AQMS-F]>PD6!'3)S$W#
M9=C"3,CE9D-+F.W+4M;:2U*F_5>FZIQQ*E-N`+ND@5E:US"T%S">()'J(6PV
MS<!M]S\1\/%,*4+9&,>W,8T<UP!ZZ5"Q_P`A^VW\PG&X+C&#B?;TUIDCC+"'
M7(FR\5;!K$38-B95+CNQ'M@<U+<Y#N:E-?3@-N+BM*`6M)':;56S<^!UR99_
M$#Z4K4:>FF-,?8%=N$VV7,=O\)MQAE&K62_6'5/=H-+=-!7IK7H`6#&]+]TV
MD-.M[O[;>>&GENO/Y#+PM*R^8@RG5K6Y(F.N)A)A(+KBE*59PVOX^=9GB,Z:
M!:9T)))#@MU..?S.G=<;Q^&Y%U#/X25CX\>%)R&(B9G7IK;<="&/3EX?+,IQ
MCJTM?O6R+:3;]RQ)&&Z`5)B?FIFO>T4>VN"E>7]KX;]Q.QXO?N.N8]#P.3.$
M@8K/XG<QEL&IU^`N08\M&43"DXIV8W!>:CK3ZH:2B,DAPDVJ6!SH1HD8=(XC
M'T5"C>QLA!+B,.A92]L^+X[XRV;*[IO?,7#$S(L03C=78QW(FN2UQ?K.Y.4R
MCJG)["(T@Q$B.VE*G"6WWN[MZ=UMU*Z4:(PXMKQ'^'Z!4BB:Q^HN!\JW!F>Y
M3@Z&27N6-%=/3I!V+'Y,CR_=QK\LD]?A6'X4IR85.7Q_GA<>^*)\'DWWI<\9
MS`3_`*^'LO)VDZQA\I$*DIEXS:>9]'P*?IE*#3R4S,*R[862>P`_;6BW\.?N
M')EI3$WVLC_=Q/=ZZ+KMA=X>T<Z7C#[FVN8#UR.:T+I)_.,IELWO.;RS\MU6
M<Y$W_+P$S%AQQC#Y#;LQ)Q++7:XXE,40G$*;[>T=B@2D&XKP[YJW?C\[;JT&
MK8PQOF8"?,25^R?]S#9G[;\@.4WOCTR7,UU,>PW$D;2>FK8VX]"]5'Y14@/^
MSW&V(/H\B;RT;>1^H@.V/P(#OZ*];^5K2.4+5QR=-(1V:J>Q?GS_`'W9V2_/
MW>XFD:HK"R8[J)A#Z>9X/E73VO15\C)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB__]?'D/V3>VG@O6LGNN7TO9N9LCKT!<YR+M$B%G/J
MBCY7DQ-191@M0D(2%]_^ML/J;;03WJ4+JUSY2QA<T8`5P%3]9[%E1L?<2QQ!
MXU.<`-1#6BN&))#6CI<2`!B2`J3Q9E...1?=!*PFKXE&N:5L&J_V?QT?^1M8
M:!-<Q,/%[!"G0\"B,PF/BIZ\4V&;MI]=JSJ;)<2:Y2T<T<Y->20+BUKB"TX"
MH%#0U[F1["OINZLYKK^[!>6DCXY)=GYAQ\-[)6`.H"6OC<YCA6Y)#FDM(Q!(
MHM^-TV)WB6#.W69&Y%Q^'UL-39N3XZV+)9N+%B?61XC:AQUF)LO"AX.K0HMP
ML-+L@J))[>G=BR<]Q$)=4\!7U?D7RH7@>_@0>STBGI4SI?N<P.R8+7>0=;Y7
MP4O!Y5[*L8#)<N:I-U=>6;:G3=?R<:!/=5QPTZ]"R,5Z*Z6L<^H.LJ22HBH_
M!D`(#FN`[*CU*ITZ@<01V'Z>=9T@<J3]3FM\@933M7S240)*"YH&VB6UF/YE
M&=;;9,?/X/7W6GWWE)=+C3DMD)0/4=3T-21^,0]D@[H'3T=1'M4!`#P\NQ&&
M&&?5CZUE_-<G:;L+3,WT]XT3+Q8\)+\W.:ELV.U03(RA&7+<VK$P)FKOR51%
M/-*=:R0/8JRS9/RZS;MNVC9[G<KK;MIMX+F[F\69S8FM=+)0-UR.:`7.H*$D
MGCTDK(NIKNX;;L?,][8FT94EP:VI=1HJ2!4\!V+(4N%QYO<*1.U3-\;<AM+4
MEV?A71@-W;7*<9"G$=S"LBJ$A8(4&UI[7"?F/PY3E'Y;<J\I;USKO6VMGDN-
M^O1<SLDD8Z-D@,KG&%NEI:'NE>Y^ISB3I`(:T-5_,-V.8+':K/=[&WFBM(M#
M`Z-I+AA0.U5K0``8#KQ-5Y'?SM]5_LW[ZMEEHB-P(FQ\>\896+$CMMLQ8R8^
MF8O$.Q8K+-V68\=['%*$H*D)2``;5W4+"QUPW54>(2,A0$"@PPH,A[59$UC(
M88XXPQC6@````4%*`#``94&`X+DE%<+;B7$$A27`M)^"DD*'Z"*ODRH1@L^T
M<YCP]I[P-1VKM^ZZB3$BRD=6Y3+;Z%=.J7FTNI-QY?-^BOCS28YYX3FUQ'F)
M"_HYCNAN.U;1N3#5EQ;LD!Z1(QKQZ"J`Z?F/7S-Q]M_+]-9K,EK:_B4`XK2#
MWCM6/'DD>)_M4RHV\D?V>6@?^&JO7OE8[_OD?#\$_P#%_(OSH_\`X@<`\7Y4
MW8S<W<F'_%-B1^T5J3J\%W*9K&P&5+"Y$ME"?207'C\Z2$1V@4EZ4Z1V,HN/
M4=4E-Q>O69'N8PN:S4_(#I)P&/`=)X#%?G*!4@$T79WVERGSQKL49Y$YA,3D
M'.,QHN1*_K(<1>)UZ2U$>2IJ.&7&O7)4@-MI"RJR$^%9MH)/`B\4M,M,:`@5
MPK0$D@5RJ2>LK"NOWISIP[%LZTX"JU[&_P`;^!\*R2L1X)!`S6`_<!M.RZZ_
MQ\SA-KS^O8^?+V)64C87*YG%?S)QAS68\3ZI_!2X<Q*(R9SEB2IL%RZAT!$,
M\PMX99W$Z6-+J"N-!56Q1%SG-+07$@8TPZU9?'FQYW/!B1FMFSV?CC;-2DXY
MC-9?+Y5.-]9S-)=,21FY$V6TW*;C-%2>_M7Z06$I"P3+'(7ECAD2,/\`#YE%
M.P:""*&AKPJK^Y?=:;UAEWN`2<U""K'S,')*/G\0?PK<;@*P"GYWUK7V!_$=
MT4^I:O/>['$M:%"XA=XVP^.EZIR#D-A=Y#QJ8RM@S,B(K,PL?&RWJ12N9&QX
MG`LI6XI"$HL$CN)KG98W.JX'`X+I(Z4C!`J,?ITT72+0_P`RW@R%Q5A<"Y$W
M7';_`('`X^+)5D$NXO6<KDFG64Y"0U-PFQM2BPIE;BFTKCAPE(N#?MK6FVF!
M)`J*Y*8FN96S7"_O,XGY-3#EY?DK5M1F1'LC&A,YG:L=`,IE;$,IDL*V:+`D
M([EEQO\`BJ<*NVX/G43HY0:NCQ[/R*HQQJMM\EOF$<U#(;)&RF/W?5F67!+_
M`)3"QVV)R+7K-QWF(Z,5.CP)9:4[_$18V2"2.E1@X\:JI%!547AS=M+V)O8Y
M?'>`UG')9D06LN<?@QJC\AY29*X?\Q3#AS$RW&4%SM/>HH[CX=W6E2:U)[%0
M#)9>R>8GKF:Y'5!5V.YKO==B26'62B/B,M*#=WU0G@?682>K?:;=3>UPQ"N(
M5PKSC;?:)$3(-%5TH"8#\T=3XK7COKDM)(\U%/VTP;]I4([*+7S%\<;)'ST%
M[.\HC;-4CKEOYK6-OU^/)>GQGH4J/&;^JRTV4&D,3Y#+I*64DI;[>@)J4N-.
M[D%:`.)Q5@<JZ_[2,)D(,7?./.+94G(LN28[J^-<!GNQM"RVIQ;D+!SI$?N<
M!`(`N11LI'O%7:<Z+`9X)]A>[8]DSL!I&-DJ0H+7CLKG^/7FE..&UD0)VNMW
M;N`#VE/3SJ3X@"@U45`WJ"P9RA[+/:)C%8A.OR.8IS.81D5/S.,N3,EL`PXA
M*@>@F2VY&V9#8FB:KTBYV)*6%W5TZW"<FM"J:6G[(5E\*^W_`(RX-YHT.?QY
MD]]FXW.;MIV[9IGD,8QW-7X]RN?V(J1+@1X*7(<R3CNY3CB00IN]:"X'Q7-W
M*\1_U0G>?*P-KY*^E=98#PN3^;'4H9G6T0_]75Z@5E/7_K(V$Q;4^0B5-#`5
M)D(;4VVXXX5NN+;:<6XMM)[S8$D@5\M\X70NN:^8)B:@W<@!^ZXM'J7[Z?W?
MMJ&U_)/Y66FFCCL=I(>V:)LSJ^60U7J__)R<2][-(;R5=W?RGR0@GK:\;)1(
M=A?X"-^FOI;Y>0F#D_96$4)8YWZ[W/\`4Y?C3_>MW)NZ_P!X+YEW#75:R\CA
M[/A[>&`CR.C*ZIUVB^>4HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41?__0V'V=Z0N!(9C/*8=>9=0T\`"67'$%*'0%A226U]1<$=*UE->H
M--"1YEL+<L8YCY(]3`14=(KB/*%Q;]I6T3H7+/%F0EIDMO8_><7K^5EN19;#
M3F0E9B1ALL'GG6@RY+<6^HNA)[K6*A?J?.ZSVW-=E/._W[@`5(-&OI3+(`/7
MWO:0[+O7]W[FC:MHM6L,6SR/>T,>T&6U#M3@7`!Q+X,=)-,`0%W<]Q>FKWK@
M/F;561W/YCCG;T1P$A9,MC"2Y<0$7%[2HZ;7(ZFO7B:-<>*_/#22X.)P5`_*
M@AX_:?9A#QV0CXYW'8/=^1L#)1$3$>P[6.RDZ)OC\=UUM/\`+6H?;M5O24`$
M(5V$#M5VY$0P(:W$G'#/M\U$D)[M%2-LY4_+IX>WJ%(US*ZGJ&ZN9>2QE7^,
MUYK%Z.S]5&E0,K+W-G4WH>@Y]2(ZW$%3C,Z7'F]BP$+3Z@J6Q-.#J.*C[[A0
MY+/$)[^VFO8?=.'N5Y8UO,M-Y/#Y/&'$[AJ6=8;DO-J+[>78D9!<3UFUMK1"
MGP%H6@CN2H&K2P/!.@*T:VDXE6_M>S<UJ7$<V7AOACW%IB+"8TB2\UI>W8ID
M!+B?Y%%WG';_`(Y+K3J/E4,]CRFX(M8WA=#$7`F*OE^OZU(U]![YI].CZEY\
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MFQZ65$CV(_[VLV`'2>U8ER:N:>@+*S3MDE:%6L1XVZ$GP/Q%34ZU@DD5+3@L
M*<Z;[F-0CZ>WCCK342>]L,B?+SN$P68?8^@&OMM?R\Y^#.BL*5]<I2PE*5++
M:!<^%4>:,<:`X&HPQZA7I2(`U-36HR]JQWH>_;#M#$1S8).O/)C;7J[D$8?!
MZ[AWFTR59=$M,T8#'XZ-+;[X*`T7&RIMP.I!/C5K'$N82,Z?X,%2=FEO=!R/
M8?/P71;2/8COWN-TN+G9NP,Z7JC\Y,[&2HT2)L&9R7H19C#;O\H1EL:(4)3L
ML*"G7`XX$$);[3WB_>]U\+^K6T!DD!QQH!U<<4VS;)'M-S*_1"X$##/++Z<5
MK%N_Y,W.>LY78,MHW)&F;5_,IJY+.-V;#;%I,U[UI#CJD-O1'-FA^H/6(ZN@
M*MY7M6AAWL1./CVDC:]&/U+=OL-0:&3-)'I6"<S^6U[L<2\N"_PO,R^08A&8
M^S@RW.B3$DK"&X&9$48]U]Y:0`AR7'>2".]M"?FK:QW=E+&9/B`#T%IKZO:L
M$PW,<A:V.K>D$$>OV*2>_+/]S4W$9O(K]OO(^'R$.`I>#PD:;K>0F9K*/NJ;
M9#TE_/&#CL5C$_Q9"E++[B4I::0M;A<;HRYL\=<W#H.?J5Y;<5%&FG'Z8+JO
M[0.)_<;[=O:/DX.U<6;K'Y#Q><VS)Q]1:R&/7E\ABY2X)B%IUI6=A@)CMJ+3
M:4%PED(2.ZPK4S2-?/K8[NX8Y+(T.T`.:N(?%7"G,N5S<G7MKD\N<6;?AFC*
M1CWN#,MDYBL:TJ-%7.ES$/X?.][,J0$.7CO!(*%%?S@5O6-MY``UK7.Z-(*P
MWN+#C@RO33T?E6VD[0_<EK6/Q\O!>\#)Q9*%)$;%3\'RII<]AQ/>R$N_RW$3
MO164J*22L?(OQL35?`@KW[8#R4]2H)34T>J?GMW]]&FM.M3>=]>G-M*5$3+>
MY.WR49:@T5.`?S)]M@+]/Q#B6[A0*000:B9#82..F,:AU.'K5S_%90O)IV@K
M,OY=/N-YBWWGW9N/-TVA[+Z_JG&>P9Z4SA<MF-CQ4J=$S^HXJ&[83,LVY].K
M.*`6V$@+%C<^$%]!%#"-#.]7I)]JDC)<X5-/(NT/*7L\U[D_CK"\\Y7DW,X)
M4QT:Z<0K7L3,Q^.AP\CD8ZYHEY;8M:$9"%LN..(?5?O5VI()`,<.U/N(&3MF
M`)X4]M5?XU'.86G!1N#?R[(_+;NRX%OG+/-1=18UQ[&[%'X8T+ME)MFXDS&(
M?W7&[OB\[B,D'$*==B21)CO0FPEU"5+2Y(ZUFMXZ.$3P3A5M<..)`5&`/>XA
MS@0.GB>GH62,K^4!MD-3KN.YHX\SY*U_ZOM_`TJ,5LFW8AN3QSRUH#$>5=)_
MBF*Z@7_T7A6,6LKWK!AQX5'M4FAU!28^OT$+FQRM[>('"/.NW:/N&\:GKN:P
MN@3GXLC7<!MB-;@0MIT7>DPMBR^:V;.3&<?)QBDD/1DRW%!+S;ET)!OK(K6U
M&_1W^H1SPVSJ,K4T<X5?7H%`W+-;TSWL6P168MW.MYKQK]8R)B#OPP`,\=6>
M6%,5A-A;<9+41IY+[;"0PB0B_8^EL>FEY*5_-VN@7'=UZU\6[E.)]ROY:UUS
M/->G4XFJ_I+Y0VK^$\G<L;8&Z6VNW6T5.CPX6,IY--%ZJ/R4TJ<]CF&R?3T<
MWRGRIE(Q!O=E6Q?1DDW(OZ\-?ATK[,Y:MS:;!L]LX4<RVC![0P5]*_G:^:^\
M,Y@^9_S#WN-U8KO>[V5IZ6ON)'-IU:2*+K56[7`)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB_]'97*12_'5VA2E)0?EMUND$C[[UJA@5
MFQG)<?\`/2$<9;GNVG-L36W('-4'DS$*<]$QH7UZLMF9Z6R$M.H3.CY7&E";
M*"3&7=0N+^9[]=.M]U+"W]W,QX-<@T84%.+=%3A[H&*_1#Y,;"-\Y!MKQLC'
M0W6VWML_/43,Z.H)Q!I*VX.>4HSJ:='_`,QK,;%B/:EE-VU#-Y7'OM9'7XST
M?$YG+XUC,8;;3_)G42F<)D,>[E1&7/:D,M/*=C%;=W&G$`IKV>H+-8/X9R/J
MQ7YOOBDAE=;W`I<,)#AQ#@:$>=>=KA_D[E`:5FN&M#V].$P,K(9+>)>!W#>T
MX'5)^?<QV.QDM^#CLC)@X!6Q386-CM(+MY#B&;>KVH"1:WQ""UKZ-1P;3O!6
M5MFA\J1'C/Y"8_ED5:&WHTW+9;'?R:6HK0^ES"NLS_Y3F0INR2&E224.7(ZI
M-4TD8D'M5&N:,&TP6?-"]X/('&C^%D:-N0T>;K4!<8-ZIC2C'[*A4-./*-FP
MN39E8#:)"&_G85.:=]![^,T4.?/5[IYJMT-:*=`]?#T*T1YFIJ>E;[<7_F6>
MX)O"[!DLK*U'=,P[BVT81&;Q,+"0L*X5I<EY"=!U_`8A6<GEE(2RVUDHS#:E
MJ[T/CM[;776FNL8]7U*AAR+2N9?N8Y^Y$]QX<W3D79)&R9'7-CC8:$I34>)C
M\3$SF*F2/H,3BX#4?'8V*M>O%2@VVE;JTE:RM94JHR=4NHG-OJ_PJ1C0T'-:
MDQUA*^IMUO\`9U\J/%1@LB%P:\$KK)HO)&I:CP3Q_/V+)M-R3K[;,/%1U-/9
M>:F!+?QP$6$7$*+8^FL7%%+:;=5#PKYCWOE_==TYXWV';[4F+QJN>:B-NIC7
M]YV5<<A4G@%^XWRL^<?(?R__`+LGRIW;FW>V-NSMI;%:QEK[J803RV_X<1<"
M6@LH7N+8VTH7!:J<H>X3.;&F1!A+7KN"=)2B!!>)RTYH]R;9"<@H4EISK=ML
M(;L>U1<M>O3N7.1;.P\.>X`GO!]IP[C3^BWI'2:GB-.2^(_G7_>SYGYR^,VO
M:G.VCEEYH((7_P!9F90C\><4(:[&L<88RATO\6FHT3V[+1G=XEHEMM)CM0DE
MII3#4@$K+W\-U+Z%(5ZX3VDV%@3X=37TA\J=MM9^9!%<VK9HO!>2'`$8"M:'
M#NY^1?GC\QMZO)]K,[7^'25H:!44J>D8DX=(]BV_1I^+D-EEN,6&`I2TM,K4
MPD%1`4HB/Z*25@?#K7V<[D#DS<+=HGY<LSAPC:TUZBT`CSKYQ_M9O=L[5'NL
MVKH+B?020IYS`2`B*W&DO0$P6$16?Y<W'@+<0CN4ER6[$CM.Y"0.ZWJOJ<=(
MZ%5@!6FG^2W(%Q0C:71FGV))!ZW$>A9D/S$YAC(+[P$=;6GV>I?+DK<L*P_)
MC;=GP&&7'4,/3UN,*]-!4$EKM"5`]O7[*Y;>?D1RC!97MY;W5XQT<3W@>(TC
MNM)QJRM,.E;S;_F-N]Q<16[HH"'N`)TD'$@8=[/R*A9WE.3GLE&QNU:!K>_8
M7`,Q%,_59#-XK-HD9?&XR9DTIE8[(,0'FENLMI+;S2@/20HB_6OF+;N7=PWB
M">YLFL+(WZ=)-''CAP/7BO6+[>++:YHH;E[F/>VM0`0.&(S\P5;/(/&BY6O0
MM.T;,Z3-_G\7(9AAY$S(M3&H+:_IQ&E?4RWGOHVEN$(2V@!*B0+UAW6T[E8/
M'Q.WS1@'/22/UJ44\-]:7;:PWT;\,J@'RC`KUM^UWFOV^;OP'Q-QUH6Z\9[;
MGL9QEI6,VQ&*SV(5G,1D3@,8=E/T6*GPMH7D8A>?*R"P$/=H]1;H+5<EN4T\
MDDXMXAXID'?<"``78D`.:7$-J<PW+$GNKMMEM]MC9#+NER?!;&\B)A&ISF,.
MEKC1P8'O`9DYY!)HUM'K)T75\+BI'IZVSG&L8PVXU'&;SF5S4QX/NB0^_*<G
MS92$.//CN"462A(2D=$BV-,\/HUM=`Z34K%!JXN(#:\`KNCXEQ"0IQ5[VZ#R
M/VBW6WZ:CTTR"IK;4A5AK'(!OV*5>WCYFWB`.OB:NT@8JPO)R"FQ"[2"$$?:
M!8_'X#X>=,,ZIK=2FA33^#QV4C.1<EC,=D(SR0'&,A#CRFG`1U"FWVUI/X@U
M9@T-TNH%0"H[RP5OOM%]N?(<5+.R<0:*B0V+-9;#:WB,'FF$^DEH(9S&)AQ<
M@AM*&T@(]0IL@"UA65#>7$)K%,?6/-DJ/BCDP>W#S>I<N^=/R:,=M*LUF.#?
M<;RQQ[E\@]+DHUO8]DR&>TAL25..+QL&)C%8;)8N$HK*$`O2&VD$`-D#M.<-
MWNZDN()\P]"QQ:0TP9E].*Y]<1^S7W>?EO[KLW)^4X*F^X#6L_I\[4G,AP]L
M+F1FX**G-XO-R<CD\&K79&>++R,,A1(B!AM/53P((K'FN6W#`PU;3RU4[8S7
M6/,O1#[+N<..?=O[4V6I&*S&LHT[+YJ-G=>F9Z!'SC&;B?59[+16_P"42D36
MU1&,UZ3J9"$%M:KJ;Z"W4[9'KLHF!I[O&F%3Y^"T]S=P1W3H'RL%P14-U`.(
M'$-J#3/&E,%EC0-MUWC]V>O!:R^MS*F%]8PO(-F"RI$AQZ7,ALF$X]]2OZEQ
M5EN*]2R4E:.JJV7PL1P(!/6`5JF;L]Q/X9IVFJS0GG3#Y!I3!9V?'+2V;KQ\
MQ^"ZD#_)>@SV%VZ_NFXO5'V4+OL,\RG9NN/>:^G;7VA<,^5M?WC?&MNYAY:@
MH<W6?A)6-V7'S9D?(N1V-4E)@PL?D&(YF825#EPL>?INQ2W7(LD!Y94IP'SV
M\L[C:=MW[<[T--RRTEJX')K&O<*8`4&8PKE4DBJ]6Y5:SG+GKD7E#;"YNW7>
M[VL+&.`.-S+'$XDXN-2['&F=`VM%H[.EF)#DR;V,>.XX/(?PT*/V6MVU\-6;
M/B+^U@S+Y6-/^,X#VK^DSF:]&S<K;_NC&XVMC-,/_A1.>!_DKV+_`)2VMP]5
M]A'!>.@K]5F7CL_L!>L`7W-HV/*;&ISI_5(R@"?@D`5]W6]#;P.#:`MK3RFG
MH7\Q$Q)N+G4_4X2$$])&!/G71^I5&E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B+__TKAY+]U_#'&BY./<SJMNV"*%)7A-1;:RJD/]H[69
MN6+K.$AE*U6<1]0M]NQNV5#M.CEGCCJ":N6;'%(_%HH%R/\`</[HLQNDA_8X
MW'VH:S'5*@HG/Q669NU9.,E3<2,S/VR=`=[!':[$H,>&S9([5E:/EK53[;M^
M\RAEQ"!([[0][N]?0O2.4OF7SGR`89-@WJ46<9=2!SBZ`F0$%QB/=+A6HJ,'
M8YK'O//O2R_)O'NF:;C=2_DTF#C6D3<_L&Q.[QF4Q<<AO&04:X[.QV.@ZM&E
M&(XN4Q%C!#I#2AV5U443F-9$YY=&QH`!Z`*?0YKS2_NY+Z]O+^8#XB:5\CJ`
M#O/<7.P``&)R``Z`%JIH\K?LTUL>8Q>#@YR-JV*&3V/(/J@8^2SBG9C#"6UR
ME2(<B:)$Q:$I9;]1U:[62;561L8H'$BIX9?D4`<<3FLF;GR7C.9,C@LMRK!V
M)O)832-4U&#F->AQ`W"U/2,+C]9UR._'CP6FIIQ>%AQHRI4@K?6AML+=40*K
M28&C7@T]F'!4K&<Z@U61(O!GMYP>O8??,SRKDMVAY['N9+!:5J>.3$SCYBSI
MF.=8V?+SK0]?9^N@+;4A*5S5-_Q6VBV4+5B>-?OD=&VV#0#BXG#R4Q)4NFW:
MT.=(2>@>WZ%8XVK:XB8GTV'BXG1-5:LVS$9=D..R5#N2GUY)0_FLY*"0$.+;
M;#8%BXA%[UDL9I-7N+Y/IY`%"XEV(:&M6OF4SV,3AI^NX6+)<B9#-XO-S,OD
MRAN<^_AX6;APV(>/C..1L;$*-A?+R5O2W'5-M*2MH!39E`<7![LP"*=M/JZE
M3#H7Q'U?ZC3SLC,M+N17LJ,)%P<:TF<]#:QCLZ?E5QV.^1%C17EQFDK<"4OJ
M>4&[EISM:G:]&GNZ:UZZY*N%*UQJJ[)+>-U;!+DKRD79$9'+-S\?+;E1PW@#
M#PBM:D--RXYCEN1.=G%24_,M"`3VA25&]L<(!)C&-:TZ:8'+S]0IAFIOC+NL
M=+A]&-#6XG`5)H,<!B3085)/2K`E+4IQ:G%E2U**BI8*E7/VGJ#52`,&C!0%
MSGN+GFKCQ6T7M.:4YN&9*4EQ:(41#20CO*W5N2BA`!"DV<4W8]P(L?C:O4OE
M&(O[5?C5#/`?B*898X]';G2N%5PWS`=*W8G>$<?$%<<QC4=G3U+?^$R`%=P%
M^AZ6ZGJ;=``.I\J^\+,M,``I5?*ET_O.+LU/EE!"NH^/Z+^'6LKJ%5C![L#7
M@K5V-NV.FD`63$?5?K8A#*RH?JZUH>9B&[#O+RZFFTF/FC<N@V%P_B=@TXZI
MHQYW!:UZK)=E?6ONI6"YDY8*R2KUDH6$-+'V(92EL?YE?(?(@+-MF-/>G<?0
MT>PKVGG.0'<(P,2R%@\Y<?:LC8W7<AM&5QF`PV,DY;,YN?#Q.)QD)E<B9D<G
MD7VXD*#%82%+>D2I#J6T)2"5*4!7H4TD44+Y;J1K86-)<3D&@5)/4`N-MVRR
M2LBA!,KG`-IG4X"G6O6#[(?R]]-]J&HMY1[&8;,<O[-CXYW#;68[2W(3;[45
M][4]>>=:8<CZ_"F,76KM0[.>0EU[HEEMGY9YEW>'>MREN+6WCALP2&!K:$BO
MOOH,7.[:#(=)^@MEVV;;;)D-Q.Z6Z(&HDD@&GNMZ`.'3FN@</6)"'!WQ'%!:
M@"L_2A*`?ZQ`E*64B_6R2?LKGJ"N8]*VA/`G)7`-<<2D'Z:R;D=X"7$_`70V
M7'@#\>VUO&U4+":T>*^55&5:8*7<P:NQP)2IHME`N6UM*<)/0L)>#:GT_'L"
MOMH(Y!G1-0/!?K6,*`GO2;F_D?FM^H]::'4J0E2ID1.R_<+V^SRM]]Q5ND`4
MI@A->U2DACY"!<'PMYV^_P`+]*H68@A75PKP5,:@]I)-U`WN2!T-O&Z1XW-5
MKJK14`(R&*^IJ6(4&7-EK"8T..])=6OP2TRVIQ:OC8)!Z>=4#2:8*[$+C^E'
M$7+$_FG=MU[M"TS8-EW\,;?B-X:TR1F]AU.%A=2QV7QCVJ93%[2QN<'9,2T6
M')'J-9!N,RR$2`\&CO-DM-ZFW^VM+:]N?X;)`YG@LD=H,FH.U>$!37PUU]T4
M(P"X#>[.^M][EYGOKQHY;M;$@A\GX;9BYP#S$X4#RQSV>('5I1E,53-JYSY)
MT?A3C7/Z`G^WDU6O\E9K9\[*C/;%*5C^-Y;40N/!,^/-G,*4\M$CTR_D7"P/
MWE^JNN^9<[/L\C+?F6=\,SY6QM%#74:UK0&@RJXX"HJ<0M1<#=]VM67?*4<5
MQ!I,A=J&DQ@5[I)%2>@8X&F2W>RNW.:EQQCMPV?"S6LS+Q6`^MU_"PG,C-_M
M%FVX;)P\&+Z[2WBWDI1;`+@44H-KJL#K]QO(;1DCXR"7$B($T+W8D-RS+03@
M,@3P6[V^WDN3"V;NG2"\@5#<M1I7($^I<U=Q]PL+?>,]F[L)GL/,RF25B7AD
ML<U'"\C+R$R4MIK^7Y*:EN$W&;=2DRTM.VL"D*4*\RYZW":/D#F&ZN6B.5]J
MYCQ7)TO<H.-*OHOIO^Z_LD6X_P!Y/Y5V$#O$BCW=DS>MMJU]P'&HP_=`D+1_
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MA\:X9[R#7@M\K1Y$QGU.H;`$H/>SCGI;8'0A<(?5H*2"#W78Z5DV$NFZ@)XN
MIY\%68EUO(*THTD>3%:>-N*?Q:5=Y4I>0G!3CG\1Y/=%AK;[G2GU3W...'I;
MN()M<5V#:`T`PHM"YSG$N<27$U)XE4V%E,ABI<:6TMQN3$?:DL.!2V7$.L.)
M<:4VXTIM84E20>Y)!'B"*NSZ%3!;=<*\I[!O6^*QNX3@MO.P<G-S.9@8O'?V
MIR$+4L!D<W'P#4Y:$Q5(RC>.,9V2^T]*]-VY<)2CMI4,&`H.I`*DK"NW<JS\
MY.E/P&A$2\ZLAUUIKU`U^ZVTW'`4PREM``ZE9/GUJ@9ABAQ6*94N3->5(EON
MR7U_O..K*U'J2!<GHD7Z`=`/"KP`!@,%10`DJ\!^/D/'Q/X4J."JO5)^5;^7
MM[,N3_9+K/._N:Y!U_CK,;;R3R?'@Y+.\B-:8[E]>TMG'PI4:-C7<Q&EY>#@
MTXZ3)><AQENQDNN+<4EOK6;:V,UXX1V\)?-I<Z@X!M:DFH```))<0`,:K"NI
MV6[?%EDTQ`@>4F@``!)))H``232@7,G\X3A[ACAKW'ZO@/;P]ALEQ+G.&M%S
M6K;)@I$N;CMG2F9F8LK.IRL\JFY=V2N,&U2G5+6[Z0/<KQ,-S;36DKH)V4EP
M)%6FE6@BA:2T@@@BA.!4EM/'<QB6%Q,9)&1&1((HX`BA%#49A<FIA!=78C][
MR^%0&E:J<##-;1^T_+8C$;)LLK-SXN-A*QL-CZZ6WD7F677#.],>GBX<^4I2
MU"P/IE(/4D"NZ^7F_6?+G,$>YWX?\,UA:=+0XXY8%S:99XGJ7(<Z[3=[SM'P
M5G3QR\$5-!A7C0]*Z!?S?`2DB1C,_KTF*XM:6WEYW$PBM(N4=T?(RX4QI:DD
M=%-)-_*OJW8/FWR=<,:VXWAL,G0]DC<<.):6_P"4>M>"7_R_YBB+M.W.>!^:
MYKNGH-?\E5*'C\M/:=?A8N;D([8*G)6/C.Y"&D6[NXRH0?CA!'GW5Z%:<X<K
M7Q:VUY@LY''@)65\Q(/H7-7/+F[VFGXC;)V-&9+'4\]**V-C;_YDRRW;(#,"
M65@W[DGZ=P'N02/"_A4?-T\)Y4YADC>'`6%QB#A^Z=DLC8('-WS:0]M!\5%V
M^^/RK7K0\+DLFU`Q^.AOSIDCZIYMB,VIQ?IH4_)D/N@7#3,2.A:WG%60TVA2
ME$)!(^4N6A%8[';S7+Q'%I+B2:#%Q-2>NH`''@O6^8R^ZWBYB@8725#0!B<&
M@4\]5V\_*0]N`V/W.X_D'<6S(P/%^MY#9&%0(XG1&MIR+K>NXN,[(D+B0YDV
M%"R$N<P8ZWX_K14'UDJ%JT/.G-MK=;9+MEAK(E(#GD4!:#4@`XFI`&(&"W7*
M?+5S!?Q[A=EH$8)#<SJ(H"?LX8X5.-.A>K8Z_A%QDRHF28DDO);,4QY4.>A*
MVUK#RVE)=A%`*.U78\L@D>(-QX^Z)CAPHO3]1!TYJHQM0:=`+3_0FX2XCI]_
M<@C]0J/P@\FF:E(TBH7T[A1'G1L5]5C3DIC#S\3'?6QD3Y4>,0)$B/"><;E/
MLL=P[U(2H)N+GK4;F-9((BYOB$5`KB0,R!U8+)%G?26DFX1VTCK*-P:^0-=H
M:YU=+7/II!=0T!()H:9*#*U^<Q_IH;[(/@I32PV;#S40`+??4FAU<6E8="*8
MJAO8RUU!JZKW40"E1(L>J@03^L&KA&>.10$]"ISN*;6;K;\?N``-[V*2/F*C
M>Y[K5;H(J2,%74J>O!W![?&Q(!O8@7LGO">I/3^J!\35A8":#-5!"EQAE-FZ
MF;!1[0?$$BUP""4D]1]U4,1'$JNKH<M'/?ORVKB3@W;_`.2OM(V;(XIV!CF4
MNH3($[)MKAXM*$*N7%_4K]=2!U++"_`=1-;P!SVXH74!)-5Q!UWASW':[[8S
MSQD.1N&M=X2U?3<GO"]=Y'T/7\IM#/(,?894;$PL>[/U[(R,_P#VT=GA+$Z1
MDV&XKCY9^G(05'<_#3_"2&.<L::BK7%KL:@BK2#1PP()H:K7$PSS%LMN'L!&
M#@'-.DAP=1V'==EA6HK@L#X+W+<6\E\&\NSLAC]DX[EZSQO$UZ-KK4QS"X>#
MOF^;\]&?R#$*2Q.QVNX;8,#%1-?")N,C2)*'6&6VU(+J.8WMFX[CN&S.FO7S
M-!()?1Q`:UM,7&H]UM#WCAPJ5M]IAL+"VOHK:VCB%'.HP4!+B:X##-[B:4SZ
MA3KOQW[R(_N5P.8R7`>O*W/'\:YS78FW[=)SRM<UUAB5B8TO8L<WK>P<?Q,Q
M-=8QJ<FQ&<1F(Z52#'>NII!^IVE[#NVYW.SSVOAL%C=&0AX#M58)H:MTD$&D
MISP!%<Z%:Z%FT6,5S'=>(Y\\5!HK5IUM<`=0Z6CIPJL*^XC6<9KFC8UR'':9
M7E<_$9*(O^K-J=;@3)KDMZ$TMMKN(;[3W-)[5+';;K;C/G'(RVY&OF`T=<30
ML`Z2'A_J85];_P!PO:Y-V_O#;/N(95FV;?>W!/`:HC:C'[UR*=:Y\[FDMZ_/
M)MVN]S:KV'S(:?DH[>G[W?'!%?+W*43I.8=KZ1*RGZ[:^@E?K5_>/W`6OR5Y
M\D<[N/V^Y:>UUO*&_P"7I7NB]C.-.$]OFMX,@C^023KP!\0->Q&'P8!%S8@8
M^OM:0U><<J#S`#V+^>2']TRN9%?/BMP*L4J41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(O_]3E=N&A[EQAD7,/R3J&P:/.2XEEES/P"SB,
MBL@*MAMFB.3-8S_177Z*9([#<*`((KBI[.Y9WM%6]6/HS]%%N631O%-5%C[8
M4L.X^6P>TAZ,^RH>90ZVM"K]/$@U%`#K:ZF1!]*E)HUP!X%:$?3JQC.5B.!7
MJ,3HCPOX!EHRXCY'_*4[):_`5W+':PUU>"T)%"0OD+9>`40E72W6W7_.\;U)
MU*GK65>#LA'P?+O'<TA*&%[3C8$D*MZ9CYET8>4%@V'8J/.4#?I;[*M>*M(5
M0<0L7;5CG,9M&?QA;*5Q,QD6`VE)Z)1*=[`$VO8-VJ*!Y?#$[CI'GXJYX`<[
MHJJ*&T))"R5J%Q9M0[0;']YRR@JRO)-P1_6%2JU?0!\`.@\`!T'X54#B47JI
M_+X]WG#6C^Q#@OC>/LFAQ>1=)S'(#^X(W[B7;]R8@2)_+FV;=C,'CYF.QL9J
M:QEM>R&/DR!&F&*H#T)!]1);'LW('+VX;OLL]UMUE),]D[HZAS&@!\='^_+%
MWM)%""0`[*JX+F1S?XE'%+,UL7@AV-<2UW=R:_NUS%!6F:WOW;VP^W[\TE[0
M>5(>0;AN<8MN:/L&0BZ/`_F.Q9=G<(?)3L%#&Q1"Q&P<;'SD1DH;QZ0N-.EM
M]_8>P?GC_?3_`+RO,G]W7YF67)NW<B1W#[C:X;H/E?(X-C<]T#12WU"H,+ZG
M6?LUH2O5?EORO;\P<OBZGW.CV3/8[0``3[]1JIGK&%!C7"B\W'YK/LCU;V=^
MX71-#X[R>:S&M[KQ!K^X&?GSB$>EE,=D\[K&63$5BL3A87H*AZY'?>!;<<5-
M?>^904@#;?W8OG9NOSQY*WCF+>]K@L]PM=Q^'\.)LC!I^&MY:D2O>ZHEEE8#
M4`M8TTK4G+YGV./8;Z*VAE+V.CU5)!^TX9@#@`:=:YTP,3E\4)3N,G28(6XA
MEXM/-);=\7&&W5N.QFI*@%$@)2JPNH"QO7TFUY;[KB`N;+`[WA571C-DV'']
MR9^04I"3VJ*8*75-V-N]SM^D2HN%-DCU$DGQ(\:RX;AS<W5'118LELUQ!:"'
M5Z2KL@\AYQEY+D1*WW$EM++L52FG0IY3A92M$>?/=0^HH4>A*DV`M8BLEMVT
M$EF!\RA=:!W!7DYSSL:X\[&S]ESDN)*@/07@<QD9L$HEQU#L#4I;!=;N".X)
M4A!%E$`IOF1;W>0L?&VYE;$]I:X->:$'@<<13,%8KMIMY"R0P1E[75%6BHIT
M=?6M[?9?AH.Y:7/R1$-SU=ND:X^^U\[PQ6&Q>#RS,8NJNMMJ;*S96^CP<7&9
M40"V*W+=XN=PVVVLG4%O``T!I/>H*5=CGZ,<EH[C;(-OO9[QA)N)23WJ85.(
M;AEZ5ZD/R_./9VHX'D'/NP\?#P>;R.M8?7A'0M,UYO!8V9-RDN4HI0T([TK8
M$--(;'C'45$W`'*[J]WBLC(&D"HZ<>GS+H-J8!"^3'4X^KH\ZZ<X5!?D,M()
M"G'6VT_YSA"1]IZFM8,2`MD:U%,UPF]S'Y^F+]J?NPY6]O>:]O4C?=4XXV:+
MK43;M=WA&,V'(2AC<:O)MR-=R6`=QP5&S$I^.VI$Y(<0T%D)[K"81QLI5QK3
MZ='K4FMQKW5<NE_GN?ET[YR5`WC>)W.O#6TXG&*P#!V7CG#[7J<9])F-+R@?
MT*7LFTOJ:9R#S:3_``T)/S^C>_=JY-HM9=WAW=TY\=D>@-(;3CC727`XG`.I
MU9U[*VYZW*UY+O.2([:(;=/<>*Z2LOB?8)93Q!#I)8TU,1?3`.RIUL]O/O2]
MKW.<C#GC+WF<);*QD(C:T8+(;9CXVTNOO2`8\:3IFYHQ&W0%NLI<2/5?2XE0
M"2VNW<=N26]97%AP)(&&*Z8-:GJ.78];Z/%Y%IU`[)$=,=85<?OH>9`-[=;]
MQ\:QS6M"**3548%6/G>+]/\`G]&-*B+!%PQ)NV$V'4(>2[X>%7M9K#M1H%9@
M*`"I6+<CH$!EPB)D'R.E@ZT@V\?$H+8\1XVJTP98T"%@SJ58NSX=6KX/+9Y]
MQMZ/CHJI#B$=P<<^8)0CM*>PCO7UZ^!-6>&YHJX]U-(X$U7E#_-RY[G,;-HN
MI0Y5IN3CO[]G(R5J4TRAKU]?P#;0]3JVE]K)I*5"Z?338FYK+M@`-5,5:\5;
MIQ7.GG/:]^]NS6DP=&WO=]VU:-E>*.5^3<%L@9CX;"[QLG'N!V56J:BT]D<I
MB9FFX?-[3-BRV7H+#4I^*GZY,]E334?I9]FWRPV>SWVYLWMVJ:;0QQ`HXD.<
M-..H@AKL=.G#!Q)6$VXM)9I;*.0&Y$>IPKC3`>LC#/'HQ71#5_S%_8MO@Q>,
MY)X!BXK8,3Q7K&`G,R.+(VTJWG8G\UAMQVE_)Y/&LR\@[J3D?58\>+DI[[CQ
M:RLM*O3;1WO:^NVR"CFTDZ=-*=A'E]"J&7+0W'@?R?3@M_="]RGL7V;4=HXB
M]G^.U32=QY$;V;+?RO6L&]B8SV29QBCGLUL?T:<BMJ:J"RF.EV4ZV[=UM3?<
M`D*D%O:D.\":KR*TJ?+GBHY)'-%9(^Z*+4KG/2]SU;%:+B-OR^7RSZ8&3*G9
MN4&5B39456.;<FL2))=R?J)CR$!2W5V<6XOY018>&?/&65FS[#8OJ"ZY>\XY
MZ&4&=3AXA]"_0S_^'18M/.GS&WQM"V+;8(`1P\>?Q*9#,VP*T4Y70F+A($#U
M2R_F<QCL=%(2I??)R.8P^(:9^2Q'U"<FXBXZ@$GRKQSY?61GYFL2UE0U^/8&
M/=7R$#T+[,_OB[Z-N^1W,\/B4DEAC:.U]Y:L]+"_R57N:]BLZ?E.!(>4R"5!
MS*;;M>484M+:%KAY*<B=%*DMN.)'IM2.P7[24H!(!-?6KJ:Y*`@:BOPXC`#&
M@'@MQZHKTHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?_5
MZ,,C#9Z!*Q&:A0,OC9K'HY'$Y:&Q-AS(SH*5,S<?/:<9D1W1T(<04*M6MTD4
MJ,%*2TM(;@XK1;W&^P;VRKUQ6QZVWG>',A+RD:!]5I"#F=;2_-3("796BYK(
M-XQB"VION6WBW<<LA-@23>K76\<CSJ`KT_ES]:HV9[!G@N07,GY7WN(@8Z9N
M'$L6#SQICI6X<IH3<F%L3"DN!1CS]$S2H^>5)*DW[('\R:21U<!!`RF.,6EK
MFG3TY_E5"6O%6YKEWG-?V'5,G+PVPX?)X++X^2[$G8S+P9./GPY3"RAZ-)BR
MFVGV'VE@A2%`*21U%937M>*M<"%801F%]XG+NX[(XW((59R!.AS4`]"%Q7VW
MTV58=>YNJG)477[3?RR.0/>#`YBW_@S9M99V;1]TB8S*<?[)-7CY.Q0<[KN.
MV'#Y["YA4=.,AB<_*DQ?IYCS;:5PE.![Y_33B,=+$'``/8'N%!@1C7C4'/I"
ME(:[3P-!V?3SK1'FWV8^YCVZ2O0Y>X@W#58:GW(T;..XQV;K<]YLK[F\?L,#
MZG#SUA*"JS+RSV]?#K4HN(B0''2_KP\W`^0JTL=F!4=2UW1#*$$J!!L;W^/V
M_C61F*JQ=`/:S+@1-+CL29,%"WMID/!B?)CQ4K<7]'&2S',EQ)=>>0R`D(2K
MYE6\:^O/DBR%O)S1XC077LCG5PJ>XT`5SP:,NS-><\WZS<S>&QQ>8-((!-,S
M4TR`KF5Z8?RQ?<-PMQ>_R;@=]VG2]>D93:=+RF!A;%MV`@9)@9;#Y;#SYV/Q
M$V;&FYH./X-#;B8S+Y!2!T79*OR>_P#XH?R_WOF;YK?+"\VKE2[W#PMGF:7P
MP32-8773BW6YE8Z4+B!)F22!3$>I_)"^^"Y?W>&:]:VMR,W`5[G"N/1DN?\`
M^=.W,]XNV\#\@^T_0]JY@@:;K_(^F\@R>*=)VW>\#IIQF;P65Q;6P;+A->=P
M>,??.0GNNM.O!3"6E+<L@I4KSG^Y+R9S/R/M7S"VO?\`ER;;;*:ZM9K=LNEI
M<71R,EHP.<X`:(^\X`.U=W)P'6<[7<-_/8SPW`E>&.:XCJ((QI3B<!CTYA:.
M8;\F3\SW*:_"V:'[:-@^ARF.:SK"9>]<98J88#T9,MJ8N%G-PQDAA#L=0(!L
M3:UKBU?=`+:Z2#J[%P]'9D8>18%YY]C'NS]KW&^`Y0]Q/".U<5:3N&QQ=6P6
M8V:1KJ%3-DG8S)9]F"_@<%E\IFX;[N)P\AT?4QXZ;L$*7W?(:NH'-831Q!Z<
M:4KZPJ`.H7:26@BOER]7H6H#4J&\'$*R<9Q*RI;H>EQ&UOJ<9::4A")"VW$#
ML80$]+)L%!([15V/E5JD=EFR8F.C1HX>:9G=]DIZ15J2293D0'U6D72ML+#*
M^P'M("00FAK6IR046WWL@]R&-XXVK+Z9R)E?H]=W&1$G8_9\I*?5'P.R0XRX
MH1D7U>H6<9GXJ6F7'W"417H[)44,J?<3LMNNA"]T;O==3'H/Y5KMRM#<1A[!
M5[>'2/K7N)]E&37E/;MJ.3=E)ELS<ALRXCZ)")#)9B[!D,=VQW6U+;],/0EW
M[3;NN?$FHMWBEAOI(IF.;(`,""",`<CVIMKFFRB<"*&N7:5O-I:@[FL8@"Y^
MK9<MX72RH/'H?B&ZUS?>':L^N+2%_.E_,*P&\,^]/FG;MLQ.0Q^/Y!Y3W[>=
M.S4IHN8[*Z]/SV2SF$>B3&^Z*^YC(TF,Q):2HKCNCL6/`JRYHG0NTN'8K(YF
M2M+FGM'0M'/JFGW5+ZMJ4\[)LY<J*GEE85UMZB%`C[?L\CC"M255PR5:$=34
M>*EM7RO$@$`J%DK5=("4GN45'[O"QH'9J-U!C7);6<*^_P!]U_M?QLN'PE[@
M^4-(DHRN$7C,1'V!W,:C&@,MY5W**_LEL2,OK27Y3R8*?_-%=Z$K"NEKRXDL
M)]P`UZ\J>U3#$5&:_HV>PKF/D_FOV2>VGECF+)M9CDCD;B?6-OV;+,X^)B49
M*1G(@GQ)ZL=!;:AQ7)F.=:<4EI#:+JNE*18"4.%"`,*JX"H!.:V/??Z]5=2>
M@(\>M_A\:L))HKEB?FR0&>*MQ>)L!!9`-[_OY"(@?=^]5DGNGR(,^M>!+\P?
M;)NW^Y3D`EYQ^+KS>,UW%H[4DM1XL%$R1'0&T!2N_,9*4L7NKY[7\`)H!I8S
MI5)N\[#H7/\`Y*V_<^6>4=FS;J,IBU[;L<K(P-/AY3(3XC3+HD1L?A&&9#4/
MM<PN/BHBK=6RVA+:?45V_-;*?N5]):BQ?>2_`AVH1ZW:`>D,KI!KC4!0MAA#
M_$$;?%TTU4%:#KS5^<9<1YK9]TFZY*P#\B4S$49#A7%':IIT)[&Y<:5ZLTNL
M6[G%I:4;D%/F<=NDXNR57.-0&YK:WV\\BX[V'<X-\C;'K&XY33?Y3EL#L.`P
M,X.3()R;D!QO8L7B\MD(F&R.0B?RM+'IOO,I#3REA9*`VO(AF9;2"7-A'KXT
M6+-&^Y9X5:/!^@]*[*<H\Y:9[A96$R>FMYJ+%P&IZV_-QV?Q2L;D\;*W;`8O
M=\='E):DSH#\EW6,SCGEEB2\$%SL60M*D)\(^=]VRZW#8[<$U9`]Y'1K+0/V
M%^F7_P##^V]VW\L<_;HX8W-_;Q`]4$;W8>6<K3;E?"Y)J).SV-<8:<X]Q&)W
MZ3)?CL2$0F\!G3D([Z42&W@AXY6/#2D]MR5!/@H@\A\LH?\`K;I<0V**1_[#
M?+@XX+TC^^]N@'RPMK;6"ZYW*TAIU-9=S.],;*^0KU5_D><U<J<^>PS6^0.9
M-D_M9NKO)'(F&>S1P^!PBW\;B,A#9QS;L+7,9B,:IUII9!<]$..>*U*/6OHV
M*X==,\5Q%:TRIZ`OR5$0A&AHH.VJZ^U(JI1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB__UN@&"#+42)$]0RC%888+SP"I`4TTE`<<NE)0
M^L)N2`DWK6ES@:BHJI&L%#0`JX<_FW,+@_J&T1LJ')3$63ALRTI^!+AK2V'$
M&8E#SS+THI=`4ZB2BZ1=`'CN[#;/XB#X<@:X-X\?(M?=7@M6ASV%P+N'!0>/
M>9N(M8E2<1E&F^*'YI9<+6QEG%Z9)?2XY&0UB-B;DN:E!??DK4&H+KL">^"'
M/I>I-0WNTWUD/Q(]48XC$?3J2VOK>YIX<@U_FG`^;CY*K)_-G`7"7.FE9Q/)
MO$FI\DOL8&?(Q;TK#LKV-:V83CL2-A-BQS:-A@N25MH2CZ5])5<=%>%:PM;5
MN8=TC`K-+B*`'!<(=Y_)\XDY9GS&/;ON6T\9[FA,J1)T3D\-YG6&WD(,A</'
M;%BL:C.X]+#:5=C,J&\[V)NIPV)J:L[0-#@\#/5@?./]'RJC7L=@X$'JQ]"Z
M'?E0>UCGSVCY#FG"\NX7$8S#;)B.-\?A<ABL[CLK"RV4T^9R!)G3H$>(^9$6
M))QFY14*,AIMQ3T=0(Z55A>\3%S""7@@8?F@<">BJOJT%K0>&?E*[,SWHF1Q
M<^',@0\M'D1'D.XV='9EPYR0V5)COL2.YAYMQ=@4J!3;QJ735NDIUC-<:^4O
M9U[+>?LJC%\I\`2N&MXRJDQQM/$##?'L@*6IG_7)6IY*"[@BA"K*<>^A>=6A
M9-R2DA'`W[#BWL^HX>A0&=U=+JGM'M6D?+WY$'..E*D2O;9S1BMNUZ/(_F$/
M6-LD.:3N*'[H7Z<3,08,_`S9#;K0[7'GL>F]B`"*Z7;.9>9-GMO@K'=)H[/7
MKTQO,9U8=[#C@,:CJ6--;6=P[7+;M+R*=X5%.CLQZ%IUH''G(WM/Y#EY'WC\
M/\ILHQ>UZ5-UK8-H3,DZV9^MS-C2N3!Y!$//:YD6(R\X'4"-.+2W#?J;6YGF
MJ]W#F">UN]PN;BXF8-(,KW/<&UKIJXDZ:FM`:5)/%9=C%!:,>RWB8QIQ[H`%
M>FE,\%ZEOR4]OTC>>#_<+)X[UG&ZKK<7W`Y%$.-`?7,C3I;^L8:;_."XEN("
M)P],E*`E':+"PK1\N6SH;G<FF/02R+#JK*!Y@*+:W7>L;1P_VLH\S8OK73&)
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M"UAP<&GB[`Z>H4/71;6QV:6=OC2]UG1EV5^I9JYJ]H$;5\KI\!6$A1-,QO'&
M1VO+9C#Q%1MAW#8XK>6RF3UC!YB/B)[4[,1,'C&51DSULMKD27'&F7&6TQDP
M\Y<O.L(+&WV[;V_!0M<Y\P:#(]QJ7!Q%7!C6M!%1I`)Q-,,?=H#!X38+>L8&
M+@.)P[W4."PO[9EX_:]XV+$8_5-:QYQ&F9.5JT)O&1&W5SF,QBD2US=AELS=
MFR\Q4.0YZ:WY+K39)])MM/8$[/Y/065QS#N#I[..6>*Q>^)KJ4UZF-K4UQ[U
M*\*F@7F7.\LT&UVQ;,]L3KAH>6YZ=+NL85`PXKVJ>P%^:Q[.N%DSX#.,GN0M
MPDR8$=SU6679?(>WR3V.@J[@XEU)\2037$<\SW=QS7O,U_;"&[,@#F!P=IHQ
MH%'#`@@`UZUO-DC@CVFQ9;OU0!F!I2M236G!=`^/<AWY_&([K=[KC22>H"W&
M'&TCQ/\`66+5RC??:>M;9N&'!>=S=.-=#Y=P&4TCDK6<?LN$EKDM+:F-E$R`
M^LK0J7B<BR6YV*GIM\KS#C;@\+VN*ZM\396:9&U85S$4CHG]UQ#J_3Z%<O\`
MD_\`)PGY*<YDN".1HAC+4I8USD9QQMUA(45!N-L&%QKGJM(%DH2Y#*[`=SBC
M<UKI=K(KX+^[T'ZUL8]T93\:/'I'U+7^3^59[QH;J(\?3<#DD-J*#*QVT0_0
M(!MWMKF(B.AMSQ-T]1XVK#.VW8_U=?*LCXZU(!U$>3_"JWKOY,ON_P!KRD7^
M=R>+]-C3I;+27,SN$C)3@IYY$=*&\?@,1E%%Q/=<!QQI)']:YK(;MEU0E[0T
M`5Q53N5J-+6DDDT^E5_09X3T:'Q#PEQ)Q3CWU/P.-^--(T>&\H!M3T;5M:QN
M%9=+8Z(+B8?<0+6)K7C`#I6S`IFKV7([UV)_$'H#^RJU'`A5J`5A?W)9$0>$
M]K7WA*G/Y:R+D"Y.2C.D7)`'RLFK7>Z0CL,00OYVW/\`MBY_).^;"\ZH)FY.
M1F%OJ;3*4TB5';GE09=7V/\`IMN]$*4$JM:]9P9H:3I[@%/-Q6*7ZB`TXJR>
M$>779>UXC3-DQ,K9=<>D..8[*P,/$G;-K#<AD+,N,MB3-EHP;<]*')>.]9:3
M&2XY&2Q(<6'L`M8]S'.%)!D:GT](ZB#TC%3U+6D5P71;B:%`P.VY#.*C-M.R
M(W8$)+3RD/%2.Y@*8<=9<(4D@%"U(4!<$CK62]S)&46/II+5OND+#/O!R2YV
M.F,3EICLY2(J-&8C^'J>JHH$I;:%NJZJ![$7!M8]WA6*YH`:`:XU4S>GBNGW
M#6%U[(:WE,WJ\UK)X3-9]Z!!FLQ'HJ78^A8G$<7-M>E(88=[8Z=&[+]H2?%)
M(()^??F;*R[YJO6M.$<4;!^J'?YR_6#^Z);':ODQLLQC#7W=U<S$\320PU_^
M5TK63W<;I)T[7.0<%!<92[M6)A:W.2>XJ&+9S&IRY+;?8E2>[ZV*+W(``5YB
MQL^74;H+C<I:8&)L?G<YQ]#0N`_OJ[U'<;-R5LXD!)O+BX-,R&00Q-\SI9!V
MUXU7J`_N\BN[\N#6S_\`W<Y5'3PZ92#\;5[GMPI:M[2OSHFIK-%W(K/4241*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(O_7W4X]D['DL-%=
MW'$,8O8HZUL3&82U&/<!*@["DH>=NRXDCN[7%)[@1Y6K7%VF@8<"I&`NU5%'
M*J\K;L.*>,-QY(G:JYOT#3<.G.9/`B='Q$Z1K\*4VUL3T'(&!,91+AXF6N2E
M"VO3>^G"%%-^].?`28FN:]S'-=6K30T&-,<QCB%=;7$=M-*9+2*:-\;FTD!(
M&H$:FT(H\9M/`].2U6/YB'Y;R\!(V/-*Y=FYB7!<D,\=0])MD)$QV/VJQ4G*
M/9:-J2&6EJ(4Z7G4K02>U9`16_CWB9K"PS!P[#7R@BGIHM5+M>W/>)!'(U_0
M"*>0TJN3.Z?G$\^0=VU^1[=M2TCV_<3:>VJ%B.(,?C8&W8?,PU.MK=_M;D,A
MC<8E4EY+00DX*+@4LM]$)[^YQ6HN'-N'ESH@!YO519K6AH`;[HZ<?2<2ND?M
MT_/+X5W3,XB-[E^,?]U>R16DQXW).J(E;?K"'76RS(,G')QZMRUN!(^H<_A-
MJRZ$@W6L>(QS%@2T^3\JN7</B[FCBGFS7XVW<2<@ZMR%KSRU1UY#6,Q%R'T<
ME2%.F)E(K:Q-Q4Y*&KEB4TR\D$$I`-6:'"I(5.E951VI/R+6TL^:"!X_O$(6
ME32BKXD7JK74S;4*@#B:`J8DQ(N4C_297%X[-Q"XA9C2X[#Z$K:)6TXF/,2[
M'6XTL`A14D@]1U%2-TZL'$*QSB[,!70UDV5K2TXLM/KZI:>2IE2R+=WIAP`/
M=I/4H*D_;64&D`4Q'G5F!.>*^\BS$R$3Z3(,1YL)]08D1);+<B+*CRDKBOL2
M&'4K:?8>9D*2I"@4J2;$$5(UNIKA0$$8J)]12AQ5F\4_R'VM/[A@>"?;AADX
M3D"9B]LS<71Y6I:'K[.SQA/QTZ<O%2U0H*\C-QZ(B5EE+*>UI)^97>4\YN)W
MJSW%[]IVF*XBDA8"YTWA!KFND-*:7$U#QB*+IMM?L\^WQQ;GN4D,S)GD-;$9
M-37-C%:ZF@4+3GB5E/9/<W[BL?K\K+:IP/KN<RS:4_1:GD-YP<'*9%U7_H[&
M0=RN-P*'^T$V<F-)-OWOC`)N<Y@?ZGM\)ZWR2>IK%DN_LFS*ZOI17[+(V5\Y
M=ZJKA!^8W^:][L6^'N0.$N3?9)MG%K&^P8L'$;9L3>+RVJLY;$YC'9_%3L=,
M5`W#6-J=Q>4Q;+OT[$U9)`!4DD&I;23FFWO[*ZN=QLV,BD:_2V!QKI<",9)'
M-S`QTE6&[V"**0V-A<_%4.ETDK2`3Q+`P##H]*\\6V>]SDGD&!$Q6^X]A+^.
MCB&U(P`.*C-!*4AUU6O.I7'$N6IM)>6V^QWKNLI)Z5[=9?-3<X+.2VDV^$RO
MSD:7!Q[:EP\U!P`"C;O=QX0A<T4'$8>?/V+(V#][.?9T1W4=DVEO,0\<S"9U
MK,F#F<5O>&8CS8$E&/.6AM2<9-Q"%PVR\V^XMY;+7:EVX;"<>+GU\EC>V]^S
M6Z1K@TBH=WL,2`06](P)%14U5K]R;);W,;S4N813(X]>2V#QG"6.DY3#<V<5
MJPD#8IV(?D9#!2P^K2MU8SD?UGYT>1`>^KU7*.>HEYEV&%1%/-MGTFTEXNZ+
M:;RYV:_BW7:Y-$PX5P(J#3LJ!YEP%T8[R)UC>,U1D^49BO7ZUZ9_8SG<C.]J
M'%+V9P;VK9%A&Y19&O/Y5K./8H1.0-K9CL+S#"E-9%*XB&W$NI)"T+!N:T?,
M.Y3;OO%YN5P*2RZ2<LPT`G``8TK@%LMN@BM+*"WA-8F@T[*D\<<,L5NMIV=:
MAYW#RBL!$?*07G.MK);DMK7]ENT&M.#0C!9QQQXKCKR#A7=(Y6Y!U1U1O@-T
MV/%(44E(>CQ<M*;C/A))LB1&2AQ/V*KJX':X8W`UJ%R]R/#N913[1].*NK7,
ML6U(*5=0!<>=C:]_$=360PU%"L=X`."RJQL@#%^\!5K$7)/R_AY5D1"N!SJJ
M5`%5?W#T61NO*FGXE`4XS'RT;)S$WNV(>-<3+=4XE1%TEQM""//NJ/<)1#9S
M/KB6T"EL(O&O8FTJ!BNQK\P"R2KM';V]M^@%[6'P`'2N*,A.#1@NS]VNHX54
MLW(22`#TO;X`GX_;48)'%5(:>VBU4]\VPMX/V[;++>["P'EO/I78H7'A8?,3
MW@M)OW(#<4DCX5EQ]^2$4P+AZQ502DB-],Z+^>1RY*:D;!FXTMWTU9-Z-C4V
M3?YGL6T'$"P`!0PVKKT'2MC</:V$AIH2L6$$N!I@,5;V!R4;5&,>G#);BNQ7
M`X9#:$I>>64%"BXM(*E!238WZ6K4-(KW@LEQ<<J46VNJ<QOM0FI@#1])*0LK
M4HJ*Q92R/#L/PZ5,R,%I(=FK'$C2&BI7SR[LV,W#`,S$28\ER,RU.5&]1)?:
M4W9Q8#9^8]OG8>'V5C5<U^DC!9#6ZFZJ"OI707VK<G9#4.+./=<EZXU,8:QL
MB<IYN<J!(^JSD^?G)C[ZG&)[<E;V1R*KCM9[4G^L18^?;WR/:[MN5UN9OI63
M2$$@M:]N#0!Q::8#B5]E?+'^\3N7)7)NQ<JNY8M[C;[5C@'-E?%)1\CI'$U;
M(TNU/)P#0?2M)/>/RW@-JPC&TQ@J"B;L)AIAS+&6\_DY>V9D,L!A*UJC);AQ
MFO5*$#N^`L3C\M<NS[=>W5K)*QQ<->H5``:UC*99DN<>Q>?_`#Z^9-E\P;_8
MKG;[6:&&UM7QN;(6D^))<S2$@MS&@1"IH:@BE`"?9I_=Z(#L+\M;0WG9^$GC
M,<A<A9QI>#SF,SC<5G*2\=(3C\FO&2)`QF<@$EJ7!?\`3DQ7DE+B!T)]%@A,
M$8C)KBOG;5KQ7<"ID2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1%__T)#BG\P366,U%T3W&:;G.$MY;2VQ,G9*!/&IR)`"P9"TRD?SK"1I
M3B1Z16B7&2DW5*[1W5@B(.!+'5'0I`\"HR=TKI:W$U3E[CS.XG'9G%;!J^^Z
MILFL?S;#9&)E,7+QNP8B7CI:X\R"Z_'>3VJ\4J-C]O2LBW_UD;L#0?5]2@<"
M"%XV=KU^9K61RF(R:6OKM;SDO&3C'=2\P9&,G.P)@8=2"AQDN-JLH=%#KX55
MCB'@<:*M.[5:]YB*8>4GQO\`UF4^W]ED.$`CH.EJR*JHR54TEQYK<]0=CK::
M?;VC7W&'7D!QEIY&6B*;<=02D+;;6`5"XN!:]4-1GDBZW\*>X+.\,\Y,<MN:
MUI#F[PYF4=7DX.!QVI&2QFL?(Q$V')8UF/C<3DH3\"4H>E+8<(=`=;=:>`='
M9[-N^S2V;-LWO889[0`TDB_!N6U.?B-[LE.`E:X<*@+17UG?^(;G;]Q?%-^:
M[\2)U.!82"VO2QS3Q-5Z*^`_?CQUS`QCH>7B/:QGWHJG)3!)?;26&0X_+_EZ
M5.ST8Y1-_5C'(QV4F[SZ`"1G7'(EO?PON^4MX9=-&/P\@$=RT=&FI9)3*K2V
MI]UIR6(S?Y;5XAWJP=#_`$K#KA/67`!T=3P<V@_.6]N-RD.?%8G8Z9%GP9*`
M]&F0Y+,J+):-[.L2&5K9>0;>*217`7%M/:S/M[B%\=PPT<UX+7-/000"#VKH
M62QS,;-%(UT;A4%I!!'2"*@CL5C\H[;OFOQL-+T[74;)%+TI.=A?0N9)WT0A
M@Q.R)$<3/45J]3YFDK"2!W"UKVQ/+.*H\&F`Q4MQ[RC&WB)FDM8J?K64P!Q\
MG(XQZ3]3%2AV0E*RW&ELMO0TM^D3Z80U8GJ3UK90R"4T/N^G)8[L`2!BL_L.
M2V>TN-(?Z`%<8A"B2>JOIWE_*E(\@XM7P%4_#>!I-.WZ_P#`JECAGZ%!VG`H
MW/"LXEB;CXDN/D(N3CHR^+7E(3SD5+J2U/Q"IF+E2(KK;ZNJ'F5)5VJ"C:QC
MTEN+F]WZ="O;4C36A5LX[#\C8_)X+`RM:Q>2T[+9/Z+;8L787MGU->#D?(M"
M]9WMB5GL0IOLNI,>?/CK!`[$];Q/#:BBD;J;0')8/YM_*+]AW/SL[(YGB5OC
M[8L@2IW/\33_`.Q:T.7:/J-ZZB--TEM:_3^=:<6'%E:B5]Q[JQW6\9)+"6D]
M!]F2F$CAT$+C/SU_=O\`>,=!RV2X`Y@PFVM,I?E0M>W&(]K>:>:0VI3>-8D-
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M"'DHW>I4>2D*^*D+`[FU+00HX<D9C=I=FLECVR"K<EK+[OL:_!Y;B;VEL?RO
MDS`8S+I>;(+8SV%BQ<!LK!%R4ON38")2@?ZLQ/D16\V^8&$,IBTK2[G$?$;)
M^</5188Q.5](H-_)-NMC:P/A6Q#LBM::D$E76K/A*.BO'RO;X6\_+KX5()"#
M6JL+!TKH+['=:<=&S\DS$A+1MK&%*TD%SM+$W+2$%5DK;[@PVDB]EH6+BQ%:
M?>+DO$-OF<SZ0%N]I@T^)<G+(>WV+?J1E2LD%8Z$CIYV^SJ*T0:MP92<`,%^
MQL@"H75U^^UC?S'6_2A;T*K9<>]DN=/YL.\C6/:MEB%D*RKDS%A*5)[B<Q%3
MK94+VOZ+6=4L@>2;UD6E?%:3BT5]14=U4QD--"?K"\#7+>:4_P`B2HZ39./?
M+[A'A]3*CLI2+7-O2CI38_\`+-3W#]6EE,@K(6D-+NE6V<HI30LKS'6]C]M8
M5**7J5YZ]EI"E-0V75`25(;*1UZJ-N@ZBYJ6$G4!7!62"K2>(7237?:/%V?C
MR'LW\X09JX[;S\9*5MK`+*7%(4A*DI5?NL3YUG.@.@N<W!0QRDO:T9+-F.E-
MZIK8C!:4?R;&%IHFZ?3^F95VVN%V/R_J\*T4P(*]#V]_X,7>R`7*CGR2J3J7
M'L5V86$041LJ(AC+=_F$^7'0T$+E(6&HZH#,9Q1"P2KU.@\;8VW0@W5_<?:J
M&CTD^Q<_NMP97L9P./H^LE>[O^[5N>I^6%JZK6OS-R]T_P#RMC[_`*ZVI6I7
M?BJ(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+__1]$O)
M'Y*.D\MXLXCD';]0V>(E"T1W,CH4G^8P"X05KQF6C[$QE<6ZKM%UQWFE'S-N
ME8K;=S2"),E(7@BFG!:`YC^[1<F:_$V37^$??WM7'>E[5!FQ,GK$G4-B>3>8
MRME8>EZYR#KD;)1RVX4=KT0.^F.U;CG<HU.UK@,7*+CG@L)P?[J5R#&PD?$R
M/>EITA;,;Z8R!PGFT@A-TM*"%<D+4"A`'GU(JFCOZP>**ULQ_=)M_P`I/?FI
M][&EL%]+/>W_`+C\XH>HAEMMUR_^\L?Z5Q)5;RO4H*44G`_NCW(D#(0)[?O?
MTLJ@S(LM*?\`<;G/F5&?0\$@_P"\WY;]GC5:^956=ME_NP&^9Z:F:S[PM4AK
M";+_`/@/9EPJ/0WNGD)NPO?IUJD9='D59IZU>_&W]W*YPXURL2?C_>?I.4B1
M74O#$Y/AG9#%]1-NV1$D1.38V0Q&0:`NU*AO1Y#2@"%VN#L[7=9[1[9(W.#A
MD02".PYA026K)6EKZ%IS%*BBW/Q/Y/W.N*;2F/[OFX3L19=QLK%Z;L..?2IY
M:G9)R3,+=8N*GR5N$`OHBL*D('^L)><)=/INV?,_;OA9+?F;E.WW&0M#?$<(
M_$<!P>YT;B:<""VG"BXZ]Y/NO&CEV;>I;1H))8TNT5/%K0X`8XD4(/0MQ-"]
MC/)6'P<>!O?,.L[1F(@2R,YB=&GX160CH;2A+F0@.;).CIR"BDEQQ@MM+)^5
MI%NOFV]W&S75])<;%8S6UF['PI'B32:Y,<&M.GH#@7"F+BNKL(;^*W9'N%RR
M6X'VVM+:]9:2<>FA`/0%=TGV12WVI_9O6*;E3H;D-<L:P[ZQ04+#(6X,NEQ;
M;+BNX)*K=.EJUD,@B>'$564Z,N8YN%2KE3[1,DFW_7J$2.H(P#X__6I\ZJ)!
MT%5+">A1U^TW*>B4IW3%O.@@MB5K\A;(ZV5>V5*A\A-B/.J^,1[I(">'^<`2
MJM']KF2C'N9WEE-PGN9=PS\ED$$E2@I>41(N0;?OA/3P\:J9FDU,?FP5HB<!
M0/5P1O;UD64I"]LB*4!8]N(>";^!(!R)(O\`JJ,R&M1DKPPTQ.*K*.#9B4*0
MK9HZ@I)3_P"TMP6N+>/U_P!M6M=I=J'2JD.(IJ7Y"X'[,'$P>2S4#*16<;%Q
MTEF3AO6BS$,1T,+]:,_,=;6V[V7[5=PJKGZBZK003Q5S1I:UO0%I7SS^3G[-
M?<1!DL;KQEJF(R<A16-@TO`0]<R3#JA9;S<1OZG7GWEFQ*GX+RNY(-[UBOMH
M'8Q@QNZ6'3Z,O.%>'NH`:$=>*TLX[_(>VKV^[BUFO;Q[P,]@-/"$M.<?;]HT
MC;,2F.V^VXW&:EL;A`=9;4TWV>FPW&AH)*TQN_M4BYGQ+#I?*)(>AP[P_P`8
M?4K',C=4ANE_5EYORK=#D7\MC-\FZ+C==SO*^'B;!A,B,KA\U!U"8[!BR9*$
M1LS%^AD[`9(QV7CLM+4A+Z5H>C,DJ6$J"LNWF,#R:5:L:XMA.P-)[PXK`F&_
M)^WZ)%;;RW/^JRY:$MA<G'<<YB#'=5Z:/4[8<K=,BZPE+O<$W?<)2`38FPSQ
MN5/]6?.L"3:BXG3-1O9^55L?E%[5:RN=<(?#_P!X2?Y>?_T3^-7C=12G@GS_
M`)%'_!W?_D#S?E6^VA>TQ/'NF8#3,-M,7Z/"06V%R%8=U#D^<LE[(9)](R)"
M7Y\Q:W%"Y">ZPZ`5JI7NED?([,GS+:PVXBC;&#@`KE5[=\DHW_M;$_\`S.]^
M%S_,?&HZ=:FTA1FO;YDFS?\`M9%/7RQ+P\^H).0)ZTIUJA8"M/\`WO\`Y;VS
M>[CC3$\>XOE_$:,(.81D9,^?I\W.MR6$%AQ,=,:/L.+4A8>C)5W%9^ZI87B(
MEQ;4D*Q\;GM#=>%5P6V/^ZB<D;%L>9V%SWI:+#7EI[\P0X_".QK9BMK59F.V
MN3R@^\M++24INI1)MY#H#GZB25(UNEH;T*21_=-^1$@#_P!6QIEA\.$<Y_3R
M55A-:X*M%=6N_P!U7WW"Y&)-?]Y>G2T1GD.EE/"V::[^Q7=VE2N1E@"X^%58
M0TUI56.82*`KI'J7Y)6R:QJ3>L_[_-:DN(C"/]<CCK(MWLVEON])6W+/@G_*
M\ZR_C"6Z2VH4#+700=7%8=V_^[_;UL>-RT*%[H]9QSV1C26&WU<5Y1Y+"WF5
M-H<4VC>&N_L*K]"F]8$C=;R_*JZ"'<O"B\/PR32F?Y%JQOW]USY&W2!A\8W[
MQM)@1<1*DR6W'.%<Y(E.A^+$CM,*<'([80S&4RZM(`M=XU%:P_#LE!=J<]Y<
M3Z@M?-)XT@?IH`*+T!_E?^QW*_EZ>U3$^W#,\B8_E&;C-VW+;5;7C-<DZM%>
M;VJ9'E-P1B967SCJ%P@Q8K]<A=^B16034U42Z'U1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41?_2]=9Y(WWI_P!;<W]O^N*%^OV(KV9F
MQ[/G_#HO,OGX<R;]3'=)OUBOS_>1OM__`*+LV!?Q^K4>E_'J*N_@>SXG^&Q>
M95_M)OO_`)2;]8J"ODO?P01MV;\Q;ZKIY?!`ZU5FP[.[43MT7F_*J-YDW[_R
MTWG'U+\')N__`/OVYKP)_P#.SY`G_)JAV+:!7_IT7F5YYBWW_P`K-^L5"5R;
MR`/_`'K\WU)_]+/_`,35(]CV=Q-=MB\RL9S)OV/_`%6;S_6OC_>?R#_[]^;'
M_P`]F_Z;5+_`=G_\;#YORJ_^TF_?^5E\_P"10%\H<AA02-QSOA?_`,[_``\D
M"K7;#LPRVV+S*P\R;\/_`':;S_D4HOE+D47(W+/?_AA^/^;5[=@V8D#^&Q9=
M"I_:3?O_`"LWZREG.5>1A:VYY\$D^$Y0\B?\FKF<O[*2?^FQ>95;S'OIK_U6
M;]90E<K<D#MMN>P6(/\`Z<KIUM>]NM2?V>V6M/X9#YORJO\`:/?=-?XM-GTJ
M7<Y8Y+2%6W78+CP/UI_#^KYT_L]L@K_TV+S?E0<R;\:4W6;]8?4H#G+7)B4@
M_P!MMAO?P^N5U\/@G[:I_9_91_[9#YORJYO,>^G#^*S>?ZU*+Y?Y.!%MWV`7
M\1]<HV^W]WQM5?X!LO';(?,JGF/??_*S?K?D4NKF#E"RK;UL72__`*<KR/\`
MFB@Y?V3/^&1>;\JM/,>_5_[M-YQ]2DWN8^4PW=.^[&"3T'UQOT*@>O9]E7MY
M>V0FG\+A\WY4;S'OI(/\6F\_Y%)JYFY6[@!O^RCRZ3CU\K_N5-_9W8C_`.U0
M?JGZU=_:+?JN_P"JS4[?R*47S3RR/#D'9NA_^;__`(S[:J.7=B(_[3!G^:?K
M5IYCWVG_`'6;SCZE+.<U\M`].0MG'_S^>O7K_4MY5?\`V<V'`_PF'S?E3^T>
M^U_[K-^M^12QYNY<N;<A[/:YM_S@>H_[RK7<O;%6@VB']57?VAWXX_Q:;SJ6
M<YPY?'=_\$;:?E'@,A:_R]/_`"9MU-2?V<V'_P`3!^K^54_M%OI'_=IO/^12
M:N<^8A?_`."/M71(/_M05XD$V_<O>G]G-AK3^$P^;\J?VCWW&NZS>=23O._,
MB4A7^\G:P2>O_.*O"QO_`%#\*N;RUL!/_:8<OS49S%OI..ZS4^\I!?/G,P1\
MO)FV7[P+?S)5_*_7L^-2_P!FM@!QVB']4*3^T&^?^4GI][\B@N\^\TA?:.3-
ML`[1<_S)7C_WOPJX<L[!I).T09_FJP<P[Y0G^*3?K%2BO<!S6!_\,_;@;]/^
M<U=?'_D5>>6.7@*_PB#]4*[^T.^@?]UFK]Y05>X'FWMZ<H;>"+?^W,__`'NH
MQRUL%?\`M$'ZJC_M'OM0/XM-Y_R*67[@^<!X<H[>/`?^U)7_`,1]E2#ECE[_
M`,1#^J$_M'OP%/XK-YU)J]P_.0('^]/<>M__`&YFW2_EZ=5'+'+Y_P#9X/U5
M:[F3?JD?Q6;SJ6=]Q/.B0HCE7<?'I;)J%A_WGV5>WE?ETG_L\.7YN:M/,>_5
M'_5IOUBI)WW'<[C_`/BMN0Z7Z910^[^I4G]E.7#C_!X:?=5/[2;]_P"4F_6*
MDE^Y'GH%"?\`>QNG4JN?YJH&P%_)O[:D;RIRV6N_Z-#YE<.8]].'\5F_6*[/
M>V;8,WM7!G'^?V+)S,SFLCC\FY/R<]TO2Y:VL_EHS:WG2`5J0PRE(^Q(KP?F
MRUM[+F'<[6UB#+=CF@-&0[C3ZS5>S<M3SW6Q[?/<RE\[FFKCB3WG#'R+.U<Z
MMXE$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+_T_5JH@*'
MW6M\;D']M>],7S(,@:8+Y418VZ?\=7]*K5II0*`OP_&_V^!_QU?'[KE8W@OA
M)`)^Y?\`XIZ5:[)RD4%?B!]BC]G2WZZI$,RK&<5#J97*"OHN_P#R#_XPJCJ4
M&"L<,5(J_=/^'F*N9[V"HI58N+_`D_A8U=%[SOIQ"O;Q[%!6>B.MN@\?/YE7
M_361Q5,:=2E7?$];7*.OP!*;?HJTTQPP56GB%+2?!'V@G\;U:5(SW2>*D%_O
M)_#^BBITJ640D&Y`O<"Y`N2?`7\2:J,E;Q*ITQ]EAM/K.M,@$J_BN(;Z?,2?
MG(Z"_C4T>.K#@JM!JJ2<A!4;IFQ#T/A)9/7J0.B_&K^(H5(:XX*&'&W4J4VM
M+@O<%"@H6Z_`GX5)3`4R49Z.*E7+WZWZ7ZGI]I'X5<*'+)%+6%KW!^%C]HJ@
M`+JG)5KT*57^ZJ_Q/ZU&WZJDI@JA2+G@?B$_K`_QU:<QTT0Y%4R1?TQ?J;_T
MVJ1F9[%6/,JG$?N?\I9/W65Y_HJ8TSZE*34.`4%VW<LWN?'X6^7_`(:N![@5
MG!O0I%=K$V^T?\'QJ]Q[JJ[M4!7[O^'QJ-E*FJC(R4HX?P_XO\=2MRKU*T\.
MU22OWQ]_^.J@U;@K7#O5X54DZ046!ZWZ_H/]-2-S(ZE0YGH5.=/C]EOZ*F&2
MLXJ27^^G[$D_IN#^RI&FC2I&Y%=\/:*;^W/C`_'%Y8__`+RYJOF[G7^:-W^^
MW]AJ]YY3_E[;/N._;<MD*Y9=$E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B+__U/5L2"H`B]K#\2/^&O>FY+YF:TN;4*&KP/W`_K_;5_`J
ME*&B@+%U6_R@+W\/A_14C?=5K,<%\`=3]ROU))JQV2O4)9ZC[!^W_BJL0HW4
MK&C"JAU(KE`</:NY\.P^'WC_`!5:ZN%%:[%22K6Z?`7^^]7L]Y6E2ZCT(^*5
M?LJ^']X>PJ]M:.[%+*`/CU/3[K5-2I<JGW6^7V*4=\#_`)R+_?WIO^NJ'`%5
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MKI2B.KO"5)?"7X_>A(!4`"/A<5)KI6L;LL/I4*PQ@N`#Q6OTX*VN:-MWG7O;
MCR-M>*S,S"[-A,;-DXC+PI,QA^#):2DQWD,";+"E(4`#=Q0L?W:D<YWP-U*'
M%L@82#E2@SS*NB:QUY%&0"TT!'3G5;@</Y+*9KBOCK,9V4J;F<KI&KY+*S7`
M$JESYN%A2)<E01\@4\^XI1">ES^%9-MW[>%Q-7.8TD])H,5@SAK9Y0T4:'$`
M>57XOKW7\1U^SQ(_$6-9.0`4?0I%S^O^/]-6G-#DJ7(/2WP_:2#4S`!57QXA
M2*CT1_G*_1W&_P"VKF\%<_'6I9[Q7;P\_N[!^N]7@4`5,`UH*DG/$@>0'[3_
M`(JD?[H5'<5`7X#[ZC'VOIT*WH/!2CO6Y^%OZ*E;@WR*AQ(/0I%:A>XOTN/Q
M(/\`356`X#J4?`=JD719*+=`KR^/A<_?UJ5OVU0U]*D'/ZQ^T#_#]%3#)1_:
M5/<4?5('DA7ZTDU(T=U2#*B[Y^T3_LY<7_\`1>5_VES5?-W.O\T;O]]O[#5[
MWRI_+^V_==^VY;(URRZ%*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$7__5]6H([C\?U7`Z5[VVM"."^90:!I3YK$@>-ON\?B/&JTP*!U"2
MI1?[WZ*O;[A5&8`%?*38W^Q7_BFJ')79J$OQ_`?X?IJZ/W0K6^Z`H=7JJE'+
M]R[_``-OT`?T5:<U0Y*47X?C50:8JU0CU!`'6Q_3;_XZKX3^(>Q2-%&N/4I4
M_O*_#]%OV]*R`:D]"H<FJ3<3<#QZNH'Z;W_95/:J5H">@*!)OW?<`1]Q)3U_
M15,PKFUP*IZCU/WG]8`JBN6G/OO`7[6^36C>SR=0:)Z6[7]ZUEOS\[K_`$5B
M7KFBWF;C[O\`G`>U9FW5^,@[3^R5@'CKC?!2]:T_9Y#3ARV/<3!B/MN*:"HD
M5I;C3$IH?PYC*7U+(2X%A"B%)[2"3)#"WPHY3G7V5QZ<5D322>))&*:"/I3Z
M>A9^].Z2+$`"UAY(">B1<D6!K(:"YW4L8@!HIG52#S14T0!Y6-P.EK=.M^G6
MJN9H=09*\D:@"<5@KW-'Z7VL<ROBX^GU[(/`!()*@$)"0#TN>XU;.=&VWY.7
MAN]BEM`?C[8<-06V'!A4GA?BCU+]W^[C3@KN%E=W]G\>3<>1ZUD6'_)6A_HV
M_LA8=R`;B8#WM1]:R4X0!U\B/UWK*4*D%VNY]H_5;_'>K>(0Y$*EOVZC[!^W
M_@J=O%5BR*D;W+?C<$G[/Z]_V5<!5I*O<:.(X*7=ZE?XC\;>'ZZO'NM"L`(=
MUJ27XF_C<7_$*/\`35TG`*KN"@+%PFWQ(^SR(JS)KE'CY5).?U_Q_P#&%2?Z
MM`*9YT4BX1VN6\1VC]-OZ#4C1B.A684:.M2;I)*?LO?[#;R^PWJ]AIK5."D'
M.@5]JA_3_CJ4>[@K34N+E37`>]T^12!<$7ZA(J4"@:KVUP7?;VB?]G+B_P#Z
M*RO^TF:KYNYV_FC=_OM_X;%[URI_+VV_==^VY;(5RRZ%*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7__6]6O2Z_#_`(AU^ZUJ][:*+YDK
MW0%\GP^'V^?[;5=TI0BAI@I98-S^W[@`:OJ-#1QHK@.-,%\CJ>GP/[#5KLBB
M@K_>_P"Y'_C*JL7N*UN2^*D55*.?O+ZWZ$_L%OPJTYH[)2B_#Q\[_=TJM#B5
M8H)'C;Q*3T^-^G[15\/[P]BD'N'HHI8WN>G4J`/V6Z5.#WBJ'W05)+'S(\2"
MO_B_15#PQ1HP<>I07Q=?0WLA((^)[UG]AJA&%5>S*A"IJNBE?>?VT"J<RM,?
M?RX$>V#?$=?X^1T2/\IMU7OVM=H^\J2!]U8EZT?#3'H:/VVK+VZINX?+^R51
M..HX9XZUA-NA]9P=UKA2@HFUO/K65%_RL.'TH%60_CR&N2O9+`["1W*!/F1T
M\0;=/,&IV=PT&2B)JH#['R!(!\1T\?#K]_C4CJ%K@/>1I`=J)X+7CW3-$>UC
MFD*3?MUG+.@'Y>XMH0KM/Q%TUAW9_P"F7H_HS[%E6A'QUL0?M!;9\.)[>(^,
MTCJ!Q]J`MX_^\]CON\#TK,LP!9VP_HV^H+$G(%Q,*_:./E60'/`"UQ?K^'A6
M2H537K]+=+GKY=!Y?;5HS*M?P5.D>)\OE%_^^J9ONJ2+(JGB_<D?$']A_;_3
M4HIIIV>WZ>17OII=TJ`K]YS_`#U6^[I5V%1V*RN+:J17<*/EX?X?KH_/)4<>
MA05'J/N_7<_KJP<.BJH,L%)/7Z_"]OUFI7$`&JM<#@1P"DG"+.?84#_PA?\`
M14C:>A1CA7#!2;Q-Q<6-@?AX_P#%5[:8D#,H?=5.<\[^-ZE.`*L&95-=(`=^
MTV_\,_L%3#,?3@IN#5WY]HO_`&<^+_\`HK*?[1YFOFSG;^:-V^^W_AL7N_*G
M\O[;]UW[;EL?7++HDHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41?_7]6A\3^/A7OHZE\QKY5^Z?P_;3I503@*X*65_7%[BY%OO\?,^-5(]
MSL5X]T]J_!T/3X']AH[)44!?[Y^Y/^'Z:K%[JH/="^:D12B_WG/N5_1_2*H4
M=D%*+\!]]*FA"L4%72UO&Q_1U/Z*OA]]RO!HPJ55<J)!M\Q-OQ\*F&9`Z?J2
ME&`=:DUGYFA_RB?V4I]/.KV4TO[%`=OZA-^EAT_#I5*>\50&C0J>OX_$$D_'
MYB/Z*K2E%4G-:6^_9LK]MFTH\2[LW&S8_P"ZY#UHG]0-8MX*VUP!^:/VVK+V
M\@74)/Z7[)431V.W0M:2JU@AX`?`_/<VZ=+=*S(12TBJ.GUJDQ'BR$8%74&[
M(/;Y'I]I)^[XUE-8`!7-0YC-2[B.AN+&Q(N+=;&J.:!5U<57H"UY]UW\/VK<
MXK\"G3\VH>/[Q;18]!:X[JP;W#;+YPS\-RS;$-^-MO\`>-6U/$MAQ1QK;H#H
M&G_[/XX']?6LRRK\':U_V;?4%@W`_K,X'Y[OVBKX7>P'=<W\?AX5D]*L5/>\
MK]2%>/P-6MS*M=P5+D&RE?\`<_H";_MJ=ONCM4L=**43U6G[$G]/054DZC3)
M5?@S'B5*J/B3\3>WQO8_KJ7#4`.A6NQ<`%)N&Y'W#]0M^'451^85IZ**77T_
M1_2:MJ,`>E,=)IFI)T]/Q'Z:D?[JH2"'!22[6/FE2P#]YZ_T5=2C0HZUQ&2D
M%GYU7-PFP'V``_LK(:!1F"M-:9J26;V_74F:M!JJ4[^Z?,E0_8HG]9J4UPZ%
M-7W0N_GM&_[.?&'_`$5E!^C8\R*^;.=OYHW?[[?V&KW?E+^7=L^Z[]MRV/KE
MET241*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(O_]#U:GH3
M]Y\?O_17O@X+YD&FAKFOPW(/G?[>O3PJJH,%**!"C?S-_P!/A5YIW:C(*\5`
MHOSIY?`W_0:L.10*`H64K[;?L_X:OC'<!5!D%\U>BDU$%3A'AVFWZJM.:H3A
M@I19ZV^X_J_Q4*M4%?B/P'ZKU?%74\#,@*\^Z%+`$%5^A[C^U7^.IXR#J(/$
MJYYKZ/4I%?\`I4#SZ?M5?]=4.;49D_L4)PCU"#?Q3^BP/]-":5Z%48L!XJ0<
M!""1X"P_#N4:KAAV)2M?IP6F?OJ;+O`&4:`)]3<^-`0/@-\P2NH^'2L:[_Y>
M<=(;^T%E6'_,QD=#OV2JMI['IZ3KGRJ"3%5^D@DGQ\S67!A:Q`GI]:LF'B2O
MH<*JO]EB#TZGJ+>/0_;XU(UQ)SP32`,%*OI!!-R>IZ'QL:D9WM6*.Z."UU]V
M22CVK<X@`D_V-S2K`_%E!MU\^V]8NX`-VR_`S\)WLJLJP/\`6K0<?%'Y%M#Q
M0.WBCC46_P#>"T_[[JU[&GK_`-]619'^IV@_HV^I8EP?ZU.1^>[UDJ]U#M[0
M?,FWZ!65QH%$I!ZX4?@5G^@508G!6.KQR5,DWNKX6/Z>VI@>Z!UJ]N0[5(I-
ME?<D_M'^*J#-2RX]U2ZOW%'XV_\`&34S35ZLI1RDE^(^ZJ/*M-2?*H#A_9;]
M)/\`CH-/=Z:H*XJ26>H^^_X#I_35\@J`.*C(J7`*2<Z)`\O5^SQ`/]-25&`5
MI!`HI!WQ</EU_24V_HJ9N31Q2H!!4BYX?@:E'!6#.JI#@5VW\B?Z.[]E3'\U
M2U\R[_\`M&M_ZG3C&W_N,RW^TN:KYKYV_FG=_OM_8:O>.4_Y=VS[A_;<MCZY
M5=$E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+_]'U;="2
M#Y7M]_Z_*O?1D%\Q@8@#-?*KVMY?L!!/3[ZJ,"E,:%2:K7Z>'_#502ZI.:D(
M`.&2)\3_`)JO_%-6N]TJB@K-R?LZ?H`'[:DC]QH5!D%\5<BDG"`MS[>X`?:+
M?=\*LS=14=D%*.6N/C53Z5;P4-76_P!O3\"@C]M218N<5>?=:I8FY)^/7]-2
M19*KLU(J'\9%_@?TCN/ZJ?;'8@P::*"Z5!9Z#MZ=?^Y'V_$54T."N%=&"D%&
M[:K^'</T_P#%>@Z>I5&3AU+3OWOH*^"I3:>I=WGC1%C?J5;QA.G3PZ)-8UV=
M,,AIAW?V@LBR($[#7$:OV2J_JJ2G4-=21;MBK2?LL"CI^":RX0?`AKT>NJM<
M:R2AQS5:4FR`1Y^7W@]?'X"LONC"B`G$*66D%"AX=/`=#^RPZU4``5!5"37$
M+73W;)/_`*E;G&R>@TK-`7\?]`+>?V&L'<G?U"_`&/A'\JR;(`7MH*XF1OKH
MMF>+$^GQ?QPWYC1-0!^_^SN.)'ZJR[1NFUML<?#;^R%C7`<;B<D?;=^T5>3I
M4$@GH;G]GWU/EBHE(N7/4^2KC]8Z_IJC30E6NQHJ;(/4V_RA^RW[:G'N`]*E
MC!`':I`="N_D@_J-_P"B@I08]ZOH5S\2%(K>0E)2;W-NG]:U[W`%R?#RJZI:
M\G2:*TYJ5=<2FQ)\NGZ+^%'&M:*T8X]:E2\E25$"W3PM]]4K0@A-0&%5*.+!
M[K>!2+'XWL1:I0=3HS3"JCJ`74S*DUD_(GRN#?SZ#_&:EH*$UQ5IQ<ZN>"DG
M3^__`)RC_P"$?\53#['9]2.X]BI[O[JO\P_TU)Q^G2HQDJ83="4GI\Q(/E8]
MJ!X?C4I4HZ>I=_?:+_V<^,/^C,M_M+FJ^;.=<>:-W/Z;?V&KWCE/^7ML^X?V
MW+9"N671)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB__2
M]6OF;?:?#Q\Z]\'!?,:_%=03YV\/@/#]0JYN)"=:DK'ITJH%*GK4AX=B_1T/
MA>P5T/W&J')44L?$CI^\J_\`WQJ]GNC!42KD4BX+J<L3^\3?["H?XZH,^M4.
M0P4JX.HZ_A^%4/I5%"5XBWQ_3<?XS4D5-3L5=]D*7\S\1;I^%20Y%5=FI`F[
M]O(>'_>^'Z3>GVDKW`**`[?U#UZ&_3R\Z',JX#N@J15;L6/^6.GV=:J."?G=
MBU']YZ2YPTE%@0K?^-1U_P#ISQ:A^M%8]Y^Y->)'H-?8I[/][7J=^R5<6`3V
MZSKZ.T=HB]3?SLI7A;QO69%^Z@%,*(X_BRX8_D4XK_1G[%"WZ+6K+:T'%6Y5
M4(`D$>-[?A8_;;RJ[(*E>E:\^[-*5>U_FUKJ;Z7F"JW3H6DIM;PMU-8.XM'\
M.O3Q\(K+LS_7K&G^T'K6S''+8;X[T)`\$Z9JR1?X)P&.`_4+UDVQ_JML#GH;
MZ@L:?O33$'[1]:NMX7`_$_JJ;@5%T*GN]0G[_P!7C_15!Q5KN"ID@@%1_P"4
M/T_\=3C%@4[?LJFN&RE$_#K\/$C^FC10@JKLZK2O)[YS=F>9.1-'PF<US7]=
MU!C#3L?_`-36\[DY\'+X^+(2Z].F;7CFFEM/NK``CD'ML16O)N'W4S&EH8*?
M9J2".G4/4LK3:LMH9'1DR.<1[Q`P/4T^M5*5(YB["$[[*=>MXITS5VF4CQZ-
M?7+7]EO4-3".ZKI=(?(UH]JM+[;[,`_7=]2M5SDKE[7\OI6.FSL'GVMEWS"Z
M>\F7K/\`*);3>48DRGYP?@;#+;6B%'BK/R-=>G0"YJT2S-\,FAJ\-Q%,^.#J
M8#')&1VTGC4:6EK"<'$Y=1:.S-;>7NI9^WP/4]4@]?&UOA6R`-<\*K6'/K4-
M7[R/\T'](/\`BJ7@4=F5(+\%_?\`MM4_%O0J..!'4I"1^XJW^2/V^%2-]X*U
MO"BIGB4I^'_Q52'@I`:`KO[[0^OMRXO/QQ>5_P!I,U7S9SK_`#1N_P!]O[#5
M[SRI_+VV?<=^VY;(URRZ%*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$7__T_5J1:X^WI_BKWQ?,M`UN.)*^?)7GT/X549A4%,:A2E^O7[O
MCTM;XBK\*$*['"J)ZJ^SK^PU:<D4O_A^FI<L%1?E$4AXE?XW_!8_Q50>\.U4
M=P4LYU4G^D_&_P!PZ6JTYH*4(.:@*N/#XWO^/[1<?HJ^/_6]053[K>E03XGX
MD#]E318@E4=T*03UD6^VQ_[WK3[:N^RI19M?[EG]:ZKQ*OK2HHI-?@?CWCK^
M"O+[*JWL5#D5JE[PDMKXGAH<N`[R'QPA/:+DJ3M,-P"POX=I-8UW7P3VC]H+
M(M*>*T`<'>HJYL0A*->PB1T2EA)`_P`]*E&]^O4UGQM[L0I@&A1DGQ'UXJ.I
M*>P^%^AZW(N2?'K\#4X)`-%52O;UMT_#\/@3>UZD&+>M4XK7WW6-A?MKYF;5
M_P"4TO,B_GT8*@"?C<"L+<:';[T?T;O4LBQJ+NSQR>/6ME]"3V:'I#?^1J.M
M)_[W!P4#](%3VX_J\'W&^H*&6GB3$?G'UJY'"21X@6/0_<>M3=-%$,PI%SK;
MK;Q_H_;5&\5:[@J0_P#-U\+KM^-R*R`.Z.Q3`T:*]"D%I"@X">H_8+&]J,P<
M"<E5V86H^-;[/<IRX5(59W3=%4@]`E83$*4E'4W`+2KUA,K\=,"*`M:5,XUM
MH!^F[SK*;C*`%+(L;]W0$&]O#Q\*V+':GZ1DL=IJ[):^;V/2W?B1M``3_OCP
M2A8'H%:_L2+#[T`7^RL2ZC8U\(9EXS?4?K63;TI.:8^"?6%MT4A-[7)LDJZW
M/0=>IZW(-9GVFT*P'&O#&J@JOW)'P2!]_0U/F#@K79GH4@Y8=P^*B!^!O^RI
MFG@J/XG@J>\;)7\+IZ?]TD?LJ]OO^1&TJ%3+CN%NA`/C]@*JE^GI52#IP-%W
M^]H?_9QXN_Z*RO\`M)FJ^:^=?YHW?[[?V&KWKE3^7ML^Z[]MRV1KEET*41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(O__4]6IM<_C^GYO^
M"O?!DOF-?)\"/.Q!_$$=#>JC!%)G^@?\/ZZJ#6O:K^A?J2`;GX'_``_10HI:
MI51*(I*X'J6\#>WXJ_X:H*:Q14=D%*+_`'OP_P"&K75X9*@IQ4%0L3U^T?C\
M;_=56:FZNL*_"@P4L38_@D"WQ((_HK(A/=5'#%2*3>03_P#)%_M4:9/)[5>1
M1H'4I5SY;D^04.ECXD_XZ`@DT*O(]*DU].I_SOZ/Z:O`H".*C(%"5JO[MDE?
M&F)0>H5R5Q[8?"V?9/X5C76,6GK'K63;4$@^Z5=&/`&"P_:"+QD'J/"YM:WV
M"];&.H$=?S`K#^\EKT+[6V>RY(OTM_X/Z.AJ3@BE0D]QZ&P!\1Y^/[!4K0=(
M"HL!^Z-!=]NO+J?(ZGE+W\_X8_5=-:_<1_4[S_=N65:'^M6O6\+9/2>FF:@G
M_)U;70/N_DT&P'QL*R[<_P!7M_N#U+%D_>RG](^M5]=[@$^-_#X6/V5(58I%
MSR_'^BK!F$.15(=!!`_Y9/[5"LIKJM:1Q"E`%*%22B`7>O4C[_$E(Z?>:#AV
MH<QTK5>$L+]Q/)8*4?PM$TXA?]=7?]5X?YMR/P-8XH;Z6N0:U2.'X$>'VG+)
M<@`(MU(5<^9\1YW^SXUE0C\0^50MS)[5KKOED[SQ(2;_`/P8-=ZW/_N%V%-O
M'Q(-JQK@_NB/]NWU%3V__P!R?Z(K;=:A_$[3UO;])!_\6LS_`%C5@@XU4!Q1
MZ6/[K8MX=%=?\=3"A*M.6`XJG+/0?'J?U6/[:G`Q5I]TTR4@_P#NG[Q^FXM4
MK!4U51[%2E^*C\!T^_P)J_I4GV0.O\J]`/M"_P"SAQ=_T5E?]I,U7S7SK_-&
M[_?;^PU>\<J?R_MOW7?MN6R5<LNA2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1%__5]6AL/#_#KT_5:O?!PZ5\R.:6G%?*N@-_O_`=3^RJ
M]2#-2JB">GP'ZNE5:*#%7="_*JBEZD&05$_P_11%("_S$??^)4#^BJ#!P5'8
M@!0'/(^?_`?\=4X*E2I99N2?.YL.O7P/_P!;5Q<6U`&:N`J`I<CN/7RZ]/CY
M_&I815J.5/3_`*97^>O^FJ_:\ZD?EY`I1S]P_C_XZ:-S/:KF>\%+*Z?C<C]'
M3]=7#CV*PY'HJM7_`'5G_P"![A1VE??R7Q^A(N+)7_.T+"R"0"`E-0W(K&">
MD+(MA62GZ)5TPT@8;$I))(C!7@`"%*-U>-A<^59[<1&:8:5&2#(X@8KX7U[;
M`#M-[#\1\?BJKU52[EP"!XD6-_B`!]E2M&`JJ+`7N@!3[=^67E_N(U3)W\3U
M]'N/0?96!N(/PE^:8&(K*MGM-W:#CK'M6Q^E`_V,U"__`+Z^O&PM8?\`,\+X
M=/&LJW-;>'[H]2QIA2:3M5?<-B+_`&7_`!!5^TU*>/8HNA2#I/AY6O1F85#6
MHZ%2G;?+^G_P:R!]E3C(=BI;RR.\`7L0?P4;#[+WJM>@Y!5?B6CJ6K4$*_\`
M5%<F)%KIT#3"KKX=_P!<FWV]36)%A>7/3I;[5>__`):$]+G+)T@I`2"?%)/3
MX``CR\ZS(JU'2"H(C@:YK7;?R?[<<3D>!YAU?]>-SI'_`(U8TX(:T?T[?45D
M0U(NB/\`9'UA;;%/:'`3UN3^!`K+!K(WL6*34@=`4FZ+=P'^2/UH_P""LAF+
M@HG#NCIJI)SR'P_I`M4K:U->E1OR!5.D^`_SZE9FKFJGJ%PL_8/Q^8#]HJ^E
M:*2I&E=__:$+>W'B_P#Z*RO^TN:KYKYV_FG=_OM_8:O>.5,>7]M/Z+OVW+9*
MN670I1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB__6]6O3
MX]?A;P^'F*]]R"^9"234KX6;)(^*>MQX7'V^!ZU2IS0`>52E7JY?*B$I)\_`
M"WC?IT^ZK2:X!%!J947PI5@JXL`#U_5?PJM,,T4F#T/X?M%6-.(5'<%+N7N!
M]E_UV_HIU*U2RNO=;K8^7X_T51V)%%(,O,H%[$BWE^B]Q<_=61#E1''O*G-V
M]3QOU423_FDG\*8ZL5<[(FBEG/W?O5;_`,*].E5;[[5*+\$V\@/_`!A?]52_
M:?Y?6J.R/:M8O=0KMT#7P!W=W*&A?CVY)Q7X=4U!<^[']X>M9%J*R_\`PW*Z
MF6RWB\7?KVQFQ;RZ@KMU)_ROU5GLP9']T?4H<Y7FJ@.7)%@?#R'3Q-7G-7J5
M4DD*))%KV^WQZ"I0:`*BP3[HFRKVY<MMD]P.I991`\^UA/A6)N/_`"-]_NC[
M%D6F%Y;88ZPMC-+M_8[4K?\`OLX#I\+XF(;?A>I+?]Q#]T>I0S_OI?O'UJMO
M=%6^"4C]"14QR40R4B]\1Y)-_P!-_P!E4&8H@5*<M\M_\+BLERF;DJ<]U0;]
M.J>O_??LM51U%6DU-2%JMCUW]RG*()LD:!HX4/(77.5]_0=*Q(C_`%V7[C?:
MIG#^JP=(<_V+)TD=>O\`DG]AZ?8:S8L\^*QV4TE:[[^;;OQ.`+G_`'OZM^D8
MO-$W^ZH+@BC.N=OJ*R;;*<\/!/L6VZSWW/A<]?P162TUU$C%80-'9*6=L/4\
M^H3>W_)\OTU,RNH4"I2A;C@I!S^J?\/`?IJ9IS4+ADJ9)/1`^T_T5*P8'M5X
MZ53W#9)Z]2H?H^:_[*N5^=,%Z`O:'_V<>+_^BLK_`+29JOFSG7^:-W^^W]AJ
M]XY4_E[;?NN_;<MD:Y9="E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B+__U_5BH@#Q^TGP_`5[V`7$#I7S$34X*`I14/O\?MM^FKS0=VO=
M4M!I'2O@E(3<^-S^@?XZLJ7&C5878T"@$E1N?N`'D+>%3-:&CK50*=J_*N12
MKR^[Y1X7O]A`^SQ\:H2JJ"?`?;U_1TJ@&"L<I=2@3<]0/V?"A(%2@Q(4NH^(
M'3K?\03^NU5H-`/2I:98J`3;N4?`I(^%NA\?QK*8W2WK5GV@J<G^L>A'8H7O
MYD']HJ)N9=12O`)`KF5++MVVZ=";6^S^FJY-S5/M!2BO$"WA^L^?[*E=Q*IF
M">DK6/W0I*]#UT6)_P#@G:24C[4S9"O@;BX_&L>XJ1'3\X+*MC24TRT'V*M9
M+-8["X7$/Y)TM-O.8Z"V`V\ONDS2III"BTASTDK4>XN*(0A*256'6L3>M]L]
M@M;>\W&0LA?+'$`&.<2^0D-'=!(U4]XC2T!SCDK[*QGOKF6.W:"0U[LQWM(!
M-`2,1G3'5DH.*S$#.15R\<ZZIEI8:4F3%>AR3W-I?8?#,A"'#&FQ'6WF%I3V
M.-J"DD@WJ3:=]L=YCEEM)"[0\,(TN`!TM>""X-U->Q[7L<!1S2"*C%77UG<[
M=(R&[BTR/-10APH!1P)`'>:\/:13"E.!4<W(7W=/A?I:QO6^S(6)TK"7N71Z
MGM_Y51:_J:GF&[?YS*>HM?R-8FX?\G>#IB=ZJ^Q9%I3XJV/](WUK8/3Q;4M7
M2.G;KN$3;X6QD46_"IK?]Q!]P>I8\HI+)]X^M5EX?-^W]`_Q5*>*L5/=O\W6
MW0W^T>56C,)T=JI;MK#J/NO]E914K<!DJ8[<`BYL5#[O`^'WU5E*5KBA&-"M
M5<>+^Y3E>_2^@Z1^DB8J_AX?TUB1#^N7!`R8SVJ5QI;05.3G^DM64I(N;C_(
M/V_U>M[6K-A^R>M8K/=<%KIOH`W7B4WZGE_63;X#^69T6^/E6+/4B.G_`.0W
MVK+M_=N&_P!$?8MN>EA;^L>OXI'7[NM9;#4//%8E!B>*E'38*OU^<?TGI^`K
M(CK6O"BB`I123GB.M_'\/`U,*8JQV`;Y52I/BG[OZ3^VI&9>57BFGK4@X.@-
M[$D#[/,$U<K@>'!>@+VA&_MQXN/_`+JLK_M)FJ^;.=?YHW?[[?V&KWCE3^7]
MM^Z[]MRV2KEET*41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(O_T/56M76WD/&_0>8-_L%?0+&Z0"<U\Q,XKXOXV\#\:@>\DH7$X<%!6;FP
MM8>/QO\`#\*EC:`-7%5:.)S7S4BN4):[7^XW-4)55*A)5U/@3;X?"P^ZQJW#
M"JM)IEFOAPW*K=+"P^RUOC]E7#&E<U:I4]`35NDN<&A7MZ5+K5UM?X$C[R?U
M=*R=(U,IEZ%=2K2ZF"E9"B$$>'A?\3VFKWUH0%8W$CH4L;):M^ZI9!^/3MMY
M_A5@;0`5Q4I(U'#`!2"[W(!\#<_B;^/V6J["@Q&"M&5>)4LM1^:_E?X>-^MO
MQ%5SQ52,6MJM6_=6\^SH>LF.H)5_O*THK_U*9D'%(]>:>UF)!/U#KQ4.EKCX
MUA7SWQQ"1KW"A&3"_P#R6@N/D!6;8-:^5P=6FD\0/2Z@`\JCS<<_MNNM8N2Z
M_&@*;9$MJ7K^9Q;TMA;3B%QUHRC3*RT^R5H5Z8"QW#M<0>U5<C?V-SS?;7.U
MW<CA:8`M?;RP.<W'6S5*WO,=2CBQ@>T'NN:2TC96]RS8[UEU$PNG+30MDC<6
MXC)T50#E@YQ&=6G$*IX?"L82(N,P$J6\ZVX\Z`I"2W'C,PH<9M"U+4AF#!CH
M9:!)4&T`$GQKI>7>7+7EZUDAA`+GN!.)-`UC8XV5.);%&UL;"ZIT-`)6%?7K
M[^83/;0`8#`XDESC@`*N<XN<0`"2313K@'ID].O=:P%^@-K^?E^NND:22L)8
M;]PZT-\%<GO.6+;.L91U8/@4H:2JQ'F%$6/V&H;^@L[LG_9N]6/H4MKC<VPX
MZV^M9XU!Q+NK:XXD6"\#A5@?`.8R*M('V!*A4D%/!AIEI'J44W[Z7[Q]:K3O
M];[_`.FU2'BHU3G/Z_W&J,]X)]:I3@!(O_DUDGAT*89*0?-T#H;]WZK$?XJM
M8,U5Q!<".A:HP+GW+<J@'_\`A]I'G_6*Y0)_[TUC1?\`/2BAQ:WVJ]V-M!T%
MS_6/:LJ/FP(_Y)'ZA>L^(5RRQ6.P`!:Z\@6&[\4?'_>]JW_A8W.`UBS4T,/'
MQV^HK(MS_P`R#_L3_FK;<V*CV^`/A\/E/^*LF.IJL-IQH.A2;H)2;^:Q^P_X
MZR6''#BK>([%)K!NH_:.GG^Z/\53"E:<58X=T45/E]`D>!`%_OZ@_LJ5@[M5
M5N1*I*Q=(/P)_0;552+T">T&Q]N'%UO#^597_:7-5\V<Z_S1N_WV_L-7N_*G
M\O[;]UW[;ELE7++H4HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41?_1]4Q)N.A`\/+X$^7W5]`R.HTD+YD.17XM5K6\3T/V"U@?&H8V:CJ-
M5:T5[%!'2_4]?+X?=60I*KX6H@=.I/@//[3^'2JJA4'MN4]P\3_BJ-SN'!65
MXK]<(`ZFYO\`X7JT-U"AR3BI)P]`#]_Z+C^FI6C435"I9SP^[K^L5?"`7:E=
MB!U*`L@'KT\!^@6J?KJE26A2KA*K#H"I=U7O:R03Y?$U:<:U04'%2C]K]MK!
M(3^OI^P"AKP."D;2E",U)+(N#Y=O3[C>U4%<%<^@*E%V";$^8)/3I8?A5W6H
MZE:K^[!8&D:LGOCMA/)6F$+DR),9A*E.Y#M]5Z$H2D)Z=?3^8>58.X]VT<XR
M!@J,22T<>+>\/(L_;0XSX`DZ3@`'$^1V!\JN+5%`XYM)EXN3_`C$#'Y#*STH
M(2DJ]1S*++J03X6'<J_4GQK4<LN$DE]HW&*7%AHR::4B@'V9C1G^)Y5E[L'!
M\>JWD;]Z-D>'8P#\JJ[@)\?#KU\!:Y/2NR-2M8%*N`@6'A;J?N-^O7R`JYH&
M9S0K!WN5_P"S[RR1Y:?F;>?C&2*Q-R']1N_]V[U*:U!-W:CAXC?6MA-//_5/
M6`/+7L(/`^6,BU/;_N(:_F-]04,O[Z7HU'UJL.*O<#S)OX_&I'*-2#A[0HGQ
M\_OMT_:*N8`7(!7`JEN=2?NM^O\`Q&IG9X*<=:IKQ)[>@\3\.IZ`_P"'V55M
M/*K23QS6JT&R?<KRC?H3Q]I1'^:IV8H'[[UB15-Y<=):ST8>JJE-1:Q#I<[V
M?6%E"20>XCR%A]O@#^PUL8:C3UU4,>`PZ5KGR#UW?BE7^3S#JOZ1C<R1]OB:
MQ;H_AQ=<S?:LB`]VX:,O"=ZEMV5W4#\;D]#Y7J:("CEA"AQ.84DH@(MU^8GK
MY6M?P\;_`#5E-%7:C@`K&YFF=%*]/F\?$GK^/4?C:IA6BL<*4[%2Y/S*4/@+
M?LM\.GS5,T=U7-]U4UU/P\KW']-#T*\5XKT`^T#_`+-_%O\`T5E?]I<U7S9S
MK_-&[_?;^PU>[\J?R_MOW7?MN6RE<LNA2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1%__2]4A)2FYN?/[1TKZ!<W51J^9"%"!OU\SXU<!I
M&D9*H%`OQ1L+_J^-.M%+FZKKOX&P^[IYU$7$JTXHI5@"JZ;=.GB?NZBE"<50
M="EU*)/4G]-ZOI0#%%!6;]/AX?TU(`1&3UHI51-U$=0?#X>7X>(J=C0UN6*J
M36BEUGH+VN?/X>%5.0Z4"@6%[D^1M]GA?S^RJ*JD7%=5J/GUL3X=18?A5IS4
M@'=4B38>%^H_1U\*#@AZU)K5?NO_`%20+^/7R`\3YU<K=)H"M5_=84C2-567
MG&`URAI:RXUET8(]%Y%("\HI;28Z+D7NJQ\*PMR(%JTUH:@UUB,\?MGW?*0M
MEMC-4^DMKW#]@OZ/LBM5<.NJ5)A0WUS<@M34=FS;FU,9V.ZE;9)6Y].VM*B.
MP]I*[V%[FQK5\NAUR^6<RSZ(30#XMEPUW:`"6TZS]:FW)K8S'$(XB3C46[H7
M#J!)H[IP'EX*X57*NI\NO7[#U\JZ^F-5K:X8*2D*"1VCQ(\`?"_Z^M^M7@*O
MD6$_<0V'N!>4FRDJ"M2RP*4FRB!'!-C^[_5\_*L6_%;&\'1$_P"I3VE?B[;_
M`'C?6%GW4R$ZOK03>R=?PXZ]?'&QK#RMY5);_N(2,M(]04$I_%E^\?655UBQ
M^-[FI"HU3I"OCYGP^X?M%JOB%3V*K:$A4UP]3;[A]M[#I4KE,!DI%Q)[AW?&
M]O(7JK:%IQH5:[`%:JP_^TQR<D__`-.M*^8^`L[+3^G_`!UB1FE](?T&^W#T
MJ4X6T/4YP]7U+)S_`$+@Z>%Q8_`GPZ=;@UL6'%HZ"5$P4`"UUY"Z;MQ6GQOR
M_JJ@?+K`S"3T^-8ET:1Q"G^O;[5-;C"8_P!$[V+;GP"3]BK_`&=363%DY8F3
M7&F*DW#?L3;_``L+_HK)C&!Q4;AI+^I2A4GYB?.]OLZFWP\*E"L?GUT5*?\`
MWUV-^OZNGZNM3M]P=*N&2D'"!W7ZV!/Q/6X'Z+@U0J\9+T`^T#_LW\6_]%97
M_:7-5\V<Z_S1N_WV_L-7N_*G\O[;]UW[;ELI7++H4HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41?_3]42S>P^SK_A]U?00KTKYD'2H2E`=
M!X_LJ]HU&BJ<%"45'PN?M`_Q5;(ZA+6Y*A4,J[0?T]O]/QM40&.6"M4`DDW)
MN?\`#RJ_U)EDORJTJB@K(%^OQL?TU.0.X**G2I11/;VCI91-[=;5*1T*X=*E
MSU4>M_*_W=#^L5:>U54-Q7:APW_J@)Z=.OC?P-6DTS"H!JTBN95*=/0"]R>I
M^[P'[**;&I%<%+KZ?@3^SQ^ZJA6%2#IZBY`%O$_&Q%Q>JH*CL6K_`+HU2/[(
M:DW%4ZB2ODS4`VY%,(R4K'\S*0RC(H7"<)MX.!2?L\QB[DY[;9K8G/$Q(`TA
MI/'\\.;^L".I;#;M!N2)*%@8<#JIPS+"'#R%0<EE]@P&I2\A%AY?8LHQ$@?3
M0G8&$=D'J5O+,7`MP#*2U<)4.XK)7T':%UPFX;UO7+>P[U?VMI->;I&&N8QS
M+8,&)+C6`0N=I8TDBI(+FX'([NSMMNW#<[*TN+B.UM7.<'N:9G5K0-QE+M-7
M.`P%`&DYXBIZ?GLAF49DY!`"HF36TP3!>QZP#%8>>B*;>*OJ50'5%OUF[-N&
M_;>Q-;ODO?\`=-^AW.;<(`UD4X8TADC*8=]KM=:F-W=<6N+23W21BL/?=OM]
MO?8,MR2)(P226D&I=0C3D'-%:'$'`XJXWTJ(!([1:YO8_#[;D5W>6`"U+6AQ
MH5AKG]79P;R<H`V_LOEP1<7/=%(3T`*K=Q'Q_"L6_P#^2NZ'O>$[U*6UPNX!
MP\1OK6<]6).LZ_U`*,'B$'X=R<=$23]WWU)!^XA^Z/4H)OWLOWCZU6%DV)))
MZ"UOM%[=/MJ_,X*-4V0>HZBZ0HD?L/Z*FB^TKFY$A4UQ5@+&Q)"@3^G^FKR,
M2%("<",%!7U-^ESX_?5S?=/:HY"<NE:FQ21[F>3KGH>.=,)MU/1^?<]?\VL6
M/#<'"F.AGK4YPM8OON]0]JRB\+E77P!%^G7P_7UK8-/?KUJP'):Z<B7_`+;\
M4=+WY=U,6^^#EOV7K#NOW<./^O:?6I;;W9C_`$9'H6W'=<*%CT'_`(R0J_X$
M_JK*8#0D98+!U5`%%*.=%>'@G]/Q/XUDLP"$UU'I*DE>!^__`!5)P4;Z:^I4
MUTGN5X>/^'X7K(&`"DX"BIZ[763X'Y;?:+?XJM51D%Z!?:$+>W#BX?\`NJRO
M^TN:KYLYU_FC=_OM_8:O=^5/Y?VW[KOVW+9*N670I1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB__4]3JU=2!X].OX`']E?0E*Y+YE&2A$
M_K/X]?.KGD-;AQ5*\5\]_:`!8JN0?@/&K&1%Q[V2M4!2KF_C^S]52O#&@-"=
M"^+CXC]-088HOE1Z>/\`Q7M^N]2QQZC4Y*A4LX>GCX$W\/(_XC4@!,E>`"K@
M`.E2BE$#YC=2CTL+_P"'2KZ^=5X+X`Z$GX=/O_XJM)I@K202`I>038)3X^)\
M^G7]8JVI)ZE<T`G4<@J8YT-CT`MX].OZ/MJHZU*2.&2EUGIT/7]=O.K\\%82
MJ9+3=2+_``)^[P\KD&WZ:OCXJYG$G)<VOS1^4IO"_MGC<CXW"8/8IVO<I<?N
M,8O8H*LEBI)DR,I'6'XJ76E$I2YW`@]"*YSG"[FL=DEN(+>*5X>WN2`.:0:U
MJ#FNEY3M8[[=V6TUS)"QT;N\PT<*4.8[%RXXA_,R]PO*L.^I^RK5MU9CI,(3
M]9+,-A"F24N)0U/982GTU@D)+A`438UX%NGS4Y#Y9<+;F79]G@N'4-#$`22*
MBH##F.C@O2Y>2+MT?BV?,=VV&IQ?(^A&1R]/L6R\#WC>]>*PAJ#[",]`BE2G
M1&A2L1'9#JQ\RTMM[+'27"K^L$`FU6V/]Y/Y:;<QS+*XLXFDXB.*1K:_XK*>
M7IQ6GN.1&32"6ZYA:^0#-Q+B*5_.)_.-#UJW]B]_7O/UXK5E?8]GHS2(JI#K
MLK(QHB&1ZH0/54WFIC90$GQ'S7/45M6?WF.2)7CP]QMC*<`-4@J?U"KXOEQ%
M.UDD&[M<P\0`?158'W?\R/E+EOVV<U*/$6`UC*P,M$T21`EY?*/*;1DLGKF-
MEROK([L-3<N,O*+*1W!NZ+$*ZUW;?F#/NW+M_N;+6(6N@!KFEQJ'EHKB!D#4
M4\HHL!W)\&W[W9V3[]SZ@N.`&(J0/1FO03I7J+T_55O@)==UW"..I%[!:L9#
M*PDDDJ`4#U\Z]6M':[:W>,C&T^=H*\YF%)I1F`X^@E5Y9Z?X>77^BIJ>=15Q
M5*DJZKM\`.OVUD-P8I8Q@.U2#ALH?9U/Z2?UU0]X@*I/G4MW_*J_E?P\1^OX
MU.T5!J<50UH%J>AF>GW)<D/,.0VT.\<:<D&1%??N42YX/5J7&!MUK"9K_B+R
MVF#&TKVGK4[@WX:/`^^[BLCR$Y&RB).-!"?/'3"+V[AT&8)M]U9K1)JIW:]A
M^M8X(`J*T[1]2U]W9J<K<^+E2G8:RWROJCEXL9]F]HN3`OZTV2!T-K`7OUO6
M-<A^B,.(_?-X=O6LB`@-FI7]V[U=BVY/1-S<E7:/M'R_LZ5FQCNYX+`K3$9A
M2KILI7V6'X]`/T5D``#J3#N*35Y#XU>HP.\3P*I[EO/JKP/7[+W_`$U-4@!3
M@"AKF%3%W[U'[3_BJT]*H."]`_M"_P"SAQ=_T5E?]I,U7S;SK_-&[_?;^PU>
M[\J?R_MOW7?MN6R5<LNA2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1%__5]3-?1M<`7"@&7TQ7S%TT\JH^5R4'%1I.1R$V-CX<-E3TN7,?
M:CQ([*$E1=?>=4A"$)"2.I%8[B"2YYH/IFK@TN(:W%V5%S!YF_,0=U+=']`X
MHXOS?)NR-!^1*;PBL5E&,4PVXT8#VUEO:L''TI>80''(D3(/M3WF$AU4="7&
M^_3W&ZEKC#!;NEF'`8T'2ZCA3J!QZEM8=KUL$KY@V.F9J*GH'=.JG$@$5PJL
M/X[\Q3W039I@R?:3N3CB5$)5@]:Q>;0`I7:.]T<R16#?N\BI-_LK$&[7NJG\
M*>3U-!_^H%,=L@IC?1AO67>BL=/2%?G_`*LSW)RW&D2/;YS+A6GK=[\/AC7\
MNF*D@64MIOF:?(=2FW@VVH_9YU?)NNX-`=_";FH_-B!/_$*P7VS(F/<U[92.
M'B!I/E+:>I?K_ND]S"I?9CN(_<7.AJ*2K(P?;KIT>*V+$+*&,IR,WE#;M%_X
M*[7%!N=V2-5A>CI_":/1KJIH((I8/$D\.*3\TR@GS@4]*I@]U?NB6Z\E?"GN
M;2$**`ZOV_\`'%G$@FQZ<F>J@$>`4E)^ZC=UO*D#;;PC_=,_TE*;&W`&FYA+
MC_2?DIZ5"5[H?=>M/;&X$]RSZ4FX6[PMQ,PE5P>@0YRNPI((/F#_`$U?_$KX
M4IMMX?\`X<8_SU>-NM,Y+V$#HUG_`$2OP^YCW<=J2>`?<(>G[KW$/%*.O4W_
M`/AN=H%_.XI_$MQ(J-KO!_\`#9_IA6FSM"\AM["!TZ__`.E53$;W(>\60JZ?
M;SRHE`/AE]#XOC)*18_,F%S6'DG[.AJYE_NCL?X9/3])C!ZI%0V-D`:WT9KT
M.^N)-G]S7O-PN,;D8WVP9#.R%H6X(C>)P<:8I2$FS;J(W+F12RZKM\"@W`N/
M&JW&Y;K$QKAM,CST!N7F?FJ1V=FZ33\:T,'$D^R,+(?MF]S/,O+6WS-/Y-]O
ML[CF5B<6SD<MGH^T8;(1,8]*2XY#Q65PS<Q^?%R#B$I"O26^VA2@%$5?MFZ7
M5[(Z*?;)8"T8DG#]7$BJI>V4$#/$AO&R-K08''K!H%O4\L*7\MR`.T?"P)/4
M=#?NKI6#NA:P&@IQ7(3\[<V]B^:[5)"O]Z/''[P)_P#3LA>W;U%K7O\`"N4Y
MV_[#<']-OK*ZODP_]>@!_P!F[U!<F?RKYV-CXZ7#>D1FY^0RLYN.RAO-*=>"
M'2X5$NI=Q*4@`VMZ9/F2>M?G#\\V32;W:$,_";&RI[M,6CA[W#B"OHH12R;*
MU[&$L:75.&&)\N1X+T%1+K9:_K?*/+X)L;V*O,5XO`!K`K047"7'$5[RU\]P
M2;:QD%GH?I7[7/2ZD`6_&MA#'"VYB`!,NH8^<GU+<[,:D5.55P)UADRN&/<!
M%0+^KS1''@?_`'Z]4`^'BH&OT!Y5;7Y:O'$Q0CT1K4;KASA9/.6E_JD7KSU5
M`3JNM#_(U[")\O+&10!^FOJ"T_Y.V_W;/V0O"9OWTI'%[O655'B0+_9UOX#Q
M`/ZZR&C'K41)KU*D/&_:1X$W_P`59)R"R&A2#A-B0/*Q'D?P\:M;2M%0YDKX
MN0GQM<`V/AX=?#RJ1O&G!65Q)HL`*@!',^V3BG_SK2<"SW=+GTI<RR?LL34$
M7_-O=Q+6^M7UI"VN0<5<;Z5`&W@?,_8?,?'I6:#5XZ0HP2YAZU@O;V"O<^/%
M$7#?)&OK^-K0\FJ_3S!-8UR,(_\`?-\V*F@U-\;_`';EM"LI-D_\HW_$6\?#
MQK*'`K$<<^E4]SJ%W\U?J\0?U5.!0-H%&,*UX!23ZK)4?L)_2>GZZD%:A6MS
MP5+'B"3X`V'Q)O\`HJ6N2F;2AJ5*J\>[XGI87^(O;[.E4XJX#+H7H&]H7_9Q
MXO\`^B\L?T[+FS7S9SK_`#1N_P!]O[#5[MRI_+^V_==^VY;)5RRZ%*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBM')\
M@:'A=FPFEYG=M1Q.X[-ZO]F]3R>R8:!LVP>@R_)?_DF!E36LIEO1CQ77%>@T
MYVH;4H]$DB9MO</BDG9`\PM]YP:2T=II09C-1.G@9(R%\S!*[)I(!/8,SY%=
MU0J5*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(O_6]2BE@@@>%OLZ
M_=7T8T/-"Z@7S%7-<I?S(N#>5M\3IG*NI9&;NG'W%;1R&_<"MY7+X%C:83+\
MIYS:X,_#.A^?DL-$EJ4N(XVM)98"V^Y2%-.<[OEI+.^.8,UVT9JYE2*X9X='
M1Y5N=HN8H2^-P#)GB@DS(_1H<,>GR+&G`VA\'Y>'CMKTIW%[%BCK\3)XMG$P
MXN&UG$SLP\XG,Q6]?AW+V7@NX\L2)<Y;\M][N<*DA034FWVUDT,DMZ.&D$4]
MT5S%.D9$G&M5=<RW#&N:\Z7UH:XN/1CT8X`8<%T:XET/61AF\ZYC8JY4MY\H
M`90$M-MN*0E"$A`':E*;'P\ZV[(VUJUJU4DDGN$X+-:<1B[)].!$"4GN`3':
M\>GGVD>(J4-`!%,/(HBXFF)JHZX,+M%X[24I'2R`.GV>5JNTLIP"IJ-:54D8
M<%Q=S'9[B22/320.E_V_MHX``GBJEQ&-5^+A0@H6C,62+D>D@`DD^13Y#[*C
MKA7BH]1H<<5`<AP^X*^F8LD`6])'EXV``\0:`DFG!7!SJ!H*D'8<;S8:N?,M
MI\+]3U%Q5V2D8ZN2LS=,<Q(US+M(;2RM4%]*76DA#B"4E/<E?4I(%62"L;^P
MJ5A_$;VK`WMQQ$?'-\I24MH2]D>3,FXMP"[CC</&8>$A!)/<EL_2]Q3\5$^=
M0;='5EP0!4O/H`"R+QP)MP.#!ZRMC%)M>UOL'@?Z*VHRHL0'&IR7(S\ZFW_J
M),L@W5W<F:$"CN4FZQ_.7&^J0HW[T"N2YW(_@,^'VV^U=3R<#_&X*9Z#[%RY
M_*WP^9BX"?-<@R(\"7D9BH[SF5D2&Y2DR'+@8YQA++24]ALXEYPJ4/#QM^:O
MSTEMY>8[>!LK3<,8TEH:-0HP?:J37J(%%]"N#3L]N',Q+S3(5&K[1)\PXKO!
MCW`8[;:7`I24I"P%)[QT2H]UC^]U^RO(+=U`PG.GIQ^HKB[O&1SZ`8Y+`GN#
M-]1G@?Z0,NDD^`2`1^-[UGPO<;JW`SU^PK;[(*N-1A1<'./!(_W:\\A"46/-
ML(H"B@W[MMU3N2;_`"^"J_0SE`__`/-Q3/1#ZHUH]ZI_:RUK^8[U/7KEP%AK
MV#0``/Y1C!86L.V%'Z6'ETKZ;M\+:VZ?#9^R/\"\0FQEFZ-1]94TZ>CI_``^
M?R@?MK('O#!0MJ3FJ2Z?FM_DCH/C<>'XU,?2L@UIU*35X#P\0+>?C;]%C5&T
MQ5G`J$X0.A^'Z+>7W5(`0UQ5HK0FJQ/]/ZO)68L!9>JXP=Q\[3)(!!/2H&=V
MX<:\!ZU<<8J'\XJY)6+2EA1O=8-Q8>0'4?A>LJ-Q+G&BM;AW:K!.R8]3VU:D
M0+_2;KA)2S\.V/*:'6X_]<J.=I.BG"1JE8:>(#Q:5G1)[BM7C8]?$V/G]QK*
MIB`L3&@"EE]+#[_U5,W$!6N/>.&"D)!^4CPN>T?@;_T5(S,GA15:,:*GJ("K
M=#:P_'Q-_P`3^JI%<*D*47T[A?[/NOUZ=?'I5O25>*G`9KT#^T$W]N'%Q/\`
M[BLK_M+FJ^;.=/YHW;[[?V&KW;E3^7MM^Z[]MRV2KEUT*41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(N3OOO\`SF/9G["<J=%W
M78<WRIS2I32%<-<01\7L6U854AM"XKFZY"=E,9K^G)?#K93&DR595UMU+K,-
MUL]XI57!I/8N8FK_`-Z?]O*=Q1K_`"Q[5.=N-L*N<TPYF868U;:LQC\?)"3'
MRF4U7((TR0TTD+2XZW'DRG`S=30>5VH4JJZ#P*N+W[<?^]_WZZ3L/N^_+O\`
M>8[M/M/D\=XW)ZYPSQ;R/R)I>Z;1DM:A+;W_`!JL!A\#A&7-I9EQU*."RLX3
M%O,J:2TF0MIA?HW*&\<K6D=M:;IMC77KI"/&<QCFMJ>[4N)(`R)#<..&*X'F
MG:N8[E]Q<[=N#FVC6`^$U[FN-!WJ4`!KF`3CPQP7CKP.^;KK&ZXCD?`;5GL7
MOV!ST':,/N$;)RQL4#8L;+;G0<RSE5NKE_S"/+92X'%*)*AUO7N,EO!+`^VD
MB:;=S2TMI@0<"*=%%XXR>:.9EPR5PG:X$.KB",C7I7]+[\OCW70?>E[2>).>
MD_0L;-G<*K!\CXK'!;<;#<DZPX<1M\1B,YW.0X,[(,?7PFE*<4B!,8NM9^8_
M,G,6TNV3=[S;\3$UU6$\6.Q;VD#`]8*^A]BW-N[[7:WN'B.%'@<'C!WDKB.H
MA>7'\UCWQ<M?F-^Z;4/9![)5;!M>BZ=MS^)AOZ/D7HZ.6^3HJ)4/-;8_F(LF
M/"8XTT+'F2U%FO.(@>FF9DG'EQUQE,^I\I[%:<M[5-OF^:63O97O#]VS@VF>
MMYI4#'W6@5K7S;F;>;KF#<XMFV?4Z%CZ=T^^_BZOYC16ARS=6E*;&<8[/[3_
M`,@:?LVT>X;W6;3[F/=+OW'6*UG)>W;C"&,L[J!DS\=L,N2_+S>RF'@\89L%
MAMJ?FUXN?,B?QHF/6"XVG@^:N;&;^V.V@L&PVT<A<#@7.P(%:``8&M`3CQ*[
M7EKEB39727$UZZ6=[`TC'2W$$TJ23B,Z#L"K^G_WK?VX9+8VX.\^USF75-7=
MR#4?^T.`VS3=QR<?'N+4E>0EZ[*:U)M*V!VJ4RS.?44]W:I2@$JXRJZ[0>E>
MD3VZ^X[ACW7\3:WS;P)O&.W[CK:$R$0<O";E0Y<'(P7/0R6#SV&R+$3+8#/8
MM_Y7XDMEIY(4E8!;<;6JJM(I@5H5[_/SF?9Q^7UEG-"Y`S.P\D\TB#&GGA_B
MZ'`RN?PL;(1Q)QDK=<SE,AB]<U"/.86AU##TEW*+C.H?;AN,K0M5*JH:3V+F
M#M/]Y$YAT;6L+RCNWY3ON#T[@C9'8:->YAVG>=HU[6L\G(17'H!PN2RWMYB:
M;E'9S[2DLI8SCGJM)+B22"BE>I5T?I8K-$/^\\>P"1PQ/W^3KG-,'E&&ZB"Q
MP0[J<-[/Y.<ZPZMO(0MZCY%S04:JV^V$O27YC.20E7<G'+-D*5305U@X<]]W
M"^]^R7C/WQ\G;)JO"'&6[\?XS<L^]M.UQI.)U+*ON2,?E=2:SKL'$N['EX6P
MP9&/CLQX:9D^2V&V8Y=4&ZJK:8T7%CE/^]&^VK`9G+-<,^VSG'F33<#/:AY'
MD*?(Q''.`?84MQ"\CC8LF'M.61%>NT8Z,FSBY#O>0MMDI`72JNT'I6\_L)_/
M,]FOORW&%Q/@W-MX9YHR@=&`X]Y48P\=G='8\9R7*C:+M>$R>2PV;G1HS:E?
M12OY=D7@A:F8[J$+6%50M([%>G-_YX?Y9/`TW-X/9?<EC-KVW`RLCCYNH\9Z
MIN6^Y,93%2'X<[%*RN&P2]/@Y!B9&4TI$S)Q@%CJ0+D*A-+CP6,O;;^>W[1>
M>N)_<QSYM$38>".'/;OL.H8")G>2I^$=VKDJ5NF+V3(X;&ZUI6MR<M)7M4M6
ML2$LXJ)*R+SC?\8K0VV\6E4+2"!Q7/1_^]>^WI&U2(4?VH<QOZ2B041]C7NF
MEL[,_&$A*`^YI_T[F,8=5%NL-_SM8[P$%0!*PJJZ#TKT)^SGWG\">^OAS'\V
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M,J75WK([E``&]K].A%A]M5)`[56K1EFEAU-@/.Y^S\/&K22<U:3505J!Z^'3
MH#\;U0"I5%).+[NX#R%RKR`(\OMJX`BIJI&@#23@I18!0!U('7[^O["#5W:,
M%?KH<!@K2V]WT]>RBB`.V$[;K8=?E\3^FK7FD;SPHKXN\]O:L!\`..*:Y#6J
MWIGD//);'P(3%"C]U1;971.[^D*R;G#P13'0/65L*H@];]>G7[+6_#K6R6*N
M-7YWL],?V:?3%929G+&CD%-@2F,SFB4W5\OS>KY_"N.YY#3L,C"3C(W'SKKN
M2:C?(W@5(8[/R+D]^7%ELDK0LQKN.U'(91><S,F,<OZN`1'CM(FQT!253&YU
M_I$H6L>I!?\`XAZ"WS#\YOG1!$WF*"X-VP!L3>Y1Y<26YX"F.6#@*9]"^D-K
M?&([>YN+SPHHBX@8C5@[N]TL(_7;T=1[7\/:;F]5FY)W+);"Y.-QV/<DH6^\
M[E9$)^=(_F4Y^0ZMQ^4A$[Z9*C=2F6$*)!/:GQ&-[GR./>#-1(&%,3D*<!GV
MDK1\U[I;;D+<6H[K7.=2E-`(:W0*84.@/-![[G9YJ7YWC"1K.43W6(A.D'Q^
M8(N.GP*AUK/C)%U`YN>H>G#VK6[*^CF@Y&JX)\?LM(XWYW"U.A+G->/4"GM-
MP-QU=JZ0FZ>CC9'CX5^AO*./RV:3EH@]3%IMXK_:NU`I01N](>?J7KBUX!&O
M8())4E.'QH22+$CZ-@W/CU-?3=L*VUN*Y1M]2\.G-)9</MGUJ:?5X_`F_P!P
M%ZRF#O`]`5D>95(<4.XD>)/3XWL3^JKSFIS@`.*EU$+)MY*[NOCT-_#\:J!I
M!*C.`*A._P!;S\.OV'IXU(?<[5;P"QTRV1R!E';&QUS&)3\+?62`1X=2";U`
M/WCSQTCUJ]WN-[5=S_5!_P`W]O2_X5DQU%>U1D?:XT6*,]':C9C&27$BSFRX
M9"/@%K4X$6^WN(%62&@Q-27M5X/=<:Y-5Z()5ZW^3WKO_P!\+#]59#*`D'-0
M.%!@5#<_8*G;E11.Q*IKY%T`B]R3]_PZ^/C4K*XJ]IHJ>Z?F41_E?'X7)_3V
MU?Q5XR"DW722>G@/U];^%JM.5%489+T%>S\]WMNXM/QQ66_VES=?-O.O\T;M
M]]O[#5[ORI_+^V_==^VY;*5RRZ%*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(N3OYV'NQW#V>?E[<M\A\;9F7KG)VY3M;XCX_P!D
M@+=9GZWF-[FN-9G/XR6P4/8_-X?2L=E7\=)0I*XV00PZDW0`:%7-%2O+9_=L
M,#[?LQ[MN9></<5N?'L?>N/=-Q<KBEWEG:=?@S9N^;UF\K*V7><"[M>2CR,M
MM^"PNO/MJDM^L\PWE775%*RA8H%>^M,%TK_O-D?VO<I^UGBWE34M[X>V3G?0
MN6\-@,;*U?=M*RN[9/B_9L#LZ=EP[L'&9A>9R^#Q^RQ,3+0KTY"8#GJ%`;3)
M?4:E6LK7J6MO]U$YCV=CDCW4^WUZ;+D:9D](U?F/&XYQP*@X?9\%GHVDYN;$
M:*@6I>R8K8L>W(4`?41BF`2.P7!5DX+03\Z/VC'VF>^3D*-@<6,?QES27.:.
M-_IVDMX^%%VS(3#M^LQD,--PX0UG=F)[4>&BYCXIV$H@!U-_H_DK>/XOL5L9
M'UNH/PW]/=`TNZ]3:5/%VKH7@'-VU?PO>9PQM+:;\1G1WCWAY'5H.#:=*P_[
M5?>C[IN,N$^7?9/[>6YTY[W9[=I^'A(P;4R3NF.R>2CRM5V/!Z"S$6VB/E^4
M\<_C,9-E.>HXS#@A+`:=<]=K,W;9-JNKZSWS<:`6C'$UII('>!?U1G4X#B3C
M48'$VS=]RM[.ZV>P!)NGM&'O`GND-ZWB@)X`84.*]G_Y2_Y8.K>P#BG^T&W,
M8[8/<SR1B(:N3=K84)475L<XIF>QQCJ4@..L_P`EPTM"53IC5E9:<WZJCZ#4
M1MGQ7F[FF7F&[\.$ENUQ'N-_..6MW6>`^R,,R2?7.5^7(]CM?$E`=N,@[[OS
M1GH;U#B?M''("E#]MGY-?`'&/N*]XON-Y[U?BSW+[;[C_<!N?*^@,\A<9X?8
M<?Q%J>V;1GMS_L]C<5MW]H\<K9V\QLBX\C*L(;6]&@1BTF/WO-5QU%UA<:`!
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M_P`)F$95MG^70(KNKY)3&547%M(B.X*4TW,8?2MM<9Z.AU"T*0E0N4(S"_F<
M_E28Y.7_`#'O9KB7L#C-G@Y7G33\;E\'F<+"V'%S<!/D.Q-A,W$Y"/*AOLQ<
M&](>*UMGT"WZHL4`BT*9V16VOY^'NVV_W`^_?E/BJ/L&1:X7]L^8:X>X[T..
M^N'K.'SFI8]C&\@9Q&$C%K&JS<W<S/BIEELOC&18L?N]-E*0*HT4'6O;U[4&
M?8GP3[3>-O;[I7)7MJ?XWQ7'D+7]JQW^\#B[+87=\O,Q#<'D',;<A.=R&*V+
M([5EQ*7E%/*?;=6M;1_AI2D7*(U)JOYP7N>C8#V^>]_G`>W';HT?5^)_<=NV
M2X.W+3,S$R<;%X/6M]G93CO):]G\>_+A9+^2PF(@9EM+6T^ID.`65:K5,,0*
MKOO_`'@'@#VW8#VM>QKW/<-\+:!Q+N7/K\S:]YEZ'KL/7?[5'D+CO6.0E/Y]
M$1MI60F0<K)=4RZZ"ZGZEVY/=T%6L)J02L:_W=[\N7VW>]C)<_<B>Y7`9'D?
M7^&,EQ[C-4XOD9C,8?3)N=W"-M,V7M&RIP62QN0S4C'1M;:8C0U.(AJ2\Z9"
M)`+:6P"/<10!9Y_O#GY5GMA]KO"_&/N@]L?'T7B=4KD_'\5<C:3K\_*R=5RT
M;8]9V;/:_MT+'9G)3TX'(8F7J*H,AJ$6V)8GMN*:#C3CCE2%1CB<"OC^Z>;!
MF&>8_>!JK<YY.`R7&?&FP3,9W7CNYC![3L&.QD[M/[KT>%L,MNXMW)=ZWL+`
MDG!>W&JJ-*(E$2B)1%__T/49<>)/E?\`HO:OHG[-1FOEU0BY\.G7[.H\_&J5
MK3I1<HOS2GFXV#]M;ZTN%*?<%B2.QU*?XJM<R[395=)-K*4/A8FM3NN5L>'C
M#U%;O9ZEURT9&(^L+>3VXS%3N(M-FK`2M_$,'][R2.R]Q\0`:SK>H:#T@+77
M>$KF]!6;B22;FY_34^>"Q5^"QL04VZ7-QT_XJ4*JH:UBW;?P/0?'\!X^-5+:
M)0BF"D'5K<<-@;#KV^!Z"W]/Z*J,E,`QK0XYE2Q43<>5[V_P\;54XFI5AKF5
M!<N#U/3K;\*5KEDE.A6+R"^&M0SCODW!<5>]@!T[NOW59,*6\IKP61;_`+QH
MXDK`G`#]XW(3:3\J-]FO#K:QF8C"RS8_:MXU%M=")J9:_6`LFZI6$?H^TK81
M;BD]`HDW4"?'SK;TZ0L,^A<6_P`\7U5>TK"MI2I:'N4]8"_D[DI+4#,R!UN!
M<EKPN.GW5Q7/@/\`!NK6%V')1IN[23]@^Q<R_P`IQ#/UTIZ.WCFI8<RR9+J<
M3*1D9+!F?P8SN0=[89CAZR@$=RQVV-O&OSL^>1<=Q@:YSZ:6%H+AHKI%>[6H
M-*XG!>^'4-J;1U*O.-109_X%Z$('5D7([@>MOLZ^?D:\-A!%!5<==&A)&96'
M.;&DG5LH^>B4PW"H>1Z6/G]G2LX-+9H<<=0]:SMG?69K!UK@'QY)+VA\]QV@
MF[7-6(<2E8N$LR-NU924IN1\MD$V^-?H9R<"/ENUM>]H@_\`IA:W>`/[4VA^
MSX9_8>O6YK]DZ]A$I!`&'Q:4W%N@@L#PZV'2OIVW_=PC]$>I>&S8OEQQU'UJ
M9DK3?K>_;U^\^-OPK*CK2M>*,:>E4I9Z@FJG/J4CL**$0`21]OW@>-JN!J5&
M[&F*E7%>()\3>UNES8_?X5*ZFGR*AJ0L6C+QH.Y9Q<V8S'8;Q&-)7)>;;0W>
M0_T!<4D"]QTK%:?Q)23W0`KSJ\.,`9D]JN<Y[#/,K=;RL!2`GN*DRV%`6']8
MA9`K(9*TTTD*QS3I(H5@G<-[P<[9M.P6-R^+DRQN^`7+8:G,*?#?^LK3VM)<
M*R0I(Z6ZUCRO:YS&QO!?XC>(P^E%*R-PC>\M.C0>'TZ5FE*5!2R?`J5?X_O=
M/`VK8L&#B1C4K$/H4-TWN?P_74P%`K#0D*GN64X+_P!5/Z.A\?M%JF;30K@,
M"53'3^NW_BV/[:J<"I,%(K-RNW]:Y_`FXJTU55Z#?9[_`-FWBS_HK+?[39NO
MF[G7^:-W^^W]AJ]VY4_E_;?NN_;<MEJY9="E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$7F__O1FNY/-_ETZ)DH#/J1=0]UO&VQ9
MM?:\?I\9)XWYEU-IZ[;3B$=V9VB(W=PMH^>P5W%*54*O9FO,A^2![3O:/[U_
M=#MW`/NH1LRG\UQAE-FXD9UO;I&IOY;:]5R6/F;#@TN18\AS(S7-.?F9%MH]
MJ41\9(63<`&@5[B0*A>M#$?W;_\`*TQOU'UG&?)F?];TO3_F_,F[L_2>GZO?
M]/\`R&=A.[U_4'?ZOJV[$]O;\W=6@5FMRZ">U#\N;V9>R&=E\Q[9>$\7QUL.
MPX1&N[!LZ]DW3;=CS.'3-BY)<"7F-UV38I;<1[)0VGU,L*99]1M/:@)2D"JM
M))S*X>_WFO>_;]*XQX)XVR<X3?<OA]OG[AJ,+&)8D2-=XKS.,D8G<#M+BGDJ
MQF,VO.8S%J@([%/2I&(646;:>)]5^6%ON`NK^Y:VFV.8&N)XR`U;IZ2T%U>@
M.Z2%YI\Q9[$VUE;N=7<0\N:!P811VKH#B!3I+>HKR4</<I[5P?RMQSS%H\E$
M7;N,MTUW=]?<=]0QG,EKF4C91B).0TMI;^.G&.6)+7<`ZPXM!Z*->NWEI%?6
MES9SBL,K"T]A%,.L9CK7EUI<RV=U;W<)I+&\.':#7'J/'J7]+3:O>CQ=KGLA
MS'OKBHEYWC+'\%N\W0<5!>;;RV595KHRT'3T/.M%F#GY>9<1B5EY"41IA/JA
M(0JWRO?6DVWWES97`I-$\M/D-*CJ.8ZE])V5S%?6MM=P'\*5@</*,NT9'K7B
M9X3]V_YCOYVWO'UWVYYWW5;/P%QKN@V;9-CUKB"1D=+TS4./=9Q[^6R.,8P>
M`R^)S_(DM]09BQ49W)SS]4^AYU8:9^3#Q*S2&M%:+9+\[?\`*2]H7Y?/L<XS
MY#X7Q>_Y_EO8O<UI^B[+RIR/O>4V#8LWK69XOYHV?+XY_!XM.!T*-]=GM8@2
M#(:Q")J?IP@/]KCP<$(UQ)Q6S?\`=-(T<Z#[WGBPR79&V<%QGW2T@N/QV<+R
MDIEAY93W.,M*E.E*5$I27%6'S&]0J29A<D/S;/RSO_J?ONOT_+>VOE;6]@/+
M7(^.V7@SA'5Y\R3[A^-MCG[`)VLXJ#J&+@2W<GK$+94M0]<R:'$2Y;J6XJF%
MOM*>?H0KFNJ,5V:Y`]P?]XB]S'`.<]LR?8=K7'&U;QJQXZY$YY=S6L:?+F:[
MFL?,QFS93"PMGY"8U;7\MG<,EUN9*QZ9OTQ>=./C1I#L,,5Q5M&`UJMEOR<_
MR+&?8AMC7N1]Q.S:WOON-1A\CBM,P&GKG2]'XEA9^$N!F9T7,Y*'BYNS;OD<
M/)>@/2!%8@PH[\AICZGU$R0`5'.K@,EXROS,,+D\!^8E[YX.6B.PI3_NU]P6
M::9=24K7C-DY2V?8L++`/_DI^&RK#Z#YH<!JA4C<@O7M[3_R'_RJ?<K[;."N
M?<+@N5,E$Y4XRT_<)O\`+N7<PF%%S^0Q$;^U>"4VB,ZY&D8#9FIF/D,^JI;#
M\9;942F]5H%&7.!(6ZFK_P!WT_*CUC*M997MPR&QNQ[*CPMHY=Y@RF*0Z""'
M7<8WO$2)/^6Z?3DI>9(-^SN`(4"IK=TKF-_>F=<P6G>UGV7:CJ^+B8/6=5Y*
MV#7-=PL!OTH.(P6#XZA8S$8N$U<^E$Q^/BMM-IN>U"`*%7,S*I']TS_^%[[V
M/_ISX/\`_P!"<ET"/S"W)_O/?_\`S<P?_P#LOQ?_`+*<E4.2HSWER?\`[J#_
M`-H3W8__`.&M*_VW>J@5S\@O<55RB2B)1$HB41?_T?4(I15U-NE_@*^B,20%
M\MZFC"N*^.[H?(>-_/IU_14K(Q7&JO`KG@N&GYV?*2>+M*]MF8E8=>7QZ>:)
M.4EMLROI9"1A-<D/I::4X%L%4E+Z@.Y-AV^(ZFN2YIW$;9#93^&7-$Q[3057
M1<MVSKMU\QDH;((JBN(Q<!P6C?%WYS4S5]?9U?6\#$8@8QJ,(2,_'R,B9&CK
M-OI7DXH.,..A/7N!L2;`"QMS?]O[:"-@='2N50?-UK/O-AEAH^Y9743BT@##
MHJ0MG,!^="T_%0O-XS6XZK?/Z;&PI<%O!0;1CGE)O]]2,^8^TG&5^/8Y:22U
MMV&C8I#Y6>NH5<3^=9QXV]Z$QK&I2/%:\9MZVK^=G(^&5WGX5D1_,';9'=PC
M3UU'H)5T>W32FK('`=;XP?,7U5Q,_G7\#K0&GY<9B2HE/J*P6^?2H(_K+(U=
MQ782+7%ZSQSQLI`)N&ZO+]2F_@=T<?!->C7'_IJE3_SHN'&V4OM;%KZE]Z4%
MF+KO(\M24*)!4M0U9I'<DV^47-6GG?:0*_$1U_QC[`I&[#>NP%HX'K?&/\]6
M;E?SHM`"4O8S:M0>2%=8\S5>4(3Q2!UZ'4RV;?$+Z_"K3SOMN<=S%Y=7U+*B
MY=NGFAMG8=#XCZGJDN?GF<38]@_SEYK)._.'(^LZ[M2W4^%DES,QL:PDK!OX
MWJ_^VVW-+=7>!_-!]N"F'*.Z2'\*"@X%SF#U$JN9/\W_`(ZW399W!V,T;:7M
MAS+3S+692J)'QT5DXYR<IQY$E[ZKN0RV1VI0?F/C;K6EYU^95ERQM-[=?P^2
M4AC".\![[@./0%3:>6[N\C%X]S8[=KG#'$]P8TIU^KK6Q?Y=/-2^7L?S2^ME
M33>%Y,FX]GU+]SC4?&8QEMY0\N\,]!UM70\C[_%S%9OOH6EK#3`YCNMS]"UN
MZQ1Q.A;&^HT5\Y*Z4J(!4HWL3<"XN+UWHRZUJ.&.:Y#_`)UIC)]E$MV0R'76
M^4M&1%<LHJ8=?C[`RMP%/4I+!4DV\+WKCN>R!R_*ZE2)&^U=9R6*[["*X:'>
MQ<H/RIY0C2BAQE:F7W<TA;J]A#J8JDO`H>:P)'>VM:CV%P*L;W(O7YS_`#RT
M_P`1C)(`TL'[O$U%:>)Y,E[\0P[4=>-'5I2E<:9Y89KT)XUQ#C*2VJXZJ%Q^
M]>Z@KKUL37A]L[%M*%M:Y8>E<?=`AQ/$8>Q8HYU1?0<ZL&UHBA?P)^4DV\+=
M2*SXOWT1-*:@L[8_^<C!XA>>W20S%Q'.4!#G<S(Y!UC(E*;%8?&^:['4@B_5
M*/E!-O`U^AG)C7.^6$-PYF#A$T=>ES/R56HW>5CN;X+=I_$9":]A:^E?9Y5Z
MY\*HIPN'O8A.)QZ;CP)^E9N1;RN.E?3L`/A0"GV!Z@O$9:F:0#\XJ(XKO5VC
M\;^0\"?T>%90RHI!W!FI%WSM?H+7(^%NOW504KGBJU!ITJ$GYDW-_#S_`!'E
M\*DH-0Z%8X\%*+/=<"U_Q^%A5SS@`.E4=P7!/\QGD25$YWP7'$/+3\<U)9P(
MR'\NEF,^^UFL6\'$KMT2GT4V3<7!ZBUP:T,@^/WO;]D?*603R,#B,^\#DL^2
M^?M&P;IN\4,<DD$3G!KP2.[IZ,<R5KSC_9WM>1;&0U[W(<B8Z%-(4<;*4KUV
MD.>+)F,RO2D);L.U90DD>%>@.^1MT-$UOS),8B1@6@$#`\":T7S-?_WN(]ON
M'VMUR+;:V$C7KDT\14M`+J5Z`>RF*S3P#Q=C>(N2M?AKV?8-NSN4Y,XZ:DY+
M/O%UN,)>15'D?0-N)7(2\\VV4J4M9Z$V`!K6<P<HLY1EM81<NF?.=1+N&-,/
M)CF5ZK\N_F7>?,C9]POI+&&V@AH&B,$5!(SU8\3F`>I=U[6)_P`/,G^FH6FK
M13)=:I1PW/7XDU*K<:XJFNFY<-STL+@=`04CJ/$@VM4H'=`JI:]T44DX!<>/
M07_P_P"Y!JO%5&2ISAZ6^[]7C^LU157H0]GIO[;>+3\<7ES^G9LW7S;SK_-&
M[_?;^PU>\<J_R_MOW#^VY;+5RRZ!*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(M<?=Q[9=#]XWMRY5]MO)*Y,;5N4-<_E2\M`;9>
MR6N9O'SH><U;:<8U(LP]D-9V;&1)S3:R&WBQZ:_D6JBJ#0U7\WOW)_E[>_K\
ML_F9G:)VE<B8EOCO9XV=XX]RG$^-S^0T26]CY27L'L&+W'$Q7$:OE';#OQN4
M,2:@]Z%-+:(6NW)2@AP77#@W^\S^_K8,1AN/$>U_C7W`\I?3B#$S&H:_R#&V
M'9)/:&HTS(:-I4C)QI61=?(+R<:W`CN'Y6V6:55"P=*ZG:A^91[U/:3[8>9/
M=1^9K%UG5^5^9,WC\+[,_97B-;P>HY'$,8#'R3L&R9M$61F^0,=JTK([!$<R
M7]H<I(GX^/C`A(0_D8;*^BY;Y>NN8;YMO&"VU;0R/I@UOM<ZE&CRG`$CG^8=
M]M=BLS,^CKAU0QE<7'V-&;CY,R%@'\HKV'[I[U.5=H_,Z]]D9?("MRV#*Y+B
MC4]N@(D8G<,NA3F+<W>9@IJ7(3.@:6PQ_+-9Q@;^E2N,'6TH9AQO6[SG#?X-
MDM(N5]A/AZ&@2.:<6C/348ZW>\]V>-,W&G%<K;)-O%S)S'O0\36XEC7#!QRU
M4_-;DP985R`KYW/?[[6\E[./=MS)P/(C2FM?US9Y&5X[F2EK?5EN,]E)S>BS
MC,62)LIK`RVHLQ8)[<A&?;/S(4!Z-R_NK=YVBROP1XCF4?U/;@\4X8XCJ(*X
M+?-M=M.Z7=D0?#:ZK.MAQ:?-@>L%=S_RGM^S/O7_`"U/>C^6"-ACP>3\9QUN
M6P<&NYN<E$"7K>XNIG)U]85ZS\+"X#E=MI60DI0OT8^S)4AM2FB%>6_,S9S!
M>V^\1-_"F&A_WVC`G[S,!]PKTCY>[KXMK/M4KOQ(3K9]QQQ`^Z['_&"\Y/$.
M,]]_L`]U&M;/HO%?+'&ON*XYSD_$XW7LGQIF\R[F#EVI^L9+"+P2\7,@;EKF
MT0Y+\=ER*7V):%H?AO=Z67D^6KTS`C/!=K_S-?;-^<W[JO;-P]SG[G,!O.][
M-F.2(D33_9C[=.']FV1KB?6YNG;'.F<F\DX?2(^RY*)MDV3&CP&6\@[D'L8S
M-<87(CNON0TC56M+0317K^0]N?N\]@&Y<D\7<M_EQ^]_)ZK[C]VX;QT3?,=[
M?>3,)B^-9>'F[3@,EG=S<V74\;!.IHC[A'E290E,G'QX+ZU)="P&P1U#Q"Y'
M_F9XCWA^V_\`,ZYBY@Y$B[SH?*D_W";1RIP;R*B'+&.SFM8G<URN+\YQOEY,
M9W&Y[!X'`-8V&B,GUC$]+Z.8TEY+K5%44("SK_\`5S?SK/Y7_+_][^P?5^MZ
MO\\_]3'PS_-.R]_IO1_W0?R7T;=+_1^I;^O?K2I5-+5;$7^\"?F\:QG$)V#W
M'1\B[CW4_6ZWLW`7`F-9=[D)<2S/;P_%FOYQA*FUA0].2RH@@WL:5*KH;T+8
M'GSVQ<L?G-<&N_F<^VWC?'2?</B,\KB#W?\``&E.K#VR[;H6KZX]KW,?$F.R
MTUW(9"/G]`RN+CSL(IUV9]5#4(:IKR)"E,\50'3W3DM4_9-^:=[Z_P`J:7FN
M*(^KKE\?R\M*R.9X%Y]U3:L0UK^>>5'3E,MJQ4_KFU:9F9264ID-!3N.=6HN
M/0W'^UU*M%4M#L5W:X9_,_\`SI?S(-AT_2/;-[9M;]MO&N:SV%B[][DG-(S.
M;QVIZTO,Q6MBRN`VOEMP<>Y*7C\,IU1QD/$9?,/+`+`;-B*U*M+6C,K7K\\;
ME7W@_F%GC?B3B;\M/WU:[JW!_(/(.0G[EL'M[Y+RC&]3)$;&ZYB9^M,ZYI^2
MB-8'TH,U]M\S'?JV9#"PE%B*'L1M!Q"Q_P#DT<O^];\LAGG#7N0/RLO??R;K
M?,60T'+-Y/3N`.6<7G-;FZ8ULT*0RO%YO0!`S,7)0]D[T$2XBV78W:?42]W,
MT&'!5<`[[07:+^\C\8<W<S>Q[C/CS@CB3E7F'99ON:TW.;!@.*..]DY'RD+4
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MV%=T=92P[%8]-M!;+=PM3394JWB%=R/B*^9=WULF?J=WJY5*^`]EN;DE\9F=
M0$UQX^7K5Y%B(H!*HL<^'4LL7\/'_15S^J4$D2N\Y^M=A\0YP:'//#'"OJ4L
M_"QUB3$B%*05$JBQC\J1<^+1Z`"IHYK@D#Q75/Z1^M0RR'[,APXX?4L,3,GI
M>4<6G%8Y"E.)4\F2-8R,",ZI'=W*;R,C%1H#J_\`)(=LH>!-=O:6V[6P`NIB
M*&E/%:XCM:'EPZ\%SF^Q;E"V.^%V?`):,)1JQX:`[5AQ[H'2M7N70TW!FH2T
MT+@E!#*`$V"_`@%0O^BO0=EJ[0:\%Z-\NC-_$;-QF<1K%<7=(Z>M<?>0"/YU
MMEDWME!VE2B>W_5HW[H-[?XZ]=VK]S8XT[O^<5^CW+H/\/V:IQ\+JZ2MD^,'
M2/>-B"E0N7'D*Z"Q_P"J<TK%_@"*@^<`#N7-SIPAB_;8I=JHW9S7W?'D\Q?1
M>C;\G]IM&#]S@0!VQ^<)#+8_R&S"6HI3\`>P?HKTWY(.KR\7'[1BQ[8:^P+R
MC>*MN8ZG_5M];EV36J_7H+GP/7[OT5[C48K59G/!<D/SJT-N^R3(]_:`GDW1
M5)*E=@#B4YFUC<6)2HVKCN>>]R_.*_;;[5UG)I/\=@HW[#O8N/\`^6I,A83!
MY[.'&"8_#?G+4K&/XV7EI$=629;6E<,F-+:98'SEYUT-);237YR_.\2S;M9P
M>,1'1N!#M(HRN#L6U/0!5?1=G:NN[:WMFRM9K+L7G2P8FE2>FE.Z":TKAEWM
MXXWS"[DT!BFY[2$XS'Y-AV=$7&;G0,@9#+<B(I145I9EPG65]P24K0>A!!/B
M$($3S$?>:2VE<:C/+HP\XXUIS>^[/>[6YOQ89B]S30UHYH:ZAZ"6O#AG45/;
M;_/KZ&>/,Z5&W^KK'0]1\JOZ*V%O4SVX`^V%#LC3\6T]2\U^/R<C%M\MR6G.
MT_VC0LH`'[W^\+35M]UR>^U[@GP\J_1_E>K?DWM)`R,GH=#3S>U<I?BOS*OV
MTP%O!Z63$_5Y%[&-8?6[JFL*ZDN:]A'%'J;J<QD91ZFYO=1KZ)LB'6EL\?[-
MO[(7E,@`FE)_.=ZRJTH!(Z>?51^`^`/E677%0DG.E:*0>4"H!)Z7MXW!O8=1
M;P\JD#"16BN!H,5!6JP*?Z.@^SX"]7D!O%68$J44JW7]`/V>51BKW8JUQR7E
MJ_,@R[Y_,03CBLEF/!XP4E/4"R]50ZL`&_4J</XUS,4NGG[8H_Z:'U.6TW.$
M.^7_`##-3'P)1Z6+H#HJ@K`P+%)/TC*B3TZ%I1ZFW]4D?C7VQ""VU@K7+_-"
M_([FX'^+7=*%XD-1VU]IP\BQFU.7'YMX^;!/^L<P\0M"Q_>#FP*#B3XW(2NU
M>(_-?N[AM(Z&M'I`7V[_`';0!R?NV&>GSXGSKM=?HKK>Q(^'7SKA(N\.K4?V
MBO>\E*J_>'^'F3612M%:.*ISA'IJ/FI9M\3X?IZBI>*EH*C%4Y1ZD'XC]5Q^
MN]%<I%SR_'^BJ*O4O0C[._\`LU\6?]%9;_:;-U\V\Z_S1N_WV_L-7N_*O_8-
MM^Z[]MRV7KEET"41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$6-N9<%OVT\0<J:QQ3LT72^4-CXYW;`\<[E.+@AZCO68UK)X[
M4MHE>E!R;BF-?STF/+4$QGRH,V[%7L<FRDMXKRTENXB^U;*TO:,W-#@7-S&8
MJ,PL>[9/+:W,=M(&7+HW!COS7$$-.1R-#D5YA$_D%^[[G?G_`$KDGWR>[G6N
M:-.A92"-Y,#8N1LMO$_4<9ZLS^R&HKSVN8G$:U!R\M*6'%1G(Z(;<EZ2TVX^
M`ASU+_\`V!LUAM\]ML6SN@F(.FK6!H<<-3J.)<0,<:UH`31><_V(W6]OH;C>
M=U;-$"-5"\N+1]EM0``<L*4J2,5ZK->U[!:E@,)JVL8G'X#6];Q./P6`P>)B
MM0L9A\-B8C4'&XS'PV$H9BPH,-A#33:`$H0D`>%>3R2232/EE>72N)))Q))Q
M))Z25Z7'&R)C(HVAL;0``,@!@`.Q<5/S>?RD\S^8=D^)N0>*]PTKC_E30H65
MU#8LENK693B=HT&8\O,8>&N3@,5F)Z,GJ^P.25Q4%E+3C.4DE:PI#:3V_)_-
MS.76W=O=PODM)"'`-I5KQ@3B0*.%*_='6N0YJY7?OSK6>VE9'<L!:2ZM"W,9
M`FH-:=I7)[BO^[S_`)@/!^[8KDCB#W<<.<<;WA!*1B]IU+.<JX?+QF9T=R).
MB_4Q=(07H4Z(ZII]AP+9>;44K2H&U=;=_,3EZ^@?;7FT320.S:X1D89?:S'`
MYA<Q;<A[Y9S-N+7=(HYADYI>#CG]GBO7MQ_A\_KNAZ3K^UYQ[:-HP6HZWA]D
MV60YZK^Q9_&8:%"S&<?=^FA>J]ELBPY(4KT6>Y3A/8G]T>/7#XY+B>2&/1$Y
M[BUO0"20..0PS7JD#'QP0QROU2-8`3TD#$^4XJ[JA4JT_P#S`.;-U]N/LI]S
M?./'#3*]]XVXAVW8=0>DPFLE&QNP-P3$QF<E8Y]I^-/C:_)E)G.,O(4PZB.4
MN#L*J*HQ(7E&_NW>(U3W9>\+W.>X_P!T&RR^:?<OQ[K''VQ<89/DW(O;;FXO
M]I<WM,3=-]PZ,PJ4F)D=*<QF$QT!UD(1BF<P6XR6@I/;0*]^``&2]O-54:\?
M/]Z\5PVQJ?M29_E^`3[@)^S;I+;R42-"1LZN(X.(C1IT?.RF8_U[V&7M\N(<
M8F2[Z27FIOH))^H(H5(SCT+?7^[B<$;=P1^6Y)W[9=<RSN:YZY(W#FG6-=9^
MBA9K)Z2QK>M:?IL>&UF\EB\2R_M+FGR9\!^5(AQWHN1CN+=2R4NU<P!SFM+@
MT$YFM!UF@)H.H$]`*LE<0'$-)(&0I4]0J0,>L@=:W8A_FJ\(?[D=4]S>P<3>
MXW3_`&W[7L4[61S7F]'TW):MK,[&[CD>/I\O=L%IO(^U<B:GB(V[8I[&?52\
M(AER5V);*PXV5=.[E.^^.FVN.\MG[FQH=X0<X.<"T/&DN8UCCI.J@=EGD5S8
MYFL_@XMQDM;AFWN=3Q"UI:"'%IU!KW/:-0I4MS6RW%7NOT[EWGOF_P!O.`TC
MDC%;5P!!U#)[QLV>A:8G1)>.Y&B.9;C6;JV;P>[YW(9Z-ONMQ9.2A*1"0(T>
M*ZS/^CFI$56LN]IFL]OL=QDGB,5P7!K07:ZLP>'`M`&AU&G'$D%NIN*V-MN<
M5U?7E@R&02P!I<3ITT?BS20XDZA4C#``AU#@OWASWC<!\Z97W%8G1=Q8+OM9
MW[,<?<P2\TJ'BL=A)V"A29>0V!B:Y-=:<U!M_%Y*,G(/>@VM_%2[#TVTN+7N
MS;A8,VU\\.%W&'QTQ)!.`I3WL6FF.#AQ-$M-VL;UU^V&7_EGELE<`"!B:_FX
M$5PQ:5B/5OS!M2WO6L5R7HOMZ]S^V<%9W9,;K>"YYQVF<>0M'S?\VV./JN/V
M+$ZGG^5,-S=.TV1EI*.W+-ZD819)="^P$C+EY=FMY7VL^XVK+]K2XQ%SRX4;
MJ(+A&8@ZGV?$KP6+'OL4T;;B&PN763G`"0-:&FIT@AI>)--?M:*<5=O'GOLX
M<Y+YQYY]L^!Q>Z0_<!P#CG,OF>*LZUI>,SV]XSZ)N=%G<:Y0[L]J6;C3&YL%
M)5-R.-$)>2CB;],/6+,5QL-[;6.W[G(]AV^X-!(-1##6E'C3J%*')KJZ3IKA
M66#>K2XO+W;F->+Z`5+#I!<,^X=6D\,R*5%:8TMB!^85QIL#?#N'TGBSF[?N
M5.<]$R7*VC<(:OB.-CR*SQ1C<@K%GDK<,GG>4,'Q7HFIS\CV1XB\OLL.3)E.
M".A@R$K:1*[EVZC-Z^>[@CM()!&Z5Q?H\0BNAH##(]P&)TL(`QK3%1-WZW?\
M(R&VF?<S,+VQM#->@&FMQ+PQK2<!J>"3A2N"I['YEGM[D:=D\RG$\H,<BXCG
MC7/;#.]OD_5,9B^:V>>=P.0<U7C]6,R>R0]%1_:#&XF7.B9E6?3KKT**\X,A
M_#4!<>6=Q$S6:XOAC;NG$P<3%X3::GU`U8$@%NC74@:50<PV!B<_1+\0)Q"8
MBT"3Q'5TMH3IQ`)#M6B@/>7UN_YAFL<;:?LNY;S[:_=7KL70\9R#F^1L?(TO
MC2=(T#!\;?V9.>S.;S.)Y=R&FY;'S6]J87CE87*954YMF0IM)#"R*0<NRW,T
M4$&YVCC(6!AU/&LOU4`!C#@1I-=36TJ*YI-OT=O%)+-M]RT,#B\:6'2&4J20
M\M(Q%-)=7'H5-S'YE''&`XWU7E',\&>Y3':YO&T\3:GJ;4G4^.$Y'.2^<H:Y
M7%F2AH'*ZH'\GVEU'TX=7(2N%(6A,M#"7$*5>SEFYDN9K5E_:F6-DCG=Y]!X
M1I(#^'6K<\L1E56OYAMV6\5R^RN!&]S&M[K*GQ/</OTH[+/`YT60<A[W]3G\
M@\D\9\1\,\[>X;9.%WH4#F-[B#$<:#`<<[#,@?S-S3Y^Q<F\I<:XC;=TQL$I
M5*Q6LNYV:PM7I%OU@IM..W8IFV]M=7E[;VT4]3'XA?5XK34`QCRUI.3GZ0<Z
MTQ4[MYB=/<6]K:3SR0T$F@,HPTKI)>]@<X#-K-1X9JWHGY@_'NP93)X_CWAS
MW!\G1M1U#A_<^4,OJ.JZ+#B\30><M3Q6\Z'B]QQ6[<DZ?M65V%S4\W%G3X>N
M8[/.8UET&1V65:0\O7$;&NN;VWB+WR-8'.<?$,3BUY:6L<T#4"`7EFHY*P;[
M!(YS8+2>0-9&YY:&]P2-#FAP<]KB=)!(8'4XK__3].I4HCYC?]EO^*OI`@Z3
M05*^7))`.Z%#4L)ZG_#\/.K&Q8G6<%C9GK7GA_O#)*^%?;ZY>P3RMFTVMX^I
MJ$SK>_0CLK@_F"T"PLM.7B'U?E7>\BMTWM^*X^`/VPO/A[3%!.ZR4GJDM8Z]
MS_[$3U_37SIS8/ZHT\:.7)?W@6:^4F@?[1WLJN[&H+O!CF_3L'V?O`_JO7S)
MO@I.\4QJOSTV5Q\>YKEXA]/Y5?0-C>P/2W7\.M<Z17C1=:'`&M*X*3G*[8DA
M7@$LNDD=#^XKP/QJ>W%9HQ^D/6HI#1CJ?FGU+"\4!S4<'Z"B&CBH[JK%1"RI
M`(N5>*OF%=X[#=K[6.]XI"XC<WOCW#0]N`<^H&50XCU`=JU7Y?6?HI'3_P`G
MVV)^*7/V=:[W9`.[T+VKY<@&^MZ#'4/V@N0&]JOFMJN/'*6\>@(C1?+[J]<V
ML4AL17[/^<5^CFPBECM/5$/6Y9WXK=1.]VD!4BY]+,9%I7:XMJYAX":V!W-%
M*DCO;Z@>72L3YI2N=R]O!;0$,8WI^TU9-A'HVB"GVB7>=U5Z5/R@5?\`,?NA
M58`?[\WP!UZD8]\6%[GRKU#Y("O+6']%_P`$+Q_>A6[CQ^P#^W]:[(W)\Q]W
MZ^GEXBO;\,J+54PJ5Q\_.\DJ9]E/R*4/6Y<T1KY>VRD_2[$H@@@@@]M<=SW0
M;!**8F1OM77<C][?6`_[-WL7(7\NO7I&S:SD\0[.RD#'S,C+7(7_`"'%_12_
MILHQ);C-9?TU3G'TR8Z5EJX18%/5)(/YV?.B?X?=[=\<;'3^&T`>([5BRE=%
M0W(X&M:XYKZ/L+T6%FR[\(/D8YP&)PKJ%>@UU8@@U;4"F8[U<>ZLG5S,R:IA
MGRLFF.AYY;2FW$!H+<4E'\5:4(=>><=6E`2E3[KCA'<KIX1;L>W%QRX4Q%.!
MS/;B:@#'!<SONYG='0#P1&V/5@#@=73TD`!K3P8`W@K:Y[*9>FYV,L_+](MP
M6Z$D)4KH>@_=/ZZV5L[1<6QK]H>M4VIM)6%N:\TL^='$_F#&)<3ZC&9B/+;%
M^Y#:]^TI"5J!Z!)6K\:_17E*X9)\GMOMR[\5OB.(Z`7P@'S^I<QN5O+'S]/=
M%A\.2&)H/20R6J]F6F.WU+5D^!_LU@2FX/@K$Q%=W4`=#<??7TG8C38VF'^J
M9^R%XU."Z:4UPU'UE5QYSH4W^_\`36=&VIK16M!`J2I(G^M^(O\`#X]+5*2:
MYXH2!4!0%*N?&HB:G2%:3@%+N*L+_`W^'X>=2&C!09J,5=BO)[^9)EXCWYC6
M4=9?2K^6Q>,XTHI_=:?8U.`MUM2NEEI2Z+CR)KBS)&SY@['5_>:^)Q'1[Q`K
MU@KIIX9)/E]O[='O1R@==-(]BZ(\>9J&YKD%:74E/TJ`JQOX(\;^=B:^X[.D
MUG">-!Z@OR9YNVFX&]WPT=X2']K!8M.2C/<X\</H=NS"YKX>^I-E$(0O9"R'
M%$>">]0\:\*^:LPEW7:PRI-0,/T7`?E7V?\`W<[1\'*&YMG;2M".T!QKUXT"
M[G)<*@OR`6;=;].EKFN-A:0TU'VG>LKVTG`%0'%=/^4JX`_:?'RJ=HJ:G(*H
M"D'R`4I2;A`-S]IZFKA7$]*O;Q/`JG.*\?B3T/V"BN4DY_6^P#\.HO15&87H
M3]G?_9KXL_Z*RW^TV;KYMYU_FC=OOM_8:O=^5?Y?VW[KOVW+9>N670)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(K<W#4=:W_4MIT/<\-#V+3]VUS-ZCM>OY%"G,?G=:V3&2L-G<-/;2
MI"G(>3Q<UUAU(()0LBXHB\@_)/\`=W_=U[6.=HWN"_*[]S.*P4K!SID_5,%R
M)EY6K\A:O$G,K:EZQ_:&-KFPZ-R3@9:%*:=9S$3&L/QE):D-22E3KE*="DU@
MBC@MEL8C^](Y9IS6Y3GM>UE093`3O^3'#LATK]5$8YIN%AF]@9];L)D%"\(&
M^P$!CNLT6*IW%,\$?W?C=.3^<$>Y[\U;W(O>ZWD=;T.:_P`<:R]FAHDR1CY#
MC^.Q6?VO,0M=R4[1\?ZI]'7L1A<!`;5\G>Y&4Y'<4Z4+L*-"]-"(T7`85$3"
M89(A87%IC8C7L(SCH"!%QT0-0,-B([[^-Q$)(:90Q'0MV/&;':"I"!<7-`)`
M+@`3F<AUX5/F!49)`)`)/1T^>@\ZX$Z#[1O>7M?Y<&*_+JV+AC$<2R]IV+=&
M>2>;-LY(X^VK5]=T/;_<'MG-&05I6JZ3E-IV/:-S7@\JQBX[,UG$0V9;JY'U
M:4M([_0KC>-EBYE?S''>F9K&MT1-8]KB]L+8QJ<X-#6U!<2-1(PIBN&@VO=I
M>7V[!):"(N<[7(Y[7`-=*Z0Z6M))=0@"ND5QK@LYZ1Q/[K^#.;_S&^0>*?;U
ME\A"Y/XC]N_'OM/F9'D3B$-9/.>WGCO9.,,;E=X9F\A-3\/B,EE=K;S,8N-?
M4/8;'NID-1L@XU#7@3W>TW]CRU;W>XM#HIIGW`#),!,\/(;1E"0&Z3P#B*$M
M!<LV&UW.RO-_GM;`D211-AJ]F)B:6`N[U0"7:AQT@U`=@M=,3^6USUQ)S/+U
M[CEWD/>>`?=-[*LO[6_<WM6R/\#:UM''>2S&K9+3=#WE&!US;,&[R%N7';$E
M2\Y+*LA(D09<A46?EI3GI(V3^9=OO+(27(CCW"TOA/`UOBN:\!P<]M2TZ&O^
MR,`"!5K`*K7MY>OK6[,=N9'V-S9F&9Q\,.:2TM:Z@<-3F?:.)()HYQP68].T
M[\SOCOVV^WOVO<=:$]QKR%PC(TKB_,<ZZKM7MMV/@/?.%=:?A:Z[LZ\#O\7,
M<S8?D*-IN,;>C1F=91&7/=>>E.R>]+#6%--RO<;GN.ZW-QXMM.'/$3FS-E9*
MZITU92,LU'$ZZTH`!F<N*+F.WV^PVVW@\.>'2PR-=$8G1C"M'5D#M(P&BE:D
MDY"=YB]B'*7-<_G3FC2,'E?;U[M^-_<CG.:/:-S%-RFAY5G9\#)XVX[TZ9HF
MW1]9V?8UJTK=Y>@RT28688;$%G(L/!MU+N2@JI9;]:6+;"RGD%SM$ML([B.C
MQI.M[@YNIH[S=8H6G$@BHHURNN]DN;QU[>0L,&Z1W!D@D)::C0UNEU">Z[2:
MAPPJ#C5S53^(/;1[M/;KS+[8?=".)X?+$R-[!=`]HGN$X;T?<..\)O.F[/HF
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ME[LC.3)*W2Y!+O&US<R;)N%8XXX!&9GLC<ULCVDN<YK`"['!H):"2,0T44T>
MU;C%L&[V)\2228O$3'O:YS&.`#0YY.G#$D`D#A4U5\^X'@CW%[C[(/9)Q/I_
M"^6S')'$/('M/V/DK5G]VXNQB\#BO;RYAI&T?1YN9O#>OYF5L,K`)3B4QI3@
M6R^%RC$6E38@V^_VV'?=\NYKX-MIH[AK':9#4S5TX!M12O>J.&%<U-?65_+L
MVSVL5H3<120E[=3!014KCJH:T[M#QQHJGPAQE[I?9=S+[JXNI<`R?<3P?[GO
M<)M7N?UC/Z7R)Q=I>_<:[SRJWCCOVG\A8'DG:]7QV4US&2<2Q]!-PL[(NI;;
M),=Q4A8C67UUM6]V6TF;<!;7]K;M@<',>YCV1UT.86-<0XU-0X#M%,;K.VW+
M:+O<Q%8FXL[F=TP+7,:YCGTU-<'N`(%!0M)[,<-=/=M[(>:^?N4=_P"3N-?;
MYN7M\]U>V9;A9S2/=SQ)[EH&OZ%B=?P6H<9Q]LA\X:ZWOT+;]QS.BYB'G<;B
MW\)I`.7Q<:`'78Q;NYLMHWRQV^UM[6YW%EQM+!+JMY(27DES])B.@M:'`L<X
M.E[KBZ@-5@;ILUY?7,]S;V+X-S<8],[)@&@!K-7B#5J<6G4&Z8^\T-J0O__4
M].*G+)L/M'6WX?H%?20SQ7RHI8]RC=7@.HM>PM^JK^*M[2O/=_>$K*X+X%(_
M>1R]DA<&Z2'-.RAZ'S_=_57G_P`P!7;K/H\7_-*[KD/_`)[<"X?ZC_/:O/'[
M421NLCN\?3QQ_0I9_HKYRYJQM6]CO8N=^?@__:;2W,/?Z@NZFHDG'11?_P`F
MF_X!5_UU\U;V!\1(:<5^<FV:A<W+7''4LBCP'W#]E<LNT&0[%(9$_P"KN#R+
M;O</B`VKI;X]UJR;7]ZWM'K6/<&@;Y?5]=%B/#OQD:KBTN+:LC'M#T^Y(4VA
M"2+*;)"T%-NH(N#Y5VMTR0[I<EH/OG'I\JXW<HY'W,FG%QD/73O&M?+6GD6G
MG.^=CPF4M?3K<1)CS7TOMN-]H^E:)#2D6*^X]YZ^7G7H>P0NT$DX@@4[5[W\
MH=FFNY_$^(#7Q21@M<'5HYPQJ13(C"H-5R/W915D=H?("2K*6*;A5@E$=I2B
MH=/%'ZZ]=VUFF*PQ^Q7TE?H5L;@+?;(14@14K^L5EO@6>B=[H<=-2KO1*V+8
MW$JZ!*D.P<N$%`4?-/@*U7S)J_EK>G=;?VVK:1LT;79,X^&VO;0$KT[?E!@(
MUKW+N];.<XS`.G6X@N^/P)O^%>N_(YO_`.VI*=,7_!;]:\2W<_UEHX!C?\Y=
MBEDD>5CTO^JW2O;O#(RS6I+@1G@N-/YX[W;[-,:W9)"^8M)O=)(NG&[*JPZB
MUKW-<5\P&ENPYYS,]178<A"N^CJA?ZPN5_Y8;["8TU"51/J"]D%.!ES*"6E!
MG((4ZR^5XT,7_KL@/>7=XU^<_P`\VD;E;.>/PJ,]X#1[G2W\3TTZ%]!G_LYK
M6FH]'3YUW_Q"KXYKM_=2@6`O>Z4C_*^;P^->'P4(&DC+"E:>2N-.W%<?+@\U
M6'^7I`EX#,L*44@PG4W/B%-MF_3KTZ5-;N+;B'B0]JW.VFA97.J\O6PRS%Y3
MYQA7".Z)`6+J_?4CD?1U#M^WM/ZS7W]R5)KY$8S@;,>?Q6?4%C;I&#NME(1C
MXE/-&]>V'2'^[3-2422HZOKY*C_R\/"40/QKZVVYFJPL#P\%G[(*^?I@!/+]
MYWK*N!2BH_'X"MC@T!1DTS4-9_J^?W_#R^VHR:#K4)/$J56JQL/'IX^0_7XU
M(UH:VM,5"XDN%5;FSY_%:U@LMG\S+9@XK!8V=E\I.D.):8AX[&QG9DV4\M92
MA#;,=A2B3T`%03.T-+R0&@5QRH,3Z`IV`RD,C:3(2`!UDT7AOY^Y>R',/N$Y
M&YB#03_:?<)N9Q453C:%IPD5WZ3!LK)=`;>;Q,9D+`_K7Z6KQZ\W&:7?G;LT
M-UM>"QM0-36GNU).!/$+U^';K=FR-VJ5]&NC+7&A-'.&.0Z5GK3O>5_(,.UB
M9^O[0T\VT6RY#<Q\Y`!N`I'J.1%73\.M>^;5\]K.VM8[:_V"_$H&)88W\*5%
M=*^<=_\`[NK=TW%][!NUDZ$FO?#V'IZ'C/I"R_PGSJUL<OE#-Q\3*V'*X#`Z
MUR1B,+(4U&DR'=$V%K(R&"\T^\AI]#10;7!4;VO:H9>?=MW.XN-Q^"?<1LM7
MGP^Z'U.JHP+@'`D&O"AP7:;1R#_9O;+3:1-'$Z29K?$874J*4^R*@BN%,<.E
M>FKCO=L1R'I&L;W@I")>$V_`8?9,5)0?E=AY?'L3FAT`/>UZQ0OH#W)/05@V
M<S;BVAG8_5$]H<#TUQ4=U`^WGD@D_>,<01T4.2NMQ=KJ\5&X3>QL#?K^-9U#
M@*=U0``]@4BZH`V)O>Y5^(\"?$5><%>VN-53UJ\57`/]4>/A\.G4=:M5RE%J
MOTO]Y_HJA5PZ5Z%O9T;^VKBL_'$Y;_:;-U\V\Z?S1NWWV_L-7NO*G\O[;]UW
M[;ELQ7+KH4HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%^=R2HH"AW)"
M5%-QW!*BH)41X@**#8^=C\*(I+&Y3&9F(F?B,C!RL%;TN.B;C9<>=$7(@2WX
M$YA,F*XZRIZ'.C.,NI"NYMUM2%`*20+G,<PZ7M(=T'#/$><8JUKFO&IC@6]6
M.6'K4]5JN2B+\2I*TI6A04E0"DJ20I*DJ%PI)%P00>AHBQ:SSGPE)Y+7PM'Y
MBXL?YC:C/3'.)F>0=2=Y+;B1X2LB_*7HB,NK:41F,>DOK68O:ED%9(3UK+-A
M?"U^--G+\%6GB:':,Z>_33GAGFL87MF;CX,7<7Q?YFINOI]VNK+')93K$62E
M$2B)1$HBL/'<J<89C?\`8.)\1R/H>4Y3U+%P\YM7&N.V_7IV_P"LX7(MX]['
MYC8--C9%W8L-BYS.6BK9D28S;3J9+12HAQ%\AUI=,MX[M]M(+1Y(:\M(8XBM
M0'4H2*&H!X'H4#;FV?/):MN&&Y:*N8'#4`:4);6H!J,2.(5^5CJ=*(J8QFL-
M)RL_!1LMC)&<Q4:#-RF&8GQ7<KC8>4,I.,ES\<VZJ7#C9%4)X,..(2AXLK["
M>Q5B*IT1*(E$2B)1$HB418[B<O<3S^2\IPO!Y0X[F\Q837F]NS7$\3==:D\E
MXC5'7<<RUL^4T1G)KVF!KSKV7B(3-=BHC*5*9`7=Q'<17S/GP<5!FY3*38F-
MQF-B29^1R,^2S#@P(,-E<B7-FRY"VX\6)%CMJ<<<<4E"$)*E$`$T11F'V9++
M,F,\U(CR&FWV'V'$.LOLNH#C3S+K94AQIQ"@I*DD@@W%$46B)1$HB41*(E$2
MB+__U?3.2>[J!U/0G[/QKZ5`'E7R<7DUHH:EI-Q<]1U%NA/P^/2C@X@@9HUU
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M<8NI!$)7"@<:`#(`5H*=2T]_ON]0[M-:P[I<-@:Z@#7N%*/-#@0<,,S3`5KB
MM2N:<;CV\59B&B,W!;DH8BP6OIVD)E(6ESTF&$&QLX39*3]U=UL\DA<2YY)=
M3$FN72?K7O7RKW"\DW73-<E\DSVESG]YQT$.%2X].`Q[,5RIW,%N;L;*B3V9
M$D^H;K*ELQW%)5W)0N_<;]4@WKU.P)?%9NP]RF'42OO;96-\#;7C/1[7!7Y[
M5TE?.NDA8[U+D9)PE?7YOY-DW`LD_P!86O?RK3_,*HY4W0DXZ6?MM6[O"&VY
M(R"]07Y/$\R-7]R"7$@%',ZW2H+NDKDXYT#_`"OW%I[01XWO]M>R_)(!NP3,
MX`Q?\(?4O!]X`$UO3,Q`GTKLRMPI!3X]W6W^'A7N1H%HQJ<<!@%QC_/)<_\`
MY.\,"2">8M.Z=_:/EQ.S>)\ZX'Y@N_Z#AEXS?4Y=OR&#_'B>`A=[%RI_+51(
MDL=GUVQPX\3(39!$?*X7^433]6@&(J`IB1DT@]W<M1+8-NA-?GA\[0T;A'2.
M)\CFM'N2>(WN^]J!#.H4KAG0KZ";((]K(+&DFN8-1B:D<.SCU+O[A)05#2V3
M979>R3]W3K>XN*\-@80&N)(_+YUR,H->M8/Y>EN(Q.3M<68?`'3KW-*^^_6U
M9T<##<P/`[I<T^I;3;C^(P5XKRV<@Y!<+G3?V'.X#,2'H7P!4SD\-F&P>MC\
M^.!M\:^Y.47"/D^T;7NNM@/\H'UA2;@TR7L3J>Y(#_DN"]Q6@K]31-,4H]5:
MGK2B+&_S86$?$^5S7V+MYI96=!AX,?[#5\Z7%!/,:8:W>LJYUJL.A_Q_9;I6
M80[.BQ"X'%2Y6`#<BWZ_^.JAH!+BHBXG@J;)?((L;6(!L#XGH!?KXVJUY%=5
M>Z`C30XYK@[^<%[Q(^MZLKVPZ'F4#9MM8BSN4)<!Y2G\)JO>),/5G%LG_5YV
MQ.,H<DH)[A!':19ZN`YUWIL$'\+@GI/**O(Q(9F&X<7=M=/:O0.3-F=-,-UN
M8?PF>X#@"[IZPWA^E3H7FN[U+!'4`?N]Z2#X7%NX`BU>3ZGN:6NKY5ZC0#$%
M?B24_P#E%`>!/<KXWZ]?*C26_;P[4(!^R*K9SVMYB?BM^F1EQB_KF=P61Q>Q
M+5<)3$=95],$K24K]5V0L-62;]CBE6ND$=[R-#??Q"5S+9[K%T;FO=4T`.5>
MLUIU@KE^9_AOA(GN?2X9("T=/3YJ5[0NRWY8GNPP6"R^P^S[;\RIIS7MFV4<
M-Y#*WC_S+#*G29TC3U+=`*,@PKU9<-"C_%:<6VB_:A-=-ROO$-G>WG+4\W[F
M9XA)PJVI.C$9C$MQR*Y+F7:I+BWMN8(6"DL;#+3@ZE-78:T/0<\UW!]4=H43
M<@63<V'G;I^->CU!R."X:A.`4HM?C?P)/<3XWM?I]]ZHK\E(K5Y_@/\`#[J*
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M/(4GVZ:DCW89C?LM(X)A<?;_`)WD'B7BS0^+\SR%DLOF^8E<QXK";-NN/RKN
M$PDUF/ID;&)F9(AEU2&?6=YAVV[*ZQWF:W%R_P"$#!XI>P,D>]X8`(_#):TC
M4X5D+J-Q&-!T+;_=VWFU13FW;\47'P]+BYC&L+B3)X@!<#I::1@5.!PJ<4>W
MZ?[F\/,_,6]U.;YF]NJ6<5R5R'I^6F#VU\A.P)Z/:/QGB=(:S>*;1[MQ(P&J
M0-DP^>3,P4B1D);F0^ID(R<=N0B+&S-Q;M;V\M[3'97-3$QP'C,J/B'EU#_5
M\7%I91P`%*#02*G&L7;BP[_N;[NWH)'M/X3J'P&!M1^/@T$.JTDFM3J%:"SH
M7O8S'$ND^V3V[:#C>#/;7O\`M'M>U3W.\JM8/@'EGE/4-,R_+TW(9ACB_ASV
M]<4[%C]LS^\[=OLK,397U6;"8C#*W2B;(EM]DSMC9=S[IN5P^>YMV73H(ZRQ
MQN<(P!KDFD!:&M8&@4;B33NAJA&\/M8=NL(&PV\[K9LSZ1/>UI>2=$<3"'%S
MG:B:NP&.)*R1L7O!]^L7;?8;QSAN*>'<?RO[L.(-_P`_R5QIN>E[YBW^$MEX
M_AX65EN2-DV>)RR^[B=`1&W""Z-4D8=[-*F07<7_`#=,J<VY!QH]FV`P[_<O
MNYC:6DS`Q[7,/BM>31@;X>+^Z?Q`[30A^BC:.R)-UWL2[);LM8A=743B]CFN
M'AEM*O)UX-[P[A;JJ"W74]W%WN,Y-]S?/7LQY8XHR>]\-KV;9?>3(]@N<V#7
M^'M\C8_E7![3RQH?&$[/Z[CFN=V)7%LS68N:SHSK4F3L<>8UB7667(:7/K$9
M6VVNU[?O5I=LMYO";9?%@&1E8RV-[P"?"_$U49IH&$:@36E%C;A<;C>[1=6K
MIX?$==_#$B-U'ASVL)`\3N4J[54O!TD"F:ZVYU[E;0^`-@R.>Y%XFB\D:=J^
M<SN0Y!@<*[5$XJ@XS`29F84\UPROGES9Q'@:;%$13(WI`<FH,I*VF5"&GD(Q
M:7&X1MCMIC;/<`&&5OB$G#]YX6G%V/[K+#$]Y=2\W,%C(Y]Q$+AC22X1NT`#
M']WXE<&X?O,\<!@N2'M%V7W.<:<4>V'C36$\";-[@/>KJ^R^ZZ9M>:X>W;"M
M<,:ILLB)R'S+R!S5F(_,^:S?..US<]S%KNOZ[CX*=+;9(4S)D>@T@-]?O$6U
MW5WNEU+\0W;[%S8-(D:?$<VK(V1#PP(F@1O>\GQ.D"I7+;5)N-O;;;;Q^`Z^
MO&F;48W#PVGO2.D/B$R.)D8U@'A]!-`L_/>]/W!Z'.Y,]N^P8;B;EKW4X?W`
M\8^W_B#/:OCMGX]XSW1_E3B-OFIO>^1]/?V'D#9M(QW&''N.RV2SL:#E)_\`
M,!#8:B+CF6A;>O&R;=.VUW&-\T.TNMWRR!Q:][?#D\+0QU&-<7O+6L):*5)-
M:+..[WT#KBPD9%+N8G9%&0"UCM;/$U/;5Q:&-#BX`FM`!2JRMR1R+[P^#YOM
MPQ.U\E>W+D;)\S>Z;2N)<K"U_P!O')>ER7=#V3%9G<MM&OO/^YO<48;8-,U'
M2\X]&R$J/DXS[28WU$5"FGG)&);6VS7S=R?%;7,;8;1T@)F8[O@AK:_@-J'.
M<T$`M(QH<0!E7%QNUF=O;+<6\CIKEK#2)[>Z07.I^,ZA:UKJ$@@X5&=9?E#W
MB<G8'<_?=A^*>/\`"<G1/9]P1Q9L&-UK'PMBD[;M/.?(&/Y"W#*ZW*DXB7.3
M+UO6>/L;KTYS'P<8<JXY.=2V^XMQMEFMKLUK)!L+[NX=$;RXD!<2-+8F%C0Z
MAI1SGEXJ7:<!AF32YW:Y9-O3+6!L@M(&$`5U&1P<XC"N`:&F@&K$X\!BK=??
M1M?#OMXXHY!R7.7MTYZVWW0<I8[4>$M_TSC3?N/>&M/P,K$2,IMN;W'!1N2^
M5=VVF!QQ_)9S2HC$O%Y:;/>BXYY$1XOR&<N#88KW<;NW;87-O#:Q%TK'/8^1
MQK1H:=$;6E]1B0YH`+A44!Q9MZEM+"UG=>V\\MS*&QN:QS8VBE7%PUO<0RAP
MJUQ-&FAJ1)Z![T_<]/U[&Z6YIFH<A\H<P\]2N+?:UR1FN,.3_;CH_(?'6#XQ
MB\D\D<W;OQ%O><VCD?7=-XQ^FR6/8]&:@[5)1#1"4RW)^K-;C9-K;(Z<3/CM
M8;?7.P/9,YCR_0R)LC`UA<_NDX?AC5JJ114@W?<G1MA\%DES+/HA>6/B:Y@9
MK?(YCB7AK,1GWS2E*U5Z>T8\C;Q[V_>/N?*V]<><E9WA;1^#/;1B=IXMXWV#
MC'4X\]X[MS=R!K_\CV/D_EZ9*S>%>Y`P427(;RX3>*AIR.V\TXI<.\?#0;'L
ML%I!)%'/)+,6O>'NIW8F&H9'@=#B!IXUJ00IMK^(FWC=IKJ:.1\+(X06,+&U
M[TCA0O?B-303JX4I4%9$_-(R,_\`]0[S+HF&?D-[!SR[Q][9,`Q"4!D)\_W*
M\EZAPA(AP$J;=#D@XC>I3A24*!;;5\JO`\J5TK<PM9_>+[5/;/[7L+[?.8/:
M]P]Q[[=^?87NP]J_&W'^3X,U#!<:S>1<7R+S-JFG\C\<;Q"U&+AH.]:SF^(L
MGL$J8WE6Y1:$(2>]M3/J)HJ@DX$X*V=G]T_*?%N-]]W/^/TKV\2-@X\]W7%G
MM3F>X3%\%<B8]G`\/8/":#FMJY,YZP.N\I[ANO)&N>WF5R[D<>O^6Y;`1)!Q
M[\HC'-NN,Q24&`6R63]P/N)?S/`?MEXHY&]O_,7/_*O&NX<Z[9[D6..=FQO`
MFG\`X;8,5AM8WW$<5Z_S'L62W;8=YG[7CL;AX4;>(T&8N+.R2GVHS2(BR4&)
MX*4B\J^]G?\`D_9O:_QOO7MX@;YP+J&N9OW#>Y78N#=_DZ3E=IY+E[#G>*>/
M.+^!8W/D;*0,RCCO$Q)VT92?N<^'%<G-_1Q27@U&JJ89K''`_P"8]NN?R7"^
M4]PF-XCX_P".-V]NWO7W7==PU>7L4G'Q.5?8S[@L;Q3R/D=8R.6RKK:N+-GT
M)R5LD",]&D9..VT$*ER$I4HTJJEN=%@/*_F@\[2LAH/&V6E\8>W_`)%Y*XWR
MWN?=D[;P3S1SSLV@\'<@;AG\/[;>&,;PGQ/MF*VKDGW%;5KV$.2V&2F?B<=B
M$`QVX$B0M%E4TJ_]L]XGYC;^V?E_<4:CQOP)JG,GN\X1W_;>6M%Y&XWY,0KV
M]9SC>/K\W8N2\UE\=S(R^WJ<F)ND!B+ILK%JRS67CJA/YONE!40E!CT+(F=]
M]W-O&O&/O%T_>,+QYMONIX3YVX[]MO`&&U#!9S7]7YHWKG[BKBW9^!\G/U_(
M[?LN2C*E[#O&1EYZ/&GMLQ,-AI"DN-J:=6@E,NA;=^XWGCD+@[1^'-/U+`:S
MRE[FN==RP/#W&N%FN933^/LCO:=2S>Y;]R#LYA_VFSV`XWT/2]/S.?E16%2Y
MKS45J`V\'9"9**J@'F7.S2MMYQ9]UGY@7,/(7,/!.T\A>RWV=Z!QWC=_U;@7
M=M<XMU3+[U(W;W%\EZOF./IWN1V79=ND8'7-,UE4J2UM>$*TRH[9:;=C/J>H
MJ\`.E6S*]QOONY4_+XU3W"<YZG[1(,7W.R_;-QUK/M?V/@[DW?L?N.N>X??,
M)Q/E(^RR7^><`['G\BJY"@9_&10WD6\+@8)B269TZ4N1#*M`#0+9C;_>SR'Q
MGJWO#XTPF@Z,[S;Q#[BN//:[[/>.L-#FXK!;Y*YLX<XOV_@9S9&G,_,"H6NN
M[/FLAL3L-6,AQ]<UN26TLO,/%)4IET+6_(?F4>Y'D'D3<-1]N2N+>0<_P[SC
MB>`7>(87!',^Z;=[BLSJ6PZ[I?._*'^\[6]TQG%_M:XGUS-R\RY@IF=<SZ9*
M,,7I#WIOL,/DH.*N_>_>;[YYO./Y@O&'&TWVT8GBSV4ZY%Y&RG/VV\0<E2<=
MBH$KB>=S!!X3E:U!Y^,?D/?_`.42H<?,[)$F8"#@X\.0^K#NR,A$B124&'6N
MN'!V[9ODOA3A_D;9L7&P>R;_`,6\?[ML&%A(DM0\1F]JU/$9W+8N(W,=D3&X
MV/GSW&FTNN+="$`*457-55I64J(E$2B)1%__UO3&M1ZBXMXV'^/SZU]+5!P7
MR0'-Q.2E5NI'[O4^?P'A]U[TK2F-5*UM<RO/_P#W@5)7[?.%'5`W;YKDI1Y_
M*YI6P7O_`-TR:\]^8'_:K;_?^PKO>0R#?[A3_P#&_P`]J\Y_M?<"=T='=8J8
M@GP\/XRSU\!X5\[\S_\`*LP_.]BUOSPC<[E&3HUN_97=72W;XR)>W1/W$W[>
MAKYOWQG]8EZU^:<;C'N4K3P/K"R.P;'NN;$>!/R^7V^5<M(,*<5T]N<2ZII3
MR*2R*C]-+4H]#&D6/D?X+EK5-;#\2(#/4/6%:\N,V.1!IUX%8.8DAO3]=;7?
MYL)CEA0-TE/TK?8`1T-[BN_\/5N=\\?[5WK6@NXGNY@O\0")I!GPU8?X%JIS
M$ZVY">4@]25$^!/1#H`\O$"NXV<%N!RI]2]Z^6$;OXI;EW!P]:Y*;P/^=MH/
MQR0%OM^FBW_&O5MM_<60_1]I7Z$;)_R>U_[KVE73[>IG\KYNT&27`RTN>MEU
MQ9L`T]CI;#AN+FZD.D5C\^P>+RWNS`*GPFD=H<T^M;6<ZK.4G$@GUKT[_DN.
MA[2_<2Y>Z7N5X3B5'JKKBWEFY^`*:]<^30T[-?-XAT7[`7AV_D">V:!CX+1Y
MZT/H7:TF_P#AXU[4<C1:(-T]-5QC_/)5;V@X$&_7F'5+6%_#%;";=O@;7KA/
MF!_V%G^_;ZG+M>1!_P!<I_0.]BY/?ERSGL;C\U-CP?JY46-FY+++N'?QK4QR
M.YZS416R>FY%<2IQ((:*5J0KYNVR;U^?/SIB9)N5L'R4;1GVPZG=S\+,=O'+
MBOH2WB;/8P0N)$<DH87"ITZC0'2,3PQHNW_'F]G9I28CF/;B)7BU9&(MN6EY
MWMC)P[<U,UCTT?3I<>S"#&(-G6T*5TM7A;XC"_PPX.K2M,,Q7`8D"GFZZK3[
MMM+K"$3^,7#Q`T@MTUUF0MI4"I:V-VOH+@%:',CW;C9X[A;TWOE\/ZIZ??85
ML;2V/C0.KAJR6-MV$C*#"OM7F`YGBD<RYR78`C9EK'E\BFHZ//XW_77W;RC8
MD?+K:IW^\UE?(7$_4K;FY!W>:)IP+:>7%>W_`([6/]W^DJ\1_9#5STOYX*`;
M?KKZPV[_`+?8#^A9^R%\\W+_`,>XX]\^LJZE*[C?PK/`)6(YU5(R7$@'[`;J
MO:P\[GRM1Y`;2J`9KE5^89^8!@O;'@GM#TF5&S/-&>AMKAQ6'&G6M,QDM*DC
M/99)"FA/6@%4*.N_>;+6.RW=R^][_:;((_&C,DKB#H!`.GI-:TZ<11V2Z?E_
MEV;>)=;ZLLVYNZ3T#IZ^A>4_;]_RNV9K,;!EW!-V+/9*5E,QL$QQ^3F,E,F+
M4X\[+DOO/H%RJW:VE"0!9-AT'F6Y\T"YDN9+;;X(KF1Y<Z4`^*:\"2YS&@9`
M,#0`O7+7;!%'$QTCC$P4#<F@#+`4]-58RGE+-R>Y0^SQ\+]+5RSYWR.UO.IR
MV0C#10"@4(GPN".H_P`?X5&3YU=3K60>-]JE:YLD1:)):CRU!AY`-FRLV]'U
M+V"0%@?,/"_PO73\M[Y=;;>-B%PYD$A%:4SX5'H6FWJQ9<VCGM8#*S$=-.*V
M!Y+CYIF;$Y6QT*+(5"_E+DG(XMZ1C-BP&2@+2F#F&)4-;1*_4#:2X4*+:@+B
MQ!/HG,=ZZ8C?KW:;:YCHQKGLK%/&YONO!80#44:XN:ZF&6"Y?8Y8W!^T^/(Q
MYJ0#0L<#F"#E[5W5_+Z]_L/W#8B+QAR,^QCN7,'`4&92EA$;>,5!0`,C&!Z#
M.18Z4_6,BWJ$%Y`[2I*-AROS5'O4<D,T0CN&8TK@YM12A/$<>DXA<YS'RX_:
M'_$0.U6CCT8M/0>H\/,NI:G@4BYN%6%P+W^%[=!X>-=J'--*+E.I05KMU_`"
MAP5V05/><\O,^-O$=1_15H"MJO1-[-/^S-Q1_P!$Y?\`VGSE?.'.O\T;O]]O
M[#5[MRICR]MOW7?MN6SE<LNA2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBQ![
M@.)D<\\'\L<)O[+D=/A\LZ!M''F2V7$18\S)XK$;=B9.#S#\&-+6B.[(<Q<U
MYM/>;`KOY6K,V^[^`OK2^$0>Z&1KPTX`EIJ*^4+$OK7XVSNK,R%@E86DC,!P
MH:>14?G7V_ZCSE[=>1?;;/D3=6T[?N-LGQLS,P5C,UO'2<3_`"S%2\<U(66Y
M)PJFF7$LNJ+;Z6O36>U2JOL-PFL-RMMS:`^:.4/Q^T:U->W''@K;VQBO;"XV
M]Q+8GQEF'`4H*=BU<T?V([GAO=)H7NYY$]RN>Y6Y5U;0=HXWS7\XXUUG`Z_D
M-5V&1AGXV(T["X;*IA<?0L4YBGGRMI$Z=+F92<MZ4IEUF-'VL^_0OVJXV>VV
MQL5H^1KQ1[B0X5Q<2*O)K3@`&MH*@DZV'99F;E!NEQN+I;EK"PU8`"TTP:`:
M-I2O$DN=4TH!/8'V+[%CN"/<O[:\K[@,SD^*.?7.8DX-J#QYKN%W/CN)SSNV
M];GR6U*VQ&3G?V]E91>]R(<=Z9$C?31VTCL6+)3;)OL;K_;-S9M[1=V_AUJ\
MEK_":QK.[0:*:`30FI56;+(VRW';W7Q-K/XE*-`<WQ'.<_O5.JNH@5`H%<^X
M>T;>XG->U<U>WOW`R.!\AR-H'&7'G(^NO<5ZIR;A\QC.(G=M;T7*:X=@R.,=
MU;,XO%;K-B**A.B.H2RI4<E"N^*'>+<V,5CN.W_$-BD>]A\1S"#)IU`T!U`E
MH/`YXJ67:YQ>2WEC?>`Z2-C'C0UX(9JTD5(H0'$<1E@LXQ>#,6W[B1[C9VP9
M+);+'X+A<&8W$/Q(#6.Q^+7O,C>MEV!M]AI#_P#,MIGQ\6T^TD-QVT8MLI22
MKY<$W[_X;_#6Q@1&<RDXU)TZ6CL:-5./>*S!9-^/^/=(3)X/A@84`U:B>UQI
M7A@%K1L/L-=>X1XKXQT?F?+Z=NW$WN5V#W3XGD^9I.%VK^T/)&T[ARCN&:&W
M:?-R4")F<6[+Y6F!E/UK;K"X<1:5D,]AV<>_@7UW=3V0?!-:B`L#BVC&MC:-
M+@#0_ACAC4]*U\FR5L[:VANRR:*X,P?I#JO<Y[CJ;45'?/'"@Z%;7OLYOUM?
M"'(_LYU/DO$;1[O.:N-\=Q#K>@X",IW>GU\PML:#EN39VK854A[4M.P.%R\_
M-3,D^XQ`QT:(K_6`L-A4NPV,GQUMO,ULYFSP2F1SS[OX??#`X^\XD!H:*EQ.
M6:BWJ\C^#N-IBN`[=9HPP-'O?B=TOH/=:`2XG``#-9?Y3]I69SF[</\`)_!G
M,>1X&Y$X@XQV3A.%E3HVN<EX'9N)]FDZ9DG]7SVN;!(Q91+Q.;T''3(,V)+C
MK:=2XEU#S;G8G#M-W8R"\M;^R%Q;32B4C46%LC=0U`BN8>000>%*%9=SM;WS
M6ES979@N(HS'72'@L.DT(-,BT$$$==58$[V`,8_5M)FZ#SKOFM\_ZASKL'N0
MR'N#V/7]0W7-[[RGNFA9OBW<W]VTES'X'57-4R7'&>7A(&*Q:<6UA\?%BMQ5
MI4RI;N0WF`NEG%Q81NV]\`A$(+FAD;7B1NEU2[4'C47.U:B37/"!VQAL<+H+
MU[;YDQE,I#7%SW-+':FT#=)8=(:W3I`%,L;RY,]JO*/)&"]O>7D>Y;+8[G7V
M^;]N.]X?ES_=;I\O"YY[>-2WS0LKC)_%*)L'666\5IN]+A8J07WY,7Z5+SRI
M+SKRUP6V[6MM)N+!M@-A<1M88];JC2YCP1)0NQ<VKA0`UH*`!2W.V7-PRP>=
MQ(O8'N<'Z&T.IKFD%F6#74!J2*5-22L=\*>Q'D'VXXOGU'#WN=RC&U\\\FXG
ME'+[YR+Q7@>0=DCY]O"XS$;/*S2CLNO0MCG;:YC52W%H;Q\2%*EO_316VE-M
MM9-]O]ON3]O-[M8,-O$6!C)"QM*DMIW3I#:TXD@"I)Q,%GLL^WMOOA-Q/BSR
M!Y<]@<:T`-<14NI7@`2:"F"_$?E[R-;UWBG(<8\\[#IO-_&'+7,/-#W+F3X^
MTO9,5N&W^X"'EX7++.8XMB)UK5\;A,LSE$)QT?'.Q58T16CWON%YQU_:(2R7
M;;K;VOL988X_##W-+6Q$&.CSJ<2*=XFNJIR%*/X$8X[5UO>N9>1RR2:RUI#G
M2UUU9@`#7`"E*#/&M_<D>U'ECD%C@/;&_=#FM>YWX.E\G(3RY#XGT67!V;`\
MLX][%;'B%<<R'D:_AY.'QT?'-XF7ZTI3"L>%RFYJWG5''MMVM+<[A"=J:ZPG
M#/P_$<"TQFH.O,U.K4,*UPTT"GN-LNIQ8R_Q(MO82_OZ&T(>*$:,A04TG&E,
M:U*M'VZ>Q'9O:]J_(>I\7>Y/<6H_)'N&P//.P['L6CZGM.[Y@!_#1^1M7V;9
M-A<R2<]+Y2P.O1(\[,)C194*4J1+B-MK?[$3;EOT6ZRVTUUMC*Q6QB`:YS6C
M/0YK12GADDAM2"*`UHHK#99-MCN(K;<'TDG$A):TN.6L$FM=8`!=0$&I`Q69
M?=S[<-E]RFI<8X;4.5U</[+Q7SAH7..#V1S2(/(>/G9KCQC.N8/$Y;6<AG==
M8E06\WE(V0"OJ04R(#0*5)*A7.+?@T5K\>>SZ<QR?J_.'N+YNW+W,\J:`SE&
M^,!L6N:AH/%?$\O.0!C,YL''O%NG8YJ*QN65Q[CT16;S.0S>5CP'W(T9]AIU
M\/$KP"IT;VG<HZ/QUG-(X/\`<B[QUE]YYLYRYFY*W/9N'M1Y0R&T2.;MZV'<
MY6`Q^'SF7QF#P<?4V<VUCH+KK,]M42$TAQ@HNW1*]2Q/B?RWY_$<O@C*^U7W
M'[CP=F>&/;ZQ[9<E(V+0].Y=QO('&<39D[K"F9/!YDZ[`P.[PML?ERV9\()A
MM-RUQD0DQ@&JHJUSJ%<FR>QOE1/)_)_(_$WO$W_AZ1[A-<XTQGN%7A^,.,\_
MM&V[1QMHT7C:+R+QULN6@(Q_%&WYO3($:/(+>+RL)A^,T_&CL+18U5*]2<I?
MEC^W_DC0O:?Q-%>S^G\6>U/)M-8W3<.^U(;Y,T1['P&-DXYY"R\N^4R>`W[*
M8:%,V%P+]?,.-NA\J]=:@HFHXGBKIY#]H/)C_N%WWW$^W[W+9#@C8N8=&XTT
M7EW"3N)]2Y8Q6R1^)).YJTG/ZXK9<IBG-2S\#&[Y/C.DIGP7QZ3BXQ4E?J$K
MA0A7IR-JO$'!W+F;]]/-G+>.TS"ZAP!KW`$W-;Q*PFNZ5JN)SG*S&P9/8YF;
M>$=,7*[]MLW`8]3-VHX7`CI0DJ<`23$B@6B'M=X$E>Y3WZ<S?F*9F+L.+]OI
MG:M#]JNH[+C\KA'.1=RUCC!CB?8/='D-4S@:R6(@JUY[*8/4#)CQ7)F)G/9'
MZ=OU8S[M%4X"G%;Z^Z#VR;%SOG.#=^X\YAR/!_*W`&Z;7M6D[I&TO!<B8U</
M>^.]EXTV[#934-BEP<9-5,P>QEV+(4Z?I)3"%EMU)*:JJ`TJM6^./RM\=Q[P
MM[UN##[AN1-FP'O7EY:?N^YY["XF3RC`R&V:5BM%W_*93<')SK.V9'=\9`??
ME!<.%$8DY"28\=II:6DTHJZL0:9+=GE_V\:URVQP+C)&5G:SKW`W-.A<RXO7
M\+&B''[#)XUP6R8_4-6R*7P?I,)B\[EX6406AZ@?Q+*18$D55*YK%C/L=XW_
M`/5NY'WP3\SF<EM[W'N.U+#Z))9B?V/P.WP\<]K#_+4;]Z:_OCW'K[FNLNJ(
M:BXJ3*0A/=)<51*X45+X']IW+G`&XY"#JWNAR.1]N\GDWESD^#PAE>(-*7G,
M?.YBWC;>3-@US_>VB?\`SB3K<+>MUFS(P.-1/#10PJ44))40FO#%1LU['-5S
M/!7O`X1.];#CT>\W?>6]VY'W*!CX#>=@L<LP<5K$[`8]IQQUB1$PW'N"B8-A
MUU7<J.UW]J2>T$KB"ME-1TK<]<WWD'.9'DJ1GN.,_BN/\9QKQ,-0UO"XSB/^
MRF+RT':'L;L^+9;V#:T[W*F19"V\DI:<;]$EJ-9M:Q1%E"BHE$2B)1%__]?T
MLJ>1:ZU>()``L/U]:^E=)\J^0@75P"E%20+A";"_17@?OJ_1Q)Q5_>=0N*X(
M?G_`+]N/#+H-RGFY((\_GT?:KW/4=2DUY[\P13:;7H\?V%=_R`?^H;@W_P#M
MC^VQ>;[VTGLW51Z=6(1^[^(I/W]*^=^9?^69VN5OSG&OE*=M?M.]07=+2G0O
M%QBD'H$]?B.T?:37SKO;*7+ZE?F+<.`W2XH,CZ@LE!0[0?`$#I7*%O>(6^:[
MNC'@I#*N6@R0%?-]-(MUMT]%?G61:-K,PTPU#UJADI)`*][5@M=\/C9$76]>
MEO;!F\@ES7L;V8V6</\`RV-ZD%AR['TV'CY`AN]D^I(7]I/2WH<DK9+Z]8VU
MC929W>&K4>\1C5Q;CQHT=5%F;MN5K<;O?6\>S6T4[9W@RM,OB.HYU:ATCHQ7
MCI8T]?!:R\NK2(KX!ZDK4;?^PW?TE(M78[6#0=GU+VCY7@OW"U!RU>LKE'O"
MB<ML-KA+F70#;K<"/%O^D&]>I[4`8K('@SVE??VRBEIMXIB(?:54^(<Y%U[D
M_7LM,6EN/#3D/XJT]Z&W'\1/C1B4W20#(?2"001XCPJ[G"VDO=JOK>(5<=&'
M4'M)]`*SKRO\.EI74>CR5]J]//Y(TDO<<\ZO*Z*=Y"PKYN?_`)HP:UD'Q\.[
MSKU7Y0M`V_=F`Y2,'F;^1>)<P`"\B']$WT%Z[?J7UN"#\!;]?Z:]CS(Z%I#V
M]Y<8?SQUA7M#P`58D\P:JJY'1)&*V$7'GU'PKA_F#0;"!_3L]3EVO(F.]U_H
M7_YJY&?EV-0\BX_`?DR$D2)SWIXK;]CQDN_<$V?P^,FQFBR0JY<-[CH0;U\"
M_.(2-O8'MCJ'-:#JC9I(IPD+2?IT+WZ)[HML\5L<;BUQ(U1M=0@X$%U?5V+O
M7J>OXK!LN2\>):I4V/&;=?FSYF0D>A#1V16?6FNO.AIEO]U/=86%J\0M[4O<
M'%HUY"E*#+H`Z/,N:W#<KF\$,<Y;HC+B`&AHJ\ESC1H'$X5Q`PKBL/\`,\H)
MQ$\W(6&7%`]>J@+6^VMM:0O?<PPZ<2\#SE26+Z#53(U7FVYD<2OF#9(_4EN:
MZM)[K)"A'B*2;#J3:_C7Z`[#$R/DUEB&]QEEZ6MKZ5IYG.-['<UQ=*/35>U_
MCI5^/=%`M;^QNJ^``!_ZOXX7Z>=Q7T+M3"W;K!KCCX+/V0O$+ONSSL_I'?M%
M78XYV`V-C6Q)#158P%<UHW[YO=QKWM/X@G[.\[&F[SL'K8;C_7%*27LEF7&R
M%9"2T%I6C%8=!+K[GA<)1XK%:#>MYMMGL9;V?%U=+&_GOX#[HS<>@4S6ZV/:
M)]XOFVT>$0Q>[@UOUG(4[5XQ]]WW9^2MMSV\;CEIF;V+8\C(R64R$YY3S[KS
MZU*`NHGL:919#:$V2A"0D``6KP3<=QN=SN9;NYD+I7'S=0ZAP7NUE906-O';
M0,`8T45HM,]Q"E7ZFXOXV\1^FL5D=2*K(<\#`*IM1P3T3?IX6K:06FL^Y58<
MLU*XX*?;A%7BW^E/^'2MM#M@=0NCP[%A/NM.3U$,`=+-BXZ@@%)!'G<'I4YV
MF%P($-#TJP79!KXBW(X&VN'FV#I^<]-W((CNM,-S?3?CYO&]O8['=:>"D.2&
M(ZCW]"I30)L;&O1^5HHKV!VW3D?$Z2!JQ#V\13\X"I[,5PV_0R6LQO;<_@EU
M33`M=V]%<1UJW.0./MDX(W7!\F\;SLA@\4C,PYF,RT%QPR=.SA676XI?22M$
M64D*,9Q14'&^YM1)'S:"]V>XY2WNVN;%VBSE>`2>\(R<V]CAD3P-%O;#<XM[
ML9;6]H^Y8PX9:QT]HX^=>D/V7>Z[!^YWC1N:Y)B1^1M2#&)Y`P;=F4B7U1%V
M#'L=Q4K$9MM'J)(Z-/\`>WT[1?OMNW6RW22X;:R#7&:/;^:[I;TM.8/#+@O/
MMVVJ7;+E@>#\/(*L/5T'K!SZJ%;B..63W'R\+?$_C]E;?JZ%JW8%2/C<G[;G
M]'2KU"\TP!Q7HN]FG7VS<4_]$Y?_`&GSE?-G.O\`-&[_`'V_L-7O/*>'+VV?
M==^VY;.5RZZ)*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M7__0]'CCG:"2JY)O:]_V$6\:^F\FUI@OD84)H`I8O*4>@'3PO<GQ^PBJ5+L`
M%)0!<*OS[U`^VOB):TE3:>;XH!!"0%+T/</3O<&X*D&]>?\`S$:?X-:EO_Y'
M^;_A7;<AM+MRO]!I_5O_`*C*^@+S5<!RG&MDE.1"&IK4=3GJ.@NMEEAMUQA*
M(Z0@J<7([;DKMV]+7KYVY@;6*$.QC)\M>.*VWS1MXI>7W1W(+K9S@*#`C40"
M2[&@#:_9.-.%0NNW&^^9M[)8K"2'<8D29P0XA;0)E1Y4ER/#BP9+4OU&,C%:
M8,A]#C)6&P+H2E7>/&]\VJU^'N;K2^K&$@CA05)((H0:Z10Y\:X'\^N8>5=M
MA-QN-K',]SF-![PI&\:7/>X>$-43G'PHWM<&U#@2Y[7,69L!R?BLY,:QZ(&1
M8?62TMUQ<1UAE_\`FTW%--=[3I*@X(B)`5;_`,UD-.6'=VCDKSEVXMHGW!E8
M6`5R()`8'D]N)%/SFN'"IU.X;-)M<0=-/&6DM`H7%QU,8X=TL;@US_#>ZND/
M8\#!II>V9<'TLP`^$.0018@@L*MUN?LK5V3#KB)'VAZUS4D@^.MV#\X>FGUK
M"4%95IFLH3?O_LYB38#I_P"8QOU?.?TUVSA3<;UQR\9WK/U*>\I_:3>-0P%U
M-_QGK4?F)3C$67WI6E2`KM^(':M)-CU/0UV^UT+6D'!?1?RH9%)?V8#AQ]E/
M2N56SA3LS**[[A6;GGHJX4GZI24?$D``!/V5ZKMH']5:!CH;YZ+[TVZC(+;#
M$0,_9%?2<52H;"FLPPA25))2TLCP-BV5?H(-;K>HG6[GL>VAT--.T*=TC9;)
M[FG"KL?*%ZF_R1EVXXYP`)Z[SKA4/(DX%RP'WVKN_E#A8[ST^*SU%>+<Q874
M).7A-_:>NXJW;`^)/@1Y`6-[]/\`CKV#,KGVDDTX+C/^>%97M!PJ@;]O,&I'
MH0"`<5L0\55Q'S"!_@33_3M]3EW'(8/\:K]GP7^Q<B_RYG9"93H*LPM@OS6^
MU36&5BDK+S2OE=:3_/%2+&_;U:MUKX/^;\,<MW#W&.?1I([^JFG//PZ>2J]V
MJ/X:["M"2<ZYKO?@YJA!9)ZD,W^RXZ?'P^6O&+9KF8L'!<E,[4\]9R6">8Y2
MG<7*5\6R1_DW]06!L?,&MMLT)EW.TU5QE:#ZUL+0@,<:\"O.3RRPL\X[+X]J
MI:5)OX]JL8RJ_P`.A17W[L=G([8Y&T[OPCQY/#6CN;AE&GHD'H<O:WQLLCCG
M0KV'_4K5+D>'_M`Q][7ZCQKW7:'.=MUFYX[QBC/G8"O&+K&YNS7_`%KO6JKG
M,Q!PN,R>9RDMJ#B\1!EY+(2WUA#$6%!CN2I4AQ9Z)0RPTI1)Z6'6LN9PI0NH
M!B3P`&94+6ESF,:VI)I3B2<AY5XE_?-[FLM[H>>=GW14N8=+Q,IW7>.L*ZXK
MT,?K4!U334TQR?21.SCR3+?4!W7="/!`%?/_`#-O#]WW*1X<?A8^ZQO"@^U3
MI=GYAP7N_+6T-VG;F1D#XA_>>>L\.QHP6GZ6._T^X_.X3=(\NU)-P+7ZUHFP
MZM'YQ)P6]+R"[H'%7'#Q,EXM_P`!?:;`&WB.GW^5=1MVR7,KHW/@(8M3<W\3
M-0#P7+(V'TYY[L*F5V4+^`^W_DUZ1M7*DDNFD!-5SESN6=7X*]X^AKMU;_`V
M%_+_`":[2VY'NG-_<'S?D6JDW6,8:TD:.XA)*8X/V6'^(=!5+CDNZB83\-Z%
M2/<XW$#Q`K<_E&5P,^+E,?ZL.=`>1*AR&[I4TZVNZ5`_"Z;&_B"1X$US-QLM
MY82LG9"YDK#4'+$+.\>&XB?$^CHW8%=%>-,QA.:./Y4/.06)"W6E8/;<*;?P
MI#@0IJ;'N5%MM[L3(8<'5IQ"@+=G7HI3;[UM6J[@&JH;(WB#3,=1S;T'L7,N
M9)M=[2)Q'%CNGZ9$+67B;=MP]C?NGQ66/UT[5O7;BY\,%2(NV\<9M00[)+1[
M&G<EB0`\$V_@Y"(47M>_C]N;_E?F-VB-\D&;B,`^(\>LMS^\"%VMPRSYCV,T
MD:V4>Z#FV0<.QWJ-5ZM\+G,=LF'QF=P\MN=B<S`B97&S&5][4J#D&$2XK[:O
M\EQAU)^(\#UKVR-[96,D;BUS01Y0O)7AS'&-_OM)!\G#R*HJ(\!:PM<_@/Z3
M4G5Q6/0ZR2O1?[,_^S+Q1_T3E_\`:C.5\W<Z_P`T;O\`?;^PU>]\I_R]MGW7
M?MN6SU<LNB2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%_
M_]'T9*5VDW-R;$>'6][D^!/6OJ'2VN*^1`_`#)0B;=2;>)'C8G[*O%!2BK6H
MPQ7"K\^Q5_;#Q0>TV3SO`[KW_P#?%W4)^)L17GOS%PV>TT^[\1Z=+EW?R_!.
MZ7XK_P#:GT/9]:\U/MW>4C>$*2DJLPW<`@7_`-90GK<6Z"XZBU?./,0K:,!_
M./J6X^;<0?RC>M<1J-0...DT]*Z:L>ZKC'2\L_KV1U78W<C@9:HCL^+#P4H)
MEM-!A]V.X[/3(1WL_*5!()3\OE7DUURCNVXQ^/'?QB&05TDO&%:BM!0XX]N*
M^,;/Y%<[;W9Q;[9[U9"VNHVO:QSY01&3J`-87C,DTRK2G2LV\:\U\6<J99W`
M:]C9T7)M0',F6,IA84%+[++K#;JFW(CKC2G6U*0#>WR@>%A7,;KL>^[-!\7<
M7;70:@WNO<:5K3WN'M7(\X_+/FKE"RBW+?/"=;.?X6J.754D.>`0&QD:@"<J
M$C&AHLSY4]L"44@`")("4IZ`)$=P6'P"4UH;85F8"?M#UA>51O/QEJ\U_>-R
MSI7A6E<.D^5:Y0).Z?V3ULQ8.JN-HP.)+*W<OEVW5MIQS`'KI;PUNI'4HN2`
M/Q[M[+#XZ\#I)@XRNKW6D5U'+O>M=[=0\JC?]Z=/=[@)?BY=0;##0'Q':J5G
M!-#QXC*JU<YQFY%.`4]+1&;RCLQE"TPCD)4-F."XA2&W`RR_>0OMZN)"0FXZ
M7%=;L[(]>EI/A!O&@-<^S#J7OORDM[#^,@6CG/M!&X@O#&/)PQ(#G`TZB34\
M%S0S;7=F9\=82`O,^FE`[+(:+C'8.U%BGQ)%^O6O6ME8R:?:8QBUQ8#UXT*^
MT;)[F64<AQ(@J<\3WNGJZ$SD;Z3:0TGR:ACS\#&/[177\_6WP^Z3LI@(X_V5
M;MLGB;8>BKO6%Z;/R2G.W0><$GK;<M94GKTNK"/`G\0*WGRAHZRWD&M/%C]1
M7E7,W=NH>CPV_M/7<53AOT/B;7^'W>'6O9PT8T'>6@8PN[Q]U<<?SN[*]H.(
M`ZVY=U(GH+=,9L-@?CU(ZUPGS#K_``%@(_U[?45V_(YIOK.CP7^Q<<?8'CL4
M_P!S\Z&P\^C)/*;=6XZTM"FUA;:@67FK]JT`];BOAKYIF;XV%C7GPRP"G:U>
MY>,^.S`C>14&OG7>3#SKP4GO3V]AO:]NJ;D"WP)KQV&V()`7+W--66'UK"'+
M$PK@OLA2;+/:`>HL5)(\A8FNFY7L#/ONTQ4&-RP'LU8^<*]L@CMYCP#%PKY5
MP*G.5L[.'S'Z;ZI=Q<=G\L<;2@6'CW)K]+=@Y:\7:[ID;.ZVWG)^Z(W_`%8+
MA-PO_#(U'N^*T>>0#VKV*\<.)/'.@D>']B]5O:_4?R#'D#]'ZZZC:V>'MMBT
MXN$+!_DA><W8(O)Q_2.RZB0N>GYL/+\CB_VG;'B,5.<A9SE#+8[1(JV%J2\,
M5)]3([&4K2H*0'L1"5')'G(`\ZT'-]X^RV6ZTNI)+2,=(KBZG^*".TBJZ;E*
MT%[O5O5M8HJO/1A@/\HCS%>0>W<M:U>1Z#I;NMY?9:O"6C4YSCFO;G&@`&2J
MN*AF5-:0$]Q2A*R/\Y7;U\O"M]LUD;K<(<*Z6@^?!:Z_N/"MG<"31;&:WK1?
M;86XT`D!-A;_`(/,FOHKEKEF2]$+C%W,%P-[?L@$CB_%9PPFJ^JE"6F0$_'M
MZ#IY6'G7O>U<KV-C#&Z2,:Z9+@KS>YII'-C=1HXGV*_HNBK4E)4E=[>```/7
M\3X5T+(;:/W(&K3RWI-2ZX<3].M?LG17$MJ4&U`@=.H/ZNI\JHZ&U?W70-H>
MA49?N`);.:]O^%6+EM06$NI>8"DE)/[M[#[;CIUK1;CROM]_'(&@:SDMK9[W
M<PN9JQ;Q*@<39E7&G)>'G2'BWK>=>1@=C9\6OHL@L,Q)RTFP]7%3E(>"O$H2
MI'@HUXCOG+\VPWCWC"%XHX<*'W2>&#J9\*CBNN^)CW2R+HS^*PZATX9CRA;0
M>\;B^-L/%LS9XL<_V@X^=;S3$IE(4]*UUR0RQGH3IL2IAAA8G)!-DEA?^77`
M\SP_$;8V\:*7-L\.-,"65`>T](XTRPZR5E;#<N9>>`\CPIVEO8[[)'EP\JWQ
M_+&Y.=WKVXP-=R$LR,OQKFYVJ*]1P./'"NI9RN!6HDE7I,Q9JHR#X$1ZVW+]
MQXM@QA/>C.GR4!:?,:5ZEI-_@$.X.<&T;(-7EQ!71%Q1N?M_3\>OP/2M\!D5
MHSQ`"]&GLPZ^V/B?_HC+_P"U&=KYLYU_FC=_OM_8:O>>4_Y>VRN>@_MN6S]<
MLNB2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%_]+T5*<[
MB``"?_%^[]%?4@'=U/."^0*8T4!:@"2>IOUM\>G7S(%Z5!P`%$&HU&J@7#C\
M^1Y(]KW%BSU2.>L2"/'][1=["3?[_"O//F*P_P`#@`&)N1^R[ZEWG(+'.W*_
M8UW>-J?^(Q>9[@!83NW>GH%1TV^[ZE/]%?.?,`/PK`<]1]2Z'YJLU<IW;78D
M?Z*O3DA7=R+MYO>^?G&__P!G)!K560I86WW!ZEH^1OY,Y9KG\#%Y]*V?]FBR
M.6ECXZ?L('WDX^UON(KC>>&UV-W^^C_:7DO]X0EO(K"#C\<W_@7%/2<.M=-L
MTHI@RNI`^CE$]3:P8<)O;R[0:\JLP#*S#[0]87PNUSAN-@`2!XC?VA7T5\BP
M="6L:3KZD*45#7,,0>HZ'&1`!T\K_LKLR`=QN:C#QG?M%=E=-!YDWMI.'Q<X
M_P#G/6I'+#ZW67@M8^4.#L`M^\E1!-QUZ#RKL]O:`T47T=\KH&LO(0UF-*]F
M(7-+++OM<X7'7-PC;[?X%[UZYRV#\7L6/^M9^V%]JPMIM$=/]@[_`#E<>>@(
MF<EPL:^XF,Q(&-4\^LI0E#2XK@<4E2K)'R)_37=_-PNM-YNPV.I%O$X=9+</
M6M;MLO@\OS7#15S=0`SXMX=2]'WY*OIL:ES]%9<^H9;WG7$M.=++0WBIC;;@
M(\NRMC\G#JL-V+VT[\>'70KS;F%SI)K"60:28`3U8O\`6NX*EV\"0/.Y'D?'
MQM7M0%*@+GP\CK7(/\ZAIR3[0H0;25EOE74G"$]3V_09U)5;J38FW2N&^84>
MK8*AONS-]H78\CR$;Y5^7@N]87%KV.SVL8IQEU0]03)"EHN%%-STN$F_W_"O
MBCYCVDC[F)Q8=-`/+1>W/=KM>Z?LE=L,+GF#CD]KB;%I*NJ@!8D*-KD`W'P\
MJ\ECLZ.\,"CO2N=D<:T-%A+E#9(?TRP7T]7@+DH2/W^T=2H?&]=OR1MCW\S;
M&/"):;N,>G/R>U6RES;>Y<YU`(SZES%W^,I.T9;,06FY*VL/DGVVB.]+C^/C
M2'4I=`\6U=+_`/))^VOU@Y7L7V'+N^7D<8+HK&9P#@<7!I<VM1TCZ8KQS?;E
ML\MK;.?1DMS$UQ'`.=B>T+U;<;NN.\?:.XZE"%KU#5UJ0W8(2I6"@%246L.Q
M*B0G_D@5QMK*Z>W@N'COR-#C3*IQ/IJ%J;EH9/,T.)(>X5/4X@>BBX=?GES'
MO[,<$0PXI,<Y[=I7I^#;LAO%XEA*SX_,VVLV^PUP_P`P88_X59S`]_QWX?\`
MPRNW^7LI_BM]#3N^`TU[9"#YZ#SKSF-IO>Y/2U_TUX["T.K7@O77DC(8K(G'
M\%N;EW$CJ$HB@FQ/B'B3X?$5Z5R%91WFZRL9B*1C]I<YOTSX[>$NPQ=[%N?J
MFO+D_3L,HN+I!\P!XG]5?;/+&T0[?812$"I&"\1WS<WOE?'J`C&:V<P.H-0H
MK`4A)<(!4JW4$CPO6_<XN/4N+GW(!SPTX`J^XV#;"1=*?+J!T_'I5`QRT<^\
M,#J%RBNX1I0MZ8*2#:P!-['RZ6IX9&).*CCWICG!K3045EYS5VULNA+=R$]?
M$=22?&PZ"@):1BMY9;F)"!6M?(M5M_P7H-RF@GM44%2""0I*DFX4E7D4+`4/
MM%<KSKMT=_LUQ)H_&#<_5CU'%=WRU>F.\9%J_"=PZ^/GR6[$#:&=UXAQ`RRT
M._S_`(S^FRC:RA*5(?UMV(^7;FP]8I*E%5KFOFUK#+:%TKFELT+J@\0:C'RK
MJPWX:[=I.$<PI^LIK\GO).@\T8CJICZ?3<@D_P!0.LIRT)RP_P`IT*'X)%8W
M*;CX$D9]W2P^4"A4O-;?QK=W27^L%=LW%^(\#^P5V4;=1QR"Y$FE*8E>CCV6
MGN]L/$I^.(R_^U&=KYKYYI_:O>*##6W_`(;%[SRD".7=L!_-=^VY;15R:Z-*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$7_]/T/%P@V!`O
M^G^FOJ@@9N7R%0'BH17XV%_M/[?$56F1"NSJ#DN'?Y\I_P#Y4N-P1U3S[KY2
M1X=AT7?#^L_MKS[YC4&RVQIC\2/V'KO/EV*[S>X__:N_;8O,YP&;;FTGS,5/
MD3_Z2FY`'7SKYNYA_P"5:?TSZETOS.H>5[XTR_T5M_G?;/R3M>QYC8\"G!3(
M&6R#\V,B3EA"E):>/>E#B93+;:G`%=0E2A]M<2.9=LLX([>X<]KVMH:-+AZ*
MT\J^>MC^>/)&P;+M>Q[LZZCO+:!L;B(@YI+10D$.K3CEY%GSVX\&<A<>;ZYG
M]HQT"%CT8#)X]+L7*Q)RW9$U4?TDH1&4LH[?1/=W6\1]MN4YHW_;-QVPVUI,
M72F1IH6D8`UX@+S_`.;GS2Y/YQY6BVS8KR62Y^*;(=4;F@-;'(TU)PJ2\`#/
MUK=7,(6Y"DH2H!3D=]L7N`.]EQ))M?H`;_;7"V9`E948!P/I"^6`[1>6DSW@
M,#Q6O17'T56`(657'P.*PR\1F8TF'AX##JLABWX[!5$B-1WB'U$H4I3J"4@=
M.VWW5VQ@#[J:X%Q&YCI"1I<"<22,/7UKT>^L(Y]WW'<X;^V?:RW#W`1R-<XZ
MWEU2*`BE:5QQ"U/Y7[BF4H@CHHVL18=JQX'K77V`&AJ^A_E<&B[MV@G(^M<U
M,V2WM,YP_NMY>&M7X&.3^H5ZOR^\,FV9QX2,/F>%]HVO>VN)O3"X>@JZ\\E_
M,\I?28MU?>U%B-J6!=*!"Q+DJ6\@=?40TUW$VZW!KTCYKS1W_--_':'6V.WB
M:>`)9$USB#T9^5:.Q,=GRF;B[C#FN<33IU/#6CRFB]%?Y)Z@=-YU*%*6V=NU
M0)=L$=_=AY3ER+D@GN!K+^3S";/><,?%9Z`Y>><U:F36>MM'>$,,P.\X+N*^
M^E">Y0Z*4$@72+DWZCN(O8"_W5[*XD$4*YL2"E0TDKE/^;^_'/M+<>3-A)D8
MWDC2IR\6\H"3E8*E92+)AQ7`Q)$5Y;4@N)=<"&PE"OF)[4JY'G@&3EZX!(!$
MC#0YG$X#/$C&N6"Z;D][7[TUA:03$\5Z,J$](KP7`+VXZOAMUW+^5ZVKD+6E
MNH<D)?1D%S,=&D+=;2(4J9@-?D.L*<2Z5INR+@'H#7@MWRO#O\WA,:QL4A_U
MC-9;U:F^C+!>K76]W&V6VJ4Q/.6`I4=-'."ZQ8CVH[7(Q<=S_>CD4(*#ZB)&
M;W]"FA;O2FR-(B_*!^]WVOUM63!\C()#XLM[;AG"D1J*=L/FJ3VE<Q+SVQIH
MVR%>L1__`*BPAS![>\;H^"F['G,[.SAQS2)T=M>7W534F0RMMY+;BI<;&I0P
MI20#;R^/A71;+\L['8+_`&^]-\U[8YV.P8&9.&.H1M.'16AXJ&3G">^MYX&0
M,!<PC$-]E5KKC,[C_0V?)SL1'Q,&-JV::QOHJGY1;\J7!DQ&IKS\MUY\NN?5
M!``]-I(-^WNN3]J3,?8\J[]<&4.@-HXA^KWFEE&U%3CB1@`*9KRNZ>RYO]KA
M#BZ5TK*T%._J&GJH,<<\5ZE-"=$?3-1C+!2MK6-=;6"#<+1A8*2"?/M`M<5Y
M-;U\&&C>YH%/,LJY#O&F)/VSZRN1'YTF@3MDX&TK>\;%=E_[O=X>3E?23ZGH
M8;9L;(BO2E``D-,383"220!W7KD>=[?QMCEF:TNEAG:XC]`L+7'TM/G73\DW
M;;?F"*!YHVXA<P'])I#VCR@.\R\P;=B%=M^MR0;>1[A:U[>%>*0C5KTYT/HQ
M7MTN%*K+W$91_/9J%`7,6.Z!8']UU2"?_EHKV/Y1F/\`M!<,>VO<8ZG8X@_M
M+DN:]7P,3QF"X>?'V+H;QS$0KTU]+V-[#J3W6'EX]*^W`/#AAC&0;[%\];E(
M2V9QS)/K6R4%H%*`1^Z$CP^[]=`%P5Y*6!Y:<U<K+0M:W0?I'0GS%JRV,!Q.
M2X3<+Y[*B.HD*BJ:386"?CX"]NH^%3^$PC`+2_Q2ZC>'/<:]`-%0\C&3Z:^Y
M-P;@]/WOU=:PY6!HP7;;+N$LT[&N%*4\M5JARK'9;]5P?,$H6.T`=/E)\/\`
ME6K4[P]C=GW$O;W!$3YL?8O7=B<\SVDI=B'T/!8:3G\PQHRL?E);SF(BZ^YC
MC!+BD,.,J0MAJ*I#:FU'O;6`!?PKY9AL+=]A+<WC*L$+@!]GWB0.T@^=>G23
M/^,:;8C6][37B,B3YUTU_*4TYW$:'RCN"T!$;/;3B\%C5$66MK`8OZV5V"P'
MI!_-I02#8K;(MTJ/ENV$44X8.X7`#L`^LX]:BYDN?&GMV$]YK"3VD_DP77%Q
M1)L?/Q\OPKK6M#1IXKE]53J&"](/LM_[,'$O_1&7_P!J,[7S)SS_`#7O'WV_
M\-B]]Y2)/+NV$_FN_;<MHJY-=&E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B+_U/0>7#XW`'^%[U]8AH&:^/PT#W5"4Z;'Q_P^SPI0$4`5
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M:L6S):D.QXR&2E"@H(2`DGTUJ!/Z0*])V21WAAKWU7TU\J]SEL[NU$LY>-8%
M>T@>U<H-K@K_`+0[#%04!S^:);0OKW)(C15)5T\@HG]%>O;(T2C;6F81@_:.
M0[QQ*^_=NNF-VW;[AW[OPJ^EWL565@LGB&,5F9,%#$Y*W$JFR&6Y"IB)33BB
MM:'DO,O);2^4H/;W)L/,=.\YOL_A]JL3=L:+YY!+OM2!U75U#`@5H.H"N*TU
MOO%E?W%[MT-SJMJ>X"0&::=%"*TJ>!K3)>DO\G?#N:]PSR;MV30UCL;F]GPY
M9EO*:BQ'8>!Q3\"1/#SBTMF.)S:VU+)`]1M5NE=1\H;>6+;=UN9`0R28%I/$
M`$$^>H7FW,4KG[E/"'%P;E6I(+G:Z=/VL!T4KBM[?<%[E<=QKHN<RFO2L5-S
MBL),EX%R9(`A/R/IEEB2SVJ[9$5A:NXJ[@E0'2Z3<^G7M^RVMYI&D:PVHZ*]
M(/TZE@6-O\5.R-VH-#@'4'H_(O//R;J?*WNSPS?*NRYB9I+L3&KUO*Y7+Y3+
M2]9VN+%G..C*P\`KZG-NR5OJ[R8C;\9"+=B4I"4CRO=[&ZYCACNWS.A='05<
M3HDH<].>/&@(ZEZ7M&ZV?+\\ML;9LL+L:-`UL)&5<OUB"L+8;VZ<DZ--3E..
M>5<:X\E+7K'"9W9L%,6OTT%ZZLAK&(B2$%15V!Q:%!!`4;BM3'LV[61\6VEA
M<<^[*6?M-'I6UEWK:;YNB[A<WHU1!V'#W7GRT'8MFM;:]R$]$7&RN2]O$PQU
M*2K([_HV/Q14E!'I/39^T-%3BT=4W3T!^-;FWN>83I:^VF\LT(;3M,GE&%>I
M::>WV%E7LFAIG^ZF+AY`P^7%4_<.`^9=LDH3F.1='?B/-!3BLKRCJ22RZEH"
MTM,/.9-YY`4GKZ;9[ONJ5S-^FE#G0L;$#F;B/T@$G/.@5C+C9HXG:+@F0X4$
M3\1U$M`\ZI.)]C/,FT.@1.?^+$8UY2+X'7,__.,HIAIUI;C3+9Q.,8<(0+@+
M<*;CYKCQZ![>?]\C.V2<W,&UO;^Z8\O-!P(#0*8<2L?^(<I;<(KO^S\C[Z-P
M(>X4`=P<,3CCT<5T+X5]P/,G#>^:CPGR5A\WE<`G&RL/A]FSF5E;-GMKE-+3
M(9S"\@Q%59U`=+:T)2S#CL^FTGN*>X[^T@WS97V5A=0R30::!Q[Q=C4G$X4R
MR``%%SUT+#<X[J]M)&L?JU%F36CB!AC7/$DU-31;L<UQ]1YLXRW[AS+9&!"S
M&]:=E\?B,=DG6H[SLV3%=&.E15/BRPQD&T$]H*T6-;FYMVW=I/:R,(9-&YIJ
M*XD=(PP->Q:BR>^">VOH1C!*'5PP(=@T\:EI(X9KQ;;1J^:TC9LWJ>PPW<?G
M=>R<S$Y6$\A2'(\N"^N.^E25`$)[VS7SI>V%UM%]+973--Q&<1U<#V$$+Z)M
MKJWO[6*Z@=6)XJ#[.T%5?1,J,5L\!]2NUN0AV(OK9)*K+:"NHZ>HD5UW(FZ_
MPOF3;YR>Z]KF=O$5\N"UF^6IN=NG:!WFD.'J*Z0<99EGN9;[Q\X!!)OW`V4+
M6/Q-??&V73+[;[>XC?44QR]G:OG/?+8POGB+,R2%M9C7VU(;5<*O:]B/'H;'
M]-9['=[%>7[M;R:'%@(<KD;6E2?$^`OY]?.U_'PK/C((`%%YQ=LD@?(^6I]J
M^O4"#U4FW2]^AMX=+=.ZI2X-H*K71VTUT9)&15;PQ_P*V\WD6&65J+@"1?K<
M7_=MY6Z=*P9GM/=&:]!Y;VR[#XY9!PK0<."TPY.V%E29D@*!0R%)0W?HXXZ6
MV6R!XD65<CX"N&Y^W5FT<M7\A<#,]A8UO27"E#3J)/:`O:.7+0W%W;0,;DZK
MCTK6C.[>-E>PN@ZVB3ELSF,G`@IBX^.M2I4^6\B+!@1[%2G75OK3Y6N:^5+_
M`)LL7V]OLUO*Z2X>]H(:TTZ`T'B>GKJO8;/8KF/Q-PEHV!K214TRXGJZ%Z@O
M;+Q0CA+AG1>/7@VK*XK&NS-B>8/<W(V+,27LGF%)64A2TM2I/I()\4-CX"N^
MVVW%M;P1#WQ75T:CB[R5_(N`OKGXRZEE^R3AV#`+/*U`7)/V_P!(/4>`K:$K
M7%]*!K:FJ](GLJ5W>U[B17QQ&8_VISU?,7//\U[Q]]O_``V+Z"Y1_ES:ZYZ'
M?MN6TE<FNC2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%_
M_]7T!J7VFQZ_</#X7Z^=?66>:^/FO-*-&*AE2CX_H'A5E<<#@I<:8C%:I>\C
MA7'^XKVX\K\1Y+(Q<,<_@#.Q.=R#H9Q^$V/7)+&?P62GNI^9O&,9#'-_4JZ@
M,*6+&]:;?=O9NNU7UC(\-#FU!.0<TU:3U5`KU56QV3<G;5NUEN(:2(WXM&;F
MN%'`=9!-.M>,#0M=V_A_E6(QM.&EQ(\9^1C'\I$29^"EH:6NTR#F(P7CY6/?
M<9[FW$KZI(O970?*G,VT70M9X'PDO82<,01E4$8$+T_GRVM.:N3]SM+"=K[D
ML#VM)HX.&0+?>!X>I=K=`WK69F.PR6\U"7)R?J-0$ID,OJENQX+T^0VVF*MT
M!3$2.M:KV-DFOFG>]KO!+.\6Y\)N?"E2`,Z9D@8+\PMVY7WJQWC==>UW+3`&
MN>2R0!K7/$;7'4T>\\AH(S)'!9?Q&4Q^:QT7*XR:Q.QTUH/Q9D=1+$ADDI]1
MM9`!3W)(^^N2NH)[6=]O-$6S--"#F"HGVEU:2RV]]$^*YC-'-<"US2,P0ZA!
M&5%/N^D1\R;V\!W`GK\`D7-ZBC$@.!6/.(G"KV5H,/\``K0SDIEMAT.)[4%)
M()24]$CQ!5:X^ZMW80O<]A!J5H'&62Z:R*/2`>-1ZUI9S+EH3,.1\P"%`%1/
M0=MPE77X6/V5Z=LL4@`)7T'\K]MN;G<+5I%7ZJ^447(^7DL?/V3+29,@)9?S
M$MU?S&[C+;GHMI!0/'TT#PKUJ"%\=M;M#<F#TXGTE?H6;>[M=IMH;>'5,V%K
M1U&E3G@LLZ;#EYK8L$UA]/RF_8N.I+:L1DG,HQACZRU-$/Y*(_CU0F6`OO"R
M^V$*3<DI[JV<#-UOY;=OA27$<>`8\N<P`Y@&H#14UP(7,/MIH+*\DN+F"SW!
M]>_&UID(`R+<:DFE<,N@KMYG=)V?A_@G6,/L64RTSCU&`Q^Y9/`<3YG'LZQ#
M:R[T[Z["[`WCYL/:\WC,7+="A);=<3)<4Y=)([A[GL^VS[5LMI:W3P;81EY;
M$10:JEP-#J<!7`XY%<#:ZY+C&;7=F0]Z0$N<12AJ10$\1D!0!:&#F).L1(24
M*RNX<601D(^*A;GF9&3QIGLR&ID1B'(CC)9;#?3%T+]/L8`23Z@NJ]8=Q>PP
M11BW+W68_P!H:@G.G$C@0*#TKJ[>T?<2/UM#+PD'NMH:<>@'M5Y9#WI<$;!'
MPL#?]4S^51`AH4N9HN;5&AXV0AL(&.@XG.Q@P]$25$J<4B,EUP75Y*.+<\R[
M4]D3+JV=+08^&0`".`!'IP67'RSNP=(^![6`G[8S'22#]9'"BRQI'(OM@V.-
M'=P>4Y5Q?U:&_IX^6T2#G_\`2%04')6!D/V[>HOZ@`\+U+:;YM4IC8VQO&D_
MT37#SZZK%N-LW.#4'OM"YO\`2%I\SF^;I6;6].X]DQ6I$3?8\1AYL.-,9+1=
MH7)*'#9)=CXV;,<2\;^!M\O0VK?.;;2-#FO>&]!C=7S`G%80FN`=+XVEXSH]
MM*^4!4/*:UP5C&TKV;FV;C%@J]5..T79V&E@?*4($Z"\M7;V&X)`\0+=*B+M
MF9(W7N%RQPSHQX]>*N#MPE)\.T:X'*KVGVJU,9S%[*>',W_.#RQG]KS"'$28
MS;FCMR3$<:1VWA2ABW'XI2ZHW(6EV][*%C5S=YV';'^.S<W.F%:=W$=A-"/)
MBKG;;S#N,9B&WM;&<#WL/-6A5=_]6+[?=QV;&Y^+)FY>1!0]]&UBL3/;R$1:
MB?IWM@ES8,*8Y`+Z@M4>&IT%0!4"0*]9Y3YGVV_VT16VZ6_QY<-0>XZ]!..!
M!&-3D[VKD=YY;W&VN`;FQ>+>AI1VD:@,#W31V(&8R6I^X\V\UYS;<OF,;L,+
M'8QE]7\FS&0<:=EEMJ05M_4)G-QTXZ("@)0PAML);MW#N))WU[=;\^^,6VWV
MSVNQ,8-!D<R1\KC347MJ2P&IIT<3P&/%MFRMM6RWT%[-NKW5)CJ`P"NG2X=Z
MH'"E.KB;>VSVH\Q^[G4MIYMU2%KV:Y#PLF!#S,+&+3BW.06VXJC(FXU,Q3,5
M>R0XZ$%\J4VS,2E(0I;X(7YC\R.5H+^VM[C;_`=S"`/$\$GPC%CH#'.SD-14
M:BT@4!J*+N.3.8F;5))87DL_\,KW#*UNIA-,"6X.9G0EH=4XBBY>9[6-DTO.
MR\#M&'R^M;!AY99FXO,PI..R,*2RKJV]'DH:=04D=#VV(Z@D5X#\-=6-VQL[
M'Q7$;@:.!!!':O7V7%O>0>)!(V2!S<VD$4/8L_<:\F(AJBQ9<@,N,V2AQPDW
M(2D6N?$*-Z^F/EK\R(;00[?N,M+?(USR&7E7F7,O+#KAKI(6]\9?E6[>K<I1
M5-->M(![DCYAU0;_``(/F+>-?2-I>66X1,FLKECV$5%#CYEXYN.R31.+;B%S
M7=.)'D.2RK#Y`QKEB)25=2>T*`OX]/OK.:7L(Z`N0O>6!.QX$??*DLSR;AHS
M2EHD)]1-QV7N;CR-K`DU622@UR.`;TDT46W<J&)QC<SNG@!4U6!]SY?C?3.%
M4M#22/W7#8^!ZBRKWKF=YYKV3987RSWD;I0,&C''K7H>T<IW,@8R.%S6Y$FO
MH6H>V;GF]QG1-=U'$Y#8,OE)@9B1,7$DY&9)=62VAJ/$C-K?>=45&W:E5KDW
MZ7'RY\POF!=;Z8[/;[8S2O?J`:"X4&`J!VFGG7KW+G*UGM8-Q<SB.-C<2X@5
MXXD_3@NP'L!]AD[CC(8SFSF[!-PMZ;[WM*TM]0E+UCUVRVK/9Y*%OL#/*;=(
MCL`J^D"N]=G@`WK>5.5W6KHMTW*T9'?GW&`DE@.;G8D:J9#@.O+`YFYD%WKV
M[;[@NL\-3L`'T^RW+N])X]B[#E*4=0#<_$]/,B]SXB]>CM8!2G6N#+P`0UM%
M+.+[B?FZ#SM]U7>3!7#N`N.+R/,O2?[)S?VN<1'_`-T^8_VJSU?,G/'\U[Q]
M]O\`PV+Z`Y0J>7-KU''0[]MRVGKDUTB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(O_];OT5I\>XF_7IUM7ULV-SN%%\<%X;@"`5"6\$@]
M3Y]2;&]OVB]4+&@JTRNX.JM//>SL<O"^W_:(>-6['G;3-Q&L!]HV*84N4B9E
M4J5>Z?7Q<)YL6ZW6*T7,+S%M=P(\'/(;7J.)]`6RVFC[R$R8M95WL'I7!6/K
M4B6_],@*4EP_.@#N0HW%KMK24*ZI^'A7E+XM%75P777-S#!$;@X$<?RK+FI\
M;;!BY,',X'NQT^$I3K$J&EN$]'[D%#BV'F4-J0XMLJ22GJ0;=0:T4][96\SZ
MP,U9>XTU]"\LWCG;9FSW,%U$UPH!0M:X&A!`-:Y&A'6*YK+_`/)L].4U)FN.
M/NH0D$REN.*)_>N/2+2/F)N;I\?$US%Z^QOIC)=[=9NZ=4$<AX_:>PN\V"\N
MW#F:SN)7:=LMWMQ-7Q1D$5KC5A=CQQ\BG'L?F5-E"F8JT6'<GZ2`MPD>?J.Q
M/F\C?N-0,LMCHW_]N[41P)LX]1[:,"U[=UVJ1SG/Y=V]U>BWCIYM-?.K`SNI
MN9(."7&:<"@$J06VV46-OWDQ&HYM:LN';MF)#?X-MS:_F6S01V=VGG%%TFW;
MGM;=+AL-@VG$01@^0T*PAL'#>L3EJ$_6<;+3W@GZE+[Z+]>O8Z^$`FY'@>E;
M^VVK:^Z&V$([(V-/G#1YEZCLV_B)K/A7")^5&,8STM8"1U56/VN*=#Q\M2H^
MG8*"XVLCOCX7%I7W"]B5F,7+D^=R:Z2VV^W%*6[!T4:%Z1%N&XRV[727CW,(
MKBXT]:O2#K#7>TVPTJ)#)'1"`VR"GK\K2$I3W'X$=I\S6>;5L6(80RM*\*]'
M:L>6ZC8)#4.FX]*Z`</:#F]ZXHV6/J4N"[G,=/:87#RL%/H3(;K3CXQ[;C;K
M+#1L7%)#B$-!3@(5<WKL=D8^>RD;%0SM<,QAU#H\^'6M')/''/$Z8%L=*X'$
M'IZ?,M*=CX!QPV;(0=AT!G&Y6.9*),+$X^3AIQ=(5ZJVUXZ1"DK]<=?4"W?E
MZ@VK`GVQDDKQ/`&GB&BAKY*'RXKIH;\MB8^.?4W/O&H]-0L#Y+VF\;1,RS.R
M.J;`RMM^/+5`R&9S[D5\(=2\F-)1D'Y:Y,9\)"3W$@A7PN*Y>\Y:MG2`ADE.
M/?<WR?:)P71VO,MVV,MCDC&%!W&FG6,J*[\-[:=69SLC+:8G>M<F2'$2&TZ]
MMXUYII:U%?H1F&X2H\=EJ]DI;0$@`6`I'RZ&RA]LZ=A_1G</\U12;X\QF*[\
M![<<71!V?76I\JSY&XDY#CQXZF=PYF=4EH=X5R!B2EEQOL("G58!QR:FX[KK
MZ@_&LNWV;>&NF/Q=^`3AIO"[`'\V1@\P6LFW/;7&(?`V9<.F$#_."MO:.+<S
MDH"XVSY_D[*PE!7K1)N\8AVY5<K^:/JJ'D!2B;V6DCR-99VF^<RD][=:<?>E
M:1Y@VJJS<+0.!@M+8.ZHW`^<NHM;,W[7^%IJH1@:QM6'DQT2#,D1=OE.NY)Q
MUSY'I3F3QLY84VD]O\+TA?QN36ODY<LI=`A\4.%=1$A;7+,Z37T+<P<PWT6M
MLKH7M--(+*TZ:!I"F]:]IVBLRXZH.NY^>"26Q/VC+O\`JI22I128BL>V4(^Q
M)`MUK>;7RI#))&0UQ'2^0G+]7`=F"U]]S'*6O,CXP*Y-8!ZZG'M6QVE>V%C,
M26X>JZ!%DNBX=>=6W+8C`$)4N1D,S)>4A%_$A)MY?"O1;79+>PB#Y!'B,FD.
M<ZO6230CH\BY.;=?'<X->0:YX^D`9]*OS8MNV'@MC,<=Z/EXB,Y+7'1MV;Q+
M=V,>N&A:$:[A5NAI%XWJ'ZN2EI-W?X:$@!1.!O.ZRAH$,36AM&DC,`9`5Z*X
MFBELK)D[FW4SB12@!_:PRZAT+4O:<2SN\A^5M\"%L\F1U>D9R''R,A73M[E/
M26G'1VCHGM5<`6'2N7D'QM?'A:]I_.`/K710O?:Z3#*YAR&DD4\RQ3,]OW&$
MQ2U*TYJ(M1_TN.R&7AD$>"FV$S?IVQ]R`/LK'_@NW%P<+,`_HDCVK8C=MP8-
M/Q9<.L`^L*69]OVI1>D&7N,!(%DM1-DD!I(\;I2XS('GX5N+03V8:VQOKV(@
M9-E>`.Q8\M_)-A-#"[K=&/K'J51;X7QS?5O8MX'0]/YU#-[?&^*-[`5OH]XY
MF9^[W[<?_5'U+"<+)QI)86OZB_!PEA%K[I&5V]\*4.[U\VV$*\RDEN$V4A5K
M=.TU!+=;U.2Z7=KQSS^=)4'JP&"E$T,6$=K`UO4Q?C?`_'A=+KVO.Y%PJN59
M#+YF4GR2;M.3TL*`5_R?U5J9=MMY7R23M>]W2YSW>?&GH4O\3NPUH9*&_=`'
MII59-U+7XF@3&,CIV+A:S-84E;,[%1&(4UM2+CO3-;09/<H&W50N/LJV.T;:
MG7;M;%UM&D^T^18TTDESW;F1TC3F#4KI1[??<`_MK[.E[F\%[!VD8?+E(:3E
MFV4%2H<I*0$-Y%MD*4E=@'TCK\]@=UMFY>/-\-*:RC)W!P'`]!'TQ6@W"Q;$
M'21-_"&8Z.SJ6WZG0H6"NX'X'Q^[SK?U!Q"U`P[5!4NWG?[/\/LJF*IJSQQ7
MI5]DAO[6N(C\</F?]JL]7S+SQ_-6\??;_P`-B^@N3L>6MJ^X[]MRVIKE%TR4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(O_]?O:XYV=!X_
MX?97U\YP:#3-?%H!.)*E%+^/V]!Y7K&))S5ZT^]Z4/\`F/%>*CD?(=TQ:UCI
MX)QF8`\?&RE"M%S"W78`'_:#U%;7:GZ+@N`Q\/VKF;JVG?4YEA@M)*G5(2.V
MW^5Y7'2_G7G-[&(X7N.0:2G-5X;?:)9`Z@!)6V$36V8C#+"(UNQ"6P$A(/<!
M92N@ZWKSZ6T\65\I)U.)*^99H_B)I9GDZG&JG!K[7:/X!3?]Y/8FP/\`W*#>
ML,V9!-%AR6^(#!4=M%+2-=:*?]&$GR^47M]HZ#P\K5*RS>"'8^15C@+234JS
MLGK;:R2EI(%S?Y4@^?3PZ^%;:"UH035;:S\3``+&>;UI-E=K=OF!/2][>'E:
MNAL[?-QZ%Z)L[WM#*DU_*%AM_5E'(..=J`A4D)LH))L4CP^T$^==-;1M#H6.
M%05[-!=M^"BCJ0_157$G`A"4L^CZC0(4+H'<`57ZJM>X)(Z5G[B)&N9;M=^"
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M@5&FX=IF0WZN/S+P39PN/RG/3%_'O*6>P@5>V%NMM8'^<JHEJQQ:]@[`J=)U
MIM]+WTC)+#JFWFVU76$*!"BZX5-H64-@&R0?.MQ\%((R625BI4`BE.G'BH6W
M6IP#R-6*W(T'V[PL=CF%[-F9&69E1FRK$0E?20$L/#ZCZ9<UM",BZPHKNI*5
MH"CT-Q6QM]L&@.FE<YI`[N0QQ[?4M:^])D<8XV@#B<2>O'!7]O,_$<5\?Y>7
M@(,'$(BQ!$Q4:-'0VA61EJ2Q#=5Z=E/+9=)=)45*[1?RK*>([5DCFU:`,!6H
MJ<A3J6-&)+B5C'.U.<:GA@,UR1GXIV=*?ER?4=D2)#TAYUU7J*=<><6ZMQ2B
M>Y3CCBBI9\U*KDR#.XN?UKK6/P`8`!3)4LX%-^T-B]^H(^(Z>/WUD1Q$N`HI
M3*6CO4TJH1=6+UKM^8!)'3PN`!;J*Z"QVSQ*.?2E5@SWQ94A5UC4HZ0#Z0-O
MB$]23]@`/Z:ZRTVI@I2@'8%J9-Q<<=9KY5/HU-KM_P!$$]>@[+^-S<FQO>MD
MS;V`!IT^8+#?N$I/ODA0W-49M8M)(\#T_2?F%N@JY^UQ.&-".Q&7[P<"0I(Z
MNVEHI#*24*-AV"]AT!Z6ZBL)^TP^&X!HIC@LAM\=;:R%4=>OI6A;:FD?`I(!
M[;"PMUZ6KE;W;P(W@9DY+;MN20QVK!4M&-DX&=%R./6Y&F1)+,N&^W8*C/QE
M)=;<"C\RE(4GH;V(Z>%<XZW%J&"+][J&/0LT2MFKK'<I3M74S1-E_M7J>#SH
M`2[D,>VJ6`0?3G,DQY:.G0$/,G]-=5"\R1QO<.\14]JY>:,1R2,:<`<.S@KH
M4H@^-S4ZQ<:XE>E_V0]?:OQ!Y_\`,^9^W_WJ\_7S+SS_`#7O'WV_\-B^A^3O
MY:VK[COVW+:NN373)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB__0[R*/=XFWP-QTOX7OXU]<EH)!KFOB[6,^"EUVL;&ZO&_@.AZW\KU4
M1MIUH'5QX+63W2QS*X]Q[:AW^GM$)P7L19,#)"]NOF;5I=\92T&.&L>HK8[>
M[\9V-.[[0M(-1Q[;620^EON>3W!-@.B+$=X)Z%76PKA[J`2PO;3AZS^50<R,
M=/MDL=</K6:(\_&,K+<R6EMY%@4+[E$$>`)"2//K6@DV69S0]@`%?RKRB3EW
M<'L9)#9E\;APITT5PQWL=,6&XLA#JP+J";V*/,_..O:/A6,[9YVBI8*+476S
M7=JP/N+0L%>/Y%]2(38'1(/P)O?P)"CY6JP6#P*$T/4L,6H<[".BM"9&CR!W
M-=RFRD=JO36$*_=_R@/$#I6=#MSVX.%7+=0[=-`VCF`.!QZNM6/EL4E?=9L7
M438?>/.QZ]#6SBM2WNTQ77;9`:`T*QFY@1]4ZHHM_'2;`7`MV@=?#K:MO%$=
M48IDO1X9-$$+2.%%..8>Y"4M@?*.J;CP456N.O6]9E^S\1AKBK8R`2"<5MM[
M;H?T4#9CU'?.QXL?/LC+N?CXJK<;`P@3FGVA]/2H9JT8<Q0K9I2^I^/QZ_+]
MU=(>*A&./!8#]PJ!(TAN.JZD+S$/O;%NUY*4.K#;@/13?>D&WV5KMS:76[0#
MFX+8;>0)G88Z5J_JNGQY;C<]I8@O!7=_":`'?_65V@I`ZUR3I'L>X,"VSW48
M`XU/L68(^*S+*`A&49<L`E/K-/(`Z]"0TZD&U9#-QNF<10=J@=%"ZIH?0?6K
M;V+7,OD8[D>7.A.H6.TE+3Z5V*@>BG2Z.X#PK(9N4LM!(UNFO7[56(0MQ8QP
M\RQ3(UQS'J?0CM6E#"[-D]ZRGLL5(6$-E7W6/0UT`D:^"08`!A\U%>6Y.U<5
MO?!6$P(5O`0XH[?($1V^GV>%;"$$QL:.@>I:K4X.`<,%K5[E)2W\-A,.D]R)
M,YZ<\V+@J5'9])@*\1VI#RC]XK`W`CX=P/%WT*SK$M\<NX-'K6ER\$22.P`#
MI:W@?P/6]:2*,&C>*WGB`4[R^&M?!=)+9Z=O6UP;_AX@?;6?9P_C$%N*LFE_
M#&."N:%@$A(2EL7ZJ[B+CR`/3X5VMI&UC6ZAFM#=W`.%2JTQ@FD6[F0K[DVN
M?B2#>M_"0![N%%K'%Q&!HIU.(:2FWH)N#UN;CKX@7OY5D![:9#SK$/B%U2_#
ML4%>)95T4PCK<?I\?`"PZU=K&0`HJCQ3ABJ-+PB`1V)[0FQN+7/4!5KBY%ON
MJ!SL:K)CD<`0?>5N9C`"/9]AOHI-U&]^Y)Z$GK_5%<]NL5&O?3WO0MUMTQ=5
MCSEP5#D:\X]#<6ED*5V!Q))!(0A/>M0ZW!(\JXYD%==75.>2W+'M:11;-^WZ
M4XG6LEBW";8_*+<93Y):FLM.*`'4`>LA2OO4:VUO0-+0,,/2%JKX#6QPSIBL
M\+)M<G[_`+;_`-%9(H%@FJ],?L?_`.RMP_Y?\S9G_:O/U\Q\\_S7O'WV_P##
M8OH?D[^6MJ^X[]MRVMKDUTR41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(O_]'NMWW)L3]]O`W\O@*^O=(Z5\4#BH7JF]O$W_P^RJHM?/<:
ME;VCLH'S*3G(JDI"25"\68B_0$6!5^NM1O0)LJ`?:'M6=85\4X`=WVA:MZA@
MEM!EU]L^HZ?4`*3\J18)'2U_CUZ5RHMR86U&)^M2[N_7;N:TX45>F8A"Y+JB
MCH7"5?+Y]H^!'7I4C;4B,88U4%FXLMH&@XZ>E5G6L9Z63"NT6^G<`^2QZ7MT
M-_/S-8MS;ZH])"T_,<?B[?I<*G57RJ^7H;2FU]$DI1U-AW?NI^-K>%80M'`-
M'%<*VUD#V4`TU%.G@K65`_U5A)'R^BBPMUN+`#H!:P/VUD&`![W$=X@+<F`F
M\G.)[W2K;G8N]RA`)/@;7\O(&I8H:'');ZS&DM#@*55DNX@*=)"+I+A)N`/.
M_P!];2*"@#SD%V,='0LKT*<9P0<?:24"PZ%-KWLE2O&]Q<"K[B(2$&G^!1M(
M%2,UG[AJ+]'$SO0@JF0U``=>C)\KV[?UUN=JB:QDFG.H44\@&CHH<%FE;WB/
M`=05'XV\JW`%36N*B:_4,J+#',R1*UV$R/F3_-&5@V)/<EEP>%@?ZWZZP=QJ
M(&].H+.L3WWTZ%B?48(0U92>H4H=MNEN[S'3QM7+RQ`$GB>*V$KO<H5D(,A/
M0`&_7XV%^GC>WA\*A\)V(#3I02<#AV*EY)@EI9Z$]IZBUQ;J?`7/05>R*A;4
M4Q"H)#W6FI6)LC#49RU@'M2`$GPZ%)!'W$*-=)$*0E]!J((\G%2MDJ&AQ*VE
MBK"8L<#J1'9^)Z^FD'K]];II8R(!OO4HM4YQ))KW0L`\UP#,5A7B.Y*$2FB#
MYJ[TJZ#Q`NK\16IOVET8"SMOPUK7IW!WNH-D*L$@]O3]`)\OQK`CC<S$$+9M
M<X8$K[BX9*"KN!)^46MY]J;6_IK96-#(XN&"LE=W<%7V,8/E'IVO;RZVN38=
M!\*ZRV<``>*T<Y[Q*J2,<".M@?*Z+?J`/ZZVL9<X!W`K#('0OTXM-@2&_,D`
M>-_LZD&I-1!H,E'4&N?G7P<9T)0TFX\>@`_20/V5=K<,SZ`JC3E4^6JI,G&$
M7);%S\`?L`ZD`$=?A5KG4:?J"F;D:G!6SD,<2PM("A9)5Y7`\+'QZ$BM-?R%
MT+VN*V-D0)*]2CM8E"<>'%-@=\19=0!^Z%-*O<6N`H>5<RPMT8BBV>MQ=B<B
MK[X9A?11\XY8I0Z]"0">MU-MO*5\+_*Z*FMF$:ZG##U*&]<*L(][%9H6J_7R
M'^'ZZRP,%@9KTT>QXW]JO#Y_]TV9_P!K,_7S'SS_`#7O'WV_\-B^B.3OY:VK
M[COVW+:ZN373)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB__2[P?R'81<_P`BS@Z=/^:IX_\`N%_.OK@W5K_^5'^LWZU\5MM;T?\`VDN/
MZ+OJ4%6%SP6"<'FFT=5J6<5/`2$V!NHQ[)!_"@N;6A/Q4=?O-^M3?!W0&-K)
M7[KOJ6/.1M0S.>Q41F-K^8FH_F+*KLXJ>\@]K4E*NJ(ZD_O6^XUAW\ML8FAT
M[`=72.OK63:V]WJ!;;24I^:[ZEA]/'6TL2DI.K;$@-GM[4X/)JL.WY?"*;)!
MM^BM(Z2W(_?LT_>'UJZ\LKLL</AI:_==]2AR./-N+JU?V4V+M6ON2H8/)JN+
M?9$^SX5426[AA.S]9OUJ"WMKGPFL-O)4'\UWU*:Q6@;8U+[UZML2$^DZ.]6"
MR@!)"0!_YIY_T5#<&!S`1-'7[P^M8FZ65R^W#&6LA)/YKOJ5=7I.RD'_`*L9
M\GM_]PV4!Z"WE%O6,##A_6&?K#ZUH1M=Z,#9RUK^8[ZE1U:+M'HM).K;%U2F
MZ4X/)BP[5=#>(`>MOQJ0>`7NU7$=/O#ZUL!MMYXSW"QEI]QWU*@R=#VON(1J
MNQ@'_P!T>44FQ'@/]5)N"*R&NM:`>+'^L/K6TMMNNW>]:2U^X[ZE0G./-K]2
MXU+8['X8'*GQ/P$,VZ5*)8`TM\=E?O#ZUNFVUV&T^'DP_1=]2C1]!VM#[:O[
M)['U^&$RQ%[6N08EOW?L\*J98!0>,P_XP^M!;79!'PL@_P`5WU+)FA:AL\%G
M*(5K6PMEV2TJZL'DTWLE0LDF*+@)-;7;I[5K)"ZYC&/YS?K4$MK=]T_"R8?H
M.^I7TO7=E^;_`*OY^PN+##9+KT\Q]-6R%U:'*YB_6;]:M%K=Y_"R5Z-+OJ6.
M.0]1VJ9C(J4:OL3I1,"@E&%R:R!Z*QW63$\OC\:PKVXM'Q@?$1G$?:;]:S;>
MUN6N_P"6>*@_9/U*Q\/H^UL(L=6V5)*B?_:#E1:YO8'Z0?"]:-\ELZH\>/#]
M(?6IA;73G@>!)I^Z[ZE<RM-VKM%M;V+P'_MBRGZ/_-0;?A5!)`,YF4^\/K5Q
MANF__;25^Z[ZE3INF[44*`U?9%62;VP65Z@__.H^/Z*JUUNXU=/'2OYS?K53
M;W6D.%O(#]UWU*Q)&A;<IQW_`*J;*H]UQ_U?RQ_R?+Z3PK:>/:B(@74=1^D,
M?2I6QS%N%M)J^Z?J6;&=9V<,M@ZWL(LV@%/\CR8MVI2+]OTOA:U9_P`7;$#^
ML1_K#ZU@"UNC6EM)G^:[ZE8>]:#M&6Q7>WJ^Q.NPGP\A*<'E.Y3-OXH'^JWZ
MI\+>)%12SVCV.I=QU'Z3?K69:0W4<A!MY`TC\TY^9875QSN*@;:=LZ3X=QP&
M7'Z$B&/PK#;/:$@&XCI]YOUK8&*X`)\!Y/W2H*>.=Q0H*.H;0>MNN`RWCUZ]
M8?6LN"ZM&O(^(B`^\/K4<D%PZ/\`Y>2OW3]2J;.@[?9*?['[1W7%O^K^7Z?'
M_P!#Z>%;J+<+-ND?%P_KM^M:R6SNB:BVDI]QWU*:.@[>#V_V/V<?!7\@RW7X
M6/TGC:LUNY68:!\;%7_>-^M8YL[KA;2?J.^I?G]@=QM;^R>SCK_[[V5O^)^C
MZBI_XG9@4^-CQ_3;]:L^!NO_`,23]5WU*"OC_<A>VI[1Y_NZ]EK>'D!"MUJH
MW*SI_P`]#^NWZU46=R/_`+20?XCOJ5.?X_W&UO[);0KITO@,N/'R_P#,P:MD
MW.STG^NQ4^^WZU7X2[)`%I)3[KOJ5`E<>;HM10-.VFZR0/\`J[E^WLMUM>%X
M`@UJKC<;-[2/C(L_SVY>=;*VL[@"IMWC_%/U*'D=#W)N,M*=-VJZD)84E&NY
MBZF[=JW`!"/5"":U#KFS'_W,7ZS?K6:VVN'$'P9*9^Z?J5^Z;H.V8S$,I.H[
M0E<EQV6X3K^7ZI<_AL#K#!!#+:>GQK,@N;01@&[BJ?TVX>E8]Q!<R2X6\E!0
M>Z?J5SKU3<`"3JFS^/RH&OY?K]_^J=0:R/BK*@`NX?UV_6H#:7(.%O)^J[ZE
MZ6?9'&E0_:SQ#&FQ9$*4UA\REZ++8=C2&2=JSRDAUAY#;K94@@@$#H0:^9>>
M',?S5O#F/#F%[<0:@_ALXA?07*#7,Y<VMKVD.#'8'#[;EM37*+I$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
A1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g693329g67l84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329g67l84.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[1$H4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!B@```94````&`&<`-@`W
M`&P`.``T`````0`````````````````````````!``````````````&5```!
MB@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#HL````!````<````&T`
M``%0``"/$```#F\`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!M`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U58G5L7(;@V',RFW8SG5-LJMK;Z<%]+'&[<=KZOI/L;8MM4.M@GI[
M@UH<XVT0UWT2?6J]K]'^UW]1)3!GU>Z"6`NZ=A.)&KFX]8!^`VO_`.J36?5_
MH+6@CIF).YH_F*^"1_(6D)@3H?`*%WT1_6;_`-4$E-/_`)N_5_\`\K,3_MBO
M_P`@F_YN_5__`,K,3_MBO_R"N9&15C5>K:2!(``!<XN/T6,8WW/>Y!]?J#W?
MH\5M;-LS=:`[<?S?3H9D,VM_X[_R:2D?[!Z'_P"5V+_VS7_Y!1_YN_5__P`K
M,3_MBO\`\@CFK/L!#KVU`G_!,EP'E9<ZQF[_`*PJ[*\.T$55V9K6MCU'O+ZW
M$2S:'7/]-_\`+])J2F-_1?JQCUFV_`P:JQ`+WTU-&IVMU<S\YR%^S/JR?H=*
MH?J1+<,$:?RO1VJY7AD.:\48U+@9EK=Y!CEKHH4[6OEHNR2V2(94T-+H(D?X
M6W^OZ:2G/=T?I)+6T]"QBXS+K:J6,``_.<UEUGN_DU(;^D]%:'C[#TP.KT?%
M+'%IT^FQK-WYRTWU5NVAM+KM1(M<[:(/TCZF_=_(]B+5CL8V"&G60&MAH_J-
M^6Y)3A_LCISQNHZ3B7`\?J3*AJ-P<YV396[9_P`558H9G1\<X.9<<+I[:68]
MQ:ZO'&\N##L<RSZ+-G]2Q;Q)O):W2D?2</SOY+?Y'[R#U<`='S0!`&-:`!_4
M<DI__]#U59'6+[WTVX]F,_T!92!<'#WCU,=VUK98YNYSWT_2_P#4>NJ'7"!T
MYQ)+0+*9<W5P_35>YHVO]W]AZ2FTVU\#]$\>1+3_`-_*SNO]7R.F8E-U/3[\
M]]N152*:2T.&XSZNI^BS9_ZKK_2+4D!NXF`!))T^]9]#7Y(IZC=9N#G!^+4-
M&,99M8Q[M-UE[Z7?G?S7K>G5_I$E,\;&>QWVC*K-V627[X;%8<-HHHEWM977
M^C_X7WV_X56_5=_HW?\`1_\`)(BHW..415RPD.](':7`:Q>[\VMVYKWU;?YO
M^=_GO224Q-KLROU+&V58;OHL``?8TZ!SX=O;79/MI9^F_P!)_H59;<X5_HL=
M\-]K6G:P0/;W=[6J;*C.^TAUG;P;V]GW_21$E-8->XDW->^3HT$!H'AMW>_^
MVILVM^A06_`-'Y'(R22D?J._T;O^C_Y)!-KLB0UCQ2.7#;[_`!:WW?0_?4R3
MD>UIBD?2</SH_-;_`"/WD8``0-`.`DI@'D"!4X`:`#;_`.253J[W'I6<-CA^
MKVZZ1]!W\I7U3ZQ_R1G?^%[?^H<DI__1]569UG)H.*ZAES!>+:=)!+2VVAY+
MVRWZ#'ML^E]!6,)UKK<KU'[P+2&-[-`#=-0@]8IK;AOLKJ:;7VT@Z`%TW4C:
M]^UWTMK6I*2]1#+\04%S7-RGLJ=W#FN/Z9K6^[=NI;8K%WT1_6;_`-4$.Z&V
MXC0(_2'0<#]%<B7?1']9O_5!)2+,M8T-8[6==D3/:MO]JW9[43'J-;9=HX]M
M-!X>T>>Y_P#PB!5.1F.NG]#6UK:V^+C+O4Y_=/T7-5Q)2DDDDE*023<=K3%0
M^DX<N/[K?Y"6XWF&G]"-'.'YQ'YK?Y'[Z*``(&@'`24H``0-`.`G2224I4^L
M?\D9W_A>W_J'*XJ?6/\`DC._\+V_]0Y)3__2]'Z:T"[.@``WS[2XS+*_I;_;
MN_XKV?\`7%'K@:[IKVN;O:;*06#EP-U7LU+?I?UE>9777.QH;)).T`22=Q.G
M\HK+ZUC!E+\IU]L;Z063+&CU:O?76&.]_P"?_A/>DIN7$_:L9@`:U@?:XDQ$
M#T6L#?\`K_[R&^S[81Z;OU5EC)>W7U'!P,,?_HF>WW?X10MK-N?70Y[G5MH=
MZA.A=O<V/H[-KOT+_P#/5VV-K?ZS>/ZP24QQ]NUVR-H<6B/!GZ./^BC*%/\`
M-@C0.EP^9W*:2E(!)R"6MTI&CG#ET?FM_D_RTB3D$M:8I&CG#0N/[K#^[^^Y
M&````$`<!)2@`!`T`X"=)))2DDDDE*5/K'_)&=_X7M_ZARMD@:DP.-?/14>K
M74NZ3F!MC7%V-:6@$&1L=J$E/__3]55#K9(Z>XM(:X6T0YVK0?6J]SM6>W^V
MKZRNL.RS4]AJ8[&]2F"XP2[U:-K?\+NK>_V>ZMG]3_3)38K:QW5[7.@V58U6
MT^`L??OC^MZ+58R7AE6\M+MKFG:T23[A]%JJ8+C9U'.>X`.K]&AP!W`%K/M&
MWZ+?^Y:L7#U'M)^A6]L"-"^?^^?]6DI-6TM8UIU+0`3\%7OO:6%QW^@##G5M
M>]SCQM8VEKW[/W[%,DY!+6Z4C1[OWOY+/Y/[ST4R&PP#3@'01\@4E-7]I8S:
M;+&UW;:&;RWT+6D@?F5-LK9ZC_Y#%%G5\2R\4-;;ZCIV34]H=MW3[WM:QG\W
M_A-G^8K+CD;'[6LW[3LU)&[\W=HWVJLQ_5VPZVNES2]I<QCCN#"S](UI=['V
M,ROH/]GJ8WYC+OYQ*88W6\?)LJK93>PVAYFQFP-V,KM=ZN\_H_Y[8W_A*[?W
M$7`ZE5G%PKKLKV,K>38T!I]5OJ;&6,<^NQ]7T;MC_8H.LZUZKFMIQ_2#CMLW
MNW%LG:#5L]KMFS>[U$-[OK"]T,;C5-WGWDO?#)VM.R*MSVM_2?3_`$G\W^B_
MG$E.FDJ+;.L%EP=32+?3#L<A[BSU(A]5WM8_T_4]U=K&^^K_``==G\Y'?UQS
M[8KQV,@^A[W.)]W-OL;MW5_N?S?_``J2F/6;:=E&+;Z@&1:UNZM@>&P=WJ7;
M_;576_8_U?S%C^O2["R7L;DUF_$M;%N.VMI:UC_2:^RMOM]/UG>DW=_X$MHV
M=<+F13CL:+O?[W.)H`'T?97LR'._KUJMU!O6&]/RQD/IMH^SW![FM<QY!9]+
M;NL:US4E/__4]56?UW_DQ\M=9^DI]C##G?I:O96=U7O=^9^DK_XQ:"S>N75C
M%]`N<U[W5O#F@Z-9=3O?NVO;N;N24OTVP&WJ=FV(R8Y!)VT8S?\`ONQ%(+ZV
ML:2VMKFA[I,N<2-P:_\`K?2L0<2LY#+6,'IT.OL-KP"#80]S2UL_1;[6,ML_
M/]__`!BO6@!C0-`',@#^L$E,P`T!K1`&@`XA,^-NKMGGI_WY/N;N+)&X`$MG
M6#,&/[*=)36N](X]N_(+*]CM]@<UI8W7=8'M'LV-_/5%F+3998UO5LEUEFZC
M;ZE8+7[?7_15^C[;?1?ZOT?YG](HX6?UC+Z([(ZCTMF+FN>:Q@V6L<US=XK:
M[U?H?1/\W_AO^NIK'=1K)^S='K+Z7!N/:7U`0W=1ZK6_3J9]F=[*_I_X%)3:
M;T<!X><S*<YI#FDV#\W;`<UK&ML;M9L_2[_YRW_">]6\6C[-0VD6/M#)A]KM
M[X)+@UUA]S]GT/?[U1=F];$QTW=-<C],S2P&YNUWN_FW>GC/;_Q__!H^-E9M
M]3;#BMK#MKA-K7`L<"[<QU+;-S__``/_`(5)3<20<5^19CL?DUBFXCWU@[@#
M_6"*'-)+002WZ0!U$^*2FEU%N.;L3ULQ^*?5'HL8\,]6S\VMS?\`"L_X-9V:
MWIGV++-.4YUQHM<RAUCI:`S:Y@HM.YC?;]!S/^FMJW&Q[G-==4RPUZL+P'0?
M%N[X*AUC%Z?7A9=_HTMRK*+@RS:T6.(K<?:^-[O97_T$E/\`_]7U5"R,>K)I
M=3<"6.@F'%IEI#VN:^LM>QS7MW;F.14DE.71TFBQMC;Z[ZFMM)K'VN]P<`?4
M;?I=[-UB*_H>`]MC7F]S;1%@.3D>X1MAWZ?]U7TDE.5^S6#-VBO(-3FP[(^U
MW@@M]S*]GK>_Z;_>C#HN"T,`-X%6E8^TY'MTV>W]/^ZKZ22G)S.F,IJ;]FIR
M,DE\EGVRY@&OJ>I[[_W_`-U6#T;"(<"[(BSZ8^TY&NFW_3_NJ6>,D[?L[K&G
M:_\`FVM=K[=G\Z]C?I?0_P#!/T6]!8WJ4LVV/'L;N-E;"/\`"_NV_P`Y]#U/
M^M?\,DIE;TG&8'75_:'VAL-'VJ\$Q[MF[UD/$Z30ZBOU:\C'=7HRK[7>[:`-
MC=6W;?H(@9U+[7K:=GIMT]-NR9LW[2+MWJ_S/TOS/Z]GIV,`90Q6#+<7W1[B
MYK6G^TVIUE>[^H])2']C84;=V1$[H^TY',[]W\_^_P"Y5ZNELLOOKNIOKI=H
M+?ME[O4_,]S!=N;[/WEK))*:7[(Q-V[?D;HB?M.1Q_V^J>9T>@AM3,:[)K:V
M&AV7<`-S7U/9[[O]$=JV4DE/_]D`.$))300A``````!5`````0$````/`$$`
M9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0
M`&@`;P!T`&\`<P!H`&\`<``@`#8`+@`P`````0`X0DE-!`8```````<`"``!
M``$!`/_N``Y!9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!
M`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`8H!E0,!$0`"$0$#$0'_W0`$`#/_
MQ`"J``$``@,!`0$!`0$`````````!PD%!@@*!`,"`0L!`0$!`0``````````
M```````!`@,0``$$`@(`!0$""@@"!@<%"00"`P4&`0<`"!$2$Q0)%1:7(=87
M5\=8&8D:2C$BU7:W&)@Y(R13)34WUSA!,C,T-KC88296>`IDU&7%1I8G9UD1
M`0`"`00"`P$``@,!```````!$0(A,4%1@1)A,D)Q(E*1H;'1_]H`#`,!``(1
M`Q$`/P#W\<!P'`C#<VXJ!H#6-SW%M.5D(+7NOX,^R6V;CJY9+4]$PL8.X4=(
M.Q%3B9N9<&&8:RI:T#J0WC\*LIQ^'@WT?CLK=&O]3KC!K?)2&)*7B;18P8.`
M@IJTV%ZJT4>-+O-L3`UT&2EEURGC3(?OB4LJPE\X49O#A98K#Q:MKD[V8TI7
MY"-!,NP9;!\-KRR$3D*,=.UF"K6W9\BK:LLEEL<0,9#P$!L&PAO#19A+R!W\
M,//94D=EUY`J5)WS):%UIV>[\?#EHC<4.7/ZUV'9.Z$=:H<&7DX$LT2-H&FY
MX1MF7AB0Y,)2).)87E33J,JPG*<_U<YQF3PUC-1E*8_X=/XIOS(7/[Z]L?C7
MQ4'OD?PZ?Q3?F0N?WU[8_&OBH/?(_AT_BF_,A<_OKVQ^-?%0>^1_#I_%-^9"
MY_?7MC\:^*@]\C^'3^*;\R%S^^O;'XU\5![Y'\.G\4WYD+G]]>V/QKXJ#WR1
M-L;X!_BRJUPT'!C:?NX;.R-LS-+D!V]I;.E$2H@.BMT[$0`\<1L".=KC39]"
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M'M?IO]3VON/;^/\`6\GF_#R5JU[3ZWR__]#W\<!P'`XB^2>IVF^]!^W%%H]:
ML%QN=TT1L*K56K5>&D9^>GI^<@2H^+C(Z,BQBBWWBBWTI\?+Y$8SE2U)3C.<
M)7'>&L;IKMFK_9ZJ]C`J-:K_`$F1Z;[QTXF(@JE/3\W%WF7N.L]E52%E*D(.
MQ8(^-V1%5H\,@EU(;`9T6*,:ZRLD?*1&U*[*_P!*-Z:QZQ;PZLRD'8[->]^]
M7^B.HJI?H9B1GZY6K=KK7D)I;:0Y]OCA/;4Z,TR5!KM0!4CEIDH(UO`#<B<T
M2*N-7%Q+-_*S"W>Q?)'\+4+KB\":VNQ]K[K-P-W.J0EZ$@"&]:ZC?((>J9TI
M"B3*2`6G6,(64UA&7<.8SG*,)RG@QVR6,5[27>2/GX,^P]ZJE8H`*8C"YROL
M]1:E"/3D.,:R])0[4RQM(QZ(=DPD+824AIU0^5^?"%93Y<UG3IW)PAP'`<!P
M()VZ:4+L#JXP.R"ZU);VL(1JRY@N,('%;ZR]BY%#T6$--Q3-B.4:`RVH,AB2
M90,MXO`R716S!1VG;@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X'Y/O
MLC,O$DO-#CCM./OOON(:989:1EQUYYUS*4-M-H3E2E*SC&,8\<\#AK:WR-]6
MM4W"4UJJQ7?9FT8F4I\*1KK2VK-A;2L#DG>\1SM:$8/K%>)J2B#195E[+:I-
M+B&\Y\4^;&4\+4L=^T`A/U2N_?\`I*V#P5\G[0"$_5*[]_Z2M@\%?+3[[\B%
M@BZA.':QZ-=W[_?V!F\5:GV;0-]UM7YV4>)88;$F+V[7[4W5H]#;JG'"\QQF
M&TH_]GGQ_`*^6W_E?^2/]1KK1_K[M?\`]$?)JM8]OE-VW\EKP9;0/23K*$:Z
M,^V&8YWRM1C8A2VEI')<$STH8P4AAW.%Y;\Z//C'E\V/'QXU*Q[82E:0^2@Z
MG5(V_=ZM:5Z]&5F!*ND!7.I56L->@[:1%BO6.'@9\S9$*7.0T9,+>9%,=#$<
M)80EQ3+2E90FIITQFPZ?W'U37,VR^_(Y38."^IQ,,V4GI#!RY!,M.G,QD1&A
M1D'LR2E3C9`\A#;;;+#BLJS_`$>'CG@TZ:C<2>T>OV+$3;_DDKT./59Z#K,T
M^KH"Z8RU-V0(@^&#!<CKN6F:P6,*OQ="R0RTYC#;BT.*2G,73IQ7<^[&]54>
MRW+1WR/ZWW4,'&5UBF2D3THLA%4NVP+%*3C(FLPS-:L;:N35I)@ZZ28$D>`,
M:.>RT/A37G6\T6NX6A?';=>U5^T?-V#MTK#U^>ON4U<S&KI[3V3**]KO74@E
MQ5)M,9"68)0UY.G1O.<&.\K#&$I]5I#9#U9FKT5]_P`R+^[2_2MR<M?CR__1
M]_'`<!P'`<!P*.?D1_W6?@[_`+Y]WO\`"?5O).\-X_7)>-RL'`<!P'`<"#ML
MM2KE]ZQ+CRB1Q&-XS[LZRPQEUHZ*SUK["L,BFN8SC`HR)MX-_"\^.,O,MH_I
M7CA>TX\(<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`X3FODKZ80%DMM2.VM./SE&
MM]IH5J8A=-;TL@47;Z3.GUBUP?UFNZTE(4TF$GXL@5Y0Y#S7J-*\JLX\,\+4
MM`V!\L/4&G4BU6J`F=H[&FZ_!R$M%T.JZ$WH-9+<<$.MX>`@R+)KB$@&9.2<
M3AME1A8P^%JQYW$I\<\6>LMO_P`UG:__`/Y@=E_OSZ)__5-R>%J/]F'@M\_)
M+88_ZMGX\=.4MHDZ6;#KNQ.^H(MU$C0Y8X**+L0>M>L>U*0`=,1HS1OMX^PR
MK8Z"$MK?RZE:4M>BL?\`9F/RO_)'^HUUH_U]VO\`^B/C4K'M!$5T>W'VQV7-
M;5^1<VK/4L&&V-1-:=3=3WB\O4FM5JY2.NY,6U7#<%5(U!-;)L8XU:DXWV9M
M?8$0))+5XJ5G&,"ZV6(Z:Z]:'Z[01=:T+IK6&FX.26"]+Q^M*/7*8W.EQH:0
M`I&PN0,<"_899D-/D]X:M\I>,YRIS.<YSFI,S.Z8N$.!JUHO-*H[`A-UN%6J
M`QY(P0)%HL$37V#3#)"/B`Q!'98L1LDDN5EA!6VT94MP@EIM.,K<0G(<QS7R
M#](8&R@4XKM+I8^U2K44[%P%:N\3<)62^N,21,0S'B5-V:=-+D!XIU;;#>%/
M92MG/E_YD?U2U/3GV'^2*?VU?ZE4.KW5;9^\*Q>X,BU57;4K*9U3JR0I0+EE
MB2=@9NMDK$C7GZF;:H^/!CQ`2CK66RY(&KA&!1`%S$M?7N6T[%U_\DF]&V@(
MG<6CNEU3?E@SW<42MV#L5MW$2`FJ2(L419K$]JFBPTF5-QDHT:L>/E!'(P]H
M?&%K8=>):G^,<6S-E^/>O7HC+]Y[)=HYIH&WWF]5&.A[O2*,+KNS7=93Z)2D
M2M)UQ!W,0RGEN#O0I!\O(DAY%]!3C@91XI=2_AG)WJ7T]U;"C[`VAK2&VQ,5
MYXRO0ENW+'C[@O96=BW.0'KU"B#;<P>N1>,G+OB%C,.XR4\DG'NR7GWBBG1<
M\)@U7K`OZG'['N,,FJG"`S@.NM21BH0.JZAK%BF$R9*'XNK#,PTILVRA@Q[D
M^4X5-!Q<BT2-"%X#?+)DA+HGA%`_\R+^[2_2MR<M_CR__]+W\<!P'`<!P'`H
M#^5E&R'/DC^%I&HB:0)L95K[K?9<C8X4](TEHK\FNH\E9G@JP?%SKX^8W#V&
M\#OMJP_E&<YRG"L9D\-X[9+GM+-;[9JQZ>Q)^H9"[9GRE1;VEHFYPU635LQT
M5@)H\6\S4[+.3Z9;!V77&WDC9&4QA*,+2XI58_B7N`X#@.`X$";@8A7MA=57
M)0CT#A=]V)^MM>]+%]Y-*ZO]D!GQ_0'K<XS)>6ND'O>B^5#-)]+UL&+=:;CS
MAVGO@.`X#@.`X#@.`X#@.`X&/DY:*A1<G3$G'Q(25H;49)F#`"I<<SX-MY(*
M<::PM><?@QX^.?\`T<"']@=F^MNIHT*:VIV$T?K.'DCL1<=+;`VQ0J9&GR61
MWB\1P1UCGXT4H[(H[CGHH6ISTT*5X>"<YP6IZ<U7#Y0^E4+*TFKZYW-5NS=\
MV#.24#6M:=3K%4NQ&R"'8>L3EPEI(FF:YL<M-!P<;`5TIYXQ;>&6_)C&<^.<
M<6>L]/J_:`0GZI7?O_25L'@KY8:`[E]G+1#@S\-\7W;%$5*-*(`Q8]D]/*1.
M9&]5QMM<E4KKV/@+7`D.81YO;GA#$)QG&5(QXXY/"U'^S4+3LOY%=W7S5U-U
MMU^N_2BEK.MIFU]R;<+ZH[V%'C1:N6148>`HVNNQ4_8'CI2TLM#O/8:2VRR]
MYU9\J<\&D<V^G7WQ7Z2%C')+L%?MX]G]KRZ`UVK9U\W7N.M+D2@F5"LI@JI3
M]C1\76HE`F&VTB8<*\F&\>#GA^#EI/;IW'I?2&KNO5$&UII^KIJ%+$F+#8&X
MGZQ8)]YR;MDT;8K)*ES%HE9N</.F9R1?)?<?)<4IUU6?_LX3=*_`<!P'`AK8
M_8C0^H721=F[@UU2I04)D_-?G;;#"VDH8HP&.#S&53!:[)+O'R,H*,,T**\Z
M022TTTE;CB$J+4H.UEW(DMV5BDWC4?53LU9:'?HR"GX.\6.,T_K&!^S<X)!R
M+,ZN-V1N&LWHZ/<!E7LBN@PIC)^0E.L.+"(#,(%=RP@\G\B&T!9?#%?Z^=3V
M&W:TF.Q9_KG9JU',$-N&6C`9%8M&I:I"D"#OCC#D%#R*$2#9;?M214"G%-3_
M`!_J/RXO5]7M\I#]J/D2-QLR4&K;,SJZ([%P'6^O1#JZI6(9)%>I]1LE7V5"
MO7%43F55GZOY,%2;RPD,X4E61_(?E)Z&Z\.[:TQ0:+KO4N]I*KS=X"V->-]3
MEI[.W76Q-<&UY*6"-5/7VU7"5JNVKD"<,_[N2>02KVZ%K;<;5G'(NNNKKFAZ
M%@J]<&MJ6[Z)9-N-1T]`,6>MQ=BI=5C:U,3QDLF-@=<DW:VU^'D7!7!QY"30
MI9\KD1M;[G@E#:*E_P#"?>$.!I=_V!5]9UHRUVTPL>.&4E@<.*B9:QV&;DG4
M.+$@ZQ5Z^%)V*T6&0PRK`X$>,06_E.?(WG&,YP$6T#7MFL]G"W+NH".:N@C2
M5:UU\TD21C='1A\,6!*(1*MR$P%/;6FV)LX*:L$>L8-R,RS'B,)9;)+DBNAN
M$.!0/_,B_NTOTK<G+?X\O__3]_'`<!P'`<!P*.?D1_W6?@[_`+Y]WO\`"?5O
M).\-X_7)>-RL'`<!P'`<"#MLOY9OO6)O$*3*8*WC/L*.8%BB&JWA/6OL*5]:
M->D*]-%@C/J&Q'8=`)B"LO'MM*+6,X0":.TX\!P'`<!P'`<!P/Q))'#'?++?
M9%$%9=)**)=0P.,.PA3K[[[[JDMLLLMIRI2E9PE*<9SG/AP-2_*-KW_\>4S_
M`/NB$_\`W[A:GIP=-?*/USDC':[I"'WCV,MC@5U4P'I7K]MFXQ`!]-,'ABL2
MTT]7(.*>CW9XGVR7@2"D*RP]_63Y4Y4*GE']#UI\C_9V,TEL#>G8$#J%4I'5
M2[7:-7]6*DS7]P,7F_1%&F8NJ;*D.Q=2W;`"KUA[63`)'CP0GW#2G/.O*6T)
M3%N(O2V\RGQB:WV+9(6:[+=A>UO;NNUXV`DXO4G8'85$?T6Y+5N6>F(Z4LFF
MM3ZMU1KZ_F>N^IIS-B!ED*'SAKRX3C&,*/;J'0]/Z.=*=>6..N%`Z?=6Z-;8
M?W?TFTT_K]J:LV.+^H`E19_TZ;A:D%)A>]C#7AWO2=3ZC#RVU>*%JQFI<]I^
MCZ538@QF0BJE68P\?U/0.CX&*",8]5I;#OHDC"MO-^HRXI"O*K'BE6<9_!G/
M"6V;@.`X&O6.W52G`/2MNL]>JT6.EI1$E8YJ-@P&$OD-",J>,DR11VDO%OH:
M3E2L>9Q:4X_#G&.!%379[KP9)0T-#[FUY9Y>Q1R)B$BJ99HZ[24E$NI>6/*#
M`U)Z:*5'%H%>RP_E.&G\,.Y;4KTG/*6I0U,]Z**2'.,ZDT]V;WG;H"1;AY2E
M5+0&QJ#(Q<D1'-28R9J:WO#:EJT<)[4EI;JDFO/MH<3X,K6I"%"OED)*#[N[
M,L<M'G6S5'6+5RP6,PDQJTI6Z>P!1CIT@EUR1+VEK..TM25"PJ!E*%1"W!&9
M$A>$F+&"QF3&C:7NM$O)2]0E;%V>[13S=5+9/*B&;O2*/$7$L>:FYMI5O9U9
MK:A%EB8=E1QEAAO`A/!1@S#C*VUFX+%_#&6;I'H*\0"ZG?$;IV!4RB!"):I7
MWM-VBN=1LF`BPCV0;94[)N.2K=LA%EQ[2W8Z1%)CWO#*5LJ2I6%"Y2?3.N77
MO7!8$AK[1.G*-(13K3\9(5#65+KD@`^R+(A-$!FP\*&4.0V',%M8<2O"_3*>
M3X^#J\*%SVF;A$*;^ND]0J'#35<?9'D)/<G7*B$//L)(PF!VAV&U=K6TX92O
M.,-&KK%M,2.[^'+#^4.8QG*<8X$A4>GP^OJ;5J+7U2;D)4*_$UN*>FY:1GYI
M\&'"9!')F9V7(+E9N6);8PX264ZX02^I3CBE+5G.0VG@.`X&FWZ^UG6M9+M5
MJ.0&`R3'18(R7!\2,]89V0&AZU58`8E\9,G9K3.FC@1PB5X6480VVG\*N!&U
M*U]8+':1MM[>89^U<>].-ZYH@LN7+5C5=?D_3`8-]%0\=%3.U9J#&\TE,*$<
M?ATR1T-&%NQRR29(OPGOA#@.!0/_`#(O[M+]*W)RW^/+_]3W\<!P'`<!P'`H
M"^5F5V!"?)'\+4IJVFU[8-^#M?=9=<IUKNY.N*_.$KUKJ-HEB2NP=/OQ,"TQ
M'N//)<1#FY<<;2UY4X7EQ$GAO';)<]I6R;MM%6/D-]:IHVG[>S8"@XVM4#;T
MANF&.K;<=%/!SI-IDM6ZC?`DR90@P=<?B-?0TT,V]@E>7\M,UF:XE+_"'`<!
MP'`@7<&2<;"ZJX8?C&FE;ZL6#&SRD#E%#?Y7^R"DL0K2W6U'2:2\-.+:3A:L
M!MON>7RMY4DO:>N$.`X#@<"*^3_I'ZYS#&VY^1^G2<I#DDP^DM^S<=]1A)$J
M(E1AY6(U<;&&^RDPGF%K9><;]1M6,*SX<+4]-*)^2B%O5W30.I_7/>W;&:'I
M9]SGCZS&US1U<K+`LN'"C1DG.=GYO3(\A(G%GM+2U%ID'D,94YEO.$*\(M=R
MV&%W=\ELK#1,F=T`Z]ULV1C`#S*[-?(!)/S,`48*T01"RS]=Z<S]?>DXIYS+
M#ZP3C0U.MJRR^\WY7%->BL?]F#I^M?DYO35BM&P>S.GNO9LK;[$17-24K2\/
MOZ*J-+69YJS'D[5GY/4TE:I9H)7D)>5!!84M/CA/X?#%33I@5?&='[BVC*[/
M[U[;;[A>GKMC6]'U^5K*,U#K>GQI,T3-6:;(K]8M$V=9K).Y]N*EY\QI@<1+
M[:F7LO(4P+Z3XW\<GQ[--MM)Z)].<I;0EM.7.LNEGG,I0G"<9<>>I2W75YQC
M\*E*RI6?PYSG/!<]RZAHU"HNL*I#T/6E+J>O*/767AJ_3*-7(>I52"')+(/(
M8AZ[`!Q\1&,OG%NO+2PRA*G75KSC*E9SDC;.!^))(X8[Y9;[(H@K+I)11+J&
M!QAV$*=????=4EMEEEM.5*4K.$I3C.<Y\.!S)_G3ZKO7"Q:_B-VTVV7>I1[4
MK9JK0GC]A3L)'/9<2@R0CJ.#8"&&<.M*;5G./ZCV/35X.?U>%J>FIV[O%K&#
M4&)3M>=A]OS!R"76HK7FBKV"*RV&WEY_W]TV?'ZXUK%E8:3E38I,VT6]_52T
MTM2VTK%,<;:OD)N<6254-1]8-(/*FUCQC&W-HW[;]A5`@FS@),C.5G5]/I=9
MBSIMMD$P!@2U2>&1%JP2MLE:F!1H_833W<>V0ONM@=L(2C6&1A;/&257TKJ&
MO?8:-+FH:QQ,1+1%@OCTKLA^1K)YL;*!KP>$U[@)P<EHIE[S(&G3^JIT;U@/
M(6&7VK)V;>4C-DJ<&7LBUW^S#1`J3IET<4-BV7FU.90U'230Z6_42&.IEUP0
M<7W9"%BV[0W23IY7Y^:M45U>T(Q9K&4Z;.6!_55+/FI0Q\B9*(++DY"'*,<*
M(>L)OJ.>?SN)(4E6<I\,8%SVDW.B])*2I"M.ZLRA:74K3G7M2RE:7\2.'DJ3
MF(\%)>Q+EX5C/_K>Z>\?_:+\Q&_PL'"5N.9AZ[#Q<#$CNEOCQ<+'B1<<P](&
M$2)[S(0++`S3IL@6Z^\I*<9<>=6M7BI6<Y#*<!P'`BK:6T7=;,UIF,UMLS:U
MCMLRY#0E3UE#P14AX"@D2DG+S=ANMEI&OJC!Q8`JE*)EYH#!+ZFQ1<$%O,CN
M!KTV;M+8P,37(2)V-H'$W6TV*:V"_P#D1LMEJ,@S."!_D]`A7)W:=7>MTC%9
M(+7)K!EX,-A#:$K)(=4V.5F:)J(.IRZ;99[;8=N;%'CI>NQ>SMAP.K0;Q"TJ
M<)K\E)4.+-U?KG6T2S5"YVM#2#K2PW"'S$)4\\XAD9#!$N\!P'`U"\WJM:ZK
MQ%FM)9(\>T\.&,-&QDG.S<O)F+](&&@*_""'S<],GN_@9%$8>>7X*5Y?*E2L
M!%NN:5;K+/!;DW&&B.N*XQIJBZR4W!'`Z1C)`8SZH*N9BRYUJ?VE-CR>0;!+
MA2*XAP8,<6.8;:047(E^'0/"'`<!P*!_YD7]VE^E;DY;_'E__]7W\<!P'`<!
MP'`HY^1'_=9^#O\`OGW>_P`)]6\D[PWC]<EXW*P<!P'`<!P()VZG&=@=7,YF
M3HS*-[6%20A'`$#V+.>LO8M/T:429.Q!#H+&%9D$I%'E'\$@,JR*AG#QH8[3
MMP'`<"DZV]A]J_(]LC>G7+HMV<TA5M%4&E]=)/8?8?6\M=Y[;XSNU[?M!5MK
M^KK?0KI#0E;LD16M3Y0EUS#1#:I5&<.HQ_63-VJ]:F8U6M:.TIKGKGJ>DZ3U
M+".U[7FOHIR(K421)2,R4P.^<7*&/&2TL29)R1Q\F>^0^^^ZMQUYU2LY_#RL
MS-ZI7X#@.`X#@.!">_\`?-,ZZZUL.R;@//3#$,T"R!6*A#FV*V62=G#VH2JU
MZ%AHYI\EPZT64L:-%<<P@=)1+>''$)SE6!$6Y4N$MW6[!U^^Z]A*%#]<:??A
MYZ@Q^Q)I+5OM]6K;TR["V*[H88V!19J.LYU1!/1!B,P90S$M(@&9D'@1W5D1
MK2*=L:UUK6=658&L5QLDA3(T:F;LLPL<RV727CH>.@\VBZ33`HBYZS'1\4.V
M\2M"<8;:;::0TPTTTBLM_P"`X#@.`X#@88^QUZ*,%CI2>AHV0.]/V0!\H"&8
M9ZKN6&O:BD/MOD>J_CR)\B<^9?X,?AX'/]>V+M/:]L7.:D)U2YUY83#C1&RB
M9%-Y/VF0IR0Q;Y?7+M*MV8:,K=:);:C&")5'N#Y08U2!\`MB%&ET\L]+4CL"
M4#`,Q&^:M%'@QC@]A.?TF-)M3\HJ0,?;DQ0U;!$Q",MQSK(^1\.$84MG+OGQ
MZGD2-.GZWC6FT+M5K15,[J+JX]EJM<@&YNG55ZNVJ"E!C`5W*Q0EBCK:S(1I
M=HC6B!P\,*:=AG"$O-O/+:QA0TZ;-1M,:SUQFMNU&KM`GU*A!:Q@YN1DYJQV
M5JC@'IE6H4^T662E[%-J(ED^[**.*)-,*\7B'G',Y5DEI0X#@.`X&EW_`&!5
M]9U@VUVR02&",IL0`%C"2)NRSQF<LPE0J,.E:3;-=+1(>0*)B@TNFR1SK8X[
M:W5I3D(UIFNYVSVH?;>XP(Q=KC#37=84<<XR;@=01),5F#6>.^4D.*F-I3X!
M!ZCIYF.$*CH^8?@A77PT$%R03]P'`<!P'`H'_F1?W:7Z5N3EO\>7_];W\<!P
M'`<!P'`H"^5FS6:G?)'\+5EINN;#MJRQ5K[K.Q6NZI,TRO6"SO.ZUU&,\+&S
M.P[)4*:"Z**^LE2CI(5M3;*DI4IQ2$*D\-X[9+GM*[!V%LBK'SFR=#WGKS.B
MV`J)$I=_M>I[A,R<2Q'11C%H&D].7[8U98C#3#GQ$,/G-'I="<6MA+2V'':S
M/]2_PAP'`<!P(`W(1%L;%ZGM2`;119F_[&/!ON,&O+CI1/5GLL6Z8PX+/1#`
MKJX44P?+A(\JQE#ZD8%0\MHT,=I_X'"/97N);M7;AUAUNT'HYWL1O[8@CUOE
M:T?=Y#65"UKJ0(>>$.V1L#8D5KO:KL$.NW`Q\0&([$IP:_)X6E]/I90LL1S,
MZ(3NVJ>\_;'9VFXC=L,_U&T#0B;Q9=@L]4N\VQW=@;7GS:^Q$4&!F9^J:*T;
M:8FH5\U\THD<68P@Q]QE;B/$9OQBZ1MK*Q/4&J*3HK5M`TWK>.(B*#K*JPU+
MI\67(G2Y(%?@0VP(P5^3DGR9`]UD9I*<NO.+<7G'BK.<\K,S>J1^`X#@.`X#
M@05V$W.'I2C#2K*&9"ZW&?CZ#K"M*%,DR[3?IU@TB.CPX.,=:F)Y$7%QIDH6
M(&I)+D?'O^12,X\Z2QJYTZ[=6PYF=ANR_8>!N,WOQ$W?7J3";#M\C8X?3].-
MV#<#:8U5:EFU6Z$@K)+U60&DR\F2,Z;7SI$J,BRP8MEB/8$SQ&RP#A#@.`X&
MHWR]U/6-.L-^O,PU`U.K1SLI-RC@QIRF!FU(;0T+'1@QLK*R)A#B&!0Q&'RS
M"7$,L-..K0A01^G>L!)UL6;J]/V],2,R9-PE9KLQI#=-#D).QQ,3]4'`G%WG
M7D"B@P<LM;8[$[.X`@U/KRC!2EMK2D,=$+[*VU#0EOA]6:69$GJ;-9F->[&G
M-VR\[#0]ECI:U4DJ+NND-31%:'MT$$[%NRK+LF2*P6ZL9IDE+!3)='TQVG[N
M-8')65[-[VL<&^[*9(H\C&=>HBONB20Y8[8#<U3="5;8H+47[I*Q7Q9U@U+C
M+:EON?U_.3P_6,ZW:6`L@%S-I+-ON474Z;2H^W;)F;#M*S!P5!G;C9JO[:;V
M++6>0&F0YV^R9#TFVM,D;EQA!+[K882!RVG'A#@.`X#@.`X&H7J\U[75:+M-
MF(>:CQR8R-&&#'69)R\W.R8D)7X"&!:_XI\S/39[`@K./#SO/)\RDI\RL!%N
MNJ3:K/8`=S;>')CK:J,D!:'K)PJ*(B].5V>+9+*$D'H110-AVE-QP$<W/G9.
MEHZ.)#<%@WD!NEDR9?AT#PAP'`<!P'`H'_F1?W:7Z5N3EO\`'E__U_?QP'`<
M!P'`<"CGY$?]UGX._P"^?=[_``GU;R3O#>/UR7C<K!P'`<!P'`@G;CKS>P.K
MB&HHZ001O:P-$EB*6D>"93UE[%/IE9/"0RL+!>(9;!3A2QL>Y,:SZF<XPTZ7
MMK/;CM7K;IYIV1VKL,ETDV0D6J3JVD`!6.2L&V]Q3T9+%:_U+50:G6K?/.V&
M\2,2L=IQF.*0*WAPAU/I-+S@1%N>.@?778M<^V';GLE-STWVD[+0,<+9X"6D
M*G.US2VIJ]L;:MOU!J77DG&ZLUM:V&HVD[#CV[+F5]T\=,QR%^#26&T8BS/$
M;+(^5DX#@.`X#@.!7%:MX]@NSU.V12NL^CVJ]6)&PW+3!.^=S;#$K=<&*KUC
M14-D6"E5K4%BEK[:(J.!%FX^-D@9F$+:LHK#?BTT@HH2-5$;RZ!U3U+T[K!5
M8F<U@&TWRKNSY8%YLA-GLLL+)64B-7)R<4J\6BYG1)V0X405IY!2WV!FE--.
M(;>>0NI;ISA#@.`X'.V\=I!"4[<%`U[?G83>D?K)TFOXJU,G]K6C7D[L,>?K
M.K;Y-:^J-.V'+/P+%OCUD943#F!Y8`?<?:6.V[PO739ZGHZD5QJ"*F/JVQ[;
M!QY\?G8.R2Q[+<95,G;G[X6X>0V%'PHZ&K8_[H(4$$,"*2TPP`P*,.PRV2TQ
M<!P'`<!P'`<!P'`<#2[_`+`J^LJR=:[8:0/'B84V,%&QY\W8)^34R\\'7JI6
MH@<V<M-GE?04@.-`8(,+<QY6FU9X$:TO74]9;6%M[<L?#+N<6MQ>L::,E,E&
MZ7C#X,F)E%#2CIAXDUL^=8F9$66GP4`LKB7VHT=C#31)4@7^)^X0X#@.`X#@
M.!0/_,B_NTOTK<G+?X\O_]#W\<!P'`<"JCY%`MFRU[T^-I6IP&W-@0^FNSTY
M-Z/N5;C)N&M.JGUZ6@+;>Z"],2<;'_Y@=>6*5A&*J`\MH28"FY<$DR/22@I,
MEJ')&S+K+6G67<39U)GK9:['K#KW\?MGZ/V.VI+,O7TNY035HH%N#6_E$X-:
M=U;A>-AK.6QY29U$8@`IDE`:&%%C>(9'Y6;-9J=\D?PM66FZYL.VK+%6ONL[
M%:[JDS3*]8+.\[K748SPL;,[#LE0IH+HHKZR5*.DA6U-LJ2E2G%(0I/!CMDL
M*"[3]IGS!&#/C*[+@B/$L-%&_ELZ+E>S&<=0A\KVS7:?#I'MVLY7Y$YPI?AX
M8_#GE\,U'^R?0-N[`,ELQQ'5S>T6'AV.;^OGV#K*Y$Y0;(1P1+^&8SL5(SOI
M1`QSI9&/9>=0X;V&$O/J'9?)Y?,/N38K\69(.]3]_AEBM/N,09%CZLJE)%;)
ML"*VP&Z)V6*A4.E,2Y!+>2#&$88BBL+4AY831@\OU>W!L)M@-Y'57?1#A)0C
M#PK-BZOI?CVB8X`YXTQ3_9!@98L>28X&]@=Q]Y1(KJFFW!\L/O%\A.X-A,$L
ML-=5=]&-.QAIZS!K%U?2,,4*W(+8A7DE]D!2U2<DH)M#*VVG`TJ+:]9]I.'\
MLCR^[&U;WDBP,_Y:=V8;ACCA(XO,]UQ]O;!Q(VQG#RE?3C?^2A@9,J$&"83*
MMQA*29@-3S+(Z#WP2/\`F<]IOD\[N=@^PM@W#.;XW'KP^%O4K-:ZHM0O%KHT
M)IY`CLO%1$36:_"28`\1-PL#)OQQ1RTJDS$N/X*>=RZYYLV[QC$15/6!\;%]
M[R=\-4=+^SW86PWS9M0U?OBQ6V!BZ)J;KW68^0E*/2[[H%NZW6_6;?U!MY[+
MS&PYLH]N'JAF%E!+2TSE6&DKL.>51,Q"_P`"V[L`HIX=_JYO:-::!ART&FV'
MK*X*01)EP@QL6RB.[%GFI.KK,J^08IQE`RV8TG`CQ3J@VRJQY?,/N38KT:X<
MYU/W^(4ATMM,*18^K*I)Y`XX[S+S;HG94F'PT>X\IIK"RT+PXRO+J6T9;6LO
MD*W)L4<!@QGJ?O\`.(=:`<<BQ;'U90>*LS,I@AA]P[LL'&*=BL1[62,M$N(5
M[YCT%/>4GVX\OID-N[`#DG@1NKF]I85IJ;<1-1]AZRMQI*XHB69!99:E>Q<9
M,)=LK<:RZ%EP1M#;9[&#%"K24@8GD$VYL`B2,!>ZN;V`%&.]HS,EV#K*N-D!
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M^]Z)[OF:F0\,^JZB0;!)Y:]L+LNC5(`U@V-J"^TBE+.9CI/8%PV'U8J%,KY1
MLE]+B&IB5M78R%>P[.$K;P(V,R2\YEY",H2[G+>"TTBB=PI[9HL#,T7I]VJG
M:C8T&N1MW<3UK@JP\S'YBT/FC.V;LE"RLK#$NR2L1\D`(7&3+(KI,<06)EA]
MX5\I&8W?LQYHUQSIWV-%6*,A]AA^S]1E.R3JC!!<A!9%[3$L-DML$K(SDA8[
M/HCN8PYEW+33@\N?X\/L$<;)%[;H_:+8<;8HBF1@E<UM8-%:$:IY47*&60R:
M)EJ3W3%GBY%1!C8$E@,Y3)0XN&<-ECJSE0T2K5C\:UG+691.DVX(<V\%RMBM
M]A@I?J\/]HYJ*?GDQWU1T[LD/*DG36&_4`RIGV[*9-K!"Q5>Z2./*0F-N[`>
M+/&<ZN;V%9#.>$'D'[#UE4)*CMBRQ")0!`W8L@]L$AV.980DI@8G#I[&5,I;
M22X./+YF]R;%7%O2"NI^_P!HMIK#B(-RQ]6<RA*\FM"Y99>:[*N0J74L.9)S
MEPQM'H-JQA67LI:4/+Z5;=V!C$-G'5S>R\R9S8AJ4V'K+C-='6!!&*E)GS=B
MTX?!:(ER!5)C\GDY?BRLI9RRL)XPGD;V[L!9Z0U=7-[-#Y!@B\RKEAZRY`01
M+XALR$6IMKL6Y)Y.JV9-_!ZL#9&<S'$>R>,\PGNAY!MN;`?%DB'>KF]@G072
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MQ]6<RZT".P#8[Z7FNRSD!AJ31,$+8QD["TIBBO62TI823">7TO;=V`T1$LHZ
MN;V);DG8]LPMFP]94CP"#(V$.)>EDD=BV"GFHDJ5?"(P`V:M1,:2IA+PZ@WR
MAY:/?^S\[K2(?G[7UAWX'"-Y`!&D&K!U<=^J6:=/;A*G2X@#/91N6D;5<[,6
M'%1C#8^6GCCV$K=;;]5QLM?*/->6/=%EMDCM7<'5C?,=9XAVV`ZTI35\ZV2%
M2I]2(9ES8TD0*-[#,A2^S;C'UN-%D)"486J%D9=0$<4U$*E#WAY3EG<FQ<1>
M9#'4_?\`DO#0KF(/%CZL_5,K(-DA'6,.Y[+8A?5!8!:)=SDS",L&LX;4X\DA
MI@>7TN[<V`V]%-(ZN;V(1('*$+):L'65+,$.E8:<2<JE_L4R0\"O!2U82"V8
M3X#.>+6,Y:PZ/+]1=LWTB58CWNL6\01'AJ\^Y.E3_6M<4*[-9A<203[(/84R
M;434<2C^9'+0;C+N(TGV+AN5"8*)Y?,'N#81,47(/=5=]1Y8_N?1@C+%U?7*
MG^@D'+7M'@.R!T(CWN2W,->N8SX9%=]3T\99RZ7R&;@V$-%"2#/57?4@61[;
MUH(.Q=7T2H'KI.R[[MX_L@#"+]ED1O#OH&/>.2FO3]3&'LM#R^X[:M[$DL@C
M]:=V28N`;$7]:!GNN+<;DB$(L#,9%X:DM_QTQ[ZX-PPSL<K(F!FFY83![P*T
M'(#(^5K;FP''I5I?5S>PZ(\Y(@A+M@ZRJ9G1U+,3F3BDL=BGB&048%0K*3FP
MR?`EOP:SG#N&B^7S8W)L7,7B0SU/W_@O+13F8/-CZL_5,+'-C1&F,NX[+9A?
M5.8.=):S@S*,,!/8<4V\H=I\>5'7V[M/\0]]?_(MLOZK^S2_^"?JNG?M/_\`
M%/VC_P#>_P`K/V,_[8_Z@_[7_P"UO^)_V7_UER<M?CR__]'W\<!P'`<#4+9K
MZB7S$=B[4RK6[Z0LQR)59(&+FEQBI(7($G@!<B*0L-$K'J4,4EO*4E#+4R[A
M;:E)R'SRNL]<3LQ`6&;H-+EYZJX!369N3J\(=+5Y$68W(QC<+(DA.%QC4=(L
MH)'2RM"62&T.HQA:4JP%.'R(_P"ZS\'?]\^[W^$^K>2=X;Q^N2\;E8.`X#@.
M`X'CUN/Q<]/.]GR:;4OT%[2M]:<[O_)5:&]3V*QU][;F^Y+1ECWY>)RNS<Y6
M[54BHJ.E:K(!3`D`N-9>25@P<IMQO*2I3I[3$?+UC:EU/KK1>MJ;J'4M4BZ/
MKF@0@U?J=7AFUMA1<:/E;BO%QY;I1IQI3KA!91#CI1A3SC[[CCKBUJKGND3@
M.`X#@.`X%??9V01V#VCK3J51;%/$1PUN>L7<%^B60V-^R&AIS4VTXH?6UVD*
M_9860AY3>LT<''!L>#T@%&^XF`\!G"1DBP6--7<E4JE9HM9@:93(&)JU3JT2
M#`URN0((\9#0D-&#MB1\9&1XC;0P808S24-MH3A*4XX1FWWV1F7B27FAQQVG
M'WWWW$-,L,M(RXZ\\ZYE*&VFT)RI2E9QC&,>.>!RB=+L]I)@FN4NT6R)TA2;
M':H2_7S7MUM>N+)>=CTN8J`\;3M>W>H8'/EM:1ABK-&W`V-E8B0'L$0+'C//
ML_5$-EV_J7J_IJFUIVIO`R.RY!5*^MYA46K=>YKNP0Y/.Y>+?LPUSOT^-=B@
MG/PQSLTB0<B/P8!4/C&.$2KP'`<!P'`<!P'`<!P'`<!P-3NMXK.O8%^R6P]X
M&-:>8$:;!BY>?F),\I64"14#7*\!*V&Q3)BL9PR$`*24]Y<^1M7AGP"**#0+
M'9[1'[JW`$D2Y-1;#6O]:O)A3X[1P,B`:W-(;E(XN;'F]ISP\P['STT&=F-<
M!&'$CV6VDEDR0=!\!P'`<!P'`<!P'`H'_F1?W:7Z5N3EO\>7_]+W\<!P'`<!
MP'`H#^5FZ/:\^2/X6KF/2[OL-Z"M?=8A%,UQ%`SEVG<OZUU&%EB!BI.5@P3"
M&$DY><2X4SA+#2U8SG.,)S)X;QVR7/:6VR5N.K'V<O4VWM..`SY4"FL;IK4/
M5K2<@6.BI#$\!'PEEM(CT`4J4R.T\HA#BB17TY;QA"5+K"7N`X#@:A?M@4G5
M=-L.P]D6J#I%&J<>N5LULLLB/$P,%&MK;:6=*2):VQQ!D..I3E:U8QXJQP*W
M;C\LFA+#`'A]/X>^=Q=H%7F!UC48#66LMQ#ZHEKK89>'ADJENR!6LWM%PE9K
M?UU@V6/7.*9&!2M?CE6,8S+:]9Y9/K'H(3J9U_\`C6T3:ZK38G8-;MX4';'J
M-&!KAR]L!]/]_9MMH?E!VX!R1DY"-A2QGI1T8I\KS)0I.4KP^T)FYF5GW*R<
M!P'`<!P.'-Z]I):KV&>UQ0@@\3L;,QM<=M,27`[/M35E7782[&TZKZ"JDL]L
M2T7)VOV&+\[9Z86*BP)=N7..9!:3E\L0DKJEH&-T!JT&,)#$5LR\*"ON\;(R
M-6&2[CN&<B0%WJQ'D5&KTV$D'39Y+ZDOM1POJX5Y\HQE6<<$S?\`$F;/V&%1
MHL$$9:3[S<""837U3#>BUV"RS38KAAST/$R4C&XE!*K$-/2LEA#GBS'B.J_"
MKR)41H=1T/*I^G&;KVU:NPLG#R\A88(:Z5'558J=3F9:MW>DRBZQ7]?T2M29
M$<=1K_(Q#@U@D[!A0KF%95E_S/*+?2=H:%AJY%A0=>B8R"A8UG`T=$0P`L7%
M@#IRI6&`H\)I@05G"E9SA+:$I\<Y_!PC)\!P'`<!P'`<!P'`<!P'`<#1MB[%
MJNK:L9;;<?[4%EX2.C0!\((G+18Y5](-=IM2B?4;)L5RM<LZT#%1@V%E'FO-
MLM)4M6,<"/:50K#:+&'MC<(`S-JCR9!W76OAIHV=K.IXTL',,B33ZC<="3FU
M9B*=+R7.ICFBX@*9,@P27@5%%R83WP'`<!P'`<!P'`<!P*!_YD7]VE^E;DY;
M_'E__]/W\<!P'`<!P'`HY^1'_=9^#O\`OGW>_P`)]6\D[PWC]<EXW*P<!P'`
MIK[9W^W=X]M'=!="2EG@-=PTP5#=P=XA:_JU_H%=CW:(+L:D4>!G,7<`P2W2
MEB`8`-\1VU!.+6G/G4C*<QJ-(N5RG*RA/:ITD)>^M(X.0<"R>[)X&:]W8B(0
MC,:WUQW_`"36(N,9L$,W<#OK$<)E4<Z-+-M#8>/P(A8*#@PFS@.`X#@:3LJ_
M0.J]=WK9MH42FMZ]J%CNL[@%A19ZXJL1!<R<S'B(_P"(9(/CAJ0PRG^N\ZI*
M$^.58X-T&#:RW%LF<#GML7=VFP`0+I%<JVF[%L.@6`<@\X8QL381HEVE:Y8R
M(Z/82.XD<?T\$9=RT[EI7@HK$Z2I--I5IVG=AFL4VJP-ZV!3(!=C^B^[GR+-
M.U^Y[)N\_<K`P7>3SK%MQV39%:?E$A+"&96AA2,B>@);A=NP[813\'IJ@S?8
MNS@S9E:L`6L[1K],!0;%'N`8,A=EV>:M(0],E!QY!#Z@UL$'>BE2L,9SY<*%
M,_2M'PD#>GMQ6P\NY[I.KTI43+HY*782O1]5D9:+D%05)UI-7>UTW78A;-;B
M<22H=D9V7+CTEEJ<>6K/!?\`PG#A#@.`X#@.`X#@.`X#@.`X#@:M<KE`T.">
ML-B)>8";)`CQF`Q"9&2DY66,9CHF(B8T)MXR0DY,\A#333:<YSE7F5E*$J4D
M(GU[1;+9K&!NC;;)@=L<AEL436!3D,]%Z5B)M22I0-]Z#</$L&SYD1H(:>DL
MR$G'BN`Y'A5LBO%O2)?AT#PAP'`<!P'`<!P'`<!P*!_YD7]VE^E;DY;_`!Y?
M_]3W\<!P'`<!P'`H"^5G8=9U1\D?PM;"N6;#BM5JU]UBI7-4I=SV)8/1*UKJ
M..9^FTS7E?M-RG7?=&(\S8(!+C;?F<4E+:%K3)X;QVR7/:5WGKWL#5C[EK95
MY5!1E@*K)>;_`*EVQIN9^K!QT5*OX&K&XZ30[,?&>SFF/(>P&X`Z[ZC2'E.L
M/H;K,Q27^$.!AK!8Z]4H@NP6J>AJS`Q_M_?S=@E`8:("]T4R$+[N2D7Q@AO<
MFDMLM^=:?.ZXE&/%2L8R%='Q+B4J4Z>QFU*=7@8]G=N[.UVT4VC%2?JL]L"K
M6KMCO*9UK;9Y$I%1%CD&I'7<A&N1KDBWZR(QQA*,);PE.)#66ZS#E903MQIY
MS8'5Q;4J='H'WM8'21!$K4/.LJZR]BF$Q4GE)@N$`LD/-G)RI!./<AM8]/&<
MX=:+VG;A#@.`X'(C<Y&=CMR6VL5W8ZI34W7JPUV$V-5J]4:K*5JY[M&3*SDE
MKZU[$DYNRO2#6L0GH&1DH".A(0N-F'A/<2YF%%189=OZW#?%L@I"%A=:QMJG
MQ[5>+SKZ*^GZZF;=&W'%5"VM1@MDNIG]>5VT6.GQ@=7-*8D)#&(O`S#J\9E(
MC/C)AB$31&L*ENF`C]90=&H5,Z\:=V:_$NTO$$Q(R$]>=(;,CT@#*B'1_LNF
MBR\?#/J*40DF2?*?;7G*/27E\;?UW"VVVRVVRRVAIII"6VFFTI0VVVA.$H;;
M0G&$H0A.,8QC&,8QC'"/[X#@.`X#@.`X#@.`X#@.`X#@:-L78M6U;53[=;3'
MF01?`<"-CA'Y6QVB<(0Y])J5-KH*79:UW*Q$MX&C(H%IXT\I:6F6U+5C'`CF
MF:[G;/:`]M[C#B7K5'/8*UE1F$NR,1I@(F%*AS2!SB2GPIW9\V++R#4A8!A(
M_+48;]*';RPV05(%_B?^$.`X#@.`X#@.`X#@.`X%`_\`,B_NTOTK<G+?X\O_
MU??QP'`<!P'`<"CGY$?]UGX._P"^?=[_``GU;R3O#>/UR7C<K!P'`I_W_4;;
MWF[?[:ZAD;<DZ_UDT;KKJ#L;;NO&=15BP0U_V]C=ELW-]A)VZW"O^[^F$4RA
M4LHD:*+>&4*<XT[CSJ(:Q&HTB^5M%?KT!4X2*K-6@X>M5N"!'BX2OU^,"AH2
M&C1&\,B1T5%1S`P$>"*TG"6V66T-H3CPQC&.5EF.!`&Y,1>=B]3\R&&LEXW_
M`&/,'EPHT=>)3_*SV6P[EAH2-.8.=^BY,QEHET)C",J<P\IYMH=\O:?^$.`X
M'.DY:]NVW;<W2]2V'54%3]>U-]C84];JC9-A3GY5K7%MRM&J($97MBZZ$@!:
MK7B`I^;04\63)Q\R`P-['U%&8*T>$=V;"5Z*ZYZTLWVEMM*HP5:V)V$N:+<W
M)PE[R#19&6LHD)):_MM#M=LEX*\JL(D238F6$O90*I*AD/N#C3=\EEJI.IB-
M*Z%T#5*]3S;I7C*Y,[@`;J%9M-'H.LG:N5,2,1$M:?N5-MUTG6;`2H(*0#CX
M=L]YTE6,XQEE0[F73]'HM:UY!Y@:O&C1XI$G+3\J\P&`$]-V6PGORUDLLFU%
MB`1ZIFQ3)3Q9:V6&6UONJRE"$^"<$;?P'`<!P'`<!P'`<!P'`<!P'`UNW6V"
MH\`79+&8D*,%(C`4YQCSD&RL[*A0-?A8]C&<*,F+!/R8P(0Z?ZY!9#;2?%2\
M<"*Z909NQ6]G<6T$&,V0<:7`USK]R2')A=55B9?%R^LP>*;9C)K9]DCXL)4P
M:\[*LPKN'XZ&,R$X65)E3QPAP'`<!P'`<!P'`<!P'`<"@?\`F1?W:7Z5N3EO
M\>7_UO?QP'`<!P'`<"@+Y6=E:_T_\D?PM;)VE<:]0*#5K7W6+L=PM<F-#5^$
M&+UKJ.-&?DI,Q;8PC3\@:RRG*U8QEQQ*?Z<XY)X;QVR7/:5W_I+L=5C[OH7:
ME&V[4(JP%562LE`L,?988&R`QT5+F09)T:\^PU)C1<X&0MK.?.EHEM6<>"L<
MK,Q,;I?X0X%7OQ\;,B>P^UN['9_7\/8<:1W)LW7<1J2\3(L>/%[($TI15Z:N
MUEJ3T=*2K,C6$WFG&LB%96C)#2$K\B?-X8+.E1RM"X0X$$[=>(:V!U<0S$NR
M39.]K"R68W'QIB(`=/67L60F6>).A)4J):>*8;`P0$_&DJ6:EA1*AWGPRAVG
M;@.!$6Z[](T"H!N5PF!8O-QM=7U[KUJSQ-NFX$FXVZ59`"S+Q](CSY]R+C(]
M)1Y2TY%&9%#<<)+#'2Z4T(:]"QH'7W7>R]BWN3C[%9IB0DMJ;9L=8AWJH!:K
M,%5Z_4QEUVMVN\69-?98J%-B(D$,B=?1A(;?G?RI:E<+NP]%,NE$#-EK=4+)
M/WW=5ZE[9)P%=%J8L?1\QE/K=3@XN5)5=)$5L%-?ID>E\Q@R1QF0)<5GR,Y3
MA`9;3E6WFJOTFS;ZV%%G;#P)-2=JI^NZVU5M<QA%JCX%;%.98.G+A-V!K71<
M>0R)+.2*7)%9+SZV6FUM,,C3AT!PAP'`<!P'`<!P'`<!P'`<!P-8N-RKU"KY
MUFM!A`D4"E.%)`BY:?ESB7<^0:,@Z[7P92PV.;/=\&Q@(\4DTIW.$--+7G"<
MA'-2I,[9;,%M3:0@[5@CVDJUU0E-1Q0>I!S(H\"4.>D1C9D>9VG.!S98$I+A
M$HCVXKT@`64I]^;*E3;PAP'`<!P'`<!P'`<!P'`<!P*!_P"9%_=I?I6Y.6_Q
MY?_7]_'`<!P'`<!P*.?D1_W6?@[_`+Y]WO\`"?5O).\-X_7)>-RL'`XR^1._
M7+5?1/MKLC7EAD*G>:1H78]EJ=FBEMMR4%/1-<-*CI0%;K;K:"1"&TK1E258
MQG']'$KCK,)VT7IRI=>=-ZRT;0G)AZEZGI<#1*N[8#&)&;<A*X`U'1ZY4X8.
M/'+.R.SCU'$,-)4K\.$X_HX29O5*_`<"!=P8)SL+JKEAB,=:3OJQ9,</%004
M*-_E?[()2_"NK:<4#)J+RTVMU.4*R&X^WYO*YE*B]IZX0X$";I7(O6GKK%1<
M%'S;LAO%@J2>.:8>^S,#!:MVA.2%H8PX0T^.\T4"-&M/-(>RDF4:;4E*'5.(
M+'+YMWSQ!YU0U7&R,?%N6N0!M-PF%[%!HLG!:VHMJJTO;?9HQ"6";D_M7&^M
M%*2.W')P,\1G$I'OX8?P&!IH)>Y=K5??X5E:7JVHU*VU_5<*S411\W=K9`NO
M)O.W`=AA[`L85LHLI!0J6X-EF'AW/`M]PC+_`)!\I&VCJ+A#@.`X#@.`X#@.
M`X#@.`X#@:M<KG7:#`$62SGH`CFB8Z.&1C'JG2TW-R`T/7JY"`H_YB7L=DFS
MF`8X)A*R##2&V6DJ6M.,A'=1I<]9;(-M':0C0U@CW9=G7M$8E2I2"US"'92"
MU+&(Q[>&FMISD2QE1DHD7*X,>0*AH\AX11ITJ$V\!P'`<!P'`<!P'`<!P'`<
M!P'`H'_F1?W:7Z5N3EO\>7__T/?QP'`<!P.+.S7:)O4E^USJ&'^K!S5QJ&Q=
MM7RYQ&O;QM$C6&D]4*K@=JLX5*H5=L<I-6FP6&WQL5$)(9P`*ITDY]!?LD1I
MY8BW.VRN]<K&5WLAMO64X#;-/=1]9=<-E&RK8$7**WK7]LP3&S;S+I*$&`4"
M"'I"2C3:\[$H"RN=+=6^R6(VV"N+6T<N=?D\MU4HGR<?"=;;Q9Z]3:K#6[NR
M_,6:US4;7:_%,OZOU.(R])3,N2''`M/%D-M)4ZXC"G%I3C\*L8RGA<=LEKL7
MV]ZFS<E'0L+VAZ[2\Q+G"1<3$Q>Z]:GR4G)'D-B`QT<")9G2C3C2G4-LLMH4
MXXXK"4XSG.,<K%3TZ)X%7GRNV2VV+K]'=1-71->F=N=ZI6R]<ZBFV%W"+K57
MA9>AV:6N6Q9N7J-*NY`L=2P0F''&G1T8>21XI5X-KRF2UCO?$+0^5DX#@03M
MUDAW8'5Q;,L[&MC;VL+Q8;<A&AHGQU=9>Q8Z8EX8Z;BBI9IDI]L_`X3$D2E8
M27U#)'9?,%':=N`X'!D;9HEM%P[D[%HU&#O&1I;6772-E-@:Z0<]K0<ATR+C
M1K^'=;C0!+9MRTM'21[T09C_`*C'C`WAG2HU]9!?AC1J7-=@]N;TJ6QX:"<J
M41)ZNI.U0@):4EXKZ94XV@;LHNI*M*FUJM-62,L)=JDS-A-R,4AD^!L<9&,/
MO^D1@,=.^(Z.CX>/`B(@`**BHH(6.C(R.%8!CXZ/!80,$``$,AH8,(,9I+;3
M3:4H;0G"4XQC&,<(^W@.`X#@.`X#@.`X#@.`X#@:]:+5!TV'>G+`8H0%IU@9
MM+(Q1YYQQ;J6`HR*C`&29&5E3WU8;8&':<>=7GP2G/`C&E5&R6:>#VKM`0F,
MG4@(12=8E.P9X&IQBTE^]),.A7I0*;V?,A&(%ECQSS8P-EC`D6KTEF&203?P
M'`<!P'`<!P'`<!P'`<!P'`<!P*!_YD7]VE^E;DY;_'E__]'WA7BVR=/$ACP*
M-;+R,;.-1TVBGI@R)"L0JHR5.(M9<7+S4.;-Q@)0#(S@D4DZ6=66C(XC_E7C
M`:QJ7?FF-[QTC)ZAV74;ZW"'%Q5A!@I9AR>J\L"83'F1%MK)&1[%4Y<8P1QM
M8DD**0G*?PH\/#/"S$QNEWA#@0#L71JK5LVJ[GIUM71=F5F@7O53DN]`"6J%
MG*!?C*[.FQLI7S#8UMV6K]LI\=(Q)GK^496"F'62&#'6^%M`#?QY:EAZHK6%
M1EI>OZ?G]<==M5[%H3XXTPNYU3K&\TU1/1G'G1E0<O:JX.Q!6DOVQ:Y2(%82
M+B/,1DU8MQ#\ET#!6CY0_A(@;+"Q-A@Y&W]VVY"&G(X.6B3FV]6ZI(;;,CCV
M2`RD-OM(6G"T*QA:<9Q^'&.2=X:QVR7`!:`T1&F"2,=I34@$@`2P:`>%K>G"
MF!&"NH?%+$*8AFWQB1GVTK;<0I*T+3C.,XSCE8N>TM\#@3LE_P"=7XW_`.^7
M:#_Y<;+PL;2[[X0X#@0!N1<0C8O4],DEU1KN_P"QHKV6P72T(E\=6>RSKRGR
M&Y^'1&-9@&SL8?6/*I4O*6?:H4ZDT,=I_P"!K-TLC-.J%HMA#2R&JW7Y>;R*
MTT2^\8J,`?+;"''"'+-)),<:PTTTPTZ\ZXO"6T+7G"<A6K5;?):H:TC79*A[
M'N%FU+2ZA3ZII.BE1DI($]@-DZUO=\NPMDM<C8J167Q-=:JC4,L'RD7'`#YG
M'\,N%%$-M"1K>U@&JM?BT&-N&?LOKBMSEVVALC8%E)UK5Q*N%:BK%:Y%-9M%
MN2.(*18-CDZ[!A19V4)RZ\8>&O*7,LI:QBLI0X#@.`X#@.`X#@.`X#@.`X&J
M76Z5W7]</M%F-4+'!)0VR..PZ=+S4H2K#$57*U#")=DK':[">M`D9&!-O'2)
MKS8X[3CSB$9"/:K1INRV5C9FU18YV;BSBR-8TIK+DA&:KCRHO,*[*.$O.Y!F
MMH3@)!N"IED45<7'2CT,&IP?WILJ$V\!P'`<!P'`<!P'`<!P'`<!P'`<!P*!
M_P"9%_=I?I6Y.6_QY?_2]7OR&'R=D$U/7OR1ZMW=JF!VJ^7LR(M_;83KT"FQ
ML:KO8T=0+S%E1R8FVUR7C;F'(NQ!Q9[!S:48+B5#J:*Q&H_[;]U;AX[<@%1V
M58*)J+4Y_7O8-UJVI*%USVK!7ZHUFE6K5U4#F:I?Y>DP-<J$@6;+3Y,LS#A#
M-AB#HAB7/.:TM?*DZ._>$.`X#@4<_(C_`+K/P=_WS[O?X3ZMY)WAO'ZY+QN5
M@X'`G9+_`,ZOQO\`]\NT'_RXV7A8VEWWPAP'`A/:I,DQ>^M+0,<Z:*9NR>&F
M26R'V41$:GKCO\MJ1>;9<0V6T[,"B"8;=PMO"RDN8QYT(4DO:;.$<2?([9HZ
MJ=(>R4C(O7$1+^K[+'A'T6MSMEL$;*E@.XC)%EF"A9Y<0.&:A"W)$IC`(6,8
M6\K&/#&4KCO#(=4JC(B63>-_E-<V2AYLTWKRH0$IL*:MUFV7L*K437T9*8N-
MFG[/L:Z-KATW>^3T=$!L@0KPPH"G7VW/<-('$\.R^$.`X#@.`X#@.`X#@.`X
M#@:Q<KC7Z#6Y&UV<Y($/&J"9<=\N7'B3I60$AX:*!83_`%RY2;F9`<,1A/\`
M7?*?;;3_`%E8X$5Z[K5KN,L!M[:\63`SOMCL:ZUB_)"&C:MKLTXEW!-D1&#M
MQTCN*<B&A&9QS!<S'0+K+P$&8L5\\Z6+\)[X0X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@4#_`,R+^[2_2MR<M_CR_]/V0=O9#1>LZI3+/LD'246!.[P#E\0^QM02
M>RG=J[(5J6\Q($+5X:FQ<O9E[=E*E`Y8"E68N=/3%1SH;01/G::P6+G9(75:
M4A9_7!MCA.MLWUA9L-G.DBZ7.U:N4LFS$LQ<-$#7QFN1&0;!&B3,-%"#MMV.
M(@+"V@+#94<QA#>5B?ZZ6X0X#@.!0%\K.M=?[@^2/X6M;;2IU>O]!M-K[K"6
M.GVN,&F:_-C":UU')#,2488AP8MIB0"9>3A:<XPXVE7].,<D\-X[9+GM*Z`T
MEUQJQ](T+JNC:BJ$K8"K5)5N@5Z/K4,=9#HZ*B#)PD&-988=DR8N##'6[G'G
M4T,VG.?!..5F9F=TO\(K4WM=`++\D/1[4]?B+?,V?5=<W'NC8QT93;*=4*3K
M[9^K=HZSH4K9KL-&.U>$)M%VI,D"&*24T0^ZQ_41GS)\2\3*ROA#@.!!VV69
M!V^]8EAF####;QGWI9E^*.D'9"/5UK["CMAA%B0THQ!DHE2!B,E%/QS"V6'!
ML$*>(:$*';.;;W)3=+0D/,VYBWR3]FG'ZM4JW0J%<]D6^V6AFKV6Y8@8.L4:
M#GI9TE=<J$B4I]YM@)AH92GWVD_UN!7QW03,7R*B![Q;K#KN3>(V?-Z?T>C-
M1-C+S#UW6-CH\_LW9EM7`BD:ZK`,1M]+90TG+,1HDP[$#+(48<R*Y&H6M)2E
M"4H0E*$(3A*4IQA*4I3CP2E*<>&$I3C'AC&/Z.5E_7`<!P'`<!P'`<!P'`<!
MP-1O5YK.N*O*W"VFD!PT0.MYU`$7*STS(O\`E5D:)KU;@0I*PV>PR;N,,A1L
M<*4>:0I+3#3CBDIR$64V@6.W6T+;FXP`F9^#-))U+KS(T48-IT(^OE5^1EBY
M860GAYO;<^#-RH<A,1Y3$>S"&-Q@H_\`5..DRN@>$.`X#@.`X#@.`X#@.`X#
M@.`X#@.`X#@4#_S(O[M+]*W)RW^/+__4]:/<N_SNLY.@P;NQNYT<]==P%W."
MM?6KJC1>P\YK^KQNG;'7)#6T$E77#<XL,";/"JEEG2,2;9%IEBQVC_I2'&!8
MU'A+O2BRVFV438TQ9+9VGNHKFV#&*M/]N]/UW1FRB:Z/KO6Z'&H:@5W4&BF@
MZ4/9/J*1R":T$20?@Q7J$LX9(<J2[*X0X#@.!1S\B/\`NL_!W_?/N]_A/JWD
MG>&\?KDO&Y6#@<!U7_=)WM_^0/J=_P#,1W1Y.6OSY=^<K)P'`Y:[$6VBU787
M3]RX2;H<B?V2?C*>&&N3)/-L5BT'O*BBK5"0U7LQ\I#M.W)MDMYQ<2!&>Y;-
M+/;98R.46.496+9G8FS;%U46GK;;Z#"";5@8&M1=]FM/6%R9^N4#;KNQ;]=I
MK6[VZDZGKFO:7$);@WP)821LD],MPY.1PR'%.C375^\Y6KRW:;9!66QC[:WW
ML2L#Q$.31*.UK*G:!TI(2PXQAKLDO:`&Q"P9RR1"GS_1M9<K.2`C7LHP,`,C
M#`_\=U\(<!P'`<!P'`<!P'`<!P-0O=[JVM:P?;[C*LQ,*"]&@I<<SYR9&8G9
M0."KE>APTY]>5L=GL,D+'1H+&%DG'E,CLH6ZXE.0B2BT6SWBSQVX]QQWTR;C
M/K#6L-8-3!<E!ZW@Y(MM`]@L`Z&P8><V].0X(ZRRUCD8K.""HN+*=8=--DBN
MBN$.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!0/_,B_NTOTK<G+?X\O__5]B';
M6.TI0Z9]I=RWCL35=?2VT)39=PL>NNS.T]1!U5%4TC8T2C,G9*UM_7EIA-4,
MUVEK.^R=7)6DVRJ2>W&//.FO\+%\/OZ+*@EZVN+\31]]ZX/E[X%9YZE]C-WV
M[?\`L2!?LFL-;R->'-N5XV'M"S5Y9-'5%$E5HV5]S"R+Y&/12P\P\^)=L\(<
M!P'`H"^5G6NO]P?)'\+6MMI4ZO7^@VFU]UA+'3[7&#3-?FQA-:ZCDAF)*,,0
MX,6TQ(!,O)PM.<8<;2K^G&.2>&\=LESVE=`:2ZXU8^D:%U71M15"5L!5JDJW
M0*]'UJ&.LAT=%1!DX2#&LL,.R9,7!ACK=SCSJ:&;3G/@G'*S,S.Z7^$<!U7_
M`'2=[?\`Y`^IW_S$=T>3EK\^7?G*R<!P*C.P%[?F>_6DX/7JIRY;SU>?=*E3
M:9<:3](T?0H?<76^]721V#:MM5^NVBP!O3INKF00!<Y%//=#D016<#9+.9C7
M'P[]J>FY<:]5S:FR=CS&Q+[6Z+-TB+%&@:_3]<P.+3+04I:Y^KU$(:4L8DW8
M4U6-'<=E+!-9%&&6V'D9!9B7ZE\,Y"/"O[PV+Z+P[SXVK]0#O8;?;==&4JV;
MO6IIUI,D\L=2_!.<^(C'G\,?\5_R^0<B6N`X#@.`X#@.`X#@.`X&LV^X5VB0
M!UFM!ZP(B/1YG5C@2,N>0YG&<M!Q<+#"2$U-29.4YPR(&.^2\K\#;:L_@X$2
M4.FVRXV".V_M^/)A9T<89W7>I"GJX>'IQDN+,'E#9>3@")L.P;;F&9H@"6D!
M)8V#'!''&BVT9]^=*%=`\(<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P*!_YD
M7]VE^E;DY;_'E__6]?WR%6ZTUG6VL`*X1;@0K=N./@K1)4#J_+=N+S'0T?KW
M8UOCRZKJB-K=P'S(M6VL1F7I$R-('"C\$J1ELC+"N%A]W02<G+%K[:\K8K5M
MNY2Q.[I5TJ;W5U85U$NKSK^M-6E/)7K=^H4DZ>CW"'UNHGB0O6->==']1:!$
M9P)=V<(<!P'`HY^1'_=9^#O^^?=[_"?5O).\-X_7)>-RL'`J_P"J5R/[`]X^
MXW8JOPTH'IFL434W4;7MIE:I<JXSL>PZ*V)O:8VO8:Z;9(6-BK'"5C9E\E*X
MHJ->(']>)SC.<*SGD:G2(CE:!RLM<M]NK-!JMBN]SFX^MU*I0TC8;)/RK^!X
MZ'A8D5TV0D#'LXSY61AF5*SX8RK/AX)QG.<8R'`MG)V?V)L-6I$S<-IZJIF\
MJK.WRJ:Y@LSW7K856U!JN]Z41:;+=-G46V';I@]TV.1O("X.(BSJQ&,UXXP&
MQ"9.;<&5&M(22K35*T+9^L]:UFQ868JR]C[-)65Z[[=V5>YLTESJWV.)>,%D
M-C7^=EYLLN4"9>?`PHL?*G")#(V'VE&,U-[=J<(AS4\<R)+[D*3&M!$2&VI5
MQTG$2B->D66JS5<,/.$8I507*M(6XYA#^7IO'CE2<2+GAE@<J8^$.`X#@.`X
M#@.`X#@:;?[_`%;656D;A<)'Z?$Q_H,,LL,/R$Q.S$@^V%!56JP03;\M:;E:
M99]D"(B`&2)&5D2&11677W6VU!$U+H%CO-I`W!N>.#8EH<R3?U)K'UR96'U3
M'%,(B6+5*+*<:B9W<L[$M$.+EVHX,FLQTV;7PWB&%'R$L7^.B^$.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@4#_P`R+^[2_2MR<M_CR__7]G_;.+F;=2Q!
MJ/+2\K8=9V079D[KZF;B&U%8[()6X"8(KXTU.JEH09RL15OD8B7.C)60C8>4
M%#](QUT=60RBP^'IC-;2NE4VAM#8$I5L5?:>VY2X::HU4V5#[B"UCK=FH4RL
M/U@G9%<>*K4P?,7^NSD\\#&$'1T(Y+JCQ2G1QVT-"78_"'`<!P*`OE9UY6=K
M_)'\+6O;EBPYK5EM?=865Q5+I<]=V#T1=:ZCD6?IMSUY8*M<H)WW0:/,X">,
MXXWYFU*4VM:%2>&\=LESVE=&:]Z_58^FZV3>4P4G8"K,7B_[:VQN29^K&1T5
M%/Y&L^X[M?+,!&>SA6/(`P8V`T[ZCJ&4NOOK<K,S:7^$<`?%]YG^D^L9E7G5
MFX7+L'L/+[GIX6;^4GLAMR_?4LM->#8OU3[2>XPQA*/;X=]/R(RCR)0N6[O_
M`(15/V:[IZSV54ZM3^JNX9C;=OF]H,5=\'K4=#W06UH_)'M"[#0)MUCM8[>!
M70L3U<C!K)+5A3!]:>+#][(@-O*:)C41V[UU]J8"NV"8V7;`ZI8=Q6=HP*3O
MXU-IL;9(>HG$Q\@-JN,M\-5X"S3U"K)L<U@/,JM\PCT6W2%*<2C"*R^';.)'
M-]ZQ>QE9./&QO&?S,"`$L,"SL=_EK["X:BIIIZ7C7#8QF7R*<AIIF0<P8&PY
MD=*&UE##M./`A+1V<&QNR+#@<$;%AW;MC&&@7ZP7C.:9;"]7K(+*J\<&RX<8
MY0\O.MFO'28V7/;E/(=:R*,64V\(<!P'`<!P'`<!P-9M]PKU$KYMGM$@B-B`
M5AL+=RA;SQ!LD:/&148",RE;YLG+29C(PS#:5.//NH0G&<YQP(BHE,LMWGHO
M<6VP)&&F&XYM>O-1FR,4;':E#DEO%%G3^(%I4;.[=EP%A#2[JSYV*@WH]0\`
M4EDB0-E"_#H/A#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@4#_P`R+^[2
M_2MR<M_CR__0]6G8OIOM3>NR;W1F8_4E=ZY[_OFO;;V/V4'-SPV_KIJ_7=0H
MT([UB!A1Z5[)JDWN?H[;I\OBSLI:AY.2$1&X??4006)IU[H+4Q.JBMM)11]:
M:UKEKV$+,4REZF->=JX=;BZ)3ZLQ,RD8JC40&$N4X=!/K-'"8)$0(T(C#[KB
M'7%B9MT/PAP()[+=@Z7U;TGL/>-\$FY:#U_5++:%URK"L2%LLV*O7)>UR456
MXXDH-DLYB`@337UN.M,!@!D%D.-CCO.(+$7--1V9VUUMJ^T76ORXTS)`:HC]
M6R^Y;-%?2E0VKHK<EF/J]'+G<&R0AQZ\N1;\C),!-$$1L*E!;B,^N*V^*E6[
M\B/^ZS\'?]\^[W^$^K>2=X:Q^N2\;E88Z8E!H.(E)HW#N0XB..E"\,)PM[(T
M>,Z6_AE"E(2MW+3.?+C*L8SG_P!..!55T,O]IK'0WH?K#64!'7K;-NZ^Z+N5
MSPY80QX75-,V964W20VILM]&)"5`58FER*:[&-B./6"<;6.UZ((DD<!&IWGI
MO,QUKUYLV<MO5*2V!>K,U6=9(NV^;E;+5<9[:-VDNRPNT:;!S5:GXC94#1=>
MS$+*:K-D7X4RE2]5S'DB!QL:",EQ/*ESNL#I%$I&LZM$T;6]-JNOZ3`-$,05
M/I%>B*I5H5DLPB0*9B:_`A@1,:T2>8Z^XEEE&%O.K7GQ4I6<D;5P(`W(W%KV
M+U/5(/--%M;_`+&Y!H<P;E9,IGJSV5:>99R*TXPEU,*X8YG).6V/(VK&%9>R
MTE1>TMW.9+KE/M=A`&:-.@:W.S(0;Z#G&2RXN+*.&&>;BQ#Y-;3[S"4JP.P\
M_G&?!MM:_!.2-?U5`2M<H\:).RH\S-2<C9[;+'AAST<#F1O5JFKJ8)'QUFG[
M/-1T=&/SZAAQW3%H8992VTV.TE`[02)P'`<!P'`<!P'`TZ^WRL:TJDM<[<:0
M)#0XZG5MQ\;)3DU*%*QG`<+7*Y""R$]9[)+D>5@"-CQR3CB5H98:<<4E.0BJ
MDT2S72T![;W+'1S,M#R+TCI_72Q!#$:?#*KY5>)FI&4]W)#S&VIZ.F91@R3"
M]H.!$R.8H=MS""SI`KH;A#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!
M0/\`S(O[M+]*W)RW^/+_T??QP'`<!P*[/D$ZN[L[#ZFW4)J#:ZH69G^KN[-2
M5S59].J,G$6NP;#J%AC3!VK?8#8]RGG7=+T?$/2*\N8C!6<N,*8P\9A\L3$5
MHB?</3;<ULC>W&MUG#[`C>ZU+Z\U:W[6RFM5;%1DJ:`WK7<DS/U#,DP4P(=K
M&-#D:^U!(,?>F7"!G7(UM#!^8MQHYN^5FEO;#^2/X6J8/=+OKQZ=M?=8=%SU
MQ*@P=V@LL:UU&;E^!E9.*G`0R'TC99<4X*]A3#JTXQC.<*PGA<=LEC%>Z43,
M!/P<ZONOWDGT0LQ&2RX*P[9HAL!-(CC63%1,X&/J8(@N'D<,^B2TV\TMQE:D
MI6G.<*Q6;^$X]GYY55ZT]A[.A9;:ZYHS;4\EP!W+)S:H>@V"02L)[#C66BTY
M'\6U>9/E7X9\<?T\$;PKXZFV:=TCUAGTZUT]8]G[5@X/K)IBGTVN3$$+`6*S
M0'03KI8*BHZ9G&*?&Z\UH"=,.CGFEOR)+/\`7=:]5;PT:S%G6=5EU%I,G7I_
M85IGUT8J=O<Y''+/J-/EZS(?1(2('B(")M<G+7.U_:^6A1FUMHD!V(8=;2L8
M2"TKSJ764F<!P(.VRTZY?>L2VX&3F$,[QGW7Y``<-X6JM9ZU]A6<3TTX5`3#
MXL80^ZB+0X.1%/9,DF$9*6TMT(P=MLW`S[C4FTF/0]SZ^NKLS[;VOOO<>I69
M-'H>R^AV?WGJ^;R^E],D?4\?+[9_Q])8;97$^2O0*/)Z?DA8M/D]/T?)Y06,
M>3TO:1_I>7P\/+Z#'E_H]-'_`*N`S/`<!P'`<!P'`U2ZW6M:\KA=JMLH/$PP
MI<-&)??<0A9LU99J.K-8@8]M:T>[F[-9I@..CQDY]0HXIIE&,K6G&0B>ET:P
MW>RQ6X-NQV8^:C6I/&L]9IF"9&%UK$2Q7BU.SXK0T;$S&X)F"%#3($.-2#=8
M<49&PQSPI!QTH5T'PAP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<"@?
M^9%_=I?I6Y.6_P`>7__2]_'`<!P'`<!P*.?D1_W6?@[_`+Y]WO\`"?5O).\-
MX_7)>-RL.(?DOFU5[X[^\<DA#JW,]4-]QK667LCNLO3FL[)",E(=PE2DJ#=D
M<.^&/#.?)X8SC.?'"5QWAI>F4@UN=TW%'R2[VY+]@>R-6JDR++6&'BJ$WJ6H
MVS5DG7(^M&`!LDQ\>]K,P'`ZO.%@AQ9HSBL.(\(L\K$N5DX#@0=MD:1?OO6)
MT'$9[8+>,^3,>_B&)(K$<OK7V%#:S"F/14@Y7Y/ZN6+YRVG@'%A^N+E]2"5C
M$#MD=]E2#6IK9&1,:#*R5P3":W!%E"%#1C9.T;'#ZY:D)%W%7NC>08A5I]V\
MAV++'=;8RAY*6E+6DL)0B0U1\5&`*\GF!CPPU>GAO#?F&&;9SZ>&1Q&L(\4?
M@PEII/A_0A./P8(R'`<!P'`<!P-3N]XK.N:S)V^W'O1\)$LY=(4'%R\]*%N>
M&<M`0M=KP$K8;%,F*QY!@(\4DTIS.$,M+7G"<A$M!I5ON-F!W%N./5#3H*6W
M=8:H=Q`&L:<$+@SXR4DIF7AI"R!S^X)T:PR($K)1TFJ#:B/;!`CX6@Z0E"NA
MN$.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!0/\`S(O[M+]*W)RW
M^/+_T_?QP'`<!P'`<"@+Y6:S9KC\D?PM5JF[&L.I;+*VONLU%;$JD-3+#8*P
M\UK749+Q4;#;#K=OIISI0K"QE).C2FTMO*4E*7$H6F3PWCMDN>TKK[86MZL?
M![)WQ>>PTZ58"I82Z7^J:GI\S&1+\=%!L5<:,TY0=<UE^,",!?+0^^"Z>ITU
MQ"WU-(8;:K,_QR]\I'E>Z*;PBEY:3BSNZMI/J/)PXAE5ZW-KNG(?PQE2,%NC
MKG,+0QYD^NM.&_,GS>.!&\,[UQ97.6QH6='JU?DJ7'[$VY^3-C7$L!-0,YV+
M[![_`'HW9S-]G+-*+Q]LX*K2[;T2,$.ZA\HDI]WT2@Q!1+N/A#@.!`NX&6'-
MA=55O&%#.#[ZL3PK+!<<,U(/JZO]D&%!FLG'ADR`J!GW",,AME$I>8;=4U@=
MM]]DO;*;?%<F#]-U=;Y`\78=S5TJ84*.*^\MO7E<MVX8-CS&PLT,,._;]<1J
M'W/^4=]#*TL$M/J:\P3-PAP'`<!P'`U&\7FL:YK9=JMLFU&Q8Q$='#I\,O'S
M$[.2(L+6ZO7XYOQ,G;5:Y\\:.BHT5#ADC($LC#MN/.H1D(JJ%"G;Q9HO;6XX
MJ.9FH(Z9(U5KMHV1F8764>:VW$AVF1^H(`B9?<$Q!,/.+E6XH0NLASLA`!DE
MBK,/E"N@^$.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!RWK7MUJ7:G97L
M!U9K,@\K9/7:&UY-VULGTV@Y<2_"R;[BZUE6<.2S-0*"9#EGFO,T(<6V.O.'
M<*3@M:1*$Z!WZ8OU/[U6T;51$<CHI=]H4&W!$71I_%[F=3UC[86!^M$MU=*H
M^.,A<IP(LIK#BRE>FXVVC&7>"MOEO%@[@K?[+B=0-5:^$V/O*"UV#M;<CA=V
M<J6K=,TN5?;"@F[!=_LA8;#-W&VG/H^D1`%?<==$\2BW`6,)6L5I<[.AM57J
MUWD&V9N>N)/6<Y4[K*4]R*/F!)\.=&CHV&D!K?7)D(4-F0JT^B6\X"UM,E>B
MC&"F!"\/ACD4L_S(O[M+]*W)RW^/+__4]_'`<!P'`<!P*.?D1_W6?@[_`+Y]
MWO\`"?5O).\-X_7)>-RL*XOE,.;3UDJE>>++!8NG;7I#7238I+#L^$$+VUT[
M:Y"0KHY+C8Q,Q&`5ETE*7?%I+++BU^"$*6F2UCNE3I%J"AT/1FI+W6EV^4LN
MPNNO6^*LEIOAA?VIG8FC:X:^SBIB!^JRD)6)9\ZTRLG)BQZO1<F98UY:W5NY
M<S4F79/"'`<"`-R$1;&Q>I[4@&T469O^QCP;[C!KRXZ43U9[+%NF,."ST0P*
MZN%%,'RX2/*L90^I&!4/+:-#';[;DLJ=W=IRLMO1XH=3"O6W#%/-QQ4E(D@U
M]_5<=%@M.R*)&-&2WM,DH@ML1Q*LC-,>LWAU:'2\2G+A#@.`X#@:M<[G7=?U
MT^TVD_Z?$1_H-J4VP^88688^V''QD9'AMO&R<M)FO-L##,-K>?>6E"$YSG@1
M#KZGVR[V".W+MX"0@Y=$>PO7.GSB88H34`AS)*I"0L!$"](1]@VW."F-BRI*
M)"3B8IH-`T.I.'9`V3*Z'X0X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X&
MLW,VTQU2L9M'A8^QW(:&D'*M!2TI]$B)2P8&<Q$B2\OA@IR-B7#LH]T^VR\Z
MVQA:FVW%X2A05!2O1/?FO.WO3OM[I>>7:[35J5;]2]N8?8T[2*W]L]6;`E,W
M*7163*'2HQ^QV^#VE-2=D:3,//-'F8&2X<SA*_-&KBIB6>UST\WWK*T?(YK-
M59I=PU+WNVG?-EUS9K=[=A3*`#N&CLTJ^P%VI;D"J8)D:JVTLB(S$D%,S'BA
MH@B+RI3S0N*CX;N3U/VWI#Y%=M=Y-.0%<VI3^RVH:9K[<^N#[4W3+_6KIKAF
MO0E/NU#D98%^HV*NG52`8$DXTTJ,*'>;]RP^1YO:\%W%2LJJ;]L*AFBKI'PD
M/.$D&.KAX"0+F`HL%1+F(T-Z8,#C52DC@+"%E.-BCL)?6IMO#B$)>=K*BO\`
MF1?W:7Z5N3EO\>7_U??QP'`<!P'`<"@+Y68K8$W\D?PM1>K;E7M?7XRU]UD5
MRXVND$['K\&2C6NHW27Y*DAW"@DSS3\>V\REM$P%EMQQ+OF5A&6UR>&\=LES
MVE:WNVKU8^/WUM:C;@M[U@*,C;+0-0R&EH8&MN1T4R'!$U:2VEMQ\^3&E!S"
M%R&))A#K1+;.!D98RZ]69KB%>WS"^R+T5H^`D&:\2).=GZH6X):FJZ[7G_R>
MZFW1M]*IS[7LOU)J!"5KK!,DY)HR`B-8(R]E",96F2N.\K2*G$O0-6K4&1@)
M)$+7X:)?3&M)8CDO1T<,&[@!E`XB&0L+9SZ2<--X2CPQA"?Z,5EL'`<!P(.V
MR3,L7WK$U&9_Y(W>,^-8O^MRHWQAD=:^PIC&/9CRL>S8/_O`(#_RC[)[2/\`
MWK#"7!FR1QV_*O2`ME["7TD60D30Z#K*DUAAM@B737P[%;+7>I.Y`NL+K8<"
M981HZI5]:U-R\@6(.\G#@D>@A#TD7A.W"'`<!P-3N]WKFNZS)VRTF/#1<8RI
M21P`#YF<F3EXRF/KU7KD0.;/6NV3Q7E%C(F.')D9,UUL85EU]Q#:@B2GZ^L%
MWM@&WMRQT>B7@Y`D[3^N5L,G":@$*AGH$BP2$@HDP6<VW8(^0D$$RHK8;45$
MR:H<9#N$FR$F5T/PAP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`A'L%U
M]UYV:UR3JW9ZK>BJERT7-.JH]ZMNNI[WL.ZMX/T[+2I:%G&AO.YGU&4OX;=Q
M^!>,XQPL33@S]B_TJ_Z?LO\`ZNNQW_B/R4OM)^Q?Z5?]/V7_`-778[_Q'XH]
MI/V+_2K_`*?LO_JZ['?^(_%'M+KSK%T\TWU&!M\=J!>QUC7@N&-G?RA[7V'M
M-[#\$S(L`?2R+_8;`]#->G)N^J@7+27L^7*\*RA/A4F;56?S(O[M+]*W)RU^
M/+__UO?QP'`<!P'`<"CGY$?]UGX._P"^?=[_``GU;R3O#>/UR7C<K"FKY=SA
M9$[H_KF1@K):XB^=@]FQTO6ZFML"9)!G.IV_M4HD\SQ$1,C047$R&VF/>OJ8
M=4V,\MQ#:U-XRF2UCRN5Y63@.`X',_8.1FHFY=49"$A)BRK:[&',2$#`HB,2
M9T7(];NQ$604V589"%@@1(!TUN4+60<(MP,%UD7W1SHH)18Y;WI2&N$?21IK
M8#20+Q><1%VMT!B,$B<U6SR]3K8]AK*A(R_[0ATJB9H!]/\`R,]*!HQG#;)1
M:$8*?(EW@.`X&IWB[UG7-9/MUODV8F$CWHL-1#N<>H7*3TN!7J["@-9SA1DS
M8K#*BQX`R/%PHTEIE&,K6G&0B>ATZRWF>B-R;;C)""FQH\U&NM5/S>#([6<-
M-'X-^HVL*'2/`S>WI:("BVY53KT\#63!"1("06,4<9)E:]V=[AZ;ZC`U"1V^
MC8ZQKP7,A07Y/-4;#VF]A^"9CGS_`*H/0*]8'H9KTY-KTEE8:2]GS81E64*\
M!$6Y#_;0=*O^@[+_`.D7L=_X<<EKZR?MH.E7_0=E_P#2+V._\..+/64W=??D
M>ZV=FMC#:MU@UNA%J+B92:9S>.O^XM=0/LH=I#QF'++=:="P;17D<QZ;*G\.
M.Y\<(QG..6TG&89SO_L6\TOK7L&MZ>NM;H.\]G56Y4[4-IL]@B:W'5RS)IT[
M,N6)4M*RD8U%EAB1N18PS.7&AY\Z.P\C+;F<9$;_``XXI'RN*?Z`]5^[$EK<
M2W52Y;!UMIWMG,?:_-*<ZZ3<O9VM87S9<G!KILPF8K<!L/T<KC\N1;V`901U
MMQ2%9RF6OKK,-AVWVMM\+VDZZ'#ZTVQ.'S?5[NWMW7^M=8;[?13-N16MOLX?
M0Q;5J8S608-LO&Q:XS%E5@EZ5#<K!,X4,\R4K_B<%:2U.D?,%6MC:^Z^25(H
M\39MD]B-G[(UA`5.(-V$?]C)O3FD@]K;(A=@5R-UI([#A;Y%V0MJN#PK,64V
M1[EF5P=]/SE65GKNZ:[,VWM#MKHG%W3KK3I;5G9"\Q.I+@'I78%F5KRXNK1/
M5RW;+T0_<VRH$NI6R?J,=+0B9,8B-+84M3H[X3_IOLU(J]=E*O;WO?;IOXU^
MX>Q-1S/;7JCV9T=MK0%9V/IW9^QM@%W[1DW;K)"QK[%3O<I,JDKAKC8\%[DH
M)TM*5.+P\ZVRT,L/"8W$:QTO(^2"X2VL^AO::<HMUGJ;L&F]>MFW6B34';Y>
M+NL<?3H1MQJPQ\HS)MSQJ8:1D`\$.K<=;]0AI+WCZJ<*LL8ZS"#/B^E;SM+3
M>D]X;&FMZ05CQHC5]"D8S:6V+-=JYV!FMA==^L6]2=_1$%+WRW5Z*DVK#)64
M$'Z<T$5@)\QLP<9QC(S$A<NGV]O];;F+[9=1+IH_L=NN`MGY:*U.;2U`->1X
M_KV%TYH\00_O29O6O<BLP\I,S,P6#&1<T;DN4;E9YEL;#;`GN`!%5-PQGR$;
M=V5"]HOC^ZZUBR6^HZZ[`([KS^S9JBV.?IEB(,T9U@FK?KB&8MU9)CIJ+&Q;
M9K$LIAHII)CL.VV\A\?#S2DF/,NB_C7W3?.P_0_JWN79[KQ>P;QJ>",MLH0.
M((_/S$:X5!$V=T8!60F5VGZ7B1REI+2,>Z_`TUC_`(2+"3I,NW^$.`X#@.`X
M#@.`X#@>?3N_WFWG`=??ESV_J:>D*Z9U%L6JNLFH!H;+Z7H><N+VI_RP;;D!
M<AN,GV8#.U_3BGG\/L18M?0\PEA11CC\[;B-<;Y=P=%MG7B8WQ\A>A[!-6RS
MTCKMV$I<1JN9NE@E;?.1U9V'IZHW.3I;MML4G*6F>%KMB=))'7)/$$,,2:&4
MON--MMLDGA2KH#MOW9OUPMVK:QM2SR>\I_KA\A=AZ[[.>M5CM^E^^UG%V,L;
M3%NTG5[NP-K_`$S,:)=K4R.P,V.`&>%@13C;D>_YEFIB/#ICK1W]G])[`[/A
M;JV#=:_K2KZSZ/00`W;69O=??T_VWVKJN4?V-1+1;MIX1-@5PH&O*M<NVDIX
M9([/GA&GG9(5@HDQ=5N=<^\FROV=<%W*<W+)[IL6J^_-BH>X%,3J)")M6KMM
M=HHS6_V2<@U$'APZ(6B;3KL[56`\)=BV6@FF%8CB2V2!,:U\)%_F1?W:7Z5N
M.3\>7__7]_'`<!P'`<!P*`_E97LAOY(_A:7J(:D%[&3:^ZWV7'V.;/1U)=*_
M)KJ/!6)XVL`2DZP/B-R]EO([#BLOX1C.,)RK.)/#>.V2Y[2SN^WJL>KL2!J&
M/NV)\I,6SI:6N<S5E5;$=%9"=/*O,+!2S<^J6R=AUMME0V!DL92O*U.)36/X
MJ'^582Q6+O+\,M3KMI.JWMNS]OV;-D@FN`.'U[7TOI,"4A<K%<;/.:LS=T3#
MD"-X6VZ#)$+(3[9IY:)/#6.V2];E9.`X#@<6;@N^)KL_U1H,?&H7'4[;UQG;
M59S3#@6`+A)=5][LTFB0H;$'*-V*9L-2F9R8*RX1'!Q8<.G+Q/N3(\,TO$NT
M^$.`X&J7:[5O7E9EK?;#2`82&$?+)R!%2]@ER_09<?P#!UNN@2UDLLV4EK*1
MH^.$*.+=\&V&7',X3D(DI5!LUQM\?N/<0*09V&5AW5&L'6X,L33C!L!(0TO,
MR4I&'V$:=W!/AV23CI*5`D?I#4&H<$(9"\2!TH5T-PAP'`<!P-#)UK43-DP^
MVR1IER\P%0GZ)$&_:VW(@PJQ:)6`FK`&BE(G4TEPR5DJK&N.G+CE'YP$RC#V
M$(PG@^'/%9Z#=3ZAK[L!JJ"U<\C77:.Q6JW[QI\M?]F6>"N-JNWC]J+",!:;
ME-,5*6EEX;4MV%Q'92L=C*/+D=GTRW.C>-B=4-#[4O=6V9<Z=(%7:DZVOVHZ
ME+PUXO\`4QH'7VSXK$+=X`.`JEIA:VKZQ'-MH22Z&X8*IAE8[K2V6E(%RC>S
M?'OU0MT8V'-:]F?K#.Y&>P3%^A]E[/K6UA]Q,04;547H?:U;N,3L,>675X<6
M/<\DDEIUAE.5H4[CU."Y3Y<-)Z[O5&@-<V.-FW:K6)6J3D&W%72[5N?`F:0>
M+*UB6:NE<L,5=/JD=*A-$J)S(>X)>3E3ZW?.YYB6@W9_0/JQNVA[%UUN#7\M
ML.O[>L=3MFTR)C8NR8RPWV<H847'TQZ?LU6MM?G%QE7%AV,`1K#[$8*O#CC8
MZ7'WUN%N6?MW2SKY?XS8,->H78MSC-HZZ?U-=`[5O[L#8&Y#7IAF3Y*MQF9;
M:!:ZNS,E>51[\5D(H_#322'74M-80+EF]7]3M(Z;)UP_0(F]1X^H:%G6.M(6
M<W5NR[U:FTGZ?#1+43#4^\[#L=5:(%B*^((P<H-9XXC>66WT-..(6+F49[2^
M.KJ%NK>T/V4V?K6PVS<<`72RX>Q%;FWD%"@_D]DL3%1!:U_$[)`UTJ$C);+A
M2X]42H$L@@APAEU9#^7!<U3-M]#NKP]<<K(.OY".&SMO9V\!I<"]W\:V1>Q]
MSQD_`;3EH.X)L^;-!1]XK-ID(PV.#*9CE!$Y2AE"TMK0+ETU2Z;5==5"KT"B
MP$95:72J_$56IUJ&&0'$P%=@0&(R'B(T5O\`J,!1X`S;3:<?T)3C^G/"-FX#
M@.`X#@.`X#@.`X''YO3_`%_)7_LP7.P]?M6G^X-6KHF]-63P96!3[M6:WFAK
MM\.6(\G#?VQH3,<%(M)P,0*9!BGC/X(>?SPM[=L@YTBZVDB58<^C2$F94^PE
M=[5B3Y]VO+]FF>P%4C/HD#L>XV'%C1*W20CX5*`T"2CI4;@1EICV_I--H2+D
MUUTDZY:E/K<AKRER%;<H5=V+4M7#,6^VG1VHJ[MN<#LNRHW5D9*S1X%'^UT[
M'LO//!-H)'::;%&<8#::'0+F4W:WU3K[4<1)PNOJT-`#3L_)VRR&J*D9>P6R
MUS2VU2MIN-JG3).S6^S'H9:;=D),LLM3#+37J>FTVA)'+T]T.TT30-<:*J4"
MQ3M!5/>[/8VV4MN6L=E/NM\BKX3MB+AGY*V2<T6#693:Q34W)I]PXEQD+$:P
MPT,2M;);G=75_,B_NTOTK<G+7X\O_]#W\<!P'`<#3;AL;7NO$0SE_O=-HS=C
MEAX&O+N%HA*RB=G2\X2+"PRIHX),I+$J5C#8S'G>7G/X$YX&2DK95H67A*_,
M66OQ,]9EE-UN$DIF.`E[`X"AMPUN$C2B6C)98B'D9=PPAS+>%8RKP\<<"EGY
M$?\`=9^#O^^?=[_"?5O).\-X_7)>-RL*1>PU>M-I^;SIB.;#ILVO*]U4V#*B
M,S1$L=#T*W9O<K:3;S7(1B2#C@[))YUS"1!)JTJ\4$!Y<;?]NREN<M1]97=<
MK)P'`CW:5Y?UW32;*%"LV*4=G*958.$)L,1519.QWZYU^AUL8R?FW$AQP2YV
MRCY>RVV6:MK"D!B&%J8%>#FXVL6JO[!T%8MC/C2ESV'V7F)5\"KCL'U2C-QO
M43?T1&Q8,A.1.9982(V'=P](L(C2R#CL-9S[53K+Y7:?"'`TZ^7VJ:TK!MNN
M<L/#PPA$;'MK=5A14I-3DD+"5RN0H>,^XE[)9YZ0'CXT!A*R3CB6F&4*<<2G
M(191Z59[O88_;NX([Z9+QZY3.L]6IEBY.#UM$G/H'$L<^/CV<'.[BF(81M9!
M^1'%U9L\V'BRWQG3CY4KH3A#@.`X#@.`X$?5O:FO[G$7"<IUE$MP%!M=OHMO
MQ5QS[#(0ETH1[T9;JH1#1`ADP]888YG+:PV6''W,J1EM*\+1E01#JSN;UGWA
MJJ.W9J':0.Q]92EZB]:,62HU^X3"QKS-3T968NOS$&+7EV.`(,F9L)M+IP@X
M^$&,.Y<PR\VXHM2FN>V+1JO;*'1;#:(>(N.SR["#KZN&E):E;<74X$FT65F%
M%\,K*5"5\1PLC./##;2?'.?'.,9(W3@:79=BT:G6"@52T6F'@[)M.PR54UY"
MGE):D;;8(>JS]VE(V'&\%+?=`JU8.+=5GRMH0SA.5>HXTA8;IP-`OFTJ!K.O
M7:SW6S!1$5KF@3^TKFAEHR9F8:@5@*0D)FS9K4$-)V,\)@:))PT@41]XIUA;
M3"''<>3@9NFVZO;`J%5OE2/5*U2[5N#MU8E%!'QRI*O62+%F84]4?*B@R@"C
M(TUIS+)+#)#7F\KB$+QE.`U"O[KUA:=K7_2$%:6C=IZNA*G9+W451<V&5!05
MY1(+JDIDXZ,&B)(29Q%$X;4&01Y%,J2ORJQX<'RUG:O9G2^E;MK/7&Q[1*0]
MXW*1/AZNK<71=@V^0NQU7!;D[!'PN*95;`R])148ZDET=2T/X'SZF$Y1C.<%
MJT>V7OGU(J&DG^QL_NB$$TJ!:G*+.7H:$M\H'4[HQ*)A"JI>(N)KQT_1+"%,
MN($(#F1`7QR'6VW$I6XC"A4W5:I^C-GT>:GZ]6X::5+'VVEKV'6"XR+F3JY/
M4QMZ)85.Q5P%CG:D8/YIX'.&T&Y>4V6RO",H<2K)'TP&Q:-:;7?:-7K1#R]P
MU<=`1NPJX&4ER6J)MJKP5KK;4R'G"7!DS=>D&BAE^&4.MY5C"O,A>$ANG`TN
M&V+1K#=+KKJ#M$/*7G7`E4.O=7#*2]+542\BRAM1>F1DX\1$V`.%*=&QG/BM
MME2O#P\,Y#=.!#EN[`:?HQVM(^Q741HC;^TY#2>O51,;.682<VG$-VM<O3R)
M"LQ<N!7SHARCRS);LDZ&,,4`Z.ZZE_&&\EJ6>V)MBA:J9K"[Q-O1Y-VLS--I
ML-%P=@M5FMMH=B9:?5"UJJU.*G++.FB5^`/D2<"B.X$CP2"GLML,N.)(R%"V
M'4MF0I$_3CS3HX*9EJZ=B2@;!69*/G8$M0$U$2,):(N&FH^0BSD*9?:>'0IM
MU*DYQYDYQ@-UX$57[>&I-7,6\K8%]@*J+K^AD[.O)4F0XD:H4,=XP9NR60AE
MIYF%#E"HTMJ.20IMZ4=#)0&A]0S^&P^G6&X==;DC;!)Z\L"YE%1M,C2+=&GP
MM@J]CJ5OBA0#SJU:JG;(J#L];F6HZ5%*PP:&PXX(4R^C"FG6UJ%4Y7U]\GG0
M_:=IL=.H?8JL3DS48&^VFSO*@+S$UV"K.K@WI#8%ADKC-U:-J`T+50F%.%%*
M.]!*<I\JE>='F+4])4K?<WK9;:SL6V0&QEF1^IX^I2M]BG:7L"/ND+'[`KC%
MMH!+&NY.J!W^<1?H`A+\'B/C"U3&<*;#P\ZA:$BI9'4/;KKCOBGZYONJMI0]
MGJ>VINQU>@2KL;8:[F<MM29.)L%-=`M,/"2<)=``XHLC$/(,BR;PP9#S3"VF
M'EH$Q,;JEOYD7]VE^E;DY:_'E__1]_'`<!P'`X+[U2/6M^@SFM-R3^C(*\[S
MUY<]4TT[=4[3HH.%J]A98CKE;1\7&3C48A*G]4%D36`GA2)8P0`3#R7O:N,E
MB^%?6\$'KIO?..HUJ+MMCMVD_CT'Z561,L/+GVZ(:(4+HF?ITF^GV\ZYGL>3
M(2CKH:_7P06A_P!1E3P[F(UU;\_E9E=@0GR1_"U*:MIM>V#?@[7W677*=:[N
M3KBOSA*]:ZC:)8DKL'3[\3`M,1[CSR7$0YN7'&TM>5.%Y<0G@QVR6,5[:WR#
MF3\&'9NF'7:!KA4Q&#6"<B^\=GL,E#0CYK+4K*QT`]TX@FIPZ.`4X\R&HT-)
M+B,-Y?:PKU$UFH[5T52V/;4^>"2@K:4Z^?H7K[,RM"P.&"RTU$2$KL>GY#*4
M.H8M21&KK(+<?7A_#KCXZ%I\4-+;G+7Y7^<K!P'`YK@:U5+UN;;DA,'2$W)Z
M]M.N@8\!B[6/$?63!J=4[P&&36(ZV.0H9+IAP\BIHB/&40AYMQ:'FUI<67IG
MMNK+3L#JXD9J(<9<WM8$2"Y*3%`-8$QUE[%.(=KPI$H`[-R^3T,(6*PT<Z@!
M9)&6$MCN$CD[3MP-9N%OK]$KTA:+.:L&(C4(RZM@,V2-(>>6ED8&,BHP<R3E
MI,U]:6V!AF77WG%82A&<Y\.!#]$I-HNEFCMR[;#D8>69CA%ZZT_(O5\H/3Z#
M!"_JDC-$UXJ9CI[;4P/)>RDS&)21B0!Q&QXK*,.'%R!70W"'`<#0M@1VT)*-
M":U7<*%3)AL[#DB=L#6]AV9&E1OMWDY$"B:YM74Q0!WNE-K]PLTEOTTJ1Z'B
MK#B`TM<!V4S)F.M[9T<F&7!J'CP%]>KZN3%LN8-L=$L9+)[.MBG0:;+A9>8Y
M`0Y&058$][AU.35!\.:YVF]A$-XW)H#$FR<<Y/&9ZU;%R!)1KF0/IHD1'8[8
M8(A#A$ME>N0\5(-D9>:\C#'HKP^-&WU.)W2':YHR\W_5]BH[[4CBNUVIZAM=
M,M<6\[)#.Q+DU<YC=]\B)YH&(2\P2AB!C<E$K0^A0Z$*'<#&[XOD_KO6<W-5
M&OV.R7.4)AZ?3`JY3K5=L`VNYRHE9@K)9HRH05CE8^AU,^31)ST@H5QD*)$?
M<SA2L(;6(4_=,:'MKHIWT[*Z1D]4[-)ZN=D:=`]DJA<Z/5MM;FU]KK>D4"Y7
MMGU:P;'C=5U:+S;MJA0JIQUOV"5*>:"$;4M]W"7(W-3$3RC^&Z7;AZ\[5ZL=
MC>JL!+Q6H^SDSU,KW?CK[+UF<KQ5<M]5M%`G8GL9#4Z4$B9:LVD&P0[H-K;=
M%;<3[U\U]ASURRA!=W$LO\DU#[#[8:B^ZN@-47J6VET>WY39C1=7=K>W(S9E
M_J-6D?H.Z:G7]18U&[*3U5W0Y8B%$2H<PD>6@:]'9;2CQ<PZ(K:>5M6I.U=:
MVYLV3U2/JS?FOIZ.U11MNC2NV=33VNZW/0MT9%R9`0!MAR-)%7&@GG,!6$!\
M,9<>8[AM*G?!>45F8K55-\GVM>P.^8&9[*Z!UM<B-I=#]O4*X]<PSJ[MJ+O-
MQFJ,2F1VZ#2-9#ZG7([#I6XA[$/%//BRB19#%0%6PKV[SON)+6-1I/+GKO\`
M3G<3=^U]E[`TS4?D`I^N)[XC:]>]<4"G0O::C@U[N4YV=BWPZS)TRHC0\6[O
M"OZ\(=24"\,X^L`;!"D+'0VYP14=;I3VC2-Y@;O^2':T#2>UL?=MM_%QK<WK
MQ<J#!=@0B3MSUO5&VA':S'E4=MH2N[1A+O*1K@E=.2-*C'D*)8$2IQ]Y0TJ/
MZZ8N:_DY,Z*29^L)"C)L3W2.N9K,7/UG<4?W*1N'&@X%NQYDS[1-,Q;>SL[$
M3)+%27&H.]SEA+O_`#7G<R32]5?6MM7[>LLQW<D-8,]N-'';6Z8]`*W3]UW;
M3W9:9F,;4K,]@;9\$2O8<(_=9:.;/G\#6T>+R^:/"FR1XK+JT*6LM[;;I/*7
MV,M6POA@V9M_K_NF)LFI]K]QIS>[M.U]OC<E<IL=.1]BJE4M?UM5;M5N@:7?
MB6FB:W%S#GU(&'?&8RE3#*'5.C3_`"U2'USZQ60R?[NWK>.F;D-I#O!WPCYF
MI:6LNN[=.2INJAHBRUZQ[-V+3XB)D3]<Q.TES/K.MS;$88`V*A1?HJ4SP7MK
MPW[J9I_L!\>NS-RZGMX6P=W]/=!Z3V5?^G$]6*M8MA;==JFP+C1I:P=9R(VO
M"2$I9;7KZ7I#"(1ML92RPI9+J%M#)]C&$FI_K1M?Z[[#=2_DSUQN=[5]TM>K
MN^NJRJGVDD]45_;.TZ]2-Y5$[[0T3<5\RQJ6G-:RA)5-D57`PCTD?1XU)*R'
ML):\R7*Z3C_%L^I.TU7V_H"4[!1NLM\U*-A';X'+ZKNVIK!'[V!E]>S<M`RT
M!^2R%S/S9L](EQ.5`BBJ?=>0^WA6&W/40W6:UI43!4CL5UI^1W0W:Q.H;[8J
M)W?UW+ZO[<B:QKFV]I*I-R'E/MAJ7:NP(H?4=6=H`E15-#TYI,@X7F(K4<YA
MQ:EI6ZN-:3$QTAO2\5W1&[C5ZT7<;O275'_ES[T4]2K-GL_):XC>F$YJV-#T
MP4U&2JGZ-!::>O,CYH662TP&RZ/AQ@A"1O,V-*\/QZN4;L_IWK_\:NO*_3.W
M5%O%0[\;XC.S$"Y`=D44E&OIV^=@IR%E+X**VY2YK4,NY8:V>N5:R[!&DD+)
MP2LCW;J71-3?\=X]K]#;4W]KS7=#[AV(NGVZ/VSF\:2[#]#*MN0*:Z[76K4N
M<<BKU>E29%UD@:P<HPF/*,\P@;.26<+?&SGW;!(TV<EP</WJL)/16D=A97L3
M;H8+M?V=HVXMK:/K&_M.C;PZTUS6I=?UCM/?\!J#,*Y4R[=:A!F8]4MD<HH8
M=DD9Q]#KI3Q=-:?E\8HG<&(V]T7D-X1W<AO[1]&]V5S?C^Z(CL*_5`MJUG>B
M/R5@75J_!KI]/N+6MHE[,>ZM(19PSGG4M]TS"GQ-5.V[XNU>A-Z;_P!+_/#I
MFO1<K,[VM^T^OMUU[!1[ACTG:]'5&FZ<N%"@ZHRLEI)H]@!UW:8ED8;^H1.X
M.'\KCWJ-Y=D5'J[!ZTSMQTQO[N%N^>U/OJS:X[H=X-,Z^TX+5-82A1D#"AZ5
MK]2FM^;!@YE$!/T32Z)^&<!-FCF\J0D)EYH7++R77"3K6NT)7VCU\K79O9':
M^I[(B9ZG:+HO5?/3VBF5^->CW@7-R08.QMZV;70*8LB.+'CZ\%KN*`]H*6UB
M2@C0U)7E*QTBZKMR?U8U3L?K+=.QG9S>IVVEU*[4CK;T_P!.7/7G7VV8VX;3
M=.TV6J>>S6Q=',C[>DZ6IVP2>6AW9B*<PV*#DPV*%$.2)@3K40B*8TON_1?Q
MPKU,2;8YG:"ODWUK(=3;B;3@Z+M&^1D_V]HERB]@;/@$"PTLW;Y>)5:S),DD
M40MR):0\0TV'A:L%N+\)._F1?W:7Z5N.3\>7_]+W\<!P'`<#`RU5K$\\V3.5
MR!F2&6O09?EH>/D7FF?.IST6W3!WEH:\Z\J\N,XQXYSG_P!/`^UR'B'2(LQV
M+CG"X1+Z84IP$99$0DH;V9*8M]3670$D"8])S#64>=O^KGQ3^#@4E?(C_NL_
M!W_?/N]_A/JWDG>&\?KDO&Y6%#/36='NWS!=P)^OFR/T*E]?[)K*:C[C.1-B
MMZ[%&]R]OG8D8<U8J)J.HJ93$T-'QS*DBQ\8U&LOJ?<0QZ$Y:GZPOFY63@0Y
MN&6LJQ*U0:>07#V'9LK*5UBX#$,CYI($969JRR,^TEY@GWDBXB(0"(RE"LI?
M,P^K&6F'$J#<J+18'7D`Q7:^N;(&;4T\5(V2R3]NL,N>@(0!V5F[%9I&5FI:
M4,9!;4^^\\M;KGBM7]92LY#1-JX(S>^M/HV`Z&;QNR>R7'"'1H@]L'_RX[_P
MFOR@YUCA"I,$8K+<JE@(:8)23&,O*#0.R^>"&]7^_P!6UE5I&X7"1^GQ,?Z#
M#++##\A,3LQ(/MA055JL$$V_+6FY6F6?9`B(@!DB1E9$AD45EU]UMM01=3J+
M8;Q98[;.XHR.9E(21/D-1ZY\I)X>J1"XIROXLDL446Y%SNW9R()/RN6&CXYV
M!BIPJ!'42W@V1E"_QT'PAP'`<!P'`<!P'`<!P'`Q(\#"BS,E8QXJ/:L$P%&Q
MLI-H$9Q+'1D,LYV(C"9#R9+<C(M^4+=''ROT67BWW$)PMYU2PRW`<!P'`<!P
M'`<!P,3"0,+6HUJ'KT5'PL6P\:2V!&"LABX+DSB923,4TPA"7#).4->*)>5X
MND$O..N*4XM2LAEN`X#@.`X#@:VNGUA=M9OGT0%%Q9@5U;-C9:R/*DUQ1V9-
MN#/)84VJ2BQ));A`S!'JMBOO.K9PA3SN5ALG`<!P,"?5Z_*S<#8Y.*$D)JK9
MD7*V<8C)"H(F6"7&2,A%,NJ4.%*%13SHF2VT))P&0^QA>&GWD+"B7^9%_=I?
MI6Y.6_QY?__3]_'`<!P'`<!P*`OE9E=@0GR1_"U*:MIM>V#?@[7W677*=:[N
M3KBOSA*]:ZC:)8DKL'3[\3`M,1[CSR7$0YN7'&TM>5.%Y<1)X;QVR7*ZCN&X
MY>DS5@[#ZPH>EK%%RTEEF"HFWY'=$$]408F--;L9MJD=6:D(CY!PYPUEP!,:
M^EID5M[!*\OY:9K,UPJ$^,%JMVGY#_EIV35Z@)`UH^R=;OL;88:QR]@@[G";
M+K%^W,;8<_7PQY2*GK&Y<!9TX#Q0S%.S7L&VTMBM\G:SMBOCY66&L=AA*C7I
MZUV62&AJY6(:4L-@F#5Y;#BH2%!?DI62+7C"LH&!`&<=<SC&?!",\""J8G9.
MTIO6FT+)&TRG4Z-@TVFNP,85=)NW2S]TI;+.56!5QI.L3J7]-Q,O-KC7HM\S
MS#(4_EAUQ8PP='<#EKLI<Z90;'U>LUV('$#%[!2@D,2]DWU_M'+=:NQ47%@Q
MC0K[+)4O.>\<CQ62,+:>>+2A"?74RI)>V:H%+M-YL<=N?<`!D/+,!O\`Y,=2
M/R;!4=JF'E27"EREJ8B4-1,[N6=B6HYJ76X1-QU9)#>#KYJF")`^6'PZ+X0X
M#@.`X#@.`X#@8&TV6&IE9L-OL1>`("K0DI89HU25+P+%0X3\@>_AM&,K<4T*
M.K.$IQE2LX\,8SG/`K[ZM?(UKS<O4C:?:#<,83I#/7J\[CHW8VFE1\Y9Y?4$
MOJ>QFH-CY>-K`$[-2L@S2B(P\M(`Y.$OD.MM^;#6<\+,:U#$;%^6+JY5^OW9
M7?%'(O6QFNM-(UA=;)4$ZYOU%FI:.WM%XD-(RP:;_6*ZZS3K^E?J(E\M+98$
M;6]Y',Y8;?EKZS<0G>A]C2KQV\V!HT"R4C[+570&N]H#T>1UYNZG[SBYJW6^
MT1!,[8S[K6X76Y&OCXR,&9!%"<S.L2316"VD-8:SFI6EN>_D9^1R`Z?:DWH1
MK)L&^=@=-:[H^SI.CR-*OUFI=?K-WO\`'4R"=V)9:C].C:>[9D_4%QJ29%IU
M>0LN+;]);>7(L1==.OH[LOJNW[5ONA:1;/?;6H,F%5[*A%3L<]6JG;YBB9V-
M%P]BE(_Z=%-E+J*T&897("8(SYQFGLDLD-L5*Y5%Z>^6O<Y'4KHOW5W90=7O
MZE[9;YE>OM^@-;Q5PA;5IJ9/V-LO7](O@,A8+A;(^]55TG6[CDP)D:+-%P8W
M[912DY;5+7UUF$QL_)!MG7_:/8'6[L-3=>Z^@]DB[5_R,[T"C;'BA[1M6I+3
M;*?9=6[)CSK>^J.V*N4@6UA"B2`:9!E3>$8;?."84L]=+AT9W2[PD]->JM9[
M`RU-5L:<?+U;(VJMUH<D1N-H,K9J>QMN]HCU2,E+`PE0K,ZX@=WS&H9EC8YH
MC.6GEJY4B+FG>\!.P]I@H6S5Z1&EX"Q1,=.P<L$YZH<I#RX;,A&2(COACU!C
M0B$.MJ_]*%8SPC+<!P'`<!P'`<!P'`<!P*J^UWR5`]?]<][=FUFGBVJ`Z/1.
MNJ=.9D7)!A-TW]MY5256JD"4'CTXZITD6_P"YDK"2""GI1QEO`GL5.%1J(NO
MET#U3[,S^Y-A=KM*7UBK?E'ZI[?A=?S<S3`9*$K]NK%TH5?OU,M+%9FK!:9>
MM&NM2AD>2*Y(G,J?CE/-/Y2[EEFI,53F*$[5=Y=8;<F8CM72^K8&MZ[UQW9V
M9LT+H8K;EMV;4:CKLFO@4NK3\I9\1=4)N5XD9LH<9F,&D&3'H&02.ORX96N+
M4<(ZZE=[.U_<W2^W[/H"Y]!-I;<JTY0Z[7Z>`WV8U]$:V,DI.2)NAF_(G84(
M!LH,+Z#$/!P.82'?9D)9+JLO^B(^G@F(C>THZ^[O;VIVIV]O]HX;2*:<!W-D
MNJMBL>F6+^'76(5VY1&DHS9\$9>)`^0EX^`[#ID(&7'<%&0N.;4:.]YA,L&B
MN(<U_P`R+^[2_2MQROX\O__4]_'`<!P'`<!P*.?D1_W6?@[_`+Y]WO\`"?5O
M).\-X_7)=+;AF3:G9PR69$D<NO30SX\.P@J7?9?C26G68L9S.$$2+J%Y2PC/
MX%NY3C/]/*PJ$^(^)'^V7R%V2,?G&H3':"EZPCX"R0[T38(!6G^N&GZUD.TM
M8??CV;KB/+%:F11_ZHAS"TY\$Y0A$AK+A<YRLH:[&/\`MNO>]B?<>T]OIK9[
M_NO>?3O;>E2)QSW'U#[15#V/H^7S>M]6B_2\/-[L;P]9!8WA,O"-0O=[K&M:
MM*W&WGO`PL2SEQQ(,;*3LQ(DK\4AP]>KD$')6&SV.5?\&`8V.%*/.)6AD=EQ
MU:4Y#DV?K&Q;%N'K+L_8,7*-.IW?81ZM0(5D5^'T_4R.K?8,=^P;!D6L6@2>
MN\_/$Y`?E`28<$5F0CXT?"U(.>FB]NX>$.`X#@.`X&A;`U5J_;,:%"[4UO0M
MF0\:=B4CHG8%/KUSC0)+`[PF)$(&QQTD**=@4AQOUD(2YZ:U)\?!6<9#!1F@
M]%0HM7!AM+:EB0J.U;6*6'&:YIX`M09OPBX^]LU<<6&::K[5U`<4Q+)$PSB2
M95E!'J)SX<#!P'5SK+4T3S=6ZZZ)K2+57CJC9T0&HM?PR+'5)1X0F3K$\F.K
MXV)BO2)`##CX1'J#/+8;4M&<H3G`MND!J35-5LR[K5]9:]K=R<K(%+<ML!2Z
MW#V9=.BF8L>+J:YZ.C1Y559C6(,)#`&7?:LH#8PA&,--X2&N;HUG8=KQ-6K,
M=<Q:I5A[K7;#L`'$+/DS5QKM;,1-AUF`M-;O-)EZ":Y8P0BER3.37,M#*']'
MR/+SPJMFT?%%)/V/Y`4:][#II&K>_P!JD>EW'7,UK>S[&D:=L4:O.UO\KPU\
MLF[FY>R3$H'(FN2(3PXV#GB$*40GT$>,I?;;39JLA\/!<YJWM[JN;[(LN1?:
MWK=T\T.Y(Q6FE1QE&E^GM,%K%:O"6S-K2[5EC[><TZ4;#_\`5[@[+F&&SU*1
M[A2CVVT=*G_'M%[&[&;'WGV%N%.V_7MJ=?=5Z4M>K`]93U(B7)C5MUD[X#=P
M)]O;=C/&$+FYA_R12V'%L-(9PHUY2'%.U+TB',O87X;(G8KO8^OZ+V]7M#:Q
M[3:/TUIW8M/D=53&S#:ZO1=P&GJ?/Z^F%[:IB(MN0ADY".$.'/2I36'6W$K=
MSEJ4L9;7#J)WH:6YW6C^[H>PJS6]E1]3FZE**J6OIJ!1M"(D]6URD0T%N@4?
M9.8J]P=(N$:;/Q3J!PIE#3H$:Y(+'BV7'1>E.<]*_$)]B.O?4#JMMSL`)MC1
MG4+<$EO:'K5=U`[K:6VCL)-XOM\JC&QYB0VIL@4ND5F5V&9AR(##%Q)>DSE]
M_P`$>7BB<M9FM7478?H'3>U?6'8W6_>4Y$SGVAO^Q-FZUO\`5JD75K%J6Y6N
M[VB]U6PPWOK=:7C)RI2%H>#((9(!:EHY3HZV&4/KQRI$U-PW"\=0!MN-72O[
M>N2;9KJ=T+'Z,J]%AA]@4IJO`'QTL'LF3LTG6MK!"["!V2MZ*27&O@`CM#P(
MC>%+7ZCJA;-=&>N-ZZC]9-:=<[UN0?>SFJ(IRJU:^IH#NN3E4D,AU57KLG"*
MO-]9(=JL8XB/'(;)92H$=A"FO40MQP3-S;KCA#@.`X#@.`X#@.`X#@5$7[X\
MXW9SGR.]=;KB9$TKWTD*=NNL[!B!A9=^A[7AZ_5H*RQ$L$20E>7H"Y:W@+1%
M8=PP-(#FD!-O-.AY6J=M7]9Z3=1>G.UM<VJZ;,I'8*,J6S-Y=JJ'OKL?(Q^I
MHF:KM]U;3*0!0G.O51BK-890ZB1DG$1(SV;*DHN8:,R^MM*&W4LMU+^.$VIT
M9<@[UV=VI`;$CH+9NYZQ2*)K"T&U+-KC]25#7%1ETU`,VMESD2Q;\";4O5GL
M)`Z"8YHIJ3:%4O&6<OK%[,-K#KK8*A<]@[YM4SKB4[*[+U%1=86JVT+7DA0J
M%)D:Y+O,K7K$;6)&WW6PR$B7)7;+93A4L^M,<`(*UY,,Y6X+XX<\;IZ:3EEZ
MB]>^B]4/+DH`:Z:#.W5LN0'0R@^I:7V#5=R;)MASA/NE/WK;E^J;2!QAU+=P
M?,NE.8P$,3P7K,N0_P"9%_=I?I6Y.6OQY?_5]_'`<!P'`<!P*`OE9LUFIWR1
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MR;1>6W$%CO>HUY?ZJD+RA>`D^\7>LZYK)]NMTFS%0H#T6%ZSN<9>.EY^7`KU
M;@(L?QPY(V"SV25$C8T-K"GSI`MD=I*G7$)R$0T6BV>\6>.W'N..^F3<9]8:
MUAK!J8+DH/6\')%MH'L%@'0V##SFWIR'!'666L<C%9P05%Q93K#IILD5E-NA
M%%;`ZN/CO`M-1N]K"::@N'+DR"!7.LO8N.0S%FC0DJS73DFGLN*,(?C65C(>
M$P2ITIL,HG:=N`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@.`X#@4#_S(O[M+]*W)RW^/+__UO?QP'`<!P'`<"CGY$?]UGX._P"^
M?=[_``GU;R3O#>/UR7/7<A@2EV\HD-J0&&J\^00`^MQIDYAF*+<=#><94EYM
MHEM.4*4C.%8PKQQGQY6%7_P=,"/?&=H*TC1K4.YL6;W?L8R)&(62%&/V_?.R
MY-J.CUN)0XD$`!3#+>%>*_!OQ5G*LYSR0UENMHY67+U\O68_8K-CL343`Z]T
MA(2;T]-9,MDO;;!+6V@`HKT14Z'!THY5C)(5/EH6V&84=Z@K38X[RR7$#EIL
M%&IEJN=FCMP;:!-A)80(?.N=1'9K);&HD%@',2LK.25=D;,#/[;F1YI^/DS@
M9@J#&CAV!XYI*\GG21'0/`Y[W.,&_L?J0Z41Z+X782R$QS?JM-^[,7U3[-AK
M'\CB<K?\L>6^[Y&\X7CTO-X^5*L9+VZ$X0X#@.`X#@:K;;#+UP%DN'HEJOQ#
MJI+"XRI&4@,X?`,#+RXJGG+W<J5&J3,2$:S%#>F0YE)\@.LC#`22C!@U$O8M
MP&][Z.A=L2'M?JGH>TF-&(^I_3_MS[3V7O\`<X7I_7/LD![7W/M_)]IXSW/M
M_2F?I("]BW`;WOHZ%VQ(>U^J>A[28T8CZG]/^W/M/9>_W.%Z?US[)`>U]S[?
MR?:>,]S[?TIGZ2&?@+9/S$X7$R.L;S5`!PCRF;//R&M2(,]\.R2<&/'"#U?8
M5DLJ#96,`:F1U/QS(Z8TUE#[K,@D@%@,!NW83VL]<3MAC6_=6<KVE<I$8F-E
MIMV4NMD);B*VQB#KX4G8I@(,\K!A[4>*46B-&(>0TOTLXX%('2_9UCFNLWR0
M=!>Q4S8[[LOK`SO$^%L&RH::KURVGU^W'#6W8VK]ARL198^!L`TXS(R)27_3
M#';B4JCVV5)SAO.(U.\3#XNO$%MGI=W,Z\?'1NH"?W'H:8VKLS<70WL#96&9
MV6KU7KNC-TRMRT1?Y8M/JJM-`(D!CHTM./%QGRN)PVTH4<$LZQ,\MN[9]J[_
M`*2[Y=7.SRK):_\`*,/L"\=']JQ;M6N`FN(,38YU02%O)5T.@0:4LL#>-2?A
M992)`K(L36&,C)\\@3A(B+B8Y7[<K!P'`<!P'`<!P'`<!P'`<!P'`<!P/-3W
MQWMO&S=:_FXV%49>Q1-NT%;-3]:=6`QJBXZ0H>H'PM,3VY[-!K',9="D-@Q&
MQYL\V39PT0]&@1Z<K<;"82B=MQ$7B[;Z/[&@M8=A?D/U=8;'3M=:4A>YVN-<
M=>(.7L$/5ZWG9.Q=$TFS6G4>LHJ06!')E9&80B28@8I:W'##RG&Q4*4XIPD[
M1_$65'K9H#J5VRVQMG0NHMG7(SJYUE-FK^+"V#<.X]A[AWKV+L:2H>-;BY"3
MO!BK%5J-KHH\P>`B$I9%O:'6A5I0T.@7,P@#J%V_N<)LKY-[<_5NT^PKG/=@
M>O%?&D?\IV^I.PZ]"GM)1XTI,/:2$I4A>Z_7:,N)/?BJX^,LE33\4@\I#$@N
M7X[68^J..N.^+54?BX@.SM:D;Z1M+3?R06$14CL6/L];M.T(3<G<:,IFP:<8
MF<"B'KF):Z-M+*)%K"%C`S\2O.4M24+Y1Q,:U\.G/YD7]VE^E;CD_'E__]?W
M\<!P'`<!P'`H#^5F\,ZV^2/X6KN15[O<V8"U]UB%UC7%7.N=VEL$:UU&#AF!
MK$9_STL0RHK#KB&_PH8;6O/X$YY)X;QVR6\TC=`.X-37JZ,:ZVMK4:&:L\.]
M7]Z:OE:)/F_3JT)+.2K-2L.4O3-8);D\,)=\<,D/,$,_TMJY64"_%7655/XW
MNDL:K"<*D.N&L+:K",#)1A5]K@EY5AML0<8=EK&;%_5;2C'II\$YRK.,JRC8
MRWEUSMC:U`TAKRU;3V?8P:K2:=%/RLS*FK\5KPWCRB1<4$WYC)JPS1BFQ(Z.
M%0Z;(G/-##MN/.H0HF^D.7>LVM+7L1$'V?W\#&?;^[LB7FBZV&C)X*`U''R]
M>!B*]*R45:!8@R2W1BEM^W?F#(:)EJ\'*GP;*$MNR#\B6>H=S<(<"`-R+B$;
M%ZGIDDNJ-=W_`&-%>RV"Z6A$OCJSV6=>4^0W/PZ(QK,`V=C#ZQY5*EY2S[5"
MG4FACM/_``'`<!P'`<!P'`<!P-4LE$H]R+K4A;Z;5+4?3)M%EIQMDKT1.%U.
MQMBD`HGZT3*!E/04V@(MUG!0JFG\-.K1YO*K.,AH,WUMZZV:U6F]6/0>EK!=
MKS6WJ;=KC-ZLHTK:KA4"$CH(JMIL)\$_+V"MOH$:PL$MYX56&D8RC/EQX%N>
MTBF4VI2/V7]]68$O%)+=.IZ7XD%Q%7,>K<Q3G2(!"F,HB77*G83HW.6,(\03
M'F?_`&;BDY(CN:ZW]=[)KD;3UBT+I>>U($;B1#U;-:MH\IKD2028Y(I/&I!T
M$_66#4R#RW\.I%PO#R\K\?-G.>%N>TN@``Q0(47%A"1L9&B#`1T<`,R&"`"&
MR@<0((0=#8XH@H[:6VVVTI0A"<)3C&,8QPCZ^`X#@.`X#@.`X#@.`X#@.`X#
M@.!!;/7^D"[2VELI@49X;>M-@*ANFC2L5&S%1V$NIQTC7Z]89(`QE6,3.:?+
M.P<EAWW`TI$#A,.M8]FVK);91GKYHEB&J5>1IS6682AWH':-+C':177Q*MLR
M,40N/V)!-OQ[GTV]!K+=RW+M>603EQ6?5\59X+GMO\-4ZU7I.U3,)"1T9+7F
M;&LEPDA!D-&V2="KT'4@Y28)QCU32PZQ6H\!I2\Y],4-IM/@E&,<(^2`H5%J
MDW;[+5Z74ZW8]@R84U?9^`KD/#S=WF8V-8AHZ6M\K'!CG663`B!6A67S7'G6
MAFTM)5A"<)P$/V#JUIV=#UU5Q:;5ZKK/7.T&MVB:QI58A:G5)_:T;,%6>OVF
MP@P@H8IF(>Z'N6%;*64+-L#(I9#KF&5M/EN52?\`,B_NTOTK<G+7X\O_T/?Q
MP'`<!P'`<"CGY$?]UGX._P"^?=[_``GU;R3O#>/UR68]SY1^#Z>=L)H8RU1Y
M,1UJWK*#GT0MJ/NX+\?JZTEM&4T]Y*V0K4,XSA<<\O&4MEI;5G&<8Y68WA"&
ML=MU[K+TTZEU<F$+L]H9ZQZWC:W2::7569`QBAZDJ$8LP`.W6:F()@7+;*0-
M>9RPM3V)6QQC2VVVGG'F1O,L_6-*[8W;::QM7LT3"1U<$K<055>MX,<MP:BS
MQCMM(FI.Z6*,LIL;8[H8`=7$O-)7*Q\'(03R8DM31A)!0TX=R\(<!P()VZ:4
M+L#JXP.R"ZU);VL(1JRY@N,('%;ZR]BY%#T6$--Q3-B.4:`RVH,AB290,MXO
M`R716S!1VG;@.`X#@.`X#@4]?,W\E\W\;'7NJ6;7E8@;7N7;EK-J&O1;9@MZ
MK0`L-&8E+1;YJ.CC8V1FDQ#1(@PX;9`Z5DG-N..9;:4R]):QBY4J_%!_^H)[
M+;O[84'KGVT$HUNJ^[Y]RIT^Z56K#T^PTFZR:2GJM'DB13^(B>JTL<EN,REP
M=!PZWFB,DN8;=;=1+66$1%P]E_*YJTODG[>WWK-!]9]<ZB;B@-M=P>S^KNLM
M/O5CA7+#6M7#W^;%C)W81D"DD-FQS$$,8UB.C7GFAWWW<O.Y<:'6.\6(NV][
MHOEVZ54FT]E=J;GV?NOK_J#2EL-V72B:5I3&T9N[_:K6K51N52+J52TS7/1!
MKZ+"U)1Y)8P[CA@ZV4Y4WY4C?3ESIO#Y9:G4M=;UEM3ZDO\`8[UI2Y]0:1,@
MW/[&P5?4YW.A:K9]>V2,)C+M*ES0U>KUL']^$[B.<7)J0/AU(V73F9:QBFVV
M_)7HRD[4L6K[!!W<%>O]E==]-;7M"VZH_!:SVEV?B#Y;6=4FE1]I.>ET@>U8
M&GCHO!H,40>QA+I#;9K@=M*E6)L7OWW,\>P>R*[9[#6Z[K[Y1H3H-`:XCZ+H
M>1A!Z//3.AQ$60&P6`\ZU_E9CA2IMM2SB2ZTZ]:QEX;2@!>!HU$1I_%IG4[M
MO7=C[&V+U1,M=RV9N+K6N3JNW-CW*'UK19RP6"#:IKWU^1UG3SHPN%AK6JY+
M;AY./AD0,CF%.RAYOQ$P769CGAS:7W1VG0/DJ[BZFN]GF+!UPZ[='A.T`M%@
MZO0_M/\`5@R(TFQ#1LX0#`2,FGZ/DCV0IDHRWDC*?4?\O]$6M([;13OF+ZY6
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M*5@YN<RU*V/=^_\`5&JCW@&X)QAT:)LDF:ZXO#@[#XK1)#%2(MANK_;BI]IO
MMQ]EZ9,U'["_9KWWU?:_5/9_U#[3_:#VWM_\L?8O?WT/VGV><\_UOZ3[GU4^
MS]UZ17MQ,4J\Z=_)#N?=.\.GZK<>T7K_`+N6CY%*]$T%-;A!Q]3-]2[97R-8
MDP]BAHEJ>-=F:+DT>=5,FF,$RKJ'1%"(RV)F-3$5*_/E8.`X#@.`X#@.`X#@
M.`X#@4#_`,R+^[2_2MR<M_CR_]'W\<!P'`<!P*D.SG9?:E--[Y7^O2DE%A=(
M:QUZF:!5`"<B@7^6L8.-E;/&L`CC2@[.G8%4E0ZI'#$X<^FDL.$@K&.>P2W&
MHC9SE\K.Q:AJ7Y(_A:V)?)$N)J-9M?=8J:D`8.?LI8S!6M=1QS"F8.KQ<U/2
M"E&&-IRD85U2<9RI6,(2I6$\+CMDD7Y`/DHZCV#HSW!J]6V!:I&S7'K5NJDU
MT(K3.]JV.1.777M@JL2EV<L&L8V%C4I/F&U>H20PUXX\,K3X^;!(B;AV1UCZ
M^W/+T'N?L4,,O8(D96!M5ZJ6S#%P?72L0-->K$9"B$1"GH6<V0AJP3_N9P9*
M5AA3I$4.Z^.ATHRI,].[^$.`X#@0GM4:2?O?6ET&1="%#W9/$S(S8[[R)>-5
MUQW^(U'/.,MK;$::F"A"\..Y0WE8J6\9\ZT)47M-G"'`U"B;`I.SZR+<]=VJ
M#NE4-D)^*$L-<D1Y6()DJK892IV0%DT5;C+A,'9H0P$E&,^+10SC:O!2<XX&
MW\!P'`<"L_Y2?C:I7R6Z#CM8R]L(UWL"B6%=QU9L!F-^MAP\T\`[&2L)8H3W
M8+DG6+*`M*",,OLDCD,#D(4XEE8S\G5K&?653GQB_P#Z=>1ZB]C*SV3[&;BJ
M.R9O5Y9,KK"BZXC)UB`^U+P9`(%MMD]8QHL]Y5>;*6\)&C!X2H[#+[A66V5#
MOHA<L[BHAZD^5AR+VBT3U][>@`]>MG3Y0%_IIM1[`4$ZCV02O[AU3/5N>/C*
M9N*BFO"2>(DV.FQRPV2"`R@GE9=9=:<QXIX6)F-7^;(ZD!;PTMM+2.]-Q[6V
M=7]K:\F=;2T@\JATXB&BYEUE]RP0T11J17ZR1<620!'D&204@TPX.I`S`XY)
M8[XNIN'-&?B2T<;4=ZU>?V]V"L!?8`CJW*VFT%3.IP)RM6/J'#UF"U/8:.S#
MZ@CX,$O,94PVI$>4#EPB<)SE#+2\^;DI?:>DC6_XU-!WG9LYLJR2MY/5>;_U
M^VWMBJJ)J;-=VOM/K+&2$5K"Y6M`U18.!60T>V].@Q+T:!+DQXF<M,M9D&9&
MI<M;G?BXT].UW:M9=V]V`!C]M]RX?O3,N1\OJ1)<%NR%,A3AAZRX7IPQH>EN
MOUJ-]0(Q!Q*L`HQ@I/G?]64OM\)V@>F>LX?LZSVU-E[-8-N`U/8-'C9:0:J@
M#B*IL2Q05A+KLY*UVL0EDNL'3W*\VQ6AILV01!CF%ML^+:A4!U+TKAH5K^/+
M5%PWWV&[$2>P=P,W+LKUSE>K]ZA@9/7;54B=;R@;8?N:D&_K4F:!LX"6_.P4
M8>>SE><^JPZGP3@7I$(8B/AXZR`5"VT*5NF[K;4;GU#I/2^5A;'/ZZRRSK77
M$T]8Z/:P'X/5T(8QLNMSCV26#EN.`*=2G+@*_+C')2^TL'<_C)ZS#P.YZ_O?
ML'NBU2O=(;K;J"9L=PLNI:I/%7SKL`2;HZ1U8JHZIK`L/L6*1#F$(QEHUHUI
M+N"&'\9=4M1[3I4.C]U=$*UV0T#_`)>M[[SWML2M'1Q#=FL)9&HXJR6:Q8BA
MXV`N)*8G48U>B)NDD#)/AVHX`0!J52DXH<LQ"7\5(FIN'7]#JS](I54IQ-KM
M-Z?J\!%0#EQNY$07<;-]*#:"3,V<R`A:[#F3AZ6<.$O#@BH==RI?IXSG/"-L
MX'#^I^@6C=/;7K^U:RJS$NT&3W[,ZFITF9%+J6JY/L]9X*W[I+J[04.%,$KL
MDQ`I2+B0,,3&A$O"CX2SEM+1;G9W!PAP'`<#6*5=:EL>I5R^T*QP]OI=OAP;
M!5[17SF)*$GX22823'RL5(#*6.8"8.O"VW$9RE2<^..!L_`<!P'`<!P'`UBN
MW6I6XVW1U8L<//'T&SJI5U$BSF#"*M;40$!:5UR;;94I4?,)KEIC3LL.>"_;
M',N>'E<3G(47?S(O[M+]*W)RW^/+_]+W\<!P'`<!P.?KWUFU9L2VR]NL`,FE
MZV"ZW"V)"1YZ!*[LP+4%J/NNLQ;N!D5YXUFK6*4(7G`KP>90-WV$GDV/0V*@
MMJCOE*OM%UA\EWPJ7S9=TJ>O*/7;9W8)L%SO-CAZE5((<G66I0!WYBQ3YD?$
M1C+YQ;3*%/O(2IUU",9RI6,9D\-8[9-@^5SO'TIV+\=/;>D:^[@=6[U=+)J>
M0CJ[4*;V!U-9[1/R"Y2*<0!"P$);3I65-6VVI6&F&G%YPG.?#PQGB4QB;C18
M3^T7^/C]>WIM_J>TE^/'*E3U*,]T_)YTIIFG=LW#7?<[IM:]@536E[LM%JW^
M8G4T[]I;C!5:5E*Q`?1(._BS<S]9FQ6!_:ANME$>IZ;2DN*3G"SUGJ32WR>=
M*;GIW4UPV)W.Z;538%KUI1++>JM_F)U-!?9JXSM6BI2SP'T2<OY4W#?1ILI\
M?VICKA0_I^FZI3B59RL]9ZE)G[1?X^/U[>FW^I[27X\<%3U+FCIQ\L/5O<76
M#2VSNP7:[IMJS=%SIHTSL37OY=-=TC[*6%TLQEZ*^R=VV-)VN"]-AEM7H'$.
MOX\WCE7AG'):SC-S433;]H]]OCVFKQUODL]W^I!>:CNB=L*7P.SFIU"QF2>O
M&^JG[Z:S'G6`1$8XFSY&1D\N"%]X0QA)SA.1XV0J5/34.H?RP]6]N:'@+WOO
MM=TVUCL\^Y;DAI6F_ETUW2_95ZG;HV#3-?2OV>N>QI*PC?:K7=?BI;UW'E,'
M>^]T,E`SS*$RUG&;TB72_P"T7^/C]>WIM_J>TE^/'*E3U*O;XMN\?2G7W2VD
M56^]P.K=(LXFV.U\B57+?V!U-6IX:/L?;?>5DKQY$/,VT*09"G:[+B'A.J;P
M@H(II]K*FG$*S(7*)O983^T7^/C]>WIM_J>TE^/'*E3U+FCK7\L/5K9'Y??R
MP]KNFU"^P79?:FM=6_\`^=-=U;[::=JWT+[$7_\`^]&QCOM']H_?%?\`6L=Z
M,69Z/_+M(\B_&6OK/4NE_P!HO\?'Z]O3;_4]I+\>.5*GJ7,^B_EBZMWG97:>
MM[,[7=-J?3]6[EB:=I*?_+IKNO\`Y1=>EZJH%J/M7U6?V,7%V[VUWGY6-]]$
M-C@H]E[=2,D,O+5+6<9TTETQ^T7^/C]>WIM_J>TE^/'*E3U*"*E\J_4"8[$;
MKUK-]LNGT3JRBZXT39M?;$7V%U@*-=;7L"4W.)LBN,3Q=Y^SLN[10Z/`.N#@
MXP2%B:3DK^J^-R6OK-1HG?\`:+_'Q^O;TV_U/:2_'CE2IZEQ&'WLZ0I^1^Q7
ME7<CJJFDO](Z94V;@KL-J/%6>M(N][[,%5IJP9M_TER?&B3&2G`\/9)0,ZAS
M*,(4E68M36SMS]HO\?'Z]O3;_4]I+\>.5*GJ4$6WY5^H$/V(TIK6$[9=/I;5
MEZUQO:S;!V(CL+K`H:E6O7\II@36]<?GA+S]G8AV]!WB?=;'.QDDW$*K(O\`
M58)Y+7UFIT3O^T7^/C]>WIM_J>TE^/'*E3U*"-H_*OU`J>TNM-3IW;+I]:*;
MM'8]VK.V[2UV%UA),ZUJD%I'9U\KUC*DHN\XBJ\U-[#JL/")(D_$9YR32.U_
MS+S'):^LZZ)W_:+_`!\?KV]-O]3VDOQXY4J>I03L3Y5^H%:W)UXI-5[9=/;%
M0MDR^RPMI7)KL+K`]C7@-6UY(V2HF$RT=><0T$FRVD5J.2N1QE!"G/29_P"-
MG'):^LZZ2G;]HO\`'Q^O;TV_U/:2_'CE2IZEQ'W/[V=(;3,=,':QW(ZJV-NK
M=W-4VRSN0/8;4<NBN5:.HVUA)"RSRX^WD)B(`$N1':>,(],9IQ]M*EXRM.,Q
M8B==';G[1?X^/U[>FW^I[27X\<J5/4H([(?*OU`UCJU5LU/VRZ?;'N6-CZ/K
M.*L+V%UA/O9JE]W=KNA[$L?TVMWE,KZ5'UY996;<(_\`=@VXY1!/_+-/<EK&
M,SPG?]HO\?'Z]O3;_4]I+\>.5*GJ4$]F?E7Z@:LT3L;8&H>V73W9FR*S$"FU
M2BB]A=86$BQG.R\:$\&U"UB\IGCU-`E.O>0;/GQAOS9_JXSR6L8SU*=OVB_Q
M\?KV]-O]3VDOQXY4J>I1QN+Y/ND=*U'M.Y4/N5TZN-XJ6N+O9J946.Q^I)5Z
MTVN!K,G*UVN,Q<->,2\D[.2XC(R1Q?\`F7LN^1K^OE/%GK/4LOKWY,>BMCH-
M'L-H[J].:_9IZH5J:L4`YV4T\"Y"3LI"A'2\0X%(WC,@&N-D'W&<M/\`_&;R
MCRK_`*V,\6>L]2W#]HO\?'Z]O3;_`%/:2_'C@J>I<1?&MWLZ0T3H#T\IMW[D
M=5:;;ZQU[UE"V2J6KL+J.O62O3(%:!8.B9R"E[>'*1,F$^C*'6"&FW6UXSA2
M<9QR0N43<Z.Q;#\DG0:-@)R1B^\/3>0DP(>3-C@$]F=,/J..%"??$#2P/>/<
M/*)(;2C"&_ZZO-X)_#X<MIZSTCCKY\I73'8^A-(;#VAV^Z>:^V7?-0ZUN>Q*
M$3V*U5!D4B]6BF0LY;:@_"6&\YGX=ZM3YQ`2A3LY,'4SEM[_`(B5<63C-SHE
M_P#:+_'Q^O;TV_U/:2_'C@J>I03UJ^5?J!M#3=;NVV^V73W6M]DY>^A2U-*[
M"ZPK[\:#7MAVJMUHQ439KRJ9'3/5:("D4K=SY'TEX=:_X*V^2UG&>I3M^T7^
M/C]>WIM_J>TE^/'*E3U*"=#_`"K]0-@A;5?V3VRZ>T,BH[VVKK^ELD=A=80N
M;5K>HS_TZEWIE$]><KDQ[5&?\P@T3_D"<?UF/ZG):^L]2G;]HO\`'Q^O;TV_
MU/:2_'CE2IZEQ%U`[V=(:SL?Y`3K)W(ZJU\*Y]W3;93S)OL+J.*%M=67U3ZI
MUU-EK1!]O'9G:^JP5V0!P8+ET;)@)#/G]1EQ*8LQ.FG#B+_.!U*_;^?EE_S1
M]=?R0?L]_L7^57\MNM/R;?;'\I?O_LG]N?M-]F/M-['_`(WL/=>Z]+^OY/+^
M'CEJI]*K5__3]_'`<!P'`<!P(!WEU6ZW=FOLO_F$TAK3<OV)^M_9'\HE3BK1
M]G/M)](^O_1_J8[_`+'ZQ]`"]QY/#U?:M>;Q\F.%B9C:7/9/Q:_&H&.^67TH
MZQ"B"LNDE%$ZLJ+`XP["%.OOOON@I;999;3E2E*SA*4XSG.?#DJ%]LNWZ)^*
M[XVEI2M'2+K.M"TX4E2=45-25)5CQ2I*L`9PI*L9\<9Q_3Q4'MEV_K]E9\;G
MZD'6C[IZI_9_%0>V79^RL^-S]2#K1]T]4_L_BH/;+L_96?&Y^I!UH^Z>J?V?
MQ4'MEV?LK/C<_4@ZT?=/5/[/XJ#VR[/V5GQN?J0=:/NGJG]G\5![9=G[*SXW
M/U(.M'W3U3^S^*@]LNWR$?%W\9PCX8Q72WJZ,3(.K8`'(UA3F7SGFVU/.,AM
M.!)<)=;91E:DHPK.$XSG/X.*@]LNW]K^+?XTFR6`G.E76!LPIHA\81>K:@DD
MED3+"2GF&%!8=>:&44WAQ2<9PC+B?'P\V/%4'MEV^C]E9\;GZD'6C[IZI_9_
M%0>V79^RL^-S]2#K1]T]4_L_BH/;+L_96?&Y^I!UH^Z>J?V?Q4'MEV?LK/C<
M_4@ZT?=/5/[/XJ#VR[/V5GQN?J0=:/NGJG]G\5![9=G[*SXW/U(.M'W3U3^S
M^*@]LNS]E9\;GZD'6C[IZI_9_%0>V7;XG?B^^,Q@,B0?Z7]7&0`_<^[.=UC3
M6PQ?9.N,&>X)6'AECVCS*T.^96/34G.%>&<9XJ#VR[?;^RL^-S]2#K1]T]4_
ML_BH/;+L_96?&Y^I!UH^Z>J?V?Q4'MEV?LK/C<_4@ZT?=/5/[/XJ#VR[/V5G
MQN?J0=:/NGJG]G\5![9=G[*SXW/U(.M'W3U3^S^*@]LNS]E9\;GZD'6C[IZI
M_9_%0>V79^RL^-S]2#K1]T]4_L_BH/;+M\N?BY^-#!B([/2OJ_B0<&<-0!G5
M]/P8L-IUMATM`OLO74,V^\A"G,)\F%KQC.?'..*@]LNW]"_%O\:1S"20NE/6
M`P9:G$H(%U;4"&%J9=6RZE+K02VU*:>;4A6,9_JJ3G&?PXSQ4'MEV^C]E9\;
MGZD'6C[IZI_9_%0>V79^RL^-S]2#K1]T]4_L_BH/;+L_96?&Y^I!UH^Z>J?V
M?Q4'MEV?LK/C<_4@ZT?=/5/[/XJ#VR[/V5GQN?J0=:/NGJG]G\5![9=G[*SX
MW/U(.M'W3U3^S^*@]LNWR._%W\9PY88#_2WJZR=())4`$[K"G-EG)#0APM08
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M*\>/]..*@]LNWY-?%O\`&D0\4.QTJZP//@NML&L-:MJ#CP;SK#133)3:`LK'
M=<%?0XE*\8SEM:58_!G&>*@]LNWS_LPOC(]+U_\`)GU8]#ZA])];\FE,]+ZK
M[SZ=],]3VGD^H?4/^!Z/CZGK?U/#S?@XJ#VR[?_4]_'`<!P'`<!P'`X<[?N2
MY&RNBM<.6M.IK5VP<CML#J;0[&2N8GKUO>V:EA+&TZV^PY!G;MKM>6VEU'IN
M2S`"/.E:D846.>W]]`29]W3>P0Y!3RJC!=JNWM9U!A]&6TCZ?KG9#9,/2(R*
MPE;@V:A!C!N@5WVZLC8K@P&&L);PE"1+N#A#@.`X#@.!7CWBTWH7;00E?M@M
M!C=U3::<_4MM68R%!M&@J;1[N%;I;:=1LLJ4.?1BX%T,AP%4<MAR<F_:BEJR
M"T^^$6)GPY&W'*7`V0[HW,8MTK>]2^0?H)5NNA0R&BI",U+.*Z>NUH&J$,^)
MN=?W5_8.QV[)D1UUM^/,GTN-Y0A]OD7KJEX_*R<!P'`<!P(&[&WVX:_UPX;1
MJ?L"VS\]-QM6P_K:LB6^Q4V-E4%N3%Y;@#'VV9!V!C0W<`MK;(8<EW@T$MX$
M40ZV6%/G6*?>GX;IE0/LAL2I:3;^2/Y*X>SP.SHDEABT3H&P^Z]]T]7;.1+G
M31-B379A3V2$'O*\+I`-84MTL5A3D6>>Z6/?'B782^L<;B9<(=A([<'9F"U<
MLQ*FS/R(UWLCM:!TJWEI"W06XL?64=&-Q6`W'0\PR!,LK4G/CRPF6[M[A#@.
M`X#@8&U2<E"UBQS$-$$6"7B8&8DXJ!$\ONIN2`CR"@8@;SK;1[B2*:2RCQ4G
M'F7CQSC^G@>>"6VQO6M]-VVS)"LVZ?[6](U]LMK=@J"!/0.QJH^G9FA8O?D+
M;I8^P3[Z8"'U1O.28J3P:(ARM`U0D04)+86%"QNM?*T[KD,5"]N.[U5K`0L7
MIV%"ZO$P43$!#@5V)VO*ZVLB]C!Q(L=C$4*MW78E#)>:0EI__F$..-X;<8=>
MK,[1V[OX0X#@.`X#@4L=E7KA&]N+9;(@$BW:(C-A]&X+L=@./$$W1JZT1E]+
MLFI['I&662U)S6J3YR=B!+L"VRHIL.5E%P2W#LRB!XUQ\L)#'795LHUM2Z2Y
MOL_YEMPZ]F2E,)S-JT@!#;<$CZ;)K;2B1^Q+74&O0LZ,)X/B>X'!D%H1E."&
M1_\`%X7*R<!P'`<!P*Y'`%@?)SLV0K$9&-V:3^/>FEH=]L./F7G!-Y[$"AUR
MY"?067Z:!6&,+=<\4,(2C"DI3CP+QY5>SEFW76.J?7.[Z#D+%G>UR^(#N7L/
M?LU'#+Q;93<,76=!V-=GM*A&QSG=PU??EIM*(#!3*GT$ESC3.<N8=;<C6ES>
MUN^*]3-,K[.;?H:0JB[U8%Z/=<;6[@T6*S4P+Z>KM151[E6WLLJ!3?I;KA&N
MIFR4LH.5`!13BO.QA/IDX^;?_]7W\<!P'`<!P'`<#$SD!!6>,(A+)"Q-AABU
MBN%1$Y'!RT82X"6Q(!.$`'LD"O+#/%:?:RI&<MO-I6GP4G&<!^T5$Q4#&1\)
M!QL?#0T2&-'141%!C1T9&1X;*!PP(\`-MD4(,5AM*&VFT)0A"<83C&,>'`R'
M`<!P'`<!P(>O/7C0&SYUNT;+T9I[8=F9"&CF;%>=94JVSK4>&Z^^(`W+S\)(
M2"`A7B7%MM8<PA"G%93C&59\1;>S*73I&R1MQD*G63K=#LI&B+49`Q95DBAT
M-RC*&(V<?%7)@LI9FS482TZE.$F/X\/!USS!LW`<!P'`<!P'`U,FA44R"*JQ
ME+J959.F3K&;72:Y#OP1EAE+(1<I.>*B'0U1Y$S(V\MV5?*6WE]Z2=62M67E
M97D,_'1T?#QX$1$`!145%!"QT9&1PK`,?'1X+"!@@``AD-#!A!C-);::;2E#
M:$X2G&,8QC@?;P'`<!P'`<#48:@4.NOSQ5?I-1@B;2Z2]9R(:MPT8_8WC#)&
M1+=GG0@F')=TJ0F"WW%$9<RMXIY:O%3J\J#[:S4:I2HSZ+3:Q7JE#8(=+Q$U
MF%C8&,]T_A&'R?810P@ON'L-I\Z_)YE>7'CG\&.!L/`<!P'`<!P-6/HU*E+"
M);I.GU:1M8`P80-G/K\2780@XXY^3CQ!)H@1R2'&!DBG2&6T.X0T^XIQ.,*5
MG.0_M%*IK5G=NS=2K+=R?&]D_;40,4BSO!Y9''R([/)%Q*N#9'$:1Z>7<H\C
M:$^'@G&,!LW`<!P'`<!P-832:8BVNW]%1K"+V_#MUYZZI@(I-M>@&7UDLP;M
MDP)B9<AVB7%.)&R]EE*\Y5A/CGQX'^PM+IU;DYJ:KM3K,#,V5[W-BEH6!BXN
M3GR/>R$CZ\T>"*P5*O?4)8I_S/K<5ZQ+J_'S.+SD-;_(QI[$+FMXU1K7%=5*
M)G%0/V%J_P!%5-HAE5U,QF+^E^QS*)KZ\@8(]/U<!YRQYO3SY>"W_];W\<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P(9VUO&JZ:EM0Q-HBK.<YNG:<+
MI^K&0$>`:!'6V?CI:6CE6-XR5CG(^+<`@RUY=:00OQ9RG#>593A1::C=^U6K
MZ#<K!49E-@(8H\MJ>!V3;XP2*(JFM)K>$\U6M8QMO>?FA9U#U@E#`\O+``.9
MBQ#QRY!8HCGKI%`W:K5Y6P!Z(TFP>V-VW+Z"`OOM(I5$-W7!4TV]RNMFC6II
MRP-3(D)%&M9+>C6HE4F&['),R?Z8[@IN.T]VUG54WK*IG14]9[KN&SR]4U]3
MJRNM,3$[(5ZH3UYL!"2KA9*E7A08:MUTAYU3IR'%KRVVTAQ:\)X*;51+T->*
MD-:WH"QTGU9"RQ1U>NX\7'3\/(5.P3-;F&9!,3+S<,ZS@R"?>8($-)%)#RA]
MIQ3:\*X1NRG&T*;2MQ"%/+RVRE2DI4ZYAMQ[+;>,YQE:\--*5X8\<^5.<_T8
MSP&'&\N*9PXC+J$-N+:PI.7$-NJ<2TXI'CYDH<4RO"<YQX9RC/A_1G@<UVCL
M855V->PKFF]D2^VK[K2Z[73I2%D=:&W6$K.L)#6L/LH(B8S?F]?2]CK4UM>&
M!8%CYDIN1+)QAE[T4N/-EKY3C5YX^<@@Y6=K4G1Y$HV3#77)^1K4A)BY"ECH
MX-QTRJ3EA@7?JXHB#&6V2W'6V7TH>2T^EUI!&LS&T(>IR4D/>Q'J/#?:^@4:
MG6:<DZZ]'[%LFQRHV'@HVK1L/,R=D8)39Y+$:XB1!!6IUIQ]O"Q$*(P$F<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`__]?W\<!P'`<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P'`<!P.,^W^N]A[!ENI!%!ILA;F-<=O=<;1O3H,O4HG%<HM>J.Q(B5G
M'DVFQP#DG[<ZR"IP,`DLQ>%*REK.$YX6.7-^].J&T;E,=T*%`5]V3JG<S:?5
M;8'V^3)UEF*U]&4&*T[K7;8$S&R$W'6=4I#T32#,G"KCA"EER<RRTEX;T'B!
MHL3M\$7U0VBS.U363]?=11ZK\E.R>[#^SUR=9<BSZ-<9C9.[XNNQT:U-HN0]
MN:VUL5JNO-?3V1OI(!1+A+C3K3!8O_Q)NX^O-DO=$B-=]E(^Q]P:P?<FK.':
MZ+`5+2NQ]`SM=BW55C9.OY2N7.LV!%CC9$EYM),*9B:;;)4EII]CUV'A$]:.
M0WM271J>Z0T+MM0YGLVZJV=T:]'Q.SXW6%^V5*Z-S"NGZG$W9[@\&B72Y"UT
M**5**&62G)_H$.862P\2D=TQU!ZE;[I8>K=1[DU!?]Y:UF-':;J%0E*1L75L
M.YU:O6LMO;1V%&0%LM-KM,5L6/KE;K-BJHWVIHI$K,EN57`V134(`4HMQQNZ
MWTIK&\@;EV`SNCK9)V:TU3;W92_43M`JT4(F`NVF]W3TV=2=;L@IO+5ZD;36
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M-USTS&P79+;]7J8^M9CK;KG8!/8K6C=5<`.>I'87>\'*P.R:,G,6$W'!NTA0
M%AL/I+<]=MC9(326VV@A\($SI':S;E9.`X#@.`X#@.`X#@.`X#@.`X#@.!__
MT/?QP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#G78_P#WY:+_
M`/+K_P#UE_WC_P#?E_V6W_W%_P#\Y_\`V7PX7MT5PAP'`<!P.8>I/_=4=_Y8
M?^\78W_E)_[JO_BH_P#]^_\`]B__`(C_`/XKZO"SNZ>X0X#@.`X#@.`X#@.`
+X#@.`X#@.`X'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g693329g72g81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329g72g81.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0W24&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````00```&0````&`&<`-P`R
M`&<`.``Q`````0`````````````````````````!``````````````!D````
M00`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"S8````!````9````$$`
M``$L``!,+```"QH`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!!`&0#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2DDDDE*4+;:Z:W6VN#*V#<Y[C``'<E36)];6.NZ2<6HDWWO
M:*JAJYY!W.8/[/O2699F&.4P+,02!^\>R>GZQ=-RW&K`L^TY$PVH!S?[9=8U
MOZ)O[ZL6=.9E-_7G&Z1K4'.;4/\`K;2-_P#UW>N*^K/1.JCK%-UE%E%=#MUC
M[&E@T'T&[HW;EZ"@U^4R3SXS+-#AUX1&O1(=^&3S>-C?L3ZQ58F,YPP.H5N+
M:220VQFIV;O]?>ND6+G1=]9^G5#G'INN=\'14W_I-6TD&3EXB/NQC\D9^D?N
M^F$I1'^&I)))%G4DDDDI_]#U5><]2^NW6ZNM7W8]G^2,;*;0ZL,80X"=_P"E
M+#9^F]*U_P!-=K]8NI?LOHN7F@[7UUD5'_A'?HZ?_!'+D.G_`%;=;_B^O.TG
M*R2<U@Y/Z/\`FVC_`(RECO\`MY3X1$`RF+!(@+\?F8<QD2(Q-$`S->'RA[K(
M]6[$L^R6;+;*SZ%H`<`XC]&^';F.7-_43ZPYW5JLO'ZE9ZF9C/!DM:P['#;M
MVUM8WV65O5KZC=2^W_5W'W.W6XLX]G]C^:_\`-:PJYZ%_C%<P`MQNJZ@=B;O
M=_[=L>A&'\Y`CU1U!_NJE/\`FY@^F6A']_9[PD`$G0#DKD?JKU?J77>N9V59
M8'=.Q2YN*WTV`@/=^CB[9ZW\U7NL]ZT_KEU+]G?5[*L:[;;<WT*B.=UGM)']
M5F]R']1NE_L[ZO4;A%N7^L6?VP/2'_;+:T(@#'*1&LCPQ_[I=(DY(Q&T1Q2_
M[EJ?4KKG5.J9G5*LZ[UF8KV"D;6-V@NN:[^;:S=_-L^DH=;^LG6,GK)^K_U=
M:P9-8F_)?!#=`YVW=N8UM>[WOV6>_P!BI_XN/^4.M_\`&5_]5D*GUK]H_53Z
MS9/6*JO6Q,]KPVSLUUD/<QSOS;*[F;V?Z2I2&,?=D`!8B."/Z/%3%QR&*))-
M6>*0^;AM-@X7UXLSKNH8^93DVTO^R6N<&^YK2'V-K#JJ_P!$QSOWZEU7UJSL
MKI_0,O,Q'^GD5!A8^`Z)>QCO:\.;]%RK?5/J_1<GIU.)A9`??6V;:G^VPO/O
MM=M=]/W_`+F]/]>?_$KG_P!6O_S[6HP29P$H@:B_3PIQCAPF5^J43(ZW4W"Z
M8[_&+U/!JSL;J&.*;P2P/;6':$L]P&,[]U;'1\7ZZUWW'J^93;2:7"D5!@(M
MEOIO/ZO7[=N]97U9^N?U?Z=T+$P\J]S+Z6N#VBM[@"7.=])K=OYRZ3H_UCZ3
MUI]C.GVNL=2`7RQS8#M&_3#?!.R<8XOU8$;WX?VIQ\)X?UA,JVXOV(]GUF]3
M;OH]/C?^=&_=ZD;-GJ>C^B_T?^$26PDHN+P'V,U>)?_1W_\`&)DW9-G3^@XW
M\]F6![@=!J?1IW?R=[G_`.8BT]*_QB44,QZL_";56T,8S:(#6C:UO]%_=1J.
M@]4R?KK9UK.K:W#H!;B^X.)VCTJ_8TG;]*RY=6II3$8QB!&6EFQQ>J3#&!E*
M4C<=:%'A],7S_P"HSLGHWUAS?J_F0'V#<T,U;O8/4EDAOM?0_<KG^,G#L&+A
M]7HTMPK0TO'(#B'5G^Q:S_IH_P!8N@=4L^L>#UOI-3;'T[?M#2\,)V'^66_S
ME+_26Y]8,:C,Z1DX=UC*OM+#74YY`'J'6GZ7_"!..0<<,EC4>L?\V2W@/MS@
M=`#Z2?\`&B\C]9\MOUCZKT3I>.?T.0QF3=&I#;1N]W\JJAC_`/MQ=\UK6-#&
M@-:T`-`X`"XSZD_57J?3<^W-ZJP->RIM6-#P_0_3^@3MVM:UJ[1,S$:0B;C$
M?C)?B!UG(5*1V\(O"_XN/^4.M_\`&5_]5D+H@QG5^J.>\"S`Z>36UKA+;,@B
M+71^<W'9^C_XQ<]]7^E]8Z1E]1QG,;7E=3<TX[@YKME;77>KDV;"[;L]5GI[
MOIVHQQ?KWT>Q]/3&49N#O<:&.+=S&DRUK][L9^_]_P!ST<@$\AJ0Z;GP88W4
M8F),8$F=#]+BXH1_[MJ_7CZN8'3,9G6NEC[%D56M#FUZ-.[Z+V-_P;VN_<6G
MU_,LSO\`%^_,M$67X]#W]O<7U;O^DJ%_0_KA]9;*J^NFK!P:G;W4U$$N/\EK
M'W>[_C;?8N@^L72K<KZMW]+Z?6"_97737(`ACJSMW._=8Q.,@/;$I"4HRLRW
MX8_WEXB3[AC$QC*-".W%+OPM/ZG],Z;=]6L&V[$ILL<QVY[ZVN<?>_ESFK>Q
M\'"Q23C45T%VCC6QK9CQV`+B^FXW^,3IN%5@XV/C^C2"&;G,)U)?J?4_E+9Z
M);]=79[1UFFAF'M=N=66[MT>SZ+WIN2))D>.)%DUQ+\<J$1P2!H"^%Z))))0
MLK__TO54DDDE*6']9'?K72&'Z+LQA/Q'T?RK<6;U[I3NIX0KJ?Z>14X6T//9
M[4BQ<Q&4L4A$7+0@?O<)XN%TE7S,L8S6M:TVWV:4TMY<?^^5M_PEGYBJ8=W7
M[&M9E8]%+A]*W>7`^;:6?^E5=IQ:ZG.L)-ES]'VNU<0/S?Y%?_!L22)&8](,
M;ZR'"8_X,G&ZS5D8'1,S,]4_;[=ALO82V/<T-JJ_.;36T^U5OJ[UBZC&RZNI
M7.MLHJ9EL>\R358QMFT;OW);_P!N+7Z_@WY_2K\3'CU;-NW<8&CFNY^2Q^I_
M5C-RJNG^@YK'UX[,;,]T`L9L^C^_[MZ#4S0RPR\>*,I"$!Z?T9RG*?%_A?+D
M:'1K^KYW4OL^1FW5_:\=US=KC[-QW5FML_N?11OLG4_^<'[)_:N5Z?I>IZF\
MS,3$;EKU='R*OK&,]C6MPVT"E@!U$`-`V_)2_967_P`Y_P!I^W[-Z/I\^Z8C
MZ*5+(\M/AB)<<B,W"9<4O5AZR_NM#JK>I=".-U&O+NR\:LBO+JM>3NGA[6N.
MU6?JT>H9SK>KYES_`$L@D8V,''8UH.W=L^C^;L3]3Z1G]6ZK2,K:WI6.=PK#
MO=8Z/SV_]'_BT_1>E=1Z3FWT,+;.E6N+ZI=[V$_R?^@Y)?&$QS%\,_8$JB+_
M`,IP_P`[7^:=U)))%OO_T_54E\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?J
MI)?*J22GZJ27RJDDI^JDE\JI)*?_V3A"24T$(0``````50````$!````#P!!
M`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``
M4`!H`&\`=`!O`',`:`!O`'``(``V`"X`,`````$`.$))300&```````'``@`
M`0`!`0#_[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`!!`&0#`1$``A$!`Q$!_]T`!``-
M_\0`L````@,!`0$!``````````````D'"`H&!`,%`0`"`P$!`0$!````````
M````!P0&"`,%`@$)$```!@(!`P,#`P$&!P`````!`@,$!08'"``1$@D3%!4A
M(A87&`HQ026V-W<943(S)'6W.1$``@$#`P($`@8%"`<)`````0(#$00&`!(%
M(0<Q02(346%Q@3(C%`B1T6*S%<%"DC-S)'0UL?%2@A8F-Z'A<J+"4X,7&/_:
M``P#`0`"$0,1`#\`W\<-&CAHT<-&CAHT<-&OP[-9J[3*],VRVS<76ZS78YU+
MSL_-O6\=$Q,8R2,L[?/WSHZ;=LV02*(F,8P!SY9E12S&BC4'D^3X[A>/O>6Y
M>^BMN,MHVDEEE8)'&BBK.[,0%4#J23JE]0\B.MV8I!Q4-=[8?-&3E'ZL9$46
M,AK/5E'1T4'#AU8'\S;("*8,:1$H-C'>2B?N$R=4TTB+.%VZ*L<W:&@B5FD)
MH!0C])(H!\?]&DOPGYBNV>:7,O#]N>:'-9/[A1+6..:`F@):5I)XHU6VC`K)
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MW$%#-8^,;&D'*ZG:U;D:%%8Y0,`C#O"-D:U]184'Q_U>.LN_F[X^\R'M'<8C
MPURYR7D[ZW2UM8P6EO&CD$KPJHZ[513,[FB((P78`Z1?XSM*MI$=O\8WFP8I
MR+BZIXLL3B?MEEO-5GZ<U509,G31>MQ@S;)@>9?S9G8-SIMP4(1!0YU!`H!W
M1XE=I$HI%#4D@BE/I_13YZP9^5[L;W7A[R8OD')XER7$\1Q5PTL\UU!+;JP5
M&4PQ^XJ&5I=VPA*J$+,QIX[#>>IK^RNEDYP3:77R=:7U5(!.\Q1AW/&6I4"A
MW>C&VY.+HT,J?Z?80TQ#'+U_XCTY"EH]Y`GFHK^FH_TC68\X$/-?F@[*<4@K
M/Q/"\M?R?)+@16L9^7WD9%>OT>>F;<FZTYHX:-'#1HX:-?_1W\<-&L7FQ_FS
MW6IVZ64KSC>XH*Z)88VEJ.&9VJL:+C>596>&A%9!K9V;2^O:8_N22^1&-`G9
M)JX1D`,T(Y2!'[2E#FGN$[5XO=8O86M];L,NNN/>=6,D@VDT*5C#!/0712"O
M6AKUUF7G.ZN46>4\A=V4D1PJSY*.UD&Q2Q\?<H]-W78Y!!Z>GIK7UD`EGNF(
M[B7#]T0K-QM./IP^,;^S90M@9PUCEZ^Y4IMI1CYQG)P,TQ:R*[=SZ3E%5NX2
M#M,`E-S-UI[%MR%O_$;8O;1S+[L9)4E0WK6JD,#2HJ#4'6D;D33V<_X*<).\
M9V/0$!B/2U#4$5H:'H1I*7@I\A&<]QZGL/CG::UC:,ZX8O42]]XXJ-4I+PE(
MLC%>%+!K0U.@Z[%'>5:W5.0!RH=L#@OR*)#G,!2@5I=V<,XG&+GA;W'X-G$7
M<)IZV?UJ=U=SEC1D=:=:>D]!YJOM-FG+93:<W99"ZGG+*YVL`JIZ"*`44`55
MT<'ZNNGXKKHM4%G+E5-!NV247<+K'*FDBBB05%555#"!2)IIE$3"(]``.O%"
M`6(515B=-PD`$D]-9T_%9M[L9Y`]WMKLL6.X1,MJI@R2M%:P1$?I7C5G(-&F
M0;.\;U-NQR,-,0R04QJ)4/>RK<LIT7<.F_KE],$B`XNX>(X[B..8O"EA_P`T
MW$8:60NY*A5'N43<4`+MM%!X*:==)3`N=O\`-\PR+F;J&W?A^.DDALW]F,RJ
M)&HVR8K[BATC5I%5@&JH844:ZSPJ[P[/;=9<WPJ^P>227R#PM<*'$XV9$IE!
MJHUYC-67,L=)HG<TRKUYW,"Y:5./)W/CN3$]#J02B=03_G=#$^!QOC<1N.'L
MS%+=PNTI+N^XA(2.CLP'5V\*>/R&IO;'+N<R;E,UM>7N%>&RNA'$`BK1=\R]
M2H&XT1>I_EUS.[?D@V_R?N8Z\</C+AZFTRO5F'O,M9NMZ$/*,*BX09QTE,-(
M=K.LYBMQD+46LLU;RK]VPE7B\DY%DT9IJH`HY[XMA&-V&,+F^=RRGCI&I#`E
M09.I`)((8EB"54,H"C<S$&@X91F^27V4G!<#@A_BD:!I[B7JD0H"0!0BH#+4
MD-4G:%J"12S!N&/.+8,WY%V2QKLKA7,MMQO=#:O7B<L4+6BMK=7ZE/1,]<(B
MEL9W&-2:K4FOSLF<ZZ[1_`OGJJ!P0,<P``<HN<[(\J;M#B=[:2JK*LH=S4@5
M'03/2IIXHPZUZ]=)W`;7-\HSC+\^X6^M+KE^-NCP<MW,@`GBMI%FN([95``A
MBFD(+#VS+(I]1"C3]O*?G+*6M>@>P>;,-V8E2R?1(FBN:S91@X"?3CG$QE"C
MUR34^$M,;.03LKJ'F'*/:X;K`GZG<7H<I3A3>W_$<?SV8\+Q/)PF2PF=PR[F
M4D")V'J4AA0@'H1^C6E\_P"8O^`P[G.8XV0)?P1*4)4,`2Z*?2:@]"?'2/\`
M6B2_D5[68-Q]L%C/<'7IG1<E1TA)U]M;:3BF*L2+>,G96O.2R<?':QS+)LJ+
M^'5$H)NE@%,2CU`1$`:?/1=E\>Y>^X:]QR^-U;L%8I)*5)*ANA-P#X$>0TL<
M?E[S9%PW'\W:9'QJ6US'O4-"-P%2.M(B*]/(Z97IWBSS35ZZY&7W/V2PM>Z*
M_P`-6^,QRSQU"4)G,0F9W$K65:=8GQFFO]-*K"L8IO)I+D75=H"9<@F:J"!3
MIT;)+_ME-;60QCA+J*Z%RAD,K.5:&C;U'W[=2=I%*'I]H>=\QJQ[CP7-X<IY
MNSFM3`1&(4"LLM11C6,`@"HH:^/AJP?Q/DR^>^/_`"/!/XEW?$_D'KC^7?%_
MJ!\S^5?'_@GP'YA^GG]Q^U[/B?=?WCZ?=_VG/']W!_:W_A[O\3X[?YE?;ILK
MOW;/<]=:[]OHK_.U8MF2^YM]ZW]BE*]=_P!JN[[.W=L]-*;:^K]G7__2V5>0
MW8Y/4[2_87.:,@E&V&JX]E8^AKJ$]7KDBV`G4\?`5MT$SE-&W33198@!]&Z2
MAC"4I3&"SX9PAR+)^&XDI6&2=3)_9KZI/_("!\R-5K,.<7',9YKF2P$D,#%*
M^<A&V,?6Y76<[`/C>D;;_'WRHLI%O5\PY><R6XM<0,@1_*K(X\],U*@V"9"@
MLZ/<\95YZJT+WF5]Q8Q'J/\`T^.OF,XCM>\G'[7`XNUI9-UH!OZ.>O0;)&%?
M*D?UZ2G"X))>]EK^"1">6O5:]%?$N*-&/CZHU`^-7/3RTX#P9;)_N-\=F'R2
M<HG(W/"`/L#VXH=Q5D$Z$5L%$%4J@BJJ9;&,C"]ZXB8%G)%AZ]P&`%MW8X+^
M!YKR8CCVVMT1.GP^\^W^B0/T\A33([3<^<@P?AYI'K=6ZF"3K4UB]*D_-H]C
M'YDZ5%7BK>/S^13-0**#N(Q/O&B+N/2,L5-D_D\TF&4!P0H`5N86NP5=?M&Z
M0`!T6SD"@'W`(L.:F8]E(IB0W(\0:'S(6'I]/6!E)/F1I>P_\F]\)HOL<;S<
M51\#(_7Z*^\C?T_GIROF4V3+K)X^,[61A)+QMOR+!&PS1EF;@K:03GLD(.85
M](,%@5261<PE7&0?$53ZG24;E,'UZ#Q8]LN"_C^9<1;NFZVA?WI.E1MB]0!\
MO4VU>O3KIF]S.?\`^',+YJ^23;<O&8H_COD]((\_2"6Z?#7#>#/6+]M'CTQ0
M>59BUNN=C.,_7#O$#'(2^LHXM&9`)DDEVY6N-8N',LW/U]%^JYZ?\P\E]V.?
M_CV:<D8VK:VO]W3_`.,G>?KD+T/F*:A]IL>_X=PCB89$I=W*_B).E#64`J#Y
M^F,(IKY@Z65_'#_S[\H?^H.+_P#&6Q'+YWM_R?`/\/)^[M]4/LC_`)YW+_QZ
M_O+G5<MT2;$>'GR99MW=JF/%LA84VK@L@QD1<3J.PCZ]8LH?$V><K\K)HLUF
MT%;:GD.N$DHUHX`4)B#3]-)8JH.A9SN&/&]S.W-EB$?)1VN1V.WVU?H&,:LJ
M,!XLC(U'V@LC`DJ13=5\_;)NV>6Y'EG#VJ2V_+6LL<,CD[8KEXZH'H"?1(@D
MI3UQU`]0-'I^)_;K2[*&O.,L,X&S+'3N1:I5PD;U1[D"M8R@\N4X[?6"]3HP
M<T5%Q9V;BR/G2WNXU:30;ME$4UG'?T`4GSN!9-AZ(G+\:PM_`2H=\1/R<>'P
M`<*Q`\-,'L0,2X3M[C6(<#S:7-_:6];@L2)I+F5FEN9BK@.P>=Y&#>JBE5+$
MC7O\XW_ROVS_`/!XT_\`=F-.>[VG_P"H6-_VDG[F35G[L_\`3O*/[%?WL>EC
M>,KS,Z`:U:+:]X/RYE2R0.1J!7;%'V>(8XOR'.M63J1O=KG6J:4M#UUY&O`/
M&RJ)Q,DJ<I3&$HCU`0Y?,[[7YESF6\WRW'<<CV4T@*$RQJ2`BKX%JCJ#XZH>
M!=U,&X3#^`XKDN:]N^@@"NOMRFAJ32H0@^/D=.QU#\CFIV\\Q=H+6^]35ODL
M>QL/+VE&5H]OJ1&3&>=/6<:HBM9HB,2>F6<1RH"5(3F(!>H@`"'%9DN$9%B4
M=K+SEHL23,0E'5ZE0"?LDT\1XZ:V-9MC67/=IC_(>^T`4OZ'6FZNW[:K6NT^
M&KT<J6K7K__3;K_(ER+;\JV#3[QVXM63/>=@<CPEIDV;EP+:.4(]GAQWC=*9
M71;NW3:&6M$E(NW"I4S@D2,]02F[.G'WV5LK;CHLES;D`?PEE`R@@=:[?<DV
M]0-VT*`//=32#[W7=UR9QG!..8?C>1N58U\`JMM0M0$[=Y+$^00GRUVM1U3_
M`)$-#I=9QW4MNM)X:E4VL0U,K5>0J4<LQBZO7XIM"0\.D#K5-=55JRBFB:(>
MH8YC$+]PB(B(P[C(.S%W=3WEQC7*-=22%V;W#4LQ+$]+GQ)->FO4@X+O-;6\
M-K!DO$+;QH%5?9-`JB@']5X`"FJH>#=]DK1WR$[.>./.*T.A8[5#M[1&(5AP
MHZJ3JZU"#;V]M(5E=XPB'YXJTXOLAWJ7>U04*BQ3*HDF<HE"Q]UTL<KPS'\W
MXD-[$;>V=_VPC,4HU"1595H>IZM6NJKVE:_Q/-<HP7EVC_$2`3J4Z1E@H8E`
M0"`T;`TITV4\JZLI_)*PY.,L9ZW;GT!,(^[ZYY1:0\A8&@F3D6<39GT;.4Z1
M45((&.A7+W6D@0^I135E#B`_<//#['\E$]_SF+7AK:7UN2%/@64$./\`>1C7
M_P`(U[G?+CIXN,X++;$4O.,NU-?V692*_(.J_P!(ZKYY-LJQWD_VG\6^HN.U
MW'X#E2HT78_(Q8\YWCV#KV6XYE-.6THDD)$FTS1\6UV4<``G+]\J4IA+].>Q
M@?'O@>/9_DMXO]\MY'M8J]*M$2M1\GE91_NZ\O/[V/.\D[=XM9M6QN%2\FI_
M[;`$`_1&K_TAK6]&1L?"QL?#Q+)M&Q42Q:1L9',D2-V;"/8()M63)HW3`J:#
M9JV2*1,A0`I2E``^@<SI([RN\LC%I&)))\23U)/S)UHA55%5$4!`*`#R`\!K
M*Q_'#_S[\H?^H.+_`/&6Q'-!=[?\GP#_``\G[NWUGSLC_GG<O_'K^\N=.92A
MHC<S:*9EIR.C[/K=J:[G*+$P\S'MY*MY,V0EF96=YE5F+SU&LO!8BKCH(A,'
M#<R1Y=\Z,D8Y4C=<XPRRF\6XAD9?9/I()!W_`!!!J*?ZNAU^6:+W9[L3<LWW
MF`8=));P@CT7?-.NVYE'6CQ\="WX=25H;B68H2(](_\`.'XY<%ZJXRK6]VI+
M%373*%%R?4V,Q$X]>.X:NRZ]B=N_C;+78M-UZ%3LT'*H)=4XXJ#%TS.KZB'J
M%[S:4[4YMRV0W\V(9(_X[CIH'*F0!F7:!56-*LK"OVJL#2AITUQ[M83Q6/\`
M'1YMC""PYBVG0M[7I5PQI7:.@8&GV0`PJ&!Z$7CWVR_/Y_\`X_=DS5;&P-;5
MDS7W72W6<A$$VJ"MBE<DXF6G'K-LD1-)NPD)/U7#<A2@4J"A`#Z<JN'<;#PW
M>2VXNW:MO!>W"+\=HCEV@_,"@/S&K;FW)2\QV;ON5G3;-<<?!(P'AN9HB:?*
MIZ?+7>>'K6/6Z\^-K5FUW77_``I;[1,52UK2UCL^+:1.SLHJADN[,T59"6E(
M-T_>J)-&Z:13**&$J9"E#Z``<A=R^=YNUSG(K>VYBZC@65:*LKJH^[0]`&`'
M7X:G=L^%X:XP/&)[CB;9YFM@2S1(6)W-U)*U)^G3;L?X2PSB=S)/,6XEQKC=
MW,H-VTNZH=&K-1<2K9HHHJU0D5H",CU'J+958YDRJ"8"&,(AT$1XN;SE.3Y!
M46_Y">=5-0)'9Z$^--Q-/JTQ;7CN/L2YLK&&$MX[$5*T\*[0*TU)_(.IFO_4
M?M2M#=G\F^:BV[S[`4J!A,$8SB9J$P&4]PKEC=R1(&O?@=*>DKL;)R4C"^^"
M7E;/T=)MS-'RY0[2JAV@X;G+^!L>UUOB7#W+MRT[AKCT,H&YM[C<0`U*)'TK
M4`^772C@P[G+WNE/F/+I$.(MX3';`/N;[.T%EIZ:[I'\?$C6@+B>TW-9Z?(K
MH'M'8?(OJKOOIY1H.U36/TZRAE^*<W:MTMW+HTR?61$ASV*5B2O_`,PQU/.H
M18R*AO3;M$RG*`"`F<F%YCP-OA.18?DERZ13[C"0C.%+K^R#3;(JN.GB3I/Y
MAAG.76<XQF6.)$9;:BSAGV%D#$=.E"3&[KY>`TT[?['%$S3J1FC"-ZMM1I@Y
MBJ;^@466N<Q%PL8?*DDBH^QHU;+RKEJF[D36^-:J)MTC>NL5,P$#K]06^-<V
M,<R#A^99J)!.I;YK6CJ/F5)&KAG<G!-C=]QO/\O:V4%__=HGGD2)6N)01#&A
M<J&D9P-B+5V(](.DL>$[Q7;,:LYVR%GG;^MQ<38H'%]?Q?AA%O=JY<U48U\J
MHC8EBC6Y&20BTH."@F3%N"IBF.D^5`@"!3#QM=T^X/`Y#Q5GQ&-2.8'N&FGJ
MC)5OYOVO&K,S'Z!I=]J^WF08UR=[RV4/$UTMM';P;'W[8UKN%:"E`%`'TZTW
M\1.GIK*UX_-8-P],,L[CXMD*Q7ZQF'=&S5*2Q+*L;A6;:2@8MK5GS`MD+-5N
M8UJ3DG,$RK+*[QS:)1>`@>4G'B2"`*`@Z])J]U<SX7)N.Q&PX.Y9[NVA=9*H
MR[:K"*BH%15&`IK)9M<RQ#D\CPS'V@&<9-<%[9E?>+&R5YOQ/(W``]"PB5$@
M4FLUTZ1IN"R%9(>8N\[VE%AM5*U2KV!-E-<C6VS2N+:O99:LA.TBI2<R[>1L
M78'=GL>$+"]LBR*H.))5%]*-W$@LLN4X>H)2S.&B[-7_``_&6O)R7MAR<,*I
M(ZAB)7`]3^E95]35/V4/E35TXG&>YG;FQAQ[#+2PO<5MP5@CD8+,JUJ6E<F+
MW)9&+23/5C)*[OTW4U&]UT=\P/E)L-%K?D)?XOU@UPI-G:VB5QWC62A).:M#
MPB*K47D3%5JW9+0=3B4>LNU0=3<XDC&E=J*HM%S&.F;W[3+.V^`0WD^&)<7_
M`#LL902R@A4'CU++&:5H2$0EJ`%@-?5[B/<?N%+9V^;26O'X]%(':"`[GD(^
M)!<>9`)?TU)VDT.G!>1'56TY9\;F5-3-;JI'KS:M%Q71<8U!>9CX..;0=!O6
M/WC6,^9GGC5BV1C*M65.PRZP"IZ0%`1.8`%;85D-OQF<<=D?-SM[(FEDE<`L
M2TB2`F@ZFK-Y?'3)S7'KCE\)Y7'.&B19G@2.)2=J@(R$"O6@"KI,NN6./Y$F
MK>%:'@/%V'-<RT+',?(1M<"PV7&DO,@VDIN3L#GWTB7)3,KI09"76[1!,G0G
M0O3Z=>,WF[_LMD'*WG,7_(\A^,G8,VU7"U`"]!L-.@'GI:<%QO>O'^(L.%L;
M3B#:6Z;%+.Q:E2>I!`)Z_`:9%I/9O-/*9WBVF[^.\&UO`IJ]8SRDI0GM+7L)
M+&1D`UM)-.%O4\_%JL]Z@J)6YB@'3N$H?7E(RF#M<G$R-BEY>OR^]:"4,%VU
M]7B@%:>'75YQ>7N>W*`9;;<<O$^VW6`L7W]-OB3Z?&OU:<WQ9:8^O__5W\<-
M&CAHT<-&E8^1Y^`9/\=,&\/VPTINMCE\^(H(>U6>Q#IH$.BX*;[#][J1-V@/
M]H<A7762U!/3?_*/UZRK^9*YVY1^7"QE/]RESBS9J_9+1D>T#Y$[GJH/F--.
MY-UJK409=RVTQE'1C"+AG=UR3<5G$9C?&\0JFG,6V70!#W"Z[A0#H0-2@0=)
M+S$PY`K.,:F`QQ%0Z*2O&:81``"LK?9`\2?Y`/,^`U4,NRV+&;>UM[6S>]R2
M\9DL[.,TDGD%-Q+=1%;Q;E:XN'^[A0@L2S(C+JW&J=_UVTHV+S67($F79N[&
MH<E=<KT]](0#F)31NT#'Q-!QZZ0.UE(+'5.BY%PS8-^I%G8KN'CKN=.UQ&+)
M&T43.S_?LRU(J//P'G0?]OGK.G>;B\@[<]D.Y>;ID$O_`-G7JVSW%_;LT31@
M7,21VMHPH\5G;([QQ)T9R\L\M9II"8;\=VWMSH6-=@ZCM)D*PW2S8OQG2=I:
MY9;G/NYB9G<2Y*QA6;6C$1[Z477>N4J_(2#)N8`$Z:;^7%$H]0[0^;:X*I)[
MA-:;A4U\ATJ?D5/TG5*_+IW@YO'\:[A\-W6R.XON3XKC+;G(9[B4O)+Q][8P
MW`C1G)9A"[(A\0)9]@/2FJ@:=7C;G/\`LFMC3)>R^;*>7.FOELRU&HP]LL)$
M,>DM=B1F:F^I\.ZE2,F2(5M-%5B*8)%1:/03)]H`)N,)DF;897!W4K4_"M0*
M]`?+Y:3W9KG>\.?]S&QG*.YO-V:Y!C-QR,:QS2TLOQ%P'MVMXV?:`(`K1$!0
MJ2[5Z"ID/])ME/\`<#_9I^_G:?\`'/TM_/\`\U_.)GYOWGQGR'Q_QOSGL/;=
M?M[^[OZ?7G58Y&EDB]]NC4K4_P"R&\*_/5@?$>YR_F&B[+?_`*"RK^&MP_XS
M\3^(?W=U"=FSW-FWIXUKJ?-JX[9/Q[N<&[+5_8'+^=L45-ZPHV?Z+D:\R+Y*
MT!+N';.-M4;#RT@_C&;]ZQ<%;#[<"G;2#1LXZ&(X=B7]9);8HXE9@3YD^/7I
M2IZ4Z#X$?/3`[MP]S/R\/@G<_C^X/+\]B-DR6O+VMY<LPG$A9$N$C=F1792$
M.RA25(Y*%9)R)K\;"^P6?7E]W0S1DJY!3<IS,^RPEA)K;I$]`JU382JL0O-N
M:RU>C$C(H*1(Q[0%4BJ]R#EZJ4ZKI)0G6V$DC-,[FG6@J:5\^GA0>`Z?$GR.
MKO\`EGE[A]P),@[UYKDMX.%Y>>5>,XQ9V-K;VR2&,RM"K;/<K'[25`/IDF8%
MI5*MMY-UKG7_UM_'#1HX:-'#1JE&^6JTAM?A9"LU*?0J64J':8K(V*K.Y,JD
MWC;C`%<%;-W;ENFLY9M)%!P8@KID4,@L":O8<""48]S#[R`#[8\/U?+]>DEW
M[[4W'=G"4XOB.16SRJPNX[VPG-:1W,-=H8@$JK@D%@"5;:U#MH?AA^V[\V&-
MBX7+>(\&X[EF22*$[D!"_P`I;V4L9(")K2$'CF!9M%4UW8@)_1<S[9-,1^@B
M'VAS1KTD*T:`?[1/_I'ZQHPWEN_?(VEK9YAB'!<=>H`);I;N2X22G0M%9QHI
M!;QVO=H!Y$^&K,4O&<'4)&4LJSE_:+Y86[5I8KY8U$7=ADF+(ZBS*$9B@BW8
M5RJQ[A=55M$1J+6/2<++./2,Y7<+J]XXE0EB:R'Q)\?H^0^0Z?7IF</C=CQ-
MQ=<D\CW/.W"JLUU*0TKJM2L:T`6&!"69((52)79Y-AEDD=X#WVPE=]B=5<H8
M?QR2)4N%M3K1(DLW(?%Q@C%6V#F7?N7P(.?1`&4>IV_8/<;H']O/FX1WCH@J
MU0?T'2^[^8/S?<?M/EF&8Y[/\9O4A$?NOL2J3Q2-N:C4]*&G0]:#2U-F_&-F
MO+-;U!)0IN$KE@JFO&-]<=DP)8SQS9_3J>E47A_B%D&!QLA&\NA(F%-4$P6!
MLT_H`=`B26LI6#:!NV`'K2A'G\_^X:S-W1_*]FV7\=V>'`<A!:\A:8[9\-S7
MWQ19+6W_``[$1D(?>I(LQHVW=MB\`#JV56T_OM1\C+;8>#C:S&8*AL`16)H!
MDVES?-QZ\-"141'L4H0S81+&M$(\$RJ"L(]I0^G.B0.ER6"CV:].O[`6E/JT
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MMDF9IKV<)]J>,*%4%C[:^HF.`2[:/.U/=IAJUL/ISFO*V/(5S7K9IC=)R0M-
M#*\L9RW7'4T[:I.4T48==J!7,>X*'QCTI5C"N=JV>D!(QG*:A#'-#*5"UA/G
M7]!I\?(_'H?*FI'93M3W$[,YKEN.64]M=]E+V=[BT#3'\392L`VT1E:-&W]3
M(`QW%(YE"DRAFI\FZU7K_]??QPT:.&C1PT:.&C1PT:.&C1PT:.&C1PT:.&C1
*PT:.&C1PT:__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g693329g79b67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329g79b67.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0_24&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````3P```&0````&`&<`-P`Y
M`&(`-@`W`````0`````````````````````````!``````````````!D````
M3P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#34````!````9````$\`
M``$L``!<E```#1D`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!/`&0#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2DDDDE*4;+*ZF.LM<&,:)<YQ@`>9*DL'ZXMLLZ;7122ZRRT
M12T$N>&AQ=M:W]SZ:1V699\$)2`OA&S?;UG!NAF%8W+N<8;56=?Z[_\`1U-_
MTBE;TXY;?URVPR/YNE[JF#_MHLLL_P"NO7(?5+!SCU:N]K'LIJ#O5>00""-O
MIZ_G;EWB`-C5AY>9SP,LD:UKA_1+S_3AD=,Z\[I9M?=B9%7K4"PEQ803[`X_
MU7_^!KH%BW?I/K9CM'^!Q'/<?ZSG5K:2"_`*$XCY8S(CY=E)))(LRDDDDE/_
MT/55P-7UYZD[K37.+/V._)=2U^W79.T.W_R6/9:NG^MG4/V?T'+N:2+'M]*H
MC0[K/T>X?U&^]<KD_5[9]0*K0W]881FNCG;9[7?YN/Z?_;:FQ1C5R'S'@"R9
M-Z=!Q/<=2.6WI^0["(&4VMSJ9$@N`W-;'\KZ*R/J;UZ_K73K'Y1:<FBS:_:(
M!:1NK=M_SF?V%=^K?43U/HF+EN,V%FRTGG>S]'8[^VYN]<QT&.B?7;-Z7HVC
M+DU#MK^L4-']5CWU)HCZ9Q(]4=?L^91.L3T.G\'N'N:QI>XPUH)<3V`7+?5;
MJ^=UO,SL^]K/LV/->*=@#P'DOV;_`.36UGJ*Y]=^HC!Z!>T&+,K]`SQAW\Y_
MX%O4_JITT=.^KE-9$6W,-]O]:P;FS_4J].M(`#&21K(U']JCK(#MK_!K_4GK
MG4.LXF1;G.:Y]5@:W:T-T+=W95^J_6;JN1U9_1?J]4VS(IGU[WP6M(^G&[V[
M:W'8]S_\(J_^+'_D_,_XUO\`U*S<S(S_`*J?6#J%[ZB^CJ(L-%PXE[O5:X._
M?I<[;96G\(]R8`!('IBM,B(`Z^-;MOI@^NKLZSJ-9IR@^T8U[X`&VLAKGUB*
M?T7_`!:Z3ZU]2RNE]%NS,0AMS',#2X;A#G-:[VI_JYE])MZ;3C].R&7BE@W@
M&'`G5[GU/BQF^S<J?U]_\3.1_7J_ZMJ9'6<1*(&NH`X50!CCO](CB-?O'YG+
MP\W_`!A9N+5EXXQW4W-#F$A@,'R)6MT<_7`V7_M44M9Z1]`LVG]+(V[MI^CM
MW*I]7OK5]7\3HF'C9&8VNZJH->PM>8(_JL6[TWK72^J^I]@O%_H[?4@.$;MV
MSZ;6_N.1G8OT`"]^%=&M/43]47J=>^CZ57/TY_-G]W=]+8DM-)1\7@%U/__1
MW/K[;?U#J6!T+$`?:[](YLZ;G2UF_P#=VL;8]6;*?\8-M#L=[,,U/::W,TC:
M1M+?\U%Z/T7J;_K7F=:ZC2:J_<,27-)(/Z*O2MSMNW':NK4TIB(C$`2H>?J*
MP1LDFQ9_!XG_`!>Y%N)D9_0\GVW4O-@;/YS3Z-VW_-K3_7VI^%G]-Z[2/?0\
M,L_L'UJO\[]*U6<_HO5,?ZY4=9P*?5QK0T91#FB)'H6^U[FN=^BV6K5^M&"S
MJ'1K\.6^O8)QFN<&EUK?=6QF\M]S_H(F0]R,^DAZORDBO01VV_[EY[ZQO;UW
MZT=-Z34?4QJFMNN(X(?%S_\`V7;7_P!NKM;/YIW]4_D7*?4KZO\`4\')R,[J
MU?IWFNNB@$M<=C`&?X-SOS*ZF+K'@EC@.2"`F9"+$0;$1^/5="]2>KQO^+'_
M`)/S/^-;_P!2MOT*>M=1L?>QMW3\+=376\!S;+C_`#]FUWTFU?S35@_5?`ZO
MTK#NZ797Z&=FO#F'<UWIU`;+<EWIN?M_<K_X1%;?]=>BEV-3@5YN$QSACED$
MADDM'Z,LL_[<J1F.+)*B/M8AKPQ(/##67]_]&/\`W33^MO0*>@>CUKHSG8KV
MVAKJP20"X%P<S=^;[=KZUJ_6[).7]2_M1&TWMQ[2WPWFM\?])4;^F?6GZT75
M-ZM4WIW3JG;S6#[G'CZ&Y[_4V_Z38MOZU=+R,OZO/Z?T^K>\>D*Z@0WVL<W\
MZPM;[6-3KUQB1!D#J?#^\OK25"@1H&O]6^@]%R.A85U^#19;94TO>ZMI<3XN
M<0MO#Z;T_`W_`&+&KQ_4C?Z;0W=MG;NV_N[ER73[?K]@85.'3TVDUT-#&ESF
M$P/WHR`M?HF9];+LTLZOA58^+L)%C"TG?(VM]MUO_4ILXG4\0([<28D:"C]C
MOI))*)>__]+U5))))2EB=</^5^C,/T3<]WS:&;?RK;65U_IN3F547X3@W+PW
M^I2#P?%G_1:@=F+."<9H608RK^[+B=55LS,&,UK6--N1;(II'+B.Y_<K9_A+
M$#&R>KW-#;<-N*_\Y[[`\?V&53N_MO8K-&*RESK"39=9`?:[D@<-'[E;?]&Q
M%=Q&0]-B^LAPU_@R<CJM>?T[I-^50XV9]SFG)O:)(;X5?NU4M]K/^W%@TY6'
M9B-L'6<JGJ!`+O4=8:]WYS9K%GL78=5IS[L-S>G7"C)!#FN,00.6:AWTE@9&
M-]8,K#.+D]*HMN+=OVLNKW3_`*3Z7TTTAJ<QC(EZ1(CAT'#.<.+^]CEZ<G]Y
MAUO.ZC3TWISQF!]CW/#[\9Y#7@%NWZ.S^TNN7'9/U7ZFSI>+CTAMUS+7VV@.
M`#=PK:UC2_;N_FUJLR_K87M#\&@-)&X[QH._^%2"<,YPG(SA/U#'6DLFT?5Z
MG#LSWNZOG59G5,C"IKML%6PO<-'D;-K)V^U;'U??C69=AHZK?U`MK,U6AX:)
M+?TGZ7\Y5&=,ZYB=5S<NC#JR*\BQY;ZKFQM+B]KHW+6Z6[JYR'#-PJ<6K88?
M40272W:WVN=_*2"W!&0R7(2^8[QR_3U\7M_\QU4DDDYOO__3]57`U?6W.R:L
MS*=U>G#;799]FQG4A[W,'NJU'Q]-=SDUFW&MJ#_2+V.:+!^;(C?_`&%F=`P^
MCX/3*<;&R*<MC"Z+P6.W$N<[\TN^C.U/A*(!L6=%L@216CF]/^MV6*,/&S,.
MW)ZCDT&_90T"6[WLJ+F'^;WUL]3<KC?K/=?8^C!Z;=DWX[&NRV![&"ISAN]`
MOL(WW,_/8U6<?!PZ_K%E9OVIMF9=2QGV66[JZV[?=MW>IM>X?NJA7T,G*ZB_
MI/6/0KRK7',I8VNTLL,^J/4W;J'ZN3KQD[5]M6KU)*_KCAY&+B68N/;?E9I<
MVK$;M#QL,/=8]SO397_+4+/KE70[+KRL*W'MP:Q9>QSF'5[FMKK8YCG-?O\`
M4:Y9&3AXN-F=.KZ&76"BEXIRL.^BVU\N?ZS7XMY:VQN_U/TC/8EC]#JR*^HN
MZWGLQ;[[Z7W,MMJ?:VMD^BW)VO;74Z_>WV_R/8CPXZOIY^K?_O47+;K^#MT_
M6UAS,;&RL*_$9F,-E-UFV"UK=[G.8UQ<QO\`60K/KB1B.ZE7TZ]_2VNV_:]S
M&DC=Z>]M#G>ILW*SU/IO3+^K5Y69ELK(Q;*68SG-:2QP?ZU[=SMWMK=^ZL]O
MU>H'2JJ,OK0MZ%60YK8KK8X;I8Q^8'>YF]`>WI^(U_!/J;.7]<L6K*?C8M/V
MAU3&V/+K:Z9#VBUC:6WN:^Y^QWT6-0.J?67JHOZ75@X=M3LTE[J[`P/<UG\[
M0UMCOT;MOO\`5>A=6Z'TZRZ[[5UC'JJR8-=>0RESZV'Z+<6^U[7UU[3^CV*P
MWHG3QE])MP.J-J=BTFO$9-=IM9[O6LJW.]VYKG[WUM2'MBOVWV1ZF-7UL;7=
MFVW>K:!D-Q,3#:QFXW`?IF5/9[K/=]-]BU,#K&7D9IPLOIUV$_9ZC;'%ME9$
MQM]:F6-L_D+&;]7^E>ECUX_5V,SJLRVZF\&MQ=>[T_5I]#?[WLVT^Q;73>F7
M8N5;DY>=9FY5K0V'0RMK1_H\9A]-O_&(2X*T2.+JZ:222C7/_]D`.$))300A
M``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P
M````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`+@`P````
M`0`X0DE-!`8```````<`"``!``$!`/_N``Y!9&]B90!D0`````'_VP"$``$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("
M`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`$\`
M9`,!$0`"$0$#$0'_W0`$``W_Q`"I```"`P$!`0`````````````)"@`'"`8%
M`P$``@(#`0$!````````````!08`!P,$"`(!"1````<``00"`0(#"`,`````
M`0(#!`4&!P@`$1()$Q05(18Q(@I!43(CMA=W.':W.1$``@$#`P($`@8&!P4)
M`````0(#$00%`!(&(3%1(A,'06%Q@9$R%!6AL5)R(PC!0F*"LB1T\#,T-3;1
MX9+"0[,E%A?_V@`,`P$``A$#$0`_`'^.IJ:G4U-3J:FIU-34ZFIKQK%8Z_48
M.4LUJG(FM5R#9K2,S/3TBTB8>*8-R^2SR1DGZJ#-FV2#_$=0Y2A_?UY9E12S
ML`H[DZU+^_L<79W.1R5Y%;V$*%I))&5(T4=V=V(50/B20-9I8<R\/O!D(3#K
M?";I?I%T=I%T:@RS5S)))I?%]NQV=RN!4JG18KYR?:F'1?K^9R(-P<.U4&RN
ML+V"3I`XDD\!_3X#Y_TZKZ#W9X;F62SX=EH,SG)&(2VMI%+@"FZ68G_<VR5&
M^=QLJ51/4E=(V]:U\>5=@8>.V:#H#TCIL0JM*RR_W/)Z'%*'03(X;I*T>5KU
MQN!3*%[G4G)!TW4.'FBS:%,*(>FMS*/X\C'Y`D#]'4_7]@UM93@AY7`%Y?G+
M]E*BL%E=7%C;H:"HK;20SSBHZFXE=">JQ1@[1AKCRVO_`!0YWS/$MSH5RT+#
MM6RMQJ>4(7N>D;+,4:0BY&33>5YC)/1!)%F0(F4!=)(A2JH_05/_`)XKF4T+
M826E^UGZA:!TW+4U(IW'Z_T:IO@R9SVS]ZKOVQESUY?\.R>--Y9"YD>9[9T=
MZQ*[=`H$<VX``%?08_Q"Y8OW1C74VIU-34ZFIJ=34U__T'^.IJ:G4U-3J:FI
MU-34ZFIH3'N)C['9^-E5H=,<2,G;+3J4,LQSRO,)&9M.@1D!"3TE*MXB#B&S
MN1DF]:/]>2==D_A2(@4QA`_Q%,(S*N]JL<9\Y;L.[4\/H[ZYC_FKAOLA[?8W
M"XEI)<I<Y.,K:Q*\DURD<<K.$BC#,XA.R9^FU0@).[:")CU,XCM[SEC4]!BZ
MW:ZS1:.TM2=\LLE"R<;!O&CJ%=Q?[,^Z\;H-'TP\EWC54S,ICK(D0%<Q2@F`
M]!\/!.;M9%4B-:U/8?1KF3^67AW,7]S\7G(,?=6V&LTF_$RO&Z1LK1LGX?<P
M"M(TC(Q0$LH7>0-M=-G=-^OTWT,RXD-9/;%D$>U2,?\`VXXCVVYR3A,HBFD2
MS76;IZ#5<X`($5!1XDH4HB`B53O_``Z&.-V6AI_5A)^TTUSSEMV0_F:XK:QQ
MFF/XO/<NP[4FN)+<*3VK4A@*U(J>W<F?1/70VIU-34ZFIJ=34U__T7]S&*4H
MF,(%*4!,8QA`"E*`=Q$1']```ZFII1ZK>\CD<^YG0CZ4=TXW!&S<H;!D$1/#
M3&K=V%'3DF4:PFE[.FL,DG(0]?LL9/N`$HB=(QDP*)>X!?,WMIAUXY($]3_[
M0EBLQ7>:;B"2-O:A*L@^W5:1\PR#9M$9$_(VNV@5J>:HH*UKV)(-:=O&FF=.
M2;S6(W`=@EL)<LFVQ0N?6:<S@)*-;2[%];(2-7EHJ'<Q[L!;+ISJS/Z7<W;P
M%QY@("4!"E\0MB^4L$R8)Q[2J)*&A"DT)!'A6OU:L*\-P+6X-J0+D(=M>HW4
MZ5&AZ^F[GG=N=G'FY3NMO()QK^::&[KEG&!CVD,U?5J<CFTW39PL,T4.1BFY
M`7[`![`"JD8<_<1$>S;[A\6MN+Y>WAL`WY?-"&7<:T8&CBOQ^!^6X:7^)9R7
M.XUI[G:+N.0JX`I\QT^@_:#HM,K*1\'%R4U+.T6$5$,'DI)OG)P3;LH^/;J.
MWKM=0?T(BV;)&.81_@4HCTAHC2.D:+5V(`'B3T`TT$@`DGH-`-]6G+G<^>.P
M<IN15\AJ8GE&1ISU)P*1&A0["X1+.XS<G:4JVI9P,XD5#P5.AXP)8A3)@[6>
MH'4$_B`%LKG'%,'QF'C]M`C'-2H#*Q8D```-0?`,^ZGR4ZK_`([)%R',WW(K
MFPMVFM`\%O-L!E6-V#.JN:E5<+&7"TW4%:[1JU?2ASAWSG'DFRW#?96N2LU2
MM`@Z[!*5NM,JT@E&/JRE*.".6[(QB.5C.SB('']0+^G6'W&XUB^-7V-@Q:.(
MY8"S;F+==U.E>W31;B>9O,S;Y"6\V[HK@H*"G0`'K\^NJCY6>S'E+I?+.>X)
M>M.@UFU:;01?DU/6+>2.?0-:>P9VC:TM8]O)NT8*-BJ?)R*,=(/I`KA567\F
M;9H8X)G7W\'PW"6>!BY1S*Z>.QEIZ425#.#7:33J2P!90*>7S$T[:V2S^1GR
MDF"X]`CW<8K)(_W(_E\SU'U]*&AIDCC.W]T[[;[=R7KK_$=S;SVIQ7'_`%.P
MKQ]=CX]>K9W-Q$-,S],CCQ&8O5J+&_=44^U$"9P\<,U5#MSG()C:44OM!DX\
MC/9V5_:7@5E5G9B'9`=NW^),H!/3J$J>]#JK?;UKGD')>5<_Q-OZMR]X<;/-
M+N"RQV152]FN\J+<L31E">HZ,S+45)J?:KR2U'B9PLT/;\<?1$=?:W8,\CHQ
MU.0[>>C2-;'=X2"E"K1KHQ45CGCWR@$$1[D,(&#]0Z"\&PUEGN1VF,R"L;5U
M<G:=I\J$CK](U=')<E<8G#W5]:[?63;2HJ.K`=OKT)7'-G_J#MXRZC[#G+7C
MO(T;0X!I9:P^?L\XBGCJ*>^7P*N8Y[))NF:HB0>Y#E`P=/>1QWM1B[ZYQ]V;
MP7,+E6`+D5'@0.NERTNN=7MK!=PBS]*10PK6M#U%=$&X@K>X-Q/:B3F"WQR.
M@2Y7,J96O4$:4]5/JZ<K#GA6\PW@I8BYX=>*!X1055$D@,8HB8#`7I3SXX`(
M[(\?-R9/7'J[]P_A4-=M1WK31W%#DY:Y&7-N%V>39U\WSK\-:;_<?.[Q_'?[
M?Y;Y?E/']Q_F&OC^"_<'E\GX;]P^7YO]K_R>/G];[O\`/W^/_+Z#>CQC[_XJ
M?M]VGQV^-/N[OKI\^NB>[)]O3C^FO]'C^BNO_])N3VN\A!XU\"]^O#!ZX86F
MQU53+:0NR<`UD$+3I8C5$)*.<>9#)/*Y%OW<J4Q1\P!B(E_F[=-W!<1^=<HQ
M5JR@P+)ZCU[;8_,0?DQ`7Z]`N2Y'\KPE_=AJ2[-J_O-Y1]A-?JT`[3/7J,%Z
M"<_MS6"(KJ-;F6',>=4;)G;O5*[HJ3.*DDW!5?$Q?P6-N(AT[(?Q`AH@XE#R
M[`-HV7+1+[J74+2_Y"0&T%>U4J1_XI0P'[VDN[X\T?!($2,_C8@)_GN/5OI(
M4T^H:8B];?(M7E/PFP'7Y)ZJ_M;^F(56_.')TC/'-]H3EQ3+7)NR)")436&4
MA#R:1/T$&[U,>P=^JEYAB/R/DF5QZK2%9"R>&Q_.H'T`[?I!T]8+(KE<38WP
M/F=!N_>'1OT@Z!5P.(TX%^[#DSQ,/].&SG?`DW5`:I_(VC42.VI]@RV*8`?^
M5?\`!UR?E((HCW[NB&*`]^K-Y17E'MOA,\*M>6E%D/QZ?PI"?I95?Z#I-PO_
M`,+S++XH]+>Y'J)X5ZMT^UA_=T4?W;\BDL`X!ZDP9OR-;7MP(XI7$2.00=J-
M+>@Y_>;A$I1!4Z;>DM'Z9Q+_`(3KD[B'<.DKVVQ'YMRJQ+K6WMOXS>'D^[]K
MD?8=,7,,C^6X*\=6I-(/37QJW2H^@5.ND]5'&Y+C+ZZ,RKCQBFSN&CT^4VJ_
M&!-5%PK8M*B$I:,:/T5NQD9&NTE.(B5R@`%^6/,(?Q$1P\XS!S7+[V=6K;Q2
M")/W8S0D?)FW,/WM9N-8T8K!6=L5I*4W/^\PJ?L[?5H<?],C_P!?.27_`"[5
M_P#1*'3=[S?\TPG^E/\`C.E[V]_X/,?ZQO\`"NL0;#?=U]/G/WF)?)JB/YS/
M>8++5GV8Z0W04+'(.]!M:U[A):-FOC.5:P9K+R:S.7B3G1<J@";L""BHT45+
M2V4?N-P+&6&'NXX\Y81JOIN2!54]/K0$A7`#(]"`?*:>:B?RM^0\6;E\F&C7
M\9D+:06TSE@D<[!MA9E5B-C,30`DT4]JZ9']<FM\4;=QQSC..,FQ4W26V=T^
M.)9HZ+>.(ZW,9J5<.)&R3MBH\^E'V^NH3]L>/5TA=M$T3"<2I&,4H#U2U_QG
M+\:$5IE+"2(CH&(JC'N2KBJMWKT-17KIU]LL)A>+\)X]QC"7<<UO96ZJS*?O
M2L2\SE3YE]25G?:>VZGPUF_WV?\`S.V'_P`NQ_\`]GUCIQ]K?^L\=^Y+_P"V
MVB'.?^F<A_<_QKJB_7W[5.`..\*^-F7Z3R+@JO?*1ET%`VFON*?I;Y:(EFOS
MBX9*NXJEOXUP=(#AW,BLH0?[##T2Y5P;E>0Y'F+VSP[O:R3LRL&C%0?CU<'[
M1K6PG)L!;XC'0392)94A4$$FH('4=M%BXW<TN,7+L]R3XYZM':8?/RU\]P!A
M`VZ$_"EM0S98`51M-?@@<_D1KKWQ^#Y1)\`^?CY$\D7,<=S6`_#_`)O8M!ZN
M[94J:[:;ONL>VX=Z=],UAE<=E!(V/NTE"4KM^%>VM1]!-$-?_],JOOKL][Y)
M<D.)WKVQQ%E/VZ;6/H4I"'D#-F9K+93RD%54+"Y1.(1C2#K$-*R+DQP`Z+%V
M5?\`0HE$;O\`:Z&UP^'S_+,B2MN@],&G7:*%MOB2Q51XD4U6_-I+G(7^'X_9
M!6F=O48'[M!VW?+H2=738:=_4#VFDS><SE>X:O*58JM)4J7KPI0"<<ZJ\M$K
M0;Z&^N1<"$9K13@Z'@4``"#V#H7%<>U<-S'=QRY$7".'#=:A@:@_37KHLZ<S
M>-HFCL/3(H1YJ4[4U5W]/EH=EQS0N6O`'4@)$WC/+M)W=A#G?D71+/5QZUSC
M3&L28WB#UF"T5$.4540^)9`QEBAXF\A(^[%K!D;7`\KL:M:S1!":?`@O&3X'
MJP(/8]-">!2S6,F6X_=D">"3<!\CT-/$=B/IUZ/OJJDQ@^[\)O8/2&2YYK-[
MO%4VUJ(M^[5Q^SK`71J,T>J)E*!B3#=:PLE_E,`*(BFF`]OTZ\>UT\>4QG)>
M)W+?PYXBZ?WEV/3Z/(13X]=9>;1FQN\'R",>:"8*_P"Z34?^8=?'7A>QF8CO
M83[/N$?#:J/!L^14F$KVN:.M&>'TWD)>VD=HD^N=V45"J-761P425DL(=B*S
M9@*`^8]\G$$?BG"N3<BG79?RLT,=>X*$H/LD9J_N?+7S/D9KDN"Q"=;>(>L_
MA3N/T#X_M:9\L)2DK<X0A2D(2$DRD(4`*4I2L%P*4I0[`4I0#L`!_#JEX>LT
M1/[0_7JPF^ZWT:6Q_ID?^OG)+_EVK_Z)0ZN#WF_YIA/]*?\`&=('M[_P>8_U
MC?X5T3XU%J/.;D1;I[0JO`W_`(Q<=$['DU0JMN@V$[4]+VN5(BVU&XGC)5DH
MTEH2AQQ4H-BJH59$9$'2[8Y?$PFI&RNKE,BM]9W#Q-;U",I*G>?O$$4-`.G@
M>ND[%Q__`*1[E7G(I!OX9QOU;.U!'DN<@X"WEP`1YH[=*6L;'<IE]9HR!7<$
M'VS<!:7ZZPS;G=P@FYS$9N'U.+KDY38N<E'D.RDYYA,R\?,5<TDY=O&T*Z/"
M+LI2%767CW#9T0B222)%$C]"<#Y1<\O-YQ;DT:W430%E<@;J*0"&I2I%05?H
MP(ZDDC3#RK#P\=$'(<'_`)>9)`K(I\C!O[/8#I0@=#WH"*Z(![<M&<;#Z7$=
M;=L$XIUJ56XLZ,YC$1.*,<XN]@S^S+,$A4,=04FBDF*9?(1-V+^HB/2KP"T%
MA[B_@0U5A>YCKX[%=:_HKH]R^7U^)7$]*;TC;[64Z[KUQ<#^%NB\%^+UYOO%
M?!;A<K/D\!*V*SV/+ZE+3DW)+_8!9_*23R+5=/7:P%#R44,8QNWZCUI\OY-R
M&UY-F[>VS5TD"7#!561@`/`"O0:W<#C,=)A<6[V,1<P(22HZFGT:*%CW&OC[
MQ[-83X7B^:9&:VEBBV@V>4Z$J@V`L$,D,,$N,,S:??"+&8=_!\GE\7V%/'MY
MCW2[_+Y3*>E^99":?97;O8MMK2M*DTK05^@:/06MM:[OP\")7OM`%?LU=O0[
M6QK_U#\\0>&7)J=]KG)3G5R9SE]2*P4MKB<!/)66BS3N1AY#XL]J2@QU2LD\
MYAE(G(XKXW!7!$!,X?F_QG^00M//\BPT7!</QC#78DFJK3T5U`8>=NK*M:R'
MI2O1?HTF8W#W[<GR><R$>V/;LAZ@^7M7H33H.Q_:.C_]59ISTOGNG"_D_G7N
M.RCF_P`=LR7N^3W9I4V.]NF-CHT*,`B_B%\JO9OP=BM$%*3/UZ0TCYQ'ZB*Q
MEI%$P=C*``&M;&\CPMW[>WW&LM>>G?Q,Q@JKG=0^HGF52!YRR=3T4^&DJYP^
M0@Y=:YJQBW6DD>V;S`4Z;:T)Z]`IZ>&B`^T7$83DCPWT_$S/JXEHMP:M7>(P
M\]98.L.K5KM9<$G:E5J\ZGY*+9.)JR*M#QQ""J!?!V83B4GD8$[A^<CX_P`C
MQF1GEV6P?:Y_L/Y6Z#J:5W4`)Z=!K>Y8^-DQ9QM]D+>"YNV$=N)9$C,LYZI'
M&&(WN2.BK5CX:'-Z6>`')7!-(V'?N8=,+6-&<T#,\4RYJ_GJ=9I5&BTVMQ$`
MY=?<ILW/1S-LUKM.K\4V\U2NE",UA4#L8#'=?<7E6&REIC\5QV??9"62:2BL
MHWNQ:E'`)\S.QZ4ZBGR&<1PF3LI[W(9H#\:ZI&O4&B(H%:CIUH`?CTJ>^F$)
MMNL[AI=JW)\CAS%OVZ"?D4OFLLT532)Y'$I"^1S`'<1``_MZJB(A9(V/8,/U
MZ>6%5('AI87U@X3RXXBY%I_$VQ4H^7\C>1EZC+#7G`V6EVLV:XM%UQ"OWC:)
M=2FV&QM8PL:^4_&PJ+HZ*K^96(")3E06$C][K<DQ?(,AB5P=YZK"W*L=K+L\
MQ)/F53V[4[G7/^4NN18N&3V^X](L7-<S,[JZD-^"L>B37\E"=NT_PK<-0R3L
M`M0CT[Z,O'NEX,.9G+J;Q-S?D5Q\@K#9&F0+TX\8]E86GN9^0DH1@\6I\K5[
M8]=),7I?M/)F`^X[="HLJX64,<XDK##>V&0Q]C''FIK&\CA17#@T9@H#-Y@R
MU9JD[7I4]AISPN,SW!\79\=P>$@EP-JFR`(U&"`]W[;I&)+R/2KNS,34G5?7
M?C'[2_;1<L^B>8=(KW$CBK2K&A:W5*CGC8+)8)!!#\<Y<-H#\[8;,\M0Q3UT
MW9NY<(UA'HNESHIJ*&,10S:YKA/`[>[DX]<O?YV5"H<CRJ._>BKMJ`2%W%B!
M4@:VI\9R+E$MNF9ACM,2CAC&IW.Y'B>M!\.M*=>A/8HGM0XP7_9O7I:>.?&N
M@EL5A9N,@BJ31V,S!0:3>LT6W5I7ZC>3MDQ$1:2$/7XD?$%G0*'*GV+Y'$`%
M*X-FK3&\LM\OF+G9"1*7<@MYG5NM%!/5C\!IBY/CKC(X*ZL+&,-,VT**@=F!
M[F@[#0R,"M/ORX[8SG&'TOA%CTA5<QK#&J03VP7/.W4TZCX_S^):2<,N0+!H
MJZ.*@^0IHIE_N*'3EE(/:W+9&\R5QR6Y$\SEF"H]`3X5A/3Z]+]C+S>QL[:S
M3"VY2)`H)D%33IU\VB,\*-?]L=YV1>%YI<9LOR3'2TV<>H6JH3M9D98]Q0>P
MY(2*%O$:[=W0-'C-9X<YOI`0!2+W4+W`#*/([#@MMCQ)QS,SW&0]0#:ZL!LH
M:FIC05!I\?JT=Q-UR::Z*Y?&PPVNT^97#'=TH*5/ST6OI$TRZ__5?XZFIJ=3
M4U.IJ:&!S=<@IRW]:L(Z,`1SO8-(F5"F$0(,G`050&&,/Z^(G*YDC`7O^O<W
MZ="[X_YS&*>Q=C]@%/UZYT]X7#^Z'\OEK*U+=LK=N>M//'%#Z?Z6(^O1/^BF
MNB]4UL6OM\Q81$7#0CJ\:A=UG<7FF;12Q$9.U2S5-([QZ^>J%.WKM-KI'*2\
MQ,.?%K'H'*`B==5!%;%++Z8``K(>P\?^[Q/PTH\LY7'QN"TMK2R>]Y)>,R6E
MI&:/,Z@;F9CTBMX@RM<7#^2)2/O.\:./WE17-TXS\3-9UK/)1W:^3.C3M;D]
MJU*NQ)WKV!K(`LS<L:&R<(+.X*@YQ%F*QBP%/Y&:"R\DMXNU5UP'7:SVUG-+
M&Q-TQ&Y@/AX#P`[#[>^J0]R;#FGMY[8\GY/@;AKKW#R$\+Y"\B3<T<-"I6V4
M@F.VM$I'#TJBM)</25I'T)^H:ED-HRF"L*'LFY4YUR>>,(]Y*I:'8-@>9D%A
M6,B$O$GD:5$6Q5"OI@H<K9XJ[4,H0A#JMTP,9),2DL+QAADI$NJ==U:5^(Z:
MYEQ7)N+9+BUC?)_,'R>Q]Q716<7,V0:R]4TWINMTGI$*G9(TA)`#-&M2JZ>Y
MK[GR(I/&WA=,->236R6RRV+0F-GU'C]=Y>-JFCQD3(0C>#7=O(-&N)R#Z.8J
M?6?)&0*0D@1Q_*4PF*&U>SW$<%@1<U8L060]&'3P_3\]6+[P<SYYB/;WVFNX
M_<!)\I<378FO,9<.L%TJ,@B):,1!V13MD7:`)0_0&H#%/3%KO+2KU@W:6E>7
M'*>H[1SVY"<<Z)5-7TIA1"U"4U"U1ZGT-!F(YM6V<'53R!(2-C(A(/A[)IHE
M*F!"_P!@=*8N2UY>)<7\D<8=MM"3_6/2@KVU^;65YE=W/NE[CXOE?O9G./X:
MVR-RMOZ#7DZ';<,HB6.$L(U5.W0+TH-$I]?DUF]CU>UNJ)S_`-RY6KQN?O49
M&@:7#Z7%P$*C(6&NF0MS8UW:M6*TLS48BS3!'R5!%ZK_``*(]RV/:%I7]*_D
ME(7LU:#J.O4:O[V+N<'?\FRDV']\<SR8QV+!K:[CNXXH]\L1$X_$`*7788QM
MZA9&^&B\=%M=3Z__UG^.IJ:G4U-3J:FL#<]>-ND[?6\OON'RL?&[AQ^O:&B9
MXA++-VT;.*$,P7D(!=R[#Z2*KUS#LU$P<F(T6^`45S$34,<NA?VTLZ1/`0)X
MVW"OZM4E[U^W_(.8V'&\WPZZ2/F.#O1=6H<@))]TM$2WE&YHXR`Y"-MV.0K%
MA8&=:/RZO$<R8V_CC5L2F2MVQ9JQ6G5X"]0Q5^Y$WJ]9K%`_(R4L;OY'3;OY
M&*(4O8!<'$/UR1R7<B@/;!'^)+`CZ@._UD:.X#/^Z.8ABARW`;;#W(5?4EFO
M8[E*UHQAAM@S/\2%DEA`%/.QKJ[J-E\+3)&9M#AV_M.@6A%DWM-]L!DEYR39
MQWRFCX*.31(DQK50BEW"RC2(CTT&**ZZS@Q%';ARX6SI$$):M7/<G_;H/D-.
M&'XY9XFYO,D\CW.<N0HFN9:&1U2NR-:46*!"6*01!8U9WD(:6221ZYY64W>[
MOD$G&<:M&;YIJ[&383$/+/4&"K"99LR.DY"LO%Y&'G4(\DHFX`Z:_P!8W@X1
M3`PE3,<P8KN.>2$BVDVRUJ/^S0'W*Q7.,OQ:YM_;S/ICN3I(KQNZHRR*M=T+
M%XY0N\&H;8:,J@D*6.A&Z)G'L"UO'W63Z=P%PZZ7MW7A@!Y`R-PQA&SHNP1!
ML%Q;-&E@0<1]J,4`5,LU<-TA7$3`W`@_#T(DBR$T!AEL(S+2FZJ_;WK7_:FN
M7,_@O?/E/%Y>-<C]D<->9E[?T_S-Y\>)@U*>NJ+*"D_];=&Z+NJ1&%\FJWT;
MU@<G(/B]@F;4R.A-!OL#IVC:=>H]K:X6+@ZHK;86A145`1,A9WT#^5010J'F
MY.@4"@\56\/),2*'Q28JZ6UMHDHTBN6/7H*TH/T?;72]R'^73W$L_;CA?'\3
M;Q7^:BR%W=W*+-$D<!GCMD2-&F:+>`(*L5_]1FI5:,=^Q.M^V%>6BT9?BKA;
M.(6DF*4J[0T**47:1BCM$C]RB0NGKF46;M#'.4H$.)C``>(_PZ)++E=R[K6+
M;7KU^'VZNZVY5_,V]S;I<>V&'2V,BAV_%1^5"PW$4O6-0M2*`]NQUDJ%XT\X
M<:Y3\F=@H'&K+-9KFN:#?)""#1+C2#M$X"8ODE9(F6:1RUK8/F+YTS7(!B+$
M*H0IA*8H#WZT4M+Z"ZNIH[>-U=R1N([5)&JTM^!>\7$_<OW"Y5@O;S'Y3'Y.
M]N&C_$SVVWTWG:5'53.K*Q%`0P!`-*:(1Q<DN72^@R;;<N+^*8K2#U.050M&
M<35>?33ZR(RL*6-A'36(LLNN,:XCUGBYSF2`A5&Y`\@$P`)*U_&>H?7MHT2G
M=>]=7E[;W?NG+G;F+F?MOB</AC:L1-:R1-(TP>/9&5CFD.PH9&)*T!0"O7KO
MOK?U=NO_UW]S&*0ICG,!2E`3&,80*4I2AW$QA'L```!^H]34THU5_;1MVH5G
MD9K#[V)8]QVCZQHFG$Q'#I_CS7+_`'*V4.-1":H14Y%BV"0(>2*_2B2J+IKK
M&6:J+J")1[]7S/P3'64N(L5XC<W;O#$9IEG9$5ST?H>G2F[H0*&FJVBY)<7*
MY&=^006ZI-((T,:LQ52=I[U-?ATJ=;LX^>W/6&]&XY9EM/&S5]AY7:_B$YM1
MJWC5:BH]P\K"VB72M9\_F*[(/&J%33L]2KK::<O5E&[!*/<IN$R^3ANV.KY;
M@=B;G+WN-S$$&!@NA#NF8FC>FK/1@#OVLQ0`58D$?`D&\?R*Y,%C;W^/E;+R
M6YE*(H[;B`#4C82*&C$`=JUZ:TE&^SNXZ%8['G^!\+-CVG1\KJ%5GN0->8W7
M-Z7"XU:[-$GE5LJ?6BX2K!&U:17#-W#20CF#83I/FJR!/-1%8$Q#\,@M88;K
M*<BM[:SG=A`Q21S,JFGJA44E8VZ%68]00?B-;XSK2R2P6F-EEN(E'J`%`(V(
MW;"S,`7`[A:@?$Z\FN>XO&]$S+`+#D.1:UJ.R\CY>XP=#X[P!*LTNK!S0)!:
M.M4S;+#)SC>IUZG-3H_*A)JN!(L@)CF32%N\*V]S>W^1M+W*PW]]!#C[-4+S
MMN*$2"J!5"EF8_L@=#\>HKCBY+9W%M8S6T$LD]P6"1``/5"0^ZI"J%(H26IX
M5UST_P"XV`H$CR%K>N\7M;RRY\8LSK]]U.MSUKS>6*E*7&RU>#IE3K,W6IZ7
MB+"M9H^XL7Z#Q-0B14_F(8@&2[FS1>W\UVF)FL,U;SV][.T<3*L@Z(K,[,&4
M%0I4@BE>Q^.L<G)X+<Y!+FQFCEMH1(ZG8?O&BJI#$$M\.M/$@U`ZNI^V6'<[
M'B.8:QQ=V_!H#D'2)J^9OH>A.Z6I'NX&N5AS:9V8FJ_!S4C-5V#8Q[0QS*/0
M1?IHJ(JKLT"*#X:\_!I!CLC?6.:MKJ6UE"21Q[ZAF;:H#%0K$D_U:CN`QIK.
MN?07MI9SV$\0GC+([!:44;FJ`Q9:#]H#7%SON(79Y+)<HZ[PMWFR<.8VRJP`
M<@%+'F]?=2[)"RC4C6B"RN5GBW9[65YP/@2=+%;)@KW36%!4BJ:>S%[?[[]<
M)+R&U3D)2OH;9&H=N[:TH78&IUH"?E76"3DR):')+C9VQ0/^]&P`K6F\(6#E
M:_&@)'4`CKKU-8]R67574;1EF29BOKDK2:+2[[89"P;#D>%(R+&^U.-O$!#Y
MY#:M8(JSZ391K<PV478QC$ZZ2ZQ4/$5#$`V.Q]O[V>Q@OKZ]%O%+*Z*!%+-0
MHQ1BYB4K&NX&A8]0*]M99^16Z7<]E;P-+/&BLPW(GWA50N]EW,1\!T\2#JJ>
M4'LIY2-KOP-IV!\:M2ITMR4F'EMFJ??F68Q]^ME<I#EV70,LA8:W6%)*JRS6
M)30DTIV0%DR=L'S=1JJ807(GO87A^%:VY1<93,P/'9J%5D,A16>FR0E5\P)J
MNP58$$,!T.M7(YR_CN,)!9X^4-<-N8-LW;5%66A>@8=.M=O@2=>G5O:Y'UVW
M\F[;=2:W=V#/D!4^+F`\:Z_2<U6L<IML)'.6VEUFB6FNOAE+>PCY,[->0DYE
MT5HU!V@1H!Q<H(G\3<'DF@PT%O\`AXV-HUS/<,\FT0D_PV=6%%)%0JH*FAW=
MB=9%Y!$CW\DAE8"X$,<81:F3:"50@]?$ER`*'X:W5A'+W5-$VI]AFS\-=MXZ
M6+]C'OT#;9J0J^EY;,1I'Z3$8-UI&>.9&L0EQ5`ZBJ<8LL97XFRGF*9A0*NM
M9/`V5ICER6/Y!;7<7J[&50T<@-*U].0!BG]H=.H^="EID)Y[EK6XQDT#A-P+
M;60BM*;D9@&'@:>(KK=O2SHIK__0?"TNON;9G&@55G9UJ0[LU)M5?:W-NDBN
MO47$S!/XY&SH(.'#1NLM`*.0=E*HJF0QD@`QBAW$-BSE$%W:S&'U`DBML_:H
M0=O][M]>O$B[XY%W;:J17PZ=_JUA/@/C?$#`N-&<Y7E6OXQO,'6W]J4;:LQF
M<WG5[3,S5QFIQX9-[!R\ZS*O$.I$&*:23I0R16Q2CV-W`&?E&0S^4S-Y?7UA
M<6LKA:Q$2+M`0`=&`-"!7J/CH/AK7&6>/MK:SN8YHD!`>JDL:FIJ.E:_IUTV
M?X;CM<]AN][P&Z5BT[KHF/T2LCA)I&K%MN89W74*^W5GDX="<=6Q2&M,Q'(N
M#.EV+9N51QX%.?R`1PW62R,W%,7C/RUTQ<-P[>M1MLDC5\M:;:J#2@)/2NLD
M-K9IF;R[%T&OGB12E5JJ+6AI]ZC'XGZ/AK*$!P<6=:AS%GN'GL?4S:J;7J%H
ME>26>4RK93KDYGNGR:LP:[Q[:[+V,)O*;.5W)/P%%5LD_CP\"B/FV2.0Y-R6
MEEQ^+D'$?6GMH%%O([2Q"2,4V$H%I*O0=0:-]9T/BQ0_$Y.3&9HI'+*3*BA'
M*R4`:C&I1J4Z&M.A`&A[:/CV699LG#2M<!7-IM:&78]=FV9;UQ+Y+<7]9U^_
MC*VJY.M(BY_`M0E8R+MT2VL+F5</)M@\4BV972K0R`%9$;MFFUR%_>X_D4W*
M%1&GN$]6&ZM[B*)**OIE9HP2AV[0$8!C0&OFJ136MC#<8:/$DLD44@CDAEB9
MF!(]0%&/G%>K,*T;O0Z^6?\`"*L:37>:,ISQY9T_#=!TO;\)L^C0&I[1B5QU
MRI9=0D9-QG$1MKR%N,34*#*ZNI8F!VK%N"31JWC&B+)$J(IHI^KKDD]I+QR/
MC&"DN;6&VG6-HX9DB>62GJ-""I=Q$`06-22Q+&O4^8<7!-^<29?(+'++/$S*
MTB%EC2GIK)U"KZAJ:#I0T4UT77DUQMXRZ'RSJ>L[CR*IE/?->*6LY17\4FK1
M3:K(.Z59XRZ$T/681[+V%K-%;PE1FW2;AP@Q.R9(LOF55*4A@!#PV8S-I@[B
MQQN)DD4WT4K3!78!U*^G$0%(\S`$`FK$T`TPWUECYLA#<W=XJN+:1%0LJ^5J
M;W'6O0"E1T`^G60F7KZHK?BMGU`V7V<Q]T]<5/EXB?AX@L3C&=TVT0:5I<OJ
M_7K%R/96=Y^=K![*^,FD1)9$JB_QII"0Z+8$3[<JNSG+NZQ_#3'R^12K&LTC
MJVVC,MN5\K;14U!H*D]S48N&MAC8(+K.;\"FTJ/X:J5!JH:4?>7MVI7IUUS'
M*WA#QSL-NT0NL^R+CQ1*3KR3&2JM0WBB<:+1>LSIKYLJXAH;"=0OEN@;)2ZH
MWB)`J,29@V$J$>DV!,YA2*J;+@N1Y>&"T-AQ&[ENK<D,\+W"I(X/4S1HK*[5
M'FJ>IK7O37S*XRQD-Q^/S4*6D@Z+(L)*"E/X;M0@4[5K3N-7,RX4<?6^L^OF
MU\>.=M7I4OB602U(X_54[_)M=?;93RC9'6CVZBI35@`)9_.P<M((23^'9/6\
M>V2*9N5L5N``/;D>5-ARN#+<9>2.YN`\[4EB$+]/35Z+T`(!57(+'O6NMD8N
MQ%U@Y;3*A6AA*Q+5']1#3<17J>@%66M!JJ&7`#BF>KY#7\S]AU(@.1--YD;)
MJV>ZO%3N1V:1L.^VHE`-H.<FS!W<EV=ELU:8P=;!Q%D<F?-2J)BX0\'@$-O-
MRG.">_EO.*2/B9,=#%)$5E4+`N_TY/4"U56)>C4VGK0^76K^3XPQ6L<&85;Q
M+R21'#(29FJ73:31B!4%>X'UZ)SQQXSV[*-4O>G;-RNT+DCL=UK[&&383(L,
M]SRFU%DLR,):?AU7EW55B7CYXQ1^Q*G35='\1*50@KNA<)N7S$%]96UGC\'%
M9X^-R:BKN[FOWYF&XT!-%Z#Y=!0_964EO-+-<W[SW+J!UHJ@#]E%Z#YGJ3XZ
(W!TMZ)Z__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g693329g92b06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693329g92b06.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0VR4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````.0```&0````&`&<`.0`R
M`&(`,``V`````0`````````````````````````!``````````````!D````
M.0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"Q4````!````9````#D`
M``$L``!"S```"OD`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``Y`&0#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))8>5]<^A8G4CTVZUPO:]M;W!I+&N='TK/Y.[WHQB9;`GR09".Y
M`\W<24+;!54^T@N#&EQ:T2XP)AH_>5'HW7NG=;ILMP'EPJ=M>UXVN!(W-]O[
MKDJ-$UH%6+`O4NBJ^?GXW3\5^7DDMJKB8$DDZ-:T?RE87/9'4^F=?S+>@TO<
M[T7%V6X-TBLCVUV_1;^E]N](`FZ&VZW+(B)X:XR*@#^_T88GUSQ<[)9B45.J
MMN<&5OM@LU_>%9W;OY'_`(*Q;;\&FY@;E$Y'B'&&G_K3-M?_`$5S/U;Z=]6K
MNIWG"??=D=/?J+H#6NES`YNQK=_N8MSJWUCZ1T<M9FW[;7B64L!>\CCZ+/\`
MOZ7!*^&C?9@Y?W3C)YDQ.NE?+P^/Z+0?B,Z/U[!&!->-G^I7=C@DLW-&]MC&
MN^CRNB7%7?6_IE_6\?*R*<FC%P:WC=949%MOM][6E^UOI?1769N?CX.#9G7[
MA14W>^`=T?U$3"0JP==EW+\(]WAH0X[B.D8\,>+_`)_&V4ES;/K[T.QNYC<E
M[3PYM+B/P5SI_P!:.G=1N=1CUW[VL=9[ZBP$-[!SOSD3CF-XEE&2!VD"["2I
M?M;&W;-EN_C;Z;N9C;/T?^^))O">RZQW?__0]'ZUU*OI?2\G.>0/182P'N\^
MVIG]JQ<-B?56_.^J&5U"T%_4<NS[97/TG-9OT_Z^VR]__;2O?72^[K'7,'ZL
MXQ.W<VW)+>TB=?\`B<??;_;6PSZJY=;&ULZWG-8P!K6AS0`!H&CVJQ$^W`:\
M,I'B_P`&.S!+US.G%&(X?\*7S)?J=U@=6Z'38YTY%`]&\=]S![7_`/7&;7KG
M<8_\V?KV_&`+,#JL;!V!L/Z./^+R=]7_`!;U'HK+/JM]<7]+NL+L/J('IV/T
MW..M+S'Y_J^I0MCZ_P#279G2!G4",KIQ]5KASZ?^&_S-OJ_];1H#(1^AE&G^
M%M_BHLRQ@_IXCK_@[_XT74^LG5V]'Z/?F2/5`V4`][':5_YO\XLOZA=&=@]*
M.=D`_:^H'U7EW(9_@A_;W>K_`&UA9&:_ZZ=1Z1T]L^A34+^H1H`_Z-W_`%.R
MK_CUZ(UK6-#&B&M$`#@`)DQP0X/TI:R\A\JZ!XY\?Z,=(^9^8O#_`%`_Y<Z[
M_P`9_P"C+D'K0R^@?6Y_7\K%=F85PBJP:^FXL#&M_D/9L_[;1/J)8ROK/7[+
M'!C&/W.<=``++I)6[AY^!U7J3LBV^L-PW;<7&<\!\D>[*MJ<=WO:?T"=DD8Y
M):<0,0)>5,0UQPB#ZS(F/A4M9%%]5NK]$OQ_3KS*[<_+<;<AKI8YUCOI,:RT
M-W-K^A[%;^M__B:ZA_Q7\6KGO\8&-]768!OJ]&KJ@>WTO1(#W:_I/597^;L_
MPCU?S79K_P#%]8[/W?:CBCU-_P!+D;-_\OT]NY-$`."<;`,@*DOB>&,L6GIA
MO'_NOZS1^IWUJZ!T[H&/B9N6*KV.L+F;+'1N>YS?<QCF_1*Z;IGUBZ-U:U]/
M3\D7V5MWN:&O;#9VS^D8S]Y8WU%OZ<SZM8S;[*6V;K9#RT._G'_O+HZ<CI[G
MAE%M)L=PUCFDGO\`FI9>'BGZ979UO3_HK\7%PPUC5#2M?^DV$DDE"RO_T?1Z
M.B],Q^H6]2JH#<VX$67%SG$@Q.CW.:WZ/YJO))(DD[FT``;"FCU'HG2^IOJL
MSJ!:^B34_<YI;,'Z5;F?NH/7LQ^/7BX[`UWV[(9C6!PD>F^6V_\`16HLSKG3
MG=1QV,Q[&UY>-8V^@G@/;]'?_)<D2:W.FS'F$O;F8#UGM\TJ9],Z#TCI+K'=
M/QQ0ZT`/(+G$@<?SCG^*NVVU4UNMM<&5MU<YQ@!4L7)ZO8/3R,:FJUOTW"[<
M/ZS:VL<_^PYW]M61B-=8VV]QM>S5@.C&G]YE?[W\M^]Z1))LFSXIC*X^B-?W
MAP5_@N$WI/3L7[9U,8QQ\(S=;2-WJ9!876[[V6N_1U;S^CH_/_PW^C6/;5TS
MKILS1T?&<\N)(^U>E:\\EQKJ]/W._EKMLL6.QK16]M;RT[7O$M!C\]O[JY?]
MAYY:YN3TG#R7DF+J;/1$'^0S8EQR!L2-][:O,0R1E$0LQ()E4.+U=/T,W#_X
M6BIQ>A]'Z=^UF=$-.358UHKR'.<9=Q959=ZK?_`UTU8Q^L=*9]IJFG,J:ZRF
M3PX;MN]NQRYQGU4ZLSHE^&ZUC[;K&/93N.Q@;NW>YP^D_<M#$/UFPL6C$&/B
MD5-%;"ZP@NVA(RD39))1AR98D>YCD('&/2("7ZSB]7%[<?W7%S^E_5W&ZL>E
MX_1&7V;0X.=DOK!EN_\`/.W_`*:O]$Z3B8W4Z;JNBUXCV[HR&Y?JELM<W^9W
M'?NG8EU+H'4\KK`ZB<>C(8:VA]-CR&[MFUW`_-?]%7.E],R\;-KM=TW$QF:A
MUM3W%X!!^B"C[DSH92^U;`9?>-Q(C[GIJ$0/;_1_R,O_`$J[Z222:Z+_`/_2
M]522224I<?\`8^M8_53UO%QG/R<V_(Q[*WR`VF&58%UO_`UNQ_5L_D6+L$E)
MBOU56VM_NL>2M+O?2OWGC*^G]9Z=?GY-#+GNR,FFG(R@T.O=2UKGY>5CU.W,
M]]UGIU>Q_IU?\6K#F_6-QM9A/RF8>1;1559DAIO8"[=F9+06[ZZ?3;L_3KJT
ME(>*]>"]-_\`!I8*Z<5:[?X5O+Y6-UPY&;AM??D8EUF+36^YK'C:\^IG7M_1
MM9Z3*_T7T=F]5V4=;QG=5R\=N3]HLRFUB6M=^JM(K;D8S'-V77LK:_TV?F;_
M`*"[!)(77Z/2_P#F[J-7^EUK_G/)7'ZQ?K'[-=F?9[65TU.RP/4%S[&^KDUL
M+6V5T4XV_?ZG^$1.K8O6J<@_9'7YGV?&MNKNM:QQ^T6[<6FNK96S9Z+-]_L7
M4I("['R?R'Z235'YOY?NO+]0_;O2['W59;[JJL)SK+,MU;:79!<VJI@=MI96
M[Z3_`*?O4.F9N3E=:Q*,?)RWU,K?=G#(-1!@;*6[:!^BW6O_`)#'[/8NDSOZ
M'=_4=^19WU:_H;_Z_P#!+]$WPW15^D*XJL.PDDDH&9__V0`X0DE-!"$`````
M`%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3
M`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"
M24T$!@``````!P`(``$``0$`_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`.0!D`P$1
M``(1`0,1`?_=``0`#?_$`*D```(#`0$!```````````````)!P@*!@4"`0`"
M`@,!`0``````````````!@4'`P0(`0(0```'`0`!`P,"`P8'``````$"`P0%
M!@<(`!$2"1,4%2$C(A87)+5V-W<8,4&TMS@Y"A$``@$#`P(#!`4&"PD`````
M`0(#$00%`!(&(0<Q01-1(C(487%"<A6!L2-S-0CPD<%B@C/#=!8V%Z'14I*B
M4V,D)?_:``P#`0`"$0,1`#\`W\>&C1X:-'AHT>&C1X:-0]O6ZYWS;EMEV#4I
M)U&U&L)M0<?CF2DE+24A(NT8^*AXB/3,3[J2DW[@B2?O.DBGZBHLHDD0ZA?E
MW6-2S>&DWG_/>.=L^*93F7*[IXL-:!=VQ2\CN[!(XXT'Q.[D**E5%=SLJ!F"
MN,G^9S+M\T6LXY0L_LE$NFA6=C5:;9],,R?4YJO)?63;.IJ/I[]W-NI59R":
M+2-24;MG;A4J:TFQ3]5RZXN0Q"A:$GSURMP_]]?B7<+DN,X7@./W5AF\C=+!
M;3WNUK8%Z@-(EN[2F0FBQP@HDCD*]U`OZ0-!FL-J5YBV\?K#B7U,2H*)/6UB
MD7<?5GOUE#JB12A5U>)IBY&IE3$;JNF3I^1'T(HY5$!..;TP:;^I_AY>&NJ+
MW@V(SMI';<LDFROND,LSLD#5)/6UA,=L0M2$9XWE"T#2N>I6G.95$<3=W\K-
M.?!D:=D749M,I&FX^VF)=_2@G:M!M[#%7"!A95Z_0@Y(KF11]YFH)$10:J))
M@1-TL4V$KZ4T93X6\1_#^`US%?<4LNQ_?SM/!V[,EEP_E?SUM>XY9)&M?5@B
M$T=S#&[.L4FYUKLVA51E4!99*N3\VM=H:/#1H\-&CPT:_]#?QX:-*NU/YEN$
ML<Z.?\O7>_V-IHD-<:]0Y^595)Z^HE?LEA&.*5K,6Q-<K5JE"JR14Y)0"&(R
M425*<?<D<`L+']L.79/!IR"TLXS9-$TB@N!(RK7JJ>)W4]T?:J*>(U7F0[H\
M/Q>?/'+N^<9`2I&Q"$QJ[TH&?P%*C=[.M?`Z9C:K"C4ZO8[4XCI>8;5N"EI]
M>*KS+\G.R:$0P7D%6,+&@JB,C*NTVXD;H`<HK*F*4!]1\0[>`W-Q!;JZJTCA
M06-%!)I5CY`>9\AI^GE$$$TY1F"*6HHJQH*T4>9/D/,ZJKQEWGSIWG4K?<.?
M+#-2C.B6%M6[3%6:"<5N?BWC^/))1CM6+<JK'-%RB(+$;K@82J*M5R?H*8^,
M7*.(9OB%S;6V9A16F0LA1MRD`T(J/,=*CV$'STN<6YA@^8VMS=X2=G2&38X9
M2C*:5%5/6A'@?.A'EJY7BOIHTGG0>EN9OD;V6\?'92K3/2Y<]FY:9Z%DH^E+
MKL@B<PGHEJI!4N].SJ0T,]6OSEJS<2145E_IHK(M2#]4SA%JR_!<]BN/V'(<
MBD46.N2FP%_TC;@67W*=*J-QKX#Z3J@NX-EQ_O6UQVH-_P#_`!DG$F2*Q$R,
MENZLD5O,P,<3M/M$DU&=45TC6KETJM\;_//QIWCIG5%\)LF]:)IW*-N0+)1N
ML(14-6*M8T+!88".DH@U?@X(]I>1\Q6'1DE%SBW*!4U!1$_H8,&=X+E^,V>)
MR635/E[Q=T6UPQIM5O>``IT8?EU3_9S]V7L;Q[G5WGL#?9C(YO#7(:-+QXQ%
M!*&94=1##"971D8J7)044[-P#::AUG\BW(_%#F'A=YTXL3=K(Q+)5G.*S`SE
MROL\S4=BP;N&T#7F+W\<V>/"'2;KR"K-NX424(F<QB&`-GCG">2<J667#V&Z
MUC-&E=E2-32M"S$5('4A0Q`()'776/).;\:XF88LSD-EW(*I$BM)(_6G1$!(
M!/0%J`FH!Z:3)<_EXYIOG;F.:YHN:=09OC7--!NS0LQ=<,FDG</L&O?8PK-:
MS0T%)3[N,@UJ"U,Y8JG(+M5<!^FW$OH?R>_TCY!<34LLOB;F=`?T<5TK25\^
MA51_U#7-&7YEAN5=].'\HO8KB/C/%L==#:8G,\>1R&R)?7A3>8XS9J7B9R'+
M5VI3WM:%-IWB@8'B5QZ!T)6;:YW1:PE;I]5C!OEIY&'6.T(025]V1C(E?`9Z
M0#MU2I+)CZE.4IBB'B3B\1>9C*VN&LPAO9I-BU8;=W7[0J*=/$5!\M=897+6
M>&Q5WF;TL+*"(R-126"C^;T-?H\=*\AOGJX;L4>C+5^#Z8G8IP94K>3AN?K;
M)QZYD%3HK%1>,E%VRID5DS$,!3#[3%$!_4/'^7L_RV%S'--8)(/$-<(#_$>N
MJ]A[Q\0N(UE@BR#Q'P9;64@^70@$>.K%<]_*+SOTU<YBA9I4M^2L4-2[#>E4
M[CCD_3(]W%5H&?WK)A*SJS6/6FG)GQ`;MS*$%4?7^(``1\A<UV_S>!M8KR_N
M;/T&E6/W)E<@M6A(6IVBG4TZ:GL'S_"<ANI;/'V]Z)TB:3])`\8(6E0&>@+&
MO05ZZL-_NMSG[_\`#_R_J?YKW?:_BOZ:6?ZGYC\A]A^%_(_:?@ON/3^T?=_=
M_B_M?W/NO3R&_P`-W^SU?7MO1\:^JGPTKNI7=]&W;OKTVZ8/QJTW^GZ4WJ>S
MTV\:TVUI2OG6NVG7=K__T=J_:725?Y'Y=VCH&?=LFYZ!295W6&CX!.E.7R11
M&*H==*B4Y%%_SEM>LVYP*/J1$YU!]"$,(3_%L'-R3/XO#0J3ZTH#$?9C'61O
MZ*`GZZ#SU`<ISL'&N/Y7-W#`""%BH/VG/2-?Z3E1^6NLIF2?%5>N@OB%WKH^
MX,9:P=8[Y?2=;4M9\FH:P3]=HI;6+2..W`"J.)/486Y6>4;%3]"/%)"+-Z?M
ME].A\EW"M,-W*P^#MG5..V</R;T^%6DV5/U1,D2GV;9/;KG?&]N;W.]L,SF;
MQ6?D]_-\\A/Q'9O*K]<JO(P^^GLUH(^';L-MV-P]F5DE9,CS3LN9-\@UA!5<
MRL@:S4Y@U:1=B>"J85E37*KBRDCJ^GL%VLX3*(BD;TIKN9QEN,\LOX(TI87!
M,T)\MKDDJ/N-N6GL`/GJYNV7*%Y5Q''7<CUR$"^C,//U(P!N/WUH_P!9(\M)
MIS=0?BK^=FP9:U;.:]S3W4I$DKK4R8)PC27T2177J(QQ4_5!(E/V8[^"0((D
M^SB)03&#VB0QK/OA_J'VCAR#,'SN(KN/VB(Q[]?OP[9#[7757V)_T[[Q7&."
ME,!FZ%!]D2.?=I]V8LE/)9!Y4T_GY(>O(SB+D#5]Q.Z9$N+:)-4\IC7GTC_F
M=1M*2["IH$:*_H^;Q"H*RKQ(/U-'QZX_\O*=X-QJ3E?)<=B0I^6+;YB/LQ)U
M?KY%NB*?^)AJY.<\FBXEQG)YEV'KJFV('[4K=$%/,`^\W\U3JA_P(\;2&`<K
MNM_TEBZ-N76KY#2K%(3`'/-LL^54=O*%&NC+`*B;F?3DW,^Z'^%14THD18/<
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MD<0)!V,60@44DQLS+5@5TU#XN.N>)[_0B5ZK])9_>>F-SGYG4]FA;`,A3;?8
M]'M*A%I6M05>NT?!O)J*J+-1.-9-XXKAN=!NHX2*!%%!"G\MV_Y?QF.2?*8:
M585-6E2DD8]AWH6"CV;MOTT)U+]@1QG$<<EBGY';7G<#,7,E_DWJ4>6\G.YX
MXUD",8K==L,2H-NU"X4;VU/_`,OO_K1[$_TE=_WY"^;O;;_/?&/[R/S'5H=R
MO\A<K_N;Z3_\.WRG<$\R<!9%C>Y=`1]#TFMS>G.YNLKT+5)Q5BWG])M,[$*&
MDJQ19N&6^\BI!%8`2<G$@']IP*8!*%E]S.WW,,]S')9/$X8S6+K$%;U(5KMC
M53T>16Z$$=1JL.U_<3AF"X3B,7ELXD-_&9-R%)21NE=AU6-AU!!Z'3SN9_D1
MXV[$MD]1N;]I9:7:JQ736N=B6U-T6MG85\LDQB#2)G5RJ%=8KE"1DT$_II*G
M5]5/7V^T#"%2Y[A7)^,V\-WG,68+>1]BDO$U6H6I1'8^`)J135NX'FW%^3W$
MUI@LLMQ<1IO8!)%HM0*U=%'B0.AKJZGBMIJU_])J/S1W6W=M]N\J_%%EK]X2
M&6LU=T7<WT0*2BT2M*LWCPKEZ50#)$#.,E"1G/I*`*3E25;AZ"HFF'G0O:VT
MMN*<4Y#W$R"#U1&T<`;SH0*#]9-MCKY;#Y$ZYX[JW-SR[E?'.VN/<B)I%FN2
MOV10D5^Y%N>AZ$LGT:8Y"_%5K%<AHFNP'RC=YPT#`QC"%A8>,MM(9QL5$1;5
M)C&QD>S0J9$&K%BR0(DDD0H$(F0"@``'B/+W#QL\LD\W;_#M,[%F8I(26)J2
M3OZDGJ3IZB[>Y2&*.&'N'F%B10J@-$``!0`#T^@`Z#2B>+8BQ_$7\Q5GY(O%
MTEI;"NN8:'"E76SMV;0+7898S]_FD^__`!Z36/;3Z%X/,U1<$$DT57+XJ@ID
M2%(263RF6#N3VS@Y):6JKE\:QWHI)V**"516I*[-DHJ2:+2M:ZK/BD-QVT[H
MW7&;R\=\/E4#1R/0;Y#4H32@#;]\1H`"64T`IID7S^\EOMOY&0Z!H39RAL/(
M<HMJ4)+19C(RW]/`,R6T1%!=/VG3&O(1;2P%4$WN1+#J@3]51]4;LYR-,5R0
MX:\8'&9)?28'P]3KZ?\`S5,?T[Q7PT]=YN-OE^,?C-B",MBV]=&'Q;!0R`?4
M`)!]SZ=*@ONTROSK]$_'5SE%K/QSF@9.PVGL,T3]5A'1-S2<(0^E,O:0/[,H
M="";QL&X]#"@I;/4"^T%!&Q;/%Q]H\)S;-R`?/37!@LJ]24I6(_3U8LX\Q%]
M6J[O<J>\.<X-@X6)QL%L+F^V]`LGPNA]A]W:GZVNMF,;',(>.81$4S;Q\7%L
MFL=&L&B14&K%@Q03;,V;9$@`1%NV;I%(0H``%*4`#SF"1WE=Y9&+2,223XDG
MJ2?K.NH41(T2.-0$4``#P`'0`?5K*;\$T[#5?L;Y=+)8Y1A!P$!>UIB;F91T
MDRC8J*CM4VQV_D'[M<Q$6S1FU2,HH<X@4I2B(^=`]XR!Q+MZ2>GH?V,.N<>U
ME_98OD7=K)9*ZC@Q]O.TDLCL%2.-)+AG=V-`JJH)))H`*Z:YD6[8-U[T?)Z-
M;]4SIG%\_P`XK"8'A\_=H&*N1IF4B4%)/?KOG\F_;S2#Z?C9%-O4T7+<#Q\?
M]1R)".G(?2HHX'-FVMLI)B+D8Z1=T4GIML85(W!@*>73KX=?8='%;K'=V>;Q
M<]SL\<?'\/(1A;*5PDCLZ>_E[BW8AE:9&"8])%#10;IBJR3#8K3_`.@'-?CO
M@,%7T&G_`-'Z7V<C=*BM029$]KL/?K6BM.M0M2]X@*>LDJ^BF$!]=TC+R#<'
M+>0;MD47)?JF15O?LW?<UFS`LKKYF7BYB?U/6#-&GN^YZ;/X$M0%%-"I8E>E
M1G[U8_A,.$>_@^6AY8)4,)A*K*YW#=O5.I`6I#L*A@H#"M#;O:9';)?_`.?&
MUR7103W]9'?*K%2X'M2:B5H7`+#'DKSNS$7]'?\`,3RJE8JOA<`#HSHYQ7`%
MA.'BSBTQ4?>:V3";/PP9'W-GP?"=P7RVA]P6G2E*=*::<J^6D[+WDF=W_BQQ
M1]3=T:M.F[^<5H6KUK6O77G?!;=>>H;XT\1C[];<9BK0C8-=,^8V^>I#&>23
M5U>X*LS.VTT[2D"$4:'(9(3E`!3$HE_A]/,O=JUS4O.LJ]G;736Y2&A19"O]
M4E:%13Q\=8NT-WAHN`81+NYM5G!EJ'9`W]<]*@FOAIT5-T#G^1FT8C/KMCK^
MQR::Z3>,IMDI3J;D$6R)WSE-%E"/3OW::"#4RQP*4P%(F)Q]`*(A5MU99E(C
M)>VET(%\2ZN%%>@ZL*#QI_LU:=M>8B241V=U;-,P\$9"QIU/134^%=3%Y&:D
MM?_3VK4?B[F3.=_N_4M0RQE';]HS:59W#27=CN4[+2;2:<1CB1;MV%@L4I!0
MR2HPS5,@,6K8$6R(()^Q$13%@N^4YZ^PUIQ^YR!;#0$%(@J*`5J!U50S>)/O
M$U)J:GKJ`M.+X&RS5YR&VQRKFK@$22EG9F!I449BJCW0/=`Z"GATU:+Q?U/Z
MJQT1Q/R_U?-4"R;[E+"^6++5WKF@3P6*Y569K2\@[BW[@[.4I5CKCU;VOH9L
MLD"QU0;JIB=("&.<3,.%Y5G^.Q7D&'R)A@N`!(NU'5J`CJ'5AX$@TI4=#6@T
MOYKBV`Y%+8SYC'+-/;,6B;<ZLA)!J"C*?%0>M:$=-1KWCL$KG5=P3.8AE!22
M72O1><\]VUC98L)J,<YOH0R,1>D5&2JJ2:RKR-6(V`3&_0K@P_KZ>+HNI[2:
MVN+:0I.LBE6'B&!J"/80:$:JOOCSW*<+@[:XK#B'YGD/*K#%R>JGJ*+:Y9EN
M"%)`W;=JBIZ;J]::[?F3@[DKCA];93FS&87,9.\M(IA:9!I.6^Q/I-C"+/7$
M<R*[N-BL*[!HDXD%#G3;&1(N?V"J!Q33$C+GN7\CY.EM'G<HUQ'"24!5%`+4
M!-$5:F@\36G6E*G5GX#A_&N+-=/@,4EN\P`<@NQ(6M!5V:@%3T%*^?@-6;M%
MIK=)@9*TV^=BJU7(=#[F4FYI\WCHUDB)R)$,NZ<G32*9990J:9?7W**&*0H"
M8P`*T2%!)-!J5RF5QN$Q]UE<Q?Q6N-A7<\LK!$45IU9B!U)``\22`*D@:3I&
M\I<\Y03HWJYOB4SDF!.6[W5[UG35U=G&B]/3%$DYR[I6?4JU?+`Z:5*A_P`Q
M2#EQ$U4J+`TD*A'4Q]%N5./3F,SRC/<@M+"US%^TMA:+2)"B+04"^*JI(HH%
M&)\*GSUS3G,1BFQO,>XO(,!<6/:^RB:^>Q"R"\R[VI:?UKZ*=@(;7U`3;V+;
M#,=LUX42EN%N62K<Q_(2O<MR9_&_S1*3KR=EW$@S_P!Y:V.;3=I8@@\D)A_4
MZ,%/2?3$VJ<Q@7DVYU'BQC&(JMZ_4-+X;N=S?"VT=IC<TXM$&U4?TY`%'0*O
MJ(Q4#R`('EJBL;W?E[OVF2Y5Q_LQQZ14E<>C+R"*VR,Q05+>A''&0SCX?5'O
M'X6<=3-M,ROAOB3G=3L:!^+R8H&L4Z^5BM(4_>+==9]\U=SQ@<1]SSZX:.UO
M<:9!B*?HD[:0[!ZDN0P?M@)%%/<QW.YMFK1K;(YF7Y9NA1`D08$'H3&B%@?`
MAB1]&GRZ[C\>[<]J[KNQ<=A[W'Y^UOH8#9W\LB,?6(VSV]S+%,'0>3+`CA@0
M0HVLSQJ^A0.V^4:RIJM"0<9]T)EU;F[9G:\_*+(%C+,P83AX(]CA0K,JN5HL
M)"_<(`S.I[/7VE`1+XM8K)WF-NK3*8^8Q7L3;D:@.T^VC`@_E!UU-Q/,6?<S
MMYQS/Y'%"*RS6,@N'MS(7"+<1+(8_4"Q%MNZF\*A-*[1X:SP[SRY\=F8=9O.
M2\Z^+VE:C:4Z_%S[";F.O-*RMD^2>UC^:'J*IK/+NX5@9@T*<I14DO<X,4`(
M4#&`GCD_>#N$LA0<@<D?^.`>5?\`M:X^Y]S?C/%^[TO:'C78VURV6%LDRRR9
MDV"L&A]9@?6B>-=B@@5FJY\!4TU;OB;DS)<QZ7SJ[T[XQ<TP&<A2VL$==KG=
M3?8Y:GMY*F6"(>*M\Z)/OS6`LRW?FCC_`+1OMB/!7_3Z7J$?E.X_,\_938K+
M99I;"6FY=L(KM8,.J(&Z,`>A^OIJQ^V-WR%^:XA+GL+CL-:D2[[R+D5M?O"/
M1>A%K&H>7>VV(T/N!]YZ*=/]\4]=9Z__U-_'AHT>&C1X:-4E[<YWD>FL^K\+
MG%TA*GN&,Z#5MHRR1DU2.&+*XU45E(QG96K=-W(-(24(\#]XJ)Q27(BI[%2%
M%,_Q-!(T2N%(%>A(-"1]/AJD^^?;.^[G<9QEOQW+16?-,-DH,ECY9.L:W5ON
M*),`&81.&ZD*2KA'VN%*M[N7:5UI9&R5>T3$,?I5RC&S=.Q2S3=3SL0H8Z1"
MC.PU.A:1*3Z;=P<X*IQ[]\T_;,!/O1'^,?0MR$5WAHA\_(_5T_EU(<6Y!WAR
M-M%:<FX#B+#*HH$LJY,RPL:4,L4$=J\M"?>$,LL?3W?7K[VIH2RMC*6&(MU_
ME75[GX!0CRNLGS=%A2JI+E!4IINKT]([E!"<!)84T9&2<2DHS2,HFW=))K+$
M4\V5(+FI'\0^H:<EXK;W61L\OG[IK^_MR&A5@%MH).OZ6"W%0):&BS3///&I
M98Y45W#>MJK2<?9K>F59L-;J=@=5:90A[%<8UM,5*)?J,E2MW5FBWBB+9]`@
M<?:[3.8`%`QO^(_IY]A))"(XEK(>@%*U/LIYZW>3VN3ON.YNSPU[;VV6EM9%
MAEGC$L*2%2%,L9H'CKT=?-:Z0V/#N\.XV7B=/^/3C/8YI^[>K1NCY7I[K!8D
MS1XF'VZJ]?J[.O.794U!%0JB"3%0Q#``A[P$XZ9BD!(:`;OKI3\FN`F[$<_E
MMKVRY9^[IPG,W[R,4O+&];$IM;P+0P)"S4-355B8@BHW#<?"A/BHZQA.)]1Q
M1]?:I/6W0-'S>UUG-R6N74HF?QE36GE9QTWFY:.*!9ZP%ED".$FC?Z`E8I"9
M98P@*?S\O($I]/A^0_[]:./_`'3>[=CV,Y=P6XY#9W&8R62LIX+/UY3:6B6[
M2&4K+(G];,'4.J)LI$E7<FJW#R5;Y+\*RW*\>;8_R@[94NJU_/ZZ^G->L;*5
ML/\`+L0DS0,#=-FBDO(KM60JG20*/H`&$`]`\S1178C(CAW*@ZGQH/::>&KK
MX;'^]%PCB7%^'VW">)RVV.LH;6-WR%P'D$$:QAB!'3<P6I"]/&G34`](\$=,
MZQV&UZ55Q_!M3KCW/*9&6#-K_>92/K;BUMJ`V@YU,H,HX\@JP@["915BJ*GJ
MJ")#&`/40\Q&*4R>H4!K3I^0#\^JX[G?N^]S>7]YHNYIX?Q_+8M\;;QRV5Y=
M2I"9UM1'+\$9<K%*2T35][:I(ZZL3R[S5K>6;75+8_XKY(R"&22FV$Y?<QOE
MIE;K$1S^$?I%2B(Z1:D9N@D)`$$%@.(>U!0Y@_4`\RHK!E/HJ![=6+VJ[7\N
MXGSC$Y>X[)\/PUD%E26ZL;NXDN8T:)P!&CJ%;>^Q6J11"Q'4#3<O-C77^O_5
MW\>&C1X:-'AHUF_)D'9V<]3R/>618A8+#KW1^Y=0X#;*C<F[V,A:ABRT?1J3
MR=I5]:D70DH_.JE*XXWGIA1'T=+QLLJDW]BRJ(#>!R7%[[CZ<0R661,;8VEK
M<(Z$%GGK(]W%&?`R.)C&E>@906J`=4P<;R6RS[\MQV)=\E>W=U;NC=%2"B):
M32=0?20P"1Z>]MD8**D5YNN<^]C<TWKJW4\\KNV667U?I3GC*==WZ)IL#9^B
MK-AU=J5@M&_[IC5$G6TG77!;!IMO2AX!NVC91*$KS!!)LR7,Q*N7//F>,9VT
MX]C[V>TCCM[&XEAMR[+;+.SJMO!/(I##;$A>0ED+R,Q9@'IK7CP_),'=\AR-
MC#=/)<WUM%-<*BM<M`B,\]Q#&P*FLLGIQJ$?9$H"H=@.I@>L?D5D75\A<,L?
M5T#A6J:IS)FE"MO0,?6G^_YVU=7%S-]%[7#,)"NA/5#-6-*B4XM)I:6QE%7S
ML56R**0E*:-1^$HMG+EH,<^7M[>ZED2W+"WD(0+;0,0VUY2YW$Q'HHHQ)U)%
M.9N;R/$SY!,5<3VL<;W`0W$0+EKJ=04W)&(P$59@3O)*J!2O5ZCG/;JFA=.8
MK'6#<]3PS1=+XNR>IV'5ZUGEY8(5NZRQ+EU9J$:1M08.OH42NTEF,`NT.R4C
M491T<")%$J94];'WW%!98'*R0VEOEH(+V9UA:2,[D&RTB-9&;U&<^H"&W%1U
M/C79OK/E'SN=QT<]U<8N:>RB0S+$X"NV^[D6D:KZ:Q_HRI!4.30:AF&H_;F5
MR??6QYI!]._U0M_651SU%%_5*K8#EXYK\C$U.-UW$8&9@FE8T[4:O5(61_"Q
MY/KQ\<QDR"JR66.)AE);OBF1CX?C+^:P_#XL<\G1W7_W6!<PSL&+11.[+O;H
MS,IHX`U&);<IL'YAD[&*_-_+D4C`*HU+)2J>K;JRA)950.8UZJ`PW(6\>KMZ
MOR&D#8C<N2?89\KO-)R+*Z%,]/0\$YU.#W*X[%74KWM%0K<A78JY4[,,\Q<L
MD,@,VBRCUI=PD+1M])$3%U[8<+)Q@SZ8S\0AEFED6U9A$T"0MZ<#L&*/+)/M
MV["S!`=S5.L\_P#C&F3.!DR7R$T4,4;707U5G>91).B,H=(HH=Q82`*7IL6@
M.NRZPRWLVCZ(X3QF6W7H$^5<U[EK=*T?1:SF]JDW'3VMA6,-S:G4!W`YU6H^
MK#F5>+)VO[:-;-C`#E0SUPL@H*9=7CN0XQ=V0.3BL[/YB^@A>*-I4'RL.Z>1
MY`TC%_5;;%5B?`!5!%=;?(+'D]K=N,7)=79@L;B9))5B8_-2[((4CVQJ$$2[
MY:*!XG>Q!IK[WU3NODNP6"YU#H"VZ!4J'PW8;!:[KT[9<EK&&63I5Y;JQ1L_
M@(^87KN<5RHSJ":CV2327DDBR2AV;=XN8RZBJWF'_P`(\CAAM;G#10W$V654
M2U69YUM@C22,5W2LZ_"I(4[?>*CI0>9<\KX]-<7=MF))K>'$NS/=-"D#W6]$
MB`;;$J-\34+`-50QZUUS_,FRZ1K'9O/F?9IN77]EI4!0-"UWJ=ANT_S_`",?
M(+-(1E6,X@DX+)HY[(4(96[VA1V#7WQ<7*-(T18INP;+K(Y\_B[''<8S-Y?X
MG&QW3S1PVAMUN`15BTC;IB!)2-:5H[*S>^5W`'!@LG?9#DN'L['*Y)[5(99K
MH7!MB#0!(EVP@F/<[E@/<1PAV!@K$/\`_*;U;NO_UM_'AHT>&C1X:-'AHT>&
MC1X:-'AHT>&C1X:-'AHU%VW?Y/Z;_@>R?W4Y\D,5^T[#]:OYQK2R7[/O?U3?
JF.J<?&I_DY9?\8K?]$CXS<Y_:5O^J_ETM\+_`&9+^L/YM,8\2=..O__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
